cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
LAML	cis	rs6565180	0.507	rs4471699	ENSG00000183604.13	SMG1P5	20.81	3.51e-32	1.14e-24	1.01	0.93	Tonsillectomy;	chr16:30308986	chr16:30267553~30335374:-
LAML	cis	rs916888	0.773	rs199447	ENSG00000262500.1	RP11-259G18.2	17.67	6.79e-28	3.27e-21	1.26	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs199457	ENSG00000262500.1	RP11-259G18.2	17.55	1.01e-27	4.23e-21	1.26	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46243606~46245044:+
LAML	cis	rs916888	0.687	rs199456	ENSG00000262500.1	RP11-259G18.2	17.55	1.01e-27	4.23e-21	1.26	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs199448	ENSG00000262500.1	RP11-259G18.2	17.32	2.18e-27	6.83e-21	1.24	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs199445	ENSG00000262500.1	RP11-259G18.2	17.32	2.18e-27	6.83e-21	1.24	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs199443	ENSG00000262500.1	RP11-259G18.2	17.32	2.18e-27	6.83e-21	1.24	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs199534	ENSG00000262500.1	RP11-259G18.2	17.32	2.18e-27	6.83e-21	1.24	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs199533	ENSG00000262500.1	RP11-259G18.2	17.32	2.18e-27	6.83e-21	1.24	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46243606~46245044:+
LAML	cis	rs916888	0.779	rs199528	ENSG00000262500.1	RP11-259G18.2	17.16	3.82e-27	1.09e-20	1.25	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46243606~46245044:+
LAML	cis	rs916888	0.821	rs199525	ENSG00000262500.1	RP11-259G18.2	17.16	3.82e-27	1.09e-20	1.25	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs199439	ENSG00000262500.1	RP11-259G18.2	16.98	7.03e-27	1.91e-20	1.25	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs1378358	ENSG00000262500.1	RP11-259G18.2	16.91	8.75e-27	2.11e-20	1.25	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs538628	ENSG00000262500.1	RP11-259G18.2	16.91	8.75e-27	2.11e-20	1.25	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs169201	ENSG00000262500.1	RP11-259G18.2	16.91	8.75e-27	2.11e-20	1.25	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46243606~46245044:+
LAML	cis	rs2739330	0.929	rs5751777	ENSG00000273295.1	AP000350.5	16.89	9.56e-27	2.22e-20	1.17	0.89	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23901432~23907068:-
LAML	cis	rs916888	0.773	rs199451	ENSG00000262500.1	RP11-259G18.2	16.76	1.5e-26	3.2e-20	1.24	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46243606~46245044:+
LAML	cis	rs2739330	0.929	rs5751775	ENSG00000273295.1	AP000350.5	16.68	1.97e-26	3.86e-20	1.18	0.89	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23901432~23907068:-
LAML	cis	rs916888	0.773	rs9896243	ENSG00000262500.1	RP11-259G18.2	16.64	2.25e-26	4.27e-20	1.22	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46243606~46245044:+
LAML	cis	rs2739330	0.929	rs5751775	ENSG00000225282.1	AP000350.6	16.63	2.33e-26	4.3e-20	1.08	0.89	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.892	rs5751776	ENSG00000225282.1	AP000350.6	16.51	3.44e-26	5.72e-20	1.08	0.89	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.929	rs5751777	ENSG00000225282.1	AP000350.6	16.47	4.03e-26	5.72e-20	1.06	0.89	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.892	rs5751776	ENSG00000273295.1	AP000350.5	16.46	4.18e-26	5.72e-20	1.18	0.89	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23901432~23907068:-
LAML	cis	rs6565180	0.525	rs1132812	ENSG00000183604.13	SMG1P5	-16.13	1.29e-25	1.59e-19	-0.95	-0.89	Tonsillectomy;	chr16:30186830	chr16:30267553~30335374:-
LAML	cis	rs916888	0.821	rs199506	ENSG00000262500.1	RP11-259G18.2	-16.1	1.45e-25	1.75e-19	-1.21	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46243606~46245044:+
LAML	cis	rs916888	0.821	rs70600	ENSG00000262500.1	RP11-259G18.2	16.03	1.84e-25	2.13e-19	1.23	0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs199535	ENSG00000262500.1	RP11-259G18.2	15.94	2.57e-25	2.93e-19	1.23	0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46243606~46245044:+
LAML	cis	rs916888	0.697	rs199516	ENSG00000262500.1	RP11-259G18.2	-15.8	4.2e-25	4.11e-19	-1.21	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46243606~46245044:+
LAML	cis	rs916888	0.821	rs199514	ENSG00000262500.1	RP11-259G18.2	-15.8	4.2e-25	4.11e-19	-1.21	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46243606~46245044:+
LAML	cis	rs916888	0.821	rs199513	ENSG00000262500.1	RP11-259G18.2	-15.8	4.2e-25	4.11e-19	-1.21	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46243606~46245044:+
LAML	cis	rs916888	0.821	rs199512	ENSG00000262500.1	RP11-259G18.2	-15.8	4.2e-25	4.11e-19	-1.21	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46243606~46245044:+
LAML	cis	rs916888	0.821	rs199509	ENSG00000262500.1	RP11-259G18.2	-15.8	4.2e-25	4.11e-19	-1.21	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46243606~46245044:+
LAML	cis	rs916888	0.821	rs199507	ENSG00000262500.1	RP11-259G18.2	-15.8	4.2e-25	4.11e-19	-1.21	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46243606~46245044:+
LAML	cis	rs916888	0.821	rs199505	ENSG00000262500.1	RP11-259G18.2	-15.8	4.2e-25	4.11e-19	-1.21	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46243606~46245044:+
LAML	cis	rs916888	0.821	rs70602	ENSG00000262500.1	RP11-259G18.2	-15.8	4.2e-25	4.11e-19	-1.21	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46243606~46245044:+
LAML	cis	rs2739330	0.929	rs5751777	ENSG00000218537.1	MIF-AS1	15.17	4.03e-24	3.66e-18	1.15	0.87	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924860	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.929	rs5751775	ENSG00000218537.1	MIF-AS1	15.06	5.93e-24	5.02e-18	1.17	0.87	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924539	chr22:23894426~23898930:-
LAML	cis	rs12931792	0.687	rs8057425	ENSG00000183604.13	SMG1P5	-14.93	9.85e-24	7.91e-18	-0.95	-0.87	Tonsillectomy;	chr16:30171220	chr16:30267553~30335374:-
LAML	cis	rs12931792	0.748	rs11150585	ENSG00000183604.13	SMG1P5	-14.93	9.85e-24	7.91e-18	-0.95	-0.87	Tonsillectomy;	chr16:30172965	chr16:30267553~30335374:-
LAML	cis	rs12931792	0.782	rs6565176	ENSG00000183604.13	SMG1P5	-14.77	1.73e-23	1.31e-17	-0.94	-0.87	Tonsillectomy;	chr16:30163605	chr16:30267553~30335374:-
LAML	cis	rs12931792	0.72	rs12102320	ENSG00000183604.13	SMG1P5	-14.77	1.73e-23	1.31e-17	-0.94	-0.87	Tonsillectomy;	chr16:30167195	chr16:30267553~30335374:-
LAML	cis	rs2739330	0.892	rs5751776	ENSG00000218537.1	MIF-AS1	14.74	1.96e-23	1.46e-17	1.16	0.87	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23924767	chr22:23894426~23898930:-
LAML	cis	rs12931792	0.782	rs12927190	ENSG00000183604.13	SMG1P5	-14.66	2.61e-23	1.86e-17	-0.96	-0.87	Tonsillectomy;	chr16:30158072	chr16:30267553~30335374:-
LAML	cis	rs12931792	0.782	rs13331817	ENSG00000183604.13	SMG1P5	-14.66	2.61e-23	1.86e-17	-0.96	-0.87	Tonsillectomy;	chr16:30161306	chr16:30267553~30335374:-
LAML	cis	rs916888	0.773	rs199535	ENSG00000262539.1	RP11-259G18.3	14.58	3.48e-23	2.27e-17	1.3	0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs199448	ENSG00000262539.1	RP11-259G18.3	14.42	6.27e-23	3.39e-17	1.29	0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs199445	ENSG00000262539.1	RP11-259G18.3	14.42	6.27e-23	3.39e-17	1.29	0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs199443	ENSG00000262539.1	RP11-259G18.3	14.42	6.27e-23	3.39e-17	1.29	0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs199534	ENSG00000262539.1	RP11-259G18.3	14.42	6.27e-23	3.39e-17	1.29	0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs199533	ENSG00000262539.1	RP11-259G18.3	14.42	6.27e-23	3.39e-17	1.29	0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs199447	ENSG00000262539.1	RP11-259G18.3	14.38	7.29e-23	3.84e-17	1.31	0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs199506	ENSG00000262539.1	RP11-259G18.3	-14.34	8.61e-23	4.46e-17	-1.28	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs199504	ENSG00000262539.1	RP11-259G18.3	-14.3	9.92e-23	5.1e-17	-1.29	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46259551~46260606:-
LAML	cis	rs916888	0.779	rs199528	ENSG00000262539.1	RP11-259G18.3	14.23	1.29e-22	6.49e-17	1.3	0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs199525	ENSG00000262539.1	RP11-259G18.3	14.23	1.29e-22	6.49e-17	1.3	0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs199451	ENSG00000262539.1	RP11-259G18.3	14.23	1.32e-22	6.54e-17	1.29	0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs199504	ENSG00000262500.1	RP11-259G18.2	-14.09	2.24e-22	1.09e-16	-1.18	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46243606~46245044:+
LAML	cis	rs2739330	1	rs2739330	ENSG00000273295.1	AP000350.5	13.98	3.39e-22	1.48e-16	1.15	0.85	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.964	rs2739338	ENSG00000273295.1	AP000350.5	13.98	3.39e-22	1.48e-16	1.15	0.85	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954943	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.615	rs2858911	ENSG00000273295.1	AP000350.5	13.98	3.39e-22	1.48e-16	1.15	0.85	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955008	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.576	rs2858912	ENSG00000273295.1	AP000350.5	13.98	3.39e-22	1.48e-16	1.15	0.85	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955010	chr22:23901432~23907068:-
LAML	cis	rs916888	0.773	rs9896243	ENSG00000262539.1	RP11-259G18.3	13.93	4e-22	1.7e-16	1.27	0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs415430	ENSG00000262500.1	RP11-259G18.2	-13.9	4.51e-22	1.88e-16	-1.22	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46243606~46245044:+
LAML	cis	rs916888	0.779	rs430685	ENSG00000262500.1	RP11-259G18.2	-13.9	4.51e-22	1.88e-16	-1.22	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46243606~46245044:+
LAML	cis	rs12931792	0.846	rs9924308	ENSG00000183604.13	SMG1P5	13.72	9.03e-22	3.7e-16	0.95	0.85	Tonsillectomy;	chr16:30143419	chr16:30267553~30335374:-
LAML	cis	rs916888	0.61	rs199529	ENSG00000262539.1	RP11-259G18.3	13.65	1.19e-21	4.74e-16	1.24	0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46259551~46260606:-
LAML	cis	rs916888	0.697	rs199516	ENSG00000262539.1	RP11-259G18.3	-13.53	1.86e-21	6.88e-16	-1.26	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs199514	ENSG00000262539.1	RP11-259G18.3	-13.53	1.86e-21	6.88e-16	-1.26	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs199513	ENSG00000262539.1	RP11-259G18.3	-13.53	1.86e-21	6.88e-16	-1.26	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs199512	ENSG00000262539.1	RP11-259G18.3	-13.53	1.86e-21	6.88e-16	-1.26	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs199509	ENSG00000262539.1	RP11-259G18.3	-13.53	1.86e-21	6.88e-16	-1.26	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs199507	ENSG00000262539.1	RP11-259G18.3	-13.53	1.86e-21	6.88e-16	-1.26	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs199505	ENSG00000262539.1	RP11-259G18.3	-13.53	1.86e-21	6.88e-16	-1.26	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs70602	ENSG00000262539.1	RP11-259G18.3	-13.53	1.86e-21	6.88e-16	-1.26	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs199457	ENSG00000262539.1	RP11-259G18.3	13.47	2.35e-21	8.43e-16	1.28	0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46259551~46260606:-
LAML	cis	rs916888	0.687	rs199456	ENSG00000262539.1	RP11-259G18.3	13.47	2.35e-21	8.43e-16	1.28	0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46259551~46260606:-
LAML	cis	rs916888	0.821	rs70600	ENSG00000262539.1	RP11-259G18.3	13.44	2.61e-21	9.26e-16	1.27	0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs199439	ENSG00000262539.1	RP11-259G18.3	13.31	4.36e-21	1.42e-15	1.28	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46259551~46260606:-
LAML	cis	rs916888	0.61	rs199529	ENSG00000262500.1	RP11-259G18.2	13.22	6.21e-21	2.01e-15	1.13	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46243606~46245044:+
LAML	cis	rs2739330	0.892	rs4822455	ENSG00000273295.1	AP000350.5	13.14	8.42e-21	2.68e-15	1.09	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23901432~23907068:-
LAML	cis	rs2739330	1	rs2739330	ENSG00000225282.1	AP000350.6	13.1	9.68e-21	2.86e-15	1.04	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.964	rs2739338	ENSG00000225282.1	AP000350.6	13.1	9.68e-21	2.86e-15	1.04	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954943	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.615	rs2858911	ENSG00000225282.1	AP000350.6	13.1	9.68e-21	2.86e-15	1.04	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955008	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.576	rs2858912	ENSG00000225282.1	AP000350.6	13.1	9.68e-21	2.86e-15	1.04	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955010	chr22:23926900~23929574:+
LAML	cis	rs916888	0.773	rs1378358	ENSG00000262539.1	RP11-259G18.3	12.96	1.68e-20	4.68e-15	1.27	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs538628	ENSG00000262539.1	RP11-259G18.3	12.96	1.68e-20	4.68e-15	1.27	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs169201	ENSG00000262539.1	RP11-259G18.3	12.96	1.68e-20	4.68e-15	1.27	0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46259551~46260606:-
LAML	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	12.91	2.07e-20	5.62e-15	1.03	0.84	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
LAML	cis	rs2739330	0.892	rs4822455	ENSG00000225282.1	AP000350.6	12.88	2.33e-20	6.26e-15	0.99	0.84	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23926900~23929574:+
LAML	cis	rs1577917	0.681	rs4707211	ENSG00000203875.9	SNHG5	12.87	2.42e-20	6.35e-15	1.06	0.83	Response to antipsychotic treatment;	chr6:85522992	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.629	rs6927475	ENSG00000203875.9	SNHG5	12.87	2.42e-20	6.35e-15	1.06	0.83	Response to antipsychotic treatment;	chr6:85497055	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.629	rs9450285	ENSG00000203875.9	SNHG5	12.87	2.42e-20	6.35e-15	1.06	0.83	Response to antipsychotic treatment;	chr6:85498378	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.655	rs12203963	ENSG00000203875.9	SNHG5	12.87	2.42e-20	6.35e-15	1.06	0.83	Response to antipsychotic treatment;	chr6:85513598	chr6:85660950~85678736:-
LAML	cis	rs11098499	0.954	rs4309825	ENSG00000248280.1	RP11-33B1.2	-12.71	4.45e-20	1.07e-14	-1.27	-0.83	Corneal astigmatism;	chr4:119393726	chr4:119440561~119450157:-
LAML	cis	rs916888	0.773	rs199448	ENSG00000261575.2	RP11-259G18.1	12.61	6.76e-20	1.59e-14	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46267037~46268694:+
LAML	cis	rs916888	0.773	rs199445	ENSG00000261575.2	RP11-259G18.1	12.61	6.76e-20	1.59e-14	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46267037~46268694:+
LAML	cis	rs916888	0.773	rs199443	ENSG00000261575.2	RP11-259G18.1	12.61	6.76e-20	1.59e-14	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46267037~46268694:+
LAML	cis	rs916888	0.773	rs199534	ENSG00000261575.2	RP11-259G18.1	12.61	6.76e-20	1.59e-14	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46267037~46268694:+
LAML	cis	rs916888	0.773	rs199533	ENSG00000261575.2	RP11-259G18.1	12.61	6.76e-20	1.59e-14	1.21	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46267037~46268694:+
LAML	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-12.58	7.46e-20	1.71e-14	-1.15	-0.83	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-12.58	7.46e-20	1.71e-14	-1.15	-0.83	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
LAML	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-12.58	7.46e-20	1.71e-14	-1.15	-0.83	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
LAML	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-12.58	7.46e-20	1.71e-14	-1.15	-0.83	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
LAML	cis	rs916888	0.821	rs415430	ENSG00000262539.1	RP11-259G18.3	-12.58	7.5e-20	1.71e-14	-1.28	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46259551~46260606:-
LAML	cis	rs916888	0.779	rs430685	ENSG00000262539.1	RP11-259G18.3	-12.58	7.5e-20	1.71e-14	-1.28	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46259551~46260606:-
LAML	cis	rs916888	0.773	rs199447	ENSG00000261575.2	RP11-259G18.1	12.54	8.94e-20	1.99e-14	1.23	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46267037~46268694:+
LAML	cis	rs916888	0.773	rs199535	ENSG00000261575.2	RP11-259G18.1	12.53	9.22e-20	2.04e-14	1.22	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46267037~46268694:+
LAML	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-12.51	9.84e-20	2.14e-14	-1.14	-0.83	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-12.51	9.84e-20	2.14e-14	-1.14	-0.83	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
LAML	cis	rs1577917	0.561	rs3087978	ENSG00000203875.9	SNHG5	12.5	1.04e-19	2.19e-14	1.01	0.83	Response to antipsychotic treatment;	chr6:85678505	chr6:85660950~85678736:-
LAML	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	12.48	1.12e-19	2.19e-14	1.04	0.83	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
LAML	cis	rs1577917	0.56	rs12193777	ENSG00000203875.9	SNHG5	12.47	1.16e-19	2.19e-14	1.01	0.83	Response to antipsychotic treatment;	chr6:85536991	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.655	rs9444351	ENSG00000203875.9	SNHG5	12.47	1.16e-19	2.19e-14	1.01	0.83	Response to antipsychotic treatment;	chr6:85538081	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.655	rs7766485	ENSG00000203875.9	SNHG5	12.47	1.16e-19	2.19e-14	1.01	0.83	Response to antipsychotic treatment;	chr6:85553837	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.61	rs11752795	ENSG00000203875.9	SNHG5	12.47	1.16e-19	2.19e-14	1.01	0.83	Response to antipsychotic treatment;	chr6:85577411	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.655	rs9444354	ENSG00000203875.9	SNHG5	12.47	1.16e-19	2.19e-14	1.01	0.83	Response to antipsychotic treatment;	chr6:85582217	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.559	rs1173418	ENSG00000203875.9	SNHG5	12.47	1.16e-19	2.19e-14	1.01	0.83	Response to antipsychotic treatment;	chr6:85693198	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.566	rs2842611	ENSG00000203875.9	SNHG5	-12.47	1.16e-19	2.19e-14	-1.01	-0.83	Response to antipsychotic treatment;	chr6:85592316	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.655	rs2842605	ENSG00000203875.9	SNHG5	-12.47	1.16e-19	2.19e-14	-1.01	-0.83	Response to antipsychotic treatment;	chr6:85625432	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.655	rs2758849	ENSG00000203875.9	SNHG5	-12.47	1.16e-19	2.19e-14	-1.01	-0.83	Response to antipsychotic treatment;	chr6:85634578	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.655	rs2758848	ENSG00000203875.9	SNHG5	-12.47	1.16e-19	2.19e-14	-1.01	-0.83	Response to antipsychotic treatment;	chr6:85637887	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.681	rs4348284	ENSG00000203875.9	SNHG5	-12.47	1.16e-19	2.19e-14	-1.01	-0.83	Response to antipsychotic treatment;	chr6:85640676	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.727	rs9344539	ENSG00000203875.9	SNHG5	-12.47	1.16e-19	2.19e-14	-1.01	-0.83	Response to antipsychotic treatment;	chr6:85643903	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs9362232	ENSG00000203875.9	SNHG5	-12.47	1.16e-19	2.19e-14	-1.01	-0.83	Response to antipsychotic treatment;	chr6:85643904	chr6:85660950~85678736:-
LAML	cis	rs2739330	1	rs2739330	ENSG00000218537.1	MIF-AS1	12.47	1.16e-19	2.19e-14	1.13	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23953099	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.964	rs2739338	ENSG00000218537.1	MIF-AS1	12.47	1.16e-19	2.19e-14	1.13	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23954943	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.615	rs2858911	ENSG00000218537.1	MIF-AS1	12.47	1.16e-19	2.19e-14	1.13	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955008	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.576	rs2858912	ENSG00000218537.1	MIF-AS1	12.47	1.16e-19	2.19e-14	1.13	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23955010	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.828	rs5751770	ENSG00000273295.1	AP000350.5	12.45	1.27e-19	2.38e-14	1.11	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.796	rs5760097	ENSG00000273295.1	AP000350.5	12.42	1.43e-19	2.68e-14	1.12	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.828	rs2877178	ENSG00000273295.1	AP000350.5	12.4	1.55e-19	2.9e-14	1.11	0.83	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23901432~23907068:-
LAML	cis	rs916888	0.779	rs199528	ENSG00000261575.2	RP11-259G18.1	12.38	1.65e-19	3.04e-14	1.22	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46267037~46268694:+
LAML	cis	rs916888	0.821	rs199525	ENSG00000261575.2	RP11-259G18.1	12.38	1.65e-19	3.04e-14	1.22	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46267037~46268694:+
LAML	cis	rs2739330	0.828	rs2154593	ENSG00000273295.1	AP000350.5	12.36	1.82e-19	3.33e-14	1.11	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.828	rs5760108	ENSG00000273295.1	AP000350.5	12.36	1.82e-19	3.33e-14	1.11	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23901432~23907068:-
LAML	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-12.35	1.88e-19	3.43e-14	-1.14	-0.82	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
LAML	cis	rs916888	0.773	rs9896243	ENSG00000261575.2	RP11-259G18.1	12.33	2.06e-19	3.75e-14	1.2	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46267037~46268694:+
LAML	cis	rs2739330	0.828	rs4822451	ENSG00000273295.1	AP000350.5	12.31	2.16e-19	3.9e-14	1.12	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.828	rs5760098	ENSG00000273295.1	AP000350.5	12.31	2.16e-19	3.9e-14	1.12	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.828	rs5760099	ENSG00000273295.1	AP000350.5	12.31	2.16e-19	3.9e-14	1.12	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23901432~23907068:-
LAML	cis	rs916888	0.738	rs199515	ENSG00000262500.1	RP11-259G18.2	-12.3	2.3e-19	4.12e-14	-1.37	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46243606~46245044:+
LAML	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	12.27	2.62e-19	4.67e-14	0.99	0.82	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
LAML	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-12.25	2.78e-19	4.9e-14	-1.11	-0.82	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	12.25	2.78e-19	4.9e-14	1.11	0.82	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
LAML	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-12.24	2.87e-19	4.95e-14	-1.1	-0.82	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
LAML	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-12.24	2.87e-19	4.95e-14	-1.1	-0.82	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
LAML	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-12.24	2.87e-19	4.95e-14	-1.1	-0.82	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	12.24	2.87e-19	4.95e-14	1.1	0.82	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	12.24	2.87e-19	4.95e-14	1.1	0.82	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	12.24	2.87e-19	4.95e-14	1.1	0.82	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
LAML	cis	rs11098499	0.909	rs10026736	ENSG00000248280.1	RP11-33B1.2	12.22	3.09e-19	5.26e-14	1.19	0.82	Corneal astigmatism;	chr4:119463167	chr4:119440561~119450157:-
LAML	cis	rs1577917	0.655	rs2842600	ENSG00000203875.9	SNHG5	-12.21	3.24e-19	5.48e-14	-1.01	-0.82	Response to antipsychotic treatment;	chr6:85615914	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.655	rs6454472	ENSG00000203875.9	SNHG5	12.2	3.36e-19	5.65e-14	1.04	0.82	Response to antipsychotic treatment;	chr6:85514335	chr6:85660950~85678736:-
LAML	cis	rs916888	0.773	rs199451	ENSG00000261575.2	RP11-259G18.1	12.18	3.68e-19	6.17e-14	1.21	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46267037~46268694:+
LAML	cis	rs11098499	0.954	rs1022145	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119309824	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs11722872	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119311875	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs1546502	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119314743	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs878373	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119316329	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs1546504	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119320024	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs1546505	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119320069	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10006877	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119321638	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs12505469	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119328430	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.908	rs2017057	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119336556	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.908	rs1002152	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119352232	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10017371	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119372621	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.908	rs7696649	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119401022	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs3890049	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119405128	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs67265404	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119438115	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs9759478	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119446843	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs71629403	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119451412	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs28571712	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119454825	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs9994730	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119460409	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs11098526	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119469204	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs12499324	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119472631	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs1480931	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119474654	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs9998585	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119475647	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs6842762	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119477081	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.908	rs11098527	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119478751	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10518328	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119480624	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs6848389	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119481467	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs6822679	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119481547	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs4577559	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119482888	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs7656252	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119483113	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs28845498	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119484031	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs28753180	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119484212	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs56270433	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119484875	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10006525	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119487776	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10006706	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119487997	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs7681544	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119490100	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs17005535	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119490407	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs11940028	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119490752	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs11935596	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119491302	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs12507964	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119491906	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs11098530	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119491999	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs6834796	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119493538	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs11729521	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119495633	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs11734241	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119495717	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs17006190	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119497683	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs28685688	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119499179	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs7687843	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119500056	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs2306455	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119500814	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10031483	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119501481	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10031665	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119501697	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs3733519	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119502293	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs3733523	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119502564	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs12510138	ENSG00000248280.1	RP11-33B1.2	12.1	5.02e-19	6.74e-14	1.18	0.82	Corneal astigmatism;	chr4:119502780	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs6849561	ENSG00000248280.1	RP11-33B1.2	-12.1	5.02e-19	6.74e-14	-1.18	-0.82	Corneal astigmatism;	chr4:119488539	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs11722183	ENSG00000248280.1	RP11-33B1.2	12.09	5.3e-19	7.01e-14	1.17	0.82	Corneal astigmatism;	chr4:119359442	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.618	rs35265692	ENSG00000248280.1	RP11-33B1.2	12.09	5.3e-19	7.01e-14	1.17	0.82	Corneal astigmatism;	chr4:119403980	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs6849171	ENSG00000248280.1	RP11-33B1.2	12.09	5.3e-19	7.01e-14	1.17	0.82	Corneal astigmatism;	chr4:119488394	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs3733520	ENSG00000248280.1	RP11-33B1.2	12.09	5.3e-19	7.01e-14	1.17	0.82	Corneal astigmatism;	chr4:119502325	chr4:119440561~119450157:-
LAML	cis	rs916888	0.773	rs199457	ENSG00000261575.2	RP11-259G18.1	12.05	6.14e-19	8.03e-14	1.21	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46267037~46268694:+
LAML	cis	rs916888	0.687	rs199456	ENSG00000261575.2	RP11-259G18.1	12.05	6.14e-19	8.03e-14	1.21	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46267037~46268694:+
LAML	cis	rs11098499	0.954	rs12502423	ENSG00000248280.1	RP11-33B1.2	12.03	6.61e-19	8.61e-14	1.19	0.82	Corneal astigmatism;	chr4:119503017	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.779	rs7699346	ENSG00000248280.1	RP11-33B1.2	12.03	6.72e-19	8.74e-14	1.21	0.82	Corneal astigmatism;	chr4:119389387	chr4:119440561~119450157:-
LAML	cis	rs2739330	0.753	rs4822452	ENSG00000273295.1	AP000350.5	12.01	7.24e-19	9.35e-14	1.11	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23901432~23907068:-
LAML	cis	rs916888	0.821	rs199506	ENSG00000261575.2	RP11-259G18.1	-12	7.5e-19	9.63e-14	-1.19	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46267037~46268694:+
LAML	cis	rs2739330	0.752	rs2330634	ENSG00000273295.1	AP000350.5	11.99	7.86e-19	1.01e-13	1.08	0.82	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23901432~23907068:-
LAML	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-11.91	1.09e-18	1.2e-13	-1.14	-0.81	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
LAML	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	11.9	1.13e-18	1.2e-13	1.14	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
LAML	cis	rs11098499	0.909	rs11723839	ENSG00000248280.1	RP11-33B1.2	11.89	1.18e-18	1.2e-13	1.22	0.81	Corneal astigmatism;	chr4:119378518	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs12506546	ENSG00000248280.1	RP11-33B1.2	11.89	1.18e-18	1.2e-13	1.22	0.81	Corneal astigmatism;	chr4:119380463	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs1155576	ENSG00000248280.1	RP11-33B1.2	11.88	1.24e-18	1.2e-13	1.13	0.81	Corneal astigmatism;	chr4:119529004	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs6858592	ENSG00000248280.1	RP11-33B1.2	11.88	1.24e-18	1.2e-13	1.13	0.81	Corneal astigmatism;	chr4:119537537	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs9997631	ENSG00000248280.1	RP11-33B1.2	11.88	1.24e-18	1.2e-13	1.13	0.81	Corneal astigmatism;	chr4:119548840	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs10018280	ENSG00000248280.1	RP11-33B1.2	11.88	1.24e-18	1.2e-13	1.13	0.81	Corneal astigmatism;	chr4:119556984	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs6534141	ENSG00000248280.1	RP11-33B1.2	11.88	1.24e-18	1.2e-13	1.13	0.81	Corneal astigmatism;	chr4:119564068	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs2127823	ENSG00000248280.1	RP11-33B1.2	11.88	1.24e-18	1.2e-13	1.13	0.81	Corneal astigmatism;	chr4:119564515	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3775858	ENSG00000248280.1	RP11-33B1.2	11.88	1.24e-18	1.2e-13	1.13	0.81	Corneal astigmatism;	chr4:119564873	chr4:119440561~119450157:-
LAML	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	11.88	1.25e-18	1.2e-13	1.17	0.81	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.954	rs9993199	ENSG00000248280.1	RP11-33B1.2	-11.87	1.31e-18	1.2e-13	-1.18	-0.81	Corneal astigmatism;	chr4:119471718	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs13145352	ENSG00000248280.1	RP11-33B1.2	-11.87	1.31e-18	1.2e-13	-1.18	-0.81	Corneal astigmatism;	chr4:119488808	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs12508173	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119397371	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.908	rs12504149	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119397422	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10008392	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119397684	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.58	rs12509234	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119398279	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs10014719	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119399560	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10017543	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119400265	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.908	rs7695996	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119400878	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10518331	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119402440	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs13133522	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119403269	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs35091806	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119404374	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs35165976	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119404475	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs6846442	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119405168	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs71614422	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119438185	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.738	rs34566984	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119440115	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.738	rs34965784	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119440431	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs17009122	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119441248	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.505	rs75122014	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119441271	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs9685777	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119444810	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs71614438	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119450097	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs66506550	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119450290	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs7659501	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119450397	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.697	rs28655325	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119451844	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.779	rs80242894	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119454597	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.779	rs28495013	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119454676	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.657	rs71614442	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119458191	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs2892848	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119460186	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.697	rs11941899	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119461603	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs7681978	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119462620	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.821	rs28665282	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119463031	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.738	rs10026493	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119463039	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs7681214	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119464165	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.908	rs28559989	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119465472	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs28632018	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119465575	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.908	rs71614449	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119465900	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs35063680	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119465947	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs34858317	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119465955	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs17046116	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119466104	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs17046118	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119466341	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs7654587	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119467251	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs11098525	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119468997	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.821	rs10032151	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119470473	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs10032158	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119470477	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs6838814	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119471288	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs7436506	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119472614	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10008459	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119473076	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs2127821	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119473380	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs12508504	ENSG00000248280.1	RP11-33B1.2	11.87	1.31e-18	1.2e-13	1.18	0.81	Corneal astigmatism;	chr4:119489452	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs10020034	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119373176	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.618	rs28491261	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119373745	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs59394118	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119374396	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs9996417	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119374707	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs59866101	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119375436	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.618	rs6858383	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119375617	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.697	rs6832410	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119375645	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs1112817	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119376645	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.779	rs10016060	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119377257	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10005644	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119377322	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.697	rs10016448	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119377690	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.657	rs9996569	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119377849	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs11723757	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119378514	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.908	rs11729050	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119378911	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs28429722	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119378938	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10014845	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119379922	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.779	rs7674500	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119382438	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs28884220	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119386056	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs28793658	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119386059	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs4507344	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119386330	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.697	rs4373140	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119386543	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs13113483	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119387884	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.542	rs10440343	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119388632	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs28668716	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119388720	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.779	rs10011097	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119389204	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.542	rs7677836	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119389483	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs10002083	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119389997	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10024844	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119390373	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs7437420	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119391748	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs4345162	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119391804	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.657	rs4463052	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119392103	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.697	rs4560394	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119392280	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs13151285	ENSG00000248280.1	RP11-33B1.2	11.85	1.41e-18	1.2e-13	1.21	0.81	Corneal astigmatism;	chr4:119393586	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs2389802	ENSG00000248280.1	RP11-33B1.2	11.83	1.49e-18	1.27e-13	1.18	0.81	Corneal astigmatism;	chr4:119404577	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs28634456	ENSG00000248280.1	RP11-33B1.2	11.74	2.21e-18	1.84e-13	1.18	0.81	Corneal astigmatism;	chr4:119454623	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs78332141	ENSG00000248280.1	RP11-33B1.2	11.74	2.21e-18	1.84e-13	1.18	0.81	Corneal astigmatism;	chr4:119454627	chr4:119440561~119450157:-
LAML	cis	rs916888	0.821	rs70600	ENSG00000261575.2	RP11-259G18.1	11.73	2.22e-18	1.85e-13	1.2	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46267037~46268694:+
LAML	cis	rs12931792	0.875	rs58175255	ENSG00000183604.13	SMG1P5	-11.71	2.49e-18	2.02e-13	-0.9	-0.81	Tonsillectomy;	chr16:30143969	chr16:30267553~30335374:-
LAML	cis	rs12931792	0.774	rs7204270	ENSG00000183604.13	SMG1P5	-11.71	2.49e-18	2.02e-13	-0.9	-0.81	Tonsillectomy;	chr16:30145642	chr16:30267553~30335374:-
LAML	cis	rs12931792	0.875	rs7199462	ENSG00000183604.13	SMG1P5	-11.71	2.49e-18	2.02e-13	-0.9	-0.81	Tonsillectomy;	chr16:30147436	chr16:30267553~30335374:-
LAML	cis	rs12931792	0.84	rs8050401	ENSG00000183604.13	SMG1P5	-11.71	2.49e-18	2.02e-13	-0.9	-0.81	Tonsillectomy;	chr16:30151836	chr16:30267553~30335374:-
LAML	cis	rs12931792	0.84	rs8049778	ENSG00000183604.13	SMG1P5	-11.71	2.49e-18	2.02e-13	-0.9	-0.81	Tonsillectomy;	chr16:30151845	chr16:30267553~30335374:-
LAML	cis	rs916888	0.773	rs199439	ENSG00000261575.2	RP11-259G18.1	11.67	2.88e-18	2.33e-13	1.2	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46267037~46268694:+
LAML	cis	rs1577917	0.655	rs9450311	ENSG00000203875.9	SNHG5	11.67	2.88e-18	2.33e-13	1	0.81	Response to antipsychotic treatment;	chr6:85666868	chr6:85660950~85678736:-
LAML	cis	rs916888	0.773	rs1378358	ENSG00000261575.2	RP11-259G18.1	11.66	2.97e-18	2.4e-13	1.2	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46267037~46268694:+
LAML	cis	rs916888	0.773	rs538628	ENSG00000261575.2	RP11-259G18.1	11.66	2.97e-18	2.4e-13	1.2	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46267037~46268694:+
LAML	cis	rs916888	0.773	rs169201	ENSG00000261575.2	RP11-259G18.1	11.66	2.97e-18	2.4e-13	1.2	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46267037~46268694:+
LAML	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	11.66	3.03e-18	2.44e-13	1.12	0.81	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
LAML	cis	rs2739330	0.791	rs9612520	ENSG00000273295.1	AP000350.5	11.64	3.31e-18	2.66e-13	1.14	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.627	rs9608219	ENSG00000273295.1	AP000350.5	11.64	3.31e-18	2.66e-13	1.14	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.752	rs2330634	ENSG00000225282.1	AP000350.6	11.62	3.59e-18	2.87e-13	0.98	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.828	rs4820572	ENSG00000273295.1	AP000350.5	11.6	3.81e-18	3.01e-13	1.09	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.796	rs5760106	ENSG00000273295.1	AP000350.5	-11.6	3.81e-18	3.01e-13	-1.09	-0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.828	rs2330635	ENSG00000273295.1	AP000350.5	11.6	3.81e-18	3.01e-13	1.09	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.828	rs5760107	ENSG00000273295.1	AP000350.5	11.6	3.81e-18	3.01e-13	1.09	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.789	rs5760109	ENSG00000273295.1	AP000350.5	11.6	3.81e-18	3.01e-13	1.09	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.796	rs2154594	ENSG00000273295.1	AP000350.5	-11.6	3.81e-18	3.01e-13	-1.09	-0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.828	rs2186366	ENSG00000273295.1	AP000350.5	-11.6	3.81e-18	3.01e-13	-1.09	-0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.828	rs4822454	ENSG00000273295.1	AP000350.5	11.6	3.81e-18	3.01e-13	1.09	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.796	rs5760097	ENSG00000225282.1	AP000350.6	11.6	3.82e-18	3.01e-13	1	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.828	rs5760102	ENSG00000273295.1	AP000350.5	11.59	3.98e-18	3.12e-13	1.12	0.81	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23901432~23907068:-
LAML	cis	rs1577917	0.655	rs9342045	ENSG00000203875.9	SNHG5	11.57	4.28e-18	3.35e-13	1.01	0.81	Response to antipsychotic treatment;	chr6:85715430	chr6:85660950~85678736:-
LAML	cis	rs916888	0.697	rs199516	ENSG00000261575.2	RP11-259G18.1	-11.56	4.52e-18	3.5e-13	-1.18	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46267037~46268694:+
LAML	cis	rs916888	0.821	rs199514	ENSG00000261575.2	RP11-259G18.1	-11.56	4.52e-18	3.5e-13	-1.18	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46267037~46268694:+
LAML	cis	rs916888	0.821	rs199513	ENSG00000261575.2	RP11-259G18.1	-11.56	4.52e-18	3.5e-13	-1.18	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46267037~46268694:+
LAML	cis	rs916888	0.821	rs199512	ENSG00000261575.2	RP11-259G18.1	-11.56	4.52e-18	3.5e-13	-1.18	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46267037~46268694:+
LAML	cis	rs916888	0.821	rs199509	ENSG00000261575.2	RP11-259G18.1	-11.56	4.52e-18	3.5e-13	-1.18	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46267037~46268694:+
LAML	cis	rs916888	0.821	rs199507	ENSG00000261575.2	RP11-259G18.1	-11.56	4.52e-18	3.5e-13	-1.18	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46267037~46268694:+
LAML	cis	rs916888	0.821	rs199505	ENSG00000261575.2	RP11-259G18.1	-11.56	4.52e-18	3.5e-13	-1.18	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46267037~46268694:+
LAML	cis	rs916888	0.821	rs70602	ENSG00000261575.2	RP11-259G18.1	-11.56	4.52e-18	3.5e-13	-1.18	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46267037~46268694:+
LAML	cis	rs916888	0.61	rs199454	ENSG00000262500.1	RP11-259G18.2	-11.54	4.9e-18	3.77e-13	-1.05	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46243606~46245044:+
LAML	cis	rs916888	0.61	rs199446	ENSG00000262500.1	RP11-259G18.2	-11.54	4.9e-18	3.77e-13	-1.05	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46243606~46245044:+
LAML	cis	rs916888	0.61	rs199536	ENSG00000262500.1	RP11-259G18.2	-11.54	4.9e-18	3.77e-13	-1.05	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46243606~46245044:+
LAML	cis	rs11098499	0.909	rs73842633	ENSG00000248280.1	RP11-33B1.2	11.52	5.35e-18	4.11e-13	1.17	0.81	Corneal astigmatism;	chr4:119454309	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.69	rs34818745	ENSG00000248280.1	RP11-33B1.2	11.51	5.52e-18	4.22e-13	1.13	0.8	Corneal astigmatism;	chr4:119335900	chr4:119440561~119450157:-
LAML	cis	rs2739330	0.796	rs5760097	ENSG00000218537.1	MIF-AS1	11.49	5.89e-18	4.5e-13	1.11	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905607	chr22:23894426~23898930:-
LAML	cis	rs11098499	0.863	rs17050695	ENSG00000248280.1	RP11-33B1.2	11.48	6.14e-18	4.68e-13	1.08	0.8	Corneal astigmatism;	chr4:119568372	chr4:119440561~119450157:-
LAML	cis	rs9457247	0.905	rs444210	ENSG00000265828.1	MIR3939	-11.48	6.16e-18	4.69e-13	-1.01	-0.8	Crohn's disease;	chr6:166976754	chr6:166997807~166997912:-
LAML	cis	rs11098499	0.863	rs10004484	ENSG00000248280.1	RP11-33B1.2	11.48	6.25e-18	4.75e-13	1.17	0.8	Corneal astigmatism;	chr4:119521273	chr4:119440561~119450157:-
LAML	cis	rs2739330	0.828	rs2877178	ENSG00000225282.1	AP000350.6	11.47	6.52e-18	4.95e-13	0.99	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23926900~23929574:+
LAML	cis	rs9457247	0.905	rs377232	ENSG00000265828.1	MIR3939	-11.47	6.53e-18	4.95e-13	-1	-0.8	Crohn's disease;	chr6:166996150	chr6:166997807~166997912:-
LAML	cis	rs2739330	0.828	rs2154593	ENSG00000225282.1	AP000350.6	11.46	6.76e-18	5.1e-13	0.99	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.828	rs5760108	ENSG00000225282.1	AP000350.6	11.46	6.76e-18	5.1e-13	0.99	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23926900~23929574:+
LAML	cis	rs9457247	0.756	rs2345572	ENSG00000265828.1	MIR3939	-11.46	6.86e-18	5.17e-13	-1	-0.8	Crohn's disease;	chr6:166989953	chr6:166997807~166997912:-
LAML	cis	rs2739330	0.828	rs5751770	ENSG00000225282.1	AP000350.6	11.44	7.26e-18	5.46e-13	0.99	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23926900~23929574:+
LAML	cis	rs9457247	1	rs400063	ENSG00000265828.1	MIR3939	-11.43	7.62e-18	5.7e-13	-1	-0.8	Crohn's disease;	chr6:166973104	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs439553	ENSG00000265828.1	MIR3939	-11.43	7.62e-18	5.7e-13	-1	-0.8	Crohn's disease;	chr6:166977724	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs408087	ENSG00000265828.1	MIR3939	-11.43	7.62e-18	5.7e-13	-1	-0.8	Crohn's disease;	chr6:166985464	chr6:166997807~166997912:-
LAML	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	11.43	7.82e-18	5.78e-13	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	11.43	7.82e-18	5.78e-13	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	11.43	7.82e-18	5.78e-13	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	11.43	7.82e-18	5.78e-13	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	11.43	7.82e-18	5.78e-13	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	11.43	7.82e-18	5.78e-13	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	11.43	7.82e-18	5.78e-13	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	11.43	7.82e-18	5.78e-13	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
LAML	cis	rs9457247	0.934	rs2345571	ENSG00000265828.1	MIR3939	-11.42	7.96e-18	5.86e-13	-1	-0.8	Crohn's disease;	chr6:166989912	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.756	rs1811123	ENSG00000265828.1	MIR3939	-11.42	7.96e-18	5.86e-13	-1	-0.8	Crohn's disease;	chr6:166989955	chr6:166997807~166997912:-
LAML	cis	rs2739330	0.828	rs4822451	ENSG00000225282.1	AP000350.6	11.41	8.43e-18	6.17e-13	0.99	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.828	rs5760098	ENSG00000225282.1	AP000350.6	11.41	8.43e-18	6.17e-13	0.99	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.828	rs5760099	ENSG00000225282.1	AP000350.6	11.41	8.43e-18	6.17e-13	0.99	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23926900~23929574:+
LAML	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	11.41	8.47e-18	6.19e-13	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	11.41	8.47e-18	6.19e-13	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
LAML	cis	rs9457247	0.967	rs433191	ENSG00000265828.1	MIR3939	-11.4	8.51e-18	6.19e-13	-1	-0.8	Crohn's disease;	chr6:166996174	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs364451	ENSG00000265828.1	MIR3939	-11.4	8.56e-18	6.19e-13	-1	-0.8	Crohn's disease;	chr6:166971268	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.935	rs427824	ENSG00000265828.1	MIR3939	-11.4	8.56e-18	6.19e-13	-1	-0.8	Crohn's disease;	chr6:166990430	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.935	rs9348211	ENSG00000265828.1	MIR3939	11.4	8.56e-18	6.19e-13	1	0.8	Crohn's disease;	chr6:166961685	chr6:166997807~166997912:-
LAML	cis	rs6920364	1	rs6920364	ENSG00000265828.1	MIR3939	11.4	8.56e-18	6.19e-13	1	0.8	Lung cancer;	chr6:166962978	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs2769352	ENSG00000265828.1	MIR3939	11.4	8.56e-18	6.19e-13	1	0.8	Crohn's disease;	chr6:166965131	chr6:166997807~166997912:-
LAML	cis	rs2739330	0.828	rs2877178	ENSG00000218537.1	MIF-AS1	11.4	8.65e-18	6.23e-13	1.09	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909330	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.828	rs5751770	ENSG00000218537.1	MIF-AS1	11.4	8.7e-18	6.23e-13	1.09	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910655	chr22:23894426~23898930:-
LAML	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	11.4	8.72e-18	6.23e-13	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
LAML	cis	rs3136516	0.503	rs17787966	ENSG00000271350.1	CTD-2384B9.1	11.39	9.08e-18	6.23e-13	0.84	0.8	Venous thromboembolism;	chr11:47048874	chr11:47041027~47041945:-
LAML	cis	rs9457247	1	rs2149090	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166959276	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs2149091	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166959298	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs2149092	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166959490	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs1819333	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166960059	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs2013815	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166960324	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs4710147	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166960751	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.935	rs2757046	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166960865	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs2757047	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166961001	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.935	rs1187530	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166963324	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.935	rs2757050	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166963677	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs1590257	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166964294	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs2769354	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166966283	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.846	rs2757052	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166966686	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs2769355	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166967005	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs2757054	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166967013	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs2015864	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166967988	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs1211447	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166968491	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs1187532	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166968532	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs448060	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166969134	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs365189	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166971057	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs376551	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166971435	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs386548	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166972045	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs402749	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166972616	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs385863	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166973127	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs397713	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166973226	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.905	rs453184	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166973916	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs436707	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166975355	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs377753	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166976008	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs430477	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166976363	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs443570	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166976437	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs376574	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166976468	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs439237	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166977904	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs9457247	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166978686	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs405553	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166981570	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.935	rs1794697	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166981922	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.902	rs34560498	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166982374	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs421214	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166983141	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs422094	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166983545	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs393558	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166984262	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs394522	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166984583	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs393727	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166985144	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs408040	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166985415	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs408918	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166985794	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs413232	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166987484	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs86755	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166989620	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs382009	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166989633	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs428805	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166989644	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.902	rs366938	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166990050	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.871	rs1811121	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166990051	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs385460	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166990400	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs385113	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166990483	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs932644	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166990699	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs10946198	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166990944	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs10946199	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166991004	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs1794694	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166991263	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs430293	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166991470	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs430097	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166991585	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs409356	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166991738	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs447042	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166991947	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs402191	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166992065	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs1794693	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166992182	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.935	rs401260	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166992400	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs422694	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166992586	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs422780	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166992721	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs400176	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166992750	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs422562	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166992830	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs415890	ENSG00000265828.1	MIR3939	11.37	9.88e-18	6.23e-13	0.99	0.8	Crohn's disease;	chr6:166993145	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs415842	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166993193	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs389956	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166993766	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs389946	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166993780	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs407515	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166994056	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs406095	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166995599	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.646	rs4710160	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166995753	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs388406	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166996074	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs430145	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166996881	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs425039	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166997039	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs376097	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166997390	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs424185	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166997419	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs400837	ENSG00000265828.1	MIR3939	-11.37	9.88e-18	6.23e-13	-0.99	-0.8	Crohn's disease;	chr6:166997520	chr6:166997807~166997912:-
LAML	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	11.37	9.96e-18	6.26e-13	1.01	0.8	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	11.37	9.96e-18	6.26e-13	1.01	0.8	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	11.37	9.96e-18	6.26e-13	1.01	0.8	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
LAML	cis	rs2739330	0.828	rs2154593	ENSG00000218537.1	MIF-AS1	11.35	1.06e-17	6.62e-13	1.09	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909898	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.828	rs5760108	ENSG00000218537.1	MIF-AS1	11.35	1.06e-17	6.62e-13	1.09	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910481	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.892	rs4822455	ENSG00000218537.1	MIF-AS1	11.35	1.07e-17	6.69e-13	1.05	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913109	chr22:23894426~23898930:-
LAML	cis	rs858239	0.601	rs6966776	ENSG00000230658.1	KLHL7-AS1	11.34	1.1e-17	6.8e-13	1.01	0.8	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23101228~23105703:-
LAML	cis	rs2739330	0.828	rs4822451	ENSG00000218537.1	MIF-AS1	11.33	1.15e-17	6.8e-13	1.1	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905979	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.828	rs5760098	ENSG00000218537.1	MIF-AS1	11.33	1.15e-17	6.8e-13	1.1	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906127	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.828	rs5760099	ENSG00000218537.1	MIF-AS1	11.33	1.15e-17	6.8e-13	1.1	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906227	chr22:23894426~23898930:-
LAML	cis	rs11098499	0.863	rs3822190	ENSG00000248280.1	RP11-33B1.2	11.26	1.54e-17	8.71e-13	1.17	0.8	Corneal astigmatism;	chr4:119506943	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3822191	ENSG00000248280.1	RP11-33B1.2	11.26	1.54e-17	8.71e-13	1.17	0.8	Corneal astigmatism;	chr4:119506946	chr4:119440561~119450157:-
LAML	cis	rs2739330	0.753	rs4822452	ENSG00000225282.1	AP000350.6	11.24	1.66e-17	9.4e-13	0.99	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23926900~23929574:+
LAML	cis	rs11098499	0.909	rs79026312	ENSG00000248280.1	RP11-33B1.2	11.24	1.7e-17	9.56e-13	1.19	0.8	Corneal astigmatism;	chr4:119519522	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs35111518	ENSG00000248280.1	RP11-33B1.2	11.24	1.7e-17	9.56e-13	1.19	0.8	Corneal astigmatism;	chr4:119519527	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs6857105	ENSG00000248280.1	RP11-33B1.2	11.23	1.72e-17	9.62e-13	1.16	0.8	Corneal astigmatism;	chr4:119301143	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs28714195	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119395795	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.738	rs72918577	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119405546	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs72676074	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119438686	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.738	rs28408407	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119454875	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs1809406	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119455967	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs2389809	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119456244	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs9994810	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119460435	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.697	rs10020027	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119460724	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.779	rs7356491	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119460819	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.908	rs28499576	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119465522	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs13107475	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119471856	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs10034623	ENSG00000248280.1	RP11-33B1.2	11.23	1.75e-17	9.62e-13	1.12	0.8	Corneal astigmatism;	chr4:119476674	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs2389803	ENSG00000248280.1	RP11-33B1.2	-11.23	1.75e-17	9.62e-13	-1.12	-0.8	Corneal astigmatism;	chr4:119472356	chr4:119440561~119450157:-
LAML	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-11.23	1.75e-17	9.62e-13	-1.08	-0.8	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
LAML	cis	rs9457247	0.646	rs239934	ENSG00000265828.1	MIR3939	-11.22	1.79e-17	9.83e-13	-1	-0.8	Crohn's disease;	chr6:166998560	chr6:166997807~166997912:-
LAML	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	11.21	1.88e-17	1.03e-12	0.99	0.8	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	11.21	1.92e-17	1.04e-12	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
LAML	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	11.21	1.92e-17	1.04e-12	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	11.21	1.92e-17	1.04e-12	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	11.21	1.92e-17	1.04e-12	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	11.21	1.92e-17	1.04e-12	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-11.21	1.92e-17	1.04e-12	-0.98	-0.8	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	11.21	1.92e-17	1.04e-12	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	11.21	1.92e-17	1.04e-12	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	11.21	1.92e-17	1.04e-12	0.98	0.8	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
LAML	cis	rs916888	0.531	rs183211	ENSG00000262500.1	RP11-259G18.2	11.2	2.01e-17	1.09e-12	1.03	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46243606~46245044:+
LAML	cis	rs916888	0.61	rs199438	ENSG00000262500.1	RP11-259G18.2	11.2	2.01e-17	1.09e-12	1.03	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46243606~46245044:+
LAML	cis	rs858239	0.6	rs13438188	ENSG00000230658.1	KLHL7-AS1	-11.19	2.08e-17	1.12e-12	-1.1	-0.8	Cerebrospinal fluid biomarker levels;	chr7:23104578	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	11.18	2.12e-17	1.14e-12	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	11.18	2.12e-17	1.14e-12	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	11.18	2.12e-17	1.14e-12	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	11.18	2.12e-17	1.14e-12	1	0.8	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	11.16	2.31e-17	1.19e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	11.16	2.31e-17	1.19e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	11.16	2.31e-17	1.19e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	11.16	2.31e-17	1.19e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	11.16	2.31e-17	1.19e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	11.16	2.31e-17	1.19e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	11.16	2.31e-17	1.19e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
LAML	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	11.16	2.31e-17	1.19e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
LAML	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	11.16	2.31e-17	1.19e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	11.16	2.31e-17	1.19e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
LAML	cis	rs9457247	1	rs416131	ENSG00000265828.1	MIR3939	11.16	2.33e-17	1.19e-12	0.99	0.8	Crohn's disease;	chr6:166993056	chr6:166997807~166997912:-
LAML	cis	rs11098499	0.863	rs13134665	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119505275	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3775843	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119506689	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3775844	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119506878	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs7699064	ENSG00000248280.1	RP11-33B1.2	-11.15	2.4e-17	1.19e-12	-1.16	-0.8	Corneal astigmatism;	chr4:119507154	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs7664986	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119508797	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.818	rs10008791	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119510314	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs11736416	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119510506	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3775845	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119511292	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs1383532	ENSG00000248280.1	RP11-33B1.2	-11.15	2.4e-17	1.19e-12	-1.16	-0.8	Corneal astigmatism;	chr4:119513249	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs1383533	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119513421	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs2291185	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119513678	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs10030660	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119515549	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs13149407	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119516670	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs34868248	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119521275	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3733525	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119525893	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3775847	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119526487	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3775848	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119526569	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs10013305	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119529269	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3775849	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119529753	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.818	rs7688802	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119530513	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs7695620	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119531621	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs12502389	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119533036	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.821	rs3775852	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119533401	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.82	rs6534140	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119534156	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs7657849	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119534339	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs10034450	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119534494	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs1480939	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119535772	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs1480940	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119536527	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.82	rs13128602	ENSG00000248280.1	RP11-33B1.2	-11.15	2.4e-17	1.19e-12	-1.16	-0.8	Corneal astigmatism;	chr4:119538211	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs58452170	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119538519	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs1552095	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119539151	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs7678400	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119540802	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs1480936	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119541706	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs1010740	ENSG00000248280.1	RP11-33B1.2	-11.15	2.4e-17	1.19e-12	-1.16	-0.8	Corneal astigmatism;	chr4:119542254	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs11098531	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119543846	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs28718422	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119545149	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs12498539	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119547215	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.818	rs12498599	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119547348	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs10009626	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119548850	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3822194	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119550493	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3822195	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119550505	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3775854	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119550816	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs2306456	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119551267	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs2306457	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119551684	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs11947234	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119553704	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs6853998	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119554705	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs6858777	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119554811	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs11933966	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119555560	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs36040693	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119556461	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs11731756	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119557541	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs34308924	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119560276	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs2170276	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119564669	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs1552092	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119567341	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs3736115	ENSG00000248280.1	RP11-33B1.2	-11.15	2.4e-17	1.19e-12	-1.16	-0.8	Corneal astigmatism;	chr4:119567548	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs59732491	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119568433	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs9884402	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119568827	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.731	rs9995026	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119569344	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs11723090	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119569437	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs11098532	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119569571	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs13140391	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119582282	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs13140409	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119582305	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs6833334	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119583072	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.82	rs6829903	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119585729	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs7669520	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119594123	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.82	rs11737395	ENSG00000248280.1	RP11-33B1.2	11.15	2.4e-17	1.19e-12	1.16	0.8	Corneal astigmatism;	chr4:119599549	chr4:119440561~119450157:-
LAML	cis	rs9457247	1	rs444988	ENSG00000265828.1	MIR3939	-11.15	2.43e-17	1.2e-12	-1.01	-0.8	Crohn's disease;	chr6:166976186	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs408080	ENSG00000265828.1	MIR3939	-11.15	2.43e-17	1.2e-12	-1.01	-0.8	Crohn's disease;	chr6:166979034	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs1794696	ENSG00000265828.1	MIR3939	-11.15	2.43e-17	1.2e-12	-1.01	-0.8	Crohn's disease;	chr6:166982686	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs404222	ENSG00000265828.1	MIR3939	-11.15	2.43e-17	1.2e-12	-1.01	-0.8	Crohn's disease;	chr6:166988662	chr6:166997807~166997912:-
LAML	cis	rs916888	0.61	rs199452	ENSG00000262500.1	RP11-259G18.2	11.14	2.5e-17	1.23e-12	1.03	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46243606~46245044:+
LAML	cis	rs916888	0.647	rs199449	ENSG00000262500.1	RP11-259G18.2	11.14	2.5e-17	1.23e-12	1.03	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46243606~46245044:+
LAML	cis	rs916888	0.61	rs199444	ENSG00000262500.1	RP11-259G18.2	11.14	2.5e-17	1.23e-12	1.03	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46243606~46245044:+
LAML	cis	rs916888	0.61	rs199442	ENSG00000262500.1	RP11-259G18.2	11.14	2.5e-17	1.23e-12	1.03	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46243606~46245044:+
LAML	cis	rs916888	0.61	rs199436	ENSG00000262500.1	RP11-259G18.2	-11.14	2.5e-17	1.23e-12	-1.03	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46243606~46245044:+
LAML	cis	rs916888	0.61	rs142167	ENSG00000262500.1	RP11-259G18.2	-11.14	2.5e-17	1.23e-12	-1.03	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46243606~46245044:+
LAML	cis	rs2739330	0.796	rs5760106	ENSG00000225282.1	AP000350.6	-11.13	2.65e-17	1.29e-12	-0.98	-0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.796	rs2154594	ENSG00000225282.1	AP000350.6	-11.13	2.65e-17	1.29e-12	-0.98	-0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.828	rs2186366	ENSG00000225282.1	AP000350.6	-11.13	2.65e-17	1.29e-12	-0.98	-0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.828	rs4820572	ENSG00000225282.1	AP000350.6	11.13	2.65e-17	1.29e-12	0.98	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.828	rs2330635	ENSG00000225282.1	AP000350.6	11.13	2.65e-17	1.29e-12	0.98	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.828	rs5760107	ENSG00000225282.1	AP000350.6	11.13	2.65e-17	1.29e-12	0.98	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.789	rs5760109	ENSG00000225282.1	AP000350.6	11.13	2.65e-17	1.29e-12	0.98	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.828	rs4822454	ENSG00000225282.1	AP000350.6	11.13	2.65e-17	1.29e-12	0.98	0.8	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23926900~23929574:+
LAML	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	11.13	2.67e-17	1.3e-12	0.97	0.8	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
LAML	cis	rs9457247	1	rs364283	ENSG00000265828.1	MIR3939	-11.11	2.84e-17	1.38e-12	-1.01	-0.79	Crohn's disease;	chr6:166970262	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs429083	ENSG00000265828.1	MIR3939	-11.11	2.84e-17	1.38e-12	-1.01	-0.79	Crohn's disease;	chr6:166970484	chr6:166997807~166997912:-
LAML	cis	rs11098499	0.908	rs9995234	ENSG00000248280.1	RP11-33B1.2	11.11	2.91e-17	1.41e-12	1.16	0.79	Corneal astigmatism;	chr4:119400672	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs3733524	ENSG00000248280.1	RP11-33B1.2	11.11	2.91e-17	1.41e-12	1.16	0.79	Corneal astigmatism;	chr4:119502574	chr4:119440561~119450157:-
LAML	cis	rs2739330	0.828	rs5760102	ENSG00000225282.1	AP000350.6	11.1	2.98e-17	1.44e-12	1.01	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23926900~23929574:+
LAML	cis	rs561341	1	rs501957	ENSG00000266379.5	RP11-640N20.8	11.08	3.2e-17	1.54e-12	1.41	0.79	Hip circumference adjusted for BMI;	chr17:31987485	chr17:32088160~32094933:-
LAML	cis	rs2739330	0.828	rs5760102	ENSG00000218537.1	MIF-AS1	11.08	3.21e-17	1.54e-12	1.12	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23906574	chr22:23894426~23898930:-
LAML	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	11.07	3.32e-17	1.6e-12	1	0.79	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	11.07	3.35e-17	1.61e-12	1.01	0.79	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	11.07	3.35e-17	1.61e-12	1.01	0.79	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
LAML	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	11.06	3.45e-17	1.65e-12	1.07	0.79	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
LAML	cis	rs2739330	0.753	rs4822452	ENSG00000218537.1	MIF-AS1	11.01	4.41e-17	2.1e-12	1.09	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912176	chr22:23894426~23898930:-
LAML	cis	rs9457247	0.935	rs2149093	ENSG00000265828.1	MIR3939	11	4.42e-17	2.1e-12	1	0.79	Crohn's disease;	chr6:166959557	chr6:166997807~166997912:-
LAML	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	11	4.53e-17	2.15e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	11	4.53e-17	2.15e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
LAML	cis	rs8013143	1	rs8013143	ENSG00000279656.1	RP11-298I3.6	-10.99	4.65e-17	2.19e-12	-1.08	-0.79	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025068	chr14:23023083~23024217:-
LAML	cis	rs8013143	1	rs941718	ENSG00000279656.1	RP11-298I3.6	-10.99	4.65e-17	2.19e-12	-1.08	-0.79	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23025839	chr14:23023083~23024217:-
LAML	cis	rs8013143	0.961	rs7147308	ENSG00000279656.1	RP11-298I3.6	-10.99	4.65e-17	2.19e-12	-1.08	-0.79	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23028420	chr14:23023083~23024217:-
LAML	cis	rs113525195	1	rs113525195	ENSG00000279656.1	RP11-298I3.6	-10.99	4.65e-17	2.19e-12	-1.08	-0.79	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin;	chr14:23030112	chr14:23023083~23024217:-
LAML	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-10.97	5.04e-17	2.37e-12	-0.97	-0.79	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.954	rs28572238	ENSG00000248280.1	RP11-33B1.2	10.96	5.41e-17	2.49e-12	1.15	0.79	Corneal astigmatism;	chr4:119395531	chr4:119440561~119450157:-
LAML	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	10.95	5.57e-17	2.56e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	10.95	5.57e-17	2.56e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
LAML	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	10.94	5.73e-17	2.63e-12	0.91	0.79	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
LAML	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	10.93	6.07e-17	2.78e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	10.93	6.07e-17	2.78e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
LAML	cis	rs916888	0.821	rs415430	ENSG00000261575.2	RP11-259G18.1	-10.86	8.05e-17	3.63e-12	-1.19	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46267037~46268694:+
LAML	cis	rs916888	0.779	rs430685	ENSG00000261575.2	RP11-259G18.1	-10.86	8.05e-17	3.63e-12	-1.19	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46267037~46268694:+
LAML	cis	rs12922317	0.556	rs11648938	ENSG00000260224.1	UBL5P4	10.86	8.17e-17	3.68e-12	0.85	0.79	Schizophrenia;	chr16:12000292	chr16:11968508~11968743:-
LAML	cis	rs11098499	0.866	rs12374244	ENSG00000248280.1	RP11-33B1.2	10.85	8.52e-17	3.83e-12	1.1	0.79	Corneal astigmatism;	chr4:119360817	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs12374352	ENSG00000248280.1	RP11-33B1.2	10.85	8.52e-17	3.83e-12	1.1	0.79	Corneal astigmatism;	chr4:119360822	chr4:119440561~119450157:-
LAML	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-10.83	9.08e-17	4.07e-12	-0.99	-0.79	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
LAML	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	10.83	9.26e-17	4.09e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	10.83	9.26e-17	4.09e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	10.82	9.39e-17	4.09e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	10.82	9.39e-17	4.09e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	10.82	9.39e-17	4.09e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	10.82	9.39e-17	4.09e-12	0.99	0.79	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.687	rs71610270	ENSG00000248280.1	RP11-33B1.2	10.81	9.9e-17	4.3e-12	1.06	0.79	Corneal astigmatism;	chr4:119366281	chr4:119440561~119450157:-
LAML	cis	rs8013143	1	rs11846575	ENSG00000279656.1	RP11-298I3.6	-10.8	1.03e-16	4.46e-12	-1.16	-0.79	Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width;	chr14:23022075	chr14:23023083~23024217:-
LAML	cis	rs11098499	0.863	rs3775841	ENSG00000248280.1	RP11-33B1.2	10.79	1.07e-16	4.61e-12	1.12	0.79	Corneal astigmatism;	chr4:119504622	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs6835635	ENSG00000248280.1	RP11-33B1.2	10.78	1.12e-16	4.82e-12	1.14	0.79	Corneal astigmatism;	chr4:119537712	chr4:119440561~119450157:-
LAML	cis	rs2739330	0.791	rs9612520	ENSG00000225282.1	AP000350.6	10.77	1.16e-16	4.99e-12	1.01	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.627	rs9608219	ENSG00000225282.1	AP000350.6	10.77	1.16e-16	4.99e-12	1.01	0.79	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23926900~23929574:+
LAML	cis	rs11098499	0.738	rs28687057	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119359657	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.775	rs67281037	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119360002	chr4:119440561~119450157:-
LAML	cis	rs10028773	0.506	rs12374346	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Educational attainment;	chr4:119360550	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.775	rs10021601	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119361408	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs6857892	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119361541	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs28581362	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119362393	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.82	rs12503082	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119363162	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs12499602	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119363232	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.774	rs11098505	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119363472	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs11098506	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119363816	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs13105020	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119364533	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs6824111	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119364813	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.779	rs10857066	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119365441	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.775	rs10029303	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119365600	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs9995136	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119365690	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs13125526	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119366864	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs12513310	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119366884	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.564	rs11098507	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119367131	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs12510451	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119367988	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.774	rs73842616	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119369528	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.645	rs72676059	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119369673	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.569	rs55845118	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119369758	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs7677068	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119370549	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs9991221	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119370952	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.731	rs6846966	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119372053	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs6847778	ENSG00000248280.1	RP11-33B1.2	10.76	1.21e-16	5.03e-12	1.06	0.79	Corneal astigmatism;	chr4:119372427	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs11098513	ENSG00000248280.1	RP11-33B1.2	10.74	1.33e-16	5.53e-12	1.15	0.78	Corneal astigmatism;	chr4:119394920	chr4:119440561~119450157:-
LAML	cis	rs561341	0.714	rs473535	ENSG00000266379.5	RP11-640N20.8	10.73	1.36e-16	5.63e-12	1.46	0.78	Hip circumference adjusted for BMI;	chr17:31985346	chr17:32088160~32094933:-
LAML	cis	rs2739330	0.796	rs5760106	ENSG00000218537.1	MIF-AS1	-10.73	1.36e-16	5.63e-12	-1.07	-0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908458	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.796	rs2154594	ENSG00000218537.1	MIF-AS1	-10.73	1.36e-16	5.63e-12	-1.07	-0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911868	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.828	rs2186366	ENSG00000218537.1	MIF-AS1	-10.73	1.36e-16	5.63e-12	-1.07	-0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23911926	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.828	rs4820572	ENSG00000218537.1	MIF-AS1	10.73	1.36e-16	5.63e-12	1.07	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908168	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.828	rs2330635	ENSG00000218537.1	MIF-AS1	10.73	1.36e-16	5.63e-12	1.07	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23909157	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.828	rs5760107	ENSG00000218537.1	MIF-AS1	10.73	1.36e-16	5.63e-12	1.07	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910410	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.789	rs5760109	ENSG00000218537.1	MIF-AS1	10.73	1.36e-16	5.63e-12	1.07	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23910751	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.828	rs4822454	ENSG00000218537.1	MIF-AS1	10.73	1.36e-16	5.63e-12	1.07	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23913021	chr22:23894426~23898930:-
LAML	cis	rs11098499	1	rs13116504	ENSG00000248280.1	RP11-33B1.2	10.73	1.37e-16	5.64e-12	1.11	0.78	Corneal astigmatism;	chr4:119288257	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.909	rs28555550	ENSG00000248280.1	RP11-33B1.2	10.73	1.37e-16	5.64e-12	1.11	0.78	Corneal astigmatism;	chr4:119289885	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs28419773	ENSG00000248280.1	RP11-33B1.2	10.73	1.37e-16	5.64e-12	1.11	0.78	Corneal astigmatism;	chr4:119289906	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs11726229	ENSG00000248280.1	RP11-33B1.2	10.73	1.37e-16	5.64e-12	1.11	0.78	Corneal astigmatism;	chr4:119290425	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs11098500	ENSG00000248280.1	RP11-33B1.2	10.73	1.37e-16	5.64e-12	1.11	0.78	Corneal astigmatism;	chr4:119298084	chr4:119440561~119450157:-
LAML	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	10.72	1.45e-16	5.96e-12	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.865	rs4001305	ENSG00000248280.1	RP11-33B1.2	10.71	1.52e-16	6.23e-12	1.11	0.78	Corneal astigmatism;	chr4:119438081	chr4:119440561~119450157:-
LAML	cis	rs9457247	1	rs239935	ENSG00000265828.1	MIR3939	-10.7	1.54e-16	6.33e-12	-0.99	-0.78	Crohn's disease;	chr6:166998300	chr6:166997807~166997912:-
LAML	cis	rs1930961	1	rs760554	ENSG00000272977.1	CTA-390C10.10	-10.68	1.67e-16	6.84e-12	-1.22	-0.78	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25476218~25479971:+
LAML	cis	rs916888	0.61	rs199453	ENSG00000262500.1	RP11-259G18.2	10.68	1.73e-16	7.09e-12	1.01	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46243606~46245044:+
LAML	cis	rs916888	0.61	rs199454	ENSG00000262539.1	RP11-259G18.3	-10.67	1.74e-16	7.1e-12	-1.1	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46259551~46260606:-
LAML	cis	rs916888	0.61	rs199446	ENSG00000262539.1	RP11-259G18.3	-10.67	1.74e-16	7.1e-12	-1.1	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46259551~46260606:-
LAML	cis	rs916888	0.61	rs199536	ENSG00000262539.1	RP11-259G18.3	-10.67	1.74e-16	7.1e-12	-1.1	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46259551~46260606:-
LAML	cis	rs11098499	0.954	rs6847248	ENSG00000248280.1	RP11-33B1.2	10.67	1.74e-16	7.11e-12	1.14	0.78	Corneal astigmatism;	chr4:119304800	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs1010739	ENSG00000248280.1	RP11-33B1.2	10.67	1.8e-16	7.22e-12	1.18	0.78	Corneal astigmatism;	chr4:119542316	chr4:119440561~119450157:-
LAML	cis	rs12922317	0.681	rs2869492	ENSG00000260224.1	UBL5P4	10.66	1.82e-16	7.33e-12	0.89	0.78	Schizophrenia;	chr16:11977484	chr16:11968508~11968743:-
LAML	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-10.66	1.84e-16	7.37e-12	-0.97	-0.78	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.909	rs10017335	ENSG00000248280.1	RP11-33B1.2	-10.65	1.96e-16	7.85e-12	-1.14	-0.78	Corneal astigmatism;	chr4:119460368	chr4:119440561~119450157:-
LAML	cis	rs916888	0.738	rs199515	ENSG00000262539.1	RP11-259G18.3	-10.64	2.04e-16	8.15e-12	-1.41	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46259551~46260606:-
LAML	cis	rs11098499	0.78	rs10013652	ENSG00000248280.1	RP11-33B1.2	10.64	2.04e-16	8.15e-12	1.05	0.78	Corneal astigmatism;	chr4:119371101	chr4:119440561~119450157:-
LAML	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	10.63	2.14e-16	8.51e-12	1	0.78	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	10.63	2.14e-16	8.51e-12	1	0.78	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
LAML	cis	rs7847628	0.587	rs3793638	ENSG00000226752.6	PSMD5-AS1	-10.62	2.19e-16	8.71e-12	-0.95	-0.78	Birth weight;	chr9:120820419	chr9:120824828~120854385:+
LAML	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	10.62	2.21e-16	8.79e-12	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	10.59	2.52e-16	1e-11	1.05	0.78	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
LAML	cis	rs11098499	1	rs35643470	ENSG00000248280.1	RP11-33B1.2	10.58	2.58e-16	1.02e-11	1.1	0.78	Corneal astigmatism;	chr4:119263793	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs6849889	ENSG00000248280.1	RP11-33B1.2	10.58	2.58e-16	1.02e-11	1.1	0.78	Corneal astigmatism;	chr4:119265193	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs58601355	ENSG00000248280.1	RP11-33B1.2	10.58	2.58e-16	1.02e-11	1.1	0.78	Corneal astigmatism;	chr4:119265212	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs11098499	ENSG00000248280.1	RP11-33B1.2	10.58	2.58e-16	1.02e-11	1.1	0.78	Corneal astigmatism;	chr4:119266456	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs7659194	ENSG00000248280.1	RP11-33B1.2	10.58	2.58e-16	1.02e-11	1.1	0.78	Corneal astigmatism;	chr4:119285992	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.73	rs12505735	ENSG00000248280.1	RP11-33B1.2	10.58	2.61e-16	1.03e-11	1.18	0.78	Corneal astigmatism;	chr4:119611801	chr4:119440561~119450157:-
LAML	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	10.57	2.74e-16	1.08e-11	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	10.57	2.74e-16	1.08e-11	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	10.57	2.74e-16	1.08e-11	0.98	0.78	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
LAML	cis	rs561341	1	rs508192	ENSG00000266379.5	RP11-640N20.8	-10.54	3.02e-16	1.13e-11	-1.45	-0.78	Hip circumference adjusted for BMI;	chr17:31988128	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs72823787	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31956790	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs72823789	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31957065	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs113115092	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31957145	chr17:32088160~32094933:-
LAML	cis	rs561341	0.943	rs508566	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31962842	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs2470243	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31963936	chr17:32088160~32094933:-
LAML	cis	rs561341	0.783	rs512698	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31965488	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs483301	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31966379	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs555629	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31967117	chr17:32088160~32094933:-
LAML	cis	rs561341	0.769	rs559228	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31967508	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs1681718	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31969426	chr17:32088160~32094933:-
LAML	cis	rs561341	0.882	rs2428337	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31972448	chr17:32088160~32094933:-
LAML	cis	rs561341	0.882	rs2521594	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31975068	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs548957	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31975392	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs542132	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31980174	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs484175	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31982022	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs4525554	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31985800	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs530209	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31988268	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs72825712	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31989100	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs561341	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31989366	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs550264	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31990521	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs564714	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31991385	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs111454793	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31992248	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs527256	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31994274	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs473356	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31994743	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs576985	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31996304	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs510264	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31996395	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs15654	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31999341	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs550923	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:31999994	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs497479	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32001586	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs498391	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32001685	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs501312	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32002047	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs554078	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32003090	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs72825736	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32003267	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs8081016	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32004732	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs55736640	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32006829	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs72825740	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32011337	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs17780080	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32016127	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs17780086	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32016263	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs72825746	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32037591	chr17:32088160~32094933:-
LAML	cis	rs561341	0.882	rs72825748	ENSG00000266379.5	RP11-640N20.8	10.54	3.02e-16	1.13e-11	1.45	0.78	Hip circumference adjusted for BMI;	chr17:32040377	chr17:32088160~32094933:-
LAML	cis	rs916888	0.738	rs199515	ENSG00000261575.2	RP11-259G18.1	-10.53	3.13e-16	1.16e-11	-1.37	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46267037~46268694:+
LAML	cis	rs916888	0.773	rs199448	ENSG00000214401.4	KANSL1-AS1	10.53	3.24e-16	1.2e-11	1.11	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46193576~46196723:+
LAML	cis	rs916888	0.773	rs199445	ENSG00000214401.4	KANSL1-AS1	10.53	3.24e-16	1.2e-11	1.11	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46193576~46196723:+
LAML	cis	rs916888	0.773	rs199443	ENSG00000214401.4	KANSL1-AS1	10.53	3.24e-16	1.2e-11	1.11	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46193576~46196723:+
LAML	cis	rs916888	0.773	rs199534	ENSG00000214401.4	KANSL1-AS1	10.53	3.24e-16	1.2e-11	1.11	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46193576~46196723:+
LAML	cis	rs916888	0.773	rs199533	ENSG00000214401.4	KANSL1-AS1	10.53	3.24e-16	1.2e-11	1.11	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46193576~46196723:+
LAML	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	10.52	3.35e-16	1.24e-11	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
LAML	cis	rs561341	1	rs117029332	ENSG00000266379.5	RP11-640N20.8	10.47	4.08e-16	1.49e-11	1.44	0.78	Hip circumference adjusted for BMI;	chr17:31939066	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs72821971	ENSG00000266379.5	RP11-640N20.8	10.47	4.08e-16	1.49e-11	1.44	0.78	Hip circumference adjusted for BMI;	chr17:31942324	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs117979353	ENSG00000266379.5	RP11-640N20.8	10.47	4.08e-16	1.49e-11	1.44	0.78	Hip circumference adjusted for BMI;	chr17:31945847	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs72823785	ENSG00000266379.5	RP11-640N20.8	10.47	4.08e-16	1.49e-11	1.44	0.78	Hip circumference adjusted for BMI;	chr17:31946765	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs55978022	ENSG00000266379.5	RP11-640N20.8	10.47	4.08e-16	1.49e-11	1.44	0.78	Hip circumference adjusted for BMI;	chr17:31948918	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs560132	ENSG00000266379.5	RP11-640N20.8	10.47	4.08e-16	1.49e-11	1.44	0.78	Hip circumference adjusted for BMI;	chr17:31993000	chr17:32088160~32094933:-
LAML	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-10.47	4.16e-16	1.51e-11	-1.11	-0.78	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
LAML	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	10.46	4.34e-16	1.58e-11	0.97	0.78	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
LAML	cis	rs2739330	0.752	rs2330634	ENSG00000218537.1	MIF-AS1	10.46	4.34e-16	1.58e-11	1.04	0.78	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23908608	chr22:23894426~23898930:-
LAML	cis	rs11098499	0.69	rs7674713	ENSG00000248280.1	RP11-33B1.2	10.45	4.36e-16	1.59e-11	1.12	0.78	Corneal astigmatism;	chr4:119401102	chr4:119440561~119450157:-
LAML	cis	rs916888	0.773	rs199447	ENSG00000214401.4	KANSL1-AS1	10.45	4.47e-16	1.62e-11	1.12	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46193576~46196723:+
LAML	cis	rs916888	0.61	rs199436	ENSG00000262539.1	RP11-259G18.3	-10.45	4.52e-16	1.64e-11	-1.09	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46259551~46260606:-
LAML	cis	rs916888	0.61	rs142167	ENSG00000262539.1	RP11-259G18.3	-10.45	4.52e-16	1.64e-11	-1.09	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46259551~46260606:-
LAML	cis	rs916888	0.61	rs199452	ENSG00000262539.1	RP11-259G18.3	10.45	4.52e-16	1.64e-11	1.09	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46259551~46260606:-
LAML	cis	rs916888	0.647	rs199449	ENSG00000262539.1	RP11-259G18.3	10.45	4.52e-16	1.64e-11	1.09	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46259551~46260606:-
LAML	cis	rs916888	0.61	rs199444	ENSG00000262539.1	RP11-259G18.3	10.45	4.52e-16	1.64e-11	1.09	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46259551~46260606:-
LAML	cis	rs916888	0.61	rs199442	ENSG00000262539.1	RP11-259G18.3	10.45	4.52e-16	1.64e-11	1.09	0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46259551~46260606:-
LAML	cis	rs9457247	1	rs398278	ENSG00000265828.1	MIR3939	-10.42	4.98e-16	1.8e-11	-0.97	-0.78	Crohn's disease;	chr6:166974681	chr6:166997807~166997912:-
LAML	cis	rs3136516	0.537	rs2291444	ENSG00000271350.1	CTD-2384B9.1	10.4	5.45e-16	1.97e-11	0.84	0.77	Venous thromboembolism;	chr11:47157592	chr11:47041027~47041945:-
LAML	cis	rs3136516	0.537	rs2291443	ENSG00000271350.1	CTD-2384B9.1	10.4	5.45e-16	1.97e-11	0.84	0.77	Venous thromboembolism;	chr11:47158310	chr11:47041027~47041945:-
LAML	cis	rs3136516	0.537	rs752850	ENSG00000271350.1	CTD-2384B9.1	-10.4	5.51e-16	1.99e-11	-0.84	-0.77	Venous thromboembolism;	chr11:47153599	chr11:47041027~47041945:-
LAML	cis	rs3136516	0.537	rs752848	ENSG00000271350.1	CTD-2384B9.1	-10.4	5.51e-16	1.99e-11	-0.84	-0.77	Venous thromboembolism;	chr11:47153625	chr11:47041027~47041945:-
LAML	cis	rs916888	0.61	rs199453	ENSG00000262539.1	RP11-259G18.3	10.4	5.55e-16	2e-11	1.08	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46259551~46260606:-
LAML	cis	rs7847628	0.551	rs10818476	ENSG00000226752.6	PSMD5-AS1	-10.39	5.67e-16	2.03e-11	-0.93	-0.77	Birth weight;	chr9:120809760	chr9:120824828~120854385:+
LAML	cis	rs7847628	0.587	rs1060817	ENSG00000226752.6	PSMD5-AS1	-10.39	5.67e-16	2.03e-11	-0.93	-0.77	Birth weight;	chr9:120820914	chr9:120824828~120854385:+
LAML	cis	rs7847628	0.587	rs10760117	ENSG00000226752.6	PSMD5-AS1	-10.39	5.67e-16	2.03e-11	-0.93	-0.77	Birth weight;	chr9:120824459	chr9:120824828~120854385:+
LAML	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	10.39	5.68e-16	2.04e-11	0.97	0.77	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
LAML	cis	rs561341	1	rs693116	ENSG00000266379.5	RP11-640N20.8	10.38	5.96e-16	2.13e-11	1.44	0.77	Hip circumference adjusted for BMI;	chr17:31919105	chr17:32088160~32094933:-
LAML	cis	rs561341	0.714	rs55925849	ENSG00000266379.5	RP11-640N20.8	10.38	5.96e-16	2.13e-11	1.44	0.77	Hip circumference adjusted for BMI;	chr17:31926066	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs55959993	ENSG00000266379.5	RP11-640N20.8	10.38	5.96e-16	2.13e-11	1.44	0.77	Hip circumference adjusted for BMI;	chr17:31927752	chr17:32088160~32094933:-
LAML	cis	rs11098499	0.866	rs12501602	ENSG00000248280.1	RP11-33B1.2	10.38	6.08e-16	2.17e-11	1.05	0.77	Corneal astigmatism;	chr4:119366780	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.82	rs28394116	ENSG00000248280.1	RP11-33B1.2	10.37	6.31e-16	2.24e-11	1.13	0.77	Corneal astigmatism;	chr4:119603128	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.866	rs3756156	ENSG00000248280.1	RP11-33B1.2	10.37	6.31e-16	2.24e-11	1.13	0.77	Corneal astigmatism;	chr4:119603686	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs13136462	ENSG00000248280.1	RP11-33B1.2	10.37	6.31e-16	2.24e-11	1.13	0.77	Corneal astigmatism;	chr4:119622018	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.82	rs13122709	ENSG00000248280.1	RP11-33B1.2	10.37	6.31e-16	2.24e-11	1.13	0.77	Corneal astigmatism;	chr4:119634201	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.82	rs28535956	ENSG00000248280.1	RP11-33B1.2	-10.37	6.31e-16	2.24e-11	-1.13	-0.77	Corneal astigmatism;	chr4:119615703	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.82	rs28578366	ENSG00000248280.1	RP11-33B1.2	-10.37	6.31e-16	2.24e-11	-1.13	-0.77	Corneal astigmatism;	chr4:119615750	chr4:119440561~119450157:-
LAML	cis	rs916888	0.61	rs199530	ENSG00000262500.1	RP11-259G18.2	-10.34	7.01e-16	2.47e-11	-0.97	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46243606~46245044:+
LAML	cis	rs916888	0.738	rs199515	ENSG00000214401.4	KANSL1-AS1	-10.32	7.55e-16	2.65e-11	-1.32	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:46193576~46196723:+
LAML	cis	rs916888	0.647	rs199523	ENSG00000262500.1	RP11-259G18.2	-10.32	7.61e-16	2.67e-11	-0.98	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46243606~46245044:+
LAML	cis	rs916888	0.773	rs199451	ENSG00000214401.4	KANSL1-AS1	10.31	7.87e-16	2.76e-11	1.1	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46193576~46196723:+
LAML	cis	rs6565180	0.962	rs35480350	ENSG00000183604.13	SMG1P5	10.31	7.99e-16	2.79e-11	0.87	0.77	Tonsillectomy;	chr16:30354718	chr16:30267553~30335374:-
LAML	cis	rs6565180	0.962	rs11642676	ENSG00000183604.13	SMG1P5	10.31	7.99e-16	2.79e-11	0.87	0.77	Tonsillectomy;	chr16:30360334	chr16:30267553~30335374:-
LAML	cis	rs6565180	0.962	rs6565182	ENSG00000183604.13	SMG1P5	10.31	7.99e-16	2.79e-11	0.87	0.77	Tonsillectomy;	chr16:30363060	chr16:30267553~30335374:-
LAML	cis	rs6565180	1	rs11646130	ENSG00000183604.13	SMG1P5	10.31	7.99e-16	2.79e-11	0.87	0.77	Tonsillectomy;	chr16:30365638	chr16:30267553~30335374:-
LAML	cis	rs12922317	0.556	rs8062691	ENSG00000260224.1	UBL5P4	-10.3	8.41e-16	2.93e-11	-0.86	-0.77	Schizophrenia;	chr16:11997972	chr16:11968508~11968743:-
LAML	cis	rs916888	0.779	rs199528	ENSG00000214401.4	KANSL1-AS1	10.3	8.42e-16	2.93e-11	1.11	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46193576~46196723:+
LAML	cis	rs916888	0.821	rs199525	ENSG00000214401.4	KANSL1-AS1	10.3	8.42e-16	2.93e-11	1.11	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46193576~46196723:+
LAML	cis	rs916888	0.821	rs199504	ENSG00000261575.2	RP11-259G18.1	-10.3	8.45e-16	2.94e-11	-1.13	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46267037~46268694:+
LAML	cis	rs2739330	0.76	rs1007888	ENSG00000273295.1	AP000350.5	10.29	8.68e-16	3.02e-11	1.07	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23901432~23907068:-
LAML	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	10.29	8.77e-16	3.05e-11	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	10.28	9e-16	3.11e-11	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.863	rs3822192	ENSG00000248280.1	RP11-33B1.2	10.28	9.01e-16	3.11e-11	1.13	0.77	Corneal astigmatism;	chr4:119524565	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.863	rs10019674	ENSG00000248280.1	RP11-33B1.2	-10.28	9.01e-16	3.11e-11	-1.13	-0.77	Corneal astigmatism;	chr4:119522334	chr4:119440561~119450157:-
LAML	cis	rs2739330	0.731	rs4822450	ENSG00000273295.1	AP000350.5	10.28	9.15e-16	3.15e-11	1.07	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	10.27	9.3e-16	3.2e-11	0.99	0.77	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
LAML	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	10.27	9.44e-16	3.24e-11	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
LAML	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	10.27	9.44e-16	3.24e-11	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.78	rs12504773	ENSG00000248280.1	RP11-33B1.2	10.27	9.57e-16	3.28e-11	1.14	0.77	Corneal astigmatism;	chr4:119640994	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.78	rs7680914	ENSG00000248280.1	RP11-33B1.2	10.27	9.57e-16	3.28e-11	1.14	0.77	Corneal astigmatism;	chr4:119641898	chr4:119440561~119450157:-
LAML	cis	rs561341	1	rs55962687	ENSG00000266379.5	RP11-640N20.8	10.24	1.08e-15	3.68e-11	1.45	0.77	Hip circumference adjusted for BMI;	chr17:31933350	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs55643307	ENSG00000266379.5	RP11-640N20.8	10.24	1.08e-15	3.68e-11	1.45	0.77	Hip circumference adjusted for BMI;	chr17:31936055	chr17:32088160~32094933:-
LAML	cis	rs11098499	0.863	rs6534139	ENSG00000248280.1	RP11-33B1.2	-10.24	1.09e-15	3.71e-11	-1.13	-0.77	Corneal astigmatism;	chr4:119528301	chr4:119440561~119450157:-
LAML	cis	rs6565180	1	rs12930787	ENSG00000183604.13	SMG1P5	10.23	1.14e-15	3.86e-11	0.88	0.77	Tonsillectomy;	chr16:30369982	chr16:30267553~30335374:-
LAML	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	10.21	1.23e-15	4.14e-11	1.03	0.77	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
LAML	cis	rs9457247	1	rs2769347	ENSG00000265828.1	MIR3939	10.2	1.27e-15	4.28e-11	0.97	0.77	Crohn's disease;	chr6:166958249	chr6:166997807~166997912:-
LAML	cis	rs916888	0.531	rs183211	ENSG00000262539.1	RP11-259G18.3	10.18	1.35e-15	4.56e-11	1.08	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46259551~46260606:-
LAML	cis	rs916888	0.61	rs199438	ENSG00000262539.1	RP11-259G18.3	10.18	1.35e-15	4.56e-11	1.08	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46259551~46260606:-
LAML	cis	rs11098499	0.818	rs55825515	ENSG00000248280.1	RP11-33B1.2	10.18	1.36e-15	4.58e-11	1.17	0.77	Corneal astigmatism;	chr4:119565247	chr4:119440561~119450157:-
LAML	cis	rs916888	0.773	rs199457	ENSG00000214401.4	KANSL1-AS1	10.18	1.37e-15	4.6e-11	1.1	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46193576~46196723:+
LAML	cis	rs916888	0.687	rs199456	ENSG00000214401.4	KANSL1-AS1	10.18	1.37e-15	4.6e-11	1.1	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46193576~46196723:+
LAML	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	10.17	1.45e-15	4.85e-11	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.955	rs11944880	ENSG00000248280.1	RP11-33B1.2	-10.16	1.49e-15	4.9e-11	-1.08	-0.77	Corneal astigmatism;	chr4:119238179	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs13129661	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119231754	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs56386062	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119233980	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs4145951	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119234662	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs35916640	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119234697	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs13113112	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119234885	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs13114751	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119235462	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.913	rs35271032	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119235504	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs6815725	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119237255	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs11931312	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119237868	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs1511018	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119240425	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs1397608	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119240589	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs7685268	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119241033	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs7684942	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119241046	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.913	rs10010696	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119243148	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs1511019	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119244852	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.913	rs11098496	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119246311	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs35197422	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119248159	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs35434465	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119248223	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs1511015	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119249318	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs10029750	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119251388	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs6837898	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119257999	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs28374891	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119262395	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs12506395	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119263939	chr4:119440561~119450157:-
LAML	cis	rs11098499	1	rs3749591	ENSG00000248280.1	RP11-33B1.2	10.16	1.49e-15	4.9e-11	1.08	0.77	Corneal astigmatism;	chr4:119292875	chr4:119440561~119450157:-
LAML	cis	rs561341	1	rs72821952	ENSG00000266379.5	RP11-640N20.8	10.16	1.5e-15	4.93e-11	1.46	0.77	Hip circumference adjusted for BMI;	chr17:31921114	chr17:32088160~32094933:-
LAML	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	10.15	1.54e-15	5.04e-11	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	10.15	1.54e-15	5.04e-11	0.96	0.77	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.78	rs7692994	ENSG00000248280.1	RP11-33B1.2	10.14	1.64e-15	5.35e-11	1.01	0.77	Corneal astigmatism;	chr4:119506334	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.73	rs78971550	ENSG00000248280.1	RP11-33B1.2	10.13	1.72e-15	5.62e-11	1.09	0.77	Corneal astigmatism;	chr4:119359886	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.645	rs78422072	ENSG00000248280.1	RP11-33B1.2	10.13	1.72e-15	5.62e-11	1.09	0.77	Corneal astigmatism;	chr4:119359887	chr4:119440561~119450157:-
LAML	cis	rs7847628	0.55	rs12343516	ENSG00000226752.6	PSMD5-AS1	-10.12	1.82e-15	5.92e-11	-0.9	-0.77	Birth weight;	chr9:120841191	chr9:120824828~120854385:+
LAML	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	10.11	1.84e-15	6e-11	0.97	0.77	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.754	rs1814813	ENSG00000248280.1	RP11-33B1.2	-10.11	1.87e-15	6.08e-11	-1.01	-0.77	Corneal astigmatism;	chr4:119337052	chr4:119440561~119450157:-
LAML	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	10.09	2.03e-15	6.57e-11	1.04	0.77	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	10.09	2.03e-15	6.57e-11	1.04	0.77	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	10.09	2.03e-15	6.57e-11	1.04	0.77	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	10.09	2.03e-15	6.57e-11	1.04	0.77	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	10.09	2.03e-15	6.57e-11	1.04	0.77	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
LAML	cis	rs916888	0.821	rs199506	ENSG00000214401.4	KANSL1-AS1	-10.08	2.07e-15	6.69e-11	-1.08	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46193576~46196723:+
LAML	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-10.07	2.19e-15	7.05e-11	-1.13	-0.76	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
LAML	cis	rs2739330	0.76	rs5751760	ENSG00000273295.1	AP000350.5	10.06	2.28e-15	7.33e-11	1.04	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.703	rs5760112	ENSG00000273295.1	AP000350.5	10.06	2.28e-15	7.33e-11	1.04	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23901432~23907068:-
LAML	cis	rs6435862	0.517	rs6757091	ENSG00000229267.2	AC072062.1	10.06	2.29e-15	7.33e-11	0.8	0.76	Neuroblastoma (high-risk);	chr2:214808069	chr2:214810229~214963274:+
LAML	cis	rs6435862	0.5	rs6756902	ENSG00000229267.2	AC072062.1	10.06	2.29e-15	7.33e-11	0.8	0.76	Neuroblastoma (high-risk);	chr2:214808103	chr2:214810229~214963274:+
LAML	cis	rs6435862	0.5	rs12477063	ENSG00000229267.2	AC072062.1	10.06	2.29e-15	7.33e-11	0.8	0.76	Neuroblastoma (high-risk);	chr2:214808940	chr2:214810229~214963274:+
LAML	cis	rs2739330	0.791	rs9612520	ENSG00000218537.1	MIF-AS1	10.05	2.43e-15	7.78e-11	1.09	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23927272	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.627	rs9608219	ENSG00000218537.1	MIF-AS1	10.05	2.43e-15	7.78e-11	1.09	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23931932	chr22:23894426~23898930:-
LAML	cis	rs561341	0.941	rs2428336	ENSG00000266379.5	RP11-640N20.8	10.05	2.44e-15	7.78e-11	1.45	0.76	Hip circumference adjusted for BMI;	chr17:31963558	chr17:32088160~32094933:-
LAML	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	10.04	2.54e-15	8.08e-11	1.03	0.76	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
LAML	cis	rs916888	0.647	rs199524	ENSG00000262500.1	RP11-259G18.2	-10.02	2.71e-15	8.57e-11	-0.98	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46243606~46245044:+
LAML	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	10.02	2.77e-15	8.77e-11	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	10.02	2.77e-15	8.77e-11	0.96	0.76	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	10	2.97e-15	9.24e-11	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	10	2.97e-15	9.24e-11	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	10	2.97e-15	9.24e-11	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
LAML	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	10	2.97e-15	9.24e-11	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	10	2.97e-15	9.24e-11	1.01	0.76	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
LAML	cis	rs916888	0.773	rs199439	ENSG00000214401.4	KANSL1-AS1	9.99	3.11e-15	9.67e-11	1.1	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46193576~46196723:+
LAML	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	9.95	3.62e-15	1.11e-10	0.98	0.76	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
LAML	cis	rs7104764	0.879	rs6421986	ENSG00000277290.1	RP11-326C3.16	-9.92	4.07e-15	1.25e-10	-1.14	-0.76	Menarche (age at onset);	chr11:221659	chr11:243099~243483:-
LAML	cis	rs916888	0.821	rs415430	ENSG00000214401.4	KANSL1-AS1	-9.91	4.29e-15	1.31e-10	-1.12	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46193576~46196723:+
LAML	cis	rs916888	0.779	rs430685	ENSG00000214401.4	KANSL1-AS1	-9.91	4.29e-15	1.31e-10	-1.12	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46193576~46196723:+
LAML	cis	rs916888	0.697	rs199516	ENSG00000214401.4	KANSL1-AS1	-9.91	4.4e-15	1.34e-10	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46193576~46196723:+
LAML	cis	rs916888	0.821	rs199514	ENSG00000214401.4	KANSL1-AS1	-9.91	4.4e-15	1.34e-10	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46193576~46196723:+
LAML	cis	rs916888	0.821	rs199513	ENSG00000214401.4	KANSL1-AS1	-9.91	4.4e-15	1.34e-10	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46193576~46196723:+
LAML	cis	rs916888	0.821	rs199512	ENSG00000214401.4	KANSL1-AS1	-9.91	4.4e-15	1.34e-10	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46193576~46196723:+
LAML	cis	rs916888	0.821	rs199509	ENSG00000214401.4	KANSL1-AS1	-9.91	4.4e-15	1.34e-10	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46193576~46196723:+
LAML	cis	rs916888	0.821	rs199507	ENSG00000214401.4	KANSL1-AS1	-9.91	4.4e-15	1.34e-10	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46193576~46196723:+
LAML	cis	rs916888	0.821	rs199505	ENSG00000214401.4	KANSL1-AS1	-9.91	4.4e-15	1.34e-10	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46193576~46196723:+
LAML	cis	rs916888	0.821	rs70602	ENSG00000214401.4	KANSL1-AS1	-9.91	4.4e-15	1.34e-10	-1.08	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46193576~46196723:+
LAML	cis	rs916888	0.61	rs199530	ENSG00000262539.1	RP11-259G18.3	-9.88	4.96e-15	1.5e-10	-1.03	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46259551~46260606:-
LAML	cis	rs2739330	0.652	rs2000469	ENSG00000218537.1	MIF-AS1	9.87	5.16e-15	1.55e-10	1.06	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23894426~23898930:-
LAML	cis	rs916888	0.773	rs1378358	ENSG00000214401.4	KANSL1-AS1	9.84	5.81e-15	1.74e-10	1.09	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46193576~46196723:+
LAML	cis	rs916888	0.773	rs538628	ENSG00000214401.4	KANSL1-AS1	9.84	5.81e-15	1.74e-10	1.09	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46193576~46196723:+
LAML	cis	rs916888	0.773	rs169201	ENSG00000214401.4	KANSL1-AS1	9.84	5.81e-15	1.74e-10	1.09	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46193576~46196723:+
LAML	cis	rs6565180	0.963	rs4787642	ENSG00000183604.13	SMG1P5	9.83	6.18e-15	1.85e-10	0.87	0.76	Tonsillectomy;	chr16:30348087	chr16:30267553~30335374:-
LAML	cis	rs2739330	0.76	rs5760095	ENSG00000225282.1	AP000350.6	9.82	6.25e-15	1.87e-10	0.96	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23926900~23929574:+
LAML	cis	rs916888	0.647	rs199524	ENSG00000262539.1	RP11-259G18.3	-9.82	6.28e-15	1.88e-10	-1.05	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46259551~46260606:-
LAML	cis	rs7104764	0.879	rs6598072	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:219793	chr11:243099~243483:-
LAML	cis	rs7104764	0.957	rs6598071	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:219800	chr11:243099~243483:-
LAML	cis	rs7104764	0.957	rs10794301	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:220401	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs7104764	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:229977	chr11:243099~243483:-
LAML	cis	rs7104764	0.957	rs3829998	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:230751	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs7483951	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:231758	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs10794302	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:234102	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs9795476	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:235894	chr11:243099~243483:-
LAML	cis	rs7104764	0.957	rs519592	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:236811	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs2272563	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:236871	chr11:243099~243483:-
LAML	cis	rs7104764	0.917	rs1045288	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:237087	chr11:243099~243483:-
LAML	cis	rs7104764	0.957	rs3817629	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:237312	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs10902110	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:237648	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs7481993	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:237875	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs6598069	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:240664	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs7395328	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:242624	chr11:243099~243483:-
LAML	cis	rs7104764	0.917	rs6598068	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:243092	chr11:243099~243483:-
LAML	cis	rs7104764	0.917	rs6598067	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:243093	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs6598065	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:243211	chr11:243099~243483:-
LAML	cis	rs7104764	0.957	rs6598064	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:243557	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs6598063	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:243672	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs6598062	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:243712	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs6598061	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:243853	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs6598060	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:243987	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs10902112	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:244106	chr11:243099~243483:-
LAML	cis	rs7104764	0.917	rs7107362	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:244108	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs7128044	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:244115	chr11:243099~243483:-
LAML	cis	rs7104764	0.957	rs7116130	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:244129	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs7128029	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:244141	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs1128320	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:244167	chr11:243099~243483:-
LAML	cis	rs7104764	0.957	rs1128321	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:244171	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs2272565	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:244414	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs10902113	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:245523	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs7482591	ENSG00000277290.1	RP11-326C3.16	-9.8	6.92e-15	2.03e-10	-1.14	-0.76	Menarche (age at onset);	chr11:245861	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs1128322	ENSG00000277290.1	RP11-326C3.16	9.8	6.92e-15	2.03e-10	1.14	0.76	Menarche (age at onset);	chr11:244197	chr11:243099~243483:-
LAML	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-9.8	6.99e-15	2.04e-10	-1.07	-0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
LAML	cis	rs916888	0.821	rs70600	ENSG00000214401.4	KANSL1-AS1	9.8	7e-15	2.04e-10	1.08	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46193576~46196723:+
LAML	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	9.79	7.33e-15	2.14e-10	1.07	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.76	rs5760095	ENSG00000273295.1	AP000350.5	9.78	7.5e-15	2.19e-10	1.05	0.76	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23901432~23907068:-
LAML	cis	rs7104764	1	rs10400248	ENSG00000277290.1	RP11-326C3.16	-9.78	7.6e-15	2.21e-10	-1.16	-0.76	Menarche (age at onset);	chr11:247029	chr11:243099~243483:-
LAML	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	9.75	8.66e-15	2.51e-10	0.79	0.75	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
LAML	cis	rs2739330	0.734	rs2000467	ENSG00000218537.1	MIF-AS1	-9.73	9.27e-15	2.68e-10	-1.06	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23894426~23898930:-
LAML	cis	rs7104764	1	rs10902114	ENSG00000277290.1	RP11-326C3.16	-9.73	9.41e-15	2.72e-10	-1.14	-0.75	Menarche (age at onset);	chr11:246234	chr11:243099~243483:-
LAML	cis	rs2739330	0.76	rs1007888	ENSG00000225282.1	AP000350.6	9.71	1.02e-14	2.93e-10	0.95	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23926900~23929574:+
LAML	cis	rs3136516	0.516	rs3740690	ENSG00000271350.1	CTD-2384B9.1	-9.71	1.02e-14	2.94e-10	-0.81	-0.75	Venous thromboembolism;	chr11:47167041	chr11:47041027~47041945:-
LAML	cis	rs916888	0.773	rs199535	ENSG00000214401.4	KANSL1-AS1	9.7	1.04e-14	2.98e-10	1.08	0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46193576~46196723:+
LAML	cis	rs2739330	0.731	rs4822450	ENSG00000225282.1	AP000350.6	9.69	1.08e-14	3.1e-10	0.95	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23926900~23929574:+
LAML	cis	rs916888	0.647	rs199523	ENSG00000262539.1	RP11-259G18.3	-9.69	1.11e-14	3.17e-10	-1.03	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46259551~46260606:-
LAML	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	9.68	1.15e-14	3.18e-10	1.39	0.75	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	9.64	1.37e-14	3.78e-10	1.38	0.75	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	9.64	1.37e-14	3.78e-10	1.38	0.75	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	9.64	1.37e-14	3.78e-10	1.38	0.75	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
LAML	cis	rs5769707	0.967	rs739241	ENSG00000280224.1	CTA-722E9.1	-9.64	1.39e-14	3.81e-10	-0.91	-0.75	Monocyte percentage of white cells;Monocyte count;	chr22:49659273	chr22:49500568~49501585:+
LAML	cis	rs11098499	0.722	rs1814814	ENSG00000248280.1	RP11-33B1.2	9.63	1.44e-14	3.96e-10	0.97	0.75	Corneal astigmatism;	chr4:119336969	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.955	rs1551	ENSG00000248280.1	RP11-33B1.2	9.62	1.46e-14	4.02e-10	1.06	0.75	Corneal astigmatism;	chr4:119237345	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs13139045	ENSG00000248280.1	RP11-33B1.2	9.61	1.54e-14	4.22e-10	1.02	0.75	Corneal astigmatism;	chr4:119247433	chr4:119440561~119450157:-
LAML	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	9.6	1.6e-14	4.37e-10	1.02	0.75	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.754	rs9999724	ENSG00000248280.1	RP11-33B1.2	9.58	1.73e-14	4.64e-10	1.07	0.75	Corneal astigmatism;	chr4:119318789	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs714899	ENSG00000248280.1	RP11-33B1.2	9.58	1.73e-14	4.64e-10	1.07	0.75	Corneal astigmatism;	chr4:119321880	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs66900435	ENSG00000248280.1	RP11-33B1.2	9.58	1.73e-14	4.64e-10	1.07	0.75	Corneal astigmatism;	chr4:119328270	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs17595608	ENSG00000248280.1	RP11-33B1.2	9.58	1.73e-14	4.64e-10	1.07	0.75	Corneal astigmatism;	chr4:119329351	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs1980027	ENSG00000248280.1	RP11-33B1.2	9.58	1.73e-14	4.64e-10	1.07	0.75	Corneal astigmatism;	chr4:119330422	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs10213554	ENSG00000248280.1	RP11-33B1.2	-9.58	1.73e-14	4.64e-10	-1.07	-0.75	Corneal astigmatism;	chr4:119339630	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.662	rs13108589	ENSG00000248280.1	RP11-33B1.2	9.58	1.73e-14	4.64e-10	1.07	0.75	Corneal astigmatism;	chr4:119346947	chr4:119440561~119450157:-
LAML	cis	rs2739330	0.685	rs4822453	ENSG00000273295.1	AP000350.5	9.58	1.76e-14	4.71e-10	1.07	0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23901432~23907068:-
LAML	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-9.57	1.8e-14	4.81e-10	-1.1	-0.75	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
LAML	cis	rs11098499	0.954	rs11098524	ENSG00000248280.1	RP11-33B1.2	9.57	1.83e-14	4.87e-10	1.09	0.75	Corneal astigmatism;	chr4:119468877	chr4:119440561~119450157:-
LAML	cis	rs561341	1	rs506766	ENSG00000266379.5	RP11-640N20.8	9.57	1.83e-14	4.87e-10	1.33	0.75	Hip circumference adjusted for BMI;	chr17:31962640	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs8069199	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31954826	chr17:32088160~32094933:-
LAML	cis	rs561341	0.882	rs111484028	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31960682	chr17:32088160~32094933:-
LAML	cis	rs561341	0.505	rs548298	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31970475	chr17:32088160~32094933:-
LAML	cis	rs561341	0.714	rs547473	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31970541	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs546519	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31970663	chr17:32088160~32094933:-
LAML	cis	rs561341	0.714	rs75861674	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31977298	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs2470236	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31977921	chr17:32088160~32094933:-
LAML	cis	rs561341	0.714	rs474455	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31985446	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs501773	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31987416	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs550213	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31990499	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs530715	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31993525	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs7214017	ENSG00000266379.5	RP11-640N20.8	9.56	1.91e-14	4.92e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:32005201	chr17:32088160~32094933:-
LAML	cis	rs11098499	0.826	rs4472123	ENSG00000248280.1	RP11-33B1.2	9.56	1.92e-14	4.94e-10	1.01	0.75	Corneal astigmatism;	chr4:119315475	chr4:119440561~119450157:-
LAML	cis	rs561341	0.941	rs112569713	ENSG00000266379.5	RP11-640N20.8	9.53	2.14e-14	5.41e-10	1.29	0.75	Hip circumference adjusted for BMI;	chr17:31944719	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs56903735	ENSG00000266379.5	RP11-640N20.8	9.53	2.16e-14	5.46e-10	1.3	0.75	Hip circumference adjusted for BMI;	chr17:31927374	chr17:32088160~32094933:-
LAML	cis	rs561341	0.714	rs111760509	ENSG00000266379.5	RP11-640N20.8	9.53	2.21e-14	5.57e-10	1.37	0.75	Hip circumference adjusted for BMI;	chr17:31977301	chr17:32088160~32094933:-
LAML	cis	rs2739330	0.76	rs1002286	ENSG00000273295.1	AP000350.5	-9.49	2.53e-14	6.37e-10	-1.04	-0.75	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23901432~23907068:-
LAML	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	9.48	2.66e-14	6.68e-10	0.92	0.75	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
LAML	cis	rs6565180	0.888	rs12447833	ENSG00000183604.13	SMG1P5	-9.47	2.85e-14	7.14e-10	-0.82	-0.74	Tonsillectomy;	chr16:30378993	chr16:30267553~30335374:-
LAML	cis	rs9457247	0.967	rs387733	ENSG00000265828.1	MIR3939	9.45	3.04e-14	7.59e-10	0.97	0.74	Crohn's disease;	chr6:166996283	chr6:166997807~166997912:-
LAML	cis	rs11098499	0.754	rs938056	ENSG00000248280.1	RP11-33B1.2	9.45	3.06e-14	7.59e-10	1.06	0.74	Corneal astigmatism;	chr4:119316298	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs878376	ENSG00000248280.1	RP11-33B1.2	9.45	3.06e-14	7.59e-10	1.06	0.74	Corneal astigmatism;	chr4:119316547	chr4:119440561~119450157:-
LAML	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	9.44	3.17e-14	7.59e-10	1.39	0.74	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	9.44	3.17e-14	7.59e-10	1.39	0.74	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
LAML	cis	rs4713118	0.621	rs9295756	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28065618	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.621	rs10484403	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28065745	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.621	rs4713132	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28066257	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.621	rs4713133	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28066263	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.621	rs4713134	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28066343	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.621	rs9368548	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28066959	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.587	rs61471148	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28069254	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380047	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28070115	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs7755442	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28071237	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4713135	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28071808	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs12174753	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28074687	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs55747925	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28076559	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs56310871	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28076704	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs34716816	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28078391	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393884	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28079011	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380049	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28080757	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380050	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28080760	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393885	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28082231	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393886	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28082261	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.515	rs9368549	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28082269	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs56364346	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28082984	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9357061	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28083994	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9368550	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28084025	chr6:28073316~28074233:+
LAML	cis	rs853679	0.542	rs2295594	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28085319	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs2273564	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28089816	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs1853097	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28090857	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393887	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28091242	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393888	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28091439	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs3734573	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28091659	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9357063	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28092227	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs3823180	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28093966	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9368551	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28094014	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393890	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28096077	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380052	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28096845	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9366715	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28096855	chr6:28073316~28074233:+
LAML	cis	rs853679	0.598	rs9380054	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28099759	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.547	rs2116981	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28100173	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9368552	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28100648	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs2281588	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28104824	chr6:28073316~28074233:+
LAML	cis	rs853679	0.542	rs34131763	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28107222	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs35193936	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28108492	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs36078605	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28110254	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.516	rs6931858	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28110633	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393891	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28111382	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9468286	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28111650	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.516	rs7739216	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28112168	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs35512245	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28112175	chr6:28073316~28074233:+
LAML	cis	rs853679	0.542	rs9393892	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28113616	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380055	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28113851	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9368553	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28114487	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9368554	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28114933	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4713137	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28115743	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9348793	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28116411	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.586	rs6905516	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28118700	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.586	rs6905522	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28118701	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.586	rs9468290	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28119896	chr6:28073316~28074233:+
LAML	cis	rs853679	0.542	rs6934769	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28123153	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs17711801	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28124529	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs6922063	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28126588	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs2275508	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28126953	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.527	rs9461433	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28127394	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9468292	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28127577	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs1947863	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28131566	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4713141	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28133900	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs1340004	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28135913	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380056	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28136698	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380057	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28136856	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs1947862	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28137418	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs6941992	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28138363	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.516	rs4713142	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28138569	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4713143	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28138981	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4713144	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28139012	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4713145	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28139049	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs3757187	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28139876	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs3757185	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28139998	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs1904841	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28140307	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs1904840	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28140454	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9368555	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28141189	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393893	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28141484	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4713146	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28143758	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393894	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28144784	chr6:28073316~28074233:+
LAML	cis	rs853679	0.513	rs9468296	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28145952	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4711164	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28147378	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4711165	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28147406	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4713148	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28148143	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9348794	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28149979	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9468297	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28151096	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9295758	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28152885	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs17774663	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28153120	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9468298	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28154567	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9295759	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28156691	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9348796	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28158424	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs11552219	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28159056	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380058	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28159666	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393895	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28159843	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393896	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28159925	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393897	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28159932	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9357065	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28161802	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9357066	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28162053	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393898	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28162598	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9368556	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28163375	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9368557	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28163759	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380059	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28164580	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380060	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28164825	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs35227624	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28164948	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380061	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28165025	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9368558	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28165528	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.587	rs9393899	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28165750	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4713150	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28168434	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.527	rs4713151	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Parkinson's disease;	chr6:28168578	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9393901	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28169019	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs3173443	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28169249	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs4713152	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28169676	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9348797	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28169755	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380062	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28169791	chr6:28073316~28074233:+
LAML	cis	rs853679	0.542	rs9380063	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28170075	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs12332979	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28173770	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs67878650	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28174809	chr6:28073316~28074233:+
LAML	cis	rs853679	0.569	rs9348798	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28175233	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9380065	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28176973	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9295761	ENSG00000220721.1	OR1F12	9.44	3.21e-14	7.59e-10	1.01	0.74	Depression;	chr6:28180209	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.621	rs9295755	ENSG00000220721.1	OR1F12	-9.44	3.21e-14	7.59e-10	-1.01	-0.74	Parkinson's disease;	chr6:28065396	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs16893666	ENSG00000220721.1	OR1F12	-9.44	3.21e-14	7.59e-10	-1.01	-0.74	Depression;	chr6:28086929	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs17711344	ENSG00000220721.1	OR1F12	-9.44	3.21e-14	7.59e-10	-1.01	-0.74	Depression;	chr6:28109824	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs6932109	ENSG00000220721.1	OR1F12	-9.44	3.21e-14	7.59e-10	-1.01	-0.74	Depression;	chr6:28110525	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs868987	ENSG00000220721.1	OR1F12	-9.44	3.21e-14	7.59e-10	-1.01	-0.74	Depression;	chr6:28142370	chr6:28073316~28074233:+
LAML	cis	rs853679	0.517	rs9283884	ENSG00000220721.1	OR1F12	-9.44	3.21e-14	7.59e-10	-1.01	-0.74	Depression;	chr6:28167882	chr6:28073316~28074233:+
LAML	cis	rs916888	0.61	rs199529	ENSG00000261575.2	RP11-259G18.1	9.43	3.27e-14	7.71e-10	1.06	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46267037~46268694:+
LAML	cis	rs1930961	1	rs6004668	ENSG00000272977.1	CTA-390C10.10	9.43	3.33e-14	7.87e-10	1.2	0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25476218~25479971:+
LAML	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	9.43	3.33e-14	7.87e-10	1.39	0.74	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
LAML	cis	rs1930961	1	rs6004657	ENSG00000272977.1	CTA-390C10.10	-9.43	3.38e-14	7.97e-10	-1.19	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25476218~25479971:+
LAML	cis	rs11098499	0.566	rs7664440	ENSG00000248280.1	RP11-33B1.2	9.4	3.7e-14	8.7e-10	1.08	0.74	Corneal astigmatism;	chr4:119657385	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.954	rs6820115	ENSG00000248280.1	RP11-33B1.2	9.4	3.74e-14	8.81e-10	0.93	0.74	Corneal astigmatism;	chr4:119477027	chr4:119440561~119450157:-
LAML	cis	rs6565180	0.888	rs8060853	ENSG00000183604.13	SMG1P5	-9.39	3.88e-14	9.11e-10	-0.82	-0.74	Tonsillectomy;	chr16:30392537	chr16:30267553~30335374:-
LAML	cis	rs2739330	0.731	rs5751792	ENSG00000273295.1	AP000350.5	9.39	3.91e-14	9.19e-10	1.02	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23901432~23907068:-
LAML	cis	rs2739330	0.761	rs5760176	ENSG00000273295.1	AP000350.5	-9.39	3.91e-14	9.19e-10	-1.02	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23901432~23907068:-
LAML	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-9.39	3.94e-14	9.25e-10	-1.27	-0.74	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
LAML	cis	rs2739330	0.734	rs2000467	ENSG00000273295.1	AP000350.5	-9.39	3.95e-14	9.26e-10	-1.03	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23901432~23907068:-
LAML	cis	rs11098499	0.913	rs67073020	ENSG00000248280.1	RP11-33B1.2	9.36	4.46e-14	1.04e-09	1.05	0.74	Corneal astigmatism;	chr4:119231402	chr4:119440561~119450157:-
LAML	cis	rs561341	0.556	rs542244	ENSG00000266379.5	RP11-640N20.8	9.36	4.47e-14	1.05e-09	1.36	0.74	Hip circumference adjusted for BMI;	chr17:31980223	chr17:32088160~32094933:-
LAML	cis	rs9457247	0.935	rs1044059	ENSG00000265828.1	MIR3939	9.35	4.67e-14	1.09e-09	0.94	0.74	Crohn's disease;	chr6:166956409	chr6:166997807~166997912:-
LAML	cis	rs3096299	0.685	rs3803682	ENSG00000274627.1	RP11-104N10.2	9.34	4.81e-14	1.12e-09	0.95	0.74	Multiple myeloma (IgH translocation);	chr16:89478228	chr16:89516797~89522217:+
LAML	cis	rs6565180	0.926	rs4788413	ENSG00000183604.13	SMG1P5	-9.33	5.04e-14	1.17e-09	-0.82	-0.74	Tonsillectomy;	chr16:30399124	chr16:30267553~30335374:-
LAML	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	9.33	5.15e-14	1.2e-09	1.36	0.74	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
LAML	cis	rs5760092	0.755	rs4585126	ENSG00000218537.1	MIF-AS1	-9.32	5.21e-14	1.21e-09	-1.2	-0.74	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23894426~23898930:-
LAML	cis	rs561341	1	rs113676348	ENSG00000266379.5	RP11-640N20.8	9.32	5.28e-14	1.23e-09	1.34	0.74	Hip circumference adjusted for BMI;	chr17:31917308	chr17:32088160~32094933:-
LAML	cis	rs9457247	0.967	rs2149083	ENSG00000265828.1	MIR3939	9.31	5.48e-14	1.27e-09	0.94	0.74	Crohn's disease;	chr6:166957483	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs2149084	ENSG00000265828.1	MIR3939	9.31	5.48e-14	1.27e-09	0.94	0.74	Crohn's disease;	chr6:166957500	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.967	rs2769346	ENSG00000265828.1	MIR3939	9.31	5.48e-14	1.27e-09	0.94	0.74	Crohn's disease;	chr6:166957511	chr6:166997807~166997912:-
LAML	cis	rs9457247	1	rs2149085	ENSG00000265828.1	MIR3939	9.31	5.48e-14	1.27e-09	0.94	0.74	Crohn's disease;	chr6:166957622	chr6:166997807~166997912:-
LAML	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-9.31	5.64e-14	1.3e-09	-0.95	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
LAML	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	9.29	5.95e-14	1.37e-09	1.19	0.74	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
LAML	cis	rs858239	0.508	rs10242104	ENSG00000230658.1	KLHL7-AS1	9.29	5.98e-14	1.38e-09	0.97	0.74	Cerebrospinal fluid biomarker levels;	chr7:23180831	chr7:23101228~23105703:-
LAML	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	9.29	6e-14	1.38e-09	1.33	0.74	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
LAML	cis	rs916888	0.821	rs199504	ENSG00000214401.4	KANSL1-AS1	-9.29	6.06e-14	1.4e-09	-1.05	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46193576~46196723:+
LAML	cis	rs1930961	1	rs6004667	ENSG00000272977.1	CTA-390C10.10	9.27	6.46e-14	1.47e-09	1.18	0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs6519611	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs9624834	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs9624835	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs9624836	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25476218~25479971:+
LAML	cis	rs1930961	0.867	rs6423498	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs6004658	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs6004659	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs6004662	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs760555	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs7285549	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs6004669	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs5996946	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs997873	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs997872	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs6004671	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs6004672	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25476218~25479971:+
LAML	cis	rs1930961	1	rs6004673	ENSG00000272977.1	CTA-390C10.10	-9.27	6.46e-14	1.47e-09	-1.18	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25476218~25479971:+
LAML	cis	rs2739330	0.652	rs2000469	ENSG00000273295.1	AP000350.5	9.27	6.58e-14	1.5e-09	1.02	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23901432~23907068:-
LAML	cis	rs5769707	0.777	rs739243	ENSG00000280224.1	CTA-722E9.1	-9.26	6.76e-14	1.53e-09	-0.81	-0.74	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49500568~49501585:+
LAML	cis	rs2739330	0.734	rs2000467	ENSG00000225282.1	AP000350.6	-9.26	6.86e-14	1.55e-09	-0.94	-0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899346	chr22:23926900~23929574:+
LAML	cis	rs16828019	0.704	rs34660906	ENSG00000235358.1	RP11-399E6.1	9.26	6.88e-14	1.56e-09	1.41	0.74	Intelligence (multi-trait analysis);	chr1:41086296	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.704	rs35071528	ENSG00000235358.1	RP11-399E6.1	9.26	6.88e-14	1.56e-09	1.41	0.74	Intelligence (multi-trait analysis);	chr1:41146985	chr1:41242373~41284861:+
LAML	cis	rs916888	0.779	rs199498	ENSG00000262500.1	RP11-259G18.2	9.26	6.91e-14	1.57e-09	0.98	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46243606~46245044:+
LAML	cis	rs2739330	0.76	rs5751760	ENSG00000225282.1	AP000350.6	9.25	7.13e-14	1.61e-09	0.92	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.703	rs5760112	ENSG00000225282.1	AP000350.6	9.25	7.13e-14	1.61e-09	0.92	0.74	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23926900~23929574:+
LAML	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	9.24	7.32e-14	1.65e-09	1.3	0.74	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
LAML	cis	rs11098499	0.82	rs2389885	ENSG00000248280.1	RP11-33B1.2	9.24	7.35e-14	1.66e-09	1.08	0.74	Corneal astigmatism;	chr4:119612776	chr4:119440561~119450157:-
LAML	cis	rs16828019	0.64	rs35201793	ENSG00000235358.1	RP11-399E6.1	9.23	7.87e-14	1.77e-09	1.42	0.74	Intelligence (multi-trait analysis);	chr1:41056250	chr1:41242373~41284861:+
LAML	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	9.23	7.92e-14	1.78e-09	0.92	0.74	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	9.23	7.92e-14	1.78e-09	0.92	0.74	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
LAML	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	9.22	8.03e-14	1.8e-09	1.37	0.74	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	9.22	8.03e-14	1.8e-09	1.37	0.74	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	9.22	8.03e-14	1.8e-09	1.37	0.74	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	9.22	8.03e-14	1.8e-09	1.37	0.74	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
LAML	cis	rs3096299	0.509	rs4785691	ENSG00000274627.1	RP11-104N10.2	9.21	8.58e-14	1.92e-09	0.96	0.74	Multiple myeloma (IgH translocation);	chr16:89530813	chr16:89516797~89522217:+
LAML	cis	rs1930961	1	rs760554	ENSG00000100058.11	CRYBB2P1	-9.21	8.6e-14	1.92e-09	-1.25	-0.74	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25448105~25520854:+
LAML	cis	rs11098499	1	rs1011054	ENSG00000248280.1	RP11-33B1.2	-9.21	8.64e-14	1.93e-09	-1.04	-0.74	Corneal astigmatism;	chr4:119281232	chr4:119440561~119450157:-
LAML	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	9.2	8.75e-14	1.95e-09	0.75	0.74	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
LAML	cis	rs6565180	0.791	rs4247355	ENSG00000183604.13	SMG1P5	-9.2	8.86e-14	1.97e-09	-0.82	-0.74	Tonsillectomy;	chr16:30380778	chr16:30267553~30335374:-
LAML	cis	rs6565180	0.926	rs4787643	ENSG00000183604.13	SMG1P5	-9.2	8.86e-14	1.97e-09	-0.82	-0.74	Tonsillectomy;	chr16:30382339	chr16:30267553~30335374:-
LAML	cis	rs6565180	0.926	rs4788409	ENSG00000183604.13	SMG1P5	-9.2	8.86e-14	1.97e-09	-0.82	-0.74	Tonsillectomy;	chr16:30382450	chr16:30267553~30335374:-
LAML	cis	rs11098499	0.697	rs35280960	ENSG00000248280.1	RP11-33B1.2	9.18	9.77e-14	2.17e-09	1.02	0.73	Corneal astigmatism;	chr4:119335904	chr4:119440561~119450157:-
LAML	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	9.18	9.86e-14	2.19e-09	1.26	0.73	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	9.15	1.1e-13	2.44e-09	1.13	0.73	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
LAML	cis	rs5769707	0.967	rs9616713	ENSG00000280224.1	CTA-722E9.1	-9.15	1.11e-13	2.46e-09	-0.9	-0.73	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49500568~49501585:+
LAML	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	9.14	1.14e-13	2.51e-09	1.13	0.73	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	9.14	1.14e-13	2.51e-09	1.13	0.73	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	9.14	1.14e-13	2.51e-09	1.13	0.73	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	9.14	1.14e-13	2.51e-09	1.13	0.73	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	9.14	1.14e-13	2.52e-09	1.13	0.73	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	9.14	1.14e-13	2.52e-09	1.13	0.73	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	9.14	1.16e-13	2.56e-09	1.13	0.73	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
LAML	cis	rs11098499	0.821	rs56155624	ENSG00000248280.1	RP11-33B1.2	9.13	1.19e-13	2.63e-09	1.04	0.73	Corneal astigmatism;	chr4:119369871	chr4:119440561~119450157:-
LAML	cis	rs9457247	1	rs2757042	ENSG00000265828.1	MIR3939	9.13	1.2e-13	2.63e-09	0.95	0.73	Crohn's disease;	chr6:166957746	chr6:166997807~166997912:-
LAML	cis	rs853679	0.55	rs1233707	ENSG00000220721.1	OR1F12	9.13	1.2e-13	2.64e-09	0.91	0.73	Depression;	chr6:28205175	chr6:28073316~28074233:+
LAML	cis	rs853679	0.55	rs1233699	ENSG00000220721.1	OR1F12	9.11	1.3e-13	2.86e-09	0.92	0.73	Depression;	chr6:28201380	chr6:28073316~28074233:+
LAML	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	9.1	1.36e-13	2.98e-09	1.37	0.73	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
LAML	cis	rs11098499	1	rs13435802	ENSG00000248280.1	RP11-33B1.2	-9.1	1.38e-13	3.02e-09	-1.09	-0.73	Corneal astigmatism;	chr4:119256805	chr4:119440561~119450157:-
LAML	cis	rs561341	1	rs4795667	ENSG00000266379.5	RP11-640N20.8	9.1	1.38e-13	3.03e-09	1.32	0.73	Hip circumference adjusted for BMI;	chr17:31917424	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs4795668	ENSG00000266379.5	RP11-640N20.8	9.1	1.38e-13	3.03e-09	1.32	0.73	Hip circumference adjusted for BMI;	chr17:31917535	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs4795669	ENSG00000266379.5	RP11-640N20.8	9.1	1.38e-13	3.03e-09	1.32	0.73	Hip circumference adjusted for BMI;	chr17:31917682	chr17:32088160~32094933:-
LAML	cis	rs2739330	0.731	rs2000468	ENSG00000273295.1	AP000350.5	9.09	1.43e-13	3.13e-09	1.01	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23901432~23907068:-
LAML	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	9.08	1.45e-13	3.14e-09	0.97	0.73	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.754	rs10518300	ENSG00000248280.1	RP11-33B1.2	-9.08	1.47e-13	3.14e-09	-1.01	-0.73	Corneal astigmatism;	chr4:119328344	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs1980025	ENSG00000248280.1	RP11-33B1.2	-9.08	1.47e-13	3.14e-09	-1.01	-0.73	Corneal astigmatism;	chr4:119331651	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs9991959	ENSG00000248280.1	RP11-33B1.2	-9.08	1.47e-13	3.14e-09	-1.01	-0.73	Corneal astigmatism;	chr4:119332618	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.789	rs9991166	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119316696	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.708	rs10005237	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119316742	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.575	rs907204	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119317499	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.575	rs907205	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119317509	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs878372	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119317625	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs10213267	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119317919	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs10212775	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119318089	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs11732087	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119318676	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs2964	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119318976	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs1511025	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119319083	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs12711071	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119319779	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs1546503	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119320012	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.708	rs1546506	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119320085	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs12506610	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119320504	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.743	rs10003567	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119320519	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs10006259	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119320990	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs28652763	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119321157	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs28643450	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119324087	chr4:119440561~119450157:-
LAML	cis	rs10028773	0.7	rs7671797	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Educational attainment;	chr4:119327002	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs7672372	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119327251	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs7672594	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119327388	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs7672778	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119327430	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs2036860	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119327779	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs12513083	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119328457	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs12509621	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119328505	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs1511017	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119329650	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.789	rs12498994	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119329663	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs12507565	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119329966	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.826	rs12511640	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119330093	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs1980026	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119330488	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.722	rs28713555	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119330840	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.743	rs11098501	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119330862	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs11098502	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119330908	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.708	rs11732686	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119331175	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs11724409	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119331206	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.789	rs1980024	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119331892	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs34425882	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119332022	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs4107728	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119332755	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.789	rs10212719	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119333282	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs17049949	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119334135	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs7689729	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119335037	chr4:119440561~119450157:-
LAML	cis	rs10028773	0.7	rs7690338	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Educational attainment;	chr4:119335313	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs3956464	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119335609	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.619	rs28502463	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119335868	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.648	rs2002047	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119336073	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.775	rs2002049	ENSG00000248280.1	RP11-33B1.2	9.08	1.47e-13	3.14e-09	1.01	0.73	Corneal astigmatism;	chr4:119336262	chr4:119440561~119450157:-
LAML	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	9.08	1.5e-13	3.21e-09	1.31	0.73	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	9.08	1.5e-13	3.21e-09	1.31	0.73	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	9.08	1.5e-13	3.21e-09	1.31	0.73	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
LAML	cis	rs561341	0.825	rs2008368	ENSG00000266379.5	RP11-640N20.8	9.04	1.78e-13	3.71e-09	1.28	0.73	Hip circumference adjusted for BMI;	chr17:32020378	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs736678	ENSG00000266379.5	RP11-640N20.8	9.04	1.78e-13	3.71e-09	1.28	0.73	Hip circumference adjusted for BMI;	chr17:32020404	chr17:32088160~32094933:-
LAML	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-9.03	1.82e-13	3.81e-09	-0.89	-0.73	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
LAML	cis	rs2739330	0.652	rs2000469	ENSG00000225282.1	AP000350.6	9.02	1.88e-13	3.93e-09	0.92	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23903105	chr22:23926900~23929574:+
LAML	cis	rs11098499	0.657	rs10434028	ENSG00000248280.1	RP11-33B1.2	9.02	1.91e-13	3.97e-09	1.01	0.73	Corneal astigmatism;	chr4:119373309	chr4:119440561~119450157:-
LAML	cis	rs7104764	1	rs6598074	ENSG00000277290.1	RP11-326C3.16	-9.02	1.94e-13	4.04e-09	-1.12	-0.73	Menarche (age at onset);	chr11:219398	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs6598066	ENSG00000277290.1	RP11-326C3.16	-9.02	1.94e-13	4.04e-09	-1.12	-0.73	Menarche (age at onset);	chr11:243185	chr11:243099~243483:-
LAML	cis	rs3096299	0.582	rs12935119	ENSG00000274627.1	RP11-104N10.2	8.99	2.19e-13	4.53e-09	0.89	0.73	Multiple myeloma (IgH translocation);	chr16:89476466	chr16:89516797~89522217:+
LAML	cis	rs853679	0.506	rs1150693	ENSG00000220721.1	OR1F12	8.98	2.24e-13	4.63e-09	0.92	0.73	Depression;	chr6:28206812	chr6:28073316~28074233:+
LAML	cis	rs11098499	0.866	rs7665125	ENSG00000248280.1	RP11-33B1.2	8.98	2.32e-13	4.77e-09	0.9	0.73	Corneal astigmatism;	chr4:119480924	chr4:119440561~119450157:-
LAML	cis	rs2015599	0.54	rs12301475	ENSG00000257176.2	RP11-996F15.2	8.97	2.34e-13	4.82e-09	0.78	0.73	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29280418~29317848:-
LAML	cis	rs2739330	0.731	rs2000468	ENSG00000225282.1	AP000350.6	8.97	2.35e-13	4.83e-09	0.92	0.73	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23926900~23929574:+
LAML	cis	rs5769707	0.749	rs7286706	ENSG00000280224.1	CTA-722E9.1	-8.96	2.44e-13	5.01e-09	-0.8	-0.73	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49500568~49501585:+
LAML	cis	rs11098499	0.913	rs56122576	ENSG00000248280.1	RP11-33B1.2	8.95	2.57e-13	5.28e-09	1.06	0.73	Corneal astigmatism;	chr4:119208181	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.913	rs68128210	ENSG00000248280.1	RP11-33B1.2	8.95	2.57e-13	5.28e-09	1.06	0.73	Corneal astigmatism;	chr4:119216664	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.913	rs13126596	ENSG00000248280.1	RP11-33B1.2	8.95	2.57e-13	5.28e-09	1.06	0.73	Corneal astigmatism;	chr4:119219574	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs9996644	ENSG00000248280.1	RP11-33B1.2	8.95	2.61e-13	5.35e-09	1.01	0.73	Corneal astigmatism;	chr4:119317722	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs9996494	ENSG00000248280.1	RP11-33B1.2	8.95	2.61e-13	5.35e-09	1.01	0.73	Corneal astigmatism;	chr4:119317725	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs9995277	ENSG00000248280.1	RP11-33B1.2	8.94	2.65e-13	5.42e-09	1.02	0.73	Corneal astigmatism;	chr4:119187448	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs10022508	ENSG00000248280.1	RP11-33B1.2	8.94	2.65e-13	5.42e-09	1.02	0.73	Corneal astigmatism;	chr4:119194073	chr4:119440561~119450157:-
LAML	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-8.94	2.75e-13	5.61e-09	-0.94	-0.73	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
LAML	cis	rs5760092	0.755	rs4585126	ENSG00000273295.1	AP000350.5	-8.92	2.95e-13	6e-09	-1.16	-0.72	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23901432~23907068:-
LAML	cis	rs853679	0.55	rs1150692	ENSG00000220721.1	OR1F12	8.92	2.99e-13	6.09e-09	0.92	0.72	Depression;	chr6:28206179	chr6:28073316~28074233:+
LAML	cis	rs11098499	0.644	rs10050092	ENSG00000248280.1	RP11-33B1.2	8.91	3.1e-13	6.31e-09	1.05	0.72	Corneal astigmatism;	chr4:119610930	chr4:119440561~119450157:-
LAML	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	8.9	3.17e-13	6.44e-09	1.11	0.72	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
LAML	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	8.9	3.22e-13	6.54e-09	1.21	0.72	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
LAML	cis	rs853679	0.55	rs6901017	ENSG00000220721.1	OR1F12	8.88	3.45e-13	7e-09	0.9	0.72	Depression;	chr6:28184805	chr6:28073316~28074233:+
LAML	cis	rs561341	0.882	rs504887	ENSG00000266379.5	RP11-640N20.8	8.88	3.56e-13	7.22e-09	1.28	0.72	Hip circumference adjusted for BMI;	chr17:31995862	chr17:32088160~32094933:-
LAML	cis	rs2015599	0.56	rs11050147	ENSG00000257176.2	RP11-996F15.2	-8.87	3.64e-13	7.36e-09	-0.78	-0.72	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.56	rs3948497	ENSG00000257176.2	RP11-996F15.2	-8.87	3.64e-13	7.36e-09	-0.78	-0.72	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29280418~29317848:-
LAML	cis	rs3096299	0.559	rs9931073	ENSG00000274627.1	RP11-104N10.2	8.86	3.76e-13	7.61e-09	0.93	0.72	Multiple myeloma (IgH translocation);	chr16:89502105	chr16:89516797~89522217:+
LAML	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	8.85	3.91e-13	7.89e-09	0.95	0.72	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
LAML	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	8.85	3.91e-13	7.89e-09	0.85	0.72	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
LAML	cis	rs916888	0.779	rs199498	ENSG00000262539.1	RP11-259G18.3	8.85	4e-13	8.05e-09	1.04	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46259551~46260606:-
LAML	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	8.84	4.13e-13	8.32e-09	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
LAML	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	8.84	4.2e-13	8.45e-09	1.11	0.72	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	8.84	4.2e-13	8.45e-09	1.11	0.72	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
LAML	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	8.84	4.23e-13	8.51e-09	0.95	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
LAML	cis	rs7104764	0.879	rs6598070	ENSG00000277290.1	RP11-326C3.16	-8.83	4.4e-13	8.83e-09	-1.1	-0.72	Menarche (age at onset);	chr11:225466	chr11:243099~243483:-
LAML	cis	rs2739330	0.76	rs1002286	ENSG00000225282.1	AP000350.6	-8.82	4.53e-13	9.09e-09	-0.91	-0.72	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23926900~23929574:+
LAML	cis	rs11098499	0.866	rs10518329	ENSG00000248280.1	RP11-33B1.2	8.82	4.54e-13	9.09e-09	0.89	0.72	Corneal astigmatism;	chr4:119480680	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs13123591	ENSG00000248280.1	RP11-33B1.2	8.82	4.55e-13	9.09e-09	1.02	0.72	Corneal astigmatism;	chr4:119184835	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs7661020	ENSG00000248280.1	RP11-33B1.2	8.82	4.55e-13	9.09e-09	1.02	0.72	Corneal astigmatism;	chr4:119185827	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs17839089	ENSG00000248280.1	RP11-33B1.2	8.82	4.55e-13	9.09e-09	1.02	0.72	Corneal astigmatism;	chr4:119189914	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs6826823	ENSG00000248280.1	RP11-33B1.2	8.82	4.55e-13	9.09e-09	1.02	0.72	Corneal astigmatism;	chr4:119190943	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs12509054	ENSG00000248280.1	RP11-33B1.2	8.82	4.55e-13	9.09e-09	1.02	0.72	Corneal astigmatism;	chr4:119193920	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs12502503	ENSG00000248280.1	RP11-33B1.2	8.82	4.55e-13	9.09e-09	1.02	0.72	Corneal astigmatism;	chr4:119195100	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs6851169	ENSG00000248280.1	RP11-33B1.2	8.82	4.55e-13	9.09e-09	1.02	0.72	Corneal astigmatism;	chr4:119196355	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs6832670	ENSG00000248280.1	RP11-33B1.2	8.82	4.55e-13	9.09e-09	1.02	0.72	Corneal astigmatism;	chr4:119197637	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.874	rs6822498	ENSG00000248280.1	RP11-33B1.2	8.82	4.55e-13	9.09e-09	1.02	0.72	Corneal astigmatism;	chr4:119199028	chr4:119440561~119450157:-
LAML	cis	rs12922317	0.535	rs8051349	ENSG00000260224.1	UBL5P4	-8.81	4.65e-13	9.3e-09	-0.8	-0.72	Schizophrenia;	chr16:12011666	chr16:11968508~11968743:-
LAML	cis	rs853679	0.628	rs9368560	ENSG00000220721.1	OR1F12	8.8	4.91e-13	9.8e-09	0.91	0.72	Depression;	chr6:28192182	chr6:28073316~28074233:+
LAML	cis	rs5769707	0.935	rs5770594	ENSG00000280224.1	CTA-722E9.1	-8.8	5.02e-13	1e-08	-0.88	-0.72	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.967	rs4524218	ENSG00000280224.1	CTA-722E9.1	-8.8	5.02e-13	1e-08	-0.88	-0.72	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.967	rs739248	ENSG00000280224.1	CTA-722E9.1	-8.8	5.02e-13	1e-08	-0.88	-0.72	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.967	rs2071904	ENSG00000280224.1	CTA-722E9.1	-8.8	5.02e-13	1e-08	-0.88	-0.72	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49500568~49501585:+
LAML	cis	rs853679	0.55	rs9295762	ENSG00000220721.1	OR1F12	-8.77	5.52e-13	1.1e-08	-0.86	-0.72	Depression;	chr6:28187640	chr6:28073316~28074233:+
LAML	cis	rs7104764	1	rs2293167	ENSG00000277290.1	RP11-326C3.16	8.77	5.55e-13	1.1e-08	1.16	0.72	Menarche (age at onset);	chr11:211644	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs76552490	ENSG00000277290.1	RP11-326C3.16	8.77	5.55e-13	1.1e-08	1.16	0.72	Menarche (age at onset);	chr11:212015	chr11:243099~243483:-
LAML	cis	rs7104764	1	rs1533825	ENSG00000277290.1	RP11-326C3.16	8.77	5.55e-13	1.1e-08	1.16	0.72	Menarche (age at onset);	chr11:214163	chr11:243099~243483:-
LAML	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-8.76	5.74e-13	1.14e-08	-0.96	-0.72	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
LAML	cis	rs12931792	0.712	rs4787495	ENSG00000183604.13	SMG1P5	8.75	5.98e-13	1.19e-08	0.83	0.72	Tonsillectomy;	chr16:30154404	chr16:30267553~30335374:-
LAML	cis	rs4713118	0.5	rs9461434	ENSG00000220721.1	OR1F12	8.75	6.12e-13	1.21e-08	1.03	0.72	Parkinson's disease;	chr6:28134687	chr6:28073316~28074233:+
LAML	cis	rs1930961	1	rs6004654	ENSG00000272977.1	CTA-390C10.10	-8.74	6.28e-13	1.24e-08	-1.16	-0.72	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25476218~25479971:+
LAML	cis	rs11098499	0.754	rs2036857	ENSG00000248280.1	RP11-33B1.2	8.74	6.33e-13	1.25e-08	0.99	0.72	Corneal astigmatism;	chr4:119328085	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs2036856	ENSG00000248280.1	RP11-33B1.2	8.74	6.33e-13	1.25e-08	0.99	0.72	Corneal astigmatism;	chr4:119328133	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs4443261	ENSG00000248280.1	RP11-33B1.2	8.74	6.33e-13	1.25e-08	0.99	0.72	Corneal astigmatism;	chr4:119328146	chr4:119440561~119450157:-
LAML	cis	rs12931792	0.712	rs56399904	ENSG00000183604.13	SMG1P5	-8.73	6.53e-13	1.29e-08	-0.83	-0.72	Tonsillectomy;	chr16:30154862	chr16:30267553~30335374:-
LAML	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	8.73	6.62e-13	1.31e-08	0.95	0.72	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
LAML	cis	rs916888	0.61	rs199529	ENSG00000214401.4	KANSL1-AS1	8.73	6.73e-13	1.33e-08	1	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:46193576~46196723:+
LAML	cis	rs11098499	0.644	rs7693919	ENSG00000248280.1	RP11-33B1.2	8.73	6.76e-13	1.33e-08	1.05	0.72	Corneal astigmatism;	chr4:119619416	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.57	rs6832740	ENSG00000248280.1	RP11-33B1.2	8.73	6.76e-13	1.33e-08	1.05	0.72	Corneal astigmatism;	chr4:119624981	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.644	rs6855918	ENSG00000248280.1	RP11-33B1.2	8.73	6.76e-13	1.33e-08	1.05	0.72	Corneal astigmatism;	chr4:119625144	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.644	rs28787668	ENSG00000248280.1	RP11-33B1.2	8.73	6.76e-13	1.33e-08	1.05	0.72	Corneal astigmatism;	chr4:119633532	chr4:119440561~119450157:-
LAML	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	8.72	7e-13	1.38e-08	0.94	0.72	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.605	rs6833140	ENSG00000248280.1	RP11-33B1.2	8.72	7.01e-13	1.38e-08	0.96	0.72	Corneal astigmatism;	chr4:119345667	chr4:119440561~119450157:-
LAML	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	8.71	7.34e-13	1.44e-08	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	8.71	7.34e-13	1.44e-08	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	8.71	7.34e-13	1.44e-08	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	8.71	7.34e-13	1.44e-08	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
LAML	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	8.71	7.34e-13	1.44e-08	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	8.71	7.34e-13	1.44e-08	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	8.71	7.34e-13	1.44e-08	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	8.71	7.34e-13	1.44e-08	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	8.71	7.34e-13	1.44e-08	0.91	0.72	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
LAML	cis	rs5769707	0.967	rs9616701	ENSG00000280224.1	CTA-722E9.1	-8.7	7.56e-13	1.48e-08	-0.89	-0.72	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49500568~49501585:+
LAML	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	8.7	7.57e-13	1.48e-08	1.31	0.72	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
LAML	cis	rs858239	0.537	rs2286272	ENSG00000230658.1	KLHL7-AS1	8.7	7.63e-13	1.49e-08	0.97	0.72	Cerebrospinal fluid biomarker levels;	chr7:23184748	chr7:23101228~23105703:-
LAML	cis	rs858239	0.537	rs6955115	ENSG00000230658.1	KLHL7-AS1	8.7	7.63e-13	1.49e-08	0.97	0.72	Cerebrospinal fluid biomarker levels;	chr7:23187525	chr7:23101228~23105703:-
LAML	cis	rs858239	0.537	rs10279691	ENSG00000230658.1	KLHL7-AS1	8.7	7.63e-13	1.49e-08	0.97	0.72	Cerebrospinal fluid biomarker levels;	chr7:23188768	chr7:23101228~23105703:-
LAML	cis	rs5769707	0.846	rs5770610	ENSG00000280224.1	CTA-722E9.1	-8.7	7.64e-13	1.49e-08	-0.87	-0.72	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.967	rs8141807	ENSG00000280224.1	CTA-722E9.1	-8.7	7.64e-13	1.49e-08	-0.87	-0.72	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.935	rs9616332	ENSG00000280224.1	CTA-722E9.1	-8.7	7.64e-13	1.49e-08	-0.87	-0.72	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.935	rs739239	ENSG00000280224.1	CTA-722E9.1	-8.7	7.64e-13	1.49e-08	-0.87	-0.72	Monocyte percentage of white cells;Monocyte count;	chr22:49656820	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.874	rs9616714	ENSG00000280224.1	CTA-722E9.1	-8.7	7.64e-13	1.49e-08	-0.87	-0.72	Monocyte percentage of white cells;Monocyte count;	chr22:49657211	chr22:49500568~49501585:+
LAML	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	8.69	7.81e-13	1.52e-08	0.9	0.72	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
LAML	cis	rs12931792	0.682	rs12373113	ENSG00000183604.13	SMG1P5	-8.69	7.99e-13	1.56e-08	-0.82	-0.72	Tonsillectomy;	chr16:30176192	chr16:30267553~30335374:-
LAML	cis	rs12931792	0.682	rs12373078	ENSG00000183604.13	SMG1P5	-8.69	7.99e-13	1.56e-08	-0.82	-0.72	Tonsillectomy;	chr16:30176355	chr16:30267553~30335374:-
LAML	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	8.68	8.4e-13	1.63e-08	0.92	0.71	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
LAML	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
LAML	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	8.64	9.77e-13	1.88e-08	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
LAML	cis	rs7104764	0.957	rs1045454	ENSG00000277290.1	RP11-326C3.16	8.64	9.88e-13	1.91e-08	1.16	0.71	Menarche (age at onset);	chr11:204228	chr11:243099~243483:-
LAML	cis	rs12922317	0.538	rs442234	ENSG00000260224.1	UBL5P4	8.63	1.02e-12	1.97e-08	0.81	0.71	Schizophrenia;	chr16:11978304	chr16:11968508~11968743:-
LAML	cis	rs3096299	0.685	rs12446145	ENSG00000274627.1	RP11-104N10.2	8.63	1.03e-12	1.99e-08	0.9	0.71	Multiple myeloma (IgH translocation);	chr16:89476287	chr16:89516797~89522217:+
LAML	cis	rs853679	0.513	rs13437444	ENSG00000220721.1	OR1F12	8.62	1.07e-12	2.05e-08	1.03	0.71	Depression;	chr6:28103220	chr6:28073316~28074233:+
LAML	cis	rs11098499	0.663	rs9996501	ENSG00000248280.1	RP11-33B1.2	8.61	1.11e-12	2.13e-08	0.99	0.71	Corneal astigmatism;	chr4:119317763	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.697	rs28458294	ENSG00000248280.1	RP11-33B1.2	8.61	1.11e-12	2.13e-08	0.99	0.71	Corneal astigmatism;	chr4:119317769	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.663	rs28369503	ENSG00000248280.1	RP11-33B1.2	8.61	1.11e-12	2.13e-08	0.99	0.71	Corneal astigmatism;	chr4:119317770	chr4:119440561~119450157:-
LAML	cis	rs2739330	0.76	rs1007888	ENSG00000218537.1	MIF-AS1	8.61	1.13e-12	2.17e-08	1	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23898914	chr22:23894426~23898930:-
LAML	cis	rs7104764	0.957	rs56357554	ENSG00000277290.1	RP11-326C3.16	8.6	1.14e-12	2.18e-08	1.15	0.71	Menarche (age at onset);	chr11:204715	chr11:243099~243483:-
LAML	cis	rs7104764	0.957	rs3782120	ENSG00000277290.1	RP11-326C3.16	8.6	1.14e-12	2.18e-08	1.15	0.71	Menarche (age at onset);	chr11:206089	chr11:243099~243483:-
LAML	cis	rs3096299	0.632	rs8051537	ENSG00000274627.1	RP11-104N10.2	8.6	1.14e-12	2.18e-08	0.91	0.71	Multiple myeloma (IgH translocation);	chr16:89477976	chr16:89516797~89522217:+
LAML	cis	rs3096299	0.685	rs3803681	ENSG00000274627.1	RP11-104N10.2	8.6	1.14e-12	2.18e-08	0.91	0.71	Multiple myeloma (IgH translocation);	chr16:89478348	chr16:89516797~89522217:+
LAML	cis	rs11098499	0.913	rs10006304	ENSG00000248280.1	RP11-33B1.2	8.6	1.14e-12	2.18e-08	1.04	0.71	Corneal astigmatism;	chr4:119203150	chr4:119440561~119450157:-
LAML	cis	rs16828019	0.777	rs13376450	ENSG00000235358.1	RP11-399E6.1	8.6	1.15e-12	2.2e-08	1.35	0.71	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.777	rs67460888	ENSG00000235358.1	RP11-399E6.1	8.6	1.15e-12	2.2e-08	1.35	0.71	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.777	rs12023079	ENSG00000235358.1	RP11-399E6.1	8.6	1.15e-12	2.2e-08	1.35	0.71	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41242373~41284861:+
LAML	cis	rs11098499	0.754	rs12510269	ENSG00000248280.1	RP11-33B1.2	8.6	1.16e-12	2.21e-08	0.99	0.71	Corneal astigmatism;	chr4:119320491	chr4:119440561~119450157:-
LAML	cis	rs3096299	0.658	rs34590044	ENSG00000274627.1	RP11-104N10.2	8.59	1.19e-12	2.27e-08	0.91	0.71	Multiple myeloma (IgH translocation);	chr16:89476749	chr16:89516797~89522217:+
LAML	cis	rs2739330	0.731	rs4822450	ENSG00000218537.1	MIF-AS1	8.58	1.25e-12	2.38e-08	1	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900700	chr22:23894426~23898930:-
LAML	cis	rs11098499	0.722	rs17595727	ENSG00000248280.1	RP11-33B1.2	-8.58	1.27e-12	2.38e-08	-0.94	-0.71	Corneal astigmatism;	chr4:119340919	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs10028773	ENSG00000248280.1	RP11-33B1.2	-8.58	1.27e-12	2.38e-08	-0.94	-0.71	Corneal astigmatism;	chr4:119344104	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs17009144	ENSG00000248280.1	RP11-33B1.2	-8.58	1.27e-12	2.38e-08	-0.94	-0.71	Corneal astigmatism;	chr4:119349640	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.698	rs4422403	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119337039	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.569	rs10023641	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119337255	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.644	rs3986377	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119339115	chr4:119440561~119450157:-
LAML	cis	rs10028773	0.556	rs4473640	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Educational attainment;	chr4:119339282	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs10010355	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119339888	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs9307471	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119340107	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.644	rs17517414	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119340946	chr4:119440561~119450157:-
LAML	cis	rs10028773	0.666	rs12498657	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Educational attainment;	chr4:119341711	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.722	rs10006192	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119341867	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.615	rs28551750	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119343746	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs9995716	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119343841	chr4:119440561~119450157:-
LAML	cis	rs10028773	0.6	rs4001390	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Educational attainment;	chr4:119344628	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs2136911	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119344704	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.554	rs2175381	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119344812	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.599	rs3864142	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119345036	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.779	rs6815934	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119346155	chr4:119440561~119450157:-
LAML	cis	rs10028773	0.568	rs6838457	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Educational attainment;	chr4:119346212	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.661	rs10015965	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119347082	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.535	rs10005542	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119347147	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs12510133	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119350189	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs12506487	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119350206	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs12502524	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119350259	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.691	rs28396837	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119350386	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.629	rs28369518	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119350475	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.722	rs10025925	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119350589	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.731	rs10015579	ENSG00000248280.1	RP11-33B1.2	8.58	1.27e-12	2.38e-08	0.94	0.71	Corneal astigmatism;	chr4:119350647	chr4:119440561~119450157:-
LAML	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-8.58	1.27e-12	2.38e-08	-1.06	-0.71	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
LAML	cis	rs11098499	0.644	rs7676296	ENSG00000248280.1	RP11-33B1.2	8.57	1.34e-12	2.48e-08	1.05	0.71	Corneal astigmatism;	chr4:119634532	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.865	rs10213221	ENSG00000248280.1	RP11-33B1.2	8.57	1.35e-12	2.5e-08	1.03	0.71	Corneal astigmatism;	chr4:119334771	chr4:119440561~119450157:-
LAML	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-8.56	1.38e-12	2.55e-08	-0.75	-0.71	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-8.56	1.38e-12	2.55e-08	-0.75	-0.71	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-8.56	1.38e-12	2.55e-08	-0.75	-0.71	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
LAML	cis	rs2739330	0.685	rs4822453	ENSG00000225282.1	AP000350.6	8.55	1.43e-12	2.64e-08	0.92	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23926900~23929574:+
LAML	cis	rs916888	0.773	rs9896243	ENSG00000214401.4	KANSL1-AS1	8.55	1.44e-12	2.67e-08	1	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46193576~46196723:+
LAML	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-8.54	1.51e-12	2.78e-08	-0.89	-0.71	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
LAML	cis	rs55794721	0.543	rs1293260	ENSG00000261349.1	RP3-465N24.5	-8.54	1.51e-12	2.79e-08	-0.78	-0.71	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25266102~25267136:-
LAML	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	8.53	1.58e-12	2.92e-08	0.92	0.71	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
LAML	cis	rs3096299	0.685	rs8050512	ENSG00000274627.1	RP11-104N10.2	8.52	1.66e-12	3.06e-08	0.89	0.71	Multiple myeloma (IgH translocation);	chr16:89485912	chr16:89516797~89522217:+
LAML	cis	rs853679	0.55	rs1225598	ENSG00000220721.1	OR1F12	8.52	1.66e-12	3.06e-08	0.87	0.71	Depression;	chr6:28193021	chr6:28073316~28074233:+
LAML	cis	rs853679	0.55	rs1150689	ENSG00000220721.1	OR1F12	8.52	1.66e-12	3.06e-08	0.87	0.71	Depression;	chr6:28197321	chr6:28073316~28074233:+
LAML	cis	rs853679	0.55	rs1225599	ENSG00000220721.1	OR1F12	8.52	1.66e-12	3.06e-08	0.87	0.71	Depression;	chr6:28197412	chr6:28073316~28074233:+
LAML	cis	rs853679	0.574	rs1233705	ENSG00000220721.1	OR1F12	8.52	1.66e-12	3.06e-08	0.87	0.71	Depression;	chr6:28198669	chr6:28073316~28074233:+
LAML	cis	rs853679	0.55	rs1233704	ENSG00000220721.1	OR1F12	-8.52	1.66e-12	3.06e-08	-0.87	-0.71	Depression;	chr6:28199145	chr6:28073316~28074233:+
LAML	cis	rs853679	0.55	rs1233701	ENSG00000220721.1	OR1F12	-8.52	1.66e-12	3.06e-08	-0.87	-0.71	Depression;	chr6:28200948	chr6:28073316~28074233:+
LAML	cis	rs853679	0.55	rs1237875	ENSG00000220721.1	OR1F12	-8.52	1.66e-12	3.06e-08	-0.87	-0.71	Depression;	chr6:28205232	chr6:28073316~28074233:+
LAML	cis	rs7104764	0.879	rs511744	ENSG00000277290.1	RP11-326C3.16	-8.52	1.67e-12	3.07e-08	-1.01	-0.71	Menarche (age at onset);	chr11:219089	chr11:243099~243483:-
LAML	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	8.51	1.68e-12	3.1e-08	0.96	0.71	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
LAML	cis	rs916888	0.779	rs199498	ENSG00000261575.2	RP11-259G18.1	8.5	1.77e-12	3.25e-08	1	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46267037~46268694:+
LAML	cis	rs6782228	0.675	rs6806687	ENSG00000277250.1	Metazoa_SRP	8.49	1.88e-12	3.45e-08	0.88	0.71	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128673681~128674021:-
LAML	cis	rs3096299	0.685	rs2911244	ENSG00000274627.1	RP11-104N10.2	8.48	1.91e-12	3.5e-08	0.9	0.71	Multiple myeloma (IgH translocation);	chr16:89455452	chr16:89516797~89522217:+
LAML	cis	rs5760092	0.755	rs4585126	ENSG00000225282.1	AP000350.6	-8.48	1.99e-12	3.63e-08	-1.04	-0.71	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23927818	chr22:23926900~23929574:+
LAML	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	8.47	2.05e-12	3.72e-08	0.76	0.71	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
LAML	cis	rs1930961	1	rs6004675	ENSG00000272977.1	CTA-390C10.10	-8.47	2.08e-12	3.78e-08	-1.03	-0.71	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25476218~25479971:+
LAML	cis	rs2739330	0.76	rs5760095	ENSG00000218537.1	MIF-AS1	8.45	2.18e-12	3.96e-08	1	0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23905106	chr22:23894426~23898930:-
LAML	cis	rs11098499	0.535	rs7671759	ENSG00000248280.1	RP11-33B1.2	8.44	2.32e-12	4.19e-08	0.98	0.71	Corneal astigmatism;	chr4:119326939	chr4:119440561~119450157:-
LAML	cis	rs561341	0.941	rs8066558	ENSG00000266379.5	RP11-640N20.8	8.44	2.33e-12	4.21e-08	1.16	0.71	Hip circumference adjusted for BMI;	chr17:31945860	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs2470267	ENSG00000266379.5	RP11-640N20.8	8.44	2.33e-12	4.21e-08	1.16	0.71	Hip circumference adjusted for BMI;	chr17:31947113	chr17:32088160~32094933:-
LAML	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-8.44	2.34e-12	4.23e-08	-1.01	-0.71	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
LAML	cis	rs12922317	0.538	rs446289	ENSG00000260224.1	UBL5P4	-8.43	2.38e-12	4.29e-08	-0.81	-0.7	Schizophrenia;	chr16:11976629	chr16:11968508~11968743:-
LAML	cis	rs3096299	0.658	rs12443705	ENSG00000274627.1	RP11-104N10.2	8.43	2.38e-12	4.29e-08	0.9	0.7	Multiple myeloma (IgH translocation);	chr16:89480646	chr16:89516797~89522217:+
LAML	cis	rs3096299	0.685	rs4785675	ENSG00000274627.1	RP11-104N10.2	8.43	2.38e-12	4.3e-08	0.89	0.7	Multiple myeloma (IgH translocation);	chr16:89473566	chr16:89516797~89522217:+
LAML	cis	rs3096299	0.685	rs4238830	ENSG00000274627.1	RP11-104N10.2	8.43	2.38e-12	4.3e-08	0.89	0.7	Multiple myeloma (IgH translocation);	chr16:89473833	chr16:89516797~89522217:+
LAML	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-8.43	2.41e-12	4.34e-08	-0.8	-0.7	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
LAML	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-8.42	2.5e-12	4.51e-08	-1.02	-0.7	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
LAML	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-8.41	2.6e-12	4.67e-08	-0.77	-0.7	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-8.41	2.6e-12	4.67e-08	-0.77	-0.7	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-8.41	2.6e-12	4.67e-08	-0.77	-0.7	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.866	rs11249249	ENSG00000261349.1	RP3-465N24.5	-8.41	2.63e-12	4.73e-08	-0.79	-0.7	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25266102~25267136:-
LAML	cis	rs3096299	0.685	rs12935112	ENSG00000274627.1	RP11-104N10.2	-8.41	2.66e-12	4.78e-08	-0.89	-0.7	Multiple myeloma (IgH translocation);	chr16:89476450	chr16:89516797~89522217:+
LAML	cis	rs55794721	0.509	rs2375313	ENSG00000261349.1	RP3-465N24.5	-8.4	2.75e-12	4.94e-08	-0.79	-0.7	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25266102~25267136:-
LAML	cis	rs11098499	0.722	rs7673476	ENSG00000248280.1	RP11-33B1.2	8.4	2.79e-12	4.99e-08	0.99	0.7	Corneal astigmatism;	chr4:119327528	chr4:119440561~119450157:-
LAML	cis	rs561341	1	rs521919	ENSG00000266379.5	RP11-640N20.8	8.38	2.94e-12	5.09e-08	1.16	0.7	Hip circumference adjusted for BMI;	chr17:31971020	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs2428338	ENSG00000266379.5	RP11-640N20.8	8.38	2.94e-12	5.09e-08	1.16	0.7	Hip circumference adjusted for BMI;	chr17:31972610	chr17:32088160~32094933:-
LAML	cis	rs561341	0.882	rs563539	ENSG00000266379.5	RP11-640N20.8	8.38	2.94e-12	5.09e-08	1.16	0.7	Hip circumference adjusted for BMI;	chr17:31980939	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs1557731	ENSG00000266379.5	RP11-640N20.8	8.38	2.94e-12	5.09e-08	1.16	0.7	Hip circumference adjusted for BMI;	chr17:31994548	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs537166	ENSG00000266379.5	RP11-640N20.8	8.38	2.94e-12	5.09e-08	1.16	0.7	Hip circumference adjusted for BMI;	chr17:31999808	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs68140514	ENSG00000266379.5	RP11-640N20.8	8.38	2.94e-12	5.09e-08	1.16	0.7	Hip circumference adjusted for BMI;	chr17:32008762	chr17:32088160~32094933:-
LAML	cis	rs4713118	0.621	rs9295755	ENSG00000182477.5	OR2B8P	-8.38	2.97e-12	5.09e-08	-1.1	-0.7	Parkinson's disease;	chr6:28065396	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.621	rs9295756	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28065618	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.621	rs10484403	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28065745	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.621	rs4713132	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28066257	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.621	rs4713133	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28066263	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.621	rs4713134	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28066343	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.621	rs9368548	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28066959	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.587	rs61471148	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28069254	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380047	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28070115	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs7755442	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28071237	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4713135	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28071808	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs12174753	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28074687	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs55747925	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28076559	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs56310871	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28076704	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs34716816	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28078391	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393884	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28079011	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380049	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28080757	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380050	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28080760	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393885	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28082231	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393886	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28082261	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.515	rs9368549	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28082269	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs56364346	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28082984	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9357061	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28083994	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9368550	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28084025	chr6:28053228~28054165:-
LAML	cis	rs853679	0.542	rs2295594	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28085319	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs16893666	ENSG00000182477.5	OR2B8P	-8.38	2.97e-12	5.09e-08	-1.1	-0.7	Depression;	chr6:28086929	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs2273564	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28089816	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs1853097	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28090857	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393887	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28091242	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393888	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28091439	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs3734573	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28091659	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9357063	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28092227	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs3823180	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28093966	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9368551	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28094014	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393890	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28096077	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380052	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28096845	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9366715	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28096855	chr6:28053228~28054165:-
LAML	cis	rs853679	0.598	rs9380054	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28099759	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.547	rs2116981	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28100173	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9368552	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28100648	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs2281588	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28104824	chr6:28053228~28054165:-
LAML	cis	rs853679	0.542	rs34131763	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28107222	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs35193936	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28108492	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs17711344	ENSG00000182477.5	OR2B8P	-8.38	2.97e-12	5.09e-08	-1.1	-0.7	Depression;	chr6:28109824	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs36078605	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28110254	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs6932109	ENSG00000182477.5	OR2B8P	-8.38	2.97e-12	5.09e-08	-1.1	-0.7	Depression;	chr6:28110525	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.516	rs6931858	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28110633	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393891	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28111382	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9468286	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28111650	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.516	rs7739216	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28112168	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs35512245	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28112175	chr6:28053228~28054165:-
LAML	cis	rs853679	0.542	rs9393892	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28113616	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380055	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28113851	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9368553	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28114487	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9368554	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28114933	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4713137	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28115743	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9348793	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28116411	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.586	rs6905516	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28118700	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.586	rs6905522	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28118701	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.586	rs9468290	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28119896	chr6:28053228~28054165:-
LAML	cis	rs853679	0.542	rs6934769	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28123153	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs17711801	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28124529	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs6922063	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28126588	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs2275508	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28126953	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.527	rs9461433	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28127394	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9468292	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28127577	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs1947863	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28131566	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4713141	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28133900	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs1340004	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28135913	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380056	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28136698	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380057	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28136856	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs1947862	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28137418	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs6941992	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28138363	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.516	rs4713142	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28138569	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4713143	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28138981	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4713144	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28139012	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4713145	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28139049	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs3757187	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28139876	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs3757185	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28139998	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs1904841	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28140307	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs1904840	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28140454	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9368555	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28141189	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393893	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28141484	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs868987	ENSG00000182477.5	OR2B8P	-8.38	2.97e-12	5.09e-08	-1.1	-0.7	Depression;	chr6:28142370	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4713146	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28143758	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393894	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28144784	chr6:28053228~28054165:-
LAML	cis	rs853679	0.513	rs9468296	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28145952	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4711164	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28147378	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4711165	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28147406	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4713148	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28148143	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9348794	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28149979	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9468297	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28151096	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9295758	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28152885	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs17774663	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28153120	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9468298	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28154567	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9295759	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28156691	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9348796	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28158424	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs11552219	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28159056	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380058	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28159666	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393895	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28159843	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393896	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28159925	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393897	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28159932	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9357065	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28161802	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9357066	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28162053	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393898	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28162598	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9368556	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28163375	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9368557	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28163759	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380059	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28164580	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380060	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28164825	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs35227624	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28164948	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380061	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28165025	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9368558	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28165528	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.587	rs9393899	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28165750	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9283884	ENSG00000182477.5	OR2B8P	-8.38	2.97e-12	5.09e-08	-1.1	-0.7	Depression;	chr6:28167882	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4713150	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28168434	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.527	rs4713151	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Parkinson's disease;	chr6:28168578	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9393901	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28169019	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs3173443	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28169249	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs4713152	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28169676	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9348797	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28169755	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380062	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28169791	chr6:28053228~28054165:-
LAML	cis	rs853679	0.542	rs9380063	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28170075	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs12332979	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28173770	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs67878650	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28174809	chr6:28053228~28054165:-
LAML	cis	rs853679	0.569	rs9348798	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28175233	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9380065	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28176973	chr6:28053228~28054165:-
LAML	cis	rs853679	0.517	rs9295761	ENSG00000182477.5	OR2B8P	8.38	2.97e-12	5.09e-08	1.1	0.7	Depression;	chr6:28180209	chr6:28053228~28054165:-
LAML	cis	rs2739330	0.76	rs5751760	ENSG00000218537.1	MIF-AS1	8.38	3e-12	5.14e-08	0.97	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901386	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.703	rs5760112	ENSG00000218537.1	MIF-AS1	8.38	3e-12	5.14e-08	0.97	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23917585	chr22:23894426~23898930:-
LAML	cis	rs16828019	0.929	rs35883594	ENSG00000235358.1	RP11-399E6.1	8.36	3.2e-12	5.47e-08	1.29	0.7	Intelligence (multi-trait analysis);	chr1:41278421	chr1:41242373~41284861:+
LAML	cis	rs2739330	0.685	rs4822453	ENSG00000218537.1	MIF-AS1	8.36	3.26e-12	5.56e-08	1.01	0.7	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23912675	chr22:23894426~23898930:-
LAML	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-8.35	3.41e-12	5.8e-08	-1.05	-0.7	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-8.35	3.41e-12	5.8e-08	-1.05	-0.7	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-8.35	3.41e-12	5.8e-08	-1.05	-0.7	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
LAML	cis	rs10927875	0.632	rs4661666	ENSG00000178715.8	RP11-169K16.8	-8.35	3.47e-12	5.89e-08	-0.81	-0.7	Dilated cardiomyopathy;	chr1:15835976	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.632	rs10927863	ENSG00000178715.8	RP11-169K16.8	-8.35	3.47e-12	5.89e-08	-0.81	-0.7	Dilated cardiomyopathy;	chr1:15838752	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.632	rs10927864	ENSG00000178715.8	RP11-169K16.8	-8.35	3.47e-12	5.89e-08	-0.81	-0.7	Dilated cardiomyopathy;	chr1:15839166	chr1:15828232~15828669:+
LAML	cis	rs5769707	0.622	rs2018467	ENSG00000280224.1	CTA-722E9.1	-8.34	3.5e-12	5.94e-08	-0.77	-0.7	Monocyte percentage of white cells;Monocyte count;	chr22:49670631	chr22:49500568~49501585:+
LAML	cis	rs3096299	0.632	rs4399533	ENSG00000274627.1	RP11-104N10.2	8.34	3.54e-12	6.01e-08	0.88	0.7	Multiple myeloma (IgH translocation);	chr16:89472974	chr16:89516797~89522217:+
LAML	cis	rs4713118	0.5	rs9461434	ENSG00000182477.5	OR2B8P	8.34	3.55e-12	6.02e-08	1.17	0.7	Parkinson's disease;	chr6:28134687	chr6:28053228~28054165:-
LAML	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	8.33	3.69e-12	6.26e-08	1.21	0.7	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
LAML	cis	rs11098499	0.604	rs2389882	ENSG00000248280.1	RP11-33B1.2	8.32	3.84e-12	6.49e-08	1.03	0.7	Corneal astigmatism;	chr4:119645578	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.604	rs2389886	ENSG00000248280.1	RP11-33B1.2	8.32	3.84e-12	6.49e-08	1.03	0.7	Corneal astigmatism;	chr4:119649267	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.604	rs2389887	ENSG00000248280.1	RP11-33B1.2	8.32	3.84e-12	6.49e-08	1.03	0.7	Corneal astigmatism;	chr4:119649489	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.604	rs34278750	ENSG00000248280.1	RP11-33B1.2	8.32	3.84e-12	6.49e-08	1.03	0.7	Corneal astigmatism;	chr4:119649981	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.604	rs10022185	ENSG00000248280.1	RP11-33B1.2	8.32	3.84e-12	6.49e-08	1.03	0.7	Corneal astigmatism;	chr4:119650610	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.604	rs12642411	ENSG00000248280.1	RP11-33B1.2	8.32	3.84e-12	6.49e-08	1.03	0.7	Corneal astigmatism;	chr4:119659370	chr4:119440561~119450157:-
LAML	cis	rs858239	1	rs156407	ENSG00000230658.1	KLHL7-AS1	8.32	3.89e-12	6.57e-08	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23276020	chr7:23101228~23105703:-
LAML	cis	rs3096299	0.719	rs2353581	ENSG00000274627.1	RP11-104N10.2	8.31	3.99e-12	6.75e-08	0.87	0.7	Multiple myeloma (IgH translocation);	chr16:89452500	chr16:89516797~89522217:+
LAML	cis	rs3096299	0.719	rs12934708	ENSG00000274627.1	RP11-104N10.2	8.31	4.04e-12	6.81e-08	0.87	0.7	Multiple myeloma (IgH translocation);	chr16:89457382	chr16:89516797~89522217:+
LAML	cis	rs16828019	1	rs16828019	ENSG00000235358.1	RP11-399E6.1	8.31	4.09e-12	6.91e-08	1.3	0.7	Intelligence (multi-trait analysis);	chr1:41279363	chr1:41242373~41284861:+
LAML	cis	rs10927875	0.632	rs4661667	ENSG00000178715.8	RP11-169K16.8	-8.31	4.13e-12	6.96e-08	-0.81	-0.7	Dilated cardiomyopathy;	chr1:15836236	chr1:15828232~15828669:+
LAML	cis	rs3096299	0.658	rs4291902	ENSG00000274627.1	RP11-104N10.2	8.3	4.29e-12	7.2e-08	0.91	0.7	Multiple myeloma (IgH translocation);	chr16:89493907	chr16:89516797~89522217:+
LAML	cis	rs3096299	0.563	rs4600467	ENSG00000274627.1	RP11-104N10.2	8.3	4.29e-12	7.2e-08	0.91	0.7	Multiple myeloma (IgH translocation);	chr16:89496108	chr16:89516797~89522217:+
LAML	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	8.29	4.42e-12	7.41e-08	0.78	0.7	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
LAML	cis	rs3091242	0.9	rs1883427	ENSG00000261349.1	RP3-465N24.5	-8.29	4.42e-12	7.42e-08	-0.79	-0.7	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25266102~25267136:-
LAML	cis	rs7104764	0.917	rs3825075	ENSG00000277290.1	RP11-326C3.16	8.28	4.55e-12	7.63e-08	0.98	0.7	Menarche (age at onset);	chr11:217140	chr11:243099~243483:-
LAML	cis	rs858239	0.537	rs6942981	ENSG00000230658.1	KLHL7-AS1	8.28	4.7e-12	7.86e-08	0.94	0.7	Cerebrospinal fluid biomarker levels;	chr7:23191929	chr7:23101228~23105703:-
LAML	cis	rs916888	0.61	rs199454	ENSG00000214401.4	KANSL1-AS1	-8.26	4.97e-12	8.31e-08	-0.93	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46193576~46196723:+
LAML	cis	rs916888	0.61	rs199446	ENSG00000214401.4	KANSL1-AS1	-8.26	4.97e-12	8.31e-08	-0.93	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46193576~46196723:+
LAML	cis	rs916888	0.61	rs199536	ENSG00000214401.4	KANSL1-AS1	-8.26	4.97e-12	8.31e-08	-0.93	-0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46193576~46196723:+
LAML	cis	rs55794721	0.509	rs6699896	ENSG00000261349.1	RP3-465N24.5	-8.25	5.18e-12	8.64e-08	-0.77	-0.7	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs35148262	ENSG00000261349.1	RP3-465N24.5	-8.25	5.18e-12	8.64e-08	-0.77	-0.7	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-8.25	5.18e-12	8.64e-08	-0.77	-0.7	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
LAML	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-8.25	5.18e-12	8.64e-08	-0.77	-0.7	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
LAML	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-8.25	5.18e-12	8.64e-08	-0.77	-0.7	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
LAML	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-8.25	5.18e-12	8.64e-08	-0.77	-0.7	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
LAML	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-8.25	5.27e-12	8.77e-08	-0.77	-0.7	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
LAML	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-8.24	5.43e-12	9.04e-08	-1.07	-0.7	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-8.24	5.43e-12	9.04e-08	-1.07	-0.7	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
LAML	cis	rs3091242	0.933	rs932372	ENSG00000261349.1	RP3-465N24.5	-8.24	5.44e-12	9.06e-08	-0.78	-0.7	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-8.24	5.47e-12	9.1e-08	-0.78	-0.7	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
LAML	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-8.24	5.51e-12	9.16e-08	-1.05	-0.7	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
LAML	cis	rs6565180	0.926	rs12446288	ENSG00000183604.13	SMG1P5	-8.24	5.53e-12	9.18e-08	-0.77	-0.7	Tonsillectomy;	chr16:30377388	chr16:30267553~30335374:-
LAML	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	8.23	5.78e-12	9.56e-08	0.72	0.7	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
LAML	cis	rs10927875	0.632	rs6699394	ENSG00000178715.8	RP11-169K16.8	-8.23	5.79e-12	9.56e-08	-0.81	-0.7	Dilated cardiomyopathy;	chr1:15818648	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.562	rs10803401	ENSG00000178715.8	RP11-169K16.8	-8.23	5.79e-12	9.56e-08	-0.81	-0.7	Dilated cardiomyopathy;	chr1:15820882	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.632	rs6677321	ENSG00000178715.8	RP11-169K16.8	-8.23	5.79e-12	9.56e-08	-0.81	-0.7	Dilated cardiomyopathy;	chr1:15822806	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.597	rs61782184	ENSG00000178715.8	RP11-169K16.8	-8.23	5.79e-12	9.56e-08	-0.81	-0.7	Dilated cardiomyopathy;	chr1:15824481	chr1:15828232~15828669:+
LAML	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	8.22	5.9e-12	9.69e-08	0.78	0.7	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
LAML	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	8.22	5.9e-12	9.69e-08	0.78	0.7	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
LAML	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
LAML	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
LAML	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
LAML	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
LAML	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
LAML	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
LAML	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
LAML	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-8.22	5.9e-12	9.69e-08	-0.78	-0.7	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
LAML	cis	rs858239	0.669	rs1618339	ENSG00000230658.1	KLHL7-AS1	8.22	5.98e-12	9.8e-08	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23190155	chr7:23101228~23105703:-
LAML	cis	rs3091242	1	rs646867	ENSG00000261349.1	RP3-465N24.5	-8.21	6.28e-12	1.03e-07	-0.79	-0.7	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25266102~25267136:-
LAML	cis	rs916888	0.61	rs199454	ENSG00000261575.2	RP11-259G18.1	-8.2	6.58e-12	1.08e-07	-0.96	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:46267037~46268694:+
LAML	cis	rs916888	0.61	rs199446	ENSG00000261575.2	RP11-259G18.1	-8.2	6.58e-12	1.08e-07	-0.96	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:46267037~46268694:+
LAML	cis	rs916888	0.61	rs199536	ENSG00000261575.2	RP11-259G18.1	-8.2	6.58e-12	1.08e-07	-0.96	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:46267037~46268694:+
LAML	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	8.19	6.84e-12	1.12e-07	0.78	0.69	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	8.19	6.84e-12	1.12e-07	0.78	0.69	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
LAML	cis	rs6452524	0.618	rs4266384	ENSG00000249664.1	CTD-2227C6.2	8.18	6.94e-12	1.13e-07	0.88	0.69	Hypertension (SNP x SNP interaction);	chr5:83080872	chr5:83012285~83013109:-
LAML	cis	rs11098499	0.644	rs34835603	ENSG00000248280.1	RP11-33B1.2	8.17	7.31e-12	1.19e-07	1.02	0.69	Corneal astigmatism;	chr4:119632273	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.615	rs28850368	ENSG00000248280.1	RP11-33B1.2	8.17	7.31e-12	1.19e-07	1.02	0.69	Corneal astigmatism;	chr4:119633158	chr4:119440561~119450157:-
LAML	cis	rs3096299	0.667	rs2965947	ENSG00000274627.1	RP11-104N10.2	8.17	7.33e-12	1.19e-07	0.85	0.69	Multiple myeloma (IgH translocation);	chr16:89452262	chr16:89516797~89522217:+
LAML	cis	rs858239	1	rs199351	ENSG00000230658.1	KLHL7-AS1	8.17	7.34e-12	1.19e-07	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23260430	chr7:23101228~23105703:-
LAML	cis	rs858239	0.568	rs6970694	ENSG00000230658.1	KLHL7-AS1	8.17	7.44e-12	1.21e-07	0.94	0.69	Cerebrospinal fluid biomarker levels;	chr7:23211209	chr7:23101228~23105703:-
LAML	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-8.17	7.45e-12	1.21e-07	-0.78	-0.69	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
LAML	cis	rs11098499	0.532	rs4504231	ENSG00000248280.1	RP11-33B1.2	8.16	7.77e-12	1.26e-07	1.09	0.69	Corneal astigmatism;	chr4:119665736	chr4:119440561~119450157:-
LAML	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	8.15	7.97e-12	1.29e-07	0.78	0.69	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
LAML	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	8.15	8.03e-12	1.3e-07	0.8	0.69	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
LAML	cis	rs7131987	0.526	rs7954375	ENSG00000257176.2	RP11-996F15.2	8.15	8.05e-12	1.3e-07	0.73	0.69	QT interval;	chr12:29241487	chr12:29280418~29317848:-
LAML	cis	rs6452524	0.56	rs6895174	ENSG00000249664.1	CTD-2227C6.2	8.15	8.09e-12	1.31e-07	0.88	0.69	Hypertension (SNP x SNP interaction);	chr5:83071606	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs6452502	ENSG00000249664.1	CTD-2227C6.2	8.15	8.09e-12	1.31e-07	0.88	0.69	Hypertension (SNP x SNP interaction);	chr5:83074578	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs6452503	ENSG00000249664.1	CTD-2227C6.2	8.15	8.09e-12	1.31e-07	0.88	0.69	Hypertension (SNP x SNP interaction);	chr5:83074596	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs6452504	ENSG00000249664.1	CTD-2227C6.2	8.15	8.09e-12	1.31e-07	0.88	0.69	Hypertension (SNP x SNP interaction);	chr5:83074625	chr5:83012285~83013109:-
LAML	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	8.14	8.42e-12	1.35e-07	0.72	0.69	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	8.14	8.42e-12	1.35e-07	0.72	0.69	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	8.14	8.42e-12	1.35e-07	0.72	0.69	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	8.14	8.42e-12	1.35e-07	0.72	0.69	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	8.14	8.42e-12	1.35e-07	0.72	0.69	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.623	rs7964831	ENSG00000257176.2	RP11-996F15.2	-8.14	8.42e-12	1.35e-07	-0.72	-0.69	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29280418~29317848:-
LAML	cis	rs2739330	0.76	rs1002286	ENSG00000218537.1	MIF-AS1	-8.13	8.78e-12	1.41e-07	-0.97	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23915150	chr22:23894426~23898930:-
LAML	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	8.12	9.26e-12	1.48e-07	1.03	0.69	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
LAML	cis	rs6452524	0.618	rs6452506	ENSG00000249664.1	CTD-2227C6.2	8.11	9.63e-12	1.54e-07	0.88	0.69	Hypertension (SNP x SNP interaction);	chr5:83075844	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs1993948	ENSG00000249664.1	CTD-2227C6.2	8.11	9.63e-12	1.54e-07	0.88	0.69	Hypertension (SNP x SNP interaction);	chr5:83076461	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs2075685	ENSG00000249664.1	CTD-2227C6.2	8.11	9.63e-12	1.54e-07	0.88	0.69	Hypertension (SNP x SNP interaction);	chr5:83076846	chr5:83012285~83013109:-
LAML	cis	rs3091242	0.836	rs34997029	ENSG00000261349.1	RP3-465N24.5	8.11	9.63e-12	1.54e-07	0.77	0.69	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs1534954	ENSG00000261349.1	RP3-465N24.5	-8.09	1.03e-11	1.65e-07	-0.77	-0.69	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.9	rs35345536	ENSG00000261349.1	RP3-465N24.5	-8.09	1.03e-11	1.65e-07	-0.77	-0.69	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25266102~25267136:-
LAML	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-8.09	1.03e-11	1.65e-07	-0.77	-0.69	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
LAML	cis	rs2739330	0.761	rs5760176	ENSG00000218537.1	MIF-AS1	-8.08	1.09e-11	1.74e-07	-0.96	-0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23894426~23898930:-
LAML	cis	rs2739330	0.731	rs5751792	ENSG00000218537.1	MIF-AS1	8.08	1.09e-11	1.74e-07	0.96	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23894426~23898930:-
LAML	cis	rs853679	1	rs10456362	ENSG00000220721.1	OR1F12	-8.07	1.12e-11	1.77e-07	-1.01	-0.69	Depression;	chr6:28254038	chr6:28073316~28074233:+
LAML	cis	rs3096299	0.658	rs3934737	ENSG00000274627.1	RP11-104N10.2	8.07	1.15e-11	1.81e-07	0.89	0.69	Multiple myeloma (IgH translocation);	chr16:89493801	chr16:89516797~89522217:+
LAML	cis	rs11098499	0.675	rs11098534	ENSG00000248280.1	RP11-33B1.2	8.06	1.19e-11	1.87e-07	1.02	0.69	Corneal astigmatism;	chr4:119635617	chr4:119440561~119450157:-
LAML	cis	rs1930961	1	rs1930961	ENSG00000272977.1	CTA-390C10.10	-8.06	1.2e-11	1.89e-07	-1.12	-0.69	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25476218~25479971:+
LAML	cis	rs9506514	0.509	rs9509294	ENSG00000238286.1	SLC35E1P1	-8.06	1.2e-11	1.9e-07	-0.74	-0.69	Coronary artery calcification;	chr13:20600506	chr13:20607268~20608131:+
LAML	cis	rs7131987	0.565	rs1991113	ENSG00000257176.2	RP11-996F15.2	-8.05	1.24e-11	1.95e-07	-0.72	-0.69	QT interval;	chr12:29239070	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs7968883	ENSG00000257176.2	RP11-996F15.2	8.05	1.24e-11	1.95e-07	0.72	0.69	QT interval;	chr12:29241258	chr12:29280418~29317848:-
LAML	cis	rs916888	0.61	rs199452	ENSG00000214401.4	KANSL1-AS1	8.05	1.26e-11	1.98e-07	0.92	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46193576~46196723:+
LAML	cis	rs916888	0.647	rs199449	ENSG00000214401.4	KANSL1-AS1	8.05	1.26e-11	1.98e-07	0.92	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46193576~46196723:+
LAML	cis	rs916888	0.61	rs199444	ENSG00000214401.4	KANSL1-AS1	8.05	1.26e-11	1.98e-07	0.92	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46193576~46196723:+
LAML	cis	rs916888	0.61	rs199442	ENSG00000214401.4	KANSL1-AS1	8.05	1.26e-11	1.98e-07	0.92	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46193576~46196723:+
LAML	cis	rs916888	0.61	rs199436	ENSG00000214401.4	KANSL1-AS1	-8.05	1.26e-11	1.98e-07	-0.92	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46193576~46196723:+
LAML	cis	rs916888	0.61	rs142167	ENSG00000214401.4	KANSL1-AS1	-8.05	1.26e-11	1.98e-07	-0.92	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46193576~46196723:+
LAML	cis	rs3096299	0.503	rs9940093	ENSG00000274627.1	RP11-104N10.2	8.04	1.29e-11	2.03e-07	0.89	0.69	Multiple myeloma (IgH translocation);	chr16:89492297	chr16:89516797~89522217:+
LAML	cis	rs916888	0.531	rs183211	ENSG00000261575.2	RP11-259G18.1	8.04	1.29e-11	2.03e-07	0.95	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46267037~46268694:+
LAML	cis	rs916888	0.61	rs199438	ENSG00000261575.2	RP11-259G18.1	8.04	1.29e-11	2.03e-07	0.95	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46267037~46268694:+
LAML	cis	rs11098499	0.754	rs10212714	ENSG00000248280.1	RP11-33B1.2	8.03	1.33e-11	2.08e-07	0.98	0.69	Corneal astigmatism;	chr4:119333147	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.754	rs1849457	ENSG00000248280.1	RP11-33B1.2	8.03	1.33e-11	2.08e-07	0.98	0.69	Corneal astigmatism;	chr4:119333200	chr4:119440561~119450157:-
LAML	cis	rs9326248	0.515	rs2727793	ENSG00000254851.1	RP11-109L13.1	-8.03	1.33e-11	2.09e-07	-0.98	-0.69	Blood protein levels;	chr11:116812658	chr11:117135528~117138582:+
LAML	cis	rs16828019	0.632	rs12749196	ENSG00000235358.1	RP11-399E6.1	8.03	1.34e-11	2.09e-07	1.38	0.69	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.777	rs12047657	ENSG00000235358.1	RP11-399E6.1	8.03	1.34e-11	2.09e-07	1.38	0.69	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.85	rs12027691	ENSG00000235358.1	RP11-399E6.1	8.03	1.34e-11	2.09e-07	1.38	0.69	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.777	rs12047078	ENSG00000235358.1	RP11-399E6.1	8.03	1.34e-11	2.09e-07	1.38	0.69	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.777	rs12739052	ENSG00000235358.1	RP11-399E6.1	8.03	1.34e-11	2.09e-07	1.38	0.69	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41242373~41284861:+
LAML	cis	rs16828019	0.777	rs12748235	ENSG00000235358.1	RP11-399E6.1	8.03	1.34e-11	2.09e-07	1.38	0.69	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41242373~41284861:+
LAML	cis	rs916888	0.61	rs199436	ENSG00000261575.2	RP11-259G18.1	-8.03	1.35e-11	2.1e-07	-0.94	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:46267037~46268694:+
LAML	cis	rs916888	0.61	rs142167	ENSG00000261575.2	RP11-259G18.1	-8.03	1.35e-11	2.1e-07	-0.94	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:46267037~46268694:+
LAML	cis	rs916888	0.61	rs199452	ENSG00000261575.2	RP11-259G18.1	8.03	1.35e-11	2.1e-07	0.94	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:46267037~46268694:+
LAML	cis	rs916888	0.647	rs199449	ENSG00000261575.2	RP11-259G18.1	8.03	1.35e-11	2.1e-07	0.94	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:46267037~46268694:+
LAML	cis	rs916888	0.61	rs199444	ENSG00000261575.2	RP11-259G18.1	8.03	1.35e-11	2.1e-07	0.94	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:46267037~46268694:+
LAML	cis	rs916888	0.61	rs199442	ENSG00000261575.2	RP11-259G18.1	8.03	1.35e-11	2.1e-07	0.94	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:46267037~46268694:+
LAML	cis	rs916888	0.61	rs199453	ENSG00000261575.2	RP11-259G18.1	8.03	1.35e-11	2.11e-07	0.94	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46267037~46268694:+
LAML	cis	rs11098499	0.644	rs3806808	ENSG00000248280.1	RP11-33B1.2	8.03	1.36e-11	2.12e-07	0.94	0.69	Corneal astigmatism;	chr4:119629930	chr4:119440561~119450157:-
LAML	cis	rs858239	0.636	rs7808488	ENSG00000230658.1	KLHL7-AS1	8.03	1.37e-11	2.13e-07	0.96	0.69	Cerebrospinal fluid biomarker levels;	chr7:23182251	chr7:23101228~23105703:-
LAML	cis	rs9506514	0.509	rs9509279	ENSG00000238286.1	SLC35E1P1	8	1.52e-11	2.36e-07	0.75	0.69	Coronary artery calcification;	chr13:20559580	chr13:20607268~20608131:+
LAML	cis	rs9506514	0.509	rs9509281	ENSG00000238286.1	SLC35E1P1	-8	1.53e-11	2.37e-07	-0.75	-0.69	Coronary artery calcification;	chr13:20564274	chr13:20607268~20608131:+
LAML	cis	rs11098499	0.566	rs17051356	ENSG00000248280.1	RP11-33B1.2	8	1.55e-11	2.41e-07	1.02	0.69	Corneal astigmatism;	chr4:119664153	chr4:119440561~119450157:-
LAML	cis	rs7131987	0.527	rs7308534	ENSG00000257176.2	RP11-996F15.2	7.99	1.58e-11	2.44e-07	0.73	0.69	QT interval;	chr12:29300269	chr12:29280418~29317848:-
LAML	cis	rs3096299	0.642	rs12934829	ENSG00000274627.1	RP11-104N10.2	7.99	1.58e-11	2.45e-07	0.86	0.69	Multiple myeloma (IgH translocation);	chr16:89456941	chr16:89516797~89522217:+
LAML	cis	rs916888	0.531	rs183211	ENSG00000214401.4	KANSL1-AS1	7.99	1.59e-11	2.46e-07	0.92	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:46193576~46196723:+
LAML	cis	rs916888	0.61	rs199438	ENSG00000214401.4	KANSL1-AS1	7.99	1.59e-11	2.46e-07	0.92	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:46193576~46196723:+
LAML	cis	rs3096299	0.504	rs4785574	ENSG00000274627.1	RP11-104N10.2	7.98	1.64e-11	2.53e-07	0.89	0.69	Multiple myeloma (IgH translocation);	chr16:89502467	chr16:89516797~89522217:+
LAML	cis	rs7587476	0.601	rs13021937	ENSG00000229267.2	AC072062.1	7.98	1.68e-11	2.6e-07	0.74	0.68	Neuroblastoma;	chr2:214809213	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.531	rs35933323	ENSG00000229267.2	AC072062.1	7.98	1.68e-11	2.6e-07	0.74	0.68	Neuroblastoma;	chr2:214809366	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.601	rs1129804	ENSG00000229267.2	AC072062.1	7.98	1.68e-11	2.6e-07	0.74	0.68	Neuroblastoma;	chr2:214809599	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.601	rs17489363	ENSG00000229267.2	AC072062.1	7.98	1.68e-11	2.6e-07	0.74	0.68	Neuroblastoma;	chr2:214809617	chr2:214810229~214963274:+
LAML	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-7.98	1.69e-11	2.6e-07	-1.03	-0.68	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-7.98	1.69e-11	2.6e-07	-1.03	-0.68	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-7.98	1.69e-11	2.6e-07	-1.03	-0.68	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-7.98	1.69e-11	2.6e-07	-1.03	-0.68	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
LAML	cis	rs561341	1	rs4795670	ENSG00000266379.5	RP11-640N20.8	7.97	1.74e-11	2.67e-07	1.12	0.68	Hip circumference adjusted for BMI;	chr17:31917820	chr17:32088160~32094933:-
LAML	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	7.97	1.75e-11	2.69e-07	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
LAML	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	7.97	1.75e-11	2.69e-07	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
LAML	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	7.97	1.75e-11	2.69e-07	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
LAML	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	7.97	1.75e-11	2.69e-07	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
LAML	cis	rs5769707	1	rs5769707	ENSG00000280224.1	CTA-722E9.1	-7.97	1.75e-11	2.69e-07	-0.88	-0.68	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49500568~49501585:+
LAML	cis	rs62070183	0.766	rs10512441	ENSG00000264458.1	RP11-220C2.1	-7.96	1.79e-11	2.75e-07	-0.97	-0.68	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32627739~32686484:+
LAML	cis	rs11098499	0.644	rs10009566	ENSG00000248280.1	RP11-33B1.2	7.96	1.81e-11	2.76e-07	0.95	0.68	Corneal astigmatism;	chr4:119637453	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.644	rs10012252	ENSG00000248280.1	RP11-33B1.2	7.96	1.81e-11	2.76e-07	0.95	0.68	Corneal astigmatism;	chr4:119637984	chr4:119440561~119450157:-
LAML	cis	rs6452524	0.618	rs1478487	ENSG00000249664.1	CTD-2227C6.2	7.96	1.81e-11	2.77e-07	0.86	0.68	Hypertension (SNP x SNP interaction);	chr5:83080900	chr5:83012285~83013109:-
LAML	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-7.96	1.82e-11	2.78e-07	-0.77	-0.68	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
LAML	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	7.95	1.9e-11	2.91e-07	1.29	0.68	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	7.95	1.9e-11	2.91e-07	1.29	0.68	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
LAML	cis	rs3096299	0.503	rs4785677	ENSG00000274627.1	RP11-104N10.2	7.94	1.96e-11	2.99e-07	0.89	0.68	Multiple myeloma (IgH translocation);	chr16:89488693	chr16:89516797~89522217:+
LAML	cis	rs7131987	0.585	rs2059362	ENSG00000257176.2	RP11-996F15.2	7.94	1.98e-11	3.01e-07	0.73	0.68	QT interval;	chr12:29243072	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs10843365	ENSG00000257176.2	RP11-996F15.2	7.94	1.98e-11	3.01e-07	0.73	0.68	QT interval;	chr12:29252691	chr12:29280418~29317848:-
LAML	cis	rs11098499	0.604	rs17051352	ENSG00000248280.1	RP11-33B1.2	7.93	2.04e-11	3.1e-07	1.01	0.68	Corneal astigmatism;	chr4:119660272	chr4:119440561~119450157:-
LAML	cis	rs12931792	0.712	rs2887799	ENSG00000183604.13	SMG1P5	-7.93	2.09e-11	3.18e-07	-0.83	-0.68	Tonsillectomy;	chr16:30152512	chr16:30267553~30335374:-
LAML	cis	rs7587476	0.601	rs6715570	ENSG00000229267.2	AC072062.1	7.93	2.09e-11	3.18e-07	0.73	0.68	Neuroblastoma;	chr2:214808716	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.601	rs17489231	ENSG00000229267.2	AC072062.1	7.93	2.09e-11	3.18e-07	0.73	0.68	Neuroblastoma;	chr2:214809015	chr2:214810229~214963274:+
LAML	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	7.92	2.12e-11	3.21e-07	0.9	0.68	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
LAML	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-7.92	2.14e-11	3.25e-07	-1.03	-0.68	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-7.92	2.14e-11	3.25e-07	-1.03	-0.68	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-7.92	2.14e-11	3.25e-07	-1.03	-0.68	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-7.92	2.14e-11	3.25e-07	-1.03	-0.68	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
LAML	cis	rs5760092	0.618	rs5996631	ENSG00000225282.1	AP000350.6	-7.91	2.28e-11	3.45e-07	-0.99	-0.68	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23926900~23929574:+
LAML	cis	rs5760092	0.618	rs4461358	ENSG00000225282.1	AP000350.6	-7.91	2.28e-11	3.45e-07	-0.99	-0.68	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23926900~23929574:+
LAML	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-7.9	2.37e-11	3.58e-07	-0.77	-0.68	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
LAML	cis	rs3096299	0.685	rs4329923	ENSG00000274627.1	RP11-104N10.2	7.9	2.38e-11	3.59e-07	0.85	0.68	Multiple myeloma (IgH translocation);	chr16:89493770	chr16:89516797~89522217:+
LAML	cis	rs3091242	0.933	rs28530483	ENSG00000261349.1	RP3-465N24.5	-7.9	2.39e-11	3.61e-07	-0.77	-0.68	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25266102~25267136:-
LAML	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-7.89	2.42e-11	3.65e-07	-0.97	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
LAML	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	7.89	2.45e-11	3.69e-07	0.7	0.68	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	7.89	2.45e-11	3.69e-07	0.7	0.68	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
LAML	cis	rs916888	0.61	rs199453	ENSG00000214401.4	KANSL1-AS1	7.89	2.5e-11	3.75e-07	0.9	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:46193576~46196723:+
LAML	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	7.89	2.5e-11	3.75e-07	0.7	0.68	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
LAML	cis	rs6452524	0.648	rs27364	ENSG00000249664.1	CTD-2227C6.2	7.88	2.52e-11	3.78e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83052137	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs255561	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83054991	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs10462394	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83058735	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs1871203	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83059567	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs7722924	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83060223	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs10051445	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83060280	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs6867727	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83061333	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs7723639	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83062610	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs2306336	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83064964	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.589	rs6882386	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83065555	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs6860752	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83065587	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.618	rs3899556	ENSG00000249664.1	CTD-2227C6.2	7.88	2.6e-11	3.89e-07	0.85	0.68	Hypertension (SNP x SNP interaction);	chr5:83067862	chr5:83012285~83013109:-
LAML	cis	rs3096299	0.685	rs4785571	ENSG00000274627.1	RP11-104N10.2	7.87	2.63e-11	3.93e-07	0.86	0.68	Multiple myeloma (IgH translocation);	chr16:89498761	chr16:89516797~89522217:+
LAML	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	7.87	2.64e-11	3.93e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	7.87	2.64e-11	3.93e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	7.87	2.64e-11	3.93e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	7.87	2.64e-11	3.93e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	7.87	2.64e-11	3.93e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
LAML	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	7.87	2.64e-11	3.93e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
LAML	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	7.87	2.64e-11	3.93e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
LAML	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	7.87	2.64e-11	3.93e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
LAML	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	7.87	2.64e-11	3.93e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
LAML	cis	rs858239	0.601	rs6461702	ENSG00000230658.1	KLHL7-AS1	7.87	2.64e-11	3.94e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23209654	chr7:23101228~23105703:-
LAML	cis	rs6565180	1	rs11863150	ENSG00000183604.13	SMG1P5	-7.87	2.72e-11	4.04e-07	-0.75	-0.68	Tonsillectomy;	chr16:30374182	chr16:30267553~30335374:-
LAML	cis	rs561341	1	rs8064843	ENSG00000266379.5	RP11-640N20.8	7.86	2.8e-11	4.17e-07	1.05	0.68	Hip circumference adjusted for BMI;	chr17:31918725	chr17:32088160~32094933:-
LAML	cis	rs11098499	0.644	rs2389880	ENSG00000248280.1	RP11-33B1.2	7.86	2.85e-11	4.25e-07	0.95	0.68	Corneal astigmatism;	chr4:119638715	chr4:119440561~119450157:-
LAML	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	7.85	2.89e-11	4.29e-07	0.87	0.68	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
LAML	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	7.85	2.9e-11	4.31e-07	0.93	0.68	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
LAML	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	7.85	2.93e-11	4.34e-07	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
LAML	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	7.85	2.93e-11	4.34e-07	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
LAML	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	7.85	2.93e-11	4.34e-07	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
LAML	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	7.85	2.95e-11	4.37e-07	0.76	0.68	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
LAML	cis	rs2739330	0.731	rs5751792	ENSG00000225282.1	AP000350.6	7.85	2.96e-11	4.38e-07	0.85	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005096	chr22:23926900~23929574:+
LAML	cis	rs2739330	0.761	rs5760176	ENSG00000225282.1	AP000350.6	-7.85	2.96e-11	4.38e-07	-0.85	-0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:24005875	chr22:23926900~23929574:+
LAML	cis	rs55794721	0.509	rs909834	ENSG00000261349.1	RP3-465N24.5	-7.84	2.99e-11	4.42e-07	-0.77	-0.68	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25266102~25267136:-
LAML	cis	rs2739330	0.731	rs2000468	ENSG00000218537.1	MIF-AS1	7.84	3.05e-11	4.51e-07	0.95	0.68	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23899424	chr22:23894426~23898930:-
LAML	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-7.84	3.09e-11	4.56e-07	-0.87	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
LAML	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-7.84	3.1e-11	4.57e-07	-0.77	-0.68	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
LAML	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-7.83	3.13e-11	4.6e-07	-0.77	-0.68	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-7.83	3.13e-11	4.6e-07	-0.77	-0.68	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
LAML	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-7.83	3.13e-11	4.6e-07	-0.77	-0.68	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
LAML	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	7.83	3.21e-11	4.71e-07	0.76	0.68	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	7.83	3.21e-11	4.71e-07	0.76	0.68	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
LAML	cis	rs3096299	0.685	rs4785676	ENSG00000274627.1	RP11-104N10.2	7.83	3.22e-11	4.72e-07	0.87	0.68	Multiple myeloma (IgH translocation);	chr16:89487216	chr16:89516797~89522217:+
LAML	cis	rs561341	0.883	rs886224	ENSG00000266379.5	RP11-640N20.8	7.82	3.27e-11	4.79e-07	1.2	0.68	Hip circumference adjusted for BMI;	chr17:31902883	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs8073186	ENSG00000266379.5	RP11-640N20.8	7.81	3.43e-11	5.02e-07	1.1	0.68	Hip circumference adjusted for BMI;	chr17:31917937	chr17:32088160~32094933:-
LAML	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-7.81	3.48e-11	5.08e-07	-0.76	-0.68	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-7.8	3.61e-11	5.24e-07	-0.76	-0.68	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
LAML	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	7.8	3.63e-11	5.26e-07	0.75	0.68	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
LAML	cis	rs853679	1	rs10456362	ENSG00000187763.3	OR2B7P	-7.8	3.69e-11	5.34e-07	-1.13	-0.68	Depression;	chr6:28254038	chr6:28046434~28047367:+
LAML	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	7.79	3.74e-11	5.42e-07	0.81	0.68	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
LAML	cis	rs853679	0.55	rs6901017	ENSG00000187763.3	OR2B7P	7.79	3.77e-11	5.45e-07	0.96	0.68	Depression;	chr6:28184805	chr6:28046434~28047367:+
LAML	cis	rs858239	0.601	rs28673077	ENSG00000230658.1	KLHL7-AS1	7.79	3.86e-11	5.58e-07	0.92	0.68	Cerebrospinal fluid biomarker levels;	chr7:23211235	chr7:23101228~23105703:-
LAML	cis	rs1930961	1	rs6004668	ENSG00000100058.11	CRYBB2P1	7.78	3.91e-11	5.66e-07	1.19	0.68	Bipolar disorder with mood-incongruent psychosis;	chr22:25478535	chr22:25448105~25520854:+
LAML	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	7.77	4.05e-11	5.84e-07	0.7	0.68	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
LAML	cis	rs6782228	0.675	rs9813845	ENSG00000277250.1	Metazoa_SRP	-7.77	4.09e-11	5.9e-07	-0.89	-0.68	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128673681~128674021:-
LAML	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-7.77	4.1e-11	5.91e-07	-0.98	-0.68	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
LAML	cis	rs1930961	1	rs6004657	ENSG00000100058.11	CRYBB2P1	-7.77	4.19e-11	6.03e-07	-1.18	-0.68	Bipolar disorder with mood-incongruent psychosis;	chr22:25459747	chr22:25448105~25520854:+
LAML	cis	rs9326248	0.53	rs11216171	ENSG00000254851.1	RP11-109L13.1	-7.76	4.27e-11	6.14e-07	-0.96	-0.67	Blood protein levels;	chr11:116878397	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.769	rs499910	ENSG00000254851.1	RP11-109L13.1	-7.76	4.27e-11	6.14e-07	-0.96	-0.67	Blood protein levels;	chr11:116892318	chr11:117135528~117138582:+
LAML	cis	rs9457247	0.811	rs239936	ENSG00000265828.1	MIR3939	-7.76	4.38e-11	6.28e-07	-0.83	-0.67	Crohn's disease;	chr6:166998128	chr6:166997807~166997912:-
LAML	cis	rs6565180	0.926	rs8046445	ENSG00000183604.13	SMG1P5	7.75	4.4e-11	6.3e-07	0.75	0.67	Tonsillectomy;	chr16:30374941	chr16:30267553~30335374:-
LAML	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	7.75	4.4e-11	6.31e-07	0.75	0.67	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
LAML	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	7.75	4.46e-11	6.38e-07	0.72	0.67	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
LAML	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-7.75	4.56e-11	6.51e-07	-0.7	-0.67	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-7.75	4.56e-11	6.51e-07	-0.7	-0.67	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
LAML	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	7.74	4.59e-11	6.55e-07	0.74	0.67	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
LAML	cis	rs9457247	0.663	rs6456143	ENSG00000265828.1	MIR3939	-7.74	4.61e-11	6.58e-07	-0.86	-0.67	Crohn's disease;	chr6:167001952	chr6:166997807~166997912:-
LAML	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	7.74	4.77e-11	6.77e-07	0.72	0.67	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
LAML	cis	rs1577917	0.796	rs12661231	ENSG00000203875.9	SNHG5	-7.74	4.78e-11	6.79e-07	-0.87	-0.67	Response to antipsychotic treatment;	chr6:85834753	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.839	rs12664634	ENSG00000203875.9	SNHG5	-7.74	4.78e-11	6.79e-07	-0.87	-0.67	Response to antipsychotic treatment;	chr6:85869696	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.839	rs6454504	ENSG00000203875.9	SNHG5	-7.74	4.78e-11	6.79e-07	-0.87	-0.67	Response to antipsychotic treatment;	chr6:85870612	chr6:85660950~85678736:-
LAML	cis	rs853679	0.628	rs9368560	ENSG00000187763.3	OR2B7P	7.73	4.87e-11	6.9e-07	0.97	0.67	Depression;	chr6:28192182	chr6:28046434~28047367:+
LAML	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	7.73	4.93e-11	6.99e-07	0.87	0.67	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
LAML	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-7.73	4.96e-11	7.03e-07	-0.76	-0.67	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
LAML	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	7.72	5e-11	7.07e-07	0.93	0.67	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
LAML	cis	rs2929278	0.617	rs694461	ENSG00000249839.1	AC011330.5	7.72	5e-11	7.08e-07	0.82	0.67	Schizophrenia;	chr15:43803865	chr15:43663654~43684339:-
LAML	cis	rs2486288	0.656	rs8041702	ENSG00000259520.4	CTD-2651B20.3	7.72	5.06e-11	7.15e-07	1.01	0.67	Glomerular filtration rate;	chr15:45254895	chr15:45251580~45279251:-
LAML	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	7.72	5.11e-11	7.22e-07	1.29	0.67	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	7.72	5.11e-11	7.22e-07	1.29	0.67	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
LAML	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	7.72	5.16e-11	7.28e-07	0.93	0.67	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
LAML	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	7.72	5.18e-11	7.28e-07	0.88	0.67	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
LAML	cis	rs1930961	1	rs6004667	ENSG00000100058.11	CRYBB2P1	7.72	5.18e-11	7.28e-07	1.17	0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25478497	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs6519611	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25449888	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs9624834	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25450048	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs9624835	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25450054	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs9624836	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25450120	chr22:25448105~25520854:+
LAML	cis	rs1930961	0.867	rs6423498	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25457401	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs6004658	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25460264	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs6004659	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25460444	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs6004662	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25466157	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs760555	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25476870	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs7285549	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25478613	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs6004669	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25479836	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs5996946	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25480021	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs997873	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25482315	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs997872	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25482647	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs6004671	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25483507	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs6004672	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25485046	chr22:25448105~25520854:+
LAML	cis	rs1930961	1	rs6004673	ENSG00000100058.11	CRYBB2P1	-7.72	5.18e-11	7.28e-07	-1.17	-0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25489386	chr22:25448105~25520854:+
LAML	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-7.72	5.21e-11	7.3e-07	-0.86	-0.67	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.793	rs9362245	ENSG00000203875.9	SNHG5	-7.72	5.21e-11	7.3e-07	-0.86	-0.67	Response to antipsychotic treatment;	chr6:85786602	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-7.72	5.21e-11	7.3e-07	-0.86	-0.67	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.839	rs6929514	ENSG00000203875.9	SNHG5	-7.72	5.21e-11	7.3e-07	-0.86	-0.67	Response to antipsychotic treatment;	chr6:85816050	chr6:85660950~85678736:-
LAML	cis	rs3096299	0.719	rs2965818	ENSG00000274627.1	RP11-104N10.2	7.71	5.22e-11	7.32e-07	0.84	0.67	Multiple myeloma (IgH translocation);	chr16:89444086	chr16:89516797~89522217:+
LAML	cis	rs3096299	0.719	rs2911265	ENSG00000274627.1	RP11-104N10.2	7.71	5.22e-11	7.32e-07	0.84	0.67	Multiple myeloma (IgH translocation);	chr16:89444920	chr16:89516797~89522217:+
LAML	cis	rs2929278	0.617	rs663214	ENSG00000249839.1	AC011330.5	7.71	5.28e-11	7.39e-07	0.82	0.67	Schizophrenia;	chr15:43821584	chr15:43663654~43684339:-
LAML	cis	rs9326248	0.559	rs12808524	ENSG00000254851.1	RP11-109L13.1	-7.71	5.3e-11	7.42e-07	-0.89	-0.67	Blood protein levels;	chr11:117020277	chr11:117135528~117138582:+
LAML	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	7.69	5.69e-11	7.96e-07	1.22	0.67	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
LAML	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-7.69	5.7e-11	7.96e-07	-0.84	-0.67	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-7.69	5.7e-11	7.96e-07	-0.84	-0.67	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
LAML	cis	rs561341	0.941	rs8066156	ENSG00000266379.5	RP11-640N20.8	7.69	5.78e-11	8.03e-07	1.04	0.67	Hip circumference adjusted for BMI;	chr17:32034610	chr17:32088160~32094933:-
LAML	cis	rs561341	0.882	rs28649357	ENSG00000266379.5	RP11-640N20.8	7.69	5.78e-11	8.03e-07	1.04	0.67	Hip circumference adjusted for BMI;	chr17:32040171	chr17:32088160~32094933:-
LAML	cis	rs12468226	1	rs7597156	ENSG00000226261.1	AC064836.3	7.69	5.81e-11	8.06e-07	1.2	0.67	Urate levels;	chr2:202329339	chr2:202336024~202336727:-
LAML	cis	rs6782228	0.606	rs7613073	ENSG00000277250.1	Metazoa_SRP	-7.69	5.9e-11	8.17e-07	-0.88	-0.67	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.628	rs7641584	ENSG00000277250.1	Metazoa_SRP	-7.69	5.9e-11	8.17e-07	-0.88	-0.67	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128673681~128674021:-
LAML	cis	rs5769707	0.967	rs739241	ENSG00000212939.2	RP1-29C18.10	-7.68	5.96e-11	8.22e-07	-0.77	-0.67	Monocyte percentage of white cells;Monocyte count;	chr22:49659273	chr22:49548681~49556473:+
LAML	cis	rs2929278	0.617	rs524908	ENSG00000249839.1	AC011330.5	7.68	6e-11	8.27e-07	0.82	0.67	Schizophrenia;	chr15:43895793	chr15:43663654~43684339:-
LAML	cis	rs6565180	0.889	rs8051096	ENSG00000183604.13	SMG1P5	7.68	6.06e-11	8.35e-07	0.78	0.67	Tonsillectomy;	chr16:30336410	chr16:30267553~30335374:-
LAML	cis	rs2015599	0.549	rs3782508	ENSG00000257176.2	RP11-996F15.2	7.68	6.16e-11	8.47e-07	0.69	0.67	Platelet count;Mean platelet volume;	chr12:29298446	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.516	rs10450679	ENSG00000257176.2	RP11-996F15.2	7.68	6.16e-11	8.47e-07	0.69	0.67	Platelet count;Mean platelet volume;	chr12:29298823	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.549	rs6487802	ENSG00000257176.2	RP11-996F15.2	7.68	6.16e-11	8.47e-07	0.69	0.67	Platelet count;Mean platelet volume;	chr12:29299480	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.549	rs6487803	ENSG00000257176.2	RP11-996F15.2	7.68	6.16e-11	8.47e-07	0.69	0.67	Platelet count;Mean platelet volume;	chr12:29299760	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.549	rs7954990	ENSG00000257176.2	RP11-996F15.2	7.68	6.16e-11	8.47e-07	0.69	0.67	Platelet count;Mean platelet volume;	chr12:29299841	chr12:29280418~29317848:-
LAML	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	7.67	6.22e-11	8.53e-07	0.89	0.67	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
LAML	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-7.67	6.26e-11	8.57e-07	-0.75	-0.67	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
LAML	cis	rs853679	1	rs1679732	ENSG00000220721.1	OR1F12	-7.67	6.35e-11	8.68e-07	-0.96	-0.67	Depression;	chr6:28253486	chr6:28073316~28074233:+
LAML	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-7.67	6.36e-11	8.68e-07	-0.75	-0.67	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
LAML	cis	rs55794721	0.509	rs2982358	ENSG00000261349.1	RP3-465N24.5	-7.67	6.36e-11	8.68e-07	-0.75	-0.67	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25266102~25267136:-
LAML	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-7.67	6.36e-11	8.68e-07	-0.75	-0.67	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-7.67	6.36e-11	8.68e-07	-0.75	-0.67	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-7.67	6.36e-11	8.68e-07	-0.75	-0.67	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
LAML	cis	rs9506514	0.509	rs9506515	ENSG00000238286.1	SLC35E1P1	-7.66	6.47e-11	8.83e-07	-0.73	-0.67	Coronary artery calcification;	chr13:20557870	chr13:20607268~20608131:+
LAML	cis	rs858239	0.73	rs858289	ENSG00000230658.1	KLHL7-AS1	7.66	6.52e-11	8.88e-07	0.95	0.67	Cerebrospinal fluid biomarker levels;	chr7:23208539	chr7:23101228~23105703:-
LAML	cis	rs5769707	0.967	rs5770585	ENSG00000280224.1	CTA-722E9.1	-7.66	6.62e-11	9e-07	-0.84	-0.67	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49500568~49501585:+
LAML	cis	rs3091242	0.933	rs9645452	ENSG00000261349.1	RP3-465N24.5	7.66	6.65e-11	9.05e-07	0.75	0.67	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25266102~25267136:-
LAML	cis	rs9457247	0.765	rs12212247	ENSG00000265828.1	MIR3939	-7.66	6.72e-11	9.13e-07	-0.86	-0.67	Crohn's disease;	chr6:167000051	chr6:166997807~166997912:-
LAML	cis	rs2486288	0.656	rs11631021	ENSG00000259520.4	CTD-2651B20.3	7.65	6.77e-11	9.19e-07	1	0.67	Glomerular filtration rate;	chr15:45264631	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11639349	ENSG00000259520.4	CTD-2651B20.3	7.65	6.77e-11	9.19e-07	1	0.67	Glomerular filtration rate;	chr15:45276062	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs1706768	ENSG00000259520.4	CTD-2651B20.3	7.65	6.77e-11	9.19e-07	1	0.67	Glomerular filtration rate;	chr15:45277245	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs2461705	ENSG00000259520.4	CTD-2651B20.3	7.65	6.77e-11	9.19e-07	1	0.67	Glomerular filtration rate;	chr15:45278043	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs12440356	ENSG00000259520.4	CTD-2651B20.3	-7.65	6.77e-11	9.19e-07	-1	-0.67	Glomerular filtration rate;	chr15:45275331	chr15:45251580~45279251:-
LAML	cis	rs5769707	0.749	rs3884944	ENSG00000280224.1	CTA-722E9.1	-7.65	6.9e-11	9.35e-07	-0.76	-0.67	Monocyte percentage of white cells;Monocyte count;	chr22:49669348	chr22:49500568~49501585:+
LAML	cis	rs1577917	0.839	rs1596990	ENSG00000203875.9	SNHG5	-7.65	6.98e-11	9.43e-07	-0.86	-0.67	Response to antipsychotic treatment;	chr6:85840974	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.916	rs12661611	ENSG00000203875.9	SNHG5	-7.65	6.98e-11	9.43e-07	-0.86	-0.67	Response to antipsychotic treatment;	chr6:85844117	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.637	rs1838957	ENSG00000203875.9	SNHG5	-7.65	6.98e-11	9.43e-07	-0.86	-0.67	Response to antipsychotic treatment;	chr6:85855338	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.839	rs1838956	ENSG00000203875.9	SNHG5	-7.65	6.98e-11	9.43e-07	-0.86	-0.67	Response to antipsychotic treatment;	chr6:85855545	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.839	rs12216103	ENSG00000203875.9	SNHG5	-7.65	6.98e-11	9.43e-07	-0.86	-0.67	Response to antipsychotic treatment;	chr6:85861410	chr6:85660950~85678736:-
LAML	cis	rs3091242	0.933	rs3093584	ENSG00000261349.1	RP3-465N24.5	7.64	7.04e-11	9.5e-07	0.76	0.67	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25266102~25267136:-
LAML	cis	rs858239	0.633	rs858300	ENSG00000230658.1	KLHL7-AS1	7.64	7.32e-11	9.81e-07	0.95	0.67	Cerebrospinal fluid biomarker levels;	chr7:23205012	chr7:23101228~23105703:-
LAML	cis	rs858239	0.698	rs858295	ENSG00000230658.1	KLHL7-AS1	7.64	7.32e-11	9.81e-07	0.95	0.67	Cerebrospinal fluid biomarker levels;	chr7:23205950	chr7:23101228~23105703:-
LAML	cis	rs858239	0.73	rs858290	ENSG00000230658.1	KLHL7-AS1	7.64	7.32e-11	9.81e-07	0.95	0.67	Cerebrospinal fluid biomarker levels;	chr7:23208417	chr7:23101228~23105703:-
LAML	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	7.63	7.55e-11	1.01e-06	0.86	0.67	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
LAML	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	7.63	7.59e-11	1.02e-06	0.91	0.67	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
LAML	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-7.63	7.6e-11	1.02e-06	-0.93	-0.67	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
LAML	cis	rs858239	0.665	rs858306	ENSG00000230658.1	KLHL7-AS1	7.63	7.66e-11	1.02e-06	0.94	0.67	Cerebrospinal fluid biomarker levels;	chr7:23203135	chr7:23101228~23105703:-
LAML	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	7.62	7.76e-11	1.03e-06	0.68	0.67	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-7.62	7.76e-11	1.03e-06	-0.68	-0.67	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-7.62	7.76e-11	1.03e-06	-0.68	-0.67	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	7.62	7.76e-11	1.03e-06	0.68	0.67	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
LAML	cis	rs6565180	0.926	rs12446288	ENSG00000273724.1	RP11-347C12.12	7.62	7.82e-11	1.04e-06	0.68	0.67	Tonsillectomy;	chr16:30377388	chr16:30336400~30343336:+
LAML	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	7.62	7.83e-11	1.04e-06	0.69	0.67	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	7.62	7.83e-11	1.04e-06	0.69	0.67	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
LAML	cis	rs7131987	0.565	rs10743652	ENSG00000257176.2	RP11-996F15.2	7.62	7.83e-11	1.04e-06	0.73	0.67	QT interval;	chr12:29255074	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs10843372	ENSG00000257176.2	RP11-996F15.2	7.62	7.83e-11	1.04e-06	0.73	0.67	QT interval;	chr12:29262863	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs7976227	ENSG00000257176.2	RP11-996F15.2	7.62	7.83e-11	1.04e-06	0.73	0.67	QT interval;	chr12:29264843	chr12:29280418~29317848:-
LAML	cis	rs2470135	1	rs2470135	ENSG00000249839.1	AC011330.5	-7.62	7.9e-11	1.05e-06	-0.81	-0.67	Diastolic blood pressure;	chr15:43703591	chr15:43663654~43684339:-
LAML	cis	rs4591358	1	rs7571836	ENSG00000223466.1	AC064834.2	-7.62	7.97e-11	1.06e-06	-0.94	-0.67	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195475768	chr2:195533035~195538681:+
LAML	cis	rs5769707	0.967	rs9616327	ENSG00000280224.1	CTA-722E9.1	-7.61	8.08e-11	1.07e-06	-0.86	-0.67	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49500568~49501585:+
LAML	cis	rs2739330	0.796	rs1006771	ENSG00000273295.1	AP000350.5	7.61	8.08e-11	1.07e-06	1	0.67	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23901432~23907068:-
LAML	cis	rs1577917	0.839	rs12055653	ENSG00000203875.9	SNHG5	-7.61	8.2e-11	1.08e-06	-0.84	-0.67	Response to antipsychotic treatment;	chr6:85836945	chr6:85660950~85678736:-
LAML	cis	rs10927875	0.501	rs61782229	ENSG00000178715.8	RP11-169K16.8	-7.61	8.26e-11	1.09e-06	-0.84	-0.67	Dilated cardiomyopathy;	chr1:15893623	chr1:15828232~15828669:+
LAML	cis	rs7104764	0.957	rs6598075	ENSG00000277290.1	RP11-326C3.16	7.61	8.3e-11	1.09e-06	1.06	0.67	Menarche (age at onset);	chr11:207275	chr11:243099~243483:-
LAML	cis	rs7104764	0.957	rs58692051	ENSG00000277290.1	RP11-326C3.16	7.61	8.3e-11	1.09e-06	1.06	0.67	Menarche (age at onset);	chr11:207410	chr11:243099~243483:-
LAML	cis	rs2486288	0.656	rs1719232	ENSG00000259520.4	CTD-2651B20.3	7.6	8.4e-11	1.11e-06	1	0.67	Glomerular filtration rate;	chr15:45279874	chr15:45251580~45279251:-
LAML	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	7.6	8.41e-11	1.11e-06	0.7	0.67	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
LAML	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	7.6	8.47e-11	1.11e-06	0.7	0.67	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	7.6	8.47e-11	1.11e-06	0.7	0.67	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	7.6	8.47e-11	1.11e-06	0.7	0.67	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
LAML	cis	rs6565180	1	rs8049108	ENSG00000183604.13	SMG1P5	7.6	8.54e-11	1.12e-06	0.75	0.67	Tonsillectomy;	chr16:30365165	chr16:30267553~30335374:-
LAML	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	7.6	8.66e-11	1.13e-06	0.7	0.67	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
LAML	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	7.6	8.71e-11	1.14e-06	0.75	0.67	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
LAML	cis	rs2015599	0.549	rs7311081	ENSG00000257176.2	RP11-996F15.2	7.6	8.71e-11	1.14e-06	0.7	0.67	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.517	rs7295212	ENSG00000257176.2	RP11-996F15.2	7.6	8.71e-11	1.14e-06	0.7	0.67	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29280418~29317848:-
LAML	cis	rs2929278	0.561	rs62018952	ENSG00000249839.1	AC011330.5	7.6	8.71e-11	1.14e-06	0.81	0.67	Schizophrenia;	chr15:43788539	chr15:43663654~43684339:-
LAML	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	7.59	8.73e-11	1.14e-06	0.74	0.67	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	7.59	8.73e-11	1.14e-06	0.74	0.67	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	7.59	8.73e-11	1.14e-06	0.74	0.67	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
LAML	cis	rs561341	0.883	rs7219239	ENSG00000266379.5	RP11-640N20.8	-7.59	8.93e-11	1.17e-06	-1.19	-0.67	Hip circumference adjusted for BMI;	chr17:31884997	chr17:32088160~32094933:-
LAML	cis	rs4853012	0.887	rs2122290	ENSG00000217702.2	RP11-287D1.4	7.58	9.27e-11	1.2e-06	1.26	0.67	Gestational age at birth (maternal effect);	chr2:74131774	chr2:74130583~74135395:+
LAML	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	7.58	9.39e-11	1.21e-06	0.74	0.67	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-7.58	9.39e-11	1.21e-06	-0.74	-0.67	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-7.58	9.39e-11	1.21e-06	-0.74	-0.67	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-7.58	9.39e-11	1.21e-06	-0.74	-0.67	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-7.58	9.39e-11	1.21e-06	-0.74	-0.67	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-7.58	9.39e-11	1.21e-06	-0.74	-0.67	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-7.58	9.39e-11	1.21e-06	-0.74	-0.67	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-7.58	9.39e-11	1.21e-06	-0.74	-0.67	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-7.58	9.39e-11	1.21e-06	-0.74	-0.67	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	7.58	9.39e-11	1.21e-06	0.74	0.67	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
LAML	cis	rs7104764	0.673	rs3782118	ENSG00000277290.1	RP11-326C3.16	-7.58	9.4e-11	1.21e-06	-0.94	-0.67	Menarche (age at onset);	chr11:222620	chr11:243099~243483:-
LAML	cis	rs9457247	0.663	rs9459835	ENSG00000265828.1	MIR3939	-7.57	9.54e-11	1.23e-06	-0.84	-0.67	Crohn's disease;	chr6:167004063	chr6:166997807~166997912:-
LAML	cis	rs853679	1	rs1679732	ENSG00000187763.3	OR2B7P	-7.57	9.69e-11	1.24e-06	-1.09	-0.67	Depression;	chr6:28253486	chr6:28046434~28047367:+
LAML	cis	rs904251	0.523	rs2797794	ENSG00000227920.2	RP1-153P14.5	-7.57	9.85e-11	1.26e-06	-0.79	-0.67	Cognitive performance;	chr6:37512828	chr6:37545145~37550860:+
LAML	cis	rs904251	0.523	rs2776920	ENSG00000227920.2	RP1-153P14.5	-7.57	9.85e-11	1.26e-06	-0.79	-0.67	Cognitive performance;	chr6:37512829	chr6:37545145~37550860:+
LAML	cis	rs904251	0.504	rs2797795	ENSG00000227920.2	RP1-153P14.5	-7.57	9.85e-11	1.26e-06	-0.79	-0.67	Cognitive performance;	chr6:37512907	chr6:37545145~37550860:+
LAML	cis	rs904251	0.523	rs2797796	ENSG00000227920.2	RP1-153P14.5	-7.57	9.85e-11	1.26e-06	-0.79	-0.67	Cognitive performance;	chr6:37513110	chr6:37545145~37550860:+
LAML	cis	rs904251	0.523	rs2776870	ENSG00000227920.2	RP1-153P14.5	-7.57	9.85e-11	1.26e-06	-0.79	-0.67	Cognitive performance;	chr6:37513588	chr6:37545145~37550860:+
LAML	cis	rs904251	0.523	rs2797798	ENSG00000227920.2	RP1-153P14.5	-7.57	9.85e-11	1.26e-06	-0.79	-0.67	Cognitive performance;	chr6:37513661	chr6:37545145~37550860:+
LAML	cis	rs904251	0.523	rs2776871	ENSG00000227920.2	RP1-153P14.5	-7.57	9.85e-11	1.26e-06	-0.79	-0.67	Cognitive performance;	chr6:37513983	chr6:37545145~37550860:+
LAML	cis	rs9457247	0.765	rs1322077	ENSG00000265828.1	MIR3939	-7.56	1e-10	1.27e-06	-0.83	-0.67	Crohn's disease;	chr6:167010805	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.765	rs9457249	ENSG00000265828.1	MIR3939	-7.56	1e-10	1.27e-06	-0.83	-0.67	Crohn's disease;	chr6:167012950	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.765	rs9457251	ENSG00000265828.1	MIR3939	-7.56	1e-10	1.27e-06	-0.83	-0.67	Crohn's disease;	chr6:167013219	chr6:166997807~166997912:-
LAML	cis	rs2486288	0.656	rs8039352	ENSG00000259520.4	CTD-2651B20.3	7.56	1.01e-10	1.28e-06	1.04	0.67	Glomerular filtration rate;	chr15:45259592	chr15:45251580~45279251:-
LAML	cis	rs3096299	0.719	rs2911262	ENSG00000274627.1	RP11-104N10.2	7.55	1.05e-10	1.32e-06	0.82	0.66	Multiple myeloma (IgH translocation);	chr16:89448633	chr16:89516797~89522217:+
LAML	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-7.55	1.07e-10	1.34e-06	-0.84	-0.66	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
LAML	cis	rs904251	0.523	rs2776872	ENSG00000227920.2	RP1-153P14.5	-7.55	1.07e-10	1.35e-06	-0.77	-0.66	Cognitive performance;	chr6:37515011	chr6:37545145~37550860:+
LAML	cis	rs3096299	0.719	rs2965817	ENSG00000274627.1	RP11-104N10.2	7.55	1.07e-10	1.35e-06	0.82	0.66	Multiple myeloma (IgH translocation);	chr16:89446826	chr16:89516797~89522217:+
LAML	cis	rs929843	1	rs929843	ENSG00000226232.7	RP11-419C5.2	-7.55	1.08e-10	1.35e-06	-1.07	-0.66	Menarche (age at onset);	chr16:70011845	chr16:69976388~69996188:-
LAML	cis	rs561341	0.824	rs1978115	ENSG00000266379.5	RP11-640N20.8	7.54	1.09e-10	1.36e-06	1.18	0.66	Hip circumference adjusted for BMI;	chr17:31893757	chr17:32088160~32094933:-
LAML	cis	rs853679	0.55	rs6901017	ENSG00000182477.5	OR2B8P	7.54	1.09e-10	1.37e-06	0.96	0.66	Depression;	chr6:28184805	chr6:28053228~28054165:-
LAML	cis	rs3096299	0.719	rs2965945	ENSG00000274627.1	RP11-104N10.2	7.54	1.1e-10	1.38e-06	0.82	0.66	Multiple myeloma (IgH translocation);	chr16:89447609	chr16:89516797~89522217:+
LAML	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	7.53	1.14e-10	1.42e-06	0.98	0.66	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-7.53	1.16e-10	1.45e-06	-1.08	-0.66	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
LAML	cis	rs7131987	0.565	rs4412790	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29253828	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs10743651	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29255006	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.546	rs7299648	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29256797	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs7300032	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29256859	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.547	rs4370971	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29257066	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs7316026	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29258881	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs6487792	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29259743	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.585	rs2194517	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29260002	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs766445	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29260560	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs7971296	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29263297	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.605	rs1120528	ENSG00000257176.2	RP11-996F15.2	7.52	1.19e-10	1.48e-06	0.72	0.66	QT interval;	chr12:29264237	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs7137141	ENSG00000257176.2	RP11-996F15.2	7.52	1.21e-10	1.49e-06	0.72	0.66	QT interval;	chr12:29272168	chr12:29280418~29317848:-
LAML	cis	rs6565180	0.962	rs6565183	ENSG00000183604.13	SMG1P5	7.52	1.21e-10	1.5e-06	0.74	0.66	Tonsillectomy;	chr16:30371434	chr16:30267553~30335374:-
LAML	cis	rs2412819	0.599	rs2470120	ENSG00000249839.1	AC011330.5	-7.52	1.22e-10	1.5e-06	-0.78	-0.66	Lung cancer;	chr15:43636872	chr15:43663654~43684339:-
LAML	cis	rs904251	0.523	rs1757191	ENSG00000227920.2	RP1-153P14.5	-7.51	1.23e-10	1.52e-06	-0.77	-0.66	Cognitive performance;	chr6:37515095	chr6:37545145~37550860:+
LAML	cis	rs10927875	0.526	rs35340817	ENSG00000178715.8	RP11-169K16.8	-7.51	1.24e-10	1.53e-06	-0.83	-0.66	Dilated cardiomyopathy;	chr1:15852422	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.55	rs12121918	ENSG00000178715.8	RP11-169K16.8	-7.51	1.24e-10	1.53e-06	-0.83	-0.66	Dilated cardiomyopathy;	chr1:15857061	chr1:15828232~15828669:+
LAML	cis	rs6565180	1	rs11863150	ENSG00000273724.1	RP11-347C12.12	7.51	1.25e-10	1.54e-06	0.68	0.66	Tonsillectomy;	chr16:30374182	chr16:30336400~30343336:+
LAML	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-7.51	1.28e-10	1.57e-06	-1.04	-0.66	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
LAML	cis	rs5769707	0.967	rs763126	ENSG00000280224.1	CTA-722E9.1	7.5	1.3e-10	1.6e-06	0.83	0.66	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49500568~49501585:+
LAML	cis	rs3096299	0.658	rs4785679	ENSG00000274627.1	RP11-104N10.2	7.5	1.33e-10	1.62e-06	0.87	0.66	Multiple myeloma (IgH translocation);	chr16:89499705	chr16:89516797~89522217:+
LAML	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-7.49	1.35e-10	1.63e-06	-0.69	-0.66	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
LAML	cis	rs853679	0.628	rs9368560	ENSG00000182477.5	OR2B8P	7.49	1.36e-10	1.64e-06	0.97	0.66	Depression;	chr6:28192182	chr6:28053228~28054165:-
LAML	cis	rs9457247	0.765	rs6904946	ENSG00000265828.1	MIR3939	7.49	1.36e-10	1.64e-06	0.82	0.66	Crohn's disease;	chr6:167020460	chr6:166997807~166997912:-
LAML	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-7.49	1.37e-10	1.65e-06	-0.9	-0.66	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
LAML	cis	rs5760092	0.755	rs915589	ENSG00000225282.1	AP000350.6	-7.49	1.37e-10	1.66e-06	-1.01	-0.66	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23926900~23929574:+
LAML	cis	rs5760092	0.627	rs6519489	ENSG00000225282.1	AP000350.6	-7.49	1.37e-10	1.66e-06	-1.01	-0.66	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23926900~23929574:+
LAML	cis	rs5769707	0.967	rs2187891	ENSG00000280224.1	CTA-722E9.1	-7.49	1.39e-10	1.68e-06	-0.79	-0.66	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49500568~49501585:+
LAML	cis	rs12468226	0.817	rs2350360	ENSG00000226261.1	AC064836.3	-7.49	1.39e-10	1.68e-06	-1.1	-0.66	Urate levels;	chr2:202222980	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs3843338	ENSG00000226261.1	AC064836.3	-7.49	1.39e-10	1.68e-06	-1.1	-0.66	Urate levels;	chr2:202246102	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs6435139	ENSG00000226261.1	AC064836.3	-7.49	1.39e-10	1.68e-06	-1.1	-0.66	Urate levels;	chr2:202255145	chr2:202336024~202336727:-
LAML	cis	rs9457247	0.73	rs9459841	ENSG00000265828.1	MIR3939	-7.49	1.39e-10	1.68e-06	-0.82	-0.66	Crohn's disease;	chr6:167018461	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.765	rs6900701	ENSG00000265828.1	MIR3939	-7.49	1.39e-10	1.68e-06	-0.82	-0.66	Crohn's disease;	chr6:167020624	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.663	rs12526548	ENSG00000265828.1	MIR3939	-7.49	1.39e-10	1.68e-06	-0.83	-0.66	Crohn's disease;	chr6:167017659	chr6:166997807~166997912:-
LAML	cis	rs1930961	1	rs6004654	ENSG00000100058.11	CRYBB2P1	-7.48	1.42e-10	1.71e-06	-1.16	-0.66	Bipolar disorder with mood-incongruent psychosis;	chr22:25459237	chr22:25448105~25520854:+
LAML	cis	rs9457247	0.663	rs9459839	ENSG00000265828.1	MIR3939	-7.48	1.43e-10	1.72e-06	-0.83	-0.66	Crohn's disease;	chr6:167018341	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.588	rs35171809	ENSG00000265828.1	MIR3939	-7.48	1.43e-10	1.72e-06	-0.83	-0.66	Crohn's disease;	chr6:167019278	chr6:166997807~166997912:-
LAML	cis	rs6565180	1	rs68051857	ENSG00000183604.13	SMG1P5	7.48	1.44e-10	1.73e-06	0.75	0.66	Tonsillectomy;	chr16:30348690	chr16:30267553~30335374:-
LAML	cis	rs6565180	1	rs6565180	ENSG00000183604.13	SMG1P5	7.48	1.44e-10	1.73e-06	0.75	0.66	Tonsillectomy;	chr16:30350020	chr16:30267553~30335374:-
LAML	cis	rs6565180	1	rs11862806	ENSG00000183604.13	SMG1P5	7.48	1.44e-10	1.73e-06	0.75	0.66	Tonsillectomy;	chr16:30352750	chr16:30267553~30335374:-
LAML	cis	rs9457247	0.765	rs1060404	ENSG00000265828.1	MIR3939	-7.48	1.46e-10	1.74e-06	-0.81	-0.66	Crohn's disease;	chr6:167015979	chr6:166997807~166997912:-
LAML	cis	rs2739330	0.796	rs1006771	ENSG00000225282.1	AP000350.6	7.47	1.46e-10	1.75e-06	0.9	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23926900~23929574:+
LAML	cis	rs6452524	0.618	rs6452501	ENSG00000249664.1	CTD-2227C6.2	7.47	1.48e-10	1.78e-06	0.81	0.66	Hypertension (SNP x SNP interaction);	chr5:83068681	chr5:83012285~83013109:-
LAML	cis	rs9457247	0.663	rs1894603	ENSG00000265828.1	MIR3939	7.47	1.5e-10	1.8e-06	0.83	0.66	Crohn's disease;	chr6:167021198	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.663	rs7749278	ENSG00000265828.1	MIR3939	7.47	1.5e-10	1.8e-06	0.83	0.66	Crohn's disease;	chr6:167021837	chr6:166997807~166997912:-
LAML	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	7.47	1.51e-10	1.81e-06	0.67	0.66	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
LAML	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-7.47	1.52e-10	1.82e-06	-0.9	-0.66	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
LAML	cis	rs916888	0.647	rs199523	ENSG00000261575.2	RP11-259G18.1	-7.46	1.55e-10	1.85e-06	-0.89	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46267037~46268694:+
LAML	cis	rs5769707	0.967	rs17182154	ENSG00000280224.1	CTA-722E9.1	-7.46	1.56e-10	1.86e-06	-0.81	-0.66	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49500568~49501585:+
LAML	cis	rs904251	0.523	rs914348	ENSG00000227920.2	RP1-153P14.5	-7.46	1.57e-10	1.87e-06	-0.73	-0.66	Cognitive performance;	chr6:37516953	chr6:37545145~37550860:+
LAML	cis	rs2739330	0.796	rs1006771	ENSG00000218537.1	MIF-AS1	7.46	1.57e-10	1.88e-06	1	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23971817	chr22:23894426~23898930:-
LAML	cis	rs9457247	0.765	rs3752520	ENSG00000265828.1	MIR3939	-7.46	1.58e-10	1.89e-06	-0.81	-0.66	Crohn's disease;	chr6:167022671	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.765	rs9457256	ENSG00000265828.1	MIR3939	-7.46	1.58e-10	1.89e-06	-0.81	-0.66	Crohn's disease;	chr6:167022973	chr6:166997807~166997912:-
LAML	cis	rs5769707	0.967	rs5769698	ENSG00000280224.1	CTA-722E9.1	-7.45	1.6e-10	1.91e-06	-0.79	-0.66	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49500568~49501585:+
LAML	cis	rs9326248	0.569	rs652455	ENSG00000254851.1	RP11-109L13.1	-7.45	1.63e-10	1.93e-06	-1.13	-0.66	Blood protein levels;	chr11:117200733	chr11:117135528~117138582:+
LAML	cis	rs9457247	0.765	rs4710171	ENSG00000265828.1	MIR3939	-7.45	1.63e-10	1.94e-06	-0.81	-0.66	Crohn's disease;	chr6:167016698	chr6:166997807~166997912:-
LAML	cis	rs5769707	0.935	rs1109320	ENSG00000280224.1	CTA-722E9.1	-7.45	1.64e-10	1.95e-06	-0.82	-0.66	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49500568~49501585:+
LAML	cis	rs561341	0.941	rs7215147	ENSG00000266379.5	RP11-640N20.8	7.44	1.67e-10	1.98e-06	0.98	0.66	Hip circumference adjusted for BMI;	chr17:31939692	chr17:32088160~32094933:-
LAML	cis	rs5769707	0.967	rs763127	ENSG00000280224.1	CTA-722E9.1	-7.44	1.69e-10	2e-06	-0.8	-0.66	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49500568~49501585:+
LAML	cis	rs2929278	0.589	rs11638972	ENSG00000249839.1	AC011330.5	7.44	1.7e-10	2.01e-06	0.79	0.66	Schizophrenia;	chr15:43782493	chr15:43663654~43684339:-
LAML	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	7.44	1.7e-10	2.01e-06	0.96	0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
LAML	cis	rs9457247	0.765	rs9459836	ENSG00000265828.1	MIR3939	-7.43	1.74e-10	2.06e-06	-0.83	-0.66	Crohn's disease;	chr6:167005617	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.765	rs9459838	ENSG00000265828.1	MIR3939	-7.43	1.74e-10	2.06e-06	-0.83	-0.66	Crohn's disease;	chr6:167013111	chr6:166997807~166997912:-
LAML	cis	rs2086824	0.538	rs4785673	ENSG00000274627.1	RP11-104N10.2	7.43	1.78e-10	2.1e-06	0.78	0.66	Multiple myeloma (IgH translocation);	chr16:89470137	chr16:89516797~89522217:+
LAML	cis	rs7131987	0.585	rs6487795	ENSG00000257176.2	RP11-996F15.2	7.42	1.81e-10	2.13e-06	0.71	0.66	QT interval;	chr12:29266228	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs6487797	ENSG00000257176.2	RP11-996F15.2	7.42	1.81e-10	2.13e-06	0.71	0.66	QT interval;	chr12:29270063	chr12:29280418~29317848:-
LAML	cis	rs9457247	0.765	rs10484531	ENSG00000265828.1	MIR3939	-7.42	1.81e-10	2.13e-06	-0.82	-0.66	Crohn's disease;	chr6:167040946	chr6:166997807~166997912:-
LAML	cis	rs853679	1	rs7740487	ENSG00000220721.1	OR1F12	7.42	1.82e-10	2.14e-06	0.96	0.66	Depression;	chr6:28248708	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs68141011	ENSG00000220721.1	OR1F12	7.42	1.82e-10	2.14e-06	0.96	0.66	Depression;	chr6:28250019	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs13200462	ENSG00000220721.1	OR1F12	7.42	1.82e-10	2.14e-06	0.96	0.66	Depression;	chr6:28250421	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs9986596	ENSG00000220721.1	OR1F12	7.42	1.82e-10	2.14e-06	0.96	0.66	Depression;	chr6:28251883	chr6:28073316~28074233:+
LAML	cis	rs12468226	1	rs7597469	ENSG00000226261.1	AC064836.3	7.42	1.83e-10	2.15e-06	1.19	0.66	Urate levels;	chr2:202329547	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs113877751	ENSG00000226261.1	AC064836.3	7.42	1.83e-10	2.15e-06	1.19	0.66	Urate levels;	chr2:202329998	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.935	rs113021930	ENSG00000226261.1	AC064836.3	7.42	1.83e-10	2.15e-06	1.19	0.66	Urate levels;	chr2:202330448	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs113491584	ENSG00000226261.1	AC064836.3	7.42	1.83e-10	2.15e-06	1.19	0.66	Urate levels;	chr2:202331724	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs112306637	ENSG00000226261.1	AC064836.3	7.42	1.83e-10	2.15e-06	1.19	0.66	Urate levels;	chr2:202334195	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs111252524	ENSG00000226261.1	AC064836.3	7.42	1.83e-10	2.15e-06	1.19	0.66	Urate levels;	chr2:202334465	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs112753638	ENSG00000226261.1	AC064836.3	7.42	1.83e-10	2.15e-06	1.19	0.66	Urate levels;	chr2:202334496	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.935	rs113188021	ENSG00000226261.1	AC064836.3	7.42	1.83e-10	2.15e-06	1.19	0.66	Urate levels;	chr2:202336237	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs6731027	ENSG00000226261.1	AC064836.3	7.42	1.83e-10	2.15e-06	1.19	0.66	Urate levels;	chr2:202337443	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs13389798	ENSG00000226261.1	AC064836.3	7.42	1.83e-10	2.15e-06	1.19	0.66	Urate levels;	chr2:202348370	chr2:202336024~202336727:-
LAML	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-7.42	1.84e-10	2.15e-06	-0.74	-0.66	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.809	rs660129	ENSG00000261349.1	RP3-465N24.5	-7.42	1.84e-10	2.15e-06	-0.74	-0.66	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.728	rs706845	ENSG00000261349.1	RP3-465N24.5	-7.42	1.84e-10	2.15e-06	-0.74	-0.66	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs28633797	ENSG00000261349.1	RP3-465N24.5	-7.42	1.84e-10	2.15e-06	-0.74	-0.66	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-7.42	1.84e-10	2.15e-06	-0.74	-0.66	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
LAML	cis	rs916888	0.61	rs199530	ENSG00000261575.2	RP11-259G18.1	-7.41	1.91e-10	2.23e-06	-0.88	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46267037~46268694:+
LAML	cis	rs3096299	0.728	rs1011749	ENSG00000274627.1	RP11-104N10.2	7.41	1.92e-10	2.25e-06	0.82	0.66	Multiple myeloma (IgH translocation);	chr16:89444461	chr16:89516797~89522217:+
LAML	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-7.41	1.96e-10	2.28e-06	-1.1	-0.66	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
LAML	cis	rs9457247	0.663	rs9295384	ENSG00000265828.1	MIR3939	-7.4	1.98e-10	2.3e-06	-0.83	-0.66	Crohn's disease;	chr6:167034625	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.663	rs10946205	ENSG00000265828.1	MIR3939	-7.4	1.98e-10	2.3e-06	-0.83	-0.66	Crohn's disease;	chr6:167037823	chr6:166997807~166997912:-
LAML	cis	rs2486288	0.656	rs62026703	ENSG00000259520.4	CTD-2651B20.3	7.4	1.98e-10	2.3e-06	1.02	0.66	Glomerular filtration rate;	chr15:45277731	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs7165039	ENSG00000259520.4	CTD-2651B20.3	7.4	1.98e-10	2.3e-06	1.02	0.66	Glomerular filtration rate;	chr15:45278215	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs7166580	ENSG00000259520.4	CTD-2651B20.3	7.4	1.98e-10	2.3e-06	1.02	0.66	Glomerular filtration rate;	chr15:45279011	chr15:45251580~45279251:-
LAML	cis	rs7104764	0.833	rs12574034	ENSG00000277290.1	RP11-326C3.16	7.4	1.98e-10	2.3e-06	0.97	0.66	Menarche (age at onset);	chr11:212262	chr11:243099~243483:-
LAML	cis	rs6565180	0.926	rs8046445	ENSG00000273724.1	RP11-347C12.12	-7.4	1.98e-10	2.31e-06	-0.67	-0.66	Tonsillectomy;	chr16:30374941	chr16:30336400~30343336:+
LAML	cis	rs853679	0.55	rs9295762	ENSG00000182477.5	OR2B8P	-7.4	1.99e-10	2.32e-06	-0.91	-0.66	Depression;	chr6:28187640	chr6:28053228~28054165:-
LAML	cis	rs10927875	0.632	rs2862162	ENSG00000178715.8	RP11-169K16.8	7.4	2.01e-10	2.33e-06	0.76	0.66	Dilated cardiomyopathy;	chr1:15816465	chr1:15828232~15828669:+
LAML	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-7.4	2.04e-10	2.36e-06	-0.83	-0.66	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-7.4	2.04e-10	2.36e-06	-0.83	-0.66	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
LAML	cis	rs5760092	0.755	rs915589	ENSG00000218537.1	MIF-AS1	-7.4	2.04e-10	2.36e-06	-1.11	-0.66	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23894426~23898930:-
LAML	cis	rs5760092	0.627	rs6519489	ENSG00000218537.1	MIF-AS1	-7.4	2.04e-10	2.36e-06	-1.11	-0.66	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23894426~23898930:-
LAML	cis	rs12468226	0.938	rs116601501	ENSG00000226261.1	AC064836.3	7.39	2.06e-10	2.38e-06	1.21	0.66	Urate levels;	chr2:202274567	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs76658848	ENSG00000226261.1	AC064836.3	7.39	2.06e-10	2.38e-06	1.21	0.66	Urate levels;	chr2:202275548	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs57571703	ENSG00000226261.1	AC064836.3	7.39	2.06e-10	2.38e-06	1.21	0.66	Urate levels;	chr2:202281997	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs60722019	ENSG00000226261.1	AC064836.3	7.39	2.06e-10	2.38e-06	1.21	0.66	Urate levels;	chr2:202282060	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs78928733	ENSG00000226261.1	AC064836.3	7.39	2.06e-10	2.38e-06	1.21	0.66	Urate levels;	chr2:202283787	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs77062060	ENSG00000226261.1	AC064836.3	7.39	2.06e-10	2.38e-06	1.21	0.66	Urate levels;	chr2:202285639	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs116109808	ENSG00000226261.1	AC064836.3	7.39	2.06e-10	2.38e-06	1.21	0.66	Urate levels;	chr2:202287356	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs78175596	ENSG00000226261.1	AC064836.3	7.39	2.06e-10	2.38e-06	1.21	0.66	Urate levels;	chr2:202287993	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs74454549	ENSG00000226261.1	AC064836.3	7.39	2.06e-10	2.38e-06	1.21	0.66	Urate levels;	chr2:202288044	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs114177656	ENSG00000226261.1	AC064836.3	7.39	2.07e-10	2.39e-06	1.12	0.66	Urate levels;	chr2:202291596	chr2:202336024~202336727:-
LAML	cis	rs9457247	0.74	rs10946204	ENSG00000265828.1	MIR3939	-7.39	2.07e-10	2.39e-06	-0.81	-0.66	Crohn's disease;	chr6:167037641	chr6:166997807~166997912:-
LAML	cis	rs12468226	0.938	rs10931993	ENSG00000226261.1	AC064836.3	7.39	2.08e-10	2.4e-06	1.09	0.66	Urate levels;	chr2:202243017	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs4675274	ENSG00000226261.1	AC064836.3	-7.39	2.08e-10	2.4e-06	-1.09	-0.66	Urate levels;	chr2:202243145	chr2:202336024~202336727:-
LAML	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-7.39	2.1e-10	2.41e-06	-0.82	-0.66	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-7.39	2.1e-10	2.41e-06	-0.82	-0.66	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-7.39	2.1e-10	2.41e-06	-0.82	-0.66	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-7.39	2.1e-10	2.41e-06	-0.82	-0.66	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
LAML	cis	rs6565180	1	rs8049108	ENSG00000273724.1	RP11-347C12.12	-7.39	2.1e-10	2.41e-06	-0.68	-0.66	Tonsillectomy;	chr16:30365165	chr16:30336400~30343336:+
LAML	cis	rs4713118	0.621	rs9295755	ENSG00000187763.3	OR2B7P	-7.38	2.15e-10	2.41e-06	-1.02	-0.66	Parkinson's disease;	chr6:28065396	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs16893666	ENSG00000187763.3	OR2B7P	-7.38	2.15e-10	2.41e-06	-1.02	-0.66	Depression;	chr6:28086929	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs17711344	ENSG00000187763.3	OR2B7P	-7.38	2.15e-10	2.41e-06	-1.02	-0.66	Depression;	chr6:28109824	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs6932109	ENSG00000187763.3	OR2B7P	-7.38	2.15e-10	2.41e-06	-1.02	-0.66	Depression;	chr6:28110525	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs868987	ENSG00000187763.3	OR2B7P	-7.38	2.15e-10	2.41e-06	-1.02	-0.66	Depression;	chr6:28142370	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9283884	ENSG00000187763.3	OR2B7P	-7.38	2.15e-10	2.41e-06	-1.02	-0.66	Depression;	chr6:28167882	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.621	rs9295756	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28065618	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.621	rs10484403	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28065745	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.621	rs4713132	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28066257	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.621	rs4713133	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28066263	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.621	rs4713134	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28066343	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.621	rs9368548	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28066959	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.587	rs61471148	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28069254	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380047	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28070115	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs7755442	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28071237	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4713135	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28071808	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs12174753	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28074687	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs55747925	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28076559	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs56310871	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28076704	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs34716816	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28078391	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393884	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28079011	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380049	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28080757	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380050	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28080760	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393885	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28082231	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393886	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28082261	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.515	rs9368549	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28082269	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs56364346	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28082984	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9357061	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28083994	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9368550	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28084025	chr6:28046434~28047367:+
LAML	cis	rs853679	0.542	rs2295594	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28085319	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs2273564	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28089816	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs1853097	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28090857	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393887	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28091242	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393888	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28091439	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs3734573	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28091659	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9357063	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28092227	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs3823180	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28093966	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9368551	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28094014	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393890	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28096077	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380052	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28096845	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9366715	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28096855	chr6:28046434~28047367:+
LAML	cis	rs853679	0.598	rs9380054	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28099759	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.547	rs2116981	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28100173	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9368552	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28100648	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs2281588	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28104824	chr6:28046434~28047367:+
LAML	cis	rs853679	0.542	rs34131763	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28107222	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs35193936	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28108492	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs36078605	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28110254	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.516	rs6931858	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28110633	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393891	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28111382	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9468286	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28111650	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.516	rs7739216	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28112168	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs35512245	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28112175	chr6:28046434~28047367:+
LAML	cis	rs853679	0.542	rs9393892	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28113616	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380055	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28113851	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9368553	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28114487	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9368554	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28114933	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4713137	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28115743	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9348793	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28116411	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.586	rs6905516	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28118700	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.586	rs6905522	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28118701	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.586	rs9468290	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28119896	chr6:28046434~28047367:+
LAML	cis	rs853679	0.542	rs6934769	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28123153	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs17711801	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28124529	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs6922063	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28126588	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs2275508	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28126953	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.527	rs9461433	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28127394	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9468292	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28127577	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs1947863	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28131566	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4713141	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28133900	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs1340004	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28135913	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380056	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28136698	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380057	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28136856	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs1947862	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28137418	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs6941992	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28138363	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.516	rs4713142	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28138569	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4713143	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28138981	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4713144	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28139012	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4713145	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28139049	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs3757187	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28139876	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs3757185	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28139998	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs1904841	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28140307	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs1904840	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28140454	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9368555	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28141189	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393893	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28141484	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4713146	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28143758	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393894	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28144784	chr6:28046434~28047367:+
LAML	cis	rs853679	0.513	rs9468296	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28145952	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4711164	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28147378	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4711165	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28147406	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4713148	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28148143	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9348794	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28149979	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9468297	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28151096	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9295758	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28152885	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs17774663	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28153120	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9468298	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28154567	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9295759	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28156691	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9348796	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28158424	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs11552219	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28159056	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380058	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28159666	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393895	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28159843	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393896	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28159925	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393897	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28159932	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9357065	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28161802	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9357066	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28162053	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393898	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28162598	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9368556	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28163375	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9368557	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28163759	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380059	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28164580	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380060	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28164825	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs35227624	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28164948	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380061	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28165025	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9368558	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28165528	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.587	rs9393899	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28165750	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4713150	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28168434	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.527	rs4713151	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Parkinson's disease;	chr6:28168578	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9393901	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28169019	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs3173443	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28169249	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs4713152	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28169676	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9348797	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28169755	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380062	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28169791	chr6:28046434~28047367:+
LAML	cis	rs853679	0.542	rs9380063	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28170075	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs12332979	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28173770	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs67878650	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28174809	chr6:28046434~28047367:+
LAML	cis	rs853679	0.569	rs9348798	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28175233	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9380065	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28176973	chr6:28046434~28047367:+
LAML	cis	rs853679	0.517	rs9295761	ENSG00000187763.3	OR2B7P	7.38	2.15e-10	2.41e-06	1.02	0.66	Depression;	chr6:28180209	chr6:28046434~28047367:+
LAML	cis	rs561341	0.941	rs2428341	ENSG00000266379.5	RP11-640N20.8	7.38	2.19e-10	2.45e-06	0.97	0.66	Hip circumference adjusted for BMI;	chr17:31990276	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs535151	ENSG00000266379.5	RP11-640N20.8	7.38	2.19e-10	2.45e-06	0.97	0.66	Hip circumference adjusted for BMI;	chr17:31990386	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs546748	ENSG00000266379.5	RP11-640N20.8	7.38	2.19e-10	2.45e-06	0.97	0.66	Hip circumference adjusted for BMI;	chr17:31997274	chr17:32088160~32094933:-
LAML	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	7.38	2.19e-10	2.45e-06	0.9	0.66	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
LAML	cis	rs3096299	0.746	rs9931120	ENSG00000274627.1	RP11-104N10.2	7.38	2.23e-10	2.49e-06	0.82	0.66	Multiple myeloma (IgH translocation);	chr16:89434949	chr16:89516797~89522217:+
LAML	cis	rs2929278	0.562	rs8033846	ENSG00000249839.1	AC011330.5	7.37	2.24e-10	2.51e-06	0.79	0.66	Schizophrenia;	chr15:43743165	chr15:43663654~43684339:-
LAML	cis	rs2929278	0.589	rs7174732	ENSG00000249839.1	AC011330.5	7.37	2.24e-10	2.51e-06	0.79	0.66	Schizophrenia;	chr15:43746265	chr15:43663654~43684339:-
LAML	cis	rs2929278	0.617	rs11070410	ENSG00000249839.1	AC011330.5	7.37	2.24e-10	2.51e-06	0.79	0.66	Schizophrenia;	chr15:43764847	chr15:43663654~43684339:-
LAML	cis	rs2929278	0.617	rs4617832	ENSG00000249839.1	AC011330.5	7.37	2.25e-10	2.51e-06	0.79	0.66	Schizophrenia;	chr15:43738381	chr15:43663654~43684339:-
LAML	cis	rs2929278	0.589	rs2411284	ENSG00000249839.1	AC011330.5	7.37	2.25e-10	2.51e-06	0.79	0.66	Schizophrenia;	chr15:43746701	chr15:43663654~43684339:-
LAML	cis	rs2929278	0.617	rs12908467	ENSG00000249839.1	AC011330.5	7.37	2.25e-10	2.51e-06	0.79	0.66	Schizophrenia;	chr15:43755232	chr15:43663654~43684339:-
LAML	cis	rs11098499	0.739	rs10031033	ENSG00000248280.1	RP11-33B1.2	7.37	2.29e-10	2.56e-06	0.91	0.66	Corneal astigmatism;	chr4:119230297	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.532	rs4833624	ENSG00000248280.1	RP11-33B1.2	7.36	2.34e-10	2.61e-06	1	0.66	Corneal astigmatism;	chr4:119664342	chr4:119440561~119450157:-
LAML	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	7.36	2.36e-10	2.63e-06	0.67	0.66	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	7.36	2.36e-10	2.63e-06	0.67	0.66	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	7.36	2.36e-10	2.63e-06	0.67	0.66	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	7.36	2.36e-10	2.63e-06	0.67	0.66	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	7.36	2.36e-10	2.63e-06	0.67	0.66	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	7.36	2.36e-10	2.63e-06	0.67	0.66	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	7.36	2.36e-10	2.63e-06	0.67	0.66	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	7.36	2.36e-10	2.63e-06	0.67	0.66	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	7.36	2.36e-10	2.63e-06	0.67	0.66	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
LAML	cis	rs5769707	0.839	rs73176988	ENSG00000280224.1	CTA-722E9.1	-7.36	2.37e-10	2.63e-06	-0.82	-0.66	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49500568~49501585:+
LAML	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	7.36	2.42e-10	2.68e-06	0.91	0.66	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
LAML	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-7.36	2.42e-10	2.68e-06	-0.84	-0.66	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
LAML	cis	rs904251	0.523	rs2797799	ENSG00000227920.2	RP1-153P14.5	-7.36	2.43e-10	2.7e-06	-0.75	-0.66	Cognitive performance;	chr6:37515844	chr6:37545145~37550860:+
LAML	cis	rs904251	0.504	rs1757188	ENSG00000227920.2	RP1-153P14.5	-7.36	2.43e-10	2.7e-06	-0.75	-0.66	Cognitive performance;	chr6:37516032	chr6:37545145~37550860:+
LAML	cis	rs5769707	0.967	rs739241	ENSG00000279597.1	RP4-566L20.1	-7.36	2.44e-10	2.7e-06	-0.73	-0.65	Monocyte percentage of white cells;Monocyte count;	chr22:49659273	chr22:49534062~49534926:+
LAML	cis	rs9457247	0.663	rs2301436	ENSG00000265828.1	MIR3939	-7.35	2.45e-10	2.71e-06	-0.83	-0.65	Crohn's disease;	chr6:167024500	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.663	rs2282861	ENSG00000265828.1	MIR3939	-7.35	2.45e-10	2.71e-06	-0.83	-0.65	Crohn's disease;	chr6:167026640	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.663	rs2282860	ENSG00000265828.1	MIR3939	-7.35	2.45e-10	2.71e-06	-0.83	-0.65	Crohn's disease;	chr6:167026756	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.663	rs9459845	ENSG00000265828.1	MIR3939	-7.35	2.45e-10	2.71e-06	-0.83	-0.65	Crohn's disease;	chr6:167027013	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.663	rs9457257	ENSG00000265828.1	MIR3939	-7.35	2.45e-10	2.71e-06	-0.83	-0.65	Crohn's disease;	chr6:167027248	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.637	rs9459846	ENSG00000265828.1	MIR3939	-7.35	2.45e-10	2.71e-06	-0.83	-0.65	Crohn's disease;	chr6:167027535	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.579	rs2181059	ENSG00000265828.1	MIR3939	-7.35	2.45e-10	2.71e-06	-0.83	-0.65	Crohn's disease;	chr6:167028136	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.663	rs2237277	ENSG00000265828.1	MIR3939	-7.35	2.45e-10	2.71e-06	-0.83	-0.65	Crohn's disease;	chr6:167028619	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.663	rs9457258	ENSG00000265828.1	MIR3939	-7.35	2.45e-10	2.71e-06	-0.83	-0.65	Crohn's disease;	chr6:167030766	chr6:166997807~166997912:-
LAML	cis	rs11098499	0.588	rs2389874	ENSG00000248280.1	RP11-33B1.2	-7.35	2.47e-10	2.73e-06	-0.91	-0.65	Corneal astigmatism;	chr4:119633836	chr4:119440561~119450157:-
LAML	cis	rs6782228	0.675	rs9841987	ENSG00000277250.1	Metazoa_SRP	-7.34	2.56e-10	2.82e-06	-0.86	-0.65	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.675	rs56141228	ENSG00000277250.1	Metazoa_SRP	-7.34	2.56e-10	2.82e-06	-0.86	-0.65	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.651	rs9852825	ENSG00000277250.1	Metazoa_SRP	-7.34	2.56e-10	2.82e-06	-0.86	-0.65	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.651	rs9289332	ENSG00000277250.1	Metazoa_SRP	-7.34	2.56e-10	2.82e-06	-0.86	-0.65	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128673681~128674021:-
LAML	cis	rs853679	0.882	rs9468300	ENSG00000220721.1	OR1F12	7.34	2.57e-10	2.83e-06	1	0.65	Depression;	chr6:28159062	chr6:28073316~28074233:+
LAML	cis	rs853679	0.825	rs8180562	ENSG00000220721.1	OR1F12	7.34	2.57e-10	2.83e-06	1	0.65	Depression;	chr6:28173682	chr6:28073316~28074233:+
LAML	cis	rs853679	0.882	rs9380064	ENSG00000220721.1	OR1F12	7.34	2.57e-10	2.83e-06	1	0.65	Depression;	chr6:28175340	chr6:28073316~28074233:+
LAML	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-7.34	2.59e-10	2.85e-06	-0.92	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
LAML	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-7.34	2.62e-10	2.87e-06	-0.77	-0.65	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
LAML	cis	rs9457247	0.765	rs9459849	ENSG00000265828.1	MIR3939	-7.34	2.62e-10	2.88e-06	-0.8	-0.65	Crohn's disease;	chr6:167030672	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.765	rs9457259	ENSG00000265828.1	MIR3939	-7.34	2.62e-10	2.88e-06	-0.8	-0.65	Crohn's disease;	chr6:167030793	chr6:166997807~166997912:-
LAML	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	7.34	2.63e-10	2.89e-06	0.85	0.65	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
LAML	cis	rs9326248	0.539	rs518181	ENSG00000254851.1	RP11-109L13.1	-7.34	2.64e-10	2.9e-06	-0.88	-0.65	Blood protein levels;	chr11:116902071	chr11:117135528~117138582:+
LAML	cis	rs2486288	0.586	rs12909625	ENSG00000259520.4	CTD-2651B20.3	7.34	2.64e-10	2.9e-06	1.02	0.65	Glomerular filtration rate;	chr15:45279855	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.586	rs12909883	ENSG00000259520.4	CTD-2651B20.3	7.34	2.64e-10	2.9e-06	1.02	0.65	Glomerular filtration rate;	chr15:45279856	chr15:45251580~45279251:-
LAML	cis	rs6565180	0.962	rs6565183	ENSG00000273724.1	RP11-347C12.12	-7.34	2.65e-10	2.9e-06	-0.68	-0.65	Tonsillectomy;	chr16:30371434	chr16:30336400~30343336:+
LAML	cis	rs9457247	0.715	rs6923582	ENSG00000265828.1	MIR3939	-7.34	2.65e-10	2.9e-06	-0.81	-0.65	Crohn's disease;	chr6:167023674	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.765	rs2237276	ENSG00000265828.1	MIR3939	-7.34	2.65e-10	2.9e-06	-0.81	-0.65	Crohn's disease;	chr6:167028627	chr6:166997807~166997912:-
LAML	cis	rs12468226	1	rs16839077	ENSG00000226261.1	AC064836.3	7.33	2.68e-10	2.92e-06	1.18	0.65	Urate levels;	chr2:202343970	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs16839090	ENSG00000226261.1	AC064836.3	7.33	2.68e-10	2.92e-06	1.18	0.65	Urate levels;	chr2:202348338	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs58288071	ENSG00000226261.1	AC064836.3	7.33	2.68e-10	2.92e-06	1.18	0.65	Urate levels;	chr2:202350016	chr2:202336024~202336727:-
LAML	cis	rs2015599	0.549	rs10771512	ENSG00000257176.2	RP11-996F15.2	7.33	2.68e-10	2.92e-06	0.66	0.65	Platelet count;Mean platelet volume;	chr12:29287303	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.549	rs9738165	ENSG00000257176.2	RP11-996F15.2	7.33	2.68e-10	2.92e-06	0.66	0.65	Platelet count;Mean platelet volume;	chr12:29290263	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.507	rs3782507	ENSG00000257176.2	RP11-996F15.2	7.33	2.68e-10	2.92e-06	0.66	0.65	QT interval;	chr12:29292597	chr12:29280418~29317848:-
LAML	cis	rs6565180	1	rs68051857	ENSG00000273724.1	RP11-347C12.12	-7.33	2.69e-10	2.93e-06	-0.68	-0.65	Tonsillectomy;	chr16:30348690	chr16:30336400~30343336:+
LAML	cis	rs6565180	1	rs6565180	ENSG00000273724.1	RP11-347C12.12	-7.33	2.69e-10	2.93e-06	-0.68	-0.65	Tonsillectomy;	chr16:30350020	chr16:30336400~30343336:+
LAML	cis	rs6565180	1	rs11862806	ENSG00000273724.1	RP11-347C12.12	-7.33	2.69e-10	2.93e-06	-0.68	-0.65	Tonsillectomy;	chr16:30352750	chr16:30336400~30343336:+
LAML	cis	rs2486288	0.656	rs12908818	ENSG00000259520.4	CTD-2651B20.3	7.33	2.72e-10	2.96e-06	1.02	0.65	Glomerular filtration rate;	chr15:45279470	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs12910009	ENSG00000259520.4	CTD-2651B20.3	7.33	2.72e-10	2.96e-06	1.02	0.65	Glomerular filtration rate;	chr15:45280210	chr15:45251580~45279251:-
LAML	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	7.33	2.75e-10	2.98e-06	0.96	0.65	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
LAML	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	7.33	2.76e-10	2.99e-06	0.84	0.65	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
LAML	cis	rs853679	1	rs7740487	ENSG00000187763.3	OR2B7P	7.32	2.84e-10	3.08e-06	1.09	0.65	Depression;	chr6:28248708	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs68141011	ENSG00000187763.3	OR2B7P	7.32	2.84e-10	3.08e-06	1.09	0.65	Depression;	chr6:28250019	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs13200462	ENSG00000187763.3	OR2B7P	7.32	2.84e-10	3.08e-06	1.09	0.65	Depression;	chr6:28250421	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs9986596	ENSG00000187763.3	OR2B7P	7.32	2.84e-10	3.08e-06	1.09	0.65	Depression;	chr6:28251883	chr6:28046434~28047367:+
LAML	cis	rs12468226	0.882	rs116437099	ENSG00000226261.1	AC064836.3	7.31	2.9e-10	3.14e-06	1.1	0.65	Urate levels;	chr2:202299250	chr2:202336024~202336727:-
LAML	cis	rs10927875	0.578	rs10927859	ENSG00000178715.8	RP11-169K16.8	-7.31	2.92e-10	3.16e-06	-0.76	-0.65	Dilated cardiomyopathy;	chr1:15815367	chr1:15828232~15828669:+
LAML	cis	rs858239	0.863	rs466225	ENSG00000230658.1	KLHL7-AS1	7.31	2.94e-10	3.17e-06	0.87	0.65	Cerebrospinal fluid biomarker levels;	chr7:23292784	chr7:23101228~23105703:-
LAML	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-7.31	2.94e-10	3.18e-06	-0.74	-0.65	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
LAML	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-7.31	2.94e-10	3.18e-06	-0.74	-0.65	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
LAML	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	7.3	3.02e-10	3.25e-06	0.86	0.65	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	7.3	3.02e-10	3.25e-06	0.86	0.65	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs10892061	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:117015398	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs11216242	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:117030833	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs12804122	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:117031900	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-7.3	3.02e-10	3.25e-06	-0.86	-0.65	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
LAML	cis	rs4879656	0.8	rs10971379	ENSG00000225693.1	LAGE3P1	-7.3	3.08e-10	3.31e-06	-0.68	-0.65	Menopause (age at onset);	chr9:33064932	chr9:33019682~33020165:-
LAML	cis	rs9457247	0.765	rs10455982	ENSG00000265828.1	MIR3939	-7.3	3.1e-10	3.33e-06	-0.82	-0.65	Crohn's disease;	chr6:167035240	chr6:166997807~166997912:-
LAML	cis	rs9326248	0.581	rs10892063	ENSG00000254851.1	RP11-109L13.1	-7.3	3.14e-10	3.36e-06	-0.85	-0.65	Blood protein levels;	chr11:117025439	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.559	rs10892064	ENSG00000254851.1	RP11-109L13.1	-7.3	3.14e-10	3.36e-06	-0.85	-0.65	Blood protein levels;	chr11:117025837	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.539	rs10892065	ENSG00000254851.1	RP11-109L13.1	-7.3	3.14e-10	3.36e-06	-0.85	-0.65	Blood protein levels;	chr11:117026308	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-7.29	3.17e-10	3.4e-06	-0.86	-0.65	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
LAML	cis	rs12468226	0.938	rs56684065	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202289528	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs1474001	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202290230	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs76664732	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202296298	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs16841867	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202303512	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs79117531	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202307690	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs16839065	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202308774	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs115418918	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202315145	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs114922024	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202315958	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs77261109	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202316233	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs12466003	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202317317	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs76501067	ENSG00000226261.1	AC064836.3	7.29	3.19e-10	3.4e-06	1.09	0.65	Urate levels;	chr2:202318042	chr2:202336024~202336727:-
LAML	cis	rs6782228	0.675	rs4443194	ENSG00000277250.1	Metazoa_SRP	-7.29	3.23e-10	3.45e-06	-0.86	-0.65	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.675	rs4857918	ENSG00000277250.1	Metazoa_SRP	-7.29	3.23e-10	3.45e-06	-0.86	-0.65	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128673681~128674021:-
LAML	cis	rs561341	0.882	rs16967101	ENSG00000266379.5	RP11-640N20.8	7.29	3.24e-10	3.45e-06	1.01	0.65	Hip circumference adjusted for BMI;	chr17:32050143	chr17:32088160~32094933:-
LAML	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	7.29	3.26e-10	3.47e-06	0.73	0.65	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
LAML	cis	rs561341	1	rs7210970	ENSG00000266379.5	RP11-640N20.8	7.28	3.35e-10	3.54e-06	0.97	0.65	Hip circumference adjusted for BMI;	chr17:31935150	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs8070262	ENSG00000266379.5	RP11-640N20.8	7.28	3.35e-10	3.54e-06	0.97	0.65	Hip circumference adjusted for BMI;	chr17:31935448	chr17:32088160~32094933:-
LAML	cis	rs561341	0.714	rs7218466	ENSG00000266379.5	RP11-640N20.8	7.28	3.35e-10	3.54e-06	0.97	0.65	Hip circumference adjusted for BMI;	chr17:31936295	chr17:32088160~32094933:-
LAML	cis	rs1757171	0.504	rs11969056	ENSG00000227920.2	RP1-153P14.5	-7.28	3.36e-10	3.55e-06	-0.75	-0.65	Cognitive performance;	chr6:37516509	chr6:37545145~37550860:+
LAML	cis	rs6452524	0.967	rs2974448	ENSG00000249664.1	CTD-2227C6.2	7.28	3.43e-10	3.62e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83190937	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10068099	ENSG00000249664.1	CTD-2227C6.2	7.27	3.44e-10	3.62e-06	0.84	0.65	Hypertension (SNP x SNP interaction);	chr5:83161373	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs7349753	ENSG00000249664.1	CTD-2227C6.2	7.27	3.44e-10	3.62e-06	0.84	0.65	Hypertension (SNP x SNP interaction);	chr5:83165632	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs67683443	ENSG00000249664.1	CTD-2227C6.2	7.27	3.44e-10	3.62e-06	0.84	0.65	Hypertension (SNP x SNP interaction);	chr5:83167884	chr5:83012285~83013109:-
LAML	cis	rs1263173	0.91	rs1263170	ENSG00000254851.1	RP11-109L13.1	-7.27	3.44e-10	3.62e-06	-0.9	-0.65	HDL cholesterol;	chr11:116807697	chr11:117135528~117138582:+
LAML	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-7.27	3.45e-10	3.63e-06	-0.82	-0.65	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
LAML	cis	rs4879656	0.835	rs7036559	ENSG00000225693.1	LAGE3P1	-7.27	3.47e-10	3.65e-06	-0.68	-0.65	Menopause (age at onset);	chr9:33064929	chr9:33019682~33020165:-
LAML	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-7.27	3.5e-10	3.67e-06	-0.84	-0.65	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-7.27	3.52e-10	3.69e-06	-0.83	-0.65	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
LAML	cis	rs904251	0.523	rs1776454	ENSG00000227920.2	RP1-153P14.5	-7.26	3.58e-10	3.76e-06	-0.78	-0.65	Cognitive performance;	chr6:37514323	chr6:37545145~37550860:+
LAML	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-7.26	3.6e-10	3.77e-06	-0.85	-0.65	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
LAML	cis	rs916888	0.647	rs199524	ENSG00000261575.2	RP11-259G18.1	-7.26	3.63e-10	3.8e-06	-0.89	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46267037~46268694:+
LAML	cis	rs11039131	0.929	rs1685404	ENSG00000271350.1	CTD-2384B9.1	-7.26	3.63e-10	3.81e-06	-0.73	-0.65	Schizophrenia;	chr11:47222114	chr11:47041027~47041945:-
LAML	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-7.26	3.67e-10	3.84e-06	-0.85	-0.65	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
LAML	cis	rs11098499	0.562	rs13101722	ENSG00000248280.1	RP11-33B1.2	-7.26	3.73e-10	3.9e-06	-0.86	-0.65	Corneal astigmatism;	chr4:119634820	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.615	rs59867181	ENSG00000248280.1	RP11-33B1.2	-7.26	3.73e-10	3.9e-06	-0.86	-0.65	Corneal astigmatism;	chr4:119635312	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.562	rs2389879	ENSG00000248280.1	RP11-33B1.2	-7.26	3.73e-10	3.9e-06	-0.86	-0.65	Corneal astigmatism;	chr4:119636529	chr4:119440561~119450157:-
LAML	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	7.26	3.73e-10	3.9e-06	0.86	0.65	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
LAML	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-7.25	3.75e-10	3.92e-06	-0.79	-0.65	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
LAML	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-7.25	3.76e-10	3.93e-06	-0.82	-0.65	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
LAML	cis	rs853679	0.882	rs9461432	ENSG00000220721.1	OR1F12	7.25	3.8e-10	3.96e-06	0.99	0.65	Depression;	chr6:28119105	chr6:28073316~28074233:+
LAML	cis	rs853679	0.882	rs4713139	ENSG00000220721.1	OR1F12	7.25	3.8e-10	3.96e-06	0.99	0.65	Depression;	chr6:28124907	chr6:28073316~28074233:+
LAML	cis	rs853679	0.882	rs3757188	ENSG00000220721.1	OR1F12	7.25	3.8e-10	3.96e-06	0.99	0.65	Depression;	chr6:28139579	chr6:28073316~28074233:+
LAML	cis	rs11098499	0.739	rs9996382	ENSG00000248280.1	RP11-33B1.2	7.25	3.8e-10	3.96e-06	0.91	0.65	Corneal astigmatism;	chr4:119229857	chr4:119440561~119450157:-
LAML	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-7.25	3.83e-10	3.99e-06	-0.82	-0.65	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
LAML	cis	rs853679	1	rs1679709	ENSG00000187763.3	OR2B7P	-7.25	3.84e-10	4e-06	-1.03	-0.65	Depression;	chr6:28260564	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs1778511	ENSG00000187763.3	OR2B7P	-7.25	3.84e-10	4e-06	-1.03	-0.65	Depression;	chr6:28261633	chr6:28046434~28047367:+
LAML	cis	rs10927875	0.501	rs9660676	ENSG00000178715.8	RP11-169K16.8	-7.25	3.88e-10	4.04e-06	-0.8	-0.65	Dilated cardiomyopathy;	chr1:15952546	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.526	rs2179615	ENSG00000178715.8	RP11-169K16.8	-7.25	3.88e-10	4.04e-06	-0.8	-0.65	Dilated cardiomyopathy;	chr1:15955931	chr1:15828232~15828669:+
LAML	cis	rs4879656	0.872	rs7876033	ENSG00000225693.1	LAGE3P1	-7.25	3.88e-10	4.04e-06	-0.68	-0.65	Menopause (age at onset);	chr9:33058561	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.8	rs1537041	ENSG00000225693.1	LAGE3P1	-7.25	3.88e-10	4.04e-06	-0.68	-0.65	Menopause (age at onset);	chr9:33060418	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.872	rs10813930	ENSG00000225693.1	LAGE3P1	-7.25	3.88e-10	4.04e-06	-0.68	-0.65	Menopause (age at onset);	chr9:33064338	chr9:33019682~33020165:-
LAML	cis	rs9457247	0.765	rs10946203	ENSG00000265828.1	MIR3939	-7.24	3.94e-10	4.09e-06	-0.82	-0.65	Crohn's disease;	chr6:167033247	chr6:166997807~166997912:-
LAML	cis	rs6452524	0.967	rs4290995	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83182177	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2974444	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83185174	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2940542	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83185734	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs965674	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83186765	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.934	rs2940543	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83187297	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2974450	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83187323	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2974449	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83187465	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2662241	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83188774	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2662242	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83189066	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2731861	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83189445	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs2940544	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83189785	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2731865	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83190570	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2731844	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83192627	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.901	rs2940540	ENSG00000249664.1	CTD-2227C6.2	7.24	3.97e-10	4.11e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83193004	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2974445	ENSG00000249664.1	CTD-2227C6.2	-7.24	3.97e-10	4.11e-06	-0.87	-0.65	Hypertension (SNP x SNP interaction);	chr5:83185561	chr5:83012285~83013109:-
LAML	cis	rs12468226	0.938	rs80282360	ENSG00000226261.1	AC064836.3	7.24	4e-10	4.14e-06	1.19	0.65	Urate levels;	chr2:202275121	chr2:202336024~202336727:-
LAML	cis	rs6435862	0.517	rs6757091	ENSG00000227769.6	AC072062.3	7.24	4.02e-10	4.15e-06	0.67	0.65	Neuroblastoma (high-risk);	chr2:214808069	chr2:215004782~215085488:+
LAML	cis	rs6435862	0.5	rs6756902	ENSG00000227769.6	AC072062.3	7.24	4.02e-10	4.15e-06	0.67	0.65	Neuroblastoma (high-risk);	chr2:214808103	chr2:215004782~215085488:+
LAML	cis	rs6435862	0.5	rs12477063	ENSG00000227769.6	AC072062.3	7.24	4.02e-10	4.15e-06	0.67	0.65	Neuroblastoma (high-risk);	chr2:214808940	chr2:215004782~215085488:+
LAML	cis	rs853679	0.55	rs9295762	ENSG00000187763.3	OR2B7P	-7.24	4.03e-10	4.17e-06	-0.89	-0.65	Depression;	chr6:28187640	chr6:28046434~28047367:+
LAML	cis	rs6452524	0.967	rs4541638	ENSG00000249664.1	CTD-2227C6.2	7.24	4.04e-10	4.17e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83181325	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs28360104	ENSG00000249664.1	CTD-2227C6.2	7.24	4.04e-10	4.17e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83181525	chr5:83012285~83013109:-
LAML	cis	rs62070183	0.938	rs75782470	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32746623	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.882	rs62070164	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32759415	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs4795719	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32776957	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.882	rs17780981	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32792019	chr17:32627739~32686484:+
LAML	cis	rs112916054	1	rs112916054	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Immature fraction of reticulocytes;	chr17:32797244	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.752	rs17781005	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32805511	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.808	rs76373015	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815023	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.808	rs79957065	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815731	chr17:32627739~32686484:+
LAML	cis	rs62070183	1	rs62070183	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32837349	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.882	rs17183600	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32848061	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.882	rs17183628	ENSG00000264458.1	RP11-220C2.1	-7.23	4.07e-10	4.19e-06	-0.91	-0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32857613	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.882	rs17781136	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32858024	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs17781142	ENSG00000264458.1	RP11-220C2.1	-7.23	4.07e-10	4.19e-06	-0.91	-0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32860198	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.882	rs62070187	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32863706	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.817	rs79640811	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32894299	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.766	rs62070229	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32900575	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.766	rs62070232	ENSG00000264458.1	RP11-220C2.1	7.23	4.07e-10	4.19e-06	0.91	0.65	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32903075	chr17:32627739~32686484:+
LAML	cis	rs6452524	0.967	rs62374399	ENSG00000249664.1	CTD-2227C6.2	7.22	4.25e-10	4.35e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83176051	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs62374401	ENSG00000249664.1	CTD-2227C6.2	7.22	4.25e-10	4.35e-06	0.87	0.65	Hypertension (SNP x SNP interaction);	chr5:83177159	chr5:83012285~83013109:-
LAML	cis	rs853679	1	rs1679709	ENSG00000220721.1	OR1F12	-7.22	4.28e-10	4.38e-06	-0.9	-0.65	Depression;	chr6:28260564	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs1778511	ENSG00000220721.1	OR1F12	-7.22	4.28e-10	4.38e-06	-0.9	-0.65	Depression;	chr6:28261633	chr6:28073316~28074233:+
LAML	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	7.22	4.3e-10	4.4e-06	0.84	0.65	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
LAML	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-7.22	4.38e-10	4.48e-06	-1.16	-0.65	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
LAML	cis	rs6435862	0.593	rs34732883	ENSG00000227769.6	AC072062.3	7.21	4.53e-10	4.62e-06	0.66	0.65	Neuroblastoma (high-risk);	chr2:214809647	chr2:215004782~215085488:+
LAML	cis	rs1577917	0.883	rs2166664	ENSG00000203875.9	SNHG5	-7.2	4.71e-10	4.77e-06	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85886904	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.883	rs9450348	ENSG00000203875.9	SNHG5	-7.2	4.71e-10	4.77e-06	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85888318	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.959	rs2816822	ENSG00000203875.9	SNHG5	-7.2	4.71e-10	4.77e-06	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85948574	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.804	rs2786854	ENSG00000203875.9	SNHG5	-7.2	4.71e-10	4.77e-06	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85959022	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.92	rs1337842	ENSG00000203875.9	SNHG5	-7.2	4.71e-10	4.77e-06	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85965379	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.883	rs2660575	ENSG00000203875.9	SNHG5	-7.2	4.71e-10	4.77e-06	-0.82	-0.65	Response to antipsychotic treatment;	chr6:85975277	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.883	rs9450375	ENSG00000203875.9	SNHG5	7.2	4.71e-10	4.77e-06	0.82	0.65	Response to antipsychotic treatment;	chr6:86046911	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.883	rs1415749	ENSG00000203875.9	SNHG5	7.2	4.71e-10	4.77e-06	0.82	0.65	Response to antipsychotic treatment;	chr6:86069366	chr6:85660950~85678736:-
LAML	cis	rs11098499	0.71	rs4145952	ENSG00000248280.1	RP11-33B1.2	7.2	4.72e-10	4.78e-06	0.83	0.65	Corneal astigmatism;	chr4:119234651	chr4:119440561~119450157:-
LAML	cis	rs12922317	0.964	rs12930612	ENSG00000260224.1	UBL5P4	7.2	4.77e-10	4.83e-06	0.85	0.65	Schizophrenia;	chr16:11978346	chr16:11968508~11968743:-
LAML	cis	rs904251	0.522	rs882322	ENSG00000227920.2	RP1-153P14.5	-7.2	4.8e-10	4.85e-06	-0.75	-0.65	Cognitive performance;	chr6:37516327	chr6:37545145~37550860:+
LAML	cis	rs12468226	0.938	rs12463937	ENSG00000226261.1	AC064836.3	7.2	4.81e-10	4.85e-06	1.08	0.65	Urate levels;	chr2:202246543	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs3731700	ENSG00000226261.1	AC064836.3	7.2	4.81e-10	4.85e-06	1.08	0.65	Urate levels;	chr2:202291213	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs12464254	ENSG00000226261.1	AC064836.3	7.2	4.81e-10	4.85e-06	1.08	0.65	Urate levels;	chr2:202301641	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs12471060	ENSG00000226261.1	AC064836.3	7.2	4.81e-10	4.85e-06	1.08	0.65	Urate levels;	chr2:202309597	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs80315897	ENSG00000226261.1	AC064836.3	7.2	4.81e-10	4.85e-06	1.08	0.65	Urate levels;	chr2:202318044	chr2:202336024~202336727:-
LAML	cis	rs1757171	0.542	rs1757186	ENSG00000227920.2	RP1-153P14.5	-7.19	4.9e-10	4.89e-06	-0.75	-0.65	Cognitive performance;	chr6:37516335	chr6:37545145~37550860:+
LAML	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-7.19	4.92e-10	4.9e-06	-0.77	-0.65	Height;	chr3:53084188	chr3:53064283~53065091:-
LAML	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	7.19	4.92e-10	4.9e-06	0.95	0.65	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
LAML	cis	rs853679	1	rs1936365	ENSG00000220721.1	OR1F12	-7.19	4.96e-10	4.93e-06	-0.82	-0.65	Depression;	chr6:28300675	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs6905391	ENSG00000220721.1	OR1F12	7.19	4.96e-10	4.93e-06	0.82	0.65	Depression;	chr6:28294909	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs853694	ENSG00000220721.1	OR1F12	7.19	4.96e-10	4.93e-06	0.82	0.65	Depression;	chr6:28311323	chr6:28073316~28074233:+
LAML	cis	rs6565180	0.926	rs4788413	ENSG00000273724.1	RP11-347C12.12	7.18	5.04e-10	5e-06	0.66	0.65	Tonsillectomy;	chr16:30399124	chr16:30336400~30343336:+
LAML	cis	rs1577917	0.696	rs2842617	ENSG00000203875.9	SNHG5	-7.18	5.04e-10	5.01e-06	-0.78	-0.65	Response to antipsychotic treatment;	chr6:85599980	chr6:85660950~85678736:-
LAML	cis	rs9457247	0.765	rs9457252	ENSG00000265828.1	MIR3939	7.18	5.11e-10	5.06e-06	0.8	0.65	Crohn's disease;	chr6:167020437	chr6:166997807~166997912:-
LAML	cis	rs9326248	0.559	rs609177	ENSG00000254851.1	RP11-109L13.1	-7.18	5.14e-10	5.08e-06	-0.86	-0.65	Blood protein levels;	chr11:116899801	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-7.18	5.14e-10	5.08e-06	-0.86	-0.65	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
LAML	cis	rs282544	0.581	rs11950328	ENSG00000271455.1	RP11-269M20.2	7.18	5.15e-10	5.09e-06	0.73	0.65	Myopia (pathological);	chr5:50734957	chr5:50603229~50603511:+
LAML	cis	rs282544	0.581	rs13159505	ENSG00000271455.1	RP11-269M20.2	7.18	5.15e-10	5.09e-06	0.73	0.65	Myopia (pathological);	chr5:50742936	chr5:50603229~50603511:+
LAML	cis	rs11098499	0.588	rs6534149	ENSG00000248280.1	RP11-33B1.2	-7.18	5.2e-10	5.13e-06	-0.85	-0.65	Corneal astigmatism;	chr4:119638137	chr4:119440561~119450157:-
LAML	cis	rs5760092	0.755	rs11090298	ENSG00000225282.1	AP000350.6	-7.17	5.28e-10	5.21e-06	-1	-0.65	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23926900~23929574:+
LAML	cis	rs6003958	1	rs6003958	ENSG00000225282.1	AP000350.6	-7.17	5.28e-10	5.21e-06	-1	-0.65	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23926900~23929574:+
LAML	cis	rs5760092	0.755	rs6003959	ENSG00000225282.1	AP000350.6	-7.17	5.28e-10	5.21e-06	-1	-0.65	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23926900~23929574:+
LAML	cis	rs13201294	1	rs13201294	ENSG00000220721.1	OR1F12	7.17	5.28e-10	5.21e-06	0.93	0.65	Squamous cell lung carcinoma;	chr6:27588362	chr6:28073316~28074233:+
LAML	cis	rs2486288	0.656	rs1706770	ENSG00000259520.4	CTD-2651B20.3	7.17	5.29e-10	5.21e-06	0.96	0.65	Glomerular filtration rate;	chr15:45282864	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.554	rs1719235	ENSG00000259520.4	CTD-2651B20.3	7.17	5.29e-10	5.21e-06	0.96	0.65	Glomerular filtration rate;	chr15:45283910	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs1719236	ENSG00000259520.4	CTD-2651B20.3	7.17	5.29e-10	5.21e-06	0.96	0.65	Glomerular filtration rate;	chr15:45285585	chr15:45251580~45279251:-
LAML	cis	rs4879656	0.866	rs10971316	ENSG00000225693.1	LAGE3P1	-7.17	5.31e-10	5.22e-06	-0.67	-0.65	Menopause (age at onset);	chr9:33013964	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.872	rs12375624	ENSG00000225693.1	LAGE3P1	-7.17	5.31e-10	5.22e-06	-0.67	-0.65	Menopause (age at onset);	chr9:33017140	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.797	rs2297218	ENSG00000225693.1	LAGE3P1	-7.17	5.31e-10	5.22e-06	-0.67	-0.65	Menopause (age at onset);	chr9:33025253	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.872	rs2274767	ENSG00000225693.1	LAGE3P1	-7.17	5.31e-10	5.22e-06	-0.67	-0.65	Menopause (age at onset);	chr9:33047400	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.797	rs7872744	ENSG00000225693.1	LAGE3P1	-7.17	5.31e-10	5.22e-06	-0.67	-0.65	Menopause (age at onset);	chr9:33054164	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.872	rs1537040	ENSG00000225693.1	LAGE3P1	-7.17	5.31e-10	5.22e-06	-0.67	-0.65	Menopause (age at onset);	chr9:33061442	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.872	rs10758180	ENSG00000225693.1	LAGE3P1	7.17	5.31e-10	5.22e-06	0.67	0.65	Menopause (age at onset);	chr9:33045149	chr9:33019682~33020165:-
LAML	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	7.17	5.32e-10	5.23e-06	0.8	0.65	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
LAML	cis	rs12468226	1	rs7587234	ENSG00000226261.1	AC064836.3	7.17	5.32e-10	5.23e-06	1.17	0.65	Urate levels;	chr2:202351699	chr2:202336024~202336727:-
LAML	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-7.17	5.33e-10	5.24e-06	-1.06	-0.65	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
LAML	cis	rs6565180	0.888	rs8060853	ENSG00000273724.1	RP11-347C12.12	7.17	5.34e-10	5.25e-06	0.66	0.65	Tonsillectomy;	chr16:30392537	chr16:30336400~30343336:+
LAML	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-7.17	5.35e-10	5.26e-06	-0.86	-0.65	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-7.17	5.35e-10	5.26e-06	-0.86	-0.65	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-7.17	5.35e-10	5.26e-06	-0.86	-0.65	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
LAML	cis	rs853679	0.55	rs1233699	ENSG00000182477.5	OR2B8P	7.17	5.4e-10	5.3e-06	0.94	0.65	Depression;	chr6:28201380	chr6:28053228~28054165:-
LAML	cis	rs1577917	0.883	rs12214536	ENSG00000203875.9	SNHG5	-7.17	5.45e-10	5.34e-06	-0.81	-0.65	Response to antipsychotic treatment;	chr6:86080592	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.883	rs2782263	ENSG00000203875.9	SNHG5	-7.17	5.45e-10	5.34e-06	-0.81	-0.65	Response to antipsychotic treatment;	chr6:86081589	chr6:85660950~85678736:-
LAML	cis	rs561341	0.83	rs2301765	ENSG00000266379.5	RP11-640N20.8	-7.16	5.53e-10	5.41e-06	-1.18	-0.65	Hip circumference adjusted for BMI;	chr17:31875037	chr17:32088160~32094933:-
LAML	cis	rs561341	0.883	rs6505274	ENSG00000266379.5	RP11-640N20.8	7.16	5.53e-10	5.41e-06	0.97	0.65	Hip circumference adjusted for BMI;	chr17:32017562	chr17:32088160~32094933:-
LAML	cis	rs4591358	1	rs4850619	ENSG00000223466.1	AC064834.2	-7.16	5.6e-10	5.48e-06	-0.93	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195468634	chr2:195533035~195538681:+
LAML	cis	rs9326248	0.52	rs2735183	ENSG00000254851.1	RP11-109L13.1	-7.16	5.61e-10	5.49e-06	-0.81	-0.64	Blood protein levels;	chr11:117144479	chr11:117135528~117138582:+
LAML	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	7.16	5.69e-10	5.56e-06	0.84	0.64	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
LAML	cis	rs1577917	0.883	rs1337854	ENSG00000203875.9	SNHG5	7.16	5.71e-10	5.58e-06	0.81	0.64	Response to antipsychotic treatment;	chr6:86014297	chr6:85660950~85678736:-
LAML	cis	rs12468226	0.808	rs73992849	ENSG00000226261.1	AC064836.3	7.16	5.72e-10	5.58e-06	1.09	0.64	Urate levels;	chr2:202152444	chr2:202336024~202336727:-
LAML	cis	rs10927875	0.632	rs2013745	ENSG00000178715.8	RP11-169K16.8	-7.16	5.72e-10	5.58e-06	-0.75	-0.64	Dilated cardiomyopathy;	chr1:15800181	chr1:15828232~15828669:+
LAML	cis	rs12922317	0.927	rs12923439	ENSG00000260224.1	UBL5P4	7.15	5.76e-10	5.62e-06	0.87	0.64	Schizophrenia;	chr16:11980101	chr16:11968508~11968743:-
LAML	cis	rs853679	0.55	rs1225598	ENSG00000187763.3	OR2B7P	7.15	5.81e-10	5.66e-06	0.91	0.64	Depression;	chr6:28193021	chr6:28046434~28047367:+
LAML	cis	rs853679	0.55	rs1150689	ENSG00000187763.3	OR2B7P	7.15	5.81e-10	5.66e-06	0.91	0.64	Depression;	chr6:28197321	chr6:28046434~28047367:+
LAML	cis	rs853679	0.55	rs1225599	ENSG00000187763.3	OR2B7P	7.15	5.81e-10	5.66e-06	0.91	0.64	Depression;	chr6:28197412	chr6:28046434~28047367:+
LAML	cis	rs853679	0.574	rs1233705	ENSG00000187763.3	OR2B7P	7.15	5.81e-10	5.66e-06	0.91	0.64	Depression;	chr6:28198669	chr6:28046434~28047367:+
LAML	cis	rs853679	0.55	rs1233704	ENSG00000187763.3	OR2B7P	-7.15	5.81e-10	5.66e-06	-0.91	-0.64	Depression;	chr6:28199145	chr6:28046434~28047367:+
LAML	cis	rs853679	0.55	rs1233701	ENSG00000187763.3	OR2B7P	-7.15	5.81e-10	5.66e-06	-0.91	-0.64	Depression;	chr6:28200948	chr6:28046434~28047367:+
LAML	cis	rs853679	0.55	rs1237875	ENSG00000187763.3	OR2B7P	-7.15	5.81e-10	5.66e-06	-0.91	-0.64	Depression;	chr6:28205232	chr6:28046434~28047367:+
LAML	cis	rs1577917	0.74	rs9353327	ENSG00000203875.9	SNHG5	-7.15	5.81e-10	5.66e-06	-0.78	-0.64	Response to antipsychotic treatment;	chr6:85684348	chr6:85660950~85678736:-
LAML	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	7.15	5.9e-10	5.74e-06	1.05	0.64	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	7.15	5.9e-10	5.74e-06	1.05	0.64	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
LAML	cis	rs4879656	0.835	rs1332096	ENSG00000225693.1	LAGE3P1	-7.15	5.93e-10	5.77e-06	-0.7	-0.64	Menopause (age at onset);	chr9:32936041	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.762	rs7868944	ENSG00000225693.1	LAGE3P1	7.15	5.93e-10	5.77e-06	0.7	0.64	Menopause (age at onset);	chr9:32938861	chr9:33019682~33020165:-
LAML	cis	rs3096299	0.754	rs2965942	ENSG00000274627.1	RP11-104N10.2	7.14	6.02e-10	5.85e-06	0.81	0.64	Multiple myeloma (IgH translocation);	chr16:89443919	chr16:89516797~89522217:+
LAML	cis	rs10927875	0.632	rs904911	ENSG00000178715.8	RP11-169K16.8	-7.14	6.09e-10	5.91e-06	-0.75	-0.64	Dilated cardiomyopathy;	chr1:15800437	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.632	rs1122068	ENSG00000178715.8	RP11-169K16.8	-7.14	6.09e-10	5.91e-06	-0.75	-0.64	Dilated cardiomyopathy;	chr1:15800985	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.632	rs4481843	ENSG00000178715.8	RP11-169K16.8	-7.14	6.09e-10	5.91e-06	-0.75	-0.64	Dilated cardiomyopathy;	chr1:15801710	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.596	rs1806990	ENSG00000178715.8	RP11-169K16.8	-7.14	6.09e-10	5.91e-06	-0.75	-0.64	Dilated cardiomyopathy;	chr1:15802882	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.632	rs7535248	ENSG00000178715.8	RP11-169K16.8	-7.14	6.09e-10	5.91e-06	-0.75	-0.64	Dilated cardiomyopathy;	chr1:15803103	chr1:15828232~15828669:+
LAML	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-7.14	6.19e-10	5.97e-06	-0.79	-0.64	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-7.14	6.19e-10	5.97e-06	-0.79	-0.64	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	7.14	6.19e-10	5.97e-06	0.79	0.64	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
LAML	cis	rs4879656	0.843	rs10813918	ENSG00000225693.1	LAGE3P1	7.13	6.44e-10	6.21e-06	0.67	0.64	Menopause (age at onset);	chr9:32996372	chr9:33019682~33020165:-
LAML	cis	rs2929278	0.561	rs3099045	ENSG00000249839.1	AC011330.5	-7.12	6.63e-10	6.34e-06	-0.78	-0.64	Schizophrenia;	chr15:43631757	chr15:43663654~43684339:-
LAML	cis	rs5760092	0.755	rs11090298	ENSG00000218537.1	MIF-AS1	-7.11	6.79e-10	6.48e-06	-1.1	-0.64	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23894426~23898930:-
LAML	cis	rs6003958	1	rs6003958	ENSG00000218537.1	MIF-AS1	-7.11	6.79e-10	6.48e-06	-1.1	-0.64	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23894426~23898930:-
LAML	cis	rs5760092	0.755	rs6003959	ENSG00000218537.1	MIF-AS1	-7.11	6.79e-10	6.48e-06	-1.1	-0.64	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23894426~23898930:-
LAML	cis	rs10927875	0.864	rs12135073	ENSG00000178715.8	RP11-169K16.8	7.11	6.95e-10	6.61e-06	0.81	0.64	Dilated cardiomyopathy;	chr1:15841304	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.864	rs12744578	ENSG00000178715.8	RP11-169K16.8	-7.11	6.95e-10	6.61e-06	-0.81	-0.64	Dilated cardiomyopathy;	chr1:15846615	chr1:15828232~15828669:+
LAML	cis	rs12468226	1	rs16824599	ENSG00000226261.1	AC064836.3	7.11	6.96e-10	6.61e-06	1.17	0.64	Urate levels;	chr2:202358243	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs11899836	ENSG00000226261.1	AC064836.3	7.11	6.96e-10	6.61e-06	1.17	0.64	Urate levels;	chr2:202371316	chr2:202336024~202336727:-
LAML	cis	rs853679	1	rs735765	ENSG00000220721.1	OR1F12	7.11	7.04e-10	6.69e-06	0.95	0.64	Depression;	chr6:28202519	chr6:28073316~28074233:+
LAML	cis	rs4879656	0.835	rs13290323	ENSG00000225693.1	LAGE3P1	-7.1	7.08e-10	6.72e-06	-0.67	-0.64	Menopause (age at onset);	chr9:33062293	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.831	rs13289835	ENSG00000225693.1	LAGE3P1	-7.1	7.08e-10	6.72e-06	-0.67	-0.64	Menopause (age at onset);	chr9:33069183	chr9:33019682~33020165:-
LAML	cis	rs561341	0.883	rs1034626	ENSG00000266379.5	RP11-640N20.8	-7.1	7.1e-10	6.73e-06	-1.1	-0.64	Hip circumference adjusted for BMI;	chr17:31892481	chr17:32088160~32094933:-
LAML	cis	rs6565180	0.888	rs12447833	ENSG00000273724.1	RP11-347C12.12	7.1	7.16e-10	6.79e-06	0.65	0.64	Tonsillectomy;	chr16:30378993	chr16:30336400~30343336:+
LAML	cis	rs9457247	0.765	rs9295385	ENSG00000265828.1	MIR3939	-7.1	7.28e-10	6.88e-06	-0.81	-0.64	Crohn's disease;	chr6:167034693	chr6:166997807~166997912:-
LAML	cis	rs16828019	0.852	rs12045171	ENSG00000213987.4	RP11-399E6.2	7.1	7.33e-10	6.9e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41264550~41264862:-
LAML	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-7.09	7.48e-10	6.97e-06	-0.8	-0.64	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
LAML	cis	rs853679	0.882	rs4713140	ENSG00000220721.1	OR1F12	7.09	7.5e-10	6.99e-06	0.98	0.64	Depression;	chr6:28129415	chr6:28073316~28074233:+
LAML	cis	rs6565180	0.962	rs35480350	ENSG00000273724.1	RP11-347C12.12	-7.09	7.68e-10	7.14e-06	-0.67	-0.64	Tonsillectomy;	chr16:30354718	chr16:30336400~30343336:+
LAML	cis	rs6565180	0.962	rs11642676	ENSG00000273724.1	RP11-347C12.12	-7.09	7.68e-10	7.14e-06	-0.67	-0.64	Tonsillectomy;	chr16:30360334	chr16:30336400~30343336:+
LAML	cis	rs6565180	0.962	rs6565182	ENSG00000273724.1	RP11-347C12.12	-7.09	7.68e-10	7.14e-06	-0.67	-0.64	Tonsillectomy;	chr16:30363060	chr16:30336400~30343336:+
LAML	cis	rs6565180	1	rs11646130	ENSG00000273724.1	RP11-347C12.12	-7.09	7.68e-10	7.14e-06	-0.67	-0.64	Tonsillectomy;	chr16:30365638	chr16:30336400~30343336:+
LAML	cis	rs5760092	0.618	rs5996631	ENSG00000218537.1	MIF-AS1	-7.08	7.86e-10	7.3e-06	-1.04	-0.64	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23894426~23898930:-
LAML	cis	rs5760092	0.618	rs4461358	ENSG00000218537.1	MIF-AS1	-7.08	7.86e-10	7.3e-06	-1.04	-0.64	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23894426~23898930:-
LAML	cis	rs9326248	0.52	rs74830	ENSG00000254851.1	RP11-109L13.1	7.08	7.87e-10	7.3e-06	0.81	0.64	Blood protein levels;	chr11:117219842	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.539	rs660443	ENSG00000254851.1	RP11-109L13.1	-7.08	7.89e-10	7.33e-06	-0.87	-0.64	Blood protein levels;	chr11:116889977	chr11:117135528~117138582:+
LAML	cis	rs6452524	0.569	rs7720588	ENSG00000249664.1	CTD-2227C6.2	7.07	8.24e-10	7.64e-06	0.86	0.64	Hypertension (SNP x SNP interaction);	chr5:83081107	chr5:83012285~83013109:-
LAML	cis	rs6565180	1	rs12930787	ENSG00000273724.1	RP11-347C12.12	-7.07	8.26e-10	7.65e-06	-0.68	-0.64	Tonsillectomy;	chr16:30369982	chr16:30336400~30343336:+
LAML	cis	rs6565180	0.791	rs4247355	ENSG00000273724.1	RP11-347C12.12	7.07	8.29e-10	7.67e-06	0.66	0.64	Tonsillectomy;	chr16:30380778	chr16:30336400~30343336:+
LAML	cis	rs6565180	0.926	rs4787643	ENSG00000273724.1	RP11-347C12.12	7.07	8.29e-10	7.67e-06	0.66	0.64	Tonsillectomy;	chr16:30382339	chr16:30336400~30343336:+
LAML	cis	rs6565180	0.926	rs4788409	ENSG00000273724.1	RP11-347C12.12	7.07	8.29e-10	7.67e-06	0.66	0.64	Tonsillectomy;	chr16:30382450	chr16:30336400~30343336:+
LAML	cis	rs62070183	0.938	rs62068432	ENSG00000264458.1	RP11-220C2.1	7.07	8.35e-10	7.7e-06	0.91	0.64	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32739479	chr17:32627739~32686484:+
LAML	cis	rs5769707	0.777	rs739243	ENSG00000212939.2	RP1-29C18.10	-7.06	8.42e-10	7.72e-06	-0.67	-0.64	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49548681~49556473:+
LAML	cis	rs853679	1	rs853685	ENSG00000220721.1	OR1F12	7.06	8.62e-10	7.9e-06	0.81	0.64	Depression;	chr6:28321008	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs853679	ENSG00000220721.1	OR1F12	7.06	8.62e-10	7.9e-06	0.81	0.64	Depression;	chr6:28329086	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs853678	ENSG00000220721.1	OR1F12	7.06	8.62e-10	7.9e-06	0.81	0.64	Depression;	chr6:28329536	chr6:28073316~28074233:+
LAML	cis	rs62070183	0.766	rs62067160	ENSG00000264458.1	RP11-220C2.1	7.05	8.85e-10	8.05e-06	0.92	0.64	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32919567	chr17:32627739~32686484:+
LAML	cis	rs904251	0.523	rs1776455	ENSG00000227920.2	RP1-153P14.5	-7.05	8.85e-10	8.05e-06	-0.73	-0.64	Cognitive performance;	chr6:37515147	chr6:37545145~37550860:+
LAML	cis	rs11098499	0.532	rs12512646	ENSG00000248280.1	RP11-33B1.2	7.05	8.98e-10	8.17e-06	0.98	0.64	Corneal astigmatism;	chr4:119664578	chr4:119440561~119450157:-
LAML	cis	rs904251	0.504	rs9380677	ENSG00000227920.2	RP1-153P14.5	-7.05	9.08e-10	8.26e-06	-0.74	-0.64	Cognitive performance;	chr6:37512590	chr6:37545145~37550860:+
LAML	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-7.05	9.13e-10	8.29e-06	-0.87	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
LAML	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	7.04	9.21e-10	8.37e-06	1.06	0.64	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
LAML	cis	rs7104764	0.719	rs3782116	ENSG00000277290.1	RP11-326C3.16	-7.04	9.27e-10	8.42e-06	-0.93	-0.64	Menarche (age at onset);	chr11:223119	chr11:243099~243483:-
LAML	cis	rs853679	0.55	rs1225598	ENSG00000182477.5	OR2B8P	7.04	9.3e-10	8.43e-06	0.91	0.64	Depression;	chr6:28193021	chr6:28053228~28054165:-
LAML	cis	rs853679	0.55	rs1150689	ENSG00000182477.5	OR2B8P	7.04	9.3e-10	8.43e-06	0.91	0.64	Depression;	chr6:28197321	chr6:28053228~28054165:-
LAML	cis	rs853679	0.55	rs1225599	ENSG00000182477.5	OR2B8P	7.04	9.3e-10	8.43e-06	0.91	0.64	Depression;	chr6:28197412	chr6:28053228~28054165:-
LAML	cis	rs853679	0.574	rs1233705	ENSG00000182477.5	OR2B8P	7.04	9.3e-10	8.43e-06	0.91	0.64	Depression;	chr6:28198669	chr6:28053228~28054165:-
LAML	cis	rs853679	0.55	rs1233704	ENSG00000182477.5	OR2B8P	-7.04	9.3e-10	8.43e-06	-0.91	-0.64	Depression;	chr6:28199145	chr6:28053228~28054165:-
LAML	cis	rs853679	0.55	rs1233701	ENSG00000182477.5	OR2B8P	-7.04	9.3e-10	8.43e-06	-0.91	-0.64	Depression;	chr6:28200948	chr6:28053228~28054165:-
LAML	cis	rs853679	0.55	rs1237875	ENSG00000182477.5	OR2B8P	-7.04	9.3e-10	8.43e-06	-0.91	-0.64	Depression;	chr6:28205232	chr6:28053228~28054165:-
LAML	cis	rs6565180	0.783	rs9888967	ENSG00000183604.13	SMG1P5	-7.04	9.46e-10	8.58e-06	-0.71	-0.64	Tonsillectomy;	chr16:30396658	chr16:30267553~30335374:-
LAML	cis	rs9326248	0.581	rs10892076	ENSG00000254851.1	RP11-109L13.1	-7.04	9.47e-10	8.59e-06	-0.82	-0.64	Blood protein levels;	chr11:117118220	chr11:117135528~117138582:+
LAML	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	7.04	9.49e-10	8.6e-06	0.84	0.64	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
LAML	cis	rs9326248	0.559	rs482371	ENSG00000254851.1	RP11-109L13.1	-7.04	9.51e-10	8.61e-06	-0.86	-0.64	Blood protein levels;	chr11:116881447	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.559	rs1269329	ENSG00000254851.1	RP11-109L13.1	-7.04	9.51e-10	8.61e-06	-0.86	-0.64	Blood protein levels;	chr11:116884325	chr11:117135528~117138582:+
LAML	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	7.03	9.65e-10	8.73e-06	0.85	0.64	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
LAML	cis	rs853679	0.55	rs1233707	ENSG00000182477.5	OR2B8P	7.03	9.72e-10	8.77e-06	0.92	0.64	Depression;	chr6:28205175	chr6:28053228~28054165:-
LAML	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-7.03	9.74e-10	8.78e-06	-0.83	-0.64	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
LAML	cis	rs9506514	0.76	rs9506518	ENSG00000238286.1	SLC35E1P1	-7.02	1.01e-09	9.13e-06	-0.73	-0.64	Coronary artery calcification;	chr13:20560843	chr13:20607268~20608131:+
LAML	cis	rs875971	0.867	rs13227219	ENSG00000222364.1	RNU6-96P	-7.02	1.02e-09	9.16e-06	-0.8	-0.64	Aortic root size;	chr7:66379075	chr7:66395191~66395286:+
LAML	cis	rs853679	0.506	rs1150693	ENSG00000182477.5	OR2B8P	7.02	1.02e-09	9.17e-06	0.93	0.64	Depression;	chr6:28206812	chr6:28053228~28054165:-
LAML	cis	rs853679	0.55	rs1150692	ENSG00000182477.5	OR2B8P	7.02	1.02e-09	9.17e-06	0.93	0.64	Depression;	chr6:28206179	chr6:28053228~28054165:-
LAML	cis	rs16828019	0.64	rs1140227	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs16911	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs2300658	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12729448	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs2268678	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs10489520	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12406620	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12729586	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.704	rs34486565	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12742379	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs16827876	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs34979067	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs35190461	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12022978	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs2300649	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs3904243	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs11209545	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs11209576	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs3766324	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12759023	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs34286980	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs71648534	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs71648535	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12048187	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs71648536	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12742803	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12408956	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs35992757	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12044539	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs12759050	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.789	rs34216154	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.929	rs1032728	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.929	rs12029321	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.929	rs35286837	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.929	rs11209734	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.929	rs12037037	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.929	rs8179465	ENSG00000213987.4	RP11-399E6.2	7.02	1.03e-09	9.17e-06	1.08	0.64	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41264550~41264862:-
LAML	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	7.02	1.03e-09	9.19e-06	1.05	0.64	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
LAML	cis	rs9326248	0.731	rs90192	ENSG00000254851.1	RP11-109L13.1	-7.02	1.03e-09	9.22e-06	-1.07	-0.64	Blood protein levels;	chr11:117188631	chr11:117135528~117138582:+
LAML	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	7.01	1.04e-09	9.27e-06	0.85	0.64	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
LAML	cis	rs5769707	0.777	rs739243	ENSG00000279597.1	RP4-566L20.1	-7.01	1.04e-09	9.29e-06	-0.65	-0.64	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49534062~49534926:+
LAML	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	7.01	1.05e-09	9.36e-06	0.77	0.64	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
LAML	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-7.01	1.05e-09	9.37e-06	-0.82	-0.64	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-7.01	1.05e-09	9.37e-06	-0.82	-0.64	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
LAML	cis	rs4879656	0.866	rs10971227	ENSG00000225693.1	LAGE3P1	7.01	1.06e-09	9.38e-06	0.7	0.64	Menopause (age at onset);	chr9:32934619	chr9:33019682~33020165:-
LAML	cis	rs561341	0.843	rs4795666	ENSG00000266379.5	RP11-640N20.8	7.01	1.06e-09	9.42e-06	0.94	0.64	Hip circumference adjusted for BMI;	chr17:31914390	chr17:32088160~32094933:-
LAML	cis	rs561341	0.843	rs879945	ENSG00000266379.5	RP11-640N20.8	7.01	1.06e-09	9.42e-06	0.94	0.64	Hip circumference adjusted for BMI;	chr17:31915777	chr17:32088160~32094933:-
LAML	cis	rs11098499	0.562	rs58583086	ENSG00000248280.1	RP11-33B1.2	-7.01	1.06e-09	9.43e-06	-0.82	-0.64	Corneal astigmatism;	chr4:119635207	chr4:119440561~119450157:-
LAML	cis	rs45509595	0.841	rs17751184	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Breast cancer;	chr6:27807250	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs67101035	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Depression;	chr6:27831109	chr6:28073316~28074233:+
LAML	cis	rs853679	0.556	rs34706883	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Depression;	chr6:27837477	chr6:28073316~28074233:+
LAML	cis	rs67340775	0.748	rs13212651	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Lung cancer in ever smokers;	chr6:27839207	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs35819751	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Depression;	chr6:27842791	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13194781	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Depression;	chr6:27847861	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs36116761	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Depression;	chr6:27850704	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs34194357	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Depression;	chr6:27850757	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13199772	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Depression;	chr6:27866307	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13199906	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Depression;	chr6:27866361	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs17763089	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Depression;	chr6:27867440	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs17695758	ENSG00000220721.1	OR1F12	7.01	1.07e-09	9.45e-06	0.99	0.64	Depression;	chr6:27869405	chr6:28073316~28074233:+
LAML	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	7.01	1.07e-09	9.48e-06	0.77	0.64	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
LAML	cis	rs4879656	0.872	rs1537039	ENSG00000225693.1	LAGE3P1	-7.01	1.08e-09	9.52e-06	-0.66	-0.64	Menopause (age at onset);	chr9:33061718	chr9:33019682~33020165:-
LAML	cis	rs3096299	0.781	rs2965819	ENSG00000274627.1	RP11-104N10.2	-7	1.09e-09	9.61e-06	-0.79	-0.64	Multiple myeloma (IgH translocation);	chr16:89434622	chr16:89516797~89522217:+
LAML	cis	rs10927875	1	rs12138117	ENSG00000178715.8	RP11-169K16.8	-7	1.09e-09	9.61e-06	-0.81	-0.64	Dilated cardiomyopathy;	chr1:15978784	chr1:15828232~15828669:+
LAML	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	7	1.1e-09	9.67e-06	0.76	0.64	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
LAML	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-7	1.11e-09	9.78e-06	-0.77	-0.64	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-7	1.11e-09	9.78e-06	-0.77	-0.64	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
LAML	cis	rs3091242	0.933	rs61775174	ENSG00000261349.1	RP3-465N24.5	7	1.11e-09	9.79e-06	0.73	0.64	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25266102~25267136:-
LAML	cis	rs561341	1	rs7216102	ENSG00000266379.5	RP11-640N20.8	7	1.11e-09	9.83e-06	0.91	0.64	Hip circumference adjusted for BMI;	chr17:31932431	chr17:32088160~32094933:-
LAML	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-6.99	1.13e-09	9.96e-06	-0.81	-0.64	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
LAML	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	6.99	1.13e-09	9.97e-06	0.7	0.64	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
LAML	cis	rs916888	0.779	rs199498	ENSG00000214401.4	KANSL1-AS1	6.99	1.14e-09	1e-05	0.87	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:46193576~46196723:+
LAML	cis	rs10927875	0.864	rs1976402	ENSG00000178715.8	RP11-169K16.8	-6.99	1.14e-09	1e-05	-0.81	-0.64	Dilated cardiomyopathy;	chr1:15817284	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.864	rs6674071	ENSG00000178715.8	RP11-169K16.8	-6.99	1.14e-09	1e-05	-0.81	-0.64	Dilated cardiomyopathy;	chr1:15818360	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.832	rs4661342	ENSG00000178715.8	RP11-169K16.8	-6.99	1.14e-09	1e-05	-0.81	-0.64	Dilated cardiomyopathy;	chr1:15834278	chr1:15828232~15828669:+
LAML	cis	rs6565180	0.851	rs3574	ENSG00000183604.13	SMG1P5	-6.99	1.14e-09	1e-05	-0.7	-0.64	Tonsillectomy;	chr16:30400061	chr16:30267553~30335374:-
LAML	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-6.99	1.14e-09	1e-05	-0.77	-0.64	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
LAML	cis	rs6565180	0.889	rs8051096	ENSG00000273724.1	RP11-347C12.12	-6.99	1.15e-09	1e-05	-0.68	-0.64	Tonsillectomy;	chr16:30336410	chr16:30336400~30343336:+
LAML	cis	rs6452524	1	rs11958314	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83132929	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.686	rs6452517	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83133041	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.686	rs6452518	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83133043	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6452520	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83133452	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6452521	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83133453	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs6452522	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83133471	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10069402	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83133776	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10076271	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83133875	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10076274	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83133908	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10061521	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83133936	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs7733151	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83134655	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs7733330	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83134774	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs7733354	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83134859	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs4634330	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83134963	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs2386238	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83135266	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs2386239	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83135339	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.934	rs7700253	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83135510	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10067439	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83136274	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs7710900	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83137201	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs62374373	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83137389	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10043018	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83138498	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs10037501	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83138722	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.904	rs6452525	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83138752	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs7716931	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83138856	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs7721416	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83139174	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6882220	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83139715	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6452526	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83140992	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6452527	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83141021	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10055844	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83141276	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10077862	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83141322	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs9293332	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83141546	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10474093	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83141612	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs10473868	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83141628	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6868817	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83142287	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs10042018	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83142490	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs10036418	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83142493	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10055948	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83143437	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10037872	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83144101	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs62374374	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83144838	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs1382372	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83145237	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs1382371	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83145300	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs1382369	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83145610	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs2386240	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83147192	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs17284288	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83148997	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs9986131	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83149037	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs11740478	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83150567	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs4591730	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83151983	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs1031902	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83152308	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10474094	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83154678	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs1382368	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83155256	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs1382366	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83156352	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs1382364	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83156677	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs1382363	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83156753	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs9293334	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83156984	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs11741897	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83157246	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs13358361	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83160237	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs2126990	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83161351	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10076000	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83161629	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6452528	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83162560	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6864479	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83166421	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs13436667	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83168948	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs7726564	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83170274	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6452531	ENSG00000249664.1	CTD-2227C6.2	6.99	1.15e-09	1e-05	0.84	0.64	Hypertension (SNP x SNP interaction);	chr5:83170355	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6452524	ENSG00000249664.1	CTD-2227C6.2	-6.99	1.15e-09	1e-05	-0.84	-0.64	Hypertension (SNP x SNP interaction);	chr5:83137962	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6887846	ENSG00000249664.1	CTD-2227C6.2	-6.99	1.15e-09	1e-05	-0.84	-0.64	Hypertension (SNP x SNP interaction);	chr5:83140542	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs10042854	ENSG00000249664.1	CTD-2227C6.2	-6.99	1.15e-09	1e-05	-0.84	-0.64	Hypertension (SNP x SNP interaction);	chr5:83143876	chr5:83012285~83013109:-
LAML	cis	rs5769707	0.837	rs5770599	ENSG00000280224.1	CTA-722E9.1	-6.99	1.17e-09	1.01e-05	-0.87	-0.64	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.837	rs5769709	ENSG00000280224.1	CTA-722E9.1	-6.99	1.17e-09	1.01e-05	-0.87	-0.64	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49500568~49501585:+
LAML	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-6.99	1.17e-09	1.01e-05	-0.83	-0.64	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-6.98	1.19e-09	1.03e-05	-0.78	-0.64	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-6.98	1.19e-09	1.03e-05	-0.79	-0.64	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
LAML	cis	rs62070183	0.873	rs80212824	ENSG00000264458.1	RP11-220C2.1	6.98	1.2e-09	1.04e-05	0.95	0.64	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32703440	chr17:32627739~32686484:+
LAML	cis	rs4591358	0.705	rs11897464	ENSG00000223466.1	AC064834.2	-6.98	1.2e-09	1.04e-05	-0.86	-0.64	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195478572	chr2:195533035~195538681:+
LAML	cis	rs16828019	0.789	rs36084778	ENSG00000213987.4	RP11-399E6.2	6.97	1.23e-09	1.06e-05	1.09	0.63	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs11209363	ENSG00000213987.4	RP11-399E6.2	6.97	1.23e-09	1.06e-05	1.09	0.63	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41264550~41264862:-
LAML	cis	rs9457247	0.663	rs2237274	ENSG00000265828.1	MIR3939	-6.97	1.24e-09	1.07e-05	-0.82	-0.63	Crohn's disease;	chr6:167029507	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.612	rs2237273	ENSG00000265828.1	MIR3939	-6.97	1.24e-09	1.07e-05	-0.82	-0.63	Crohn's disease;	chr6:167029529	chr6:166997807~166997912:-
LAML	cis	rs2486288	0.656	rs2413771	ENSG00000259520.4	CTD-2651B20.3	6.97	1.25e-09	1.08e-05	1	0.63	Glomerular filtration rate;	chr15:45260942	chr15:45251580~45279251:-
LAML	cis	rs6565180	0.963	rs4787642	ENSG00000273724.1	RP11-347C12.12	-6.97	1.25e-09	1.08e-05	-0.68	-0.63	Tonsillectomy;	chr16:30348087	chr16:30336400~30343336:+
LAML	cis	rs1930961	1	rs1930961	ENSG00000100058.11	CRYBB2P1	-6.97	1.25e-09	1.08e-05	-1.13	-0.63	Bipolar disorder with mood-incongruent psychosis;	chr22:25479298	chr22:25448105~25520854:+
LAML	cis	rs62070183	0.766	rs10512441	ENSG00000265337.1	RP11-466A19.5	-6.97	1.26e-09	1.08e-05	-1	-0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32529008~32530049:-
LAML	cis	rs9326248	0.861	rs494356	ENSG00000254851.1	RP11-109L13.1	-6.97	1.27e-09	1.09e-05	-1.01	-0.63	Blood protein levels;	chr11:117201254	chr11:117135528~117138582:+
LAML	cis	rs7104764	0.701	rs3782115	ENSG00000277290.1	RP11-326C3.16	-6.97	1.28e-09	1.1e-05	-0.94	-0.63	Menarche (age at onset);	chr11:223272	chr11:243099~243483:-
LAML	cis	rs9326248	0.509	rs533556	ENSG00000254851.1	RP11-109L13.1	-6.96	1.29e-09	1.11e-05	-0.86	-0.63	Blood protein levels;	chr11:116870856	chr11:117135528~117138582:+
LAML	cis	rs561341	0.505	rs28708703	ENSG00000266379.5	RP11-640N20.8	6.96	1.29e-09	1.11e-05	1	0.63	Hip circumference adjusted for BMI;	chr17:32059826	chr17:32088160~32094933:-
LAML	cis	rs853679	0.513	rs13437444	ENSG00000182477.5	OR2B8P	6.96	1.29e-09	1.11e-05	1.05	0.63	Depression;	chr6:28103220	chr6:28053228~28054165:-
LAML	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	6.96	1.33e-09	1.14e-05	0.78	0.63	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
LAML	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	6.96	1.33e-09	1.14e-05	0.78	0.63	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
LAML	cis	rs1930961	1	rs6004675	ENSG00000100058.11	CRYBB2P1	-6.95	1.35e-09	1.16e-05	-1	-0.63	Bipolar disorder with mood-incongruent psychosis;	chr22:25493418	chr22:25448105~25520854:+
LAML	cis	rs4591358	0.648	rs7557471	ENSG00000223466.1	AC064834.2	-6.95	1.39e-09	1.18e-05	-0.91	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520713	chr2:195533035~195538681:+
LAML	cis	rs62070183	0.938	rs9911168	ENSG00000264458.1	RP11-220C2.1	6.94	1.42e-09	1.21e-05	0.9	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709136	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs9912761	ENSG00000264458.1	RP11-220C2.1	6.94	1.42e-09	1.21e-05	0.9	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709475	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs9303654	ENSG00000264458.1	RP11-220C2.1	6.94	1.42e-09	1.21e-05	0.9	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709747	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs9898762	ENSG00000264458.1	RP11-220C2.1	6.94	1.42e-09	1.21e-05	0.9	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32711641	chr17:32627739~32686484:+
LAML	cis	rs16828019	0.929	rs2363805	ENSG00000213987.4	RP11-399E6.2	6.94	1.44e-09	1.22e-05	1.07	0.63	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.852	rs71648540	ENSG00000213987.4	RP11-399E6.2	6.94	1.44e-09	1.22e-05	1.07	0.63	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.929	rs10524	ENSG00000213987.4	RP11-399E6.2	6.94	1.44e-09	1.22e-05	1.07	0.63	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41264550~41264862:-
LAML	cis	rs6452524	0.967	rs2974443	ENSG00000249664.1	CTD-2227C6.2	6.93	1.46e-09	1.24e-05	0.86	0.63	Hypertension (SNP x SNP interaction);	chr5:83184595	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs2974441	ENSG00000249664.1	CTD-2227C6.2	6.93	1.46e-09	1.24e-05	0.86	0.63	Hypertension (SNP x SNP interaction);	chr5:83193330	chr5:83012285~83013109:-
LAML	cis	rs4713118	0.662	rs149961	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28047791	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.629	rs149899	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28052201	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.629	rs172165	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28053036	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.597	rs172166	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28053042	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.629	rs203888	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28053811	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.629	rs203889	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28053997	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.629	rs203890	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28054470	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs9357060	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28056708	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs9468271	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28056792	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs9380045	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28057501	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.616	rs9348789	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28057708	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs9468274	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28058299	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs9468275	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28058358	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs9468276	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28059910	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs9468277	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28060612	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs9468278	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28060704	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs13218430	ENSG00000220721.1	OR1F12	6.93	1.48e-09	1.26e-05	0.81	0.63	Parkinson's disease;	chr6:28062059	chr6:28073316~28074233:+
LAML	cis	rs6452524	0.967	rs11741420	ENSG00000249664.1	CTD-2227C6.2	6.93	1.49e-09	1.26e-05	0.86	0.63	Hypertension (SNP x SNP interaction);	chr5:83174913	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs4401555	ENSG00000249664.1	CTD-2227C6.2	6.93	1.49e-09	1.26e-05	0.86	0.63	Hypertension (SNP x SNP interaction);	chr5:83175267	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs4616871	ENSG00000249664.1	CTD-2227C6.2	6.93	1.49e-09	1.26e-05	0.86	0.63	Hypertension (SNP x SNP interaction);	chr5:83175271	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs62374400	ENSG00000249664.1	CTD-2227C6.2	6.93	1.49e-09	1.26e-05	0.86	0.63	Hypertension (SNP x SNP interaction);	chr5:83177053	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs10040363	ENSG00000249664.1	CTD-2227C6.2	6.93	1.49e-09	1.26e-05	0.86	0.63	Hypertension (SNP x SNP interaction);	chr5:83177826	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs10051542	ENSG00000249664.1	CTD-2227C6.2	6.93	1.49e-09	1.26e-05	0.86	0.63	Hypertension (SNP x SNP interaction);	chr5:83178268	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs10051557	ENSG00000249664.1	CTD-2227C6.2	6.93	1.49e-09	1.26e-05	0.86	0.63	Hypertension (SNP x SNP interaction);	chr5:83178307	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs11949474	ENSG00000249664.1	CTD-2227C6.2	6.93	1.49e-09	1.26e-05	0.86	0.63	Hypertension (SNP x SNP interaction);	chr5:83179759	chr5:83012285~83013109:-
LAML	cis	rs5760092	0.755	rs915589	ENSG00000273295.1	AP000350.5	-6.93	1.5e-09	1.27e-05	-1.06	-0.63	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23918817	chr22:23901432~23907068:-
LAML	cis	rs5760092	0.627	rs6519489	ENSG00000273295.1	AP000350.5	-6.93	1.5e-09	1.27e-05	-1.06	-0.63	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919659	chr22:23901432~23907068:-
LAML	cis	rs5760092	0.618	rs5996631	ENSG00000273295.1	AP000350.5	-6.93	1.5e-09	1.27e-05	-1.01	-0.63	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23914707	chr22:23901432~23907068:-
LAML	cis	rs5760092	0.618	rs4461358	ENSG00000273295.1	AP000350.5	-6.93	1.5e-09	1.27e-05	-1.01	-0.63	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23917919	chr22:23901432~23907068:-
LAML	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	6.93	1.51e-09	1.27e-05	0.86	0.63	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
LAML	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-6.93	1.51e-09	1.27e-05	-0.86	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
LAML	cis	rs561341	0.883	rs2074102	ENSG00000266379.5	RP11-640N20.8	6.92	1.52e-09	1.28e-05	1.08	0.63	Hip circumference adjusted for BMI;	chr17:31901865	chr17:32088160~32094933:-
LAML	cis	rs561341	0.941	rs4795664	ENSG00000266379.5	RP11-640N20.8	6.92	1.52e-09	1.28e-05	1.08	0.63	Hip circumference adjusted for BMI;	chr17:31906448	chr17:32088160~32094933:-
LAML	cis	rs6452524	0.934	rs10473870	ENSG00000249664.1	CTD-2227C6.2	6.92	1.53e-09	1.29e-05	0.88	0.63	Hypertension (SNP x SNP interaction);	chr5:83199768	chr5:83012285~83013109:-
LAML	cis	rs4713118	0.869	rs4713121	ENSG00000220721.1	OR1F12	6.92	1.56e-09	1.31e-05	0.73	0.63	Parkinson's disease;	chr6:27754285	chr6:28073316~28074233:+
LAML	cis	rs13201294	1	rs13201294	ENSG00000187763.3	OR2B7P	6.92	1.57e-09	1.32e-05	1.04	0.63	Squamous cell lung carcinoma;	chr6:27588362	chr6:28046434~28047367:+
LAML	cis	rs62070183	0.873	rs113602044	ENSG00000264458.1	RP11-220C2.1	6.92	1.57e-09	1.32e-05	0.94	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32691685	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs77819475	ENSG00000264458.1	RP11-220C2.1	6.92	1.57e-09	1.32e-05	0.94	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32699823	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs17183113	ENSG00000264458.1	RP11-220C2.1	6.92	1.57e-09	1.32e-05	0.94	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702107	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs78418651	ENSG00000264458.1	RP11-220C2.1	6.92	1.57e-09	1.32e-05	0.94	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702530	chr17:32627739~32686484:+
LAML	cis	rs853679	0.55	rs1233699	ENSG00000187763.3	OR2B7P	6.91	1.59e-09	1.33e-05	0.91	0.63	Depression;	chr6:28201380	chr6:28046434~28047367:+
LAML	cis	rs911555	0.57	rs752624	ENSG00000258851.1	RP11-894P9.2	-6.91	1.6e-09	1.34e-05	-0.71	-0.63	Intelligence (multi-trait analysis);	chr14:103554117	chr14:103553421~103561877:+
LAML	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	6.91	1.6e-09	1.34e-05	0.84	0.63	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
LAML	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-6.91	1.6e-09	1.34e-05	-0.84	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
LAML	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-6.91	1.62e-09	1.36e-05	-0.8	-0.63	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
LAML	cis	rs2486288	0.656	rs6493144	ENSG00000259520.4	CTD-2651B20.3	-6.91	1.63e-09	1.36e-05	-0.98	-0.63	Glomerular filtration rate;	chr15:45281291	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs6493145	ENSG00000259520.4	CTD-2651B20.3	6.91	1.63e-09	1.36e-05	0.98	0.63	Glomerular filtration rate;	chr15:45281664	chr15:45251580~45279251:-
LAML	cis	rs1577917	0.74	rs9344533	ENSG00000203875.9	SNHG5	6.91	1.64e-09	1.37e-05	0.76	0.63	Response to antipsychotic treatment;	chr6:85526470	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.74	rs9353320	ENSG00000203875.9	SNHG5	6.91	1.64e-09	1.37e-05	0.76	0.63	Response to antipsychotic treatment;	chr6:85535130	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.74	rs7775864	ENSG00000203875.9	SNHG5	6.91	1.64e-09	1.37e-05	0.76	0.63	Response to antipsychotic treatment;	chr6:85538041	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.74	rs7771612	ENSG00000203875.9	SNHG5	6.91	1.64e-09	1.37e-05	0.76	0.63	Response to antipsychotic treatment;	chr6:85554656	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.655	rs7742691	ENSG00000203875.9	SNHG5	6.91	1.64e-09	1.37e-05	0.76	0.63	Response to antipsychotic treatment;	chr6:85568973	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.71	rs9342041	ENSG00000203875.9	SNHG5	6.91	1.64e-09	1.37e-05	0.76	0.63	Response to antipsychotic treatment;	chr6:85571157	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.682	rs6935918	ENSG00000203875.9	SNHG5	6.91	1.64e-09	1.37e-05	0.76	0.63	Response to antipsychotic treatment;	chr6:85573857	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.655	rs9359658	ENSG00000203875.9	SNHG5	6.91	1.64e-09	1.37e-05	0.76	0.63	Response to antipsychotic treatment;	chr6:85596051	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.74	rs2842614	ENSG00000203875.9	SNHG5	-6.91	1.64e-09	1.37e-05	-0.76	-0.63	Response to antipsychotic treatment;	chr6:85596351	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.74	rs2758842	ENSG00000203875.9	SNHG5	-6.91	1.64e-09	1.37e-05	-0.76	-0.63	Response to antipsychotic treatment;	chr6:85599013	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.572	rs911927	ENSG00000203875.9	SNHG5	-6.91	1.64e-09	1.37e-05	-0.76	-0.63	Response to antipsychotic treatment;	chr6:85618142	chr6:85660950~85678736:-
LAML	cis	rs9506514	0.93	rs9315710	ENSG00000238286.1	SLC35E1P1	-6.91	1.65e-09	1.38e-05	-0.7	-0.63	Coronary artery calcification;	chr13:20559340	chr13:20607268~20608131:+
LAML	cis	rs5769707	0.749	rs7286706	ENSG00000212939.2	RP1-29C18.10	-6.9	1.67e-09	1.38e-05	-0.66	-0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49548681~49556473:+
LAML	cis	rs6452524	0.562	rs10474080	ENSG00000249664.1	CTD-2227C6.2	6.9	1.68e-09	1.4e-05	0.84	0.63	Hypertension (SNP x SNP interaction);	chr5:83078300	chr5:83012285~83013109:-
LAML	cis	rs1577917	0.74	rs2758843	ENSG00000203875.9	SNHG5	-6.9	1.71e-09	1.41e-05	-0.76	-0.63	Response to antipsychotic treatment;	chr6:85618713	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.696	rs2842603	ENSG00000203875.9	SNHG5	-6.9	1.71e-09	1.41e-05	-0.76	-0.63	Response to antipsychotic treatment;	chr6:85626619	chr6:85660950~85678736:-
LAML	cis	rs16828019	0.852	rs3820090	ENSG00000213987.4	RP11-399E6.2	6.89	1.73e-09	1.42e-05	1.09	0.63	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41264550~41264862:-
LAML	cis	rs6452524	1	rs4590162	ENSG00000249664.1	CTD-2227C6.2	6.89	1.73e-09	1.43e-05	0.82	0.63	Hypertension (SNP x SNP interaction);	chr5:83145621	chr5:83012285~83013109:-
LAML	cis	rs853679	1	rs2799077	ENSG00000220721.1	OR1F12	6.89	1.74e-09	1.43e-05	0.81	0.63	Depression;	chr6:28266819	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs11965538	ENSG00000220721.1	OR1F12	6.89	1.74e-09	1.43e-05	0.81	0.63	Depression;	chr6:28272137	chr6:28073316~28074233:+
LAML	cis	rs853679	0.882	rs2743555	ENSG00000220721.1	OR1F12	6.89	1.74e-09	1.43e-05	0.81	0.63	Depression;	chr6:28273304	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs1419183	ENSG00000220721.1	OR1F12	6.89	1.74e-09	1.43e-05	0.81	0.63	Depression;	chr6:28275017	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs6901575	ENSG00000220721.1	OR1F12	6.89	1.74e-09	1.43e-05	0.81	0.63	Depression;	chr6:28283207	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs1778508	ENSG00000220721.1	OR1F12	-6.89	1.74e-09	1.43e-05	-0.81	-0.63	Depression;	chr6:28262103	chr6:28073316~28074233:+
LAML	cis	rs904251	0.523	rs9349039	ENSG00000227920.2	RP1-153P14.5	-6.89	1.76e-09	1.45e-05	-0.73	-0.63	Cognitive performance;	chr6:37512616	chr6:37545145~37550860:+
LAML	cis	rs904251	0.523	rs9366935	ENSG00000227920.2	RP1-153P14.5	-6.89	1.76e-09	1.45e-05	-0.73	-0.63	Cognitive performance;	chr6:37512628	chr6:37545145~37550860:+
LAML	cis	rs5769707	0.967	rs2051626	ENSG00000280224.1	CTA-722E9.1	-6.89	1.77e-09	1.46e-05	-0.83	-0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.967	rs1018812	ENSG00000280224.1	CTA-722E9.1	-6.89	1.77e-09	1.46e-05	-0.83	-0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49500568~49501585:+
LAML	cis	rs4591358	0.773	rs35070116	ENSG00000223466.1	AC064834.2	-6.88	1.81e-09	1.49e-05	-0.92	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515729	chr2:195533035~195538681:+
LAML	cis	rs6452524	0.901	rs1039786	ENSG00000249664.1	CTD-2227C6.2	6.88	1.82e-09	1.49e-05	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83204222	chr5:83012285~83013109:-
LAML	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-6.88	1.82e-09	1.49e-05	-0.79	-0.63	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-6.88	1.82e-09	1.49e-05	-0.79	-0.63	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-6.88	1.82e-09	1.49e-05	-0.79	-0.63	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
LAML	cis	rs1577917	0.816	rs12664099	ENSG00000203875.9	SNHG5	-6.88	1.83e-09	1.5e-05	-0.79	-0.63	Response to antipsychotic treatment;	chr6:85938854	chr6:85660950~85678736:-
LAML	cis	rs62070183	0.938	rs75393526	ENSG00000264458.1	RP11-220C2.1	6.88	1.83e-09	1.5e-05	0.89	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32708000	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs75822124	ENSG00000264458.1	RP11-220C2.1	6.88	1.83e-09	1.5e-05	0.89	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32710876	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs17183176	ENSG00000264458.1	RP11-220C2.1	6.88	1.83e-09	1.5e-05	0.89	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32727107	chr17:32627739~32686484:+
LAML	cis	rs62070183	0.938	rs1990825	ENSG00000264458.1	RP11-220C2.1	6.88	1.83e-09	1.5e-05	0.89	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32729274	chr17:32627739~32686484:+
LAML	cis	rs16828019	0.777	rs35044078	ENSG00000213987.4	RP11-399E6.2	6.88	1.84e-09	1.5e-05	1.08	0.63	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.704	rs4996176	ENSG00000213987.4	RP11-399E6.2	6.88	1.84e-09	1.5e-05	1.08	0.63	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs35496942	ENSG00000213987.4	RP11-399E6.2	6.88	1.84e-09	1.5e-05	1.08	0.63	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.704	rs12031277	ENSG00000213987.4	RP11-399E6.2	6.88	1.84e-09	1.5e-05	1.08	0.63	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs3738369	ENSG00000213987.4	RP11-399E6.2	6.88	1.84e-09	1.5e-05	1.08	0.63	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41264550~41264862:-
LAML	cis	rs6452524	0.967	rs62372752	ENSG00000249664.1	CTD-2227C6.2	6.88	1.85e-09	1.51e-05	0.82	0.63	Hypertension (SNP x SNP interaction);	chr5:83134239	chr5:83012285~83013109:-
LAML	cis	rs5769707	0.967	rs9616713	ENSG00000212939.2	RP1-29C18.10	-6.88	1.85e-09	1.52e-05	-0.73	-0.63	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49548681~49556473:+
LAML	cis	rs1577917	0.883	rs13212415	ENSG00000203875.9	SNHG5	-6.88	1.87e-09	1.53e-05	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85898365	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.839	rs1447159	ENSG00000203875.9	SNHG5	-6.88	1.87e-09	1.53e-05	-0.81	-0.63	Response to antipsychotic treatment;	chr6:85899531	chr6:85660950~85678736:-
LAML	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-6.87	1.88e-09	1.54e-05	-0.79	-0.63	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
LAML	cis	rs6452524	1	rs2126988	ENSG00000249664.1	CTD-2227C6.2	6.87	1.9e-09	1.55e-05	0.82	0.63	Hypertension (SNP x SNP interaction);	chr5:83146496	chr5:83012285~83013109:-
LAML	cis	rs561341	0.831	rs11658469	ENSG00000266379.5	RP11-640N20.8	-6.87	1.93e-09	1.57e-05	-1.08	-0.63	Hip circumference adjusted for BMI;	chr17:31879407	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs2344312	ENSG00000266379.5	RP11-640N20.8	6.87	1.96e-09	1.6e-05	0.94	0.63	Hip circumference adjusted for BMI;	chr17:31916564	chr17:32088160~32094933:-
LAML	cis	rs561341	1	rs757009	ENSG00000266379.5	RP11-640N20.8	6.87	1.96e-09	1.6e-05	0.94	0.63	Hip circumference adjusted for BMI;	chr17:31916918	chr17:32088160~32094933:-
LAML	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-6.86	1.96e-09	1.6e-05	-0.78	-0.63	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
LAML	cis	rs16828019	0.777	rs13376450	ENSG00000213987.4	RP11-399E6.2	6.86	2.01e-09	1.63e-05	1.1	0.63	Intelligence (multi-trait analysis);	chr1:41003371	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs67460888	ENSG00000213987.4	RP11-399E6.2	6.86	2.01e-09	1.63e-05	1.1	0.63	Intelligence (multi-trait analysis);	chr1:41003665	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs12023079	ENSG00000213987.4	RP11-399E6.2	6.86	2.01e-09	1.63e-05	1.1	0.63	Intelligence (multi-trait analysis);	chr1:41004439	chr1:41264550~41264862:-
LAML	cis	rs4713118	0.5	rs9461434	ENSG00000187763.3	OR2B7P	6.86	2.01e-09	1.64e-05	1.04	0.63	Parkinson's disease;	chr6:28134687	chr6:28046434~28047367:+
LAML	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-6.86	2.03e-09	1.65e-05	-0.78	-0.63	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
LAML	cis	rs7587476	0.505	rs6435862	ENSG00000229267.2	AC072062.1	6.86	2.03e-09	1.65e-05	0.72	0.63	Neuroblastoma;	chr2:214807822	chr2:214810229~214963274:+
LAML	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	6.85	2.07e-09	1.67e-05	0.85	0.63	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.739	rs9884728	ENSG00000248280.1	RP11-33B1.2	-6.85	2.07e-09	1.68e-05	-0.92	-0.63	Corneal astigmatism;	chr4:119205924	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.739	rs2203039	ENSG00000248280.1	RP11-33B1.2	-6.85	2.07e-09	1.68e-05	-0.92	-0.63	Corneal astigmatism;	chr4:119211192	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.739	rs7441137	ENSG00000248280.1	RP11-33B1.2	-6.85	2.07e-09	1.68e-05	-0.92	-0.63	Corneal astigmatism;	chr4:119212066	chr4:119440561~119450157:-
LAML	cis	rs6452524	1	rs6452519	ENSG00000249664.1	CTD-2227C6.2	6.84	2.16e-09	1.74e-05	0.83	0.63	Hypertension (SNP x SNP interaction);	chr5:83133429	chr5:83012285~83013109:-
LAML	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-6.84	2.17e-09	1.74e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-6.84	2.17e-09	1.74e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-6.84	2.17e-09	1.74e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-6.84	2.17e-09	1.74e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-6.84	2.17e-09	1.74e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-6.84	2.17e-09	1.74e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-6.84	2.17e-09	1.74e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-6.84	2.17e-09	1.74e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-6.84	2.17e-09	1.74e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
LAML	cis	rs12468226	0.808	rs77251002	ENSG00000226261.1	AC064836.3	6.84	2.22e-09	1.77e-05	1.07	0.63	Urate levels;	chr2:202150236	chr2:202336024~202336727:-
LAML	cis	rs1577917	0.682	rs6909767	ENSG00000203875.9	SNHG5	6.84	2.22e-09	1.78e-05	0.74	0.63	Response to antipsychotic treatment;	chr6:85518391	chr6:85660950~85678736:-
LAML	cis	rs6782228	0.606	rs6775270	ENSG00000277250.1	Metazoa_SRP	-6.83	2.23e-09	1.78e-05	-0.78	-0.63	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.527	rs7426806	ENSG00000277250.1	Metazoa_SRP	-6.83	2.23e-09	1.78e-05	-0.78	-0.63	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.585	rs6774515	ENSG00000277250.1	Metazoa_SRP	-6.83	2.23e-09	1.78e-05	-0.78	-0.63	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.565	rs12695509	ENSG00000277250.1	Metazoa_SRP	-6.83	2.23e-09	1.78e-05	-0.78	-0.63	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128673681~128674021:-
LAML	cis	rs10927875	0.929	rs4661674	ENSG00000178715.8	RP11-169K16.8	-6.83	2.23e-09	1.78e-05	-0.79	-0.63	Dilated cardiomyopathy;	chr1:15969544	chr1:15828232~15828669:+
LAML	cis	rs561341	0.883	rs72821942	ENSG00000266379.5	RP11-640N20.8	6.83	2.23e-09	1.78e-05	1.08	0.63	Hip circumference adjusted for BMI;	chr17:31907441	chr17:32088160~32094933:-
LAML	cis	rs1577917	0.816	rs1838952	ENSG00000203875.9	SNHG5	-6.83	2.28e-09	1.82e-05	-0.79	-0.63	Response to antipsychotic treatment;	chr6:85891426	chr6:85660950~85678736:-
LAML	cis	rs4591358	0.773	rs35785148	ENSG00000223466.1	AC064834.2	-6.83	2.3e-09	1.83e-05	-0.92	-0.63	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195516751	chr2:195533035~195538681:+
LAML	cis	rs12468226	0.752	rs79058237	ENSG00000226261.1	AC064836.3	6.83	2.31e-09	1.84e-05	1.07	0.63	Urate levels;	chr2:202140247	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.702	rs114634431	ENSG00000226261.1	AC064836.3	6.83	2.31e-09	1.84e-05	1.07	0.63	Urate levels;	chr2:202142530	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.752	rs34829484	ENSG00000226261.1	AC064836.3	-6.83	2.31e-09	1.84e-05	-1	-0.63	Urate levels;	chr2:202137267	chr2:202336024~202336727:-
LAML	cis	rs5760092	0.755	rs11090298	ENSG00000273295.1	AP000350.5	-6.82	2.33e-09	1.85e-05	-1.06	-0.63	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23919874	chr22:23901432~23907068:-
LAML	cis	rs6003958	1	rs6003958	ENSG00000273295.1	AP000350.5	-6.82	2.33e-09	1.85e-05	-1.06	-0.63	S-phenylmercapturic acid levels in smokers;	chr22:23921902	chr22:23901432~23907068:-
LAML	cis	rs5760092	0.755	rs6003959	ENSG00000273295.1	AP000350.5	-6.82	2.33e-09	1.85e-05	-1.06	-0.63	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23922208	chr22:23901432~23907068:-
LAML	cis	rs62070183	0.766	rs10512441	ENSG00000265222.1	RP11-466A19.8	-6.82	2.33e-09	1.86e-05	-0.98	-0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32509954~32523424:-
LAML	cis	rs853679	0.55	rs1150692	ENSG00000187763.3	OR2B7P	6.82	2.38e-09	1.89e-05	0.91	0.63	Depression;	chr6:28206179	chr6:28046434~28047367:+
LAML	cis	rs6452524	0.967	rs6452509	ENSG00000249664.1	CTD-2227C6.2	6.82	2.39e-09	1.9e-05	0.85	0.63	Hypertension (SNP x SNP interaction);	chr5:83125564	chr5:83012285~83013109:-
LAML	cis	rs12468226	0.873	rs1474267	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202178596	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.817	rs6722588	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202187163	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs2350358	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202199771	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs3181153	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202205155	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.679	rs6435133	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202209237	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.817	rs12693965	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202210188	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs3769817	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202214584	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs6435134	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202214857	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.817	rs6435135	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202217469	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs6435138	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202234310	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs6761131	ENSG00000226261.1	AC064836.3	-6.82	2.4e-09	1.9e-05	-1.06	-0.63	Urate levels;	chr2:202237675	chr2:202336024~202336727:-
LAML	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-6.81	2.42e-09	1.91e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-6.81	2.42e-09	1.91e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-6.81	2.42e-09	1.91e-05	-0.77	-0.63	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
LAML	cis	rs12468226	0.689	rs73989731	ENSG00000226261.1	AC064836.3	6.81	2.43e-09	1.92e-05	1.01	0.63	Urate levels;	chr2:202109309	chr2:202336024~202336727:-
LAML	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-6.81	2.5e-09	1.97e-05	-0.81	-0.63	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-6.81	2.5e-09	1.97e-05	-0.81	-0.63	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-6.81	2.5e-09	1.97e-05	-0.81	-0.63	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
LAML	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-6.81	2.51e-09	1.97e-05	-0.77	-0.63	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
LAML	cis	rs4713118	0.662	rs9380046	ENSG00000220721.1	OR1F12	6.81	2.52e-09	1.99e-05	0.78	0.63	Parkinson's disease;	chr6:28062721	chr6:28073316~28074233:+
LAML	cis	rs561341	0.66	rs7406043	ENSG00000266379.5	RP11-640N20.8	6.8	2.53e-09	1.99e-05	1.05	0.63	Hip circumference adjusted for BMI;	chr17:31893133	chr17:32088160~32094933:-
LAML	cis	rs561341	0.883	rs7406056	ENSG00000266379.5	RP11-640N20.8	6.8	2.53e-09	1.99e-05	1.05	0.63	Hip circumference adjusted for BMI;	chr17:31893205	chr17:32088160~32094933:-
LAML	cis	rs2929278	0.617	rs575082	ENSG00000249839.1	AC011330.5	6.8	2.62e-09	2.06e-05	0.78	0.63	Schizophrenia;	chr15:43817944	chr15:43663654~43684339:-
LAML	cis	rs2929278	0.617	rs2955969	ENSG00000249839.1	AC011330.5	6.8	2.62e-09	2.06e-05	0.78	0.63	Schizophrenia;	chr15:43822329	chr15:43663654~43684339:-
LAML	cis	rs62070183	0.882	rs17183295	ENSG00000264458.1	RP11-220C2.1	6.79	2.65e-09	2.07e-05	0.88	0.63	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32751254	chr17:32627739~32686484:+
LAML	cis	rs904251	0.766	rs1757175	ENSG00000227920.2	RP1-153P14.5	-6.79	2.74e-09	2.15e-05	-0.8	-0.62	Cognitive performance;	chr6:37518918	chr6:37545145~37550860:+
LAML	cis	rs904251	0.828	rs1757174	ENSG00000227920.2	RP1-153P14.5	-6.79	2.74e-09	2.15e-05	-0.8	-0.62	Cognitive performance;	chr6:37518919	chr6:37545145~37550860:+
LAML	cis	rs853679	1	rs2799077	ENSG00000187763.3	OR2B7P	6.78	2.78e-09	2.18e-05	0.91	0.62	Depression;	chr6:28266819	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs11965538	ENSG00000187763.3	OR2B7P	6.78	2.78e-09	2.18e-05	0.91	0.62	Depression;	chr6:28272137	chr6:28046434~28047367:+
LAML	cis	rs853679	0.882	rs2743555	ENSG00000187763.3	OR2B7P	6.78	2.78e-09	2.18e-05	0.91	0.62	Depression;	chr6:28273304	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs1419183	ENSG00000187763.3	OR2B7P	6.78	2.78e-09	2.18e-05	0.91	0.62	Depression;	chr6:28275017	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs6901575	ENSG00000187763.3	OR2B7P	6.78	2.78e-09	2.18e-05	0.91	0.62	Depression;	chr6:28283207	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs1778508	ENSG00000187763.3	OR2B7P	-6.78	2.78e-09	2.18e-05	-0.91	-0.62	Depression;	chr6:28262103	chr6:28046434~28047367:+
LAML	cis	rs5769707	0.732	rs135865	ENSG00000280224.1	CTA-722E9.1	-6.78	2.79e-09	2.18e-05	-0.79	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49500568~49501585:+
LAML	cis	rs6452524	0.71	rs7708124	ENSG00000249664.1	CTD-2227C6.2	6.78	2.79e-09	2.18e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83132035	chr5:83012285~83013109:-
LAML	cis	rs911555	0.57	rs11625397	ENSG00000258851.1	RP11-894P9.2	6.78	2.81e-09	2.19e-05	0.69	0.62	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103553421~103561877:+
LAML	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-6.78	2.83e-09	2.21e-05	-0.8	-0.62	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
LAML	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	6.78	2.83e-09	2.21e-05	0.84	0.62	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	6.78	2.83e-09	2.21e-05	0.84	0.62	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	6.78	2.83e-09	2.21e-05	0.84	0.62	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
LAML	cis	rs4273100	0.688	rs28760541	ENSG00000262319.1	CTC-457L16.2	-6.78	2.85e-09	2.22e-05	-0.92	-0.62	Schizophrenia;	chr17:19269192	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.688	rs1467028	ENSG00000262319.1	CTC-457L16.2	-6.78	2.85e-09	2.22e-05	-0.92	-0.62	Schizophrenia;	chr17:19271561	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.605	rs28591622	ENSG00000262319.1	CTC-457L16.2	-6.78	2.85e-09	2.22e-05	-0.92	-0.62	Schizophrenia;	chr17:19272004	chr17:19141017~19143689:-
LAML	cis	rs6782228	0.565	rs67445542	ENSG00000277250.1	Metazoa_SRP	-6.77	2.9e-09	2.26e-05	-0.8	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128673681~128674021:-
LAML	cis	rs9309473	1	rs7576245	ENSG00000163016.8	ALMS1P	6.77	2.91e-09	2.26e-05	0.7	0.62	Metabolite levels;	chr2:73602551	chr2:73644919~73685576:+
LAML	cis	rs11098499	0.71	rs6851130	ENSG00000248280.1	RP11-33B1.2	-6.77	2.93e-09	2.27e-05	-0.91	-0.62	Corneal astigmatism;	chr4:119212557	chr4:119440561~119450157:-
LAML	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	6.77	2.93e-09	2.27e-05	0.77	0.62	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
LAML	cis	rs3096299	0.692	rs4785565	ENSG00000274627.1	RP11-104N10.2	6.77	2.95e-09	2.29e-05	0.75	0.62	Multiple myeloma (IgH translocation);	chr16:89449351	chr16:89516797~89522217:+
LAML	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-6.77	2.96e-09	2.3e-05	-0.78	-0.62	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	6.77	2.98e-09	2.31e-05	0.81	0.62	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-6.77	2.98e-09	2.31e-05	-0.81	-0.62	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-6.77	2.98e-09	2.31e-05	-0.81	-0.62	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-6.77	2.98e-09	2.31e-05	-0.81	-0.62	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	6.77	2.98e-09	2.31e-05	0.81	0.62	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
LAML	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-6.77	2.99e-09	2.32e-05	-0.79	-0.62	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
LAML	cis	rs62070183	0.766	rs10512441	ENSG00000266718.1	RP11-466A19.1	-6.76	2.99e-09	2.32e-05	-0.99	-0.62	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32495536~32499333:+
LAML	cis	rs5769707	0.749	rs7286706	ENSG00000279597.1	RP4-566L20.1	-6.76	3.02e-09	2.33e-05	-0.64	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49534062~49534926:+
LAML	cis	rs6452524	0.905	rs7736289	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83082401	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs7736296	ENSG00000249664.1	CTD-2227C6.2	-6.76	3.02e-09	2.33e-05	-0.85	-0.62	Hypertension (SNP x SNP interaction);	chr5:83082421	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs7718472	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83082603	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs11750799	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83082983	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs10942321	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83083200	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs6868416	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83084320	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs1478485	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83084708	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.836	rs1478484	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83085055	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs7714710	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83085750	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs1017794	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83086236	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs6880566	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83086909	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.905	rs6884981	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83087339	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.905	rs6896548	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83089247	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.901	rs1600362	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83091354	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs1580311	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83091667	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs1580310	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83091792	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs1382376	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83095418	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs12109517	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83095947	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs12109514	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83095965	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs1011979	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83097431	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.901	rs17284211	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83098706	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs1382374	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83101010	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs9293330	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83102299	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.868	rs10071617	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83103207	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs10076059	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83105698	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs7736783	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83107050	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs11951257	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83107492	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs767771	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83108117	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.905	rs1478482	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83111279	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs10045744	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83113688	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs1542539	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83116033	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs1543847	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83116044	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs1564211	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83117014	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs7703318	ENSG00000249664.1	CTD-2227C6.2	6.76	3.02e-09	2.33e-05	0.85	0.62	Hypertension (SNP x SNP interaction);	chr5:83118234	chr5:83012285~83013109:-
LAML	cis	rs10927875	1	rs10927875	ENSG00000178715.8	RP11-169K16.8	6.76	3.06e-09	2.36e-05	0.82	0.62	Dilated cardiomyopathy;	chr1:15972817	chr1:15828232~15828669:+
LAML	cis	rs2929278	0.617	rs693919	ENSG00000249839.1	AC011330.5	6.76	3.1e-09	2.38e-05	0.77	0.62	Schizophrenia;	chr15:43810130	chr15:43663654~43684339:-
LAML	cis	rs853679	0.506	rs1150693	ENSG00000187763.3	OR2B7P	6.75	3.21e-09	2.46e-05	0.9	0.62	Depression;	chr6:28206812	chr6:28046434~28047367:+
LAML	cis	rs6452524	1	rs7716962	ENSG00000249664.1	CTD-2227C6.2	6.75	3.23e-09	2.48e-05	0.8	0.62	Hypertension (SNP x SNP interaction);	chr5:83138913	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6882179	ENSG00000249664.1	CTD-2227C6.2	6.75	3.23e-09	2.48e-05	0.8	0.62	Hypertension (SNP x SNP interaction);	chr5:83139582	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6863300	ENSG00000249664.1	CTD-2227C6.2	6.75	3.23e-09	2.48e-05	0.8	0.62	Hypertension (SNP x SNP interaction);	chr5:83139629	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs7732092	ENSG00000249664.1	CTD-2227C6.2	6.75	3.23e-09	2.48e-05	0.8	0.62	Hypertension (SNP x SNP interaction);	chr5:83141110	chr5:83012285~83013109:-
LAML	cis	rs16828019	0.852	rs34386859	ENSG00000213987.4	RP11-399E6.2	6.75	3.24e-09	2.48e-05	1.01	0.62	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41264550~41264862:-
LAML	cis	rs11098499	0.739	rs4833612	ENSG00000248280.1	RP11-33B1.2	-6.74	3.25e-09	2.49e-05	-0.91	-0.62	Corneal astigmatism;	chr4:119226441	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.739	rs10013032	ENSG00000248280.1	RP11-33B1.2	-6.74	3.25e-09	2.49e-05	-0.91	-0.62	Corneal astigmatism;	chr4:119228264	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.739	rs951570	ENSG00000248280.1	RP11-33B1.2	-6.74	3.25e-09	2.49e-05	-0.91	-0.62	Corneal astigmatism;	chr4:119229312	chr4:119440561~119450157:-
LAML	cis	rs4591358	0.689	rs7578371	ENSG00000223466.1	AC064834.2	-6.74	3.28e-09	2.51e-05	-0.91	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510222	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.773	rs34480328	ENSG00000223466.1	AC064834.2	-6.74	3.28e-09	2.51e-05	-0.91	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510684	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.773	rs16836736	ENSG00000223466.1	AC064834.2	-6.74	3.28e-09	2.51e-05	-0.91	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511283	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs72925794	ENSG00000223466.1	AC064834.2	-6.74	3.28e-09	2.51e-05	-0.91	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511813	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.773	rs72925795	ENSG00000223466.1	AC064834.2	-6.74	3.28e-09	2.51e-05	-0.91	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511814	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.773	rs13035516	ENSG00000223466.1	AC064834.2	-6.74	3.28e-09	2.51e-05	-0.91	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195513234	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.773	rs34475459	ENSG00000223466.1	AC064834.2	-6.74	3.28e-09	2.51e-05	-0.91	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515682	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.773	rs13002794	ENSG00000223466.1	AC064834.2	-6.74	3.28e-09	2.51e-05	-0.91	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195517175	chr2:195533035~195538681:+
LAML	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-6.74	3.39e-09	2.58e-05	-0.78	-0.62	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	6.74	3.39e-09	2.58e-05	0.78	0.62	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-6.74	3.39e-09	2.58e-05	-0.78	-0.62	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-6.74	3.39e-09	2.58e-05	-0.78	-0.62	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
LAML	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	6.73	3.4e-09	2.58e-05	0.74	0.62	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	6.73	3.4e-09	2.58e-05	0.74	0.62	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	6.73	3.4e-09	2.58e-05	0.74	0.62	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	6.73	3.4e-09	2.58e-05	0.74	0.62	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-6.73	3.4e-09	2.58e-05	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
LAML	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	6.73	3.5e-09	2.66e-05	0.66	0.62	Height;	chr3:53082835	chr3:53064283~53065091:-
LAML	cis	rs6782228	0.565	rs11719239	ENSG00000277250.1	Metazoa_SRP	-6.72	3.6e-09	2.73e-05	-0.76	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2001950	ENSG00000277250.1	Metazoa_SRP	-6.72	3.6e-09	2.73e-05	-0.76	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128673681~128674021:-
LAML	cis	rs4273100	0.646	rs1472932	ENSG00000262319.1	CTC-457L16.2	6.72	3.61e-09	2.74e-05	0.98	0.62	Schizophrenia;	chr17:19317353	chr17:19141017~19143689:-
LAML	cis	rs9309473	1	rs11903916	ENSG00000163016.8	ALMS1P	6.72	3.62e-09	2.74e-05	0.68	0.62	Metabolite levels;	chr2:73588201	chr2:73644919~73685576:+
LAML	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	6.71	3.75e-09	2.83e-05	0.86	0.62	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	6.71	3.75e-09	2.83e-05	0.86	0.62	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
LAML	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-6.71	3.79e-09	2.87e-05	-0.77	-0.62	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
LAML	cis	rs4591358	0.773	rs13008940	ENSG00000223466.1	AC064834.2	-6.71	3.81e-09	2.88e-05	-0.91	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509828	chr2:195533035~195538681:+
LAML	cis	rs5760092	0.755	rs3884794	ENSG00000225282.1	AP000350.6	6.71	3.81e-09	2.88e-05	0.98	0.62	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23926900~23929574:+
LAML	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	6.7	3.86e-09	2.92e-05	0.75	0.62	Height;	chr3:53072864	chr3:53064283~53065091:-
LAML	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-6.7	3.89e-09	2.94e-05	-0.76	-0.62	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
LAML	cis	rs12468226	0.689	rs73989733	ENSG00000226261.1	AC064836.3	6.7	3.9e-09	2.94e-05	1.02	0.62	Urate levels;	chr2:202115241	chr2:202336024~202336727:-
LAML	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	6.7	3.92e-09	2.96e-05	0.78	0.62	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	6.7	3.92e-09	2.96e-05	0.78	0.62	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
LAML	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	6.7	3.93e-09	2.97e-05	0.63	0.62	Height;	chr3:53073764	chr3:53064283~53065091:-
LAML	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-6.7	3.94e-09	2.97e-05	-0.68	-0.62	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
LAML	cis	rs561341	0.883	rs1034627	ENSG00000266379.5	RP11-640N20.8	6.7	3.99e-09	3.01e-05	1.02	0.62	Hip circumference adjusted for BMI;	chr17:31892550	chr17:32088160~32094933:-
LAML	cis	rs1577917	0.74	rs2758845	ENSG00000203875.9	SNHG5	-6.7	4e-09	3.02e-05	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85625130	chr6:85660950~85678736:-
LAML	cis	rs5769707	0.935	rs5770594	ENSG00000212939.2	RP1-29C18.10	-6.7	4.01e-09	3.02e-05	-0.72	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.967	rs4524218	ENSG00000212939.2	RP1-29C18.10	-6.7	4.01e-09	3.02e-05	-0.72	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.967	rs739248	ENSG00000212939.2	RP1-29C18.10	-6.7	4.01e-09	3.02e-05	-0.72	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.967	rs2071904	ENSG00000212939.2	RP1-29C18.10	-6.7	4.01e-09	3.02e-05	-0.72	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49548681~49556473:+
LAML	cis	rs12468226	0.689	rs60584169	ENSG00000226261.1	AC064836.3	6.69	4.08e-09	3.07e-05	1.01	0.62	Urate levels;	chr2:202111695	chr2:202336024~202336727:-
LAML	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	6.69	4.1e-09	3.07e-05	0.83	0.62	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	6.69	4.1e-09	3.07e-05	0.83	0.62	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	6.69	4.1e-09	3.07e-05	0.83	0.62	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	6.69	4.1e-09	3.07e-05	0.83	0.62	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
LAML	cis	rs9326248	0.501	rs4938351	ENSG00000254851.1	RP11-109L13.1	-6.69	4.15e-09	3.11e-05	-0.79	-0.62	Blood protein levels;	chr11:117151636	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.52	rs6589602	ENSG00000254851.1	RP11-109L13.1	-6.69	4.15e-09	3.11e-05	-0.79	-0.62	Blood protein levels;	chr11:117166349	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.539	rs7120565	ENSG00000254851.1	RP11-109L13.1	-6.69	4.15e-09	3.11e-05	-0.79	-0.62	Blood protein levels;	chr11:117172233	chr11:117135528~117138582:+
LAML	cis	rs1577917	0.696	rs10806334	ENSG00000203875.9	SNHG5	-6.69	4.17e-09	3.12e-05	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85729611	chr6:85660950~85678736:-
LAML	cis	rs6452524	0.561	rs4331874	ENSG00000249664.1	CTD-2227C6.2	6.69	4.17e-09	3.12e-05	0.81	0.62	Hypertension (SNP x SNP interaction);	chr5:83068253	chr5:83012285~83013109:-
LAML	cis	rs1577917	0.74	rs9450302	ENSG00000203875.9	SNHG5	6.69	4.18e-09	3.13e-05	0.74	0.62	Response to antipsychotic treatment;	chr6:85579955	chr6:85660950~85678736:-
LAML	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	6.69	4.18e-09	3.13e-05	0.43	0.62	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
LAML	cis	rs6782228	0.509	rs6780447	ENSG00000277250.1	Metazoa_SRP	-6.68	4.23e-09	3.16e-05	-0.77	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.527	rs6767383	ENSG00000277250.1	Metazoa_SRP	-6.68	4.33e-09	3.23e-05	-0.78	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128673681~128674021:-
LAML	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	6.68	4.35e-09	3.25e-05	0.72	0.62	Height;	chr3:53091453	chr3:53064283~53065091:-
LAML	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-6.67	4.42e-09	3.3e-05	-0.75	-0.62	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
LAML	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-6.67	4.42e-09	3.3e-05	-0.72	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-6.67	4.42e-09	3.3e-05	-0.72	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
LAML	cis	rs6565180	0.888	rs13333093	ENSG00000183604.13	SMG1P5	-6.67	4.42e-09	3.3e-05	-0.68	-0.62	Tonsillectomy;	chr16:30395948	chr16:30267553~30335374:-
LAML	cis	rs6565180	0.888	rs12921440	ENSG00000183604.13	SMG1P5	-6.67	4.42e-09	3.3e-05	-0.68	-0.62	Tonsillectomy;	chr16:30397444	chr16:30267553~30335374:-
LAML	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	6.67	4.43e-09	3.3e-05	0.69	0.62	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	6.67	4.43e-09	3.3e-05	0.69	0.62	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
LAML	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-6.67	4.48e-09	3.34e-05	-0.73	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-6.67	4.48e-09	3.34e-05	-0.73	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-6.67	4.48e-09	3.34e-05	-0.73	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-6.67	4.48e-09	3.34e-05	-0.73	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
LAML	cis	rs904251	0.523	rs2797799	ENSG00000204110.6	RP1-153P14.8	-6.67	4.55e-09	3.39e-05	-0.74	-0.62	Cognitive performance;	chr6:37515844	chr6:37507348~37535616:+
LAML	cis	rs904251	0.504	rs1757188	ENSG00000204110.6	RP1-153P14.8	-6.67	4.55e-09	3.39e-05	-0.74	-0.62	Cognitive performance;	chr6:37516032	chr6:37507348~37535616:+
LAML	cis	rs4713118	0.662	rs175954	ENSG00000220721.1	OR1F12	6.66	4.57e-09	3.4e-05	0.8	0.62	Parkinson's disease;	chr6:28043807	chr6:28073316~28074233:+
LAML	cis	rs6782228	0.606	rs2253144	ENSG00000277250.1	Metazoa_SRP	6.66	4.57e-09	3.4e-05	0.78	0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2712404	ENSG00000277250.1	Metazoa_SRP	6.66	4.57e-09	3.4e-05	0.78	0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.585	rs9841161	ENSG00000277250.1	Metazoa_SRP	-6.66	4.57e-09	3.4e-05	-0.78	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2712405	ENSG00000277250.1	Metazoa_SRP	-6.66	4.57e-09	3.4e-05	-0.78	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs9828893	ENSG00000277250.1	Metazoa_SRP	-6.66	4.57e-09	3.4e-05	-0.78	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128673681~128674021:-
LAML	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	6.66	4.6e-09	3.4e-05	0.77	0.62	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
LAML	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	6.66	4.6e-09	3.4e-05	0.77	0.62	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
LAML	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	6.66	4.62e-09	3.42e-05	0.78	0.62	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs4383777	ENSG00000203875.9	SNHG5	6.66	4.66e-09	3.44e-05	0.79	0.62	Response to antipsychotic treatment;	chr6:85726242	chr6:85660950~85678736:-
LAML	cis	rs2564921	0.704	rs2336720	ENSG00000242142.1	SERBP1P3	-6.66	4.69e-09	3.46e-05	-0.64	-0.62	Height;	chr3:52994045	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.73	rs56384586	ENSG00000242142.1	SERBP1P3	-6.66	4.69e-09	3.46e-05	-0.64	-0.62	Height;	chr3:52994990	chr3:53064283~53065091:-
LAML	cis	rs6597981	0.543	rs3901233	ENSG00000279672.1	CMB9-55F22.1	6.66	4.69e-09	3.46e-05	0.6	0.62	Breast cancer;	chr11:749452	chr11:779617~780755:+
LAML	cis	rs1577917	0.74	rs12212560	ENSG00000203875.9	SNHG5	-6.66	4.69e-09	3.47e-05	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85632961	chr6:85660950~85678736:-
LAML	cis	rs7131987	0.565	rs2882294	ENSG00000257176.2	RP11-996F15.2	6.66	4.74e-09	3.49e-05	0.64	0.62	QT interval;	chr12:29245019	chr12:29280418~29317848:-
LAML	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-6.66	4.74e-09	3.5e-05	-0.75	-0.62	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-6.66	4.74e-09	3.5e-05	-0.75	-0.62	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-6.66	4.74e-09	3.5e-05	-0.75	-0.62	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
LAML	cis	rs904251	0.522	rs882322	ENSG00000204110.6	RP1-153P14.8	-6.65	4.76e-09	3.51e-05	-0.75	-0.62	Cognitive performance;	chr6:37516327	chr6:37507348~37535616:+
LAML	cis	rs7617773	1	rs7617773	ENSG00000229759.1	MRPS18AP1	-6.65	4.77e-09	3.51e-05	-0.76	-0.62	Coronary artery disease;	chr3:48152025	chr3:48256350~48256938:-
LAML	cis	rs4591358	0.731	rs12693768	ENSG00000223466.1	AC064834.2	-6.65	4.84e-09	3.56e-05	-0.93	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195451897	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.731	rs12693769	ENSG00000223466.1	AC064834.2	-6.65	4.84e-09	3.56e-05	-0.93	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195453722	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.68	rs12693771	ENSG00000223466.1	AC064834.2	-6.65	4.84e-09	3.56e-05	-0.93	-0.62	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195461651	chr2:195533035~195538681:+
LAML	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-6.65	4.87e-09	3.58e-05	-0.64	-0.62	Height;	chr3:53074760	chr3:53064283~53065091:-
LAML	cis	rs1577917	0.633	rs7770835	ENSG00000203875.9	SNHG5	-6.65	4.91e-09	3.61e-05	-0.8	-0.62	Response to antipsychotic treatment;	chr6:85899189	chr6:85660950~85678736:-
LAML	cis	rs709400	0.859	rs7154948	ENSG00000258851.1	RP11-894P9.2	-6.65	4.93e-09	3.62e-05	-0.77	-0.62	Body mass index;	chr14:103556607	chr14:103553421~103561877:+
LAML	cis	rs853679	1	rs853676	ENSG00000220721.1	OR1F12	6.64	4.99e-09	3.67e-05	0.79	0.62	Depression;	chr6:28331910	chr6:28073316~28074233:+
LAML	cis	rs6435862	0.636	rs717548	ENSG00000227769.6	AC072062.3	6.64	5.01e-09	3.68e-05	0.62	0.62	Neuroblastoma (high-risk);	chr2:214812181	chr2:215004782~215085488:+
LAML	cis	rs6452524	0.935	rs6896953	ENSG00000249664.1	CTD-2227C6.2	-6.64	5.03e-09	3.7e-05	-0.85	-0.62	Hypertension (SNP x SNP interaction);	chr5:83089284	chr5:83012285~83013109:-
LAML	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-6.64	5.08e-09	3.73e-05	-0.75	-0.62	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
LAML	cis	rs6452524	0.901	rs10079680	ENSG00000249664.1	CTD-2227C6.2	6.64	5.09e-09	3.73e-05	0.82	0.62	Hypertension (SNP x SNP interaction);	chr5:83082746	chr5:83012285~83013109:-
LAML	cis	rs12468226	0.873	rs76552560	ENSG00000226261.1	AC064836.3	6.64	5.1e-09	3.73e-05	1.05	0.62	Urate levels;	chr2:202173123	chr2:202336024~202336727:-
LAML	cis	rs904251	0.861	rs1776456	ENSG00000227920.2	RP1-153P14.5	-6.64	5.15e-09	3.77e-05	-0.78	-0.62	Cognitive performance;	chr6:37516922	chr6:37545145~37550860:+
LAML	cis	rs1555322	0.53	rs2425043	ENSG00000279253.1	RP4-614O4.13	-6.64	5.15e-09	3.77e-05	-0.77	-0.62	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35262727~35264187:-
LAML	cis	rs2564921	0.693	rs2336721	ENSG00000242142.1	SERBP1P3	-6.64	5.16e-09	3.78e-05	-0.63	-0.62	Height;	chr3:52994359	chr3:53064283~53065091:-
LAML	cis	rs1555322	0.53	rs2425042	ENSG00000279253.1	RP4-614O4.13	-6.64	5.17e-09	3.78e-05	-0.78	-0.62	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35262727~35264187:-
LAML	cis	rs1555322	0.53	rs7004	ENSG00000279253.1	RP4-614O4.13	-6.64	5.17e-09	3.78e-05	-0.78	-0.62	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35262727~35264187:-
LAML	cis	rs1555322	0.53	rs2297789	ENSG00000279253.1	RP4-614O4.13	-6.64	5.17e-09	3.78e-05	-0.78	-0.62	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35262727~35264187:-
LAML	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-6.64	5.17e-09	3.78e-05	-0.78	-0.62	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
LAML	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	6.64	5.17e-09	3.78e-05	0.78	0.62	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
LAML	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	6.64	5.17e-09	3.78e-05	0.78	0.62	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
LAML	cis	rs1555322	0.53	rs2425047	ENSG00000279253.1	RP4-614O4.13	6.64	5.17e-09	3.78e-05	0.78	0.62	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35262727~35264187:-
LAML	cis	rs1757171	0.542	rs1757186	ENSG00000204110.6	RP1-153P14.8	-6.64	5.17e-09	3.78e-05	-0.75	-0.62	Cognitive performance;	chr6:37516335	chr6:37507348~37535616:+
LAML	cis	rs9309473	1	rs10187416	ENSG00000163016.8	ALMS1P	6.63	5.22e-09	3.82e-05	0.69	0.62	Metabolite levels;	chr2:73486614	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs10207264	ENSG00000163016.8	ALMS1P	6.63	5.22e-09	3.82e-05	0.69	0.62	Metabolite levels;	chr2:73486970	chr2:73644919~73685576:+
LAML	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	6.63	5.23e-09	3.83e-05	0.78	0.62	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
LAML	cis	rs5769707	0.846	rs5770610	ENSG00000212939.2	RP1-29C18.10	-6.63	5.34e-09	3.89e-05	-0.71	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.967	rs8141807	ENSG00000212939.2	RP1-29C18.10	-6.63	5.34e-09	3.89e-05	-0.71	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.935	rs9616332	ENSG00000212939.2	RP1-29C18.10	-6.63	5.34e-09	3.89e-05	-0.71	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.935	rs739239	ENSG00000212939.2	RP1-29C18.10	-6.63	5.34e-09	3.89e-05	-0.71	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49656820	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.874	rs9616714	ENSG00000212939.2	RP1-29C18.10	-6.63	5.34e-09	3.89e-05	-0.71	-0.62	Monocyte percentage of white cells;Monocyte count;	chr22:49657211	chr22:49548681~49556473:+
LAML	cis	rs2564921	0.791	rs36033494	ENSG00000280417.1	RP11-5O17.1	6.63	5.37e-09	3.91e-05	0.8	0.62	Height;	chr3:53082835	chr3:53046166~53048122:+
LAML	cis	rs6452524	0.534	rs10061690	ENSG00000249664.1	CTD-2227C6.2	6.62	5.43e-09	3.95e-05	0.8	0.62	Hypertension (SNP x SNP interaction);	chr5:83063226	chr5:83012285~83013109:-
LAML	cis	rs6782228	0.606	rs6787559	ENSG00000277250.1	Metazoa_SRP	-6.62	5.46e-09	3.97e-05	-0.83	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2001703	ENSG00000277250.1	Metazoa_SRP	-6.62	5.46e-09	3.97e-05	-0.83	-0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128673681~128674021:-
LAML	cis	rs12468226	0.752	rs116078354	ENSG00000226261.1	AC064836.3	6.62	5.5e-09	4e-05	1.03	0.62	Urate levels;	chr2:202136356	chr2:202336024~202336727:-
LAML	cis	rs6565180	0.851	rs3574	ENSG00000273724.1	RP11-347C12.12	6.62	5.5e-09	4e-05	0.63	0.62	Tonsillectomy;	chr16:30400061	chr16:30336400~30343336:+
LAML	cis	rs4591358	0.773	rs35261538	ENSG00000223466.1	AC064834.2	-6.62	5.59e-09	4.06e-05	-0.91	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509681	chr2:195533035~195538681:+
LAML	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-6.62	5.6e-09	4.07e-05	-0.8	-0.61	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-6.62	5.6e-09	4.07e-05	-0.8	-0.61	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
LAML	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-6.62	5.61e-09	4.08e-05	-0.75	-0.61	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
LAML	cis	rs3096299	0.754	rs2965816	ENSG00000274627.1	RP11-104N10.2	-6.62	5.62e-09	4.08e-05	-0.73	-0.61	Multiple myeloma (IgH translocation);	chr16:89447775	chr16:89516797~89522217:+
LAML	cis	rs853679	0.882	rs9393908	ENSG00000220721.1	OR1F12	6.61	5.62e-09	4.08e-05	0.92	0.61	Depression;	chr6:28223052	chr6:28073316~28074233:+
LAML	cis	rs853679	0.882	rs9366717	ENSG00000220721.1	OR1F12	6.61	5.62e-09	4.08e-05	0.92	0.61	Depression;	chr6:28223279	chr6:28073316~28074233:+
LAML	cis	rs853679	0.882	rs9380069	ENSG00000220721.1	OR1F12	6.61	5.62e-09	4.08e-05	0.92	0.61	Depression;	chr6:28235522	chr6:28073316~28074233:+
LAML	cis	rs6565180	0.783	rs9888967	ENSG00000273724.1	RP11-347C12.12	6.61	5.64e-09	4.1e-05	0.63	0.61	Tonsillectomy;	chr16:30396658	chr16:30336400~30343336:+
LAML	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-6.61	5.65e-09	4.1e-05	-0.76	-0.61	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
LAML	cis	rs11098499	0.739	rs6534130	ENSG00000248280.1	RP11-33B1.2	-6.61	5.71e-09	4.14e-05	-0.9	-0.61	Corneal astigmatism;	chr4:119210184	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.592	rs28580295	ENSG00000248280.1	RP11-33B1.2	6.61	5.71e-09	4.14e-05	0.76	0.61	Diastolic blood pressure;	chr4:119357718	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.592	rs62320740	ENSG00000248280.1	RP11-33B1.2	6.61	5.71e-09	4.14e-05	0.76	0.61	Diastolic blood pressure;	chr4:119358331	chr4:119440561~119450157:-
LAML	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	6.61	5.77e-09	4.18e-05	0.85	0.61	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
LAML	cis	rs4591358	0.731	rs10208012	ENSG00000223466.1	AC064834.2	6.61	5.77e-09	4.18e-05	0.92	0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195452137	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.731	rs13031745	ENSG00000223466.1	AC064834.2	-6.61	5.77e-09	4.18e-05	-0.92	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195440458	chr2:195533035~195538681:+
LAML	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	6.61	5.81e-09	4.2e-05	0.83	0.61	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
LAML	cis	rs12468226	0.938	rs10166594	ENSG00000226261.1	AC064836.3	6.61	5.82e-09	4.21e-05	0.99	0.61	Urate levels;	chr2:202250262	chr2:202336024~202336727:-
LAML	cis	rs6452524	0.967	rs6897075	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83122959	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs10065973	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83123181	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs12153441	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83125181	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs12152891	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83125217	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs6452507	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83125537	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs6452508	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83125546	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.934	rs1120477	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83127062	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.934	rs1120478	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83127072	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.934	rs6452512	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83127523	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs6452514	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83127627	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs6884543	ENSG00000249664.1	CTD-2227C6.2	6.6	5.93e-09	4.27e-05	0.86	0.61	Hypertension (SNP x SNP interaction);	chr5:83127939	chr5:83012285~83013109:-
LAML	cis	rs1555322	0.53	rs2425044	ENSG00000279253.1	RP4-614O4.13	-6.6	6e-09	4.32e-05	-0.77	-0.61	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35262727~35264187:-
LAML	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-6.6	6e-09	4.32e-05	-0.77	-0.61	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
LAML	cis	rs16828019	0.704	rs34660906	ENSG00000213987.4	RP11-399E6.2	6.6	6.04e-09	4.35e-05	1.08	0.61	Intelligence (multi-trait analysis);	chr1:41086296	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.704	rs35071528	ENSG00000213987.4	RP11-399E6.2	6.6	6.04e-09	4.35e-05	1.08	0.61	Intelligence (multi-trait analysis);	chr1:41146985	chr1:41264550~41264862:-
LAML	cis	rs5760092	0.755	rs3884794	ENSG00000218537.1	MIF-AS1	6.59	6.16e-09	4.43e-05	1.08	0.61	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23894426~23898930:-
LAML	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	6.59	6.18e-09	4.44e-05	0.84	0.61	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
LAML	cis	rs853679	0.55	rs1233707	ENSG00000187763.3	OR2B7P	6.59	6.28e-09	4.51e-05	0.88	0.61	Depression;	chr6:28205175	chr6:28046434~28047367:+
LAML	cis	rs6452524	0.901	rs2662238	ENSG00000249664.1	CTD-2227C6.2	6.59	6.36e-09	4.56e-05	0.8	0.61	Hypertension (SNP x SNP interaction);	chr5:83203488	chr5:83012285~83013109:-
LAML	cis	rs66887589	0.616	rs11098498	ENSG00000248280.1	RP11-33B1.2	6.58	6.44e-09	4.61e-05	0.72	0.61	Diastolic blood pressure;	chr4:119265964	chr4:119440561~119450157:-
LAML	cis	rs911555	0.57	rs942862	ENSG00000258851.1	RP11-894P9.2	-6.58	6.47e-09	4.64e-05	-0.69	-0.61	Intelligence (multi-trait analysis);	chr14:103555787	chr14:103553421~103561877:+
LAML	cis	rs6452524	1	rs10080123	ENSG00000249664.1	CTD-2227C6.2	-6.58	6.59e-09	4.72e-05	-0.8	-0.61	Hypertension (SNP x SNP interaction);	chr5:83165447	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.534	rs10514246	ENSG00000249664.1	CTD-2227C6.2	6.57	6.66e-09	4.76e-05	0.81	0.61	Hypertension (SNP x SNP interaction);	chr5:83069979	chr5:83012285~83013109:-
LAML	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	6.57	6.69e-09	4.78e-05	0.83	0.61	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
LAML	cis	rs2015599	0.623	rs12581107	ENSG00000275476.1	RP11-996F15.4	-6.57	6.69e-09	4.78e-05	-0.68	-0.61	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.645	rs12578931	ENSG00000275476.1	RP11-996F15.4	-6.57	6.69e-09	4.78e-05	-0.68	-0.61	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.623	rs4931174	ENSG00000275476.1	RP11-996F15.4	-6.57	6.69e-09	4.78e-05	-0.68	-0.61	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29277397~29277882:-
LAML	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-6.57	6.71e-09	4.79e-05	-0.76	-0.61	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
LAML	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	6.57	6.72e-09	4.8e-05	0.82	0.61	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
LAML	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	6.57	6.85e-09	4.89e-05	0.68	0.61	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
LAML	cis	rs6452524	0.534	rs10037377	ENSG00000249664.1	CTD-2227C6.2	6.57	6.86e-09	4.89e-05	0.81	0.61	Hypertension (SNP x SNP interaction);	chr5:83071150	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.507	rs28592576	ENSG00000249664.1	CTD-2227C6.2	6.57	6.86e-09	4.89e-05	0.81	0.61	Hypertension (SNP x SNP interaction);	chr5:83074772	chr5:83012285~83013109:-
LAML	cis	rs9309473	0.653	rs6718843	ENSG00000163016.8	ALMS1P	6.57	6.88e-09	4.9e-05	0.7	0.61	Metabolite levels;	chr2:73625378	chr2:73644919~73685576:+
LAML	cis	rs9457247	0.74	rs13195812	ENSG00000265828.1	MIR3939	-6.56	6.94e-09	4.95e-05	-0.81	-0.61	Crohn's disease;	chr6:167030414	chr6:166997807~166997912:-
LAML	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-6.56	7.02e-09	4.99e-05	-0.71	-0.61	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-6.56	7.02e-09	4.99e-05	-0.71	-0.61	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
LAML	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-6.56	7.02e-09	4.99e-05	-0.71	-0.61	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
LAML	cis	rs853679	0.882	rs4713140	ENSG00000187763.3	OR2B7P	6.56	7.04e-09	5.01e-05	1.07	0.61	Depression;	chr6:28129415	chr6:28046434~28047367:+
LAML	cis	rs12468226	0.873	rs79071680	ENSG00000226261.1	AC064836.3	6.56	7.1e-09	5.04e-05	1.05	0.61	Urate levels;	chr2:202191520	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs79860867	ENSG00000226261.1	AC064836.3	6.56	7.1e-09	5.04e-05	1.05	0.61	Urate levels;	chr2:202192397	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs78798541	ENSG00000226261.1	AC064836.3	6.56	7.1e-09	5.04e-05	1.05	0.61	Urate levels;	chr2:202194708	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs59293950	ENSG00000226261.1	AC064836.3	6.56	7.1e-09	5.04e-05	1.05	0.61	Urate levels;	chr2:202214069	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs12472035	ENSG00000226261.1	AC064836.3	6.56	7.1e-09	5.04e-05	1.05	0.61	Urate levels;	chr2:202221970	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.873	rs12470401	ENSG00000226261.1	AC064836.3	6.56	7.1e-09	5.04e-05	1.05	0.61	Urate levels;	chr2:202236436	chr2:202336024~202336727:-
LAML	cis	rs5769707	0.967	rs2187891	ENSG00000212939.2	RP1-29C18.10	-6.56	7.19e-09	5.11e-05	-0.69	-0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49548681~49556473:+
LAML	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	6.55	7.35e-09	5.2e-05	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
LAML	cis	rs11098499	0.526	rs10026625	ENSG00000248280.1	RP11-33B1.2	6.55	7.46e-09	5.27e-05	0.76	0.61	Corneal astigmatism;	chr4:119358981	chr4:119440561~119450157:-
LAML	cis	rs904251	0.737	rs914347	ENSG00000227920.2	RP1-153P14.5	-6.54	7.55e-09	5.33e-05	-0.73	-0.61	Cognitive performance;	chr6:37517194	chr6:37545145~37550860:+
LAML	cis	rs904251	0.797	rs1776460	ENSG00000227920.2	RP1-153P14.5	-6.54	7.55e-09	5.33e-05	-0.73	-0.61	Cognitive performance;	chr6:37517708	chr6:37545145~37550860:+
LAML	cis	rs904251	0.828	rs1757178	ENSG00000227920.2	RP1-153P14.5	6.54	7.55e-09	5.33e-05	0.73	0.61	Cognitive performance;	chr6:37518534	chr6:37545145~37550860:+
LAML	cis	rs4713118	0.662	rs9393881	ENSG00000220721.1	OR1F12	6.54	7.64e-09	5.39e-05	0.78	0.61	Parkinson's disease;	chr6:28055973	chr6:28073316~28074233:+
LAML	cis	rs6452524	0.905	rs10040244	ENSG00000249664.1	CTD-2227C6.2	6.54	7.76e-09	5.47e-05	0.81	0.61	Hypertension (SNP x SNP interaction);	chr5:83089242	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs10474081	ENSG00000249664.1	CTD-2227C6.2	6.54	7.76e-09	5.47e-05	0.81	0.61	Hypertension (SNP x SNP interaction);	chr5:83095064	chr5:83012285~83013109:-
LAML	cis	rs9309473	1	rs2056486	ENSG00000163016.8	ALMS1P	6.54	7.8e-09	5.49e-05	0.67	0.61	Metabolite levels;	chr2:73490440	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs10193972	ENSG00000163016.8	ALMS1P	6.54	7.8e-09	5.49e-05	0.67	0.61	Metabolite levels;	chr2:73490529	chr2:73644919~73685576:+
LAML	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	6.54	7.83e-09	5.51e-05	0.72	0.61	Height;	chr3:53073584	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.73	rs56026870	ENSG00000242142.1	SERBP1P3	-6.54	7.84e-09	5.52e-05	-0.63	-0.61	Height;	chr3:52998472	chr3:53064283~53065091:-
LAML	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	6.54	7.85e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	6.54	7.86e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs7566364	ENSG00000163016.8	ALMS1P	6.54	7.86e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73615762	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs6546860	ENSG00000163016.8	ALMS1P	6.54	7.86e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73617122	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs13427832	ENSG00000163016.8	ALMS1P	6.54	7.86e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73617691	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs10209517	ENSG00000163016.8	ALMS1P	6.54	7.86e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73618265	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.797	rs6723247	ENSG00000163016.8	ALMS1P	6.54	7.86e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73619622	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs13391258	ENSG00000163016.8	ALMS1P	6.54	7.86e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73621806	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs6705977	ENSG00000163016.8	ALMS1P	6.54	7.86e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73622043	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs6546861	ENSG00000163016.8	ALMS1P	6.54	7.86e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73622734	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs6711001	ENSG00000163016.8	ALMS1P	6.54	7.86e-09	5.52e-05	0.69	0.61	Metabolite levels;	chr2:73623693	chr2:73644919~73685576:+
LAML	cis	rs9457247	0.668	rs2236313	ENSG00000265828.1	MIR3939	-6.53	7.89e-09	5.54e-05	-0.75	-0.61	Crohn's disease;	chr6:166946901	chr6:166997807~166997912:-
LAML	cis	rs3136516	1	rs3136516	ENSG00000271350.1	CTD-2384B9.1	-6.53	7.95e-09	5.58e-05	-0.59	-0.61	Venous thromboembolism;	chr11:46739206	chr11:47041027~47041945:-
LAML	cis	rs4591358	0.689	rs1500605	ENSG00000223466.1	AC064834.2	-6.53	7.97e-09	5.59e-05	-0.89	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530584	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs16836990	ENSG00000223466.1	AC064834.2	-6.53	7.97e-09	5.59e-05	-0.89	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195532968	chr2:195533035~195538681:+
LAML	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	6.53	7.99e-09	5.59e-05	0.85	0.61	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	6.53	7.99e-09	5.59e-05	0.85	0.61	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
LAML	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	6.53	8.01e-09	5.59e-05	0.75	0.61	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	6.53	8.01e-09	5.59e-05	0.75	0.61	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	6.53	8.01e-09	5.59e-05	0.75	0.61	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	6.53	8.01e-09	5.59e-05	0.75	0.61	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
LAML	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	6.53	8.01e-09	5.59e-05	0.75	0.61	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
LAML	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
LAML	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
LAML	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
LAML	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
LAML	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
LAML	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
LAML	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-6.53	8.01e-09	5.59e-05	-0.75	-0.61	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
LAML	cis	rs5769707	0.967	rs9616701	ENSG00000212939.2	RP1-29C18.10	-6.53	8.02e-09	5.6e-05	-0.72	-0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49548681~49556473:+
LAML	cis	rs4591358	0.636	rs6712400	ENSG00000223466.1	AC064834.2	-6.53	8.1e-09	5.65e-05	-0.87	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506646	chr2:195533035~195538681:+
LAML	cis	rs2581828	0.549	rs7611386	ENSG00000242142.1	SERBP1P3	-6.53	8.13e-09	5.67e-05	-0.65	-0.61	Crohn's disease;	chr3:53019386	chr3:53064283~53065091:-
LAML	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	6.53	8.15e-09	5.68e-05	0.8	0.61	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	6.53	8.15e-09	5.68e-05	0.8	0.61	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
LAML	cis	rs4713118	0.629	rs203887	ENSG00000220721.1	OR1F12	6.52	8.25e-09	5.75e-05	0.81	0.61	Parkinson's disease;	chr6:28053491	chr6:28073316~28074233:+
LAML	cis	rs12468226	0.689	rs17656903	ENSG00000226261.1	AC064836.3	-6.52	8.39e-09	5.83e-05	-1	-0.61	Urate levels;	chr2:202106312	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.689	rs17651413	ENSG00000226261.1	AC064836.3	6.52	8.39e-09	5.83e-05	1	0.61	Urate levels;	chr2:202104086	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.752	rs77319662	ENSG00000226261.1	AC064836.3	6.52	8.39e-09	5.83e-05	1	0.61	Urate levels;	chr2:202126928	chr2:202336024~202336727:-
LAML	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-6.52	8.43e-09	5.86e-05	-0.73	-0.61	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
LAML	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-6.51	8.58e-09	5.96e-05	-0.74	-0.61	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
LAML	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-6.51	8.62e-09	5.99e-05	-0.75	-0.61	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
LAML	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	6.51	8.65e-09	6.01e-05	0.67	0.61	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.851	rs6546850	ENSG00000163016.8	ALMS1P	6.51	8.69e-09	6.03e-05	0.69	0.61	Metabolite levels;	chr2:73604020	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs6546851	ENSG00000163016.8	ALMS1P	6.51	8.69e-09	6.03e-05	0.69	0.61	Metabolite levels;	chr2:73606156	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs6546852	ENSG00000163016.8	ALMS1P	6.51	8.69e-09	6.03e-05	0.69	0.61	Metabolite levels;	chr2:73606304	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs6546853	ENSG00000163016.8	ALMS1P	6.51	8.69e-09	6.03e-05	0.69	0.61	Metabolite levels;	chr2:73606612	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs6546858	ENSG00000163016.8	ALMS1P	6.51	8.69e-09	6.03e-05	0.69	0.61	Metabolite levels;	chr2:73611486	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.948	rs2421577	ENSG00000163016.8	ALMS1P	6.51	8.69e-09	6.03e-05	0.69	0.61	Metabolite levels;	chr2:73613871	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs6546849	ENSG00000163016.8	ALMS1P	6.51	8.73e-09	6.06e-05	0.68	0.61	Metabolite levels;	chr2:73603910	chr2:73644919~73685576:+
LAML	cis	rs2929278	0.561	rs2927071	ENSG00000249839.1	AC011330.5	-6.51	8.82e-09	6.11e-05	-0.74	-0.61	Schizophrenia;	chr15:43626883	chr15:43663654~43684339:-
LAML	cis	rs7617773	0.962	rs6797587	ENSG00000229759.1	MRPS18AP1	-6.51	8.88e-09	6.15e-05	-0.75	-0.61	Coronary artery disease;	chr3:48156124	chr3:48256350~48256938:-
LAML	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	6.51	8.9e-09	6.16e-05	0.84	0.61	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	6.51	8.9e-09	6.16e-05	0.84	0.61	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
LAML	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-6.5	8.97e-09	6.22e-05	-0.72	-0.61	Height;	chr3:53085518	chr3:53064283~53065091:-
LAML	cis	rs16828019	0.64	rs35201793	ENSG00000213987.4	RP11-399E6.2	6.5	8.98e-09	6.22e-05	1.08	0.61	Intelligence (multi-trait analysis);	chr1:41056250	chr1:41264550~41264862:-
LAML	cis	rs9457247	0.566	rs10946207	ENSG00000265828.1	MIR3939	-6.5	9.1e-09	6.3e-05	-0.88	-0.61	Crohn's disease;	chr6:167042548	chr6:166997807~166997912:-
LAML	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-6.5	9.22e-09	6.37e-05	-0.74	-0.61	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-6.5	9.22e-09	6.37e-05	-0.74	-0.61	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-6.5	9.22e-09	6.37e-05	-0.74	-0.61	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-6.5	9.22e-09	6.37e-05	-0.74	-0.61	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-6.5	9.22e-09	6.37e-05	-0.74	-0.61	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-6.5	9.22e-09	6.37e-05	-0.74	-0.61	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-6.5	9.22e-09	6.37e-05	-0.74	-0.61	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-6.5	9.22e-09	6.37e-05	-0.74	-0.61	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	6.5	9.22e-09	6.37e-05	0.74	0.61	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
LAML	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	6.5	9.24e-09	6.38e-05	0.84	0.61	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	6.5	9.24e-09	6.38e-05	0.84	0.61	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
LAML	cis	rs4273100	0.688	rs4924980	ENSG00000262319.1	CTC-457L16.2	6.5	9.27e-09	6.39e-05	0.89	0.61	Schizophrenia;	chr17:19301550	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.607	rs8072587	ENSG00000262319.1	CTC-457L16.2	6.5	9.27e-09	6.39e-05	0.89	0.61	Schizophrenia;	chr17:19307760	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.646	rs11652784	ENSG00000262319.1	CTC-457L16.2	6.5	9.27e-09	6.39e-05	0.89	0.61	Schizophrenia;	chr17:19313948	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.607	rs1043809	ENSG00000262319.1	CTC-457L16.2	6.5	9.27e-09	6.39e-05	0.89	0.61	Schizophrenia;	chr17:19336119	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.688	rs4143829	ENSG00000262319.1	CTC-457L16.2	6.5	9.27e-09	6.39e-05	0.89	0.61	Schizophrenia;	chr17:19338192	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.646	rs4924987	ENSG00000262319.1	CTC-457L16.2	6.5	9.27e-09	6.39e-05	0.89	0.61	Schizophrenia;	chr17:19343762	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.688	rs12939947	ENSG00000262319.1	CTC-457L16.2	-6.5	9.27e-09	6.39e-05	-0.89	-0.61	Schizophrenia;	chr17:19301218	chr17:19141017~19143689:-
LAML	cis	rs561341	0.883	rs4450460	ENSG00000266379.5	RP11-640N20.8	-6.5	9.29e-09	6.4e-05	-1.07	-0.61	Hip circumference adjusted for BMI;	chr17:31874290	chr17:32088160~32094933:-
LAML	cis	rs561341	0.883	rs4795661	ENSG00000266379.5	RP11-640N20.8	-6.5	9.29e-09	6.4e-05	-1.07	-0.61	Hip circumference adjusted for BMI;	chr17:31874755	chr17:32088160~32094933:-
LAML	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	6.5	9.29e-09	6.41e-05	0.75	0.61	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
LAML	cis	rs6452524	0.534	rs7727691	ENSG00000249664.1	CTD-2227C6.2	6.49	9.33e-09	6.43e-05	0.8	0.61	Hypertension (SNP x SNP interaction);	chr5:83075876	chr5:83012285~83013109:-
LAML	cis	rs7617773	0.823	rs9839446	ENSG00000229759.1	MRPS18AP1	-6.49	9.34e-09	6.43e-05	-0.75	-0.61	Coronary artery disease;	chr3:48153176	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.823	rs9839447	ENSG00000229759.1	MRPS18AP1	-6.49	9.34e-09	6.43e-05	-0.75	-0.61	Coronary artery disease;	chr3:48153177	chr3:48256350~48256938:-
LAML	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-6.49	9.34e-09	6.43e-05	-0.72	-0.61	Height;	chr3:53080524	chr3:53064283~53065091:-
LAML	cis	rs709400	0.859	rs942863	ENSG00000258851.1	RP11-894P9.2	-6.49	9.37e-09	6.45e-05	-0.76	-0.61	Body mass index;	chr14:103554931	chr14:103553421~103561877:+
LAML	cis	rs709400	0.859	rs7693	ENSG00000258851.1	RP11-894P9.2	-6.49	9.37e-09	6.45e-05	-0.76	-0.61	Body mass index;	chr14:103557367	chr14:103553421~103561877:+
LAML	cis	rs6456156	0.586	rs1358883	ENSG00000265828.1	MIR3939	6.49	9.42e-09	6.45e-05	0.9	0.61	Primary biliary cholangitis;	chr6:167053945	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.583	rs7748224	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167043372	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs6909180	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167047049	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs12213683	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167047230	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs12529876	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167048013	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs12528323	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167048157	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs12528689	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167048258	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs13208636	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167048477	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs6456149	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167050414	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.565	rs2181058	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167051842	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.565	rs12529238	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167052088	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs9459853	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167052286	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.524	rs6932740	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167052951	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.524	rs6934043	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167052961	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs1358882	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167053613	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs720325	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167053861	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs9457261	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167054191	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs1407315	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167055171	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs6456150	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167055434	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs12527827	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167055783	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.565	rs12529959	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167055804	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.528	rs6936261	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167056188	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs911632	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167057973	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs2017338	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167058226	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.51	rs6456151	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Crohn's disease;	chr6:167058363	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.565	rs6456153	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167058679	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs6456154	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167058768	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs12203510	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167059518	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs13210649	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167059705	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs12213801	ENSG00000265828.1	MIR3939	-6.49	9.42e-09	6.45e-05	-0.9	-0.61	Primary biliary cholangitis;	chr6:167060596	chr6:166997807~166997912:-
LAML	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	6.49	9.47e-09	6.48e-05	0.81	0.61	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
LAML	cis	rs10927875	1	rs3979179	ENSG00000178715.8	RP11-169K16.8	6.49	9.48e-09	6.49e-05	0.76	0.61	Dilated cardiomyopathy;	chr1:15980351	chr1:15828232~15828669:+
LAML	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-6.49	9.59e-09	6.56e-05	-0.72	-0.61	Height;	chr3:53097932	chr3:53064283~53065091:-
LAML	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-6.49	9.6e-09	6.57e-05	-0.78	-0.61	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
LAML	cis	rs6452524	0.868	rs10079372	ENSG00000249664.1	CTD-2227C6.2	6.49	9.61e-09	6.57e-05	0.83	0.61	Hypertension (SNP x SNP interaction);	chr5:83117113	chr5:83012285~83013109:-
LAML	cis	rs853679	0.766	rs9368561	ENSG00000220721.1	OR1F12	6.49	9.65e-09	6.59e-05	0.94	0.61	Depression;	chr6:28200565	chr6:28073316~28074233:+
LAML	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-6.48	9.7e-09	6.62e-05	-0.75	-0.61	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-6.48	9.74e-09	6.65e-05	-0.75	-0.61	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
LAML	cis	rs16828019	0.929	rs111309254	ENSG00000213987.4	RP11-399E6.2	6.48	9.83e-09	6.7e-05	1.01	0.61	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.929	rs4131949	ENSG00000213987.4	RP11-399E6.2	6.48	9.83e-09	6.7e-05	1.01	0.61	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.929	rs35813191	ENSG00000213987.4	RP11-399E6.2	6.48	9.83e-09	6.7e-05	1.01	0.61	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41264550~41264862:-
LAML	cis	rs4591358	0.689	rs72927705	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518341	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs72927707	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518526	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs16836823	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518785	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs57244991	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519331	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs72927708	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519789	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs72927711	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520309	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs72927717	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520887	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.648	rs16836855	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522267	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs72927725	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529140	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs7574191	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529995	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.648	rs1515877	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530995	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs16837006	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533245	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs16837010	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533302	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs16837051	ENSG00000223466.1	AC064834.2	-6.48	9.87e-09	6.71e-05	-0.88	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195536281	chr2:195533035~195538681:+
LAML	cis	rs9309473	0.861	rs6546856	ENSG00000163016.8	ALMS1P	6.48	9.9e-09	6.73e-05	0.69	0.61	Metabolite levels;	chr2:73610624	chr2:73644919~73685576:+
LAML	cis	rs5769707	0.967	rs17182154	ENSG00000212939.2	RP1-29C18.10	-6.48	9.98e-09	6.78e-05	-0.7	-0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49548681~49556473:+
LAML	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	6.48	1.01e-08	6.82e-05	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
LAML	cis	rs5769707	0.967	rs763126	ENSG00000212939.2	RP1-29C18.10	6.48	1.01e-08	6.83e-05	0.72	0.61	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49548681~49556473:+
LAML	cis	rs16828019	0.704	rs12024115	ENSG00000213987.4	RP11-399E6.2	6.48	1.01e-08	6.84e-05	1.02	0.61	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41264550~41264862:-
LAML	cis	rs2015599	0.549	rs7956305	ENSG00000257176.2	RP11-996F15.2	6.47	1.01e-08	6.85e-05	0.63	0.61	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.543	rs6487807	ENSG00000257176.2	RP11-996F15.2	6.47	1.01e-08	6.85e-05	0.63	0.61	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.525	rs10771514	ENSG00000257176.2	RP11-996F15.2	6.47	1.01e-08	6.85e-05	0.63	0.61	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.525	rs7298031	ENSG00000257176.2	RP11-996F15.2	6.47	1.01e-08	6.85e-05	0.63	0.61	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.525	rs2016832	ENSG00000257176.2	RP11-996F15.2	6.47	1.01e-08	6.85e-05	0.63	0.61	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.525	rs7959145	ENSG00000257176.2	RP11-996F15.2	6.47	1.01e-08	6.85e-05	0.63	0.61	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.525	rs7961943	ENSG00000257176.2	RP11-996F15.2	6.47	1.01e-08	6.85e-05	0.63	0.61	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.525	rs10743656	ENSG00000257176.2	RP11-996F15.2	6.47	1.01e-08	6.85e-05	0.63	0.61	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29280418~29317848:-
LAML	cis	rs6597981	0.592	rs10902218	ENSG00000279672.1	CMB9-55F22.1	-6.47	1.02e-08	6.86e-05	-0.56	-0.61	Breast cancer;	chr11:743813	chr11:779617~780755:+
LAML	cis	rs2929278	0.638	rs2016840	ENSG00000249839.1	AC011330.5	6.47	1.02e-08	6.87e-05	0.75	0.61	Schizophrenia;	chr15:43919670	chr15:43663654~43684339:-
LAML	cis	rs16828019	0.632	rs12749196	ENSG00000213987.4	RP11-399E6.2	6.47	1.03e-08	6.94e-05	1.12	0.61	Intelligence (multi-trait analysis);	chr1:40995111	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs12047657	ENSG00000213987.4	RP11-399E6.2	6.47	1.03e-08	6.94e-05	1.12	0.61	Intelligence (multi-trait analysis);	chr1:40995841	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.85	rs12027691	ENSG00000213987.4	RP11-399E6.2	6.47	1.03e-08	6.94e-05	1.12	0.61	Intelligence (multi-trait analysis);	chr1:40996360	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs12047078	ENSG00000213987.4	RP11-399E6.2	6.47	1.03e-08	6.94e-05	1.12	0.61	Intelligence (multi-trait analysis);	chr1:40997314	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs12739052	ENSG00000213987.4	RP11-399E6.2	6.47	1.03e-08	6.94e-05	1.12	0.61	Intelligence (multi-trait analysis);	chr1:40998783	chr1:41264550~41264862:-
LAML	cis	rs16828019	0.777	rs12748235	ENSG00000213987.4	RP11-399E6.2	6.47	1.03e-08	6.94e-05	1.12	0.61	Intelligence (multi-trait analysis);	chr1:41000549	chr1:41264550~41264862:-
LAML	cis	rs2015599	0.56	rs11050147	ENSG00000275476.1	RP11-996F15.4	-6.47	1.03e-08	6.95e-05	-0.69	-0.61	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.56	rs3948497	ENSG00000275476.1	RP11-996F15.4	-6.47	1.03e-08	6.95e-05	-0.69	-0.61	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29277397~29277882:-
LAML	cis	rs9457247	0.602	rs17615336	ENSG00000265828.1	MIR3939	-6.47	1.05e-08	7.05e-05	-0.95	-0.61	Crohn's disease;	chr6:167093246	chr6:166997807~166997912:-
LAML	cis	rs6452524	0.901	rs1842020	ENSG00000249664.1	CTD-2227C6.2	6.47	1.05e-08	7.05e-05	0.83	0.61	Hypertension (SNP x SNP interaction);	chr5:83125814	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.934	rs1120476	ENSG00000249664.1	CTD-2227C6.2	6.47	1.05e-08	7.05e-05	0.83	0.61	Hypertension (SNP x SNP interaction);	chr5:83126824	chr5:83012285~83013109:-
LAML	cis	rs3096299	0.738	rs9929606	ENSG00000274627.1	RP11-104N10.2	6.47	1.05e-08	7.1e-05	0.73	0.61	Multiple myeloma (IgH translocation);	chr16:89461129	chr16:89516797~89522217:+
LAML	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-6.46	1.05e-08	7.1e-05	-0.72	-0.61	Height;	chr3:53093751	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-6.46	1.05e-08	7.1e-05	-0.72	-0.61	Height;	chr3:53094335	chr3:53064283~53065091:-
LAML	cis	rs7587476	0.765	rs2121284	ENSG00000229267.2	AC072062.1	6.46	1.05e-08	7.1e-05	0.67	0.61	Neuroblastoma;	chr2:214791536	chr2:214810229~214963274:+
LAML	cis	rs4273100	0.688	rs12938803	ENSG00000262319.1	CTC-457L16.2	6.46	1.06e-08	7.15e-05	0.89	0.61	Schizophrenia;	chr17:19301119	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.646	rs2296981	ENSG00000262319.1	CTC-457L16.2	6.46	1.06e-08	7.15e-05	0.89	0.61	Schizophrenia;	chr17:19310022	chr17:19141017~19143689:-
LAML	cis	rs9309473	0.95	rs6546847	ENSG00000163016.8	ALMS1P	6.46	1.07e-08	7.19e-05	0.67	0.61	Metabolite levels;	chr2:73558231	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs7580750	ENSG00000163016.8	ALMS1P	6.46	1.07e-08	7.19e-05	0.67	0.61	Metabolite levels;	chr2:73560999	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs11126403	ENSG00000163016.8	ALMS1P	6.46	1.07e-08	7.19e-05	0.67	0.61	Metabolite levels;	chr2:73569796	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs11126404	ENSG00000163016.8	ALMS1P	6.46	1.07e-08	7.19e-05	0.67	0.61	Metabolite levels;	chr2:73569797	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs2421555	ENSG00000163016.8	ALMS1P	6.46	1.07e-08	7.19e-05	0.67	0.61	Metabolite levels;	chr2:73589828	chr2:73644919~73685576:+
LAML	cis	rs3758911	0.751	rs590699	ENSG00000261098.1	RP11-819C21.1	6.46	1.08e-08	7.23e-05	0.6	0.61	Coronary artery disease;	chr11:107447553	chr11:107312132~107316271:-
LAML	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-6.46	1.08e-08	7.24e-05	-0.79	-0.61	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
LAML	cis	rs4713118	0.866	rs9468217	ENSG00000220721.1	OR1F12	6.46	1.08e-08	7.24e-05	0.71	0.61	Parkinson's disease;	chr6:27758688	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.911	rs9295746	ENSG00000220721.1	OR1F12	6.46	1.08e-08	7.24e-05	0.71	0.61	Parkinson's disease;	chr6:27762285	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.911	rs9461406	ENSG00000220721.1	OR1F12	-6.46	1.08e-08	7.24e-05	-0.71	-0.61	Parkinson's disease;	chr6:27751985	chr6:28073316~28074233:+
LAML	cis	rs7617773	1	rs6442108	ENSG00000229759.1	MRPS18AP1	-6.46	1.08e-08	7.24e-05	-0.74	-0.61	Coronary artery disease;	chr3:48151469	chr3:48256350~48256938:-
LAML	cis	rs7617773	1	rs6442109	ENSG00000229759.1	MRPS18AP1	-6.46	1.08e-08	7.24e-05	-0.74	-0.61	Coronary artery disease;	chr3:48151491	chr3:48256350~48256938:-
LAML	cis	rs7617773	1	rs11711766	ENSG00000229759.1	MRPS18AP1	-6.46	1.08e-08	7.24e-05	-0.74	-0.61	Coronary artery disease;	chr3:48151680	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.963	rs6771787	ENSG00000229759.1	MRPS18AP1	-6.46	1.08e-08	7.24e-05	-0.74	-0.61	Coronary artery disease;	chr3:48152752	chr3:48256350~48256938:-
LAML	cis	rs7617773	1	rs6771889	ENSG00000229759.1	MRPS18AP1	-6.46	1.08e-08	7.24e-05	-0.74	-0.61	Coronary artery disease;	chr3:48152836	chr3:48256350~48256938:-
LAML	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	6.46	1.09e-08	7.29e-05	0.83	0.61	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
LAML	cis	rs2929278	0.588	rs688009	ENSG00000249839.1	AC011330.5	-6.46	1.09e-08	7.32e-05	-0.75	-0.61	Schizophrenia;	chr15:43864104	chr15:43663654~43684339:-
LAML	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-6.46	1.1e-08	7.33e-05	-0.78	-0.61	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-6.46	1.1e-08	7.33e-05	-0.78	-0.61	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-6.46	1.1e-08	7.33e-05	-0.78	-0.61	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-6.46	1.1e-08	7.33e-05	-0.78	-0.61	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
LAML	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-6.46	1.1e-08	7.33e-05	-0.42	-0.61	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
LAML	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	6.46	1.1e-08	7.33e-05	0.42	0.61	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	6.46	1.1e-08	7.33e-05	0.42	0.61	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	6.46	1.1e-08	7.33e-05	0.42	0.61	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	6.46	1.1e-08	7.33e-05	0.42	0.61	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	6.46	1.1e-08	7.33e-05	0.42	0.61	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	6.46	1.1e-08	7.33e-05	0.42	0.61	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	6.46	1.1e-08	7.33e-05	0.42	0.61	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.55	rs3803657	ENSG00000279344.1	RP11-44F14.7	6.46	1.1e-08	7.33e-05	0.42	0.61	Intelligence (multi-trait analysis);	chr16:53482047	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs7199401	ENSG00000279344.1	RP11-44F14.7	6.46	1.1e-08	7.33e-05	0.42	0.61	Intelligence (multi-trait analysis);	chr16:53483038	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs8046307	ENSG00000279344.1	RP11-44F14.7	6.46	1.1e-08	7.33e-05	0.42	0.61	Intelligence (multi-trait analysis);	chr16:53484774	chr16:53478957~53481550:-
LAML	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	6.45	1.11e-08	7.39e-05	0.79	0.61	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
LAML	cis	rs6452524	0.868	rs1011981	ENSG00000249664.1	CTD-2227C6.2	6.45	1.11e-08	7.39e-05	0.83	0.61	Hypertension (SNP x SNP interaction);	chr5:83097869	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.868	rs17284218	ENSG00000249664.1	CTD-2227C6.2	6.45	1.11e-08	7.39e-05	0.83	0.61	Hypertension (SNP x SNP interaction);	chr5:83099530	chr5:83012285~83013109:-
LAML	cis	rs3136516	0.935	rs11038993	ENSG00000271350.1	CTD-2384B9.1	6.45	1.11e-08	7.39e-05	0.59	0.61	Venous thromboembolism;	chr11:46789366	chr11:47041027~47041945:-
LAML	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	6.45	1.13e-08	7.51e-05	0.7	0.61	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	6.45	1.13e-08	7.51e-05	0.7	0.61	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
LAML	cis	rs4591358	0.871	rs1500608	ENSG00000223466.1	AC064834.2	-6.45	1.13e-08	7.53e-05	-0.78	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195482075	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.834	rs4850621	ENSG00000223466.1	AC064834.2	-6.45	1.13e-08	7.53e-05	-0.78	-0.61	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195484850	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.68	rs12995102	ENSG00000223466.1	AC064834.2	-6.45	1.14e-08	7.56e-05	-0.92	-0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195447752	chr2:195533035~195538681:+
LAML	cis	rs7746199	0.673	rs72847313	ENSG00000220721.1	OR1F12	6.45	1.14e-08	7.57e-05	0.96	0.6	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.611	rs17750747	ENSG00000220721.1	OR1F12	6.45	1.14e-08	7.57e-05	0.96	0.6	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.673	rs35501037	ENSG00000220721.1	OR1F12	6.45	1.14e-08	7.57e-05	0.96	0.6	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28073316~28074233:+
LAML	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-6.45	1.14e-08	7.57e-05	-0.75	-0.6	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	6.45	1.14e-08	7.57e-05	0.75	0.6	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
LAML	cis	rs9326248	0.689	rs236916	ENSG00000254851.1	RP11-109L13.1	6.45	1.14e-08	7.58e-05	1.02	0.6	Blood protein levels;	chr11:117218912	chr11:117135528~117138582:+
LAML	cis	rs2929278	0.546	rs686666	ENSG00000249839.1	AC011330.5	-6.45	1.14e-08	7.59e-05	-0.75	-0.6	Schizophrenia;	chr15:43869352	chr15:43663654~43684339:-
LAML	cis	rs2516839	0.652	rs2516841	ENSG00000232879.2	RP11-544M22.3	-6.45	1.14e-08	7.59e-05	-0.8	-0.6	Granulocyte percentage of myeloid white cells;	chr1:161040984	chr1:161034834~161035006:+
LAML	cis	rs2516839	0.652	rs2774276	ENSG00000232879.2	RP11-544M22.3	-6.45	1.14e-08	7.59e-05	-0.8	-0.6	Granulocyte percentage of myeloid white cells;	chr1:161041926	chr1:161034834~161035006:+
LAML	cis	rs4591358	0.549	rs10200021	ENSG00000223466.1	AC064834.2	-6.44	1.15e-08	7.63e-05	-0.92	-0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549863	chr2:195533035~195538681:+
LAML	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-6.44	1.16e-08	7.67e-05	-0.76	-0.6	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
LAML	cis	rs6456156	0.565	rs12525345	ENSG00000265828.1	MIR3939	-6.44	1.16e-08	7.7e-05	-0.93	-0.6	Primary biliary cholangitis;	chr6:167065387	chr6:166997807~166997912:-
LAML	cis	rs9309473	0.948	rs10170849	ENSG00000163016.8	ALMS1P	6.44	1.17e-08	7.74e-05	0.67	0.6	Metabolite levels;	chr2:73520805	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.948	rs6719753	ENSG00000163016.8	ALMS1P	6.44	1.17e-08	7.74e-05	0.67	0.6	Metabolite levels;	chr2:73521927	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs7567585	ENSG00000163016.8	ALMS1P	6.44	1.17e-08	7.74e-05	0.67	0.6	Metabolite levels;	chr2:73524839	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.948	rs7566385	ENSG00000163016.8	ALMS1P	6.44	1.17e-08	7.74e-05	0.67	0.6	Metabolite levels;	chr2:73529690	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs3738848	ENSG00000163016.8	ALMS1P	6.44	1.17e-08	7.74e-05	0.67	0.6	Metabolite levels;	chr2:73534754	chr2:73644919~73685576:+
LAML	cis	rs4500972	1	rs4500972	ENSG00000163016.8	ALMS1P	6.44	1.17e-08	7.74e-05	0.67	0.6	Glomerular filtration rate (creatinine);	chr2:73540770	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs10496193	ENSG00000163016.8	ALMS1P	6.44	1.17e-08	7.74e-05	0.67	0.6	Metabolite levels;	chr2:73546376	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7604682	ENSG00000163016.8	ALMS1P	6.44	1.17e-08	7.74e-05	0.67	0.6	Metabolite levels;	chr2:73560899	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs10170786	ENSG00000163016.8	ALMS1P	6.44	1.17e-08	7.74e-05	0.67	0.6	Metabolite levels;	chr2:73585861	chr2:73644919~73685576:+
LAML	cis	rs5769707	1	rs5769707	ENSG00000212939.2	RP1-29C18.10	-6.44	1.18e-08	7.78e-05	-0.74	-0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.935	rs1109320	ENSG00000212939.2	RP1-29C18.10	-6.44	1.18e-08	7.78e-05	-0.71	-0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49548681~49556473:+
LAML	cis	rs4803480	0.678	rs3745936	ENSG00000239736.2	CEACAMP3	-6.44	1.18e-08	7.8e-05	-0.81	-0.6	Schizophrenia;	chr19:41586462	chr19:41599735~41605984:+
LAML	cis	rs4853012	0.887	rs7570950	ENSG00000217702.2	RP11-287D1.4	6.44	1.19e-08	7.87e-05	0.94	0.6	Gestational age at birth (maternal effect);	chr2:74111815	chr2:74130583~74135395:+
LAML	cis	rs904251	0.523	rs10947675	ENSG00000227920.2	RP1-153P14.5	-6.44	1.19e-08	7.88e-05	-0.67	-0.6	Cognitive performance;	chr6:37512196	chr6:37545145~37550860:+
LAML	cis	rs2929278	0.617	rs533143	ENSG00000249839.1	AC011330.5	-6.43	1.2e-08	7.89e-05	-0.7	-0.6	Schizophrenia;	chr15:43896656	chr15:43663654~43684339:-
LAML	cis	rs904251	0.861	rs1757183	ENSG00000227920.2	RP1-153P14.5	6.43	1.2e-08	7.92e-05	0.75	0.6	Cognitive performance;	chr6:37517014	chr6:37545145~37550860:+
LAML	cis	rs904251	0.861	rs1757180	ENSG00000227920.2	RP1-153P14.5	-6.43	1.2e-08	7.92e-05	-0.75	-0.6	Cognitive performance;	chr6:37518369	chr6:37545145~37550860:+
LAML	cis	rs6452524	0.934	rs6452510	ENSG00000249664.1	CTD-2227C6.2	6.43	1.2e-08	7.93e-05	0.83	0.6	Hypertension (SNP x SNP interaction);	chr5:83127401	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	6.43	1.21e-08	7.94e-05	0.81	0.6	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.532	rs26263	ENSG00000249664.1	CTD-2227C6.2	6.43	1.21e-08	7.94e-05	0.81	0.6	Hypertension (SNP x SNP interaction);	chr5:83044465	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.537	rs1583	ENSG00000249664.1	CTD-2227C6.2	6.43	1.21e-08	7.99e-05	0.79	0.6	Hypertension (SNP x SNP interaction);	chr5:83052403	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.506	rs7891	ENSG00000249664.1	CTD-2227C6.2	6.43	1.21e-08	7.99e-05	0.79	0.6	Hypertension (SNP x SNP interaction);	chr5:83053558	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.534	rs7724935	ENSG00000249664.1	CTD-2227C6.2	6.43	1.21e-08	7.99e-05	0.79	0.6	Hypertension (SNP x SNP interaction);	chr5:83057264	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.506	rs7707143	ENSG00000249664.1	CTD-2227C6.2	6.43	1.21e-08	7.99e-05	0.79	0.6	Hypertension (SNP x SNP interaction);	chr5:83057268	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.563	rs10473863	ENSG00000249664.1	CTD-2227C6.2	6.43	1.21e-08	7.99e-05	0.79	0.6	Hypertension (SNP x SNP interaction);	chr5:83057500	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.534	rs72765386	ENSG00000249664.1	CTD-2227C6.2	6.43	1.21e-08	7.99e-05	0.79	0.6	Hypertension (SNP x SNP interaction);	chr5:83061502	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.534	rs9293328	ENSG00000249664.1	CTD-2227C6.2	6.43	1.21e-08	7.99e-05	0.79	0.6	Hypertension (SNP x SNP interaction);	chr5:83066855	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.534	rs11746747	ENSG00000249664.1	CTD-2227C6.2	6.43	1.21e-08	7.99e-05	0.79	0.6	Hypertension (SNP x SNP interaction);	chr5:83067666	chr5:83012285~83013109:-
LAML	cis	rs9457247	0.565	rs2038580	ENSG00000265828.1	MIR3939	-6.43	1.22e-08	8.06e-05	-0.86	-0.6	Crohn's disease;	chr6:167043002	chr6:166997807~166997912:-
LAML	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-6.43	1.23e-08	8.11e-05	-0.75	-0.6	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
LAML	cis	rs3136516	0.935	rs4506602	ENSG00000271350.1	CTD-2384B9.1	-6.43	1.24e-08	8.17e-05	-0.58	-0.6	Venous thromboembolism;	chr11:46794083	chr11:47041027~47041945:-
LAML	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-6.42	1.28e-08	8.33e-05	-0.66	-0.6	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.66	0.6	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6546835	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.66	0.6	Metabolite levels;	chr2:73437587	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs2901438	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.66	0.6	Metabolite levels;	chr2:73438528	chr2:73644919~73685576:+
LAML	cis	rs6565180	0.888	rs13333093	ENSG00000273724.1	RP11-347C12.12	6.42	1.28e-08	8.33e-05	0.62	0.6	Tonsillectomy;	chr16:30395948	chr16:30336400~30343336:+
LAML	cis	rs6565180	0.888	rs12921440	ENSG00000273724.1	RP11-347C12.12	6.42	1.28e-08	8.33e-05	0.62	0.6	Tonsillectomy;	chr16:30397444	chr16:30336400~30343336:+
LAML	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	6.42	1.28e-08	8.33e-05	0.83	0.6	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-6.42	1.28e-08	8.33e-05	-0.83	-0.6	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-6.42	1.28e-08	8.33e-05	-0.83	-0.6	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
LAML	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	6.42	1.28e-08	8.33e-05	0.68	0.6	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	6.42	1.29e-08	8.4e-05	0.66	0.6	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs2140195	ENSG00000163016.8	ALMS1P	6.42	1.29e-08	8.4e-05	0.66	0.6	Metabolite levels;	chr2:73475217	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	6.42	1.3e-08	8.43e-05	0.7	0.6	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
LAML	cis	rs6456156	0.586	rs10946208	ENSG00000265828.1	MIR3939	-6.41	1.31e-08	8.48e-05	-0.91	-0.6	Primary biliary cholangitis;	chr6:167046108	chr6:166997807~166997912:-
LAML	cis	rs2015599	0.54	rs12301475	ENSG00000275476.1	RP11-996F15.4	6.41	1.32e-08	8.52e-05	0.68	0.6	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29277397~29277882:-
LAML	cis	rs853679	0.824	rs34712084	ENSG00000220721.1	OR1F12	6.41	1.32e-08	8.55e-05	0.94	0.6	Depression;	chr6:28076050	chr6:28073316~28074233:+
LAML	cis	rs853679	0.824	rs1321505	ENSG00000220721.1	OR1F12	6.41	1.32e-08	8.55e-05	0.94	0.6	Depression;	chr6:28085045	chr6:28073316~28074233:+
LAML	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-6.41	1.33e-08	8.57e-05	-0.78	-0.6	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-6.41	1.33e-08	8.57e-05	-0.78	-0.6	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-6.41	1.33e-08	8.57e-05	-0.78	-0.6	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-6.41	1.33e-08	8.57e-05	-0.78	-0.6	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-6.41	1.35e-08	8.73e-05	-0.74	-0.6	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
LAML	cis	rs9309473	1	rs10189574	ENSG00000163016.8	ALMS1P	6.41	1.35e-08	8.74e-05	0.67	0.6	Metabolite levels;	chr2:73471391	chr2:73644919~73685576:+
LAML	cis	rs9457247	0.565	rs2239824	ENSG00000265828.1	MIR3939	-6.4	1.36e-08	8.77e-05	-0.93	-0.6	Crohn's disease;	chr6:167098311	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.565	rs12193698	ENSG00000265828.1	MIR3939	-6.4	1.36e-08	8.77e-05	-0.93	-0.6	Crohn's disease;	chr6:167098585	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.565	rs2239823	ENSG00000265828.1	MIR3939	-6.4	1.36e-08	8.77e-05	-0.93	-0.6	Crohn's disease;	chr6:167098643	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.565	rs12178491	ENSG00000265828.1	MIR3939	-6.4	1.36e-08	8.77e-05	-0.93	-0.6	Crohn's disease;	chr6:167098986	chr6:166997807~166997912:-
LAML	cis	rs4713118	0.868	rs10484401	ENSG00000220721.1	OR1F12	-6.4	1.36e-08	8.78e-05	-0.75	-0.6	Parkinson's disease;	chr6:27778811	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.868	rs35069907	ENSG00000220721.1	OR1F12	6.4	1.36e-08	8.78e-05	0.75	0.6	Parkinson's disease;	chr6:27778913	chr6:28073316~28074233:+
LAML	cis	rs853679	0.769	rs17720293	ENSG00000220721.1	OR1F12	6.4	1.36e-08	8.79e-05	0.93	0.6	Depression;	chr6:28246920	chr6:28073316~28074233:+
LAML	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-6.4	1.36e-08	8.8e-05	-0.88	-0.6	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
LAML	cis	rs7131987	0.565	rs7974254	ENSG00000257176.2	RP11-996F15.2	6.4	1.37e-08	8.85e-05	0.63	0.6	QT interval;	chr12:29246592	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs6487787	ENSG00000257176.2	RP11-996F15.2	6.4	1.37e-08	8.85e-05	0.63	0.6	QT interval;	chr12:29248353	chr12:29280418~29317848:-
LAML	cis	rs7131987	0.565	rs6487791	ENSG00000257176.2	RP11-996F15.2	6.4	1.37e-08	8.85e-05	0.63	0.6	QT interval;	chr12:29250989	chr12:29280418~29317848:-
LAML	cis	rs1757171	0.504	rs11969056	ENSG00000204110.6	RP1-153P14.8	-6.4	1.38e-08	8.88e-05	-0.72	-0.6	Cognitive performance;	chr6:37516509	chr6:37507348~37535616:+
LAML	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-6.4	1.38e-08	8.88e-05	-0.69	-0.6	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
LAML	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-6.4	1.38e-08	8.9e-05	-0.76	-0.6	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	6.4	1.38e-08	8.9e-05	0.76	0.6	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
LAML	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	6.4	1.38e-08	8.9e-05	0.65	0.6	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs9807961	ENSG00000163016.8	ALMS1P	6.4	1.38e-08	8.9e-05	0.65	0.6	Metabolite levels;	chr2:73466916	chr2:73644919~73685576:+
LAML	cis	rs2564921	0.73	rs2564922	ENSG00000280417.1	RP11-5O17.1	6.4	1.38e-08	8.92e-05	0.86	0.6	Height;	chr3:53091453	chr3:53046166~53048122:+
LAML	cis	rs904251	0.523	rs914348	ENSG00000204110.6	RP1-153P14.8	-6.4	1.39e-08	8.93e-05	-0.69	-0.6	Cognitive performance;	chr6:37516953	chr6:37507348~37535616:+
LAML	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-6.4	1.39e-08	8.96e-05	-0.72	-0.6	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
LAML	cis	rs16828019	0.852	rs11209531	ENSG00000213987.4	RP11-399E6.2	6.4	1.4e-08	8.98e-05	1	0.6	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41264550~41264862:-
LAML	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	6.4	1.4e-08	9e-05	0.72	0.6	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	6.4	1.4e-08	9e-05	0.72	0.6	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	6.4	1.4e-08	9e-05	0.72	0.6	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	6.4	1.4e-08	9e-05	0.72	0.6	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
LAML	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	6.4	1.4e-08	9.02e-05	0.71	0.6	Height;	chr3:53085313	chr3:53064283~53065091:-
LAML	cis	rs904251	0.504	rs12202664	ENSG00000227920.2	RP1-153P14.5	-6.4	1.41e-08	9.02e-05	-0.66	-0.6	Cognitive performance;	chr6:37513422	chr6:37545145~37550860:+
LAML	cis	rs853679	0.882	rs9468287	ENSG00000220721.1	OR1F12	6.39	1.41e-08	9.08e-05	0.93	0.6	Depression;	chr6:28111963	chr6:28073316~28074233:+
LAML	cis	rs9309473	1	rs10175180	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73445995	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs10496191	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73446670	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6546836	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73450706	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6546837	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73450771	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6546838	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73452153	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6724782	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73452863	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6546839	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73453381	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6756987	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73459950	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs10186501	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73470717	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs11901272	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73493317	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs58603761	ENSG00000163016.8	ALMS1P	6.39	1.46e-08	9.32e-05	0.66	0.6	Metabolite levels;	chr2:73499478	chr2:73644919~73685576:+
LAML	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	6.39	1.46e-08	9.35e-05	0.79	0.6	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	6.39	1.46e-08	9.35e-05	0.79	0.6	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
LAML	cis	rs6456156	0.586	rs9459862	ENSG00000265828.1	MIR3939	6.39	1.47e-08	9.37e-05	0.92	0.6	Primary biliary cholangitis;	chr6:167073523	chr6:166997807~166997912:-
LAML	cis	rs5769707	0.967	rs9616713	ENSG00000279597.1	RP4-566L20.1	-6.39	1.47e-08	9.38e-05	-0.68	-0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49534062~49534926:+
LAML	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	6.38	1.47e-08	9.4e-05	0.82	0.6	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	6.38	1.47e-08	9.4e-05	0.82	0.6	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	6.38	1.47e-08	9.4e-05	0.82	0.6	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	6.38	1.47e-08	9.4e-05	0.82	0.6	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	6.38	1.47e-08	9.4e-05	0.82	0.6	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	6.38	1.47e-08	9.4e-05	0.82	0.6	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	6.38	1.47e-08	9.4e-05	0.82	0.6	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	6.38	1.47e-08	9.4e-05	0.82	0.6	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	6.38	1.47e-08	9.4e-05	0.82	0.6	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
LAML	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	6.38	1.48e-08	9.42e-05	0.93	0.6	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
LAML	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	6.38	1.48e-08	9.42e-05	0.93	0.6	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
LAML	cis	rs66887589	0.616	rs6822808	ENSG00000248280.1	RP11-33B1.2	6.38	1.49e-08	9.49e-05	0.71	0.6	Diastolic blood pressure;	chr4:119296210	chr4:119440561~119450157:-
LAML	cis	rs5769707	0.839	rs73176988	ENSG00000212939.2	RP1-29C18.10	-6.38	1.49e-08	9.51e-05	-0.71	-0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49548681~49556473:+
LAML	cis	rs904251	0.797	rs1757181	ENSG00000227920.2	RP1-153P14.5	6.38	1.5e-08	9.55e-05	0.74	0.6	Cognitive performance;	chr6:37517952	chr6:37545145~37550860:+
LAML	cis	rs904251	0.861	rs914349	ENSG00000227920.2	RP1-153P14.5	-6.38	1.51e-08	9.64e-05	-0.74	-0.6	Cognitive performance;	chr6:37516939	chr6:37545145~37550860:+
LAML	cis	rs2273156	0.57	rs941653	ENSG00000241052.1	RP11-173D9.1	-6.38	1.51e-08	9.65e-05	-1.04	-0.6	Immunoglobulin light chain (AL) amyloidosis;	chr14:35123332	chr14:35144021~35144480:-
LAML	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	6.38	1.53e-08	9.75e-05	0.61	0.6	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
LAML	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	6.37	1.55e-08	9.84e-05	0.75	0.6	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
LAML	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	6.37	1.55e-08	9.86e-05	0.75	0.6	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	6.37	1.55e-08	9.86e-05	0.75	0.6	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
LAML	cis	rs1555322	0.53	rs6058224	ENSG00000279253.1	RP4-614O4.13	-6.37	1.56e-08	9.89e-05	-0.68	-0.6	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35262727~35264187:-
LAML	cis	rs1555322	0.53	rs2425053	ENSG00000279253.1	RP4-614O4.13	-6.37	1.56e-08	9.89e-05	-0.68	-0.6	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35262727~35264187:-
LAML	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	6.37	1.56e-08	9.92e-05	0.82	0.6	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	6.37	1.56e-08	9.92e-05	0.82	0.6	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
LAML	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-6.37	1.57e-08	9.95e-05	-0.75	-0.6	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
LAML	cis	rs911555	0.511	rs8007489	ENSG00000258851.1	RP11-894P9.2	6.37	1.57e-08	9.95e-05	0.68	0.6	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103553421~103561877:+
LAML	cis	rs9457247	0.602	rs10484530	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167048074	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.602	rs12209395	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167050426	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.544	rs6920858	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167051142	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.602	rs9459854	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167052394	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.582	rs9459855	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167052662	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.624	rs9457260	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167053177	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.624	rs17524252	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167053490	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.602	rs4710175	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167054312	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.561	rs916331	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167057071	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.602	rs13204839	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167057631	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.602	rs6456152	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167058574	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.602	rs9457262	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Crohn's disease;	chr6:167060197	chr6:166997807~166997912:-
LAML	cis	rs3093024	0.595	rs4412174	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Rheumatoid arthritis;	chr6:167062578	chr6:166997807~166997912:-
LAML	cis	rs3093024	0.595	rs4458654	ENSG00000265828.1	MIR3939	-6.37	1.59e-08	0.000101	-0.89	-0.6	Rheumatoid arthritis;	chr6:167062580	chr6:166997807~166997912:-
LAML	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-6.37	1.6e-08	0.000101	-0.72	-0.6	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
LAML	cis	rs4713118	0.662	rs149900	ENSG00000220721.1	OR1F12	6.36	1.61e-08	0.000101	0.8	0.6	Parkinson's disease;	chr6:28046819	chr6:28073316~28074233:+
LAML	cis	rs4591358	0.731	rs34634374	ENSG00000223466.1	AC064834.2	-6.36	1.61e-08	0.000102	-0.89	-0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509437	chr2:195533035~195538681:+
LAML	cis	rs5769707	0.521	rs739244	ENSG00000280224.1	CTA-722E9.1	-6.36	1.62e-08	0.000102	-0.8	-0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49500568~49501585:+
LAML	cis	rs7847628	0.666	rs2031974	ENSG00000226752.6	PSMD5-AS1	-6.36	1.62e-08	0.000102	-0.79	-0.6	Birth weight;	chr9:120765243	chr9:120824828~120854385:+
LAML	cis	rs6782228	1	rs6782228	ENSG00000242551.2	POU5F1P6	6.36	1.62e-08	0.000102	0.87	0.6	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128604581	chr3:128674735~128677005:-
LAML	cis	rs1555322	0.53	rs8122819	ENSG00000279253.1	RP4-614O4.13	-6.36	1.63e-08	0.000102	-0.68	-0.6	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35262727~35264187:-
LAML	cis	rs9309473	1	rs13384952	ENSG00000163016.8	ALMS1P	-6.36	1.63e-08	0.000102	-0.67	-0.6	Metabolite levels;	chr2:73496832	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7607014	ENSG00000163016.8	ALMS1P	-6.36	1.63e-08	0.000102	-0.67	-0.6	Metabolite levels;	chr2:73503047	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.948	rs7607892	ENSG00000163016.8	ALMS1P	6.36	1.63e-08	0.000102	0.67	0.6	Metabolite levels;	chr2:73591580	chr2:73644919~73685576:+
LAML	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-6.36	1.64e-08	0.000102	-0.73	-0.6	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
LAML	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
LAML	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
LAML	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
LAML	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
LAML	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
LAML	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
LAML	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
LAML	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
LAML	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
LAML	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
LAML	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-6.36	1.64e-08	0.000102	-0.74	-0.6	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
LAML	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-6.36	1.64e-08	0.000103	-0.74	-0.6	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
LAML	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-6.36	1.64e-08	0.000103	-0.51	-0.6	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-6.36	1.64e-08	0.000103	-0.51	-0.6	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	6.36	1.64e-08	0.000103	0.51	0.6	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-6.36	1.64e-08	0.000103	-0.51	-0.6	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-6.36	1.64e-08	0.000103	-0.51	-0.6	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-6.36	1.64e-08	0.000103	-0.51	-0.6	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-6.36	1.64e-08	0.000103	-0.51	-0.6	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-6.36	1.64e-08	0.000103	-0.51	-0.6	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-6.36	1.64e-08	0.000103	-0.51	-0.6	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
LAML	cis	rs4591358	0.773	rs17781713	ENSG00000223466.1	AC064834.2	-6.36	1.66e-08	0.000104	-0.85	-0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506827	chr2:195533035~195538681:+
LAML	cis	rs853679	0.556	rs45509595	ENSG00000220721.1	OR1F12	6.36	1.66e-08	0.000104	0.96	0.6	Depression;	chr6:27873148	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs66868086	ENSG00000220721.1	OR1F12	6.36	1.66e-08	0.000104	0.96	0.6	Depression;	chr6:27898124	chr6:28073316~28074233:+
LAML	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-6.35	1.72e-08	0.000107	-0.71	-0.6	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
LAML	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-6.35	1.72e-08	0.000107	-0.75	-0.6	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
LAML	cis	rs5769707	0.622	rs2018467	ENSG00000212939.2	RP1-29C18.10	-6.35	1.73e-08	0.000107	-0.62	-0.6	Monocyte percentage of white cells;Monocyte count;	chr22:49670631	chr22:49548681~49556473:+
LAML	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	6.35	1.73e-08	0.000107	0.42	0.6	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	6.35	1.73e-08	0.000107	0.42	0.6	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	6.35	1.73e-08	0.000107	0.42	0.6	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	6.35	1.73e-08	0.000107	0.42	0.6	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	6.35	1.73e-08	0.000107	0.42	0.6	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	6.35	1.73e-08	0.000107	0.42	0.6	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
LAML	cis	rs12220777	1	rs11201298	ENSG00000230091.5	TMEM254-AS1	6.35	1.73e-08	0.000108	1.27	0.6	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033995	chr10:80046860~80078912:-
LAML	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-6.35	1.73e-08	0.000108	-0.75	-0.6	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
LAML	cis	rs7189233	0.531	rs9932007	ENSG00000279344.1	RP11-44F14.7	6.35	1.74e-08	0.000108	0.42	0.6	Intelligence (multi-trait analysis);	chr16:53422749	chr16:53478957~53481550:-
LAML	cis	rs4713118	0.662	rs149948	ENSG00000220721.1	OR1F12	6.35	1.74e-08	0.000108	0.76	0.6	Parkinson's disease;	chr6:28007039	chr6:28073316~28074233:+
LAML	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	6.34	1.74e-08	0.000108	0.83	0.6	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
LAML	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-6.34	1.77e-08	0.00011	-0.74	-0.6	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
LAML	cis	rs904251	0.523	rs914348	ENSG00000279942.1	RP1-153P14.7	-6.34	1.77e-08	0.00011	-0.63	-0.6	Cognitive performance;	chr6:37516953	chr6:37567716~37571460:+
LAML	cis	rs6452524	0.934	rs12153179	ENSG00000249664.1	CTD-2227C6.2	6.34	1.77e-08	0.00011	0.84	0.6	Hypertension (SNP x SNP interaction);	chr5:83125109	chr5:83012285~83013109:-
LAML	cis	rs1577917	0.771	rs2842602	ENSG00000203875.9	SNHG5	-6.34	1.78e-08	0.00011	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85622169	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.739	rs2758846	ENSG00000203875.9	SNHG5	-6.34	1.78e-08	0.00011	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85639852	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs4441928	ENSG00000203875.9	SNHG5	6.34	1.78e-08	0.00011	0.74	0.6	Response to antipsychotic treatment;	chr6:85532176	chr6:85660950~85678736:-
LAML	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	6.34	1.78e-08	0.00011	0.84	0.6	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
LAML	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-6.34	1.78e-08	0.00011	-0.79	-0.6	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
LAML	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	6.34	1.8e-08	0.000111	0.78	0.6	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
LAML	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-6.34	1.81e-08	0.000112	-0.75	-0.6	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
LAML	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	6.34	1.81e-08	0.000112	0.78	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
LAML	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	6.34	1.81e-08	0.000112	0.78	0.6	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
LAML	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-6.33	1.82e-08	0.000113	-0.68	-0.6	Height;	chr3:52967831	chr3:53064283~53065091:-
LAML	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	6.33	1.84e-08	0.000114	0.79	0.6	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	6.33	1.84e-08	0.000114	0.79	0.6	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
LAML	cis	rs4591358	0.871	rs6434780	ENSG00000223466.1	AC064834.2	6.33	1.85e-08	0.000114	0.77	0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195470558	chr2:195533035~195538681:+
LAML	cis	rs9309473	1	rs11689392	ENSG00000163016.8	ALMS1P	6.33	1.86e-08	0.000115	0.68	0.6	Metabolite levels;	chr2:73394898	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs10184268	ENSG00000163016.8	ALMS1P	6.33	1.86e-08	0.000115	0.68	0.6	Metabolite levels;	chr2:73399916	chr2:73644919~73685576:+
LAML	cis	rs2564921	0.73	rs62253602	ENSG00000242142.1	SERBP1P3	-6.33	1.86e-08	0.000115	-0.68	-0.6	Height;	chr3:52936861	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.704	rs62253603	ENSG00000242142.1	SERBP1P3	-6.33	1.86e-08	0.000115	-0.68	-0.6	Height;	chr3:52938846	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-6.33	1.86e-08	0.000115	-0.68	-0.6	Height;	chr3:52941053	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-6.33	1.86e-08	0.000115	-0.68	-0.6	Height;	chr3:52949886	chr3:53064283~53065091:-
LAML	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	6.33	1.86e-08	0.000115	0.74	0.6	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
LAML	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-6.33	1.88e-08	0.000116	-0.72	-0.6	Height;	chr3:53070344	chr3:53064283~53065091:-
LAML	cis	rs858239	0.829	rs2268744	ENSG00000230658.1	KLHL7-AS1	6.33	1.89e-08	0.000116	0.82	0.6	Cerebrospinal fluid biomarker levels;	chr7:23292661	chr7:23101228~23105703:-
LAML	cis	rs4591358	0.773	rs17781737	ENSG00000223466.1	AC064834.2	-6.32	1.89e-08	0.000117	-0.85	-0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508251	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.773	rs17177580	ENSG00000223466.1	AC064834.2	6.32	1.89e-08	0.000117	0.85	0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508426	chr2:195533035~195538681:+
LAML	cis	rs7044106	0.791	rs10760116	ENSG00000226752.6	PSMD5-AS1	-6.32	1.9e-08	0.000117	-0.75	-0.6	Hip circumference adjusted for BMI;	chr9:120732403	chr9:120824828~120854385:+
LAML	cis	rs7044106	0.791	rs2900177	ENSG00000226752.6	PSMD5-AS1	-6.32	1.9e-08	0.000117	-0.75	-0.6	Hip circumference adjusted for BMI;	chr9:120735367	chr9:120824828~120854385:+
LAML	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-6.32	1.9e-08	0.000117	-0.73	-0.6	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
LAML	cis	rs853679	0.607	rs34788973	ENSG00000220721.1	OR1F12	6.32	1.91e-08	0.000117	0.94	0.6	Depression;	chr6:27911422	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs61742093	ENSG00000220721.1	OR1F12	6.32	1.91e-08	0.000117	0.94	0.6	Depression;	chr6:27912204	chr6:28073316~28074233:+
LAML	cis	rs1577917	0.771	rs2842608	ENSG00000203875.9	SNHG5	-6.32	1.93e-08	0.000118	-0.74	-0.6	Response to antipsychotic treatment;	chr6:85586140	chr6:85660950~85678736:-
LAML	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-6.32	1.94e-08	0.000119	-0.78	-0.6	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
LAML	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-6.32	1.95e-08	0.000119	-0.72	-0.6	Height;	chr3:53027361	chr3:53064283~53065091:-
LAML	cis	rs904251	0.861	rs1757173	ENSG00000227920.2	RP1-153P14.5	-6.31	1.99e-08	0.000121	-0.74	-0.6	Cognitive performance;	chr6:37519176	chr6:37545145~37550860:+
LAML	cis	rs904251	0.861	rs1757169	ENSG00000227920.2	RP1-153P14.5	-6.31	1.99e-08	0.000121	-0.74	-0.6	Cognitive performance;	chr6:37519300	chr6:37545145~37550860:+
LAML	cis	rs904251	0.861	rs2776877	ENSG00000227920.2	RP1-153P14.5	-6.31	1.99e-08	0.000121	-0.74	-0.6	Cognitive performance;	chr6:37519359	chr6:37545145~37550860:+
LAML	cis	rs904251	0.864	rs2797801	ENSG00000227920.2	RP1-153P14.5	-6.31	1.99e-08	0.000121	-0.74	-0.6	Cognitive performance;	chr6:37519385	chr6:37545145~37550860:+
LAML	cis	rs904251	0.797	rs2776878	ENSG00000227920.2	RP1-153P14.5	-6.31	1.99e-08	0.000121	-0.74	-0.6	Cognitive performance;	chr6:37519497	chr6:37545145~37550860:+
LAML	cis	rs904251	0.828	rs2797803	ENSG00000227920.2	RP1-153P14.5	-6.31	1.99e-08	0.000121	-0.74	-0.6	Cognitive performance;	chr6:37519564	chr6:37545145~37550860:+
LAML	cis	rs904251	0.523	rs1757191	ENSG00000204110.6	RP1-153P14.8	-6.31	2e-08	0.000122	-0.72	-0.6	Cognitive performance;	chr6:37515095	chr6:37507348~37535616:+
LAML	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	6.31	2.01e-08	0.000123	0.69	0.6	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
LAML	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-6.31	2.03e-08	0.000124	-0.73	-0.6	Height;	chr3:52977358	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-6.31	2.05e-08	0.000125	-0.7	-0.6	Height;	chr3:53069965	chr3:53064283~53065091:-
LAML	cis	rs62070183	0.938	rs9911168	ENSG00000265337.1	RP11-466A19.5	6.3	2.06e-08	0.000125	0.95	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709136	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs9912761	ENSG00000265337.1	RP11-466A19.5	6.3	2.06e-08	0.000125	0.95	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709475	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs9303654	ENSG00000265337.1	RP11-466A19.5	6.3	2.06e-08	0.000125	0.95	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709747	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs9898762	ENSG00000265337.1	RP11-466A19.5	6.3	2.06e-08	0.000125	0.95	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32711641	chr17:32529008~32530049:-
LAML	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	6.3	2.07e-08	0.000126	0.7	0.6	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	6.3	2.07e-08	0.000126	0.7	0.6	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	6.3	2.07e-08	0.000126	0.7	0.6	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	6.3	2.07e-08	0.000126	0.7	0.6	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	6.3	2.07e-08	0.000126	0.7	0.6	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	6.3	2.07e-08	0.000126	0.7	0.6	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
LAML	cis	rs904251	0.523	rs2776872	ENSG00000204110.6	RP1-153P14.8	-6.3	2.07e-08	0.000126	-0.72	-0.6	Cognitive performance;	chr6:37515011	chr6:37507348~37535616:+
LAML	cis	rs7131987	0.526	rs7954375	ENSG00000275476.1	RP11-996F15.4	6.3	2.09e-08	0.000127	0.66	0.6	QT interval;	chr12:29241487	chr12:29277397~29277882:-
LAML	cis	rs904251	0.523	rs2776874	ENSG00000227920.2	RP1-153P14.5	-6.3	2.09e-08	0.000127	-0.64	-0.6	Cognitive performance;	chr6:37515421	chr6:37545145~37550860:+
LAML	cis	rs4879656	0.815	rs2774271	ENSG00000225693.1	LAGE3P1	6.3	2.09e-08	0.000127	0.66	0.6	Menopause (age at onset);	chr9:33098774	chr9:33019682~33020165:-
LAML	cis	rs4591358	0.689	rs72927780	ENSG00000223466.1	AC064834.2	-6.3	2.1e-08	0.000128	-0.9	-0.6	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548569	chr2:195533035~195538681:+
LAML	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-6.3	2.11e-08	0.000128	-0.72	-0.6	Height;	chr3:52989619	chr3:53064283~53065091:-
LAML	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	6.3	2.13e-08	0.000129	0.69	0.6	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	6.3	2.13e-08	0.000129	0.69	0.6	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	6.3	2.13e-08	0.000129	0.69	0.6	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
LAML	cis	rs2516839	0.605	rs12749496	ENSG00000232879.2	RP11-544M22.3	-6.3	2.13e-08	0.000129	-0.79	-0.6	Granulocyte percentage of myeloid white cells;	chr1:161052103	chr1:161034834~161035006:+
LAML	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	6.3	2.13e-08	0.000129	0.67	0.6	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
LAML	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	6.29	2.16e-08	0.00013	0.68	0.6	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-6.29	2.16e-08	0.00013	-0.68	-0.6	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	6.29	2.16e-08	0.00013	0.68	0.6	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	6.29	2.16e-08	0.00013	0.68	0.6	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	6.29	2.16e-08	0.00013	0.68	0.6	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	6.29	2.16e-08	0.00013	0.68	0.6	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	6.29	2.16e-08	0.00013	0.68	0.6	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
LAML	cis	rs2486288	0.656	rs7171312	ENSG00000259520.4	CTD-2651B20.3	6.29	2.16e-08	0.00013	0.92	0.6	Glomerular filtration rate;	chr15:45278027	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs6493143	ENSG00000259520.4	CTD-2651B20.3	6.29	2.16e-08	0.00013	0.92	0.6	Glomerular filtration rate;	chr15:45278583	chr15:45251580~45279251:-
LAML	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-6.29	2.16e-08	0.000131	-0.73	-0.6	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
LAML	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	6.29	2.19e-08	0.000132	0.75	0.6	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
LAML	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	6.29	2.2e-08	0.000133	0.81	0.6	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
LAML	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-6.29	2.23e-08	0.000135	-0.73	-0.6	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
LAML	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	6.28	2.23e-08	0.000135	0.71	0.6	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
LAML	cis	rs1555322	0.505	rs639763	ENSG00000279253.1	RP4-614O4.13	-6.28	2.25e-08	0.000135	-0.71	-0.6	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35262727~35264187:-
LAML	cis	rs62070183	0.938	rs75782470	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32746623	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.882	rs62070164	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32759415	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs4795719	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32776957	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.882	rs17780981	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32792019	chr17:32495536~32499333:+
LAML	cis	rs112916054	1	rs112916054	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Immature fraction of reticulocytes;	chr17:32797244	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.752	rs17781005	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32805511	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.808	rs76373015	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815023	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.808	rs79957065	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815731	chr17:32495536~32499333:+
LAML	cis	rs62070183	1	rs62070183	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32837349	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.882	rs17183600	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32848061	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.882	rs17183628	ENSG00000266718.1	RP11-466A19.1	-6.28	2.25e-08	0.000135	-0.94	-0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32857613	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.882	rs17781136	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32858024	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs17781142	ENSG00000266718.1	RP11-466A19.1	-6.28	2.25e-08	0.000135	-0.94	-0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32860198	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.882	rs62070187	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32863706	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.817	rs79640811	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32894299	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.766	rs62070229	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32900575	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.766	rs62070232	ENSG00000266718.1	RP11-466A19.1	6.28	2.25e-08	0.000135	0.94	0.6	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32903075	chr17:32495536~32499333:+
LAML	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	6.28	2.26e-08	0.000136	0.69	0.6	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
LAML	cis	rs4713118	0.868	rs760587	ENSG00000220721.1	OR1F12	6.28	2.27e-08	0.000136	0.71	0.59	Parkinson's disease;	chr6:27772521	chr6:28073316~28074233:+
LAML	cis	rs7104764	0.778	rs7930823	ENSG00000277290.1	RP11-326C3.16	6.28	2.28e-08	0.000136	0.87	0.59	Menarche (age at onset);	chr11:206767	chr11:243099~243483:-
LAML	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	6.28	2.28e-08	0.000137	0.7	0.59	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
LAML	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	6.28	2.29e-08	0.000137	0.73	0.59	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
LAML	cis	rs9322193	0.884	rs9397036	ENSG00000216906.2	RP11-350J20.9	6.28	2.29e-08	0.000137	0.94	0.59	Lung cancer;	chr6:149851787	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs9383864	ENSG00000216906.2	RP11-350J20.9	6.28	2.29e-08	0.000137	0.94	0.59	Lung cancer;	chr6:149851969	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs9383865	ENSG00000216906.2	RP11-350J20.9	6.28	2.29e-08	0.000137	0.94	0.59	Lung cancer;	chr6:149852043	chr6:149904243~149906418:+
LAML	cis	rs9660180	0.62	rs34298494	ENSG00000268575.1	RP1-283E3.8	6.28	2.3e-08	0.000137	0.66	0.59	Body mass index;	chr1:1731963	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.592	rs2076325	ENSG00000268575.1	RP1-283E3.8	6.28	2.3e-08	0.000137	0.66	0.59	Body mass index;	chr1:1735176	chr1:1702736~1737688:-
LAML	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	6.28	2.3e-08	0.000137	0.78	0.59	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
LAML	cis	rs7189233	0.55	rs1861350	ENSG00000279344.1	RP11-44F14.7	6.28	2.32e-08	0.000139	0.41	0.59	Intelligence (multi-trait analysis);	chr16:53499430	chr16:53478957~53481550:-
LAML	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-6.28	2.33e-08	0.000139	-0.69	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
LAML	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	6.28	2.33e-08	0.000139	0.69	0.59	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
LAML	cis	rs4591358	0.608	rs12693770	ENSG00000223466.1	AC064834.2	6.27	2.33e-08	0.000139	0.88	0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195461422	chr2:195533035~195538681:+
LAML	cis	rs2486288	0.656	rs12911861	ENSG00000259520.4	CTD-2651B20.3	6.27	2.35e-08	0.00014	0.92	0.59	Glomerular filtration rate;	chr15:45274520	chr15:45251580~45279251:-
LAML	cis	rs1075265	0.783	rs6708095	ENSG00000235937.1	AC008280.1	6.27	2.35e-08	0.00014	0.49	0.59	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54029552~54030682:-
LAML	cis	rs6456156	0.586	rs12198816	ENSG00000265828.1	MIR3939	-6.27	2.35e-08	0.00014	-0.89	-0.59	Primary biliary cholangitis;	chr6:167070058	chr6:166997807~166997912:-
LAML	cis	rs904251	0.523	rs10807184	ENSG00000227920.2	RP1-153P14.5	-6.27	2.36e-08	0.00014	-0.62	-0.59	Cognitive performance;	chr6:37515937	chr6:37545145~37550860:+
LAML	cis	rs904251	0.561	rs1757189	ENSG00000227920.2	RP1-153P14.5	-6.27	2.36e-08	0.00014	-0.62	-0.59	Cognitive performance;	chr6:37515951	chr6:37545145~37550860:+
LAML	cis	rs9506514	0.722	rs10400670	ENSG00000238286.1	SLC35E1P1	6.27	2.36e-08	0.000141	0.67	0.59	Coronary artery calcification;	chr13:20679350	chr13:20607268~20608131:+
LAML	cis	rs9506514	0.712	rs11838795	ENSG00000238286.1	SLC35E1P1	6.27	2.36e-08	0.000141	0.67	0.59	Coronary artery calcification;	chr13:20684189	chr13:20607268~20608131:+
LAML	cis	rs1555322	0.53	rs6060347	ENSG00000279253.1	RP4-614O4.13	-6.27	2.37e-08	0.000141	-0.75	-0.59	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35262727~35264187:-
LAML	cis	rs1757171	0.542	rs3818985	ENSG00000227920.2	RP1-153P14.5	-6.27	2.37e-08	0.000141	-0.62	-0.59	Cognitive performance;	chr6:37516438	chr6:37545145~37550860:+
LAML	cis	rs8081395	0.651	rs1292067	ENSG00000267302.4	RP11-178C3.2	-6.27	2.38e-08	0.000141	-0.76	-0.59	White blood cell count;	chr17:59853285	chr17:59964832~59996972:+
LAML	cis	rs9506514	0.722	rs11147813	ENSG00000238286.1	SLC35E1P1	6.27	2.39e-08	0.000142	0.67	0.59	Coronary artery calcification;	chr13:20684419	chr13:20607268~20608131:+
LAML	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	6.27	2.39e-08	0.000142	0.75	0.59	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
LAML	cis	rs911555	0.511	rs2296483	ENSG00000258851.1	RP11-894P9.2	-6.27	2.39e-08	0.000142	-0.67	-0.59	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103553421~103561877:+
LAML	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-6.27	2.41e-08	0.000143	-0.72	-0.59	Height;	chr3:52975027	chr3:53064283~53065091:-
LAML	cis	rs904251	0.523	rs9369005	ENSG00000227920.2	RP1-153P14.5	-6.27	2.41e-08	0.000143	-0.62	-0.59	Cognitive performance;	chr6:37515333	chr6:37545145~37550860:+
LAML	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-6.27	2.42e-08	0.000143	-0.71	-0.59	Height;	chr3:52989412	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-6.27	2.42e-08	0.000143	-0.71	-0.59	Height;	chr3:52991821	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-6.27	2.42e-08	0.000143	-0.71	-0.59	Height;	chr3:52992698	chr3:53064283~53065091:-
LAML	cis	rs62070183	0.766	rs10512441	ENSG00000280245.1	RP11-466A19.4	-6.26	2.43e-08	0.000144	-0.89	-0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32504567~32505644:-
LAML	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	6.26	2.45e-08	0.000145	0.78	0.59	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
LAML	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	6.26	2.47e-08	0.000146	0.69	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	6.26	2.47e-08	0.000146	0.69	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
LAML	cis	rs853679	0.882	rs9468300	ENSG00000187763.3	OR2B7P	6.26	2.48e-08	0.000146	1.04	0.59	Depression;	chr6:28159062	chr6:28046434~28047367:+
LAML	cis	rs853679	0.825	rs8180562	ENSG00000187763.3	OR2B7P	6.26	2.48e-08	0.000146	1.04	0.59	Depression;	chr6:28173682	chr6:28046434~28047367:+
LAML	cis	rs853679	0.882	rs9380064	ENSG00000187763.3	OR2B7P	6.26	2.48e-08	0.000146	1.04	0.59	Depression;	chr6:28175340	chr6:28046434~28047367:+
LAML	cis	rs6456156	0.586	rs13195158	ENSG00000265828.1	MIR3939	-6.26	2.48e-08	0.000146	-0.87	-0.59	Primary biliary cholangitis;	chr6:167067904	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs9457266	ENSG00000265828.1	MIR3939	-6.26	2.48e-08	0.000146	-0.87	-0.59	Primary biliary cholangitis;	chr6:167069067	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.565	rs7750209	ENSG00000265828.1	MIR3939	-6.26	2.48e-08	0.000146	-0.87	-0.59	Primary biliary cholangitis;	chr6:167069407	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs7746628	ENSG00000265828.1	MIR3939	-6.26	2.48e-08	0.000146	-0.87	-0.59	Primary biliary cholangitis;	chr6:167069747	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs2345753	ENSG00000265828.1	MIR3939	-6.26	2.48e-08	0.000146	-0.87	-0.59	Primary biliary cholangitis;	chr6:167070856	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.603	rs2345754	ENSG00000265828.1	MIR3939	-6.26	2.48e-08	0.000146	-0.87	-0.59	Primary biliary cholangitis;	chr6:167070873	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs7761977	ENSG00000265828.1	MIR3939	-6.26	2.48e-08	0.000146	-0.87	-0.59	Primary biliary cholangitis;	chr6:167072190	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs7742305	ENSG00000265828.1	MIR3939	-6.26	2.48e-08	0.000146	-0.87	-0.59	Primary biliary cholangitis;	chr6:167072235	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs7762156	ENSG00000265828.1	MIR3939	-6.26	2.48e-08	0.000146	-0.87	-0.59	Primary biliary cholangitis;	chr6:167072343	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs2001115	ENSG00000265828.1	MIR3939	-6.26	2.48e-08	0.000146	-0.87	-0.59	Primary biliary cholangitis;	chr6:167072730	chr6:166997807~166997912:-
LAML	cis	rs2564921	0.73	rs2253675	ENSG00000280417.1	RP11-5O17.1	-6.26	2.48e-08	0.000147	-0.86	-0.59	Height;	chr3:53085518	chr3:53046166~53048122:+
LAML	cis	rs853679	1	rs10456362	ENSG00000182477.5	OR2B8P	-6.26	2.49e-08	0.000147	-1	-0.59	Depression;	chr6:28254038	chr6:28053228~28054165:-
LAML	cis	rs9309473	1	rs7585004	ENSG00000163016.8	ALMS1P	6.26	2.49e-08	0.000147	0.72	0.59	Metabolite levels;	chr2:73439517	chr2:73644919~73685576:+
LAML	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	6.26	2.5e-08	0.000147	0.69	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
LAML	cis	rs7044106	0.791	rs4836831	ENSG00000226752.6	PSMD5-AS1	-6.26	2.5e-08	0.000148	-0.75	-0.59	Hip circumference adjusted for BMI;	chr9:120734292	chr9:120824828~120854385:+
LAML	cis	rs904251	0.861	rs1757171	ENSG00000227920.2	RP1-153P14.5	-6.26	2.51e-08	0.000148	-0.74	-0.59	Cognitive performance;	chr6:37519268	chr6:37545145~37550860:+
LAML	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-6.26	2.52e-08	0.000148	-0.66	-0.59	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
LAML	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	6.26	2.53e-08	0.000149	0.63	0.59	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
LAML	cis	rs4713118	0.868	rs742047	ENSG00000220721.1	OR1F12	6.25	2.55e-08	0.00015	0.71	0.59	Parkinson's disease;	chr6:27771601	chr6:28073316~28074233:+
LAML	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	6.25	2.56e-08	0.000151	0.69	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	6.25	2.56e-08	0.000151	0.69	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	6.25	2.56e-08	0.000151	0.69	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
LAML	cis	rs4591358	0.689	rs55876968	ENSG00000223466.1	AC064834.2	-6.25	2.56e-08	0.000151	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549015	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs55974440	ENSG00000223466.1	AC064834.2	-6.25	2.56e-08	0.000151	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549056	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs2173773	ENSG00000223466.1	AC064834.2	-6.25	2.56e-08	0.000151	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549701	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs12471810	ENSG00000223466.1	AC064834.2	-6.25	2.56e-08	0.000151	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549969	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs72927784	ENSG00000223466.1	AC064834.2	-6.25	2.56e-08	0.000151	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195550329	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs2133860	ENSG00000223466.1	AC064834.2	-6.25	2.56e-08	0.000151	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195551243	chr2:195533035~195538681:+
LAML	cis	rs5769707	0.622	rs2018467	ENSG00000279597.1	RP4-566L20.1	-6.25	2.6e-08	0.000152	-0.6	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49670631	chr22:49534062~49534926:+
LAML	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-6.25	2.6e-08	0.000153	-0.79	-0.59	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	6.25	2.61e-08	0.000153	0.82	0.59	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
LAML	cis	rs2581828	0.656	rs2253209	ENSG00000280417.1	RP11-5O17.1	6.25	2.61e-08	0.000153	0.75	0.59	Crohn's disease;	chr3:53081144	chr3:53046166~53048122:+
LAML	cis	rs4713118	0.588	rs200994	ENSG00000220721.1	OR1F12	-6.24	2.64e-08	0.000155	-0.71	-0.59	Parkinson's disease;	chr6:27846035	chr6:28073316~28074233:+
LAML	cis	rs7131987	0.565	rs7968883	ENSG00000275476.1	RP11-996F15.4	6.24	2.66e-08	0.000156	0.65	0.59	QT interval;	chr12:29241258	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs1991113	ENSG00000275476.1	RP11-996F15.4	-6.24	2.66e-08	0.000156	-0.65	-0.59	QT interval;	chr12:29239070	chr12:29277397~29277882:-
LAML	cis	rs7746199	0.736	rs13209332	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs34965299	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28073316~28074233:+
LAML	cis	rs35491132	1	rs35491132	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Urinary tract infection frequency;	chr6:27559449	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs10484399	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs34105070	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.673	rs72845046	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs67652222	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs13212093	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs34038546	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28073316~28074233:+
LAML	cis	rs141342723	1	rs141342723	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs34543938	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs56405707	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs13210634	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs13215275	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs17749927	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs13192965	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28073316~28074233:+
LAML	cis	rs45509595	0.556	rs34409918	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Breast cancer;	chr6:27717569	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs34064842	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs13212318	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs13202291	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs17750424	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs13193542	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs13193480	ENSG00000220721.1	OR1F12	6.24	2.66e-08	0.000156	0.94	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28073316~28074233:+
LAML	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	6.24	2.67e-08	0.000156	0.62	0.59	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
LAML	cis	rs904251	0.523	rs12202055	ENSG00000227920.2	RP1-153P14.5	-6.24	2.69e-08	0.000157	-0.62	-0.59	Cognitive performance;	chr6:37518304	chr6:37545145~37550860:+
LAML	cis	rs4591358	0.648	rs56906982	ENSG00000223466.1	AC064834.2	-6.24	2.71e-08	0.000158	-0.87	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512939	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.773	rs13035226	ENSG00000223466.1	AC064834.2	-6.24	2.71e-08	0.000158	-0.87	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512957	chr2:195533035~195538681:+
LAML	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-6.24	2.71e-08	0.000158	-0.69	-0.59	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	6.24	2.71e-08	0.000158	0.69	0.59	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	6.24	2.71e-08	0.000158	0.69	0.59	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	6.24	2.71e-08	0.000158	0.69	0.59	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	6.24	2.71e-08	0.000158	0.69	0.59	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
LAML	cis	rs62070183	0.938	rs62068432	ENSG00000265337.1	RP11-466A19.5	6.24	2.74e-08	0.000159	0.94	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32739479	chr17:32529008~32530049:-
LAML	cis	rs66887589	0.616	rs11731675	ENSG00000248280.1	RP11-33B1.2	6.24	2.74e-08	0.000159	0.71	0.59	Diastolic blood pressure;	chr4:119291359	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.616	rs11732621	ENSG00000248280.1	RP11-33B1.2	6.24	2.74e-08	0.000159	0.71	0.59	Diastolic blood pressure;	chr4:119291728	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.616	rs1052633	ENSG00000248280.1	RP11-33B1.2	6.24	2.74e-08	0.000159	0.71	0.59	Diastolic blood pressure;	chr4:119294159	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.592	rs2175383	ENSG00000248280.1	RP11-33B1.2	6.24	2.74e-08	0.000159	0.71	0.59	Diastolic blood pressure;	chr4:119294681	chr4:119440561~119450157:-
LAML	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-6.23	2.75e-08	0.000159	-0.68	-0.59	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
LAML	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-6.23	2.75e-08	0.000159	-0.68	-0.59	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
LAML	cis	rs853679	0.607	rs13199649	ENSG00000220721.1	OR1F12	6.23	2.76e-08	0.000159	0.94	0.59	Depression;	chr6:27901014	chr6:28073316~28074233:+
LAML	cis	rs67340775	0.834	rs13218875	ENSG00000220721.1	OR1F12	6.23	2.76e-08	0.000159	0.94	0.59	Lung cancer in ever smokers;	chr6:27916234	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs67040724	ENSG00000220721.1	OR1F12	6.23	2.76e-08	0.000159	0.94	0.59	Depression;	chr6:27937731	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs67662114	ENSG00000220721.1	OR1F12	6.23	2.76e-08	0.000159	0.94	0.59	Depression;	chr6:27964523	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13216117	ENSG00000220721.1	OR1F12	6.23	2.76e-08	0.000159	0.94	0.59	Depression;	chr6:27970706	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs36101351	ENSG00000220721.1	OR1F12	6.23	2.76e-08	0.000159	0.94	0.59	Depression;	chr6:27975591	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs28360499	ENSG00000220721.1	OR1F12	6.23	2.76e-08	0.000159	0.94	0.59	Depression;	chr6:27977618	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs71537572	ENSG00000220721.1	OR1F12	6.23	2.76e-08	0.000159	0.94	0.59	Depression;	chr6:28002937	chr6:28073316~28074233:+
LAML	cis	rs853679	0.599	rs13193295	ENSG00000220721.1	OR1F12	6.23	2.76e-08	0.000159	0.94	0.59	Depression;	chr6:28035450	chr6:28073316~28074233:+
LAML	cis	rs4591358	0.731	rs12693772	ENSG00000223466.1	AC064834.2	-6.23	2.76e-08	0.000159	-0.92	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195473636	chr2:195533035~195538681:+
LAML	cis	rs6452524	0.967	rs7717964	ENSG00000249664.1	CTD-2227C6.2	6.23	2.77e-08	0.00016	0.84	0.59	Hypertension (SNP x SNP interaction);	chr5:83126323	chr5:83012285~83013109:-
LAML	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-6.23	2.77e-08	0.00016	-0.72	-0.59	Height;	chr3:53029854	chr3:53064283~53065091:-
LAML	cis	rs5769707	0.521	rs5769719	ENSG00000280224.1	CTA-722E9.1	-6.23	2.77e-08	0.00016	-0.8	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.521	rs5769720	ENSG00000280224.1	CTA-722E9.1	-6.23	2.77e-08	0.00016	-0.8	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.521	rs5770633	ENSG00000280224.1	CTA-722E9.1	-6.23	2.77e-08	0.00016	-0.8	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49500568~49501585:+
LAML	cis	rs7746199	0.736	rs72845070	ENSG00000220721.1	OR1F12	6.23	2.78e-08	0.000161	0.98	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28073316~28074233:+
LAML	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-6.23	2.79e-08	0.000161	-0.72	-0.59	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
LAML	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	6.23	2.8e-08	0.000161	0.67	0.59	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	6.23	2.8e-08	0.000161	0.67	0.59	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	6.23	2.8e-08	0.000161	0.67	0.59	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	6.23	2.8e-08	0.000161	0.67	0.59	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	6.23	2.8e-08	0.000161	0.67	0.59	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	6.23	2.8e-08	0.000161	0.67	0.59	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
LAML	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	6.23	2.8e-08	0.000161	0.67	0.59	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	6.23	2.8e-08	0.000161	0.67	0.59	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
LAML	cis	rs1930961	1	rs59226697	ENSG00000272977.1	CTA-390C10.10	-6.23	2.82e-08	0.000162	-1.26	-0.59	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25476218~25479971:+
LAML	cis	rs9309473	0.861	rs6546857	ENSG00000163016.8	ALMS1P	6.23	2.83e-08	0.000163	0.7	0.59	Metabolite levels;	chr2:73610828	chr2:73644919~73685576:+
LAML	cis	rs62070183	0.938	rs75393526	ENSG00000265337.1	RP11-466A19.5	6.23	2.83e-08	0.000163	0.93	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32708000	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs75822124	ENSG00000265337.1	RP11-466A19.5	6.23	2.83e-08	0.000163	0.93	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32710876	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs17183176	ENSG00000265337.1	RP11-466A19.5	6.23	2.83e-08	0.000163	0.93	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32727107	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs1990825	ENSG00000265337.1	RP11-466A19.5	6.23	2.83e-08	0.000163	0.93	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32729274	chr17:32529008~32530049:-
LAML	cis	rs9322193	0.923	rs9371207	ENSG00000216906.2	RP11-350J20.9	6.23	2.85e-08	0.000164	0.98	0.59	Lung cancer;	chr6:149858087	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs2880436	ENSG00000216906.2	RP11-350J20.9	6.23	2.85e-08	0.000164	0.98	0.59	Lung cancer;	chr6:149859123	chr6:149904243~149906418:+
LAML	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	6.23	2.86e-08	0.000164	0.67	0.59	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
LAML	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	6.22	2.87e-08	0.000165	0.84	0.59	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
LAML	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	6.22	2.87e-08	0.000165	0.41	0.59	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	6.22	2.87e-08	0.000165	0.41	0.59	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	6.22	2.87e-08	0.000165	0.41	0.59	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	6.22	2.87e-08	0.000165	0.41	0.59	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	6.22	2.87e-08	0.000165	0.41	0.59	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
LAML	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-6.22	2.88e-08	0.000165	-0.72	-0.59	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
LAML	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-6.22	2.88e-08	0.000165	-0.71	-0.59	Height;	chr3:53064759	chr3:53064283~53065091:-
LAML	cis	rs5769707	0.749	rs3884944	ENSG00000212939.2	RP1-29C18.10	-6.22	2.9e-08	0.000166	-0.63	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49669348	chr22:49548681~49556473:+
LAML	cis	rs6452524	0.87	rs2174976	ENSG00000249664.1	CTD-2227C6.2	6.22	2.96e-08	0.000169	0.79	0.59	Hypertension (SNP x SNP interaction);	chr5:83197136	chr5:83012285~83013109:-
LAML	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	6.22	2.96e-08	0.000169	0.71	0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	6.22	2.96e-08	0.000169	0.71	0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-6.22	2.96e-08	0.000169	-0.71	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-6.22	2.96e-08	0.000169	-0.71	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-6.22	2.96e-08	0.000169	-0.71	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
LAML	cis	rs904251	0.523	rs2797799	ENSG00000279942.1	RP1-153P14.7	-6.21	2.99e-08	0.000171	-0.64	-0.59	Cognitive performance;	chr6:37515844	chr6:37567716~37571460:+
LAML	cis	rs904251	0.504	rs1757188	ENSG00000279942.1	RP1-153P14.7	-6.21	2.99e-08	0.000171	-0.64	-0.59	Cognitive performance;	chr6:37516032	chr6:37567716~37571460:+
LAML	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	6.21	2.99e-08	0.000171	0.81	0.59	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	6.21	2.99e-08	0.000171	0.81	0.59	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
LAML	cis	rs904251	0.861	rs2776875	ENSG00000279942.1	RP1-153P14.7	-6.21	3.1e-08	0.000176	-0.69	-0.59	Cognitive performance;	chr6:37519020	chr6:37567716~37571460:+
LAML	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-6.21	3.11e-08	0.000177	-0.76	-0.59	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.52	rs7127881	ENSG00000254851.1	RP11-109L13.1	-6.21	3.11e-08	0.000177	-0.76	-0.59	Blood protein levels;	chr11:117010082	chr11:117135528~117138582:+
LAML	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-6.2	3.11e-08	0.000177	-0.71	-0.59	Height;	chr3:53047596	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-6.2	3.11e-08	0.000177	-0.71	-0.59	Height;	chr3:53052712	chr3:53064283~53065091:-
LAML	cis	rs6452524	0.934	rs12153440	ENSG00000249664.1	CTD-2227C6.2	6.2	3.11e-08	0.000177	0.81	0.59	Hypertension (SNP x SNP interaction);	chr5:83125097	chr5:83012285~83013109:-
LAML	cis	rs9368481	0.569	rs6907403	ENSG00000243307.2	POM121L6P	6.2	3.13e-08	0.000178	0.75	0.59	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.502	rs3933232	ENSG00000243307.2	POM121L6P	6.2	3.13e-08	0.000178	0.75	0.59	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.524	rs12530345	ENSG00000243307.2	POM121L6P	6.2	3.13e-08	0.000178	0.75	0.59	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.546	rs12664610	ENSG00000243307.2	POM121L6P	6.2	3.13e-08	0.000178	0.75	0.59	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.524	rs9393768	ENSG00000243307.2	POM121L6P	6.2	3.13e-08	0.000178	0.75	0.59	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.569	rs10946868	ENSG00000243307.2	POM121L6P	6.2	3.13e-08	0.000178	0.75	0.59	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26896952~26898777:+
LAML	cis	rs4591358	0.689	rs2102745	ENSG00000223466.1	AC064834.2	-6.2	3.14e-08	0.000178	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559315	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.638	rs6704955	ENSG00000223466.1	AC064834.2	-6.2	3.14e-08	0.000178	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559393	chr2:195533035~195538681:+
LAML	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	6.2	3.17e-08	0.00018	0.4	0.59	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs4783813	ENSG00000279344.1	RP11-44F14.7	6.2	3.17e-08	0.00018	0.4	0.59	Intelligence (multi-trait analysis);	chr16:53484458	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs13337544	ENSG00000279344.1	RP11-44F14.7	6.2	3.17e-08	0.00018	0.4	0.59	Intelligence (multi-trait analysis);	chr16:53485123	chr16:53478957~53481550:-
LAML	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-6.2	3.18e-08	0.00018	-1	-0.59	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
LAML	cis	rs1577917	0.771	rs12199873	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85585229	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs2842609	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85587070	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs2842612	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85593373	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.727	rs2758840	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85594907	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs9362230	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85595295	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs2758844	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85620397	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs2842601	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85620415	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs12205013	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85623311	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.74	rs2842604	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85626582	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs2842607	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85635321	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs2758847	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85639385	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs4145082	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85642298	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs9362233	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85648529	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs10944133	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85649266	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.727	rs9351065	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85650710	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs2475790	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85658350	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs2475791	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85658446	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-6.2	3.2e-08	0.000181	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.739	rs6922	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85495605	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.666	rs6454471	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85504738	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.665	rs4304137	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85507730	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs4419647	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85516021	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs9353318	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85522003	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs9450290	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85523679	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs4351223	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85528079	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs7452605	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85531233	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs9294337	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85538742	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.74	rs6926049	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85556415	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs2842613	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85595984	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs2783171	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85673047	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.71	rs1059306	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85678391	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	6.2	3.2e-08	0.000181	0.73	0.59	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
LAML	cis	rs6700559	0.692	rs2809342	ENSG00000260088.1	RP11-92G12.3	-6.2	3.21e-08	0.000181	-0.74	-0.59	Coronary artery disease;	chr1:200628522	chr1:200669507~200694250:+
LAML	cis	rs6452524	0.935	rs7718284	ENSG00000249664.1	CTD-2227C6.2	-6.2	3.23e-08	0.000182	-0.8	-0.59	Hypertension (SNP x SNP interaction);	chr5:83082488	chr5:83012285~83013109:-
LAML	cis	rs45509595	0.841	rs17751184	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Breast cancer;	chr6:27807250	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs67101035	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Depression;	chr6:27831109	chr6:28046434~28047367:+
LAML	cis	rs853679	0.556	rs34706883	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Depression;	chr6:27837477	chr6:28046434~28047367:+
LAML	cis	rs67340775	0.748	rs13212651	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Lung cancer in ever smokers;	chr6:27839207	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs35819751	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Depression;	chr6:27842791	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13194781	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Depression;	chr6:27847861	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs36116761	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Depression;	chr6:27850704	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs34194357	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Depression;	chr6:27850757	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13199772	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Depression;	chr6:27866307	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13199906	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Depression;	chr6:27866361	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs17763089	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Depression;	chr6:27867440	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs17695758	ENSG00000187763.3	OR2B7P	6.2	3.24e-08	0.000182	1.05	0.59	Depression;	chr6:27869405	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs2799079	ENSG00000187763.3	OR2B7P	6.19	3.27e-08	0.000184	0.85	0.59	Depression;	chr6:28267398	chr6:28046434~28047367:+
LAML	cis	rs66887589	0.616	rs11098497	ENSG00000248280.1	RP11-33B1.2	6.19	3.29e-08	0.000185	0.71	0.59	Diastolic blood pressure;	chr4:119265913	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.616	rs10032299	ENSG00000248280.1	RP11-33B1.2	6.19	3.29e-08	0.000185	0.71	0.59	Diastolic blood pressure;	chr4:119285264	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.616	rs7659403	ENSG00000248280.1	RP11-33B1.2	6.19	3.29e-08	0.000185	0.71	0.59	Diastolic blood pressure;	chr4:119286099	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.616	rs6843509	ENSG00000248280.1	RP11-33B1.2	6.19	3.3e-08	0.000186	0.71	0.59	Diastolic blood pressure;	chr4:119299041	chr4:119440561~119450157:-
LAML	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	6.19	3.35e-08	0.000189	0.71	0.59	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
LAML	cis	rs904251	0.766	rs1757175	ENSG00000279942.1	RP1-153P14.7	-6.19	3.36e-08	0.000189	-0.71	-0.59	Cognitive performance;	chr6:37518918	chr6:37567716~37571460:+
LAML	cis	rs904251	0.828	rs1757174	ENSG00000279942.1	RP1-153P14.7	-6.19	3.36e-08	0.000189	-0.71	-0.59	Cognitive performance;	chr6:37518919	chr6:37567716~37571460:+
LAML	cis	rs5769707	0.749	rs3884944	ENSG00000279597.1	RP4-566L20.1	-6.19	3.37e-08	0.000189	-0.62	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49669348	chr22:49534062~49534926:+
LAML	cis	rs6452524	0.836	rs2731849	ENSG00000249664.1	CTD-2227C6.2	-6.19	3.38e-08	0.00019	-0.78	-0.59	Hypertension (SNP x SNP interaction);	chr5:83214060	chr5:83012285~83013109:-
LAML	cis	rs1757171	0.504	rs11969056	ENSG00000279942.1	RP1-153P14.7	-6.18	3.39e-08	0.00019	-0.64	-0.59	Cognitive performance;	chr6:37516509	chr6:37567716~37571460:+
LAML	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	6.18	3.46e-08	0.000194	0.77	0.59	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	6.18	3.46e-08	0.000194	0.77	0.59	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	6.18	3.46e-08	0.000194	0.77	0.59	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	6.18	3.46e-08	0.000194	0.77	0.59	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	6.18	3.49e-08	0.000195	0.78	0.59	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
LAML	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	6.18	3.49e-08	0.000195	0.67	0.59	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
LAML	cis	rs2564921	0.73	rs930122	ENSG00000280417.1	RP11-5O17.1	6.18	3.5e-08	0.000196	0.85	0.59	Height;	chr3:53085313	chr3:53046166~53048122:+
LAML	cis	rs10149470	0.549	rs9652403	ENSG00000258851.1	RP11-894P9.2	-6.18	3.51e-08	0.000196	-0.67	-0.59	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Cognitive ability;	chr14:103569687	chr14:103553421~103561877:+
LAML	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	6.18	3.52e-08	0.000197	0.68	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
LAML	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-6.17	3.53e-08	0.000197	-0.71	-0.59	Height;	chr3:53007328	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-6.17	3.53e-08	0.000197	-0.71	-0.59	Height;	chr3:53009621	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-6.17	3.53e-08	0.000197	-0.71	-0.59	Height;	chr3:53015087	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-6.17	3.53e-08	0.000197	-0.71	-0.59	Height;	chr3:53027969	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-6.17	3.53e-08	0.000197	-0.71	-0.59	Height;	chr3:53029908	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-6.17	3.53e-08	0.000197	-0.71	-0.59	Height;	chr3:53034139	chr3:53064283~53065091:-
LAML	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	6.17	3.53e-08	0.000197	0.4	0.59	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
LAML	cis	rs9660180	0.62	rs3817856	ENSG00000268575.1	RP1-283E3.8	6.17	3.53e-08	0.000197	0.63	0.59	Body mass index;	chr1:1732392	chr1:1702736~1737688:-
LAML	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-6.17	3.54e-08	0.000198	-0.73	-0.59	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
LAML	cis	rs9322193	0.772	rs7738696	ENSG00000216906.2	RP11-350J20.9	6.17	3.58e-08	2e-04	0.93	0.59	Lung cancer;	chr6:149848985	chr6:149904243~149906418:+
LAML	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	6.17	3.58e-08	2e-04	0.72	0.59	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
LAML	cis	rs6782228	0.675	rs2253151	ENSG00000277250.1	Metazoa_SRP	-6.17	3.59e-08	0.000201	-0.78	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128673681~128674021:-
LAML	cis	rs4713118	0.662	rs149946	ENSG00000220721.1	OR1F12	-6.17	3.62e-08	0.000202	-0.74	-0.59	Parkinson's disease;	chr6:28002253	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs156744	ENSG00000220721.1	OR1F12	6.17	3.62e-08	0.000202	0.74	0.59	Parkinson's disease;	chr6:27999496	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs149947	ENSG00000220721.1	OR1F12	6.17	3.62e-08	0.000202	0.74	0.59	Parkinson's disease;	chr6:28004655	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs149969	ENSG00000220721.1	OR1F12	6.17	3.62e-08	0.000202	0.74	0.59	Parkinson's disease;	chr6:28009959	chr6:28073316~28074233:+
LAML	cis	rs5769707	0.967	rs9616701	ENSG00000279597.1	RP4-566L20.1	-6.17	3.63e-08	0.000202	-0.68	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49534062~49534926:+
LAML	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	6.17	3.63e-08	0.000202	0.62	0.59	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
LAML	cis	rs2015599	0.549	rs7134187	ENSG00000257176.2	RP11-996F15.2	-6.17	3.63e-08	0.000202	-0.64	-0.59	Platelet count;Mean platelet volume;	chr12:29294113	chr12:29280418~29317848:-
LAML	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	6.17	3.64e-08	0.000203	0.68	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	6.17	3.64e-08	0.000203	0.68	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	6.17	3.64e-08	0.000203	0.68	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
LAML	cis	rs4591358	0.689	rs6759817	ENSG00000223466.1	AC064834.2	-6.17	3.66e-08	0.000203	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553739	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs6760142	ENSG00000223466.1	AC064834.2	-6.17	3.66e-08	0.000203	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553911	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs6434785	ENSG00000223466.1	AC064834.2	-6.17	3.66e-08	0.000203	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195554142	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.638	rs16837243	ENSG00000223466.1	AC064834.2	-6.17	3.66e-08	0.000203	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195556458	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs72927794	ENSG00000223466.1	AC064834.2	-6.17	3.66e-08	0.000203	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195558607	chr2:195533035~195538681:+
LAML	cis	rs172166	0.543	rs1150691	ENSG00000220721.1	OR1F12	6.17	3.66e-08	0.000203	0.61	0.59	Cardiac Troponin-T levels;	chr6:28200255	chr6:28073316~28074233:+
LAML	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-6.17	3.67e-08	0.000204	-0.74	-0.59	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
LAML	cis	rs6782228	0.606	rs4634140	ENSG00000277250.1	Metazoa_SRP	6.17	3.67e-08	0.000204	0.71	0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128673681~128674021:-
LAML	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	6.16	3.68e-08	0.000204	0.81	0.59	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	6.16	3.68e-08	0.000204	0.81	0.59	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-6.16	3.68e-08	0.000204	-0.81	-0.59	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-6.16	3.68e-08	0.000204	-0.81	-0.59	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	6.16	3.68e-08	0.000204	0.76	0.59	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
LAML	cis	rs7587476	0.601	rs13021937	ENSG00000227769.6	AC072062.3	6.16	3.69e-08	0.000205	0.62	0.59	Neuroblastoma;	chr2:214809213	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.531	rs35933323	ENSG00000227769.6	AC072062.3	6.16	3.69e-08	0.000205	0.62	0.59	Neuroblastoma;	chr2:214809366	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.601	rs1129804	ENSG00000227769.6	AC072062.3	6.16	3.69e-08	0.000205	0.62	0.59	Neuroblastoma;	chr2:214809599	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.601	rs17489363	ENSG00000227769.6	AC072062.3	6.16	3.69e-08	0.000205	0.62	0.59	Neuroblastoma;	chr2:214809617	chr2:215004782~215085488:+
LAML	cis	rs853679	0.882	rs9461432	ENSG00000187763.3	OR2B7P	6.16	3.73e-08	0.000207	1.03	0.59	Depression;	chr6:28119105	chr6:28046434~28047367:+
LAML	cis	rs853679	0.882	rs4713139	ENSG00000187763.3	OR2B7P	6.16	3.73e-08	0.000207	1.03	0.59	Depression;	chr6:28124907	chr6:28046434~28047367:+
LAML	cis	rs853679	0.882	rs3757188	ENSG00000187763.3	OR2B7P	6.16	3.73e-08	0.000207	1.03	0.59	Depression;	chr6:28139579	chr6:28046434~28047367:+
LAML	cis	rs6456156	0.586	rs12525855	ENSG00000265828.1	MIR3939	-6.16	3.74e-08	0.000207	-0.88	-0.59	Primary biliary cholangitis;	chr6:167066525	chr6:166997807~166997912:-
LAML	cis	rs6456156	0.586	rs2001114	ENSG00000265828.1	MIR3939	-6.16	3.74e-08	0.000207	-0.88	-0.59	Primary biliary cholangitis;	chr6:167073090	chr6:166997807~166997912:-
LAML	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-6.16	3.76e-08	0.000208	-0.73	-0.59	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-6.16	3.76e-08	0.000208	-0.73	-0.59	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
LAML	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-6.16	3.77e-08	0.000209	-0.61	-0.59	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	6.16	3.77e-08	0.000209	0.61	0.59	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
LAML	cis	rs4591358	0.678	rs13015934	ENSG00000223466.1	AC064834.2	-6.16	3.77e-08	0.000209	-0.89	-0.59	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195504897	chr2:195533035~195538681:+
LAML	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	6.16	3.78e-08	0.000209	0.72	0.59	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
LAML	cis	rs7189233	0.531	rs8055279	ENSG00000279344.1	RP11-44F14.7	6.16	3.8e-08	0.00021	0.4	0.59	Intelligence (multi-trait analysis);	chr16:53488837	chr16:53478957~53481550:-
LAML	cis	rs6456156	0.586	rs10946209	ENSG00000265828.1	MIR3939	-6.16	3.81e-08	0.000211	-0.88	-0.59	Primary biliary cholangitis;	chr6:167067503	chr6:166997807~166997912:-
LAML	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	6.16	3.82e-08	0.000211	0.68	0.59	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
LAML	cis	rs9506514	0.722	rs4769124	ENSG00000238286.1	SLC35E1P1	6.16	3.82e-08	0.000211	0.66	0.59	Coronary artery calcification;	chr13:20652706	chr13:20607268~20608131:+
LAML	cis	rs763121	0.853	rs3788545	ENSG00000230912.1	RP3-508I15.10	-6.15	3.83e-08	0.000212	-0.54	-0.59	Menopause (age at onset);	chr22:38669167	chr22:38666508~38668750:-
LAML	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	6.15	3.83e-08	0.000212	0.4	0.59	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
LAML	cis	rs66887589	0.807	rs7694483	ENSG00000248280.1	RP11-33B1.2	6.15	3.84e-08	0.000212	0.74	0.59	Diastolic blood pressure;	chr4:119484774	chr4:119440561~119450157:-
LAML	cis	rs2301436	0.512	rs6925969	ENSG00000265828.1	MIR3939	-6.15	3.86e-08	0.000213	-0.89	-0.59	Crohn's disease;	chr6:167088250	chr6:166997807~166997912:-
LAML	cis	rs62070183	0.766	rs62067160	ENSG00000265337.1	RP11-466A19.5	6.15	3.87e-08	0.000214	0.94	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32919567	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.766	rs62067160	ENSG00000266718.1	RP11-466A19.1	6.15	3.9e-08	0.000216	0.94	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32919567	chr17:32495536~32499333:+
LAML	cis	rs67311347	0.635	rs73071706	ENSG00000223797.4	ENTPD3-AS1	6.15	3.91e-08	0.000216	0.83	0.59	Renal cell carcinoma;	chr3:40246699	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.668	rs73071710	ENSG00000223797.4	ENTPD3-AS1	6.15	3.91e-08	0.000216	0.83	0.59	Renal cell carcinoma;	chr3:40247096	chr3:40313802~40453329:-
LAML	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-6.15	3.92e-08	0.000216	-0.79	-0.59	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
LAML	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-6.15	3.92e-08	0.000216	-0.79	-0.59	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
LAML	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	6.15	3.95e-08	0.000217	0.68	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	6.15	3.95e-08	0.000217	0.68	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
LAML	cis	rs62070183	0.938	rs75782470	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32746623	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.882	rs62070164	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32759415	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs4795719	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32776957	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.882	rs17780981	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32792019	chr17:32529008~32530049:-
LAML	cis	rs112916054	1	rs112916054	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Immature fraction of reticulocytes;	chr17:32797244	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.752	rs17781005	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32805511	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.808	rs76373015	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815023	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.808	rs79957065	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815731	chr17:32529008~32530049:-
LAML	cis	rs62070183	1	rs62070183	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32837349	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.882	rs17183600	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32848061	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.882	rs17183628	ENSG00000265337.1	RP11-466A19.5	-6.15	3.95e-08	0.000217	-0.92	-0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32857613	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.882	rs17781136	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32858024	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs17781142	ENSG00000265337.1	RP11-466A19.5	-6.15	3.95e-08	0.000217	-0.92	-0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32860198	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.882	rs62070187	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32863706	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.817	rs79640811	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32894299	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.766	rs62070229	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32900575	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.766	rs62070232	ENSG00000265337.1	RP11-466A19.5	6.15	3.95e-08	0.000217	0.92	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32903075	chr17:32529008~32530049:-
LAML	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	6.15	3.95e-08	0.000217	0.78	0.59	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	6.15	3.95e-08	0.000217	0.78	0.59	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	6.15	3.95e-08	0.000217	0.78	0.59	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	6.15	3.95e-08	0.000217	0.78	0.59	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
LAML	cis	rs6452524	0.836	rs2089565	ENSG00000249664.1	CTD-2227C6.2	-6.15	3.96e-08	0.000218	-0.77	-0.59	Hypertension (SNP x SNP interaction);	chr5:83214410	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.713	rs2386245	ENSG00000249664.1	CTD-2227C6.2	-6.15	3.96e-08	0.000218	-0.77	-0.59	Hypertension (SNP x SNP interaction);	chr5:83214866	chr5:83012285~83013109:-
LAML	cis	rs9457247	0.602	rs2157388	ENSG00000265828.1	MIR3939	-6.15	3.96e-08	0.000218	-0.86	-0.59	Crohn's disease;	chr6:167068424	chr6:166997807~166997912:-
LAML	cis	rs6782228	0.585	rs2712392	ENSG00000277250.1	Metazoa_SRP	-6.15	3.98e-08	0.000218	-0.71	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128673681~128674021:-
LAML	cis	rs6456156	0.586	rs2285148	ENSG00000265828.1	MIR3939	-6.15	3.98e-08	0.000219	-0.9	-0.59	Primary biliary cholangitis;	chr6:167077511	chr6:166997807~166997912:-
LAML	cis	rs62070183	0.938	rs62068432	ENSG00000266718.1	RP11-466A19.1	6.14	3.99e-08	0.000219	0.93	0.59	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32739479	chr17:32495536~32499333:+
LAML	cis	rs853679	1	rs2799079	ENSG00000220721.1	OR1F12	6.14	4.01e-08	0.00022	0.74	0.59	Depression;	chr6:28267398	chr6:28073316~28074233:+
LAML	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-6.14	4.03e-08	0.000221	-0.75	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-6.14	4.03e-08	0.000221	-0.75	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
LAML	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	6.14	4.03e-08	0.000221	0.72	0.59	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	6.14	4.03e-08	0.000221	0.72	0.59	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	6.14	4.03e-08	0.000221	0.72	0.59	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	6.14	4.03e-08	0.000221	0.72	0.59	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	6.14	4.03e-08	0.000221	0.72	0.59	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	6.14	4.03e-08	0.000221	0.72	0.59	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	6.14	4.03e-08	0.000221	0.72	0.59	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	6.14	4.03e-08	0.000221	0.72	0.59	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
LAML	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	6.14	4.03e-08	0.000221	0.72	0.59	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	6.14	4.03e-08	0.000221	0.72	0.59	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
LAML	cis	rs1075265	0.783	rs805438	ENSG00000235937.1	AC008280.1	6.14	4.04e-08	0.000221	0.46	0.59	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54029552~54030682:-
LAML	cis	rs6456156	0.692	rs9457270	ENSG00000265828.1	MIR3939	-6.14	4.07e-08	0.000222	-0.92	-0.59	Primary biliary cholangitis;	chr6:167099440	chr6:166997807~166997912:-
LAML	cis	rs4713118	0.868	rs2893928	ENSG00000220721.1	OR1F12	6.14	4.07e-08	0.000223	0.7	0.59	Parkinson's disease;	chr6:27770651	chr6:28073316~28074233:+
LAML	cis	rs7429990	0.932	rs11720151	ENSG00000229759.1	MRPS18AP1	-6.14	4.08e-08	0.000223	-0.72	-0.59	Educational attainment (years of education);	chr3:48099144	chr3:48256350~48256938:-
LAML	cis	rs6452524	0.836	rs1015440	ENSG00000249664.1	CTD-2227C6.2	6.14	4.12e-08	0.000225	0.78	0.59	Hypertension (SNP x SNP interaction);	chr5:83202986	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.806	rs10078084	ENSG00000249664.1	CTD-2227C6.2	6.13	4.16e-08	0.000227	0.82	0.59	Hypertension (SNP x SNP interaction);	chr5:83106588	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.868	rs11750836	ENSG00000249664.1	CTD-2227C6.2	6.13	4.16e-08	0.000227	0.82	0.59	Hypertension (SNP x SNP interaction);	chr5:83107368	chr5:83012285~83013109:-
LAML	cis	rs1555322	0.53	rs2250205	ENSG00000279253.1	RP4-614O4.13	-6.13	4.18e-08	0.000228	-0.78	-0.59	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35262727~35264187:-
LAML	cis	rs5760092	0.755	rs3884794	ENSG00000273295.1	AP000350.5	6.13	4.19e-08	0.000228	1.02	0.59	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23909579	chr22:23901432~23907068:-
LAML	cis	rs5769707	0.967	rs9616327	ENSG00000212939.2	RP1-29C18.10	-6.13	4.25e-08	0.000231	-0.71	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.935	rs5770594	ENSG00000279597.1	RP4-566L20.1	-6.13	4.3e-08	0.000233	-0.66	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.967	rs4524218	ENSG00000279597.1	RP4-566L20.1	-6.13	4.3e-08	0.000233	-0.66	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.967	rs739248	ENSG00000279597.1	RP4-566L20.1	-6.13	4.3e-08	0.000233	-0.66	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.967	rs2071904	ENSG00000279597.1	RP4-566L20.1	-6.13	4.3e-08	0.000233	-0.66	-0.59	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49534062~49534926:+
LAML	cis	rs2581828	0.694	rs2336725	ENSG00000280417.1	RP11-5O17.1	6.13	4.32e-08	0.000234	0.73	0.59	Crohn's disease;	chr3:53084723	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs2564921	ENSG00000280417.1	RP11-5O17.1	-6.13	4.32e-08	0.000234	-0.73	-0.59	Crohn's disease;	chr3:53091569	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs11242	ENSG00000280417.1	RP11-5O17.1	-6.13	4.32e-08	0.000234	-0.73	-0.59	Crohn's disease;	chr3:53091906	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs2581786	ENSG00000280417.1	RP11-5O17.1	6.13	4.32e-08	0.000234	0.73	0.59	Crohn's disease;	chr3:53092127	chr3:53046166~53048122:+
LAML	cis	rs9368481	0.7	rs6911401	ENSG00000241549.7	GUSBP2	6.13	4.32e-08	0.000234	0.61	0.59	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.729	rs10946881	ENSG00000241549.7	GUSBP2	6.13	4.32e-08	0.000234	0.61	0.59	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26871484~26956554:-
LAML	cis	rs62402013	1	rs62402013	ENSG00000241549.7	GUSBP2	6.13	4.32e-08	0.000234	0.61	0.59	Schizophrenia;	chr6:26947221	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.678	rs62402024	ENSG00000241549.7	GUSBP2	6.13	4.32e-08	0.000234	0.61	0.59	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26871484~26956554:-
LAML	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	6.13	4.32e-08	0.000234	0.68	0.59	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
LAML	cis	rs9322193	0.923	rs9322225	ENSG00000216906.2	RP11-350J20.9	6.13	4.33e-08	0.000234	0.88	0.59	Lung cancer;	chr6:149863746	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.676	rs1889472	ENSG00000216906.2	RP11-350J20.9	6.13	4.33e-08	0.000234	0.88	0.59	Lung cancer;	chr6:149864373	chr6:149904243~149906418:+
LAML	cis	rs6700559	0.716	rs12140579	ENSG00000260088.1	RP11-92G12.3	6.12	4.33e-08	0.000235	0.68	0.59	Coronary artery disease;	chr1:200655368	chr1:200669507~200694250:+
LAML	cis	rs9457247	0.602	rs2239827	ENSG00000265828.1	MIR3939	-6.12	4.37e-08	0.000236	-0.88	-0.59	Crohn's disease;	chr6:167077457	chr6:166997807~166997912:-
LAML	cis	rs7746199	0.736	rs17693963	ENSG00000220721.1	OR1F12	6.12	4.37e-08	0.000236	0.91	0.59	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28073316~28074233:+
LAML	cis	rs853679	0.513	rs13437444	ENSG00000187763.3	OR2B7P	6.12	4.38e-08	0.000237	0.96	0.59	Depression;	chr6:28103220	chr6:28046434~28047367:+
LAML	cis	rs6565180	0.632	rs8050812	ENSG00000183604.13	SMG1P5	6.12	4.39e-08	0.000237	0.75	0.59	Tonsillectomy;	chr16:30374516	chr16:30267553~30335374:-
LAML	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	6.12	4.44e-08	0.00024	0.77	0.58	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
LAML	cis	rs6452524	0.836	rs4343818	ENSG00000249664.1	CTD-2227C6.2	6.12	4.44e-08	0.00024	0.78	0.58	Hypertension (SNP x SNP interaction);	chr5:83205603	chr5:83012285~83013109:-
LAML	cis	rs709400	0.832	rs55864158	ENSG00000258851.1	RP11-894P9.2	-6.12	4.46e-08	0.000241	-0.78	-0.58	Body mass index;	chr14:103602242	chr14:103553421~103561877:+
LAML	cis	rs12220777	1	rs11201297	ENSG00000230091.5	TMEM254-AS1	6.12	4.46e-08	0.000241	1.25	0.58	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80033993	chr10:80046860~80078912:-
LAML	cis	rs4591358	0.508	rs11884880	ENSG00000223466.1	AC064834.2	-6.12	4.47e-08	0.000241	-0.93	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195562897	chr2:195533035~195538681:+
LAML	cis	rs3931020	0.745	rs7555459	ENSG00000272864.1	RP11-17E13.2	-6.12	4.48e-08	0.000242	-0.79	-0.58	Resistin levels;	chr1:74808022	chr1:74698769~74699333:-
LAML	cis	rs9309473	0.95	rs6726694	ENSG00000163016.8	ALMS1P	6.12	4.49e-08	0.000242	0.68	0.58	Metabolite levels;	chr2:73620103	chr2:73644919~73685576:+
LAML	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	6.12	4.49e-08	0.000242	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.513	rs1344491	ENSG00000279344.1	RP11-44F14.7	6.12	4.49e-08	0.000242	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53405497	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs13332071	ENSG00000279344.1	RP11-44F14.7	6.12	4.49e-08	0.000242	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53409724	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs1861353	ENSG00000279344.1	RP11-44F14.7	6.12	4.49e-08	0.000242	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53418169	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs6499617	ENSG00000279344.1	RP11-44F14.7	6.12	4.49e-08	0.000242	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53433810	chr16:53478957~53481550:-
LAML	cis	rs6452524	0.967	rs7718278	ENSG00000249664.1	CTD-2227C6.2	6.12	4.5e-08	0.000243	0.82	0.58	Hypertension (SNP x SNP interaction);	chr5:83126600	chr5:83012285~83013109:-
LAML	cis	rs9322193	0.884	rs7769115	ENSG00000216906.2	RP11-350J20.9	6.11	4.52e-08	0.000244	0.92	0.58	Lung cancer;	chr6:149848796	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs7743823	ENSG00000216906.2	RP11-350J20.9	6.11	4.52e-08	0.000244	0.92	0.58	Lung cancer;	chr6:149849744	chr6:149904243~149906418:+
LAML	cis	rs10927875	0.965	rs3961710	ENSG00000178715.8	RP11-169K16.8	-6.11	4.53e-08	0.000244	-0.77	-0.58	Dilated cardiomyopathy;	chr1:15986677	chr1:15828232~15828669:+
LAML	cis	rs10927875	1	rs4307563	ENSG00000178715.8	RP11-169K16.8	-6.11	4.53e-08	0.000244	-0.77	-0.58	Dilated cardiomyopathy;	chr1:15987293	chr1:15828232~15828669:+
LAML	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	6.11	4.54e-08	0.000244	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	6.11	4.54e-08	0.000244	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	6.11	4.54e-08	0.000244	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.513	rs8044091	ENSG00000279344.1	RP11-44F14.7	6.11	4.54e-08	0.000244	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53487086	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs1861351	ENSG00000279344.1	RP11-44F14.7	6.11	4.54e-08	0.000244	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53499315	chr16:53478957~53481550:-
LAML	cis	rs7587476	0.601	rs6715570	ENSG00000227769.6	AC072062.3	6.11	4.56e-08	0.000245	0.62	0.58	Neuroblastoma;	chr2:214808716	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.601	rs17489231	ENSG00000227769.6	AC072062.3	6.11	4.56e-08	0.000245	0.62	0.58	Neuroblastoma;	chr2:214809015	chr2:215004782~215085488:+
LAML	cis	rs5769707	0.967	rs17182154	ENSG00000279597.1	RP4-566L20.1	-6.11	4.58e-08	0.000246	-0.66	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49534062~49534926:+
LAML	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	6.11	4.64e-08	0.000249	0.67	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	6.11	4.64e-08	0.000249	0.67	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	6.11	4.64e-08	0.000249	0.67	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	6.11	4.64e-08	0.000249	0.67	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	6.11	4.64e-08	0.000249	0.67	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	6.11	4.64e-08	0.000249	0.67	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	6.11	4.64e-08	0.000249	0.67	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	6.11	4.64e-08	0.000249	0.67	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	6.11	4.64e-08	0.000249	0.67	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	6.11	4.64e-08	0.000249	0.67	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
LAML	cis	rs4591358	0.689	rs72927760	ENSG00000223466.1	AC064834.2	-6.11	4.65e-08	0.000249	-0.9	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544584	chr2:195533035~195538681:+
LAML	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-6.11	4.66e-08	0.00025	-0.8	-0.58	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-6.11	4.66e-08	0.00025	-0.8	-0.58	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
LAML	cis	rs2015599	0.549	rs6487799	ENSG00000257176.2	RP11-996F15.2	6.11	4.7e-08	0.000252	0.57	0.58	Platelet count;Mean platelet volume;	chr12:29291087	chr12:29280418~29317848:-
LAML	cis	rs2015599	0.549	rs7972032	ENSG00000257176.2	RP11-996F15.2	6.11	4.7e-08	0.000252	0.57	0.58	Platelet count;Mean platelet volume;	chr12:29291351	chr12:29280418~29317848:-
LAML	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	6.11	4.7e-08	0.000252	0.77	0.58	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
LAML	cis	rs4879656	0.564	rs4879657	ENSG00000225693.1	LAGE3P1	-6.1	4.74e-08	0.000253	-0.62	-0.58	Menopause (age at onset);	chr9:33012467	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.525	rs7852206	ENSG00000225693.1	LAGE3P1	-6.1	4.74e-08	0.000253	-0.62	-0.58	Menopause (age at onset);	chr9:33017383	chr9:33019682~33020165:-
LAML	cis	rs904251	0.797	rs1757177	ENSG00000227920.2	RP1-153P14.5	-6.1	4.75e-08	0.000254	-0.68	-0.58	Cognitive performance;	chr6:37518594	chr6:37545145~37550860:+
LAML	cis	rs1555322	0.505	rs2254207	ENSG00000279253.1	RP4-614O4.13	-6.1	4.77e-08	0.000255	-0.62	-0.58	Attention deficit hyperactivity disorder;	chr20:35269908	chr20:35262727~35264187:-
LAML	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-6.1	4.78e-08	0.000256	-0.74	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
LAML	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-6.1	4.8e-08	0.000256	-0.81	-0.58	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	6.1	4.8e-08	0.000256	0.81	0.58	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
LAML	cis	rs62070183	0.938	rs9911168	ENSG00000266718.1	RP11-466A19.1	6.1	4.81e-08	0.000257	0.93	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709136	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs9912761	ENSG00000266718.1	RP11-466A19.1	6.1	4.81e-08	0.000257	0.93	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709475	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs9303654	ENSG00000266718.1	RP11-466A19.1	6.1	4.81e-08	0.000257	0.93	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709747	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs9898762	ENSG00000266718.1	RP11-466A19.1	6.1	4.81e-08	0.000257	0.93	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32711641	chr17:32495536~32499333:+
LAML	cis	rs1577917	0.739	rs9344532	ENSG00000203875.9	SNHG5	6.1	4.82e-08	0.000257	0.73	0.58	Response to antipsychotic treatment;	chr6:85524352	chr6:85660950~85678736:-
LAML	cis	rs6452524	0.901	rs1580309	ENSG00000249664.1	CTD-2227C6.2	6.1	4.83e-08	0.000258	0.81	0.58	Hypertension (SNP x SNP interaction);	chr5:83091948	chr5:83012285~83013109:-
LAML	cis	rs10927875	0.929	rs10927879	ENSG00000178715.8	RP11-169K16.8	-6.1	4.84e-08	0.000258	-0.74	-0.58	Dilated cardiomyopathy;	chr1:15993533	chr1:15828232~15828669:+
LAML	cis	rs5769707	0.967	rs5769698	ENSG00000212939.2	RP1-29C18.10	-6.1	4.86e-08	0.000259	-0.66	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49548681~49556473:+
LAML	cis	rs1075265	0.704	rs10181999	ENSG00000235937.1	AC008280.1	6.1	4.88e-08	0.00026	0.46	0.58	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54029552~54030682:-
LAML	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	6.1	4.89e-08	0.000261	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
LAML	cis	rs1075265	0.749	rs805430	ENSG00000235937.1	AC008280.1	6.1	4.89e-08	0.000261	0.46	0.58	Chronotype;Morning vs. evening chronotype;	chr2:53848279	chr2:54029552~54030682:-
LAML	cis	rs6452524	0.868	rs1564379	ENSG00000249664.1	CTD-2227C6.2	6.09	4.91e-08	0.000262	0.81	0.58	Hypertension (SNP x SNP interaction);	chr5:83082143	chr5:83012285~83013109:-
LAML	cis	rs2273156	0.57	rs7144423	ENSG00000241052.1	RP11-173D9.1	-6.09	4.95e-08	0.000264	-1.06	-0.58	Immunoglobulin light chain (AL) amyloidosis;	chr14:35103341	chr14:35144021~35144480:-
LAML	cis	rs1075265	0.749	rs805436	ENSG00000235937.1	AC008280.1	6.09	4.96e-08	0.000264	0.46	0.58	Chronotype;Morning vs. evening chronotype;	chr2:53837843	chr2:54029552~54030682:-
LAML	cis	rs904251	0.522	rs882322	ENSG00000279942.1	RP1-153P14.7	-6.09	4.96e-08	0.000264	-0.64	-0.58	Cognitive performance;	chr6:37516327	chr6:37567716~37571460:+
LAML	cis	rs904251	0.523	rs2797794	ENSG00000204110.6	RP1-153P14.8	-6.09	4.97e-08	0.000265	-0.72	-0.58	Cognitive performance;	chr6:37512828	chr6:37507348~37535616:+
LAML	cis	rs904251	0.523	rs2776920	ENSG00000204110.6	RP1-153P14.8	-6.09	4.97e-08	0.000265	-0.72	-0.58	Cognitive performance;	chr6:37512829	chr6:37507348~37535616:+
LAML	cis	rs904251	0.504	rs2797795	ENSG00000204110.6	RP1-153P14.8	-6.09	4.97e-08	0.000265	-0.72	-0.58	Cognitive performance;	chr6:37512907	chr6:37507348~37535616:+
LAML	cis	rs904251	0.523	rs2797796	ENSG00000204110.6	RP1-153P14.8	-6.09	4.97e-08	0.000265	-0.72	-0.58	Cognitive performance;	chr6:37513110	chr6:37507348~37535616:+
LAML	cis	rs904251	0.523	rs2776870	ENSG00000204110.6	RP1-153P14.8	-6.09	4.97e-08	0.000265	-0.72	-0.58	Cognitive performance;	chr6:37513588	chr6:37507348~37535616:+
LAML	cis	rs904251	0.523	rs2797798	ENSG00000204110.6	RP1-153P14.8	-6.09	4.97e-08	0.000265	-0.72	-0.58	Cognitive performance;	chr6:37513661	chr6:37507348~37535616:+
LAML	cis	rs904251	0.523	rs2776871	ENSG00000204110.6	RP1-153P14.8	-6.09	4.97e-08	0.000265	-0.72	-0.58	Cognitive performance;	chr6:37513983	chr6:37507348~37535616:+
LAML	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	6.09	5.01e-08	0.000265	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
LAML	cis	rs7189233	0.513	rs28759393	ENSG00000279344.1	RP11-44F14.7	6.09	5.02e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53411446	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs8063294	ENSG00000279344.1	RP11-44F14.7	6.09	5.02e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53412845	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs8061398	ENSG00000279344.1	RP11-44F14.7	6.09	5.02e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53420239	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs1978337	ENSG00000279344.1	RP11-44F14.7	6.09	5.02e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53425833	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs6499613	ENSG00000279344.1	RP11-44F14.7	6.09	5.02e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53429506	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	6.09	5.02e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
LAML	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	6.09	5.04e-08	0.000266	0.71	0.58	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
LAML	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	6.09	5.04e-08	0.000266	0.71	0.58	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	6.09	5.04e-08	0.000266	0.71	0.58	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	6.09	5.04e-08	0.000266	0.71	0.58	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	6.09	5.04e-08	0.000266	0.71	0.58	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
LAML	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-6.09	5.04e-08	0.000266	-0.71	-0.58	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-6.09	5.04e-08	0.000266	-0.71	-0.58	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-6.09	5.04e-08	0.000266	-0.71	-0.58	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
LAML	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	6.09	5.05e-08	0.000266	0.68	0.58	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	6.09	5.05e-08	0.000266	0.68	0.58	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	6.09	5.05e-08	0.000266	0.68	0.58	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	6.09	5.05e-08	0.000266	0.68	0.58	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
LAML	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-6.09	5.05e-08	0.000266	-0.74	-0.58	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	6.09	5.05e-08	0.000266	0.74	0.58	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
LAML	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	6.09	5.06e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	6.09	5.06e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	6.09	5.06e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	6.09	5.06e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	6.09	5.06e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	6.09	5.06e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.55	rs17193176	ENSG00000279344.1	RP11-44F14.7	6.09	5.06e-08	0.000266	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53484316	chr16:53478957~53481550:-
LAML	cis	rs7189233	0.531	rs3929	ENSG00000279344.1	RP11-44F14.7	-6.09	5.06e-08	0.000266	-0.4	-0.58	Intelligence (multi-trait analysis);	chr16:53490396	chr16:53478957~53481550:-
LAML	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-6.09	5.06e-08	0.000266	-0.78	-0.58	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
LAML	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-6.09	5.08e-08	0.000267	-0.79	-0.58	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
LAML	cis	rs9322193	0.847	rs4870054	ENSG00000216906.2	RP11-350J20.9	6.09	5.1e-08	0.000268	0.94	0.58	Lung cancer;	chr6:149848402	chr6:149904243~149906418:+
LAML	cis	rs66887589	0.967	rs59516282	ENSG00000248280.1	RP11-33B1.2	-6.09	5.1e-08	0.000268	-0.71	-0.58	Diastolic blood pressure;	chr4:119580861	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.934	rs12648182	ENSG00000248280.1	RP11-33B1.2	-6.09	5.1e-08	0.000268	-0.71	-0.58	Diastolic blood pressure;	chr4:119582736	chr4:119440561~119450157:-
LAML	cis	rs4591358	0.648	rs6732306	ENSG00000223466.1	AC064834.2	-6.08	5.12e-08	0.000268	-0.89	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541396	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs2889034	ENSG00000223466.1	AC064834.2	-6.08	5.12e-08	0.000268	-0.89	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548022	chr2:195533035~195538681:+
LAML	cis	rs7829975	0.593	rs2979241	ENSG00000268955.2	RP11-556O5.6	-6.08	5.14e-08	0.00027	-0.69	-0.58	Mood instability;	chr8:8445843	chr8:8188535~8189195:-
LAML	cis	rs2581828	0.656	rs2163167	ENSG00000280417.1	RP11-5O17.1	6.08	5.14e-08	0.00027	0.74	0.58	Crohn's disease;	chr3:53097756	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.541	rs2115781	ENSG00000280417.1	RP11-5O17.1	6.08	5.14e-08	0.00027	0.74	0.58	Crohn's disease;	chr3:53097813	chr3:53046166~53048122:+
LAML	cis	rs4713118	0.868	rs7756968	ENSG00000220721.1	OR1F12	6.08	5.18e-08	0.000271	0.69	0.58	Parkinson's disease;	chr6:27767175	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.868	rs9468220	ENSG00000220721.1	OR1F12	-6.08	5.18e-08	0.000271	-0.69	-0.58	Parkinson's disease;	chr6:27765197	chr6:28073316~28074233:+
LAML	cis	rs1757171	0.542	rs1757186	ENSG00000279942.1	RP1-153P14.7	-6.08	5.2e-08	0.000272	-0.64	-0.58	Cognitive performance;	chr6:37516335	chr6:37567716~37571460:+
LAML	cis	rs282544	0.632	rs2442107	ENSG00000271455.1	RP11-269M20.2	-6.08	5.23e-08	0.000274	-0.66	-0.58	Myopia (pathological);	chr5:50750133	chr5:50603229~50603511:+
LAML	cis	rs2581828	0.656	rs4687701	ENSG00000280417.1	RP11-5O17.1	-6.08	5.25e-08	0.000275	-0.74	-0.58	Crohn's disease;	chr3:53087260	chr3:53046166~53048122:+
LAML	cis	rs9368481	0.569	rs6907403	ENSG00000241549.7	GUSBP2	6.08	5.3e-08	0.000276	0.64	0.58	Autism spectrum disorder or schizophrenia;	chr6:26909518	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.502	rs3933232	ENSG00000241549.7	GUSBP2	6.08	5.3e-08	0.000276	0.64	0.58	Autism spectrum disorder or schizophrenia;	chr6:26909667	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.524	rs12530345	ENSG00000241549.7	GUSBP2	6.08	5.3e-08	0.000276	0.64	0.58	Autism spectrum disorder or schizophrenia;	chr6:26916464	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.546	rs12664610	ENSG00000241549.7	GUSBP2	6.08	5.3e-08	0.000276	0.64	0.58	Autism spectrum disorder or schizophrenia;	chr6:26917252	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.524	rs9393768	ENSG00000241549.7	GUSBP2	6.08	5.3e-08	0.000276	0.64	0.58	Autism spectrum disorder or schizophrenia;	chr6:26917840	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.569	rs10946868	ENSG00000241549.7	GUSBP2	6.08	5.3e-08	0.000276	0.64	0.58	Autism spectrum disorder or schizophrenia;	chr6:26920151	chr6:26871484~26956554:-
LAML	cis	rs4591358	0.734	rs11904194	ENSG00000223466.1	AC064834.2	6.07	5.34e-08	0.000278	0.75	0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195495211	chr2:195533035~195538681:+
LAML	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-6.07	5.41e-08	0.000281	-0.8	-0.58	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-6.07	5.41e-08	0.000281	-0.8	-0.58	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-6.07	5.41e-08	0.000281	-0.8	-0.58	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-6.07	5.41e-08	0.000281	-0.8	-0.58	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-6.07	5.41e-08	0.000281	-0.8	-0.58	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-6.07	5.41e-08	0.000281	-0.8	-0.58	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-6.07	5.41e-08	0.000281	-0.8	-0.58	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-6.07	5.43e-08	0.000282	-0.8	-0.58	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-6.07	5.43e-08	0.000282	-0.8	-0.58	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-6.07	5.43e-08	0.000282	-0.8	-0.58	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
LAML	cis	rs9326248	0.53	rs7114963	ENSG00000254851.1	RP11-109L13.1	-6.07	5.44e-08	0.000282	-1.06	-0.58	Blood protein levels;	chr11:117005267	chr11:117135528~117138582:+
LAML	cis	rs7115242	0.72	rs10790169	ENSG00000254851.1	RP11-109L13.1	-6.07	5.44e-08	0.000282	-1.06	-0.58	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117006443	chr11:117135528~117138582:+
LAML	cis	rs10927875	0.894	rs10927878	ENSG00000178715.8	RP11-169K16.8	-6.07	5.46e-08	0.000283	-0.76	-0.58	Dilated cardiomyopathy;	chr1:15993462	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.894	rs34957618	ENSG00000178715.8	RP11-169K16.8	-6.07	5.46e-08	0.000283	-0.76	-0.58	Dilated cardiomyopathy;	chr1:15994004	chr1:15828232~15828669:+
LAML	cis	rs5769707	0.967	rs763126	ENSG00000279597.1	RP4-566L20.1	6.07	5.47e-08	0.000283	0.67	0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49534062~49534926:+
LAML	cis	rs2581828	0.931	rs2336722	ENSG00000242142.1	SERBP1P3	6.07	5.48e-08	0.000284	0.61	0.58	Crohn's disease;	chr3:53105961	chr3:53064283~53065091:-
LAML	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-6.07	5.5e-08	0.000285	-0.67	-0.58	Height;	chr3:52971094	chr3:53064283~53065091:-
LAML	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	6.07	5.51e-08	0.000285	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
LAML	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	6.07	5.51e-08	0.000285	0.68	0.58	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	6.07	5.51e-08	0.000285	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	6.07	5.51e-08	0.000285	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	6.07	5.51e-08	0.000285	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	6.07	5.51e-08	0.000285	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
LAML	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	6.07	5.51e-08	0.000285	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
LAML	cis	rs5769707	0.846	rs5770610	ENSG00000279597.1	RP4-566L20.1	-6.07	5.54e-08	0.000286	-0.66	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.967	rs8141807	ENSG00000279597.1	RP4-566L20.1	-6.07	5.54e-08	0.000286	-0.66	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.935	rs9616332	ENSG00000279597.1	RP4-566L20.1	-6.07	5.54e-08	0.000286	-0.66	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.935	rs739239	ENSG00000279597.1	RP4-566L20.1	-6.07	5.54e-08	0.000286	-0.66	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49656820	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.874	rs9616714	ENSG00000279597.1	RP4-566L20.1	-6.07	5.54e-08	0.000286	-0.66	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49657211	chr22:49534062~49534926:+
LAML	cis	rs66887589	0.592	rs11731571	ENSG00000248280.1	RP11-33B1.2	6.06	5.58e-08	0.000288	0.71	0.58	Diastolic blood pressure;	chr4:119300030	chr4:119440561~119450157:-
LAML	cis	rs5769707	0.706	rs763128	ENSG00000280224.1	CTA-722E9.1	-6.06	5.62e-08	0.00029	-0.83	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.967	rs2187891	ENSG00000279597.1	RP4-566L20.1	-6.06	5.62e-08	0.00029	-0.64	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49534062~49534926:+
LAML	cis	rs57024841	0.562	rs2071006	ENSG00000238268.2	RP11-229P13.19	-6.06	5.63e-08	0.00029	-0.71	-0.58	Beta-trace protein levels;	chr9:136945452	chr9:136975094~136976981:+
LAML	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-6.06	5.63e-08	0.000291	-0.67	-0.58	Height;	chr3:52972039	chr3:53064283~53065091:-
LAML	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	6.06	5.64e-08	0.000291	0.76	0.58	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
LAML	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	6.06	5.64e-08	0.000291	0.76	0.58	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
LAML	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	6.06	5.64e-08	0.000291	0.76	0.58	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
LAML	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	6.06	5.64e-08	0.000291	0.76	0.58	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
LAML	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	6.06	5.64e-08	0.000291	0.76	0.58	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
LAML	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	6.06	5.64e-08	0.000291	0.76	0.58	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
LAML	cis	rs7131987	0.585	rs2059362	ENSG00000275476.1	RP11-996F15.4	6.06	5.65e-08	0.000291	0.66	0.58	QT interval;	chr12:29243072	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs10843365	ENSG00000275476.1	RP11-996F15.4	6.06	5.65e-08	0.000291	0.66	0.58	QT interval;	chr12:29252691	chr12:29277397~29277882:-
LAML	cis	rs5769707	0.935	rs1109320	ENSG00000279597.1	RP4-566L20.1	-6.06	5.65e-08	0.000291	-0.67	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49534062~49534926:+
LAML	cis	rs67383717	0.643	rs10759883	ENSG00000175611.10	LINC00476	-6.06	5.72e-08	0.000295	-0.58	-0.58	Parkinson's disease (pesticide exposure interaction);	chr9:95790481	chr9:95759231~95875977:-
LAML	cis	rs2581828	0.656	rs2581787	ENSG00000280417.1	RP11-5O17.1	6.06	5.75e-08	0.000296	0.72	0.58	Crohn's disease;	chr3:53093661	chr3:53046166~53048122:+
LAML	cis	rs5769707	0.542	rs739242	ENSG00000280224.1	CTA-722E9.1	-6.06	5.76e-08	0.000296	-0.78	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.521	rs7285764	ENSG00000280224.1	CTA-722E9.1	-6.06	5.76e-08	0.000296	-0.78	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.521	rs9616715	ENSG00000280224.1	CTA-722E9.1	-6.06	5.76e-08	0.000296	-0.78	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.521	rs6009805	ENSG00000280224.1	CTA-722E9.1	-6.06	5.76e-08	0.000296	-0.78	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.521	rs6009807	ENSG00000280224.1	CTA-722E9.1	-6.06	5.76e-08	0.000296	-0.78	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49500568~49501585:+
LAML	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	6.06	5.76e-08	0.000296	0.68	0.58	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
LAML	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	6.05	5.81e-08	0.000298	0.76	0.58	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
LAML	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	6.05	5.83e-08	0.000299	0.76	0.58	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
LAML	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	6.05	5.83e-08	0.000299	0.76	0.58	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
LAML	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	6.05	5.83e-08	0.000299	0.76	0.58	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
LAML	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	6.05	5.83e-08	0.000299	0.76	0.58	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
LAML	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-6.05	5.88e-08	0.000301	-0.8	-0.58	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
LAML	cis	rs62070183	0.938	rs9911168	ENSG00000280245.1	RP11-466A19.4	6.05	5.91e-08	0.000302	0.87	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709136	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs9912761	ENSG00000280245.1	RP11-466A19.4	6.05	5.91e-08	0.000302	0.87	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709475	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs9303654	ENSG00000280245.1	RP11-466A19.4	6.05	5.91e-08	0.000302	0.87	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709747	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs9898762	ENSG00000280245.1	RP11-466A19.4	6.05	5.91e-08	0.000302	0.87	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32711641	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.766	rs10512441	ENSG00000266599.1	RP11-466A19.3	-6.05	5.93e-08	0.000304	-0.9	-0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32518953~32531492:+
LAML	cis	rs709400	1	rs61995780	ENSG00000258851.1	RP11-894P9.2	-6.05	5.96e-08	0.000305	-0.72	-0.58	Body mass index;	chr14:103654275	chr14:103553421~103561877:+
LAML	cis	rs709400	1	rs57218990	ENSG00000258851.1	RP11-894P9.2	-6.05	5.96e-08	0.000305	-0.72	-0.58	Body mass index;	chr14:103661670	chr14:103553421~103561877:+
LAML	cis	rs853679	1	rs6905391	ENSG00000187763.3	OR2B7P	6.05	5.98e-08	0.000306	0.84	0.58	Depression;	chr6:28294909	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs1936365	ENSG00000187763.3	OR2B7P	-6.05	5.98e-08	0.000306	-0.84	-0.58	Depression;	chr6:28300675	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs853694	ENSG00000187763.3	OR2B7P	6.05	5.98e-08	0.000306	0.84	0.58	Depression;	chr6:28311323	chr6:28046434~28047367:+
LAML	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-6.05	6e-08	0.000306	-0.5	-0.58	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
LAML	cis	rs5769707	0.777	rs5770622	ENSG00000280224.1	CTA-722E9.1	-6.05	6.01e-08	0.000307	-0.72	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49657900	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.967	rs5770585	ENSG00000212939.2	RP1-29C18.10	-6.04	6.02e-08	0.000308	-0.69	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49548681~49556473:+
LAML	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-6.04	6.04e-08	0.000308	-0.74	-0.58	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.904	rs10474095	ENSG00000249664.1	CTD-2227C6.2	6.04	6.04e-08	0.000308	0.74	0.58	Hypertension (SNP x SNP interaction);	chr5:83154887	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.869	rs10051155	ENSG00000249664.1	CTD-2227C6.2	6.04	6.04e-08	0.000308	0.74	0.58	Hypertension (SNP x SNP interaction);	chr5:83160851	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs72767160	ENSG00000249664.1	CTD-2227C6.2	6.04	6.04e-08	0.000308	0.74	0.58	Hypertension (SNP x SNP interaction);	chr5:83161102	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs5000997	ENSG00000249664.1	CTD-2227C6.2	6.04	6.04e-08	0.000308	0.74	0.58	Hypertension (SNP x SNP interaction);	chr5:83164248	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs10043698	ENSG00000249664.1	CTD-2227C6.2	6.04	6.04e-08	0.000308	0.74	0.58	Hypertension (SNP x SNP interaction);	chr5:83169100	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs6887915	ENSG00000249664.1	CTD-2227C6.2	6.04	6.04e-08	0.000308	0.74	0.58	Hypertension (SNP x SNP interaction);	chr5:83170837	chr5:83012285~83013109:-
LAML	cis	rs16828019	0.561	rs12025777	ENSG00000235358.1	RP11-399E6.1	6.04	6.08e-08	0.00031	1.21	0.58	Intelligence (multi-trait analysis);	chr1:41283225	chr1:41242373~41284861:+
LAML	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-6.04	6.13e-08	0.000311	-0.74	-0.58	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	6.04	6.13e-08	0.000311	0.74	0.58	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
LAML	cis	rs67311347	0.549	rs60249586	ENSG00000223797.4	ENTPD3-AS1	6.04	6.17e-08	0.000313	0.82	0.58	Renal cell carcinoma;	chr3:40205168	chr3:40313802~40453329:-
LAML	cis	rs853679	1	rs1679732	ENSG00000182477.5	OR2B8P	-6.04	6.17e-08	0.000313	-0.96	-0.58	Depression;	chr6:28253486	chr6:28053228~28054165:-
LAML	cis	rs2273156	0.5	rs75741665	ENSG00000241052.1	RP11-173D9.1	-6.04	6.17e-08	0.000313	-1.08	-0.58	Immunoglobulin light chain (AL) amyloidosis;	chr14:35096834	chr14:35144021~35144480:-
LAML	cis	rs9457247	0.624	rs2239826	ENSG00000265828.1	MIR3939	-6.04	6.18e-08	0.000313	-0.89	-0.58	Crohn's disease;	chr6:167091392	chr6:166997807~166997912:-
LAML	cis	rs4591358	0.638	rs6732435	ENSG00000223466.1	AC064834.2	-6.04	6.18e-08	0.000313	-0.88	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541501	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs34373729	ENSG00000223466.1	AC064834.2	-6.04	6.18e-08	0.000313	-0.88	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195543775	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs59639651	ENSG00000223466.1	AC064834.2	-6.04	6.18e-08	0.000313	-0.88	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544426	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs72927766	ENSG00000223466.1	AC064834.2	-6.04	6.18e-08	0.000313	-0.88	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545003	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs7580459	ENSG00000223466.1	AC064834.2	-6.04	6.18e-08	0.000313	-0.88	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545963	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs57555936	ENSG00000223466.1	AC064834.2	-6.04	6.18e-08	0.000313	-0.88	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546440	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs59017643	ENSG00000223466.1	AC064834.2	-6.04	6.18e-08	0.000313	-0.88	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546835	chr2:195533035~195538681:+
LAML	cis	rs9309473	0.95	rs6745480	ENSG00000163016.8	ALMS1P	6.04	6.19e-08	0.000314	0.66	0.58	Metabolite levels;	chr2:73612928	chr2:73644919~73685576:+
LAML	cis	rs11295209	1	rs11295209	ENSG00000248280.1	RP11-33B1.2	-6.04	6.21e-08	0.000315	-0.72	-0.58	Plateletcrit;	chr4:119559079	chr4:119440561~119450157:-
LAML	cis	rs12468226	1	rs7597156	ENSG00000272966.1	RP11-686O6.1	6.04	6.22e-08	0.000316	1	0.58	Urate levels;	chr2:202329339	chr2:202336739~202337200:+
LAML	cis	rs709400	1	rs2403205	ENSG00000258851.1	RP11-894P9.2	-6.04	6.26e-08	0.000317	-0.72	-0.58	Body mass index;	chr14:103677048	chr14:103553421~103561877:+
LAML	cis	rs709400	1	rs3915733	ENSG00000258851.1	RP11-894P9.2	-6.04	6.26e-08	0.000317	-0.72	-0.58	Body mass index;	chr14:103681016	chr14:103553421~103561877:+
LAML	cis	rs709400	1	rs709400	ENSG00000258851.1	RP11-894P9.2	-6.04	6.26e-08	0.000317	-0.72	-0.58	Body mass index;	chr14:103683138	chr14:103553421~103561877:+
LAML	cis	rs904251	0.523	rs1757191	ENSG00000279942.1	RP1-153P14.7	-6.03	6.29e-08	0.000318	-0.63	-0.58	Cognitive performance;	chr6:37515095	chr6:37567716~37571460:+
LAML	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	6.03	6.3e-08	0.000319	0.41	0.58	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
LAML	cis	rs709400	0.93	rs10134399	ENSG00000258851.1	RP11-894P9.2	-6.03	6.33e-08	0.00032	-0.74	-0.58	Body mass index;	chr14:103617120	chr14:103553421~103561877:+
LAML	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	6.03	6.34e-08	0.000321	0.71	0.58	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
LAML	cis	rs4853012	1	rs4853012	ENSG00000217702.2	RP11-287D1.4	6.03	6.4e-08	0.000324	1.17	0.58	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74130583~74135395:+
LAML	cis	rs858239	0.712	rs199650	ENSG00000230658.1	KLHL7-AS1	-6.03	6.4e-08	0.000324	-0.77	-0.58	Cerebrospinal fluid biomarker levels;	chr7:23327570	chr7:23101228~23105703:-
LAML	cis	rs709400	0.894	rs61996721	ENSG00000258851.1	RP11-894P9.2	-6.03	6.41e-08	0.000324	-0.77	-0.58	Body mass index;	chr14:103595015	chr14:103553421~103561877:+
LAML	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-6.03	6.46e-08	0.000326	-0.74	-0.58	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
LAML	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	6.03	6.46e-08	0.000326	0.73	0.58	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	6.03	6.46e-08	0.000326	0.73	0.58	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	6.03	6.46e-08	0.000326	0.73	0.58	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	6.03	6.46e-08	0.000326	0.73	0.58	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	6.03	6.46e-08	0.000326	0.73	0.58	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	6.03	6.46e-08	0.000326	0.73	0.58	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
LAML	cis	rs7746199	0.736	rs35848276	ENSG00000220721.1	OR1F12	6.03	6.47e-08	0.000326	0.94	0.58	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs13202295	ENSG00000220721.1	OR1F12	6.03	6.47e-08	0.000326	0.94	0.58	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28073316~28074233:+
LAML	cis	rs6452524	0.904	rs10473867	ENSG00000249664.1	CTD-2227C6.2	6.03	6.49e-08	0.000327	0.73	0.58	Hypertension (SNP x SNP interaction);	chr5:83141613	chr5:83012285~83013109:-
LAML	cis	rs5769707	0.839	rs73176988	ENSG00000279597.1	RP4-566L20.1	-6.02	6.65e-08	0.000335	-0.67	-0.58	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49534062~49534926:+
LAML	cis	rs9326248	0.53	rs10750101	ENSG00000254851.1	RP11-109L13.1	-6.02	6.74e-08	0.000339	-1.07	-0.58	Blood protein levels;	chr11:117108973	chr11:117135528~117138582:+
LAML	cis	rs904251	0.523	rs2776872	ENSG00000279942.1	RP1-153P14.7	-6.02	6.79e-08	0.000341	-0.63	-0.58	Cognitive performance;	chr6:37515011	chr6:37567716~37571460:+
LAML	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	6.02	6.79e-08	0.000341	0.77	0.58	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
LAML	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	6.02	6.8e-08	0.000341	0.7	0.58	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
LAML	cis	rs12468226	0.938	rs55668474	ENSG00000226261.1	AC064836.3	6.01	6.83e-08	0.000343	0.85	0.58	Urate levels;	chr2:202265559	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs13392645	ENSG00000226261.1	AC064836.3	6.01	6.83e-08	0.000343	0.85	0.58	Urate levels;	chr2:202270116	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs1474002	ENSG00000226261.1	AC064836.3	6.01	6.83e-08	0.000343	0.85	0.58	Urate levels;	chr2:202290195	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs55681656	ENSG00000226261.1	AC064836.3	6.01	6.83e-08	0.000343	0.85	0.58	Urate levels;	chr2:202319041	chr2:202336024~202336727:-
LAML	cis	rs67311347	0.506	rs55962832	ENSG00000223797.4	ENTPD3-AS1	6.01	6.83e-08	0.000343	0.82	0.58	Renal cell carcinoma;	chr3:40202960	chr3:40313802~40453329:-
LAML	cis	rs66887589	0.807	rs9799664	ENSG00000248280.1	RP11-33B1.2	6.01	6.88e-08	0.000344	0.71	0.58	Diastolic blood pressure;	chr4:119405523	chr4:119440561~119450157:-
LAML	cis	rs11098499	0.575	rs9996586	ENSG00000248280.1	RP11-33B1.2	6.01	6.88e-08	0.000344	0.71	0.58	Corneal astigmatism;	chr4:119405787	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.627	rs3872807	ENSG00000248280.1	RP11-33B1.2	6.01	6.88e-08	0.000344	0.71	0.58	Diastolic blood pressure;	chr4:119439096	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.56	rs9684327	ENSG00000248280.1	RP11-33B1.2	6.01	6.88e-08	0.000344	0.71	0.58	Diastolic blood pressure;	chr4:119444286	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.807	rs13134517	ENSG00000248280.1	RP11-33B1.2	6.01	6.88e-08	0.000344	0.71	0.58	Diastolic blood pressure;	chr4:119484107	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.837	rs6534135	ENSG00000248280.1	RP11-33B1.2	6.01	6.88e-08	0.000344	0.71	0.58	Diastolic blood pressure;	chr4:119485147	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.837	rs7661498	ENSG00000248280.1	RP11-33B1.2	6.01	6.88e-08	0.000344	0.71	0.58	Diastolic blood pressure;	chr4:119486953	chr4:119440561~119450157:-
LAML	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	6.01	6.9e-08	0.000346	0.74	0.58	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
LAML	cis	rs12468226	0.938	rs116601501	ENSG00000272966.1	RP11-686O6.1	6.01	6.97e-08	0.000348	1.03	0.58	Urate levels;	chr2:202274567	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs76658848	ENSG00000272966.1	RP11-686O6.1	6.01	6.97e-08	0.000348	1.03	0.58	Urate levels;	chr2:202275548	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs57571703	ENSG00000272966.1	RP11-686O6.1	6.01	6.97e-08	0.000348	1.03	0.58	Urate levels;	chr2:202281997	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs60722019	ENSG00000272966.1	RP11-686O6.1	6.01	6.97e-08	0.000348	1.03	0.58	Urate levels;	chr2:202282060	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs78928733	ENSG00000272966.1	RP11-686O6.1	6.01	6.97e-08	0.000348	1.03	0.58	Urate levels;	chr2:202283787	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs77062060	ENSG00000272966.1	RP11-686O6.1	6.01	6.97e-08	0.000348	1.03	0.58	Urate levels;	chr2:202285639	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs116109808	ENSG00000272966.1	RP11-686O6.1	6.01	6.97e-08	0.000348	1.03	0.58	Urate levels;	chr2:202287356	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs78175596	ENSG00000272966.1	RP11-686O6.1	6.01	6.97e-08	0.000348	1.03	0.58	Urate levels;	chr2:202287993	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs74454549	ENSG00000272966.1	RP11-686O6.1	6.01	6.97e-08	0.000348	1.03	0.58	Urate levels;	chr2:202288044	chr2:202336739~202337200:+
LAML	cis	rs2564921	0.704	rs62255931	ENSG00000280417.1	RP11-5O17.1	-6.01	6.98e-08	0.000349	-0.84	-0.58	Height;	chr3:53097932	chr3:53046166~53048122:+
LAML	cis	rs66887589	0.774	rs9307477	ENSG00000248280.1	RP11-33B1.2	6.01	7.01e-08	0.00035	0.71	0.58	Diastolic blood pressure;	chr4:119500654	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.775	rs6843229	ENSG00000248280.1	RP11-33B1.2	6.01	7.01e-08	0.00035	0.71	0.58	Diastolic blood pressure;	chr4:119502932	chr4:119440561~119450157:-
LAML	cis	rs9368481	0.7	rs6911401	ENSG00000243307.2	POM121L6P	6.01	7.07e-08	0.000353	0.7	0.58	Autism spectrum disorder or schizophrenia;	chr6:26945435	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.729	rs10946881	ENSG00000243307.2	POM121L6P	6.01	7.07e-08	0.000353	0.7	0.58	Autism spectrum disorder or schizophrenia;	chr6:26946832	chr6:26896952~26898777:+
LAML	cis	rs62402013	1	rs62402013	ENSG00000243307.2	POM121L6P	6.01	7.07e-08	0.000353	0.7	0.58	Schizophrenia;	chr6:26947221	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.678	rs62402024	ENSG00000243307.2	POM121L6P	6.01	7.07e-08	0.000353	0.7	0.58	Autism spectrum disorder or schizophrenia;	chr6:26956197	chr6:26896952~26898777:+
LAML	cis	rs6772840	1	rs4280612	ENSG00000272077.1	RP11-348P10.2	-6	7.1e-08	0.000354	-0.99	-0.58	Subjective well-being;	chr3:43833080	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs11710439	ENSG00000272077.1	RP11-348P10.2	-6	7.1e-08	0.000354	-0.99	-0.58	Subjective well-being;	chr3:43833405	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs62251003	ENSG00000272077.1	RP11-348P10.2	-6	7.1e-08	0.000354	-0.99	-0.58	Subjective well-being;	chr3:43833609	chr3:44667412~44669364:+
LAML	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-6	7.19e-08	0.000357	-0.72	-0.58	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
LAML	cis	rs6452524	0.904	rs10076056	ENSG00000249664.1	CTD-2227C6.2	-6	7.21e-08	0.000358	-0.73	-0.58	Hypertension (SNP x SNP interaction);	chr5:83161702	chr5:83012285~83013109:-
LAML	cis	rs4591358	0.705	rs7585547	ENSG00000223466.1	AC064834.2	6	7.24e-08	0.000359	0.7	0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195424335	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.677	rs7562869	ENSG00000223466.1	AC064834.2	6	7.24e-08	0.000359	0.7	0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195425224	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.626	rs7565624	ENSG00000223466.1	AC064834.2	6	7.24e-08	0.000359	0.7	0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195431262	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.651	rs66489016	ENSG00000223466.1	AC064834.2	6	7.24e-08	0.000359	0.7	0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195431900	chr2:195533035~195538681:+
LAML	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-6	7.26e-08	0.000359	-0.76	-0.58	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
LAML	cis	rs9368481	0.547	rs2093303	ENSG00000243307.2	POM121L6P	6	7.26e-08	0.000359	0.74	0.58	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.594	rs7768643	ENSG00000243307.2	POM121L6P	6	7.26e-08	0.000359	0.74	0.58	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.594	rs7768814	ENSG00000243307.2	POM121L6P	6	7.26e-08	0.000359	0.74	0.58	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26896952~26898777:+
LAML	cis	rs2929278	0.588	rs1975364	ENSG00000249839.1	AC011330.5	-6	7.27e-08	0.000359	-0.72	-0.58	Schizophrenia;	chr15:43857991	chr15:43663654~43684339:-
LAML	cis	rs6951245	0.507	rs11763865	ENSG00000229043.2	AC091729.9	-6	7.27e-08	0.000359	-0.8	-0.58	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1154638	chr7:1160374~1165267:+
LAML	cis	rs10927875	0.619	rs7537101	ENSG00000178715.8	RP11-169K16.8	-6	7.32e-08	0.000362	-0.67	-0.58	Dilated cardiomyopathy;	chr1:15823889	chr1:15828232~15828669:+
LAML	cis	rs9326248	0.569	rs473172	ENSG00000254851.1	RP11-109L13.1	-6	7.37e-08	0.000364	-1.04	-0.58	Blood protein levels;	chr11:116937254	chr11:117135528~117138582:+
LAML	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	6	7.38e-08	0.000364	0.78	0.58	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	6	7.38e-08	0.000364	0.78	0.58	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	6	7.38e-08	0.000364	0.78	0.58	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	6	7.38e-08	0.000364	0.78	0.58	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
LAML	cis	rs62070183	0.938	rs75393526	ENSG00000266718.1	RP11-466A19.1	5.99	7.4e-08	0.000365	0.91	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32708000	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs75822124	ENSG00000266718.1	RP11-466A19.1	5.99	7.4e-08	0.000365	0.91	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32710876	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs17183176	ENSG00000266718.1	RP11-466A19.1	5.99	7.4e-08	0.000365	0.91	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32727107	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs1990825	ENSG00000266718.1	RP11-466A19.1	5.99	7.4e-08	0.000365	0.91	0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32729274	chr17:32495536~32499333:+
LAML	cis	rs709400	1	rs58133129	ENSG00000258851.1	RP11-894P9.2	-5.99	7.43e-08	0.000366	-0.72	-0.58	Body mass index;	chr14:103638422	chr14:103553421~103561877:+
LAML	cis	rs62070183	0.766	rs10512441	ENSG00000279781.1	RP11-466A19.7	-5.99	7.44e-08	0.000367	-0.85	-0.58	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32518322~32518934:-
LAML	cis	rs4591358	0.648	rs17177798	ENSG00000223466.1	AC064834.2	-5.99	7.47e-08	0.000368	-0.84	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195521352	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.689	rs1913894	ENSG00000223466.1	AC064834.2	-5.99	7.47e-08	0.000368	-0.84	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195534032	chr2:195533035~195538681:+
LAML	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-5.99	7.65e-08	0.000376	-0.69	-0.58	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
LAML	cis	rs10028773	0.515	rs9994488	ENSG00000248280.1	RP11-33B1.2	5.99	7.67e-08	0.000377	0.82	0.58	Educational attainment;	chr4:119666626	chr4:119440561~119450157:-
LAML	cis	rs4273100	0.688	rs28582509	ENSG00000262319.1	CTC-457L16.2	-5.99	7.68e-08	0.000378	-0.9	-0.58	Schizophrenia;	chr17:19261866	chr17:19141017~19143689:-
LAML	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-5.98	7.74e-08	0.00038	-0.71	-0.58	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-5.98	7.74e-08	0.00038	-0.71	-0.58	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
LAML	cis	rs3758911	0.894	rs999984	ENSG00000261098.1	RP11-819C21.1	-5.98	7.81e-08	0.000384	-0.54	-0.58	Coronary artery disease;	chr11:107321266	chr11:107312132~107316271:-
LAML	cis	rs9457247	0.602	rs12208359	ENSG00000265828.1	MIR3939	-5.98	7.84e-08	0.000385	-0.83	-0.58	Crohn's disease;	chr6:167044967	chr6:166997807~166997912:-
LAML	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	5.98	7.86e-08	0.000386	0.74	0.58	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
LAML	cis	rs4879656	0.564	rs2183870	ENSG00000225693.1	LAGE3P1	5.98	7.96e-08	0.00039	0.63	0.58	Menopause (age at onset);	chr9:32994502	chr9:33019682~33020165:-
LAML	cis	rs1075265	0.87	rs6749817	ENSG00000235937.1	AC008280.1	5.98	7.96e-08	0.00039	0.47	0.58	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.87	rs1421617	ENSG00000235937.1	AC008280.1	5.98	7.96e-08	0.00039	0.47	0.58	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54029552~54030682:-
LAML	cis	rs2564921	0.73	rs56386026	ENSG00000280417.1	RP11-5O17.1	-5.98	8e-08	0.000392	-0.84	-0.58	Height;	chr3:53080524	chr3:53046166~53048122:+
LAML	cis	rs709400	0.93	rs10149249	ENSG00000258851.1	RP11-894P9.2	-5.97	8.06e-08	0.000394	-0.77	-0.58	Body mass index;	chr14:103581420	chr14:103553421~103561877:+
LAML	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	5.97	8.21e-08	0.000401	0.4	0.58	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
LAML	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-5.97	8.25e-08	0.000403	-0.71	-0.58	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-5.97	8.25e-08	0.000403	-0.71	-0.58	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
LAML	cis	rs6452524	0.78	rs10078661	ENSG00000249664.1	CTD-2227C6.2	5.97	8.25e-08	0.000403	0.76	0.58	Hypertension (SNP x SNP interaction);	chr5:83182136	chr5:83012285~83013109:-
LAML	cis	rs7429990	0.901	rs9825114	ENSG00000229759.1	MRPS18AP1	-5.97	8.26e-08	0.000403	-0.71	-0.58	Educational attainment (years of education);	chr3:48096592	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.932	rs6766641	ENSG00000229759.1	MRPS18AP1	-5.97	8.26e-08	0.000403	-0.71	-0.58	Educational attainment (years of education);	chr3:48103734	chr3:48256350~48256938:-
LAML	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-5.97	8.26e-08	0.000403	-0.86	-0.58	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
LAML	cis	rs2581828	0.656	rs2253656	ENSG00000280417.1	RP11-5O17.1	5.97	8.29e-08	0.000404	0.72	0.58	Crohn's disease;	chr3:53085083	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs2253685	ENSG00000280417.1	RP11-5O17.1	5.97	8.29e-08	0.000404	0.72	0.58	Crohn's disease;	chr3:53085687	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs2253796	ENSG00000280417.1	RP11-5O17.1	5.97	8.29e-08	0.000404	0.72	0.58	Crohn's disease;	chr3:53086082	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs11130338	ENSG00000280417.1	RP11-5O17.1	5.97	8.29e-08	0.000404	0.72	0.58	Crohn's disease;	chr3:53086908	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs2581782	ENSG00000280417.1	RP11-5O17.1	5.97	8.29e-08	0.000404	0.72	0.58	Crohn's disease;	chr3:53088241	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs2581783	ENSG00000280417.1	RP11-5O17.1	5.97	8.29e-08	0.000404	0.72	0.58	Crohn's disease;	chr3:53088242	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.607	rs2581784	ENSG00000280417.1	RP11-5O17.1	5.97	8.29e-08	0.000404	0.72	0.58	Crohn's disease;	chr3:53088354	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs891368	ENSG00000280417.1	RP11-5O17.1	5.97	8.29e-08	0.000404	0.72	0.58	Crohn's disease;	chr3:53089257	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs1078968	ENSG00000280417.1	RP11-5O17.1	5.97	8.29e-08	0.000404	0.72	0.58	Crohn's disease;	chr3:53089470	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs2564944	ENSG00000280417.1	RP11-5O17.1	5.97	8.29e-08	0.000404	0.77	0.58	Crohn's disease;	chr3:53114439	chr3:53046166~53048122:+
LAML	cis	rs853679	1	rs735765	ENSG00000187763.3	OR2B7P	5.97	8.3e-08	0.000405	0.97	0.58	Depression;	chr6:28202519	chr6:28046434~28047367:+
LAML	cis	rs6452524	0.78	rs2386237	ENSG00000249664.1	CTD-2227C6.2	5.97	8.32e-08	0.000406	0.78	0.58	Hypertension (SNP x SNP interaction);	chr5:83101852	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.804	rs1478481	ENSG00000249664.1	CTD-2227C6.2	5.97	8.32e-08	0.000406	0.78	0.58	Hypertension (SNP x SNP interaction);	chr5:83111286	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.868	rs10045104	ENSG00000249664.1	CTD-2227C6.2	5.97	8.32e-08	0.000406	0.78	0.58	Hypertension (SNP x SNP interaction);	chr5:83116543	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.836	rs62372713	ENSG00000249664.1	CTD-2227C6.2	5.97	8.32e-08	0.000406	0.78	0.58	Hypertension (SNP x SNP interaction);	chr5:83090635	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.868	rs62372714	ENSG00000249664.1	CTD-2227C6.2	5.97	8.32e-08	0.000406	0.78	0.58	Hypertension (SNP x SNP interaction);	chr5:83095449	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.868	rs17205699	ENSG00000249664.1	CTD-2227C6.2	5.97	8.32e-08	0.000406	0.78	0.58	Hypertension (SNP x SNP interaction);	chr5:83098479	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.868	rs10057303	ENSG00000249664.1	CTD-2227C6.2	5.97	8.32e-08	0.000406	0.78	0.58	Hypertension (SNP x SNP interaction);	chr5:83098564	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.868	rs2386235	ENSG00000249664.1	CTD-2227C6.2	5.97	8.32e-08	0.000406	0.78	0.58	Hypertension (SNP x SNP interaction);	chr5:83101452	chr5:83012285~83013109:-
LAML	cis	rs904251	0.523	rs2797794	ENSG00000279942.1	RP1-153P14.7	-5.97	8.35e-08	0.000407	-0.64	-0.58	Cognitive performance;	chr6:37512828	chr6:37567716~37571460:+
LAML	cis	rs904251	0.523	rs2776920	ENSG00000279942.1	RP1-153P14.7	-5.97	8.35e-08	0.000407	-0.64	-0.58	Cognitive performance;	chr6:37512829	chr6:37567716~37571460:+
LAML	cis	rs904251	0.504	rs2797795	ENSG00000279942.1	RP1-153P14.7	-5.97	8.35e-08	0.000407	-0.64	-0.58	Cognitive performance;	chr6:37512907	chr6:37567716~37571460:+
LAML	cis	rs904251	0.523	rs2797796	ENSG00000279942.1	RP1-153P14.7	-5.97	8.35e-08	0.000407	-0.64	-0.58	Cognitive performance;	chr6:37513110	chr6:37567716~37571460:+
LAML	cis	rs904251	0.523	rs2776870	ENSG00000279942.1	RP1-153P14.7	-5.97	8.35e-08	0.000407	-0.64	-0.58	Cognitive performance;	chr6:37513588	chr6:37567716~37571460:+
LAML	cis	rs904251	0.523	rs2797798	ENSG00000279942.1	RP1-153P14.7	-5.97	8.35e-08	0.000407	-0.64	-0.58	Cognitive performance;	chr6:37513661	chr6:37567716~37571460:+
LAML	cis	rs904251	0.523	rs2776871	ENSG00000279942.1	RP1-153P14.7	-5.97	8.35e-08	0.000407	-0.64	-0.58	Cognitive performance;	chr6:37513983	chr6:37567716~37571460:+
LAML	cis	rs4591358	0.731	rs13036252	ENSG00000223466.1	AC064834.2	-5.96	8.36e-08	0.000407	-0.89	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195425834	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.68	rs7568240	ENSG00000223466.1	AC064834.2	-5.96	8.36e-08	0.000407	-0.89	-0.58	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195428263	chr2:195533035~195538681:+
LAML	cis	rs62070183	0.938	rs62068432	ENSG00000280245.1	RP11-466A19.4	5.96	8.47e-08	0.000412	0.86	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32739479	chr17:32504567~32505644:-
LAML	cis	rs911555	1	rs911555	ENSG00000258851.1	RP11-894P9.2	5.96	8.49e-08	0.000413	0.66	0.57	Intelligence (multi-trait analysis);	chr14:103533010	chr14:103553421~103561877:+
LAML	cis	rs904251	0.523	rs1776455	ENSG00000204110.6	RP1-153P14.8	-5.96	8.51e-08	0.000413	-0.69	-0.57	Cognitive performance;	chr6:37515147	chr6:37507348~37535616:+
LAML	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-5.96	8.52e-08	0.000413	-1.06	-0.57	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-5.96	8.52e-08	0.000413	-1.06	-0.57	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs7122944	ENSG00000254851.1	RP11-109L13.1	-5.96	8.52e-08	0.000413	-1.06	-0.57	Blood protein levels;	chr11:117163903	chr11:117135528~117138582:+
LAML	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-5.96	8.52e-08	0.000413	-1.06	-0.57	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-5.96	8.52e-08	0.000413	-1.06	-0.57	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs1242229	ENSG00000254851.1	RP11-109L13.1	-5.96	8.52e-08	0.000413	-1.06	-0.57	Blood protein levels;	chr11:117191654	chr11:117135528~117138582:+
LAML	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	5.96	8.52e-08	0.000413	1.06	0.57	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
LAML	cis	rs5769707	0.681	rs135879	ENSG00000280224.1	CTA-722E9.1	-5.96	8.59e-08	0.000417	-0.83	-0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.642	rs135880	ENSG00000280224.1	CTA-722E9.1	-5.96	8.59e-08	0.000417	-0.83	-0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49500568~49501585:+
LAML	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-5.95	8.72e-08	0.000422	-1.06	-0.57	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-5.95	8.72e-08	0.000422	-1.06	-0.57	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
LAML	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-5.95	8.8e-08	0.000425	-0.71	-0.57	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
LAML	cis	rs916888	0.61	rs199530	ENSG00000214401.4	KANSL1-AS1	-5.95	8.84e-08	0.000427	-0.74	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:46193576~46196723:+
LAML	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-5.95	8.99e-08	0.000434	-0.71	-0.57	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
LAML	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	5.95	8.99e-08	0.000434	0.65	0.57	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
LAML	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	5.95	9.04e-08	0.000436	0.8	0.57	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
LAML	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	5.95	9.04e-08	0.000436	0.8	0.57	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
LAML	cis	rs6452524	0.901	rs4571449	ENSG00000249664.1	CTD-2227C6.2	5.95	9.06e-08	0.000437	0.76	0.57	Hypertension (SNP x SNP interaction);	chr5:83175392	chr5:83012285~83013109:-
LAML	cis	rs6597981	0.592	rs28625355	ENSG00000279672.1	CMB9-55F22.1	5.94	9.14e-08	0.00044	0.56	0.57	Breast cancer;	chr11:736334	chr11:779617~780755:+
LAML	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-5.94	9.17e-08	0.000441	-0.68	-0.57	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
LAML	cis	rs2564921	0.704	rs56058643	ENSG00000280417.1	RP11-5O17.1	-5.94	9.19e-08	0.000442	-0.83	-0.57	Height;	chr3:53093751	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.704	rs55950520	ENSG00000280417.1	RP11-5O17.1	-5.94	9.19e-08	0.000442	-0.83	-0.57	Height;	chr3:53094335	chr3:53046166~53048122:+
LAML	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	5.94	9.23e-08	0.000444	0.62	0.57	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
LAML	cis	rs5769707	0.706	rs2071903	ENSG00000280224.1	CTA-722E9.1	-5.94	9.25e-08	0.000445	-0.84	-0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49500568~49501585:+
LAML	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	5.94	9.26e-08	0.000445	0.75	0.57	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	5.94	9.26e-08	0.000445	0.75	0.57	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
LAML	cis	rs12468226	0.938	rs114177656	ENSG00000272966.1	RP11-686O6.1	5.94	9.43e-08	0.000452	0.94	0.57	Urate levels;	chr2:202291596	chr2:202336739~202337200:+
LAML	cis	rs7587476	1	rs2121285	ENSG00000229267.2	AC072062.1	5.93	9.47e-08	0.000454	0.67	0.57	Neuroblastoma;	chr2:214791444	chr2:214810229~214963274:+
LAML	cis	rs7587476	1	rs1542173	ENSG00000229267.2	AC072062.1	5.93	9.47e-08	0.000454	0.67	0.57	Neuroblastoma;	chr2:214792836	chr2:214810229~214963274:+
LAML	cis	rs62070183	0.938	rs75782470	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32746623	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.882	rs62070164	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32759415	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs4795719	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32776957	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.882	rs17780981	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32792019	chr17:32504567~32505644:-
LAML	cis	rs112916054	1	rs112916054	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Immature fraction of reticulocytes;	chr17:32797244	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.752	rs17781005	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32805511	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.808	rs76373015	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815023	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.808	rs79957065	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815731	chr17:32504567~32505644:-
LAML	cis	rs62070183	1	rs62070183	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32837349	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.882	rs17183600	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32848061	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.882	rs17183628	ENSG00000280245.1	RP11-466A19.4	-5.93	9.49e-08	0.000454	-0.85	-0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32857613	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.882	rs17781136	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32858024	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs17781142	ENSG00000280245.1	RP11-466A19.4	-5.93	9.49e-08	0.000454	-0.85	-0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32860198	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.882	rs62070187	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32863706	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.817	rs79640811	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32894299	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.766	rs62070229	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32900575	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.766	rs62070232	ENSG00000280245.1	RP11-466A19.4	5.93	9.49e-08	0.000454	0.85	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32903075	chr17:32504567~32505644:-
LAML	cis	rs8037818	1	rs4643284	ENSG00000276724.1	RP11-1000B6.7	-5.93	9.49e-08	0.000454	-0.77	-0.57	Obesity-related traits;	chr15:32639897	chr15:32583612~32584312:+
LAML	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-5.93	9.51e-08	0.000455	-0.79	-0.57	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
LAML	cis	rs2564921	0.693	rs2581798	ENSG00000280417.1	RP11-5O17.1	5.93	9.55e-08	0.000457	0.82	0.57	Height;	chr3:53073584	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.73	rs2564929	ENSG00000280417.1	RP11-5O17.1	-5.93	9.58e-08	0.000458	-0.84	-0.57	Height;	chr3:53084188	chr3:53046166~53048122:+
LAML	cis	rs12468226	0.938	rs6753044	ENSG00000226261.1	AC064836.3	5.93	9.62e-08	0.00046	0.84	0.57	Urate levels;	chr2:202300710	chr2:202336024~202336727:-
LAML	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	5.93	9.66e-08	0.000462	0.75	0.57	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
LAML	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-5.93	9.67e-08	0.000463	-0.71	-0.57	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-5.93	9.67e-08	0.000463	-0.71	-0.57	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
LAML	cis	rs6782228	0.509	rs2811495	ENSG00000277250.1	Metazoa_SRP	-5.93	9.71e-08	0.000464	-0.78	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.565	rs2811496	ENSG00000277250.1	Metazoa_SRP	-5.93	9.71e-08	0.000464	-0.78	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128673681~128674021:-
LAML	cis	rs6452524	0.836	rs2731852	ENSG00000249664.1	CTD-2227C6.2	-5.93	9.72e-08	0.000464	-0.75	-0.57	Hypertension (SNP x SNP interaction);	chr5:83212591	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.805	rs2731850	ENSG00000249664.1	CTD-2227C6.2	-5.93	9.72e-08	0.000464	-0.75	-0.57	Hypertension (SNP x SNP interaction);	chr5:83213024	chr5:83012285~83013109:-
LAML	cis	rs1075265	0.749	rs2692518	ENSG00000235937.1	AC008280.1	5.93	9.72e-08	0.000465	0.45	0.57	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.756	rs2542576	ENSG00000235937.1	AC008280.1	5.93	9.72e-08	0.000465	0.45	0.57	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54029552~54030682:-
LAML	cis	rs6700559	0.703	rs10919993	ENSG00000260088.1	RP11-92G12.3	5.93	9.73e-08	0.000465	0.66	0.57	Coronary artery disease;	chr1:200658184	chr1:200669507~200694250:+
LAML	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-5.93	9.84e-08	0.00047	-0.66	-0.57	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-5.93	9.84e-08	0.00047	-0.66	-0.57	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
LAML	cis	rs12468226	0.817	rs2350360	ENSG00000272966.1	RP11-686O6.1	-5.92	9.86e-08	0.00047	-0.91	-0.57	Urate levels;	chr2:202222980	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs3843338	ENSG00000272966.1	RP11-686O6.1	-5.92	9.86e-08	0.00047	-0.91	-0.57	Urate levels;	chr2:202246102	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs6435139	ENSG00000272966.1	RP11-686O6.1	-5.92	9.86e-08	0.00047	-0.91	-0.57	Urate levels;	chr2:202255145	chr2:202336739~202337200:+
LAML	cis	rs6782228	0.606	rs4857861	ENSG00000277250.1	Metazoa_SRP	-5.92	1e-07	0.000476	-0.7	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs4857919	ENSG00000277250.1	Metazoa_SRP	-5.92	1e-07	0.000476	-0.7	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128673681~128674021:-
LAML	cis	rs66887589	0.934	rs2715016	ENSG00000248280.1	RP11-33B1.2	-5.92	1e-07	0.000477	-0.71	-0.57	Diastolic blood pressure;	chr4:119531201	chr4:119440561~119450157:-
LAML	cis	rs62070183	0.938	rs75393526	ENSG00000280245.1	RP11-466A19.4	5.92	1.01e-07	0.000479	0.86	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32708000	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs75822124	ENSG00000280245.1	RP11-466A19.4	5.92	1.01e-07	0.000479	0.86	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32710876	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs17183176	ENSG00000280245.1	RP11-466A19.4	5.92	1.01e-07	0.000479	0.86	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32727107	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs1990825	ENSG00000280245.1	RP11-466A19.4	5.92	1.01e-07	0.000479	0.86	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32729274	chr17:32504567~32505644:-
LAML	cis	rs7714584	1	rs59531858	ENSG00000197083.10	ZNF300P1	5.92	1.01e-07	0.000481	1.3	0.57	Crohn's disease;	chr5:150867501	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs12656538	ENSG00000197083.10	ZNF300P1	5.92	1.01e-07	0.000481	1.3	0.57	Crohn's disease;	chr5:150871818	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11743488	ENSG00000197083.10	ZNF300P1	5.92	1.01e-07	0.000481	1.3	0.57	Crohn's disease;	chr5:150899656	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs58717741	ENSG00000197083.10	ZNF300P1	5.92	1.01e-07	0.000481	1.3	0.57	Crohn's disease;	chr5:150905374	chr5:150930645~150946289:-
LAML	cis	rs2486288	0.656	rs11632920	ENSG00000259520.4	CTD-2651B20.3	5.92	1.01e-07	0.000481	0.87	0.57	Glomerular filtration rate;	chr15:45259066	chr15:45251580~45279251:-
LAML	cis	rs4713118	0.826	rs2893929	ENSG00000220721.1	OR1F12	5.92	1.01e-07	0.000482	0.68	0.57	Parkinson's disease;	chr6:27770953	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.666	rs4140646	ENSG00000220721.1	OR1F12	5.92	1.01e-07	0.000482	0.68	0.57	Parkinson's disease;	chr6:27771022	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.666	rs2893930	ENSG00000220721.1	OR1F12	5.92	1.01e-07	0.000482	0.68	0.57	Parkinson's disease;	chr6:27771027	chr6:28073316~28074233:+
LAML	cis	rs709400	1	rs6593	ENSG00000258851.1	RP11-894P9.2	-5.91	1.04e-07	0.000493	-0.72	-0.57	Body mass index;	chr14:103696945	chr14:103553421~103561877:+
LAML	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	5.91	1.04e-07	0.000495	0.64	0.57	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
LAML	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	5.91	1.04e-07	0.000495	0.6	0.57	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
LAML	cis	rs67311347	0.955	rs73080163	ENSG00000223797.4	ENTPD3-AS1	5.91	1.05e-07	0.000497	0.8	0.57	Renal cell carcinoma;	chr3:40491570	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs73080165	ENSG00000223797.4	ENTPD3-AS1	5.91	1.05e-07	0.000497	0.8	0.57	Renal cell carcinoma;	chr3:40491571	chr3:40313802~40453329:-
LAML	cis	rs709400	0.93	rs61996717	ENSG00000258851.1	RP11-894P9.2	-5.91	1.05e-07	0.000498	-0.75	-0.57	Body mass index;	chr14:103582234	chr14:103553421~103561877:+
LAML	cis	rs4591358	0.765	rs16836629	ENSG00000223466.1	AC064834.2	5.91	1.06e-07	0.000499	0.76	0.57	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195499385	chr2:195533035~195538681:+
LAML	cis	rs4713118	0.662	rs149961	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28047791	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.629	rs149899	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28052201	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.629	rs172165	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28053036	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.597	rs172166	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28053042	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.629	rs203888	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28053811	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.629	rs203889	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28053997	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.629	rs203890	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28054470	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs9357060	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28056708	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs9468271	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28056792	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs9380045	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28057501	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.616	rs9348789	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28057708	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs9468274	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28058299	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs9468275	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28058358	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs9468276	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28059910	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs9468277	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28060612	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs9468278	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28060704	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs13218430	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.84	0.57	Parkinson's disease;	chr6:28062059	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs7740487	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.96	0.57	Depression;	chr6:28248708	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs68141011	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.96	0.57	Depression;	chr6:28250019	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs13200462	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.96	0.57	Depression;	chr6:28250421	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs9986596	ENSG00000182477.5	OR2B8P	5.91	1.06e-07	0.000499	0.96	0.57	Depression;	chr6:28251883	chr6:28053228~28054165:-
LAML	cis	rs66887589	0.616	rs13113885	ENSG00000248280.1	RP11-33B1.2	5.91	1.06e-07	0.000499	0.69	0.57	Diastolic blood pressure;	chr4:119300021	chr4:119440561~119450157:-
LAML	cis	rs7587476	0.954	rs3768708	ENSG00000229267.2	AC072062.1	5.91	1.07e-07	0.000502	0.65	0.57	Neuroblastoma;	chr2:214780322	chr2:214810229~214963274:+
LAML	cis	rs7746199	0.673	rs72847313	ENSG00000187763.3	OR2B7P	5.91	1.07e-07	0.000503	1.04	0.57	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.611	rs17750747	ENSG00000187763.3	OR2B7P	5.91	1.07e-07	0.000503	1.04	0.57	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.673	rs35501037	ENSG00000187763.3	OR2B7P	5.91	1.07e-07	0.000503	1.04	0.57	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28046434~28047367:+
LAML	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	5.9	1.08e-07	0.000509	0.71	0.57	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
LAML	cis	rs6452524	0.836	rs62374402	ENSG00000249664.1	CTD-2227C6.2	5.9	1.08e-07	0.000509	0.75	0.57	Hypertension (SNP x SNP interaction);	chr5:83207343	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.804	rs2048215	ENSG00000249664.1	CTD-2227C6.2	-5.9	1.08e-07	0.000509	-0.75	-0.57	Hypertension (SNP x SNP interaction);	chr5:83208589	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.836	rs11949301	ENSG00000249664.1	CTD-2227C6.2	-5.9	1.08e-07	0.000509	-0.75	-0.57	Hypertension (SNP x SNP interaction);	chr5:83209334	chr5:83012285~83013109:-
LAML	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-5.9	1.08e-07	0.00051	-0.66	-0.57	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-5.9	1.08e-07	0.00051	-0.66	-0.57	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
LAML	cis	rs916888	0.647	rs199524	ENSG00000214401.4	KANSL1-AS1	-5.9	1.09e-07	0.000511	-0.75	-0.57	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:46193576~46196723:+
LAML	cis	rs2015599	0.623	rs7964831	ENSG00000275476.1	RP11-996F15.4	-5.9	1.09e-07	0.000511	-0.62	-0.57	Platelet count;Mean platelet volume;	chr12:29286655	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	5.9	1.09e-07	0.000511	0.62	0.57	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	5.9	1.09e-07	0.000511	0.62	0.57	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	5.9	1.09e-07	0.000511	0.62	0.57	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	5.9	1.09e-07	0.000511	0.62	0.57	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	5.9	1.09e-07	0.000511	0.62	0.57	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
LAML	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	5.9	1.11e-07	0.000521	0.72	0.57	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
LAML	cis	rs9326248	0.608	rs1076485	ENSG00000254851.1	RP11-109L13.1	5.89	1.12e-07	0.000524	1	0.57	Blood protein levels;	chr11:116901725	chr11:117135528~117138582:+
LAML	cis	rs4591358	0.734	rs1553255	ENSG00000223466.1	AC064834.2	-5.89	1.12e-07	0.000525	-0.74	-0.57	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195492147	chr2:195533035~195538681:+
LAML	cis	rs4753788	0.534	rs7931436	ENSG00000261098.1	RP11-819C21.1	-5.89	1.13e-07	0.00053	-0.56	-0.57	Coronary artery disease;	chr11:107266386	chr11:107312132~107316271:-
LAML	cis	rs4753788	0.534	rs10789590	ENSG00000261098.1	RP11-819C21.1	-5.89	1.13e-07	0.00053	-0.56	-0.57	Coronary artery disease;	chr11:107266877	chr11:107312132~107316271:-
LAML	cis	rs4753788	0.511	rs1388168	ENSG00000261098.1	RP11-819C21.1	-5.89	1.13e-07	0.00053	-0.56	-0.57	Coronary artery disease;	chr11:107267191	chr11:107312132~107316271:-
LAML	cis	rs1930961	1	rs59226697	ENSG00000100058.11	CRYBB2P1	-5.89	1.13e-07	0.000531	-1.32	-0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25474070	chr22:25448105~25520854:+
LAML	cis	rs7429990	0.864	rs6777081	ENSG00000229759.1	MRPS18AP1	-5.89	1.14e-07	0.000531	-0.7	-0.57	Educational attainment (years of education);	chr3:48114079	chr3:48256350~48256938:-
LAML	cis	rs1075265	0.87	rs17268179	ENSG00000235937.1	AC008280.1	5.89	1.14e-07	0.000533	0.47	0.57	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.818	rs12713253	ENSG00000235937.1	AC008280.1	5.89	1.14e-07	0.000533	0.47	0.57	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54029552~54030682:-
LAML	cis	rs5769707	0.837	rs5770599	ENSG00000212939.2	RP1-29C18.10	-5.89	1.14e-07	0.000534	-0.74	-0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.837	rs5769709	ENSG00000212939.2	RP1-29C18.10	-5.89	1.14e-07	0.000534	-0.74	-0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49548681~49556473:+
LAML	cis	rs2486288	0.656	rs8024620	ENSG00000259520.4	CTD-2651B20.3	5.89	1.15e-07	0.000536	0.87	0.57	Glomerular filtration rate;	chr15:45282131	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11637364	ENSG00000259520.4	CTD-2651B20.3	5.89	1.15e-07	0.000536	0.87	0.57	Glomerular filtration rate;	chr15:45287040	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs8039153	ENSG00000259520.4	CTD-2651B20.3	5.89	1.15e-07	0.000536	0.87	0.57	Glomerular filtration rate;	chr15:45287615	chr15:45251580~45279251:-
LAML	cis	rs1075265	0.722	rs7596349	ENSG00000235937.1	AC008280.1	5.88	1.16e-07	0.000542	0.46	0.57	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54029552~54030682:-
LAML	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-5.88	1.16e-07	0.000542	-0.55	-0.57	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
LAML	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	5.88	1.16e-07	0.000542	0.81	0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
LAML	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-5.88	1.16e-07	0.000542	-0.84	-0.57	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
LAML	cis	rs67311347	0.521	rs2887963	ENSG00000223797.4	ENTPD3-AS1	-5.88	1.17e-07	0.000544	-0.77	-0.57	Renal cell carcinoma;	chr3:40201975	chr3:40313802~40453329:-
LAML	cis	rs16828019	0.929	rs35883594	ENSG00000213987.4	RP11-399E6.2	5.88	1.18e-07	0.000548	0.97	0.57	Intelligence (multi-trait analysis);	chr1:41278421	chr1:41264550~41264862:-
LAML	cis	rs911555	1	rs754287	ENSG00000258851.1	RP11-894P9.2	5.88	1.18e-07	0.000548	0.66	0.57	Intelligence (multi-trait analysis);	chr14:103531188	chr14:103553421~103561877:+
LAML	cis	rs911555	1	rs911552	ENSG00000258851.1	RP11-894P9.2	5.88	1.18e-07	0.000548	0.66	0.57	Intelligence (multi-trait analysis);	chr14:103533171	chr14:103553421~103561877:+
LAML	cis	rs911555	1	rs2756127	ENSG00000258851.1	RP11-894P9.2	5.88	1.18e-07	0.000548	0.66	0.57	Intelligence (multi-trait analysis);	chr14:103533846	chr14:103553421~103561877:+
LAML	cis	rs7847628	0.765	rs10985024	ENSG00000226752.6	PSMD5-AS1	-5.88	1.19e-07	0.00055	-0.78	-0.57	Birth weight;	chr9:120754534	chr9:120824828~120854385:+
LAML	cis	rs62070183	0.882	rs17183295	ENSG00000266718.1	RP11-466A19.1	5.88	1.2e-07	0.000556	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32751254	chr17:32495536~32499333:+
LAML	cis	rs7587476	0.765	rs2121284	ENSG00000227769.6	AC072062.3	5.87	1.22e-07	0.000562	0.61	0.57	Neuroblastoma;	chr2:214791536	chr2:215004782~215085488:+
LAML	cis	rs4713118	0.662	rs149901	ENSG00000220721.1	OR1F12	5.87	1.23e-07	0.000566	0.72	0.57	Parkinson's disease;	chr6:27997725	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs464312	ENSG00000220721.1	OR1F12	5.87	1.23e-07	0.000566	0.72	0.57	Parkinson's disease;	chr6:27999813	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.662	rs469228	ENSG00000220721.1	OR1F12	5.87	1.23e-07	0.000566	0.72	0.57	Parkinson's disease;	chr6:28002926	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.54	rs469227	ENSG00000220721.1	OR1F12	5.87	1.23e-07	0.000566	0.72	0.57	Parkinson's disease;	chr6:28002927	chr6:28073316~28074233:+
LAML	cis	rs2564921	0.704	rs62253649	ENSG00000280417.1	RP11-5O17.1	-5.87	1.23e-07	0.000568	-0.79	-0.57	Height;	chr3:52967831	chr3:53046166~53048122:+
LAML	cis	rs6782228	0.606	rs6807019	ENSG00000277250.1	Metazoa_SRP	-5.87	1.23e-07	0.000569	-0.7	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128673681~128674021:-
LAML	cis	rs911555	0.504	rs745079	ENSG00000258851.1	RP11-894P9.2	-5.87	1.24e-07	0.000569	-0.65	-0.57	Intelligence (multi-trait analysis);	chr14:103607214	chr14:103553421~103561877:+
LAML	cis	rs911555	0.504	rs8006526	ENSG00000258851.1	RP11-894P9.2	-5.87	1.24e-07	0.000569	-0.65	-0.57	Intelligence (multi-trait analysis);	chr14:103608678	chr14:103553421~103561877:+
LAML	cis	rs911555	0.504	rs61995761	ENSG00000258851.1	RP11-894P9.2	-5.87	1.24e-07	0.000569	-0.65	-0.57	Intelligence (multi-trait analysis);	chr14:103609375	chr14:103553421~103561877:+
LAML	cis	rs4713118	0.699	rs200969	ENSG00000220721.1	OR1F12	5.87	1.24e-07	0.00057	0.65	0.57	Parkinson's disease;	chr6:27891675	chr6:28073316~28074233:+
LAML	cis	rs5769707	0.967	rs739241	ENSG00000213279.2	RP1-29C18.9	-5.87	1.24e-07	0.000572	-0.63	-0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49659273	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.521	rs6009810	ENSG00000280224.1	CTA-722E9.1	-5.87	1.24e-07	0.000573	-0.76	-0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49500568~49501585:+
LAML	cis	rs7714584	1	rs4579248	ENSG00000197083.10	ZNF300P1	5.87	1.25e-07	0.000577	1.29	0.57	Crohn's disease;	chr5:150888589	chr5:150930645~150946289:-
LAML	cis	rs67311347	0.594	rs12629111	ENSG00000223797.4	ENTPD3-AS1	5.87	1.26e-07	0.000578	0.79	0.57	Renal cell carcinoma;	chr3:40243860	chr3:40313802~40453329:-
LAML	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	5.86	1.26e-07	0.000579	0.7	0.57	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	5.86	1.26e-07	0.000579	0.7	0.57	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
LAML	cis	rs1075265	0.716	rs7573991	ENSG00000235937.1	AC008280.1	5.86	1.26e-07	0.00058	0.45	0.57	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54029552~54030682:-
LAML	cis	rs2564921	0.73	rs62253602	ENSG00000280417.1	RP11-5O17.1	-5.86	1.26e-07	0.000581	-0.79	-0.57	Height;	chr3:52936861	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.704	rs62253603	ENSG00000280417.1	RP11-5O17.1	-5.86	1.26e-07	0.000581	-0.79	-0.57	Height;	chr3:52938846	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.704	rs62253604	ENSG00000280417.1	RP11-5O17.1	-5.86	1.26e-07	0.000581	-0.79	-0.57	Height;	chr3:52941053	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.704	rs62253606	ENSG00000280417.1	RP11-5O17.1	-5.86	1.26e-07	0.000581	-0.79	-0.57	Height;	chr3:52949886	chr3:53046166~53048122:+
LAML	cis	rs1075265	0.744	rs2909460	ENSG00000235937.1	AC008280.1	5.86	1.27e-07	0.000582	0.47	0.57	Chronotype;Morning vs. evening chronotype;	chr2:53967611	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.811	rs805308	ENSG00000235937.1	AC008280.1	5.86	1.27e-07	0.000582	0.47	0.57	Chronotype;Morning vs. evening chronotype;	chr2:53967797	chr2:54029552~54030682:-
LAML	cis	rs904251	0.523	rs1776454	ENSG00000204110.6	RP1-153P14.8	-5.86	1.29e-07	0.000591	-0.71	-0.57	Cognitive performance;	chr6:37514323	chr6:37507348~37535616:+
LAML	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	5.86	1.3e-07	0.000596	0.73	0.57	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
LAML	cis	rs709400	0.77	rs7142883	ENSG00000258851.1	RP11-894P9.2	-5.86	1.3e-07	0.000596	-0.76	-0.57	Body mass index;	chr14:103600308	chr14:103553421~103561877:+
LAML	cis	rs709400	0.643	rs11621777	ENSG00000258851.1	RP11-894P9.2	-5.86	1.3e-07	0.000596	-0.76	-0.57	Body mass index;	chr14:103605753	chr14:103553421~103561877:+
LAML	cis	rs709400	0.894	rs56017123	ENSG00000258851.1	RP11-894P9.2	-5.86	1.3e-07	0.000596	-0.76	-0.57	Body mass index;	chr14:103608940	chr14:103553421~103561877:+
LAML	cis	rs4713118	0.868	rs2893928	ENSG00000182477.5	OR2B8P	5.86	1.3e-07	0.000597	0.78	0.57	Parkinson's disease;	chr6:27770651	chr6:28053228~28054165:-
LAML	cis	rs9322193	0.923	rs4870052	ENSG00000216906.2	RP11-350J20.9	5.86	1.3e-07	0.000598	0.86	0.57	Lung cancer;	chr6:149839978	chr6:149904243~149906418:+
LAML	cis	rs8037818	1	rs4544214	ENSG00000276724.1	RP11-1000B6.7	5.86	1.3e-07	0.000598	0.78	0.57	Obesity-related traits;	chr15:32639703	chr15:32583612~32584312:+
LAML	cis	rs6686842	0.689	rs2885697	ENSG00000235358.1	RP11-399E6.1	-5.86	1.31e-07	0.000599	-0.67	-0.57	Height;	chr1:41078607	chr1:41242373~41284861:+
LAML	cis	rs12468226	1	rs111542497	ENSG00000226261.1	AC064836.3	5.85	1.31e-07	0.000602	0.87	0.57	Urate levels;	chr2:202330369	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs77435512	ENSG00000226261.1	AC064836.3	5.85	1.31e-07	0.000602	0.87	0.57	Urate levels;	chr2:202334165	chr2:202336024~202336727:-
LAML	cis	rs1075265	0.749	rs2357693	ENSG00000235937.1	AC008280.1	5.85	1.31e-07	0.000602	0.45	0.57	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.749	rs10203095	ENSG00000235937.1	AC008280.1	5.85	1.31e-07	0.000602	0.45	0.57	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54029552~54030682:-
LAML	cis	rs7189233	0.531	rs8055642	ENSG00000279344.1	RP11-44F14.7	5.85	1.32e-07	0.000603	0.4	0.57	Intelligence (multi-trait analysis);	chr16:53503669	chr16:53478957~53481550:-
LAML	cis	rs1153858	0.621	rs2413769	ENSG00000259520.4	CTD-2651B20.3	-5.85	1.32e-07	0.000604	-0.82	-0.57	Homoarginine levels;	chr15:45269670	chr15:45251580~45279251:-
LAML	cis	rs1153858	0.621	rs1719237	ENSG00000259520.4	CTD-2651B20.3	-5.85	1.32e-07	0.000604	-0.82	-0.57	Homoarginine levels;	chr15:45287624	chr15:45251580~45279251:-
LAML	cis	rs1153858	0.621	rs1706824	ENSG00000259520.4	CTD-2651B20.3	-5.85	1.32e-07	0.000604	-0.82	-0.57	Homoarginine levels;	chr15:45287750	chr15:45251580~45279251:-
LAML	cis	rs1153858	0.621	rs12913645	ENSG00000259520.4	CTD-2651B20.3	5.85	1.32e-07	0.000604	0.82	0.57	Homoarginine levels;	chr15:45262868	chr15:45251580~45279251:-
LAML	cis	rs5769707	0.681	rs9616329	ENSG00000280224.1	CTA-722E9.1	-5.85	1.32e-07	0.000605	-0.79	-0.57	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49500568~49501585:+
LAML	cis	rs7714584	0.793	rs2161363	ENSG00000197083.10	ZNF300P1	5.85	1.32e-07	0.000605	1.29	0.57	Crohn's disease;	chr5:150802517	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs6875011	ENSG00000197083.10	ZNF300P1	5.85	1.32e-07	0.000605	1.29	0.57	Crohn's disease;	chr5:150803148	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs73282234	ENSG00000197083.10	ZNF300P1	5.85	1.32e-07	0.000605	1.29	0.57	Crohn's disease;	chr5:150816362	chr5:150930645~150946289:-
LAML	cis	rs62070183	0.938	rs9911168	ENSG00000265222.1	RP11-466A19.8	5.85	1.32e-07	0.000606	0.9	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709136	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs9912761	ENSG00000265222.1	RP11-466A19.8	5.85	1.32e-07	0.000606	0.9	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709475	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs9303654	ENSG00000265222.1	RP11-466A19.8	5.85	1.32e-07	0.000606	0.9	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709747	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs9898762	ENSG00000265222.1	RP11-466A19.8	5.85	1.32e-07	0.000606	0.9	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32711641	chr17:32509954~32523424:-
LAML	cis	rs4713118	0.699	rs573179	ENSG00000220721.1	OR1F12	5.85	1.33e-07	0.000607	0.65	0.57	Parkinson's disease;	chr6:27881898	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.699	rs200978	ENSG00000220721.1	OR1F12	5.85	1.33e-07	0.000607	0.65	0.57	Parkinson's disease;	chr6:27885390	chr6:28073316~28074233:+
LAML	cis	rs4591358	0.765	rs1392658	ENSG00000223466.1	AC064834.2	5.85	1.33e-07	0.000609	0.71	0.57	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195463666	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.734	rs16836256	ENSG00000223466.1	AC064834.2	5.85	1.33e-07	0.000609	0.71	0.57	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195470381	chr2:195533035~195538681:+
LAML	cis	rs62070183	0.938	rs62068432	ENSG00000265222.1	RP11-466A19.8	5.85	1.36e-07	0.000618	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32739479	chr17:32509954~32523424:-
LAML	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	5.84	1.37e-07	0.000622	0.7	0.57	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
LAML	cis	rs7044106	1	rs7044106	ENSG00000226752.6	PSMD5-AS1	-5.84	1.38e-07	0.000626	-0.83	-0.57	Hip circumference adjusted for BMI;	chr9:120731784	chr9:120824828~120854385:+
LAML	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	5.84	1.38e-07	0.000626	0.65	0.57	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	5.84	1.38e-07	0.000626	0.65	0.57	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	5.84	1.38e-07	0.000626	0.65	0.57	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	5.84	1.38e-07	0.000626	0.65	0.57	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
LAML	cis	rs62070183	0.938	rs75782470	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32746623	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.882	rs62070164	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32759415	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs4795719	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32776957	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.882	rs17780981	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32792019	chr17:32509954~32523424:-
LAML	cis	rs112916054	1	rs112916054	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Immature fraction of reticulocytes;	chr17:32797244	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.752	rs17781005	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32805511	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.808	rs76373015	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815023	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.808	rs79957065	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815731	chr17:32509954~32523424:-
LAML	cis	rs62070183	1	rs62070183	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32837349	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.882	rs17183600	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32848061	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.882	rs17781136	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32858024	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.882	rs62070187	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32863706	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.817	rs79640811	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32894299	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.766	rs62070229	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32900575	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.766	rs62070232	ENSG00000265222.1	RP11-466A19.8	5.84	1.38e-07	0.000626	0.89	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32903075	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.882	rs17183628	ENSG00000265222.1	RP11-466A19.8	-5.84	1.38e-07	0.000626	-0.89	-0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32857613	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs17781142	ENSG00000265222.1	RP11-466A19.8	-5.84	1.38e-07	0.000626	-0.89	-0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32860198	chr17:32509954~32523424:-
LAML	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	5.84	1.39e-07	0.000628	0.63	0.57	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
LAML	cis	rs66887589	0.967	rs3775842	ENSG00000248280.1	RP11-33B1.2	5.84	1.4e-07	0.000635	0.7	0.57	Diastolic blood pressure;	chr4:119506577	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.967	rs1480933	ENSG00000248280.1	RP11-33B1.2	5.84	1.4e-07	0.000635	0.7	0.57	Diastolic blood pressure;	chr4:119512093	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.967	rs6844263	ENSG00000248280.1	RP11-33B1.2	5.84	1.4e-07	0.000635	0.7	0.57	Diastolic blood pressure;	chr4:119512652	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.967	rs13104219	ENSG00000248280.1	RP11-33B1.2	5.84	1.4e-07	0.000635	0.7	0.57	Diastolic blood pressure;	chr4:119517019	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.967	rs1155577	ENSG00000248280.1	RP11-33B1.2	-5.84	1.4e-07	0.000635	-0.7	-0.57	Diastolic blood pressure;	chr4:119528655	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.967	rs56173225	ENSG00000248280.1	RP11-33B1.2	-5.84	1.4e-07	0.000635	-0.7	-0.57	Diastolic blood pressure;	chr4:119588817	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.967	rs7678973	ENSG00000248280.1	RP11-33B1.2	-5.84	1.4e-07	0.000635	-0.7	-0.57	Diastolic blood pressure;	chr4:119590662	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.934	rs56843000	ENSG00000248280.1	RP11-33B1.2	-5.84	1.4e-07	0.000635	-0.7	-0.57	Diastolic blood pressure;	chr4:119595442	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.967	rs2892869	ENSG00000248280.1	RP11-33B1.2	-5.84	1.4e-07	0.000635	-0.7	-0.57	Diastolic blood pressure;	chr4:119600142	chr4:119440561~119450157:-
LAML	cis	rs709400	1	rs861539	ENSG00000258851.1	RP11-894P9.2	-5.84	1.42e-07	0.000642	-0.71	-0.57	Body mass index;	chr14:103699416	chr14:103553421~103561877:+
LAML	cis	rs709400	1	rs861538	ENSG00000258851.1	RP11-894P9.2	-5.84	1.42e-07	0.000642	-0.71	-0.57	Body mass index;	chr14:103700396	chr14:103553421~103561877:+
LAML	cis	rs709400	1	rs861536	ENSG00000258851.1	RP11-894P9.2	-5.84	1.42e-07	0.000642	-0.71	-0.57	Body mass index;	chr14:103701227	chr14:103553421~103561877:+
LAML	cis	rs2273156	0.57	rs7156322	ENSG00000241052.1	RP11-173D9.1	-5.83	1.43e-07	0.000646	-1.06	-0.57	Immunoglobulin light chain (AL) amyloidosis;	chr14:35075124	chr14:35144021~35144480:-
LAML	cis	rs62070183	0.873	rs80212824	ENSG00000266718.1	RP11-466A19.1	5.83	1.44e-07	0.000651	0.95	0.57	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32703440	chr17:32495536~32499333:+
LAML	cis	rs12220777	0.892	rs72644219	ENSG00000230091.5	TMEM254-AS1	5.83	1.45e-07	0.000653	1.23	0.57	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036457	chr10:80046860~80078912:-
LAML	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-5.83	1.45e-07	0.000653	-0.48	-0.57	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-5.83	1.45e-07	0.000653	-0.48	-0.57	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-5.83	1.45e-07	0.000653	-0.48	-0.57	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-5.83	1.45e-07	0.000653	-0.48	-0.57	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-5.83	1.45e-07	0.000653	-0.48	-0.57	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-5.83	1.45e-07	0.000653	-0.48	-0.57	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
LAML	cis	rs853679	0.607	rs34788973	ENSG00000187763.3	OR2B7P	5.83	1.45e-07	0.000653	1.02	0.57	Depression;	chr6:27911422	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs61742093	ENSG00000187763.3	OR2B7P	5.83	1.45e-07	0.000653	1.02	0.57	Depression;	chr6:27912204	chr6:28046434~28047367:+
LAML	cis	rs9368481	0.547	rs2093303	ENSG00000241549.7	GUSBP2	5.83	1.45e-07	0.000653	0.63	0.57	Autism spectrum disorder or schizophrenia;	chr6:26896627	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.594	rs7768643	ENSG00000241549.7	GUSBP2	5.83	1.45e-07	0.000653	0.63	0.57	Autism spectrum disorder or schizophrenia;	chr6:26924140	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.594	rs7768814	ENSG00000241549.7	GUSBP2	5.83	1.45e-07	0.000653	0.63	0.57	Autism spectrum disorder or schizophrenia;	chr6:26924257	chr6:26871484~26956554:-
LAML	cis	rs4591358	0.705	rs12994849	ENSG00000223466.1	AC064834.2	-5.83	1.46e-07	0.000656	-0.7	-0.57	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195447620	chr2:195533035~195538681:+
LAML	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-5.83	1.46e-07	0.000657	-0.48	-0.57	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-5.83	1.46e-07	0.000657	-0.48	-0.57	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
LAML	cis	rs282544	0.581	rs11950328	ENSG00000213956.4	RP11-269M20.1	5.83	1.47e-07	0.00066	0.7	0.57	Myopia (pathological);	chr5:50734957	chr5:50633124~50633602:+
LAML	cis	rs282544	0.581	rs13159505	ENSG00000213956.4	RP11-269M20.1	5.83	1.47e-07	0.00066	0.7	0.57	Myopia (pathological);	chr5:50742936	chr5:50633124~50633602:+
LAML	cis	rs57024841	0.562	rs7862602	ENSG00000238268.2	RP11-229P13.19	5.83	1.47e-07	0.000662	0.69	0.57	Beta-trace protein levels;	chr9:136946019	chr9:136975094~136976981:+
LAML	cis	rs12477438	0.501	rs11688004	ENSG00000231822.1	AC019097.7	5.82	1.48e-07	0.000665	0.74	0.57	Chronic sinus infection;	chr2:99118589	chr2:99102018~99102752:+
LAML	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-5.82	1.48e-07	0.000665	-0.71	-0.57	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
LAML	cis	rs4273100	0.688	rs4924967	ENSG00000262319.1	CTC-457L16.2	-5.82	1.48e-07	0.000666	-0.88	-0.57	Schizophrenia;	chr17:19268883	chr17:19141017~19143689:-
LAML	cis	rs1153858	0.621	rs2687512	ENSG00000259520.4	CTD-2651B20.3	5.82	1.49e-07	0.00067	0.83	0.57	Homoarginine levels;	chr15:45289297	chr15:45251580~45279251:-
LAML	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-5.82	1.5e-07	0.000672	-1.04	-0.57	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-5.82	1.5e-07	0.000672	-1.04	-0.57	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
LAML	cis	rs853679	1	rs10456362	ENSG00000217315.1	OR2W2P	-5.82	1.5e-07	0.000673	-0.97	-0.57	Depression;	chr6:28254038	chr6:28033947~28034855:+
LAML	cis	rs709400	1	rs3783404	ENSG00000258851.1	RP11-894P9.2	-5.82	1.5e-07	0.000673	-0.71	-0.57	Body mass index;	chr14:103652161	chr14:103553421~103561877:+
LAML	cis	rs709400	0.832	rs10145755	ENSG00000258851.1	RP11-894P9.2	-5.82	1.5e-07	0.000673	-0.71	-0.57	Body mass index;	chr14:103655647	chr14:103553421~103561877:+
LAML	cis	rs709400	1	rs55885592	ENSG00000258851.1	RP11-894P9.2	-5.82	1.5e-07	0.000673	-0.71	-0.57	Body mass index;	chr14:103659687	chr14:103553421~103561877:+
LAML	cis	rs709400	1	rs56660916	ENSG00000258851.1	RP11-894P9.2	-5.82	1.5e-07	0.000673	-0.71	-0.57	Body mass index;	chr14:103659800	chr14:103553421~103561877:+
LAML	cis	rs1075265	0.722	rs2111623	ENSG00000235937.1	AC008280.1	-5.82	1.51e-07	0.000674	-0.48	-0.57	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54029552~54030682:-
LAML	cis	rs9326248	0.53	rs11216316	ENSG00000254851.1	RP11-109L13.1	5.82	1.52e-07	0.00068	1.04	0.57	Blood protein levels;	chr11:117210784	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs236918	ENSG00000254851.1	RP11-109L13.1	5.82	1.52e-07	0.00068	1.04	0.57	Blood protein levels;	chr11:117220893	chr11:117135528~117138582:+
LAML	cis	rs853679	0.882	rs9393908	ENSG00000187763.3	OR2B7P	5.82	1.52e-07	0.00068	0.97	0.57	Depression;	chr6:28223052	chr6:28046434~28047367:+
LAML	cis	rs853679	0.882	rs9366717	ENSG00000187763.3	OR2B7P	5.82	1.52e-07	0.00068	0.97	0.57	Depression;	chr6:28223279	chr6:28046434~28047367:+
LAML	cis	rs853679	0.882	rs9380069	ENSG00000187763.3	OR2B7P	5.82	1.52e-07	0.00068	0.97	0.57	Depression;	chr6:28235522	chr6:28046434~28047367:+
LAML	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-5.82	1.52e-07	0.00068	-0.72	-0.57	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	5.82	1.52e-07	0.00068	0.72	0.57	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	5.82	1.52e-07	0.00068	0.72	0.57	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
LAML	cis	rs12468226	1	rs7597469	ENSG00000272966.1	RP11-686O6.1	5.82	1.52e-07	0.00068	0.99	0.57	Urate levels;	chr2:202329547	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs113877751	ENSG00000272966.1	RP11-686O6.1	5.82	1.52e-07	0.00068	0.99	0.57	Urate levels;	chr2:202329998	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.935	rs113021930	ENSG00000272966.1	RP11-686O6.1	5.82	1.52e-07	0.00068	0.99	0.57	Urate levels;	chr2:202330448	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs113491584	ENSG00000272966.1	RP11-686O6.1	5.82	1.52e-07	0.00068	0.99	0.57	Urate levels;	chr2:202331724	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs112306637	ENSG00000272966.1	RP11-686O6.1	5.82	1.52e-07	0.00068	0.99	0.57	Urate levels;	chr2:202334195	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs111252524	ENSG00000272966.1	RP11-686O6.1	5.82	1.52e-07	0.00068	0.99	0.57	Urate levels;	chr2:202334465	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs112753638	ENSG00000272966.1	RP11-686O6.1	5.82	1.52e-07	0.00068	0.99	0.57	Urate levels;	chr2:202334496	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.935	rs113188021	ENSG00000272966.1	RP11-686O6.1	5.82	1.52e-07	0.00068	0.99	0.57	Urate levels;	chr2:202336237	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs6731027	ENSG00000272966.1	RP11-686O6.1	5.82	1.52e-07	0.00068	0.99	0.57	Urate levels;	chr2:202337443	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs13389798	ENSG00000272966.1	RP11-686O6.1	5.82	1.52e-07	0.00068	0.99	0.57	Urate levels;	chr2:202348370	chr2:202336739~202337200:+
LAML	cis	rs67311347	0.635	rs62261855	ENSG00000223797.4	ENTPD3-AS1	5.82	1.53e-07	0.000683	0.79	0.57	Renal cell carcinoma;	chr3:40253447	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.524	rs11129869	ENSG00000223797.4	ENTPD3-AS1	5.82	1.54e-07	0.000683	0.8	0.57	Renal cell carcinoma;	chr3:40218247	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.577	rs11712626	ENSG00000223797.4	ENTPD3-AS1	5.82	1.54e-07	0.000683	0.8	0.57	Renal cell carcinoma;	chr3:40218436	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.577	rs11129870	ENSG00000223797.4	ENTPD3-AS1	5.82	1.54e-07	0.000683	0.8	0.57	Renal cell carcinoma;	chr3:40218915	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.577	rs1317217	ENSG00000223797.4	ENTPD3-AS1	5.82	1.54e-07	0.000683	0.8	0.57	Renal cell carcinoma;	chr3:40230206	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.605	rs1880762	ENSG00000223797.4	ENTPD3-AS1	5.82	1.54e-07	0.000683	0.8	0.57	Renal cell carcinoma;	chr3:40241724	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.577	rs2371129	ENSG00000223797.4	ENTPD3-AS1	-5.82	1.54e-07	0.000683	-0.8	-0.57	Renal cell carcinoma;	chr3:40206902	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.577	rs1880763	ENSG00000223797.4	ENTPD3-AS1	-5.82	1.54e-07	0.000683	-0.8	-0.57	Renal cell carcinoma;	chr3:40241764	chr3:40313802~40453329:-
LAML	cis	rs7746199	0.736	rs35037868	ENSG00000220721.1	OR1F12	5.81	1.55e-07	0.000689	0.92	0.57	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28073316~28074233:+
LAML	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-5.81	1.55e-07	0.00069	-0.71	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
LAML	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	5.81	1.56e-07	0.000691	0.65	0.57	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
LAML	cis	rs7131987	0.527	rs7308534	ENSG00000275476.1	RP11-996F15.4	5.81	1.56e-07	0.000694	0.64	0.57	QT interval;	chr12:29300269	chr12:29277397~29277882:-
LAML	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-5.81	1.57e-07	0.000695	-0.74	-0.57	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
LAML	cis	rs2581828	0.646	rs2564923	ENSG00000280417.1	RP11-5O17.1	5.81	1.57e-07	0.000696	0.72	0.57	Crohn's disease;	chr3:53069246	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs34530577	ENSG00000280417.1	RP11-5O17.1	5.81	1.57e-07	0.000696	0.72	0.57	Crohn's disease;	chr3:53069780	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.656	rs2564940	ENSG00000280417.1	RP11-5O17.1	5.81	1.57e-07	0.000696	0.72	0.57	Crohn's disease;	chr3:53073553	chr3:53046166~53048122:+
LAML	cis	rs7131987	0.565	rs7968883	ENSG00000274315.1	RP11-996F15.5	5.81	1.57e-07	0.000698	0.57	0.56	QT interval;	chr12:29241258	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs1991113	ENSG00000274315.1	RP11-996F15.5	-5.81	1.57e-07	0.000698	-0.57	-0.56	QT interval;	chr12:29239070	chr12:29331434~29331936:-
LAML	cis	rs2581828	0.656	rs1864367	ENSG00000280417.1	RP11-5O17.1	5.81	1.58e-07	0.000699	0.72	0.56	Crohn's disease;	chr3:53077688	chr3:53046166~53048122:+
LAML	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	5.81	1.58e-07	0.000701	0.61	0.56	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
LAML	cis	rs853679	0.882	rs4713140	ENSG00000182477.5	OR2B8P	5.81	1.58e-07	0.000702	1	0.56	Depression;	chr6:28129415	chr6:28053228~28054165:-
LAML	cis	rs5769707	0.732	rs135865	ENSG00000212939.2	RP1-29C18.10	-5.81	1.59e-07	0.000703	-0.67	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49548681~49556473:+
LAML	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	5.81	1.59e-07	0.000704	0.61	0.56	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
LAML	cis	rs4591358	0.765	rs4355137	ENSG00000223466.1	AC064834.2	5.81	1.59e-07	0.000704	0.72	0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195486465	chr2:195533035~195538681:+
LAML	cis	rs62070183	0.766	rs10512441	ENSG00000201178.1	Y_RNA	-5.8	1.62e-07	0.000715	-0.82	-0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32830219~32830329:-
LAML	cis	rs4591358	0.53	rs72927723	ENSG00000223466.1	AC064834.2	-5.8	1.62e-07	0.000717	-0.92	-0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522498	chr2:195533035~195538681:+
LAML	cis	rs9326248	0.52	rs10892060	ENSG00000254851.1	RP11-109L13.1	-5.8	1.62e-07	0.000717	-0.72	-0.56	Blood protein levels;	chr11:117010946	chr11:117135528~117138582:+
LAML	cis	rs2564921	0.73	rs2564939	ENSG00000280417.1	RP11-5O17.1	5.8	1.63e-07	0.000719	0.83	0.56	Height;	chr3:53072864	chr3:53046166~53048122:+
LAML	cis	rs853679	0.882	rs9468300	ENSG00000182477.5	OR2B8P	5.8	1.63e-07	0.000721	1	0.56	Depression;	chr6:28159062	chr6:28053228~28054165:-
LAML	cis	rs853679	0.825	rs8180562	ENSG00000182477.5	OR2B8P	5.8	1.63e-07	0.000721	1	0.56	Depression;	chr6:28173682	chr6:28053228~28054165:-
LAML	cis	rs853679	0.882	rs9380064	ENSG00000182477.5	OR2B8P	5.8	1.63e-07	0.000721	1	0.56	Depression;	chr6:28175340	chr6:28053228~28054165:-
LAML	cis	rs7131987	0.526	rs7954375	ENSG00000274315.1	RP11-996F15.5	5.8	1.63e-07	0.000721	0.57	0.56	QT interval;	chr12:29241487	chr12:29331434~29331936:-
LAML	cis	rs4713118	0.662	rs9380046	ENSG00000182477.5	OR2B8P	5.8	1.64e-07	0.000725	0.81	0.56	Parkinson's disease;	chr6:28062721	chr6:28053228~28054165:-
LAML	cis	rs853679	0.882	rs9393908	ENSG00000182477.5	OR2B8P	5.8	1.65e-07	0.000728	0.98	0.56	Depression;	chr6:28223052	chr6:28053228~28054165:-
LAML	cis	rs853679	0.882	rs9366717	ENSG00000182477.5	OR2B8P	5.8	1.65e-07	0.000728	0.98	0.56	Depression;	chr6:28223279	chr6:28053228~28054165:-
LAML	cis	rs853679	0.882	rs9380069	ENSG00000182477.5	OR2B8P	5.8	1.65e-07	0.000728	0.98	0.56	Depression;	chr6:28235522	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs1679709	ENSG00000182477.5	OR2B8P	-5.8	1.65e-07	0.000729	-0.9	-0.56	Depression;	chr6:28260564	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs1778511	ENSG00000182477.5	OR2B8P	-5.8	1.65e-07	0.000729	-0.9	-0.56	Depression;	chr6:28261633	chr6:28053228~28054165:-
LAML	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	5.8	1.67e-07	0.000736	0.87	0.56	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
LAML	cis	rs66887589	1	rs66887589	ENSG00000248280.1	RP11-33B1.2	-5.8	1.67e-07	0.000738	-0.71	-0.56	Diastolic blood pressure;	chr4:119588124	chr4:119440561~119450157:-
LAML	cis	rs2921073	0.51	rs2976945	ENSG00000268955.2	RP11-556O5.6	-5.79	1.68e-07	0.00074	-0.61	-0.56	Parkinson's disease;	chr8:8413361	chr8:8188535~8189195:-
LAML	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-5.79	1.68e-07	0.00074	-0.7	-0.56	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
LAML	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	5.79	1.7e-07	0.000748	0.63	0.56	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
LAML	cis	rs62070183	0.938	rs75393526	ENSG00000265222.1	RP11-466A19.8	5.79	1.7e-07	0.000751	0.89	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32708000	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs75822124	ENSG00000265222.1	RP11-466A19.8	5.79	1.7e-07	0.000751	0.89	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32710876	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs17183176	ENSG00000265222.1	RP11-466A19.8	5.79	1.7e-07	0.000751	0.89	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32727107	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs1990825	ENSG00000265222.1	RP11-466A19.8	5.79	1.7e-07	0.000751	0.89	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32729274	chr17:32509954~32523424:-
LAML	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	5.79	1.71e-07	0.000754	0.76	0.56	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
LAML	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	5.79	1.71e-07	0.000755	0.65	0.56	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	5.79	1.71e-07	0.000755	0.65	0.56	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	5.79	1.71e-07	0.000755	0.65	0.56	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
LAML	cis	rs3758911	0.894	rs11212156	ENSG00000261098.1	RP11-819C21.1	-5.79	1.72e-07	0.000755	-0.54	-0.56	Coronary artery disease;	chr11:107323381	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.894	rs11212162	ENSG00000261098.1	RP11-819C21.1	-5.79	1.72e-07	0.000755	-0.54	-0.56	Coronary artery disease;	chr11:107327884	chr11:107312132~107316271:-
LAML	cis	rs4753788	0.511	rs12224337	ENSG00000261098.1	RP11-819C21.1	-5.79	1.72e-07	0.000756	-0.56	-0.56	Coronary artery disease;	chr11:107269351	chr11:107312132~107316271:-
LAML	cis	rs12468226	0.935	rs75597391	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202398850	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs12472408	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202413973	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs115170232	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202416790	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs16839149	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202427621	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs74766638	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202445168	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs116635509	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202460027	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs2350809	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202464210	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs76528043	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202466116	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs12468226	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202472278	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs75040639	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202486973	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.872	rs115187557	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202495351	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs74508472	ENSG00000226261.1	AC064836.3	5.79	1.72e-07	0.000756	0.98	0.56	Urate levels;	chr2:202517290	chr2:202336024~202336727:-
LAML	cis	rs12477438	0.501	rs12619780	ENSG00000231822.1	AC019097.7	5.79	1.72e-07	0.000757	0.72	0.56	Chronic sinus infection;	chr2:99090844	chr2:99102018~99102752:+
LAML	cis	rs1075265	0.749	rs6738369	ENSG00000235937.1	AC008280.1	5.79	1.72e-07	0.000758	0.47	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54029552~54030682:-
LAML	cis	rs5769707	0.681	rs4824068	ENSG00000280224.1	CTA-722E9.1	-5.79	1.72e-07	0.000758	-0.83	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49500568~49501585:+
LAML	cis	rs9368481	0.761	rs12661756	ENSG00000243307.2	POM121L6P	5.79	1.73e-07	0.000762	0.68	0.56	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.761	rs9348746	ENSG00000243307.2	POM121L6P	-5.79	1.73e-07	0.000762	-0.68	-0.56	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.761	rs9379952	ENSG00000243307.2	POM121L6P	-5.79	1.73e-07	0.000762	-0.68	-0.56	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26896952~26898777:+
LAML	cis	rs904251	0.861	rs1757173	ENSG00000279942.1	RP1-153P14.7	-5.79	1.74e-07	0.000764	-0.66	-0.56	Cognitive performance;	chr6:37519176	chr6:37567716~37571460:+
LAML	cis	rs904251	0.861	rs1757169	ENSG00000279942.1	RP1-153P14.7	-5.79	1.74e-07	0.000764	-0.66	-0.56	Cognitive performance;	chr6:37519300	chr6:37567716~37571460:+
LAML	cis	rs904251	0.861	rs2776877	ENSG00000279942.1	RP1-153P14.7	-5.79	1.74e-07	0.000764	-0.66	-0.56	Cognitive performance;	chr6:37519359	chr6:37567716~37571460:+
LAML	cis	rs904251	0.864	rs2797801	ENSG00000279942.1	RP1-153P14.7	-5.79	1.74e-07	0.000764	-0.66	-0.56	Cognitive performance;	chr6:37519385	chr6:37567716~37571460:+
LAML	cis	rs904251	0.797	rs2776878	ENSG00000279942.1	RP1-153P14.7	-5.79	1.74e-07	0.000764	-0.66	-0.56	Cognitive performance;	chr6:37519497	chr6:37567716~37571460:+
LAML	cis	rs904251	0.828	rs2797803	ENSG00000279942.1	RP1-153P14.7	-5.79	1.74e-07	0.000764	-0.66	-0.56	Cognitive performance;	chr6:37519564	chr6:37567716~37571460:+
LAML	cis	rs12468226	0.938	rs80282360	ENSG00000272966.1	RP11-686O6.1	5.78	1.74e-07	0.000766	1	0.56	Urate levels;	chr2:202275121	chr2:202336739~202337200:+
LAML	cis	rs2564921	0.73	rs6781896	ENSG00000280417.1	RP11-5O17.1	-5.78	1.75e-07	0.000766	-0.83	-0.56	Height;	chr3:53047596	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.73	rs58492539	ENSG00000280417.1	RP11-5O17.1	-5.78	1.75e-07	0.000766	-0.83	-0.56	Height;	chr3:53052712	chr3:53046166~53048122:+
LAML	cis	rs62070183	0.766	rs62067160	ENSG00000265222.1	RP11-466A19.8	5.78	1.75e-07	0.000767	0.9	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32919567	chr17:32509954~32523424:-
LAML	cis	rs709400	0.894	rs10143293	ENSG00000258851.1	RP11-894P9.2	-5.78	1.75e-07	0.000768	-0.75	-0.56	Body mass index;	chr14:103596677	chr14:103553421~103561877:+
LAML	cis	rs12468226	1	rs76284304	ENSG00000226261.1	AC064836.3	5.78	1.75e-07	0.00077	0.98	0.56	Urate levels;	chr2:202427116	chr2:202336024~202336727:-
LAML	cis	rs62070183	0.873	rs80212824	ENSG00000265337.1	RP11-466A19.5	5.78	1.76e-07	0.00077	0.94	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32703440	chr17:32529008~32530049:-
LAML	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-5.78	1.76e-07	0.00077	-0.74	-0.56	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
LAML	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-5.78	1.76e-07	0.000771	-0.66	-0.56	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-5.78	1.76e-07	0.000771	-0.66	-0.56	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-5.78	1.76e-07	0.000771	-0.66	-0.56	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
LAML	cis	rs12145833	0.538	rs10754798	ENSG00000253326.2	RP11-261C10.7	5.78	1.76e-07	0.000771	0.92	0.56	Obesity (early onset extreme);	chr1:243146656	chr1:243054861~243056394:-
LAML	cis	rs12145833	0.596	rs12043646	ENSG00000253326.2	RP11-261C10.7	-5.78	1.76e-07	0.000771	-0.92	-0.56	Obesity (early onset extreme);	chr1:243118690	chr1:243054861~243056394:-
LAML	cis	rs12145833	0.596	rs12123491	ENSG00000253326.2	RP11-261C10.7	-5.78	1.76e-07	0.000771	-0.92	-0.56	Obesity (early onset extreme);	chr1:243134622	chr1:243054861~243056394:-
LAML	cis	rs6782228	0.606	rs2811488	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2811489	ENSG00000277250.1	Metazoa_SRP	5.78	1.76e-07	0.000772	0.75	0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs58977394	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2712381	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs1127030	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2712419	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2712417	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.527	rs2712371	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2811490	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs7627549	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.585	rs2811492	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs1697	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.585	rs3122175	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs7650156	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2811497	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.606	rs2811500	ENSG00000277250.1	Metazoa_SRP	-5.78	1.76e-07	0.000772	-0.75	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128673681~128674021:-
LAML	cis	rs2273156	0.57	rs77477310	ENSG00000241052.1	RP11-173D9.1	-5.78	1.77e-07	0.000772	-0.97	-0.56	Immunoglobulin light chain (AL) amyloidosis;	chr14:35146587	chr14:35144021~35144480:-
LAML	cis	rs904251	0.797	rs1757181	ENSG00000279942.1	RP1-153P14.7	5.78	1.77e-07	0.000772	0.65	0.56	Cognitive performance;	chr6:37517952	chr6:37567716~37571460:+
LAML	cis	rs911555	0.546	rs28798508	ENSG00000258851.1	RP11-894P9.2	-5.78	1.77e-07	0.000775	-0.62	-0.56	Intelligence (multi-trait analysis);	chr14:103602633	chr14:103553421~103561877:+
LAML	cis	rs911555	0.504	rs4444269	ENSG00000258851.1	RP11-894P9.2	-5.78	1.77e-07	0.000775	-0.62	-0.56	Intelligence (multi-trait analysis);	chr14:103606387	chr14:103553421~103561877:+
LAML	cis	rs911555	0.504	rs8021368	ENSG00000258851.1	RP11-894P9.2	-5.78	1.77e-07	0.000775	-0.62	-0.56	Intelligence (multi-trait analysis);	chr14:103608473	chr14:103553421~103561877:+
LAML	cis	rs9326248	0.681	rs641620	ENSG00000254851.1	RP11-109L13.1	5.78	1.78e-07	0.000775	0.96	0.56	Blood protein levels;	chr11:117203513	chr11:117135528~117138582:+
LAML	cis	rs9368481	0.761	rs9357030	ENSG00000243307.2	POM121L6P	-5.78	1.79e-07	0.000781	-0.69	-0.56	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.672	rs3931463	ENSG00000241549.7	GUSBP2	5.78	1.79e-07	0.000781	0.59	0.56	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.761	rs3931464	ENSG00000241549.7	GUSBP2	5.78	1.79e-07	0.000781	0.59	0.56	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26871484~26956554:-
LAML	cis	rs4591358	0.608	rs13003168	ENSG00000223466.1	AC064834.2	-5.78	1.8e-07	0.000783	-0.9	-0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195496394	chr2:195533035~195538681:+
LAML	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-5.78	1.8e-07	0.000784	-0.65	-0.56	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
LAML	cis	rs12220777	1	rs11201660	ENSG00000230091.5	TMEM254-AS1	-5.78	1.81e-07	0.000786	-1.27	-0.56	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80094775	chr10:80046860~80078912:-
LAML	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-5.78	1.81e-07	0.000786	-1.27	-0.56	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
LAML	cis	rs12220777	1	rs11201312	ENSG00000230091.5	TMEM254-AS1	5.78	1.81e-07	0.000786	1.27	0.56	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80036022	chr10:80046860~80078912:-
LAML	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	5.78	1.81e-07	0.000786	1.27	0.56	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
LAML	cis	rs9322193	0.847	rs880246	ENSG00000216906.2	RP11-350J20.9	5.78	1.81e-07	0.000789	0.91	0.56	Lung cancer;	chr6:149845972	chr6:149904243~149906418:+
LAML	cis	rs16828019	1	rs16828019	ENSG00000213987.4	RP11-399E6.2	5.77	1.82e-07	0.000791	0.96	0.56	Intelligence (multi-trait analysis);	chr1:41279363	chr1:41264550~41264862:-
LAML	cis	rs7746199	0.736	rs13209332	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs34965299	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28046434~28047367:+
LAML	cis	rs35491132	1	rs35491132	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Urinary tract infection frequency;	chr6:27559449	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs10484399	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs34105070	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.673	rs72845046	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs67652222	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs13212093	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs34038546	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28046434~28047367:+
LAML	cis	rs141342723	1	rs141342723	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs34543938	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs56405707	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs13210634	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs13215275	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs17749927	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs13192965	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28046434~28047367:+
LAML	cis	rs45509595	0.556	rs34409918	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Breast cancer;	chr6:27717569	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs34064842	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs13212318	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs13202291	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs17750424	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs13193542	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs13193480	ENSG00000187763.3	OR2B7P	5.77	1.83e-07	0.000793	1.02	0.56	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28046434~28047367:+
LAML	cis	rs55794721	0.543	rs1293260	ENSG00000224183.1	SDHDP6	-5.77	1.83e-07	0.000793	-0.67	-0.56	Mean corpuscular volume;Plateletcrit;	chr1:25382613	chr1:25294164~25294643:-
LAML	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-5.77	1.83e-07	0.000794	-0.7	-0.56	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
LAML	cis	rs709400	1	rs8018979	ENSG00000258851.1	RP11-894P9.2	-5.77	1.83e-07	0.000795	-0.7	-0.56	Body mass index;	chr14:103642750	chr14:103553421~103561877:+
LAML	cis	rs916888	0.647	rs199523	ENSG00000214401.4	KANSL1-AS1	-5.77	1.83e-07	0.000795	-0.74	-0.56	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:46193576~46196723:+
LAML	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	5.77	1.83e-07	0.000796	0.61	0.56	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	5.77	1.83e-07	0.000796	0.61	0.56	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
LAML	cis	rs10829156	0.625	rs7082235	ENSG00000240291.1	RP11-499P20.2	5.77	1.84e-07	0.000799	0.72	0.56	Sudden cardiac arrest;	chr10:18536765	chr10:18513115~18545651:-
LAML	cis	rs2015599	0.623	rs10843385	ENSG00000275476.1	RP11-996F15.4	-5.77	1.84e-07	0.000799	-0.61	-0.56	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.601	rs17715086	ENSG00000275476.1	RP11-996F15.4	-5.77	1.84e-07	0.000799	-0.61	-0.56	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29277397~29277882:-
LAML	cis	rs2712381	0.797	rs62270806	ENSG00000277250.1	Metazoa_SRP	-5.77	1.85e-07	8e-04	-0.75	-0.56	Monocyte count;	chr3:128657426	chr3:128673681~128674021:-
LAML	cis	rs853679	1	rs853685	ENSG00000187763.3	OR2B7P	5.77	1.85e-07	0.000801	0.82	0.56	Depression;	chr6:28321008	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs853679	ENSG00000187763.3	OR2B7P	5.77	1.85e-07	0.000801	0.82	0.56	Depression;	chr6:28329086	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs853678	ENSG00000187763.3	OR2B7P	5.77	1.85e-07	0.000801	0.82	0.56	Depression;	chr6:28329536	chr6:28046434~28047367:+
LAML	cis	rs5769707	0.521	rs739244	ENSG00000212939.2	RP1-29C18.10	-5.77	1.86e-07	0.000804	-0.71	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49548681~49556473:+
LAML	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-5.77	1.87e-07	0.000807	-0.38	-0.56	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
LAML	cis	rs2283792	0.633	rs240068	ENSG00000228050.1	TOP3BP1	5.77	1.87e-07	0.000807	0.64	0.56	Multiple sclerosis;	chr22:21936031	chr22:22223187~22224566:-
LAML	cis	rs6782228	0.527	rs2811491	ENSG00000277250.1	Metazoa_SRP	-5.77	1.88e-07	0.000812	-0.76	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128673681~128674021:-
LAML	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	5.77	1.88e-07	0.000813	0.65	0.56	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
LAML	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	5.77	1.88e-07	0.000813	0.72	0.56	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	5.77	1.88e-07	0.000813	0.72	0.56	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	5.77	1.88e-07	0.000813	0.72	0.56	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
LAML	cis	rs4803480	0.935	rs9304595	ENSG00000239736.2	CEACAMP3	5.77	1.88e-07	0.000813	0.82	0.56	Schizophrenia;	chr19:41571639	chr19:41599735~41605984:+
LAML	cis	rs4713118	0.869	rs4713121	ENSG00000187763.3	OR2B7P	5.77	1.89e-07	0.000815	0.75	0.56	Parkinson's disease;	chr6:27754285	chr6:28046434~28047367:+
LAML	cis	rs2564921	0.73	rs62255897	ENSG00000280417.1	RP11-5O17.1	-5.76	1.9e-07	0.000819	-0.84	-0.56	Height;	chr3:53029854	chr3:53046166~53048122:+
LAML	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-5.76	1.91e-07	0.000824	-0.67	-0.56	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
LAML	cis	rs8037818	1	rs11071856	ENSG00000276724.1	RP11-1000B6.7	-5.76	1.92e-07	0.000827	-0.79	-0.56	Obesity-related traits;	chr15:32633591	chr15:32583612~32584312:+
LAML	cis	rs1930961	0.702	rs8141065	ENSG00000272977.1	CTA-390C10.10	5.76	1.93e-07	0.000832	0.96	0.56	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25476218~25479971:+
LAML	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	5.76	1.93e-07	0.000833	0.66	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
LAML	cis	rs4713118	0.662	rs175954	ENSG00000182477.5	OR2B8P	5.76	1.96e-07	0.000844	0.83	0.56	Parkinson's disease;	chr6:28043807	chr6:28053228~28054165:-
LAML	cis	rs12468226	0.938	rs10931993	ENSG00000272966.1	RP11-686O6.1	5.76	1.96e-07	0.000844	0.9	0.56	Urate levels;	chr2:202243017	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs4675274	ENSG00000272966.1	RP11-686O6.1	-5.76	1.96e-07	0.000844	-0.9	-0.56	Urate levels;	chr2:202243145	chr2:202336739~202337200:+
LAML	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	5.75	1.97e-07	0.000849	0.72	0.56	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
LAML	cis	rs12468226	0.938	rs56684065	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202289528	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs1474001	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202290230	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs76664732	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202296298	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs16841867	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202303512	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs79117531	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202307690	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs16839065	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202308774	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs115418918	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202315145	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs114922024	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202315958	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs77261109	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202316233	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs12466003	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202317317	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs76501067	ENSG00000272966.1	RP11-686O6.1	5.75	1.98e-07	0.00085	0.91	0.56	Urate levels;	chr2:202318042	chr2:202336739~202337200:+
LAML	cis	rs1153858	0.723	rs1719238	ENSG00000259520.4	CTD-2651B20.3	5.75	1.98e-07	0.000852	0.82	0.56	Homoarginine levels;	chr15:45302568	chr15:45251580~45279251:-
LAML	cis	rs1153858	0.723	rs4580098	ENSG00000259520.4	CTD-2651B20.3	-5.75	1.98e-07	0.000852	-0.82	-0.56	Homoarginine levels;	chr15:45304711	chr15:45251580~45279251:-
LAML	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	5.75	1.99e-07	0.000855	0.79	0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
LAML	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-5.75	1.99e-07	0.000856	-0.68	-0.56	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
LAML	cis	rs2038255	1	rs2038255	ENSG00000241052.1	RP11-173D9.1	-5.75	2e-07	0.000857	-1.01	-0.56	Lymphocyte counts;	chr14:35089920	chr14:35144021~35144480:-
LAML	cis	rs4713118	0.868	rs760587	ENSG00000182477.5	OR2B8P	5.75	2e-07	0.000857	0.78	0.56	Parkinson's disease;	chr6:27772521	chr6:28053228~28054165:-
LAML	cis	rs8062405	1	rs8061590	ENSG00000259982.1	CDC37P1	5.75	2.01e-07	0.000862	0.67	0.56	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28700294~28701540:-
LAML	cis	rs7587476	0.505	rs6435862	ENSG00000227769.6	AC072062.3	5.75	2.01e-07	0.000864	0.63	0.56	Neuroblastoma;	chr2:214807822	chr2:215004782~215085488:+
LAML	cis	rs2273156	0.57	rs2010648	ENSG00000241052.1	RP11-173D9.1	-5.75	2.02e-07	0.000866	-0.97	-0.56	Immunoglobulin light chain (AL) amyloidosis;	chr14:35135686	chr14:35144021~35144480:-
LAML	cis	rs2564921	0.615	rs56129941	ENSG00000280417.1	RP11-5O17.1	-5.75	2.02e-07	0.000866	-0.82	-0.56	Height;	chr3:53007328	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.704	rs56155510	ENSG00000280417.1	RP11-5O17.1	-5.75	2.02e-07	0.000866	-0.82	-0.56	Height;	chr3:53009621	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.679	rs12635933	ENSG00000280417.1	RP11-5O17.1	-5.75	2.02e-07	0.000866	-0.82	-0.56	Height;	chr3:53015087	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.73	rs62255895	ENSG00000280417.1	RP11-5O17.1	-5.75	2.02e-07	0.000866	-0.82	-0.56	Height;	chr3:53027969	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.73	rs62255898	ENSG00000280417.1	RP11-5O17.1	-5.75	2.02e-07	0.000866	-0.82	-0.56	Height;	chr3:53029908	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.73	rs73079924	ENSG00000280417.1	RP11-5O17.1	-5.75	2.02e-07	0.000866	-0.82	-0.56	Height;	chr3:53034139	chr3:53046166~53048122:+
LAML	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	5.75	2.02e-07	0.000866	0.65	0.56	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-5.75	2.02e-07	0.000866	-0.65	-0.56	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-5.75	2.02e-07	0.000866	-0.65	-0.56	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-5.75	2.02e-07	0.000866	-0.65	-0.56	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
LAML	cis	rs12468226	0.938	rs16824590	ENSG00000226261.1	AC064836.3	5.75	2.03e-07	0.000866	0.86	0.56	Urate levels;	chr2:202272624	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs77018809	ENSG00000226261.1	AC064836.3	5.75	2.03e-07	0.000866	0.86	0.56	Urate levels;	chr2:202273166	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs7568159	ENSG00000226261.1	AC064836.3	5.75	2.03e-07	0.000866	0.86	0.56	Urate levels;	chr2:202286226	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs7585867	ENSG00000226261.1	AC064836.3	5.75	2.03e-07	0.000866	0.86	0.56	Urate levels;	chr2:202287040	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.938	rs58834901	ENSG00000226261.1	AC064836.3	5.75	2.03e-07	0.000866	0.86	0.56	Urate levels;	chr2:202288169	chr2:202336024~202336727:-
LAML	cis	rs67383717	0.643	rs72756397	ENSG00000175611.10	LINC00476	-5.75	2.03e-07	0.000866	-0.56	-0.56	Parkinson's disease (pesticide exposure interaction);	chr9:95790861	chr9:95759231~95875977:-
LAML	cis	rs904251	0.861	rs1776456	ENSG00000279942.1	RP1-153P14.7	-5.75	2.03e-07	0.000866	-0.67	-0.56	Cognitive performance;	chr6:37516922	chr6:37567716~37571460:+
LAML	cis	rs6452524	0.839	rs28745307	ENSG00000249664.1	CTD-2227C6.2	5.75	2.03e-07	0.000867	0.77	0.56	Hypertension (SNP x SNP interaction);	chr5:83122099	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.746	rs28745311	ENSG00000249664.1	CTD-2227C6.2	5.75	2.03e-07	0.000867	0.77	0.56	Hypertension (SNP x SNP interaction);	chr5:83123030	chr5:83012285~83013109:-
LAML	cis	rs2273156	0.57	rs114200987	ENSG00000241052.1	RP11-173D9.1	-5.75	2.04e-07	0.00087	-1.01	-0.56	Immunoglobulin light chain (AL) amyloidosis;	chr14:35117710	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs28365850	ENSG00000241052.1	RP11-173D9.1	-5.75	2.04e-07	0.00087	-1.01	-0.56	Immunoglobulin light chain (AL) amyloidosis;	chr14:35122110	chr14:35144021~35144480:-
LAML	cis	rs7826238	0.509	rs2948288	ENSG00000253893.2	FAM85B	-5.75	2.05e-07	0.000873	-0.68	-0.56	Systolic blood pressure;	chr8:8257782	chr8:8167819~8226614:-
LAML	cis	rs12468226	1	rs7587234	ENSG00000272966.1	RP11-686O6.1	5.74	2.05e-07	0.000875	0.98	0.56	Urate levels;	chr2:202351699	chr2:202336739~202337200:+
LAML	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	5.74	2.07e-07	0.000881	0.59	0.56	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
LAML	cis	rs62070183	0.766	rs62067160	ENSG00000280245.1	RP11-466A19.4	5.74	2.07e-07	0.000881	0.85	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32919567	chr17:32504567~32505644:-
LAML	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-5.74	2.07e-07	0.000881	-0.72	-0.56	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
LAML	cis	rs2283792	0.566	rs1005579	ENSG00000228050.1	TOP3BP1	5.74	2.07e-07	0.000883	0.63	0.56	Multiple sclerosis;	chr22:21946569	chr22:22223187~22224566:-
LAML	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	5.74	2.08e-07	0.000886	0.82	0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
LAML	cis	rs62070183	0.873	rs80212824	ENSG00000280245.1	RP11-466A19.4	5.74	2.09e-07	0.000891	0.88	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32703440	chr17:32504567~32505644:-
LAML	cis	rs911555	0.539	rs4374097	ENSG00000258851.1	RP11-894P9.2	-5.74	2.1e-07	0.000894	-0.64	-0.56	Intelligence (multi-trait analysis);	chr14:103606429	chr14:103553421~103561877:+
LAML	cis	rs763121	0.651	rs738249	ENSG00000230912.1	RP3-508I15.10	-5.74	2.11e-07	0.000896	-0.49	-0.56	Menopause (age at onset);	chr22:38641974	chr22:38666508~38668750:-
LAML	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	5.74	2.11e-07	0.000896	0.67	0.56	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
LAML	cis	rs1075265	0.84	rs805309	ENSG00000235937.1	AC008280.1	5.74	2.12e-07	9e-04	0.46	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53968877	chr2:54029552~54030682:-
LAML	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-5.74	2.12e-07	0.000901	-0.63	-0.56	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
LAML	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	5.73	2.14e-07	0.000906	0.68	0.56	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	5.73	2.14e-07	0.000906	0.68	0.56	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	5.73	2.14e-07	0.000906	0.68	0.56	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
LAML	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	5.73	2.14e-07	0.000906	0.68	0.56	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
LAML	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	5.73	2.14e-07	0.000906	0.72	0.56	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
LAML	cis	rs2564921	0.693	rs2336721	ENSG00000280417.1	RP11-5O17.1	-5.73	2.14e-07	0.000907	-0.7	-0.56	Height;	chr3:52994359	chr3:53046166~53048122:+
LAML	cis	rs9368481	0.761	rs9348746	ENSG00000241549.7	GUSBP2	-5.73	2.16e-07	0.000915	-0.59	-0.56	Autism spectrum disorder or schizophrenia;	chr6:27002578	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.761	rs9379952	ENSG00000241549.7	GUSBP2	-5.73	2.16e-07	0.000915	-0.59	-0.56	Autism spectrum disorder or schizophrenia;	chr6:27020121	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.761	rs12661756	ENSG00000241549.7	GUSBP2	5.73	2.16e-07	0.000915	0.59	0.56	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26871484~26956554:-
LAML	cis	rs7714584	1	rs11957134	ENSG00000197083.10	ZNF300P1	-5.73	2.17e-07	0.000916	-1.27	-0.56	Crohn's disease;	chr5:150851388	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs4958842	ENSG00000197083.10	ZNF300P1	5.73	2.17e-07	0.000916	1.27	0.56	Crohn's disease;	chr5:150845315	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs12652003	ENSG00000197083.10	ZNF300P1	5.73	2.17e-07	0.000916	1.27	0.56	Crohn's disease;	chr5:150852383	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11167515	ENSG00000197083.10	ZNF300P1	5.73	2.17e-07	0.000916	1.27	0.56	Crohn's disease;	chr5:150859909	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs1000113	ENSG00000197083.10	ZNF300P1	5.73	2.17e-07	0.000916	1.27	0.56	Crohn's disease;	chr5:150860514	chr5:150930645~150946289:-
LAML	cis	rs7714584	0.793	rs12653039	ENSG00000197083.10	ZNF300P1	5.73	2.17e-07	0.000916	1.27	0.56	Crohn's disease;	chr5:150873069	chr5:150930645~150946289:-
LAML	cis	rs2564921	0.704	rs35671032	ENSG00000280417.1	RP11-5O17.1	-5.73	2.17e-07	0.000916	-0.79	-0.56	Height;	chr3:52972039	chr3:53046166~53048122:+
LAML	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	5.73	2.17e-07	0.000917	0.58	0.56	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
LAML	cis	rs62070183	0.873	rs113602044	ENSG00000265337.1	RP11-466A19.5	5.73	2.18e-07	0.000921	0.93	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32691685	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs77819475	ENSG00000265337.1	RP11-466A19.5	5.73	2.18e-07	0.000921	0.93	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32699823	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs17183113	ENSG00000265337.1	RP11-466A19.5	5.73	2.18e-07	0.000921	0.93	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702107	chr17:32529008~32530049:-
LAML	cis	rs62070183	0.938	rs78418651	ENSG00000265337.1	RP11-466A19.5	5.73	2.18e-07	0.000921	0.93	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702530	chr17:32529008~32530049:-
LAML	cis	rs12220777	1	rs72644213	ENSG00000230091.5	TMEM254-AS1	5.73	2.18e-07	0.000921	1.21	0.56	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80023904	chr10:80046860~80078912:-
LAML	cis	rs3091242	0.933	rs3093584	ENSG00000224183.1	SDHDP6	5.73	2.18e-07	0.000921	0.68	0.56	Erythrocyte sedimentation rate;	chr1:25342223	chr1:25294164~25294643:-
LAML	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	5.73	2.19e-07	0.000925	0.63	0.56	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	5.73	2.19e-07	0.000925	0.63	0.56	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
LAML	cis	rs56145559	1	rs56145559	ENSG00000163016.8	ALMS1P	5.73	2.19e-07	0.000925	0.68	0.56	Schizophrenia;	chr2:73396311	chr2:73644919~73685576:+
LAML	cis	rs1032757	0.793	rs11738941	ENSG00000236447.2	ATG10-IT1	5.73	2.2e-07	0.000928	0.95	0.56	Eosinophilic esophagitis (pediatric);	chr5:82643715	chr5:81991995~81992481:+
LAML	cis	rs6452524	0.775	rs10071579	ENSG00000249664.1	CTD-2227C6.2	5.73	2.22e-07	0.000935	0.75	0.56	Hypertension (SNP x SNP interaction);	chr5:83113925	chr5:83012285~83013109:-
LAML	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	5.72	2.22e-07	0.000936	0.54	0.56	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
LAML	cis	rs62070183	0.873	rs113602044	ENSG00000266718.1	RP11-466A19.1	5.72	2.23e-07	0.000938	0.93	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32691685	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs77819475	ENSG00000266718.1	RP11-466A19.1	5.72	2.23e-07	0.000938	0.93	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32699823	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs17183113	ENSG00000266718.1	RP11-466A19.1	5.72	2.23e-07	0.000938	0.93	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702107	chr17:32495536~32499333:+
LAML	cis	rs62070183	0.938	rs78418651	ENSG00000266718.1	RP11-466A19.1	5.72	2.23e-07	0.000938	0.93	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702530	chr17:32495536~32499333:+
LAML	cis	rs2564921	0.654	rs73087044	ENSG00000280417.1	RP11-5O17.1	-5.72	2.24e-07	0.000944	-0.83	-0.56	Height;	chr3:52975027	chr3:53046166~53048122:+
LAML	cis	rs9368481	0.729	rs9379950	ENSG00000243307.2	POM121L6P	-5.72	2.25e-07	0.000944	-0.68	-0.56	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26896952~26898777:+
LAML	cis	rs9368481	1	rs9368481	ENSG00000243307.2	POM121L6P	-5.72	2.25e-07	0.000944	-0.68	-0.56	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.554	rs2754603	ENSG00000243307.2	POM121L6P	-5.72	2.25e-07	0.000944	-0.68	-0.56	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.761	rs9357028	ENSG00000243307.2	POM121L6P	-5.72	2.25e-07	0.000944	-0.68	-0.56	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26896952~26898777:+
LAML	cis	rs904251	0.737	rs914347	ENSG00000279942.1	RP1-153P14.7	-5.72	2.25e-07	0.000944	-0.63	-0.56	Cognitive performance;	chr6:37517194	chr6:37567716~37571460:+
LAML	cis	rs904251	0.797	rs1776460	ENSG00000279942.1	RP1-153P14.7	-5.72	2.25e-07	0.000944	-0.63	-0.56	Cognitive performance;	chr6:37517708	chr6:37567716~37571460:+
LAML	cis	rs904251	0.828	rs1757178	ENSG00000279942.1	RP1-153P14.7	5.72	2.25e-07	0.000944	0.63	0.56	Cognitive performance;	chr6:37518534	chr6:37567716~37571460:+
LAML	cis	rs1075265	0.749	rs805434	ENSG00000235937.1	AC008280.1	5.72	2.25e-07	0.000945	0.45	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53836196	chr2:54029552~54030682:-
LAML	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-5.72	2.25e-07	0.000945	-0.69	-0.56	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-5.72	2.25e-07	0.000945	-0.69	-0.56	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
LAML	cis	rs3091242	1	rs646867	ENSG00000224183.1	SDHDP6	-5.72	2.25e-07	0.000946	-0.68	-0.56	Erythrocyte sedimentation rate;	chr1:25382767	chr1:25294164~25294643:-
LAML	cis	rs853679	0.882	rs9461432	ENSG00000182477.5	OR2B8P	5.72	2.25e-07	0.000946	0.99	0.56	Depression;	chr6:28119105	chr6:28053228~28054165:-
LAML	cis	rs853679	0.882	rs4713139	ENSG00000182477.5	OR2B8P	5.72	2.25e-07	0.000946	0.99	0.56	Depression;	chr6:28124907	chr6:28053228~28054165:-
LAML	cis	rs853679	0.882	rs3757188	ENSG00000182477.5	OR2B8P	5.72	2.25e-07	0.000946	0.99	0.56	Depression;	chr6:28139579	chr6:28053228~28054165:-
LAML	cis	rs904251	0.861	rs1757183	ENSG00000279942.1	RP1-153P14.7	5.72	2.26e-07	0.000947	0.65	0.56	Cognitive performance;	chr6:37517014	chr6:37567716~37571460:+
LAML	cis	rs904251	0.861	rs1757180	ENSG00000279942.1	RP1-153P14.7	-5.72	2.26e-07	0.000947	-0.65	-0.56	Cognitive performance;	chr6:37518369	chr6:37567716~37571460:+
LAML	cis	rs7131987	0.565	rs10743652	ENSG00000275476.1	RP11-996F15.4	5.72	2.27e-07	0.000953	0.64	0.56	QT interval;	chr12:29255074	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs10843372	ENSG00000275476.1	RP11-996F15.4	5.72	2.27e-07	0.000953	0.64	0.56	QT interval;	chr12:29262863	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs7976227	ENSG00000275476.1	RP11-996F15.4	5.72	2.27e-07	0.000953	0.64	0.56	QT interval;	chr12:29264843	chr12:29277397~29277882:-
LAML	cis	rs9368481	0.672	rs3931463	ENSG00000243307.2	POM121L6P	5.72	2.27e-07	0.000953	0.68	0.56	Autism spectrum disorder or schizophrenia;	chr6:26972018	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.761	rs3931464	ENSG00000243307.2	POM121L6P	5.72	2.27e-07	0.000953	0.68	0.56	Autism spectrum disorder or schizophrenia;	chr6:26972077	chr6:26896952~26898777:+
LAML	cis	rs12922317	0.589	rs7192491	ENSG00000260224.1	UBL5P4	-5.72	2.28e-07	0.000957	-0.68	-0.56	Schizophrenia;	chr16:12050169	chr16:11968508~11968743:-
LAML	cis	rs1075265	0.68	rs6715488	ENSG00000235937.1	AC008280.1	5.72	2.29e-07	0.000958	0.44	0.56	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.73	rs6711105	ENSG00000235937.1	AC008280.1	5.72	2.29e-07	0.000958	0.44	0.56	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.704	rs6711217	ENSG00000235937.1	AC008280.1	5.72	2.29e-07	0.000958	0.44	0.56	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.704	rs10084374	ENSG00000235937.1	AC008280.1	5.72	2.29e-07	0.000958	0.44	0.56	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54029552~54030682:-
LAML	cis	rs62070183	0.882	rs17183295	ENSG00000265337.1	RP11-466A19.5	5.72	2.3e-07	0.000963	0.87	0.56	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32751254	chr17:32529008~32530049:-
LAML	cis	rs9322193	0.884	rs880245	ENSG00000216906.2	RP11-350J20.9	-5.72	2.3e-07	0.000963	-0.89	-0.56	Lung cancer;	chr6:149846262	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs1108889	ENSG00000216906.2	RP11-350J20.9	5.72	2.3e-07	0.000963	0.89	0.56	Lung cancer;	chr6:149845433	chr6:149904243~149906418:+
LAML	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-5.71	2.33e-07	0.000973	-0.65	-0.56	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	5.71	2.33e-07	0.000973	0.65	0.56	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
LAML	cis	rs1075265	0.783	rs805439	ENSG00000235937.1	AC008280.1	5.71	2.33e-07	0.000975	0.44	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54029552~54030682:-
LAML	cis	rs67311347	1	rs67311347	ENSG00000223797.4	ENTPD3-AS1	5.71	2.33e-07	0.000975	0.78	0.56	Renal cell carcinoma;	chr3:40491752	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	5.71	2.34e-07	0.000978	0.71	0.56	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	5.71	2.34e-07	0.000978	0.71	0.56	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	5.71	2.34e-07	0.000978	0.71	0.56	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
LAML	cis	rs5769707	0.967	rs2051626	ENSG00000212939.2	RP1-29C18.10	-5.71	2.35e-07	0.000979	-0.7	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.967	rs1018812	ENSG00000212939.2	RP1-29C18.10	-5.71	2.35e-07	0.000979	-0.7	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49548681~49556473:+
LAML	cis	rs4879656	0.788	rs10758186	ENSG00000225693.1	LAGE3P1	5.71	2.35e-07	0.000979	0.63	0.56	Menopause (age at onset);	chr9:33101840	chr9:33019682~33020165:-
LAML	cis	rs6782228	0.509	rs4481172	ENSG00000277250.1	Metazoa_SRP	-5.71	2.36e-07	0.000984	-0.74	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128673681~128674021:-
LAML	cis	rs67340775	0.541	rs200968	ENSG00000220721.1	OR1F12	5.71	2.36e-07	0.000985	0.66	0.56	Lung cancer in ever smokers;	chr6:27891790	chr6:28073316~28074233:+
LAML	cis	rs67340775	0.541	rs200966	ENSG00000220721.1	OR1F12	5.71	2.36e-07	0.000985	0.66	0.56	Lung cancer in ever smokers;	chr6:27894374	chr6:28073316~28074233:+
LAML	cis	rs67340775	0.541	rs200965	ENSG00000220721.1	OR1F12	5.71	2.36e-07	0.000985	0.66	0.56	Lung cancer in ever smokers;	chr6:27898606	chr6:28073316~28074233:+
LAML	cis	rs67340775	0.541	rs200964	ENSG00000220721.1	OR1F12	5.71	2.36e-07	0.000985	0.66	0.56	Lung cancer in ever smokers;	chr6:27899165	chr6:28073316~28074233:+
LAML	cis	rs10028773	0.546	rs13117947	ENSG00000248280.1	RP11-33B1.2	5.71	2.37e-07	0.000985	0.68	0.56	Educational attainment;	chr4:119335905	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.777	rs2017058	ENSG00000248280.1	RP11-33B1.2	5.71	2.37e-07	0.000988	0.68	0.56	Diastolic blood pressure;	chr4:119336584	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.777	rs1814815	ENSG00000248280.1	RP11-33B1.2	5.71	2.37e-07	0.000988	0.68	0.56	Diastolic blood pressure;	chr4:119336936	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.748	rs28439855	ENSG00000248280.1	RP11-33B1.2	5.71	2.37e-07	0.000988	0.68	0.56	Diastolic blood pressure;	chr4:119341101	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.777	rs10015883	ENSG00000248280.1	RP11-33B1.2	5.71	2.37e-07	0.000988	0.68	0.56	Diastolic blood pressure;	chr4:119346991	chr4:119440561~119450157:-
LAML	cis	rs1075265	0.783	rs805359	ENSG00000235937.1	AC008280.1	5.71	2.38e-07	0.000989	0.46	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.783	rs698858	ENSG00000235937.1	AC008280.1	5.71	2.38e-07	0.000989	0.46	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.756	rs805367	ENSG00000235937.1	AC008280.1	5.71	2.38e-07	0.000989	0.46	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.783	rs718872	ENSG00000235937.1	AC008280.1	5.71	2.38e-07	0.000989	0.46	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54029552~54030682:-
LAML	cis	rs853679	0.556	rs13200214	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Depression;	chr6:28049472	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs71559070	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Depression;	chr6:28071151	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs35902873	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Depression;	chr6:28091171	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13197574	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Depression;	chr6:28092461	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34166054	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Depression;	chr6:28098023	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34662244	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Depression;	chr6:28106103	chr6:28073316~28074233:+
LAML	cis	rs35952432	1	rs35952432	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Lung cancer;	chr6:28107123	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13203816	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Depression;	chr6:28111820	chr6:28073316~28074233:+
LAML	cis	rs853679	0.556	rs34588114	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Depression;	chr6:28112850	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs68188794	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Depression;	chr6:28112999	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs34371502	ENSG00000220721.1	OR1F12	5.71	2.39e-07	0.000992	0.91	0.56	Depression;	chr6:28113980	chr6:28073316~28074233:+
LAML	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-5.71	2.4e-07	0.000995	-0.63	-0.56	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-5.71	2.4e-07	0.000995	-0.63	-0.56	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
LAML	cis	rs9368481	0.594	rs2636425	ENSG00000243307.2	POM121L6P	5.71	2.4e-07	0.000998	0.73	0.56	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26896952~26898777:+
LAML	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	5.71	2.41e-07	0.001	0.58	0.56	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	5.71	2.41e-07	0.001	0.58	0.56	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	5.71	2.41e-07	0.001	0.58	0.56	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
LAML	cis	rs1075265	0.87	rs1363062	ENSG00000235937.1	AC008280.1	5.7	2.41e-07	0.001	0.47	0.56	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54029552~54030682:-
LAML	cis	rs9898641	1	rs9898641	ENSG00000267302.4	RP11-178C3.2	5.7	2.41e-07	0.001	0.72	0.56	Interleukin-1-beta levels;	chr17:59493672	chr17:59964832~59996972:+
LAML	cis	rs1075265	0.749	rs805380	ENSG00000235937.1	AC008280.1	5.7	2.41e-07	0.001	0.44	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53867284	chr2:54029552~54030682:-
LAML	cis	rs2564921	0.704	rs11130333	ENSG00000280417.1	RP11-5O17.1	-5.7	2.41e-07	0.001	-0.83	-0.56	Height;	chr3:52977358	chr3:53046166~53048122:+
LAML	cis	rs10716631	1	rs10716631	ENSG00000261338.2	RP11-378A13.1	5.7	2.42e-07	0.001	0.74	0.56	Plateletcrit;High light scatter reticulocyte percentage of red cells;	chr2:218273447	chr2:218255319~218257366:+
LAML	cis	rs1263173	0.566	rs4225	ENSG00000254851.1	RP11-109L13.1	-5.7	2.42e-07	0.001	-0.78	-0.56	HDL cholesterol;	chr11:116832955	chr11:117135528~117138582:+
LAML	cis	rs3758911	0.828	rs10890684	ENSG00000261098.1	RP11-819C21.1	-5.7	2.42e-07	0.001	-0.53	-0.56	Coronary artery disease;	chr11:107266325	chr11:107312132~107316271:-
LAML	cis	rs3091242	0.933	rs9645452	ENSG00000224183.1	SDHDP6	5.7	2.43e-07	0.00101	0.67	0.56	Erythrocyte sedimentation rate;	chr1:25341835	chr1:25294164~25294643:-
LAML	cis	rs12468226	1	rs79919139	ENSG00000226261.1	AC064836.3	5.7	2.44e-07	0.00101	0.98	0.56	Urate levels;	chr2:202382786	chr2:202336024~202336727:-
LAML	cis	rs7714584	1	rs17727568	ENSG00000197083.10	ZNF300P1	5.7	2.44e-07	0.00101	1.25	0.56	Crohn's disease;	chr5:150865126	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11741861	ENSG00000197083.10	ZNF300P1	-5.7	2.44e-07	0.00101	-1.25	-0.56	Crohn's disease;	chr5:150898347	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs4958426	ENSG00000197083.10	ZNF300P1	5.7	2.44e-07	0.00101	1.25	0.56	Crohn's disease;	chr5:150898784	chr5:150930645~150946289:-
LAML	cis	rs1075265	0.783	rs805450	ENSG00000235937.1	AC008280.1	5.7	2.45e-07	0.00102	0.46	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.783	rs805453	ENSG00000235937.1	AC008280.1	5.7	2.45e-07	0.00102	0.46	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.73	rs2111868	ENSG00000235937.1	AC008280.1	5.7	2.45e-07	0.00102	0.46	0.56	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54029552~54030682:-
LAML	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-5.7	2.46e-07	0.00102	-0.69	-0.56	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
LAML	cis	rs5769707	1	rs5769707	ENSG00000279597.1	RP4-566L20.1	-5.7	2.47e-07	0.00102	-0.66	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49534062~49534926:+
LAML	cis	rs10927875	0.619	rs28537253	ENSG00000178715.8	RP11-169K16.8	-5.7	2.47e-07	0.00102	-0.63	-0.56	Dilated cardiomyopathy;	chr1:15822105	chr1:15828232~15828669:+
LAML	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-5.7	2.47e-07	0.00102	-0.66	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
LAML	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-5.7	2.48e-07	0.00102	-1	-0.56	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
LAML	cis	rs7829975	0.593	rs2921051	ENSG00000253893.2	FAM85B	-5.7	2.48e-07	0.00103	-0.69	-0.56	Mood instability;	chr8:8462594	chr8:8167819~8226614:-
LAML	cis	rs1757171	0.542	rs3818986	ENSG00000227920.2	RP1-153P14.5	-5.7	2.48e-07	0.00103	-0.6	-0.56	Cognitive performance;	chr6:37516573	chr6:37545145~37550860:+
LAML	cis	rs12477438	0.501	rs12613624	ENSG00000231822.1	AC019097.7	-5.7	2.49e-07	0.00103	-0.72	-0.56	Chronic sinus infection;	chr2:99116278	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs1453563	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99103804	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs11683188	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99108049	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.559	rs6733285	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99109112	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs34272114	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99120980	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs11692336	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99124143	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs1133978	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99125501	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs13008171	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99126956	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs4850897	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99151956	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs2516830	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99157239	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs2632283	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99159537	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs2516833	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99160942	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs2516835	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99162668	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs7608938	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99165763	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs6542868	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99166385	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs6727749	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99177127	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs13033012	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99178686	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs13000731	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99178768	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs6708878	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99185101	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs4347885	ENSG00000231822.1	AC019097.7	5.7	2.49e-07	0.00103	0.72	0.56	Chronic sinus infection;	chr2:99187544	chr2:99102018~99102752:+
LAML	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-5.7	2.49e-07	0.00103	-0.71	-0.56	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs897117	ENSG00000223797.4	ENTPD3-AS1	-5.7	2.49e-07	0.00103	-0.71	-0.56	Renal cell carcinoma;	chr3:40395803	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-5.7	2.49e-07	0.00103	-0.71	-0.56	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-5.7	2.49e-07	0.00103	-0.71	-0.56	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	5.7	2.49e-07	0.00103	0.71	0.56	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
LAML	cis	rs7587476	1	rs7587476	ENSG00000229267.2	AC072062.1	5.7	2.49e-07	0.00103	0.64	0.56	Neuroblastoma;	chr2:214789163	chr2:214810229~214963274:+
LAML	cis	rs5769707	0.967	rs763127	ENSG00000212939.2	RP1-29C18.10	-5.69	2.53e-07	0.00104	-0.64	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49548681~49556473:+
LAML	cis	rs10927875	0.793	rs1763619	ENSG00000178715.8	RP11-169K16.8	5.69	2.54e-07	0.00104	0.67	0.56	Dilated cardiomyopathy;	chr1:16000440	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.8	rs1627145	ENSG00000178715.8	RP11-169K16.8	5.69	2.54e-07	0.00104	0.67	0.56	Dilated cardiomyopathy;	chr1:16001621	chr1:15828232~15828669:+
LAML	cis	rs2120335	0.928	rs17035004	ENSG00000221443.1	AC017083.1	5.69	2.54e-07	0.00104	0.7	0.56	Height;	chr2:68131521	chr2:68273104~68273206:+
LAML	cis	rs4591358	0.765	rs979821	ENSG00000223466.1	AC064834.2	5.69	2.54e-07	0.00104	0.71	0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195456015	chr2:195533035~195538681:+
LAML	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	5.69	2.54e-07	0.00104	0.69	0.56	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
LAML	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	5.69	2.54e-07	0.00104	0.63	0.56	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	5.69	2.54e-07	0.00104	0.63	0.56	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	5.69	2.54e-07	0.00104	0.63	0.56	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	5.69	2.54e-07	0.00105	0.65	0.56	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.699	rs1736895	ENSG00000216901.1	AL022393.7	5.69	2.55e-07	0.00105	0.64	0.56	Pubertal anthropometrics;	chr6:28252048	chr6:28176188~28176674:+
LAML	cis	rs9309473	1	rs6715819	ENSG00000163016.8	ALMS1P	5.69	2.55e-07	0.00105	0.64	0.56	Metabolite levels;	chr2:73545182	chr2:73644919~73685576:+
LAML	cis	rs2564921	0.704	rs57916015	ENSG00000280417.1	RP11-5O17.1	-5.69	2.57e-07	0.00105	-0.79	-0.56	Height;	chr3:52971094	chr3:53046166~53048122:+
LAML	cis	rs6452524	0.87	rs6452511	ENSG00000249664.1	CTD-2227C6.2	5.69	2.57e-07	0.00105	0.77	0.56	Hypertension (SNP x SNP interaction);	chr5:83127403	chr5:83012285~83013109:-
LAML	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	5.69	2.57e-07	0.00105	0.69	0.56	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	5.69	2.57e-07	0.00105	0.69	0.56	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	5.69	2.57e-07	0.00105	0.69	0.56	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	5.69	2.57e-07	0.00105	0.69	0.56	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	5.69	2.57e-07	0.00105	0.69	0.56	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	5.69	2.57e-07	0.00105	0.69	0.56	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	5.69	2.57e-07	0.00105	0.69	0.56	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	5.69	2.57e-07	0.00105	0.69	0.56	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	5.69	2.57e-07	0.00105	0.69	0.56	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	5.69	2.57e-07	0.00105	0.69	0.56	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
LAML	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-5.69	2.57e-07	0.00105	-1.18	-0.56	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
LAML	cis	rs1555322	0.53	rs2425049	ENSG00000279253.1	RP4-614O4.13	-5.68	2.62e-07	0.00107	-0.62	-0.56	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35262727~35264187:-
LAML	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	5.68	2.62e-07	0.00107	0.67	0.56	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	5.68	2.62e-07	0.00107	0.67	0.56	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
LAML	cis	rs2120335	0.928	rs62145930	ENSG00000221443.1	AC017083.1	5.68	2.63e-07	0.00107	0.7	0.56	Height;	chr2:68131209	chr2:68273104~68273206:+
LAML	cis	rs4591358	0.689	rs17178460	ENSG00000223466.1	AC064834.2	-5.68	2.63e-07	0.00107	-0.84	-0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195555365	chr2:195533035~195538681:+
LAML	cis	rs5769707	0.521	rs5769719	ENSG00000212939.2	RP1-29C18.10	-5.68	2.63e-07	0.00107	-0.71	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.521	rs5769720	ENSG00000212939.2	RP1-29C18.10	-5.68	2.63e-07	0.00107	-0.71	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.521	rs5770633	ENSG00000212939.2	RP1-29C18.10	-5.68	2.63e-07	0.00107	-0.71	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49548681~49556473:+
LAML	cis	rs1150668	0.699	rs13408	ENSG00000216901.1	AL022393.7	5.68	2.64e-07	0.00108	0.64	0.56	Pubertal anthropometrics;	chr6:28244970	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	5.68	2.64e-07	0.00108	0.64	0.56	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-5.68	2.64e-07	0.00108	-0.64	-0.56	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
LAML	cis	rs2581828	0.608	rs9868263	ENSG00000280417.1	RP11-5O17.1	-5.68	2.65e-07	0.00108	-0.78	-0.56	Crohn's disease;	chr3:53130078	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.618	rs9868406	ENSG00000280417.1	RP11-5O17.1	-5.68	2.65e-07	0.00108	-0.78	-0.56	Crohn's disease;	chr3:53130177	chr3:53046166~53048122:+
LAML	cis	rs992157	1	rs4791	ENSG00000261338.2	RP11-378A13.1	5.68	2.65e-07	0.00108	0.73	0.56	Colorectal cancer;	chr2:218274217	chr2:218255319~218257366:+
LAML	cis	rs4591358	0.765	rs9288249	ENSG00000223466.1	AC064834.2	-5.68	2.65e-07	0.00108	-0.71	-0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195452555	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.705	rs6741348	ENSG00000223466.1	AC064834.2	-5.68	2.65e-07	0.00108	-0.71	-0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195466190	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.705	rs6717199	ENSG00000223466.1	AC064834.2	5.68	2.65e-07	0.00108	0.71	0.56	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195467140	chr2:195533035~195538681:+
LAML	cis	rs5769707	0.542	rs739242	ENSG00000212939.2	RP1-29C18.10	-5.68	2.66e-07	0.00108	-0.71	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.521	rs7285764	ENSG00000212939.2	RP1-29C18.10	-5.68	2.66e-07	0.00108	-0.71	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.521	rs9616715	ENSG00000212939.2	RP1-29C18.10	-5.68	2.66e-07	0.00108	-0.71	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.521	rs6009805	ENSG00000212939.2	RP1-29C18.10	-5.68	2.66e-07	0.00108	-0.71	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.521	rs6009807	ENSG00000212939.2	RP1-29C18.10	-5.68	2.66e-07	0.00108	-0.71	-0.56	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49548681~49556473:+
LAML	cis	rs12468226	0.882	rs116437099	ENSG00000272966.1	RP11-686O6.1	5.68	2.66e-07	0.00109	0.9	0.56	Urate levels;	chr2:202299250	chr2:202336739~202337200:+
LAML	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-5.68	2.68e-07	0.00109	-1	-0.56	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
LAML	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-5.68	2.68e-07	0.00109	-1	-0.56	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
LAML	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-5.68	2.68e-07	0.00109	-0.71	-0.56	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
LAML	cis	rs66887589	0.87	rs10518336	ENSG00000248280.1	RP11-33B1.2	5.68	2.68e-07	0.00109	0.71	0.56	Diastolic blood pressure;	chr4:119601779	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.72	rs11724758	ENSG00000248280.1	RP11-33B1.2	5.68	2.69e-07	0.0011	0.69	0.56	Diastolic blood pressure;	chr4:119318723	chr4:119440561~119450157:-
LAML	cis	rs2564921	0.666	rs62253656	ENSG00000280417.1	RP11-5O17.1	-5.68	2.69e-07	0.0011	-0.82	-0.56	Height;	chr3:52989412	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.704	rs12053904	ENSG00000280417.1	RP11-5O17.1	-5.68	2.69e-07	0.0011	-0.82	-0.56	Height;	chr3:52991821	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.679	rs2115779	ENSG00000280417.1	RP11-5O17.1	-5.68	2.69e-07	0.0011	-0.82	-0.56	Height;	chr3:52992698	chr3:53046166~53048122:+
LAML	cis	rs10028773	0.515	rs9994651	ENSG00000248280.1	RP11-33B1.2	5.68	2.69e-07	0.0011	0.79	0.56	Educational attainment;	chr4:119666648	chr4:119440561~119450157:-
LAML	cis	rs6700559	0.565	rs12728040	ENSG00000260088.1	RP11-92G12.3	5.68	2.7e-07	0.0011	0.69	0.56	Coronary artery disease;	chr1:200626751	chr1:200669507~200694250:+
LAML	cis	rs4713118	0.629	rs203887	ENSG00000182477.5	OR2B8P	5.68	2.71e-07	0.0011	0.85	0.56	Parkinson's disease;	chr6:28053491	chr6:28053228~28054165:-
LAML	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-5.67	2.73e-07	0.00111	-0.63	-0.56	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-5.67	2.73e-07	0.00111	-0.63	-0.56	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-5.67	2.73e-07	0.00111	-0.63	-0.56	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
LAML	cis	rs7829975	0.514	rs2979139	ENSG00000253893.2	FAM85B	-5.67	2.73e-07	0.00111	-0.62	-0.56	Mood instability;	chr8:8410803	chr8:8167819~8226614:-
LAML	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	5.67	2.74e-07	0.00112	0.68	0.56	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
LAML	cis	rs2581828	0.656	rs2581800	ENSG00000280417.1	RP11-5O17.1	5.67	2.75e-07	0.00112	0.72	0.56	Crohn's disease;	chr3:53075336	chr3:53046166~53048122:+
LAML	cis	rs10927875	0.619	rs2013019	ENSG00000178715.8	RP11-169K16.8	-5.67	2.75e-07	0.00112	-0.66	-0.56	Dilated cardiomyopathy;	chr1:15802825	chr1:15828232~15828669:+
LAML	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-5.67	2.77e-07	0.00112	-0.7	-0.56	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
LAML	cis	rs904251	0.523	rs1776455	ENSG00000279942.1	RP1-153P14.7	-5.67	2.77e-07	0.00112	-0.6	-0.56	Cognitive performance;	chr6:37515147	chr6:37567716~37571460:+
LAML	cis	rs2581828	0.656	rs2336723	ENSG00000280417.1	RP11-5O17.1	5.67	2.78e-07	0.00113	0.72	0.56	Crohn's disease;	chr3:53072031	chr3:53046166~53048122:+
LAML	cis	rs2143950	0.831	rs80031420	ENSG00000241052.1	RP11-173D9.1	-5.67	2.79e-07	0.00113	-1	-0.56	Atopic dermatitis;	chr14:35086915	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs79702597	ENSG00000241052.1	RP11-173D9.1	-5.67	2.79e-07	0.00113	-1	-0.56	Immunoglobulin light chain (AL) amyloidosis;	chr14:35089650	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs2143950	ENSG00000241052.1	RP11-173D9.1	-5.67	2.79e-07	0.00113	-1	-0.56	Immunoglobulin light chain (AL) amyloidosis;	chr14:35103151	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs57075379	ENSG00000241052.1	RP11-173D9.1	-5.67	2.79e-07	0.00113	-1	-0.56	Immunoglobulin light chain (AL) amyloidosis;	chr14:35108595	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs79436302	ENSG00000241052.1	RP11-173D9.1	-5.67	2.79e-07	0.00113	-1	-0.56	Immunoglobulin light chain (AL) amyloidosis;	chr14:35109591	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs79199019	ENSG00000241052.1	RP11-173D9.1	-5.67	2.79e-07	0.00113	-1	-0.56	Immunoglobulin light chain (AL) amyloidosis;	chr14:35111919	chr14:35144021~35144480:-
LAML	cis	rs763121	0.853	rs5750672	ENSG00000230912.1	RP3-508I15.10	5.67	2.79e-07	0.00113	0.48	0.56	Menopause (age at onset);	chr22:38708163	chr22:38666508~38668750:-
LAML	cis	rs1075265	0.73	rs7597188	ENSG00000235937.1	AC008280.1	5.67	2.82e-07	0.00114	0.43	0.56	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.73	rs7597189	ENSG00000235937.1	AC008280.1	5.67	2.82e-07	0.00114	0.43	0.56	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.704	rs9631059	ENSG00000235937.1	AC008280.1	5.67	2.82e-07	0.00114	0.43	0.56	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.73	rs11893270	ENSG00000235937.1	AC008280.1	5.67	2.82e-07	0.00114	0.43	0.56	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54029552~54030682:-
LAML	cis	rs853679	1	rs1778508	ENSG00000182477.5	OR2B8P	-5.67	2.82e-07	0.00114	-0.82	-0.56	Depression;	chr6:28262103	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs2799077	ENSG00000182477.5	OR2B8P	5.67	2.82e-07	0.00114	0.82	0.56	Depression;	chr6:28266819	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs11965538	ENSG00000182477.5	OR2B8P	5.67	2.82e-07	0.00114	0.82	0.56	Depression;	chr6:28272137	chr6:28053228~28054165:-
LAML	cis	rs853679	0.882	rs2743555	ENSG00000182477.5	OR2B8P	5.67	2.82e-07	0.00114	0.82	0.56	Depression;	chr6:28273304	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs1419183	ENSG00000182477.5	OR2B8P	5.67	2.82e-07	0.00114	0.82	0.56	Depression;	chr6:28275017	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs6901575	ENSG00000182477.5	OR2B8P	5.67	2.82e-07	0.00114	0.82	0.56	Depression;	chr6:28283207	chr6:28053228~28054165:-
LAML	cis	rs709400	1	rs10135248	ENSG00000258851.1	RP11-894P9.2	-5.66	2.83e-07	0.00115	-0.69	-0.56	Body mass index;	chr14:103655973	chr14:103553421~103561877:+
LAML	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-5.66	2.84e-07	0.00115	-0.69	-0.56	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
LAML	cis	rs10927875	0.619	rs1806991	ENSG00000178715.8	RP11-169K16.8	-5.66	2.84e-07	0.00115	-0.66	-0.56	Dilated cardiomyopathy;	chr1:15802946	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.619	rs2102664	ENSG00000178715.8	RP11-169K16.8	-5.66	2.84e-07	0.00115	-0.66	-0.56	Dilated cardiomyopathy;	chr1:15803674	chr1:15828232~15828669:+
LAML	cis	rs997154	0.579	rs12889177	ENSG00000279656.1	RP11-298I3.6	-5.66	2.86e-07	0.00115	-0.96	-0.56	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:23022120	chr14:23023083~23024217:-
LAML	cis	rs7131987	0.565	rs4412790	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29253828	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs10743651	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29255006	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.546	rs7299648	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29256797	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs7300032	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29256859	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.547	rs4370971	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29257066	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs7316026	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29258881	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs6487792	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29259743	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.585	rs2194517	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29260002	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs766445	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29260560	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs7971296	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29263297	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.605	rs1120528	ENSG00000275476.1	RP11-996F15.4	5.66	2.86e-07	0.00115	0.63	0.56	QT interval;	chr12:29264237	chr12:29277397~29277882:-
LAML	cis	rs12477438	0.501	rs17759607	ENSG00000231822.1	AC019097.7	5.66	2.87e-07	0.00116	0.72	0.55	Chronic sinus infection;	chr2:99120542	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs1133977	ENSG00000231822.1	AC019097.7	-5.66	2.87e-07	0.00116	-0.72	-0.55	Chronic sinus infection;	chr2:99125521	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs4851188	ENSG00000231822.1	AC019097.7	5.66	2.87e-07	0.00116	0.72	0.55	Chronic sinus infection;	chr2:99129435	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs11683107	ENSG00000231822.1	AC019097.7	5.66	2.87e-07	0.00116	0.72	0.55	Chronic sinus infection;	chr2:99142772	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs6542866	ENSG00000231822.1	AC019097.7	5.66	2.87e-07	0.00116	0.72	0.55	Chronic sinus infection;	chr2:99148129	chr2:99102018~99102752:+
LAML	cis	rs1075265	0.87	rs6724389	ENSG00000235937.1	AC008280.1	5.66	2.88e-07	0.00116	0.46	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54029552~54030682:-
LAML	cis	rs709400	1	rs7150141	ENSG00000258851.1	RP11-894P9.2	-5.66	2.91e-07	0.00117	-0.69	-0.55	Body mass index;	chr14:103663015	chr14:103553421~103561877:+
LAML	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	5.66	2.93e-07	0.00118	0.57	0.55	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	5.66	2.93e-07	0.00118	0.57	0.55	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	5.66	2.93e-07	0.00118	0.57	0.55	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
LAML	cis	rs904251	0.523	rs2776874	ENSG00000204110.6	RP1-153P14.8	-5.66	2.94e-07	0.00118	-0.62	-0.55	Cognitive performance;	chr6:37515421	chr6:37507348~37535616:+
LAML	cis	rs12477438	0.52	rs720229	ENSG00000231822.1	AC019097.7	5.65	2.98e-07	0.0012	0.71	0.55	Chronic sinus infection;	chr2:99087810	chr2:99102018~99102752:+
LAML	cis	rs853679	0.556	rs45509595	ENSG00000187763.3	OR2B7P	5.65	3.01e-07	0.00121	1.01	0.55	Depression;	chr6:27873148	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs66868086	ENSG00000187763.3	OR2B7P	5.65	3.01e-07	0.00121	1.01	0.55	Depression;	chr6:27898124	chr6:28046434~28047367:+
LAML	cis	rs904251	0.504	rs9380677	ENSG00000279942.1	RP1-153P14.7	-5.65	3.03e-07	0.00122	-0.6	-0.55	Cognitive performance;	chr6:37512590	chr6:37567716~37571460:+
LAML	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-5.65	3.03e-07	0.00122	-0.77	-0.55	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
LAML	cis	rs7829975	0.5	rs7841082	ENSG00000268955.2	RP11-556O5.6	5.65	3.06e-07	0.00123	0.63	0.55	Mood instability;	chr8:8311465	chr8:8188535~8189195:-
LAML	cis	rs12468226	1	rs16839077	ENSG00000272966.1	RP11-686O6.1	5.64	3.07e-07	0.00123	0.97	0.55	Urate levels;	chr2:202343970	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs16839090	ENSG00000272966.1	RP11-686O6.1	5.64	3.07e-07	0.00123	0.97	0.55	Urate levels;	chr2:202348338	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs58288071	ENSG00000272966.1	RP11-686O6.1	5.64	3.07e-07	0.00123	0.97	0.55	Urate levels;	chr2:202350016	chr2:202336739~202337200:+
LAML	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-5.64	3.07e-07	0.00123	-0.67	-0.55	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
LAML	cis	rs2980436	1	rs2980436	ENSG00000268955.2	RP11-556O5.6	5.64	3.08e-07	0.00123	0.67	0.55	Schizophrenia;	chr8:8234503	chr8:8188535~8189195:-
LAML	cis	rs6558530	0.64	rs7844748	ENSG00000253982.1	CTD-2336O2.1	-5.64	3.08e-07	0.00123	-0.85	-0.55	Systolic blood pressure;	chr8:1754177	chr8:1761990~1764502:-
LAML	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-5.64	3.09e-07	0.00124	-0.99	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
LAML	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-5.64	3.09e-07	0.00124	-0.99	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
LAML	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-5.64	3.09e-07	0.00124	-0.99	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-5.64	3.09e-07	0.00124	-0.99	-0.55	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-5.64	3.09e-07	0.00124	-0.99	-0.55	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-5.64	3.09e-07	0.00124	-0.99	-0.55	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs10750100	ENSG00000254851.1	RP11-109L13.1	-5.64	3.09e-07	0.00124	-0.99	-0.55	Blood protein levels;	chr11:117046528	chr11:117135528~117138582:+
LAML	cis	rs1815787	1	rs1815787	ENSG00000254851.1	RP11-109L13.1	-5.64	3.09e-07	0.00124	-0.99	-0.55	Subjective well-being;	chr11:117050681	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	5.64	3.09e-07	0.00124	0.99	0.55	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
LAML	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-5.64	3.09e-07	0.00124	-0.99	-0.55	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
LAML	cis	rs1577917	0.57	rs114854865	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85844518	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.916	rs4706252	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85845462	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs1838959	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85847086	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs1579886	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85847473	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs1816937	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85847533	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs2324840	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85847902	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs7382798	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85850116	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12202188	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85852982	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs36035797	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85853162	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs1838958	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85854250	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs2084293	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85856284	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12209668	ENSG00000203875.9	SNHG5	-5.64	3.09e-07	0.00124	-0.73	-0.55	Response to antipsychotic treatment;	chr6:85856799	chr6:85660950~85678736:-
LAML	cis	rs7714584	1	rs6874560	ENSG00000197083.10	ZNF300P1	5.64	3.12e-07	0.00124	1.24	0.55	Crohn's disease;	chr5:150803151	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11748553	ENSG00000197083.10	ZNF300P1	5.64	3.12e-07	0.00124	1.24	0.55	Crohn's disease;	chr5:150804991	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11746560	ENSG00000197083.10	ZNF300P1	5.64	3.12e-07	0.00124	1.24	0.55	Crohn's disease;	chr5:150806363	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs59715748	ENSG00000197083.10	ZNF300P1	5.64	3.12e-07	0.00124	1.24	0.55	Crohn's disease;	chr5:150809725	chr5:150930645~150946289:-
LAML	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	5.64	3.15e-07	0.00126	0.59	0.55	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	5.64	3.15e-07	0.00126	0.59	0.55	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	5.64	3.15e-07	0.00126	0.59	0.55	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
LAML	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	5.64	3.15e-07	0.00126	0.7	0.55	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
LAML	cis	rs904251	0.861	rs2776875	ENSG00000227920.2	RP1-153P14.5	-5.64	3.16e-07	0.00126	-0.68	-0.55	Cognitive performance;	chr6:37519020	chr6:37545145~37550860:+
LAML	cis	rs1075265	0.597	rs11694711	ENSG00000235937.1	AC008280.1	5.64	3.17e-07	0.00126	0.43	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.554	rs10168293	ENSG00000235937.1	AC008280.1	5.64	3.17e-07	0.00126	0.43	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.567	rs66773232	ENSG00000235937.1	AC008280.1	5.64	3.17e-07	0.00126	0.43	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.633	rs10183655	ENSG00000235937.1	AC008280.1	5.64	3.17e-07	0.00126	0.43	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.633	rs3731967	ENSG00000235937.1	AC008280.1	-5.64	3.17e-07	0.00126	-0.43	-0.55	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54029552~54030682:-
LAML	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	5.64	3.18e-07	0.00126	0.58	0.55	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	5.64	3.18e-07	0.00126	0.58	0.55	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	5.64	3.18e-07	0.00126	0.58	0.55	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
LAML	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	5.64	3.18e-07	0.00126	0.57	0.55	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	5.64	3.18e-07	0.00126	0.57	0.55	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	5.64	3.18e-07	0.00126	0.57	0.55	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	5.64	3.18e-07	0.00126	0.57	0.55	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	5.64	3.18e-07	0.00126	0.57	0.55	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-5.64	3.18e-07	0.00126	-0.57	-0.55	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
LAML	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	5.64	3.18e-07	0.00127	0.58	0.55	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	5.64	3.18e-07	0.00127	0.58	0.55	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	5.64	3.18e-07	0.00127	0.58	0.55	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	5.64	3.18e-07	0.00127	0.58	0.55	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	5.64	3.18e-07	0.00127	0.58	0.55	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	5.64	3.18e-07	0.00127	0.58	0.55	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
LAML	cis	rs67311347	0.544	rs2123998	ENSG00000223797.4	ENTPD3-AS1	-5.64	3.19e-07	0.00127	-0.71	-0.55	Renal cell carcinoma;	chr3:40317514	chr3:40313802~40453329:-
LAML	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	5.63	3.2e-07	0.00127	0.62	0.55	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
LAML	cis	rs67311347	0.64	rs7434088	ENSG00000223797.4	ENTPD3-AS1	5.63	3.21e-07	0.00127	0.75	0.55	Renal cell carcinoma;	chr3:40255797	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-5.63	3.21e-07	0.00128	-0.72	-0.55	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
LAML	cis	rs9368481	0.761	rs4713062	ENSG00000243307.2	POM121L6P	-5.63	3.22e-07	0.00128	-0.67	-0.55	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26896952~26898777:+
LAML	cis	rs9368481	0.729	rs9379948	ENSG00000243307.2	POM121L6P	5.63	3.22e-07	0.00128	0.67	0.55	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26896952~26898777:+
LAML	cis	rs2564921	0.666	rs11130335	ENSG00000280417.1	RP11-5O17.1	-5.63	3.22e-07	0.00128	-0.82	-0.55	Height;	chr3:52989619	chr3:53046166~53048122:+
LAML	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	5.63	3.23e-07	0.00128	0.57	0.55	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
LAML	cis	rs10829156	0.66	rs7910506	ENSG00000240291.1	RP11-499P20.2	-5.63	3.25e-07	0.00129	-0.72	-0.55	Sudden cardiac arrest;	chr10:18518128	chr10:18513115~18545651:-
LAML	cis	rs3758911	0.964	rs10749896	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107314102	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs10789607	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107314128	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs10789608	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107314132	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs2046903	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107315208	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10890705	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107315308	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs4387327	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107315334	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs12286342	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107315568	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs12273125	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107315602	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10789611	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107316810	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10789612	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107316931	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10890707	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107317153	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10890708	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107317315	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs10890709	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107317378	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs10890710	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107317423	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs10890711	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107317424	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs12290112	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107317487	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs12270655	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107317507	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs10890712	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107317583	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs10789614	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107318047	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10789615	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107318088	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10789616	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107318365	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10789617	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107318968	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10789618	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107319003	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs11212153	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107319234	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs10890715	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107322457	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs12146472	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107323450	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs12146473	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107323540	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.929	rs55837508	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107323756	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10890716	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107324310	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10789619	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107324570	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs11212157	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107324572	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs10749901	ENSG00000261098.1	RP11-819C21.1	-5.63	3.27e-07	0.00129	-0.52	-0.55	Coronary artery disease;	chr11:107324776	chr11:107312132~107316271:-
LAML	cis	rs561341	0.739	rs7213369	ENSG00000266379.5	RP11-640N20.8	-5.63	3.28e-07	0.0013	-0.82	-0.55	Hip circumference adjusted for BMI;	chr17:31884859	chr17:32088160~32094933:-
LAML	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	5.63	3.29e-07	0.0013	0.64	0.55	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
LAML	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	5.63	3.29e-07	0.0013	0.64	0.55	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
LAML	cis	rs172166	0.516	rs2791333	ENSG00000216901.1	AL022393.7	5.63	3.29e-07	0.0013	0.64	0.55	Cardiac Troponin-T levels;	chr6:28143336	chr6:28176188~28176674:+
LAML	cis	rs172166	0.516	rs2622322	ENSG00000216901.1	AL022393.7	5.63	3.29e-07	0.0013	0.64	0.55	Cardiac Troponin-T levels;	chr6:28149665	chr6:28176188~28176674:+
LAML	cis	rs172166	0.516	rs1225618	ENSG00000216901.1	AL022393.7	5.63	3.29e-07	0.0013	0.64	0.55	Cardiac Troponin-T levels;	chr6:28161935	chr6:28176188~28176674:+
LAML	cis	rs172166	0.516	rs1150670	ENSG00000216901.1	AL022393.7	5.63	3.29e-07	0.0013	0.64	0.55	Cardiac Troponin-T levels;	chr6:28162781	chr6:28176188~28176674:+
LAML	cis	rs172166	0.516	rs2021826	ENSG00000216901.1	AL022393.7	5.63	3.29e-07	0.0013	0.64	0.55	Cardiac Troponin-T levels;	chr6:28164978	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.835	rs1233696	ENSG00000216901.1	AL022393.7	5.63	3.29e-07	0.0013	0.64	0.55	Pubertal anthropometrics;	chr6:28175232	chr6:28176188~28176674:+
LAML	cis	rs172166	0.538	rs1150686	ENSG00000216901.1	AL022393.7	5.63	3.29e-07	0.0013	0.64	0.55	Cardiac Troponin-T levels;	chr6:28193493	chr6:28176188~28176674:+
LAML	cis	rs1150688	1	rs1150688	ENSG00000216901.1	AL022393.7	5.63	3.29e-07	0.0013	0.64	0.55	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28176188~28176674:+
LAML	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-5.63	3.29e-07	0.0013	-0.64	-0.55	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
LAML	cis	rs172166	0.516	rs1225715	ENSG00000216901.1	AL022393.7	-5.63	3.29e-07	0.0013	-0.64	-0.55	Cardiac Troponin-T levels;	chr6:28145595	chr6:28176188~28176674:+
LAML	cis	rs7131987	0.565	rs7137141	ENSG00000275476.1	RP11-996F15.4	5.63	3.3e-07	0.0013	0.63	0.55	QT interval;	chr12:29272168	chr12:29277397~29277882:-
LAML	cis	rs4879656	0.525	rs10122739	ENSG00000225693.1	LAGE3P1	-5.63	3.3e-07	0.0013	-0.6	-0.55	Menopause (age at onset);	chr9:33085601	chr9:33019682~33020165:-
LAML	cis	rs6782228	0.606	rs6439135	ENSG00000277250.1	Metazoa_SRP	-5.63	3.31e-07	0.00131	-0.74	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128673681~128674021:-
LAML	cis	rs7829975	0.593	rs2921077	ENSG00000268955.2	RP11-556O5.6	-5.63	3.32e-07	0.00131	-0.64	-0.55	Mood instability;	chr8:8446992	chr8:8188535~8189195:-
LAML	cis	rs4803480	0.872	rs10420470	ENSG00000239736.2	CEACAMP3	-5.62	3.33e-07	0.00131	-0.84	-0.55	Schizophrenia;	chr19:41567075	chr19:41599735~41605984:+
LAML	cis	rs7587476	1	rs3768707	ENSG00000229267.2	AC072062.1	-5.62	3.35e-07	0.00132	-0.64	-0.55	Neuroblastoma;	chr2:214780411	chr2:214810229~214963274:+
LAML	cis	rs62070183	0.873	rs113602044	ENSG00000280245.1	RP11-466A19.4	5.62	3.36e-07	0.00132	0.87	0.55	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32691685	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs77819475	ENSG00000280245.1	RP11-466A19.4	5.62	3.36e-07	0.00132	0.87	0.55	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32699823	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs17183113	ENSG00000280245.1	RP11-466A19.4	5.62	3.36e-07	0.00132	0.87	0.55	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702107	chr17:32504567~32505644:-
LAML	cis	rs62070183	0.938	rs78418651	ENSG00000280245.1	RP11-466A19.4	5.62	3.36e-07	0.00132	0.87	0.55	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702530	chr17:32504567~32505644:-
LAML	cis	rs9399135	0.933	rs9389262	ENSG00000232876.1	CTA-212D2.2	-5.62	3.36e-07	0.00132	-0.7	-0.55	Red blood cell count;	chr6:135055271	chr6:135055033~135060550:+
LAML	cis	rs1075265	0.704	rs805402	ENSG00000235937.1	AC008280.1	5.62	3.36e-07	0.00133	0.44	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54029552~54030682:-
LAML	cis	rs853679	1	rs1679732	ENSG00000217315.1	OR2W2P	-5.62	3.37e-07	0.00133	-0.93	-0.55	Depression;	chr6:28253486	chr6:28033947~28034855:+
LAML	cis	rs9368481	0.645	rs10456350	ENSG00000243307.2	POM121L6P	5.62	3.38e-07	0.00133	0.67	0.55	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26896952~26898777:+
LAML	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	5.62	3.38e-07	0.00133	0.68	0.55	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
LAML	cis	rs7829975	0.514	rs2920983	ENSG00000253893.2	FAM85B	-5.62	3.41e-07	0.00134	-0.61	-0.55	Mood instability;	chr8:8410553	chr8:8167819~8226614:-
LAML	cis	rs1075265	0.875	rs12616212	ENSG00000235937.1	AC008280.1	5.62	3.43e-07	0.00135	0.45	0.55	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54029552~54030682:-
LAML	cis	rs4591358	0.684	rs35306440	ENSG00000223466.1	AC064834.2	5.62	3.44e-07	0.00135	0.72	0.55	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195507507	chr2:195533035~195538681:+
LAML	cis	rs12220777	0.786	rs2342607	ENSG00000230091.5	TMEM254-AS1	5.62	3.44e-07	0.00135	1.3	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80061733	chr10:80046860~80078912:-
LAML	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	5.62	3.45e-07	0.00135	0.67	0.55	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
LAML	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	5.62	3.45e-07	0.00135	0.67	0.55	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-5.62	3.45e-07	0.00135	-0.67	-0.55	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-5.62	3.45e-07	0.00135	-0.67	-0.55	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
LAML	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-5.62	3.45e-07	0.00135	-0.67	-0.55	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
LAML	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-5.62	3.45e-07	0.00135	-0.67	-0.55	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
LAML	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-5.62	3.45e-07	0.00135	-0.67	-0.55	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
LAML	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-5.62	3.45e-07	0.00135	-0.67	-0.55	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
LAML	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-5.62	3.45e-07	0.00135	-0.67	-0.55	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
LAML	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-5.62	3.45e-07	0.00135	-0.67	-0.55	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
LAML	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-5.62	3.45e-07	0.00135	-0.67	-0.55	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
LAML	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-5.62	3.45e-07	0.00135	-0.67	-0.55	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
LAML	cis	rs9326248	0.569	rs10892082	ENSG00000254851.1	RP11-109L13.1	-5.62	3.45e-07	0.00135	-1.09	-0.55	Blood protein levels;	chr11:117168609	chr11:117135528~117138582:+
LAML	cis	rs709400	0.93	rs28513222	ENSG00000258851.1	RP11-894P9.2	-5.62	3.45e-07	0.00135	-0.72	-0.55	Body mass index;	chr14:103561732	chr14:103553421~103561877:+
LAML	cis	rs709400	0.827	rs2274269	ENSG00000258851.1	RP11-894P9.2	-5.62	3.45e-07	0.00135	-0.72	-0.55	Body mass index;	chr14:103562909	chr14:103553421~103561877:+
LAML	cis	rs8037818	1	rs8037102	ENSG00000276724.1	RP11-1000B6.7	-5.61	3.47e-07	0.00136	-0.75	-0.55	Obesity-related traits;	chr15:32640449	chr15:32583612~32584312:+
LAML	cis	rs904251	0.861	rs1757171	ENSG00000279942.1	RP1-153P14.7	-5.61	3.49e-07	0.00137	-0.65	-0.55	Cognitive performance;	chr6:37519268	chr6:37567716~37571460:+
LAML	cis	rs853679	0.607	rs34243448	ENSG00000220721.1	OR1F12	5.61	3.5e-07	0.00137	0.89	0.55	Depression;	chr6:28225324	chr6:28073316~28074233:+
LAML	cis	rs12220777	1	rs72644212	ENSG00000230091.5	TMEM254-AS1	5.61	3.52e-07	0.00137	1.2	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80022758	chr10:80046860~80078912:-
LAML	cis	rs7714584	1	rs4958422	ENSG00000197083.10	ZNF300P1	5.61	3.53e-07	0.00137	1.23	0.55	Crohn's disease;	chr5:150807172	chr5:150930645~150946289:-
LAML	cis	rs4713118	0.868	rs10484401	ENSG00000182477.5	OR2B8P	-5.61	3.53e-07	0.00137	-0.79	-0.55	Parkinson's disease;	chr6:27778811	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.868	rs35069907	ENSG00000182477.5	OR2B8P	5.61	3.53e-07	0.00137	0.79	0.55	Parkinson's disease;	chr6:27778913	chr6:28053228~28054165:-
LAML	cis	rs11903757	0.738	rs71414946	ENSG00000281467.1	Clostridiales-1	-5.61	3.54e-07	0.00137	-0.89	-0.55	Colorectal cancer;	chr2:191692418	chr2:191699476~191699631:-
LAML	cis	rs2581828	0.646	rs28501212	ENSG00000280417.1	RP11-5O17.1	-5.61	3.56e-07	0.00138	-0.76	-0.55	Crohn's disease;	chr3:53129041	chr3:53046166~53048122:+
LAML	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	5.61	3.56e-07	0.00138	0.58	0.55	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
LAML	cis	rs2564921	0.73	rs60579898	ENSG00000280417.1	RP11-5O17.1	-5.61	3.56e-07	0.00138	-0.79	-0.55	Height;	chr3:53069965	chr3:53046166~53048122:+
LAML	cis	rs7746199	0.736	rs35848276	ENSG00000187763.3	OR2B7P	5.61	3.58e-07	0.00139	1.02	0.55	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs13202295	ENSG00000187763.3	OR2B7P	5.61	3.58e-07	0.00139	1.02	0.55	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28046434~28047367:+
LAML	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-5.61	3.59e-07	0.00139	-0.64	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-5.61	3.59e-07	0.00139	-0.64	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
LAML	cis	rs763121	0.853	rs3788544	ENSG00000230912.1	RP3-508I15.10	-5.61	3.6e-07	0.00139	-0.49	-0.55	Menopause (age at onset);	chr22:38668961	chr22:38666508~38668750:-
LAML	cis	rs4273100	0.688	rs1533034	ENSG00000262319.1	CTC-457L16.2	-5.61	3.6e-07	0.0014	-0.86	-0.55	Schizophrenia;	chr17:19249862	chr17:19141017~19143689:-
LAML	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-5.6	3.61e-07	0.0014	-0.58	-0.55	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
LAML	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-5.6	3.61e-07	0.0014	-0.58	-0.55	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.554	rs2754603	ENSG00000241549.7	GUSBP2	-5.6	3.61e-07	0.0014	-0.58	-0.55	Autism spectrum disorder or schizophrenia;	chr6:26997360	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.761	rs9357028	ENSG00000241549.7	GUSBP2	-5.6	3.61e-07	0.0014	-0.58	-0.55	Autism spectrum disorder or schizophrenia;	chr6:26999445	chr6:26871484~26956554:-
LAML	cis	rs12200782	0.932	rs12202419	ENSG00000275846.1	RP11-457M11.7	5.6	3.64e-07	0.00141	1.19	0.55	Small cell lung carcinoma;	chr6:26465156	chr6:26602733~26606661:+
LAML	cis	rs12200782	1	rs3927423	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26393259	chr6:26602733~26606661:+
LAML	cis	rs12200782	1	rs12201802	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26398436	chr6:26602733~26606661:+
LAML	cis	rs12200782	1	rs12200782	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26402808	chr6:26602733~26606661:+
LAML	cis	rs12200782	1	rs12207181	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26431057	chr6:26602733~26606661:+
LAML	cis	rs12200782	1	rs12199239	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26432342	chr6:26602733~26606661:+
LAML	cis	rs12200782	1	rs10456330	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26436464	chr6:26602733~26606661:+
LAML	cis	rs12200782	1	rs12208390	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26436878	chr6:26602733~26606661:+
LAML	cis	rs12200782	0.929	rs72843734	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26448116	chr6:26602733~26606661:+
LAML	cis	rs12200782	1	rs12213722	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26472855	chr6:26602733~26606661:+
LAML	cis	rs12200782	1	rs72843802	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26517287	chr6:26602733~26606661:+
LAML	cis	rs12200782	0.674	rs12207224	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26519052	chr6:26602733~26606661:+
LAML	cis	rs12200782	0.932	rs12189841	ENSG00000275846.1	RP11-457M11.7	-5.6	3.64e-07	0.00141	-1.19	-0.55	Small cell lung carcinoma;	chr6:26544570	chr6:26602733~26606661:+
LAML	cis	rs3136516	0.805	rs3136512	ENSG00000271350.1	CTD-2384B9.1	-5.6	3.68e-07	0.00142	-0.54	-0.55	Venous thromboembolism;	chr11:46738570	chr11:47041027~47041945:-
LAML	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-5.6	3.69e-07	0.00142	-0.66	-0.55	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-5.6	3.69e-07	0.00142	-0.66	-0.55	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
LAML	cis	rs12468226	0.808	rs73992849	ENSG00000272966.1	RP11-686O6.1	5.6	3.69e-07	0.00142	0.9	0.55	Urate levels;	chr2:202152444	chr2:202336739~202337200:+
LAML	cis	rs7746199	0.736	rs13195636	ENSG00000220721.1	OR1F12	5.6	3.69e-07	0.00142	0.94	0.55	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28073316~28074233:+
LAML	cis	rs2015599	0.549	rs7311081	ENSG00000275476.1	RP11-996F15.4	5.6	3.7e-07	0.00143	0.61	0.55	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.517	rs7295212	ENSG00000275476.1	RP11-996F15.4	5.6	3.7e-07	0.00143	0.61	0.55	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29277397~29277882:-
LAML	cis	rs5769707	0.632	rs6009782	ENSG00000280224.1	CTA-722E9.1	-5.6	3.7e-07	0.00143	-0.8	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.592	rs6009783	ENSG00000280224.1	CTA-722E9.1	-5.6	3.7e-07	0.00143	-0.8	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.656	rs135875	ENSG00000280224.1	CTA-722E9.1	-5.6	3.7e-07	0.00143	-0.8	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49500568~49501585:+
LAML	cis	rs9326248	0.53	rs9919599	ENSG00000254851.1	RP11-109L13.1	-5.6	3.73e-07	0.00144	-0.99	-0.55	Blood protein levels;	chr11:116874768	chr11:117135528~117138582:+
LAML	cis	rs904251	0.6	rs12211110	ENSG00000227920.2	RP1-153P14.5	-5.6	3.73e-07	0.00144	-0.6	-0.55	Cognitive performance;	chr6:37498456	chr6:37545145~37550860:+
LAML	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-5.59	3.76e-07	0.00145	-0.61	-0.55	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.514	rs2976929	ENSG00000253893.2	FAM85B	-5.59	3.76e-07	0.00145	-0.61	-0.55	Mood instability;	chr8:8401202	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.514	rs2920991	ENSG00000253893.2	FAM85B	-5.59	3.76e-07	0.00145	-0.61	-0.55	Mood instability;	chr8:8401607	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.514	rs2976926	ENSG00000253893.2	FAM85B	-5.59	3.76e-07	0.00145	-0.61	-0.55	Mood instability;	chr8:8404114	chr8:8167819~8226614:-
LAML	cis	rs7587476	0.954	rs3768708	ENSG00000227769.6	AC072062.3	5.59	3.76e-07	0.00145	0.61	0.55	Neuroblastoma;	chr2:214780322	chr2:215004782~215085488:+
LAML	cis	rs6700559	0.647	rs11801159	ENSG00000260088.1	RP11-92G12.3	5.59	3.79e-07	0.00146	0.68	0.55	Coronary artery disease;	chr1:200623974	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.605	rs11802836	ENSG00000260088.1	RP11-92G12.3	5.59	3.79e-07	0.00146	0.68	0.55	Coronary artery disease;	chr1:200624027	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.692	rs12744809	ENSG00000260088.1	RP11-92G12.3	5.59	3.79e-07	0.00146	0.68	0.55	Coronary artery disease;	chr1:200624197	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.692	rs4915447	ENSG00000260088.1	RP11-92G12.3	5.59	3.79e-07	0.00146	0.68	0.55	Coronary artery disease;	chr1:200624340	chr1:200669507~200694250:+
LAML	cis	rs62070183	0.882	rs17183295	ENSG00000280245.1	RP11-466A19.4	5.59	3.79e-07	0.00146	0.81	0.55	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32751254	chr17:32504567~32505644:-
LAML	cis	rs1075265	0.749	rs805375	ENSG00000235937.1	AC008280.1	5.59	3.8e-07	0.00146	0.43	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53863268	chr2:54029552~54030682:-
LAML	cis	rs9506514	0.509	rs9506515	ENSG00000222726.1	RNU2-7P	-5.59	3.81e-07	0.00146	-0.69	-0.55	Coronary artery calcification;	chr13:20557870	chr13:20612161~20612338:+
LAML	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-5.59	3.81e-07	0.00146	-0.56	-0.55	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
LAML	cis	rs1075265	0.756	rs698854	ENSG00000235937.1	AC008280.1	5.59	3.83e-07	0.00147	0.45	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54029552~54030682:-
LAML	cis	rs4713118	0.869	rs4713121	ENSG00000182477.5	OR2B8P	5.59	3.84e-07	0.00147	0.74	0.55	Parkinson's disease;	chr6:27754285	chr6:28053228~28054165:-
LAML	cis	rs965604	1	rs1062980	ENSG00000259474.1	RP11-650L12.1	5.59	3.85e-07	0.00148	0.53	0.55	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78500185	chr15:78480057~78481820:-
LAML	cis	rs2945232	1	rs2945232	ENSG00000253893.2	FAM85B	-5.59	3.88e-07	0.00149	-0.69	-0.55	Schizophrenia;	chr8:8240516	chr8:8167819~8226614:-
LAML	cis	rs2704588	0.505	rs28718401	ENSG00000270720.1	RP11-84C13.2	-5.59	3.89e-07	0.00149	-0.95	-0.55	Longevity;	chr4:89051438	chr4:89119284~89119871:+
LAML	cis	rs7829975	0.514	rs2979139	ENSG00000268955.2	RP11-556O5.6	-5.59	3.9e-07	0.00149	-0.61	-0.55	Mood instability;	chr8:8410803	chr8:8188535~8189195:-
LAML	cis	rs12468226	0.938	rs12463937	ENSG00000272966.1	RP11-686O6.1	5.58	3.91e-07	0.00149	0.89	0.55	Urate levels;	chr2:202246543	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs3731700	ENSG00000272966.1	RP11-686O6.1	5.58	3.91e-07	0.00149	0.89	0.55	Urate levels;	chr2:202291213	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs12464254	ENSG00000272966.1	RP11-686O6.1	5.58	3.91e-07	0.00149	0.89	0.55	Urate levels;	chr2:202301641	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs12471060	ENSG00000272966.1	RP11-686O6.1	5.58	3.91e-07	0.00149	0.89	0.55	Urate levels;	chr2:202309597	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.938	rs80315897	ENSG00000272966.1	RP11-686O6.1	5.58	3.91e-07	0.00149	0.89	0.55	Urate levels;	chr2:202318044	chr2:202336739~202337200:+
LAML	cis	rs561341	0.739	rs6505267	ENSG00000266379.5	RP11-640N20.8	5.58	3.93e-07	0.0015	0.8	0.55	Hip circumference adjusted for BMI;	chr17:31898931	chr17:32088160~32094933:-
LAML	cis	rs12468226	1	rs16824599	ENSG00000272966.1	RP11-686O6.1	5.58	3.93e-07	0.0015	0.96	0.55	Urate levels;	chr2:202358243	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs11899836	ENSG00000272966.1	RP11-686O6.1	5.58	3.93e-07	0.0015	0.96	0.55	Urate levels;	chr2:202371316	chr2:202336739~202337200:+
LAML	cis	rs1577917	0.958	rs7739241	ENSG00000203875.9	SNHG5	-5.58	3.97e-07	0.00152	-0.72	-0.55	Response to antipsychotic treatment;	chr6:85866078	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-5.58	3.97e-07	0.00152	-0.72	-0.55	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12202712	ENSG00000203875.9	SNHG5	-5.58	3.97e-07	0.00152	-0.72	-0.55	Response to antipsychotic treatment;	chr6:85868823	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs4707236	ENSG00000203875.9	SNHG5	-5.58	3.97e-07	0.00152	-0.72	-0.55	Response to antipsychotic treatment;	chr6:85874249	chr6:85660950~85678736:-
LAML	cis	rs763121	0.853	rs35565791	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38667006	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs35522482	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38667010	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2072795	ENSG00000230912.1	RP3-508I15.10	5.58	4e-07	0.00152	0.48	0.55	Menopause (age at onset);	chr22:38668204	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2072796	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38668225	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2281019	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38668373	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2281020	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38668401	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2281021	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38668662	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5995610	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38668676	chr22:38666508~38668750:-
LAML	cis	rs763121	0.813	rs4821807	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38669577	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs4821808	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38669734	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs4821809	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38669738	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs3761454	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38670815	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs3747170	ENSG00000230912.1	RP3-508I15.10	-5.58	4e-07	0.00152	-0.48	-0.55	Menopause (age at onset);	chr22:38671326	chr22:38666508~38668750:-
LAML	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-5.58	4.02e-07	0.00153	-0.68	-0.55	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.857	rs17015199	ENSG00000236682.1	AC068282.3	-5.58	4.02e-07	0.00153	-0.68	-0.55	Protein C levels;	chr2:127336477	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-5.58	4.02e-07	0.00153	-0.68	-0.55	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-5.58	4.02e-07	0.00153	-0.68	-0.55	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-5.58	4.02e-07	0.00153	-0.68	-0.55	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.895	rs7589451	ENSG00000236682.1	AC068282.3	-5.58	4.02e-07	0.00153	-0.68	-0.55	Protein C levels;	chr2:127371199	chr2:127389130~127400580:+
LAML	cis	rs2980439	0.807	rs2980438	ENSG00000268955.2	RP11-556O5.6	-5.58	4.05e-07	0.00154	-0.66	-0.55	Neuroticism;	chr8:8237303	chr8:8188535~8189195:-
LAML	cis	rs9368481	0.761	rs4358615	ENSG00000243307.2	POM121L6P	5.57	4.09e-07	0.00155	0.67	0.55	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26896952~26898777:+
LAML	cis	rs2581828	0.632	rs73088322	ENSG00000280417.1	RP11-5O17.1	-5.57	4.09e-07	0.00155	-0.75	-0.55	Crohn's disease;	chr3:53107500	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.659	rs73088327	ENSG00000280417.1	RP11-5O17.1	-5.57	4.09e-07	0.00155	-0.75	-0.55	Crohn's disease;	chr3:53107533	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.659	rs4282053	ENSG00000280417.1	RP11-5O17.1	-5.57	4.09e-07	0.00155	-0.75	-0.55	Crohn's disease;	chr3:53107949	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.659	rs9845352	ENSG00000280417.1	RP11-5O17.1	-5.57	4.09e-07	0.00155	-0.75	-0.55	Crohn's disease;	chr3:53108205	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.659	rs9845484	ENSG00000280417.1	RP11-5O17.1	-5.57	4.09e-07	0.00155	-0.75	-0.55	Crohn's disease;	chr3:53108240	chr3:53046166~53048122:+
LAML	cis	rs7131987	0.585	rs6487795	ENSG00000275476.1	RP11-996F15.4	5.57	4.11e-07	0.00156	0.62	0.55	QT interval;	chr12:29266228	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs6487797	ENSG00000275476.1	RP11-996F15.4	5.57	4.11e-07	0.00156	0.62	0.55	QT interval;	chr12:29270063	chr12:29277397~29277882:-
LAML	cis	rs6456156	0.524	rs4710185	ENSG00000265828.1	MIR3939	-5.57	4.12e-07	0.00156	-0.83	-0.55	Primary biliary cholangitis;	chr6:167108898	chr6:166997807~166997912:-
LAML	cis	rs12200782	1	rs12195971	ENSG00000275846.1	RP11-457M11.7	-5.57	4.13e-07	0.00157	-1.18	-0.55	Small cell lung carcinoma;	chr6:26460196	chr6:26602733~26606661:+
LAML	cis	rs12200782	1	rs12211201	ENSG00000275846.1	RP11-457M11.7	-5.57	4.13e-07	0.00157	-1.18	-0.55	Small cell lung carcinoma;	chr6:26461233	chr6:26602733~26606661:+
LAML	cis	rs2980439	0.607	rs2980419	ENSG00000253893.2	FAM85B	-5.57	4.17e-07	0.00158	-0.66	-0.55	Neuroticism;	chr8:8256619	chr8:8167819~8226614:-
LAML	cis	rs2564921	0.73	rs56026870	ENSG00000280417.1	RP11-5O17.1	-5.57	4.17e-07	0.00158	-0.7	-0.55	Height;	chr3:52998472	chr3:53046166~53048122:+
LAML	cis	rs7829975	0.514	rs2979151	ENSG00000268955.2	RP11-556O5.6	5.57	4.18e-07	0.00158	0.61	0.55	Mood instability;	chr8:8400509	chr8:8188535~8189195:-
LAML	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	5.57	4.19e-07	0.00159	0.77	0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
LAML	cis	rs2581828	0.646	rs13433700	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53113870	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.609	rs73088342	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53117648	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs6783748	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53119415	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs9757079	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53121142	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs3796351	ENSG00000280417.1	RP11-5O17.1	5.57	4.19e-07	0.00159	0.75	0.55	Crohn's disease;	chr3:53122049	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs9878875	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53122851	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs12630819	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53123286	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs12638996	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53123530	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs9867023	ENSG00000280417.1	RP11-5O17.1	5.57	4.19e-07	0.00159	0.75	0.55	Crohn's disease;	chr3:53126116	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs6769931	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53126177	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs6809973	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53126200	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.608	rs6769944	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53126227	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs9858469	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53128390	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.646	rs9820324	ENSG00000280417.1	RP11-5O17.1	-5.57	4.19e-07	0.00159	-0.75	-0.55	Crohn's disease;	chr3:53128429	chr3:53046166~53048122:+
LAML	cis	rs1075265	0.704	rs13417926	ENSG00000235937.1	AC008280.1	5.57	4.21e-07	0.00159	0.43	0.55	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54029552~54030682:-
LAML	cis	rs904251	0.523	rs1776454	ENSG00000279942.1	RP1-153P14.7	-5.56	4.25e-07	0.0016	-0.62	-0.55	Cognitive performance;	chr6:37514323	chr6:37567716~37571460:+
LAML	cis	rs1577917	0.874	rs1838954	ENSG00000203875.9	SNHG5	-5.56	4.26e-07	0.00161	-0.72	-0.55	Response to antipsychotic treatment;	chr6:85855760	chr6:85660950~85678736:-
LAML	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	5.56	4.28e-07	0.00161	0.73	0.55	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
LAML	cis	rs1150668	0.965	rs1654774	ENSG00000216901.1	AL022393.7	5.56	4.29e-07	0.00161	0.66	0.55	Pubertal anthropometrics;	chr6:28128502	chr6:28176188~28176674:+
LAML	cis	rs1150668	1	rs1150668	ENSG00000216901.1	AL022393.7	5.56	4.29e-07	0.00161	0.66	0.55	Pubertal anthropometrics;	chr6:28162011	chr6:28176188~28176674:+
LAML	cis	rs6456156	0.586	rs4710176	ENSG00000265828.1	MIR3939	-5.56	4.3e-07	0.00161	-0.84	-0.55	Primary biliary cholangitis;	chr6:167078151	chr6:166997807~166997912:-
LAML	cis	rs10829156	0.699	rs4747353	ENSG00000240291.1	RP11-499P20.2	5.56	4.32e-07	0.00162	0.69	0.55	Sudden cardiac arrest;	chr10:18548028	chr10:18513115~18545651:-
LAML	cis	rs10829156	0.625	rs10828906	ENSG00000240291.1	RP11-499P20.2	5.56	4.32e-07	0.00162	0.69	0.55	Sudden cardiac arrest;	chr10:18552866	chr10:18513115~18545651:-
LAML	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	5.56	4.34e-07	0.00163	0.68	0.55	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
LAML	cis	rs4713118	0.662	rs9393881	ENSG00000182477.5	OR2B8P	5.56	4.37e-07	0.00164	0.8	0.55	Parkinson's disease;	chr6:28055973	chr6:28053228~28054165:-
LAML	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	5.56	4.38e-07	0.00164	0.68	0.55	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
LAML	cis	rs7829975	0.509	rs2945269	ENSG00000253893.2	FAM85B	-5.56	4.38e-07	0.00164	-0.67	-0.55	Mood instability;	chr8:8258056	chr8:8167819~8226614:-
LAML	cis	rs904251	0.6	rs9380673	ENSG00000227920.2	RP1-153P14.5	-5.56	4.39e-07	0.00164	-0.57	-0.55	Cognitive performance;	chr6:37447349	chr6:37545145~37550860:+
LAML	cis	rs904251	0.6	rs2270687	ENSG00000227920.2	RP1-153P14.5	-5.56	4.39e-07	0.00164	-0.57	-0.55	Cognitive performance;	chr6:37450487	chr6:37545145~37550860:+
LAML	cis	rs904251	0.525	rs12200378	ENSG00000227920.2	RP1-153P14.5	-5.56	4.39e-07	0.00164	-0.57	-0.55	Cognitive performance;	chr6:37457528	chr6:37545145~37550860:+
LAML	cis	rs904251	0.6	rs11756241	ENSG00000227920.2	RP1-153P14.5	-5.56	4.39e-07	0.00164	-0.57	-0.55	Cognitive performance;	chr6:37477325	chr6:37545145~37550860:+
LAML	cis	rs904251	0.6	rs1874736	ENSG00000227920.2	RP1-153P14.5	-5.56	4.39e-07	0.00164	-0.57	-0.55	Cognitive performance;	chr6:37480218	chr6:37545145~37550860:+
LAML	cis	rs561341	0.769	rs7217004	ENSG00000266379.5	RP11-640N20.8	-5.56	4.4e-07	0.00165	-1.1	-0.55	Hip circumference adjusted for BMI;	chr17:31851073	chr17:32088160~32094933:-
LAML	cis	rs561341	0.769	rs8074383	ENSG00000266379.5	RP11-640N20.8	-5.56	4.4e-07	0.00165	-1.1	-0.55	Hip circumference adjusted for BMI;	chr17:31851774	chr17:32088160~32094933:-
LAML	cis	rs6597981	0.604	rs7945912	ENSG00000279672.1	CMB9-55F22.1	5.55	4.42e-07	0.00166	0.51	0.55	Breast cancer;	chr11:750849	chr11:779617~780755:+
LAML	cis	rs853679	0.766	rs9368561	ENSG00000187763.3	OR2B7P	5.55	4.45e-07	0.00167	0.97	0.55	Depression;	chr6:28200565	chr6:28046434~28047367:+
LAML	cis	rs853679	0.769	rs17720293	ENSG00000187763.3	OR2B7P	5.55	4.49e-07	0.00168	0.97	0.55	Depression;	chr6:28246920	chr6:28046434~28047367:+
LAML	cis	rs3758911	0.796	rs11212206	ENSG00000261098.1	RP11-819C21.1	-5.55	4.5e-07	0.00168	-0.52	-0.55	Coronary artery disease;	chr11:107404525	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.828	rs17106875	ENSG00000261098.1	RP11-819C21.1	-5.55	4.5e-07	0.00168	-0.52	-0.55	Coronary artery disease;	chr11:107407957	chr11:107312132~107316271:-
LAML	cis	rs4803480	1	rs7255679	ENSG00000239736.2	CEACAMP3	-5.55	4.5e-07	0.00168	-0.83	-0.55	Schizophrenia;	chr19:41557611	chr19:41599735~41605984:+
LAML	cis	rs4803480	1	rs4803480	ENSG00000239736.2	CEACAMP3	-5.55	4.5e-07	0.00168	-0.83	-0.55	Schizophrenia;	chr19:41559909	chr19:41599735~41605984:+
LAML	cis	rs4803480	1	rs3745937	ENSG00000239736.2	CEACAMP3	-5.55	4.5e-07	0.00168	-0.83	-0.55	Schizophrenia;	chr19:41564935	chr19:41599735~41605984:+
LAML	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-5.55	4.52e-07	0.00169	-0.59	-0.55	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-5.55	4.52e-07	0.00169	-0.59	-0.55	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
LAML	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	5.55	4.52e-07	0.00169	0.56	0.55	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
LAML	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-5.55	4.52e-07	0.00169	-0.56	-0.55	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
LAML	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-5.55	4.52e-07	0.00169	-0.56	-0.55	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
LAML	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-5.55	4.52e-07	0.00169	-0.56	-0.55	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
LAML	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-5.55	4.52e-07	0.00169	-0.56	-0.55	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
LAML	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-5.55	4.52e-07	0.00169	-0.56	-0.55	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
LAML	cis	rs4803480	0.935	rs1476769	ENSG00000239736.2	CEACAMP3	-5.55	4.56e-07	0.0017	-0.79	-0.55	Schizophrenia;	chr19:41577925	chr19:41599735~41605984:+
LAML	cis	rs4803480	0.873	rs1476770	ENSG00000239736.2	CEACAMP3	-5.55	4.56e-07	0.0017	-0.79	-0.55	Schizophrenia;	chr19:41578033	chr19:41599735~41605984:+
LAML	cis	rs4803480	0.935	rs758349	ENSG00000239736.2	CEACAMP3	-5.55	4.56e-07	0.0017	-0.79	-0.55	Schizophrenia;	chr19:41578753	chr19:41599735~41605984:+
LAML	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-5.55	4.57e-07	0.0017	-0.84	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
LAML	cis	rs7829975	0.536	rs2980439	ENSG00000253893.2	FAM85B	-5.54	4.62e-07	0.00172	-0.68	-0.55	Mood instability;	chr8:8237348	chr8:8167819~8226614:-
LAML	cis	rs853679	0.607	rs13199649	ENSG00000187763.3	OR2B7P	5.54	4.62e-07	0.00172	0.99	0.55	Depression;	chr6:27901014	chr6:28046434~28047367:+
LAML	cis	rs67340775	0.834	rs13218875	ENSG00000187763.3	OR2B7P	5.54	4.62e-07	0.00172	0.99	0.55	Lung cancer in ever smokers;	chr6:27916234	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs67040724	ENSG00000187763.3	OR2B7P	5.54	4.62e-07	0.00172	0.99	0.55	Depression;	chr6:27937731	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs67662114	ENSG00000187763.3	OR2B7P	5.54	4.62e-07	0.00172	0.99	0.55	Depression;	chr6:27964523	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13216117	ENSG00000187763.3	OR2B7P	5.54	4.62e-07	0.00172	0.99	0.55	Depression;	chr6:27970706	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs36101351	ENSG00000187763.3	OR2B7P	5.54	4.62e-07	0.00172	0.99	0.55	Depression;	chr6:27975591	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs28360499	ENSG00000187763.3	OR2B7P	5.54	4.62e-07	0.00172	0.99	0.55	Depression;	chr6:27977618	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs71537572	ENSG00000187763.3	OR2B7P	5.54	4.62e-07	0.00172	0.99	0.55	Depression;	chr6:28002937	chr6:28046434~28047367:+
LAML	cis	rs853679	0.599	rs13193295	ENSG00000187763.3	OR2B7P	5.54	4.62e-07	0.00172	0.99	0.55	Depression;	chr6:28035450	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs66886492	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28121953	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs35345226	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28123802	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs35749575	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28147040	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs72846780	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28151277	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13205911	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28156336	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13197176	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28161454	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13201308	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28162311	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34765154	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28162672	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34505829	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28165461	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs35098436	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28166443	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs72846794	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28169721	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13217984	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28171932	chr6:28073316~28074233:+
LAML	cis	rs853679	0.556	rs67297533	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28173475	chr6:28073316~28074233:+
LAML	cis	rs853679	0.505	rs35781323	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28177054	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs13195291	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28201463	chr6:28073316~28074233:+
LAML	cis	rs853679	0.556	rs13197633	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28206979	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs35001169	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28219854	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs35656932	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28223510	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13204012	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28233753	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13205211	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28235278	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13208096	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28257533	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13207345	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28297795	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs72854513	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28298177	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs33932084	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28301047	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs56189111	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28304196	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs35072899	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28313764	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs56075693	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28322551	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34218844	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28322870	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs35030260	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28337731	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13217619	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28338894	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs35016036	ENSG00000220721.1	OR1F12	5.54	4.63e-07	0.00172	0.89	0.55	Depression;	chr6:28347103	chr6:28073316~28074233:+
LAML	cis	rs763121	0.719	rs9610995	ENSG00000230912.1	RP3-508I15.10	-5.54	4.64e-07	0.00172	-0.48	-0.55	Menopause (age at onset);	chr22:38661758	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs8142098	ENSG00000230912.1	RP3-508I15.10	-5.54	4.64e-07	0.00172	-0.48	-0.55	Menopause (age at onset);	chr22:38662752	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2413544	ENSG00000230912.1	RP3-508I15.10	-5.54	4.64e-07	0.00172	-0.48	-0.55	Menopause (age at onset);	chr22:38663399	chr22:38666508~38668750:-
LAML	cis	rs763121	0.752	rs5757222	ENSG00000230912.1	RP3-508I15.10	-5.54	4.64e-07	0.00172	-0.48	-0.55	Menopause (age at onset);	chr22:38664468	chr22:38666508~38668750:-
LAML	cis	rs763121	0.819	rs5750658	ENSG00000230912.1	RP3-508I15.10	-5.54	4.64e-07	0.00172	-0.48	-0.55	Menopause (age at onset);	chr22:38664912	chr22:38666508~38668750:-
LAML	cis	rs763121	0.819	rs8137829	ENSG00000230912.1	RP3-508I15.10	-5.54	4.64e-07	0.00172	-0.48	-0.55	Menopause (age at onset);	chr22:38665025	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs6001188	ENSG00000230912.1	RP3-508I15.10	-5.54	4.64e-07	0.00172	-0.48	-0.55	Menopause (age at onset);	chr22:38666189	chr22:38666508~38668750:-
LAML	cis	rs11039798	1	rs7942284	ENSG00000263693.1	MIR3161	-5.54	4.64e-07	0.00172	-0.57	-0.55	Axial length;	chr11:48498872	chr11:48096782~48096858:+
LAML	cis	rs9368481	0.743	rs9368480	ENSG00000241549.7	GUSBP2	5.54	4.65e-07	0.00172	0.58	0.55	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26871484~26956554:-
LAML	cis	rs67311347	0.91	rs13089215	ENSG00000223797.4	ENTPD3-AS1	-5.54	4.65e-07	0.00172	-0.72	-0.55	Renal cell carcinoma;	chr3:40454403	chr3:40313802~40453329:-
LAML	cis	rs6782228	1	rs6782228	ENSG00000277250.1	Metazoa_SRP	5.54	4.67e-07	0.00173	0.83	0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128604581	chr3:128673681~128674021:-
LAML	cis	rs2564921	0.704	rs2336720	ENSG00000280417.1	RP11-5O17.1	-5.53	4.77e-07	0.00176	-0.69	-0.55	Height;	chr3:52994045	chr3:53046166~53048122:+
LAML	cis	rs2564921	0.73	rs56384586	ENSG00000280417.1	RP11-5O17.1	-5.53	4.77e-07	0.00176	-0.69	-0.55	Height;	chr3:52994990	chr3:53046166~53048122:+
LAML	cis	rs5769707	0.521	rs6009810	ENSG00000212939.2	RP1-29C18.10	-5.53	4.79e-07	0.00177	-0.7	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49548681~49556473:+
LAML	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-5.53	4.8e-07	0.00177	-0.99	-0.55	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
LAML	cis	rs3758911	0.828	rs10789605	ENSG00000261098.1	RP11-819C21.1	-5.53	4.82e-07	0.00178	-0.51	-0.55	Coronary artery disease;	chr11:107313859	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.828	rs10789606	ENSG00000261098.1	RP11-819C21.1	-5.53	4.82e-07	0.00178	-0.51	-0.55	Coronary artery disease;	chr11:107313862	chr11:107312132~107316271:-
LAML	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-5.53	4.83e-07	0.00178	-0.64	-0.55	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-5.53	4.83e-07	0.00178	-0.64	-0.55	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
LAML	cis	rs12220777	1	rs74372131	ENSG00000230091.5	TMEM254-AS1	5.53	4.83e-07	0.00178	1.23	0.55	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80027458	chr10:80046860~80078912:-
LAML	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	5.53	4.85e-07	0.00179	0.67	0.55	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
LAML	cis	rs11155671	0.53	rs9371504	ENSG00000216906.2	RP11-350J20.9	5.53	4.86e-07	0.00179	0.8	0.55	Testicular germ cell tumor;	chr6:149862944	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs9371505	ENSG00000216906.2	RP11-350J20.9	5.53	4.86e-07	0.00179	0.8	0.55	Testicular germ cell tumor;	chr6:149863012	chr6:149904243~149906418:+
LAML	cis	rs3136516	0.772	rs7947747	ENSG00000271350.1	CTD-2384B9.1	-5.53	4.86e-07	0.00179	-0.53	-0.55	Venous thromboembolism;	chr11:46831288	chr11:47041027~47041945:-
LAML	cis	rs5769707	0.609	rs2071890	ENSG00000280224.1	CTA-722E9.1	-5.53	4.86e-07	0.00179	-0.76	-0.55	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49500568~49501585:+
LAML	cis	rs7587476	0.861	rs3768716	ENSG00000229267.2	AC072062.1	-5.53	4.89e-07	0.0018	-0.69	-0.55	Neuroblastoma;	chr2:214771070	chr2:214810229~214963274:+
LAML	cis	rs4713118	0.911	rs9461406	ENSG00000182477.5	OR2B8P	-5.53	4.91e-07	0.00181	-0.74	-0.55	Parkinson's disease;	chr6:27751985	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.866	rs9468217	ENSG00000182477.5	OR2B8P	5.53	4.91e-07	0.00181	0.74	0.55	Parkinson's disease;	chr6:27758688	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.911	rs9295746	ENSG00000182477.5	OR2B8P	5.53	4.91e-07	0.00181	0.74	0.55	Parkinson's disease;	chr6:27762285	chr6:28053228~28054165:-
LAML	cis	rs6772840	1	rs6772840	ENSG00000272077.1	RP11-348P10.2	-5.53	4.91e-07	0.00181	-0.92	-0.55	Subjective well-being;	chr3:43812828	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs73074608	ENSG00000272077.1	RP11-348P10.2	-5.53	4.91e-07	0.00181	-0.92	-0.55	Subjective well-being;	chr3:43813500	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs6786149	ENSG00000272077.1	RP11-348P10.2	-5.53	4.91e-07	0.00181	-0.92	-0.55	Subjective well-being;	chr3:43816311	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs4575872	ENSG00000272077.1	RP11-348P10.2	-5.53	4.91e-07	0.00181	-0.92	-0.55	Subjective well-being;	chr3:43817737	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs6778205	ENSG00000272077.1	RP11-348P10.2	-5.53	4.91e-07	0.00181	-0.92	-0.55	Subjective well-being;	chr3:43819370	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs4383486	ENSG00000272077.1	RP11-348P10.2	-5.53	4.91e-07	0.00181	-0.92	-0.55	Subjective well-being;	chr3:43822659	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs11708881	ENSG00000272077.1	RP11-348P10.2	-5.53	4.91e-07	0.00181	-0.92	-0.55	Subjective well-being;	chr3:43825535	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs4075820	ENSG00000272077.1	RP11-348P10.2	-5.53	4.91e-07	0.00181	-0.92	-0.55	Subjective well-being;	chr3:43825951	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs7631350	ENSG00000272077.1	RP11-348P10.2	-5.53	4.91e-07	0.00181	-0.92	-0.55	Subjective well-being;	chr3:43831203	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs4547675	ENSG00000272077.1	RP11-348P10.2	-5.53	4.91e-07	0.00181	-0.92	-0.55	Subjective well-being;	chr3:43832971	chr3:44667412~44669364:+
LAML	cis	rs2564921	0.73	rs73082047	ENSG00000280417.1	RP11-5O17.1	-5.53	4.92e-07	0.00181	-0.8	-0.55	Height;	chr3:53070344	chr3:53046166~53048122:+
LAML	cis	rs67340775	0.541	rs200979	ENSG00000220721.1	OR1F12	5.53	4.94e-07	0.00181	0.65	0.55	Lung cancer in ever smokers;	chr6:27884579	chr6:28073316~28074233:+
LAML	cis	rs67340775	0.541	rs169287	ENSG00000220721.1	OR1F12	5.53	4.94e-07	0.00181	0.65	0.55	Lung cancer in ever smokers;	chr6:27886982	chr6:28073316~28074233:+
LAML	cis	rs67340775	0.541	rs200975	ENSG00000220721.1	OR1F12	5.53	4.94e-07	0.00181	0.65	0.55	Lung cancer in ever smokers;	chr6:27887847	chr6:28073316~28074233:+
LAML	cis	rs67340775	0.541	rs200974	ENSG00000220721.1	OR1F12	5.53	4.94e-07	0.00181	0.65	0.55	Lung cancer in ever smokers;	chr6:27888067	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34788973	ENSG00000182477.5	OR2B8P	5.53	4.95e-07	0.00182	0.99	0.55	Depression;	chr6:27911422	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs61742093	ENSG00000182477.5	OR2B8P	5.53	4.95e-07	0.00182	0.99	0.55	Depression;	chr6:27912204	chr6:28053228~28054165:-
LAML	cis	rs8037137	0.731	rs113343095	ENSG00000258725.1	PRC1-AS1	-5.53	4.95e-07	0.00182	-1.06	-0.55	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90978862	chr15:90966345~90988624:+
LAML	cis	rs3091242	0.836	rs34997029	ENSG00000224183.1	SDHDP6	5.52	4.97e-07	0.00182	0.65	0.55	Erythrocyte sedimentation rate;	chr1:25457332	chr1:25294164~25294643:-
LAML	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-5.52	4.99e-07	0.00183	-0.7	-0.55	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
LAML	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-5.52	4.99e-07	0.00183	-0.69	-0.55	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
LAML	cis	rs561341	0.739	rs1978116	ENSG00000266379.5	RP11-640N20.8	5.52	5.01e-07	0.00184	0.78	0.55	Hip circumference adjusted for BMI;	chr17:31893959	chr17:32088160~32094933:-
LAML	cis	rs4273100	0.573	rs4924783	ENSG00000262319.1	CTC-457L16.2	5.52	5.07e-07	0.00185	0.8	0.55	Schizophrenia;	chr17:19350668	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.564	rs10445411	ENSG00000262319.1	CTC-457L16.2	5.52	5.07e-07	0.00185	0.8	0.55	Schizophrenia;	chr17:19362484	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.512	rs2233072	ENSG00000262319.1	CTC-457L16.2	5.52	5.07e-07	0.00185	0.8	0.55	Schizophrenia;	chr17:19378515	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.512	rs973650	ENSG00000262319.1	CTC-457L16.2	5.52	5.07e-07	0.00185	0.8	0.55	Schizophrenia;	chr17:19388472	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.541	rs973649	ENSG00000262319.1	CTC-457L16.2	5.52	5.07e-07	0.00185	0.8	0.55	Schizophrenia;	chr17:19388755	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.541	rs7501702	ENSG00000262319.1	CTC-457L16.2	5.52	5.07e-07	0.00185	0.8	0.55	Schizophrenia;	chr17:19390414	chr17:19141017~19143689:-
LAML	cis	rs4273100	0.512	rs7502682	ENSG00000262319.1	CTC-457L16.2	5.52	5.07e-07	0.00185	0.8	0.55	Schizophrenia;	chr17:19392137	chr17:19141017~19143689:-
LAML	cis	rs3091242	0.933	rs1534954	ENSG00000224183.1	SDHDP6	-5.52	5.08e-07	0.00186	-0.65	-0.55	Erythrocyte sedimentation rate;	chr1:25435433	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.9	rs35345536	ENSG00000224183.1	SDHDP6	-5.52	5.08e-07	0.00186	-0.65	-0.55	Erythrocyte sedimentation rate;	chr1:25439997	chr1:25294164~25294643:-
LAML	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-5.52	5.08e-07	0.00186	-0.65	-0.55	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
LAML	cis	rs4713118	0.662	rs149900	ENSG00000182477.5	OR2B8P	5.52	5.08e-07	0.00186	0.84	0.55	Parkinson's disease;	chr6:28046819	chr6:28053228~28054165:-
LAML	cis	rs4591358	0.559	rs2133858	ENSG00000223466.1	AC064834.2	5.52	5.1e-07	0.00187	0.72	0.55	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519925	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.618	rs4850625	ENSG00000223466.1	AC064834.2	5.52	5.1e-07	0.00187	0.72	0.55	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522138	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.587	rs7604146	ENSG00000223466.1	AC064834.2	5.52	5.1e-07	0.00187	0.72	0.55	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522900	chr2:195533035~195538681:+
LAML	cis	rs2564921	0.73	rs12633064	ENSG00000280417.1	RP11-5O17.1	-5.52	5.12e-07	0.00187	-0.8	-0.55	Height;	chr3:53027361	chr3:53046166~53048122:+
LAML	cis	rs6452524	0.87	rs12152892	ENSG00000249664.1	CTD-2227C6.2	5.52	5.13e-07	0.00187	0.75	0.55	Hypertension (SNP x SNP interaction);	chr5:83125110	chr5:83012285~83013109:-
LAML	cis	rs4879656	0.966	rs7869475	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:32986250	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs10758178	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:32999421	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.897	rs1537255	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33004377	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.897	rs1537256	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33004419	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs10971309	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33009857	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.931	rs10971314	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33013945	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.931	rs3758275	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33024960	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs4879658	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33029017	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs12000958	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33031432	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs7469374	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33035116	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs4879661	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33035248	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.864	rs7861851	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33037351	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.931	rs7875733	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33037352	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs10971358	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33038051	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs7296	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33039026	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs10971361	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33042564	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs10758181	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33045163	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.897	rs1537042	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33045278	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.933	rs10813934	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33078146	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs3758274	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33078321	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.797	rs10971389	ENSG00000225693.1	LAGE3P1	-5.52	5.13e-07	0.00187	-0.62	-0.55	Menopause (age at onset);	chr9:33081125	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs3780475	ENSG00000225693.1	LAGE3P1	5.52	5.13e-07	0.00187	0.62	0.55	Menopause (age at onset);	chr9:32984393	chr9:33019682~33020165:-
LAML	cis	rs112721625	1	rs112721625	ENSG00000267302.4	RP11-178C3.2	5.52	5.14e-07	0.00187	0.71	0.55	Monocyte count;	chr17:59850066	chr17:59964832~59996972:+
LAML	cis	rs561341	0.739	rs9906455	ENSG00000266379.5	RP11-640N20.8	-5.51	5.17e-07	0.00188	-0.78	-0.54	Hip circumference adjusted for BMI;	chr17:31888650	chr17:32088160~32094933:-
LAML	cis	rs561341	0.739	rs8070554	ENSG00000266379.5	RP11-640N20.8	-5.51	5.17e-07	0.00188	-0.78	-0.54	Hip circumference adjusted for BMI;	chr17:31889849	chr17:32088160~32094933:-
LAML	cis	rs10927875	0.691	rs1048302	ENSG00000178715.8	RP11-169K16.8	5.51	5.18e-07	0.00189	0.63	0.54	Dilated cardiomyopathy;	chr1:16014384	chr1:15828232~15828669:+
LAML	cis	rs7829975	0.536	rs2980439	ENSG00000268955.2	RP11-556O5.6	-5.51	5.25e-07	0.00191	-0.67	-0.54	Mood instability;	chr8:8237348	chr8:8188535~8189195:-
LAML	cis	rs875971	1	rs2220626	ENSG00000222364.1	RNU6-96P	5.51	5.27e-07	0.00191	0.67	0.54	Aortic root size;	chr7:66081075	chr7:66395191~66395286:+
LAML	cis	rs5769707	0.967	rs5769698	ENSG00000279597.1	RP4-566L20.1	-5.51	5.28e-07	0.00192	-0.6	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49534062~49534926:+
LAML	cis	rs3758911	0.894	rs10502087	ENSG00000261098.1	RP11-819C21.1	-5.51	5.31e-07	0.00193	-0.52	-0.54	Coronary artery disease;	chr11:107381482	chr11:107312132~107316271:-
LAML	cis	rs7429990	0.932	rs936428	ENSG00000229759.1	MRPS18AP1	-5.51	5.31e-07	0.00193	-0.66	-0.54	Educational attainment (years of education);	chr3:48125791	chr3:48256350~48256938:-
LAML	cis	rs5769707	0.777	rs739243	ENSG00000213279.2	RP1-29C18.9	-5.51	5.32e-07	0.00193	-0.55	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49572264~49575426:-
LAML	cis	rs4713118	0.868	rs742047	ENSG00000182477.5	OR2B8P	5.51	5.33e-07	0.00193	0.75	0.54	Parkinson's disease;	chr6:27771601	chr6:28053228~28054165:-
LAML	cis	rs1153858	0.668	rs63603561	ENSG00000259520.4	CTD-2651B20.3	5.51	5.33e-07	0.00194	0.8	0.54	Homoarginine levels;	chr15:45301125	chr15:45251580~45279251:-
LAML	cis	rs853679	0.527	rs9461443	ENSG00000220721.1	OR1F12	5.51	5.34e-07	0.00194	0.66	0.54	Depression;	chr6:28226851	chr6:28073316~28074233:+
LAML	cis	rs853679	0.55	rs34477097	ENSG00000220721.1	OR1F12	5.51	5.34e-07	0.00194	0.66	0.54	Depression;	chr6:28229408	chr6:28073316~28074233:+
LAML	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-5.51	5.34e-07	0.00194	-0.68	-0.54	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
LAML	cis	rs12220777	1	rs12220777	ENSG00000230091.5	TMEM254-AS1	-5.51	5.35e-07	0.00194	-1.2	-0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80028348	chr10:80046860~80078912:-
LAML	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	5.51	5.37e-07	0.00195	0.67	0.54	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	5.51	5.37e-07	0.00195	0.67	0.54	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	5.51	5.37e-07	0.00195	0.67	0.54	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
LAML	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-5.51	5.38e-07	0.00195	-0.5	-0.54	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-5.5	5.39e-07	0.00195	-0.46	-0.54	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-5.5	5.39e-07	0.00195	-0.46	-0.54	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
LAML	cis	rs911555	0.504	rs4906340	ENSG00000258851.1	RP11-894P9.2	5.5	5.39e-07	0.00195	0.68	0.54	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103553421~103561877:+
LAML	cis	rs853679	0.769	rs7752608	ENSG00000187763.3	OR2B7P	5.5	5.4e-07	0.00196	0.91	0.54	Depression;	chr6:28333418	chr6:28046434~28047367:+
LAML	cis	rs5769707	0.967	rs9616327	ENSG00000279597.1	RP4-566L20.1	-5.5	5.42e-07	0.00196	-0.65	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49534062~49534926:+
LAML	cis	rs45509595	0.841	rs17751184	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Breast cancer;	chr6:27807250	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs67101035	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Depression;	chr6:27831109	chr6:28053228~28054165:-
LAML	cis	rs853679	0.556	rs34706883	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Depression;	chr6:27837477	chr6:28053228~28054165:-
LAML	cis	rs67340775	0.748	rs13212651	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Lung cancer in ever smokers;	chr6:27839207	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs35819751	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Depression;	chr6:27842791	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13194781	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Depression;	chr6:27847861	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs36116761	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Depression;	chr6:27850704	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs34194357	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Depression;	chr6:27850757	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13199772	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Depression;	chr6:27866307	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13199906	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Depression;	chr6:27866361	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs17763089	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Depression;	chr6:27867440	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs17695758	ENSG00000182477.5	OR2B8P	5.5	5.43e-07	0.00196	0.98	0.54	Depression;	chr6:27869405	chr6:28053228~28054165:-
LAML	cis	rs62070183	0.873	rs80212824	ENSG00000265222.1	RP11-466A19.8	5.5	5.53e-07	0.00199	0.9	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32703440	chr17:32509954~32523424:-
LAML	cis	rs11155671	0.53	rs9968871	ENSG00000216906.2	RP11-350J20.9	5.5	5.53e-07	0.00199	0.79	0.54	Testicular germ cell tumor;	chr6:149888060	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs9969044	ENSG00000216906.2	RP11-350J20.9	5.5	5.53e-07	0.00199	0.79	0.54	Testicular germ cell tumor;	chr6:149888068	chr6:149904243~149906418:+
LAML	cis	rs9399135	0.844	rs13209789	ENSG00000232876.1	CTA-212D2.2	-5.5	5.53e-07	0.00199	-0.68	-0.54	Red blood cell count;	chr6:135046778	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs6915770	ENSG00000232876.1	CTA-212D2.2	-5.5	5.53e-07	0.00199	-0.68	-0.54	Red blood cell count;	chr6:135048076	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.935	rs11759999	ENSG00000232876.1	CTA-212D2.2	-5.5	5.53e-07	0.00199	-0.68	-0.54	Red blood cell count;	chr6:135049357	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.935	rs11760000	ENSG00000232876.1	CTA-212D2.2	-5.5	5.53e-07	0.00199	-0.68	-0.54	Red blood cell count;	chr6:135049358	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.935	rs9376086	ENSG00000232876.1	CTA-212D2.2	-5.5	5.53e-07	0.00199	-0.68	-0.54	Red blood cell count;	chr6:135050191	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs1041480	ENSG00000232876.1	CTA-212D2.2	-5.5	5.53e-07	0.00199	-0.68	-0.54	Red blood cell count;	chr6:135051938	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs2297338	ENSG00000232876.1	CTA-212D2.2	-5.5	5.53e-07	0.00199	-0.68	-0.54	Red blood cell count;	chr6:135054624	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs2297340	ENSG00000232876.1	CTA-212D2.2	-5.5	5.53e-07	0.00199	-0.68	-0.54	Red blood cell count;	chr6:135054920	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs7741515	ENSG00000232876.1	CTA-212D2.2	5.5	5.53e-07	0.00199	0.68	0.54	Red blood cell count;	chr6:135053230	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs2183709	ENSG00000232876.1	CTA-212D2.2	-5.5	5.54e-07	0.00199	-0.68	-0.54	Red blood cell count;	chr6:135055953	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4142299	ENSG00000232876.1	CTA-212D2.2	-5.5	5.54e-07	0.00199	-0.68	-0.54	Red blood cell count;	chr6:135056048	chr6:135055033~135060550:+
LAML	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-5.5	5.55e-07	0.002	-0.58	-0.54	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
LAML	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-5.5	5.58e-07	0.00201	-0.72	-0.54	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
LAML	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-5.49	5.65e-07	0.00203	-0.69	-0.54	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
LAML	cis	rs763121	0.853	rs5750621	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38560161	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750622	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38560459	chr22:38666508~38668750:-
LAML	cis	rs763121	0.744	rs5757140	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38561008	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757141	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38561478	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750626	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38581885	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750630	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38589813	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs6519119	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38593002	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757162	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38597365	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs9622833	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38604392	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757181	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38617517	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs4820345	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38695146	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2413545	ENSG00000230912.1	RP3-508I15.10	-5.49	5.66e-07	0.00203	-0.47	-0.54	Menopause (age at onset);	chr22:38696519	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757193	ENSG00000230912.1	RP3-508I15.10	5.49	5.66e-07	0.00203	0.47	0.54	Menopause (age at onset);	chr22:38638862	chr22:38666508~38668750:-
LAML	cis	rs561341	0.74	rs11080174	ENSG00000266379.5	RP11-640N20.8	-5.49	5.71e-07	0.00205	-0.8	-0.54	Hip circumference adjusted for BMI;	chr17:31881502	chr17:32088160~32094933:-
LAML	cis	rs1577917	0.958	rs2100109	ENSG00000203875.9	SNHG5	-5.49	5.72e-07	0.00205	-0.72	-0.54	Response to antipsychotic treatment;	chr6:85835208	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs1447160	ENSG00000203875.9	SNHG5	-5.49	5.72e-07	0.00205	-0.72	-0.54	Response to antipsychotic treatment;	chr6:85836405	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs4707229	ENSG00000203875.9	SNHG5	-5.49	5.72e-07	0.00205	-0.72	-0.54	Response to antipsychotic treatment;	chr6:85836519	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12198061	ENSG00000203875.9	SNHG5	-5.49	5.72e-07	0.00205	-0.72	-0.54	Response to antipsychotic treatment;	chr6:85841267	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs1838955	ENSG00000203875.9	SNHG5	-5.49	5.72e-07	0.00205	-0.72	-0.54	Response to antipsychotic treatment;	chr6:85855731	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs2084294	ENSG00000203875.9	SNHG5	-5.49	5.72e-07	0.00205	-0.72	-0.54	Response to antipsychotic treatment;	chr6:85856225	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-5.49	5.74e-07	0.00205	-0.71	-0.54	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-5.49	5.74e-07	0.00205	-0.71	-0.54	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-5.49	5.74e-07	0.00205	-0.71	-0.54	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-5.49	5.74e-07	0.00205	-0.71	-0.54	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
LAML	cis	rs709400	0.965	rs861534	ENSG00000258851.1	RP11-894P9.2	-5.49	5.76e-07	0.00206	-0.7	-0.54	Body mass index;	chr14:103702364	chr14:103553421~103561877:+
LAML	cis	rs2704588	0.542	rs11734924	ENSG00000270720.1	RP11-84C13.2	5.49	5.76e-07	0.00206	0.98	0.54	Longevity;	chr4:89107365	chr4:89119284~89119871:+
LAML	cis	rs4591358	0.654	rs6745113	ENSG00000223466.1	AC064834.2	-5.49	5.78e-07	0.00207	-0.72	-0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195505888	chr2:195533035~195538681:+
LAML	cis	rs2945232	1	rs2945232	ENSG00000268955.2	RP11-556O5.6	-5.49	5.8e-07	0.00207	-0.67	-0.54	Schizophrenia;	chr8:8240516	chr8:8188535~8189195:-
LAML	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	5.49	5.81e-07	0.00207	0.57	0.54	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
LAML	cis	rs67311347	0.955	rs1129200	ENSG00000223797.4	ENTPD3-AS1	5.48	5.83e-07	0.00208	0.76	0.54	Renal cell carcinoma;	chr3:40490766	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs67680017	ENSG00000223797.4	ENTPD3-AS1	5.48	5.83e-07	0.00208	0.76	0.54	Renal cell carcinoma;	chr3:40491673	chr3:40313802~40453329:-
LAML	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs3807302	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:129004803	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.604	rs13221560	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:129023121	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.544	rs12532542	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:129027358	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs4731540	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:129028196	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs1072767	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:129033151	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs6973975	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:129035495	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs921403	ENSG00000275106.1	RP11-309L24.10	-5.48	5.84e-07	0.00208	-0.46	-0.54	Sjögren's syndrome;	chr7:129036670	chr7:128952527~128953316:-
LAML	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-5.48	5.84e-07	0.00208	-0.65	-0.54	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
LAML	cis	rs904251	0.523	rs10807184	ENSG00000279942.1	RP1-153P14.7	-5.48	5.85e-07	0.00208	-0.54	-0.54	Cognitive performance;	chr6:37515937	chr6:37567716~37571460:+
LAML	cis	rs904251	0.561	rs1757189	ENSG00000279942.1	RP1-153P14.7	-5.48	5.85e-07	0.00208	-0.54	-0.54	Cognitive performance;	chr6:37515951	chr6:37567716~37571460:+
LAML	cis	rs11155671	0.53	rs7763849	ENSG00000216906.2	RP11-350J20.9	5.48	5.85e-07	0.00209	0.78	0.54	Testicular germ cell tumor;	chr6:149885244	chr6:149904243~149906418:+
LAML	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	5.48	5.86e-07	0.00209	0.74	0.54	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
LAML	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-5.48	5.96e-07	0.00212	-0.71	-0.54	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs11752180	ENSG00000203875.9	SNHG5	-5.48	5.96e-07	0.00212	-0.71	-0.54	Response to antipsychotic treatment;	chr6:85863447	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs12665464	ENSG00000203875.9	SNHG5	-5.48	5.96e-07	0.00212	-0.71	-0.54	Response to antipsychotic treatment;	chr6:85864415	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-5.48	5.96e-07	0.00212	-0.71	-0.54	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
LAML	cis	rs763121	0.752	rs6001190	ENSG00000230912.1	RP3-508I15.10	-5.48	5.97e-07	0.00212	-0.47	-0.54	Menopause (age at onset);	chr22:38677806	chr22:38666508~38668750:-
LAML	cis	rs62070183	0.656	rs17780628	ENSG00000264458.1	RP11-220C2.1	5.48	5.97e-07	0.00213	0.8	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32668202	chr17:32627739~32686484:+
LAML	cis	rs9322193	0.847	rs868375	ENSG00000216906.2	RP11-350J20.9	5.48	5.98e-07	0.00213	0.86	0.54	Lung cancer;	chr6:149844905	chr6:149904243~149906418:+
LAML	cis	rs7580658	0.711	rs12469035	ENSG00000236682.1	AC068282.3	-5.48	6.02e-07	0.00214	-0.66	-0.54	Protein C levels;	chr2:127227341	chr2:127389130~127400580:+
LAML	cis	rs4713118	0.662	rs149970	ENSG00000220721.1	OR1F12	5.48	6.02e-07	0.00214	0.69	0.54	Parkinson's disease;	chr6:28012442	chr6:28073316~28074233:+
LAML	cis	rs748404	0.56	rs572837	ENSG00000249839.1	AC011330.5	-5.48	6.04e-07	0.00215	-0.64	-0.54	Lung cancer;	chr15:43531615	chr15:43663654~43684339:-
LAML	cis	rs2283792	0.622	rs5756323	ENSG00000228050.1	TOP3BP1	-5.48	6.05e-07	0.00215	-0.61	-0.54	Multiple sclerosis;	chr22:21980398	chr22:22223187~22224566:-
LAML	cis	rs2581828	0.646	rs9861233	ENSG00000280417.1	RP11-5O17.1	-5.48	6.06e-07	0.00215	-0.74	-0.54	Crohn's disease;	chr3:53124815	chr3:53046166~53048122:+
LAML	cis	rs10829156	0.699	rs6482516	ENSG00000240291.1	RP11-499P20.2	5.47	6.08e-07	0.00216	0.65	0.54	Sudden cardiac arrest;	chr10:18550421	chr10:18513115~18545651:-
LAML	cis	rs10829156	0.66	rs11014830	ENSG00000240291.1	RP11-499P20.2	5.47	6.08e-07	0.00216	0.65	0.54	Sudden cardiac arrest;	chr10:18551504	chr10:18513115~18545651:-
LAML	cis	rs10829156	0.66	rs10828901	ENSG00000240291.1	RP11-499P20.2	5.47	6.08e-07	0.00216	0.65	0.54	Sudden cardiac arrest;	chr10:18552161	chr10:18513115~18545651:-
LAML	cis	rs5769707	0.521	rs739244	ENSG00000279597.1	RP4-566L20.1	-5.47	6.09e-07	0.00216	-0.67	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49534062~49534926:+
LAML	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-5.47	6.13e-07	0.00218	-0.69	-0.54	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-5.47	6.13e-07	0.00218	-0.69	-0.54	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
LAML	cis	rs6782228	0.848	rs3935016	ENSG00000242551.2	POU5F1P6	5.47	6.14e-07	0.00218	0.68	0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.848	rs6439141	ENSG00000242551.2	POU5F1P6	5.47	6.14e-07	0.00218	0.68	0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.883	rs6439142	ENSG00000242551.2	POU5F1P6	5.47	6.14e-07	0.00218	0.68	0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128674735~128677005:-
LAML	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-5.47	6.15e-07	0.00218	-0.46	-0.54	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-5.47	6.15e-07	0.00218	-0.46	-0.54	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-5.47	6.15e-07	0.00218	-0.46	-0.54	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-5.47	6.15e-07	0.00218	-0.46	-0.54	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-5.47	6.16e-07	0.00219	-0.46	-0.54	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
LAML	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-5.47	6.16e-07	0.00219	-0.46	-0.54	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
LAML	cis	rs7829975	0.514	rs2920983	ENSG00000268955.2	RP11-556O5.6	-5.47	6.17e-07	0.00219	-0.6	-0.54	Mood instability;	chr8:8410553	chr8:8188535~8189195:-
LAML	cis	rs62070183	0.873	rs80212824	ENSG00000201178.1	Y_RNA	5.47	6.17e-07	0.00219	0.83	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32703440	chr17:32830219~32830329:-
LAML	cis	rs1757171	0.542	rs3818985	ENSG00000279942.1	RP1-153P14.7	-5.47	6.2e-07	0.0022	-0.54	-0.54	Cognitive performance;	chr6:37516438	chr6:37567716~37571460:+
LAML	cis	rs853679	0.824	rs34712084	ENSG00000187763.3	OR2B7P	5.47	6.2e-07	0.0022	0.96	0.54	Depression;	chr6:28076050	chr6:28046434~28047367:+
LAML	cis	rs853679	0.824	rs1321505	ENSG00000187763.3	OR2B7P	5.47	6.2e-07	0.0022	0.96	0.54	Depression;	chr6:28085045	chr6:28046434~28047367:+
LAML	cis	rs2921073	0.509	rs2976931	ENSG00000268955.2	RP11-556O5.6	-5.47	6.2e-07	0.0022	-0.6	-0.54	Parkinson's disease;	chr8:8399807	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.514	rs2976929	ENSG00000268955.2	RP11-556O5.6	-5.47	6.2e-07	0.0022	-0.6	-0.54	Mood instability;	chr8:8401202	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.514	rs2920991	ENSG00000268955.2	RP11-556O5.6	-5.47	6.2e-07	0.0022	-0.6	-0.54	Mood instability;	chr8:8401607	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.514	rs2976926	ENSG00000268955.2	RP11-556O5.6	-5.47	6.2e-07	0.0022	-0.6	-0.54	Mood instability;	chr8:8404114	chr8:8188535~8189195:-
LAML	cis	rs4879656	0.527	rs510380	ENSG00000225693.1	LAGE3P1	5.47	6.28e-07	0.00222	0.61	0.54	Menopause (age at onset);	chr9:33098869	chr9:33019682~33020165:-
LAML	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	5.47	6.28e-07	0.00222	0.57	0.54	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
LAML	cis	rs904251	0.523	rs9369005	ENSG00000279942.1	RP1-153P14.7	-5.47	6.3e-07	0.00223	-0.54	-0.54	Cognitive performance;	chr6:37515333	chr6:37567716~37571460:+
LAML	cis	rs992157	0.932	rs4672884	ENSG00000261338.2	RP11-378A13.1	-5.47	6.3e-07	0.00223	-0.7	-0.54	Colorectal cancer;	chr2:218317758	chr2:218255319~218257366:+
LAML	cis	rs2273156	0.517	rs7159324	ENSG00000241052.1	RP11-173D9.1	5.47	6.3e-07	0.00223	0.93	0.54	Immunoglobulin light chain (AL) amyloidosis;	chr14:35157791	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs11156875	ENSG00000241052.1	RP11-173D9.1	-5.47	6.3e-07	0.00223	-0.93	-0.54	Immunoglobulin light chain (AL) amyloidosis;	chr14:35150610	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs28399702	ENSG00000241052.1	RP11-173D9.1	-5.47	6.3e-07	0.00223	-0.93	-0.54	Immunoglobulin light chain (AL) amyloidosis;	chr14:35156011	chr14:35144021~35144480:-
LAML	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-5.47	6.31e-07	0.00223	-0.63	-0.54	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
LAML	cis	rs12468226	1	rs13426118	ENSG00000226261.1	AC064836.3	5.46	6.32e-07	0.00223	0.9	0.54	Urate levels;	chr2:202390762	chr2:202336024~202336727:-
LAML	cis	rs9326248	0.53	rs7124741	ENSG00000254851.1	RP11-109L13.1	-5.46	6.33e-07	0.00224	-0.98	-0.54	Blood protein levels;	chr11:116881503	chr11:117135528~117138582:+
LAML	cis	rs66887589	0.72	rs2036858	ENSG00000248280.1	RP11-33B1.2	5.46	6.33e-07	0.00224	0.68	0.54	Diastolic blood pressure;	chr4:119328082	chr4:119440561~119450157:-
LAML	cis	rs6728642	1	rs59178801	ENSG00000235833.1	AC159540.14	5.46	6.34e-07	0.00224	0.88	0.54	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96938718	chr2:97523949~97524976:-
LAML	cis	rs6728642	1	rs73959416	ENSG00000235833.1	AC159540.14	5.46	6.34e-07	0.00224	0.88	0.54	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96938781	chr2:97523949~97524976:-
LAML	cis	rs763121	0.853	rs6519120	ENSG00000230912.1	RP3-508I15.10	5.46	6.36e-07	0.00224	0.47	0.54	Menopause (age at onset);	chr22:38595388	chr22:38666508~38668750:-
LAML	cis	rs4879656	0.966	rs10813912	ENSG00000225693.1	LAGE3P1	-5.46	6.38e-07	0.00225	-0.61	-0.54	Menopause (age at onset);	chr9:32975212	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs1016673	ENSG00000225693.1	LAGE3P1	5.46	6.38e-07	0.00225	0.61	0.54	Menopause (age at onset);	chr9:32982450	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.966	rs1016674	ENSG00000225693.1	LAGE3P1	5.46	6.38e-07	0.00225	0.61	0.54	Menopause (age at onset);	chr9:32982689	chr9:33019682~33020165:-
LAML	cis	rs4879656	1	rs4879656	ENSG00000225693.1	LAGE3P1	-5.46	6.38e-07	0.00225	-0.61	-0.54	Menopause (age at onset);	chr9:33012384	chr9:33019682~33020165:-
LAML	cis	rs763121	0.853	rs9610986	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38629272	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757196	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38643850	chr22:38666508~38668750:-
LAML	cis	rs763121	0.785	rs5757199	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38644612	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs7289577	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38646209	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs9610993	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38646813	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757200	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38647486	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757203	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38648147	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2205802	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38650322	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757204	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38650695	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs8138996	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38651430	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs6001182	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38651438	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757208	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38653225	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs6001184	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38656111	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs6001185	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38656150	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2294296	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38657044	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2064088	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38657377	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757213	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38657883	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs3747172	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38671519	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750659	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38672784	chr22:38666508~38668750:-
LAML	cis	rs763121	0.819	rs3747173	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38673040	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs3747174	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38673176	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs1065201	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38673505	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757226	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38674545	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs9306329	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38676449	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750662	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38676467	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750664	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38676764	chr22:38666508~38668750:-
LAML	cis	rs763121	0.626	rs5757236	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38677819	chr22:38666508~38668750:-
LAML	cis	rs763121	0.819	rs5757237	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38677830	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs6001191	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38678447	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs11704021	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38678711	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs4821811	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38679140	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs4821812	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38679230	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs9607566	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38679429	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs3827357	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38683408	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750668	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38683959	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750669	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38684633	chr22:38666508~38668750:-
LAML	cis	rs763121	0.819	rs6001205	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38704259	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2413546	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38710996	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2413547	ENSG00000230912.1	RP3-508I15.10	-5.46	6.4e-07	0.00225	-0.47	-0.54	Menopause (age at onset);	chr22:38711333	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757187	ENSG00000230912.1	RP3-508I15.10	5.46	6.4e-07	0.00225	0.47	0.54	Menopause (age at onset);	chr22:38625517	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757231	ENSG00000230912.1	RP3-508I15.10	5.46	6.4e-07	0.00225	0.47	0.54	Menopause (age at onset);	chr22:38675653	chr22:38666508~38668750:-
LAML	cis	rs2404602	0.598	rs11855999	ENSG00000259422.1	RP11-593F23.1	-5.46	6.4e-07	0.00225	-0.74	-0.54	Blood metabolite levels;	chr15:76334992	chr15:76174891~76181486:-
LAML	cis	rs10927875	0.83	rs1763610	ENSG00000178715.8	RP11-169K16.8	-5.46	6.42e-07	0.00226	-0.62	-0.54	Dilated cardiomyopathy;	chr1:16009032	chr1:15828232~15828669:+
LAML	cis	rs6452524	0.901	rs12188673	ENSG00000249664.1	CTD-2227C6.2	5.46	6.45e-07	0.00226	0.75	0.54	Hypertension (SNP x SNP interaction);	chr5:83126268	chr5:83012285~83013109:-
LAML	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-5.46	6.46e-07	0.00226	-0.66	-0.54	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
LAML	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
LAML	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
LAML	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	5.46	6.46e-07	0.00226	0.66	0.54	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
LAML	cis	rs9457247	0.534	rs9347170	ENSG00000265828.1	MIR3939	5.46	6.47e-07	0.00227	0.68	0.54	Crohn's disease;	chr6:166991699	chr6:166997807~166997912:-
LAML	cis	rs904251	0.523	rs12202055	ENSG00000279942.1	RP1-153P14.7	-5.46	6.48e-07	0.00227	-0.53	-0.54	Cognitive performance;	chr6:37518304	chr6:37567716~37571460:+
LAML	cis	rs709400	1	rs861531	ENSG00000258851.1	RP11-894P9.2	-5.46	6.48e-07	0.00227	-0.69	-0.54	Body mass index;	chr14:103706470	chr14:103553421~103561877:+
LAML	cis	rs7587476	1	rs2121285	ENSG00000227769.6	AC072062.3	5.46	6.49e-07	0.00227	0.62	0.54	Neuroblastoma;	chr2:214791444	chr2:215004782~215085488:+
LAML	cis	rs7587476	1	rs1542173	ENSG00000227769.6	AC072062.3	5.46	6.49e-07	0.00227	0.62	0.54	Neuroblastoma;	chr2:214792836	chr2:215004782~215085488:+
LAML	cis	rs12220777	1	rs75913297	ENSG00000230091.5	TMEM254-AS1	5.46	6.49e-07	0.00227	1.11	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80030089	chr10:80046860~80078912:-
LAML	cis	rs7746199	0.736	rs72845070	ENSG00000187763.3	OR2B7P	5.46	6.5e-07	0.00228	1.03	0.54	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28046434~28047367:+
LAML	cis	rs853679	1	rs7740487	ENSG00000217315.1	OR2W2P	5.46	6.51e-07	0.00228	0.92	0.54	Depression;	chr6:28248708	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs68141011	ENSG00000217315.1	OR2W2P	5.46	6.51e-07	0.00228	0.92	0.54	Depression;	chr6:28250019	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs13200462	ENSG00000217315.1	OR2W2P	5.46	6.51e-07	0.00228	0.92	0.54	Depression;	chr6:28250421	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs9986596	ENSG00000217315.1	OR2W2P	5.46	6.51e-07	0.00228	0.92	0.54	Depression;	chr6:28251883	chr6:28033947~28034855:+
LAML	cis	rs904251	0.6	rs4714068	ENSG00000227920.2	RP1-153P14.5	-5.46	6.52e-07	0.00228	-0.55	-0.54	Cognitive performance;	chr6:37487866	chr6:37545145~37550860:+
LAML	cis	rs1555322	0.53	rs2425043	ENSG00000261582.1	RP4-614O4.11	-5.46	6.52e-07	0.00228	-0.65	-0.54	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35267885~35280043:-
LAML	cis	rs73219805	0.671	rs13267955	ENSG00000228451.3	SDAD1P1	-5.46	6.56e-07	0.0023	-0.61	-0.54	Schizophrenia;	chr8:26367077	chr8:26379259~26382953:-
LAML	cis	rs62070183	0.882	rs17183295	ENSG00000265222.1	RP11-466A19.8	5.45	6.57e-07	0.0023	0.84	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32751254	chr17:32509954~32523424:-
LAML	cis	rs1075265	0.84	rs10084355	ENSG00000235937.1	AC008280.1	5.45	6.66e-07	0.00233	0.45	0.54	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54029552~54030682:-
LAML	cis	rs2564921	0.73	rs1811351	ENSG00000280417.1	RP11-5O17.1	-5.45	6.67e-07	0.00233	-0.79	-0.54	Height;	chr3:53064759	chr3:53046166~53048122:+
LAML	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	5.45	6.69e-07	0.00234	0.66	0.54	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
LAML	cis	rs1075265	0.87	rs7569214	ENSG00000235937.1	AC008280.1	5.45	6.73e-07	0.00235	0.45	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.729	rs10201364	ENSG00000235937.1	AC008280.1	5.45	6.73e-07	0.00235	0.45	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54029552~54030682:-
LAML	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	5.45	6.75e-07	0.00236	0.59	0.54	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
LAML	cis	rs853679	1	rs853676	ENSG00000187763.3	OR2B7P	5.45	6.75e-07	0.00236	0.79	0.54	Depression;	chr6:28331910	chr6:28046434~28047367:+
LAML	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	5.45	6.76e-07	0.00236	0.66	0.54	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	5.45	6.76e-07	0.00236	0.66	0.54	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
LAML	cis	rs6452524	0.868	rs11746977	ENSG00000249664.1	CTD-2227C6.2	5.45	6.81e-07	0.00238	0.73	0.54	Hypertension (SNP x SNP interaction);	chr5:83085581	chr5:83012285~83013109:-
LAML	cis	rs7927771	0.965	rs12364432	ENSG00000280615.1	Y_RNA	-5.44	6.86e-07	0.00239	-0.73	-0.54	Subjective well-being;	chr11:47881331	chr11:47614898~47614994:-
LAML	cis	rs2120335	1	rs13395335	ENSG00000221443.1	AC017083.1	5.44	6.86e-07	0.00239	0.68	0.54	Height;	chr2:68199492	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs13402188	ENSG00000221443.1	AC017083.1	5.44	6.86e-07	0.00239	0.68	0.54	Height;	chr2:68201151	chr2:68273104~68273206:+
LAML	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	5.44	6.93e-07	0.00242	0.65	0.54	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
LAML	cis	rs6782228	1	rs11711038	ENSG00000277250.1	Metazoa_SRP	5.44	6.94e-07	0.00242	0.8	0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128673681~128674021:-
LAML	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	5.44	6.98e-07	0.00243	0.64	0.54	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	5.44	6.98e-07	0.00243	0.64	0.54	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	5.44	6.98e-07	0.00243	0.64	0.54	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
LAML	cis	rs1555322	0.53	rs6060341	ENSG00000261582.1	RP4-614O4.11	5.44	6.98e-07	0.00243	0.66	0.54	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35267885~35280043:-
LAML	cis	rs1555322	0.53	rs2425042	ENSG00000261582.1	RP4-614O4.11	-5.44	6.98e-07	0.00243	-0.66	-0.54	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35267885~35280043:-
LAML	cis	rs1555322	0.505	rs591590	ENSG00000261582.1	RP4-614O4.11	5.44	6.98e-07	0.00243	0.66	0.54	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35267885~35280043:-
LAML	cis	rs1555322	0.53	rs7004	ENSG00000261582.1	RP4-614O4.11	-5.44	6.98e-07	0.00243	-0.66	-0.54	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35267885~35280043:-
LAML	cis	rs1555322	0.53	rs2297789	ENSG00000261582.1	RP4-614O4.11	-5.44	6.98e-07	0.00243	-0.66	-0.54	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35267885~35280043:-
LAML	cis	rs1555322	0.53	rs932562	ENSG00000261582.1	RP4-614O4.11	-5.44	6.98e-07	0.00243	-0.66	-0.54	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35267885~35280043:-
LAML	cis	rs1555322	0.53	rs2425047	ENSG00000261582.1	RP4-614O4.11	5.44	6.98e-07	0.00243	0.66	0.54	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35267885~35280043:-
LAML	cis	rs7495132	0.526	rs60433006	ENSG00000259314.1	CTD-3065B20.3	5.44	7e-07	0.00244	0.56	0.54	Ulcerative colitis;Inflammatory bowel disease;	chr15:90654244	chr15:90604225~90614558:-
LAML	cis	rs7165170	0.808	rs12915979	ENSG00000259314.1	CTD-3065B20.3	5.44	7e-07	0.00244	0.56	0.54	Crohn's disease;Inflammatory bowel disease;	chr15:90655794	chr15:90604225~90614558:-
LAML	cis	rs2015599	0.549	rs3782508	ENSG00000275476.1	RP11-996F15.4	5.44	7.01e-07	0.00244	0.58	0.54	Platelet count;Mean platelet volume;	chr12:29298446	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.516	rs10450679	ENSG00000275476.1	RP11-996F15.4	5.44	7.01e-07	0.00244	0.58	0.54	Platelet count;Mean platelet volume;	chr12:29298823	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.549	rs6487802	ENSG00000275476.1	RP11-996F15.4	5.44	7.01e-07	0.00244	0.58	0.54	Platelet count;Mean platelet volume;	chr12:29299480	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.549	rs6487803	ENSG00000275476.1	RP11-996F15.4	5.44	7.01e-07	0.00244	0.58	0.54	Platelet count;Mean platelet volume;	chr12:29299760	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.549	rs7954990	ENSG00000275476.1	RP11-996F15.4	5.44	7.01e-07	0.00244	0.58	0.54	Platelet count;Mean platelet volume;	chr12:29299841	chr12:29277397~29277882:-
LAML	cis	rs5769707	0.967	rs5770585	ENSG00000279597.1	RP4-566L20.1	-5.44	7.02e-07	0.00244	-0.63	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49534062~49534926:+
LAML	cis	rs9368481	0.594	rs2636425	ENSG00000241549.7	GUSBP2	5.44	7.03e-07	0.00244	0.61	0.54	Autism spectrum disorder or schizophrenia;	chr6:26831681	chr6:26871484~26956554:-
LAML	cis	rs62070183	0.873	rs113602044	ENSG00000265222.1	RP11-466A19.8	5.44	7.03e-07	0.00244	0.89	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32691685	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs77819475	ENSG00000265222.1	RP11-466A19.8	5.44	7.03e-07	0.00244	0.89	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32699823	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs17183113	ENSG00000265222.1	RP11-466A19.8	5.44	7.03e-07	0.00244	0.89	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702107	chr17:32509954~32523424:-
LAML	cis	rs62070183	0.938	rs78418651	ENSG00000265222.1	RP11-466A19.8	5.44	7.03e-07	0.00244	0.89	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702530	chr17:32509954~32523424:-
LAML	cis	rs10829156	0.699	rs7911922	ENSG00000240291.1	RP11-499P20.2	5.44	7.06e-07	0.00245	0.67	0.54	Sudden cardiac arrest;	chr10:18542768	chr10:18513115~18545651:-
LAML	cis	rs1930961	0.702	rs1930966	ENSG00000272977.1	CTA-390C10.10	-5.43	7.15e-07	0.00248	-0.82	-0.54	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25476218~25479971:+
LAML	cis	rs785830	0.749	rs2479325	ENSG00000235880.1	RP11-59O6.3	-5.43	7.16e-07	0.00248	-0.46	-0.54	Platelet distribution width;	chr9:253282	chr9:267966~273002:-
LAML	cis	rs66887589	0.66	rs4833613	ENSG00000248280.1	RP11-33B1.2	-5.43	7.17e-07	0.00248	-0.69	-0.54	Diastolic blood pressure;	chr4:119229001	chr4:119440561~119450157:-
LAML	cis	rs904251	0.523	rs2776874	ENSG00000279942.1	RP1-153P14.7	-5.43	7.17e-07	0.00248	-0.54	-0.54	Cognitive performance;	chr6:37515421	chr6:37567716~37571460:+
LAML	cis	rs904251	0.797	rs1757177	ENSG00000204110.6	RP1-153P14.8	-5.43	7.17e-07	0.00249	-0.66	-0.54	Cognitive performance;	chr6:37518594	chr6:37507348~37535616:+
LAML	cis	rs66887589	0.934	rs7681980	ENSG00000248280.1	RP11-33B1.2	-5.43	7.18e-07	0.00249	-0.65	-0.54	Diastolic blood pressure;	chr4:119612068	chr4:119440561~119450157:-
LAML	cis	rs62070183	0.938	rs75782470	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32746623	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.882	rs62070164	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32759415	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs4795719	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32776957	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.882	rs17780981	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32792019	chr17:32830219~32830329:-
LAML	cis	rs112916054	1	rs112916054	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Immature fraction of reticulocytes;	chr17:32797244	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.752	rs17781005	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32805511	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.808	rs76373015	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815023	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.808	rs79957065	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815731	chr17:32830219~32830329:-
LAML	cis	rs62070183	1	rs62070183	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32837349	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.882	rs17183600	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32848061	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.882	rs17781136	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32858024	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.882	rs62070187	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32863706	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.817	rs79640811	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32894299	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.766	rs62070229	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32900575	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.766	rs62070232	ENSG00000201178.1	Y_RNA	5.43	7.2e-07	0.00249	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32903075	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.882	rs17183628	ENSG00000201178.1	Y_RNA	-5.43	7.2e-07	0.00249	-0.78	-0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32857613	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs17781142	ENSG00000201178.1	Y_RNA	-5.43	7.2e-07	0.00249	-0.78	-0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32860198	chr17:32830219~32830329:-
LAML	cis	rs6728642	0.901	rs7584641	ENSG00000235833.1	AC159540.14	5.43	7.22e-07	0.0025	0.92	0.54	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941918	chr2:97523949~97524976:-
LAML	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-5.43	7.24e-07	0.0025	-0.65	-0.54	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
LAML	cis	rs2486288	0.656	rs9921035	ENSG00000259520.4	CTD-2651B20.3	5.43	7.26e-07	0.00251	0.84	0.54	Glomerular filtration rate;	chr15:45254462	chr15:45251580~45279251:-
LAML	cis	rs9506514	0.509	rs9509294	ENSG00000222726.1	RNU2-7P	-5.43	7.29e-07	0.00252	-0.67	-0.54	Coronary artery calcification;	chr13:20600506	chr13:20612161~20612338:+
LAML	cis	rs5769707	0.542	rs739242	ENSG00000279597.1	RP4-566L20.1	-5.43	7.29e-07	0.00252	-0.67	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.521	rs7285764	ENSG00000279597.1	RP4-566L20.1	-5.43	7.29e-07	0.00252	-0.67	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.521	rs9616715	ENSG00000279597.1	RP4-566L20.1	-5.43	7.29e-07	0.00252	-0.67	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.521	rs6009805	ENSG00000279597.1	RP4-566L20.1	-5.43	7.29e-07	0.00252	-0.67	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.521	rs6009807	ENSG00000279597.1	RP4-566L20.1	-5.43	7.29e-07	0.00252	-0.67	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49534062~49534926:+
LAML	cis	rs904251	0.797	rs1757181	ENSG00000204110.6	RP1-153P14.8	5.43	7.3e-07	0.00252	0.69	0.54	Cognitive performance;	chr6:37517952	chr6:37507348~37535616:+
LAML	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	5.43	7.3e-07	0.00252	0.56	0.54	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
LAML	cis	rs67311347	0.955	rs2123999	ENSG00000223797.4	ENTPD3-AS1	5.43	7.34e-07	0.00254	0.69	0.54	Renal cell carcinoma;	chr3:40337247	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-5.43	7.34e-07	0.00254	-0.69	-0.54	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
LAML	cis	rs12903285	1	rs12903285	ENSG00000259474.1	RP11-650L12.1	-5.43	7.38e-07	0.00255	-0.53	-0.54	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78486611	chr15:78480057~78481820:-
LAML	cis	rs965604	1	rs12903295	ENSG00000259474.1	RP11-650L12.1	-5.43	7.38e-07	0.00255	-0.53	-0.54	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78486630	chr15:78480057~78481820:-
LAML	cis	rs9506514	0.509	rs9509279	ENSG00000222726.1	RNU2-7P	5.42	7.4e-07	0.00255	0.68	0.54	Coronary artery calcification;	chr13:20559580	chr13:20612161~20612338:+
LAML	cis	rs2581828	0.632	rs891369	ENSG00000280417.1	RP11-5O17.1	-5.42	7.4e-07	0.00255	-0.79	-0.54	Crohn's disease;	chr3:53102535	chr3:53046166~53048122:+
LAML	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-5.42	7.43e-07	0.00256	-0.58	-0.54	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
LAML	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	5.42	7.43e-07	0.00256	0.57	0.54	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
LAML	cis	rs9368481	0.761	rs4713062	ENSG00000241549.7	GUSBP2	-5.42	7.43e-07	0.00256	-0.57	-0.54	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26871484~26956554:-
LAML	cis	rs4803480	0.72	rs4141218	ENSG00000239736.2	CEACAMP3	-5.42	7.44e-07	0.00256	-0.79	-0.54	Schizophrenia;	chr19:41575555	chr19:41599735~41605984:+
LAML	cis	rs3758911	0.861	rs11212197	ENSG00000261098.1	RP11-819C21.1	-5.42	7.44e-07	0.00257	-0.52	-0.54	Coronary artery disease;	chr11:107391784	chr11:107312132~107316271:-
LAML	cis	rs1075265	0.621	rs2542593	ENSG00000235937.1	AC008280.1	5.42	7.46e-07	0.00257	0.42	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53804299	chr2:54029552~54030682:-
LAML	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	5.42	7.46e-07	0.00257	0.57	0.54	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
LAML	cis	rs9506514	0.509	rs9509281	ENSG00000222726.1	RNU2-7P	-5.42	7.48e-07	0.00257	-0.68	-0.54	Coronary artery calcification;	chr13:20564274	chr13:20612161~20612338:+
LAML	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	5.42	7.48e-07	0.00258	0.64	0.54	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	5.42	7.48e-07	0.00258	0.64	0.54	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	5.42	7.48e-07	0.00258	0.64	0.54	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
LAML	cis	rs5769707	0.521	rs5769719	ENSG00000279597.1	RP4-566L20.1	-5.42	7.49e-07	0.00258	-0.67	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.521	rs5769720	ENSG00000279597.1	RP4-566L20.1	-5.42	7.49e-07	0.00258	-0.67	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.521	rs5770633	ENSG00000279597.1	RP4-566L20.1	-5.42	7.49e-07	0.00258	-0.67	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49534062~49534926:+
LAML	cis	rs3091242	0.933	rs28530483	ENSG00000224183.1	SDHDP6	-5.42	7.53e-07	0.00259	-0.66	-0.54	Erythrocyte sedimentation rate;	chr1:25414356	chr1:25294164~25294643:-
LAML	cis	rs12468226	1	rs6739198	ENSG00000226261.1	AC064836.3	5.42	7.54e-07	0.00259	0.92	0.54	Urate levels;	chr2:202492273	chr2:202336024~202336727:-
LAML	cis	rs904251	0.58	rs62408367	ENSG00000227920.2	RP1-153P14.5	-5.42	7.56e-07	0.0026	-0.58	-0.54	Cognitive performance;	chr6:37477037	chr6:37545145~37550860:+
LAML	cis	rs4591358	0.684	rs17177643	ENSG00000223466.1	AC064834.2	5.42	7.56e-07	0.0026	0.69	0.54	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510796	chr2:195533035~195538681:+
LAML	cis	rs748404	0.56	rs1060939	ENSG00000249839.1	AC011330.5	-5.42	7.57e-07	0.0026	-0.62	-0.54	Lung cancer;	chr15:43524719	chr15:43663654~43684339:-
LAML	cis	rs748404	0.518	rs480108	ENSG00000249839.1	AC011330.5	-5.42	7.57e-07	0.0026	-0.62	-0.54	Lung cancer;	chr15:43525208	chr15:43663654~43684339:-
LAML	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	5.42	7.59e-07	0.00261	0.55	0.54	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	5.42	7.59e-07	0.00261	0.55	0.54	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	5.42	7.59e-07	0.00261	0.55	0.54	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	5.42	7.59e-07	0.00261	0.55	0.54	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
LAML	cis	rs3758911	0.861	rs10890721	ENSG00000261098.1	RP11-819C21.1	-5.42	7.6e-07	0.00261	-0.52	-0.54	Coronary artery disease;	chr11:107336876	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.828	rs11212173	ENSG00000261098.1	RP11-819C21.1	-5.42	7.6e-07	0.00261	-0.52	-0.54	Coronary artery disease;	chr11:107343881	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs11212175	ENSG00000261098.1	RP11-819C21.1	-5.42	7.6e-07	0.00261	-0.52	-0.54	Coronary artery disease;	chr11:107348581	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.894	rs72990443	ENSG00000261098.1	RP11-819C21.1	-5.42	7.6e-07	0.00261	-0.52	-0.54	Coronary artery disease;	chr11:107352050	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.894	rs4343000	ENSG00000261098.1	RP11-819C21.1	-5.42	7.6e-07	0.00261	-0.52	-0.54	Coronary artery disease;	chr11:107353992	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.894	rs11212179	ENSG00000261098.1	RP11-819C21.1	-5.42	7.6e-07	0.00261	-0.52	-0.54	Coronary artery disease;	chr11:107357254	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.856	rs11212180	ENSG00000261098.1	RP11-819C21.1	-5.42	7.6e-07	0.00261	-0.52	-0.54	Coronary artery disease;	chr11:107358630	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.856	rs11212181	ENSG00000261098.1	RP11-819C21.1	-5.42	7.6e-07	0.00261	-0.52	-0.54	Coronary artery disease;	chr11:107360169	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.894	rs11212182	ENSG00000261098.1	RP11-819C21.1	-5.42	7.6e-07	0.00261	-0.52	-0.54	Coronary artery disease;	chr11:107360879	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.894	rs11607304	ENSG00000261098.1	RP11-819C21.1	-5.42	7.6e-07	0.00261	-0.52	-0.54	Coronary artery disease;	chr11:107361870	chr11:107312132~107316271:-
LAML	cis	rs853679	0.607	rs34788973	ENSG00000217315.1	OR2W2P	5.42	7.62e-07	0.00262	0.99	0.54	Depression;	chr6:27911422	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs61742093	ENSG00000217315.1	OR2W2P	5.42	7.62e-07	0.00262	0.99	0.54	Depression;	chr6:27912204	chr6:28033947~28034855:+
LAML	cis	rs1075265	0.575	rs2692531	ENSG00000235937.1	AC008280.1	5.42	7.63e-07	0.00262	0.42	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.587	rs2949812	ENSG00000235937.1	AC008280.1	5.42	7.63e-07	0.00262	0.42	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53797190	chr2:54029552~54030682:-
LAML	cis	rs853679	0.607	rs34243448	ENSG00000187763.3	OR2B7P	5.42	7.63e-07	0.00262	0.99	0.54	Depression;	chr6:28225324	chr6:28046434~28047367:+
LAML	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-5.42	7.64e-07	0.00262	-0.64	-0.54	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-5.42	7.64e-07	0.00262	-0.64	-0.54	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-5.42	7.64e-07	0.00262	-0.64	-0.54	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-5.42	7.64e-07	0.00262	-0.64	-0.54	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-5.42	7.64e-07	0.00262	-0.64	-0.54	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-5.42	7.64e-07	0.00262	-0.64	-0.54	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-5.42	7.64e-07	0.00262	-0.64	-0.54	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-5.42	7.64e-07	0.00262	-0.64	-0.54	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	5.42	7.64e-07	0.00262	0.64	0.54	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	5.42	7.64e-07	0.00262	0.64	0.54	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
LAML	cis	rs561341	0.709	rs8068049	ENSG00000266379.5	RP11-640N20.8	-5.42	7.66e-07	0.00262	-1.14	-0.54	Hip circumference adjusted for BMI;	chr17:31856838	chr17:32088160~32094933:-
LAML	cis	rs2486288	0.656	rs11629858	ENSG00000259520.4	CTD-2651B20.3	5.42	7.66e-07	0.00262	0.8	0.54	Glomerular filtration rate;	chr15:45254916	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11629859	ENSG00000259520.4	CTD-2651B20.3	5.42	7.66e-07	0.00262	0.8	0.54	Glomerular filtration rate;	chr15:45254923	chr15:45251580~45279251:-
LAML	cis	rs10927875	0.619	rs12121764	ENSG00000178715.8	RP11-169K16.8	-5.42	7.67e-07	0.00263	-0.63	-0.54	Dilated cardiomyopathy;	chr1:15811564	chr1:15828232~15828669:+
LAML	cis	rs9368481	0.761	rs4358615	ENSG00000241549.7	GUSBP2	5.42	7.67e-07	0.00263	0.57	0.54	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26871484~26956554:-
LAML	cis	rs172166	0.637	rs1233708	ENSG00000220721.1	OR1F12	5.42	7.68e-07	0.00263	0.59	0.54	Cardiac Troponin-T levels;	chr6:28205441	chr6:28073316~28074233:+
LAML	cis	rs7131987	0.565	rs2882294	ENSG00000274315.1	RP11-996F15.5	5.41	7.71e-07	0.00264	0.54	0.54	QT interval;	chr12:29245019	chr12:29331434~29331936:-
LAML	cis	rs62070183	0.873	rs113602044	ENSG00000201178.1	Y_RNA	5.41	7.74e-07	0.00265	0.82	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32691685	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs77819475	ENSG00000201178.1	Y_RNA	5.41	7.74e-07	0.00265	0.82	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32699823	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs17183113	ENSG00000201178.1	Y_RNA	5.41	7.74e-07	0.00265	0.82	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702107	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs78418651	ENSG00000201178.1	Y_RNA	5.41	7.74e-07	0.00265	0.82	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702530	chr17:32830219~32830329:-
LAML	cis	rs6700559	0.565	rs2809341	ENSG00000260088.1	RP11-92G12.3	-5.41	7.76e-07	0.00265	-0.67	-0.54	Coronary artery disease;	chr1:200628560	chr1:200669507~200694250:+
LAML	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	5.41	7.77e-07	0.00265	0.61	0.54	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
LAML	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	5.41	7.78e-07	0.00265	0.91	0.54	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
LAML	cis	rs62070183	0.938	rs75393526	ENSG00000279781.1	RP11-466A19.7	5.41	7.79e-07	0.00266	0.79	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32708000	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs75822124	ENSG00000279781.1	RP11-466A19.7	5.41	7.79e-07	0.00266	0.79	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32710876	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs17183176	ENSG00000279781.1	RP11-466A19.7	5.41	7.79e-07	0.00266	0.79	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32727107	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs1990825	ENSG00000279781.1	RP11-466A19.7	5.41	7.79e-07	0.00266	0.79	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32729274	chr17:32518322~32518934:-
LAML	cis	rs7714584	1	rs11747065	ENSG00000197083.10	ZNF300P1	5.41	7.8e-07	0.00266	1.22	0.54	Crohn's disease;	chr5:150915924	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11740172	ENSG00000197083.10	ZNF300P1	5.41	7.8e-07	0.00266	1.22	0.54	Crohn's disease;	chr5:150920716	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11746807	ENSG00000197083.10	ZNF300P1	5.41	7.8e-07	0.00266	1.22	0.54	Crohn's disease;	chr5:150920857	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs12656600	ENSG00000197083.10	ZNF300P1	5.41	7.8e-07	0.00266	1.22	0.54	Crohn's disease;	chr5:150932310	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs17800987	ENSG00000197083.10	ZNF300P1	5.41	7.8e-07	0.00266	1.22	0.54	Crohn's disease;	chr5:150943866	chr5:150930645~150946289:-
LAML	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-5.41	7.8e-07	0.00266	-0.67	-0.54	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
LAML	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-5.41	7.8e-07	0.00266	-0.67	-0.54	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-5.41	7.8e-07	0.00266	-0.67	-0.54	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
LAML	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-5.41	7.8e-07	0.00266	-0.67	-0.54	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-5.41	7.8e-07	0.00266	-0.67	-0.54	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
LAML	cis	rs2486288	0.656	rs2413773	ENSG00000259520.4	CTD-2651B20.3	5.41	7.8e-07	0.00266	0.8	0.54	Glomerular filtration rate;	chr15:45257244	chr15:45251580~45279251:-
LAML	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-5.41	7.81e-07	0.00266	-0.64	-0.54	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
LAML	cis	rs62070183	0.656	rs77727254	ENSG00000264458.1	RP11-220C2.1	5.41	7.82e-07	0.00266	0.85	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32659966	chr17:32627739~32686484:+
LAML	cis	rs1075265	0.73	rs805391	ENSG00000235937.1	AC008280.1	-5.41	7.85e-07	0.00267	-0.43	-0.54	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54029552~54030682:-
LAML	cis	rs2581828	0.608	rs9830353	ENSG00000280417.1	RP11-5O17.1	-5.41	7.88e-07	0.00268	-0.77	-0.54	Crohn's disease;	chr3:53129937	chr3:53046166~53048122:+
LAML	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	5.41	7.91e-07	0.00268	0.6	0.54	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
LAML	cis	rs5769707	0.837	rs5770599	ENSG00000279597.1	RP4-566L20.1	-5.41	7.93e-07	0.00269	-0.68	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.837	rs5769709	ENSG00000279597.1	RP4-566L20.1	-5.41	7.93e-07	0.00269	-0.68	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49534062~49534926:+
LAML	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-5.41	7.96e-07	0.0027	-0.64	-0.54	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-5.41	7.96e-07	0.0027	-0.64	-0.54	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
LAML	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-5.41	7.97e-07	0.0027	-0.68	-0.54	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
LAML	cis	rs5769707	0.933	rs2157444	ENSG00000280224.1	CTA-722E9.1	-5.4	8.01e-07	0.00271	-0.68	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49500568~49501585:+
LAML	cis	rs2486288	0.656	rs8037583	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45254180	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs9921025	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45254404	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11629807	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45254839	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.587	rs12899942	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45255082	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs12899058	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45255126	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs12904150	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45255407	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs9920290	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45255837	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11854325	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45256761	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs10519018	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45257067	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs2413774	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45257225	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs2413772	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45257664	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11632724	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45258593	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11632651	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45258640	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11637920	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45258707	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11632777	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45258847	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11632778	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45258858	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11632752	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45258942	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs12911186	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45259225	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs12915314	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45259293	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs8039138	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45259394	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs8039540	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45259644	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs8040185	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45259883	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs1060896	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45262069	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11632419	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45265258	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs2271438	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45265270	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11854365	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45265885	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs11639420	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45267070	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs2413768	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45269786	chr15:45251580~45279251:-
LAML	cis	rs2486288	0.656	rs7162022	ENSG00000259520.4	CTD-2651B20.3	5.4	8.02e-07	0.00271	0.8	0.54	Glomerular filtration rate;	chr15:45273055	chr15:45251580~45279251:-
LAML	cis	rs1048238	0.548	rs848217	ENSG00000178715.8	RP11-169K16.8	-5.4	8.02e-07	0.00271	-0.62	-0.54	Systolic blood pressure;	chr1:15945755	chr1:15828232~15828669:+
LAML	cis	rs1075265	0.633	rs28653587	ENSG00000235937.1	AC008280.1	5.4	8.12e-07	0.00274	0.42	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.633	rs7564912	ENSG00000235937.1	AC008280.1	5.4	8.12e-07	0.00274	0.42	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.61	rs6746965	ENSG00000235937.1	AC008280.1	5.4	8.12e-07	0.00274	0.42	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.527	rs10167891	ENSG00000235937.1	AC008280.1	5.4	8.12e-07	0.00274	0.42	0.54	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54029552~54030682:-
LAML	cis	rs2273156	0.587	rs8014377	ENSG00000241052.1	RP11-173D9.1	-5.4	8.14e-07	0.00275	-0.99	-0.54	Immunoglobulin light chain (AL) amyloidosis;	chr14:35061851	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.587	rs61125355	ENSG00000241052.1	RP11-173D9.1	-5.4	8.14e-07	0.00275	-0.99	-0.54	Immunoglobulin light chain (AL) amyloidosis;	chr14:35065995	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.587	rs7145474	ENSG00000241052.1	RP11-173D9.1	-5.4	8.14e-07	0.00275	-0.99	-0.54	Immunoglobulin light chain (AL) amyloidosis;	chr14:35067909	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs75889859	ENSG00000241052.1	RP11-173D9.1	-5.4	8.14e-07	0.00275	-0.99	-0.54	Immunoglobulin light chain (AL) amyloidosis;	chr14:35069848	chr14:35144021~35144480:-
LAML	cis	rs79403677	1	rs79403677	ENSG00000241052.1	RP11-173D9.1	-5.4	8.14e-07	0.00275	-0.99	-0.54	Bipolar disorder lithium response (continuous) or schizophrenia;	chr14:35069925	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs7154306	ENSG00000241052.1	RP11-173D9.1	-5.4	8.14e-07	0.00275	-0.99	-0.54	Immunoglobulin light chain (AL) amyloidosis;	chr14:35071293	chr14:35144021~35144480:-
LAML	cis	rs2143950	0.831	rs12589079	ENSG00000241052.1	RP11-173D9.1	-5.4	8.14e-07	0.00275	-0.99	-0.54	Atopic dermatitis;	chr14:35073287	chr14:35144021~35144480:-
LAML	cis	rs7714584	1	rs61530785	ENSG00000197083.10	ZNF300P1	5.4	8.15e-07	0.00275	1.21	0.54	Crohn's disease;	chr5:150881802	chr5:150930645~150946289:-
LAML	cis	rs4803480	1	rs11882144	ENSG00000239736.2	CEACAMP3	-5.4	8.17e-07	0.00275	-0.79	-0.54	Schizophrenia;	chr19:41566244	chr19:41599735~41605984:+
LAML	cis	rs1075265	0.84	rs2884254	ENSG00000235937.1	AC008280.1	5.4	8.19e-07	0.00276	0.44	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54029552~54030682:-
LAML	cis	rs10927875	0.691	rs1048261	ENSG00000178715.8	RP11-169K16.8	5.4	8.21e-07	0.00276	0.62	0.54	Dilated cardiomyopathy;	chr1:16014456	chr1:15828232~15828669:+
LAML	cis	rs911555	0.962	rs2765042	ENSG00000258851.1	RP11-894P9.2	5.4	8.26e-07	0.00278	0.64	0.54	Intelligence (multi-trait analysis);	chr14:103524408	chr14:103553421~103561877:+
LAML	cis	rs911555	0.815	rs2756118	ENSG00000258851.1	RP11-894P9.2	5.4	8.26e-07	0.00278	0.64	0.54	Intelligence (multi-trait analysis);	chr14:103526136	chr14:103553421~103561877:+
LAML	cis	rs11643134	1	rs11643134	ENSG00000259940.2	CTD-3203P2.1	-5.4	8.29e-07	0.00279	-0.62	-0.54	Night sleep phenotypes;	chr16:27231559	chr16:27213308~27214993:-
LAML	cis	rs12149695	0.735	rs28456036	ENSG00000259940.2	CTD-3203P2.1	-5.4	8.29e-07	0.00279	-0.62	-0.54	Gut microbiota (bacterial taxa);	chr16:27233227	chr16:27213308~27214993:-
LAML	cis	rs1577917	0.816	rs9353349	ENSG00000203875.9	SNHG5	5.4	8.3e-07	0.00279	0.68	0.54	Response to antipsychotic treatment;	chr6:85998007	chr6:85660950~85678736:-
LAML	cis	rs2283792	0.622	rs2266979	ENSG00000228050.1	TOP3BP1	5.39	8.35e-07	0.00281	0.6	0.54	Multiple sclerosis;	chr22:21977447	chr22:22223187~22224566:-
LAML	cis	rs5769707	0.568	rs2011097	ENSG00000280224.1	CTA-722E9.1	-5.39	8.36e-07	0.00281	-0.79	-0.54	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49500568~49501585:+
LAML	cis	rs3091242	0.933	rs932372	ENSG00000224183.1	SDHDP6	-5.39	8.41e-07	0.00283	-0.65	-0.54	Erythrocyte sedimentation rate;	chr1:25428523	chr1:25294164~25294643:-
LAML	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	5.39	8.42e-07	0.00283	0.57	0.54	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	5.39	8.42e-07	0.00283	0.57	0.54	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	5.39	8.42e-07	0.00283	0.57	0.54	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
LAML	cis	rs3758911	0.828	rs10890701	ENSG00000261098.1	RP11-819C21.1	-5.39	8.43e-07	0.00283	-0.52	-0.54	Coronary artery disease;	chr11:107309216	chr11:107312132~107316271:-
LAML	cis	rs9457247	0.534	rs2757053	ENSG00000265828.1	MIR3939	5.39	8.44e-07	0.00283	0.67	0.54	Crohn's disease;	chr6:166966850	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.534	rs2345568	ENSG00000265828.1	MIR3939	5.39	8.44e-07	0.00283	0.67	0.54	Crohn's disease;	chr6:166968316	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.534	rs4710149	ENSG00000265828.1	MIR3939	5.39	8.44e-07	0.00283	0.67	0.54	Crohn's disease;	chr6:166972858	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.534	rs4710154	ENSG00000265828.1	MIR3939	5.39	8.44e-07	0.00283	0.67	0.54	Crohn's disease;	chr6:166981146	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.534	rs9366078	ENSG00000265828.1	MIR3939	5.39	8.44e-07	0.00283	0.67	0.54	Crohn's disease;	chr6:166986024	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.534	rs9356551	ENSG00000265828.1	MIR3939	5.39	8.44e-07	0.00283	0.67	0.54	Crohn's disease;	chr6:166986857	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.534	rs933243	ENSG00000265828.1	MIR3939	-5.39	8.44e-07	0.00283	-0.67	-0.54	Crohn's disease;	chr6:166990385	chr6:166997807~166997912:-
LAML	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	5.39	8.47e-07	0.00285	0.67	0.54	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
LAML	cis	rs853679	1	rs1679709	ENSG00000217315.1	OR2W2P	-5.39	8.48e-07	0.00285	-0.87	-0.54	Depression;	chr6:28260564	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs1778511	ENSG00000217315.1	OR2W2P	-5.39	8.48e-07	0.00285	-0.87	-0.54	Depression;	chr6:28261633	chr6:28033947~28034855:+
LAML	cis	rs66887589	0.934	rs41464847	ENSG00000248280.1	RP11-33B1.2	-5.39	8.49e-07	0.00285	-0.65	-0.54	Diastolic blood pressure;	chr4:119611246	chr4:119440561~119450157:-
LAML	cis	rs7495132	0.562	rs6496714	ENSG00000259314.1	CTD-3065B20.3	5.39	8.51e-07	0.00286	0.56	0.54	Ulcerative colitis;Inflammatory bowel disease;	chr15:90631672	chr15:90604225~90614558:-
LAML	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	5.39	8.52e-07	0.00286	0.66	0.54	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
LAML	cis	rs6951245	1	rs11764748	ENSG00000229043.2	AC091729.9	-5.39	8.53e-07	0.00286	-0.86	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054872	chr7:1160374~1165267:+
LAML	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	5.39	8.53e-07	0.00286	0.6	0.54	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
LAML	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-5.39	8.53e-07	0.00286	-0.6	-0.54	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
LAML	cis	rs7829975	0.593	rs2921051	ENSG00000268955.2	RP11-556O5.6	-5.39	8.55e-07	0.00287	-0.66	-0.54	Mood instability;	chr8:8462594	chr8:8188535~8189195:-
LAML	cis	rs1075265	0.656	rs2542574	ENSG00000235937.1	AC008280.1	5.39	8.58e-07	0.00288	0.43	0.54	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54029552~54030682:-
LAML	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	5.39	8.61e-07	0.00289	0.64	0.54	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	5.39	8.61e-07	0.00289	0.64	0.54	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
LAML	cis	rs3758911	0.861	rs2355840	ENSG00000261098.1	RP11-819C21.1	-5.39	8.65e-07	0.0029	-0.52	-0.54	Coronary artery disease;	chr11:107287251	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs11212132	ENSG00000261098.1	RP11-819C21.1	-5.39	8.65e-07	0.0029	-0.52	-0.54	Coronary artery disease;	chr11:107288576	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs10789594	ENSG00000261098.1	RP11-819C21.1	-5.39	8.65e-07	0.0029	-0.52	-0.54	Coronary artery disease;	chr11:107290391	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.828	rs11212138	ENSG00000261098.1	RP11-819C21.1	-5.39	8.65e-07	0.0029	-0.52	-0.54	Coronary artery disease;	chr11:107294553	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.828	rs11212141	ENSG00000261098.1	RP11-819C21.1	-5.39	8.65e-07	0.0029	-0.52	-0.54	Coronary artery disease;	chr11:107298200	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.828	rs10789598	ENSG00000261098.1	RP11-819C21.1	-5.39	8.65e-07	0.0029	-0.52	-0.54	Coronary artery disease;	chr11:107307878	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs11212143	ENSG00000261098.1	RP11-819C21.1	-5.39	8.65e-07	0.0029	-0.52	-0.54	Coronary artery disease;	chr11:107308554	chr11:107312132~107316271:-
LAML	cis	rs62070183	0.938	rs62068432	ENSG00000201178.1	Y_RNA	5.38	8.68e-07	0.00291	0.78	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32739479	chr17:32830219~32830329:-
LAML	cis	rs12468226	1	rs76021735	ENSG00000226261.1	AC064836.3	5.38	8.69e-07	0.00291	0.95	0.54	Urate levels;	chr2:202511476	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs57080353	ENSG00000226261.1	AC064836.3	5.38	8.69e-07	0.00291	0.95	0.54	Urate levels;	chr2:202511824	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.81	rs3736578	ENSG00000226261.1	AC064836.3	5.38	8.69e-07	0.00291	0.95	0.54	Urate levels;	chr2:202519989	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs116439150	ENSG00000226261.1	AC064836.3	5.38	8.69e-07	0.00291	0.95	0.54	Urate levels;	chr2:202523814	chr2:202336024~202336727:-
LAML	cis	rs12468226	1	rs12467409	ENSG00000226261.1	AC064836.3	5.38	8.69e-07	0.00291	0.95	0.54	Urate levels;	chr2:202529625	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.81	rs77090459	ENSG00000226261.1	AC064836.3	5.38	8.69e-07	0.00291	0.95	0.54	Urate levels;	chr2:202542132	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.872	rs1061157	ENSG00000226261.1	AC064836.3	5.38	8.69e-07	0.00291	0.95	0.54	Urate levels;	chr2:202556476	chr2:202336024~202336727:-
LAML	cis	rs7746199	0.736	rs13195636	ENSG00000187763.3	OR2B7P	5.38	8.7e-07	0.00291	1.05	0.54	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28046434~28047367:+
LAML	cis	rs763121	0.853	rs5757232	ENSG00000230912.1	RP3-508I15.10	-5.38	8.73e-07	0.00292	-0.46	-0.54	Menopause (age at onset);	chr22:38675672	chr22:38666508~38668750:-
LAML	cis	rs904251	0.861	rs914349	ENSG00000279942.1	RP1-153P14.7	-5.38	8.74e-07	0.00293	-0.62	-0.54	Cognitive performance;	chr6:37516939	chr6:37567716~37571460:+
LAML	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-5.38	8.81e-07	0.00295	-0.61	-0.54	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
LAML	cis	rs6782228	0.848	rs6439140	ENSG00000242551.2	POU5F1P6	5.38	8.83e-07	0.00295	0.69	0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128674735~128677005:-
LAML	cis	rs9457247	0.534	rs12055488	ENSG00000265828.1	MIR3939	5.38	8.83e-07	0.00295	0.67	0.54	Crohn's disease;	chr6:166966082	chr6:166997807~166997912:-
LAML	cis	rs709400	0.663	rs1467561	ENSG00000258851.1	RP11-894P9.2	-5.38	8.87e-07	0.00296	-0.67	-0.54	Body mass index;	chr14:103528624	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs1022736	ENSG00000258851.1	RP11-894P9.2	-5.38	8.87e-07	0.00296	-0.67	-0.54	Body mass index;	chr14:103532086	chr14:103553421~103561877:+
LAML	cis	rs709400	0.598	rs11627529	ENSG00000258851.1	RP11-894P9.2	-5.38	8.87e-07	0.00296	-0.67	-0.54	Body mass index;	chr14:103538220	chr14:103553421~103561877:+
LAML	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	5.38	8.88e-07	0.00297	0.74	0.54	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
LAML	cis	rs709400	0.93	rs2274268	ENSG00000258851.1	RP11-894P9.2	-5.38	8.89e-07	0.00297	-0.7	-0.54	Body mass index;	chr14:103563041	chr14:103553421~103561877:+
LAML	cis	rs709400	0.93	rs57447494	ENSG00000258851.1	RP11-894P9.2	-5.38	8.89e-07	0.00297	-0.7	-0.54	Body mass index;	chr14:103568232	chr14:103553421~103561877:+
LAML	cis	rs9399135	0.967	rs9376077	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:134978575	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs13218642	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:134988802	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs6925424	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:134992810	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs6902954	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:134992856	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs17638970	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:134998925	chr6:135055033~135060550:+
LAML	cis	rs9402673	0.558	rs9688342	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	High light scatter reticulocyte count;Reticulocyte count;	chr6:135001888	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs45544135	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135002913	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.933	rs4559100	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135002947	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs12527707	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135003373	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9389251	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135004579	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs6929661	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135007654	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs2327578	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135008831	chr6:135055033~135060550:+
LAML	cis	rs9389248	0.5	rs116273677	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	High light scatter reticulocyte percentage of red cells;	chr6:135017997	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs59329760	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135021299	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4896125	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135021431	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.935	rs949547	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135022361	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.935	rs2150680	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135025993	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs11756988	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135026457	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs11754783	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135026523	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs6919862	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135031305	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs10872427	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135032314	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs7766189	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135032713	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9402676	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135034369	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9389258	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135040002	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs2327580	ENSG00000232876.1	CTA-212D2.2	-5.38	8.91e-07	0.00297	-0.68	-0.54	Red blood cell count;	chr6:135043279	chr6:135055033~135060550:+
LAML	cis	rs4803480	0.507	rs10420992	ENSG00000239736.2	CEACAMP3	-5.38	8.91e-07	0.00297	-0.69	-0.54	Schizophrenia;	chr19:41558092	chr19:41599735~41605984:+
LAML	cis	rs4803480	0.529	rs4803481	ENSG00000239736.2	CEACAMP3	-5.38	8.91e-07	0.00297	-0.69	-0.54	Schizophrenia;	chr19:41560186	chr19:41599735~41605984:+
LAML	cis	rs4803480	0.507	rs11083627	ENSG00000239736.2	CEACAMP3	-5.38	8.91e-07	0.00297	-0.69	-0.54	Schizophrenia;	chr19:41563530	chr19:41599735~41605984:+
LAML	cis	rs4803480	0.554	rs12150975	ENSG00000239736.2	CEACAMP3	-5.38	8.91e-07	0.00297	-0.69	-0.54	Schizophrenia;	chr19:41563990	chr19:41599735~41605984:+
LAML	cis	rs4803480	0.554	rs12983999	ENSG00000239736.2	CEACAMP3	-5.38	8.91e-07	0.00297	-0.69	-0.54	Schizophrenia;	chr19:41564158	chr19:41599735~41605984:+
LAML	cis	rs4803480	0.554	rs12462194	ENSG00000239736.2	CEACAMP3	-5.38	8.91e-07	0.00297	-0.69	-0.54	Schizophrenia;	chr19:41565931	chr19:41599735~41605984:+
LAML	cis	rs1075265	0.729	rs7571086	ENSG00000235937.1	AC008280.1	5.38	8.92e-07	0.00297	0.44	0.54	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54029552~54030682:-
LAML	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	5.38	8.93e-07	0.00297	0.7	0.54	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-5.38	8.93e-07	0.00297	-0.7	-0.54	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
LAML	cis	rs6951245	1	rs77868187	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054332	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs75016635	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054485	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs113066613	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054492	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs11763793	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054706	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs11763835	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1054877	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs78861357	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1055782	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.872	rs76713558	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056230	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.748	rs79658522	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056241	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.935	rs76525951	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056377	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs79683221	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056503	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs78185801	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1056731	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs80031817	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057157	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs78143408	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057210	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.938	rs78351779	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057387	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs11761941	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057547	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs11767527	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1057758	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.935	rs61910751	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058259	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.872	rs77434655	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058769	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.872	rs75398423	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1058778	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.872	rs112309216	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060660	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.872	rs76161580	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1060671	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs76388414	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061058	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs77305932	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061225	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.745	rs79788515	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061443	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.872	rs11768486	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061654	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs11766526	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1061797	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs80094748	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1064322	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs113146460	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065528	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.935	rs61753396	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1065736	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.938	rs113642700	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1066018	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs79327308	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068505	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.938	rs117729148	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1068895	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.935	rs113365567	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1069149	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.935	rs79143504	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1070576	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs74887741	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1071022	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs79617366	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072322	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs111899361	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1072712	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs80212261	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074376	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs77346188	ENSG00000229043.2	AC091729.9	-5.38	8.96e-07	0.00297	-0.85	-0.54	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074387	chr7:1160374~1165267:+
LAML	cis	rs6452524	0.901	rs72767146	ENSG00000249664.1	CTD-2227C6.2	5.38	8.96e-07	0.00297	0.73	0.54	Hypertension (SNP x SNP interaction);	chr5:83126365	chr5:83012285~83013109:-
LAML	cis	rs10927875	0.722	rs1763606	ENSG00000178715.8	RP11-169K16.8	5.38	8.96e-07	0.00297	0.61	0.54	Dilated cardiomyopathy;	chr1:16011787	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.722	rs1763605	ENSG00000178715.8	RP11-169K16.8	5.38	8.96e-07	0.00297	0.61	0.54	Dilated cardiomyopathy;	chr1:16012430	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.726	rs1763603	ENSG00000178715.8	RP11-169K16.8	5.38	8.96e-07	0.00297	0.61	0.54	Dilated cardiomyopathy;	chr1:16013314	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.631	rs945418	ENSG00000178715.8	RP11-169K16.8	5.38	8.96e-07	0.00297	0.61	0.54	Dilated cardiomyopathy;	chr1:16018235	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.722	rs6660685	ENSG00000178715.8	RP11-169K16.8	5.38	8.96e-07	0.00297	0.61	0.54	Dilated cardiomyopathy;	chr1:16020493	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.631	rs28579893	ENSG00000178715.8	RP11-169K16.8	5.38	8.96e-07	0.00297	0.61	0.54	Dilated cardiomyopathy;	chr1:16021039	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.688	rs2009371	ENSG00000178715.8	RP11-169K16.8	5.38	8.96e-07	0.00297	0.61	0.54	Dilated cardiomyopathy;	chr1:16021588	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.722	rs945425	ENSG00000178715.8	RP11-169K16.8	5.38	8.96e-07	0.00297	0.61	0.54	Dilated cardiomyopathy;	chr1:16021917	chr1:15828232~15828669:+
LAML	cis	rs10927875	0.691	rs2017583	ENSG00000178715.8	RP11-169K16.8	5.38	8.96e-07	0.00297	0.61	0.54	Dilated cardiomyopathy;	chr1:16023533	chr1:15828232~15828669:+
LAML	cis	rs2283792	0.622	rs381523	ENSG00000228050.1	TOP3BP1	5.38	8.96e-07	0.00297	0.6	0.54	Multiple sclerosis;	chr22:21951257	chr22:22223187~22224566:-
LAML	cis	rs2283792	0.622	rs239917	ENSG00000228050.1	TOP3BP1	5.38	8.96e-07	0.00297	0.6	0.54	Multiple sclerosis;	chr22:21960091	chr22:22223187~22224566:-
LAML	cis	rs9457247	0.534	rs7750593	ENSG00000265828.1	MIR3939	5.38	8.97e-07	0.00297	0.67	0.54	Crohn's disease;	chr6:166973871	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.515	rs1951459	ENSG00000265828.1	MIR3939	5.38	8.97e-07	0.00297	0.67	0.54	Crohn's disease;	chr6:166989048	chr6:166997807~166997912:-
LAML	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	5.38	8.97e-07	0.00297	0.67	0.54	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	5.38	8.97e-07	0.00297	0.67	0.54	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	5.38	8.97e-07	0.00297	0.67	0.54	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	5.38	8.97e-07	0.00297	0.67	0.54	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
LAML	cis	rs62070183	0.938	rs9911168	ENSG00000279781.1	RP11-466A19.7	5.38	8.97e-07	0.00297	0.79	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709136	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs9912761	ENSG00000279781.1	RP11-466A19.7	5.38	8.97e-07	0.00297	0.79	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709475	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs9303654	ENSG00000279781.1	RP11-466A19.7	5.38	8.97e-07	0.00297	0.79	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709747	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs9898762	ENSG00000279781.1	RP11-466A19.7	5.38	8.97e-07	0.00297	0.79	0.54	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32711641	chr17:32518322~32518934:-
LAML	cis	rs4713118	0.869	rs2056925	ENSG00000220721.1	OR1F12	5.38	8.98e-07	0.00297	0.59	0.54	Parkinson's disease;	chr6:27723126	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs6922574	ENSG00000220721.1	OR1F12	5.38	8.98e-07	0.00297	0.59	0.54	Parkinson's disease;	chr6:27725224	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9348775	ENSG00000220721.1	OR1F12	5.38	8.98e-07	0.00297	0.59	0.54	Parkinson's disease;	chr6:27727550	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9283880	ENSG00000220721.1	OR1F12	5.38	8.99e-07	0.00298	0.59	0.54	Parkinson's disease;	chr6:27747464	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9283881	ENSG00000220721.1	OR1F12	5.38	8.99e-07	0.00298	0.59	0.54	Parkinson's disease;	chr6:27747476	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9283882	ENSG00000220721.1	OR1F12	5.38	8.99e-07	0.00298	0.59	0.54	Parkinson's disease;	chr6:27747479	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9283883	ENSG00000220721.1	OR1F12	5.38	8.99e-07	0.00298	0.59	0.54	Parkinson's disease;	chr6:27747691	chr6:28073316~28074233:+
LAML	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-5.37	9.07e-07	0.00299	-0.64	-0.54	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
LAML	cis	rs12220777	0.892	rs7083787	ENSG00000230091.5	TMEM254-AS1	5.37	9.07e-07	0.00299	1.19	0.54	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80029185	chr10:80046860~80078912:-
LAML	cis	rs4273100	0.512	rs1355128	ENSG00000262319.1	CTC-457L16.2	5.37	9.1e-07	0.003	0.78	0.53	Schizophrenia;	chr17:19395831	chr17:19141017~19143689:-
LAML	cis	rs62070183	0.938	rs9911168	ENSG00000201178.1	Y_RNA	5.37	9.12e-07	0.003	0.78	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709136	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs9912761	ENSG00000201178.1	Y_RNA	5.37	9.12e-07	0.003	0.78	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709475	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs9303654	ENSG00000201178.1	Y_RNA	5.37	9.12e-07	0.003	0.78	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709747	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs9898762	ENSG00000201178.1	Y_RNA	5.37	9.12e-07	0.003	0.78	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32711641	chr17:32830219~32830329:-
LAML	cis	rs10927875	0.619	rs7546589	ENSG00000178715.8	RP11-169K16.8	-5.37	9.19e-07	0.00302	-0.62	-0.53	Dilated cardiomyopathy;	chr1:15803035	chr1:15828232~15828669:+
LAML	cis	rs6951245	0.786	rs77943789	ENSG00000229043.2	AC091729.9	-5.37	9.21e-07	0.00303	-0.82	-0.53	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100522	chr7:1160374~1165267:+
LAML	cis	rs1150668	0.799	rs1736891	ENSG00000216901.1	AL022393.7	5.37	9.22e-07	0.00303	0.61	0.53	Pubertal anthropometrics;	chr6:28219323	chr6:28176188~28176674:+
LAML	cis	rs73219805	0.554	rs3808566	ENSG00000228451.3	SDAD1P1	5.37	9.24e-07	0.00303	0.65	0.53	Schizophrenia;	chr8:26365942	chr8:26379259~26382953:-
LAML	cis	rs763121	0.657	rs5995603	ENSG00000230912.1	RP3-508I15.10	-5.37	9.26e-07	0.00304	-0.47	-0.53	Menopause (age at onset);	chr22:38644728	chr22:38666508~38668750:-
LAML	cis	rs9399135	0.967	rs12661423	ENSG00000232876.1	CTA-212D2.2	-5.37	9.28e-07	0.00305	-0.72	-0.53	Red blood cell count;	chr6:135028432	chr6:135055033~135060550:+
LAML	cis	rs62070183	0.766	rs62067160	ENSG00000279781.1	RP11-466A19.7	5.37	9.3e-07	0.00305	0.79	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32919567	chr17:32518322~32518934:-
LAML	cis	rs2283792	0.567	rs2027789	ENSG00000228050.1	TOP3BP1	5.37	9.3e-07	0.00305	0.64	0.53	Multiple sclerosis;	chr22:21933490	chr22:22223187~22224566:-
LAML	cis	rs1757171	0.542	rs3818986	ENSG00000279942.1	RP1-153P14.7	-5.37	9.37e-07	0.00307	-0.54	-0.53	Cognitive performance;	chr6:37516573	chr6:37567716~37571460:+
LAML	cis	rs9322193	0.923	rs2342765	ENSG00000216906.2	RP11-350J20.9	5.36	9.42e-07	0.00309	0.75	0.53	Lung cancer;	chr6:149858873	chr6:149904243~149906418:+
LAML	cis	rs5769707	0.749	rs7286706	ENSG00000213279.2	RP1-29C18.9	-5.36	9.45e-07	0.00309	-0.54	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49572264~49575426:-
LAML	cis	rs7131987	0.565	rs7968883	ENSG00000273680.1	RP11-996F15.6	5.36	9.51e-07	0.00311	0.54	0.53	QT interval;	chr12:29241258	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs1991113	ENSG00000273680.1	RP11-996F15.6	-5.36	9.51e-07	0.00311	-0.54	-0.53	QT interval;	chr12:29239070	chr12:29332733~29333383:-
LAML	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	5.36	9.53e-07	0.00312	0.64	0.53	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
LAML	cis	rs12145833	0.538	rs12026408	ENSG00000253326.2	RP11-261C10.7	-5.36	9.55e-07	0.00312	-0.87	-0.53	Obesity (early onset extreme);	chr1:243203503	chr1:243054861~243056394:-
LAML	cis	rs7746199	0.736	rs35037868	ENSG00000187763.3	OR2B7P	5.36	9.56e-07	0.00312	1	0.53	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28046434~28047367:+
LAML	cis	rs66887589	0.777	rs4643791	ENSG00000248280.1	RP11-33B1.2	-5.36	9.57e-07	0.00313	-0.66	-0.53	Diastolic blood pressure;	chr4:119344464	chr4:119440561~119450157:-
LAML	cis	rs763121	0.853	rs138705	ENSG00000230912.1	RP3-508I15.10	-5.36	9.57e-07	0.00313	-0.47	-0.53	Menopause (age at onset);	chr22:38737798	chr22:38666508~38668750:-
LAML	cis	rs904251	0.504	rs9380677	ENSG00000204110.6	RP1-153P14.8	-5.36	9.59e-07	0.00313	-0.64	-0.53	Cognitive performance;	chr6:37512590	chr6:37507348~37535616:+
LAML	cis	rs4879656	0.564	rs1197774	ENSG00000225693.1	LAGE3P1	-5.36	9.62e-07	0.00314	-0.57	-0.53	Menopause (age at onset);	chr9:33001451	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.564	rs20583	ENSG00000225693.1	LAGE3P1	-5.36	9.62e-07	0.00314	-0.57	-0.53	Menopause (age at onset);	chr9:33026574	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.564	rs1537253	ENSG00000225693.1	LAGE3P1	5.36	9.62e-07	0.00314	0.57	0.53	Menopause (age at onset);	chr9:32983373	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.564	rs1888869	ENSG00000225693.1	LAGE3P1	5.36	9.62e-07	0.00314	0.57	0.53	Menopause (age at onset);	chr9:32998239	chr9:33019682~33020165:-
LAML	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-5.36	9.65e-07	0.00315	-0.59	-0.53	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-5.36	9.65e-07	0.00315	-0.59	-0.53	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-5.36	9.65e-07	0.00315	-0.59	-0.53	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-5.36	9.65e-07	0.00315	-0.59	-0.53	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-5.36	9.65e-07	0.00315	-0.59	-0.53	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
LAML	cis	rs7829975	0.509	rs2945269	ENSG00000268955.2	RP11-556O5.6	-5.36	9.66e-07	0.00315	-0.65	-0.53	Mood instability;	chr8:8258056	chr8:8188535~8189195:-
LAML	cis	rs10829156	0.66	rs7918933	ENSG00000240291.1	RP11-499P20.2	5.36	9.68e-07	0.00316	0.68	0.53	Sudden cardiac arrest;	chr10:18517434	chr10:18513115~18545651:-
LAML	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	5.36	9.7e-07	0.00316	0.63	0.53	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	5.36	9.7e-07	0.00316	0.63	0.53	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	5.36	9.7e-07	0.00316	0.63	0.53	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	5.36	9.7e-07	0.00316	0.63	0.53	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	5.36	9.7e-07	0.00316	0.63	0.53	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
LAML	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-5.36	9.75e-07	0.00318	-0.67	-0.53	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
LAML	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-5.36	9.75e-07	0.00318	-0.67	-0.53	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
LAML	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-5.36	9.75e-07	0.00318	-0.67	-0.53	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
LAML	cis	rs1075265	0.704	rs805410	ENSG00000235937.1	AC008280.1	5.36	9.75e-07	0.00318	0.43	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54029552~54030682:-
LAML	cis	rs6700559	0.565	rs11807125	ENSG00000260088.1	RP11-92G12.3	5.35	9.79e-07	0.00319	0.66	0.53	Coronary artery disease;	chr1:200623167	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.545	rs12744758	ENSG00000260088.1	RP11-92G12.3	5.35	9.79e-07	0.00319	0.66	0.53	Coronary artery disease;	chr1:200624010	chr1:200669507~200694250:+
LAML	cis	rs55794721	0.509	rs6699896	ENSG00000224183.1	SDHDP6	-5.35	9.83e-07	0.0032	-0.64	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25436411	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs35148262	ENSG00000224183.1	SDHDP6	-5.35	9.83e-07	0.0032	-0.64	-0.53	Erythrocyte sedimentation rate;	chr1:25440132	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-5.35	9.83e-07	0.0032	-0.64	-0.53	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
LAML	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-5.35	9.83e-07	0.0032	-0.64	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
LAML	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-5.35	9.83e-07	0.0032	-0.64	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
LAML	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-5.35	9.83e-07	0.0032	-0.64	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
LAML	cis	rs2564921	0.765	rs35333155	ENSG00000280417.1	RP11-5O17.1	5.35	9.85e-07	0.0032	0.67	0.53	Height;	chr3:53073764	chr3:53046166~53048122:+
LAML	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-5.35	9.91e-07	0.0032	-0.97	-0.53	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
LAML	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-5.35	9.92e-07	0.00321	-0.64	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
LAML	cis	rs11903757	1	rs75610640	ENSG00000281467.1	Clostridiales-1	-5.35	9.96e-07	0.00322	-1.1	-0.53	Colorectal cancer;	chr2:191698038	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs78771268	ENSG00000281467.1	Clostridiales-1	-5.35	9.96e-07	0.00322	-1.1	-0.53	Colorectal cancer;	chr2:191699167	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs78934362	ENSG00000281467.1	Clostridiales-1	-5.35	9.96e-07	0.00322	-1.1	-0.53	Colorectal cancer;	chr2:191701161	chr2:191699476~191699631:-
LAML	cis	rs10829156	0.699	rs1917209	ENSG00000240291.1	RP11-499P20.2	5.35	1e-06	0.00323	0.68	0.53	Sudden cardiac arrest;	chr10:18543631	chr10:18513115~18545651:-
LAML	cis	rs10829156	0.66	rs10764587	ENSG00000240291.1	RP11-499P20.2	5.35	1e-06	0.00323	0.68	0.53	Sudden cardiac arrest;	chr10:18548901	chr10:18513115~18545651:-
LAML	cis	rs10829156	0.699	rs10764584	ENSG00000240291.1	RP11-499P20.2	-5.35	1e-06	0.00323	-0.68	-0.53	Sudden cardiac arrest;	chr10:18546396	chr10:18513115~18545651:-
LAML	cis	rs763121	0.819	rs5757126	ENSG00000230912.1	RP3-508I15.10	-5.35	1e-06	0.00323	-0.46	-0.53	Menopause (age at onset);	chr22:38527670	chr22:38666508~38668750:-
LAML	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	5.35	1e-06	0.00324	0.58	0.53	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
LAML	cis	rs4591358	0.527	rs16836742	ENSG00000223466.1	AC064834.2	5.35	1.01e-06	0.00326	0.73	0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512919	chr2:195533035~195538681:+
LAML	cis	rs12145833	0.538	rs61833885	ENSG00000253326.2	RP11-261C10.7	-5.35	1.01e-06	0.00327	-0.87	-0.53	Obesity (early onset extreme);	chr1:243233886	chr1:243054861~243056394:-
LAML	cis	rs12145833	0.538	rs10926977	ENSG00000253326.2	RP11-261C10.7	-5.35	1.01e-06	0.00327	-0.87	-0.53	Obesity (early onset extreme);	chr1:243248065	chr1:243054861~243056394:-
LAML	cis	rs6964833	0.935	rs13238996	ENSG00000277053.3	GTF2IP1	-5.35	1.01e-06	0.00327	-0.76	-0.53	Menarche (age at onset);	chr7:74655318	chr7:75185385~75237696:-
LAML	cis	rs3091242	0.933	rs61775174	ENSG00000224183.1	SDHDP6	5.34	1.02e-06	0.00327	0.66	0.53	Erythrocyte sedimentation rate;	chr1:25460822	chr1:25294164~25294643:-
LAML	cis	rs12468226	0.808	rs77251002	ENSG00000272966.1	RP11-686O6.1	5.34	1.02e-06	0.00329	0.88	0.53	Urate levels;	chr2:202150236	chr2:202336739~202337200:+
LAML	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-5.34	1.02e-06	0.00329	-0.64	-0.53	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-5.34	1.02e-06	0.00329	-0.64	-0.53	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-5.34	1.02e-06	0.00329	-0.64	-0.53	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
LAML	cis	rs367615	0.512	rs246104	ENSG00000249476.1	CTD-2587M2.1	-5.34	1.02e-06	0.00329	-0.67	-0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109365281	chr5:109237120~109326369:-
LAML	cis	rs367615	0.552	rs7720036	ENSG00000249476.1	CTD-2587M2.1	-5.34	1.02e-06	0.00329	-0.67	-0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109374998	chr5:109237120~109326369:-
LAML	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	5.34	1.02e-06	0.0033	0.6	0.53	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
LAML	cis	rs4591358	0.765	rs11884957	ENSG00000223466.1	AC064834.2	5.34	1.02e-06	0.0033	0.69	0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195498120	chr2:195533035~195538681:+
LAML	cis	rs7131987	0.526	rs7954375	ENSG00000273680.1	RP11-996F15.6	5.34	1.02e-06	0.0033	0.54	0.53	QT interval;	chr12:29241487	chr12:29332733~29333383:-
LAML	cis	rs1577917	0.958	rs12213343	ENSG00000203875.9	SNHG5	-5.34	1.03e-06	0.0033	-0.72	-0.53	Response to antipsychotic treatment;	chr6:85733301	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12215265	ENSG00000203875.9	SNHG5	-5.34	1.03e-06	0.0033	-0.72	-0.53	Response to antipsychotic treatment;	chr6:85734251	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12197463	ENSG00000203875.9	SNHG5	-5.34	1.03e-06	0.0033	-0.72	-0.53	Response to antipsychotic treatment;	chr6:85735524	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-5.34	1.03e-06	0.0033	-0.72	-0.53	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-5.34	1.03e-06	0.0033	-0.72	-0.53	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-5.34	1.03e-06	0.0033	-0.72	-0.53	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
LAML	cis	rs4713118	0.869	rs6914924	ENSG00000220721.1	OR1F12	5.34	1.03e-06	0.00331	0.58	0.53	Parkinson's disease;	chr6:27743751	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs6930992	ENSG00000220721.1	OR1F12	5.34	1.03e-06	0.00331	0.58	0.53	Parkinson's disease;	chr6:27744341	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9468214	ENSG00000220721.1	OR1F12	5.34	1.03e-06	0.00331	0.58	0.53	Parkinson's disease;	chr6:27745520	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs6901520	ENSG00000220721.1	OR1F12	5.34	1.03e-06	0.00331	0.58	0.53	Parkinson's disease;	chr6:27746796	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9295743	ENSG00000220721.1	OR1F12	5.34	1.03e-06	0.00331	0.58	0.53	Parkinson's disease;	chr6:27747323	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9461405	ENSG00000220721.1	OR1F12	5.34	1.03e-06	0.00331	0.58	0.53	Parkinson's disease;	chr6:27751596	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs7773070	ENSG00000220721.1	OR1F12	5.34	1.03e-06	0.00331	0.58	0.53	Parkinson's disease;	chr6:27761048	chr6:28073316~28074233:+
LAML	cis	rs5769707	0.609	rs739247	ENSG00000280224.1	CTA-722E9.1	-5.34	1.03e-06	0.00331	-0.76	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.609	rs135861	ENSG00000280224.1	CTA-722E9.1	-5.34	1.03e-06	0.00331	-0.76	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49500568~49501585:+
LAML	cis	rs992157	0.965	rs13419763	ENSG00000261338.2	RP11-378A13.1	5.34	1.04e-06	0.00334	0.71	0.53	Colorectal cancer;	chr2:218270227	chr2:218255319~218257366:+
LAML	cis	rs7829975	0.564	rs2976855	ENSG00000268955.2	RP11-556O5.6	-5.34	1.04e-06	0.00335	-0.64	-0.53	Mood instability;	chr8:8444284	chr8:8188535~8189195:-
LAML	cis	rs4879656	0.966	rs2274769	ENSG00000225693.1	LAGE3P1	-5.34	1.05e-06	0.00335	-0.6	-0.53	Menopause (age at onset);	chr9:33026640	chr9:33019682~33020165:-
LAML	cis	rs4879656	0.835	rs10813927	ENSG00000225693.1	LAGE3P1	-5.34	1.05e-06	0.00335	-0.6	-0.53	Menopause (age at onset);	chr9:33047912	chr9:33019682~33020165:-
LAML	cis	rs1075265	0.73	rs4413193	ENSG00000235937.1	AC008280.1	5.34	1.05e-06	0.00337	0.43	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.756	rs2160931	ENSG00000235937.1	AC008280.1	5.34	1.05e-06	0.00337	0.43	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.655	rs13432632	ENSG00000235937.1	AC008280.1	5.34	1.05e-06	0.00337	0.43	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54029552~54030682:-
LAML	cis	rs6782228	0.606	rs10048945	ENSG00000277250.1	Metazoa_SRP	-5.34	1.05e-06	0.00338	-0.67	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128673681~128674021:-
LAML	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-5.34	1.06e-06	0.00338	-0.97	-0.53	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
LAML	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-5.34	1.06e-06	0.00338	-0.97	-0.53	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-5.34	1.06e-06	0.00338	-0.97	-0.53	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
LAML	cis	rs904251	0.504	rs12202664	ENSG00000279942.1	RP1-153P14.7	-5.33	1.06e-06	0.00339	-0.55	-0.53	Cognitive performance;	chr6:37513422	chr6:37567716~37571460:+
LAML	cis	rs875971	0.965	rs697968	ENSG00000222364.1	RNU6-96P	5.33	1.06e-06	0.00339	0.66	0.53	Aortic root size;	chr7:66070046	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1167411	ENSG00000222364.1	RNU6-96P	5.33	1.06e-06	0.00339	0.66	0.53	Aortic root size;	chr7:66074277	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1183245	ENSG00000222364.1	RNU6-96P	5.33	1.06e-06	0.00339	0.66	0.53	Aortic root size;	chr7:66076198	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1144895	ENSG00000222364.1	RNU6-96P	5.33	1.06e-06	0.00339	0.66	0.53	Aortic root size;	chr7:66076320	chr7:66395191~66395286:+
LAML	cis	rs875971	1	rs1144894	ENSG00000222364.1	RNU6-96P	5.33	1.06e-06	0.00339	0.66	0.53	Aortic root size;	chr7:66077907	chr7:66395191~66395286:+
LAML	cis	rs1577917	0.917	rs2218594	ENSG00000203875.9	SNHG5	-5.33	1.06e-06	0.00339	-0.7	-0.53	Response to antipsychotic treatment;	chr6:85834048	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs2197648	ENSG00000203875.9	SNHG5	-5.33	1.06e-06	0.00339	-0.7	-0.53	Response to antipsychotic treatment;	chr6:85834169	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.876	rs11752223	ENSG00000203875.9	SNHG5	-5.33	1.06e-06	0.00339	-0.7	-0.53	Response to antipsychotic treatment;	chr6:85863676	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12660846	ENSG00000203875.9	SNHG5	-5.33	1.06e-06	0.00339	-0.7	-0.53	Response to antipsychotic treatment;	chr6:85864091	chr6:85660950~85678736:-
LAML	cis	rs9326248	0.516	rs6589577	ENSG00000254851.1	RP11-109L13.1	-5.33	1.06e-06	0.00339	-1.06	-0.53	Blood protein levels;	chr11:116879261	chr11:117135528~117138582:+
LAML	cis	rs853679	0.766	rs9368561	ENSG00000182477.5	OR2B8P	5.33	1.06e-06	0.0034	0.96	0.53	Depression;	chr6:28200565	chr6:28053228~28054165:-
LAML	cis	rs11155671	0.53	rs4870080	ENSG00000216906.2	RP11-350J20.9	5.33	1.06e-06	0.00341	0.77	0.53	Testicular germ cell tumor;	chr6:149881508	chr6:149904243~149906418:+
LAML	cis	rs853679	0.882	rs9468287	ENSG00000187763.3	OR2B7P	5.33	1.07e-06	0.00341	0.94	0.53	Depression;	chr6:28111963	chr6:28046434~28047367:+
LAML	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
LAML	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
LAML	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-5.33	1.07e-06	0.00342	-0.65	-0.53	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
LAML	cis	rs7131987	0.565	rs7976667	ENSG00000257176.2	RP11-996F15.2	5.33	1.07e-06	0.00342	0.51	0.53	QT interval;	chr12:29273098	chr12:29280418~29317848:-
LAML	cis	rs6700559	0.692	rs12126676	ENSG00000260088.1	RP11-92G12.3	5.33	1.07e-06	0.00342	0.64	0.53	Coronary artery disease;	chr1:200631692	chr1:200669507~200694250:+
LAML	cis	rs6728642	1	rs6728642	ENSG00000235833.1	AC159540.14	5.33	1.07e-06	0.00342	0.94	0.53	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941334	chr2:97523949~97524976:-
LAML	cis	rs6728642	1	rs7593754	ENSG00000235833.1	AC159540.14	5.33	1.07e-06	0.00342	0.94	0.53	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96941807	chr2:97523949~97524976:-
LAML	cis	rs6728642	1	rs60608738	ENSG00000235833.1	AC159540.14	5.33	1.07e-06	0.00342	0.94	0.53	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96942348	chr2:97523949~97524976:-
LAML	cis	rs6728642	1	rs57035274	ENSG00000235833.1	AC159540.14	5.33	1.07e-06	0.00342	0.94	0.53	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96942387	chr2:97523949~97524976:-
LAML	cis	rs9326248	0.53	rs562179	ENSG00000254851.1	RP11-109L13.1	-5.33	1.07e-06	0.00343	-0.96	-0.53	Blood protein levels;	chr11:116934488	chr11:117135528~117138582:+
LAML	cis	rs67311347	0.577	rs2887951	ENSG00000223797.4	ENTPD3-AS1	5.33	1.07e-06	0.00343	0.75	0.53	Renal cell carcinoma;	chr3:40240613	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.521	rs6769540	ENSG00000223797.4	ENTPD3-AS1	5.33	1.08e-06	0.00343	0.68	0.53	Renal cell carcinoma;	chr3:40316413	chr3:40313802~40453329:-
LAML	cis	rs5769707	0.967	rs763127	ENSG00000279597.1	RP4-566L20.1	-5.33	1.08e-06	0.00344	-0.6	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49612430	chr22:49534062~49534926:+
LAML	cis	rs4273100	0.646	rs4924990	ENSG00000265185.4	SNORD3B-1	-5.33	1.08e-06	0.00344	-0.82	-0.53	Schizophrenia;	chr17:19391511	chr17:19061912~19062669:+
LAML	cis	rs73219805	0.793	rs1564576	ENSG00000228451.3	SDAD1P1	-5.33	1.08e-06	0.00345	-0.61	-0.53	Schizophrenia;	chr8:26333320	chr8:26379259~26382953:-
LAML	cis	rs73219805	0.793	rs3808573	ENSG00000228451.3	SDAD1P1	-5.33	1.08e-06	0.00345	-0.61	-0.53	Schizophrenia;	chr8:26339117	chr8:26379259~26382953:-
LAML	cis	rs748404	0.578	rs552701	ENSG00000249839.1	AC011330.5	-5.33	1.09e-06	0.00349	-0.59	-0.53	Lung cancer;	chr15:43321612	chr15:43663654~43684339:-
LAML	cis	rs3758911	0.861	rs10890688	ENSG00000261098.1	RP11-819C21.1	-5.33	1.1e-06	0.00349	-0.52	-0.53	Coronary artery disease;	chr11:107272020	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs1388170	ENSG00000261098.1	RP11-819C21.1	-5.33	1.1e-06	0.00349	-0.52	-0.53	Coronary artery disease;	chr11:107272130	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs1388171	ENSG00000261098.1	RP11-819C21.1	-5.33	1.1e-06	0.00349	-0.52	-0.53	Coronary artery disease;	chr11:107272411	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs11212112	ENSG00000261098.1	RP11-819C21.1	-5.33	1.1e-06	0.00349	-0.52	-0.53	Coronary artery disease;	chr11:107272667	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs11212113	ENSG00000261098.1	RP11-819C21.1	-5.33	1.1e-06	0.00349	-0.52	-0.53	Coronary artery disease;	chr11:107272776	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs11212114	ENSG00000261098.1	RP11-819C21.1	5.33	1.1e-06	0.00349	0.52	0.53	Coronary artery disease;	chr11:107274940	chr11:107312132~107316271:-
LAML	cis	rs13113518	0.729	rs13120134	ENSG00000249700.7	SRD5A3-AS1	5.33	1.1e-06	0.00349	0.57	0.53	Height;	chr4:55415153	chr4:55363971~55395847:-
LAML	cis	rs904251	0.523	rs10807184	ENSG00000204110.6	RP1-153P14.8	-5.32	1.1e-06	0.0035	-0.58	-0.53	Cognitive performance;	chr6:37515937	chr6:37507348~37535616:+
LAML	cis	rs904251	0.561	rs1757189	ENSG00000204110.6	RP1-153P14.8	-5.32	1.1e-06	0.0035	-0.58	-0.53	Cognitive performance;	chr6:37515951	chr6:37507348~37535616:+
LAML	cis	rs763121	0.853	rs1043441	ENSG00000230912.1	RP3-508I15.10	-5.32	1.1e-06	0.0035	-0.47	-0.53	Menopause (age at onset);	chr22:38734959	chr22:38666508~38668750:-
LAML	cis	rs11623869	0.772	rs12587310	ENSG00000258851.1	RP11-894P9.2	5.32	1.1e-06	0.0035	0.65	0.53	Bone mineral density;	chr14:103440949	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs62007718	ENSG00000258851.1	RP11-894P9.2	-5.32	1.1e-06	0.0035	-0.65	-0.53	Body mass index;	chr14:103474099	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs62007719	ENSG00000258851.1	RP11-894P9.2	-5.32	1.1e-06	0.0035	-0.65	-0.53	Body mass index;	chr14:103476793	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs11628213	ENSG00000258851.1	RP11-894P9.2	-5.32	1.1e-06	0.0035	-0.65	-0.53	Body mass index;	chr14:103486116	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs17617941	ENSG00000258851.1	RP11-894P9.2	-5.32	1.1e-06	0.0035	-0.65	-0.53	Body mass index;	chr14:103486695	chr14:103553421~103561877:+
LAML	cis	rs4713118	0.868	rs7756968	ENSG00000182477.5	OR2B8P	5.32	1.1e-06	0.0035	0.73	0.53	Parkinson's disease;	chr6:27767175	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.868	rs9468220	ENSG00000182477.5	OR2B8P	-5.32	1.1e-06	0.0035	-0.73	-0.53	Parkinson's disease;	chr6:27765197	chr6:28053228~28054165:-
LAML	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	5.32	1.1e-06	0.00351	0.59	0.53	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
LAML	cis	rs9368481	0.761	rs7775041	ENSG00000241549.7	GUSBP2	-5.32	1.11e-06	0.00352	-0.56	-0.53	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26871484~26956554:-
LAML	cis	rs73219805	0.597	rs71517887	ENSG00000228451.3	SDAD1P1	-5.32	1.12e-06	0.00356	-0.7	-0.53	Schizophrenia;	chr8:26374081	chr8:26379259~26382953:-
LAML	cis	rs73219805	0.759	rs3758098	ENSG00000228451.3	SDAD1P1	-5.32	1.12e-06	0.00356	-0.7	-0.53	Schizophrenia;	chr8:26381867	chr8:26379259~26382953:-
LAML	cis	rs73219805	0.759	rs3808578	ENSG00000228451.3	SDAD1P1	-5.32	1.12e-06	0.00356	-0.7	-0.53	Schizophrenia;	chr8:26393906	chr8:26379259~26382953:-
LAML	cis	rs5769707	0.681	rs135879	ENSG00000212939.2	RP1-29C18.10	-5.32	1.12e-06	0.00356	-0.73	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.642	rs135880	ENSG00000212939.2	RP1-29C18.10	-5.32	1.12e-06	0.00356	-0.73	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49548681~49556473:+
LAML	cis	rs2015599	0.549	rs10771512	ENSG00000274315.1	RP11-996F15.5	5.32	1.12e-06	0.00356	0.51	0.53	Platelet count;Mean platelet volume;	chr12:29287303	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.549	rs9738165	ENSG00000274315.1	RP11-996F15.5	5.32	1.12e-06	0.00356	0.51	0.53	Platelet count;Mean platelet volume;	chr12:29290263	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.507	rs3782507	ENSG00000274315.1	RP11-996F15.5	5.32	1.12e-06	0.00356	0.51	0.53	QT interval;	chr12:29292597	chr12:29331434~29331936:-
LAML	cis	rs9426935	0.715	rs3791186	ENSG00000273026.1	RP11-422P24.10	-5.32	1.13e-06	0.00357	-0.69	-0.53	Lentiform nucleus volume;	chr1:153961827	chr1:153966516~153966930:+
LAML	cis	rs62070183	0.766	rs62067160	ENSG00000201178.1	Y_RNA	5.32	1.13e-06	0.00357	0.78	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32919567	chr17:32830219~32830329:-
LAML	cis	rs3758911	0.796	rs112617433	ENSG00000261098.1	RP11-819C21.1	-5.32	1.13e-06	0.00357	-0.52	-0.53	Coronary artery disease;	chr11:107282855	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs7929343	ENSG00000261098.1	RP11-819C21.1	-5.32	1.13e-06	0.00357	-0.52	-0.53	Coronary artery disease;	chr11:107285183	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs7929345	ENSG00000261098.1	RP11-819C21.1	-5.32	1.13e-06	0.00357	-0.52	-0.53	Coronary artery disease;	chr11:107285185	chr11:107312132~107316271:-
LAML	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	5.32	1.13e-06	0.00357	0.78	0.53	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
LAML	cis	rs9399135	0.967	rs4451151	ENSG00000232876.1	CTA-212D2.2	-5.32	1.13e-06	0.00358	-0.7	-0.53	Red blood cell count;	chr6:134989408	chr6:135055033~135060550:+
LAML	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-5.32	1.13e-06	0.00358	-1.12	-0.53	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
LAML	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	5.32	1.13e-06	0.00358	0.77	0.53	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
LAML	cis	rs62070183	0.656	rs17780664	ENSG00000264458.1	RP11-220C2.1	5.32	1.14e-06	0.0036	0.78	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32675720	chr17:32627739~32686484:+
LAML	cis	rs5769707	0.521	rs6009810	ENSG00000279597.1	RP4-566L20.1	-5.31	1.14e-06	0.00362	-0.66	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49665892	chr22:49534062~49534926:+
LAML	cis	rs2120335	0.893	rs58916116	ENSG00000221443.1	AC017083.1	5.31	1.14e-06	0.00362	0.64	0.53	Height;	chr2:68235546	chr2:68273104~68273206:+
LAML	cis	rs965604	0.965	rs4299116	ENSG00000259474.1	RP11-650L12.1	-5.31	1.15e-06	0.00362	-0.52	-0.53	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78473852	chr15:78480057~78481820:-
LAML	cis	rs965604	1	rs8043227	ENSG00000259474.1	RP11-650L12.1	-5.31	1.15e-06	0.00362	-0.52	-0.53	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78476529	chr15:78480057~78481820:-
LAML	cis	rs965604	1	rs12916801	ENSG00000259474.1	RP11-650L12.1	-5.31	1.15e-06	0.00362	-0.52	-0.53	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78476788	chr15:78480057~78481820:-
LAML	cis	rs965604	0.965	rs36146269	ENSG00000259474.1	RP11-650L12.1	-5.31	1.15e-06	0.00362	-0.52	-0.53	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78487168	chr15:78480057~78481820:-
LAML	cis	rs4887059	1	rs4887059	ENSG00000259474.1	RP11-650L12.1	-5.31	1.15e-06	0.00362	-0.52	-0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78489753	chr15:78480057~78481820:-
LAML	cis	rs965604	1	rs965604	ENSG00000259474.1	RP11-650L12.1	-5.31	1.15e-06	0.00362	-0.52	-0.53	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78496881	chr15:78480057~78481820:-
LAML	cis	rs965604	0.965	rs13180	ENSG00000259474.1	RP11-650L12.1	-5.31	1.15e-06	0.00362	-0.52	-0.53	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78497146	chr15:78480057~78481820:-
LAML	cis	rs965604	0.965	rs12899351	ENSG00000259474.1	RP11-650L12.1	-5.31	1.15e-06	0.00362	-0.52	-0.53	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78500056	chr15:78480057~78481820:-
LAML	cis	rs12594711	1	rs12594711	ENSG00000259474.1	RP11-650L12.1	-5.31	1.15e-06	0.00362	-0.52	-0.53	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr15:78501579	chr15:78480057~78481820:-
LAML	cis	rs965604	1	rs4362358	ENSG00000259474.1	RP11-650L12.1	-5.31	1.15e-06	0.00362	-0.52	-0.53	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78503762	chr15:78480057~78481820:-
LAML	cis	rs763121	0.853	rs138702	ENSG00000230912.1	RP3-508I15.10	5.31	1.15e-06	0.00363	0.46	0.53	Menopause (age at onset);	chr22:38736596	chr22:38666508~38668750:-
LAML	cis	rs3091242	0.9	rs1883427	ENSG00000224183.1	SDHDP6	-5.31	1.15e-06	0.00364	-0.64	-0.53	Erythrocyte sedimentation rate;	chr1:25417977	chr1:25294164~25294643:-
LAML	cis	rs4591358	0.592	rs57856685	ENSG00000223466.1	AC064834.2	-5.31	1.16e-06	0.00365	-0.86	-0.53	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195565401	chr2:195533035~195538681:+
LAML	cis	rs853679	1	rs2799079	ENSG00000182477.5	OR2B8P	5.31	1.16e-06	0.00366	0.77	0.53	Depression;	chr6:28267398	chr6:28053228~28054165:-
LAML	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-5.31	1.17e-06	0.00368	-0.75	-0.53	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs9371544	ENSG00000216906.2	RP11-350J20.9	5.31	1.17e-06	0.00368	0.76	0.53	Testicular germ cell tumor;	chr6:149896224	chr6:149904243~149906418:+
LAML	cis	rs763121	0.853	rs5757211	ENSG00000230912.1	RP3-508I15.10	-5.31	1.17e-06	0.00368	-0.46	-0.53	Menopause (age at onset);	chr22:38655700	chr22:38666508~38668750:-
LAML	cis	rs17780086	0.527	rs72827712	ENSG00000266379.5	RP11-640N20.8	5.31	1.17e-06	0.00369	0.95	0.53	Height;	chr17:32211581	chr17:32088160~32094933:-
LAML	cis	rs1757171	0.534	rs2797793	ENSG00000227920.2	RP1-153P14.5	5.31	1.17e-06	0.00369	0.67	0.53	Cognitive performance;	chr6:37509486	chr6:37545145~37550860:+
LAML	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-5.31	1.17e-06	0.00369	-0.7	-0.53	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
LAML	cis	rs561341	0.769	rs12941700	ENSG00000266379.5	RP11-640N20.8	-5.31	1.17e-06	0.0037	-1	-0.53	Hip circumference adjusted for BMI;	chr17:31858003	chr17:32088160~32094933:-
LAML	cis	rs561341	0.769	rs9899093	ENSG00000266379.5	RP11-640N20.8	5.31	1.17e-06	0.0037	1	0.53	Hip circumference adjusted for BMI;	chr17:31864935	chr17:32088160~32094933:-
LAML	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-5.31	1.17e-06	0.0037	-0.96	-0.53	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs7950364	ENSG00000254851.1	RP11-109L13.1	-5.31	1.17e-06	0.0037	-0.96	-0.53	Blood protein levels;	chr11:117028170	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-5.31	1.17e-06	0.0037	-0.96	-0.53	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-5.31	1.17e-06	0.0037	-0.96	-0.53	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs10790172	ENSG00000254851.1	RP11-109L13.1	-5.31	1.17e-06	0.0037	-0.96	-0.53	Blood protein levels;	chr11:117057024	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-5.31	1.17e-06	0.0037	-0.96	-0.53	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
LAML	cis	rs6782228	1	rs6775011	ENSG00000277250.1	Metazoa_SRP	5.31	1.17e-06	0.0037	0.79	0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128673681~128674021:-
LAML	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	5.31	1.18e-06	0.0037	0.52	0.53	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
LAML	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	5.31	1.18e-06	0.00371	0.69	0.53	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
LAML	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-5.3	1.19e-06	0.00372	-0.56	-0.53	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
LAML	cis	rs7746199	0.736	rs17693963	ENSG00000187763.3	OR2B7P	5.3	1.19e-06	0.00373	0.95	0.53	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28046434~28047367:+
LAML	cis	rs1075265	0.783	rs6545376	ENSG00000235937.1	AC008280.1	5.3	1.2e-06	0.00374	0.44	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54029552~54030682:-
LAML	cis	rs62070183	0.938	rs75393526	ENSG00000201178.1	Y_RNA	5.3	1.2e-06	0.00374	0.77	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32708000	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs75822124	ENSG00000201178.1	Y_RNA	5.3	1.2e-06	0.00374	0.77	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32710876	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs17183176	ENSG00000201178.1	Y_RNA	5.3	1.2e-06	0.00374	0.77	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32727107	chr17:32830219~32830329:-
LAML	cis	rs62070183	0.938	rs1990825	ENSG00000201178.1	Y_RNA	5.3	1.2e-06	0.00374	0.77	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32729274	chr17:32830219~32830329:-
LAML	cis	rs1555322	0.505	rs639763	ENSG00000261582.1	RP4-614O4.11	-5.3	1.2e-06	0.00375	-0.61	-0.53	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35267885~35280043:-
LAML	cis	rs1757171	0.542	rs3818985	ENSG00000204110.6	RP1-153P14.8	-5.3	1.2e-06	0.00375	-0.58	-0.53	Cognitive performance;	chr6:37516438	chr6:37507348~37535616:+
LAML	cis	rs2581828	1	rs2581828	ENSG00000280417.1	RP11-5O17.1	5.3	1.2e-06	0.00375	0.67	0.53	Crohn's disease;	chr3:53099133	chr3:53046166~53048122:+
LAML	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-5.3	1.21e-06	0.00377	-0.65	-0.53	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
LAML	cis	rs7189233	0.531	rs17801498	ENSG00000279344.1	RP11-44F14.7	5.3	1.21e-06	0.00377	0.38	0.53	Intelligence (multi-trait analysis);	chr16:53479540	chr16:53478957~53481550:-
LAML	cis	rs6951245	0.832	rs10266519	ENSG00000229043.2	AC091729.9	-5.3	1.21e-06	0.00377	-0.79	-0.53	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1103341	chr7:1160374~1165267:+
LAML	cis	rs5769707	0.706	rs763128	ENSG00000212939.2	RP1-29C18.10	-5.3	1.21e-06	0.00377	-0.72	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49548681~49556473:+
LAML	cis	rs2486288	0.656	rs11637838	ENSG00000259520.4	CTD-2651B20.3	5.3	1.21e-06	0.00377	0.78	0.53	Glomerular filtration rate;	chr15:45258459	chr15:45251580~45279251:-
LAML	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-5.3	1.21e-06	0.00378	-0.65	-0.53	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
LAML	cis	rs904251	0.523	rs9369005	ENSG00000204110.6	RP1-153P14.8	-5.3	1.21e-06	0.00379	-0.58	-0.53	Cognitive performance;	chr6:37515333	chr6:37507348~37535616:+
LAML	cis	rs11155671	0.53	rs7742993	ENSG00000216906.2	RP11-350J20.9	5.3	1.21e-06	0.00379	0.77	0.53	Testicular germ cell tumor;	chr6:149883959	chr6:149904243~149906418:+
LAML	cis	rs1075265	0.756	rs3821081	ENSG00000235937.1	AC008280.1	-5.3	1.22e-06	0.00379	-0.43	-0.53	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54029552~54030682:-
LAML	cis	rs2120335	0.822	rs62145926	ENSG00000221443.1	AC017083.1	5.3	1.22e-06	0.00379	0.64	0.53	Height;	chr2:68128079	chr2:68273104~68273206:+
LAML	cis	rs875971	0.522	rs1701760	ENSG00000224316.1	RP11-479O9.2	5.3	1.22e-06	0.0038	0.57	0.53	Aortic root size;	chr7:66008701	chr7:65773620~65802067:+
LAML	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	5.3	1.22e-06	0.0038	0.63	0.53	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
LAML	cis	rs1075265	0.722	rs805374	ENSG00000235937.1	AC008280.1	5.3	1.23e-06	0.00384	0.42	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53862720	chr2:54029552~54030682:-
LAML	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-5.3	1.23e-06	0.00384	-0.66	-0.53	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	5.3	1.23e-06	0.00384	0.66	0.53	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
LAML	cis	rs7829975	0.522	rs6601689	ENSG00000268955.2	RP11-556O5.6	-5.29	1.24e-06	0.00387	-0.61	-0.53	Mood instability;	chr8:8314761	chr8:8188535~8189195:-
LAML	cis	rs73225423	0.85	rs79821194	ENSG00000275389.1	RP11-214K3.24	-5.29	1.24e-06	0.00387	-0.9	-0.53	Mosquito bite size;	chr12:124437191	chr12:124085761~124088598:+
LAML	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-5.29	1.24e-06	0.00388	-0.65	-0.53	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
LAML	cis	rs62070183	0.938	rs62068432	ENSG00000279781.1	RP11-466A19.7	5.29	1.25e-06	0.00388	0.78	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32739479	chr17:32518322~32518934:-
LAML	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-5.29	1.25e-06	0.00388	-0.69	-0.53	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
LAML	cis	rs763121	0.925	rs5750654	ENSG00000230912.1	RP3-508I15.10	-5.29	1.25e-06	0.00389	-0.44	-0.53	Menopause (age at onset);	chr22:38655423	chr22:38666508~38668750:-
LAML	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-5.29	1.25e-06	0.00389	-0.58	-0.53	Height;	chr3:52819385	chr3:53064283~53065091:-
LAML	cis	rs2120335	1	rs2120332	ENSG00000221443.1	AC017083.1	5.29	1.25e-06	0.0039	0.64	0.53	Height;	chr2:68235460	chr2:68273104~68273206:+
LAML	cis	rs10829156	0.699	rs10828879	ENSG00000240291.1	RP11-499P20.2	5.29	1.26e-06	0.00391	0.64	0.53	Sudden cardiac arrest;	chr10:18546425	chr10:18513115~18545651:-
LAML	cis	rs1075265	0.811	rs805322	ENSG00000235937.1	AC008280.1	-5.29	1.26e-06	0.00392	-0.43	-0.53	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54029552~54030682:-
LAML	cis	rs12052801	0.868	rs4671874	ENSG00000221443.1	AC017083.1	5.29	1.26e-06	0.00392	0.61	0.53	Schizophrenia;	chr2:68128508	chr2:68273104~68273206:+
LAML	cis	rs8081395	0.801	rs2665405	ENSG00000267302.4	RP11-178C3.2	-5.29	1.27e-06	0.00394	-0.65	-0.53	White blood cell count;	chr17:59797931	chr17:59964832~59996972:+
LAML	cis	rs1555322	0.53	rs2425044	ENSG00000261582.1	RP4-614O4.11	-5.29	1.28e-06	0.00396	-0.64	-0.53	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35267885~35280043:-
LAML	cis	rs1555322	0.53	rs2275275	ENSG00000261582.1	RP4-614O4.11	-5.29	1.28e-06	0.00396	-0.64	-0.53	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35267885~35280043:-
LAML	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-5.29	1.28e-06	0.00396	-0.74	-0.53	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
LAML	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-5.28	1.29e-06	0.00399	-0.59	-0.53	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	5.28	1.29e-06	0.00399	0.59	0.53	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
LAML	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-5.28	1.29e-06	0.00399	-0.64	-0.53	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
LAML	cis	rs9399135	0.967	rs6910530	ENSG00000232876.1	CTA-212D2.2	-5.28	1.29e-06	0.004	-0.68	-0.53	Red blood cell count;	chr6:135011632	chr6:135055033~135060550:+
LAML	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-5.28	1.29e-06	0.004	-0.66	-0.53	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-5.28	1.29e-06	0.004	-0.66	-0.53	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-5.28	1.29e-06	0.004	-0.66	-0.53	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
LAML	cis	rs9322193	0.567	rs7747457	ENSG00000216906.2	RP11-350J20.9	5.28	1.3e-06	0.00402	0.75	0.53	Lung cancer;	chr6:149892366	chr6:149904243~149906418:+
LAML	cis	rs12220777	1	rs118110670	ENSG00000230091.5	TMEM254-AS1	5.28	1.3e-06	0.00402	1.22	0.53	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80032486	chr10:80046860~80078912:-
LAML	cis	rs13113518	0.557	rs13142096	ENSG00000249700.7	SRD5A3-AS1	5.28	1.3e-06	0.00402	0.57	0.53	Height;	chr4:55566291	chr4:55363971~55395847:-
LAML	cis	rs992157	0.932	rs10194082	ENSG00000261338.2	RP11-378A13.1	5.28	1.3e-06	0.00403	0.69	0.53	Colorectal cancer;	chr2:218323854	chr2:218255319~218257366:+
LAML	cis	rs992157	0.932	rs1473901	ENSG00000261338.2	RP11-378A13.1	5.28	1.3e-06	0.00403	0.69	0.53	Colorectal cancer;	chr2:218324115	chr2:218255319~218257366:+
LAML	cis	rs9368481	0.743	rs9368480	ENSG00000243307.2	POM121L6P	5.28	1.3e-06	0.00403	0.65	0.53	Autism spectrum disorder or schizophrenia;	chr6:26987971	chr6:26896952~26898777:+
LAML	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-5.28	1.3e-06	0.00403	-0.74	-0.53	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
LAML	cis	rs1789	0.706	rs7696938	ENSG00000249930.1	AC007016.3	5.28	1.3e-06	0.00403	0.72	0.53	Blood protein levels;	chr4:15701954	chr4:15492729~15492972:-
LAML	cis	rs13201294	1	rs13201294	ENSG00000182477.5	OR2B8P	5.28	1.3e-06	0.00404	0.88	0.53	Squamous cell lung carcinoma;	chr6:27588362	chr6:28053228~28054165:-
LAML	cis	rs2564921	0.513	rs12638195	ENSG00000242142.1	SERBP1P3	-5.28	1.31e-06	0.00405	-0.59	-0.53	Height;	chr3:52842623	chr3:53064283~53065091:-
LAML	cis	rs2120335	0.928	rs17589929	ENSG00000221443.1	AC017083.1	5.28	1.31e-06	0.00405	0.63	0.53	Height;	chr2:68152015	chr2:68273104~68273206:+
LAML	cis	rs853679	0.546	rs200949	ENSG00000220721.1	OR1F12	5.28	1.31e-06	0.00405	0.71	0.53	Depression;	chr6:27867657	chr6:28073316~28074233:+
LAML	cis	rs11155671	0.53	rs4458704	ENSG00000216906.2	RP11-350J20.9	5.28	1.31e-06	0.00405	0.71	0.53	Testicular germ cell tumor;	chr6:149911743	chr6:149904243~149906418:+
LAML	cis	rs1075265	0.783	rs805424	ENSG00000235937.1	AC008280.1	5.28	1.31e-06	0.00405	0.42	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54029552~54030682:-
LAML	cis	rs904251	0.6	rs4714068	ENSG00000204110.6	RP1-153P14.8	-5.28	1.31e-06	0.00405	-0.56	-0.53	Cognitive performance;	chr6:37487866	chr6:37507348~37535616:+
LAML	cis	rs2564921	0.765	rs2581799	ENSG00000280417.1	RP11-5O17.1	-5.28	1.32e-06	0.00407	-0.67	-0.53	Height;	chr3:53074760	chr3:53046166~53048122:+
LAML	cis	rs904251	0.523	rs12202055	ENSG00000204110.6	RP1-153P14.8	-5.28	1.32e-06	0.00408	-0.57	-0.53	Cognitive performance;	chr6:37518304	chr6:37507348~37535616:+
LAML	cis	rs5760092	0.572	rs738806	ENSG00000225282.1	AP000350.6	5.28	1.33e-06	0.00411	0.78	0.53	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23926900~23929574:+
LAML	cis	rs763121	0.853	rs7289855	ENSG00000230912.1	RP3-508I15.10	-5.28	1.33e-06	0.00411	-0.45	-0.53	Menopause (age at onset);	chr22:38646216	chr22:38666508~38668750:-
LAML	cis	rs9322193	0.923	rs4869750	ENSG00000216906.2	RP11-350J20.9	5.28	1.33e-06	0.00411	0.76	0.53	Lung cancer;	chr6:149855996	chr6:149904243~149906418:+
LAML	cis	rs11903757	1	rs78345298	ENSG00000281467.1	Clostridiales-1	-5.28	1.34e-06	0.00412	-1.07	-0.53	Colorectal cancer;	chr2:191700286	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs77127860	ENSG00000281467.1	Clostridiales-1	-5.28	1.34e-06	0.00412	-1.07	-0.53	Colorectal cancer;	chr2:191700674	chr2:191699476~191699631:-
LAML	cis	rs62070183	0.532	rs78021166	ENSG00000264458.1	RP11-220C2.1	5.27	1.34e-06	0.00414	0.86	0.53	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32648513	chr17:32627739~32686484:+
LAML	cis	rs1075265	0.587	rs2542585	ENSG00000235937.1	AC008280.1	5.27	1.35e-06	0.00417	0.42	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53786407	chr2:54029552~54030682:-
LAML	cis	rs1555322	0.53	rs6060347	ENSG00000261582.1	RP4-614O4.11	-5.27	1.36e-06	0.00417	-0.64	-0.53	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35267885~35280043:-
LAML	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-5.27	1.36e-06	0.0042	-0.63	-0.53	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
LAML	cis	rs367615	0.512	rs414724	ENSG00000249476.1	CTD-2587M2.1	5.27	1.37e-06	0.0042	0.66	0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109334720	chr5:109237120~109326369:-
LAML	cis	rs1577917	0.958	rs6454487	ENSG00000203875.9	SNHG5	5.27	1.37e-06	0.00422	0.7	0.53	Response to antipsychotic treatment;	chr6:85737150	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-5.27	1.37e-06	0.00422	-0.7	-0.53	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-5.27	1.37e-06	0.00422	-0.7	-0.53	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-5.27	1.37e-06	0.00422	-0.7	-0.53	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-5.27	1.37e-06	0.00422	-0.7	-0.53	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-5.27	1.37e-06	0.00422	-0.7	-0.53	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
LAML	cis	rs9322193	0.962	rs2065664	ENSG00000216906.2	RP11-350J20.9	5.27	1.37e-06	0.00422	0.74	0.53	Lung cancer;	chr6:149762485	chr6:149904243~149906418:+
LAML	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-5.27	1.37e-06	0.00422	-0.76	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
LAML	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-5.27	1.38e-06	0.00424	-0.64	-0.53	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
LAML	cis	rs12477438	0.501	rs11123770	ENSG00000231822.1	AC019097.7	5.27	1.38e-06	0.00424	0.66	0.53	Chronic sinus infection;	chr2:99208639	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs13031919	ENSG00000231822.1	AC019097.7	5.27	1.38e-06	0.00424	0.66	0.53	Chronic sinus infection;	chr2:99232469	chr2:99102018~99102752:+
LAML	cis	rs6782228	1	rs12495411	ENSG00000277250.1	Metazoa_SRP	5.27	1.39e-06	0.00426	0.77	0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128673681~128674021:-
LAML	cis	rs12468226	0.873	rs1474267	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202178596	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.817	rs6722588	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202187163	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs2350358	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202199771	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs3181153	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202205155	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.679	rs6435133	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202209237	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.817	rs12693965	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202210188	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs3769817	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202214584	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs6435134	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202214857	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.817	rs6435135	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202217469	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs6435138	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202234310	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs6761131	ENSG00000272966.1	RP11-686O6.1	-5.27	1.39e-06	0.00426	-0.86	-0.53	Urate levels;	chr2:202237675	chr2:202336739~202337200:+
LAML	cis	rs2980439	0.607	rs2980419	ENSG00000268955.2	RP11-556O5.6	-5.27	1.39e-06	0.00426	-0.63	-0.53	Neuroticism;	chr8:8256619	chr8:8188535~8189195:-
LAML	cis	rs875971	0.522	rs9530	ENSG00000224316.1	RP11-479O9.2	5.26	1.39e-06	0.00426	0.57	0.53	Aortic root size;	chr7:65960907	chr7:65773620~65802067:+
LAML	cis	rs11903757	1	rs80113293	ENSG00000281467.1	Clostridiales-1	-5.26	1.39e-06	0.00426	-1.06	-0.53	Colorectal cancer;	chr2:191703011	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs12464838	ENSG00000281467.1	Clostridiales-1	-5.26	1.39e-06	0.00426	-1.06	-0.53	Colorectal cancer;	chr2:191703186	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs12469001	ENSG00000281467.1	Clostridiales-1	-5.26	1.39e-06	0.00426	-1.06	-0.53	Colorectal cancer;	chr2:191703205	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs11888351	ENSG00000281467.1	Clostridiales-1	-5.26	1.39e-06	0.00426	-1.06	-0.53	Colorectal cancer;	chr2:191704936	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs75226604	ENSG00000281467.1	Clostridiales-1	-5.26	1.39e-06	0.00426	-1.06	-0.53	Colorectal cancer;	chr2:191709807	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs4425034	ENSG00000281467.1	Clostridiales-1	-5.26	1.39e-06	0.00426	-1.06	-0.53	Colorectal cancer;	chr2:191715885	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs10202549	ENSG00000281467.1	Clostridiales-1	-5.26	1.39e-06	0.00426	-1.06	-0.53	Colorectal cancer;	chr2:191720289	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs13416906	ENSG00000281467.1	Clostridiales-1	-5.26	1.39e-06	0.00426	-1.06	-0.53	Colorectal cancer;	chr2:191722103	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs11903675	ENSG00000281467.1	Clostridiales-1	-5.26	1.39e-06	0.00426	-1.06	-0.53	Colorectal cancer;	chr2:191722329	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs11903757	ENSG00000281467.1	Clostridiales-1	-5.26	1.39e-06	0.00426	-1.06	-0.53	Colorectal cancer;	chr2:191722478	chr2:191699476~191699631:-
LAML	cis	rs3758911	0.861	rs10789593	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107286154	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.828	rs10890695	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107294923	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs11212142	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107302994	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs10789597	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107304314	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs12285607	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107304608	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs10890696	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107306487	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.828	rs10890697	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107307915	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.894	rs10890698	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107308080	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.929	rs10890700	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107308243	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs10789599	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107309145	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.929	rs10749894	ENSG00000261098.1	RP11-819C21.1	-5.26	1.39e-06	0.00426	-0.52	-0.53	Coronary artery disease;	chr11:107309586	chr11:107312132~107316271:-
LAML	cis	rs853679	0.824	rs34712084	ENSG00000182477.5	OR2B8P	5.26	1.4e-06	0.00427	0.95	0.53	Depression;	chr6:28076050	chr6:28053228~28054165:-
LAML	cis	rs853679	0.824	rs1321505	ENSG00000182477.5	OR2B8P	5.26	1.4e-06	0.00427	0.95	0.53	Depression;	chr6:28085045	chr6:28053228~28054165:-
LAML	cis	rs7944735	0.517	rs11039538	ENSG00000263693.1	MIR3161	5.26	1.4e-06	0.00428	0.52	0.53	Intraocular pressure;	chr11:48133438	chr11:48096782~48096858:+
LAML	cis	rs853679	0.556	rs13200214	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Depression;	chr6:28049472	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs71559070	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Depression;	chr6:28071151	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs35902873	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Depression;	chr6:28091171	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13197574	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Depression;	chr6:28092461	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs34166054	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Depression;	chr6:28098023	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs34662244	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Depression;	chr6:28106103	chr6:28046434~28047367:+
LAML	cis	rs35952432	1	rs35952432	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Lung cancer;	chr6:28107123	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13203816	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Depression;	chr6:28111820	chr6:28046434~28047367:+
LAML	cis	rs853679	0.556	rs34588114	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Depression;	chr6:28112850	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs68188794	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Depression;	chr6:28112999	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs34371502	ENSG00000187763.3	OR2B7P	5.26	1.41e-06	0.00429	0.98	0.53	Depression;	chr6:28113980	chr6:28046434~28047367:+
LAML	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	5.26	1.41e-06	0.0043	0.71	0.53	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
LAML	cis	rs763121	0.853	rs138716	ENSG00000230912.1	RP3-508I15.10	-5.26	1.41e-06	0.0043	-0.47	-0.53	Menopause (age at onset);	chr22:38750522	chr22:38666508~38668750:-
LAML	cis	rs67340775	0.541	rs200973	ENSG00000220721.1	OR1F12	5.26	1.41e-06	0.00431	0.64	0.53	Lung cancer in ever smokers;	chr6:27890643	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.826	rs2893929	ENSG00000182477.5	OR2B8P	5.26	1.41e-06	0.00431	0.73	0.53	Parkinson's disease;	chr6:27770953	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.666	rs4140646	ENSG00000182477.5	OR2B8P	5.26	1.41e-06	0.00431	0.73	0.53	Parkinson's disease;	chr6:27771022	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.666	rs2893930	ENSG00000182477.5	OR2B8P	5.26	1.41e-06	0.00431	0.73	0.53	Parkinson's disease;	chr6:27771027	chr6:28053228~28054165:-
LAML	cis	rs2015599	0.549	rs10771512	ENSG00000275476.1	RP11-996F15.4	5.26	1.43e-06	0.00434	0.56	0.53	Platelet count;Mean platelet volume;	chr12:29287303	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.549	rs9738165	ENSG00000275476.1	RP11-996F15.4	5.26	1.43e-06	0.00434	0.56	0.53	Platelet count;Mean platelet volume;	chr12:29290263	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.507	rs3782507	ENSG00000275476.1	RP11-996F15.4	5.26	1.43e-06	0.00434	0.56	0.53	QT interval;	chr12:29292597	chr12:29277397~29277882:-
LAML	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs2887965	ENSG00000223797.4	ENTPD3-AS1	-5.26	1.43e-06	0.00436	-0.66	-0.53	Renal cell carcinoma;	chr3:40292663	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs9814779	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40298940	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs9821440	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40300856	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs13098483	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40301252	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs9864601	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40303827	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs9868700	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40303917	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs2278930	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40309601	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs1454492	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40311393	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs9833640	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40313450	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs6762121	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40313822	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs6787516	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40314125	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.524	rs7649168	ENSG00000223797.4	ENTPD3-AS1	5.26	1.43e-06	0.00436	0.66	0.53	Renal cell carcinoma;	chr3:40314667	chr3:40313802~40453329:-
LAML	cis	rs748404	0.578	rs576557	ENSG00000249839.1	AC011330.5	-5.26	1.44e-06	0.00436	-0.58	-0.53	Lung cancer;	chr15:43305539	chr15:43663654~43684339:-
LAML	cis	rs748404	0.578	rs510108	ENSG00000249839.1	AC011330.5	-5.26	1.44e-06	0.00436	-0.58	-0.53	Lung cancer;	chr15:43313241	chr15:43663654~43684339:-
LAML	cis	rs748404	0.578	rs507178	ENSG00000249839.1	AC011330.5	-5.26	1.44e-06	0.00436	-0.58	-0.53	Lung cancer;	chr15:43317937	chr15:43663654~43684339:-
LAML	cis	rs748404	0.578	rs478028	ENSG00000249839.1	AC011330.5	-5.26	1.44e-06	0.00436	-0.58	-0.53	Lung cancer;	chr15:43318574	chr15:43663654~43684339:-
LAML	cis	rs748404	0.578	rs573615	ENSG00000249839.1	AC011330.5	-5.26	1.44e-06	0.00436	-0.58	-0.53	Lung cancer;	chr15:43322083	chr15:43663654~43684339:-
LAML	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-5.26	1.44e-06	0.00437	-0.7	-0.53	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
LAML	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-5.26	1.44e-06	0.00437	-0.63	-0.53	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
LAML	cis	rs55794721	0.509	rs2982358	ENSG00000224183.1	SDHDP6	-5.26	1.44e-06	0.00437	-0.63	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25418713	chr1:25294164~25294643:-
LAML	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-5.26	1.44e-06	0.00437	-0.63	-0.53	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-5.26	1.44e-06	0.00437	-0.63	-0.53	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-5.26	1.44e-06	0.00437	-0.63	-0.53	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
LAML	cis	rs66887589	0.87	rs59590064	ENSG00000248280.1	RP11-33B1.2	-5.26	1.44e-06	0.00437	-0.64	-0.53	Diastolic blood pressure;	chr4:119618598	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.934	rs6817317	ENSG00000248280.1	RP11-33B1.2	-5.26	1.44e-06	0.00437	-0.64	-0.53	Diastolic blood pressure;	chr4:119621672	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.934	rs7672519	ENSG00000248280.1	RP11-33B1.2	-5.26	1.44e-06	0.00437	-0.64	-0.53	Diastolic blood pressure;	chr4:119622957	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.934	rs2389873	ENSG00000248280.1	RP11-33B1.2	-5.26	1.44e-06	0.00437	-0.64	-0.53	Diastolic blood pressure;	chr4:119633559	chr4:119440561~119450157:-
LAML	cis	rs66887589	0.934	rs4834792	ENSG00000248280.1	RP11-33B1.2	-5.26	1.44e-06	0.00437	-0.64	-0.53	Diastolic blood pressure;	chr4:119634541	chr4:119440561~119450157:-
LAML	cis	rs801193	1	rs2659912	ENSG00000224316.1	RP11-479O9.2	5.26	1.44e-06	0.00438	0.55	0.53	Aortic root size;	chr7:66693012	chr7:65773620~65802067:+
LAML	cis	rs2581828	0.608	rs9868263	ENSG00000242142.1	SERBP1P3	-5.26	1.45e-06	0.00439	-0.61	-0.53	Crohn's disease;	chr3:53130078	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.618	rs9868406	ENSG00000242142.1	SERBP1P3	-5.26	1.45e-06	0.00439	-0.61	-0.53	Crohn's disease;	chr3:53130177	chr3:53064283~53065091:-
LAML	cis	rs2273156	0.57	rs78207779	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35037181	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.501	rs5014384	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35038468	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs4594164	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35040365	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs79888893	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35041470	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.517	rs77803033	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35042646	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.517	rs8007274	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043012	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.706	rs8009093	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043497	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs1028449	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35043789	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs8013540	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35044554	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.57	rs60693825	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35045250	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.587	rs3809449	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35045751	chr14:35144021~35144480:-
LAML	cis	rs2273156	0.587	rs76767804	ENSG00000241052.1	RP11-173D9.1	-5.25	1.45e-06	0.00439	-0.97	-0.53	Immunoglobulin light chain (AL) amyloidosis;	chr14:35050161	chr14:35144021~35144480:-
LAML	cis	rs6565180	0.632	rs8050812	ENSG00000273724.1	RP11-347C12.12	-5.25	1.45e-06	0.00441	-0.62	-0.53	Tonsillectomy;	chr16:30374516	chr16:30336400~30343336:+
LAML	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-5.25	1.46e-06	0.00441	-0.65	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-5.25	1.46e-06	0.00441	-0.65	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
LAML	cis	rs9322193	0.923	rs4242279	ENSG00000216906.2	RP11-350J20.9	5.25	1.47e-06	0.00444	0.76	0.53	Lung cancer;	chr6:149839815	chr6:149904243~149906418:+
LAML	cis	rs2015599	0.549	rs7956305	ENSG00000275476.1	RP11-996F15.4	5.25	1.47e-06	0.00444	0.58	0.53	Platelet count;Mean platelet volume;	chr12:29308639	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.543	rs6487807	ENSG00000275476.1	RP11-996F15.4	5.25	1.47e-06	0.00444	0.58	0.53	Platelet count;Mean platelet volume;	chr12:29309291	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.525	rs10771514	ENSG00000275476.1	RP11-996F15.4	5.25	1.47e-06	0.00444	0.58	0.53	Platelet count;Mean platelet volume;	chr12:29315751	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.525	rs7298031	ENSG00000275476.1	RP11-996F15.4	5.25	1.47e-06	0.00444	0.58	0.53	Platelet count;Mean platelet volume;	chr12:29317333	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.525	rs2016832	ENSG00000275476.1	RP11-996F15.4	5.25	1.47e-06	0.00444	0.58	0.53	Platelet count;Mean platelet volume;	chr12:29318199	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.525	rs7959145	ENSG00000275476.1	RP11-996F15.4	5.25	1.47e-06	0.00444	0.58	0.53	Platelet count;Mean platelet volume;	chr12:29330850	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.525	rs7961943	ENSG00000275476.1	RP11-996F15.4	5.25	1.47e-06	0.00444	0.58	0.53	Platelet count;Mean platelet volume;	chr12:29331146	chr12:29277397~29277882:-
LAML	cis	rs2015599	0.525	rs10743656	ENSG00000275476.1	RP11-996F15.4	5.25	1.47e-06	0.00444	0.58	0.53	Platelet count;Mean platelet volume;	chr12:29332516	chr12:29277397~29277882:-
LAML	cis	rs367615	0.552	rs2963010	ENSG00000249476.1	CTD-2587M2.1	-5.25	1.47e-06	0.00445	-0.66	-0.53	Colorectal cancer (SNP x SNP interaction);	chr5:109401342	chr5:109237120~109326369:-
LAML	cis	rs6940638	0.715	rs9348751	ENSG00000220721.1	OR1F12	5.25	1.47e-06	0.00445	0.55	0.53	Intelligence (multi-trait analysis);	chr6:27099411	chr6:28073316~28074233:+
LAML	cis	rs6940638	0.688	rs6921388	ENSG00000220721.1	OR1F12	5.25	1.47e-06	0.00445	0.55	0.53	Intelligence (multi-trait analysis);	chr6:27112426	chr6:28073316~28074233:+
LAML	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	5.25	1.47e-06	0.00445	0.61	0.53	Depression;	chr6:28301886	chr6:28176188~28176674:+
LAML	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	5.25	1.47e-06	0.00445	0.61	0.53	Depression;	chr6:28303421	chr6:28176188~28176674:+
LAML	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	5.25	1.47e-06	0.00445	0.61	0.53	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
LAML	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	5.25	1.47e-06	0.00445	0.61	0.53	Depression;	chr6:28314871	chr6:28176188~28176674:+
LAML	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	5.25	1.47e-06	0.00445	0.61	0.53	Depression;	chr6:28317705	chr6:28176188~28176674:+
LAML	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	5.25	1.47e-06	0.00445	0.61	0.53	Depression;	chr6:28323463	chr6:28176188~28176674:+
LAML	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	5.25	1.47e-06	0.00445	0.61	0.53	Depression;	chr6:28327262	chr6:28176188~28176674:+
LAML	cis	rs2455601	0.744	rs2163626	ENSG00000254860.4	TMEM9B-AS1	5.25	1.48e-06	0.00446	0.69	0.53	Schizophrenia;	chr11:8962000	chr11:8964675~8977527:+
LAML	cis	rs7587476	0.861	rs17488049	ENSG00000229267.2	AC072062.1	-5.25	1.48e-06	0.00447	-0.68	-0.53	Neuroblastoma;	chr2:214787026	chr2:214810229~214963274:+
LAML	cis	rs2120335	0.928	rs58845160	ENSG00000221443.1	AC017083.1	5.25	1.48e-06	0.00447	0.63	0.53	Height;	chr2:68159129	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.893	rs55752505	ENSG00000221443.1	AC017083.1	5.25	1.48e-06	0.00447	0.63	0.53	Height;	chr2:68161000	chr2:68273104~68273206:+
LAML	cis	rs5769707	0.967	rs2051626	ENSG00000279597.1	RP4-566L20.1	-5.25	1.48e-06	0.00447	-0.64	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49615325	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.967	rs1018812	ENSG00000279597.1	RP4-566L20.1	-5.25	1.48e-06	0.00447	-0.64	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49616425	chr22:49534062~49534926:+
LAML	cis	rs7746199	0.673	rs72847313	ENSG00000182477.5	OR2B8P	5.25	1.49e-06	0.00449	0.97	0.53	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.611	rs17750747	ENSG00000182477.5	OR2B8P	5.25	1.49e-06	0.00449	0.97	0.53	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.673	rs35501037	ENSG00000182477.5	OR2B8P	5.25	1.49e-06	0.00449	0.97	0.53	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28053228~28054165:-
LAML	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	5.25	1.49e-06	0.0045	0.71	0.53	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
LAML	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	5.25	1.49e-06	0.0045	0.71	0.53	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
LAML	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	5.25	1.49e-06	0.0045	0.71	0.53	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
LAML	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	5.25	1.49e-06	0.0045	0.71	0.53	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
LAML	cis	rs12468226	0.752	rs79058237	ENSG00000272966.1	RP11-686O6.1	5.25	1.49e-06	0.00451	0.86	0.53	Urate levels;	chr2:202140247	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.702	rs114634431	ENSG00000272966.1	RP11-686O6.1	5.25	1.49e-06	0.00451	0.86	0.53	Urate levels;	chr2:202142530	chr2:202336739~202337200:+
LAML	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	5.25	1.5e-06	0.00451	0.58	0.53	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
LAML	cis	rs853679	0.769	rs17720293	ENSG00000182477.5	OR2B8P	5.25	1.5e-06	0.00452	0.94	0.53	Depression;	chr6:28246920	chr6:28053228~28054165:-
LAML	cis	rs3758911	0.964	rs10890703	ENSG00000261098.1	RP11-819C21.1	-5.25	1.5e-06	0.00452	-0.5	-0.53	Coronary artery disease;	chr11:107310403	chr11:107312132~107316271:-
LAML	cis	rs17780086	0.527	rs72827711	ENSG00000266379.5	RP11-640N20.8	5.25	1.5e-06	0.00453	0.94	0.53	Height;	chr17:32210901	chr17:32088160~32094933:-
LAML	cis	rs17780086	0.527	rs17182651	ENSG00000266379.5	RP11-640N20.8	5.25	1.5e-06	0.00453	0.94	0.53	Height;	chr17:32220518	chr17:32088160~32094933:-
LAML	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	5.25	1.5e-06	0.00453	0.63	0.53	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	5.25	1.5e-06	0.00453	0.63	0.53	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	5.25	1.5e-06	0.00453	0.63	0.53	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	5.25	1.5e-06	0.00453	0.63	0.53	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
LAML	cis	rs11155671	0.53	rs9322228	ENSG00000216906.2	RP11-350J20.9	5.24	1.51e-06	0.00453	0.76	0.53	Testicular germ cell tumor;	chr6:149888173	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs7774787	ENSG00000216906.2	RP11-350J20.9	5.24	1.51e-06	0.00453	0.76	0.53	Testicular germ cell tumor;	chr6:149888296	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs2342767	ENSG00000216906.2	RP11-350J20.9	5.24	1.51e-06	0.00453	0.76	0.53	Testicular germ cell tumor;	chr6:149888581	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs7764376	ENSG00000216906.2	RP11-350J20.9	5.24	1.51e-06	0.00453	0.76	0.53	Testicular germ cell tumor;	chr6:149889208	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs6933882	ENSG00000216906.2	RP11-350J20.9	5.24	1.51e-06	0.00453	0.76	0.53	Testicular germ cell tumor;	chr6:149889666	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs6939761	ENSG00000216906.2	RP11-350J20.9	5.24	1.51e-06	0.00453	0.76	0.53	Testicular germ cell tumor;	chr6:149889858	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs3823021	ENSG00000216906.2	RP11-350J20.9	5.24	1.51e-06	0.00453	0.76	0.53	Testicular germ cell tumor;	chr6:149889863	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs4869763	ENSG00000216906.2	RP11-350J20.9	5.24	1.51e-06	0.00453	0.76	0.53	Testicular germ cell tumor;	chr6:149890548	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs4869764	ENSG00000216906.2	RP11-350J20.9	5.24	1.51e-06	0.00453	0.76	0.53	Testicular germ cell tumor;	chr6:149890692	chr6:149904243~149906418:+
LAML	cis	rs7829975	0.627	rs876954	ENSG00000268955.2	RP11-556O5.6	-5.24	1.51e-06	0.00455	-0.65	-0.53	Mood instability;	chr8:8453413	chr8:8188535~8189195:-
LAML	cis	rs904251	0.797	rs1757177	ENSG00000279942.1	RP1-153P14.7	-5.24	1.51e-06	0.00455	-0.58	-0.53	Cognitive performance;	chr6:37518594	chr6:37567716~37571460:+
LAML	cis	rs748404	0.56	rs1869258	ENSG00000249839.1	AC011330.5	-5.24	1.52e-06	0.00456	-0.6	-0.53	Lung cancer;	chr15:43511423	chr15:43663654~43684339:-
LAML	cis	rs748404	0.56	rs529611	ENSG00000249839.1	AC011330.5	-5.24	1.52e-06	0.00456	-0.6	-0.53	Lung cancer;	chr15:43513790	chr15:43663654~43684339:-
LAML	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-5.24	1.52e-06	0.00456	-0.63	-0.53	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
LAML	cis	rs11903757	1	rs4076769	ENSG00000281467.1	Clostridiales-1	5.24	1.52e-06	0.00456	1.07	0.53	Colorectal cancer;	chr2:191719480	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs6731095	ENSG00000281467.1	Clostridiales-1	5.24	1.52e-06	0.00456	1.07	0.53	Colorectal cancer;	chr2:191724716	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs78894429	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191702130	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs77674344	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191704157	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs75225465	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191704615	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs77866902	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191705588	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs77827994	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191707401	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs6730901	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191708079	chr2:191699476~191699631:-
LAML	cis	rs11903757	0.945	rs77282295	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191709580	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs74747990	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191709742	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs75823023	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191712122	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs80201920	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191712510	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs78893166	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191713930	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs4299283	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191716161	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs75521628	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191717363	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs12475675	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191723588	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs12463776	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191723608	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs77399531	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191724338	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs79858889	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191724366	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs6717663	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191724659	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs6717668	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191724673	chr2:191699476~191699631:-
LAML	cis	rs11903757	1	rs6759665	ENSG00000281467.1	Clostridiales-1	-5.24	1.52e-06	0.00456	-1.07	-0.53	Colorectal cancer;	chr2:191724728	chr2:191699476~191699631:-
LAML	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-5.24	1.52e-06	0.00457	-0.62	-0.53	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
LAML	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-5.24	1.52e-06	0.00457	-0.62	-0.53	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
LAML	cis	rs858239	0.704	rs199657	ENSG00000230658.1	KLHL7-AS1	-5.24	1.52e-06	0.00457	-0.76	-0.53	Cerebrospinal fluid biomarker levels;	chr7:23297888	chr7:23101228~23105703:-
LAML	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	5.24	1.52e-06	0.00457	0.71	0.53	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
LAML	cis	rs1075265	0.62	rs10192626	ENSG00000235937.1	AC008280.1	5.24	1.53e-06	0.00459	0.44	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53760885	chr2:54029552~54030682:-
LAML	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-5.24	1.54e-06	0.0046	-0.54	-0.53	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
LAML	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-5.24	1.54e-06	0.0046	-0.54	-0.53	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
LAML	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-5.24	1.54e-06	0.0046	-0.54	-0.53	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
LAML	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-5.24	1.54e-06	0.0046	-0.54	-0.53	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
LAML	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-5.24	1.54e-06	0.0046	-0.54	-0.53	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
LAML	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	5.24	1.54e-06	0.0046	0.54	0.53	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
LAML	cis	rs73219805	0.838	rs7840859	ENSG00000228451.3	SDAD1P1	-5.24	1.54e-06	0.0046	-0.61	-0.53	Schizophrenia;	chr8:26377501	chr8:26379259~26382953:-
LAML	cis	rs73219805	0.818	rs117325001	ENSG00000228451.3	SDAD1P1	-5.24	1.54e-06	0.0046	-0.61	-0.53	Schizophrenia;	chr8:26384756	chr8:26379259~26382953:-
LAML	cis	rs73219805	1	rs3808581	ENSG00000228451.3	SDAD1P1	-5.24	1.54e-06	0.0046	-0.61	-0.53	Schizophrenia;	chr8:26392531	chr8:26379259~26382953:-
LAML	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-5.24	1.54e-06	0.00461	-0.69	-0.53	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
LAML	cis	rs7714584	1	rs75294883	ENSG00000197083.10	ZNF300P1	5.24	1.54e-06	0.00461	1.17	0.53	Crohn's disease;	chr5:150816941	chr5:150930645~150946289:-
LAML	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-5.24	1.55e-06	0.00462	-0.57	-0.53	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
LAML	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	5.24	1.55e-06	0.00462	0.56	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	5.24	1.55e-06	0.00462	0.56	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	5.24	1.55e-06	0.00462	0.56	0.53	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	5.24	1.55e-06	0.00462	0.56	0.53	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
LAML	cis	rs5769707	0.967	rs9616713	ENSG00000213279.2	RP1-29C18.9	-5.24	1.56e-06	0.00464	-0.59	-0.53	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49572264~49575426:-
LAML	cis	rs8062405	0.721	rs151181	ENSG00000271623.1	RP11-435I10.5	-5.24	1.56e-06	0.00466	-0.61	-0.53	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28364700~28365333:+
LAML	cis	rs8031584	0.752	rs7174744	ENSG00000260382.1	RP11-540B6.2	-5.23	1.57e-06	0.00468	-0.56	-0.53	Huntington's disease progression;	chr15:30891544	chr15:30882267~30883231:-
LAML	cis	rs4713118	0.868	rs2893928	ENSG00000187763.3	OR2B7P	5.23	1.57e-06	0.00469	0.71	0.52	Parkinson's disease;	chr6:27770651	chr6:28046434~28047367:+
LAML	cis	rs3758911	0.894	rs10890718	ENSG00000261098.1	RP11-819C21.1	-5.23	1.57e-06	0.00469	-0.52	-0.52	Coronary artery disease;	chr11:107326257	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.894	rs6588964	ENSG00000261098.1	RP11-819C21.1	-5.23	1.57e-06	0.00469	-0.52	-0.52	Coronary artery disease;	chr11:107330725	chr11:107312132~107316271:-
LAML	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-5.23	1.58e-06	0.0047	-0.97	-0.52	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
LAML	cis	rs7115242	0.8	rs1320668	ENSG00000254851.1	RP11-109L13.1	-5.23	1.58e-06	0.0047	-0.97	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117096950	chr11:117135528~117138582:+
LAML	cis	rs76917914	0.821	rs112500293	ENSG00000236896.1	RP11-535C21.3	5.23	1.58e-06	0.00471	0.52	0.52	Immature fraction of reticulocytes;	chr9:98001173	chr9:97986551~97987656:-
LAML	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	5.23	1.6e-06	0.00474	0.63	0.52	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
LAML	cis	rs853679	1	rs1936365	ENSG00000182477.5	OR2B8P	-5.23	1.6e-06	0.00475	-0.77	-0.52	Depression;	chr6:28300675	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs6905391	ENSG00000182477.5	OR2B8P	5.23	1.6e-06	0.00475	0.77	0.52	Depression;	chr6:28294909	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs853694	ENSG00000182477.5	OR2B8P	5.23	1.6e-06	0.00475	0.77	0.52	Depression;	chr6:28311323	chr6:28053228~28054165:-
LAML	cis	rs11992186	0.505	rs7845203	ENSG00000268955.2	RP11-556O5.6	-5.23	1.6e-06	0.00476	-0.59	-0.52	Neuroticism;	chr8:8287918	chr8:8188535~8189195:-
LAML	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	5.23	1.6e-06	0.00476	0.55	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
LAML	cis	rs4713118	0.662	rs149946	ENSG00000182477.5	OR2B8P	-5.23	1.61e-06	0.00479	-0.76	-0.52	Parkinson's disease;	chr6:28002253	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs156744	ENSG00000182477.5	OR2B8P	5.23	1.61e-06	0.00479	0.76	0.52	Parkinson's disease;	chr6:27999496	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs149947	ENSG00000182477.5	OR2B8P	5.23	1.61e-06	0.00479	0.76	0.52	Parkinson's disease;	chr6:28004655	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs149969	ENSG00000182477.5	OR2B8P	5.23	1.61e-06	0.00479	0.76	0.52	Parkinson's disease;	chr6:28009959	chr6:28053228~28054165:-
LAML	cis	rs4728142	0.779	rs3778753	ENSG00000275106.1	RP11-309L24.10	-5.23	1.61e-06	0.00479	-0.47	-0.52	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128939988	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.744	rs3778752	ENSG00000275106.1	RP11-309L24.10	-5.23	1.61e-06	0.00479	-0.47	-0.52	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128939993	chr7:128952527~128953316:-
LAML	cis	rs7944735	0.517	rs11039520	ENSG00000263693.1	MIR3161	5.23	1.61e-06	0.00479	0.52	0.52	Intraocular pressure;	chr11:48109242	chr11:48096782~48096858:+
LAML	cis	rs747782	0.527	rs7113857	ENSG00000263693.1	MIR3161	5.23	1.61e-06	0.00479	0.52	0.52	Intraocular pressure;	chr11:48120307	chr11:48096782~48096858:+
LAML	cis	rs747782	0.527	rs2270993	ENSG00000263693.1	MIR3161	5.23	1.61e-06	0.00479	0.52	0.52	Intraocular pressure;	chr11:48123614	chr11:48096782~48096858:+
LAML	cis	rs747782	0.527	rs2279822	ENSG00000263693.1	MIR3161	5.23	1.61e-06	0.00479	0.52	0.52	Intraocular pressure;	chr11:48124562	chr11:48096782~48096858:+
LAML	cis	rs747782	0.527	rs7129364	ENSG00000263693.1	MIR3161	5.23	1.61e-06	0.00479	0.52	0.52	Intraocular pressure;	chr11:48129024	chr11:48096782~48096858:+
LAML	cis	rs7826238	0.509	rs2948288	ENSG00000268955.2	RP11-556O5.6	-5.23	1.62e-06	0.00479	-0.63	-0.52	Systolic blood pressure;	chr8:8257782	chr8:8188535~8189195:-
LAML	cis	rs9426935	0.715	rs10908512	ENSG00000273026.1	RP11-422P24.10	5.23	1.62e-06	0.00479	0.69	0.52	Lentiform nucleus volume;	chr1:153884022	chr1:153966516~153966930:+
LAML	cis	rs3091242	0.866	rs11249249	ENSG00000224183.1	SDHDP6	-5.23	1.62e-06	0.00479	-0.63	-0.52	Erythrocyte sedimentation rate;	chr1:25431643	chr1:25294164~25294643:-
LAML	cis	rs7829975	0.514	rs2945873	ENSG00000253893.2	FAM85B	-5.22	1.63e-06	0.00482	-0.59	-0.52	Mood instability;	chr8:8402935	chr8:8167819~8226614:-
LAML	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	5.22	1.64e-06	0.00484	0.56	0.52	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
LAML	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	5.22	1.64e-06	0.00484	0.56	0.52	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
LAML	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	5.22	1.64e-06	0.00484	0.56	0.52	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
LAML	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-5.22	1.64e-06	0.00484	-0.63	-0.52	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
LAML	cis	rs11155671	0.53	rs9383912	ENSG00000216906.2	RP11-350J20.9	5.22	1.64e-06	0.00484	0.75	0.52	Testicular germ cell tumor;	chr6:149885479	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs9397420	ENSG00000216906.2	RP11-350J20.9	-5.22	1.64e-06	0.00484	-0.75	-0.52	Testicular germ cell tumor;	chr6:149885645	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs9383577	ENSG00000216906.2	RP11-350J20.9	5.22	1.64e-06	0.00484	0.75	0.52	Testicular germ cell tumor;	chr6:149886059	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs9383914	ENSG00000216906.2	RP11-350J20.9	5.22	1.64e-06	0.00484	0.75	0.52	Testicular germ cell tumor;	chr6:149886098	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.517	rs9397058	ENSG00000216906.2	RP11-350J20.9	5.22	1.64e-06	0.00484	0.75	0.52	Testicular germ cell tumor;	chr6:149886113	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs7768626	ENSG00000216906.2	RP11-350J20.9	5.22	1.64e-06	0.00484	0.75	0.52	Testicular germ cell tumor;	chr6:149886826	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs7768665	ENSG00000216906.2	RP11-350J20.9	5.22	1.64e-06	0.00484	0.75	0.52	Testicular germ cell tumor;	chr6:149886888	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs7758020	ENSG00000216906.2	RP11-350J20.9	5.22	1.64e-06	0.00484	0.75	0.52	Testicular germ cell tumor;	chr6:149886975	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs7757984	ENSG00000216906.2	RP11-350J20.9	5.22	1.64e-06	0.00484	0.75	0.52	Testicular germ cell tumor;	chr6:149887515	chr6:149904243~149906418:+
LAML	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-5.22	1.65e-06	0.00486	-0.68	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-5.22	1.65e-06	0.00486	-0.68	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
LAML	cis	rs1075265	0.588	rs1477258	ENSG00000235937.1	AC008280.1	5.22	1.65e-06	0.00488	0.41	0.52	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54029552~54030682:-
LAML	cis	rs9402673	0.58	rs2297339	ENSG00000232876.1	CTA-212D2.2	-5.22	1.65e-06	0.00488	-0.67	-0.52	High light scatter reticulocyte count;Reticulocyte count;	chr6:135054853	chr6:135055033~135060550:+
LAML	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	5.22	1.66e-06	0.00489	0.61	0.52	Depression;	chr6:28240757	chr6:28176188~28176674:+
LAML	cis	rs763121	0.853	rs8140617	ENSG00000230912.1	RP3-508I15.10	5.22	1.67e-06	0.00491	0.46	0.52	Menopause (age at onset);	chr22:38574434	chr22:38666508~38668750:-
LAML	cis	rs853679	1	rs1778508	ENSG00000217315.1	OR2W2P	-5.22	1.68e-06	0.00494	-0.78	-0.52	Depression;	chr6:28262103	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs2799077	ENSG00000217315.1	OR2W2P	5.22	1.68e-06	0.00494	0.78	0.52	Depression;	chr6:28266819	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs11965538	ENSG00000217315.1	OR2W2P	5.22	1.68e-06	0.00494	0.78	0.52	Depression;	chr6:28272137	chr6:28033947~28034855:+
LAML	cis	rs853679	0.882	rs2743555	ENSG00000217315.1	OR2W2P	5.22	1.68e-06	0.00494	0.78	0.52	Depression;	chr6:28273304	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs1419183	ENSG00000217315.1	OR2W2P	5.22	1.68e-06	0.00494	0.78	0.52	Depression;	chr6:28275017	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs6901575	ENSG00000217315.1	OR2W2P	5.22	1.68e-06	0.00494	0.78	0.52	Depression;	chr6:28283207	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.869	rs6902689	ENSG00000220721.1	OR1F12	5.22	1.68e-06	0.00494	0.58	0.52	Parkinson's disease;	chr6:27741662	chr6:28073316~28074233:+
LAML	cis	rs904251	0.737	rs914347	ENSG00000204110.6	RP1-153P14.8	-5.22	1.68e-06	0.00494	-0.65	-0.52	Cognitive performance;	chr6:37517194	chr6:37507348~37535616:+
LAML	cis	rs904251	0.797	rs1776460	ENSG00000204110.6	RP1-153P14.8	-5.22	1.68e-06	0.00494	-0.65	-0.52	Cognitive performance;	chr6:37517708	chr6:37507348~37535616:+
LAML	cis	rs904251	0.828	rs1757178	ENSG00000204110.6	RP1-153P14.8	5.22	1.68e-06	0.00494	0.65	0.52	Cognitive performance;	chr6:37518534	chr6:37507348~37535616:+
LAML	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
LAML	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
LAML	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
LAML	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
LAML	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-5.22	1.68e-06	0.00494	-0.69	-0.52	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
LAML	cis	rs763121	0.819	rs138700	ENSG00000230912.1	RP3-508I15.10	-5.22	1.68e-06	0.00494	-0.46	-0.52	Menopause (age at onset);	chr22:38733994	chr22:38666508~38668750:-
LAML	cis	rs6951245	0.744	rs10265736	ENSG00000229043.2	AC091729.9	-5.22	1.68e-06	0.00494	-0.77	-0.52	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1160374~1165267:+
LAML	cis	rs7826238	0.601	rs2979206	ENSG00000268955.2	RP11-556O5.6	-5.22	1.69e-06	0.00495	-0.71	-0.52	Systolic blood pressure;	chr8:8488071	chr8:8188535~8189195:-
LAML	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	5.22	1.69e-06	0.00496	0.65	0.52	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
LAML	cis	rs992157	0.932	rs10203039	ENSG00000261338.2	RP11-378A13.1	5.21	1.7e-06	0.00498	0.69	0.52	Colorectal cancer;	chr2:218322644	chr2:218255319~218257366:+
LAML	cis	rs709400	0.628	rs3783394	ENSG00000258851.1	RP11-894P9.2	-5.21	1.7e-06	0.00498	-0.66	-0.52	Body mass index;	chr14:103392336	chr14:103553421~103561877:+
LAML	cis	rs709400	0.567	rs11624343	ENSG00000258851.1	RP11-894P9.2	-5.21	1.7e-06	0.00498	-0.66	-0.52	Body mass index;	chr14:103392819	chr14:103553421~103561877:+
LAML	cis	rs709400	0.567	rs1961600	ENSG00000258851.1	RP11-894P9.2	-5.21	1.7e-06	0.00498	-0.66	-0.52	Body mass index;	chr14:103395807	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs2010281	ENSG00000258851.1	RP11-894P9.2	-5.21	1.7e-06	0.00498	-0.66	-0.52	Body mass index;	chr14:103395985	chr14:103553421~103561877:+
LAML	cis	rs2980439	0.87	rs2945230	ENSG00000268955.2	RP11-556O5.6	-5.21	1.7e-06	0.00498	-0.62	-0.52	Neuroticism;	chr8:8252414	chr8:8188535~8189195:-
LAML	cis	rs7714584	1	rs73282209	ENSG00000197083.10	ZNF300P1	5.21	1.7e-06	0.00498	1.16	0.52	Crohn's disease;	chr5:150795397	chr5:150930645~150946289:-
LAML	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	5.21	1.7e-06	0.00498	0.65	0.52	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
LAML	cis	rs7495132	0.646	rs2286287	ENSG00000259314.1	CTD-3065B20.3	5.21	1.7e-06	0.00499	0.55	0.52	Ulcerative colitis;Inflammatory bowel disease;	chr15:90642253	chr15:90604225~90614558:-
LAML	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-5.21	1.71e-06	0.005	-0.66	-0.52	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-5.21	1.71e-06	0.005	-0.66	-0.52	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-5.21	1.71e-06	0.005	-0.66	-0.52	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-5.21	1.71e-06	0.005	-0.66	-0.52	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-5.21	1.71e-06	0.005	-0.66	-0.52	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
LAML	cis	rs2921073	0.51	rs2976944	ENSG00000268955.2	RP11-556O5.6	-5.21	1.71e-06	0.005	-0.56	-0.52	Parkinson's disease;	chr8:8413404	chr8:8188535~8189195:-
LAML	cis	rs9322193	0.923	rs4870050	ENSG00000216906.2	RP11-350J20.9	5.21	1.71e-06	0.00501	0.76	0.52	Lung cancer;	chr6:149838917	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs7752089	ENSG00000216906.2	RP11-350J20.9	5.21	1.71e-06	0.00501	0.76	0.52	Lung cancer;	chr6:149839298	chr6:149904243~149906418:+
LAML	cis	rs55794721	0.509	rs2375313	ENSG00000224183.1	SDHDP6	-5.21	1.72e-06	0.00502	-0.63	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25421744	chr1:25294164~25294643:-
LAML	cis	rs853679	0.607	rs67998226	ENSG00000220721.1	OR1F12	5.21	1.72e-06	0.00502	0.82	0.52	Depression;	chr6:28270281	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34878803	ENSG00000220721.1	OR1F12	5.21	1.72e-06	0.00502	0.82	0.52	Depression;	chr6:28282402	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34396849	ENSG00000220721.1	OR1F12	5.21	1.72e-06	0.00502	0.82	0.52	Depression;	chr6:28283178	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13211507	ENSG00000220721.1	OR1F12	5.21	1.72e-06	0.00502	0.82	0.52	Depression;	chr6:28289600	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34691223	ENSG00000220721.1	OR1F12	5.21	1.72e-06	0.00502	0.82	0.52	Depression;	chr6:28290431	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34950484	ENSG00000220721.1	OR1F12	5.21	1.72e-06	0.00502	0.82	0.52	Depression;	chr6:28310911	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs34661125	ENSG00000220721.1	OR1F12	5.21	1.72e-06	0.00502	0.82	0.52	Depression;	chr6:28314117	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs13190888	ENSG00000220721.1	OR1F12	5.21	1.72e-06	0.00502	0.82	0.52	Depression;	chr6:28318208	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs67340775	ENSG00000220721.1	OR1F12	5.21	1.72e-06	0.00502	0.82	0.52	Depression;	chr6:28336607	chr6:28073316~28074233:+
LAML	cis	rs11155671	0.53	rs2342770	ENSG00000216906.2	RP11-350J20.9	5.21	1.72e-06	0.00504	0.75	0.52	Testicular germ cell tumor;	chr6:149895549	chr6:149904243~149906418:+
LAML	cis	rs709400	0.628	rs72708854	ENSG00000258851.1	RP11-894P9.2	-5.21	1.73e-06	0.00505	-0.66	-0.52	Body mass index;	chr14:103398548	chr14:103553421~103561877:+
LAML	cis	rs763121	0.706	rs3827356	ENSG00000230912.1	RP3-508I15.10	5.21	1.73e-06	0.00507	0.45	0.52	Menopause (age at onset);	chr22:38668801	chr22:38666508~38668750:-
LAML	cis	rs11155671	0.53	rs7758033	ENSG00000216906.2	RP11-350J20.9	5.21	1.73e-06	0.00507	0.74	0.52	Testicular germ cell tumor;	chr6:149886999	chr6:149904243~149906418:+
LAML	cis	rs79040073	1	rs79040073	ENSG00000276593.1	RP11-295H24.5	5.21	1.74e-06	0.00507	0.55	0.52	Lung cancer in ever smokers;	chr15:49038657	chr15:49353485~49354034:+
LAML	cis	rs7829975	0.688	rs7837587	ENSG00000268955.2	RP11-556O5.6	-5.21	1.74e-06	0.00508	-0.69	-0.52	Mood instability;	chr8:8521482	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.688	rs7826654	ENSG00000268955.2	RP11-556O5.6	-5.21	1.74e-06	0.00508	-0.69	-0.52	Mood instability;	chr8:8521596	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.688	rs7826660	ENSG00000268955.2	RP11-556O5.6	-5.21	1.74e-06	0.00508	-0.69	-0.52	Mood instability;	chr8:8521597	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.688	rs6601703	ENSG00000268955.2	RP11-556O5.6	-5.21	1.74e-06	0.00508	-0.69	-0.52	Mood instability;	chr8:8522714	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.688	rs7827182	ENSG00000268955.2	RP11-556O5.6	-5.21	1.74e-06	0.00508	-0.69	-0.52	Mood instability;	chr8:8522961	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.688	rs7817376	ENSG00000268955.2	RP11-556O5.6	5.21	1.74e-06	0.00508	0.69	0.52	Mood instability;	chr8:8523020	chr8:8188535~8189195:-
LAML	cis	rs3829655	0.504	rs7251234	ENSG00000268375.1	CTD-2568A17.8	5.21	1.75e-06	0.0051	0.53	0.52	Cerebrospinal fluid biomarker levels;	chr19:51614767	chr19:50792685~50793584:-
LAML	cis	rs6940638	0.688	rs9348750	ENSG00000220721.1	OR1F12	5.21	1.75e-06	0.00511	0.54	0.52	Intelligence (multi-trait analysis);	chr6:27090166	chr6:28073316~28074233:+
LAML	cis	rs6940638	0.688	rs7744759	ENSG00000220721.1	OR1F12	5.21	1.75e-06	0.00511	0.54	0.52	Intelligence (multi-trait analysis);	chr6:27152047	chr6:28073316~28074233:+
LAML	cis	rs6940638	0.688	rs9379960	ENSG00000220721.1	OR1F12	5.21	1.75e-06	0.00511	0.54	0.52	Intelligence (multi-trait analysis);	chr6:27153546	chr6:28073316~28074233:+
LAML	cis	rs6940638	0.688	rs9295730	ENSG00000220721.1	OR1F12	5.21	1.75e-06	0.00511	0.54	0.52	Intelligence (multi-trait analysis);	chr6:27161027	chr6:28073316~28074233:+
LAML	cis	rs6940638	0.688	rs1028308	ENSG00000220721.1	OR1F12	5.21	1.75e-06	0.00511	0.54	0.52	Intelligence (multi-trait analysis);	chr6:27161978	chr6:28073316~28074233:+
LAML	cis	rs9399135	0.967	rs3756799	ENSG00000232876.1	CTA-212D2.2	-5.21	1.75e-06	0.00511	-0.67	-0.52	Red blood cell count;	chr6:135019873	chr6:135055033~135060550:+
LAML	cis	rs3758911	0.894	rs999985	ENSG00000261098.1	RP11-819C21.1	-5.21	1.75e-06	0.00511	-0.51	-0.52	Coronary artery disease;	chr11:107321531	chr11:107312132~107316271:-
LAML	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-5.21	1.75e-06	0.00511	-0.66	-0.52	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
LAML	cis	rs3758911	0.861	rs10890689	ENSG00000261098.1	RP11-819C21.1	-5.21	1.76e-06	0.00511	-0.52	-0.52	Coronary artery disease;	chr11:107275626	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs10890690	ENSG00000261098.1	RP11-819C21.1	-5.21	1.76e-06	0.00511	-0.52	-0.52	Coronary artery disease;	chr11:107276174	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs11212116	ENSG00000261098.1	RP11-819C21.1	-5.21	1.76e-06	0.00511	-0.52	-0.52	Coronary artery disease;	chr11:107276621	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs10890692	ENSG00000261098.1	RP11-819C21.1	-5.21	1.76e-06	0.00511	-0.52	-0.52	Coronary artery disease;	chr11:107277053	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs10749890	ENSG00000261098.1	RP11-819C21.1	-5.21	1.76e-06	0.00511	-0.52	-0.52	Coronary artery disease;	chr11:107278357	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.861	rs10454489	ENSG00000261098.1	RP11-819C21.1	-5.21	1.76e-06	0.00511	-0.52	-0.52	Coronary artery disease;	chr11:107279206	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.765	rs10789592	ENSG00000261098.1	RP11-819C21.1	-5.21	1.76e-06	0.00511	-0.52	-0.52	Coronary artery disease;	chr11:107283589	chr11:107312132~107316271:-
LAML	cis	rs172166	0.637	rs1225597	ENSG00000220721.1	OR1F12	5.21	1.76e-06	0.00511	0.57	0.52	Cardiac Troponin-T levels;	chr6:28194309	chr6:28073316~28074233:+
LAML	cis	rs172166	0.637	rs1071893	ENSG00000220721.1	OR1F12	5.21	1.76e-06	0.00511	0.57	0.52	Cardiac Troponin-T levels;	chr6:28199857	chr6:28073316~28074233:+
LAML	cis	rs7829975	0.688	rs13270194	ENSG00000268955.2	RP11-556O5.6	-5.21	1.76e-06	0.00511	-0.69	-0.52	Mood instability;	chr8:8520592	chr8:8188535~8189195:-
LAML	cis	rs9399135	0.967	rs4896119	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134972253	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4896121	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134972507	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.933	rs7755680	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134973121	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4895436	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134973863	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4896122	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134973943	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9376075	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134975825	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.935	rs4273704	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134976382	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4637662	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134977020	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4376365	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134986602	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4388304	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134988459	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs7741626	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134993044	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.904	rs4895438	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134996527	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4895439	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:134997716	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.935	rs11754504	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135000371	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.869	rs9402675	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135004656	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs12526055	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135004780	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9389253	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135008617	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9389254	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135009571	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9389256	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135010116	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs1014020	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135013288	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs1041481	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135013925	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs6902438	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135015449	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.935	rs6908681	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135016595	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.838	rs4896126	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135021648	chr6:135055033~135060550:+
LAML	cis	rs9402673	0.517	rs978036	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	High light scatter reticulocyte count;Reticulocyte count;	chr6:135021765	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs1023179	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135022691	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9376082	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135025251	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs952674	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135028019	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.935	rs987690	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135029241	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs7750300	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135029812	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.816	rs4134030	ENSG00000232876.1	CTA-212D2.2	-5.2	1.76e-06	0.00512	-0.67	-0.52	Red blood cell count;	chr6:135032956	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	5.2	1.76e-06	0.00512	0.67	0.52	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
LAML	cis	rs763121	0.889	rs1043402	ENSG00000230912.1	RP3-508I15.10	-5.2	1.76e-06	0.00512	-0.45	-0.52	Menopause (age at onset);	chr22:38483683	chr22:38666508~38668750:-
LAML	cis	rs11155671	0.53	rs9397398	ENSG00000216906.2	RP11-350J20.9	5.2	1.76e-06	0.00512	0.74	0.52	Testicular germ cell tumor;	chr6:149872467	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs9371215	ENSG00000216906.2	RP11-350J20.9	5.2	1.76e-06	0.00512	0.74	0.52	Testicular germ cell tumor;	chr6:149873162	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs6557133	ENSG00000216906.2	RP11-350J20.9	5.2	1.76e-06	0.00512	0.74	0.52	Testicular germ cell tumor;	chr6:149874248	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs1334510	ENSG00000216906.2	RP11-350J20.9	5.2	1.76e-06	0.00512	0.74	0.52	Testicular germ cell tumor;	chr6:149880043	chr6:149904243~149906418:+
LAML	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	5.2	1.77e-06	0.00513	0.71	0.52	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
LAML	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	5.2	1.77e-06	0.00513	0.71	0.52	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
LAML	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	5.2	1.77e-06	0.00513	0.64	0.52	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
LAML	cis	rs4713118	0.662	rs149948	ENSG00000182477.5	OR2B8P	5.2	1.77e-06	0.00515	0.76	0.52	Parkinson's disease;	chr6:28007039	chr6:28053228~28054165:-
LAML	cis	rs2120335	0.928	rs62145932	ENSG00000221443.1	AC017083.1	5.2	1.78e-06	0.00515	0.63	0.52	Height;	chr2:68140975	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.928	rs62145933	ENSG00000221443.1	AC017083.1	5.2	1.78e-06	0.00515	0.63	0.52	Height;	chr2:68141048	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.928	rs17589735	ENSG00000221443.1	AC017083.1	5.2	1.78e-06	0.00515	0.63	0.52	Height;	chr2:68148075	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.928	rs2278789	ENSG00000221443.1	AC017083.1	5.2	1.78e-06	0.00515	0.63	0.52	Height;	chr2:68149244	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.859	rs17524216	ENSG00000221443.1	AC017083.1	5.2	1.78e-06	0.00515	0.63	0.52	Height;	chr2:68150193	chr2:68273104~68273206:+
LAML	cis	rs853679	0.882	rs9468287	ENSG00000182477.5	OR2B8P	5.2	1.78e-06	0.00517	0.93	0.52	Depression;	chr6:28111963	chr6:28053228~28054165:-
LAML	cis	rs3931020	0.705	rs28482086	ENSG00000272864.1	RP11-17E13.2	-5.2	1.79e-06	0.0052	-0.67	-0.52	Resistin levels;	chr1:74760568	chr1:74698769~74699333:-
LAML	cis	rs2581828	0.965	rs2581830	ENSG00000280417.1	RP11-5O17.1	5.2	1.8e-06	0.00521	0.65	0.52	Crohn's disease;	chr3:53100082	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.965	rs35783750	ENSG00000280417.1	RP11-5O17.1	5.2	1.8e-06	0.00521	0.65	0.52	Crohn's disease;	chr3:53100847	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.965	rs34454739	ENSG00000280417.1	RP11-5O17.1	5.2	1.8e-06	0.00521	0.65	0.52	Crohn's disease;	chr3:53100955	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.965	rs2564961	ENSG00000280417.1	RP11-5O17.1	5.2	1.8e-06	0.00521	0.65	0.52	Crohn's disease;	chr3:53102445	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.965	rs4337632	ENSG00000280417.1	RP11-5O17.1	5.2	1.8e-06	0.00521	0.65	0.52	Crohn's disease;	chr3:53103295	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.965	rs2581829	ENSG00000280417.1	RP11-5O17.1	-5.2	1.8e-06	0.00521	-0.65	-0.52	Crohn's disease;	chr3:53099510	chr3:53046166~53048122:+
LAML	cis	rs904251	0.523	rs9349039	ENSG00000204110.6	RP1-153P14.8	-5.2	1.81e-06	0.00523	-0.63	-0.52	Cognitive performance;	chr6:37512616	chr6:37507348~37535616:+
LAML	cis	rs904251	0.523	rs9366935	ENSG00000204110.6	RP1-153P14.8	-5.2	1.81e-06	0.00523	-0.63	-0.52	Cognitive performance;	chr6:37512628	chr6:37507348~37535616:+
LAML	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-5.2	1.82e-06	0.00525	-0.63	-0.52	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-5.2	1.82e-06	0.00525	-0.63	-0.52	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
LAML	cis	rs2015599	0.549	rs3782508	ENSG00000274315.1	RP11-996F15.5	5.2	1.83e-06	0.00528	0.51	0.52	Platelet count;Mean platelet volume;	chr12:29298446	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.516	rs10450679	ENSG00000274315.1	RP11-996F15.5	5.2	1.83e-06	0.00528	0.51	0.52	Platelet count;Mean platelet volume;	chr12:29298823	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.549	rs6487802	ENSG00000274315.1	RP11-996F15.5	5.2	1.83e-06	0.00528	0.51	0.52	Platelet count;Mean platelet volume;	chr12:29299480	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.549	rs6487803	ENSG00000274315.1	RP11-996F15.5	5.2	1.83e-06	0.00528	0.51	0.52	Platelet count;Mean platelet volume;	chr12:29299760	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.549	rs7954990	ENSG00000274315.1	RP11-996F15.5	5.2	1.83e-06	0.00528	0.51	0.52	Platelet count;Mean platelet volume;	chr12:29299841	chr12:29331434~29331936:-
LAML	cis	rs67311347	0.544	rs7652439	ENSG00000223797.4	ENTPD3-AS1	5.19	1.83e-06	0.00528	0.63	0.52	Renal cell carcinoma;	chr3:40308457	chr3:40313802~40453329:-
LAML	cis	rs2120335	0.928	rs11126180	ENSG00000221443.1	AC017083.1	5.19	1.85e-06	0.00532	0.65	0.52	Height;	chr2:68136779	chr2:68273104~68273206:+
LAML	cis	rs11903757	0.945	rs76571691	ENSG00000281467.1	Clostridiales-1	-5.19	1.85e-06	0.00532	-1.04	-0.52	Colorectal cancer;	chr2:191693665	chr2:191699476~191699631:-
LAML	cis	rs55794721	0.509	rs909834	ENSG00000224183.1	SDHDP6	-5.19	1.85e-06	0.00533	-0.63	-0.52	Mean corpuscular volume;Plateletcrit;	chr1:25431505	chr1:25294164~25294643:-
LAML	cis	rs7301826	0.651	rs10848206	ENSG00000256299.1	RP11-989F5.3	-5.19	1.85e-06	0.00534	-0.68	-0.52	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810821~130812622:-
LAML	cis	rs763121	0.889	rs2267390	ENSG00000230912.1	RP3-508I15.10	-5.19	1.85e-06	0.00534	-0.45	-0.52	Menopause (age at onset);	chr22:38493652	chr22:38666508~38668750:-
LAML	cis	rs763121	0.889	rs9610971	ENSG00000230912.1	RP3-508I15.10	-5.19	1.85e-06	0.00534	-0.45	-0.52	Menopause (age at onset);	chr22:38514805	chr22:38666508~38668750:-
LAML	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-5.19	1.86e-06	0.00534	-0.64	-0.52	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
LAML	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
LAML	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
LAML	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
LAML	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
LAML	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	5.19	1.86e-06	0.00534	0.64	0.52	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
LAML	cis	rs709400	0.663	rs55723020	ENSG00000258851.1	RP11-894P9.2	-5.19	1.86e-06	0.00534	-0.65	-0.52	Body mass index;	chr14:103525064	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs11626787	ENSG00000258851.1	RP11-894P9.2	-5.19	1.86e-06	0.00534	-0.65	-0.52	Body mass index;	chr14:103525412	chr14:103553421~103561877:+
LAML	cis	rs1075265	0.756	rs805423	ENSG00000235937.1	AC008280.1	5.19	1.86e-06	0.00535	0.43	0.52	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54029552~54030682:-
LAML	cis	rs73219805	0.554	rs3808569	ENSG00000228451.3	SDAD1P1	-5.19	1.87e-06	0.00537	-0.7	-0.52	Schizophrenia;	chr8:26356252	chr8:26379259~26382953:-
LAML	cis	rs965604	1	rs12904234	ENSG00000259474.1	RP11-650L12.1	-5.19	1.87e-06	0.00538	-0.51	-0.52	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78487042	chr15:78480057~78481820:-
LAML	cis	rs12592111	1	rs12592111	ENSG00000259474.1	RP11-650L12.1	-5.19	1.87e-06	0.00538	-0.52	-0.52	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Parental longevity (combined parental age at death);	chr15:78475004	chr15:78480057~78481820:-
LAML	cis	rs911555	0.855	rs2071408	ENSG00000258851.1	RP11-894P9.2	5.19	1.88e-06	0.00541	0.62	0.52	Intelligence (multi-trait analysis);	chr14:103520741	chr14:103553421~103561877:+
LAML	cis	rs3758911	0.861	rs7131522	ENSG00000261098.1	RP11-819C21.1	-5.19	1.89e-06	0.00541	-0.51	-0.52	Coronary artery disease;	chr11:107293773	chr11:107312132~107316271:-
LAML	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-5.19	1.89e-06	0.00541	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
LAML	cis	rs4713118	0.824	rs9468223	ENSG00000220721.1	OR1F12	5.19	1.9e-06	0.00544	0.58	0.52	Parkinson's disease;	chr6:27772887	chr6:28073316~28074233:+
LAML	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	5.19	1.9e-06	0.00544	0.66	0.52	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
LAML	cis	rs7714584	1	rs11739677	ENSG00000197083.10	ZNF300P1	5.18	1.9e-06	0.00546	1.16	0.52	Crohn's disease;	chr5:150915321	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs76433514	ENSG00000197083.10	ZNF300P1	5.18	1.9e-06	0.00546	1.16	0.52	Crohn's disease;	chr5:150926970	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs59321715	ENSG00000197083.10	ZNF300P1	5.18	1.9e-06	0.00546	1.16	0.52	Crohn's disease;	chr5:150933918	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs12659118	ENSG00000197083.10	ZNF300P1	5.18	1.9e-06	0.00546	1.16	0.52	Crohn's disease;	chr5:150945060	chr5:150930645~150946289:-
LAML	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-5.18	1.91e-06	0.00546	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
LAML	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	5.18	1.91e-06	0.00546	0.66	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
LAML	cis	rs853679	0.607	rs34243448	ENSG00000217315.1	OR2W2P	5.18	1.91e-06	0.00548	0.98	0.52	Depression;	chr6:28225324	chr6:28033947~28034855:+
LAML	cis	rs12200782	0.932	rs72844476	ENSG00000275846.1	RP11-457M11.7	-5.18	1.92e-06	0.00548	-1.18	-0.52	Small cell lung carcinoma;	chr6:26573922	chr6:26602733~26606661:+
LAML	cis	rs141670911	1	rs141670911	ENSG00000275846.1	RP11-457M11.7	-5.18	1.92e-06	0.00548	-1.18	-0.52	Small cell lung carcinoma;	chr6:26581030	chr6:26602733~26606661:+
LAML	cis	rs4803480	0.872	rs2058149	ENSG00000239736.2	CEACAMP3	-5.18	1.92e-06	0.00549	-0.77	-0.52	Schizophrenia;	chr19:41580312	chr19:41599735~41605984:+
LAML	cis	rs12595025	1	rs12595025	ENSG00000258725.1	PRC1-AS1	-5.18	1.93e-06	0.00551	-0.92	-0.52	Mean platelet volume;	chr15:90976901	chr15:90966345~90988624:+
LAML	cis	rs8037137	0.915	rs8026714	ENSG00000258725.1	PRC1-AS1	-5.18	1.93e-06	0.00551	-0.92	-0.52	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90979023	chr15:90966345~90988624:+
LAML	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	5.18	1.93e-06	0.00551	0.61	0.52	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
LAML	cis	rs73219805	0.759	rs17055186	ENSG00000228451.3	SDAD1P1	-5.18	1.93e-06	0.00552	-0.72	-0.52	Schizophrenia;	chr8:26403394	chr8:26379259~26382953:-
LAML	cis	rs9322193	0.923	rs9767554	ENSG00000216906.2	RP11-350J20.9	5.18	1.93e-06	0.00553	0.74	0.52	Lung cancer;	chr6:149616860	chr6:149904243~149906418:+
LAML	cis	rs7581030	0.55	rs11678786	ENSG00000236469.1	AC007040.8	5.18	1.93e-06	0.00553	0.67	0.52	Testicular germ cell tumor;	chr2:71233555	chr2:71002531~71064743:-
LAML	cis	rs11903757	0.738	rs10931515	ENSG00000281467.1	Clostridiales-1	-5.18	1.94e-06	0.00553	-0.8	-0.52	Colorectal cancer;	chr2:191710385	chr2:191699476~191699631:-
LAML	cis	rs7829975	0.688	rs6995407	ENSG00000268955.2	RP11-556O5.6	-5.18	1.94e-06	0.00555	-0.68	-0.52	Mood instability;	chr8:8527137	chr8:8188535~8189195:-
LAML	cis	rs904251	0.6	rs9380673	ENSG00000204110.6	RP1-153P14.8	-5.18	1.94e-06	0.00556	-0.57	-0.52	Cognitive performance;	chr6:37447349	chr6:37507348~37535616:+
LAML	cis	rs904251	0.6	rs2270687	ENSG00000204110.6	RP1-153P14.8	-5.18	1.94e-06	0.00556	-0.57	-0.52	Cognitive performance;	chr6:37450487	chr6:37507348~37535616:+
LAML	cis	rs904251	0.525	rs12200378	ENSG00000204110.6	RP1-153P14.8	-5.18	1.94e-06	0.00556	-0.57	-0.52	Cognitive performance;	chr6:37457528	chr6:37507348~37535616:+
LAML	cis	rs904251	0.6	rs11756241	ENSG00000204110.6	RP1-153P14.8	-5.18	1.94e-06	0.00556	-0.57	-0.52	Cognitive performance;	chr6:37477325	chr6:37507348~37535616:+
LAML	cis	rs904251	0.6	rs1874736	ENSG00000204110.6	RP1-153P14.8	-5.18	1.94e-06	0.00556	-0.57	-0.52	Cognitive performance;	chr6:37480218	chr6:37507348~37535616:+
LAML	cis	rs6452524	0.508	rs40214	ENSG00000249664.1	CTD-2227C6.2	-5.18	1.95e-06	0.00557	-0.69	-0.52	Hypertension (SNP x SNP interaction);	chr5:83000359	chr5:83012285~83013109:-
LAML	cis	rs1150668	0.965	rs1150690	ENSG00000216901.1	AL022393.7	5.18	1.96e-06	0.00559	0.64	0.52	Pubertal anthropometrics;	chr6:28197520	chr6:28176188~28176674:+
LAML	cis	rs7746199	0.736	rs58616630	ENSG00000220721.1	OR1F12	5.18	1.96e-06	0.00559	0.87	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28073316~28074233:+
LAML	cis	rs7746199	0.736	rs34573979	ENSG00000220721.1	OR1F12	5.18	1.96e-06	0.00559	0.87	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28073316~28074233:+
LAML	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-5.17	1.99e-06	0.00566	-0.68	-0.52	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
LAML	cis	rs7495132	0.646	rs11073941	ENSG00000259314.1	CTD-3065B20.3	5.17	1.99e-06	0.00567	0.55	0.52	Ulcerative colitis;Inflammatory bowel disease;	chr15:90633963	chr15:90604225~90614558:-
LAML	cis	rs1075265	0.749	rs805379	ENSG00000235937.1	AC008280.1	5.17	1.99e-06	0.00568	0.42	0.52	Chronotype;Morning vs. evening chronotype;	chr2:53865847	chr2:54029552~54030682:-
LAML	cis	rs748404	0.588	rs2255410	ENSG00000249839.1	AC011330.5	-5.17	2e-06	0.0057	-0.61	-0.52	Lung cancer;	chr15:43538899	chr15:43663654~43684339:-
LAML	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-5.17	2.01e-06	0.00571	-0.65	-0.52	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
LAML	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	5.17	2.01e-06	0.00571	0.65	0.52	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
LAML	cis	rs172166	0.694	rs203884	ENSG00000220721.1	OR1F12	5.17	2.01e-06	0.00571	0.6	0.52	Cardiac Troponin-T levels;	chr6:28109596	chr6:28073316~28074233:+
LAML	cis	rs62070183	0.938	rs75782470	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32746623	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.882	rs62070164	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32759415	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs4795719	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32776957	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.882	rs17780981	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32792019	chr17:32518953~32531492:+
LAML	cis	rs112916054	1	rs112916054	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Immature fraction of reticulocytes;	chr17:32797244	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.752	rs17781005	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32805511	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.808	rs76373015	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815023	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.808	rs79957065	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815731	chr17:32518953~32531492:+
LAML	cis	rs62070183	1	rs62070183	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32837349	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.882	rs17183600	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32848061	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.882	rs17781136	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32858024	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.882	rs62070187	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32863706	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.817	rs79640811	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32894299	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.766	rs62070229	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32900575	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.766	rs62070232	ENSG00000266599.1	RP11-466A19.3	5.17	2.02e-06	0.00573	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32903075	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.882	rs17183628	ENSG00000266599.1	RP11-466A19.3	-5.17	2.02e-06	0.00573	-0.8	-0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32857613	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs17781142	ENSG00000266599.1	RP11-466A19.3	-5.17	2.02e-06	0.00573	-0.8	-0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32860198	chr17:32518953~32531492:+
LAML	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-5.17	2.02e-06	0.00573	-0.63	-0.52	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
LAML	cis	rs2980439	0.525	rs1850511	ENSG00000268955.2	RP11-556O5.6	-5.17	2.02e-06	0.00573	-0.59	-0.52	Neuroticism;	chr8:8312807	chr8:8188535~8189195:-
LAML	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-5.17	2.04e-06	0.00577	-0.66	-0.52	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
LAML	cis	rs5769707	0.681	rs9616329	ENSG00000212939.2	RP1-29C18.10	-5.17	2.04e-06	0.00577	-0.69	-0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49548681~49556473:+
LAML	cis	rs4591358	0.689	rs7575160	ENSG00000223466.1	AC064834.2	-5.17	2.04e-06	0.00577	-0.84	-0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195560896	chr2:195533035~195538681:+
LAML	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-5.17	2.04e-06	0.00577	-0.62	-0.52	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
LAML	cis	rs67311347	1	rs73078162	ENSG00000230274.1	PGAM1P3	5.17	2.05e-06	0.00578	0.68	0.52	Renal cell carcinoma;	chr3:40435618	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs73078163	ENSG00000230274.1	PGAM1P3	5.17	2.05e-06	0.00578	0.68	0.52	Renal cell carcinoma;	chr3:40438467	chr3:40322715~40323279:-
LAML	cis	rs11903757	1	rs12470148	ENSG00000281467.1	Clostridiales-1	-5.17	2.05e-06	0.00579	-1.05	-0.52	Colorectal cancer;	chr2:191706143	chr2:191699476~191699631:-
LAML	cis	rs13113518	0.783	rs12504300	ENSG00000249700.7	SRD5A3-AS1	5.17	2.05e-06	0.0058	0.56	0.52	Height;	chr4:55482360	chr4:55363971~55395847:-
LAML	cis	rs7429990	0.932	rs11130155	ENSG00000229759.1	MRPS18AP1	-5.17	2.05e-06	0.0058	-0.62	-0.52	Educational attainment (years of education);	chr3:48098938	chr3:48256350~48256938:-
LAML	cis	rs11155671	0.53	rs7756850	ENSG00000216906.2	RP11-350J20.9	5.16	2.06e-06	0.00582	0.75	0.52	Testicular germ cell tumor;	chr6:149891460	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs9371542	ENSG00000216906.2	RP11-350J20.9	5.16	2.06e-06	0.00582	0.75	0.52	Testicular germ cell tumor;	chr6:149891949	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs9371223	ENSG00000216906.2	RP11-350J20.9	5.16	2.06e-06	0.00582	0.75	0.52	Testicular germ cell tumor;	chr6:149893670	chr6:149904243~149906418:+
LAML	cis	rs11155671	0.53	rs2342769	ENSG00000216906.2	RP11-350J20.9	5.16	2.06e-06	0.00582	0.75	0.52	Testicular germ cell tumor;	chr6:149895371	chr6:149904243~149906418:+
LAML	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-5.16	2.06e-06	0.00582	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-5.16	2.06e-06	0.00582	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-5.16	2.06e-06	0.00582	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-5.16	2.06e-06	0.00582	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-5.16	2.06e-06	0.00582	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-5.16	2.06e-06	0.00582	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-5.16	2.06e-06	0.00582	-0.68	-0.52	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
LAML	cis	rs853679	0.556	rs45509595	ENSG00000182477.5	OR2B8P	5.16	2.07e-06	0.00582	0.96	0.52	Depression;	chr6:27873148	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs66868086	ENSG00000182477.5	OR2B8P	5.16	2.07e-06	0.00582	0.96	0.52	Depression;	chr6:27898124	chr6:28053228~28054165:-
LAML	cis	rs7829975	0.633	rs2979181	ENSG00000268955.2	RP11-556O5.6	-5.16	2.07e-06	0.00582	-0.64	-0.52	Mood instability;	chr8:8465578	chr8:8188535~8189195:-
LAML	cis	rs875971	0.54	rs35510581	ENSG00000224316.1	RP11-479O9.2	-5.16	2.07e-06	0.00583	-0.56	-0.52	Aortic root size;	chr7:66113790	chr7:65773620~65802067:+
LAML	cis	rs7495132	0.646	rs3743403	ENSG00000259314.1	CTD-3065B20.3	5.16	2.07e-06	0.00583	0.54	0.52	Ulcerative colitis;Inflammatory bowel disease;	chr15:90642610	chr15:90604225~90614558:-
LAML	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-5.16	2.09e-06	0.00588	-0.67	-0.52	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
LAML	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-5.16	2.09e-06	0.00588	-0.67	-0.52	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
LAML	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-5.16	2.09e-06	0.00588	-0.73	-0.52	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
LAML	cis	rs4774565	0.762	rs7164848	ENSG00000244879.4	GABPB1-AS1	5.16	2.09e-06	0.00589	0.56	0.52	Breast cancer;	chr15:50370833	chr15:50354959~50372202:+
LAML	cis	rs9426935	0.932	rs12142733	ENSG00000273026.1	RP11-422P24.10	5.16	2.09e-06	0.00589	0.67	0.52	Lentiform nucleus volume;	chr1:153887765	chr1:153966516~153966930:+
LAML	cis	rs4713118	0.866	rs2179094	ENSG00000220721.1	OR1F12	5.16	2.1e-06	0.00591	0.57	0.52	Parkinson's disease;	chr6:27774046	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.824	rs9468225	ENSG00000220721.1	OR1F12	5.16	2.1e-06	0.00591	0.57	0.52	Parkinson's disease;	chr6:27777940	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.739	rs2893931	ENSG00000220721.1	OR1F12	5.16	2.1e-06	0.00591	0.57	0.52	Parkinson's disease;	chr6:27780231	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.824	rs2092075	ENSG00000220721.1	OR1F12	5.16	2.1e-06	0.00591	0.57	0.52	Parkinson's disease;	chr6:27781551	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.824	rs13211701	ENSG00000220721.1	OR1F12	5.16	2.1e-06	0.00591	0.57	0.52	Parkinson's disease;	chr6:27782300	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.824	rs9468229	ENSG00000220721.1	OR1F12	5.16	2.1e-06	0.00591	0.57	0.52	Parkinson's disease;	chr6:27782307	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.824	rs2179095	ENSG00000220721.1	OR1F12	-5.16	2.1e-06	0.00591	-0.57	-0.52	Parkinson's disease;	chr6:27783079	chr6:28073316~28074233:+
LAML	cis	rs9368481	0.761	rs7775041	ENSG00000243307.2	POM121L6P	-5.16	2.1e-06	0.00591	-0.63	-0.52	Autism spectrum disorder or schizophrenia;	chr6:27041733	chr6:26896952~26898777:+
LAML	cis	rs763121	0.886	rs1013339	ENSG00000230912.1	RP3-508I15.10	-5.16	2.1e-06	0.00591	-0.42	-0.52	Menopause (age at onset);	chr22:38578675	chr22:38666508~38668750:-
LAML	cis	rs763121	0.819	rs5757161	ENSG00000230912.1	RP3-508I15.10	-5.16	2.1e-06	0.00591	-0.42	-0.52	Menopause (age at onset);	chr22:38594657	chr22:38666508~38668750:-
LAML	cis	rs763121	0.925	rs5757165	ENSG00000230912.1	RP3-508I15.10	-5.16	2.1e-06	0.00591	-0.42	-0.52	Menopause (age at onset);	chr22:38598572	chr22:38666508~38668750:-
LAML	cis	rs763121	0.925	rs4821797	ENSG00000230912.1	RP3-508I15.10	-5.16	2.1e-06	0.00591	-0.42	-0.52	Menopause (age at onset);	chr22:38620177	chr22:38666508~38668750:-
LAML	cis	rs763121	0.889	rs9607557	ENSG00000230912.1	RP3-508I15.10	-5.16	2.1e-06	0.00591	-0.42	-0.52	Menopause (age at onset);	chr22:38644274	chr22:38666508~38668750:-
LAML	cis	rs7829975	0.627	rs2979172	ENSG00000268955.2	RP11-556O5.6	-5.16	2.12e-06	0.00594	-0.63	-0.52	Mood instability;	chr8:8452998	chr8:8188535~8189195:-
LAML	cis	rs9457247	0.534	rs12055488	ENSG00000231654.1	RPS6KA2-AS1	5.16	2.12e-06	0.00594	0.51	0.52	Crohn's disease;	chr6:166966082	chr6:166903698~166904835:+
LAML	cis	rs172166	0.538	rs149956	ENSG00000216901.1	AL022393.7	5.16	2.13e-06	0.00595	0.59	0.52	Cardiac Troponin-T levels;	chr6:28068473	chr6:28176188~28176674:+
LAML	cis	rs1757171	0.542	rs3818986	ENSG00000204110.6	RP1-153P14.8	-5.16	2.13e-06	0.00597	-0.58	-0.52	Cognitive performance;	chr6:37516573	chr6:37507348~37535616:+
LAML	cis	rs62070183	0.873	rs113602044	ENSG00000279781.1	RP11-466A19.7	5.15	2.14e-06	0.00598	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32691685	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs77819475	ENSG00000279781.1	RP11-466A19.7	5.15	2.14e-06	0.00598	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32699823	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs17183113	ENSG00000279781.1	RP11-466A19.7	5.15	2.14e-06	0.00598	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702107	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs78418651	ENSG00000279781.1	RP11-466A19.7	5.15	2.14e-06	0.00598	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702530	chr17:32518322~32518934:-
LAML	cis	rs853679	0.607	rs66886492	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28121953	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs35345226	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28123802	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs35749575	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28147040	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs72846780	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28151277	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13205911	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28156336	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13197176	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28161454	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13201308	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28162311	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs34765154	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28162672	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs34505829	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28165461	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs35098436	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28166443	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs72846794	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28169721	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13217984	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28171932	chr6:28046434~28047367:+
LAML	cis	rs853679	0.556	rs67297533	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28173475	chr6:28046434~28047367:+
LAML	cis	rs853679	0.505	rs35781323	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28177054	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs13195291	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28201463	chr6:28046434~28047367:+
LAML	cis	rs853679	0.556	rs13197633	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28206979	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs35001169	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28219854	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs35656932	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28223510	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13204012	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28233753	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13205211	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28235278	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13208096	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28257533	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13207345	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28297795	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs72854513	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28298177	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs33932084	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28301047	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs56189111	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28304196	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs35072899	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28313764	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs56075693	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28322551	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs34218844	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28322870	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs35030260	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28337731	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13217619	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28338894	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs35016036	ENSG00000187763.3	OR2B7P	5.15	2.15e-06	0.00598	0.97	0.52	Depression;	chr6:28347103	chr6:28046434~28047367:+
LAML	cis	rs875971	1	rs697970	ENSG00000222364.1	RNU6-96P	5.15	2.15e-06	0.00599	0.64	0.52	Aortic root size;	chr7:66095065	chr7:66395191~66395286:+
LAML	cis	rs6940638	0.688	rs9461335	ENSG00000220721.1	OR1F12	5.15	2.16e-06	0.00601	0.54	0.52	Intelligence (multi-trait analysis);	chr6:27170750	chr6:28073316~28074233:+
LAML	cis	rs9918079	0.56	rs6449153	ENSG00000249930.1	AC007016.3	-5.15	2.16e-06	0.00601	-0.64	-0.52	Obesity-related traits;	chr4:15629593	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.56	rs4698406	ENSG00000249930.1	AC007016.3	-5.15	2.16e-06	0.00601	-0.64	-0.52	Obesity-related traits;	chr4:15638994	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.542	rs7688984	ENSG00000249930.1	AC007016.3	-5.15	2.16e-06	0.00601	-0.64	-0.52	Obesity-related traits;	chr4:15655630	chr4:15492729~15492972:-
LAML	cis	rs73219805	0.597	rs3824232	ENSG00000228451.3	SDAD1P1	-5.15	2.17e-06	0.00602	-0.64	-0.52	Schizophrenia;	chr8:26370083	chr8:26379259~26382953:-
LAML	cis	rs2120335	0.928	rs1373197	ENSG00000221443.1	AC017083.1	5.15	2.18e-06	0.00605	0.65	0.52	Height;	chr2:68227271	chr2:68273104~68273206:+
LAML	cis	rs2980439	0.557	rs2921056	ENSG00000253893.2	FAM85B	-5.15	2.18e-06	0.00605	-0.62	-0.52	Neuroticism;	chr8:8461672	chr8:8167819~8226614:-
LAML	cis	rs7826238	0.524	rs2921055	ENSG00000253893.2	FAM85B	-5.15	2.18e-06	0.00605	-0.62	-0.52	Systolic blood pressure;	chr8:8461832	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.501	rs2980769	ENSG00000253893.2	FAM85B	-5.15	2.18e-06	0.00605	-0.62	-0.52	Mood instability;	chr8:8462781	chr8:8167819~8226614:-
LAML	cis	rs7131987	0.565	rs4412790	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29253828	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs10743651	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29255006	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.546	rs7299648	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29256797	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs7300032	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29256859	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.547	rs4370971	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29257066	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs7316026	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29258881	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs6487792	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29259743	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.585	rs2194517	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29260002	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs766445	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29260560	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs7971296	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29263297	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.605	rs1120528	ENSG00000274315.1	RP11-996F15.5	5.15	2.18e-06	0.00605	0.54	0.52	QT interval;	chr12:29264237	chr12:29331434~29331936:-
LAML	cis	rs853679	0.607	rs34243448	ENSG00000182477.5	OR2B8P	5.15	2.19e-06	0.00607	0.96	0.52	Depression;	chr6:28225324	chr6:28053228~28054165:-
LAML	cis	rs904251	0.6	rs9380673	ENSG00000279942.1	RP1-153P14.7	-5.15	2.19e-06	0.00607	-0.51	-0.52	Cognitive performance;	chr6:37447349	chr6:37567716~37571460:+
LAML	cis	rs904251	0.6	rs2270687	ENSG00000279942.1	RP1-153P14.7	-5.15	2.19e-06	0.00607	-0.51	-0.52	Cognitive performance;	chr6:37450487	chr6:37567716~37571460:+
LAML	cis	rs904251	0.525	rs12200378	ENSG00000279942.1	RP1-153P14.7	-5.15	2.19e-06	0.00607	-0.51	-0.52	Cognitive performance;	chr6:37457528	chr6:37567716~37571460:+
LAML	cis	rs904251	0.6	rs11756241	ENSG00000279942.1	RP1-153P14.7	-5.15	2.19e-06	0.00607	-0.51	-0.52	Cognitive performance;	chr6:37477325	chr6:37567716~37571460:+
LAML	cis	rs904251	0.6	rs1874736	ENSG00000279942.1	RP1-153P14.7	-5.15	2.19e-06	0.00607	-0.51	-0.52	Cognitive performance;	chr6:37480218	chr6:37567716~37571460:+
LAML	cis	rs7944735	0.817	rs747782	ENSG00000263693.1	MIR3161	5.15	2.19e-06	0.00608	0.4	0.52	Intraocular pressure;	chr11:47919373	chr11:48096782~48096858:+
LAML	cis	rs2581828	0.618	rs9838517	ENSG00000280417.1	RP11-5O17.1	-5.15	2.2e-06	0.0061	-0.7	-0.52	Crohn's disease;	chr3:53110347	chr3:53046166~53048122:+
LAML	cis	rs853679	1	rs1936365	ENSG00000217315.1	OR2W2P	-5.15	2.2e-06	0.00611	-0.77	-0.52	Depression;	chr6:28300675	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs6905391	ENSG00000217315.1	OR2W2P	5.15	2.2e-06	0.00611	0.77	0.52	Depression;	chr6:28294909	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs853694	ENSG00000217315.1	OR2W2P	5.15	2.2e-06	0.00611	0.77	0.52	Depression;	chr6:28311323	chr6:28033947~28034855:+
LAML	cis	rs7944735	0.767	rs1017875	ENSG00000263693.1	MIR3161	5.15	2.21e-06	0.00612	0.41	0.52	Intraocular pressure;	chr11:47977666	chr11:48096782~48096858:+
LAML	cis	rs10500715	0.691	rs12295754	ENSG00000254719.1	RP11-351I24.3	-5.15	2.21e-06	0.00612	-0.64	-0.52	Pancreatic cancer;	chr11:9990190	chr11:10272052~10272259:-
LAML	cis	rs10500715	0.567	rs4309158	ENSG00000254719.1	RP11-351I24.3	-5.15	2.21e-06	0.00612	-0.64	-0.52	Pancreatic cancer;	chr11:9995275	chr11:10272052~10272259:-
LAML	cis	rs10500715	0.554	rs7129239	ENSG00000254719.1	RP11-351I24.3	-5.15	2.21e-06	0.00612	-0.64	-0.52	Pancreatic cancer;	chr11:10004629	chr11:10272052~10272259:-
LAML	cis	rs10500715	0.554	rs2403259	ENSG00000254719.1	RP11-351I24.3	-5.15	2.21e-06	0.00612	-0.64	-0.52	Pancreatic cancer;	chr11:10005886	chr11:10272052~10272259:-
LAML	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	5.15	2.22e-06	0.00614	0.6	0.52	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
LAML	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-5.15	2.22e-06	0.00614	-0.64	-0.52	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-5.15	2.22e-06	0.00614	-0.64	-0.52	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
LAML	cis	rs7826238	0.535	rs2979179	ENSG00000253893.2	FAM85B	-5.15	2.22e-06	0.00615	-0.62	-0.52	Systolic blood pressure;	chr8:8462519	chr8:8167819~8226614:-
LAML	cis	rs2015599	0.535	rs11050200	ENSG00000257176.2	RP11-996F15.2	5.15	2.22e-06	0.00615	0.52	0.52	Platelet count;Mean platelet volume;	chr12:29333415	chr12:29280418~29317848:-
LAML	cis	rs7849270	0.879	rs6478866	ENSG00000268707.1	RP11-247A12.7	-5.14	2.24e-06	0.00619	-0.61	-0.52	Blood metabolite ratios;	chr9:129133585	chr9:129170434~129170940:+
LAML	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	5.14	2.24e-06	0.00619	0.67	0.52	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs7763836	ENSG00000232876.1	CTA-212D2.2	-5.14	2.24e-06	0.00619	-0.67	-0.52	Red blood cell count;	chr6:135041240	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs34546690	ENSG00000232876.1	CTA-212D2.2	-5.14	2.24e-06	0.00619	-0.67	-0.52	Red blood cell count;	chr6:135048571	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9373122	ENSG00000232876.1	CTA-212D2.2	-5.14	2.24e-06	0.00619	-0.67	-0.52	Red blood cell count;	chr6:135052396	chr6:135055033~135060550:+
LAML	cis	rs6951245	0.744	rs10265758	ENSG00000229043.2	AC091729.9	-5.14	2.24e-06	0.0062	-0.74	-0.52	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1160374~1165267:+
LAML	cis	rs9322193	0.567	rs7742692	ENSG00000216906.2	RP11-350J20.9	5.14	2.24e-06	0.0062	0.74	0.52	Lung cancer;	chr6:149892363	chr6:149904243~149906418:+
LAML	cis	rs9918079	0.56	rs10008975	ENSG00000249930.1	AC007016.3	-5.14	2.24e-06	0.0062	-0.64	-0.52	Obesity-related traits;	chr4:15622948	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.56	rs7438356	ENSG00000249930.1	AC007016.3	-5.14	2.24e-06	0.0062	-0.64	-0.52	Obesity-related traits;	chr4:15623147	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.56	rs4557256	ENSG00000249930.1	AC007016.3	-5.14	2.24e-06	0.0062	-0.64	-0.52	Obesity-related traits;	chr4:15625024	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.56	rs4698402	ENSG00000249930.1	AC007016.3	-5.14	2.24e-06	0.0062	-0.64	-0.52	Obesity-related traits;	chr4:15628180	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.56	rs7662032	ENSG00000249930.1	AC007016.3	-5.14	2.24e-06	0.0062	-0.64	-0.52	Obesity-related traits;	chr4:15633791	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.56	rs12651550	ENSG00000249930.1	AC007016.3	-5.14	2.24e-06	0.0062	-0.64	-0.52	Obesity-related traits;	chr4:15639395	chr4:15492729~15492972:-
LAML	cis	rs1789	0.839	rs9997068	ENSG00000249930.1	AC007016.3	-5.14	2.24e-06	0.0062	-0.64	-0.52	Blood protein levels;	chr4:15649367	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.56	rs6414767	ENSG00000249930.1	AC007016.3	-5.14	2.24e-06	0.0062	-0.64	-0.52	Obesity-related traits;	chr4:15654098	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.542	rs12499412	ENSG00000249930.1	AC007016.3	5.14	2.24e-06	0.0062	0.64	0.52	Obesity-related traits;	chr4:15600629	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.58	rs13120905	ENSG00000249930.1	AC007016.3	5.14	2.24e-06	0.0062	0.64	0.52	Obesity-related traits;	chr4:15610665	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.56	rs13147590	ENSG00000249930.1	AC007016.3	5.14	2.24e-06	0.0062	0.64	0.52	Obesity-related traits;	chr4:15619565	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.56	rs10008376	ENSG00000249930.1	AC007016.3	5.14	2.24e-06	0.0062	0.64	0.52	Obesity-related traits;	chr4:15622332	chr4:15492729~15492972:-
LAML	cis	rs67311347	1	rs73078158	ENSG00000230274.1	PGAM1P3	5.14	2.25e-06	0.0062	0.68	0.52	Renal cell carcinoma;	chr3:40431076	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs73078164	ENSG00000230274.1	PGAM1P3	5.14	2.25e-06	0.0062	0.68	0.52	Renal cell carcinoma;	chr3:40438798	chr3:40322715~40323279:-
LAML	cis	rs1075265	0.589	rs2542571	ENSG00000235937.1	AC008280.1	5.14	2.25e-06	0.00621	0.4	0.52	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54029552~54030682:-
LAML	cis	rs9399135	0.933	rs28384512	ENSG00000232876.1	CTA-212D2.2	-5.14	2.25e-06	0.00622	-0.67	-0.52	Red blood cell count;	chr6:135055094	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.933	rs41294852	ENSG00000232876.1	CTA-212D2.2	-5.14	2.25e-06	0.00622	-0.67	-0.52	Red blood cell count;	chr6:135055241	chr6:135055033~135060550:+
LAML	cis	rs7131987	0.565	rs10743652	ENSG00000274315.1	RP11-996F15.5	5.14	2.25e-06	0.00622	0.54	0.52	QT interval;	chr12:29255074	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs10843372	ENSG00000274315.1	RP11-996F15.5	5.14	2.25e-06	0.00622	0.54	0.52	QT interval;	chr12:29262863	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs7976227	ENSG00000274315.1	RP11-996F15.5	5.14	2.25e-06	0.00622	0.54	0.52	QT interval;	chr12:29264843	chr12:29331434~29331936:-
LAML	cis	rs5769707	0.605	rs6009791	ENSG00000280224.1	CTA-722E9.1	-5.14	2.26e-06	0.00624	-0.78	-0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.605	rs9616702	ENSG00000280224.1	CTA-722E9.1	-5.14	2.26e-06	0.00624	-0.78	-0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49500568~49501585:+
LAML	cis	rs5769707	0.667	rs4824069	ENSG00000280224.1	CTA-722E9.1	-5.14	2.26e-06	0.00624	-0.78	-0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49500568~49501585:+
LAML	cis	rs8031584	0.678	rs3122	ENSG00000260382.1	RP11-540B6.2	-5.14	2.27e-06	0.00625	-0.57	-0.52	Huntington's disease progression;	chr15:30878087	chr15:30882267~30883231:-
LAML	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	5.14	2.27e-06	0.00626	0.55	0.52	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
LAML	cis	rs1577917	0.958	rs66807489	ENSG00000203875.9	SNHG5	-5.14	2.27e-06	0.00626	-0.69	-0.52	Response to antipsychotic treatment;	chr6:85730984	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs10944136	ENSG00000203875.9	SNHG5	-5.14	2.27e-06	0.00626	-0.69	-0.52	Response to antipsychotic treatment;	chr6:85738781	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-5.14	2.27e-06	0.00626	-0.69	-0.52	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
LAML	cis	rs12149695	0.872	rs4787415	ENSG00000259940.2	CTD-3203P2.1	5.14	2.27e-06	0.00626	0.58	0.52	Gut microbiota (bacterial taxa);	chr16:27239885	chr16:27213308~27214993:-
LAML	cis	rs73219805	1	rs73217798	ENSG00000228451.3	SDAD1P1	-5.14	2.27e-06	0.00627	-0.6	-0.52	Schizophrenia;	chr8:26406847	chr8:26379259~26382953:-
LAML	cis	rs73219805	1	rs17310286	ENSG00000228451.3	SDAD1P1	5.14	2.27e-06	0.00627	0.6	0.52	Schizophrenia;	chr8:26411516	chr8:26379259~26382953:-
LAML	cis	rs709400	0.663	rs62007683	ENSG00000258851.1	RP11-894P9.2	-5.14	2.27e-06	0.00627	-0.64	-0.52	Body mass index;	chr14:103427734	chr14:103553421~103561877:+
LAML	cis	rs11155671	0.53	rs9383940	ENSG00000216906.2	RP11-350J20.9	5.14	2.28e-06	0.00629	0.69	0.52	Testicular germ cell tumor;	chr6:149904923	chr6:149904243~149906418:+
LAML	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-5.14	2.29e-06	0.0063	-0.64	-0.52	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
LAML	cis	rs7131987	0.585	rs2059362	ENSG00000274315.1	RP11-996F15.5	5.14	2.29e-06	0.00631	0.53	0.52	QT interval;	chr12:29243072	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs10843365	ENSG00000274315.1	RP11-996F15.5	5.14	2.29e-06	0.00631	0.53	0.52	QT interval;	chr12:29252691	chr12:29331434~29331936:-
LAML	cis	rs965604	1	rs11637656	ENSG00000259474.1	RP11-650L12.1	-5.14	2.29e-06	0.00631	-0.52	-0.52	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78459619	chr15:78480057~78481820:-
LAML	cis	rs57024841	0.5	rs6560652	ENSG00000238268.2	RP11-229P13.19	-5.14	2.3e-06	0.00634	-0.6	-0.52	Beta-trace protein levels;	chr9:136936488	chr9:136975094~136976981:+
LAML	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-5.14	2.31e-06	0.00635	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
LAML	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	5.14	2.31e-06	0.00635	0.54	0.52	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
LAML	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	5.13	2.31e-06	0.00636	0.7	0.52	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
LAML	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	5.13	2.31e-06	0.00636	0.7	0.52	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
LAML	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	5.13	2.31e-06	0.00636	0.7	0.52	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
LAML	cis	rs7131987	0.585	rs6487795	ENSG00000274315.1	RP11-996F15.5	5.13	2.32e-06	0.00636	0.54	0.52	QT interval;	chr12:29266228	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs6487797	ENSG00000274315.1	RP11-996F15.5	5.13	2.32e-06	0.00636	0.54	0.52	QT interval;	chr12:29270063	chr12:29331434~29331936:-
LAML	cis	rs7746199	0.736	rs13209332	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs34965299	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28053228~28054165:-
LAML	cis	rs35491132	1	rs35491132	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Urinary tract infection frequency;	chr6:27559449	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs10484399	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs34105070	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.673	rs72845046	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs67652222	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs13212093	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs34038546	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28053228~28054165:-
LAML	cis	rs141342723	1	rs141342723	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs34543938	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs56405707	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs13210634	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs13215275	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs17749927	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs13192965	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28053228~28054165:-
LAML	cis	rs45509595	0.556	rs34409918	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Breast cancer;	chr6:27717569	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs34064842	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs13212318	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs13202291	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs17750424	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs13193542	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs13193480	ENSG00000182477.5	OR2B8P	5.13	2.32e-06	0.00636	0.95	0.52	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28053228~28054165:-
LAML	cis	rs709400	0.628	rs11621510	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103403283	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs62007681	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103418314	chr14:103553421~103561877:+
LAML	cis	rs709400	0.604	rs7158144	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103421278	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs1028613	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103421987	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs11624367	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103426481	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs62007684	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103427886	chr14:103553421~103561877:+
LAML	cis	rs709400	0.658	rs72708874	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103432914	chr14:103553421~103561877:+
LAML	cis	rs709400	0.627	rs62007686	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103433007	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs62007687	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103437426	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs11622320	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103445857	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs11622356	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103445858	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs17679475	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103450621	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs2273700	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103457077	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs72708893	ENSG00000258851.1	RP11-894P9.2	-5.13	2.32e-06	0.00636	-0.64	-0.52	Body mass index;	chr14:103463198	chr14:103553421~103561877:+
LAML	cis	rs6951245	1	rs76214082	ENSG00000229043.2	AC091729.9	-5.13	2.33e-06	0.00639	-0.89	-0.52	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062461	chr7:1160374~1165267:+
LAML	cis	rs965604	1	rs4887057	ENSG00000259474.1	RP11-650L12.1	5.13	2.33e-06	0.00639	0.5	0.52	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78468576	chr15:78480057~78481820:-
LAML	cis	rs4713118	0.826	rs2893929	ENSG00000187763.3	OR2B7P	5.13	2.34e-06	0.0064	0.71	0.52	Parkinson's disease;	chr6:27770953	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.666	rs4140646	ENSG00000187763.3	OR2B7P	5.13	2.34e-06	0.0064	0.71	0.52	Parkinson's disease;	chr6:27771022	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.666	rs2893930	ENSG00000187763.3	OR2B7P	5.13	2.34e-06	0.0064	0.71	0.52	Parkinson's disease;	chr6:27771027	chr6:28046434~28047367:+
LAML	cis	rs2980439	0.517	rs17594093	ENSG00000268955.2	RP11-556O5.6	5.13	2.34e-06	0.0064	0.62	0.52	Neuroticism;	chr8:8248884	chr8:8188535~8189195:-
LAML	cis	rs6951245	0.638	rs74976697	ENSG00000229043.2	AC091729.9	-5.13	2.34e-06	0.0064	-0.77	-0.52	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1160374~1165267:+
LAML	cis	rs7829975	0.514	rs2945873	ENSG00000268955.2	RP11-556O5.6	-5.13	2.34e-06	0.00641	-0.58	-0.52	Mood instability;	chr8:8402935	chr8:8188535~8189195:-
LAML	cis	rs79040073	0.911	rs17393193	ENSG00000276593.1	RP11-295H24.5	5.13	2.35e-06	0.00642	0.55	0.52	Lung cancer in ever smokers;	chr15:49039882	chr15:49353485~49354034:+
LAML	cis	rs10500715	0.519	rs10770080	ENSG00000254719.1	RP11-351I24.3	-5.13	2.35e-06	0.00643	-0.62	-0.52	Pancreatic cancer;	chr11:10002146	chr11:10272052~10272259:-
LAML	cis	rs7131987	0.565	rs2882294	ENSG00000275476.1	RP11-996F15.4	5.13	2.35e-06	0.00643	0.57	0.52	QT interval;	chr12:29245019	chr12:29277397~29277882:-
LAML	cis	rs67311347	0.544	rs2278929	ENSG00000223797.4	ENTPD3-AS1	-5.13	2.35e-06	0.00643	-0.63	-0.52	Renal cell carcinoma;	chr3:40309517	chr3:40313802~40453329:-
LAML	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-5.13	2.35e-06	0.00643	-0.63	-0.52	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
LAML	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-5.13	2.35e-06	0.00644	-0.7	-0.52	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
LAML	cis	rs2486288	0.656	rs8039354	ENSG00000259520.4	CTD-2651B20.3	-5.13	2.36e-06	0.00645	-0.76	-0.52	Glomerular filtration rate;	chr15:45259558	chr15:45251580~45279251:-
LAML	cis	rs1075265	0.756	rs809280	ENSG00000235937.1	AC008280.1	5.13	2.36e-06	0.00646	0.43	0.52	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54029552~54030682:-
LAML	cis	rs4591358	0.648	rs72927801	ENSG00000223466.1	AC064834.2	-5.13	2.36e-06	0.00646	-0.84	-0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195565736	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.608	rs56323139	ENSG00000223466.1	AC064834.2	-5.13	2.36e-06	0.00646	-0.84	-0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195567001	chr2:195533035~195538681:+
LAML	cis	rs2921073	0.51	rs2976945	ENSG00000253893.2	FAM85B	-5.13	2.36e-06	0.00646	-0.57	-0.52	Parkinson's disease;	chr8:8413361	chr8:8167819~8226614:-
LAML	cis	rs1075265	0.54	rs2542587	ENSG00000235937.1	AC008280.1	5.13	2.36e-06	0.00646	0.41	0.52	Chronotype;Morning vs. evening chronotype;	chr2:53788839	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.563	rs2692537	ENSG00000235937.1	AC008280.1	5.13	2.36e-06	0.00646	0.41	0.52	Chronotype;Morning vs. evening chronotype;	chr2:53788840	chr2:54029552~54030682:-
LAML	cis	rs2404602	0.598	rs71405204	ENSG00000259422.1	RP11-593F23.1	-5.13	2.37e-06	0.00647	-0.67	-0.52	Blood metabolite levels;	chr15:76342964	chr15:76174891~76181486:-
LAML	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	5.13	2.37e-06	0.00647	0.61	0.52	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
LAML	cis	rs12571093	0.773	rs61854802	ENSG00000234102.1	KRT19P4	-5.13	2.37e-06	0.00647	-0.82	-0.52	Optic nerve measurement (disc area);	chr10:68249815	chr10:68260557~68261499:+
LAML	cis	rs2120335	0.891	rs6758142	ENSG00000221443.1	AC017083.1	5.13	2.37e-06	0.00648	0.63	0.52	Height;	chr2:68127766	chr2:68273104~68273206:+
LAML	cis	rs62070183	0.882	rs17183295	ENSG00000201178.1	Y_RNA	5.13	2.37e-06	0.00648	0.74	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32751254	chr17:32830219~32830329:-
LAML	cis	rs4803480	0.573	rs2302188	ENSG00000239736.2	CEACAMP3	5.13	2.37e-06	0.00649	0.66	0.52	Schizophrenia;	chr19:41579520	chr19:41599735~41605984:+
LAML	cis	rs6782228	0.848	rs3935016	ENSG00000277250.1	Metazoa_SRP	5.13	2.38e-06	0.0065	0.68	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701591	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.848	rs6439141	ENSG00000277250.1	Metazoa_SRP	5.13	2.38e-06	0.0065	0.68	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701691	chr3:128673681~128674021:-
LAML	cis	rs6782228	0.883	rs6439142	ENSG00000277250.1	Metazoa_SRP	5.13	2.38e-06	0.0065	0.68	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128701714	chr3:128673681~128674021:-
LAML	cis	rs6951245	0.81	rs117800627	ENSG00000229043.2	AC091729.9	-5.13	2.38e-06	0.0065	-0.87	-0.52	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1041439	chr7:1160374~1165267:+
LAML	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	5.13	2.38e-06	0.00651	0.59	0.52	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
LAML	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-5.13	2.38e-06	0.00651	-0.66	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
LAML	cis	rs785830	0.749	rs487275	ENSG00000235880.1	RP11-59O6.3	5.13	2.38e-06	0.00651	0.44	0.52	Platelet distribution width;	chr9:257349	chr9:267966~273002:-
LAML	cis	rs965604	1	rs12593229	ENSG00000259474.1	RP11-650L12.1	-5.13	2.39e-06	0.00651	-0.51	-0.52	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78472948	chr15:78480057~78481820:-
LAML	cis	rs7131987	0.565	rs7137141	ENSG00000274315.1	RP11-996F15.5	5.13	2.39e-06	0.00652	0.54	0.52	QT interval;	chr12:29272168	chr12:29331434~29331936:-
LAML	cis	rs73219805	0.838	rs17055172	ENSG00000228451.3	SDAD1P1	-5.13	2.39e-06	0.00653	-0.6	-0.52	Schizophrenia;	chr8:26368096	chr8:26379259~26382953:-
LAML	cis	rs763121	0.962	rs138703	ENSG00000230912.1	RP3-508I15.10	-5.13	2.39e-06	0.00653	-0.4	-0.52	Menopause (age at onset);	chr22:38736743	chr22:38666508~38668750:-
LAML	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-5.13	2.4e-06	0.00654	-0.65	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
LAML	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	5.13	2.4e-06	0.00654	0.63	0.52	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
LAML	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-5.13	2.4e-06	0.00654	-0.62	-0.52	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
LAML	cis	rs7429990	0.901	rs6442102	ENSG00000229759.1	MRPS18AP1	-5.12	2.4e-06	0.00655	-0.62	-0.52	Educational attainment (years of education);	chr3:48111072	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.803	rs11714518	ENSG00000229759.1	MRPS18AP1	-5.12	2.4e-06	0.00655	-0.62	-0.52	Educational attainment (years of education);	chr3:48115145	chr3:48256350~48256938:-
LAML	cis	rs2120335	1	rs62143871	ENSG00000221443.1	AC017083.1	5.12	2.41e-06	0.00656	0.64	0.52	Height;	chr2:68273446	chr2:68273104~68273206:+
LAML	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-5.12	2.42e-06	0.00658	-0.62	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
LAML	cis	rs9918079	0.56	rs7685083	ENSG00000249930.1	AC007016.3	5.12	2.42e-06	0.00659	0.64	0.52	Obesity-related traits;	chr4:15609148	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.506	rs7696127	ENSG00000249930.1	AC007016.3	-5.12	2.42e-06	0.00659	-0.64	-0.52	Obesity-related traits;	chr4:15641330	chr4:15492729~15492972:-
LAML	cis	rs2581828	0.549	rs7611386	ENSG00000280417.1	RP11-5O17.1	-5.12	2.42e-06	0.00659	-0.67	-0.52	Crohn's disease;	chr3:53019386	chr3:53046166~53048122:+
LAML	cis	rs904251	0.6	rs4714068	ENSG00000279942.1	RP1-153P14.7	-5.12	2.42e-06	0.00659	-0.5	-0.52	Cognitive performance;	chr6:37487866	chr6:37567716~37571460:+
LAML	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-5.12	2.43e-06	0.0066	-0.68	-0.52	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
LAML	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-5.12	2.43e-06	0.00661	-0.63	-0.52	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
LAML	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-5.12	2.43e-06	0.00661	-0.63	-0.52	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
LAML	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-5.12	2.43e-06	0.00661	-0.63	-0.52	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
LAML	cis	rs7826238	0.539	rs2945891	ENSG00000253893.2	FAM85B	-5.12	2.44e-06	0.00664	-0.59	-0.52	Systolic blood pressure;	chr8:8297953	chr8:8167819~8226614:-
LAML	cis	rs1555322	0.86	rs2425016	ENSG00000279253.1	RP4-614O4.13	-5.12	2.44e-06	0.00664	-0.68	-0.52	Attention deficit hyperactivity disorder;	chr20:35219446	chr20:35262727~35264187:-
LAML	cis	rs1555322	0.789	rs10211823	ENSG00000279253.1	RP4-614O4.13	-5.12	2.44e-06	0.00664	-0.68	-0.52	Attention deficit hyperactivity disorder;	chr20:35220467	chr20:35262727~35264187:-
LAML	cis	rs858239	0.799	rs10279941	ENSG00000230658.1	KLHL7-AS1	5.12	2.45e-06	0.00665	0.77	0.52	Cerebrospinal fluid biomarker levels;	chr7:23330889	chr7:23101228~23105703:-
LAML	cis	rs7495132	0.688	rs10048037	ENSG00000259314.1	CTD-3065B20.3	5.12	2.46e-06	0.00668	0.56	0.52	Ulcerative colitis;Inflammatory bowel disease;	chr15:90623604	chr15:90604225~90614558:-
LAML	cis	rs7115242	0.702	rs672058	ENSG00000254851.1	RP11-109L13.1	-5.12	2.47e-06	0.00669	-0.89	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116893305	chr11:117135528~117138582:+
LAML	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	5.12	2.47e-06	0.0067	0.7	0.52	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
LAML	cis	rs9322193	0.543	rs9371533	ENSG00000216906.2	RP11-350J20.9	5.12	2.47e-06	0.0067	0.69	0.52	Lung cancer;	chr6:149889545	chr6:149904243~149906418:+
LAML	cis	rs62070183	0.873	rs80212824	ENSG00000279781.1	RP11-466A19.7	5.12	2.47e-06	0.00671	0.8	0.52	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32703440	chr17:32518322~32518934:-
LAML	cis	rs2120335	1	rs2861818	ENSG00000221443.1	AC017083.1	5.12	2.48e-06	0.00672	0.63	0.52	Height;	chr2:68255216	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs7593613	ENSG00000221443.1	AC017083.1	5.12	2.48e-06	0.00672	0.63	0.52	Height;	chr2:68256264	chr2:68273104~68273206:+
LAML	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-5.12	2.49e-06	0.00674	-0.59	-0.52	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-5.12	2.49e-06	0.00674	-0.59	-0.52	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
LAML	cis	rs2120335	1	rs6742684	ENSG00000221443.1	AC017083.1	5.11	2.51e-06	0.00678	0.63	0.52	Height;	chr2:68243682	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs2029091	ENSG00000221443.1	AC017083.1	5.11	2.51e-06	0.00678	0.63	0.52	Height;	chr2:68250816	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.859	rs4519508	ENSG00000221443.1	AC017083.1	5.11	2.51e-06	0.00678	0.63	0.52	Height;	chr2:68252444	chr2:68273104~68273206:+
LAML	cis	rs3858145	0.588	rs61854833	ENSG00000234102.1	KRT19P4	-5.11	2.51e-06	0.00678	-0.72	-0.52	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68260557~68261499:+
LAML	cis	rs3758911	0.861	rs12287772	ENSG00000261098.1	RP11-819C21.1	-5.11	2.51e-06	0.00678	-0.51	-0.52	Coronary artery disease;	chr11:107271121	chr11:107312132~107316271:-
LAML	cis	rs11903757	1	rs4477849	ENSG00000281467.1	Clostridiales-1	5.11	2.52e-06	0.00681	1.05	0.52	Colorectal cancer;	chr2:191716203	chr2:191699476~191699631:-
LAML	cis	rs709400	0.628	rs59217746	ENSG00000258851.1	RP11-894P9.2	-5.11	2.52e-06	0.00682	-0.78	-0.52	Body mass index;	chr14:103638426	chr14:103553421~103561877:+
LAML	cis	rs3758911	0.929	rs10789600	ENSG00000261098.1	RP11-819C21.1	-5.11	2.53e-06	0.00683	-0.5	-0.52	Coronary artery disease;	chr11:107310335	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs10789602	ENSG00000261098.1	RP11-819C21.1	-5.11	2.53e-06	0.00683	-0.5	-0.52	Coronary artery disease;	chr11:107310729	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.964	rs10789603	ENSG00000261098.1	RP11-819C21.1	-5.11	2.53e-06	0.00683	-0.5	-0.52	Coronary artery disease;	chr11:107311050	chr11:107312132~107316271:-
LAML	cis	rs9918079	0.56	rs4270584	ENSG00000249930.1	AC007016.3	5.11	2.53e-06	0.00683	0.64	0.52	Obesity-related traits;	chr4:15599176	chr4:15492729~15492972:-
LAML	cis	rs9322193	0.961	rs9285521	ENSG00000216906.2	RP11-350J20.9	5.11	2.54e-06	0.00685	0.81	0.52	Lung cancer;	chr6:149585576	chr6:149904243~149906418:+
LAML	cis	rs11903757	0.945	rs115980813	ENSG00000281467.1	Clostridiales-1	-5.11	2.54e-06	0.00686	-1.17	-0.52	Colorectal cancer;	chr2:191692564	chr2:191699476~191699631:-
LAML	cis	rs763121	0.962	rs5757130	ENSG00000230912.1	RP3-508I15.10	-5.11	2.54e-06	0.00686	-0.41	-0.52	Menopause (age at onset);	chr22:38541789	chr22:38666508~38668750:-
LAML	cis	rs2455601	0.574	rs2568094	ENSG00000254860.4	TMEM9B-AS1	5.11	2.54e-06	0.00686	0.7	0.52	Schizophrenia;	chr11:8970671	chr11:8964675~8977527:+
LAML	cis	rs2455601	0.638	rs2742478	ENSG00000254860.4	TMEM9B-AS1	5.11	2.54e-06	0.00686	0.7	0.52	Schizophrenia;	chr11:8974552	chr11:8964675~8977527:+
LAML	cis	rs7301826	0.651	rs7968675	ENSG00000256299.1	RP11-989F5.3	-5.11	2.54e-06	0.00686	-0.67	-0.52	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810821~130812622:-
LAML	cis	rs1789	0.903	rs6850422	ENSG00000249930.1	AC007016.3	-5.11	2.55e-06	0.00687	-0.64	-0.52	Blood protein levels;	chr4:15680814	chr4:15492729~15492972:-
LAML	cis	rs7944735	0.69	rs7927682	ENSG00000263693.1	MIR3161	5.11	2.55e-06	0.00687	0.4	0.52	Intraocular pressure;	chr11:47926106	chr11:48096782~48096858:+
LAML	cis	rs853679	0.769	rs7752448	ENSG00000187763.3	OR2B7P	5.11	2.55e-06	0.00687	0.82	0.52	Depression;	chr6:28333322	chr6:28046434~28047367:+
LAML	cis	rs950027	0.549	rs11070452	ENSG00000259520.4	CTD-2651B20.3	5.11	2.55e-06	0.00688	0.75	0.52	Response to fenofibrate (adiponectin levels);	chr15:45302638	chr15:45251580~45279251:-
LAML	cis	rs950027	0.549	rs2899375	ENSG00000259520.4	CTD-2651B20.3	5.11	2.55e-06	0.00688	0.75	0.52	Response to fenofibrate (adiponectin levels);	chr15:45306137	chr15:45251580~45279251:-
LAML	cis	rs9326248	0.53	rs72645460	ENSG00000254851.1	RP11-109L13.1	5.11	2.55e-06	0.00688	0.95	0.52	Blood protein levels;	chr11:116900659	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs17120139	ENSG00000254851.1	RP11-109L13.1	5.11	2.55e-06	0.00688	0.95	0.52	Blood protein levels;	chr11:116903485	chr11:117135528~117138582:+
LAML	cis	rs12149695	0.872	rs12934078	ENSG00000259940.2	CTD-3203P2.1	-5.11	2.55e-06	0.00688	-0.57	-0.52	Gut microbiota (bacterial taxa);	chr16:27236340	chr16:27213308~27214993:-
LAML	cis	rs7826238	0.653	rs2979202	ENSG00000268955.2	RP11-556O5.6	-5.11	2.57e-06	0.00691	-0.69	-0.52	Systolic blood pressure;	chr8:8486617	chr8:8188535~8189195:-
LAML	cis	rs7944735	0.832	rs7130876	ENSG00000263693.1	MIR3161	5.11	2.57e-06	0.00692	0.42	0.52	Intraocular pressure;	chr11:48029443	chr11:48096782~48096858:+
LAML	cis	rs56114371	0.777	rs200481	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27806054	chr6:28073316~28074233:+
LAML	cis	rs56114371	0.777	rs200482	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27806126	chr6:28073316~28074233:+
LAML	cis	rs56114371	0.777	rs200483	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27807046	chr6:28073316~28074233:+
LAML	cis	rs45509595	0.822	rs200484	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27807896	chr6:28073316~28074233:+
LAML	cis	rs45509595	0.841	rs200485	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27807919	chr6:28073316~28074233:+
LAML	cis	rs45509595	0.841	rs9368531	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27814094	chr6:28073316~28074233:+
LAML	cis	rs45509595	0.841	rs370155	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27814253	chr6:28073316~28074233:+
LAML	cis	rs45509595	0.749	rs401763	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27814750	chr6:28073316~28074233:+
LAML	cis	rs45509595	0.659	rs390764	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27814757	chr6:28073316~28074233:+
LAML	cis	rs45509595	0.841	rs401754	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27814760	chr6:28073316~28074233:+
LAML	cis	rs45509595	0.841	rs2747054	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27815581	chr6:28073316~28074233:+
LAML	cis	rs45509595	0.841	rs200501	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Breast cancer;	chr6:27821164	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200490	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27829157	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs200489	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27830479	chr6:28073316~28074233:+
LAML	cis	rs853679	0.607	rs201002	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27840414	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs175597	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27842848	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200996	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27844050	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200990	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27848045	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200989	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27848664	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs34295134	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27860373	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200981	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27865396	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200948	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27867494	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200950	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27867994	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200952	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27869198	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200953	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27869489	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200954	ENSG00000220721.1	OR1F12	5.11	2.58e-06	0.00692	0.7	0.52	Depression;	chr6:27870986	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs200995	ENSG00000220721.1	OR1F12	-5.11	2.58e-06	0.00692	-0.7	-0.52	Depression;	chr6:27845916	chr6:28073316~28074233:+
LAML	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	5.11	2.58e-06	0.00692	0.57	0.52	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
LAML	cis	rs4591358	0.618	rs12993381	ENSG00000223466.1	AC064834.2	5.11	2.58e-06	0.00694	0.69	0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195542171	chr2:195533035~195538681:+
LAML	cis	rs4591358	0.634	rs13034419	ENSG00000223466.1	AC064834.2	5.11	2.58e-06	0.00694	0.69	0.52	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546166	chr2:195533035~195538681:+
LAML	cis	rs12149695	0.902	rs12924419	ENSG00000259940.2	CTD-3203P2.1	-5.11	2.59e-06	0.00694	-0.58	-0.52	Gut microbiota (bacterial taxa);	chr16:27243007	chr16:27213308~27214993:-
LAML	cis	rs4713118	0.955	rs9468201	ENSG00000220721.1	OR1F12	5.11	2.59e-06	0.00694	0.55	0.52	Parkinson's disease;	chr6:27719256	chr6:28073316~28074233:+
LAML	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	5.11	2.59e-06	0.00695	0.6	0.52	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
LAML	cis	rs67311347	0.544	rs2278927	ENSG00000223797.4	ENTPD3-AS1	5.11	2.59e-06	0.00695	0.64	0.52	Renal cell carcinoma;	chr3:40308956	chr3:40313802~40453329:-
LAML	cis	rs2726040	0.902	rs33957528	ENSG00000271623.1	RP11-435I10.5	5.11	2.59e-06	0.00695	0.59	0.52	Hip circumference;	chr16:28296619	chr16:28364700~28365333:+
LAML	cis	rs12468226	0.873	rs76552560	ENSG00000272966.1	RP11-686O6.1	5.1	2.6e-06	0.00698	0.85	0.52	Urate levels;	chr2:202173123	chr2:202336739~202337200:+
LAML	cis	rs853679	0.769	rs7752608	ENSG00000220721.1	OR1F12	5.1	2.61e-06	0.007	0.75	0.52	Depression;	chr6:28333418	chr6:28073316~28074233:+
LAML	cis	rs763121	0.925	rs9835	ENSG00000230912.1	RP3-508I15.10	-5.1	2.61e-06	0.00701	-0.42	-0.52	Menopause (age at onset);	chr22:38734966	chr22:38666508~38668750:-
LAML	cis	rs6940638	0.688	rs2022272	ENSG00000220721.1	OR1F12	5.1	2.62e-06	0.00701	0.54	0.52	Intelligence (multi-trait analysis);	chr6:27135801	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.955	rs9468204	ENSG00000220721.1	OR1F12	5.1	2.62e-06	0.00702	0.57	0.52	Parkinson's disease;	chr6:27721030	chr6:28073316~28074233:+
LAML	cis	rs12468226	0.689	rs73989731	ENSG00000272966.1	RP11-686O6.1	5.1	2.62e-06	0.00702	0.8	0.52	Urate levels;	chr2:202109309	chr2:202336739~202337200:+
LAML	cis	rs1757171	0.534	rs2797793	ENSG00000204110.6	RP1-153P14.8	5.1	2.62e-06	0.00702	0.68	0.52	Cognitive performance;	chr6:37509486	chr6:37507348~37535616:+
LAML	cis	rs709400	0.633	rs1951391	ENSG00000258851.1	RP11-894P9.2	-5.1	2.62e-06	0.00702	-0.65	-0.52	Body mass index;	chr14:103431976	chr14:103553421~103561877:+
LAML	cis	rs763121	0.962	rs6001193	ENSG00000230912.1	RP3-508I15.10	-5.1	2.63e-06	0.00703	-0.41	-0.52	Menopause (age at onset);	chr22:38678732	chr22:38666508~38668750:-
LAML	cis	rs763121	0.925	rs1056661	ENSG00000230912.1	RP3-508I15.10	-5.1	2.63e-06	0.00703	-0.41	-0.52	Menopause (age at onset);	chr22:38684240	chr22:38666508~38668750:-
LAML	cis	rs6951245	0.935	rs79067319	ENSG00000229043.2	AC091729.9	-5.1	2.63e-06	0.00703	-0.86	-0.52	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025912	chr7:1160374~1165267:+
LAML	cis	rs709400	0.663	rs72710714	ENSG00000258851.1	RP11-894P9.2	-5.1	2.63e-06	0.00704	-0.64	-0.52	Body mass index;	chr14:103515512	chr14:103553421~103561877:+
LAML	cis	rs79040073	0.911	rs11638981	ENSG00000276593.1	RP11-295H24.5	5.1	2.63e-06	0.00705	0.55	0.52	Lung cancer in ever smokers;	chr15:49029332	chr15:49353485~49354034:+
LAML	cis	rs8081395	0.603	rs1292047	ENSG00000267302.4	RP11-178C3.2	5.1	2.64e-06	0.00706	0.68	0.52	White blood cell count;	chr17:59877805	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.627	rs12952730	ENSG00000267302.4	RP11-178C3.2	5.1	2.64e-06	0.00706	0.68	0.52	White blood cell count;	chr17:59901475	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.627	rs180536	ENSG00000267302.4	RP11-178C3.2	5.1	2.64e-06	0.00706	0.68	0.52	White blood cell count;	chr17:59919445	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.58	rs180515	ENSG00000267302.4	RP11-178C3.2	5.1	2.64e-06	0.00706	0.68	0.52	White blood cell count;	chr17:59946914	chr17:59964832~59996972:+
LAML	cis	rs1789	0.903	rs4470622	ENSG00000249930.1	AC007016.3	-5.1	2.64e-06	0.00707	-0.64	-0.52	Blood protein levels;	chr4:15672552	chr4:15492729~15492972:-
LAML	cis	rs4713118	0.868	rs10484401	ENSG00000187763.3	OR2B7P	-5.1	2.64e-06	0.00707	-0.73	-0.52	Parkinson's disease;	chr6:27778811	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.868	rs35069907	ENSG00000187763.3	OR2B7P	5.1	2.64e-06	0.00707	0.73	0.52	Parkinson's disease;	chr6:27778913	chr6:28046434~28047367:+
LAML	cis	rs6700559	0.74	rs6663322	ENSG00000260088.1	RP11-92G12.3	5.1	2.64e-06	0.00707	0.62	0.52	Coronary artery disease;	chr1:200680741	chr1:200669507~200694250:+
LAML	cis	rs1075265	0.589	rs2253760	ENSG00000235937.1	AC008280.1	5.1	2.64e-06	0.00707	0.39	0.52	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54029552~54030682:-
LAML	cis	rs763121	0.962	rs909564	ENSG00000230912.1	RP3-508I15.10	-5.1	2.65e-06	0.00707	-0.42	-0.52	Menopause (age at onset);	chr22:38730503	chr22:38666508~38668750:-
LAML	cis	rs1075265	0.548	rs805448	ENSG00000235937.1	AC008280.1	5.1	2.65e-06	0.00708	0.41	0.52	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54029552~54030682:-
LAML	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-5.1	2.65e-06	0.00709	-0.64	-0.52	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
LAML	cis	rs785830	0.749	rs578216	ENSG00000235880.1	RP11-59O6.3	5.1	2.65e-06	0.00709	0.44	0.52	Platelet distribution width;	chr9:250935	chr9:267966~273002:-
LAML	cis	rs785830	0.655	rs588412	ENSG00000235880.1	RP11-59O6.3	-5.1	2.65e-06	0.00709	-0.44	-0.52	Platelet distribution width;	chr9:249391	chr9:267966~273002:-
LAML	cis	rs2455601	0.638	rs2742484	ENSG00000254860.4	TMEM9B-AS1	5.1	2.66e-06	0.0071	0.69	0.52	Schizophrenia;	chr11:8966536	chr11:8964675~8977527:+
LAML	cis	rs2455601	0.638	rs2248245	ENSG00000254860.4	TMEM9B-AS1	5.1	2.66e-06	0.0071	0.69	0.52	Schizophrenia;	chr11:8966803	chr11:8964675~8977527:+
LAML	cis	rs5769707	0.706	rs2071903	ENSG00000212939.2	RP1-29C18.10	-5.1	2.66e-06	0.00711	-0.71	-0.52	Monocyte percentage of white cells;Monocyte count;	chr22:49640869	chr22:49548681~49556473:+
LAML	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	5.1	2.66e-06	0.00712	0.58	0.52	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
LAML	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	5.1	2.66e-06	0.00712	0.58	0.52	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
LAML	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	5.1	2.66e-06	0.00712	0.58	0.52	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
LAML	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	5.1	2.66e-06	0.00712	0.58	0.52	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
LAML	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	5.1	2.66e-06	0.00712	0.58	0.52	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
LAML	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	5.1	2.66e-06	0.00712	0.58	0.52	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
LAML	cis	rs12468226	0.752	rs34829484	ENSG00000272966.1	RP11-686O6.1	-5.1	2.67e-06	0.00713	-0.8	-0.52	Urate levels;	chr2:202137267	chr2:202336739~202337200:+
LAML	cis	rs66887589	0.87	rs2389875	ENSG00000248280.1	RP11-33B1.2	-5.1	2.68e-06	0.00715	-0.62	-0.51	Diastolic blood pressure;	chr4:119635859	chr4:119440561~119450157:-
LAML	cis	rs67311347	1	rs9854493	ENSG00000230274.1	PGAM1P3	5.1	2.68e-06	0.00715	0.68	0.51	Renal cell carcinoma;	chr3:40382131	chr3:40322715~40323279:-
LAML	cis	rs172166	0.585	rs149963	ENSG00000216901.1	AL022393.7	5.1	2.69e-06	0.00718	0.59	0.51	Cardiac Troponin-T levels;	chr6:28049354	chr6:28176188~28176674:+
LAML	cis	rs911555	0.511	rs2296483	ENSG00000252469.1	RNU7-160P	-5.1	2.69e-06	0.00718	-0.61	-0.51	Intelligence (multi-trait analysis);	chr14:103563455	chr14:103550345~103550406:+
LAML	cis	rs4713118	0.824	rs742046	ENSG00000220721.1	OR1F12	5.1	2.69e-06	0.00718	0.56	0.51	Parkinson's disease;	chr6:27771475	chr6:28073316~28074233:+
LAML	cis	rs7581030	0.55	rs2670713	ENSG00000236469.1	AC007040.8	5.1	2.69e-06	0.00718	0.64	0.51	Testicular germ cell tumor;	chr2:71287846	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.583	rs71416704	ENSG00000236469.1	AC007040.8	5.1	2.69e-06	0.00718	0.64	0.51	Testicular germ cell tumor;	chr2:71291157	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2670747	ENSG00000236469.1	AC007040.8	5.1	2.69e-06	0.00718	0.64	0.51	Testicular germ cell tumor;	chr2:71298654	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542544	ENSG00000236469.1	AC007040.8	5.1	2.69e-06	0.00718	0.64	0.51	Testicular germ cell tumor;	chr2:71299491	chr2:71002531~71064743:-
LAML	cis	rs6964833	1	rs34324835	ENSG00000277053.3	GTF2IP1	-5.1	2.7e-06	0.00719	-0.71	-0.51	Menarche (age at onset);	chr7:74717986	chr7:75185385~75237696:-
LAML	cis	rs2120335	1	rs2278790	ENSG00000221443.1	AC017083.1	5.09	2.7e-06	0.0072	0.63	0.51	Height;	chr2:68218437	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs55801147	ENSG00000221443.1	AC017083.1	5.09	2.7e-06	0.0072	0.63	0.51	Height;	chr2:68220788	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.963	rs62143861	ENSG00000221443.1	AC017083.1	5.09	2.7e-06	0.0072	0.63	0.51	Height;	chr2:68224315	chr2:68273104~68273206:+
LAML	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-5.09	2.71e-06	0.00722	-0.62	-0.51	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.809	rs660129	ENSG00000224183.1	SDHDP6	-5.09	2.71e-06	0.00722	-0.62	-0.51	Erythrocyte sedimentation rate;	chr1:25400947	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.728	rs706845	ENSG00000224183.1	SDHDP6	-5.09	2.71e-06	0.00722	-0.62	-0.51	Erythrocyte sedimentation rate;	chr1:25404222	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs28633797	ENSG00000224183.1	SDHDP6	-5.09	2.71e-06	0.00722	-0.62	-0.51	Erythrocyte sedimentation rate;	chr1:25415138	chr1:25294164~25294643:-
LAML	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-5.09	2.71e-06	0.00722	-0.62	-0.51	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
LAML	cis	rs79040073	0.911	rs34895054	ENSG00000276593.1	RP11-295H24.5	5.09	2.73e-06	0.00723	0.55	0.51	Lung cancer in ever smokers;	chr15:48992804	chr15:49353485~49354034:+
LAML	cis	rs5769707	0.935	rs5770594	ENSG00000213279.2	RP1-29C18.9	-5.09	2.73e-06	0.00723	-0.57	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49624849	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.967	rs4524218	ENSG00000213279.2	RP1-29C18.9	-5.09	2.73e-06	0.00723	-0.57	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49624991	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.967	rs739248	ENSG00000213279.2	RP1-29C18.9	-5.09	2.73e-06	0.00723	-0.57	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49631557	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.967	rs2071904	ENSG00000213279.2	RP1-29C18.9	-5.09	2.73e-06	0.00723	-0.57	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49640829	chr22:49572264~49575426:-
LAML	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
LAML	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
LAML	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
LAML	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-5.09	2.73e-06	0.00723	-0.64	-0.51	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
LAML	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
LAML	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
LAML	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
LAML	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
LAML	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
LAML	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
LAML	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
LAML	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
LAML	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
LAML	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
LAML	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
LAML	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
LAML	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
LAML	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
LAML	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	5.09	2.73e-06	0.00723	0.64	0.51	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
LAML	cis	rs853679	0.505	rs200992	ENSG00000220721.1	OR1F12	5.09	2.73e-06	0.00723	0.71	0.51	Depression;	chr6:27846899	chr6:28073316~28074233:+
LAML	cis	rs2120335	1	rs7560138	ENSG00000221443.1	AC017083.1	5.09	2.73e-06	0.00724	0.63	0.51	Height;	chr2:68247634	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs6546365	ENSG00000221443.1	AC017083.1	5.09	2.73e-06	0.00724	0.63	0.51	Height;	chr2:68248154	chr2:68273104~68273206:+
LAML	cis	rs7495132	0.688	rs7165170	ENSG00000259314.1	CTD-3065B20.3	5.09	2.74e-06	0.00725	0.55	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90638257	chr15:90604225~90614558:-
LAML	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-5.09	2.74e-06	0.00726	-0.68	-0.51	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
LAML	cis	rs400736	0.765	rs225115	ENSG00000238249.2	HMGN2P17	-5.09	2.75e-06	0.00727	-0.63	-0.51	Response to antidepressants and depression;	chr1:7954388	chr1:8893409~8894151:+
LAML	cis	rs853679	0.607	rs13199649	ENSG00000182477.5	OR2B8P	5.09	2.75e-06	0.00727	0.94	0.51	Depression;	chr6:27901014	chr6:28053228~28054165:-
LAML	cis	rs67340775	0.834	rs13218875	ENSG00000182477.5	OR2B8P	5.09	2.75e-06	0.00727	0.94	0.51	Lung cancer in ever smokers;	chr6:27916234	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs67040724	ENSG00000182477.5	OR2B8P	5.09	2.75e-06	0.00727	0.94	0.51	Depression;	chr6:27937731	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs67662114	ENSG00000182477.5	OR2B8P	5.09	2.75e-06	0.00727	0.94	0.51	Depression;	chr6:27964523	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13216117	ENSG00000182477.5	OR2B8P	5.09	2.75e-06	0.00727	0.94	0.51	Depression;	chr6:27970706	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs36101351	ENSG00000182477.5	OR2B8P	5.09	2.75e-06	0.00727	0.94	0.51	Depression;	chr6:27975591	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs28360499	ENSG00000182477.5	OR2B8P	5.09	2.75e-06	0.00727	0.94	0.51	Depression;	chr6:27977618	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs71537572	ENSG00000182477.5	OR2B8P	5.09	2.75e-06	0.00727	0.94	0.51	Depression;	chr6:28002937	chr6:28053228~28054165:-
LAML	cis	rs853679	0.599	rs13193295	ENSG00000182477.5	OR2B8P	5.09	2.75e-06	0.00727	0.94	0.51	Depression;	chr6:28035450	chr6:28053228~28054165:-
LAML	cis	rs9660180	0.967	rs66701417	ENSG00000268575.1	RP1-283E3.8	-5.09	2.76e-06	0.00729	-0.58	-0.51	Body mass index;	chr1:1766653	chr1:1702736~1737688:-
LAML	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-5.09	2.76e-06	0.00729	-0.69	-0.51	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
LAML	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-5.09	2.76e-06	0.00729	-0.69	-0.51	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
LAML	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-5.09	2.76e-06	0.00729	-0.69	-0.51	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
LAML	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	5.09	2.76e-06	0.00729	0.69	0.51	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
LAML	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	5.09	2.76e-06	0.00729	0.69	0.51	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
LAML	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	5.09	2.76e-06	0.00729	0.69	0.51	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
LAML	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	5.09	2.76e-06	0.00729	0.69	0.51	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
LAML	cis	rs7613595	0.507	rs34937985	ENSG00000272498.1	RP11-415F23.3	5.09	2.76e-06	0.00729	0.67	0.51	Sum eosinophil basophil counts;	chr3:17084754	chr3:16339308~16339871:+
LAML	cis	rs6951245	1	rs75488469	ENSG00000229043.2	AC091729.9	-5.09	2.77e-06	0.00732	-0.88	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1062486	chr7:1160374~1165267:+
LAML	cis	rs763121	0.853	rs2235230	ENSG00000230912.1	RP3-508I15.10	5.09	2.77e-06	0.00732	0.45	0.51	Menopause (age at onset);	chr22:38728462	chr22:38666508~38668750:-
LAML	cis	rs11155671	0.53	rs6935829	ENSG00000216906.2	RP11-350J20.9	5.09	2.77e-06	0.00732	0.74	0.51	Testicular germ cell tumor;	chr6:149896675	chr6:149904243~149906418:+
LAML	cis	rs965604	1	rs1504549	ENSG00000259474.1	RP11-650L12.1	-5.09	2.77e-06	0.00732	-0.5	-0.51	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78474287	chr15:78480057~78481820:-
LAML	cis	rs965604	1	rs12910910	ENSG00000259474.1	RP11-650L12.1	-5.09	2.77e-06	0.00732	-0.5	-0.51	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78475508	chr15:78480057~78481820:-
LAML	cis	rs965604	1	rs8042238	ENSG00000259474.1	RP11-650L12.1	-5.09	2.77e-06	0.00732	-0.5	-0.51	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78481929	chr15:78480057~78481820:-
LAML	cis	rs965604	1	rs8042260	ENSG00000259474.1	RP11-650L12.1	-5.09	2.77e-06	0.00732	-0.5	-0.51	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78482032	chr15:78480057~78481820:-
LAML	cis	rs172166	0.637	rs1225592	ENSG00000220721.1	OR1F12	5.09	2.79e-06	0.00735	0.56	0.51	Cardiac Troponin-T levels;	chr6:28182464	chr6:28073316~28074233:+
LAML	cis	rs172166	0.637	rs1225595	ENSG00000220721.1	OR1F12	5.09	2.79e-06	0.00735	0.56	0.51	Cardiac Troponin-T levels;	chr6:28183562	chr6:28073316~28074233:+
LAML	cis	rs172166	0.637	rs1233691	ENSG00000220721.1	OR1F12	5.09	2.79e-06	0.00735	0.56	0.51	Cardiac Troponin-T levels;	chr6:28186119	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs35744819	ENSG00000220721.1	OR1F12	5.09	2.79e-06	0.00736	0.85	0.51	Depression;	chr6:28350554	chr6:28073316~28074233:+
LAML	cis	rs6921919	0.562	rs13198809	ENSG00000220721.1	OR1F12	5.09	2.79e-06	0.00736	0.85	0.51	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28073316~28074233:+
LAML	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-5.09	2.79e-06	0.00736	-0.63	-0.51	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
LAML	cis	rs3758911	0.964	rs11212158	ENSG00000261098.1	RP11-819C21.1	-5.09	2.79e-06	0.00736	-0.5	-0.51	Coronary artery disease;	chr11:107325745	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs11212159	ENSG00000261098.1	RP11-819C21.1	-5.09	2.79e-06	0.00736	-0.5	-0.51	Coronary artery disease;	chr11:107326003	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs11212160	ENSG00000261098.1	RP11-819C21.1	-5.09	2.79e-06	0.00736	-0.5	-0.51	Coronary artery disease;	chr11:107326192	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs1046095	ENSG00000261098.1	RP11-819C21.1	-5.09	2.79e-06	0.00736	-0.5	-0.51	Coronary artery disease;	chr11:107326509	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs3758911	ENSG00000261098.1	RP11-819C21.1	-5.09	2.79e-06	0.00736	-0.5	-0.51	Coronary artery disease;	chr11:107326914	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs11212164	ENSG00000261098.1	RP11-819C21.1	-5.09	2.79e-06	0.00736	-0.5	-0.51	Coronary artery disease;	chr11:107328113	chr11:107312132~107316271:-
LAML	cis	rs3758911	1	rs6588965	ENSG00000261098.1	RP11-819C21.1	-5.09	2.79e-06	0.00736	-0.5	-0.51	Coronary artery disease;	chr11:107330963	chr11:107312132~107316271:-
LAML	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	5.09	2.8e-06	0.00737	0.65	0.51	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
LAML	cis	rs9322193	0.504	rs7771014	ENSG00000216906.2	RP11-350J20.9	5.09	2.8e-06	0.00738	0.73	0.51	Lung cancer;	chr6:149884310	chr6:149904243~149906418:+
LAML	cis	rs7580658	0.614	rs2896888	ENSG00000236682.1	AC068282.3	-5.08	2.81e-06	0.0074	-0.63	-0.51	Protein C levels;	chr2:127208235	chr2:127389130~127400580:+
LAML	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	5.08	2.83e-06	0.00742	0.65	0.51	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
LAML	cis	rs748404	0.56	rs570933	ENSG00000249839.1	AC011330.5	-5.08	2.83e-06	0.00743	-0.6	-0.51	Lung cancer;	chr15:43531832	chr15:43663654~43684339:-
LAML	cis	rs748404	0.56	rs689797	ENSG00000249839.1	AC011330.5	-5.08	2.83e-06	0.00743	-0.6	-0.51	Lung cancer;	chr15:43534359	chr15:43663654~43684339:-
LAML	cis	rs748404	0.56	rs2255663	ENSG00000249839.1	AC011330.5	5.08	2.83e-06	0.00743	0.6	0.51	Lung cancer;	chr15:43536810	chr15:43663654~43684339:-
LAML	cis	rs2143950	0.607	rs58770366	ENSG00000241052.1	RP11-173D9.1	-5.08	2.83e-06	0.00744	-0.92	-0.51	Atopic dermatitis;	chr14:35058817	chr14:35144021~35144480:-
LAML	cis	rs6951245	0.935	rs11766669	ENSG00000229043.2	AC091729.9	-5.08	2.84e-06	0.00747	-0.86	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1023957	chr7:1160374~1165267:+
LAML	cis	rs7587476	0.862	rs13001462	ENSG00000227769.6	AC072062.3	-5.08	2.85e-06	0.00748	-0.58	-0.51	Neuroblastoma;	chr2:214813622	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.822	rs13018304	ENSG00000227769.6	AC072062.3	-5.08	2.85e-06	0.00748	-0.58	-0.51	Neuroblastoma;	chr2:214817494	chr2:215004782~215085488:+
LAML	cis	rs2980439	0.525	rs2945238	ENSG00000268955.2	RP11-556O5.6	-5.08	2.85e-06	0.00749	-0.58	-0.51	Neuroticism;	chr8:8312614	chr8:8188535~8189195:-
LAML	cis	rs7495132	0.563	rs71407322	ENSG00000259314.1	CTD-3065B20.3	5.08	2.86e-06	0.00749	0.55	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90652986	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.563	rs4516207	ENSG00000259314.1	CTD-3065B20.3	5.08	2.86e-06	0.00749	0.55	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90653136	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.563	rs62025073	ENSG00000259314.1	CTD-3065B20.3	5.08	2.86e-06	0.00749	0.55	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90654016	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.563	rs62025074	ENSG00000259314.1	CTD-3065B20.3	5.08	2.86e-06	0.00749	0.55	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90654019	chr15:90604225~90614558:-
LAML	cis	rs7131987	0.834	rs1989478	ENSG00000274315.1	RP11-996F15.5	5.08	2.86e-06	0.00749	0.52	0.51	QT interval;	chr12:29289296	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.834	rs12228468	ENSG00000274315.1	RP11-996F15.5	-5.08	2.86e-06	0.00749	-0.52	-0.51	QT interval;	chr12:29300677	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.801	rs6487804	ENSG00000274315.1	RP11-996F15.5	5.08	2.86e-06	0.00749	0.52	0.51	QT interval;	chr12:29302001	chr12:29331434~29331936:-
LAML	cis	rs1075265	0.87	rs7569370	ENSG00000235937.1	AC008280.1	5.08	2.86e-06	0.0075	0.43	0.51	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54029552~54030682:-
LAML	cis	rs1577917	0.958	rs28442244	ENSG00000203875.9	SNHG5	5.08	2.88e-06	0.00753	0.66	0.51	Response to antipsychotic treatment;	chr6:85991518	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-5.08	2.88e-06	0.00754	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
LAML	cis	rs9322193	0.923	rs9505982	ENSG00000216906.2	RP11-350J20.9	5.08	2.89e-06	0.00755	0.73	0.51	Lung cancer;	chr6:149618465	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9322196	ENSG00000216906.2	RP11-350J20.9	5.08	2.89e-06	0.00755	0.73	0.51	Lung cancer;	chr6:149619645	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs10747275	ENSG00000216906.2	RP11-350J20.9	5.08	2.89e-06	0.00755	0.73	0.51	Lung cancer;	chr6:149622782	chr6:149904243~149906418:+
LAML	cis	rs9457247	0.534	rs1130033	ENSG00000265828.1	MIR3939	-5.08	2.9e-06	0.00758	-0.64	-0.51	Crohn's disease;	chr6:166972135	chr6:166997807~166997912:-
LAML	cis	rs709400	0.659	rs7160366	ENSG00000258851.1	RP11-894P9.2	-5.08	2.9e-06	0.00759	-0.63	-0.51	Body mass index;	chr14:103477800	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs7145113	ENSG00000258851.1	RP11-894P9.2	-5.08	2.9e-06	0.00759	-0.63	-0.51	Body mass index;	chr14:103479077	chr14:103553421~103561877:+
LAML	cis	rs1789	0.786	rs6449161	ENSG00000249930.1	AC007016.3	-5.08	2.9e-06	0.00759	-0.67	-0.51	Blood protein levels;	chr4:15691331	chr4:15492729~15492972:-
LAML	cis	rs6782228	0.876	rs34198449	ENSG00000277250.1	Metazoa_SRP	5.08	2.91e-06	0.0076	0.79	0.51	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128673681~128674021:-
LAML	cis	rs9918079	0.56	rs4698409	ENSG00000249930.1	AC007016.3	-5.07	2.92e-06	0.00763	-0.64	-0.51	Obesity-related traits;	chr4:15658143	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.542	rs1789	ENSG00000249930.1	AC007016.3	-5.07	2.92e-06	0.00763	-0.64	-0.51	Obesity-related traits;	chr4:15662912	chr4:15492729~15492972:-
LAML	cis	rs2015599	0.54	rs12301475	ENSG00000274315.1	RP11-996F15.5	5.07	2.92e-06	0.00764	0.52	0.51	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29331434~29331936:-
LAML	cis	rs73219805	1	rs73219805	ENSG00000228451.3	SDAD1P1	-5.07	2.94e-06	0.00767	-0.6	-0.51	Schizophrenia;	chr8:26415252	chr8:26379259~26382953:-
LAML	cis	rs7587476	0.784	rs13026390	ENSG00000227769.6	AC072062.3	5.07	2.96e-06	0.00772	0.58	0.51	Neuroblastoma;	chr2:214822351	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.784	rs17424051	ENSG00000227769.6	AC072062.3	-5.07	2.96e-06	0.00772	-0.58	-0.51	Neuroblastoma;	chr2:214824268	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.784	rs62202001	ENSG00000227769.6	AC072062.3	-5.07	2.96e-06	0.00772	-0.58	-0.51	Neuroblastoma;	chr2:214825635	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.736	rs62202002	ENSG00000227769.6	AC072062.3	-5.07	2.96e-06	0.00772	-0.58	-0.51	Neuroblastoma;	chr2:214825876	chr2:215004782~215085488:+
LAML	cis	rs13113518	0.729	rs12641881	ENSG00000249700.7	SRD5A3-AS1	5.07	2.96e-06	0.00773	0.55	0.51	Height;	chr4:55401306	chr4:55363971~55395847:-
LAML	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	5.07	2.96e-06	0.00773	0.63	0.51	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	5.07	2.96e-06	0.00773	0.63	0.51	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	5.07	2.96e-06	0.00773	0.63	0.51	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
LAML	cis	rs9322193	0.576	rs7452592	ENSG00000216906.2	RP11-350J20.9	5.07	2.97e-06	0.00775	0.77	0.51	Lung cancer;	chr6:149875445	chr6:149904243~149906418:+
LAML	cis	rs763121	0.853	rs5750673	ENSG00000230912.1	RP3-508I15.10	-5.07	2.97e-06	0.00775	-0.45	-0.51	Menopause (age at onset);	chr22:38714119	chr22:38666508~38668750:-
LAML	cis	rs6951245	0.678	rs28600085	ENSG00000229043.2	AC091729.9	-5.07	2.97e-06	0.00775	-0.76	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.706	rs28483034	ENSG00000229043.2	AC091729.9	-5.07	2.97e-06	0.00775	-0.76	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1160374~1165267:+
LAML	cis	rs7429990	0.896	rs7427648	ENSG00000229759.1	MRPS18AP1	-5.07	2.97e-06	0.00776	-0.62	-0.51	Educational attainment (years of education);	chr3:48116749	chr3:48256350~48256938:-
LAML	cis	rs2455601	0.638	rs2568092	ENSG00000254860.4	TMEM9B-AS1	-5.07	2.98e-06	0.00776	-0.67	-0.51	Schizophrenia;	chr11:8965891	chr11:8964675~8977527:+
LAML	cis	rs1555322	0.53	rs6058224	ENSG00000261582.1	RP4-614O4.11	-5.07	2.98e-06	0.00776	-0.56	-0.51	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35267885~35280043:-
LAML	cis	rs1555322	0.53	rs2425053	ENSG00000261582.1	RP4-614O4.11	-5.07	2.98e-06	0.00776	-0.56	-0.51	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35267885~35280043:-
LAML	cis	rs7301826	0.651	rs1554807	ENSG00000256299.1	RP11-989F5.3	5.07	2.98e-06	0.00776	0.67	0.51	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs2037789	ENSG00000256299.1	RP11-989F5.3	5.07	2.98e-06	0.00776	0.67	0.51	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.61	rs7957899	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs1973834	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs4759517	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs7132657	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs7971046	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs10734979	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs4759519	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.627	rs10773823	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.627	rs73162873	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs12228957	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs12228959	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.61	rs4759789	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.61	rs4759791	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs4759521	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs10734981	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs10744483	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs10744484	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs10773825	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs7295705	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs10848210	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.627	rs4325342	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.627	rs1077317	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs4759525	ENSG00000256299.1	RP11-989F5.3	-5.07	2.98e-06	0.00776	-0.67	-0.51	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810821~130812622:-
LAML	cis	rs2455601	0.671	rs2568091	ENSG00000254860.4	TMEM9B-AS1	5.07	3e-06	0.00781	0.68	0.51	Schizophrenia;	chr11:8964501	chr11:8964675~8977527:+
LAML	cis	rs2455601	0.638	rs2742485	ENSG00000254860.4	TMEM9B-AS1	5.07	3e-06	0.00781	0.68	0.51	Schizophrenia;	chr11:8965240	chr11:8964675~8977527:+
LAML	cis	rs13217239	0.574	rs9366680	ENSG00000241549.7	GUSBP2	5.07	3.02e-06	0.00785	0.52	0.51	Schizophrenia;	chr6:27038344	chr6:26871484~26956554:-
LAML	cis	rs748404	0.578	rs512628	ENSG00000249839.1	AC011330.5	-5.07	3.02e-06	0.00785	-0.57	-0.51	Lung cancer;	chr15:43326536	chr15:43663654~43684339:-
LAML	cis	rs8031584	0.678	rs798127	ENSG00000260382.1	RP11-540B6.2	-5.07	3.02e-06	0.00786	-0.57	-0.51	Huntington's disease progression;	chr15:30825200	chr15:30882267~30883231:-
LAML	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-5.07	3.02e-06	0.00786	-0.64	-0.51	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
LAML	cis	rs709400	0.628	rs7155014	ENSG00000258851.1	RP11-894P9.2	-5.07	3.02e-06	0.00786	-0.64	-0.51	Body mass index;	chr14:103397633	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs1989565	ENSG00000258851.1	RP11-894P9.2	5.07	3.02e-06	0.00786	0.64	0.51	Body mass index;	chr14:103395856	chr14:103553421~103561877:+
LAML	cis	rs7587476	0.784	rs34112702	ENSG00000227769.6	AC072062.3	-5.07	3.02e-06	0.00786	-0.58	-0.51	Neuroblastoma;	chr2:214831278	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.784	rs13008641	ENSG00000227769.6	AC072062.3	-5.07	3.02e-06	0.00786	-0.58	-0.51	Neuroblastoma;	chr2:214833309	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.784	rs13032278	ENSG00000227769.6	AC072062.3	-5.07	3.02e-06	0.00786	-0.58	-0.51	Neuroblastoma;	chr2:214833310	chr2:215004782~215085488:+
LAML	cis	rs7131987	0.868	rs7958210	ENSG00000274315.1	RP11-996F15.5	5.07	3.02e-06	0.00786	0.52	0.51	QT interval;	chr12:29242248	chr12:29331434~29331936:-
LAML	cis	rs763121	1	rs763121	ENSG00000230912.1	RP3-508I15.10	5.07	3.03e-06	0.00787	0.43	0.51	Menopause (age at onset);	chr22:38483935	chr22:38666508~38668750:-
LAML	cis	rs6940638	0.688	rs9393791	ENSG00000220721.1	OR1F12	5.07	3.03e-06	0.00787	0.53	0.51	Intelligence (multi-trait analysis);	chr6:27164750	chr6:28073316~28074233:+
LAML	cis	rs709400	0.603	rs2296486	ENSG00000258851.1	RP11-894P9.2	-5.07	3.03e-06	0.00789	-0.64	-0.51	Body mass index;	chr14:103536733	chr14:103553421~103561877:+
LAML	cis	rs709400	0.633	rs2296484	ENSG00000258851.1	RP11-894P9.2	-5.07	3.03e-06	0.00789	-0.64	-0.51	Body mass index;	chr14:103536757	chr14:103553421~103561877:+
LAML	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	5.06	3.05e-06	0.00792	0.67	0.51	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-5.06	3.05e-06	0.00792	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-5.06	3.05e-06	0.00792	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-5.06	3.05e-06	0.00792	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-5.06	3.05e-06	0.00792	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-5.06	3.05e-06	0.00792	-0.67	-0.51	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
LAML	cis	rs6668108	1	rs6668108	ENSG00000224358.1	RP11-466F5.8	-5.06	3.05e-06	0.00793	-0.76	-0.51	Intraocular pressure;	chr1:165722083	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.887	rs7518099	ENSG00000224358.1	RP11-466F5.8	-5.06	3.05e-06	0.00793	-0.76	-0.51	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165767643	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.887	rs2790053	ENSG00000224358.1	RP11-466F5.8	-5.06	3.05e-06	0.00793	-0.76	-0.51	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165768467	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.778	rs2790052	ENSG00000224358.1	RP11-466F5.8	-5.06	3.05e-06	0.00793	-0.76	-0.51	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769226	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.887	rs4657476	ENSG00000224358.1	RP11-466F5.8	5.06	3.05e-06	0.00793	0.76	0.51	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165763424	chr1:165768929~165775176:+
LAML	cis	rs7587476	1	rs3768707	ENSG00000227769.6	AC072062.3	-5.06	3.06e-06	0.00794	-0.58	-0.51	Neuroblastoma;	chr2:214780411	chr2:215004782~215085488:+
LAML	cis	rs2704588	0.542	rs11734924	ENSG00000207524.1	RNU6-33P	5.06	3.06e-06	0.00794	0.81	0.51	Longevity;	chr4:89107365	chr4:88684848~88684954:-
LAML	cis	rs763121	0.819	rs5757133	ENSG00000230912.1	RP3-508I15.10	5.06	3.06e-06	0.00794	0.43	0.51	Menopause (age at onset);	chr22:38551830	chr22:38666508~38668750:-
LAML	cis	rs935334	0.866	rs12587652	ENSG00000280078.1	RP11-361H10.5	-5.06	3.06e-06	0.00794	-0.78	-0.51	Blood pressure;	chr14:76222270	chr14:76279173~76283103:+
LAML	cis	rs935334	0.877	rs2197480	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76159099	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs1900120	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76160173	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs2543384	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76160958	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs2543387	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76162703	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs1900122	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76163174	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs2591092	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76163790	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs2591094	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76165992	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs8005686	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76167624	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs12437310	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76176414	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs4304957	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76181229	chr14:76279173~76283103:+
LAML	cis	rs935334	0.825	rs4389088	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76181254	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs4442739	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76181302	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs2121070	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76184421	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs2360977	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76188138	chr14:76279173~76283103:+
LAML	cis	rs935334	0.935	rs1900124	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76190323	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs4899586	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76194513	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs11159183	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76196559	chr14:76279173~76283103:+
LAML	cis	rs935334	0.877	rs7158766	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76197208	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs6574278	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76197495	chr14:76279173~76283103:+
LAML	cis	rs935334	0.935	rs6574279	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76197595	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs2121071	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76199134	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs4903386	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76203315	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs2121075	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76209197	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs8006048	ENSG00000280078.1	RP11-361H10.5	5.06	3.06e-06	0.00794	0.78	0.51	Blood pressure;	chr14:76217165	chr14:76279173~76283103:+
LAML	cis	rs853679	1	rs735765	ENSG00000182477.5	OR2B8P	5.06	3.07e-06	0.00794	0.87	0.51	Depression;	chr6:28202519	chr6:28053228~28054165:-
LAML	cis	rs935334	1	rs1900125	ENSG00000280078.1	RP11-361H10.5	-5.06	3.07e-06	0.00795	-0.78	-0.51	Blood pressure;	chr14:76191127	chr14:76279173~76283103:+
LAML	cis	rs1075265	0.73	rs7601692	ENSG00000235937.1	AC008280.1	5.06	3.09e-06	0.00799	0.42	0.51	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54029552~54030682:-
LAML	cis	rs7429990	0.828	rs10446426	ENSG00000229759.1	MRPS18AP1	-5.06	3.09e-06	0.00801	-0.66	-0.51	Educational attainment (years of education);	chr3:48129031	chr3:48256350~48256938:-
LAML	cis	rs7581030	0.501	rs2542524	ENSG00000236469.1	AC007040.8	5.06	3.1e-06	0.00802	0.63	0.51	Testicular germ cell tumor;	chr2:71384699	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542486	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71312914	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2670730	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71315006	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs113259129	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71318389	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs13010975	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71330169	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542491	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71334126	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.517	rs2542497	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71343612	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2670753	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71348513	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2670729	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71351571	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.517	rs2542500	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71356044	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542501	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71356061	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2670704	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71357277	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.517	rs2670705	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71358382	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542502	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71358798	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542507	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71361233	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542515	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71369597	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs35616139	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71373891	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs12373702	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71374014	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs1861849	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71377355	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs1861850	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71377729	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542519	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71378671	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542521	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71382303	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs34607567	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71387348	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.583	rs2542529	ENSG00000236469.1	AC007040.8	-5.06	3.11e-06	0.00803	-0.63	-0.51	Testicular germ cell tumor;	chr2:71388441	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.534	rs6729375	ENSG00000236469.1	AC007040.8	-5.06	3.11e-06	0.00803	-0.63	-0.51	Testicular germ cell tumor;	chr2:71390514	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2900811	ENSG00000236469.1	AC007040.8	-5.06	3.11e-06	0.00803	-0.63	-0.51	Testicular germ cell tumor;	chr2:71407458	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs12466025	ENSG00000236469.1	AC007040.8	-5.06	3.11e-06	0.00803	-0.63	-0.51	Testicular germ cell tumor;	chr2:71408801	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs3732257	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71421934	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs11674310	ENSG00000236469.1	AC007040.8	5.06	3.11e-06	0.00803	0.63	0.51	Testicular germ cell tumor;	chr2:71431036	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs7561348	ENSG00000236469.1	AC007040.8	-5.06	3.11e-06	0.00803	-0.63	-0.51	Testicular germ cell tumor;	chr2:71440568	chr2:71002531~71064743:-
LAML	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs7747824	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85937388	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs6914463	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85943697	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs34852683	ENSG00000203875.9	SNHG5	-5.06	3.11e-06	0.00803	-0.65	-0.51	Response to antipsychotic treatment;	chr6:85992612	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	5.06	3.11e-06	0.00803	0.65	0.51	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	5.06	3.11e-06	0.00803	0.65	0.51	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	5.06	3.11e-06	0.00803	0.65	0.51	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
LAML	cis	rs3758911	0.861	rs11212117	ENSG00000261098.1	RP11-819C21.1	-5.06	3.12e-06	0.00803	-0.5	-0.51	Coronary artery disease;	chr11:107276757	chr11:107312132~107316271:-
LAML	cis	rs8037137	0.915	rs2290202	ENSG00000258725.1	PRC1-AS1	-5.06	3.12e-06	0.00803	-0.91	-0.51	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90969037	chr15:90966345~90988624:+
LAML	cis	rs8037137	0.749	rs12594925	ENSG00000258725.1	PRC1-AS1	-5.06	3.12e-06	0.00803	-0.91	-0.51	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90977057	chr15:90966345~90988624:+
LAML	cis	rs8037137	0.915	rs2301825	ENSG00000258725.1	PRC1-AS1	-5.06	3.12e-06	0.00803	-0.91	-0.51	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90984840	chr15:90966345~90988624:+
LAML	cis	rs8037137	0.915	rs12594752	ENSG00000258725.1	PRC1-AS1	-5.06	3.12e-06	0.00803	-0.91	-0.51	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90988765	chr15:90966345~90988624:+
LAML	cis	rs8037137	0.915	rs76119208	ENSG00000258725.1	PRC1-AS1	-5.06	3.12e-06	0.00803	-0.91	-0.51	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90992099	chr15:90966345~90988624:+
LAML	cis	rs8037137	0.731	rs78029804	ENSG00000258725.1	PRC1-AS1	-5.06	3.12e-06	0.00803	-0.91	-0.51	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90995690	chr15:90966345~90988624:+
LAML	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	5.06	3.13e-06	0.00806	0.58	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
LAML	cis	rs853679	0.723	rs1736904	ENSG00000220721.1	OR1F12	5.06	3.13e-06	0.00806	0.59	0.51	Depression;	chr6:28251492	chr6:28073316~28074233:+
LAML	cis	rs7587476	1	rs7587476	ENSG00000227769.6	AC072062.3	5.06	3.13e-06	0.00806	0.58	0.51	Neuroblastoma;	chr2:214789163	chr2:215004782~215085488:+
LAML	cis	rs9467773	0.511	rs17278688	ENSG00000241549.7	GUSBP2	5.06	3.13e-06	0.00806	0.55	0.51	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26871484~26956554:-
LAML	cis	rs9467773	0.511	rs11755443	ENSG00000241549.7	GUSBP2	5.06	3.13e-06	0.00806	0.55	0.51	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26871484~26956554:-
LAML	cis	rs4713118	0.868	rs742047	ENSG00000187763.3	OR2B7P	5.06	3.14e-06	0.00807	0.7	0.51	Parkinson's disease;	chr6:27771601	chr6:28046434~28047367:+
LAML	cis	rs6951245	0.882	rs10252404	ENSG00000229043.2	AC091729.9	-5.06	3.15e-06	0.00809	-0.77	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1169971	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.882	rs10256720	ENSG00000229043.2	AC091729.9	-5.06	3.15e-06	0.00809	-0.77	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1171189	chr7:1160374~1165267:+
LAML	cis	rs916888	0.773	rs199535	ENSG00000280985.1	AC217773.1	5.06	3.15e-06	0.0081	0.71	0.51	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:46172089~46172239:-
LAML	cis	rs2015599	0.563	rs11050168	ENSG00000274315.1	RP11-996F15.5	5.05	3.15e-06	0.0081	0.53	0.51	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29331434~29331936:-
LAML	cis	rs6964833	0.786	rs35633336	ENSG00000277053.3	GTF2IP1	-5.05	3.15e-06	0.0081	-0.7	-0.51	Menarche (age at onset);	chr7:74643961	chr7:75185385~75237696:-
LAML	cis	rs6964833	0.935	rs34630792	ENSG00000277053.3	GTF2IP1	-5.05	3.15e-06	0.0081	-0.7	-0.51	Menarche (age at onset);	chr7:74646869	chr7:75185385~75237696:-
LAML	cis	rs6964833	0.935	rs35735900	ENSG00000277053.3	GTF2IP1	-5.05	3.15e-06	0.0081	-0.7	-0.51	Menarche (age at onset);	chr7:74651887	chr7:75185385~75237696:-
LAML	cis	rs6964833	0.872	rs4717903	ENSG00000277053.3	GTF2IP1	-5.05	3.15e-06	0.0081	-0.7	-0.51	Menarche (age at onset);	chr7:74653827	chr7:75185385~75237696:-
LAML	cis	rs2120335	1	rs2122127	ENSG00000221443.1	AC017083.1	5.05	3.16e-06	0.0081	0.63	0.51	Height;	chr2:68218222	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs1822469	ENSG00000221443.1	AC017083.1	5.05	3.16e-06	0.0081	0.63	0.51	Height;	chr2:68227553	chr2:68273104~68273206:+
LAML	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-5.05	3.16e-06	0.0081	-0.62	-0.51	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
LAML	cis	rs2280018	0.538	rs7404526	ENSG00000260735.1	RP11-72I8.1	-5.05	3.17e-06	0.0081	-0.58	-0.51	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035305	chr16:15094411~15109197:+
LAML	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
LAML	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
LAML	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
LAML	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs801192	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66566965	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs801190	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66568046	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs3857686	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66571204	chr7:65773620~65802067:+
LAML	cis	rs875971	0.638	rs3898855	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66571411	chr7:65773620~65802067:+
LAML	cis	rs875971	0.638	rs10278816	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66572000	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs10281080	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66577454	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs10950044	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66577989	chr7:65773620~65802067:+
LAML	cis	rs6952407	1	rs6952407	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Cotinine glucuronidation;	chr7:66580525	chr7:65773620~65802067:+
LAML	cis	rs875971	0.638	rs10249404	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66581737	chr7:65773620~65802067:+
LAML	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs10215132	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66589419	chr7:65773620~65802067:+
LAML	cis	rs875971	0.522	rs1968127	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66591816	chr7:65773620~65802067:+
LAML	cis	rs875971	0.638	rs6460305	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66595421	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs10272357	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66598087	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
LAML	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs7807930	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66622178	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs7807944	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66622208	chr7:65773620~65802067:+
LAML	cis	rs875971	0.638	rs7793569	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66651646	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs6975195	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66659787	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs3857688	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66662819	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs2286684	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66664843	chr7:65773620~65802067:+
LAML	cis	rs801193	0.935	rs2286683	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66664856	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs10274773	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66668591	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs7785213	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66673991	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs11773829	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66676087	chr7:65773620~65802067:+
LAML	cis	rs801193	0.935	rs3800820	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66682191	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs2003301	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66682669	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs7788576	ENSG00000224316.1	RP11-479O9.2	-5.05	3.17e-06	0.0081	-0.53	-0.51	Aortic root size;	chr7:66683315	chr7:65773620~65802067:+
LAML	cis	rs801193	0.935	rs2659916	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66686365	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs6958520	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66686466	chr7:65773620~65802067:+
LAML	cis	rs801193	0.967	rs2707849	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66687725	chr7:65773620~65802067:+
LAML	cis	rs801193	0.967	rs2707841	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66692033	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs2707836	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66695448	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs4717310	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66696020	chr7:65773620~65802067:+
LAML	cis	rs801193	0.844	rs7779971	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66696803	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs2659906	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66700323	chr7:65773620~65802067:+
LAML	cis	rs801193	0.935	rs11772264	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66711400	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs7782320	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66712111	chr7:65773620~65802067:+
LAML	cis	rs801193	0.935	rs2659899	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66721734	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs62466793	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66726530	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs62466794	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66726592	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs1553609	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66732152	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs1553610	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66732246	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs2707845	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66733811	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs2707850	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66738883	chr7:65773620~65802067:+
LAML	cis	rs801193	0.967	rs1110414	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66740595	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs7783924	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66744070	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs7789184	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66745208	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs2707856	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66746023	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs2707854	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66747610	chr7:65773620~65802067:+
LAML	cis	rs801193	0.967	rs2707853	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66749023	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs2659889	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66752125	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs3800812	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66758474	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs4279493	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66761633	chr7:65773620~65802067:+
LAML	cis	rs801193	1	rs10252765	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66763745	chr7:65773620~65802067:+
LAML	cis	rs801193	0.761	rs2659888	ENSG00000224316.1	RP11-479O9.2	5.05	3.17e-06	0.0081	0.53	0.51	Aortic root size;	chr7:66765184	chr7:65773620~65802067:+
LAML	cis	rs7165170	0.808	rs34935401	ENSG00000259314.1	CTD-3065B20.3	5.05	3.17e-06	0.0081	0.55	0.51	Crohn's disease;Inflammatory bowel disease;	chr15:90651053	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.563	rs35392347	ENSG00000259314.1	CTD-3065B20.3	5.05	3.17e-06	0.0081	0.55	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90651196	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.563	rs71407321	ENSG00000259314.1	CTD-3065B20.3	5.05	3.17e-06	0.0081	0.55	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90652870	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.563	rs35583150	ENSG00000259314.1	CTD-3065B20.3	5.05	3.17e-06	0.0081	0.55	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90652920	chr15:90604225~90614558:-
LAML	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-5.05	3.17e-06	0.0081	-0.63	-0.51	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
LAML	cis	rs7581030	0.55	rs12991834	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71243338	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs71414900	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71244548	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs34909753	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71251196	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs11675407	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71252197	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs71414902	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71252966	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs71416703	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71253269	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs74941436	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71253319	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs74183186	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71255141	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs35360709	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71257636	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs12987985	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71258234	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs36083616	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71258363	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs7421916	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71259266	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2609505	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71261814	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2609506	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71262313	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2609504	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71264481	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2609503	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71264510	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542531	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71268418	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2670741	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71271281	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2670743	ENSG00000236469.1	AC007040.8	5.05	3.17e-06	0.0081	0.63	0.51	Testicular germ cell tumor;	chr2:71271400	chr2:71002531~71064743:-
LAML	cis	rs853679	0.666	rs200956	ENSG00000220721.1	OR1F12	5.05	3.17e-06	0.0081	0.62	0.51	Depression;	chr6:27871968	chr6:28073316~28074233:+
LAML	cis	rs904251	0.523	rs10947675	ENSG00000279942.1	RP1-153P14.7	-5.05	3.18e-06	0.00811	-0.53	-0.51	Cognitive performance;	chr6:37512196	chr6:37567716~37571460:+
LAML	cis	rs748404	0.631	rs28702649	ENSG00000249839.1	AC011330.5	-5.05	3.18e-06	0.00812	-0.55	-0.51	Lung cancer;	chr15:43356431	chr15:43663654~43684339:-
LAML	cis	rs4774565	0.84	rs55948407	ENSG00000244879.4	GABPB1-AS1	-5.05	3.19e-06	0.00813	-0.56	-0.51	Breast cancer;	chr15:50376704	chr15:50354959~50372202:+
LAML	cis	rs875971	0.577	rs34888281	ENSG00000224316.1	RP11-479O9.2	-5.05	3.19e-06	0.00813	-0.55	-0.51	Aortic root size;	chr7:66120784	chr7:65773620~65802067:+
LAML	cis	rs8031584	0.678	rs4779496	ENSG00000260382.1	RP11-540B6.2	5.05	3.2e-06	0.00815	0.57	0.51	Huntington's disease progression;	chr15:30858851	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.678	rs4779497	ENSG00000260382.1	RP11-540B6.2	5.05	3.2e-06	0.00815	0.57	0.51	Huntington's disease progression;	chr15:30859162	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.678	rs8028173	ENSG00000260382.1	RP11-540B6.2	5.05	3.2e-06	0.00815	0.57	0.51	Huntington's disease progression;	chr15:30863546	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.706	rs2177670	ENSG00000260382.1	RP11-540B6.2	5.05	3.2e-06	0.00815	0.57	0.51	Huntington's disease progression;	chr15:30865548	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.678	rs36047941	ENSG00000260382.1	RP11-540B6.2	5.05	3.2e-06	0.00815	0.57	0.51	Huntington's disease progression;	chr15:30867032	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.678	rs4779790	ENSG00000260382.1	RP11-540B6.2	5.05	3.2e-06	0.00815	0.57	0.51	Huntington's disease progression;	chr15:30872392	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.678	rs8035703	ENSG00000260382.1	RP11-540B6.2	5.05	3.2e-06	0.00815	0.57	0.51	Huntington's disease progression;	chr15:30876269	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.678	rs798125	ENSG00000260382.1	RP11-540B6.2	-5.05	3.2e-06	0.00815	-0.57	-0.51	Huntington's disease progression;	chr15:30824597	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.697	rs798080	ENSG00000260382.1	RP11-540B6.2	-5.05	3.2e-06	0.00815	-0.57	-0.51	Huntington's disease progression;	chr15:30829966	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.723	rs711224	ENSG00000260382.1	RP11-540B6.2	-5.05	3.2e-06	0.00815	-0.57	-0.51	Huntington's disease progression;	chr15:30835718	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.652	rs2691683	ENSG00000260382.1	RP11-540B6.2	-5.05	3.2e-06	0.00815	-0.57	-0.51	Huntington's disease progression;	chr15:30842857	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.578	rs1088473	ENSG00000260382.1	RP11-540B6.2	-5.05	3.2e-06	0.00815	-0.57	-0.51	Huntington's disease progression;	chr15:30847095	chr15:30882267~30883231:-
LAML	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	5.05	3.2e-06	0.00816	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
LAML	cis	rs367615	0.512	rs246105	ENSG00000249476.1	CTD-2587M2.1	5.05	3.2e-06	0.00816	0.62	0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109337245	chr5:109237120~109326369:-
LAML	cis	rs9457247	0.529	rs6907666	ENSG00000265828.1	MIR3939	5.05	3.21e-06	0.00817	0.75	0.51	Crohn's disease;	chr6:167109907	chr6:166997807~166997912:-
LAML	cis	rs875971	0.522	rs1880556	ENSG00000224316.1	RP11-479O9.2	5.05	3.21e-06	0.00818	0.56	0.51	Aortic root size;	chr7:65967557	chr7:65773620~65802067:+
LAML	cis	rs875971	0.522	rs781144	ENSG00000224316.1	RP11-479O9.2	5.05	3.21e-06	0.00818	0.56	0.51	Aortic root size;	chr7:65975357	chr7:65773620~65802067:+
LAML	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-5.05	3.22e-06	0.00819	-0.68	-0.51	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
LAML	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	5.05	3.22e-06	0.00819	0.68	0.51	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
LAML	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	5.05	3.22e-06	0.00819	0.68	0.51	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
LAML	cis	rs7301826	1	rs2001483	ENSG00000256299.1	RP11-989F5.3	-5.05	3.23e-06	0.00821	-0.65	-0.51	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810821~130812622:-
LAML	cis	rs7301826	1	rs1609985	ENSG00000256299.1	RP11-989F5.3	-5.05	3.23e-06	0.00821	-0.65	-0.51	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810821~130812622:-
LAML	cis	rs911555	0.887	rs2071407	ENSG00000258851.1	RP11-894P9.2	-5.05	3.23e-06	0.00822	-0.61	-0.51	Intelligence (multi-trait analysis);	chr14:103520803	chr14:103553421~103561877:+
LAML	cis	rs7587476	0.784	rs36086595	ENSG00000227769.6	AC072062.3	-5.05	3.24e-06	0.00825	-0.58	-0.51	Neuroblastoma;	chr2:214815569	chr2:215004782~215085488:+
LAML	cis	rs7587476	0.822	rs6726763	ENSG00000227769.6	AC072062.3	-5.05	3.24e-06	0.00825	-0.58	-0.51	Neuroblastoma;	chr2:214816856	chr2:215004782~215085488:+
LAML	cis	rs9355610	0.727	rs2247315	ENSG00000265828.1	MIR3939	5.05	3.24e-06	0.00825	0.65	0.51	Graves' disease;	chr6:166956723	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.515	rs2757039	ENSG00000265828.1	MIR3939	5.05	3.24e-06	0.00825	0.65	0.51	Crohn's disease;	chr6:166956865	chr6:166997807~166997912:-
LAML	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-5.05	3.25e-06	0.00825	-0.53	-0.51	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	5.05	3.25e-06	0.00825	0.53	0.51	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	5.05	3.25e-06	0.00825	0.53	0.51	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
LAML	cis	rs7495132	0.688	rs35696015	ENSG00000259314.1	CTD-3065B20.3	5.05	3.26e-06	0.00827	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90640397	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.646	rs71407319	ENSG00000259314.1	CTD-3065B20.3	5.05	3.26e-06	0.00827	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90640629	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.604	rs7171177	ENSG00000259314.1	CTD-3065B20.3	5.05	3.26e-06	0.00827	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90641426	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.688	rs7178774	ENSG00000259314.1	CTD-3065B20.3	5.05	3.26e-06	0.00827	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90641767	chr15:90604225~90614558:-
LAML	cis	rs2280018	0.581	rs7404524	ENSG00000260735.1	RP11-72I8.1	-5.05	3.26e-06	0.00828	-0.58	-0.51	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15035301	chr16:15094411~15109197:+
LAML	cis	rs7581030	0.517	rs71414899	ENSG00000236469.1	AC007040.8	5.05	3.27e-06	0.00829	0.63	0.51	Testicular germ cell tumor;	chr2:71235550	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs74414154	ENSG00000236469.1	AC007040.8	5.05	3.27e-06	0.00829	0.63	0.51	Testicular germ cell tumor;	chr2:71238325	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs9967713	ENSG00000236469.1	AC007040.8	5.05	3.27e-06	0.00829	0.63	0.51	Testicular germ cell tumor;	chr2:71238824	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs1824307	ENSG00000236469.1	AC007040.8	5.05	3.27e-06	0.00829	0.63	0.51	Testicular germ cell tumor;	chr2:71240300	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs17006804	ENSG00000236469.1	AC007040.8	5.05	3.27e-06	0.00829	0.63	0.51	Testicular germ cell tumor;	chr2:71240989	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs2542539	ENSG00000236469.1	AC007040.8	5.05	3.27e-06	0.00829	0.63	0.51	Testicular germ cell tumor;	chr2:71281382	chr2:71002531~71064743:-
LAML	cis	rs904251	0.523	rs9349039	ENSG00000279942.1	RP1-153P14.7	-5.05	3.27e-06	0.00829	-0.56	-0.51	Cognitive performance;	chr6:37512616	chr6:37567716~37571460:+
LAML	cis	rs904251	0.523	rs9366935	ENSG00000279942.1	RP1-153P14.7	-5.05	3.27e-06	0.00829	-0.56	-0.51	Cognitive performance;	chr6:37512628	chr6:37567716~37571460:+
LAML	cis	rs1789	0.872	rs4333182	ENSG00000249930.1	AC007016.3	-5.04	3.28e-06	0.00833	-0.68	-0.51	Blood protein levels;	chr4:15683089	chr4:15492729~15492972:-
LAML	cis	rs3758911	0.894	rs11212154	ENSG00000261098.1	RP11-819C21.1	-5.04	3.28e-06	0.00833	-0.51	-0.51	Coronary artery disease;	chr11:107319238	chr11:107312132~107316271:-
LAML	cis	rs9322193	0.923	rs55993747	ENSG00000216906.2	RP11-350J20.9	5.04	3.28e-06	0.00833	0.75	0.51	Lung cancer;	chr6:149622016	chr6:149904243~149906418:+
LAML	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	5.04	3.29e-06	0.00834	0.58	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
LAML	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	5.04	3.29e-06	0.00835	0.59	0.51	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
LAML	cis	rs4803480	0.578	rs7252454	ENSG00000239736.2	CEACAMP3	-5.04	3.3e-06	0.00836	-0.71	-0.51	Schizophrenia;	chr19:41527343	chr19:41599735~41605984:+
LAML	cis	rs9457247	0.508	rs7760495	ENSG00000265828.1	MIR3939	-5.04	3.31e-06	0.00838	-0.78	-0.51	Crohn's disease;	chr6:167093307	chr6:166997807~166997912:-
LAML	cis	rs3758911	0.964	rs10890702	ENSG00000261098.1	RP11-819C21.1	5.04	3.32e-06	0.00841	0.5	0.51	Coronary artery disease;	chr11:107310159	chr11:107312132~107316271:-
LAML	cis	rs62070183	0.766	rs10512441	ENSG00000263717.1	RP11-466A19.6	-5.04	3.32e-06	0.00841	-0.75	-0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32912627	chr17:32512869~32519350:-
LAML	cis	rs7587476	0.682	rs13009646	ENSG00000227769.6	AC072062.3	-5.04	3.32e-06	0.00842	-0.58	-0.51	Neuroblastoma;	chr2:214826535	chr2:215004782~215085488:+
LAML	cis	rs3096299	0.967	rs2965830	ENSG00000274627.1	RP11-104N10.2	5.04	3.33e-06	0.00843	0.64	0.51	Multiple myeloma (IgH translocation);	chr16:89393882	chr16:89516797~89522217:+
LAML	cis	rs7932354	0.528	rs12796744	ENSG00000271350.1	CTD-2384B9.1	5.04	3.33e-06	0.00844	0.5	0.51	Bone mineral density (hip);Bone mineral density;	chr11:47111173	chr11:47041027~47041945:-
LAML	cis	rs6940638	0.688	rs9393790	ENSG00000220721.1	OR1F12	-5.04	3.34e-06	0.00845	-0.53	-0.51	Intelligence (multi-trait analysis);	chr6:27146273	chr6:28073316~28074233:+
LAML	cis	rs7555523	0.887	rs4657477	ENSG00000224358.1	RP11-466F5.8	-5.04	3.34e-06	0.00846	-0.66	-0.51	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165766938	chr1:165768929~165775176:+
LAML	cis	rs13113518	0.729	rs11133377	ENSG00000249700.7	SRD5A3-AS1	5.04	3.35e-06	0.00847	0.58	0.51	Height;	chr4:55413708	chr4:55363971~55395847:-
LAML	cis	rs62070183	0.938	rs75782470	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32746623	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.882	rs62070164	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32759415	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs4795719	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32776957	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.882	rs17780981	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32792019	chr17:32518322~32518934:-
LAML	cis	rs112916054	1	rs112916054	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Immature fraction of reticulocytes;	chr17:32797244	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.752	rs17781005	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32805511	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.808	rs76373015	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815023	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.808	rs79957065	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32815731	chr17:32518322~32518934:-
LAML	cis	rs62070183	1	rs62070183	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32837349	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.882	rs17183600	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32848061	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.882	rs17781136	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32858024	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.882	rs62070187	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32863706	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.817	rs79640811	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32894299	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.766	rs62070229	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32900575	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.766	rs62070232	ENSG00000279781.1	RP11-466A19.7	5.04	3.38e-06	0.00853	0.75	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32903075	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.882	rs17183628	ENSG00000279781.1	RP11-466A19.7	-5.04	3.38e-06	0.00853	-0.75	-0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32857613	chr17:32518322~32518934:-
LAML	cis	rs62070183	0.938	rs17781142	ENSG00000279781.1	RP11-466A19.7	-5.04	3.38e-06	0.00853	-0.75	-0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32860198	chr17:32518322~32518934:-
LAML	cis	rs282544	0.632	rs2442107	ENSG00000213956.4	RP11-269M20.1	-5.04	3.39e-06	0.00855	-0.64	-0.51	Myopia (pathological);	chr5:50750133	chr5:50633124~50633602:+
LAML	cis	rs9399135	0.967	rs9399129	ENSG00000232876.1	CTA-212D2.2	-5.04	3.39e-06	0.00856	-0.67	-0.51	Red blood cell count;	chr6:134964010	chr6:135055033~135060550:+
LAML	cis	rs9322193	0.923	rs9766037	ENSG00000216906.2	RP11-350J20.9	5.04	3.4e-06	0.00857	0.73	0.51	Lung cancer;	chr6:149616921	chr6:149904243~149906418:+
LAML	cis	rs67311347	0.544	rs7644643	ENSG00000223797.4	ENTPD3-AS1	-5.04	3.4e-06	0.00857	-0.64	-0.51	Renal cell carcinoma;	chr3:40308718	chr3:40313802~40453329:-
LAML	cis	rs4713118	0.868	rs760587	ENSG00000187763.3	OR2B7P	5.04	3.4e-06	0.00858	0.7	0.51	Parkinson's disease;	chr6:27772521	chr6:28046434~28047367:+
LAML	cis	rs2120335	1	rs6733029	ENSG00000221443.1	AC017083.1	-5.04	3.4e-06	0.00859	-0.63	-0.51	Height;	chr2:68207025	chr2:68273104~68273206:+
LAML	cis	rs13201294	1	rs13201294	ENSG00000217315.1	OR2W2P	5.04	3.4e-06	0.00859	0.86	0.51	Squamous cell lung carcinoma;	chr6:27588362	chr6:28033947~28034855:+
LAML	cis	rs748404	0.646	rs2253268	ENSG00000249839.1	AC011330.5	-5.03	3.41e-06	0.00861	-0.59	-0.51	Lung cancer;	chr15:43508770	chr15:43663654~43684339:-
LAML	cis	rs67311347	1	rs73078169	ENSG00000230274.1	PGAM1P3	5.03	3.41e-06	0.00861	0.67	0.51	Renal cell carcinoma;	chr3:40442307	chr3:40322715~40323279:-
LAML	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-5.03	3.42e-06	0.00861	-0.64	-0.51	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
LAML	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-5.03	3.42e-06	0.00861	-0.64	-0.51	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
LAML	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-5.03	3.42e-06	0.00861	-0.64	-0.51	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-5.03	3.42e-06	0.00861	-0.64	-0.51	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
LAML	cis	rs7932354	0.528	rs4752952	ENSG00000271350.1	CTD-2384B9.1	-5.03	3.42e-06	0.00861	-0.52	-0.51	Bone mineral density (hip);Bone mineral density;	chr11:47061307	chr11:47041027~47041945:-
LAML	cis	rs7932354	0.528	rs7946709	ENSG00000271350.1	CTD-2384B9.1	-5.03	3.42e-06	0.00861	-0.52	-0.51	Bone mineral density (hip);Bone mineral density;	chr11:47079245	chr11:47041027~47041945:-
LAML	cis	rs763121	0.785	rs5750646	ENSG00000230912.1	RP3-508I15.10	-5.03	3.42e-06	0.00863	-0.42	-0.51	Menopause (age at onset);	chr22:38617825	chr22:38666508~38668750:-
LAML	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	5.03	3.44e-06	0.00865	0.54	0.51	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
LAML	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	5.03	3.44e-06	0.00865	0.54	0.51	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
LAML	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	5.03	3.44e-06	0.00865	0.54	0.51	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
LAML	cis	rs7932354	0.528	rs10838654	ENSG00000271350.1	CTD-2384B9.1	-5.03	3.44e-06	0.00865	-0.52	-0.51	Bone mineral density (hip);Bone mineral density;	chr11:47073960	chr11:47041027~47041945:-
LAML	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	5.03	3.44e-06	0.00865	0.55	0.51	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
LAML	cis	rs801193	0.967	rs3800823	ENSG00000224316.1	RP11-479O9.2	-5.03	3.45e-06	0.00867	-0.55	-0.51	Aortic root size;	chr7:66682123	chr7:65773620~65802067:+
LAML	cis	rs2581828	0.646	rs28501212	ENSG00000242142.1	SERBP1P3	-5.03	3.45e-06	0.00867	-0.57	-0.51	Crohn's disease;	chr3:53129041	chr3:53064283~53065091:-
LAML	cis	rs10500715	0.668	rs11042582	ENSG00000254719.1	RP11-351I24.3	-5.03	3.45e-06	0.00869	-0.63	-0.51	Pancreatic cancer;	chr11:9987250	chr11:10272052~10272259:-
LAML	cis	rs2980439	0.517	rs17594065	ENSG00000268955.2	RP11-556O5.6	5.03	3.46e-06	0.00869	0.6	0.51	Neuroticism;	chr8:8247883	chr8:8188535~8189195:-
LAML	cis	rs5769707	0.846	rs5770610	ENSG00000213279.2	RP1-29C18.9	-5.03	3.46e-06	0.00869	-0.57	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49643249	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.967	rs8141807	ENSG00000213279.2	RP1-29C18.9	-5.03	3.46e-06	0.00869	-0.57	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49650090	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.935	rs9616332	ENSG00000213279.2	RP1-29C18.9	-5.03	3.46e-06	0.00869	-0.57	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49654030	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.935	rs739239	ENSG00000213279.2	RP1-29C18.9	-5.03	3.46e-06	0.00869	-0.57	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49656820	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.874	rs9616714	ENSG00000213279.2	RP1-29C18.9	-5.03	3.46e-06	0.00869	-0.57	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49657211	chr22:49572264~49575426:-
LAML	cis	rs2412819	0.571	rs4923964	ENSG00000249839.1	AC011330.5	5.03	3.46e-06	0.0087	0.72	0.51	Lung cancer;	chr15:43722882	chr15:43663654~43684339:-
LAML	cis	rs763121	0.853	rs5750677	ENSG00000230912.1	RP3-508I15.10	-5.03	3.48e-06	0.00873	-0.43	-0.51	Menopause (age at onset);	chr22:38751710	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2072798	ENSG00000230912.1	RP3-508I15.10	-5.03	3.48e-06	0.00873	-0.43	-0.51	Menopause (age at onset);	chr22:38752478	chr22:38666508~38668750:-
LAML	cis	rs7714584	1	rs57406211	ENSG00000197083.10	ZNF300P1	5.03	3.5e-06	0.00876	1.11	0.51	Crohn's disease;	chr5:150791404	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs79442859	ENSG00000197083.10	ZNF300P1	5.03	3.5e-06	0.00876	1.11	0.51	Crohn's disease;	chr5:150791648	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs76872831	ENSG00000197083.10	ZNF300P1	5.03	3.5e-06	0.00876	1.11	0.51	Crohn's disease;	chr5:150791997	chr5:150930645~150946289:-
LAML	cis	rs7714584	0.826	rs12655654	ENSG00000197083.10	ZNF300P1	5.03	3.5e-06	0.00876	1.11	0.51	Crohn's disease;	chr5:150794733	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs74955473	ENSG00000197083.10	ZNF300P1	5.03	3.5e-06	0.00876	1.11	0.51	Crohn's disease;	chr5:150794996	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs79780973	ENSG00000197083.10	ZNF300P1	5.03	3.5e-06	0.00876	1.11	0.51	Crohn's disease;	chr5:150795248	chr5:150930645~150946289:-
LAML	cis	rs7495132	0.688	rs11073942	ENSG00000259314.1	CTD-3065B20.3	5.03	3.51e-06	0.0088	0.53	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90634402	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.688	rs7163000	ENSG00000259314.1	CTD-3065B20.3	5.03	3.51e-06	0.0088	0.53	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90635046	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.688	rs4932361	ENSG00000259314.1	CTD-3065B20.3	5.03	3.51e-06	0.0088	0.53	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90635817	chr15:90604225~90614558:-
LAML	cis	rs2581828	0.618	rs7615099	ENSG00000280417.1	RP11-5O17.1	-5.03	3.51e-06	0.0088	-0.69	-0.51	Crohn's disease;	chr3:53109885	chr3:53046166~53048122:+
LAML	cis	rs66887589	0.776	rs10518337	ENSG00000248280.1	RP11-33B1.2	-5.03	3.51e-06	0.0088	-0.63	-0.51	Diastolic blood pressure;	chr4:119653719	chr4:119440561~119450157:-
LAML	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-5.03	3.51e-06	0.0088	-0.68	-0.51	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
LAML	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	5.03	3.53e-06	0.00883	0.53	0.51	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	5.03	3.53e-06	0.00883	0.53	0.51	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	5.03	3.53e-06	0.00883	0.53	0.51	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	5.03	3.53e-06	0.00883	0.53	0.51	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	5.03	3.53e-06	0.00883	0.53	0.51	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
LAML	cis	rs12468226	1	rs7565875	ENSG00000226261.1	AC064836.3	5.02	3.54e-06	0.00887	0.89	0.51	Urate levels;	chr2:202516412	chr2:202336024~202336727:-
LAML	cis	rs9918079	0.643	rs35414597	ENSG00000249930.1	AC007016.3	5.02	3.55e-06	0.00888	0.63	0.51	Obesity-related traits;	chr4:15564113	chr4:15492729~15492972:-
LAML	cis	rs1577917	1	rs1999852	ENSG00000203875.9	SNHG5	-5.02	3.55e-06	0.00889	-0.64	-0.51	Response to antipsychotic treatment;	chr6:85996020	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs35797755	ENSG00000203875.9	SNHG5	-5.02	3.55e-06	0.00889	-0.64	-0.51	Response to antipsychotic treatment;	chr6:85996836	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-5.02	3.55e-06	0.00889	-0.64	-0.51	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
LAML	cis	rs12468226	1	rs3731696	ENSG00000226261.1	AC064836.3	5.02	3.56e-06	0.0089	0.93	0.51	Urate levels;	chr2:202567081	chr2:202336024~202336727:-
LAML	cis	rs12468226	0.81	rs115255999	ENSG00000226261.1	AC064836.3	5.02	3.56e-06	0.0089	0.93	0.51	Urate levels;	chr2:202572326	chr2:202336024~202336727:-
LAML	cis	rs9918079	0.524	rs4235379	ENSG00000249930.1	AC007016.3	-5.02	3.56e-06	0.0089	-0.62	-0.51	Obesity-related traits;	chr4:15657655	chr4:15492729~15492972:-
LAML	cis	rs7746199	0.736	rs35848276	ENSG00000182477.5	OR2B8P	5.02	3.56e-06	0.00891	0.95	0.51	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs13202295	ENSG00000182477.5	OR2B8P	5.02	3.56e-06	0.00891	0.95	0.51	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28053228~28054165:-
LAML	cis	rs785830	0.522	rs600509	ENSG00000235880.1	RP11-59O6.3	5.02	3.56e-06	0.00891	0.43	0.51	Platelet distribution width;	chr9:263645	chr9:267966~273002:-
LAML	cis	rs5769707	0.632	rs135871	ENSG00000280224.1	CTA-722E9.1	-5.02	3.56e-06	0.00892	-0.75	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49500568~49501585:+
LAML	cis	rs1863918	0.533	rs34346845	ENSG00000272431.1	RP11-281O15.8	5.02	3.58e-06	0.00894	0.79	0.51	Depression in response to interferon-based therapy in chronic hepatitis C;	chr5:179144506	chr5:178938677~178939223:-
LAML	cis	rs1863918	0.533	rs34132209	ENSG00000272431.1	RP11-281O15.8	5.02	3.58e-06	0.00894	0.79	0.51	Depression in response to interferon-based therapy in chronic hepatitis C;	chr5:179145883	chr5:178938677~178939223:-
LAML	cis	rs7714584	1	rs59980321	ENSG00000197083.10	ZNF300P1	5.02	3.58e-06	0.00894	1.03	0.51	Crohn's disease;	chr5:150862251	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs7709650	ENSG00000197083.10	ZNF300P1	5.02	3.58e-06	0.00894	1.03	0.51	Crohn's disease;	chr5:150867123	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs2115069	ENSG00000197083.10	ZNF300P1	5.02	3.58e-06	0.00894	1.03	0.51	Crohn's disease;	chr5:150872803	chr5:150930645~150946289:-
LAML	cis	rs12149695	0.966	rs4499236	ENSG00000259940.2	CTD-3203P2.1	-5.02	3.58e-06	0.00894	-0.57	-0.51	Gut microbiota (bacterial taxa);	chr16:27242810	chr16:27213308~27214993:-
LAML	cis	rs7829975	0.564	rs2921060	ENSG00000268955.2	RP11-556O5.6	5.02	3.58e-06	0.00895	0.62	0.51	Mood instability;	chr8:8460307	chr8:8188535~8189195:-
LAML	cis	rs9918079	0.6	rs61021642	ENSG00000249930.1	AC007016.3	5.02	3.59e-06	0.00897	0.63	0.51	Obesity-related traits;	chr4:15575702	chr4:15492729~15492972:-
LAML	cis	rs9918079	0.6	rs12500587	ENSG00000249930.1	AC007016.3	5.02	3.59e-06	0.00897	0.63	0.51	Obesity-related traits;	chr4:15579131	chr4:15492729~15492972:-
LAML	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	5.02	3.59e-06	0.00898	0.54	0.51	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
LAML	cis	rs747782	0.639	rs17198985	ENSG00000263693.1	MIR3161	5.02	3.6e-06	0.00899	0.49	0.51	Intraocular pressure;	chr11:48162013	chr11:48096782~48096858:+
LAML	cis	rs7944735	0.517	rs1827503	ENSG00000263693.1	MIR3161	5.02	3.6e-06	0.00899	0.49	0.51	Intraocular pressure;	chr11:48203563	chr11:48096782~48096858:+
LAML	cis	rs747782	0.527	rs75915859	ENSG00000263693.1	MIR3161	5.02	3.6e-06	0.00899	0.49	0.51	Intraocular pressure;	chr11:48211379	chr11:48096782~48096858:+
LAML	cis	rs2581828	0.608	rs9830353	ENSG00000242142.1	SERBP1P3	-5.02	3.61e-06	0.00901	-0.59	-0.51	Crohn's disease;	chr3:53129937	chr3:53064283~53065091:-
LAML	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-5.02	3.62e-06	0.00903	-0.56	-0.51	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
LAML	cis	rs7581030	0.583	rs6546688	ENSG00000236469.1	AC007040.8	-5.02	3.63e-06	0.00906	-0.63	-0.51	Testicular germ cell tumor;	chr2:71392062	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs6759859	ENSG00000236469.1	AC007040.8	-5.02	3.63e-06	0.00906	-0.63	-0.51	Testicular germ cell tumor;	chr2:71393965	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.617	rs10183833	ENSG00000236469.1	AC007040.8	-5.02	3.63e-06	0.00906	-0.63	-0.51	Testicular germ cell tumor;	chr2:71394251	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.617	rs12467344	ENSG00000236469.1	AC007040.8	-5.02	3.63e-06	0.00906	-0.63	-0.51	Testicular germ cell tumor;	chr2:71397236	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.583	rs13423885	ENSG00000236469.1	AC007040.8	-5.02	3.63e-06	0.00906	-0.63	-0.51	Testicular germ cell tumor;	chr2:71398052	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs6546689	ENSG00000236469.1	AC007040.8	-5.02	3.63e-06	0.00906	-0.63	-0.51	Testicular germ cell tumor;	chr2:71402314	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.5	rs7565768	ENSG00000236469.1	AC007040.8	-5.02	3.63e-06	0.00906	-0.63	-0.51	Testicular germ cell tumor;	chr2:71402901	chr2:71002531~71064743:-
LAML	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-5.02	3.65e-06	0.00909	-0.62	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
LAML	cis	rs13113518	0.812	rs12648271	ENSG00000249700.7	SRD5A3-AS1	5.02	3.65e-06	0.00909	0.54	0.51	Height;	chr4:55501955	chr4:55363971~55395847:-
LAML	cis	rs12145833	0.538	rs10754798	ENSG00000214837.7	LINC01347	5.02	3.65e-06	0.00909	0.85	0.51	Obesity (early onset extreme);	chr1:243146656	chr1:243056307~243101744:-
LAML	cis	rs12145833	0.596	rs12043646	ENSG00000214837.7	LINC01347	-5.02	3.65e-06	0.00909	-0.85	-0.51	Obesity (early onset extreme);	chr1:243118690	chr1:243056307~243101744:-
LAML	cis	rs12145833	0.596	rs12123491	ENSG00000214837.7	LINC01347	-5.02	3.65e-06	0.00909	-0.85	-0.51	Obesity (early onset extreme);	chr1:243134622	chr1:243056307~243101744:-
LAML	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	5.02	3.65e-06	0.00909	0.73	0.51	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
LAML	cis	rs7746199	0.736	rs58616630	ENSG00000187763.3	OR2B7P	5.02	3.67e-06	0.00913	0.97	0.51	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28046434~28047367:+
LAML	cis	rs7746199	0.736	rs34573979	ENSG00000187763.3	OR2B7P	5.02	3.67e-06	0.00913	0.97	0.51	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28046434~28047367:+
LAML	cis	rs7131987	0.903	rs918873	ENSG00000274315.1	RP11-996F15.5	5.01	3.68e-06	0.00916	0.52	0.51	QT interval;	chr12:29237568	chr12:29331434~29331936:-
LAML	cis	rs7555523	0.887	rs2251768	ENSG00000224358.1	RP11-466F5.8	-5.01	3.7e-06	0.00919	-0.76	-0.51	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769074	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.887	rs2814471	ENSG00000224358.1	RP11-466F5.8	-5.01	3.7e-06	0.00919	-0.76	-0.51	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165770361	chr1:165768929~165775176:+
LAML	cis	rs7131987	0.903	rs7970390	ENSG00000274315.1	RP11-996F15.5	5.01	3.71e-06	0.0092	0.52	0.51	QT interval;	chr12:29245722	chr12:29331434~29331936:-
LAML	cis	rs933769	0.867	rs12101666	ENSG00000242295.1	RP11-522B15.1	5.01	3.71e-06	0.00922	0.7	0.51	Alcoholism (alcohol dependence factor score);	chr15:95527058	chr15:96448154~96448493:+
LAML	cis	rs933769	0.867	rs6496116	ENSG00000242295.1	RP11-522B15.1	-5.01	3.71e-06	0.00922	-0.7	-0.51	Alcoholism (alcohol dependence factor score);	chr15:95527724	chr15:96448154~96448493:+
LAML	cis	rs763121	0.853	rs5750627	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38586316	chr22:38666508~38668750:-
LAML	cis	rs763121	0.819	rs5750629	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38589060	chr22:38666508~38668750:-
LAML	cis	rs763121	0.819	rs5757160	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38593641	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750633	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38597462	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757166	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38599380	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs1569716	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38602514	chr22:38666508~38668750:-
LAML	cis	rs763121	0.819	rs5757169	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38607490	chr22:38666508~38668750:-
LAML	cis	rs763121	0.626	rs5750643	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38613012	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs6001175	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38622329	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs4821798	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38625160	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750649	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38640764	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2179142	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38641949	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs6519124	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38649094	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750652	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38652311	chr22:38666508~38668750:-
LAML	cis	rs763121	0.814	rs5757212	ENSG00000230912.1	RP3-508I15.10	-5.01	3.72e-06	0.00923	-0.41	-0.51	Menopause (age at onset);	chr22:38657752	chr22:38666508~38668750:-
LAML	cis	rs9322193	0.886	rs4870055	ENSG00000216906.2	RP11-350J20.9	5.01	3.73e-06	0.00925	0.72	0.51	Lung cancer;	chr6:149848433	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs7769101	ENSG00000216906.2	RP11-350J20.9	5.01	3.73e-06	0.00925	0.72	0.51	Lung cancer;	chr6:149848768	chr6:149904243~149906418:+
LAML	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-5.01	3.74e-06	0.00927	-0.54	-0.51	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
LAML	cis	rs3758911	0.724	rs2216998	ENSG00000261098.1	RP11-819C21.1	-5.01	3.74e-06	0.00927	-0.48	-0.51	Coronary artery disease;	chr11:107246965	chr11:107312132~107316271:-
LAML	cis	rs801193	1	rs2659915	ENSG00000224316.1	RP11-479O9.2	5.01	3.75e-06	0.00928	0.53	0.51	Aortic root size;	chr7:66688114	chr7:65773620~65802067:+
LAML	cis	rs875971	0.638	rs35986979	ENSG00000224316.1	RP11-479O9.2	-5.01	3.75e-06	0.00928	-0.53	-0.51	Aortic root size;	chr7:66624003	chr7:65773620~65802067:+
LAML	cis	rs875971	0.642	rs35526611	ENSG00000224316.1	RP11-479O9.2	-5.01	3.75e-06	0.00928	-0.53	-0.51	Aortic root size;	chr7:66629021	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs3764903	ENSG00000224316.1	RP11-479O9.2	-5.01	3.75e-06	0.00928	-0.53	-0.51	Aortic root size;	chr7:66633495	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs1860470	ENSG00000224316.1	RP11-479O9.2	-5.01	3.75e-06	0.00928	-0.53	-0.51	Aortic root size;	chr7:66638707	chr7:65773620~65802067:+
LAML	cis	rs875971	0.66	rs1860468	ENSG00000224316.1	RP11-479O9.2	-5.01	3.75e-06	0.00928	-0.53	-0.51	Aortic root size;	chr7:66642265	chr7:65773620~65802067:+
LAML	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-5.01	3.76e-06	0.0093	-0.62	-0.51	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
LAML	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-5.01	3.76e-06	0.0093	-0.62	-0.51	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
LAML	cis	rs67383717	0.689	rs1836404	ENSG00000175611.10	LINC00476	-5.01	3.77e-06	0.00932	-0.52	-0.51	Parkinson's disease (pesticide exposure interaction);	chr9:95787982	chr9:95759231~95875977:-
LAML	cis	rs7495132	0.646	rs4932359	ENSG00000259314.1	CTD-3065B20.3	5.01	3.78e-06	0.00933	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90628992	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.646	rs74497428	ENSG00000259314.1	CTD-3065B20.3	5.01	3.78e-06	0.00933	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90629745	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.646	rs28621895	ENSG00000259314.1	CTD-3065B20.3	5.01	3.78e-06	0.00933	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90630394	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.688	rs16944683	ENSG00000259314.1	CTD-3065B20.3	5.01	3.78e-06	0.00933	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90631183	chr15:90604225~90614558:-
LAML	cis	rs853679	1	rs2799079	ENSG00000217315.1	OR2W2P	5.01	3.78e-06	0.00934	0.75	0.51	Depression;	chr6:28267398	chr6:28033947~28034855:+
LAML	cis	rs9457247	0.508	rs6941355	ENSG00000265828.1	MIR3939	-5.01	3.78e-06	0.00935	-0.77	-0.51	Crohn's disease;	chr6:167092750	chr6:166997807~166997912:-
LAML	cis	rs4879656	0.741	rs10813942	ENSG00000225693.1	LAGE3P1	-5.01	3.79e-06	0.00936	-0.56	-0.51	Menopause (age at onset);	chr9:33092837	chr9:33019682~33020165:-
LAML	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-5.01	3.8e-06	0.00938	-0.61	-0.51	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
LAML	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-5.01	3.8e-06	0.00938	-0.61	-0.51	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
LAML	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-5.01	3.8e-06	0.00938	-0.61	-0.51	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
LAML	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-5.01	3.8e-06	0.00938	-0.61	-0.51	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
LAML	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	5.01	3.8e-06	0.00938	0.61	0.51	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	5.01	3.8e-06	0.00938	0.61	0.51	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	5.01	3.8e-06	0.00938	0.61	0.51	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	5.01	3.8e-06	0.00938	0.61	0.51	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	5.01	3.8e-06	0.00938	0.61	0.51	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	5.01	3.8e-06	0.00938	0.61	0.51	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	5.01	3.8e-06	0.00938	0.61	0.51	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	5.01	3.8e-06	0.00938	0.61	0.51	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	5.01	3.8e-06	0.00938	0.61	0.51	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
LAML	cis	rs12052801	0.967	rs13019043	ENSG00000221443.1	AC017083.1	5.01	3.81e-06	0.00941	0.55	0.51	Schizophrenia;	chr2:68265654	chr2:68273104~68273206:+
LAML	cis	rs1419607	0.807	rs10954082	ENSG00000224897.5	POT1-AS1	5.01	3.82e-06	0.00942	0.56	0.51	Obesity-related traits;	chr7:125784109	chr7:124929873~125179315:+
LAML	cis	rs2412819	0.571	rs2930529	ENSG00000249839.1	AC011330.5	5.01	3.82e-06	0.00942	0.73	0.51	Lung cancer;	chr15:43819467	chr15:43663654~43684339:-
LAML	cis	rs2412819	0.571	rs2930530	ENSG00000249839.1	AC011330.5	5.01	3.82e-06	0.00942	0.73	0.51	Lung cancer;	chr15:43823268	chr15:43663654~43684339:-
LAML	cis	rs6772840	1	rs11721249	ENSG00000272077.1	RP11-348P10.2	-5.01	3.82e-06	0.00942	-0.98	-0.51	Subjective well-being;	chr3:43783562	chr3:44667412~44669364:+
LAML	cis	rs11903757	1	rs75519345	ENSG00000281467.1	Clostridiales-1	-5	3.83e-06	0.00943	-1.04	-0.51	Colorectal cancer;	chr2:191729446	chr2:191699476~191699631:-
LAML	cis	rs933769	0.867	rs6496113	ENSG00000242295.1	RP11-522B15.1	-5	3.83e-06	0.00945	-0.69	-0.51	Alcoholism (alcohol dependence factor score);	chr15:95526324	chr15:96448154~96448493:+
LAML	cis	rs763121	0.853	rs2076028	ENSG00000230912.1	RP3-508I15.10	-5	3.83e-06	0.00945	-0.43	-0.51	Menopause (age at onset);	chr22:38754445	chr22:38666508~38668750:-
LAML	cis	rs6964833	1	rs4717907	ENSG00000277053.3	GTF2IP1	-5	3.84e-06	0.00946	-0.69	-0.51	Menarche (age at onset);	chr7:74672169	chr7:75185385~75237696:-
LAML	cis	rs1075265	0.73	rs805392	ENSG00000235937.1	AC008280.1	5	3.85e-06	0.00948	0.4	0.51	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54029552~54030682:-
LAML	cis	rs875971	0.522	rs1617484	ENSG00000224316.1	RP11-479O9.2	5	3.85e-06	0.00948	0.55	0.51	Aortic root size;	chr7:65998108	chr7:65773620~65802067:+
LAML	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	5	3.85e-06	0.00948	0.63	0.51	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
LAML	cis	rs7944735	0.786	rs7123436	ENSG00000263693.1	MIR3161	5	3.85e-06	0.00948	0.41	0.51	Intraocular pressure;	chr11:47991932	chr11:48096782~48096858:+
LAML	cis	rs10500715	0.715	rs10840339	ENSG00000254719.1	RP11-351I24.3	-5	3.86e-06	0.00951	-0.63	-0.51	Pancreatic cancer;	chr11:9984330	chr11:10272052~10272259:-
LAML	cis	rs992157	0.737	rs3731860	ENSG00000261338.2	RP11-378A13.1	-5	3.87e-06	0.00952	-0.68	-0.51	Colorectal cancer;	chr2:218292256	chr2:218255319~218257366:+
LAML	cis	rs9457247	0.555	rs2247325	ENSG00000265828.1	MIR3939	5	3.88e-06	0.00954	0.63	0.51	Crohn's disease;	chr6:166956504	chr6:166997807~166997912:-
LAML	cis	rs9322193	0.923	rs9404048	ENSG00000216906.2	RP11-350J20.9	5	3.88e-06	0.00954	0.73	0.51	Lung cancer;	chr6:149616188	chr6:149904243~149906418:+
LAML	cis	rs8062405	0.754	rs151179	ENSG00000271623.1	RP11-435I10.5	-5	3.88e-06	0.00955	-0.6	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.721	rs151303	ENSG00000271623.1	RP11-435I10.5	-5	3.88e-06	0.00955	-0.6	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.756	rs151182	ENSG00000271623.1	RP11-435I10.5	-5	3.88e-06	0.00955	-0.6	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.756	rs151301	ENSG00000271623.1	RP11-435I10.5	-5	3.88e-06	0.00955	-0.6	-0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28364700~28365333:+
LAML	cis	rs471756	0.594	rs785843	ENSG00000235880.1	RP11-59O6.3	5	3.89e-06	0.00955	0.42	0.51	Mean platelet volume;	chr9:262617	chr9:267966~273002:-
LAML	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	5	3.89e-06	0.00955	0.74	0.51	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
LAML	cis	rs62070183	0.938	rs62068432	ENSG00000266599.1	RP11-466A19.3	5	3.9e-06	0.00958	0.79	0.51	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32739479	chr17:32518953~32531492:+
LAML	cis	rs9457247	0.534	rs7750593	ENSG00000231654.1	RPS6KA2-AS1	5	3.9e-06	0.00959	0.49	0.51	Crohn's disease;	chr6:166973871	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.515	rs1951459	ENSG00000231654.1	RPS6KA2-AS1	5	3.9e-06	0.00959	0.49	0.51	Crohn's disease;	chr6:166989048	chr6:166903698~166904835:+
LAML	cis	rs785830	0.749	rs543379	ENSG00000235880.1	RP11-59O6.3	5	3.91e-06	0.00959	0.44	0.51	Platelet distribution width;	chr9:265469	chr9:267966~273002:-
LAML	cis	rs7826238	0.539	rs2945891	ENSG00000268955.2	RP11-556O5.6	-5	3.92e-06	0.00962	-0.58	-0.51	Systolic blood pressure;	chr8:8297953	chr8:8188535~8189195:-
LAML	cis	rs763121	0.925	rs17032	ENSG00000230912.1	RP3-508I15.10	-5	3.92e-06	0.00962	-0.42	-0.51	Menopause (age at onset);	chr22:38734838	chr22:38666508~38668750:-
LAML	cis	rs904251	0.522	rs882322	ENSG00000229559.2	RP1-153P14.3	-5	3.92e-06	0.00962	-0.53	-0.51	Cognitive performance;	chr6:37516327	chr6:37543553~37547280:-
LAML	cis	rs2581828	0.896	rs12637287	ENSG00000280417.1	RP11-5O17.1	5	3.92e-06	0.00962	0.65	0.51	Crohn's disease;	chr3:53105425	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.931	rs2564942	ENSG00000280417.1	RP11-5O17.1	5	3.92e-06	0.00962	0.65	0.51	Crohn's disease;	chr3:53105490	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.931	rs2581774	ENSG00000280417.1	RP11-5O17.1	5	3.92e-06	0.00962	0.65	0.51	Crohn's disease;	chr3:53105491	chr3:53046166~53048122:+
LAML	cis	rs8081395	0.836	rs2063353	ENSG00000267302.4	RP11-178C3.2	-5	3.92e-06	0.00962	-0.63	-0.51	White blood cell count;	chr17:59811831	chr17:59964832~59996972:+
LAML	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	5	3.92e-06	0.00962	0.53	0.51	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	5	3.92e-06	0.00962	0.53	0.51	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	5	3.92e-06	0.00962	0.53	0.51	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	5	3.92e-06	0.00962	0.53	0.51	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	5	3.92e-06	0.00962	0.53	0.51	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
LAML	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	5	3.92e-06	0.00962	0.53	0.51	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
LAML	cis	rs4713118	0.955	rs9468200	ENSG00000220721.1	OR1F12	5	3.93e-06	0.00964	0.56	0.51	Parkinson's disease;	chr6:27715284	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.955	rs34752872	ENSG00000220721.1	OR1F12	5	3.93e-06	0.00964	0.56	0.51	Parkinson's disease;	chr6:27715465	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.955	rs9380010	ENSG00000220721.1	OR1F12	5	3.93e-06	0.00964	0.56	0.51	Parkinson's disease;	chr6:27715793	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.955	rs9368528	ENSG00000220721.1	OR1F12	5	3.93e-06	0.00964	0.56	0.51	Parkinson's disease;	chr6:27716019	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.955	rs9380011	ENSG00000220721.1	OR1F12	5	3.93e-06	0.00964	0.56	0.51	Parkinson's disease;	chr6:27716145	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.955	rs9368529	ENSG00000220721.1	OR1F12	5	3.93e-06	0.00964	0.56	0.51	Parkinson's disease;	chr6:27716852	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.955	rs9380012	ENSG00000220721.1	OR1F12	5	3.93e-06	0.00964	0.56	0.51	Parkinson's disease;	chr6:27716875	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.911	rs2394000	ENSG00000220721.1	OR1F12	5	3.93e-06	0.00964	0.56	0.51	Parkinson's disease;	chr6:27719212	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.955	rs9393847	ENSG00000220721.1	OR1F12	5	3.93e-06	0.00964	0.56	0.51	Parkinson's disease;	chr6:27720194	chr6:28073316~28074233:+
LAML	cis	rs7131987	0.585	rs2059362	ENSG00000273680.1	RP11-996F15.6	5	3.94e-06	0.00965	0.53	0.51	QT interval;	chr12:29243072	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs10843365	ENSG00000273680.1	RP11-996F15.6	5	3.94e-06	0.00965	0.53	0.51	QT interval;	chr12:29252691	chr12:29332733~29333383:-
LAML	cis	rs1075265	0.563	rs2542588	ENSG00000235937.1	AC008280.1	-5	3.94e-06	0.00965	-0.4	-0.51	Chronotype;Morning vs. evening chronotype;	chr2:53791787	chr2:54029552~54030682:-
LAML	cis	rs67311347	0.955	rs73078170	ENSG00000230274.1	PGAM1P3	5	3.95e-06	0.00966	0.7	0.51	Renal cell carcinoma;	chr3:40442456	chr3:40322715~40323279:-
LAML	cis	rs5769707	0.967	rs739241	ENSG00000264139.1	MIR3667	-5	3.95e-06	0.00967	-0.64	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49659273	chr22:49543393~49543466:-
LAML	cis	rs4713118	0.696	rs2394002	ENSG00000220721.1	OR1F12	5	3.96e-06	0.00968	0.56	0.51	Parkinson's disease;	chr6:27780236	chr6:28073316~28074233:+
LAML	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-5	3.96e-06	0.00968	-0.55	-0.51	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
LAML	cis	rs7555523	0.887	rs10800155	ENSG00000224358.1	RP11-466F5.8	-5	3.96e-06	0.00969	-0.76	-0.51	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165754533	chr1:165768929~165775176:+
LAML	cis	rs67311347	0.955	rs11711994	ENSG00000230274.1	PGAM1P3	5	3.97e-06	0.00971	0.66	0.51	Renal cell carcinoma;	chr3:40349595	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs11706148	ENSG00000230274.1	PGAM1P3	5	3.97e-06	0.00971	0.66	0.51	Renal cell carcinoma;	chr3:40365752	chr3:40322715~40323279:-
LAML	cis	rs6728642	1	rs11890407	ENSG00000235833.1	AC159540.14	5	3.97e-06	0.00971	0.91	0.51	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96955910	chr2:97523949~97524976:-
LAML	cis	rs67311347	1	rs1004655	ENSG00000230274.1	PGAM1P3	4.99	3.98e-06	0.00973	0.66	0.51	Renal cell carcinoma;	chr3:40448518	chr3:40322715~40323279:-
LAML	cis	rs5769707	0.681	rs4824068	ENSG00000212939.2	RP1-29C18.10	-4.99	3.99e-06	0.00974	-0.71	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49631153	chr22:49548681~49556473:+
LAML	cis	rs2564921	0.57	rs3821831	ENSG00000280417.1	RP11-5O17.1	-4.99	4e-06	0.00977	-0.68	-0.51	Height;	chr3:52819385	chr3:53046166~53048122:+
LAML	cis	rs763121	0.925	rs9611008	ENSG00000230912.1	RP3-508I15.10	-4.99	4e-06	0.00978	-0.41	-0.51	Menopause (age at onset);	chr22:38702782	chr22:38666508~38668750:-
LAML	cis	rs763121	0.925	rs4821815	ENSG00000230912.1	RP3-508I15.10	-4.99	4e-06	0.00978	-0.41	-0.51	Menopause (age at onset);	chr22:38709702	chr22:38666508~38668750:-
LAML	cis	rs1757171	0.542	rs1757186	ENSG00000229559.2	RP1-153P14.3	-4.99	4.01e-06	0.00979	-0.53	-0.51	Cognitive performance;	chr6:37516335	chr6:37543553~37547280:-
LAML	cis	rs12468226	0.689	rs60584169	ENSG00000272966.1	RP11-686O6.1	4.99	4.01e-06	0.0098	0.8	0.51	Urate levels;	chr2:202111695	chr2:202336739~202337200:+
LAML	cis	rs5769707	0.967	rs9616701	ENSG00000213279.2	RP1-29C18.9	-4.99	4.01e-06	0.0098	-0.57	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49631898	chr22:49572264~49575426:-
LAML	cis	rs7829975	0.593	rs2921061	ENSG00000268955.2	RP11-556O5.6	-4.99	4.02e-06	0.00981	-0.62	-0.51	Mood instability;	chr8:8460105	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.564	rs2921057	ENSG00000268955.2	RP11-556O5.6	-4.99	4.02e-06	0.00981	-0.62	-0.51	Mood instability;	chr8:8461157	chr8:8188535~8189195:-
LAML	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	4.99	4.04e-06	0.00983	0.7	0.51	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
LAML	cis	rs748404	0.588	rs506120	ENSG00000249839.1	AC011330.5	-4.99	4.04e-06	0.00984	-0.58	-0.51	Lung cancer;	chr15:43509826	chr15:43663654~43684339:-
LAML	cis	rs7580658	0.614	rs7585198	ENSG00000236682.1	AC068282.3	4.99	4.04e-06	0.00984	0.63	0.51	Protein C levels;	chr2:127205059	chr2:127389130~127400580:+
LAML	cis	rs367615	0.537	rs431669	ENSG00000249476.1	CTD-2587M2.1	4.99	4.05e-06	0.00984	0.63	0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109327414	chr5:109237120~109326369:-
LAML	cis	rs367615	0.537	rs10463600	ENSG00000249476.1	CTD-2587M2.1	4.99	4.05e-06	0.00984	0.63	0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109327935	chr5:109237120~109326369:-
LAML	cis	rs367615	0.512	rs814153	ENSG00000249476.1	CTD-2587M2.1	4.99	4.05e-06	0.00984	0.63	0.51	Colorectal cancer (SNP x SNP interaction);	chr5:109332128	chr5:109237120~109326369:-
LAML	cis	rs9399135	1	rs1014021	ENSG00000232876.1	CTA-212D2.2	4.99	4.05e-06	0.00984	0.66	0.51	Red blood cell count;	chr6:135013462	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs1590975	ENSG00000232876.1	CTA-212D2.2	-4.99	4.05e-06	0.00984	-0.66	-0.51	Red blood cell count;	chr6:135030950	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs1854865	ENSG00000232876.1	CTA-212D2.2	-4.99	4.05e-06	0.00984	-0.66	-0.51	Red blood cell count;	chr6:135039162	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs6569990	ENSG00000232876.1	CTA-212D2.2	-4.99	4.05e-06	0.00984	-0.66	-0.51	Red blood cell count;	chr6:135044680	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs13191501	ENSG00000232876.1	CTA-212D2.2	-4.99	4.05e-06	0.00984	-0.66	-0.51	Red blood cell count;	chr6:135045742	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs6908512	ENSG00000232876.1	CTA-212D2.2	-4.99	4.05e-06	0.00984	-0.66	-0.51	Red blood cell count;	chr6:135046619	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs11755229	ENSG00000232876.1	CTA-212D2.2	-4.99	4.05e-06	0.00984	-0.66	-0.51	Red blood cell count;	chr6:135048775	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9389261	ENSG00000232876.1	CTA-212D2.2	-4.99	4.05e-06	0.00984	-0.66	-0.51	Red blood cell count;	chr6:135050010	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs9376085	ENSG00000232876.1	CTA-212D2.2	-4.99	4.05e-06	0.00984	-0.66	-0.51	Red blood cell count;	chr6:135050086	chr6:135055033~135060550:+
LAML	cis	rs935334	1	rs2543383	ENSG00000280078.1	RP11-361H10.5	4.99	4.06e-06	0.00986	0.77	0.51	Blood pressure;	chr14:76160360	chr14:76279173~76283103:+
LAML	cis	rs9355610	0.892	rs2247314	ENSG00000265828.1	MIR3939	4.99	4.09e-06	0.00992	0.63	0.51	Graves' disease;	chr6:166956742	chr6:166997807~166997912:-
LAML	cis	rs1757171	0.534	rs2797793	ENSG00000279942.1	RP1-153P14.7	4.99	4.09e-06	0.00993	0.6	0.51	Cognitive performance;	chr6:37509486	chr6:37567716~37571460:+
LAML	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-4.99	4.11e-06	0.00996	-0.68	-0.51	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
LAML	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-4.99	4.11e-06	0.00997	-0.68	-0.51	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
LAML	cis	rs7301826	0.651	rs4514465	ENSG00000256299.1	RP11-989F5.3	-4.99	4.12e-06	0.00998	-0.65	-0.51	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810821~130812622:-
LAML	cis	rs12468226	0.689	rs73989733	ENSG00000272966.1	RP11-686O6.1	4.99	4.12e-06	0.00998	0.8	0.51	Urate levels;	chr2:202115241	chr2:202336739~202337200:+
LAML	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	4.99	4.12e-06	0.00999	0.63	0.51	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
LAML	cis	rs7495132	0.688	rs35977271	ENSG00000259314.1	CTD-3065B20.3	4.99	4.12e-06	0.00999	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90634550	chr15:90604225~90614558:-
LAML	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-4.99	4.13e-06	0.01	-0.54	-0.51	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
LAML	cis	rs9399135	0.967	rs13199205	ENSG00000232876.1	CTA-212D2.2	-4.99	4.13e-06	0.01	-0.66	-0.51	Red blood cell count;	chr6:134965367	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.935	rs4445070	ENSG00000232876.1	CTA-212D2.2	-4.99	4.13e-06	0.01	-0.66	-0.51	Red blood cell count;	chr6:134988074	chr6:135055033~135060550:+
LAML	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	4.98	4.13e-06	0.01	0.51	0.51	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
LAML	cis	rs11690935	0.959	rs6738445	ENSG00000228389.1	AC068039.4	-4.98	4.14e-06	0.01	-0.58	-0.51	Schizophrenia;	chr2:171743105	chr2:171773482~171775844:+
LAML	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	4.98	4.16e-06	0.0101	0.58	0.51	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
LAML	cis	rs6782228	0.848	rs6439140	ENSG00000277250.1	Metazoa_SRP	4.98	4.16e-06	0.0101	0.69	0.51	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128699917	chr3:128673681~128674021:-
LAML	cis	rs6964833	1	rs4717906	ENSG00000277053.3	GTF2IP1	-4.98	4.16e-06	0.0101	-0.69	-0.51	Menarche (age at onset);	chr7:74671923	chr7:75185385~75237696:-
LAML	cis	rs6951245	0.872	rs74360401	ENSG00000229043.2	AC091729.9	-4.98	4.17e-06	0.0101	-0.84	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1027767	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.935	rs118132455	ENSG00000229043.2	AC091729.9	-4.98	4.17e-06	0.0101	-0.84	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028596	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs78628466	ENSG00000229043.2	AC091729.9	-4.98	4.17e-06	0.0101	-0.84	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1028817	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs11768761	ENSG00000229043.2	AC091729.9	-4.98	4.17e-06	0.0101	-0.84	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030171	chr7:1160374~1165267:+
LAML	cis	rs9322193	0.923	rs4869750	ENSG00000217733.2	CCT7P1	4.98	4.17e-06	0.0101	0.73	0.51	Lung cancer;	chr6:149855996	chr6:149879962~149881572:+
LAML	cis	rs3758911	0.788	rs10890676	ENSG00000261098.1	RP11-819C21.1	-4.98	4.17e-06	0.0101	-0.48	-0.51	Coronary artery disease;	chr11:107254631	chr11:107312132~107316271:-
LAML	cis	rs3758911	0.788	rs10890680	ENSG00000261098.1	RP11-819C21.1	-4.98	4.17e-06	0.0101	-0.48	-0.51	Coronary artery disease;	chr11:107255139	chr11:107312132~107316271:-
LAML	cis	rs9891572	0.777	rs12453691	ENSG00000262884.1	CTD-3060P21.1	-4.98	4.18e-06	0.0101	-0.6	-0.51	HDL cholesterol;	chr17:2528316	chr17:2962248~2965895:-
LAML	cis	rs9393777	0.528	rs7745603	ENSG00000220721.1	OR1F12	4.98	4.18e-06	0.0101	0.58	0.51	Intelligence (multi-trait analysis);	chr6:27122625	chr6:28073316~28074233:+
LAML	cis	rs6772840	1	rs17076032	ENSG00000272077.1	RP11-348P10.2	-4.98	4.19e-06	0.0101	-0.98	-0.51	Subjective well-being;	chr3:43781480	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs11717087	ENSG00000272077.1	RP11-348P10.2	-4.98	4.19e-06	0.0101	-0.98	-0.51	Subjective well-being;	chr3:43783652	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs62250960	ENSG00000272077.1	RP11-348P10.2	-4.98	4.19e-06	0.0101	-0.98	-0.51	Subjective well-being;	chr3:43799411	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs11706464	ENSG00000272077.1	RP11-348P10.2	-4.98	4.19e-06	0.0101	-0.98	-0.51	Subjective well-being;	chr3:43800148	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs7617144	ENSG00000272077.1	RP11-348P10.2	-4.98	4.19e-06	0.0101	-0.98	-0.51	Subjective well-being;	chr3:43806958	chr3:44667412~44669364:+
LAML	cis	rs6772840	1	rs62250966	ENSG00000272077.1	RP11-348P10.2	-4.98	4.19e-06	0.0101	-0.98	-0.51	Subjective well-being;	chr3:43813771	chr3:44667412~44669364:+
LAML	cis	rs4753788	0.901	rs1907400	ENSG00000261098.1	RP11-819C21.1	-4.98	4.21e-06	0.0102	-0.48	-0.51	Coronary artery disease;	chr11:107217966	chr11:107312132~107316271:-
LAML	cis	rs4753788	1	rs4753788	ENSG00000261098.1	RP11-819C21.1	-4.98	4.21e-06	0.0102	-0.48	-0.51	Coronary artery disease;	chr11:107221129	chr11:107312132~107316271:-
LAML	cis	rs4713118	0.824	rs7759217	ENSG00000220721.1	OR1F12	4.98	4.21e-06	0.0102	0.55	0.51	Parkinson's disease;	chr6:27762684	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.784	rs9468219	ENSG00000220721.1	OR1F12	4.98	4.21e-06	0.0102	0.55	0.51	Parkinson's disease;	chr6:27763976	chr6:28073316~28074233:+
LAML	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	4.98	4.22e-06	0.0102	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	4.98	4.22e-06	0.0102	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	4.98	4.22e-06	0.0102	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.756	rs151301	ENSG00000259982.1	CDC37P1	4.98	4.22e-06	0.0102	0.62	0.51	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28700294~28701540:-
LAML	cis	rs5769707	0.622	rs2018467	ENSG00000213279.2	RP1-29C18.9	-4.98	4.26e-06	0.0103	-0.51	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49670631	chr22:49572264~49575426:-
LAML	cis	rs7131987	0.903	rs67150462	ENSG00000274315.1	RP11-996F15.5	4.98	4.26e-06	0.0103	0.51	0.51	QT interval;	chr12:29240392	chr12:29331434~29331936:-
LAML	cis	rs4753788	0.901	rs7117780	ENSG00000261098.1	RP11-819C21.1	-4.98	4.28e-06	0.0103	-0.48	-0.51	Coronary artery disease;	chr11:107215397	chr11:107312132~107316271:-
LAML	cis	rs7495132	0.688	rs8031293	ENSG00000259314.1	CTD-3065B20.3	4.98	4.28e-06	0.0103	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90624185	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.688	rs8041597	ENSG00000259314.1	CTD-3065B20.3	4.98	4.28e-06	0.0103	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90624262	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.688	rs6496711	ENSG00000259314.1	CTD-3065B20.3	4.98	4.28e-06	0.0103	0.54	0.51	Ulcerative colitis;Inflammatory bowel disease;	chr15:90626654	chr15:90604225~90614558:-
LAML	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-4.98	4.28e-06	0.0103	-0.54	-0.51	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-4.98	4.28e-06	0.0103	-0.54	-0.51	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	4.98	4.28e-06	0.0103	0.54	0.51	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-4.98	4.29e-06	0.0103	-0.56	-0.51	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
LAML	cis	rs875971	0.66	rs10229345	ENSG00000224316.1	RP11-479O9.2	4.97	4.29e-06	0.0103	0.55	0.51	Aortic root size;	chr7:66517181	chr7:65773620~65802067:+
LAML	cis	rs5769707	0.777	rs5770622	ENSG00000212939.2	RP1-29C18.10	-4.97	4.29e-06	0.0103	-0.6	-0.51	Monocyte percentage of white cells;Monocyte count;	chr22:49657900	chr22:49548681~49556473:+
LAML	cis	rs6951245	0.882	rs11764817	ENSG00000229043.2	AC091729.9	-4.97	4.3e-06	0.0104	-0.75	-0.51	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1024974	chr7:1160374~1165267:+
LAML	cis	rs4774565	0.762	rs11634585	ENSG00000244879.4	GABPB1-AS1	4.97	4.31e-06	0.0104	0.54	0.51	Breast cancer;	chr15:50364252	chr15:50354959~50372202:+
LAML	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-4.97	4.31e-06	0.0104	-0.54	-0.51	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
LAML	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-4.97	4.31e-06	0.0104	-0.54	-0.51	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
LAML	cis	rs7826238	0.601	rs2976907	ENSG00000268955.2	RP11-556O5.6	-4.97	4.33e-06	0.0104	-0.69	-0.51	Systolic blood pressure;	chr8:8487658	chr8:8188535~8189195:-
LAML	cis	rs67311347	1	rs12488805	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40381378	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.956	rs9817233	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40384127	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9817142	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40384283	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9822644	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40385118	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs12494022	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40385161	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs11714032	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40390114	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs7634375	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40390455	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs17078813	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40392671	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.826	rs9863679	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40398123	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.911	rs9863737	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40398345	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9875245	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40400789	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs954589	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40403054	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs17078916	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40403947	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs73076046	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40406233	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs11720360	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40406906	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs11707673	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40409113	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs4973989	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40410052	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs12634013	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40410897	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs4973993	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40411469	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs4973994	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40411533	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9822909	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40415593	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs6793596	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40416304	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs73078123	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40417472	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9833430	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40417552	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9857824	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40417921	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.784	rs13326389	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40418233	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs4973998	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40418861	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs12492035	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40425619	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs11707278	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40445584	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs12108041	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40446044	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs1123019	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40446789	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs2371186	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40447222	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9827461	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40447860	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs28491638	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40454772	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs28536038	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40454891	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.955	rs2085114	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40455946	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs2085115	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40456049	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs28707772	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40463175	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs73080126	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40467662	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs28871903	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40469603	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs56291770	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40473879	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs12630072	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40475699	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs56303661	ENSG00000230274.1	PGAM1P3	4.97	4.34e-06	0.0104	0.66	0.51	Renal cell carcinoma;	chr3:40479287	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs17078941	ENSG00000230274.1	PGAM1P3	-4.97	4.34e-06	0.0104	-0.66	-0.51	Renal cell carcinoma;	chr3:40409397	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs1047855	ENSG00000230274.1	PGAM1P3	-4.97	4.34e-06	0.0104	-0.66	-0.51	Renal cell carcinoma;	chr3:40427405	chr3:40322715~40323279:-
LAML	cis	rs2120335	0.573	rs12463718	ENSG00000221443.1	AC017083.1	4.97	4.34e-06	0.0104	0.63	0.51	Height;	chr2:68145022	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.614	rs12465178	ENSG00000221443.1	AC017083.1	4.97	4.34e-06	0.0104	0.63	0.51	Height;	chr2:68146797	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.614	rs1137930	ENSG00000221443.1	AC017083.1	4.97	4.34e-06	0.0104	0.63	0.51	Height;	chr2:68161691	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs6546367	ENSG00000221443.1	AC017083.1	4.97	4.34e-06	0.0104	0.62	0.51	Height;	chr2:68268111	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs2120335	ENSG00000221443.1	AC017083.1	-4.97	4.34e-06	0.0104	-0.62	-0.51	Height;	chr2:68267870	chr2:68273104~68273206:+
LAML	cis	rs853679	0.546	rs13214023	ENSG00000220721.1	OR1F12	-4.97	4.35e-06	0.0104	-0.81	-0.51	Depression;	chr6:28364364	chr6:28073316~28074233:+
LAML	cis	rs4753788	0.901	rs7951348	ENSG00000261098.1	RP11-819C21.1	-4.97	4.37e-06	0.0105	-0.47	-0.51	Coronary artery disease;	chr11:107211115	chr11:107312132~107316271:-
LAML	cis	rs763121	0.962	rs1980455	ENSG00000230912.1	RP3-508I15.10	-4.97	4.37e-06	0.0105	-0.41	-0.51	Menopause (age at onset);	chr22:38529714	chr22:38666508~38668750:-
LAML	cis	rs4273100	0.736	rs1509160	ENSG00000265185.4	SNORD3B-1	4.97	4.39e-06	0.0105	0.88	0.51	Schizophrenia;	chr17:19400180	chr17:19061912~19062669:+
LAML	cis	rs11039798	0.687	rs11499938	ENSG00000263693.1	MIR3161	4.97	4.39e-06	0.0105	0.5	0.51	Axial length;	chr11:48935745	chr11:48096782~48096858:+
LAML	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-4.97	4.41e-06	0.0105	-0.55	-0.51	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
LAML	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-4.97	4.41e-06	0.0105	-0.55	-0.51	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
LAML	cis	rs57024841	0.5	rs10116414	ENSG00000238268.2	RP11-229P13.19	4.97	4.41e-06	0.0106	0.6	0.51	Beta-trace protein levels;	chr9:136937244	chr9:136975094~136976981:+
LAML	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-4.97	4.42e-06	0.0106	-0.64	-0.51	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	4.97	4.42e-06	0.0106	0.64	0.51	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
LAML	cis	rs9660180	0.967	rs12040325	ENSG00000268575.1	RP1-283E3.8	-4.97	4.43e-06	0.0106	-0.56	-0.51	Body mass index;	chr1:1770997	chr1:1702736~1737688:-
LAML	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-4.97	4.43e-06	0.0106	-0.64	-0.51	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
LAML	cis	rs904251	0.58	rs62408367	ENSG00000279942.1	RP1-153P14.7	-4.97	4.43e-06	0.0106	-0.51	-0.51	Cognitive performance;	chr6:37477037	chr6:37567716~37571460:+
LAML	cis	rs1075265	0.806	rs805341	ENSG00000235937.1	AC008280.1	4.97	4.44e-06	0.0106	0.42	0.51	Chronotype;Morning vs. evening chronotype;	chr2:53965020	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.774	rs805342	ENSG00000235937.1	AC008280.1	4.97	4.44e-06	0.0106	0.42	0.51	Chronotype;Morning vs. evening chronotype;	chr2:53965962	chr2:54029552~54030682:-
LAML	cis	rs4713118	0.955	rs9393848	ENSG00000220721.1	OR1F12	4.97	4.44e-06	0.0106	0.56	0.51	Parkinson's disease;	chr6:27720590	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.955	rs9468203	ENSG00000220721.1	OR1F12	4.97	4.44e-06	0.0106	0.56	0.51	Parkinson's disease;	chr6:27720888	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.955	rs9468206	ENSG00000220721.1	OR1F12	4.97	4.44e-06	0.0106	0.56	0.51	Parkinson's disease;	chr6:27722674	chr6:28073316~28074233:+
LAML	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-4.97	4.45e-06	0.0106	-0.59	-0.51	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
LAML	cis	rs4753788	0.83	rs11608075	ENSG00000261098.1	RP11-819C21.1	-4.97	4.45e-06	0.0106	-0.47	-0.51	Coronary artery disease;	chr11:107202560	chr11:107312132~107316271:-
LAML	cis	rs4753788	0.901	rs1490938	ENSG00000261098.1	RP11-819C21.1	-4.97	4.45e-06	0.0106	-0.47	-0.51	Coronary artery disease;	chr11:107208272	chr11:107312132~107316271:-
LAML	cis	rs7555523	1	rs7555523	ENSG00000224358.1	RP11-466F5.8	-4.97	4.45e-06	0.0106	-0.74	-0.51	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165749742	chr1:165768929~165775176:+
LAML	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-4.96	4.46e-06	0.0106	-0.69	-0.51	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
LAML	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-4.96	4.47e-06	0.0107	-0.63	-0.5	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
LAML	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-4.96	4.47e-06	0.0107	-0.63	-0.5	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-4.96	4.47e-06	0.0107	-0.63	-0.5	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-4.96	4.47e-06	0.0107	-0.63	-0.5	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-4.96	4.47e-06	0.0107	-0.63	-0.5	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-4.96	4.47e-06	0.0107	-0.63	-0.5	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
LAML	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-4.96	4.47e-06	0.0107	-0.63	-0.5	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-4.96	4.47e-06	0.0107	-0.63	-0.5	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-4.96	4.47e-06	0.0107	-0.63	-0.5	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
LAML	cis	rs853679	0.607	rs67998226	ENSG00000187763.3	OR2B7P	4.96	4.48e-06	0.0107	0.91	0.5	Depression;	chr6:28270281	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs34878803	ENSG00000187763.3	OR2B7P	4.96	4.48e-06	0.0107	0.91	0.5	Depression;	chr6:28282402	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs34396849	ENSG00000187763.3	OR2B7P	4.96	4.48e-06	0.0107	0.91	0.5	Depression;	chr6:28283178	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13211507	ENSG00000187763.3	OR2B7P	4.96	4.48e-06	0.0107	0.91	0.5	Depression;	chr6:28289600	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs34691223	ENSG00000187763.3	OR2B7P	4.96	4.48e-06	0.0107	0.91	0.5	Depression;	chr6:28290431	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs34950484	ENSG00000187763.3	OR2B7P	4.96	4.48e-06	0.0107	0.91	0.5	Depression;	chr6:28310911	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs34661125	ENSG00000187763.3	OR2B7P	4.96	4.48e-06	0.0107	0.91	0.5	Depression;	chr6:28314117	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs13190888	ENSG00000187763.3	OR2B7P	4.96	4.48e-06	0.0107	0.91	0.5	Depression;	chr6:28318208	chr6:28046434~28047367:+
LAML	cis	rs853679	0.607	rs67340775	ENSG00000187763.3	OR2B7P	4.96	4.48e-06	0.0107	0.91	0.5	Depression;	chr6:28336607	chr6:28046434~28047367:+
LAML	cis	rs2980439	0.525	rs2980508	ENSG00000268955.2	RP11-556O5.6	-4.96	4.48e-06	0.0107	-0.58	-0.5	Neuroticism;	chr8:8314210	chr8:8188535~8189195:-
LAML	cis	rs7587476	0.906	rs17487792	ENSG00000229267.2	AC072062.1	4.96	4.48e-06	0.0107	0.63	0.5	Neuroblastoma;	chr2:214778776	chr2:214810229~214963274:+
LAML	cis	rs2015599	0.549	rs6487799	ENSG00000274315.1	RP11-996F15.5	4.96	4.48e-06	0.0107	0.47	0.5	Platelet count;Mean platelet volume;	chr12:29291087	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.549	rs7972032	ENSG00000274315.1	RP11-996F15.5	4.96	4.48e-06	0.0107	0.47	0.5	Platelet count;Mean platelet volume;	chr12:29291351	chr12:29331434~29331936:-
LAML	cis	rs17711722	0.727	rs35850374	ENSG00000224316.1	RP11-479O9.2	4.96	4.49e-06	0.0107	0.55	0.5	Calcium levels;	chr7:65892789	chr7:65773620~65802067:+
LAML	cis	rs935334	1	rs2543382	ENSG00000280078.1	RP11-361H10.5	4.96	4.49e-06	0.0107	0.77	0.5	Blood pressure;	chr14:76158544	chr14:76279173~76283103:+
LAML	cis	rs4713118	0.866	rs9468217	ENSG00000187763.3	OR2B7P	4.96	4.49e-06	0.0107	0.68	0.5	Parkinson's disease;	chr6:27758688	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.911	rs9295746	ENSG00000187763.3	OR2B7P	4.96	4.49e-06	0.0107	0.68	0.5	Parkinson's disease;	chr6:27762285	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.911	rs9461406	ENSG00000187763.3	OR2B7P	-4.96	4.49e-06	0.0107	-0.68	-0.5	Parkinson's disease;	chr6:27751985	chr6:28046434~28047367:+
LAML	cis	rs9399135	0.967	rs6923765	ENSG00000232876.1	CTA-212D2.2	4.96	4.49e-06	0.0107	0.64	0.5	Red blood cell count;	chr6:135014038	chr6:135055033~135060550:+
LAML	cis	rs2704588	0.505	rs9999793	ENSG00000270720.1	RP11-84C13.2	-4.96	4.49e-06	0.0107	-0.89	-0.5	Longevity;	chr4:89005389	chr4:89119284~89119871:+
LAML	cis	rs2704588	0.505	rs1513811	ENSG00000270720.1	RP11-84C13.2	-4.96	4.49e-06	0.0107	-0.89	-0.5	Longevity;	chr4:89074647	chr4:89119284~89119871:+
LAML	cis	rs3758911	0.765	rs609821	ENSG00000261098.1	RP11-819C21.1	4.96	4.49e-06	0.0107	0.51	0.5	Coronary artery disease;	chr11:107468429	chr11:107312132~107316271:-
LAML	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-4.96	4.49e-06	0.0107	-0.64	-0.5	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
LAML	cis	rs9457247	0.534	rs2757053	ENSG00000231654.1	RPS6KA2-AS1	4.96	4.51e-06	0.0107	0.49	0.5	Crohn's disease;	chr6:166966850	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.534	rs2345568	ENSG00000231654.1	RPS6KA2-AS1	4.96	4.51e-06	0.0107	0.49	0.5	Crohn's disease;	chr6:166968316	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.534	rs4710149	ENSG00000231654.1	RPS6KA2-AS1	4.96	4.51e-06	0.0107	0.49	0.5	Crohn's disease;	chr6:166972858	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.534	rs4710154	ENSG00000231654.1	RPS6KA2-AS1	4.96	4.51e-06	0.0107	0.49	0.5	Crohn's disease;	chr6:166981146	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.534	rs9366078	ENSG00000231654.1	RPS6KA2-AS1	4.96	4.51e-06	0.0107	0.49	0.5	Crohn's disease;	chr6:166986024	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.534	rs9356551	ENSG00000231654.1	RPS6KA2-AS1	4.96	4.51e-06	0.0107	0.49	0.5	Crohn's disease;	chr6:166986857	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.534	rs933243	ENSG00000231654.1	RPS6KA2-AS1	-4.96	4.51e-06	0.0107	-0.49	-0.5	Crohn's disease;	chr6:166990385	chr6:166903698~166904835:+
LAML	cis	rs7944735	1	rs7944735	ENSG00000263693.1	MIR3161	4.96	4.52e-06	0.0107	0.39	0.5	Intraocular pressure;	chr11:47934056	chr11:48096782~48096858:+
LAML	cis	rs7944735	0.938	rs59185955	ENSG00000263693.1	MIR3161	4.96	4.52e-06	0.0107	0.39	0.5	Intraocular pressure;	chr11:47940014	chr11:48096782~48096858:+
LAML	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-4.96	4.52e-06	0.0108	-0.56	-0.5	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-4.96	4.52e-06	0.0108	-0.56	-0.5	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
LAML	cis	rs2120335	0.927	rs12053466	ENSG00000221443.1	AC017083.1	4.96	4.53e-06	0.0108	0.62	0.5	Height;	chr2:68196360	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs61247217	ENSG00000221443.1	AC017083.1	4.96	4.53e-06	0.0108	0.62	0.5	Height;	chr2:68198322	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs59883268	ENSG00000221443.1	AC017083.1	4.96	4.53e-06	0.0108	0.62	0.5	Height;	chr2:68199395	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs62145958	ENSG00000221443.1	AC017083.1	4.96	4.53e-06	0.0108	0.62	0.5	Height;	chr2:68199770	chr2:68273104~68273206:+
LAML	cis	rs2120335	1	rs17590779	ENSG00000221443.1	AC017083.1	4.96	4.53e-06	0.0108	0.62	0.5	Height;	chr2:68204938	chr2:68273104~68273206:+
LAML	cis	rs5769707	0.632	rs135876	ENSG00000280224.1	CTA-722E9.1	-4.96	4.53e-06	0.0108	-0.75	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49500568~49501585:+
LAML	cis	rs8037137	0.915	rs3826033	ENSG00000258725.1	PRC1-AS1	-4.96	4.53e-06	0.0108	-0.9	-0.5	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:91005371	chr15:90966345~90988624:+
LAML	cis	rs2015599	0.54	rs12301475	ENSG00000273680.1	RP11-996F15.6	4.96	4.53e-06	0.0108	0.52	0.5	Platelet count;Mean platelet volume;	chr12:29253144	chr12:29332733~29333383:-
LAML	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	4.96	4.54e-06	0.0108	0.76	0.5	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
LAML	cis	rs2120335	0.586	rs1135547	ENSG00000221443.1	AC017083.1	4.96	4.55e-06	0.0108	0.64	0.5	Height;	chr2:68132374	chr2:68273104~68273206:+
LAML	cis	rs853679	0.546	rs35353359	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Depression;	chr6:28356601	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs13213152	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Depression;	chr6:28381921	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs13213986	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Depression;	chr6:28390232	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs34546986	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Depression;	chr6:28394532	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs34871267	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Depression;	chr6:28396455	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs35883476	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Depression;	chr6:28400731	chr6:28073316~28074233:+
LAML	cis	rs6921919	0.673	rs13201681	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28073316~28074233:+
LAML	cis	rs6921919	0.778	rs67381177	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28073316~28074233:+
LAML	cis	rs138024639	1	rs138024639	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Breast cancer;	chr6:28468244	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs55690788	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Depression;	chr6:28468368	chr6:28073316~28074233:+
LAML	cis	rs13191038	1	rs13191038	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Urinary tract infection frequency;	chr6:28515140	chr6:28073316~28074233:+
LAML	cis	rs34119086	1	rs34119086	ENSG00000220721.1	OR1F12	4.96	4.57e-06	0.0108	0.83	0.5	Breast cancer;	chr6:28594471	chr6:28073316~28074233:+
LAML	cis	rs7826238	0.623	rs2976893	ENSG00000268955.2	RP11-556O5.6	4.96	4.57e-06	0.0108	0.65	0.5	Systolic blood pressure;	chr8:8480709	chr8:8188535~8189195:-
LAML	cis	rs2980439	0.556	rs2921059	ENSG00000253893.2	FAM85B	-4.96	4.58e-06	0.0109	-0.61	-0.5	Neuroticism;	chr8:8460377	chr8:8167819~8226614:-
LAML	cis	rs2980439	0.557	rs2976876	ENSG00000253893.2	FAM85B	-4.96	4.58e-06	0.0109	-0.61	-0.5	Neuroticism;	chr8:8461340	chr8:8167819~8226614:-
LAML	cis	rs67383717	0.689	rs62559007	ENSG00000175611.10	LINC00476	-4.96	4.58e-06	0.0109	-0.51	-0.5	Parkinson's disease (pesticide exposure interaction);	chr9:95790981	chr9:95759231~95875977:-
LAML	cis	rs172166	0.561	rs149973	ENSG00000216901.1	AL022393.7	4.96	4.58e-06	0.0109	0.57	0.5	Cardiac Troponin-T levels;	chr6:28015835	chr6:28176188~28176674:+
LAML	cis	rs172166	0.561	rs149974	ENSG00000216901.1	AL022393.7	4.96	4.58e-06	0.0109	0.57	0.5	Cardiac Troponin-T levels;	chr6:28017318	chr6:28176188~28176674:+
LAML	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-4.96	4.58e-06	0.0109	-0.57	-0.5	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
LAML	cis	rs4728142	0.789	rs3807307	ENSG00000275106.1	RP11-309L24.10	-4.96	4.59e-06	0.0109	-0.45	-0.5	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128939148	chr7:128952527~128953316:-
LAML	cis	rs4728142	0.816	rs3823536	ENSG00000275106.1	RP11-309L24.10	-4.96	4.59e-06	0.0109	-0.45	-0.5	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128939612	chr7:128952527~128953316:-
LAML	cis	rs172166	0.61	rs156737	ENSG00000216901.1	AL022393.7	4.96	4.59e-06	0.0109	0.57	0.5	Cardiac Troponin-T levels;	chr6:27927435	chr6:28176188~28176674:+
LAML	cis	rs8031584	0.752	rs1852035	ENSG00000260382.1	RP11-540B6.2	4.96	4.59e-06	0.0109	0.53	0.5	Huntington's disease progression;	chr15:30892600	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.752	rs2001686	ENSG00000260382.1	RP11-540B6.2	4.96	4.59e-06	0.0109	0.53	0.5	Huntington's disease progression;	chr15:30893569	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.663	rs1917421	ENSG00000260382.1	RP11-540B6.2	4.96	4.59e-06	0.0109	0.53	0.5	Huntington's disease progression;	chr15:30895460	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.707	rs4556757	ENSG00000260382.1	RP11-540B6.2	4.96	4.59e-06	0.0109	0.53	0.5	Huntington's disease progression;	chr15:30895976	chr15:30882267~30883231:-
LAML	cis	rs853679	0.882	rs9393908	ENSG00000217315.1	OR2W2P	4.96	4.6e-06	0.0109	0.88	0.5	Depression;	chr6:28223052	chr6:28033947~28034855:+
LAML	cis	rs853679	0.882	rs9366717	ENSG00000217315.1	OR2W2P	4.96	4.6e-06	0.0109	0.88	0.5	Depression;	chr6:28223279	chr6:28033947~28034855:+
LAML	cis	rs853679	0.882	rs9380069	ENSG00000217315.1	OR2W2P	4.96	4.6e-06	0.0109	0.88	0.5	Depression;	chr6:28235522	chr6:28033947~28034855:+
LAML	cis	rs10463316	0.779	rs6861968	ENSG00000260581.1	CTB-113P19.4	4.96	4.62e-06	0.0109	0.44	0.5	Metabolite levels (Pyroglutamine);	chr5:151438164	chr5:151652275~151655449:+
LAML	cis	rs9322193	0.566	rs4870118	ENSG00000216906.2	RP11-350J20.9	-4.96	4.62e-06	0.0109	-0.74	-0.5	Lung cancer;	chr6:149923877	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.566	rs4869767	ENSG00000216906.2	RP11-350J20.9	-4.96	4.62e-06	0.0109	-0.74	-0.5	Lung cancer;	chr6:149923974	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.566	rs4869768	ENSG00000216906.2	RP11-350J20.9	-4.96	4.62e-06	0.0109	-0.74	-0.5	Lung cancer;	chr6:149924067	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.566	rs3922947	ENSG00000216906.2	RP11-350J20.9	-4.96	4.62e-06	0.0109	-0.74	-0.5	Lung cancer;	chr6:149924856	chr6:149904243~149906418:+
LAML	cis	rs6951245	1	rs884977	ENSG00000229043.2	AC091729.9	-4.96	4.63e-06	0.0109	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1026774	chr7:1160374~1165267:+
LAML	cis	rs9322193	0.566	rs5024811	ENSG00000216906.2	RP11-350J20.9	-4.96	4.63e-06	0.0109	-0.77	-0.5	Lung cancer;	chr6:149924898	chr6:149904243~149906418:+
LAML	cis	rs73219805	0.554	rs13266943	ENSG00000228451.3	SDAD1P1	-4.95	4.63e-06	0.011	-0.63	-0.5	Schizophrenia;	chr8:26336629	chr8:26379259~26382953:-
LAML	cis	rs9788721	0.836	rs7181486	ENSG00000259474.1	RP11-650L12.1	4.95	4.64e-06	0.011	0.53	0.5	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78449276	chr15:78480057~78481820:-
LAML	cis	rs12468226	0.873	rs79071680	ENSG00000272966.1	RP11-686O6.1	4.95	4.64e-06	0.011	0.83	0.5	Urate levels;	chr2:202191520	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs79860867	ENSG00000272966.1	RP11-686O6.1	4.95	4.64e-06	0.011	0.83	0.5	Urate levels;	chr2:202192397	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs78798541	ENSG00000272966.1	RP11-686O6.1	4.95	4.64e-06	0.011	0.83	0.5	Urate levels;	chr2:202194708	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs59293950	ENSG00000272966.1	RP11-686O6.1	4.95	4.64e-06	0.011	0.83	0.5	Urate levels;	chr2:202214069	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs12472035	ENSG00000272966.1	RP11-686O6.1	4.95	4.64e-06	0.011	0.83	0.5	Urate levels;	chr2:202221970	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.873	rs12470401	ENSG00000272966.1	RP11-686O6.1	4.95	4.64e-06	0.011	0.83	0.5	Urate levels;	chr2:202236436	chr2:202336739~202337200:+
LAML	cis	rs1075265	0.68	rs805396	ENSG00000235937.1	AC008280.1	4.95	4.65e-06	0.011	0.41	0.5	Chronotype;Morning vs. evening chronotype;	chr2:53882314	chr2:54029552~54030682:-
LAML	cis	rs3758911	0.964	rs10789601	ENSG00000261098.1	RP11-819C21.1	-4.95	4.66e-06	0.011	-0.48	-0.5	Coronary artery disease;	chr11:107310693	chr11:107312132~107316271:-
LAML	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-4.95	4.66e-06	0.011	-0.56	-0.5	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-4.95	4.66e-06	0.011	-0.56	-0.5	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-4.95	4.66e-06	0.011	-0.56	-0.5	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-4.95	4.66e-06	0.011	-0.56	-0.5	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-4.95	4.66e-06	0.011	-0.56	-0.5	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
LAML	cis	rs4713118	0.513	rs149897	ENSG00000220721.1	OR1F12	4.95	4.66e-06	0.011	0.56	0.5	Parkinson's disease;	chr6:28038872	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs156734	ENSG00000220721.1	OR1F12	4.95	4.66e-06	0.011	0.56	0.5	Parkinson's disease;	chr6:28039579	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs202908	ENSG00000220721.1	OR1F12	4.95	4.66e-06	0.011	0.56	0.5	Parkinson's disease;	chr6:28043773	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs156739	ENSG00000220721.1	OR1F12	4.95	4.66e-06	0.011	0.56	0.5	Parkinson's disease;	chr6:28045632	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs149958	ENSG00000220721.1	OR1F12	4.95	4.66e-06	0.011	0.56	0.5	Parkinson's disease;	chr6:28045839	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs156738	ENSG00000220721.1	OR1F12	4.95	4.66e-06	0.011	0.56	0.5	Parkinson's disease;	chr6:28046247	chr6:28073316~28074233:+
LAML	cis	rs5769707	0.732	rs135865	ENSG00000279597.1	RP4-566L20.1	-4.95	4.67e-06	0.011	-0.59	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49534062~49534926:+
LAML	cis	rs79040073	0.859	rs77468143	ENSG00000276593.1	RP11-295H24.5	4.95	4.67e-06	0.011	0.55	0.5	Lung cancer in ever smokers;	chr15:49084427	chr15:49353485~49354034:+
LAML	cis	rs73219805	1	rs1042992	ENSG00000228451.3	SDAD1P1	4.95	4.67e-06	0.011	0.57	0.5	Schizophrenia;	chr8:26411675	chr8:26379259~26382953:-
LAML	cis	rs8031584	0.781	rs4779498	ENSG00000260382.1	RP11-540B6.2	4.95	4.68e-06	0.011	0.56	0.5	Huntington's disease progression;	chr15:30885273	chr15:30882267~30883231:-
LAML	cis	rs7714584	1	rs7724558	ENSG00000197083.10	ZNF300P1	4.95	4.68e-06	0.011	1.26	0.5	Crohn's disease;	chr5:150949304	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs4958852	ENSG00000197083.10	ZNF300P1	4.95	4.68e-06	0.011	1.26	0.5	Crohn's disease;	chr5:150951069	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11167526	ENSG00000197083.10	ZNF300P1	4.95	4.68e-06	0.011	1.26	0.5	Crohn's disease;	chr5:150952919	chr5:150930645~150946289:-
LAML	cis	rs1075265	0.633	rs7591431	ENSG00000235937.1	AC008280.1	4.95	4.69e-06	0.0111	0.39	0.5	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54029552~54030682:-
LAML	cis	rs1555322	0.505	rs2254207	ENSG00000261582.1	RP4-614O4.11	-4.95	4.69e-06	0.0111	-0.52	-0.5	Attention deficit hyperactivity disorder;	chr20:35269908	chr20:35267885~35280043:-
LAML	cis	rs2980439	0.517	rs712253	ENSG00000268955.2	RP11-556O5.6	4.95	4.69e-06	0.0111	0.6	0.5	Neuroticism;	chr8:8246260	chr8:8188535~8189195:-
LAML	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	4.95	4.69e-06	0.0111	0.55	0.5	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
LAML	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	4.95	4.69e-06	0.0111	0.55	0.5	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
LAML	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	4.95	4.69e-06	0.0111	0.55	0.5	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
LAML	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	4.95	4.69e-06	0.0111	0.55	0.5	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
LAML	cis	rs2581828	0.539	rs114317830	ENSG00000280417.1	RP11-5O17.1	-4.95	4.7e-06	0.0111	-0.7	-0.5	Crohn's disease;	chr3:53126253	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.539	rs114670283	ENSG00000280417.1	RP11-5O17.1	-4.95	4.7e-06	0.0111	-0.7	-0.5	Crohn's disease;	chr3:53126254	chr3:53046166~53048122:+
LAML	cis	rs2404602	0.598	rs11634019	ENSG00000259422.1	RP11-593F23.1	-4.95	4.71e-06	0.0111	-0.63	-0.5	Blood metabolite levels;	chr15:76342339	chr15:76174891~76181486:-
LAML	cis	rs9918079	0.542	rs6414765	ENSG00000249930.1	AC007016.3	-4.95	4.72e-06	0.0111	-0.63	-0.5	Obesity-related traits;	chr4:15624870	chr4:15492729~15492972:-
LAML	cis	rs13217239	0.646	rs35691005	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27004291	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs10946891	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27005436	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs12201393	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27007911	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs12209886	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27016978	chr6:26871484~26956554:-
LAML	cis	rs6940638	0.531	rs12211984	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Intelligence (multi-trait analysis);	chr6:27018275	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs10456351	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27019013	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs10456352	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27022579	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs4583981	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27024244	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs10946897	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27027472	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs4403259	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27029838	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs6937880	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27032457	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.621	rs12527231	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27033509	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs12523820	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27033723	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs10946898	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27036105	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs12527111	ENSG00000241549.7	GUSBP2	4.95	4.72e-06	0.0111	0.51	0.5	Schizophrenia;	chr6:27038696	chr6:26871484~26956554:-
LAML	cis	rs2120335	1	rs6749303	ENSG00000221443.1	AC017083.1	4.95	4.73e-06	0.0111	0.62	0.5	Height;	chr2:68190087	chr2:68273104~68273206:+
LAML	cis	rs9322193	0.886	rs9485408	ENSG00000216906.2	RP11-350J20.9	4.95	4.74e-06	0.0111	0.71	0.5	Lung cancer;	chr6:149618888	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs1080670	ENSG00000216906.2	RP11-350J20.9	4.95	4.74e-06	0.0111	0.71	0.5	Lung cancer;	chr6:149620161	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs10782312	ENSG00000216906.2	RP11-350J20.9	4.95	4.74e-06	0.0111	0.71	0.5	Lung cancer;	chr6:149622669	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.886	rs9322198	ENSG00000216906.2	RP11-350J20.9	4.95	4.74e-06	0.0111	0.71	0.5	Lung cancer;	chr6:149623772	chr6:149904243~149906418:+
LAML	cis	rs6951245	1	rs76833820	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030642	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs28379681	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030903	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs28528096	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031276	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs74369356	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032075	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs77083167	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032187	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs74347384	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032804	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs78308415	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1032998	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.872	rs75493422	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033254	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs118059236	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033566	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs113858334	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1033840	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs79765398	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1034128	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs79443843	ENSG00000229043.2	AC091729.9	-4.95	4.76e-06	0.0112	-0.85	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1035609	chr7:1160374~1165267:+
LAML	cis	rs716804	0.507	rs10770089	ENSG00000254719.1	RP11-351I24.3	-4.95	4.76e-06	0.0112	-0.64	-0.5	Neuroticism;	chr11:10094502	chr11:10272052~10272259:-
LAML	cis	rs172166	0.61	rs276369	ENSG00000216901.1	AL022393.7	4.95	4.78e-06	0.0112	0.57	0.5	Cardiac Troponin-T levels;	chr6:27951465	chr6:28176188~28176674:+
LAML	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	4.95	4.78e-06	0.0112	0.57	0.5	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
LAML	cis	rs4879656	0.735	rs10733465	ENSG00000225693.1	LAGE3P1	4.95	4.78e-06	0.0112	0.63	0.5	Menopause (age at onset);	chr9:32932196	chr9:33019682~33020165:-
LAML	cis	rs911186	0.947	rs9379962	ENSG00000220721.1	OR1F12	4.95	4.79e-06	0.0112	0.58	0.5	Autism spectrum disorder or schizophrenia;	chr6:27177532	chr6:28073316~28074233:+
LAML	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	4.95	4.8e-06	0.0112	0.69	0.5	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
LAML	cis	rs6964833	0.873	rs4717905	ENSG00000277053.3	GTF2IP1	-4.95	4.8e-06	0.0113	-0.7	-0.5	Menarche (age at onset);	chr7:74668903	chr7:75185385~75237696:-
LAML	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-4.94	4.83e-06	0.0113	-0.54	-0.5	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-4.94	4.83e-06	0.0113	-0.54	-0.5	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
LAML	cis	rs9457247	0.534	rs9355610	ENSG00000265828.1	MIR3939	4.94	4.83e-06	0.0113	0.63	0.5	Crohn's disease;	chr6:166969587	chr6:166997807~166997912:-
LAML	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-4.94	4.85e-06	0.0114	-0.54	-0.5	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
LAML	cis	rs1555322	0.53	rs2250205	ENSG00000261582.1	RP4-614O4.11	-4.94	4.85e-06	0.0114	-0.64	-0.5	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35267885~35280043:-
LAML	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-4.94	4.86e-06	0.0114	-0.56	-0.5	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
LAML	cis	rs2404602	0.622	rs2003344	ENSG00000259422.1	RP11-593F23.1	-4.94	4.87e-06	0.0114	-0.66	-0.5	Blood metabolite levels;	chr15:76339960	chr15:76174891~76181486:-
LAML	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	4.94	4.88e-06	0.0114	0.77	0.5	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.607	rs4870078	ENSG00000216906.2	RP11-350J20.9	-4.94	4.88e-06	0.0114	-0.77	-0.5	Lung cancer;	chr6:149880676	chr6:149904243~149906418:+
LAML	cis	rs853679	0.546	rs200977	ENSG00000220721.1	OR1F12	4.94	4.9e-06	0.0115	0.66	0.5	Depression;	chr6:27886523	chr6:28073316~28074233:+
LAML	cis	rs3096299	0.933	rs2965939	ENSG00000274627.1	RP11-104N10.2	4.94	4.9e-06	0.0115	0.63	0.5	Multiple myeloma (IgH translocation);	chr16:89426635	chr16:89516797~89522217:+
LAML	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	4.94	4.91e-06	0.0115	0.43	0.5	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
LAML	cis	rs67311347	1	rs66841330	ENSG00000230274.1	PGAM1P3	4.94	4.91e-06	0.0115	0.68	0.5	Renal cell carcinoma;	chr3:40489632	chr3:40322715~40323279:-
LAML	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	4.94	4.91e-06	0.0115	0.63	0.5	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	4.94	4.91e-06	0.0115	0.63	0.5	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	4.94	4.91e-06	0.0115	0.63	0.5	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	4.94	4.91e-06	0.0115	0.63	0.5	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	4.94	4.91e-06	0.0115	0.63	0.5	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
LAML	cis	rs7555523	0.887	rs4657471	ENSG00000224358.1	RP11-466F5.8	-4.94	4.92e-06	0.0115	-0.76	-0.5	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717636	chr1:165768929~165775176:+
LAML	cis	rs13217239	0.646	rs11756275	ENSG00000241549.7	GUSBP2	-4.94	4.92e-06	0.0115	-0.51	-0.5	Schizophrenia;	chr6:27039334	chr6:26871484~26956554:-
LAML	cis	rs1555322	0.53	rs8122819	ENSG00000261582.1	RP4-614O4.11	-4.94	4.93e-06	0.0115	-0.55	-0.5	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35267885~35280043:-
LAML	cis	rs763121	0.853	rs1013338	ENSG00000230912.1	RP3-508I15.10	-4.94	4.94e-06	0.0115	-0.41	-0.5	Menopause (age at onset);	chr22:38578149	chr22:38666508~38668750:-
LAML	cis	rs4713118	0.869	rs9366700	ENSG00000220721.1	OR1F12	4.94	4.94e-06	0.0115	0.55	0.5	Parkinson's disease;	chr6:27729172	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs6456802	ENSG00000220721.1	OR1F12	4.94	4.94e-06	0.0115	0.55	0.5	Parkinson's disease;	chr6:27730576	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9393851	ENSG00000220721.1	OR1F12	4.94	4.94e-06	0.0115	0.55	0.5	Parkinson's disease;	chr6:27731802	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9461400	ENSG00000220721.1	OR1F12	4.94	4.94e-06	0.0115	0.55	0.5	Parkinson's disease;	chr6:27732780	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs10214440	ENSG00000220721.1	OR1F12	4.94	4.94e-06	0.0115	0.55	0.5	Parkinson's disease;	chr6:27734661	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9295742	ENSG00000220721.1	OR1F12	4.94	4.94e-06	0.0115	0.55	0.5	Parkinson's disease;	chr6:27735053	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.869	rs9461401	ENSG00000220721.1	OR1F12	4.94	4.94e-06	0.0115	0.55	0.5	Parkinson's disease;	chr6:27735512	chr6:28073316~28074233:+
LAML	cis	rs6728642	1	rs11900461	ENSG00000235833.1	AC159540.14	4.94	4.95e-06	0.0116	0.92	0.5	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96950256	chr2:97523949~97524976:-
LAML	cis	rs10463316	0.823	rs7700340	ENSG00000260581.1	CTB-113P19.4	4.94	4.95e-06	0.0116	0.46	0.5	Metabolite levels (Pyroglutamine);	chr5:151396759	chr5:151652275~151655449:+
LAML	cis	rs7927771	0.929	rs12787646	ENSG00000280615.1	Y_RNA	-4.94	4.96e-06	0.0116	-0.66	-0.5	Subjective well-being;	chr11:47648113	chr11:47614898~47614994:-
LAML	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	4.94	4.96e-06	0.0116	0.62	0.5	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
LAML	cis	rs3758911	1	rs1046094	ENSG00000261098.1	RP11-819C21.1	-4.94	4.96e-06	0.0116	-0.51	-0.5	Coronary artery disease;	chr11:107326530	chr11:107312132~107316271:-
LAML	cis	rs853679	0.628	rs9368560	ENSG00000217315.1	OR2W2P	4.94	4.98e-06	0.0116	0.74	0.5	Depression;	chr6:28192182	chr6:28033947~28034855:+
LAML	cis	rs9918079	0.506	rs10214	ENSG00000249930.1	AC007016.3	4.94	4.99e-06	0.0116	0.63	0.5	Obesity-related traits;	chr4:15604808	chr4:15492729~15492972:-
LAML	cis	rs9393777	0.668	rs16897515	ENSG00000243307.2	POM121L6P	4.94	4.99e-06	0.0116	0.69	0.5	Intelligence (multi-trait analysis);	chr6:27310241	chr6:26896952~26898777:+
LAML	cis	rs1757171	0.504	rs11969056	ENSG00000229559.2	RP1-153P14.3	-4.94	4.99e-06	0.0116	-0.52	-0.5	Cognitive performance;	chr6:37516509	chr6:37543553~37547280:-
LAML	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-4.94	5e-06	0.0117	-0.56	-0.5	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-4.94	5e-06	0.0117	-0.56	-0.5	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-4.94	5e-06	0.0117	-0.56	-0.5	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
LAML	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	4.93	5.02e-06	0.0117	0.64	0.5	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
LAML	cis	rs12145833	0.538	rs4658547	ENSG00000253326.2	RP11-261C10.7	4.93	5.02e-06	0.0117	0.8	0.5	Obesity (early onset extreme);	chr1:243227829	chr1:243054861~243056394:-
LAML	cis	rs12145833	0.538	rs9803701	ENSG00000253326.2	RP11-261C10.7	4.93	5.02e-06	0.0117	0.8	0.5	Obesity (early onset extreme);	chr1:243228332	chr1:243054861~243056394:-
LAML	cis	rs12468226	0.935	rs75597391	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202398850	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs12472408	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202413973	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs115170232	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202416790	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs16839149	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202427621	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs74766638	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202445168	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs116635509	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202460027	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs2350809	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202464210	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs76528043	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202466116	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs12468226	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202472278	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs75040639	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202486973	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.872	rs115187557	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202495351	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs74508472	ENSG00000272966.1	RP11-686O6.1	4.93	5.04e-06	0.0117	0.84	0.5	Urate levels;	chr2:202517290	chr2:202336739~202337200:+
LAML	cis	rs3931020	0.566	rs1327086	ENSG00000272864.1	RP11-17E13.2	-4.93	5.04e-06	0.0117	-0.63	-0.5	Resistin levels;	chr1:74805348	chr1:74698769~74699333:-
LAML	cis	rs4713118	0.868	rs9468220	ENSG00000187763.3	OR2B7P	-4.93	5.05e-06	0.0117	-0.68	-0.5	Parkinson's disease;	chr6:27765197	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.868	rs7756968	ENSG00000187763.3	OR2B7P	4.93	5.05e-06	0.0117	0.68	0.5	Parkinson's disease;	chr6:27767175	chr6:28046434~28047367:+
LAML	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	4.93	5.05e-06	0.0117	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	4.93	5.05e-06	0.0117	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	4.93	5.05e-06	0.0117	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	4.93	5.05e-06	0.0117	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	4.93	5.05e-06	0.0117	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	4.93	5.05e-06	0.0117	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	4.93	5.05e-06	0.0117	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	4.93	5.05e-06	0.0117	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
LAML	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	4.93	5.05e-06	0.0117	0.62	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
LAML	cis	rs7165170	0.678	rs12593759	ENSG00000259314.1	CTD-3065B20.3	-4.93	5.06e-06	0.0118	-0.49	-0.5	Crohn's disease;Inflammatory bowel disease;	chr15:90659370	chr15:90604225~90614558:-
LAML	cis	rs7932354	0.528	rs10838660	ENSG00000271350.1	CTD-2384B9.1	-4.93	5.07e-06	0.0118	-0.49	-0.5	Bone mineral density (hip);Bone mineral density;	chr11:47130722	chr11:47041027~47041945:-
LAML	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	4.93	5.09e-06	0.0118	0.63	0.5	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
LAML	cis	rs2412819	0.571	rs12443084	ENSG00000249839.1	AC011330.5	4.93	5.11e-06	0.0118	0.71	0.5	Lung cancer;	chr15:43748767	chr15:43663654~43684339:-
LAML	cis	rs2412819	0.571	rs10163069	ENSG00000249839.1	AC011330.5	4.93	5.11e-06	0.0118	0.71	0.5	Lung cancer;	chr15:43755372	chr15:43663654~43684339:-
LAML	cis	rs2929278	0.617	rs3986209	ENSG00000249839.1	AC011330.5	4.93	5.11e-06	0.0118	0.71	0.5	Schizophrenia;	chr15:43758675	chr15:43663654~43684339:-
LAML	cis	rs7044106	0.578	rs4837788	ENSG00000226752.6	PSMD5-AS1	-4.93	5.11e-06	0.0118	-0.84	-0.5	Hip circumference adjusted for BMI;	chr9:120634523	chr9:120824828~120854385:+
LAML	cis	rs9322193	0.923	rs9322197	ENSG00000216906.2	RP11-350J20.9	4.93	5.11e-06	0.0118	0.68	0.5	Lung cancer;	chr6:149622577	chr6:149904243~149906418:+
LAML	cis	rs7301826	0.967	rs4759792	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810821~130812622:-
LAML	cis	rs904251	0.523	rs2797799	ENSG00000229559.2	RP1-153P14.3	-4.93	5.12e-06	0.0119	-0.52	-0.5	Cognitive performance;	chr6:37515844	chr6:37543553~37547280:-
LAML	cis	rs904251	0.504	rs1757188	ENSG00000229559.2	RP1-153P14.3	-4.93	5.12e-06	0.0119	-0.52	-0.5	Cognitive performance;	chr6:37516032	chr6:37543553~37547280:-
LAML	cis	rs7301826	0.932	rs1007246	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810821~130812622:-
LAML	cis	rs7301826	1	rs10773822	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810821~130812622:-
LAML	cis	rs7301826	1	rs4759787	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810821~130812622:-
LAML	cis	rs7301826	1	rs7301826	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.966	rs10734980	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.967	rs4759790	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810821~130812622:-
LAML	cis	rs7301826	1	rs4759793	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810821~130812622:-
LAML	cis	rs7301826	1	rs1106369	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810821~130812622:-
LAML	cis	rs7301826	1	rs4759523	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810821~130812622:-
LAML	cis	rs7301826	1	rs4759524	ENSG00000256299.1	RP11-989F5.3	-4.93	5.12e-06	0.0119	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.585	rs6486600	ENSG00000256299.1	RP11-989F5.3	-4.93	5.13e-06	0.0119	-0.67	-0.5	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810821~130812622:-
LAML	cis	rs8081395	0.801	rs2777895	ENSG00000267302.4	RP11-178C3.2	-4.93	5.16e-06	0.0119	-0.64	-0.5	White blood cell count;	chr17:59802249	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.769	rs12449331	ENSG00000267302.4	RP11-178C3.2	-4.93	5.16e-06	0.0119	-0.64	-0.5	White blood cell count;	chr17:59806285	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.801	rs12938273	ENSG00000267302.4	RP11-178C3.2	-4.93	5.16e-06	0.0119	-0.64	-0.5	White blood cell count;	chr17:59824291	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.836	rs1295926	ENSG00000267302.4	RP11-178C3.2	-4.93	5.16e-06	0.0119	-0.64	-0.5	White blood cell count;	chr17:59832012	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.836	rs1292061	ENSG00000267302.4	RP11-178C3.2	-4.93	5.16e-06	0.0119	-0.64	-0.5	White blood cell count;	chr17:59833869	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.801	rs2665404	ENSG00000267302.4	RP11-178C3.2	4.93	5.16e-06	0.0119	0.64	0.5	White blood cell count;	chr17:59798035	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.801	rs2645479	ENSG00000267302.4	RP11-178C3.2	4.93	5.16e-06	0.0119	0.64	0.5	White blood cell count;	chr17:59843171	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.805	rs1295927	ENSG00000267302.4	RP11-178C3.2	4.93	5.16e-06	0.0119	0.64	0.5	White blood cell count;	chr17:59852174	chr17:59964832~59996972:+
LAML	cis	rs62070183	0.766	rs62067160	ENSG00000266599.1	RP11-466A19.3	4.93	5.17e-06	0.0119	0.79	0.5	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32919567	chr17:32518953~32531492:+
LAML	cis	rs763121	0.813	rs2179143	ENSG00000230912.1	RP3-508I15.10	-4.93	5.17e-06	0.0119	-0.39	-0.5	Menopause (age at onset);	chr22:38641979	chr22:38666508~38668750:-
LAML	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	4.93	5.19e-06	0.012	0.62	0.5	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	4.93	5.19e-06	0.012	0.62	0.5	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	4.93	5.19e-06	0.012	0.62	0.5	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
LAML	cis	rs748404	0.66	rs693510	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43422427	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs509306	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43422973	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs690512	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43425480	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs542898	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43427194	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs690012	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43427557	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs2249952	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43428335	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs689767	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43429879	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs2439845	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43430412	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs2467745	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43430544	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs2602141	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43432448	chr15:43663654~43684339:-
LAML	cis	rs748404	0.69	rs2467737	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43444990	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs2439846	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43448772	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs2467741	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43450428	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	4.92	5.2e-06	0.012	0.57	0.5	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs2467742	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43458039	chr15:43663654~43684339:-
LAML	cis	rs748404	0.69	rs2244981	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43460553	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs690446	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43469066	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs518288	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43471801	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs690472	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43472170	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs560191	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43475576	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs2444251	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43496397	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs548704	ENSG00000249839.1	AC011330.5	-4.92	5.2e-06	0.012	-0.57	-0.5	Lung cancer;	chr15:43499508	chr15:43663654~43684339:-
LAML	cis	rs3758911	0.788	rs10890704	ENSG00000261098.1	RP11-819C21.1	-4.92	5.2e-06	0.012	-0.49	-0.5	Coronary artery disease;	chr11:107312779	chr11:107312132~107316271:-
LAML	cis	rs9322193	0.962	rs2275046	ENSG00000216906.2	RP11-350J20.9	4.92	5.21e-06	0.012	0.69	0.5	Lung cancer;	chr6:149835865	chr6:149904243~149906418:+
LAML	cis	rs9457247	0.534	rs9347170	ENSG00000231654.1	RPS6KA2-AS1	4.92	5.21e-06	0.012	0.49	0.5	Crohn's disease;	chr6:166991699	chr6:166903698~166904835:+
LAML	cis	rs7237497	0.532	rs515151	ENSG00000260302.1	RP11-973H7.1	-4.92	5.22e-06	0.012	-0.89	-0.5	Inflammatory skin disease;	chr18:12860935	chr18:12774651~12775923:-
LAML	cis	rs1075265	0.553	rs2692532	ENSG00000235937.1	AC008280.1	4.92	5.25e-06	0.0121	0.4	0.5	Chronotype;Morning vs. evening chronotype;	chr2:53778962	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.62	rs2542584	ENSG00000235937.1	AC008280.1	4.92	5.25e-06	0.0121	0.4	0.5	Chronotype;Morning vs. evening chronotype;	chr2:53782707	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.587	rs2949811	ENSG00000235937.1	AC008280.1	4.92	5.25e-06	0.0121	0.4	0.5	Chronotype;Morning vs. evening chronotype;	chr2:53797028	chr2:54029552~54030682:-
LAML	cis	rs7829975	0.511	rs2976902	ENSG00000268955.2	RP11-556O5.6	-4.92	5.25e-06	0.0121	-0.69	-0.5	Mood instability;	chr8:8483595	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.511	rs2976906	ENSG00000268955.2	RP11-556O5.6	-4.92	5.25e-06	0.0121	-0.69	-0.5	Mood instability;	chr8:8484905	chr8:8188535~8189195:-
LAML	cis	rs875971	0.66	rs2191268	ENSG00000224316.1	RP11-479O9.2	4.92	5.25e-06	0.0121	0.53	0.5	Aortic root size;	chr7:66645237	chr7:65773620~65802067:+
LAML	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-4.92	5.26e-06	0.0121	-0.62	-0.5	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
LAML	cis	rs4728142	0.738	rs3807306	ENSG00000275106.1	RP11-309L24.10	4.92	5.26e-06	0.0121	0.43	0.5	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128940626	chr7:128952527~128953316:-
LAML	cis	rs5769707	1	rs5769707	ENSG00000213279.2	RP1-29C18.9	-4.92	5.28e-06	0.0121	-0.59	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49619754	chr22:49572264~49575426:-
LAML	cis	rs911555	0.57	rs11625397	ENSG00000252469.1	RNU7-160P	4.92	5.28e-06	0.0121	0.58	0.5	Intelligence (multi-trait analysis);	chr14:103561220	chr14:103550345~103550406:+
LAML	cis	rs8062405	0.754	rs149299	ENSG00000271623.1	RP11-435I10.5	-4.92	5.28e-06	0.0121	-0.59	-0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28364700~28365333:+
LAML	cis	rs875971	0.66	rs2013222	ENSG00000224316.1	RP11-479O9.2	-4.92	5.29e-06	0.0121	-0.52	-0.5	Aortic root size;	chr7:66570949	chr7:65773620~65802067:+
LAML	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	4.92	5.31e-06	0.0122	0.62	0.5	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	4.92	5.31e-06	0.0122	0.62	0.5	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	4.92	5.31e-06	0.0122	0.62	0.5	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	4.92	5.31e-06	0.0122	0.62	0.5	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	4.92	5.31e-06	0.0122	0.62	0.5	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	4.92	5.31e-06	0.0122	0.62	0.5	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	4.92	5.31e-06	0.0122	0.62	0.5	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	4.92	5.31e-06	0.0122	0.62	0.5	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-4.92	5.31e-06	0.0122	-0.62	-0.5	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
LAML	cis	rs801193	1	rs2659909	ENSG00000224316.1	RP11-479O9.2	4.92	5.33e-06	0.0122	0.53	0.5	Aortic root size;	chr7:66695292	chr7:65773620~65802067:+
LAML	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	4.92	5.33e-06	0.0122	0.58	0.5	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	4.92	5.33e-06	0.0122	0.58	0.5	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
LAML	cis	rs1789	0.706	rs8180240	ENSG00000249930.1	AC007016.3	-4.92	5.34e-06	0.0122	-0.69	-0.5	Blood protein levels;	chr4:15699952	chr4:15492729~15492972:-
LAML	cis	rs6951245	0.744	rs1133122	ENSG00000229043.2	AC091729.9	-4.92	5.34e-06	0.0122	-0.75	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1152936	chr7:1160374~1165267:+
LAML	cis	rs11332131	1	rs11332131	ENSG00000267302.4	RP11-178C3.2	4.92	5.36e-06	0.0123	0.64	0.5	Platelet distribution width;	chr17:59849031	chr17:59964832~59996972:+
LAML	cis	rs10500715	0.59	rs10840342	ENSG00000254719.1	RP11-351I24.3	-4.92	5.37e-06	0.0123	-0.61	-0.5	Pancreatic cancer;	chr11:10020482	chr11:10272052~10272259:-
LAML	cis	rs9322193	0.607	rs12527391	ENSG00000216906.2	RP11-350J20.9	4.92	5.37e-06	0.0123	0.76	0.5	Lung cancer;	chr6:149882156	chr6:149904243~149906418:+
LAML	cis	rs9891572	0.929	rs7214927	ENSG00000262884.1	CTD-3060P21.1	-4.92	5.38e-06	0.0123	-0.61	-0.5	HDL cholesterol;	chr17:2523079	chr17:2962248~2965895:-
LAML	cis	rs11039798	0.925	rs12277669	ENSG00000263693.1	MIR3161	4.92	5.39e-06	0.0123	0.49	0.5	Axial length;	chr11:48903764	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.841	rs10839174	ENSG00000263693.1	MIR3161	4.92	5.39e-06	0.0123	0.49	0.5	Axial length;	chr11:48909633	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.925	rs7929225	ENSG00000263693.1	MIR3161	4.92	5.39e-06	0.0123	0.49	0.5	Axial length;	chr11:48910187	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.764	rs76882342	ENSG00000263693.1	MIR3161	4.92	5.39e-06	0.0123	0.49	0.5	Axial length;	chr11:48917539	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.844	rs7126949	ENSG00000263693.1	MIR3161	4.92	5.39e-06	0.0123	0.49	0.5	Axial length;	chr11:48950614	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.844	rs11040177	ENSG00000263693.1	MIR3161	4.92	5.39e-06	0.0123	0.49	0.5	Axial length;	chr11:48954659	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.92	rs116109043	ENSG00000263693.1	MIR3161	4.92	5.39e-06	0.0123	0.49	0.5	Axial length;	chr11:48955388	chr11:48096782~48096858:+
LAML	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	4.92	5.39e-06	0.0123	0.71	0.5	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
LAML	cis	rs3131082	1	rs3131082	ENSG00000220721.1	OR1F12	4.92	5.39e-06	0.0123	0.84	0.5	Tuberculosis;	chr6:29015497	chr6:28073316~28074233:+
LAML	cis	rs9322193	0.923	rs9688452	ENSG00000216906.2	RP11-350J20.9	4.92	5.39e-06	0.0123	0.69	0.5	Lung cancer;	chr6:149658764	chr6:149904243~149906418:+
LAML	cis	rs748404	0.516	rs523156	ENSG00000249839.1	AC011330.5	4.91	5.4e-06	0.0123	0.65	0.5	Lung cancer;	chr15:43519645	chr15:43663654~43684339:-
LAML	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	4.91	5.41e-06	0.0123	0.55	0.5	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
LAML	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	4.91	5.41e-06	0.0123	0.55	0.5	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
LAML	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	4.91	5.41e-06	0.0123	0.55	0.5	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
LAML	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	4.91	5.41e-06	0.0123	0.55	0.5	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
LAML	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	4.91	5.41e-06	0.0123	0.55	0.5	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
LAML	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-4.91	5.41e-06	0.0123	-0.55	-0.5	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
LAML	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-4.91	5.41e-06	0.0123	-0.55	-0.5	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
LAML	cis	rs7495132	0.688	rs56961537	ENSG00000259314.1	CTD-3065B20.3	4.91	5.41e-06	0.0123	0.53	0.5	Ulcerative colitis;Inflammatory bowel disease;	chr15:90624175	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.688	rs11856388	ENSG00000259314.1	CTD-3065B20.3	4.91	5.41e-06	0.0123	0.53	0.5	Ulcerative colitis;Inflammatory bowel disease;	chr15:90627136	chr15:90604225~90614558:-
LAML	cis	rs2404602	0.735	rs283789	ENSG00000259422.1	RP11-593F23.1	4.91	5.41e-06	0.0124	0.57	0.5	Blood metabolite levels;	chr15:76485236	chr15:76174891~76181486:-
LAML	cis	rs709400	0.597	rs3759584	ENSG00000258851.1	RP11-894P9.2	-4.91	5.43e-06	0.0124	-0.63	-0.5	Body mass index;	chr14:103524462	chr14:103553421~103561877:+
LAML	cis	rs10463316	0.817	rs1318783	ENSG00000260581.1	CTB-113P19.4	4.91	5.46e-06	0.0125	0.44	0.5	Metabolite levels (Pyroglutamine);	chr5:151435246	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.817	rs1508772	ENSG00000260581.1	CTB-113P19.4	4.91	5.46e-06	0.0125	0.44	0.5	Metabolite levels (Pyroglutamine);	chr5:151437000	chr5:151652275~151655449:+
LAML	cis	rs7829975	0.511	rs2921028	ENSG00000268955.2	RP11-556O5.6	-4.91	5.46e-06	0.0125	-0.69	-0.5	Mood instability;	chr8:8482967	chr8:8188535~8189195:-
LAML	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-4.91	5.47e-06	0.0125	-0.56	-0.5	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	4.91	5.47e-06	0.0125	0.56	0.5	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
LAML	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	4.91	5.47e-06	0.0125	0.56	0.5	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
LAML	cis	rs7714584	1	rs10463307	ENSG00000197083.10	ZNF300P1	4.91	5.49e-06	0.0125	1.02	0.5	Crohn's disease;	chr5:150875058	chr5:150930645~150946289:-
LAML	cis	rs748404	0.578	rs2278856	ENSG00000249839.1	AC011330.5	-4.91	5.49e-06	0.0125	-0.55	-0.5	Lung cancer;	chr15:43339158	chr15:43663654~43684339:-
LAML	cis	rs748404	0.586	rs2584700	ENSG00000249839.1	AC011330.5	-4.91	5.5e-06	0.0125	-0.57	-0.5	Lung cancer;	chr15:43393134	chr15:43663654~43684339:-
LAML	cis	rs748404	0.587	rs690276	ENSG00000249839.1	AC011330.5	-4.91	5.5e-06	0.0125	-0.57	-0.5	Lung cancer;	chr15:43412360	chr15:43663654~43684339:-
LAML	cis	rs716804	0.74	rs11042714	ENSG00000254719.1	RP11-351I24.3	4.91	5.5e-06	0.0125	0.6	0.5	Neuroticism;	chr11:10274104	chr11:10272052~10272259:-
LAML	cis	rs7581030	0.55	rs7561181	ENSG00000236469.1	AC007040.8	4.91	5.5e-06	0.0125	0.63	0.5	Testicular germ cell tumor;	chr2:71234658	chr2:71002531~71064743:-
LAML	cis	rs11039798	1	rs7125559	ENSG00000263693.1	MIR3161	4.91	5.51e-06	0.0125	0.49	0.5	Axial length;	chr11:48962655	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs7125913	ENSG00000263693.1	MIR3161	4.91	5.51e-06	0.0125	0.49	0.5	Axial length;	chr11:48962766	chr11:48096782~48096858:+
LAML	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	4.91	5.51e-06	0.0125	0.56	0.5	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
LAML	cis	rs7301826	0.934	rs10773826	ENSG00000256299.1	RP11-989F5.3	-4.91	5.52e-06	0.0125	-0.64	-0.5	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810821~130812622:-
LAML	cis	rs2948294	0.524	rs13270062	ENSG00000253893.2	FAM85B	-4.91	5.52e-06	0.0125	-0.67	-0.5	Red cell distribution width;	chr8:8255128	chr8:8167819~8226614:-
LAML	cis	rs2948294	0.588	rs7011221	ENSG00000253893.2	FAM85B	-4.91	5.52e-06	0.0125	-0.67	-0.5	Red cell distribution width;	chr8:8256724	chr8:8167819~8226614:-
LAML	cis	rs2948294	0.545	rs11776397	ENSG00000253893.2	FAM85B	-4.91	5.52e-06	0.0125	-0.67	-0.5	Red cell distribution width;	chr8:8257639	chr8:8167819~8226614:-
LAML	cis	rs2948294	0.588	rs12544596	ENSG00000253893.2	FAM85B	-4.91	5.52e-06	0.0125	-0.67	-0.5	Red cell distribution width;	chr8:8258824	chr8:8167819~8226614:-
LAML	cis	rs1789	0.786	rs6414768	ENSG00000249930.1	AC007016.3	-4.91	5.52e-06	0.0126	-0.67	-0.5	Blood protein levels;	chr4:15693740	chr4:15492729~15492972:-
LAML	cis	rs9891572	0.852	rs12452016	ENSG00000262884.1	CTD-3060P21.1	-4.91	5.52e-06	0.0126	-0.59	-0.5	HDL cholesterol;	chr17:2528221	chr17:2962248~2965895:-
LAML	cis	rs3758911	0.765	rs687991	ENSG00000261098.1	RP11-819C21.1	4.91	5.53e-06	0.0126	0.51	0.5	Coronary artery disease;	chr11:107449918	chr11:107312132~107316271:-
LAML	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs13207354	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85990545	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12204365	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85990814	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12663651	ENSG00000203875.9	SNHG5	-4.91	5.53e-06	0.0126	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85991937	chr6:85660950~85678736:-
LAML	cis	rs2980439	0.807	rs2980438	ENSG00000253893.2	FAM85B	-4.91	5.54e-06	0.0126	-0.6	-0.5	Neuroticism;	chr8:8237303	chr8:8167819~8226614:-
LAML	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	4.91	5.56e-06	0.0126	0.71	0.5	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
LAML	cis	rs748404	0.69	rs2924369	ENSG00000249839.1	AC011330.5	4.91	5.57e-06	0.0126	0.57	0.5	Lung cancer;	chr15:43485787	chr15:43663654~43684339:-
LAML	cis	rs748404	0.66	rs493377	ENSG00000249839.1	AC011330.5	-4.91	5.57e-06	0.0126	-0.57	-0.5	Lung cancer;	chr15:43481269	chr15:43663654~43684339:-
LAML	cis	rs748404	0.69	rs1079309	ENSG00000249839.1	AC011330.5	-4.91	5.57e-06	0.0126	-0.57	-0.5	Lung cancer;	chr15:43490966	chr15:43663654~43684339:-
LAML	cis	rs4809324	0.585	rs3761121	ENSG00000199805.1	RNU1-134P	4.91	5.59e-06	0.0127	0.56	0.5	Glioma (high-grade);	chr20:63711343	chr20:63908955~63909119:+
LAML	cis	rs748404	0.578	rs4547312	ENSG00000249839.1	AC011330.5	-4.91	5.6e-06	0.0127	-0.54	-0.5	Lung cancer;	chr15:43339940	chr15:43663654~43684339:-
LAML	cis	rs748404	0.604	rs2278857	ENSG00000249839.1	AC011330.5	-4.91	5.6e-06	0.0127	-0.54	-0.5	Lung cancer;	chr15:43340351	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs2412781	ENSG00000249839.1	AC011330.5	4.9	5.61e-06	0.0127	0.56	0.5	Lung cancer;	chr15:43375702	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs6493083	ENSG00000249839.1	AC011330.5	-4.9	5.61e-06	0.0127	-0.56	-0.5	Lung cancer;	chr15:43345787	chr15:43663654~43684339:-
LAML	cis	rs748404	0.587	rs9920879	ENSG00000249839.1	AC011330.5	-4.9	5.61e-06	0.0127	-0.56	-0.5	Lung cancer;	chr15:43347572	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs7166812	ENSG00000249839.1	AC011330.5	-4.9	5.61e-06	0.0127	-0.56	-0.5	Lung cancer;	chr15:43352562	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs1133395	ENSG00000249839.1	AC011330.5	-4.9	5.61e-06	0.0127	-0.56	-0.5	Lung cancer;	chr15:43358186	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs3809482	ENSG00000249839.1	AC011330.5	-4.9	5.61e-06	0.0127	-0.56	-0.5	Lung cancer;	chr15:43369604	chr15:43663654~43684339:-
LAML	cis	rs6968355	0.799	rs2017598	ENSG00000225329.2	LHFPL3-AS2	4.9	5.63e-06	0.0127	0.71	0.5	Myopia (pathological);	chr7:104952522	chr7:104894628~104926645:-
LAML	cis	rs7746199	0.736	rs35037868	ENSG00000182477.5	OR2B8P	4.9	5.63e-06	0.0127	0.94	0.5	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28053228~28054165:-
LAML	cis	rs41563	0.557	rs17777642	ENSG00000225329.2	LHFPL3-AS2	4.9	5.63e-06	0.0128	0.59	0.5	Autism spectrum disorder or schizophrenia;	chr7:104958761	chr7:104894628~104926645:-
LAML	cis	rs763121	0.925	rs5757251	ENSG00000230912.1	RP3-508I15.10	-4.9	5.64e-06	0.0128	-0.4	-0.5	Menopause (age at onset);	chr22:38704123	chr22:38666508~38668750:-
LAML	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	4.9	5.64e-06	0.0128	0.6	0.5	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
LAML	cis	rs875971	0.54	rs781152	ENSG00000224316.1	RP11-479O9.2	4.9	5.65e-06	0.0128	0.56	0.5	Aortic root size;	chr7:66014585	chr7:65773620~65802067:+
LAML	cis	rs17711722	0.727	rs781151	ENSG00000224316.1	RP11-479O9.2	4.9	5.65e-06	0.0128	0.56	0.5	Calcium levels;	chr7:66014891	chr7:65773620~65802067:+
LAML	cis	rs67311347	1	rs73076035	ENSG00000230274.1	PGAM1P3	4.9	5.65e-06	0.0128	0.66	0.5	Renal cell carcinoma;	chr3:40398390	chr3:40322715~40323279:-
LAML	cis	rs1075265	0.597	rs10490471	ENSG00000235937.1	AC008280.1	4.9	5.66e-06	0.0128	0.42	0.5	Chronotype;Morning vs. evening chronotype;	chr2:53769446	chr2:54029552~54030682:-
LAML	cis	rs34787248	1	rs34787248	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28046434~28047367:+
LAML	cis	rs853679	0.76	rs9468317	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28230678	chr6:28046434~28047367:+
LAML	cis	rs853679	0.76	rs2299029	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28231053	chr6:28046434~28047367:+
LAML	cis	rs853679	0.76	rs11967137	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28231986	chr6:28046434~28047367:+
LAML	cis	rs853679	0.76	rs11962305	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28232159	chr6:28046434~28047367:+
LAML	cis	rs853679	0.723	rs9366718	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28237724	chr6:28046434~28047367:+
LAML	cis	rs853679	0.76	rs9393909	ENSG00000187763.3	OR2B7P	-4.9	5.67e-06	0.0128	-0.7	-0.5	Depression;	chr6:28239422	chr6:28046434~28047367:+
LAML	cis	rs853679	0.76	rs9393910	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28240414	chr6:28046434~28047367:+
LAML	cis	rs853679	0.76	rs9368563	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28240780	chr6:28046434~28047367:+
LAML	cis	rs853679	0.76	rs9295768	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28241324	chr6:28046434~28047367:+
LAML	cis	rs853679	0.699	rs9468318	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28241753	chr6:28046434~28047367:+
LAML	cis	rs853679	0.76	rs9357067	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28242515	chr6:28046434~28047367:+
LAML	cis	rs853679	0.76	rs967005	ENSG00000187763.3	OR2B7P	4.9	5.67e-06	0.0128	0.7	0.5	Depression;	chr6:28242910	chr6:28046434~28047367:+
LAML	cis	rs7301826	1	rs10773819	ENSG00000256299.1	RP11-989F5.3	-4.9	5.69e-06	0.0128	-0.63	-0.5	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810821~130812622:-
LAML	cis	rs561341	0.689	rs578635	ENSG00000266379.5	RP11-640N20.8	4.9	5.69e-06	0.0128	0.72	0.5	Hip circumference adjusted for BMI;	chr17:31962878	chr17:32088160~32094933:-
LAML	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	4.9	5.69e-06	0.0128	0.64	0.5	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
LAML	cis	rs965604	1	rs1964678	ENSG00000259474.1	RP11-650L12.1	-4.9	5.69e-06	0.0128	-0.49	-0.5	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr15:78461658	chr15:78480057~78481820:-
LAML	cis	rs6968355	0.799	rs6961188	ENSG00000225329.2	LHFPL3-AS2	-4.9	5.7e-06	0.0129	-0.79	-0.5	Myopia (pathological);	chr7:104956308	chr7:104894628~104926645:-
LAML	cis	rs7534824	1	rs76336747	ENSG00000213421.4	RP11-84O12.2	-4.9	5.7e-06	0.0129	-1.07	-0.5	Refractive astigmatism;	chr1:101182762	chr1:100586649~100587431:-
LAML	cis	rs7534824	1	rs74431709	ENSG00000213421.4	RP11-84O12.2	-4.9	5.7e-06	0.0129	-1.07	-0.5	Refractive astigmatism;	chr1:101187569	chr1:100586649~100587431:-
LAML	cis	rs2462686	1	rs2453835	ENSG00000229628.1	AC073115.7	4.9	5.7e-06	0.0129	0.64	0.5	Major depressive disorder;	chr7:45927575	chr7:45990905~46000898:+
LAML	cis	rs2462686	1	rs28552707	ENSG00000229628.1	AC073115.7	4.9	5.7e-06	0.0129	0.64	0.5	Major depressive disorder;	chr7:45929117	chr7:45990905~46000898:+
LAML	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-4.9	5.72e-06	0.0129	-0.65	-0.5	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
LAML	cis	rs911555	0.926	rs2756121	ENSG00000258851.1	RP11-894P9.2	4.9	5.73e-06	0.0129	0.59	0.5	Intelligence (multi-trait analysis);	chr14:103523244	chr14:103553421~103561877:+
LAML	cis	rs8037137	0.571	rs3743445	ENSG00000258725.1	PRC1-AS1	-4.9	5.73e-06	0.0129	-0.82	-0.5	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:91017952	chr15:90966345~90988624:+
LAML	cis	rs12468226	1	rs79919139	ENSG00000272966.1	RP11-686O6.1	4.9	5.74e-06	0.0129	0.85	0.5	Urate levels;	chr2:202382786	chr2:202336739~202337200:+
LAML	cis	rs2742417	1	rs2742421	ENSG00000244357.3	RN7SL145P	-4.9	5.74e-06	0.0129	-0.53	-0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45691023	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs1969624	ENSG00000244357.3	RN7SL145P	-4.9	5.74e-06	0.0129	-0.53	-0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45693326	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742431	ENSG00000244357.3	RN7SL145P	-4.9	5.74e-06	0.0129	-0.53	-0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45695629	chr3:45742675~45742970:+
LAML	cis	rs12149695	0.703	rs12924923	ENSG00000259940.2	CTD-3203P2.1	-4.9	5.75e-06	0.0129	-0.57	-0.5	Gut microbiota (bacterial taxa);	chr16:27221530	chr16:27213308~27214993:-
LAML	cis	rs801193	1	rs2420824	ENSG00000224316.1	RP11-479O9.2	-4.9	5.75e-06	0.0129	-0.53	-0.5	Aortic root size;	chr7:66666129	chr7:65773620~65802067:+
LAML	cis	rs1419607	0.814	rs2896366	ENSG00000224897.5	POT1-AS1	4.9	5.77e-06	0.013	0.59	0.5	Obesity-related traits;	chr7:125790785	chr7:124929873~125179315:+
LAML	cis	rs1419607	0.68	rs1419604	ENSG00000224897.5	POT1-AS1	4.9	5.77e-06	0.013	0.59	0.5	Obesity-related traits;	chr7:125793813	chr7:124929873~125179315:+
LAML	cis	rs7587476	0.906	rs62201985	ENSG00000229267.2	AC072062.1	-4.9	5.8e-06	0.013	-0.64	-0.5	Neuroblastoma;	chr2:214793914	chr2:214810229~214963274:+
LAML	cis	rs12149695	0.735	rs11641348	ENSG00000259940.2	CTD-3203P2.1	-4.9	5.8e-06	0.013	-0.57	-0.5	Gut microbiota (bacterial taxa);	chr16:27233765	chr16:27213308~27214993:-
LAML	cis	rs9916302	0.904	rs35285898	ENSG00000223091.1	RNU6-981P	4.9	5.8e-06	0.013	0.59	0.5	Glomerular filtration rate (creatinine);	chr17:39399619	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs9905432	ENSG00000223091.1	RNU6-981P	4.9	5.8e-06	0.013	0.59	0.5	Glomerular filtration rate (creatinine);	chr17:39399665	chr17:39482486~39482590:-
LAML	cis	rs709400	0.663	rs11623869	ENSG00000258851.1	RP11-894P9.2	-4.9	5.81e-06	0.013	-0.62	-0.5	Body mass index;	chr14:103417296	chr14:103553421~103561877:+
LAML	cis	rs7495132	0.688	rs3743405	ENSG00000259314.1	CTD-3065B20.3	4.9	5.82e-06	0.0131	0.53	0.5	Ulcerative colitis;Inflammatory bowel disease;	chr15:90625744	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.688	rs12908911	ENSG00000259314.1	CTD-3065B20.3	4.9	5.82e-06	0.0131	0.53	0.5	Ulcerative colitis;Inflammatory bowel disease;	chr15:90627487	chr15:90604225~90614558:-
LAML	cis	rs12922317	0.589	rs350215	ENSG00000260224.1	UBL5P4	-4.9	5.83e-06	0.0131	-0.62	-0.5	Schizophrenia;	chr16:12057426	chr16:11968508~11968743:-
LAML	cis	rs12922317	0.589	rs350216	ENSG00000260224.1	UBL5P4	4.9	5.83e-06	0.0131	0.62	0.5	Schizophrenia;	chr16:12057283	chr16:11968508~11968743:-
LAML	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-4.9	5.83e-06	0.0131	-0.63	-0.5	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
LAML	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-4.89	5.84e-06	0.0131	-0.64	-0.5	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
LAML	cis	rs785830	1	rs785830	ENSG00000235880.1	RP11-59O6.3	4.89	5.84e-06	0.0131	0.45	0.5	Platelet distribution width;	chr9:246357	chr9:267966~273002:-
LAML	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-4.89	5.84e-06	0.0131	-0.62	-0.5	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
LAML	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-4.89	5.84e-06	0.0131	-0.62	-0.5	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
LAML	cis	rs5760092	0.572	rs738806	ENSG00000218537.1	MIF-AS1	4.89	5.85e-06	0.0131	0.82	0.5	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23894426~23898930:-
LAML	cis	rs8031584	0.723	rs11632229	ENSG00000260382.1	RP11-540B6.2	-4.89	5.85e-06	0.0131	-0.55	-0.5	Huntington's disease progression;	chr15:30887331	chr15:30882267~30883231:-
LAML	cis	rs748404	0.66	rs694725	ENSG00000249839.1	AC011330.5	-4.89	5.86e-06	0.0131	-0.55	-0.5	Lung cancer;	chr15:43464012	chr15:43663654~43684339:-
LAML	cis	rs7555523	0.887	rs12691499	ENSG00000224358.1	RP11-466F5.8	-4.89	5.86e-06	0.0131	-0.7	-0.5	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165718428	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.83	rs12691500	ENSG00000224358.1	RP11-466F5.8	-4.89	5.86e-06	0.0131	-0.7	-0.5	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165718524	chr1:165768929~165775176:+
LAML	cis	rs5769707	0.609	rs739247	ENSG00000212939.2	RP1-29C18.10	-4.89	5.87e-06	0.0131	-0.67	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49603009	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.609	rs135861	ENSG00000212939.2	RP1-29C18.10	-4.89	5.87e-06	0.0131	-0.67	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49604470	chr22:49548681~49556473:+
LAML	cis	rs4591358	0.571	rs4850366	ENSG00000223466.1	AC064834.2	-4.89	5.87e-06	0.0131	-0.69	-0.5	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195538742	chr2:195533035~195538681:+
LAML	cis	rs7397814	0.558	rs4764447	ENSG00000255753.1	RP11-22B23.2	-4.89	5.89e-06	0.0132	-0.67	-0.5	IgG glycosylation;	chr12:9426513	chr12:9314402~9316173:-
LAML	cis	rs12468226	0.938	rs10166594	ENSG00000272966.1	RP11-686O6.1	4.89	5.9e-06	0.0132	0.78	0.5	Urate levels;	chr2:202250262	chr2:202336739~202337200:+
LAML	cis	rs9393777	0.528	rs7745603	ENSG00000187763.3	OR2B7P	4.89	5.9e-06	0.0132	0.65	0.5	Intelligence (multi-trait analysis);	chr6:27122625	chr6:28046434~28047367:+
LAML	cis	rs62070183	0.882	rs17183295	ENSG00000266599.1	RP11-466A19.3	4.89	5.91e-06	0.0132	0.77	0.5	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32751254	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs9911168	ENSG00000266599.1	RP11-466A19.3	4.89	5.91e-06	0.0132	0.78	0.5	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709136	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs9912761	ENSG00000266599.1	RP11-466A19.3	4.89	5.91e-06	0.0132	0.78	0.5	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709475	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs9303654	ENSG00000266599.1	RP11-466A19.3	4.89	5.91e-06	0.0132	0.78	0.5	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32709747	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs9898762	ENSG00000266599.1	RP11-466A19.3	4.89	5.91e-06	0.0132	0.78	0.5	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32711641	chr17:32518953~32531492:+
LAML	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-4.89	5.94e-06	0.0133	-0.55	-0.5	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-4.89	5.94e-06	0.0133	-0.55	-0.5	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-4.89	5.94e-06	0.0133	-0.55	-0.5	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-4.89	5.94e-06	0.0133	-0.55	-0.5	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-4.89	5.94e-06	0.0133	-0.55	-0.5	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-4.89	5.94e-06	0.0133	-0.55	-0.5	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-4.89	5.94e-06	0.0133	-0.55	-0.5	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-4.89	5.94e-06	0.0133	-0.55	-0.5	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-4.89	5.94e-06	0.0133	-0.55	-0.5	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
LAML	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-4.89	5.94e-06	0.0133	-0.55	-0.5	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
LAML	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	4.89	5.95e-06	0.0133	0.61	0.5	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
LAML	cis	rs7131987	0.565	rs4412790	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29253828	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs10743651	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29255006	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.546	rs7299648	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29256797	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs7300032	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29256859	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.547	rs4370971	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29257066	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs7316026	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29258881	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs6487792	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29259743	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.585	rs2194517	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29260002	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs766445	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29260560	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs7971296	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29263297	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.605	rs1120528	ENSG00000273680.1	RP11-996F15.6	4.89	5.95e-06	0.0133	0.52	0.5	QT interval;	chr12:29264237	chr12:29332733~29333383:-
LAML	cis	rs34787248	1	rs34787248	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28073316~28074233:+
LAML	cis	rs853679	0.76	rs9468317	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28230678	chr6:28073316~28074233:+
LAML	cis	rs853679	0.76	rs2299029	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28231053	chr6:28073316~28074233:+
LAML	cis	rs853679	0.76	rs11967137	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28231986	chr6:28073316~28074233:+
LAML	cis	rs853679	0.76	rs11962305	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28232159	chr6:28073316~28074233:+
LAML	cis	rs853679	0.723	rs9366718	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28237724	chr6:28073316~28074233:+
LAML	cis	rs853679	0.76	rs9393909	ENSG00000220721.1	OR1F12	-4.89	5.96e-06	0.0133	-0.61	-0.5	Depression;	chr6:28239422	chr6:28073316~28074233:+
LAML	cis	rs853679	0.76	rs9393910	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28240414	chr6:28073316~28074233:+
LAML	cis	rs853679	0.76	rs9368563	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28240780	chr6:28073316~28074233:+
LAML	cis	rs853679	0.76	rs9295768	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28241324	chr6:28073316~28074233:+
LAML	cis	rs853679	0.699	rs9468318	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28241753	chr6:28073316~28074233:+
LAML	cis	rs853679	0.76	rs9357067	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28242515	chr6:28073316~28074233:+
LAML	cis	rs853679	0.76	rs967005	ENSG00000220721.1	OR1F12	4.89	5.96e-06	0.0133	0.61	0.5	Depression;	chr6:28242910	chr6:28073316~28074233:+
LAML	cis	rs9426935	0.681	rs9427318	ENSG00000273026.1	RP11-422P24.10	-4.89	5.98e-06	0.0133	-0.61	-0.5	Lentiform nucleus volume;	chr1:154008428	chr1:153966516~153966930:+
LAML	cis	rs11039798	0.541	rs12283728	ENSG00000263693.1	MIR3161	4.89	5.99e-06	0.0133	0.49	0.5	Axial length;	chr11:48774855	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.92	rs8186465	ENSG00000263693.1	MIR3161	4.89	5.99e-06	0.0133	0.49	0.5	Axial length;	chr11:48775219	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.764	rs11040030	ENSG00000263693.1	MIR3161	4.89	5.99e-06	0.0133	0.49	0.5	Axial length;	chr11:48779433	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.614	rs8188910	ENSG00000263693.1	MIR3161	4.89	5.99e-06	0.0133	0.49	0.5	Axial length;	chr11:48804188	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.61	rs11530356	ENSG00000263693.1	MIR3161	4.89	5.99e-06	0.0133	0.49	0.5	Axial length;	chr11:48814738	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.688	rs12277029	ENSG00000263693.1	MIR3161	4.89	5.99e-06	0.0133	0.49	0.5	Axial length;	chr11:48831281	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.778	rs7944523	ENSG00000263693.1	MIR3161	4.89	5.99e-06	0.0133	0.49	0.5	Axial length;	chr11:48889467	chr11:48096782~48096858:+
LAML	cis	rs8081395	0.741	rs1292051	ENSG00000267302.4	RP11-178C3.2	4.89	6e-06	0.0133	0.6	0.5	White blood cell count;	chr17:59886562	chr17:59964832~59996972:+
LAML	cis	rs2404602	0.735	rs4886805	ENSG00000259422.1	RP11-593F23.1	4.89	6.02e-06	0.0134	0.58	0.5	Blood metabolite levels;	chr15:76447043	chr15:76174891~76181486:-
LAML	cis	rs11039798	1	rs10838918	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48485897	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.764	rs11039771	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48491721	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs10769370	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48493878	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs7942042	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48498718	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.841	rs11039783	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48505276	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs34044596	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48506384	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.925	rs10769373	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48510428	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs6485848	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48519965	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs10838942	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48535611	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.92	rs12279378	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48549478	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.92	rs12292685	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48549480	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs7479655	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48555162	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs7123704	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48558983	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs3902927	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48559905	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs3902928	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48559906	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs7104642	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48566982	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs7928243	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48567640	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.841	rs7950737	ENSG00000263693.1	MIR3161	4.89	6.04e-06	0.0134	0.5	0.5	Axial length;	chr11:48569126	chr11:48096782~48096858:+
LAML	cis	rs716804	0.74	rs7118500	ENSG00000254719.1	RP11-351I24.3	-4.89	6.05e-06	0.0134	-0.6	-0.5	Neuroticism;	chr11:10263215	chr11:10272052~10272259:-
LAML	cis	rs950169	0.922	rs4842939	ENSG00000259728.4	LINC00933	-4.89	6.05e-06	0.0134	-0.71	-0.5	Schizophrenia;	chr15:84159214	chr15:84570649~84580175:+
LAML	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-4.88	6.06e-06	0.0134	-0.59	-0.5	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
LAML	cis	rs6558530	0.897	rs10481354	ENSG00000253982.1	CTD-2336O2.1	-4.88	6.07e-06	0.0134	-0.69	-0.5	Systolic blood pressure;	chr8:1755864	chr8:1761990~1764502:-
LAML	cis	rs748404	0.631	rs8042688	ENSG00000249839.1	AC011330.5	-4.88	6.07e-06	0.0134	-0.54	-0.5	Lung cancer;	chr15:43346327	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs4296223	ENSG00000249839.1	AC011330.5	-4.88	6.07e-06	0.0134	-0.54	-0.5	Lung cancer;	chr15:43353048	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs11070399	ENSG00000249839.1	AC011330.5	-4.88	6.07e-06	0.0134	-0.54	-0.5	Lung cancer;	chr15:43354149	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs6493084	ENSG00000249839.1	AC011330.5	-4.88	6.07e-06	0.0134	-0.54	-0.5	Lung cancer;	chr15:43355429	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs12905772	ENSG00000249839.1	AC011330.5	-4.88	6.07e-06	0.0134	-0.54	-0.5	Lung cancer;	chr15:43356246	chr15:43663654~43684339:-
LAML	cis	rs748404	0.676	rs4401024	ENSG00000249839.1	AC011330.5	-4.88	6.07e-06	0.0134	-0.54	-0.5	Lung cancer;	chr15:43358137	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs6493086	ENSG00000249839.1	AC011330.5	-4.88	6.07e-06	0.0134	-0.54	-0.5	Lung cancer;	chr15:43363196	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs7163288	ENSG00000249839.1	AC011330.5	-4.88	6.07e-06	0.0134	-0.54	-0.5	Lung cancer;	chr15:43379157	chr15:43663654~43684339:-
LAML	cis	rs748404	0.631	rs7167882	ENSG00000249839.1	AC011330.5	-4.88	6.07e-06	0.0134	-0.54	-0.5	Lung cancer;	chr15:43386465	chr15:43663654~43684339:-
LAML	cis	rs9457247	0.534	rs9355610	ENSG00000231654.1	RPS6KA2-AS1	4.88	6.07e-06	0.0134	0.49	0.5	Crohn's disease;	chr6:166969587	chr6:166903698~166904835:+
LAML	cis	rs6480314	0.636	rs34888891	ENSG00000234102.1	KRT19P4	-4.88	6.1e-06	0.0135	-0.78	-0.5	Optic nerve measurement (disc area);	chr10:68242351	chr10:68260557~68261499:+
LAML	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-4.88	6.11e-06	0.0135	-0.63	-0.5	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
LAML	cis	rs763121	0.925	rs1043312	ENSG00000230912.1	RP3-508I15.10	-4.88	6.12e-06	0.0135	-0.4	-0.5	Menopause (age at onset);	chr22:38735722	chr22:38666508~38668750:-
LAML	cis	rs79040073	0.765	rs7169304	ENSG00000276593.1	RP11-295H24.5	4.88	6.13e-06	0.0135	0.54	0.5	Lung cancer in ever smokers;	chr15:49186829	chr15:49353485~49354034:+
LAML	cis	rs853679	0.546	rs35744819	ENSG00000187763.3	OR2B7P	4.88	6.14e-06	0.0136	0.94	0.5	Depression;	chr6:28350554	chr6:28046434~28047367:+
LAML	cis	rs6921919	0.562	rs13198809	ENSG00000187763.3	OR2B7P	4.88	6.14e-06	0.0136	0.94	0.5	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28046434~28047367:+
LAML	cis	rs716804	0.654	rs7102016	ENSG00000254719.1	RP11-351I24.3	-4.88	6.15e-06	0.0136	-0.61	-0.5	Neuroticism;	chr11:10105762	chr11:10272052~10272259:-
LAML	cis	rs7131987	0.903	rs918873	ENSG00000273680.1	RP11-996F15.6	4.88	6.15e-06	0.0136	0.51	0.5	QT interval;	chr12:29237568	chr12:29332733~29333383:-
LAML	cis	rs9426935	0.966	rs1127091	ENSG00000273026.1	RP11-422P24.10	4.88	6.17e-06	0.0136	0.63	0.5	Lentiform nucleus volume;	chr1:153806936	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.966	rs6700115	ENSG00000273026.1	RP11-422P24.10	4.88	6.17e-06	0.0136	0.63	0.5	Lentiform nucleus volume;	chr1:153809412	chr1:153966516~153966930:+
LAML	cis	rs716804	0.74	rs6484147	ENSG00000254719.1	RP11-351I24.3	4.88	6.18e-06	0.0136	0.59	0.5	Neuroticism;	chr11:10273556	chr11:10272052~10272259:-
LAML	cis	rs1075265	0.704	rs805405	ENSG00000235937.1	AC008280.1	4.88	6.19e-06	0.0137	0.39	0.5	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54029552~54030682:-
LAML	cis	rs763121	0.853	rs6001214	ENSG00000230912.1	RP3-508I15.10	-4.88	6.21e-06	0.0137	-0.43	-0.5	Menopause (age at onset);	chr22:38753150	chr22:38666508~38668750:-
LAML	cis	rs11096990	0.964	rs4974999	ENSG00000206675.1	RNU6-32P	4.88	6.22e-06	0.0137	0.5	0.5	Cognitive function;	chr4:39262294	chr4:39297605~39297711:-
LAML	cis	rs11096990	0.927	rs56009503	ENSG00000206675.1	RNU6-32P	-4.88	6.22e-06	0.0137	-0.5	-0.5	Cognitive function;	chr4:39242642	chr4:39297605~39297711:-
LAML	cis	rs3758911	0.929	rs1843	ENSG00000261098.1	RP11-819C21.1	-4.88	6.22e-06	0.0137	-0.48	-0.5	Coronary artery disease;	chr11:107312219	chr11:107312132~107316271:-
LAML	cis	rs11039798	0.764	rs2089208	ENSG00000263693.1	MIR3161	4.88	6.24e-06	0.0137	0.49	0.5	Axial length;	chr11:48878308	chr11:48096782~48096858:+
LAML	cis	rs4713118	0.738	rs200465	ENSG00000220721.1	OR1F12	4.88	6.24e-06	0.0138	0.56	0.5	Parkinson's disease;	chr6:27789875	chr6:28073316~28074233:+
LAML	cis	rs12468226	1	rs76284304	ENSG00000272966.1	RP11-686O6.1	4.88	6.25e-06	0.0138	0.84	0.5	Urate levels;	chr2:202427116	chr2:202336739~202337200:+
LAML	cis	rs9322193	0.962	rs1413655	ENSG00000216906.2	RP11-350J20.9	4.88	6.26e-06	0.0138	0.7	0.5	Lung cancer;	chr6:149821815	chr6:149904243~149906418:+
LAML	cis	rs7944735	0.517	rs74763661	ENSG00000263693.1	MIR3161	4.88	6.27e-06	0.0138	0.48	0.5	Intraocular pressure;	chr11:48212220	chr11:48096782~48096858:+
LAML	cis	rs747782	0.527	rs12289516	ENSG00000263693.1	MIR3161	4.88	6.27e-06	0.0138	0.48	0.5	Intraocular pressure;	chr11:48213128	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.62	rs10838833	ENSG00000263693.1	MIR3161	4.88	6.27e-06	0.0138	0.48	0.5	Axial length;	chr11:48217328	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.698	rs76315297	ENSG00000263693.1	MIR3161	4.88	6.27e-06	0.0138	0.48	0.5	Axial length;	chr11:48218923	chr11:48096782~48096858:+
LAML	cis	rs904251	0.965	rs62406516	ENSG00000227920.2	RP1-153P14.5	-4.88	6.27e-06	0.0138	-0.58	-0.5	Cognitive performance;	chr6:37471588	chr6:37545145~37550860:+
LAML	cis	rs904251	1	rs904251	ENSG00000227920.2	RP1-153P14.5	-4.88	6.27e-06	0.0138	-0.58	-0.5	Cognitive performance;	chr6:37483920	chr6:37545145~37550860:+
LAML	cis	rs716804	0.74	rs7479039	ENSG00000254719.1	RP11-351I24.3	-4.88	6.27e-06	0.0138	-0.61	-0.5	Neuroticism;	chr11:10181476	chr11:10272052~10272259:-
LAML	cis	rs7714584	1	rs75774363	ENSG00000197083.10	ZNF300P1	4.87	6.3e-06	0.0138	1.01	0.5	Crohn's disease;	chr5:150844160	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs12054923	ENSG00000197083.10	ZNF300P1	4.87	6.3e-06	0.0138	1.01	0.5	Crohn's disease;	chr5:150869497	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs77698001	ENSG00000197083.10	ZNF300P1	4.87	6.3e-06	0.0138	1.01	0.5	Crohn's disease;	chr5:150870805	chr5:150930645~150946289:-
LAML	cis	rs11039798	1	rs10769383	ENSG00000263693.1	MIR3161	4.87	6.32e-06	0.0139	0.47	0.5	Axial length;	chr11:48570958	chr11:48096782~48096858:+
LAML	cis	rs5769707	0.632	rs5770601	ENSG00000280224.1	CTA-722E9.1	-4.87	6.35e-06	0.0139	-0.75	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49628255	chr22:49500568~49501585:+
LAML	cis	rs7131987	0.565	rs10743652	ENSG00000273680.1	RP11-996F15.6	4.87	6.36e-06	0.0139	0.52	0.5	QT interval;	chr12:29255074	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs10843372	ENSG00000273680.1	RP11-996F15.6	4.87	6.36e-06	0.0139	0.52	0.5	QT interval;	chr12:29262863	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs7976227	ENSG00000273680.1	RP11-996F15.6	4.87	6.36e-06	0.0139	0.52	0.5	QT interval;	chr12:29264843	chr12:29332733~29333383:-
LAML	cis	rs763121	0.853	rs6001173	ENSG00000230912.1	RP3-508I15.10	-4.87	6.36e-06	0.014	-0.39	-0.5	Menopause (age at onset);	chr22:38619297	chr22:38666508~38668750:-
LAML	cis	rs4774565	0.801	rs12911017	ENSG00000244879.4	GABPB1-AS1	-4.87	6.37e-06	0.014	-0.53	-0.5	Breast cancer;	chr15:50375802	chr15:50354959~50372202:+
LAML	cis	rs67311347	0.866	rs11712426	ENSG00000230274.1	PGAM1P3	4.87	6.37e-06	0.014	0.63	0.5	Renal cell carcinoma;	chr3:40288831	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.824	rs59922539	ENSG00000230274.1	PGAM1P3	4.87	6.37e-06	0.014	0.63	0.5	Renal cell carcinoma;	chr3:40295619	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.822	rs9826847	ENSG00000230274.1	PGAM1P3	4.87	6.37e-06	0.014	0.63	0.5	Renal cell carcinoma;	chr3:40303821	chr3:40322715~40323279:-
LAML	cis	rs9916302	0.851	rs9904919	ENSG00000223091.1	RNU6-981P	4.87	6.38e-06	0.014	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39400178	chr17:39482486~39482590:-
LAML	cis	rs3096299	0.9	rs4785666	ENSG00000274627.1	RP11-104N10.2	4.87	6.4e-06	0.014	0.6	0.5	Multiple myeloma (IgH translocation);	chr16:89396363	chr16:89516797~89522217:+
LAML	cis	rs911555	0.519	rs8014069	ENSG00000258851.1	RP11-894P9.2	-4.87	6.4e-06	0.014	-0.64	-0.5	Intelligence (multi-trait analysis);	chr14:103537974	chr14:103553421~103561877:+
LAML	cis	rs79040073	0.954	rs79539506	ENSG00000276593.1	RP11-295H24.5	4.87	6.42e-06	0.0141	0.54	0.5	Lung cancer in ever smokers;	chr15:49104538	chr15:49353485~49354034:+
LAML	cis	rs79040073	0.954	rs79234094	ENSG00000276593.1	RP11-295H24.5	4.87	6.42e-06	0.0141	0.54	0.5	Lung cancer in ever smokers;	chr15:49117330	chr15:49353485~49354034:+
LAML	cis	rs875971	0.66	rs801193	ENSG00000224316.1	RP11-479O9.2	-4.87	6.45e-06	0.0141	-0.51	-0.5	Aortic root size;	chr7:66565625	chr7:65773620~65802067:+
LAML	cis	rs67311347	0.544	rs6804545	ENSG00000223797.4	ENTPD3-AS1	4.87	6.45e-06	0.0141	0.61	0.5	Renal cell carcinoma;	chr3:40312549	chr3:40313802~40453329:-
LAML	cis	rs5769707	0.568	rs2011097	ENSG00000212939.2	RP1-29C18.10	-4.87	6.46e-06	0.0141	-0.69	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49624421	chr22:49548681~49556473:+
LAML	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	4.87	6.49e-06	0.0142	0.6	0.5	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
LAML	cis	rs12303914	0.89	rs765791	ENSG00000256667.5	KLRAP1	4.87	6.51e-06	0.0142	0.71	0.5	Thiazide-induced adverse metabolic effects in hypertensive patients;	chr12:10249789	chr12:10588063~10599669:-
LAML	cis	rs6558530	1	rs6558530	ENSG00000253982.1	CTD-2336O2.1	4.87	6.53e-06	0.0143	0.69	0.5	Systolic blood pressure;	chr8:1758041	chr8:1761990~1764502:-
LAML	cis	rs6558530	0.897	rs7838456	ENSG00000253982.1	CTD-2336O2.1	4.87	6.53e-06	0.0143	0.69	0.5	Systolic blood pressure;	chr8:1759425	chr8:1761990~1764502:-
LAML	cis	rs8031584	0.706	rs798084	ENSG00000260382.1	RP11-540B6.2	4.87	6.53e-06	0.0143	0.54	0.5	Huntington's disease progression;	chr15:30834732	chr15:30882267~30883231:-
LAML	cis	rs9322193	0.607	rs9371228	ENSG00000216906.2	RP11-350J20.9	-4.86	6.55e-06	0.0143	-0.73	-0.5	Lung cancer;	chr6:149921977	chr6:149904243~149906418:+
LAML	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	4.86	6.55e-06	0.0143	0.55	0.5	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
LAML	cis	rs282544	1	rs27934	ENSG00000271455.1	RP11-269M20.2	4.86	6.58e-06	0.0143	0.52	0.5	Myopia (pathological);	chr5:50823125	chr5:50603229~50603511:+
LAML	cis	rs6964833	1	rs13227433	ENSG00000277053.3	GTF2IP1	-4.86	6.58e-06	0.0143	-0.68	-0.5	Menarche (age at onset);	chr7:74680386	chr7:75185385~75237696:-
LAML	cis	rs6951245	1	rs78896566	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040546	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs79422648	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040605	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.872	rs113119264	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1040928	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs76804143	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1042385	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs1997243	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044141	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs77760339	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044291	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs113575110	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1044758	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs1881123	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045070	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.872	rs77569514	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1045872	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs11770909	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1047080	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs74785791	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048858	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs74366004	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1048994	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs77702926	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049202	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.935	rs78573577	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049451	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs76129108	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049523	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs78523927	ENSG00000229043.2	AC091729.9	-4.86	6.59e-06	0.0143	-0.84	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1049822	chr7:1160374~1165267:+
LAML	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	4.86	6.59e-06	0.0143	0.55	0.5	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
LAML	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-4.86	6.59e-06	0.0143	-0.55	-0.5	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
LAML	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-4.86	6.59e-06	0.0143	-0.55	-0.5	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-4.86	6.59e-06	0.0143	-0.55	-0.5	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-4.86	6.59e-06	0.0143	-0.55	-0.5	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
LAML	cis	rs11039798	0.925	rs7482967	ENSG00000263693.1	MIR3161	4.86	6.59e-06	0.0143	0.49	0.5	Axial length;	chr11:48591975	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs12280020	ENSG00000263693.1	MIR3161	4.86	6.59e-06	0.0143	0.49	0.5	Axial length;	chr11:48597292	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs7131020	ENSG00000263693.1	MIR3161	4.86	6.59e-06	0.0143	0.49	0.5	Axial length;	chr11:48620580	chr11:48096782~48096858:+
LAML	cis	rs1930961	0.702	rs8141065	ENSG00000100058.11	CRYBB2P1	4.86	6.6e-06	0.0143	0.93	0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25489221	chr22:25448105~25520854:+
LAML	cis	rs3130844	1	rs3130844	ENSG00000220721.1	OR1F12	4.86	6.6e-06	0.0143	0.84	0.5	Urinary tract infection frequency;	chr6:28948817	chr6:28073316~28074233:+
LAML	cis	rs148696809	1	rs148696809	ENSG00000220721.1	OR1F12	4.86	6.6e-06	0.0143	0.84	0.5	Lung cancer;Squamous cell lung carcinoma;	chr6:28966575	chr6:28073316~28074233:+
LAML	cis	rs853679	1	rs853685	ENSG00000182477.5	OR2B8P	4.86	6.6e-06	0.0143	0.73	0.5	Depression;	chr6:28321008	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs853679	ENSG00000182477.5	OR2B8P	4.86	6.6e-06	0.0143	0.73	0.5	Depression;	chr6:28329086	chr6:28053228~28054165:-
LAML	cis	rs853679	1	rs853678	ENSG00000182477.5	OR2B8P	4.86	6.6e-06	0.0143	0.73	0.5	Depression;	chr6:28329536	chr6:28053228~28054165:-
LAML	cis	rs7131987	0.903	rs67150462	ENSG00000273680.1	RP11-996F15.6	4.86	6.6e-06	0.0143	0.51	0.5	QT interval;	chr12:29240392	chr12:29332733~29333383:-
LAML	cis	rs716804	0.678	rs4323860	ENSG00000254719.1	RP11-351I24.3	-4.86	6.61e-06	0.0143	-0.6	-0.5	Neuroticism;	chr11:10138336	chr11:10272052~10272259:-
LAML	cis	rs716804	0.703	rs7123728	ENSG00000254719.1	RP11-351I24.3	-4.86	6.61e-06	0.0143	-0.6	-0.5	Neuroticism;	chr11:10141659	chr11:10272052~10272259:-
LAML	cis	rs716804	0.654	rs7924499	ENSG00000254719.1	RP11-351I24.3	-4.86	6.61e-06	0.0143	-0.61	-0.5	Neuroticism;	chr11:10119250	chr11:10272052~10272259:-
LAML	cis	rs916888	0.773	rs199448	ENSG00000280985.1	AC217773.1	4.86	6.63e-06	0.0143	0.69	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:46172089~46172239:-
LAML	cis	rs916888	0.773	rs199445	ENSG00000280985.1	AC217773.1	4.86	6.63e-06	0.0143	0.69	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:46172089~46172239:-
LAML	cis	rs916888	0.773	rs199443	ENSG00000280985.1	AC217773.1	4.86	6.63e-06	0.0143	0.69	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:46172089~46172239:-
LAML	cis	rs916888	0.773	rs199534	ENSG00000280985.1	AC217773.1	4.86	6.63e-06	0.0143	0.69	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:46172089~46172239:-
LAML	cis	rs916888	0.773	rs199533	ENSG00000280985.1	AC217773.1	4.86	6.63e-06	0.0143	0.69	0.5	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:46172089~46172239:-
LAML	cis	rs801193	0.967	rs2420827	ENSG00000224316.1	RP11-479O9.2	-4.86	6.63e-06	0.0143	-0.54	-0.5	Aortic root size;	chr7:66682114	chr7:65773620~65802067:+
LAML	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	4.86	6.63e-06	0.0143	0.6	0.5	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
LAML	cis	rs853679	0.546	rs34676049	ENSG00000220721.1	OR1F12	4.86	6.64e-06	0.0143	0.86	0.5	Depression;	chr6:28485841	chr6:28073316~28074233:+
LAML	cis	rs5769707	0.749	rs3884944	ENSG00000213279.2	RP1-29C18.9	-4.86	6.64e-06	0.0143	-0.51	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49669348	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.632	rs6009782	ENSG00000212939.2	RP1-29C18.10	-4.86	6.69e-06	0.0144	-0.68	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49617164	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.592	rs6009783	ENSG00000212939.2	RP1-29C18.10	-4.86	6.69e-06	0.0144	-0.68	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49617353	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.656	rs135875	ENSG00000212939.2	RP1-29C18.10	-4.86	6.69e-06	0.0144	-0.68	-0.5	Monocyte percentage of white cells;Monocyte count;	chr22:49618771	chr22:49548681~49556473:+
LAML	cis	rs6951245	0.935	rs112554101	ENSG00000229043.2	AC091729.9	-4.86	6.7e-06	0.0144	-0.74	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1025899	chr7:1160374~1165267:+
LAML	cis	rs3758911	0.861	rs10789621	ENSG00000261098.1	RP11-819C21.1	4.86	6.7e-06	0.0144	0.49	0.5	Coronary artery disease;	chr11:107388345	chr11:107312132~107316271:-
LAML	cis	rs9916302	0.904	rs2338755	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39263064	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs588193	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39284186	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs801426	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39284856	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs612194	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39286454	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs612209	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39286460	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs585961	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39287783	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs650106	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39295306	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs620686	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39297364	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs801420	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39309850	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs9904334	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39312083	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8079355	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39316765	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8066704	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39320965	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs7220650	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39330915	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8079560	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39341408	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs2338800	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39341896	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs9903363	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39343351	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs8081033	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39350397	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs7208274	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39357543	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8065879	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39359725	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8077104	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39374257	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8079303	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39374502	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs11078898	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39380227	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs7210488	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39383566	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs2338797	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39391988	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs57399933	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39394936	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs12936996	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39509301	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs11654018	ENSG00000223091.1	RNU6-981P	4.86	6.73e-06	0.0144	0.58	0.5	Glomerular filtration rate (creatinine);	chr17:39547487	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs752314	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39254447	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs11078897	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39259617	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs2061338	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39265514	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs1966916	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39268985	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.821	rs1966915	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39269009	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs8079590	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39269948	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs634365	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39280713	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs4795359	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39416893	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs12452509	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39418469	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs7501488	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39420164	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs12150493	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39429901	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.718	rs10445306	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39435169	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs34363096	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39438041	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs11867312	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39441495	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs12947620	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39449111	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.808	rs6503515	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39450180	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.808	rs12943928	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39455077	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs4390625	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39464094	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs11657899	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39470710	chr17:39482486~39482590:-
LAML	cis	rs11650776	1	rs11650776	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Lung function (FEV1);	chr17:39485149	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs11870631	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39488876	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.731	rs11868030	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39494079	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs11078904	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39494316	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.808	rs12947281	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39495957	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs11078907	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39506701	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs7225096	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39508190	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs4795377	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39512803	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs12952384	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39513283	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs7503705	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39513451	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs11078910	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39515016	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8065963	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39525079	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs55660616	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39528737	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs12450559	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39538456	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs4794814	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39540599	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs7503069	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39540875	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs10852933	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39541941	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.784	rs4795382	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39544607	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.718	rs7219909	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39549990	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs6503519	ENSG00000223091.1	RNU6-981P	-4.86	6.73e-06	0.0144	-0.58	-0.5	Glomerular filtration rate (creatinine);	chr17:39550325	chr17:39482486~39482590:-
LAML	cis	rs9322193	0.923	rs9767105	ENSG00000216906.2	RP11-350J20.9	4.86	6.73e-06	0.0145	0.71	0.5	Lung cancer;	chr6:149659591	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9800736	ENSG00000216906.2	RP11-350J20.9	4.86	6.73e-06	0.0145	0.71	0.5	Lung cancer;	chr6:149661281	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs66516768	ENSG00000216906.2	RP11-350J20.9	4.86	6.73e-06	0.0145	0.71	0.5	Lung cancer;	chr6:149671999	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9383812	ENSG00000216906.2	RP11-350J20.9	4.86	6.73e-06	0.0145	0.71	0.5	Lung cancer;	chr6:149712355	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.847	rs9383844	ENSG00000216906.2	RP11-350J20.9	4.86	6.73e-06	0.0145	0.71	0.5	Lung cancer;	chr6:149716268	chr6:149904243~149906418:+
LAML	cis	rs6951245	0.706	rs1133116	ENSG00000229043.2	AC091729.9	-4.86	6.73e-06	0.0145	-0.74	-0.5	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1155579	chr7:1160374~1165267:+
LAML	cis	rs9916302	0.821	rs11078916	ENSG00000223091.1	RNU6-981P	-4.86	6.75e-06	0.0145	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39590054	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.821	rs4795386	ENSG00000223091.1	RNU6-981P	-4.86	6.75e-06	0.0145	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39590594	chr17:39482486~39482590:-
LAML	cis	rs11096990	0.891	rs61691409	ENSG00000206675.1	RNU6-32P	-4.85	6.79e-06	0.0146	-0.5	-0.5	Cognitive function;	chr4:39243801	chr4:39297605~39297711:-
LAML	cis	rs11096990	0.964	rs35494908	ENSG00000206675.1	RNU6-32P	-4.85	6.79e-06	0.0146	-0.5	-0.5	Cognitive function;	chr4:39252574	chr4:39297605~39297711:-
LAML	cis	rs11096990	0.964	rs56284364	ENSG00000206675.1	RNU6-32P	-4.85	6.79e-06	0.0146	-0.5	-0.5	Cognitive function;	chr4:39255028	chr4:39297605~39297711:-
LAML	cis	rs11096990	0.964	rs11096986	ENSG00000206675.1	RNU6-32P	-4.85	6.79e-06	0.0146	-0.5	-0.5	Cognitive function;	chr4:39257122	chr4:39297605~39297711:-
LAML	cis	rs11096990	0.964	rs6828598	ENSG00000206675.1	RNU6-32P	-4.85	6.79e-06	0.0146	-0.5	-0.5	Cognitive function;	chr4:39259850	chr4:39297605~39297711:-
LAML	cis	rs11096990	0.964	rs7678689	ENSG00000206675.1	RNU6-32P	-4.85	6.79e-06	0.0146	-0.5	-0.5	Cognitive function;	chr4:39261140	chr4:39297605~39297711:-
LAML	cis	rs11096990	0.964	rs16995206	ENSG00000206675.1	RNU6-32P	-4.85	6.79e-06	0.0146	-0.5	-0.5	Cognitive function;	chr4:39262887	chr4:39297605~39297711:-
LAML	cis	rs11096990	0.928	rs2008681	ENSG00000206675.1	RNU6-32P	-4.85	6.79e-06	0.0146	-0.5	-0.5	Cognitive function;	chr4:39266396	chr4:39297605~39297711:-
LAML	cis	rs1075265	0.669	rs805317	ENSG00000235937.1	AC008280.1	4.85	6.8e-06	0.0146	0.4	0.5	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.692	rs805318	ENSG00000235937.1	AC008280.1	4.85	6.8e-06	0.0146	0.4	0.5	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54029552~54030682:-
LAML	cis	rs904251	0.861	rs914349	ENSG00000204110.6	RP1-153P14.8	-4.85	6.81e-06	0.0146	-0.63	-0.5	Cognitive performance;	chr6:37516939	chr6:37507348~37535616:+
LAML	cis	rs8037137	0.915	rs60290423	ENSG00000258725.1	PRC1-AS1	-4.85	6.81e-06	0.0146	-0.87	-0.5	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90986222	chr15:90966345~90988624:+
LAML	cis	rs947474	0.564	rs10796055	ENSG00000213994.3	RP11-414H17.5	-4.85	6.81e-06	0.0146	-0.52	-0.5	Rheumatoid arthritis;Type 1 diabetes;	chr10:6365498	chr10:6197612~6202693:-
LAML	cis	rs9322193	0.923	rs12529698	ENSG00000216906.2	RP11-350J20.9	4.85	6.82e-06	0.0146	0.71	0.5	Lung cancer;	chr6:149650951	chr6:149904243~149906418:+
LAML	cis	rs11096990	0.964	rs7687651	ENSG00000206675.1	RNU6-32P	-4.85	6.82e-06	0.0146	-0.5	-0.5	Cognitive function;	chr4:39243072	chr4:39297605~39297711:-
LAML	cis	rs17608059	0.71	rs8080167	ENSG00000265494.1	RP11-131K5.2	4.85	6.83e-06	0.0146	0.61	0.5	Temperament;	chr17:14046511	chr17:13909231~13911212:+
LAML	cis	rs17608059	0.679	rs9898056	ENSG00000265494.1	RP11-131K5.2	4.85	6.83e-06	0.0146	0.61	0.5	Temperament;	chr17:14048649	chr17:13909231~13911212:+
LAML	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	4.85	6.84e-06	0.0146	0.63	0.5	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
LAML	cis	rs3096299	0.866	rs4238829	ENSG00000274627.1	RP11-104N10.2	4.85	6.84e-06	0.0147	0.57	0.5	Multiple myeloma (IgH translocation);	chr16:89395854	chr16:89516797~89522217:+
LAML	cis	rs4803480	0.786	rs4803479	ENSG00000239736.2	CEACAMP3	-4.85	6.85e-06	0.0147	-0.64	-0.5	Schizophrenia;	chr19:41551234	chr19:41599735~41605984:+
LAML	cis	rs9322193	0.923	rs9377230	ENSG00000216906.2	RP11-350J20.9	4.85	6.85e-06	0.0147	0.7	0.5	Lung cancer;	chr6:149613607	chr6:149904243~149906418:+
LAML	cis	rs2404602	0.647	rs11072612	ENSG00000259422.1	RP11-593F23.1	-4.85	6.86e-06	0.0147	-0.62	-0.5	Blood metabolite levels;	chr15:76668643	chr15:76174891~76181486:-
LAML	cis	rs716804	0.654	rs10770085	ENSG00000254719.1	RP11-351I24.3	-4.85	6.87e-06	0.0147	-0.6	-0.5	Neuroticism;	chr11:10058934	chr11:10272052~10272259:-
LAML	cis	rs9322193	0.884	rs9688699	ENSG00000216906.2	RP11-350J20.9	4.85	6.87e-06	0.0147	0.71	0.5	Lung cancer;	chr6:149733680	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs56397000	ENSG00000216906.2	RP11-350J20.9	4.85	6.87e-06	0.0147	0.71	0.5	Lung cancer;	chr6:149739347	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs12660304	ENSG00000216906.2	RP11-350J20.9	4.85	6.87e-06	0.0147	0.71	0.5	Lung cancer;	chr6:149739647	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs9689702	ENSG00000216906.2	RP11-350J20.9	4.85	6.87e-06	0.0147	0.71	0.5	Lung cancer;	chr6:149740720	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs10782315	ENSG00000216906.2	RP11-350J20.9	4.85	6.87e-06	0.0147	0.71	0.5	Lung cancer;	chr6:149743093	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs10747276	ENSG00000216906.2	RP11-350J20.9	4.85	6.87e-06	0.0147	0.71	0.5	Lung cancer;	chr6:149758739	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs12526675	ENSG00000216906.2	RP11-350J20.9	-4.85	6.87e-06	0.0147	-0.71	-0.5	Lung cancer;	chr6:149729540	chr6:149904243~149906418:+
LAML	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-4.85	6.88e-06	0.0147	-0.64	-0.5	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
LAML	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	4.85	6.88e-06	0.0147	0.64	0.5	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
LAML	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	4.85	6.89e-06	0.0147	0.59	0.5	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	4.85	6.89e-06	0.0147	0.59	0.5	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
LAML	cis	rs7714584	1	rs73268545	ENSG00000197083.10	ZNF300P1	4.85	6.91e-06	0.0148	1.31	0.5	Crohn's disease;	chr5:150955720	chr5:150930645~150946289:-
LAML	cis	rs763121	0.853	rs4821810	ENSG00000230912.1	RP3-508I15.10	-4.85	6.91e-06	0.0148	-0.4	-0.5	Menopause (age at onset);	chr22:38676093	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757234	ENSG00000230912.1	RP3-508I15.10	-4.85	6.91e-06	0.0148	-0.4	-0.5	Menopause (age at onset);	chr22:38676681	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5750671	ENSG00000230912.1	RP3-508I15.10	-4.85	6.91e-06	0.0148	-0.4	-0.5	Menopause (age at onset);	chr22:38698614	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs926299	ENSG00000230912.1	RP3-508I15.10	-4.85	6.91e-06	0.0148	-0.4	-0.5	Menopause (age at onset);	chr22:38699693	chr22:38666508~38668750:-
LAML	cis	rs763121	0.785	rs6001203	ENSG00000230912.1	RP3-508I15.10	-4.85	6.91e-06	0.0148	-0.4	-0.5	Menopause (age at onset);	chr22:38703597	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs6001204	ENSG00000230912.1	RP3-508I15.10	-4.85	6.91e-06	0.0148	-0.4	-0.5	Menopause (age at onset);	chr22:38704234	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2267393	ENSG00000230912.1	RP3-508I15.10	-4.85	6.91e-06	0.0148	-0.4	-0.5	Menopause (age at onset);	chr22:38705614	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2267394	ENSG00000230912.1	RP3-508I15.10	-4.85	6.91e-06	0.0148	-0.4	-0.5	Menopause (age at onset);	chr22:38705628	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs5757253	ENSG00000230912.1	RP3-508I15.10	-4.85	6.91e-06	0.0148	-0.4	-0.5	Menopause (age at onset);	chr22:38708315	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2284073	ENSG00000230912.1	RP3-508I15.10	-4.85	6.91e-06	0.0148	-0.4	-0.5	Menopause (age at onset);	chr22:38709943	chr22:38666508~38668750:-
LAML	cis	rs904251	0.58	rs62408367	ENSG00000204110.6	RP1-153P14.8	-4.85	6.92e-06	0.0148	-0.56	-0.5	Cognitive performance;	chr6:37477037	chr6:37507348~37535616:+
LAML	cis	rs11039798	0.764	rs1121450	ENSG00000263693.1	MIR3161	4.85	6.95e-06	0.0148	0.49	0.5	Axial length;	chr11:48875924	chr11:48096782~48096858:+
LAML	cis	rs67311347	1	rs4128740	ENSG00000230274.1	PGAM1P3	4.85	6.95e-06	0.0148	0.65	0.5	Renal cell carcinoma;	chr3:40478041	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs4571217	ENSG00000230274.1	PGAM1P3	4.85	6.95e-06	0.0148	0.65	0.5	Renal cell carcinoma;	chr3:40480482	chr3:40322715~40323279:-
LAML	cis	rs8031584	0.752	rs7174744	ENSG00000259845.1	HERC2P10	-4.85	6.95e-06	0.0148	-0.53	-0.5	Huntington's disease progression;	chr15:30891544	chr15:30815271~30844153:+
LAML	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-4.85	6.95e-06	0.0148	-0.53	-0.5	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
LAML	cis	rs62070183	0.938	rs75393526	ENSG00000266599.1	RP11-466A19.3	4.85	6.96e-06	0.0148	0.77	0.5	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32708000	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs75822124	ENSG00000266599.1	RP11-466A19.3	4.85	6.96e-06	0.0148	0.77	0.5	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32710876	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs17183176	ENSG00000266599.1	RP11-466A19.3	4.85	6.96e-06	0.0148	0.77	0.5	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32727107	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs1990825	ENSG00000266599.1	RP11-466A19.3	4.85	6.96e-06	0.0148	0.77	0.5	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32729274	chr17:32518953~32531492:+
LAML	cis	rs7301826	0.627	rs4334059	ENSG00000256299.1	RP11-989F5.3	-4.85	6.97e-06	0.0149	-0.66	-0.5	Plasma plasminogen activator levels;	chr12:130829669	chr12:130810821~130812622:-
LAML	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	4.85	6.98e-06	0.0149	0.68	0.5	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
LAML	cis	rs853679	0.546	rs493161	ENSG00000220721.1	OR1F12	4.85	6.98e-06	0.0149	0.65	0.5	Depression;	chr6:27882936	chr6:28073316~28074233:+
LAML	cis	rs950027	0.549	rs11636114	ENSG00000259520.4	CTD-2651B20.3	-4.85	6.99e-06	0.0149	-0.73	-0.5	Response to fenofibrate (adiponectin levels);	chr15:45309214	chr15:45251580~45279251:-
LAML	cis	rs950027	0.549	rs12909409	ENSG00000259520.4	CTD-2651B20.3	4.85	6.99e-06	0.0149	0.73	0.5	Response to fenofibrate (adiponectin levels);	chr15:45316384	chr15:45251580~45279251:-
LAML	cis	rs950027	0.572	rs12910764	ENSG00000259520.4	CTD-2651B20.3	4.85	6.99e-06	0.0149	0.73	0.5	Response to fenofibrate (adiponectin levels);	chr15:45317162	chr15:45251580~45279251:-
LAML	cis	rs4713118	0.824	rs9366702	ENSG00000220721.1	OR1F12	4.85	6.99e-06	0.0149	0.55	0.5	Parkinson's disease;	chr6:27766691	chr6:28073316~28074233:+
LAML	cis	rs7131987	0.585	rs6487795	ENSG00000273680.1	RP11-996F15.6	4.85	6.99e-06	0.0149	0.52	0.5	QT interval;	chr12:29266228	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs6487797	ENSG00000273680.1	RP11-996F15.6	4.85	6.99e-06	0.0149	0.52	0.5	QT interval;	chr12:29270063	chr12:29332733~29333383:-
LAML	cis	rs9426935	0.681	rs4845360	ENSG00000273026.1	RP11-422P24.10	-4.85	7e-06	0.0149	-0.61	-0.5	Lentiform nucleus volume;	chr1:153994184	chr1:153966516~153966930:+
LAML	cis	rs282544	1	rs27255	ENSG00000271455.1	RP11-269M20.2	4.85	7e-06	0.0149	0.52	0.5	Myopia (pathological);	chr5:50825789	chr5:50603229~50603511:+
LAML	cis	rs400736	0.729	rs2493215	ENSG00000238249.2	HMGN2P17	-4.85	7.02e-06	0.0149	-0.61	-0.5	Response to antidepressants and depression;	chr1:7947656	chr1:8893409~8894151:+
LAML	cis	rs400736	0.729	rs2493216	ENSG00000238249.2	HMGN2P17	4.85	7.02e-06	0.0149	0.61	0.5	Response to antidepressants and depression;	chr1:7948306	chr1:8893409~8894151:+
LAML	cis	rs8081395	0.775	rs2645482	ENSG00000267302.4	RP11-178C3.2	4.85	7.03e-06	0.0149	0.63	0.5	White blood cell count;	chr17:59865754	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.805	rs2645485	ENSG00000267302.4	RP11-178C3.2	4.85	7.03e-06	0.0149	0.63	0.5	White blood cell count;	chr17:59866920	chr17:59964832~59996972:+
LAML	cis	rs9322193	0.607	rs4869755	ENSG00000216906.2	RP11-350J20.9	4.85	7.05e-06	0.015	0.75	0.5	Lung cancer;	chr6:149886347	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.639	rs4869756	ENSG00000216906.2	RP11-350J20.9	4.85	7.05e-06	0.015	0.75	0.5	Lung cancer;	chr6:149886360	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.607	rs3798763	ENSG00000216906.2	RP11-350J20.9	4.85	7.05e-06	0.015	0.75	0.5	Lung cancer;	chr6:149889964	chr6:149904243~149906418:+
LAML	cis	rs7829975	0.511	rs2948286	ENSG00000253893.2	FAM85B	-4.84	7.06e-06	0.015	-0.61	-0.5	Mood instability;	chr8:8272638	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.511	rs1543238	ENSG00000253893.2	FAM85B	-4.84	7.06e-06	0.015	-0.61	-0.5	Mood instability;	chr8:8277287	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.511	rs1401390	ENSG00000253893.2	FAM85B	-4.84	7.06e-06	0.015	-0.61	-0.5	Mood instability;	chr8:8278888	chr8:8167819~8226614:-
LAML	cis	rs8031584	0.697	rs8036176	ENSG00000260382.1	RP11-540B6.2	4.84	7.09e-06	0.015	0.54	0.5	Huntington's disease progression;	chr15:30883066	chr15:30882267~30883231:-
LAML	cis	rs1075265	0.836	rs1421622	ENSG00000235937.1	AC008280.1	-4.84	7.11e-06	0.0151	-0.42	-0.5	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.744	rs10203576	ENSG00000235937.1	AC008280.1	4.84	7.11e-06	0.0151	0.42	0.5	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54029552~54030682:-
LAML	cis	rs71281886	1	rs71281886	ENSG00000229759.1	MRPS18AP1	4.84	7.12e-06	0.0151	0.67	0.5	Breast cancer;	chr3:48311088	chr3:48256350~48256938:-
LAML	cis	rs12200782	0.505	rs7765920	ENSG00000241549.7	GUSBP2	4.84	7.13e-06	0.0151	0.59	0.5	Small cell lung carcinoma;	chr6:26514543	chr6:26871484~26956554:-
LAML	cis	rs12200782	0.505	rs1535275	ENSG00000241549.7	GUSBP2	4.84	7.13e-06	0.0151	0.59	0.5	Small cell lung carcinoma;	chr6:26520539	chr6:26871484~26956554:-
LAML	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	4.84	7.17e-06	0.0151	0.62	0.5	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
LAML	cis	rs9322193	0.607	rs12204653	ENSG00000216906.2	RP11-350J20.9	4.84	7.18e-06	0.0151	0.75	0.5	Lung cancer;	chr6:149891885	chr6:149904243~149906418:+
LAML	cis	rs9916302	0.861	rs10491129	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39305390	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs2024073	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39315077	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8070695	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39321809	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs7223331	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39326677	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.847	rs7218670	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39344171	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs9909064	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39344181	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs6503502	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39345602	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs9892055	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39354149	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.8	rs11869259	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39361888	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs11869109	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39361952	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs6503506	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39368400	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs6503507	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39369021	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs4794807	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39375465	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs9898773	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39376254	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs4795356	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39379378	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs13341996	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39380609	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs2338798	ENSG00000223091.1	RNU6-981P	4.84	7.19e-06	0.0151	0.57	0.5	Glomerular filtration rate (creatinine);	chr17:39391016	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs2168785	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39250882	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs3744348	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39261322	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs33933929	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39270188	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs4795355	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39271129	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs644173	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39274266	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs602282	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39276768	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs600010	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39277264	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs602688	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39283243	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.784	rs4795361	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39417193	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs12452880	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39434896	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs4794810	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39447521	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.768	rs11078900	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39458388	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.808	rs12948906	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39488601	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs12936646	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39491197	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.555	rs12940193	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39495925	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs6503518	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39504216	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs11078906	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39506514	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs11078912	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39515237	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs1077715	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39527295	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs11655531	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39541706	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs2303316	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39547964	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs7216086	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39553169	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs11658219	ENSG00000223091.1	RNU6-981P	-4.84	7.19e-06	0.0151	-0.57	-0.5	Glomerular filtration rate (creatinine);	chr17:39553529	chr17:39482486~39482590:-
LAML	cis	rs3198697	1	rs3198697	ENSG00000260735.1	RP11-72I8.1	-4.84	7.19e-06	0.0151	-0.51	-0.5	Triglycerides;	chr16:15036083	chr16:15094411~15109197:+
LAML	cis	rs8081395	0.707	rs1024637	ENSG00000267302.4	RP11-178C3.2	-4.84	7.19e-06	0.0152	-0.6	-0.5	White blood cell count;	chr17:59961532	chr17:59964832~59996972:+
LAML	cis	rs990871	0.962	rs3101337	ENSG00000227207.2	RPL31P12	-4.84	7.2e-06	0.0152	-0.67	-0.5	Subcutaneous adipose tissue;	chr1:72285451	chr1:72301472~72301829:+
LAML	cis	rs990871	1	rs3101336	ENSG00000227207.2	RPL31P12	-4.84	7.2e-06	0.0152	-0.67	-0.5	Subcutaneous adipose tissue;	chr1:72285502	chr1:72301472~72301829:+
LAML	cis	rs990871	1	rs2815765	ENSG00000227207.2	RPL31P12	-4.84	7.2e-06	0.0152	-0.67	-0.5	Subcutaneous adipose tissue;	chr1:72286547	chr1:72301472~72301829:+
LAML	cis	rs990871	1	rs2568952	ENSG00000227207.2	RPL31P12	-4.84	7.2e-06	0.0152	-0.67	-0.5	Subcutaneous adipose tissue;	chr1:72289422	chr1:72301472~72301829:+
LAML	cis	rs990871	0.924	rs2568956	ENSG00000227207.2	RPL31P12	-4.84	7.2e-06	0.0152	-0.67	-0.5	Subcutaneous adipose tissue;	chr1:72298693	chr1:72301472~72301829:+
LAML	cis	rs990871	0.962	rs2815752	ENSG00000227207.2	RPL31P12	4.84	7.2e-06	0.0152	0.67	0.5	Subcutaneous adipose tissue;	chr1:72346757	chr1:72301472~72301829:+
LAML	cis	rs990871	0.927	rs1460943	ENSG00000227207.2	RPL31P12	-4.84	7.2e-06	0.0152	-0.67	-0.5	Subcutaneous adipose tissue;	chr1:72347446	chr1:72301472~72301829:+
LAML	cis	rs400736	0.729	rs1546846	ENSG00000238249.2	HMGN2P17	4.84	7.2e-06	0.0152	0.62	0.5	Response to antidepressants and depression;	chr1:7944199	chr1:8893409~8894151:+
LAML	cis	rs400736	0.729	rs9434948	ENSG00000238249.2	HMGN2P17	4.84	7.2e-06	0.0152	0.62	0.5	Response to antidepressants and depression;	chr1:7944903	chr1:8893409~8894151:+
LAML	cis	rs400736	0.729	rs9434949	ENSG00000238249.2	HMGN2P17	4.84	7.2e-06	0.0152	0.62	0.5	Response to antidepressants and depression;	chr1:7946023	chr1:8893409~8894151:+
LAML	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-4.84	7.22e-06	0.0152	-0.52	-0.5	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
LAML	cis	rs9322193	0.566	rs12528243	ENSG00000216906.2	RP11-350J20.9	4.84	7.23e-06	0.0152	0.72	0.5	Lung cancer;	chr6:149898491	chr6:149904243~149906418:+
LAML	cis	rs2742417	1	rs9821974	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45743471	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742379	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45746343	chr3:45742675~45742970:+
LAML	cis	rs9322193	0.651	rs9322188	ENSG00000216906.2	RP11-350J20.9	-4.84	7.24e-06	0.0152	-0.66	-0.5	Lung cancer;	chr6:149588355	chr6:149904243~149906418:+
LAML	cis	rs2742417	1	rs2742436	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45699905	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742437	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45701785	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673039	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45706943	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742392	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45715790	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2249357	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45716889	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.935	rs2673028	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45718162	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742406	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45719108	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs9311378	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45721643	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742447	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45722485	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742454	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45724730	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs767280	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45730109	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.935	rs1468543	ENSG00000244357.3	RN7SL145P	4.84	7.24e-06	0.0152	0.54	0.5	Response to anti-depressant treatment in major depressive disorder;	chr3:45735408	chr3:45742675~45742970:+
LAML	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-4.84	7.24e-06	0.0152	-0.63	-0.5	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
LAML	cis	rs716804	0.678	rs10770096	ENSG00000254719.1	RP11-351I24.3	-4.84	7.26e-06	0.0153	-0.61	-0.5	Neuroticism;	chr11:10156812	chr11:10272052~10272259:-
LAML	cis	rs716804	0.654	rs7928170	ENSG00000254719.1	RP11-351I24.3	-4.84	7.26e-06	0.0153	-0.61	-0.5	Neuroticism;	chr11:10157298	chr11:10272052~10272259:-
LAML	cis	rs9322193	1	rs9399693	ENSG00000216906.2	RP11-350J20.9	4.84	7.26e-06	0.0153	0.69	0.5	Lung cancer;	chr6:149612718	chr6:149904243~149906418:+
LAML	cis	rs7916697	0.52	rs12246624	ENSG00000234102.1	KRT19P4	-4.84	7.26e-06	0.0153	-0.68	-0.5	Optic disc area;	chr10:68276805	chr10:68260557~68261499:+
LAML	cis	rs7916697	0.52	rs12265247	ENSG00000234102.1	KRT19P4	-4.84	7.26e-06	0.0153	-0.68	-0.5	Optic disc area;	chr10:68278641	chr10:68260557~68261499:+
LAML	cis	rs67311347	1	rs11539046	ENSG00000230274.1	PGAM1P3	-4.84	7.27e-06	0.0153	-0.65	-0.5	Renal cell carcinoma;	chr3:40462318	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs12633431	ENSG00000230274.1	PGAM1P3	-4.84	7.27e-06	0.0153	-0.65	-0.5	Renal cell carcinoma;	chr3:40464249	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.956	rs6771527	ENSG00000230274.1	PGAM1P3	-4.84	7.27e-06	0.0153	-0.65	-0.5	Renal cell carcinoma;	chr3:40465057	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs7628796	ENSG00000230274.1	PGAM1P3	-4.84	7.27e-06	0.0153	-0.65	-0.5	Renal cell carcinoma;	chr3:40465841	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.955	rs6782746	ENSG00000230274.1	PGAM1P3	-4.84	7.27e-06	0.0153	-0.65	-0.5	Renal cell carcinoma;	chr3:40469101	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs7628247	ENSG00000230274.1	PGAM1P3	-4.84	7.27e-06	0.0153	-0.65	-0.5	Renal cell carcinoma;	chr3:40471191	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.91	rs7651204	ENSG00000230274.1	PGAM1P3	-4.84	7.27e-06	0.0153	-0.65	-0.5	Renal cell carcinoma;	chr3:40471344	chr3:40322715~40323279:-
LAML	cis	rs7714584	1	rs1896708	ENSG00000197083.10	ZNF300P1	4.84	7.27e-06	0.0153	1.01	0.5	Crohn's disease;	chr5:150865514	chr5:150930645~150946289:-
LAML	cis	rs2581828	0.931	rs2336722	ENSG00000280417.1	RP11-5O17.1	4.84	7.27e-06	0.0153	0.64	0.5	Crohn's disease;	chr3:53105961	chr3:53046166~53048122:+
LAML	cis	rs853679	0.556	rs13200214	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Depression;	chr6:28049472	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs71559070	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Depression;	chr6:28071151	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs35902873	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Depression;	chr6:28091171	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13197574	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Depression;	chr6:28092461	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs34166054	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Depression;	chr6:28098023	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs34662244	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Depression;	chr6:28106103	chr6:28053228~28054165:-
LAML	cis	rs35952432	1	rs35952432	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Lung cancer;	chr6:28107123	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13203816	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Depression;	chr6:28111820	chr6:28053228~28054165:-
LAML	cis	rs853679	0.556	rs34588114	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Depression;	chr6:28112850	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs68188794	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Depression;	chr6:28112999	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs34371502	ENSG00000182477.5	OR2B8P	4.84	7.28e-06	0.0153	0.93	0.5	Depression;	chr6:28113980	chr6:28053228~28054165:-
LAML	cis	rs59482735	1	rs59482735	ENSG00000226752.6	PSMD5-AS1	-4.84	7.28e-06	0.0153	-0.63	-0.5	Prostate-specific antigen levels;	chr9:120881148	chr9:120824828~120854385:+
LAML	cis	rs56114371	0.53	rs2056923	ENSG00000220721.1	OR1F12	4.84	7.28e-06	0.0153	0.64	0.5	Breast cancer;	chr6:27722160	chr6:28073316~28074233:+
LAML	cis	rs9393777	0.528	rs9467989	ENSG00000220721.1	OR1F12	4.84	7.29e-06	0.0153	0.58	0.5	Intelligence (multi-trait analysis);	chr6:27096496	chr6:28073316~28074233:+
LAML	cis	rs1930961	1	rs760554	ENSG00000265978.1	AL008721.1	-4.84	7.29e-06	0.0153	-0.94	-0.5	Bipolar disorder with mood-incongruent psychosis;	chr22:25476625	chr22:25532720~25532809:-
LAML	cis	rs6009824	0.545	rs5770659	ENSG00000280224.1	CTA-722E9.1	-4.84	7.3e-06	0.0153	-0.6	-0.5	Natriuretic peptide levels;	chr22:49690204	chr22:49500568~49501585:+
LAML	cis	rs904251	0.861	rs1776456	ENSG00000204110.6	RP1-153P14.8	-4.84	7.31e-06	0.0153	-0.65	-0.5	Cognitive performance;	chr6:37516922	chr6:37507348~37535616:+
LAML	cis	rs8031584	0.651	rs28664821	ENSG00000260382.1	RP11-540B6.2	-4.83	7.33e-06	0.0153	-0.56	-0.5	Huntington's disease progression;	chr15:30880120	chr15:30882267~30883231:-
LAML	cis	rs9322193	0.887	rs4870139	ENSG00000216906.2	RP11-350J20.9	4.83	7.33e-06	0.0153	0.79	0.5	Lung cancer;	chr6:149575182	chr6:149904243~149906418:+
LAML	cis	rs10457838	0.675	rs10782309	ENSG00000220848.4	RPS18P9	-4.83	7.33e-06	0.0153	-0.55	-0.5	Post-traumatic stress disorder;	chr6:149012041	chr6:149594084~149594543:+
LAML	cis	rs9322193	0.607	rs915140	ENSG00000216906.2	RP11-350J20.9	4.83	7.34e-06	0.0154	0.72	0.5	Lung cancer;	chr6:149899674	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.607	rs12209310	ENSG00000216906.2	RP11-350J20.9	4.83	7.34e-06	0.0154	0.72	0.5	Lung cancer;	chr6:149904882	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.607	rs12210822	ENSG00000216906.2	RP11-350J20.9	4.83	7.34e-06	0.0154	0.72	0.5	Lung cancer;	chr6:149905356	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.607	rs9383941	ENSG00000216906.2	RP11-350J20.9	-4.83	7.34e-06	0.0154	-0.72	-0.5	Lung cancer;	chr6:149912100	chr6:149904243~149906418:+
LAML	cis	rs67311347	1	rs9874499	ENSG00000230274.1	PGAM1P3	4.83	7.35e-06	0.0154	0.65	0.49	Renal cell carcinoma;	chr3:40400417	chr3:40322715~40323279:-
LAML	cis	rs7426056	0.671	rs10515944	ENSG00000224791.1	KRT18P39	-4.83	7.35e-06	0.0154	-0.74	-0.49	Primary sclerosing cholangitis;	chr2:203722546	chr2:203764295~203765593:-
LAML	cis	rs5769707	0.967	rs2187891	ENSG00000213279.2	RP1-29C18.9	-4.83	7.36e-06	0.0154	-0.54	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49600446	chr22:49572264~49575426:-
LAML	cis	rs79040073	0.607	rs73400205	ENSG00000276593.1	RP11-295H24.5	4.83	7.36e-06	0.0154	0.58	0.49	Lung cancer in ever smokers;	chr15:49442346	chr15:49353485~49354034:+
LAML	cis	rs12468226	0.752	rs116078354	ENSG00000272966.1	RP11-686O6.1	4.83	7.38e-06	0.0154	0.8	0.49	Urate levels;	chr2:202136356	chr2:202336739~202337200:+
LAML	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-4.83	7.39e-06	0.0154	-0.66	-0.49	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
LAML	cis	rs904251	1	rs12212090	ENSG00000227920.2	RP1-153P14.5	-4.83	7.41e-06	0.0155	-0.57	-0.49	Cognitive performance;	chr6:37464032	chr6:37545145~37550860:+
LAML	cis	rs904251	1	rs10947673	ENSG00000227920.2	RP1-153P14.5	-4.83	7.41e-06	0.0155	-0.57	-0.49	Cognitive performance;	chr6:37477303	chr6:37545145~37550860:+
LAML	cis	rs6951245	1	rs6951245	ENSG00000229043.2	AC091729.9	-4.83	7.42e-06	0.0155	-0.82	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018557	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.872	rs75280240	ENSG00000229043.2	AC091729.9	-4.83	7.42e-06	0.0155	-0.82	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1018875	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs11763020	ENSG00000229043.2	AC091729.9	-4.83	7.42e-06	0.0155	-0.82	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020652	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.935	rs11763765	ENSG00000229043.2	AC091729.9	-4.83	7.42e-06	0.0155	-0.82	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020874	chr7:1160374~1165267:+
LAML	cis	rs801193	1	rs10234018	ENSG00000224316.1	RP11-479O9.2	-4.83	7.43e-06	0.0155	-0.51	-0.49	Aortic root size;	chr7:66681297	chr7:65773620~65802067:+
LAML	cis	rs875971	0.54	rs1723268	ENSG00000224316.1	RP11-479O9.2	4.83	7.47e-06	0.0156	0.52	0.49	Aortic root size;	chr7:66008093	chr7:65773620~65802067:+
LAML	cis	rs875971	0.522	rs2949690	ENSG00000224316.1	RP11-479O9.2	-4.83	7.47e-06	0.0156	-0.52	-0.49	Aortic root size;	chr7:66018255	chr7:65773620~65802067:+
LAML	cis	rs11078917	1	rs11078917	ENSG00000223091.1	RNU6-981P	-4.83	7.47e-06	0.0156	-0.56	-0.49	Mean corpuscular volume;	chr17:39590106	chr17:39482486~39482590:-
LAML	cis	rs7131987	0.565	rs7137141	ENSG00000273680.1	RP11-996F15.6	4.83	7.47e-06	0.0156	0.52	0.49	QT interval;	chr12:29272168	chr12:29332733~29333383:-
LAML	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-4.83	7.47e-06	0.0156	-0.57	-0.49	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
LAML	cis	rs10838798	0.517	rs1967210	ENSG00000263693.1	MIR3161	-4.83	7.48e-06	0.0156	-0.4	-0.49	Height;	chr11:48075140	chr11:48096782~48096858:+
LAML	cis	rs9426935	0.966	rs12133923	ENSG00000273026.1	RP11-422P24.10	4.83	7.52e-06	0.0157	0.63	0.49	Lentiform nucleus volume;	chr1:153800764	chr1:153966516~153966930:+
LAML	cis	rs4834770	0.746	rs2389747	ENSG00000248280.1	RP11-33B1.2	4.83	7.53e-06	0.0157	0.69	0.49	Blood protein levels;	chr4:119314947	chr4:119440561~119450157:-
LAML	cis	rs4834770	0.717	rs1022146	ENSG00000248280.1	RP11-33B1.2	4.83	7.53e-06	0.0157	0.69	0.49	Blood protein levels;	chr4:119314948	chr4:119440561~119450157:-
LAML	cis	rs6951245	0.872	rs57068908	ENSG00000229043.2	AC091729.9	-4.83	7.54e-06	0.0157	-0.81	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1020448	chr7:1160374~1165267:+
LAML	cis	rs172166	0.694	rs203876	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28078895	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs203877	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28080846	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs203893	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28094288	chr6:28073316~28074233:+
LAML	cis	rs172166	0.652	rs476167	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28098110	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs203892	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28099418	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs188105	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28103615	chr6:28073316~28074233:+
LAML	cis	rs172166	0.611	rs203883	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28110578	chr6:28073316~28074233:+
LAML	cis	rs172166	0.611	rs203882	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28110724	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs1770131	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28118635	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs1631552	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28121921	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs536704	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28124825	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs2791332	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28141010	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs1225716	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28145968	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.512	rs2622319	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Parkinson's disease;	chr6:28152623	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs1150666	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28156150	chr6:28073316~28074233:+
LAML	cis	rs172166	0.694	rs9295760	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Cardiac Troponin-T levels;	chr6:28179607	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs1225591	ENSG00000220721.1	OR1F12	4.83	7.54e-06	0.0157	0.56	0.49	Parkinson's disease;	chr6:28180974	chr6:28073316~28074233:+
LAML	cis	rs12220777	0.892	rs11201236	ENSG00000230091.5	TMEM254-AS1	4.83	7.56e-06	0.0157	1.15	0.49	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80021122	chr10:80046860~80078912:-
LAML	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-4.83	7.57e-06	0.0158	-0.52	-0.49	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
LAML	cis	rs7927771	0.698	rs34467936	ENSG00000280615.1	Y_RNA	-4.83	7.58e-06	0.0158	-0.65	-0.49	Subjective well-being;	chr11:47893747	chr11:47614898~47614994:-
LAML	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-4.83	7.58e-06	0.0158	-0.62	-0.49	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-4.83	7.58e-06	0.0158	-0.62	-0.49	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-4.83	7.58e-06	0.0158	-0.62	-0.49	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-4.83	7.58e-06	0.0158	-0.62	-0.49	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-4.83	7.58e-06	0.0158	-0.62	-0.49	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-4.83	7.58e-06	0.0158	-0.62	-0.49	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-4.83	7.58e-06	0.0158	-0.62	-0.49	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
LAML	cis	rs6480314	0.636	rs61854797	ENSG00000234102.1	KRT19P4	-4.83	7.6e-06	0.0158	-0.78	-0.49	Optic nerve measurement (disc area);	chr10:68245854	chr10:68260557~68261499:+
LAML	cis	rs9322193	0.923	rs9689716	ENSG00000216906.2	RP11-350J20.9	4.82	7.61e-06	0.0158	0.68	0.49	Lung cancer;	chr6:149655662	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9322207	ENSG00000216906.2	RP11-350J20.9	4.82	7.61e-06	0.0158	0.68	0.49	Lung cancer;	chr6:149657185	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9968911	ENSG00000216906.2	RP11-350J20.9	4.82	7.61e-06	0.0158	0.68	0.49	Lung cancer;	chr6:149657419	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9322208	ENSG00000216906.2	RP11-350J20.9	4.82	7.61e-06	0.0158	0.68	0.49	Lung cancer;	chr6:149658547	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs3924871	ENSG00000216906.2	RP11-350J20.9	4.82	7.61e-06	0.0158	0.68	0.49	Lung cancer;	chr6:149662080	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs35961297	ENSG00000216906.2	RP11-350J20.9	4.82	7.61e-06	0.0158	0.68	0.49	Lung cancer;	chr6:149667929	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs35830138	ENSG00000216906.2	RP11-350J20.9	4.82	7.61e-06	0.0158	0.68	0.49	Lung cancer;	chr6:149668635	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs35967444	ENSG00000216906.2	RP11-350J20.9	4.82	7.61e-06	0.0158	0.68	0.49	Lung cancer;	chr6:149675588	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs62439842	ENSG00000216906.2	RP11-350J20.9	4.82	7.61e-06	0.0158	0.68	0.49	Lung cancer;	chr6:149675847	chr6:149904243~149906418:+
LAML	cis	rs7131987	0.565	rs7976667	ENSG00000274315.1	RP11-996F15.5	4.82	7.62e-06	0.0158	0.46	0.49	QT interval;	chr12:29273098	chr12:29331434~29331936:-
LAML	cis	rs1577917	1	rs6936048	ENSG00000203875.9	SNHG5	-4.82	7.62e-06	0.0158	-0.63	-0.49	Response to antipsychotic treatment;	chr6:85992890	chr6:85660950~85678736:-
LAML	cis	rs6964833	0.935	rs34762099	ENSG00000277053.3	GTF2IP1	-4.82	7.64e-06	0.0159	-0.68	-0.49	Menarche (age at onset);	chr7:74636378	chr7:75185385~75237696:-
LAML	cis	rs2412819	0.571	rs56226333	ENSG00000249839.1	AC011330.5	-4.82	7.65e-06	0.0159	-0.71	-0.49	Lung cancer;	chr15:43632410	chr15:43663654~43684339:-
LAML	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-4.82	7.65e-06	0.0159	-0.62	-0.49	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-4.82	7.65e-06	0.0159	-0.62	-0.49	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
LAML	cis	rs853679	0.769	rs7752448	ENSG00000220721.1	OR1F12	4.82	7.66e-06	0.0159	0.69	0.49	Depression;	chr6:28333322	chr6:28073316~28074233:+
LAML	cis	rs935334	0.866	rs11850433	ENSG00000280078.1	RP11-361H10.5	-4.82	7.7e-06	0.016	-0.78	-0.49	Blood pressure;	chr14:76215140	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs57844481	ENSG00000280078.1	RP11-361H10.5	-4.82	7.7e-06	0.016	-0.78	-0.49	Blood pressure;	chr14:76218150	chr14:76279173~76283103:+
LAML	cis	rs935334	1	rs10137323	ENSG00000280078.1	RP11-361H10.5	-4.82	7.7e-06	0.016	-0.78	-0.49	Blood pressure;	chr14:76219390	chr14:76279173~76283103:+
LAML	cis	rs9393777	0.557	rs6933999	ENSG00000220721.1	OR1F12	4.82	7.72e-06	0.016	0.58	0.49	Intelligence (multi-trait analysis);	chr6:27107150	chr6:28073316~28074233:+
LAML	cis	rs2412819	0.571	rs28410121	ENSG00000249839.1	AC011330.5	4.82	7.73e-06	0.016	0.71	0.49	Lung cancer;	chr15:43777831	chr15:43663654~43684339:-
LAML	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	4.82	7.74e-06	0.016	0.62	0.49	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	4.82	7.74e-06	0.016	0.62	0.49	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	4.82	7.74e-06	0.016	0.62	0.49	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
LAML	cis	rs2120335	1	rs28694054	ENSG00000221443.1	AC017083.1	4.82	7.78e-06	0.0161	0.6	0.49	Height;	chr2:68178413	chr2:68273104~68273206:+
LAML	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	4.82	7.79e-06	0.0161	1.01	0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
LAML	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-4.82	7.79e-06	0.0161	-1.01	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
LAML	cis	rs6951245	1	rs74652290	ENSG00000229043.2	AC091729.9	-4.82	7.79e-06	0.0161	-0.83	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050473	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs78185558	ENSG00000229043.2	AC091729.9	-4.82	7.79e-06	0.0161	-0.83	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050547	chr7:1160374~1165267:+
LAML	cis	rs13217239	0.646	rs10946888	ENSG00000241549.7	GUSBP2	4.82	7.8e-06	0.0161	0.51	0.49	Schizophrenia;	chr6:26983899	chr6:26871484~26956554:-
LAML	cis	rs6951245	1	rs78158942	ENSG00000229043.2	AC091729.9	-4.82	7.8e-06	0.0161	-0.83	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1050804	chr7:1160374~1165267:+
LAML	cis	rs6951245	1	rs2363286	ENSG00000229043.2	AC091729.9	-4.82	7.8e-06	0.0161	-0.83	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1051989	chr7:1160374~1165267:+
LAML	cis	rs9916302	0.904	rs35335692	ENSG00000223091.1	RNU6-981P	-4.82	7.8e-06	0.0161	-0.58	-0.49	Glomerular filtration rate (creatinine);	chr17:39553753	chr17:39482486~39482590:-
LAML	cis	rs2015599	0.549	rs7311081	ENSG00000274315.1	RP11-996F15.5	4.82	7.81e-06	0.0161	0.5	0.49	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.517	rs7295212	ENSG00000274315.1	RP11-996F15.5	4.82	7.81e-06	0.0161	0.5	0.49	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29331434~29331936:-
LAML	cis	rs9426935	0.932	rs2252508	ENSG00000273026.1	RP11-422P24.10	-4.82	7.82e-06	0.0161	-0.63	-0.49	Lentiform nucleus volume;	chr1:153941294	chr1:153966516~153966930:+
LAML	cis	rs62070183	0.532	rs2035955	ENSG00000264458.1	RP11-220C2.1	4.82	7.87e-06	0.0162	0.8	0.49	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32638167	chr17:32627739~32686484:+
LAML	cis	rs716804	0.703	rs2083717	ENSG00000254719.1	RP11-351I24.3	-4.82	7.87e-06	0.0162	-0.6	-0.49	Neuroticism;	chr11:10156588	chr11:10272052~10272259:-
LAML	cis	rs7495132	0.512	rs35248424	ENSG00000259314.1	CTD-3065B20.3	4.82	7.89e-06	0.0162	0.49	0.49	Ulcerative colitis;Inflammatory bowel disease;	chr15:90646084	chr15:90604225~90614558:-
LAML	cis	rs3096299	0.967	rs3102341	ENSG00000274627.1	RP11-104N10.2	4.81	7.91e-06	0.0162	0.57	0.49	Multiple myeloma (IgH translocation);	chr16:89384336	chr16:89516797~89522217:+
LAML	cis	rs3096299	0.933	rs3114848	ENSG00000274627.1	RP11-104N10.2	4.81	7.91e-06	0.0162	0.57	0.49	Multiple myeloma (IgH translocation);	chr16:89386363	chr16:89516797~89522217:+
LAML	cis	rs904251	0.861	rs1757183	ENSG00000204110.6	RP1-153P14.8	4.81	7.91e-06	0.0162	0.63	0.49	Cognitive performance;	chr6:37517014	chr6:37507348~37535616:+
LAML	cis	rs904251	0.861	rs1757180	ENSG00000204110.6	RP1-153P14.8	-4.81	7.91e-06	0.0162	-0.63	-0.49	Cognitive performance;	chr6:37518369	chr6:37507348~37535616:+
LAML	cis	rs7916697	0.52	rs10762201	ENSG00000234102.1	KRT19P4	4.81	7.91e-06	0.0162	0.65	0.49	Optic disc area;	chr10:68280354	chr10:68260557~68261499:+
LAML	cis	rs9309473	1	rs1403284	ENSG00000163016.8	ALMS1P	-4.81	7.98e-06	0.0164	-0.58	-0.49	Metabolite levels;	chr2:73499535	chr2:73644919~73685576:+
LAML	cis	rs9309473	0.95	rs73947808	ENSG00000163016.8	ALMS1P	4.81	7.98e-06	0.0164	0.58	0.49	Metabolite levels;	chr2:73494123	chr2:73644919~73685576:+
LAML	cis	rs1863918	0.568	rs35814218	ENSG00000272431.1	RP11-281O15.8	4.81	7.99e-06	0.0164	0.77	0.49	Depression in response to interferon-based therapy in chronic hepatitis C;	chr5:179150569	chr5:178938677~178939223:-
LAML	cis	rs7131987	0.565	rs7974254	ENSG00000275476.1	RP11-996F15.4	4.81	8e-06	0.0164	0.54	0.49	QT interval;	chr12:29246592	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs6487787	ENSG00000275476.1	RP11-996F15.4	4.81	8e-06	0.0164	0.54	0.49	QT interval;	chr12:29248353	chr12:29277397~29277882:-
LAML	cis	rs7131987	0.565	rs6487791	ENSG00000275476.1	RP11-996F15.4	4.81	8e-06	0.0164	0.54	0.49	QT interval;	chr12:29250989	chr12:29277397~29277882:-
LAML	cis	rs9399135	0.967	rs12527683	ENSG00000232876.1	CTA-212D2.2	-4.81	8e-06	0.0164	-0.67	-0.49	Red blood cell count;	chr6:135003396	chr6:135055033~135060550:+
LAML	cis	rs5769707	0.933	rs2157444	ENSG00000212939.2	RP1-29C18.10	-4.81	8.01e-06	0.0164	-0.59	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49548681~49556473:+
LAML	cis	rs2404602	0.575	rs11072611	ENSG00000259422.1	RP11-593F23.1	4.81	8.04e-06	0.0165	0.58	0.49	Blood metabolite levels;	chr15:76655642	chr15:76174891~76181486:-
LAML	cis	rs9322193	0.962	rs2342764	ENSG00000216906.2	RP11-350J20.9	4.81	8.04e-06	0.0165	0.71	0.49	Lung cancer;	chr6:149835068	chr6:149904243~149906418:+
LAML	cis	rs916888	0.773	rs199447	ENSG00000280985.1	AC217773.1	4.81	8.05e-06	0.0165	0.69	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:46172089~46172239:-
LAML	cis	rs9916302	0.851	rs2338795	ENSG00000223091.1	RNU6-981P	-4.81	8.06e-06	0.0165	-0.58	-0.49	Glomerular filtration rate (creatinine);	chr17:39243111	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs55689507	ENSG00000223091.1	RNU6-981P	-4.81	8.06e-06	0.0165	-0.58	-0.49	Glomerular filtration rate (creatinine);	chr17:39248183	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.61	rs11078902	ENSG00000223091.1	RNU6-981P	-4.81	8.07e-06	0.0165	-0.59	-0.49	Glomerular filtration rate (creatinine);	chr17:39475630	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.707	rs11078903	ENSG00000223091.1	RNU6-981P	-4.81	8.07e-06	0.0165	-0.59	-0.49	Glomerular filtration rate (creatinine);	chr17:39475671	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs11078915	ENSG00000223091.1	RNU6-981P	-4.81	8.07e-06	0.0165	-0.59	-0.49	Glomerular filtration rate (creatinine);	chr17:39559173	chr17:39482486~39482590:-
LAML	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-4.81	8.09e-06	0.0166	-0.67	-0.49	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
LAML	cis	rs9322193	0.962	rs13215691	ENSG00000216906.2	RP11-350J20.9	4.81	8.1e-06	0.0166	0.68	0.49	Lung cancer;	chr6:149792666	chr6:149904243~149906418:+
LAML	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-4.81	8.11e-06	0.0166	-0.55	-0.49	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
LAML	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-4.81	8.11e-06	0.0166	-0.55	-0.49	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
LAML	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-4.81	8.11e-06	0.0166	-0.55	-0.49	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
LAML	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	4.81	8.11e-06	0.0166	0.61	0.49	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	4.81	8.11e-06	0.0166	0.61	0.49	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	4.81	8.11e-06	0.0166	0.61	0.49	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	4.81	8.11e-06	0.0166	0.61	0.49	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	4.81	8.11e-06	0.0166	0.61	0.49	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	4.81	8.11e-06	0.0166	0.61	0.49	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
LAML	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	4.81	8.11e-06	0.0166	0.61	0.49	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
LAML	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-4.81	8.12e-06	0.0166	-0.54	-0.49	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-4.81	8.12e-06	0.0166	-0.54	-0.49	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
LAML	cis	rs67311347	0.822	rs11709089	ENSG00000230274.1	PGAM1P3	4.81	8.18e-06	0.0167	0.63	0.49	Renal cell carcinoma;	chr3:40309993	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.866	rs9826419	ENSG00000230274.1	PGAM1P3	4.81	8.18e-06	0.0167	0.63	0.49	Renal cell carcinoma;	chr3:40310560	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.866	rs3214006	ENSG00000230274.1	PGAM1P3	4.81	8.18e-06	0.0167	0.63	0.49	Renal cell carcinoma;	chr3:40310643	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.824	rs73073561	ENSG00000230274.1	PGAM1P3	4.81	8.18e-06	0.0167	0.63	0.49	Renal cell carcinoma;	chr3:40315807	chr3:40322715~40323279:-
LAML	cis	rs9322193	0.923	rs2342765	ENSG00000217733.2	CCT7P1	4.81	8.18e-06	0.0167	0.69	0.49	Lung cancer;	chr6:149858873	chr6:149879962~149881572:+
LAML	cis	rs12200782	0.872	rs41266837	ENSG00000275846.1	RP11-457M11.7	-4.81	8.18e-06	0.0167	-1	-0.49	Small cell lung carcinoma;	chr6:26409501	chr6:26602733~26606661:+
LAML	cis	rs12200782	0.872	rs59438701	ENSG00000275846.1	RP11-457M11.7	-4.81	8.18e-06	0.0167	-1	-0.49	Small cell lung carcinoma;	chr6:26412299	chr6:26602733~26606661:+
LAML	cis	rs12200782	0.769	rs10456329	ENSG00000275846.1	RP11-457M11.7	-4.81	8.18e-06	0.0167	-1	-0.49	Small cell lung carcinoma;	chr6:26436171	chr6:26602733~26606661:+
LAML	cis	rs4591358	0.68	rs4277541	ENSG00000223466.1	AC064834.2	-4.81	8.19e-06	0.0167	-0.65	-0.49	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195449705	chr2:195533035~195538681:+
LAML	cis	rs904251	0.6	rs12211110	ENSG00000279942.1	RP1-153P14.7	-4.8	8.21e-06	0.0168	-0.5	-0.49	Cognitive performance;	chr6:37498456	chr6:37567716~37571460:+
LAML	cis	rs4879656	0.564	rs7864363	ENSG00000225693.1	LAGE3P1	4.8	8.23e-06	0.0168	0.52	0.49	Menopause (age at onset);	chr9:33022002	chr9:33019682~33020165:-
LAML	cis	rs5769707	0.609	rs2071890	ENSG00000212939.2	RP1-29C18.10	-4.8	8.23e-06	0.0168	-0.65	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49607643	chr22:49548681~49556473:+
LAML	cis	rs950169	0.84	rs2896002	ENSG00000259728.4	LINC00933	4.8	8.23e-06	0.0168	0.72	0.49	Schizophrenia;	chr15:84390423	chr15:84570649~84580175:+
LAML	cis	rs7944735	0.517	rs12274550	ENSG00000263693.1	MIR3161	4.8	8.24e-06	0.0168	0.45	0.49	Intraocular pressure;	chr11:48175200	chr11:48096782~48096858:+
LAML	cis	rs7944735	0.517	rs7952205	ENSG00000263693.1	MIR3161	4.8	8.24e-06	0.0168	0.45	0.49	Intraocular pressure;	chr11:48177675	chr11:48096782~48096858:+
LAML	cis	rs747782	0.582	rs11039571	ENSG00000263693.1	MIR3161	4.8	8.24e-06	0.0168	0.45	0.49	Intraocular pressure;	chr11:48185707	chr11:48096782~48096858:+
LAML	cis	rs4713118	0.513	rs149954	ENSG00000220721.1	OR1F12	4.8	8.24e-06	0.0168	0.55	0.49	Parkinson's disease;	chr6:28067468	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs149955	ENSG00000220721.1	OR1F12	4.8	8.24e-06	0.0168	0.55	0.49	Parkinson's disease;	chr6:28068447	chr6:28073316~28074233:+
LAML	cis	rs916888	0.821	rs199506	ENSG00000280985.1	AC217773.1	-4.8	8.25e-06	0.0168	-0.68	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:46172089~46172239:-
LAML	cis	rs2015599	0.549	rs7134187	ENSG00000274315.1	RP11-996F15.5	-4.8	8.25e-06	0.0168	-0.51	-0.49	Platelet count;Mean platelet volume;	chr12:29294113	chr12:29331434~29331936:-
LAML	cis	rs1823874	0.581	rs11855419	ENSG00000182397.13	DNM1P46	4.8	8.26e-06	0.0169	0.63	0.49	IgG glycosylation;	chr15:99787275	chr15:99790156~99806927:-
LAML	cis	rs5769707	0.967	rs17182154	ENSG00000213279.2	RP1-29C18.9	-4.8	8.27e-06	0.0169	-0.55	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49596822	chr22:49572264~49575426:-
LAML	cis	rs904251	0.504	rs12202664	ENSG00000204110.6	RP1-153P14.8	-4.8	8.28e-06	0.0169	-0.56	-0.49	Cognitive performance;	chr6:37513422	chr6:37507348~37535616:+
LAML	cis	rs7495132	0.573	rs6496712	ENSG00000259314.1	CTD-3065B20.3	-4.8	8.28e-06	0.0169	-0.49	-0.49	Ulcerative colitis;Inflammatory bowel disease;	chr15:90630469	chr15:90604225~90614558:-
LAML	cis	rs6480314	0.636	rs7914274	ENSG00000234102.1	KRT19P4	-4.8	8.29e-06	0.0169	-0.78	-0.49	Optic nerve measurement (disc area);	chr10:68240300	chr10:68260557~68261499:+
LAML	cis	rs6480314	0.573	rs12573244	ENSG00000234102.1	KRT19P4	-4.8	8.29e-06	0.0169	-0.78	-0.49	Optic nerve measurement (disc area);	chr10:68241488	chr10:68260557~68261499:+
LAML	cis	rs6480314	0.542	rs11814858	ENSG00000234102.1	KRT19P4	-4.8	8.29e-06	0.0169	-0.78	-0.49	Optic nerve measurement (disc area);	chr10:68241950	chr10:68260557~68261499:+
LAML	cis	rs6480314	0.636	rs61854788	ENSG00000234102.1	KRT19P4	-4.8	8.29e-06	0.0169	-0.78	-0.49	Optic nerve measurement (disc area);	chr10:68241980	chr10:68260557~68261499:+
LAML	cis	rs6480314	0.636	rs61854790	ENSG00000234102.1	KRT19P4	-4.8	8.29e-06	0.0169	-0.78	-0.49	Optic nerve measurement (disc area);	chr10:68242491	chr10:68260557~68261499:+
LAML	cis	rs6480314	0.636	rs61854792	ENSG00000234102.1	KRT19P4	-4.8	8.29e-06	0.0169	-0.78	-0.49	Optic nerve measurement (disc area);	chr10:68243902	chr10:68260557~68261499:+
LAML	cis	rs6480314	0.636	rs77760458	ENSG00000234102.1	KRT19P4	-4.8	8.29e-06	0.0169	-0.78	-0.49	Optic nerve measurement (disc area);	chr10:68244248	chr10:68260557~68261499:+
LAML	cis	rs12468226	1	rs76021735	ENSG00000272966.1	RP11-686O6.1	4.8	8.29e-06	0.0169	0.85	0.49	Urate levels;	chr2:202511476	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs57080353	ENSG00000272966.1	RP11-686O6.1	4.8	8.29e-06	0.0169	0.85	0.49	Urate levels;	chr2:202511824	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.81	rs3736578	ENSG00000272966.1	RP11-686O6.1	4.8	8.29e-06	0.0169	0.85	0.49	Urate levels;	chr2:202519989	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs116439150	ENSG00000272966.1	RP11-686O6.1	4.8	8.29e-06	0.0169	0.85	0.49	Urate levels;	chr2:202523814	chr2:202336739~202337200:+
LAML	cis	rs12468226	1	rs12467409	ENSG00000272966.1	RP11-686O6.1	4.8	8.29e-06	0.0169	0.85	0.49	Urate levels;	chr2:202529625	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.81	rs77090459	ENSG00000272966.1	RP11-686O6.1	4.8	8.29e-06	0.0169	0.85	0.49	Urate levels;	chr2:202542132	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.872	rs1061157	ENSG00000272966.1	RP11-686O6.1	4.8	8.29e-06	0.0169	0.85	0.49	Urate levels;	chr2:202556476	chr2:202336739~202337200:+
LAML	cis	rs716804	0.74	rs4482025	ENSG00000254719.1	RP11-351I24.3	-4.8	8.3e-06	0.0169	-0.6	-0.49	Neuroticism;	chr11:10166755	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs11602090	ENSG00000254719.1	RP11-351I24.3	-4.8	8.3e-06	0.0169	-0.6	-0.49	Neuroticism;	chr11:10173147	chr11:10272052~10272259:-
LAML	cis	rs12200782	1	rs10946822	ENSG00000275846.1	RP11-457M11.7	-4.8	8.3e-06	0.0169	-1.01	-0.49	Small cell lung carcinoma;	chr6:26414450	chr6:26602733~26606661:+
LAML	cis	rs7534824	1	rs74977884	ENSG00000213421.4	RP11-84O12.2	-4.8	8.3e-06	0.0169	-1.07	-0.49	Refractive astigmatism;	chr1:101179359	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.929	rs113894440	ENSG00000213421.4	RP11-84O12.2	-4.8	8.3e-06	0.0169	-1.07	-0.49	Refractive astigmatism;	chr1:101180329	chr1:100586649~100587431:-
LAML	cis	rs9322193	0.923	rs9688350	ENSG00000216906.2	RP11-350J20.9	4.8	8.33e-06	0.017	0.7	0.49	Lung cancer;	chr6:149730977	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9767652	ENSG00000216906.2	RP11-350J20.9	4.8	8.33e-06	0.017	0.7	0.49	Lung cancer;	chr6:149734502	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs10782314	ENSG00000216906.2	RP11-350J20.9	4.8	8.33e-06	0.017	0.7	0.49	Lung cancer;	chr6:149735527	chr6:149904243~149906418:+
LAML	cis	rs7849270	1	rs7020708	ENSG00000268707.1	RP11-247A12.7	-4.8	8.35e-06	0.017	-0.59	-0.49	Blood metabolite ratios;	chr9:129122852	chr9:129170434~129170940:+
LAML	cis	rs8062405	0.824	rs153106	ENSG00000271623.1	RP11-435I10.5	-4.8	8.4e-06	0.0171	-0.59	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.789	rs240704	ENSG00000271623.1	RP11-435I10.5	-4.8	8.4e-06	0.0171	-0.59	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.824	rs240702	ENSG00000271623.1	RP11-435I10.5	-4.8	8.4e-06	0.0171	-0.59	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.824	rs62034319	ENSG00000271623.1	RP11-435I10.5	-4.8	8.4e-06	0.0171	-0.59	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.824	rs28698667	ENSG00000271623.1	RP11-435I10.5	-4.8	8.4e-06	0.0171	-0.59	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.754	rs62034323	ENSG00000271623.1	RP11-435I10.5	-4.8	8.4e-06	0.0171	-0.59	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.824	rs62034324	ENSG00000271623.1	RP11-435I10.5	-4.8	8.4e-06	0.0171	-0.59	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.824	rs62034326	ENSG00000271623.1	RP11-435I10.5	-4.8	8.4e-06	0.0171	-0.59	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.824	rs4788084	ENSG00000271623.1	RP11-435I10.5	-4.8	8.4e-06	0.0171	-0.59	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28364700~28365333:+
LAML	cis	rs7511633	0.518	rs35225630	ENSG00000225650.2	EIF2S2P5	4.8	8.4e-06	0.0171	0.36	0.49	Autism;	chr1:114525736	chr1:114468315~114469282:+
LAML	cis	rs6452524	1	rs7738033	ENSG00000249664.1	CTD-2227C6.2	4.8	8.41e-06	0.0171	0.66	0.49	Hypertension (SNP x SNP interaction);	chr5:83135470	chr5:83012285~83013109:-
LAML	cis	rs6452524	1	rs6860239	ENSG00000249664.1	CTD-2227C6.2	4.8	8.41e-06	0.0171	0.66	0.49	Hypertension (SNP x SNP interaction);	chr5:83136022	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.967	rs1031901	ENSG00000249664.1	CTD-2227C6.2	4.8	8.41e-06	0.0171	0.66	0.49	Hypertension (SNP x SNP interaction);	chr5:83147904	chr5:83012285~83013109:-
LAML	cis	rs67311347	1	rs28434528	ENSG00000230274.1	PGAM1P3	4.8	8.41e-06	0.0171	0.61	0.49	Renal cell carcinoma;	chr3:40443402	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs11716675	ENSG00000230274.1	PGAM1P3	4.8	8.41e-06	0.0171	0.61	0.49	Renal cell carcinoma;	chr3:40443789	chr3:40322715~40323279:-
LAML	cis	rs76917914	0.954	rs111292969	ENSG00000236896.1	RP11-535C21.3	4.8	8.43e-06	0.0171	0.47	0.49	Immature fraction of reticulocytes;	chr9:98025909	chr9:97986551~97987656:-
LAML	cis	rs853679	0.607	rs13199649	ENSG00000217315.1	OR2W2P	4.8	8.43e-06	0.0171	0.91	0.49	Depression;	chr6:27901014	chr6:28033947~28034855:+
LAML	cis	rs67340775	0.834	rs13218875	ENSG00000217315.1	OR2W2P	4.8	8.43e-06	0.0171	0.91	0.49	Lung cancer in ever smokers;	chr6:27916234	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs67040724	ENSG00000217315.1	OR2W2P	4.8	8.43e-06	0.0171	0.91	0.49	Depression;	chr6:27937731	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs67662114	ENSG00000217315.1	OR2W2P	4.8	8.43e-06	0.0171	0.91	0.49	Depression;	chr6:27964523	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13216117	ENSG00000217315.1	OR2W2P	4.8	8.43e-06	0.0171	0.91	0.49	Depression;	chr6:27970706	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs36101351	ENSG00000217315.1	OR2W2P	4.8	8.43e-06	0.0171	0.91	0.49	Depression;	chr6:27975591	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs28360499	ENSG00000217315.1	OR2W2P	4.8	8.43e-06	0.0171	0.91	0.49	Depression;	chr6:27977618	chr6:28033947~28034855:+
LAML	cis	rs853679	0.546	rs71537572	ENSG00000217315.1	OR2W2P	4.8	8.43e-06	0.0171	0.91	0.49	Depression;	chr6:28002937	chr6:28033947~28034855:+
LAML	cis	rs853679	0.599	rs13193295	ENSG00000217315.1	OR2W2P	4.8	8.43e-06	0.0171	0.91	0.49	Depression;	chr6:28035450	chr6:28033947~28034855:+
LAML	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	4.8	8.44e-06	0.0171	0.66	0.49	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
LAML	cis	rs4713118	0.786	rs200503	ENSG00000220721.1	OR1F12	4.8	8.46e-06	0.0171	0.55	0.49	Parkinson's disease;	chr6:27818104	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.786	rs200502	ENSG00000220721.1	OR1F12	4.8	8.46e-06	0.0171	0.55	0.49	Parkinson's disease;	chr6:27820284	chr6:28073316~28074233:+
LAML	cis	rs9916302	0.784	rs34473775	ENSG00000223091.1	RNU6-981P	-4.8	8.47e-06	0.0172	-0.57	-0.49	Glomerular filtration rate (creatinine);	chr17:39239948	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs10432031	ENSG00000223091.1	RNU6-981P	-4.8	8.47e-06	0.0172	-0.57	-0.49	Glomerular filtration rate (creatinine);	chr17:39241599	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs2061342	ENSG00000223091.1	RNU6-981P	-4.8	8.47e-06	0.0172	-0.57	-0.49	Glomerular filtration rate (creatinine);	chr17:39249404	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8081338	ENSG00000223091.1	RNU6-981P	-4.8	8.47e-06	0.0172	-0.57	-0.49	Glomerular filtration rate (creatinine);	chr17:39249886	chr17:39482486~39482590:-
LAML	cis	rs79040073	0.682	rs12592277	ENSG00000276593.1	RP11-295H24.5	4.8	8.51e-06	0.0172	0.57	0.49	Lung cancer in ever smokers;	chr15:49436562	chr15:49353485~49354034:+
LAML	cis	rs79040073	0.607	rs7168316	ENSG00000276593.1	RP11-295H24.5	4.8	8.51e-06	0.0172	0.57	0.49	Lung cancer in ever smokers;	chr15:49441549	chr15:49353485~49354034:+
LAML	cis	rs79040073	0.607	rs10519227	ENSG00000276593.1	RP11-295H24.5	4.8	8.51e-06	0.0172	0.57	0.49	Lung cancer in ever smokers;	chr15:49454167	chr15:49353485~49354034:+
LAML	cis	rs79040073	0.607	rs17479205	ENSG00000276593.1	RP11-295H24.5	4.8	8.51e-06	0.0172	0.57	0.49	Lung cancer in ever smokers;	chr15:49456065	chr15:49353485~49354034:+
LAML	cis	rs79040073	0.607	rs17479289	ENSG00000276593.1	RP11-295H24.5	4.8	8.51e-06	0.0172	0.57	0.49	Lung cancer in ever smokers;	chr15:49456416	chr15:49353485~49354034:+
LAML	cis	rs7131987	0.565	rs7974254	ENSG00000274315.1	RP11-996F15.5	4.79	8.52e-06	0.0173	0.49	0.49	QT interval;	chr12:29246592	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs6487787	ENSG00000274315.1	RP11-996F15.5	4.79	8.52e-06	0.0173	0.49	0.49	QT interval;	chr12:29248353	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.565	rs6487791	ENSG00000274315.1	RP11-996F15.5	4.79	8.52e-06	0.0173	0.49	0.49	QT interval;	chr12:29250989	chr12:29331434~29331936:-
LAML	cis	rs716804	0.74	rs2083715	ENSG00000254719.1	RP11-351I24.3	-4.79	8.52e-06	0.0173	-0.6	-0.49	Neuroticism;	chr11:10232249	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs56063978	ENSG00000254719.1	RP11-351I24.3	-4.79	8.52e-06	0.0173	-0.6	-0.49	Neuroticism;	chr11:10235394	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs35737881	ENSG00000254719.1	RP11-351I24.3	-4.79	8.54e-06	0.0173	-0.59	-0.49	Neuroticism;	chr11:10267583	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs34051776	ENSG00000254719.1	RP11-351I24.3	-4.79	8.54e-06	0.0173	-0.59	-0.49	Neuroticism;	chr11:10272525	chr11:10272052~10272259:-
LAML	cis	rs716804	0.703	rs36167833	ENSG00000254719.1	RP11-351I24.3	-4.79	8.54e-06	0.0173	-0.59	-0.49	Neuroticism;	chr11:10272690	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs34692066	ENSG00000254719.1	RP11-351I24.3	-4.79	8.54e-06	0.0173	-0.59	-0.49	Neuroticism;	chr11:10272791	chr11:10272052~10272259:-
LAML	cis	rs716804	0.667	rs7108358	ENSG00000254719.1	RP11-351I24.3	-4.79	8.54e-06	0.0173	-0.59	-0.49	Neuroticism;	chr11:10273293	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs7107399	ENSG00000254719.1	RP11-351I24.3	-4.79	8.54e-06	0.0173	-0.59	-0.49	Neuroticism;	chr11:10273340	chr11:10272052~10272259:-
LAML	cis	rs716804	0.703	rs7110652	ENSG00000254719.1	RP11-351I24.3	-4.79	8.54e-06	0.0173	-0.59	-0.49	Neuroticism;	chr11:10273355	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs6484148	ENSG00000254719.1	RP11-351I24.3	-4.79	8.54e-06	0.0173	-0.59	-0.49	Neuroticism;	chr11:10273597	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs7952105	ENSG00000254719.1	RP11-351I24.3	-4.79	8.54e-06	0.0173	-0.59	-0.49	Neuroticism;	chr11:10273920	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs11607174	ENSG00000254719.1	RP11-351I24.3	4.79	8.54e-06	0.0173	0.59	0.49	Neuroticism;	chr11:10284481	chr11:10272052~10272259:-
LAML	cis	rs7165170	0.613	rs76758258	ENSG00000259314.1	CTD-3065B20.3	4.79	8.55e-06	0.0173	0.49	0.49	Crohn's disease;Inflammatory bowel disease;	chr15:90647704	chr15:90604225~90614558:-
LAML	cis	rs801193	1	rs17566701	ENSG00000224316.1	RP11-479O9.2	4.79	8.56e-06	0.0173	0.53	0.49	Aortic root size;	chr7:66728196	chr7:65773620~65802067:+
LAML	cis	rs2581828	0.618	rs6777975	ENSG00000280417.1	RP11-5O17.1	-4.79	8.56e-06	0.0173	-0.7	-0.49	Crohn's disease;	chr3:53132119	chr3:53046166~53048122:+
LAML	cis	rs763121	0.819	rs4560233	ENSG00000230912.1	RP3-508I15.10	-4.79	8.58e-06	0.0173	-0.41	-0.49	Menopause (age at onset);	chr22:38586437	chr22:38666508~38668750:-
LAML	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	4.79	8.58e-06	0.0174	0.61	0.49	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
LAML	cis	rs853679	0.769	rs7752608	ENSG00000217315.1	OR2W2P	4.79	8.59e-06	0.0174	0.84	0.49	Depression;	chr6:28333418	chr6:28033947~28034855:+
LAML	cis	rs2933343	0.859	rs789247	ENSG00000231305.3	RP11-723O4.2	4.79	8.6e-06	0.0174	0.6	0.49	IgG glycosylation;	chr3:128861742	chr3:128861313~128871540:-
LAML	cis	rs2933343	0.903	rs2638846	ENSG00000231305.3	RP11-723O4.2	4.79	8.6e-06	0.0174	0.6	0.49	IgG glycosylation;	chr3:128868320	chr3:128861313~128871540:-
LAML	cis	rs2933343	0.951	rs1055128	ENSG00000231305.3	RP11-723O4.2	4.79	8.6e-06	0.0174	0.6	0.49	IgG glycosylation;	chr3:128872205	chr3:128861313~128871540:-
LAML	cis	rs2933343	0.951	rs796862	ENSG00000231305.3	RP11-723O4.2	4.79	8.6e-06	0.0174	0.6	0.49	IgG glycosylation;	chr3:128874197	chr3:128861313~128871540:-
LAML	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	4.79	8.6e-06	0.0174	0.6	0.49	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
LAML	cis	rs2933343	1	rs789227	ENSG00000231305.3	RP11-723O4.2	4.79	8.6e-06	0.0174	0.6	0.49	IgG glycosylation;	chr3:128881742	chr3:128861313~128871540:-
LAML	cis	rs2933343	1	rs789232	ENSG00000231305.3	RP11-723O4.2	4.79	8.6e-06	0.0174	0.6	0.49	IgG glycosylation;	chr3:128884237	chr3:128861313~128871540:-
LAML	cis	rs2933343	1	rs2929859	ENSG00000231305.3	RP11-723O4.2	4.79	8.6e-06	0.0174	0.6	0.49	IgG glycosylation;	chr3:128889498	chr3:128861313~128871540:-
LAML	cis	rs2933343	1	rs1683811	ENSG00000231305.3	RP11-723O4.2	4.79	8.6e-06	0.0174	0.6	0.49	IgG glycosylation;	chr3:128893270	chr3:128861313~128871540:-
LAML	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-4.79	8.6e-06	0.0174	-0.59	-0.49	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
LAML	cis	rs911186	0.73	rs2393911	ENSG00000220721.1	OR1F12	4.79	8.61e-06	0.0174	0.57	0.49	Autism spectrum disorder or schizophrenia;	chr6:27089300	chr6:28073316~28074233:+
LAML	cis	rs9952991	0.528	rs612058	ENSG00000260302.1	RP11-973H7.1	-4.79	8.62e-06	0.0174	-0.9	-0.49	Inflammatory skin disease;	chr18:12850212	chr18:12774651~12775923:-
LAML	cis	rs9952991	0.566	rs487273	ENSG00000260302.1	RP11-973H7.1	-4.79	8.62e-06	0.0174	-0.9	-0.49	Inflammatory skin disease;	chr18:12853459	chr18:12774651~12775923:-
LAML	cis	rs853679	0.546	rs35353359	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Depression;	chr6:28356601	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs13213152	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Depression;	chr6:28381921	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs13213986	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Depression;	chr6:28390232	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs34546986	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Depression;	chr6:28394532	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs34871267	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Depression;	chr6:28396455	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs35883476	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Depression;	chr6:28400731	chr6:28046434~28047367:+
LAML	cis	rs6921919	0.673	rs13201681	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28046434~28047367:+
LAML	cis	rs6921919	0.778	rs67381177	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28046434~28047367:+
LAML	cis	rs138024639	1	rs138024639	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Breast cancer;	chr6:28468244	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs55690788	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Depression;	chr6:28468368	chr6:28046434~28047367:+
LAML	cis	rs13191038	1	rs13191038	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Urinary tract infection frequency;	chr6:28515140	chr6:28046434~28047367:+
LAML	cis	rs34119086	1	rs34119086	ENSG00000187763.3	OR2B7P	4.79	8.65e-06	0.0175	0.92	0.49	Breast cancer;	chr6:28594471	chr6:28046434~28047367:+
LAML	cis	rs471756	0.523	rs605001	ENSG00000235880.1	RP11-59O6.3	4.79	8.67e-06	0.0175	0.4	0.49	Mean platelet volume;	chr9:223843	chr9:267966~273002:-
LAML	cis	rs10492681	0.555	rs9603697	ENSG00000239827.7	SUGT1P3	-4.79	8.67e-06	0.0175	-0.65	-0.49	Select biomarker traits;	chr13:40209186	chr13:40908159~40921774:-
LAML	cis	rs10492681	0.555	rs1336486	ENSG00000239827.7	SUGT1P3	-4.79	8.67e-06	0.0175	-0.65	-0.49	Select biomarker traits;	chr13:40210677	chr13:40908159~40921774:-
LAML	cis	rs853679	0.556	rs45509595	ENSG00000217315.1	OR2W2P	4.79	8.67e-06	0.0175	0.92	0.49	Depression;	chr6:27873148	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs66868086	ENSG00000217315.1	OR2W2P	4.79	8.67e-06	0.0175	0.92	0.49	Depression;	chr6:27898124	chr6:28033947~28034855:+
LAML	cis	rs2015599	0.56	rs11050147	ENSG00000274315.1	RP11-996F15.5	-4.79	8.69e-06	0.0175	-0.51	-0.49	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.56	rs3948497	ENSG00000274315.1	RP11-996F15.5	-4.79	8.69e-06	0.0175	-0.51	-0.49	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29331434~29331936:-
LAML	cis	rs9916302	0.595	rs4795371	ENSG00000223091.1	RNU6-981P	-4.79	8.71e-06	0.0175	-0.6	-0.49	Glomerular filtration rate (creatinine);	chr17:39480442	chr17:39482486~39482590:-
LAML	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-4.79	8.71e-06	0.0175	-0.54	-0.49	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
LAML	cis	rs2938670	1	rs2938670	ENSG00000259474.1	RP11-650L12.1	-4.79	8.72e-06	0.0176	-0.51	-0.49	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;	chr15:78448346	chr15:78480057~78481820:-
LAML	cis	rs9788721	0.836	rs2656052	ENSG00000259474.1	RP11-650L12.1	-4.79	8.72e-06	0.0176	-0.51	-0.49	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78448590	chr15:78480057~78481820:-
LAML	cis	rs9788721	0.836	rs2568494	ENSG00000259474.1	RP11-650L12.1	-4.79	8.72e-06	0.0176	-0.51	-0.49	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78448622	chr15:78480057~78481820:-
LAML	cis	rs6951245	0.744	rs10275401	ENSG00000229043.2	AC091729.9	-4.79	8.75e-06	0.0176	-0.74	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1174307	chr7:1160374~1165267:+
LAML	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	4.79	8.75e-06	0.0176	0.55	0.49	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
LAML	cis	rs9788721	0.836	rs17483686	ENSG00000259474.1	RP11-650L12.1	-4.79	8.75e-06	0.0176	-0.51	-0.49	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78441048	chr15:78480057~78481820:-
LAML	cis	rs911186	0.947	rs9379962	ENSG00000187763.3	OR2B7P	4.79	8.76e-06	0.0176	0.65	0.49	Autism spectrum disorder or schizophrenia;	chr6:27177532	chr6:28046434~28047367:+
LAML	cis	rs2015599	0.563	rs11050168	ENSG00000273680.1	RP11-996F15.6	4.79	8.76e-06	0.0176	0.51	0.49	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29332733~29333383:-
LAML	cis	rs4713118	0.869	rs7776351	ENSG00000220721.1	OR1F12	-4.79	8.82e-06	0.0177	-0.54	-0.49	Parkinson's disease;	chr6:27758952	chr6:28073316~28074233:+
LAML	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-4.79	8.84e-06	0.0177	-0.51	-0.49	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	4.79	8.84e-06	0.0177	0.51	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	4.79	8.84e-06	0.0177	0.51	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	4.79	8.84e-06	0.0177	0.51	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	4.79	8.84e-06	0.0177	0.51	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
LAML	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-4.78	8.86e-06	0.0178	-0.87	-0.49	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-4.78	8.86e-06	0.0178	-0.87	-0.49	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
LAML	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-4.78	8.86e-06	0.0178	-0.87	-0.49	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
LAML	cis	rs1075265	0.836	rs10208233	ENSG00000235937.1	AC008280.1	4.78	8.86e-06	0.0178	0.42	0.49	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54029552~54030682:-
LAML	cis	rs2933343	1	rs1680790	ENSG00000231305.3	RP11-723O4.2	4.78	8.88e-06	0.0178	0.59	0.49	IgG glycosylation;	chr3:128907010	chr3:128861313~128871540:-
LAML	cis	rs11039100	0.512	rs6578683	ENSG00000232381.1	OR52U1P	4.78	8.88e-06	0.0178	0.54	0.49	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5760970	chr11:5719290~5720212:+
LAML	cis	rs763121	0.889	rs1837988	ENSG00000230912.1	RP3-508I15.10	-4.78	8.89e-06	0.0178	-0.43	-0.49	Menopause (age at onset);	chr22:38505089	chr22:38666508~38668750:-
LAML	cis	rs6686842	0.965	rs4660184	ENSG00000235358.1	RP11-399E6.1	-4.78	8.89e-06	0.0178	-0.55	-0.49	Height;	chr1:41058866	chr1:41242373~41284861:+
LAML	cis	rs4713118	0.55	rs9368527	ENSG00000216915.2	RP1-97D16.1	-4.78	8.89e-06	0.0178	-0.58	-0.49	Parkinson's disease;	chr6:27711666	chr6:27737000~27738494:-
LAML	cis	rs716804	0.703	rs11042687	ENSG00000254719.1	RP11-351I24.3	-4.78	8.92e-06	0.0179	-0.6	-0.49	Neuroticism;	chr11:10243489	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs10743131	ENSG00000254719.1	RP11-351I24.3	-4.78	8.92e-06	0.0179	-0.6	-0.49	Neuroticism;	chr11:10245309	chr11:10272052~10272259:-
LAML	cis	rs3858145	0.588	rs61854831	ENSG00000234102.1	KRT19P4	-4.78	8.94e-06	0.0179	-0.69	-0.49	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276080	chr10:68260557~68261499:+
LAML	cis	rs3858145	0.588	rs55888445	ENSG00000234102.1	KRT19P4	-4.78	8.94e-06	0.0179	-0.69	-0.49	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68276699	chr10:68260557~68261499:+
LAML	cis	rs3858145	0.588	rs76854765	ENSG00000234102.1	KRT19P4	-4.78	8.94e-06	0.0179	-0.69	-0.49	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68260557~68261499:+
LAML	cis	rs3858145	0.588	rs78041174	ENSG00000234102.1	KRT19P4	-4.78	8.94e-06	0.0179	-0.69	-0.49	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68260557~68261499:+
LAML	cis	rs67311347	1	rs2276870	ENSG00000230274.1	PGAM1P3	-4.78	8.94e-06	0.0179	-0.64	-0.49	Renal cell carcinoma;	chr3:40457691	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs2276871	ENSG00000230274.1	PGAM1P3	4.78	8.94e-06	0.0179	0.64	0.49	Renal cell carcinoma;	chr3:40457782	chr3:40322715~40323279:-
LAML	cis	rs916888	0.779	rs199528	ENSG00000280985.1	AC217773.1	4.78	8.95e-06	0.0179	0.69	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:46172089~46172239:-
LAML	cis	rs916888	0.821	rs199525	ENSG00000280985.1	AC217773.1	4.78	8.95e-06	0.0179	0.69	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:46172089~46172239:-
LAML	cis	rs67311347	1	rs6795475	ENSG00000230274.1	PGAM1P3	4.78	8.96e-06	0.0179	0.61	0.49	Renal cell carcinoma;	chr3:40447790	chr3:40322715~40323279:-
LAML	cis	rs853679	0.713	rs200991	ENSG00000220721.1	OR1F12	-4.78	8.97e-06	0.018	-0.61	-0.49	Depression;	chr6:27847716	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs483143	ENSG00000220721.1	OR1F12	4.78	8.98e-06	0.018	0.64	0.49	Depression;	chr6:27878966	chr6:28073316~28074233:+
LAML	cis	rs5769707	0.967	rs763126	ENSG00000213279.2	RP1-29C18.9	4.78	8.99e-06	0.018	0.56	0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49572264~49575426:-
LAML	cis	rs1075265	0.804	rs805343	ENSG00000235937.1	AC008280.1	4.78	8.99e-06	0.018	0.41	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53966056	chr2:54029552~54030682:-
LAML	cis	rs716804	0.819	rs716803	ENSG00000254719.1	RP11-351I24.3	-4.78	8.99e-06	0.018	-0.6	-0.49	Neuroticism;	chr11:10225736	chr11:10272052~10272259:-
LAML	cis	rs7927771	0.965	rs17788930	ENSG00000280615.1	Y_RNA	-4.78	9e-06	0.018	-0.67	-0.49	Subjective well-being;	chr11:47731223	chr11:47614898~47614994:-
LAML	cis	rs76935404	0.773	rs72480748	ENSG00000198251.7	CTC-490E21.13	-4.78	9e-06	0.018	-0.54	-0.49	nicotine metabolite ratio in current smokers;	chr19:40908576	chr19:40908480~40910685:-
LAML	cis	rs10463316	0.823	rs7700342	ENSG00000260581.1	CTB-113P19.4	4.78	9.02e-06	0.0181	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151396762	chr5:151652275~151655449:+
LAML	cis	rs2980439	0.557	rs2921056	ENSG00000268955.2	RP11-556O5.6	-4.78	9.07e-06	0.0181	-0.58	-0.49	Neuroticism;	chr8:8461672	chr8:8188535~8189195:-
LAML	cis	rs7826238	0.524	rs2921055	ENSG00000268955.2	RP11-556O5.6	-4.78	9.07e-06	0.0181	-0.58	-0.49	Systolic blood pressure;	chr8:8461832	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.501	rs2980769	ENSG00000268955.2	RP11-556O5.6	-4.78	9.07e-06	0.0181	-0.58	-0.49	Mood instability;	chr8:8462781	chr8:8188535~8189195:-
LAML	cis	rs875971	0.66	rs10263935	ENSG00000224316.1	RP11-479O9.2	4.78	9.1e-06	0.0182	0.53	0.49	Aortic root size;	chr7:66631041	chr7:65773620~65802067:+
LAML	cis	rs7927771	0.965	rs12787112	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47665595	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs10838747	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47694772	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs10838748	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47694829	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs34910028	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47736897	chr11:47614898~47614994:-
LAML	cis	rs11602339	1	rs11602339	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Body mass index;	chr11:47739919	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs10838757	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47741464	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs12421210	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47758034	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs7927771	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47759754	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs12361031	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47761524	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs7947730	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47764632	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs35902101	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47773617	chr11:47614898~47614994:-
LAML	cis	rs11039389	1	rs11039389	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Neuroticism;	chr11:47774510	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs11039390	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47774743	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs9909	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47778223	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs7105282	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47784062	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs12787330	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47790759	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs7120333	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47795889	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs11605774	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47811241	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs11039412	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47820029	chr11:47614898~47614994:-
LAML	cis	rs7927771	0.965	rs11039416	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47825159	chr11:47614898~47614994:-
LAML	cis	rs7927771	0.965	rs35985502	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47825876	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs34128973	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47829824	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs4752873	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47835968	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs11039426	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47841567	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs12418852	ENSG00000280615.1	Y_RNA	-4.78	9.11e-06	0.0182	-0.67	-0.49	Subjective well-being;	chr11:47847301	chr11:47614898~47614994:-
LAML	cis	rs853679	0.55	rs6901017	ENSG00000217315.1	OR2W2P	4.78	9.12e-06	0.0182	0.71	0.49	Depression;	chr6:28184805	chr6:28033947~28034855:+
LAML	cis	rs3096299	0.967	rs7205785	ENSG00000274627.1	RP11-104N10.2	4.78	9.13e-06	0.0182	0.59	0.49	Multiple myeloma (IgH translocation);	chr16:89392576	chr16:89516797~89522217:+
LAML	cis	rs9322193	0.923	rs62441284	ENSG00000216906.2	RP11-350J20.9	4.78	9.16e-06	0.0183	0.69	0.49	Lung cancer;	chr6:149751542	chr6:149904243~149906418:+
LAML	cis	rs7131987	0.903	rs2194520	ENSG00000275278.1	RP11-946L16.2	4.78	9.17e-06	0.0183	0.59	0.49	QT interval;	chr12:29270779	chr12:29156448~29156991:-
LAML	cis	rs6558530	0.863	rs4595147	ENSG00000253982.1	CTD-2336O2.1	4.78	9.17e-06	0.0183	0.7	0.49	Systolic blood pressure;	chr8:1755403	chr8:1761990~1764502:-
LAML	cis	rs10457838	0.638	rs12203658	ENSG00000220848.4	RPS18P9	-4.78	9.17e-06	0.0183	-0.54	-0.49	Post-traumatic stress disorder;	chr6:148996111	chr6:149594084~149594543:+
LAML	cis	rs12468226	0.689	rs17651413	ENSG00000272966.1	RP11-686O6.1	4.78	9.18e-06	0.0183	0.77	0.49	Urate levels;	chr2:202104086	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.752	rs77319662	ENSG00000272966.1	RP11-686O6.1	4.78	9.18e-06	0.0183	0.77	0.49	Urate levels;	chr2:202126928	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.689	rs17656903	ENSG00000272966.1	RP11-686O6.1	-4.78	9.18e-06	0.0183	-0.77	-0.49	Urate levels;	chr2:202106312	chr2:202336739~202337200:+
LAML	cis	rs7581030	0.55	rs13028024	ENSG00000236469.1	AC007040.8	4.77	9.21e-06	0.0183	0.67	0.49	Testicular germ cell tumor;	chr2:71211750	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs34807546	ENSG00000236469.1	AC007040.8	4.77	9.21e-06	0.0183	0.67	0.49	Testicular germ cell tumor;	chr2:71212752	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs35226067	ENSG00000236469.1	AC007040.8	4.77	9.21e-06	0.0183	0.67	0.49	Testicular germ cell tumor;	chr2:71213394	chr2:71002531~71064743:-
LAML	cis	rs9952991	0.566	rs657555	ENSG00000260302.1	RP11-973H7.1	-4.77	9.21e-06	0.0183	-0.89	-0.49	Inflammatory skin disease;	chr18:12847137	chr18:12774651~12775923:-
LAML	cis	rs9916302	0.861	rs632202	ENSG00000223091.1	RNU6-981P	4.77	9.21e-06	0.0183	0.57	0.49	Glomerular filtration rate (creatinine);	chr17:39297041	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs593480	ENSG00000223091.1	RNU6-981P	4.77	9.21e-06	0.0183	0.57	0.49	Glomerular filtration rate (creatinine);	chr17:39297527	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs2338801	ENSG00000223091.1	RNU6-981P	4.77	9.21e-06	0.0183	0.57	0.49	Glomerular filtration rate (creatinine);	chr17:39334527	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs7221875	ENSG00000223091.1	RNU6-981P	4.77	9.21e-06	0.0183	0.57	0.49	Glomerular filtration rate (creatinine);	chr17:39387075	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs11078896	ENSG00000223091.1	RNU6-981P	-4.77	9.21e-06	0.0183	-0.57	-0.49	Glomerular filtration rate (creatinine);	chr17:39259291	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.768	rs62077464	ENSG00000223091.1	RNU6-981P	-4.77	9.21e-06	0.0183	-0.57	-0.49	Glomerular filtration rate (creatinine);	chr17:39499803	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs4795376	ENSG00000223091.1	RNU6-981P	-4.77	9.21e-06	0.0183	-0.57	-0.49	Glomerular filtration rate (creatinine);	chr17:39512790	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs7503514	ENSG00000223091.1	RNU6-981P	-4.77	9.21e-06	0.0183	-0.57	-0.49	Glomerular filtration rate (creatinine);	chr17:39513631	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs11078913	ENSG00000223091.1	RNU6-981P	-4.77	9.21e-06	0.0183	-0.57	-0.49	Glomerular filtration rate (creatinine);	chr17:39515461	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.861	rs3889368	ENSG00000223091.1	RNU6-981P	-4.77	9.21e-06	0.0183	-0.57	-0.49	Glomerular filtration rate (creatinine);	chr17:39526978	chr17:39482486~39482590:-
LAML	cis	rs2581828	0.606	rs1004807	ENSG00000280417.1	RP11-5O17.1	4.77	9.21e-06	0.0183	0.73	0.49	Crohn's disease;	chr3:53106587	chr3:53046166~53048122:+
LAML	cis	rs7131987	0.565	rs2882294	ENSG00000273680.1	RP11-996F15.6	4.77	9.21e-06	0.0183	0.49	0.49	QT interval;	chr12:29245019	chr12:29332733~29333383:-
LAML	cis	rs9921222	0.509	rs3743883	ENSG00000230428.1	RP1-196A12.1	-4.77	9.24e-06	0.0184	-0.61	-0.49	Bone mineral density (spine);Bone mineral density;	chr16:354750	chr16:451404~453461:+
LAML	cis	rs9322193	0.923	rs7767622	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149681766	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs4421206	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149682891	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs3798761	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149683643	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9322209	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149691226	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs9322210	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149695440	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs11155674	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149711111	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs2185352	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149714640	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs12174349	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149718012	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs2297932	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149718225	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs2297930	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149718360	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs2297928	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149718584	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9479094	ENSG00000216906.2	RP11-350J20.9	4.77	9.24e-06	0.0184	0.67	0.49	Lung cancer;	chr6:149725083	chr6:149904243~149906418:+
LAML	cis	rs709400	0.633	rs7160208	ENSG00000258851.1	RP11-894P9.2	-4.77	9.25e-06	0.0184	-0.59	-0.49	Body mass index;	chr14:103499191	chr14:103553421~103561877:+
LAML	cis	rs8031584	0.678	rs798086	ENSG00000260382.1	RP11-540B6.2	-4.77	9.25e-06	0.0184	-0.53	-0.49	Huntington's disease progression;	chr15:30837008	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.736	rs11635775	ENSG00000260382.1	RP11-540B6.2	4.77	9.25e-06	0.0184	0.53	0.49	Huntington's disease progression;	chr15:30868437	chr15:30882267~30883231:-
LAML	cis	rs4803480	0.542	rs7255742	ENSG00000239736.2	CEACAMP3	-4.77	9.28e-06	0.0185	-0.67	-0.49	Schizophrenia;	chr19:41543459	chr19:41599735~41605984:+
LAML	cis	rs2933343	1	rs876756	ENSG00000231305.3	RP11-723O4.2	4.77	9.3e-06	0.0185	0.59	0.49	IgG glycosylation;	chr3:128908780	chr3:128861313~128871540:-
LAML	cis	rs2933343	1	rs876755	ENSG00000231305.3	RP11-723O4.2	4.77	9.3e-06	0.0185	0.59	0.49	IgG glycosylation;	chr3:128909090	chr3:128861313~128871540:-
LAML	cis	rs9322193	0.923	rs9800614	ENSG00000216906.2	RP11-350J20.9	4.77	9.34e-06	0.0186	0.7	0.49	Lung cancer;	chr6:149644604	chr6:149904243~149906418:+
LAML	cis	rs1930961	0.702	rs6004684	ENSG00000272977.1	CTA-390C10.10	4.77	9.36e-06	0.0186	0.81	0.49	Bipolar disorder with mood-incongruent psychosis;	chr22:25503972	chr22:25476218~25479971:+
LAML	cis	rs709400	0.663	rs9671911	ENSG00000258851.1	RP11-894P9.2	-4.77	9.37e-06	0.0186	-0.59	-0.49	Body mass index;	chr14:103501006	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs3783402	ENSG00000258851.1	RP11-894P9.2	-4.77	9.37e-06	0.0186	-0.59	-0.49	Body mass index;	chr14:103501592	chr14:103553421~103561877:+
LAML	cis	rs67311347	1	rs6762251	ENSG00000230274.1	PGAM1P3	-4.77	9.42e-06	0.0187	-0.65	-0.49	Renal cell carcinoma;	chr3:40489645	chr3:40322715~40323279:-
LAML	cis	rs904251	0.861	rs1757173	ENSG00000204110.6	RP1-153P14.8	-4.77	9.43e-06	0.0187	-0.63	-0.49	Cognitive performance;	chr6:37519176	chr6:37507348~37535616:+
LAML	cis	rs904251	0.861	rs1757169	ENSG00000204110.6	RP1-153P14.8	-4.77	9.43e-06	0.0187	-0.63	-0.49	Cognitive performance;	chr6:37519300	chr6:37507348~37535616:+
LAML	cis	rs904251	0.861	rs2776877	ENSG00000204110.6	RP1-153P14.8	-4.77	9.43e-06	0.0187	-0.63	-0.49	Cognitive performance;	chr6:37519359	chr6:37507348~37535616:+
LAML	cis	rs904251	0.864	rs2797801	ENSG00000204110.6	RP1-153P14.8	-4.77	9.43e-06	0.0187	-0.63	-0.49	Cognitive performance;	chr6:37519385	chr6:37507348~37535616:+
LAML	cis	rs904251	0.797	rs2776878	ENSG00000204110.6	RP1-153P14.8	-4.77	9.43e-06	0.0187	-0.63	-0.49	Cognitive performance;	chr6:37519497	chr6:37507348~37535616:+
LAML	cis	rs904251	0.828	rs2797803	ENSG00000204110.6	RP1-153P14.8	-4.77	9.43e-06	0.0187	-0.63	-0.49	Cognitive performance;	chr6:37519564	chr6:37507348~37535616:+
LAML	cis	rs6940116	1	rs6940116	ENSG00000220721.1	OR1F12	4.77	9.43e-06	0.0187	0.63	0.49	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28073316~28074233:+
LAML	cis	rs6964833	1	rs17515241	ENSG00000277053.3	GTF2IP1	4.77	9.43e-06	0.0187	0.66	0.49	Menarche (age at onset);	chr7:74717695	chr7:75185385~75237696:-
LAML	cis	rs904251	0.861	rs1757171	ENSG00000204110.6	RP1-153P14.8	-4.77	9.46e-06	0.0188	-0.64	-0.49	Cognitive performance;	chr6:37519268	chr6:37507348~37535616:+
LAML	cis	rs2980436	1	rs2980436	ENSG00000249188.1	ENPP7P1	4.77	9.48e-06	0.0188	0.6	0.49	Schizophrenia;	chr8:8234503	chr8:8154308~8216916:+
LAML	cis	rs7555523	0.887	rs4657475	ENSG00000224358.1	RP11-466F5.8	-4.77	9.49e-06	0.0188	-0.69	-0.49	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717938	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.887	rs4656461	ENSG00000224358.1	RP11-466F5.8	-4.77	9.49e-06	0.0188	-0.69	-0.49	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717968	chr1:165768929~165775176:+
LAML	cis	rs9457247	0.508	rs2285147	ENSG00000265828.1	MIR3939	-4.77	9.49e-06	0.0188	-0.73	-0.49	Crohn's disease;	chr6:167092060	chr6:166997807~166997912:-
LAML	cis	rs2404602	0.53	rs11072614	ENSG00000259422.1	RP11-593F23.1	-4.77	9.5e-06	0.0188	-0.61	-0.49	Blood metabolite levels;	chr15:76674864	chr15:76174891~76181486:-
LAML	cis	rs67311347	0.955	rs12487955	ENSG00000230274.1	PGAM1P3	4.77	9.51e-06	0.0188	0.64	0.49	Renal cell carcinoma;	chr3:40371362	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.911	rs58282210	ENSG00000230274.1	PGAM1P3	4.77	9.51e-06	0.0188	0.64	0.49	Renal cell carcinoma;	chr3:40376452	chr3:40322715~40323279:-
LAML	cis	rs11577318	0.579	rs11247936	ENSG00000225854.2	RP11-569G9.7	-4.77	9.51e-06	0.0188	-0.66	-0.49	Granulocyte percentage of myeloid white cells;	chr1:26372393	chr1:26326688~26327033:+
LAML	cis	rs9322193	0.736	rs3828701	ENSG00000216906.2	RP11-350J20.9	4.77	9.53e-06	0.0189	0.68	0.49	Lung cancer;	chr6:149791063	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.736	rs3805750	ENSG00000216906.2	RP11-350J20.9	4.77	9.53e-06	0.0189	0.68	0.49	Lung cancer;	chr6:149791065	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.926	rs3805751	ENSG00000216906.2	RP11-350J20.9	4.77	9.53e-06	0.0189	0.68	0.49	Lung cancer;	chr6:149791193	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs10872656	ENSG00000216906.2	RP11-350J20.9	4.77	9.53e-06	0.0189	0.68	0.49	Lung cancer;	chr6:149799444	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs17673294	ENSG00000216906.2	RP11-350J20.9	4.77	9.53e-06	0.0189	0.68	0.49	Lung cancer;	chr6:149813857	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs3763162	ENSG00000216906.2	RP11-350J20.9	-4.77	9.53e-06	0.0189	-0.68	-0.49	Lung cancer;	chr6:149819674	chr6:149904243~149906418:+
LAML	cis	rs2742417	1	rs2742432	ENSG00000244357.3	RN7SL145P	4.77	9.54e-06	0.0189	0.52	0.49	Response to anti-depressant treatment in major depressive disorder;	chr3:45695975	chr3:45742675~45742970:+
LAML	cis	rs3096299	0.933	rs2930219	ENSG00000274627.1	RP11-104N10.2	4.76	9.54e-06	0.0189	0.61	0.49	Multiple myeloma (IgH translocation);	chr16:89425641	chr16:89516797~89522217:+
LAML	cis	rs5769707	0.935	rs1109320	ENSG00000213279.2	RP1-29C18.9	-4.76	9.55e-06	0.0189	-0.56	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49595458	chr22:49572264~49575426:-
LAML	cis	rs7826238	0.535	rs2979179	ENSG00000268955.2	RP11-556O5.6	-4.76	9.55e-06	0.0189	-0.58	-0.49	Systolic blood pressure;	chr8:8462519	chr8:8188535~8189195:-
LAML	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-4.76	9.56e-06	0.0189	-0.54	-0.49	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
LAML	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	4.76	9.56e-06	0.0189	0.63	0.49	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
LAML	cis	rs12200782	0.505	rs9295696	ENSG00000241549.7	GUSBP2	4.76	9.59e-06	0.0189	0.6	0.49	Small cell lung carcinoma;	chr6:26550060	chr6:26871484~26956554:-
LAML	cis	rs763121	0.889	rs4820335	ENSG00000230912.1	RP3-508I15.10	4.76	9.61e-06	0.0189	0.4	0.49	Menopause (age at onset);	chr22:38539922	chr22:38666508~38668750:-
LAML	cis	rs916888	0.821	rs415430	ENSG00000280985.1	AC217773.1	-4.76	9.63e-06	0.019	-0.7	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:46172089~46172239:-
LAML	cis	rs916888	0.779	rs430685	ENSG00000280985.1	AC217773.1	-4.76	9.63e-06	0.019	-0.7	-0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:46172089~46172239:-
LAML	cis	rs1075265	0.692	rs805358	ENSG00000235937.1	AC008280.1	4.76	9.63e-06	0.019	0.4	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54029552~54030682:-
LAML	cis	rs916888	0.773	rs199451	ENSG00000280985.1	AC217773.1	4.76	9.64e-06	0.019	0.68	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:46172089~46172239:-
LAML	cis	rs67311347	0.868	rs10865895	ENSG00000230274.1	PGAM1P3	4.76	9.64e-06	0.019	0.62	0.49	Renal cell carcinoma;	chr3:40337186	chr3:40322715~40323279:-
LAML	cis	rs10500715	0.676	rs6483860	ENSG00000254719.1	RP11-351I24.3	-4.76	9.66e-06	0.019	-0.6	-0.49	Pancreatic cancer;	chr11:9972340	chr11:10272052~10272259:-
LAML	cis	rs1075265	0.692	rs805361	ENSG00000235937.1	AC008280.1	4.76	9.66e-06	0.019	0.4	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54029552~54030682:-
LAML	cis	rs67311347	0.866	rs56331709	ENSG00000230274.1	PGAM1P3	4.76	9.67e-06	0.019	0.62	0.49	Renal cell carcinoma;	chr3:40315067	chr3:40322715~40323279:-
LAML	cis	rs7944735	0.817	rs6485774	ENSG00000263693.1	MIR3161	4.76	9.68e-06	0.0191	0.39	0.49	Intraocular pressure;	chr11:47751674	chr11:48096782~48096858:+
LAML	cis	rs875971	0.577	rs35072105	ENSG00000224316.1	RP11-479O9.2	-4.76	9.69e-06	0.0191	-0.53	-0.49	Aortic root size;	chr7:66144830	chr7:65773620~65802067:+
LAML	cis	rs875971	0.558	rs4433015	ENSG00000224316.1	RP11-479O9.2	-4.76	9.69e-06	0.0191	-0.53	-0.49	Aortic root size;	chr7:66174736	chr7:65773620~65802067:+
LAML	cis	rs875971	0.666	rs13242072	ENSG00000224316.1	RP11-479O9.2	-4.76	9.69e-06	0.0191	-0.53	-0.49	Aortic root size;	chr7:66301001	chr7:65773620~65802067:+
LAML	cis	rs875971	0.706	rs1643374	ENSG00000224316.1	RP11-479O9.2	4.76	9.69e-06	0.0191	0.53	0.49	Aortic root size;	chr7:66407695	chr7:65773620~65802067:+
LAML	cis	rs747650	0.504	rs7945558	ENSG00000271350.1	CTD-2384B9.1	-4.76	9.72e-06	0.0191	-0.58	-0.49	Acne (severe);	chr11:46936257	chr11:47041027~47041945:-
LAML	cis	rs904251	0.766	rs1757175	ENSG00000204110.6	RP1-153P14.8	-4.76	9.73e-06	0.0191	-0.65	-0.49	Cognitive performance;	chr6:37518918	chr6:37507348~37535616:+
LAML	cis	rs904251	0.828	rs1757174	ENSG00000204110.6	RP1-153P14.8	-4.76	9.73e-06	0.0191	-0.65	-0.49	Cognitive performance;	chr6:37518919	chr6:37507348~37535616:+
LAML	cis	rs785830	0.811	rs661356	ENSG00000235880.1	RP11-59O6.3	4.76	9.76e-06	0.0192	0.43	0.49	Platelet distribution width;	chr9:244457	chr9:267966~273002:-
LAML	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-4.76	9.77e-06	0.0192	-0.63	-0.49	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
LAML	cis	rs8062405	1	rs8061590	ENSG00000271623.1	RP11-435I10.5	-4.76	9.77e-06	0.0192	-0.56	-0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28883809	chr16:28364700~28365333:+
LAML	cis	rs9322193	0.923	rs10782310	ENSG00000216906.2	RP11-350J20.9	4.76	9.78e-06	0.0192	0.69	0.49	Lung cancer;	chr6:149622458	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs10782311	ENSG00000216906.2	RP11-350J20.9	4.76	9.78e-06	0.0192	0.69	0.49	Lung cancer;	chr6:149622592	chr6:149904243~149906418:+
LAML	cis	rs9457247	0.508	rs9459874	ENSG00000265828.1	MIR3939	4.76	9.78e-06	0.0192	0.73	0.49	Crohn's disease;	chr6:167090639	chr6:166997807~166997912:-
LAML	cis	rs875971	0.628	rs6974355	ENSG00000224316.1	RP11-479O9.2	4.76	9.79e-06	0.0192	0.53	0.49	Aortic root size;	chr7:66376994	chr7:65773620~65802067:+
LAML	cis	rs41563	0.593	rs6466034	ENSG00000225329.2	LHFPL3-AS2	4.76	9.79e-06	0.0192	0.57	0.49	Autism spectrum disorder or schizophrenia;	chr7:104958303	chr7:104894628~104926645:-
LAML	cis	rs41563	0.593	rs7807853	ENSG00000225329.2	LHFPL3-AS2	4.76	9.83e-06	0.0193	0.57	0.49	Autism spectrum disorder or schizophrenia;	chr7:104957222	chr7:104894628~104926645:-
LAML	cis	rs911555	0.511	rs8007489	ENSG00000252469.1	RNU7-160P	4.76	9.89e-06	0.0194	0.58	0.49	Intelligence (multi-trait analysis);	chr14:103588235	chr14:103550345~103550406:+
LAML	cis	rs2980439	0.783	rs2955587	ENSG00000253893.2	FAM85B	-4.76	9.89e-06	0.0194	-0.61	-0.49	Neuroticism;	chr8:8240557	chr8:8167819~8226614:-
LAML	cis	rs4879656	0.771	rs10971231	ENSG00000225693.1	LAGE3P1	-4.76	9.89e-06	0.0194	-0.59	-0.49	Menopause (age at onset);	chr9:32939760	chr9:33019682~33020165:-
LAML	cis	rs2404602	0.735	rs11635463	ENSG00000259422.1	RP11-593F23.1	-4.75	9.91e-06	0.0194	-0.57	-0.49	Blood metabolite levels;	chr15:76470645	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.709	rs11072597	ENSG00000259422.1	RP11-593F23.1	-4.75	9.91e-06	0.0194	-0.57	-0.49	Blood metabolite levels;	chr15:76471173	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.735	rs11857327	ENSG00000259422.1	RP11-593F23.1	-4.75	9.91e-06	0.0194	-0.57	-0.49	Blood metabolite levels;	chr15:76471922	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.735	rs11072598	ENSG00000259422.1	RP11-593F23.1	-4.75	9.91e-06	0.0194	-0.57	-0.49	Blood metabolite levels;	chr15:76472447	chr15:76174891~76181486:-
LAML	cis	rs2704588	0.505	rs28718401	ENSG00000207524.1	RNU6-33P	-4.75	9.94e-06	0.0195	-0.74	-0.49	Longevity;	chr4:89051438	chr4:88684848~88684954:-
LAML	cis	rs76917914	1	rs874610	ENSG00000236896.1	RP11-535C21.3	4.75	9.95e-06	0.0195	0.47	0.49	Immature fraction of reticulocytes;	chr9:98020413	chr9:97986551~97987656:-
LAML	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	4.75	9.95e-06	0.0195	0.64	0.49	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
LAML	cis	rs67311347	0.869	rs6790495	ENSG00000230274.1	PGAM1P3	4.75	9.96e-06	0.0195	0.63	0.49	Renal cell carcinoma;	chr3:40325279	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.869	rs7646899	ENSG00000230274.1	PGAM1P3	4.75	9.96e-06	0.0195	0.63	0.49	Renal cell carcinoma;	chr3:40325491	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.955	rs4974067	ENSG00000230274.1	PGAM1P3	4.75	9.96e-06	0.0195	0.63	0.49	Renal cell carcinoma;	chr3:40333060	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs17078511	ENSG00000230274.1	PGAM1P3	4.75	9.96e-06	0.0195	0.63	0.49	Renal cell carcinoma;	chr3:40354763	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9865348	ENSG00000230274.1	PGAM1P3	4.75	9.96e-06	0.0195	0.63	0.49	Renal cell carcinoma;	chr3:40356167	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9849992	ENSG00000230274.1	PGAM1P3	4.75	9.96e-06	0.0195	0.63	0.49	Renal cell carcinoma;	chr3:40360649	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs11715214	ENSG00000230274.1	PGAM1P3	4.75	9.96e-06	0.0195	0.63	0.49	Renal cell carcinoma;	chr3:40361513	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9860162	ENSG00000230274.1	PGAM1P3	4.75	9.96e-06	0.0195	0.63	0.49	Renal cell carcinoma;	chr3:40362384	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs11914297	ENSG00000230274.1	PGAM1P3	4.75	9.96e-06	0.0195	0.63	0.49	Renal cell carcinoma;	chr3:40368579	chr3:40322715~40323279:-
LAML	cis	rs9952991	0.599	rs71353227	ENSG00000260302.1	RP11-973H7.1	4.75	9.99e-06	0.0196	0.87	0.49	Inflammatory skin disease;	chr18:12872425	chr18:12774651~12775923:-
LAML	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-4.75	1e-05	0.0196	-0.86	-0.49	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
LAML	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-4.75	1e-05	0.0197	-0.54	-0.49	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-4.75	1e-05	0.0197	-0.54	-0.49	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-4.75	1e-05	0.0197	-0.54	-0.49	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-4.75	1e-05	0.0197	-0.54	-0.49	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
LAML	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-4.75	1e-05	0.0197	-0.54	-0.49	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
LAML	cis	rs4834770	1	rs4336213	ENSG00000248280.1	RP11-33B1.2	4.75	1e-05	0.0197	0.7	0.49	Blood protein levels;	chr4:119315314	chr4:119440561~119450157:-
LAML	cis	rs2742417	1	rs2742397	ENSG00000244357.3	RN7SL145P	-4.75	1.01e-05	0.0197	-0.54	-0.49	Response to anti-depressant treatment in major depressive disorder;	chr3:45717454	chr3:45742675~45742970:+
LAML	cis	rs3096299	0.933	rs2965938	ENSG00000274627.1	RP11-104N10.2	4.75	1.01e-05	0.0197	0.62	0.49	Multiple myeloma (IgH translocation);	chr16:89424928	chr16:89516797~89522217:+
LAML	cis	rs7131987	0.834	rs12228468	ENSG00000275278.1	RP11-946L16.2	-4.75	1.01e-05	0.0197	-0.6	-0.49	QT interval;	chr12:29300677	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.834	rs1989478	ENSG00000275278.1	RP11-946L16.2	4.75	1.01e-05	0.0197	0.6	0.49	QT interval;	chr12:29289296	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.801	rs6487804	ENSG00000275278.1	RP11-946L16.2	4.75	1.01e-05	0.0197	0.6	0.49	QT interval;	chr12:29302001	chr12:29156448~29156991:-
LAML	cis	rs3758911	0.765	rs588921	ENSG00000261098.1	RP11-819C21.1	4.75	1.01e-05	0.0197	0.48	0.49	Coronary artery disease;	chr11:107415274	chr11:107312132~107316271:-
LAML	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-4.75	1.01e-05	0.0197	-0.53	-0.49	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
LAML	cis	rs4713118	0.513	rs149962	ENSG00000220721.1	OR1F12	4.75	1.01e-05	0.0197	0.54	0.49	Parkinson's disease;	chr6:28048140	chr6:28073316~28074233:+
LAML	cis	rs172166	0.769	rs149965	ENSG00000220721.1	OR1F12	4.75	1.01e-05	0.0197	0.54	0.49	Cardiac Troponin-T levels;	chr6:28050911	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs9368547	ENSG00000220721.1	OR1F12	4.75	1.01e-05	0.0197	0.54	0.49	Parkinson's disease;	chr6:28060289	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs183244	ENSG00000220721.1	OR1F12	4.75	1.01e-05	0.0197	0.54	0.49	Parkinson's disease;	chr6:28064060	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs149950	ENSG00000220721.1	OR1F12	4.75	1.01e-05	0.0197	0.54	0.49	Parkinson's disease;	chr6:28065261	chr6:28073316~28074233:+
LAML	cis	rs4713118	0.513	rs149951	ENSG00000220721.1	OR1F12	4.75	1.01e-05	0.0197	0.54	0.49	Parkinson's disease;	chr6:28065309	chr6:28073316~28074233:+
LAML	cis	rs9322193	0.923	rs12174035	ENSG00000216906.2	RP11-350J20.9	4.75	1.01e-05	0.0197	0.67	0.49	Lung cancer;	chr6:149763311	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9505974	ENSG00000216906.2	RP11-350J20.9	4.75	1.01e-05	0.0197	0.67	0.49	Lung cancer;	chr6:149779294	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.926	rs9689036	ENSG00000216906.2	RP11-350J20.9	4.75	1.01e-05	0.0197	0.67	0.49	Lung cancer;	chr6:149780563	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9322218	ENSG00000216906.2	RP11-350J20.9	4.75	1.01e-05	0.0197	0.67	0.49	Lung cancer;	chr6:149782183	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9322219	ENSG00000216906.2	RP11-350J20.9	4.75	1.01e-05	0.0197	0.67	0.49	Lung cancer;	chr6:149782263	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9322223	ENSG00000216906.2	RP11-350J20.9	4.75	1.01e-05	0.0197	0.67	0.49	Lung cancer;	chr6:149801509	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9397022	ENSG00000216906.2	RP11-350J20.9	4.75	1.01e-05	0.0197	0.67	0.49	Lung cancer;	chr6:149812052	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9397357	ENSG00000216906.2	RP11-350J20.9	4.75	1.01e-05	0.0197	0.67	0.49	Lung cancer;	chr6:149812465	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs3763163	ENSG00000216906.2	RP11-350J20.9	4.75	1.01e-05	0.0197	0.67	0.49	Lung cancer;	chr6:149819770	chr6:149904243~149906418:+
LAML	cis	rs6456156	0.565	rs6921588	ENSG00000265828.1	MIR3939	-4.75	1.01e-05	0.0197	-0.79	-0.49	Primary biliary cholangitis;	chr6:167080909	chr6:166997807~166997912:-
LAML	cis	rs7534824	1	rs114082061	ENSG00000213421.4	RP11-84O12.2	-4.75	1.01e-05	0.0197	-1.06	-0.49	Refractive astigmatism;	chr1:101172295	chr1:100586649~100587431:-
LAML	cis	rs597539	0.503	rs7131462	ENSG00000250508.1	RP11-757G1.6	4.75	1.01e-05	0.0197	0.46	0.49	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68842675	chr11:68870664~68874542:+
LAML	cis	rs6728642	0.708	rs56807297	ENSG00000235833.1	AC159540.14	4.75	1.01e-05	0.0198	0.92	0.49	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97195603	chr2:97523949~97524976:-
LAML	cis	rs11039100	0.688	rs1993225	ENSG00000232381.1	OR52U1P	4.75	1.01e-05	0.0198	0.7	0.49	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5819838	chr11:5719290~5720212:+
LAML	cis	rs7944735	0.817	rs6485788	ENSG00000263693.1	MIR3161	-4.75	1.01e-05	0.0198	-0.39	-0.49	Intraocular pressure;	chr11:47852331	chr11:48096782~48096858:+
LAML	cis	rs7944735	0.817	rs6485784	ENSG00000263693.1	MIR3161	4.75	1.01e-05	0.0198	0.39	0.49	Intraocular pressure;	chr11:47810708	chr11:48096782~48096858:+
LAML	cis	rs7944735	0.817	rs2305983	ENSG00000263693.1	MIR3161	4.75	1.01e-05	0.0198	0.39	0.49	Intraocular pressure;	chr11:47837203	chr11:48096782~48096858:+
LAML	cis	rs7944735	0.817	rs7942031	ENSG00000263693.1	MIR3161	4.75	1.01e-05	0.0198	0.39	0.49	Intraocular pressure;	chr11:47846922	chr11:48096782~48096858:+
LAML	cis	rs6951245	1	rs28399710	ENSG00000229043.2	AC091729.9	-4.75	1.01e-05	0.0198	-0.83	-0.49	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1030995	chr7:1160374~1165267:+
LAML	cis	rs282544	1	rs32396	ENSG00000271455.1	RP11-269M20.2	4.75	1.02e-05	0.0198	0.5	0.49	Myopia (pathological);	chr5:50810605	chr5:50603229~50603511:+
LAML	cis	rs282544	1	rs27964	ENSG00000271455.1	RP11-269M20.2	4.75	1.02e-05	0.0198	0.5	0.49	Myopia (pathological);	chr5:50856633	chr5:50603229~50603511:+
LAML	cis	rs282544	0.686	rs282547	ENSG00000271455.1	RP11-269M20.2	-4.75	1.02e-05	0.0198	-0.5	-0.49	Myopia (pathological);	chr5:50761895	chr5:50603229~50603511:+
LAML	cis	rs4713118	0.662	rs149901	ENSG00000182477.5	OR2B8P	4.75	1.02e-05	0.0198	0.71	0.49	Parkinson's disease;	chr6:27997725	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs464312	ENSG00000182477.5	OR2B8P	4.75	1.02e-05	0.0198	0.71	0.49	Parkinson's disease;	chr6:27999813	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.662	rs469228	ENSG00000182477.5	OR2B8P	4.75	1.02e-05	0.0198	0.71	0.49	Parkinson's disease;	chr6:28002926	chr6:28053228~28054165:-
LAML	cis	rs4713118	0.54	rs469227	ENSG00000182477.5	OR2B8P	4.75	1.02e-05	0.0198	0.71	0.49	Parkinson's disease;	chr6:28002927	chr6:28053228~28054165:-
LAML	cis	rs8031584	0.678	rs3122	ENSG00000259845.1	HERC2P10	-4.75	1.02e-05	0.0198	-0.54	-0.49	Huntington's disease progression;	chr15:30878087	chr15:30815271~30844153:+
LAML	cis	rs2383876	0.55	rs10102747	ENSG00000253302.1	STAU2-AS1	-4.75	1.02e-05	0.0198	-0.61	-0.49	Corneal curvature;	chr8:73164127	chr8:73420004~73441526:+
LAML	cis	rs67311347	0.911	rs6775936	ENSG00000230274.1	PGAM1P3	4.75	1.02e-05	0.0199	0.61	0.49	Renal cell carcinoma;	chr3:40335908	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.911	rs6776044	ENSG00000230274.1	PGAM1P3	4.75	1.02e-05	0.0199	0.61	0.49	Renal cell carcinoma;	chr3:40336012	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.955	rs9821036	ENSG00000230274.1	PGAM1P3	4.75	1.02e-05	0.0199	0.61	0.49	Renal cell carcinoma;	chr3:40337516	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.869	rs9832311	ENSG00000230274.1	PGAM1P3	4.75	1.02e-05	0.0199	0.61	0.49	Renal cell carcinoma;	chr3:40339831	chr3:40322715~40323279:-
LAML	cis	rs8081395	0.603	rs1292047	ENSG00000266960.1	FAM106DP	4.75	1.02e-05	0.0199	0.6	0.49	White blood cell count;	chr17:59877805	chr17:60173322~60173822:+
LAML	cis	rs8081395	0.627	rs12952730	ENSG00000266960.1	FAM106DP	4.75	1.02e-05	0.0199	0.6	0.49	White blood cell count;	chr17:59901475	chr17:60173322~60173822:+
LAML	cis	rs8081395	0.627	rs180536	ENSG00000266960.1	FAM106DP	4.75	1.02e-05	0.0199	0.6	0.49	White blood cell count;	chr17:59919445	chr17:60173322~60173822:+
LAML	cis	rs8081395	0.58	rs180515	ENSG00000266960.1	FAM106DP	4.75	1.02e-05	0.0199	0.6	0.49	White blood cell count;	chr17:59946914	chr17:60173322~60173822:+
LAML	cis	rs561341	0.7	rs6505266	ENSG00000266379.5	RP11-640N20.8	4.75	1.02e-05	0.0199	0.67	0.49	Hip circumference adjusted for BMI;	chr17:31898794	chr17:32088160~32094933:-
LAML	cis	rs561341	0.7	rs79272796	ENSG00000266379.5	RP11-640N20.8	4.75	1.02e-05	0.0199	0.67	0.49	Hip circumference adjusted for BMI;	chr17:31899955	chr17:32088160~32094933:-
LAML	cis	rs1007738	0.597	rs10838635	ENSG00000271350.1	CTD-2384B9.1	-4.75	1.02e-05	0.0199	-0.59	-0.49	Bone mineral density (hip);	chr11:46923676	chr11:47041027~47041945:-
LAML	cis	rs11038871	0.962	rs12273290	ENSG00000271350.1	CTD-2384B9.1	4.75	1.02e-05	0.0199	0.52	0.49	Immunoglobulin A;	chr11:46340428	chr11:47041027~47041945:-
LAML	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-4.75	1.03e-05	0.0199	-0.62	-0.49	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
LAML	cis	rs3758911	0.929	rs10749895	ENSG00000261098.1	RP11-819C21.1	-4.74	1.03e-05	0.02	-0.48	-0.49	Coronary artery disease;	chr11:107310855	chr11:107312132~107316271:-
LAML	cis	rs950169	0.922	rs11639244	ENSG00000259728.4	LINC00933	4.74	1.03e-05	0.02	0.7	0.49	Schizophrenia;	chr15:84163898	chr15:84570649~84580175:+
LAML	cis	rs950169	0.845	rs4106951	ENSG00000259728.4	LINC00933	4.74	1.03e-05	0.02	0.7	0.49	Schizophrenia;	chr15:84164642	chr15:84570649~84580175:+
LAML	cis	rs950169	0.922	rs6603022	ENSG00000259728.4	LINC00933	-4.74	1.03e-05	0.02	-0.7	-0.49	Schizophrenia;	chr15:84161418	chr15:84570649~84580175:+
LAML	cis	rs950169	0.922	rs4842940	ENSG00000259728.4	LINC00933	-4.74	1.03e-05	0.02	-0.7	-0.49	Schizophrenia;	chr15:84162473	chr15:84570649~84580175:+
LAML	cis	rs950169	0.922	rs4842941	ENSG00000259728.4	LINC00933	-4.74	1.03e-05	0.02	-0.7	-0.49	Schizophrenia;	chr15:84162560	chr15:84570649~84580175:+
LAML	cis	rs950169	0.922	rs12911223	ENSG00000259728.4	LINC00933	-4.74	1.03e-05	0.02	-0.7	-0.49	Schizophrenia;	chr15:84162919	chr15:84570649~84580175:+
LAML	cis	rs76917914	0.954	rs3739672	ENSG00000236896.1	RP11-535C21.3	4.74	1.03e-05	0.02	0.47	0.49	Immature fraction of reticulocytes;	chr9:97983620	chr9:97986551~97987656:-
LAML	cis	rs6565180	0.525	rs1132812	ENSG00000273724.1	RP11-347C12.12	4.74	1.03e-05	0.02	0.49	0.49	Tonsillectomy;	chr16:30186830	chr16:30336400~30343336:+
LAML	cis	rs4774565	0.8	rs34174311	ENSG00000244879.4	GABPB1-AS1	-4.74	1.03e-05	0.02	-0.55	-0.49	Breast cancer;	chr15:50381084	chr15:50354959~50372202:+
LAML	cis	rs2439831	0.85	rs12702	ENSG00000275601.1	AC011330.13	4.74	1.03e-05	0.0201	0.86	0.49	Lung cancer in ever smokers;	chr15:43801729	chr15:43642389~43643023:-
LAML	cis	rs9322193	1	rs9322193	ENSG00000216906.2	RP11-350J20.9	4.74	1.03e-05	0.0201	0.65	0.49	Lung cancer;	chr6:149598007	chr6:149904243~149906418:+
LAML	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	4.74	1.04e-05	0.0201	0.5	0.49	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
LAML	cis	rs709400	0.628	rs1951392	ENSG00000258851.1	RP11-894P9.2	-4.74	1.04e-05	0.0201	-0.62	-0.49	Body mass index;	chr14:103387030	chr14:103553421~103561877:+
LAML	cis	rs11039798	1	rs6485908	ENSG00000263693.1	MIR3161	-4.74	1.04e-05	0.0201	-0.48	-0.49	Axial length;	chr11:48630646	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs12281162	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48628939	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs11039904	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48661045	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs8188963	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48664141	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.92	rs9667596	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48669641	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.764	rs11039929	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48681737	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.841	rs11500573	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48692348	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.92	rs11500574	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48692434	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.92	rs11039940	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48694764	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.614	rs11039954	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48720266	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.688	rs8188953	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48727649	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs12225599	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48734316	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs11039978	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48738685	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs115429994	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48739631	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.764	rs7294013	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48740864	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.92	rs11040015	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48761578	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.614	rs2174703	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48766690	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.777	rs2202454	ENSG00000263693.1	MIR3161	4.74	1.04e-05	0.0201	0.48	0.49	Axial length;	chr11:48989457	chr11:48096782~48096858:+
LAML	cis	rs916888	0.773	rs199457	ENSG00000280985.1	AC217773.1	4.74	1.04e-05	0.0201	0.68	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:46172089~46172239:-
LAML	cis	rs916888	0.687	rs199456	ENSG00000280985.1	AC217773.1	4.74	1.04e-05	0.0201	0.68	0.49	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:46172089~46172239:-
LAML	cis	rs9457247	0.508	rs9457268	ENSG00000265828.1	MIR3939	-4.74	1.04e-05	0.0201	-0.73	-0.49	Crohn's disease;	chr6:167090151	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.508	rs6902119	ENSG00000265828.1	MIR3939	-4.74	1.04e-05	0.0201	-0.73	-0.49	Crohn's disease;	chr6:167092303	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.508	rs6918286	ENSG00000265828.1	MIR3939	-4.74	1.04e-05	0.0201	-0.73	-0.49	Crohn's disease;	chr6:167092341	chr6:166997807~166997912:-
LAML	cis	rs9380516	0.524	rs749523	ENSG00000264878.1	Z85986.1	4.74	1.04e-05	0.0201	0.54	0.49	Hepatitis C induced liver fibrosis;	chr6:35521998	chr6:36510517~36510598:-
LAML	cis	rs4713118	0.513	rs149959	ENSG00000220721.1	OR1F12	4.74	1.04e-05	0.0202	0.54	0.49	Parkinson's disease;	chr6:28046076	chr6:28073316~28074233:+
LAML	cis	rs9457247	0.905	rs444210	ENSG00000231654.1	RPS6KA2-AS1	-4.74	1.05e-05	0.0202	-0.48	-0.49	Crohn's disease;	chr6:166976754	chr6:166903698~166904835:+
LAML	cis	rs709400	0.628	rs12889639	ENSG00000258851.1	RP11-894P9.2	4.74	1.05e-05	0.0203	0.59	0.49	Body mass index;	chr14:103393869	chr14:103553421~103561877:+
LAML	cis	rs853679	0.607	rs66886492	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28121953	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs35345226	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28123802	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs35749575	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28147040	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs72846780	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28151277	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13205911	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28156336	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13197176	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28161454	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13201308	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28162311	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs34765154	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28162672	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs34505829	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28165461	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs35098436	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28166443	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs72846794	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28169721	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13217984	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28171932	chr6:28053228~28054165:-
LAML	cis	rs853679	0.556	rs67297533	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28173475	chr6:28053228~28054165:-
LAML	cis	rs853679	0.505	rs35781323	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28177054	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs13195291	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28201463	chr6:28053228~28054165:-
LAML	cis	rs853679	0.556	rs13197633	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28206979	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs35001169	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28219854	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs35656932	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28223510	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13204012	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28233753	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13205211	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28235278	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13208096	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28257533	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13207345	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28297795	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs72854513	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28298177	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs33932084	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28301047	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs56189111	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28304196	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs35072899	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28313764	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs56075693	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28322551	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs34218844	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28322870	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs35030260	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28337731	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13217619	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28338894	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs35016036	ENSG00000182477.5	OR2B8P	4.74	1.05e-05	0.0203	0.92	0.49	Depression;	chr6:28347103	chr6:28053228~28054165:-
LAML	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	4.74	1.05e-05	0.0203	0.68	0.49	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
LAML	cis	rs6558530	0.799	rs62477060	ENSG00000253982.1	CTD-2336O2.1	4.74	1.05e-05	0.0203	0.68	0.49	Systolic blood pressure;	chr8:1758332	chr8:1761990~1764502:-
LAML	cis	rs2404602	0.735	rs1607015	ENSG00000259422.1	RP11-593F23.1	-4.74	1.05e-05	0.0203	-0.56	-0.49	Blood metabolite levels;	chr15:76410088	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.735	rs12906143	ENSG00000259422.1	RP11-593F23.1	-4.74	1.05e-05	0.0203	-0.56	-0.49	Blood metabolite levels;	chr15:76417182	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.735	rs11632222	ENSG00000259422.1	RP11-593F23.1	-4.74	1.05e-05	0.0203	-0.56	-0.49	Blood metabolite levels;	chr15:76420586	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.735	rs1607017	ENSG00000259422.1	RP11-593F23.1	-4.74	1.05e-05	0.0203	-0.56	-0.49	Blood metabolite levels;	chr15:76434124	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.735	rs2436996	ENSG00000259422.1	RP11-593F23.1	-4.74	1.05e-05	0.0203	-0.56	-0.49	Blood metabolite levels;	chr15:76525079	chr15:76174891~76181486:-
LAML	cis	rs7944735	0.671	rs1228044	ENSG00000263693.1	MIR3161	4.74	1.05e-05	0.0203	0.35	0.49	Intraocular pressure;	chr11:47989628	chr11:48096782~48096858:+
LAML	cis	rs763121	1	rs138457	ENSG00000230912.1	RP3-508I15.10	4.74	1.05e-05	0.0203	0.39	0.49	Menopause (age at onset);	chr22:38502046	chr22:38666508~38668750:-
LAML	cis	rs763121	1	rs1946990	ENSG00000230912.1	RP3-508I15.10	4.74	1.05e-05	0.0203	0.39	0.49	Menopause (age at onset);	chr22:38516766	chr22:38666508~38668750:-
LAML	cis	rs11096990	1	rs11096990	ENSG00000206675.1	RNU6-32P	4.74	1.06e-05	0.0203	0.51	0.49	Cognitive function;	chr4:39285329	chr4:39297605~39297711:-
LAML	cis	rs4713118	0.614	rs9380007	ENSG00000216915.2	RP1-97D16.1	-4.74	1.06e-05	0.0203	-0.55	-0.49	Parkinson's disease;	chr6:27692729	chr6:27737000~27738494:-
LAML	cis	rs1577917	1	rs11758849	ENSG00000203875.9	SNHG5	-4.74	1.06e-05	0.0204	-0.63	-0.49	Response to antipsychotic treatment;	chr6:85998544	chr6:85660950~85678736:-
LAML	cis	rs7829975	0.593	rs2979241	ENSG00000253893.2	FAM85B	-4.74	1.06e-05	0.0204	-0.59	-0.49	Mood instability;	chr8:8445843	chr8:8167819~8226614:-
LAML	cis	rs67311347	1	rs6762997	ENSG00000230274.1	PGAM1P3	4.74	1.06e-05	0.0204	0.61	0.49	Renal cell carcinoma;	chr3:40436660	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs977652	ENSG00000230274.1	PGAM1P3	4.74	1.06e-05	0.0204	0.61	0.49	Renal cell carcinoma;	chr3:40437678	chr3:40322715~40323279:-
LAML	cis	rs4604234	0.803	rs73463518	ENSG00000272129.1	RP11-250B2.6	-4.74	1.06e-05	0.0204	-0.79	-0.49	Cancer;	chr6:80266300	chr6:80355424~80356859:+
LAML	cis	rs62070183	0.873	rs80212824	ENSG00000266599.1	RP11-466A19.3	4.74	1.06e-05	0.0205	0.8	0.49	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32703440	chr17:32518953~32531492:+
LAML	cis	rs2980439	0.818	rs2948300	ENSG00000268955.2	RP11-556O5.6	-4.74	1.07e-05	0.0205	-0.61	-0.49	Neuroticism;	chr8:8248986	chr8:8188535~8189195:-
LAML	cis	rs561341	0.709	rs11542477	ENSG00000266379.5	RP11-640N20.8	-4.74	1.07e-05	0.0205	-0.88	-0.49	Hip circumference adjusted for BMI;	chr17:31858873	chr17:32088160~32094933:-
LAML	cis	rs4834770	0.718	rs4833618	ENSG00000248280.1	RP11-33B1.2	-4.73	1.07e-05	0.0205	-0.63	-0.49	Blood protein levels;	chr4:119388345	chr4:119440561~119450157:-
LAML	cis	rs709400	0.628	rs10150072	ENSG00000258851.1	RP11-894P9.2	-4.73	1.07e-05	0.0205	-0.59	-0.49	Body mass index;	chr14:103511268	chr14:103553421~103561877:+
LAML	cis	rs709400	0.633	rs8019578	ENSG00000258851.1	RP11-894P9.2	-4.73	1.07e-05	0.0205	-0.59	-0.49	Body mass index;	chr14:103511387	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs10133035	ENSG00000258851.1	RP11-894P9.2	-4.73	1.07e-05	0.0205	-0.59	-0.49	Body mass index;	chr14:103512790	chr14:103553421~103561877:+
LAML	cis	rs2019137	1	rs2019137	ENSG00000189223.12	PAX8-AS1	4.73	1.07e-05	0.0206	0.68	0.49	Lymphocyte counts;	chr2:113216055	chr2:113211522~113276581:+
LAML	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-4.73	1.07e-05	0.0206	-0.52	-0.49	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
LAML	cis	rs11039798	0.764	rs12277213	ENSG00000263693.1	MIR3161	4.73	1.07e-05	0.0206	0.48	0.49	Axial length;	chr11:48760624	chr11:48096782~48096858:+
LAML	cis	rs853679	0.527	rs9461443	ENSG00000187763.3	OR2B7P	4.73	1.07e-05	0.0206	0.68	0.49	Depression;	chr6:28226851	chr6:28046434~28047367:+
LAML	cis	rs853679	0.55	rs34477097	ENSG00000187763.3	OR2B7P	4.73	1.07e-05	0.0206	0.68	0.49	Depression;	chr6:28229408	chr6:28046434~28047367:+
LAML	cis	rs3131082	1	rs3131082	ENSG00000187763.3	OR2B7P	4.73	1.07e-05	0.0206	0.94	0.49	Tuberculosis;	chr6:29015497	chr6:28046434~28047367:+
LAML	cis	rs67383717	0.713	rs1369156	ENSG00000175611.10	LINC00476	-4.73	1.07e-05	0.0206	-0.48	-0.49	Parkinson's disease (pesticide exposure interaction);	chr9:95794612	chr9:95759231~95875977:-
LAML	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-4.73	1.08e-05	0.0207	-0.6	-0.49	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
LAML	cis	rs763121	0.853	rs1056610	ENSG00000230912.1	RP3-508I15.10	4.73	1.08e-05	0.0207	0.38	0.49	Menopause (age at onset);	chr22:38684073	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs10135	ENSG00000230912.1	RP3-508I15.10	4.73	1.08e-05	0.0207	0.38	0.49	Menopause (age at onset);	chr22:38686169	chr22:38666508~38668750:-
LAML	cis	rs4604234	0.803	rs79048064	ENSG00000272129.1	RP11-250B2.6	-4.73	1.08e-05	0.0207	-0.79	-0.49	Cancer;	chr6:80267381	chr6:80355424~80356859:+
LAML	cis	rs4604234	0.803	rs76568328	ENSG00000272129.1	RP11-250B2.6	-4.73	1.08e-05	0.0207	-0.79	-0.49	Cancer;	chr6:80267384	chr6:80355424~80356859:+
LAML	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	4.73	1.08e-05	0.0208	0.63	0.49	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
LAML	cis	rs709400	0.691	rs12888077	ENSG00000258851.1	RP11-894P9.2	4.73	1.08e-05	0.0208	0.59	0.49	Body mass index;	chr14:103406216	chr14:103553421~103561877:+
LAML	cis	rs2407156	0.861	rs17790303	ENSG00000214857.4	SHFM1P1	4.73	1.08e-05	0.0208	0.78	0.49	Breast cancer;	chr5:82394223	chr5:81892490~81892721:+
LAML	cis	rs935334	0.932	rs8008819	ENSG00000280078.1	RP11-361H10.5	-4.73	1.09e-05	0.0208	-0.77	-0.49	Blood pressure;	chr14:76155693	chr14:76279173~76283103:+
LAML	cis	rs7587476	0.505	rs777323	ENSG00000229267.2	AC072062.1	4.73	1.09e-05	0.0208	0.55	0.49	Neuroblastoma;	chr2:214873761	chr2:214810229~214963274:+
LAML	cis	rs3768716	0.5	rs777329	ENSG00000229267.2	AC072062.1	4.73	1.09e-05	0.0208	0.55	0.49	Neuroblastoma;	chr2:214877871	chr2:214810229~214963274:+
LAML	cis	rs12802244	1	rs12802244	ENSG00000280615.1	Y_RNA	-4.73	1.09e-05	0.0208	-0.64	-0.49	Neuroticism;	chr11:47911114	chr11:47614898~47614994:-
LAML	cis	rs7301826	1	rs10773819	ENSG00000256250.1	RP11-989F5.1	-4.73	1.09e-05	0.0209	-0.6	-0.49	Plasma plasminogen activator levels;	chr12:130794477	chr12:130810606~130812438:+
LAML	cis	rs2404602	0.735	rs4886798	ENSG00000259422.1	RP11-593F23.1	4.73	1.09e-05	0.021	0.57	0.49	Blood metabolite levels;	chr15:76380885	chr15:76174891~76181486:-
LAML	cis	rs763121	0.962	rs6001159	ENSG00000230912.1	RP3-508I15.10	-4.73	1.09e-05	0.021	-0.39	-0.49	Menopause (age at onset);	chr22:38570482	chr22:38666508~38668750:-
LAML	cis	rs9322193	0.607	rs7764677	ENSG00000216906.2	RP11-350J20.9	4.73	1.1e-05	0.021	0.7	0.49	Lung cancer;	chr6:149906197	chr6:149904243~149906418:+
LAML	cis	rs709400	0.663	rs7152202	ENSG00000258851.1	RP11-894P9.2	-4.73	1.1e-05	0.021	-0.58	-0.49	Body mass index;	chr14:103420420	chr14:103553421~103561877:+
LAML	cis	rs709400	0.52	rs28583452	ENSG00000258851.1	RP11-894P9.2	-4.73	1.1e-05	0.021	-0.58	-0.49	Body mass index;	chr14:103472327	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs10141388	ENSG00000258851.1	RP11-894P9.2	-4.73	1.1e-05	0.021	-0.58	-0.49	Body mass index;	chr14:103473342	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs11628969	ENSG00000258851.1	RP11-894P9.2	-4.73	1.1e-05	0.021	-0.58	-0.49	Body mass index;	chr14:103474574	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs8015918	ENSG00000258851.1	RP11-894P9.2	-4.73	1.1e-05	0.021	-0.58	-0.49	Body mass index;	chr14:103476654	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs3742458	ENSG00000258851.1	RP11-894P9.2	-4.73	1.1e-05	0.021	-0.58	-0.49	Body mass index;	chr14:103484031	chr14:103553421~103561877:+
LAML	cis	rs709400	0.633	rs8013101	ENSG00000258851.1	RP11-894P9.2	-4.73	1.1e-05	0.021	-0.58	-0.49	Body mass index;	chr14:103485435	chr14:103553421~103561877:+
LAML	cis	rs7301826	0.571	rs4759788	ENSG00000256299.1	RP11-989F5.3	-4.73	1.1e-05	0.021	-0.64	-0.49	Plasma plasminogen activator levels;	chr12:130811769	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.61	rs9668291	ENSG00000256299.1	RP11-989F5.3	-4.73	1.1e-05	0.021	-0.64	-0.49	Plasma plasminogen activator levels;	chr12:130812363	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs4759794	ENSG00000256299.1	RP11-989F5.3	-4.73	1.1e-05	0.021	-0.64	-0.49	Plasma plasminogen activator levels;	chr12:130812803	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs10744485	ENSG00000256299.1	RP11-989F5.3	-4.73	1.1e-05	0.021	-0.64	-0.49	Plasma plasminogen activator levels;	chr12:130814005	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs10773824	ENSG00000256299.1	RP11-989F5.3	-4.73	1.1e-05	0.021	-0.64	-0.49	Plasma plasminogen activator levels;	chr12:130814306	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.651	rs10848209	ENSG00000256299.1	RP11-989F5.3	-4.73	1.1e-05	0.021	-0.64	-0.49	Plasma plasminogen activator levels;	chr12:130826727	chr12:130810821~130812622:-
LAML	cis	rs76917914	1	rs7850685	ENSG00000236896.1	RP11-535C21.3	-4.73	1.1e-05	0.0211	-0.47	-0.49	Immature fraction of reticulocytes;	chr9:98001608	chr9:97986551~97987656:-
LAML	cis	rs785830	0.644	rs1184590	ENSG00000235880.1	RP11-59O6.3	4.73	1.1e-05	0.0211	0.43	0.49	Platelet distribution width;	chr9:262298	chr9:267966~273002:-
LAML	cis	rs7426056	0.671	rs3116496	ENSG00000224791.1	KRT18P39	4.73	1.1e-05	0.0211	0.72	0.49	Primary sclerosing cholangitis;	chr2:203729789	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs45620941	ENSG00000224791.1	KRT18P39	4.73	1.1e-05	0.0211	0.72	0.49	Primary sclerosing cholangitis;	chr2:203735734	chr2:203764295~203765593:-
LAML	cis	rs5769707	0.839	rs73176988	ENSG00000213279.2	RP1-29C18.9	-4.73	1.1e-05	0.0211	-0.55	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49596001	chr22:49572264~49575426:-
LAML	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	4.73	1.1e-05	0.0211	0.7	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
LAML	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	4.73	1.1e-05	0.0211	0.7	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
LAML	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	4.73	1.1e-05	0.0211	0.7	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
LAML	cis	rs7131987	0.903	rs918873	ENSG00000275278.1	RP11-946L16.2	4.73	1.1e-05	0.0211	0.6	0.49	QT interval;	chr12:29237568	chr12:29156448~29156991:-
LAML	cis	rs9322193	0.886	rs4870055	ENSG00000217733.2	CCT7P1	4.73	1.1e-05	0.0211	0.69	0.49	Lung cancer;	chr6:149848433	chr6:149879962~149881572:+
LAML	cis	rs9322193	0.923	rs7769101	ENSG00000217733.2	CCT7P1	4.73	1.1e-05	0.0211	0.69	0.49	Lung cancer;	chr6:149848768	chr6:149879962~149881572:+
LAML	cis	rs367615	0.537	rs1965670	ENSG00000249476.1	CTD-2587M2.1	-4.73	1.11e-05	0.0212	-0.58	-0.49	Colorectal cancer (SNP x SNP interaction);	chr5:109314097	chr5:109237120~109326369:-
LAML	cis	rs7707921	0.881	rs4391141	ENSG00000214857.4	SHFM1P1	4.73	1.11e-05	0.0212	0.69	0.49	Breast cancer;	chr5:81967703	chr5:81892490~81892721:+
LAML	cis	rs8037137	0.915	rs77554484	ENSG00000258725.1	PRC1-AS1	-4.73	1.11e-05	0.0212	-0.9	-0.49	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90965985	chr15:90966345~90988624:+
LAML	cis	rs597539	0.521	rs7943745	ENSG00000250508.1	RP11-757G1.6	4.72	1.11e-05	0.0212	0.46	0.49	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68838360	chr11:68870664~68874542:+
LAML	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	4.72	1.11e-05	0.0212	0.6	0.49	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
LAML	cis	rs7829975	0.51	rs2921073	ENSG00000268955.2	RP11-556O5.6	-4.72	1.11e-05	0.0212	-0.57	-0.49	Mood instability;	chr8:8450133	chr8:8188535~8189195:-
LAML	cis	rs7829975	0.51	rs2979160	ENSG00000268955.2	RP11-556O5.6	-4.72	1.11e-05	0.0212	-0.57	-0.49	Mood instability;	chr8:8450156	chr8:8188535~8189195:-
LAML	cis	rs10463316	0.894	rs10062856	ENSG00000260581.1	CTB-113P19.4	4.72	1.11e-05	0.0212	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151388635	chr5:151652275~151655449:+
LAML	cis	rs9355610	0.892	rs2247314	ENSG00000231654.1	RPS6KA2-AS1	4.72	1.11e-05	0.0213	0.47	0.49	Graves' disease;	chr6:166956742	chr6:166903698~166904835:+
LAML	cis	rs911555	0.57	rs752624	ENSG00000252469.1	RNU7-160P	-4.72	1.11e-05	0.0213	-0.57	-0.49	Intelligence (multi-trait analysis);	chr14:103554117	chr14:103550345~103550406:+
LAML	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-4.72	1.12e-05	0.0213	-0.54	-0.49	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
LAML	cis	rs9322193	1	rs9377228	ENSG00000216906.2	RP11-350J20.9	4.72	1.12e-05	0.0213	0.67	0.49	Lung cancer;	chr6:149600862	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.924	rs9498382	ENSG00000216906.2	RP11-350J20.9	4.72	1.12e-05	0.0213	0.67	0.49	Lung cancer;	chr6:149610982	chr6:149904243~149906418:+
LAML	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-4.72	1.12e-05	0.0214	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-4.72	1.12e-05	0.0214	-0.65	-0.49	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
LAML	cis	rs875971	0.522	rs4502988	ENSG00000224316.1	RP11-479O9.2	4.72	1.12e-05	0.0214	0.53	0.49	Aortic root size;	chr7:65832759	chr7:65773620~65802067:+
LAML	cis	rs67311347	0.956	rs7640228	ENSG00000230274.1	PGAM1P3	-4.72	1.12e-05	0.0214	-0.64	-0.49	Renal cell carcinoma;	chr3:40474699	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs7633809	ENSG00000230274.1	PGAM1P3	-4.72	1.12e-05	0.0214	-0.64	-0.49	Renal cell carcinoma;	chr3:40476246	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs73080137	ENSG00000230274.1	PGAM1P3	4.72	1.12e-05	0.0214	0.64	0.49	Renal cell carcinoma;	chr3:40474921	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.956	rs4974029	ENSG00000230274.1	PGAM1P3	4.72	1.12e-05	0.0214	0.64	0.49	Renal cell carcinoma;	chr3:40479827	chr3:40322715~40323279:-
LAML	cis	rs7165170	0.766	rs78609837	ENSG00000259314.1	CTD-3065B20.3	4.72	1.13e-05	0.0214	0.55	0.49	Crohn's disease;Inflammatory bowel disease;	chr15:90677611	chr15:90604225~90614558:-
LAML	cis	rs67311347	1	rs9874006	ENSG00000230274.1	PGAM1P3	4.72	1.13e-05	0.0214	0.6	0.49	Renal cell carcinoma;	chr3:40430105	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs12638199	ENSG00000230274.1	PGAM1P3	4.72	1.13e-05	0.0214	0.6	0.49	Renal cell carcinoma;	chr3:40433794	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs34762643	ENSG00000230274.1	PGAM1P3	4.72	1.13e-05	0.0214	0.6	0.49	Renal cell carcinoma;	chr3:40433942	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9841335	ENSG00000230274.1	PGAM1P3	4.72	1.13e-05	0.0214	0.6	0.49	Renal cell carcinoma;	chr3:40434367	chr3:40322715~40323279:-
LAML	cis	rs5769707	0.632	rs1476037	ENSG00000280224.1	CTA-722E9.1	-4.72	1.13e-05	0.0215	-0.7	-0.49	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49500568~49501585:+
LAML	cis	rs785830	0.521	rs553489	ENSG00000235880.1	RP11-59O6.3	4.72	1.13e-05	0.0215	0.4	0.49	Platelet distribution width;	chr9:259990	chr9:267966~273002:-
LAML	cis	rs67311347	1	rs1454497	ENSG00000230274.1	PGAM1P3	-4.72	1.13e-05	0.0215	-0.63	-0.49	Renal cell carcinoma;	chr3:40454835	chr3:40322715~40323279:-
LAML	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	4.72	1.13e-05	0.0215	0.51	0.49	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
LAML	cis	rs9322193	1	rs9377229	ENSG00000216906.2	RP11-350J20.9	4.72	1.13e-05	0.0215	0.64	0.49	Lung cancer;	chr6:149607655	chr6:149904243~149906418:+
LAML	cis	rs716804	0.633	rs7947588	ENSG00000254719.1	RP11-351I24.3	-4.72	1.13e-05	0.0216	-0.59	-0.49	Neuroticism;	chr11:10072858	chr11:10272052~10272259:-
LAML	cis	rs7555523	0.832	rs7524755	ENSG00000224358.1	RP11-466F5.8	-4.72	1.13e-05	0.0216	-0.76	-0.49	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165725660	chr1:165768929~165775176:+
LAML	cis	rs2015599	0.549	rs10771512	ENSG00000273680.1	RP11-996F15.6	4.72	1.13e-05	0.0216	0.47	0.49	Platelet count;Mean platelet volume;	chr12:29287303	chr12:29332733~29333383:-
LAML	cis	rs2015599	0.549	rs9738165	ENSG00000273680.1	RP11-996F15.6	4.72	1.13e-05	0.0216	0.47	0.49	Platelet count;Mean platelet volume;	chr12:29290263	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.507	rs3782507	ENSG00000273680.1	RP11-996F15.6	4.72	1.13e-05	0.0216	0.47	0.49	QT interval;	chr12:29292597	chr12:29332733~29333383:-
LAML	cis	rs11577318	0.579	rs12131370	ENSG00000225854.2	RP11-569G9.7	-4.72	1.14e-05	0.0216	-0.65	-0.49	Granulocyte percentage of myeloid white cells;	chr1:26371939	chr1:26326688~26327033:+
LAML	cis	rs11577318	0.528	rs11247935	ENSG00000225854.2	RP11-569G9.7	-4.72	1.14e-05	0.0216	-0.65	-0.49	Granulocyte percentage of myeloid white cells;	chr1:26372131	chr1:26326688~26327033:+
LAML	cis	rs950169	0.922	rs8037078	ENSG00000259728.4	LINC00933	-4.72	1.14e-05	0.0216	-0.69	-0.49	Schizophrenia;	chr15:84150119	chr15:84570649~84580175:+
LAML	cis	rs950169	0.922	rs4586394	ENSG00000259728.4	LINC00933	-4.72	1.14e-05	0.0216	-0.69	-0.49	Schizophrenia;	chr15:84153633	chr15:84570649~84580175:+
LAML	cis	rs9916302	0.851	rs677888	ENSG00000223091.1	RNU6-981P	4.72	1.14e-05	0.0216	0.6	0.49	Glomerular filtration rate (creatinine);	chr17:39304765	chr17:39482486~39482590:-
LAML	cis	rs1453414	1	rs1453414	ENSG00000232381.1	OR52U1P	4.72	1.14e-05	0.0216	0.6	0.49	Oral cavity and pharyngeal cancer;Oropharynx cancer;	chr11:5807854	chr11:5719290~5720212:+
LAML	cis	rs10463316	0.894	rs11167542	ENSG00000260581.1	CTB-113P19.4	-4.72	1.14e-05	0.0216	-0.44	-0.49	Metabolite levels (Pyroglutamine);	chr5:151380721	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.862	rs7720582	ENSG00000260581.1	CTB-113P19.4	-4.72	1.14e-05	0.0216	-0.44	-0.49	Metabolite levels (Pyroglutamine);	chr5:151396941	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6880137	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151375671	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs3846712	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151380252	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7719630	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151381400	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6579863	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151382385	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6579864	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151382620	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7729438	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151382636	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7729216	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151382716	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6579865	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151382774	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6579866	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151382963	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6891272	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151383281	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.744	rs6579869	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151384060	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs10476769	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151384409	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs10476980	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151384596	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7723016	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151385267	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7703283	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151385343	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7723379	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151385464	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs13361298	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151385988	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.855	rs13359064	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151386014	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs13361316	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151386032	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7708499	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151386345	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7712569	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151386528	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs4099168	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151386906	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs4099170	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151387022	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs4099171	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151387062	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7727770	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151387555	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7727926	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151387655	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7710277	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151387844	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs10042030	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151388467	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs3905511	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151388643	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.747	rs10077700	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151388763	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.862	rs10062928	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151388794	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.862	rs10071166	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151389234	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.817	rs6895187	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151396348	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.862	rs59390562	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151396531	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.862	rs7700650	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151396912	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.862	rs11740475	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0216	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151398436	chr5:151652275~151655449:+
LAML	cis	rs947474	0.517	rs11258303	ENSG00000213994.3	RP11-414H17.5	-4.72	1.14e-05	0.0217	-0.51	-0.49	Rheumatoid arthritis;Type 1 diabetes;	chr10:6363572	chr10:6197612~6202693:-
LAML	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	4.72	1.14e-05	0.0217	0.59	0.49	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	4.72	1.14e-05	0.0217	0.59	0.49	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	4.72	1.14e-05	0.0217	0.59	0.49	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	4.72	1.14e-05	0.0217	0.59	0.49	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
LAML	cis	rs10463316	0.817	rs13355052	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0217	0.43	0.49	Metabolite levels (Pyroglutamine);	chr5:151422442	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.817	rs13359941	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0217	0.43	0.49	Metabolite levels (Pyroglutamine);	chr5:151422557	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.817	rs6877498	ENSG00000260581.1	CTB-113P19.4	4.72	1.14e-05	0.0217	0.43	0.49	Metabolite levels (Pyroglutamine);	chr5:151423315	chr5:151652275~151655449:+
LAML	cis	rs7944735	0.671	rs7106731	ENSG00000263693.1	MIR3161	4.72	1.15e-05	0.0217	0.34	0.49	Intraocular pressure;	chr11:47981840	chr11:48096782~48096858:+
LAML	cis	rs2564921	0.513	rs12638195	ENSG00000280417.1	RP11-5O17.1	-4.71	1.15e-05	0.0218	-0.66	-0.49	Height;	chr3:52842623	chr3:53046166~53048122:+
LAML	cis	rs2980439	0.846	rs2980437	ENSG00000268955.2	RP11-556O5.6	4.71	1.15e-05	0.0218	0.6	0.49	Neuroticism;	chr8:8237241	chr8:8188535~8189195:-
LAML	cis	rs2980439	0.818	rs2945249	ENSG00000268955.2	RP11-556O5.6	-4.71	1.15e-05	0.0218	-0.6	-0.49	Neuroticism;	chr8:8237204	chr8:8188535~8189195:-
LAML	cis	rs12052801	0.868	rs4671204	ENSG00000221443.1	AC017083.1	4.71	1.15e-05	0.0218	0.56	0.49	Schizophrenia;	chr2:68127832	chr2:68273104~68273206:+
LAML	cis	rs8031584	0.56	rs7171208	ENSG00000260382.1	RP11-540B6.2	-4.71	1.15e-05	0.0219	-0.48	-0.49	Huntington's disease progression;	chr15:30906726	chr15:30882267~30883231:-
LAML	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-4.71	1.16e-05	0.0219	-0.65	-0.49	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
LAML	cis	rs12145833	0.538	rs12026408	ENSG00000214837.7	LINC01347	-4.71	1.16e-05	0.0219	-0.81	-0.49	Obesity (early onset extreme);	chr1:243203503	chr1:243056307~243101744:-
LAML	cis	rs10458771	0.527	rs4442450	ENSG00000212332.1	RNU6-780P	-4.71	1.16e-05	0.022	-0.65	-0.49	Amyotrophic lateral sclerosis (sporadic);	chr10:86468430	chr10:86488446~86488549:+
LAML	cis	rs10458771	0.527	rs2288362	ENSG00000212332.1	RNU6-780P	-4.71	1.16e-05	0.022	-0.65	-0.49	Amyotrophic lateral sclerosis (sporadic);	chr10:86471117	chr10:86488446~86488549:+
LAML	cis	rs7849270	1	rs3814492	ENSG00000268707.1	RP11-247A12.7	-4.71	1.16e-05	0.022	-0.57	-0.49	Blood metabolite ratios;	chr9:129110943	chr9:129170434~129170940:+
LAML	cis	rs716804	0.74	rs4597056	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10269376	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs7107290	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10273225	chr11:10272052~10272259:-
LAML	cis	rs716804	0.598	rs10840381	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10276410	chr11:10272052~10272259:-
LAML	cis	rs716804	0.729	rs10840382	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10276503	chr11:10272052~10272259:-
LAML	cis	rs716804	0.721	rs6484152	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10276905	chr11:10272052~10272259:-
LAML	cis	rs716804	0.703	rs7947666	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10283548	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs4442543	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10285227	chr11:10272052~10272259:-
LAML	cis	rs716804	0.765	rs4366477	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10285334	chr11:10272052~10272259:-
LAML	cis	rs716804	0.703	rs4491213	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10285335	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs10840385	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10286089	chr11:10272052~10272259:-
LAML	cis	rs716804	0.765	rs10743133	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10286332	chr11:10272052~10272259:-
LAML	cis	rs716804	0.729	rs6484160	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10287432	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs7945930	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10287879	chr11:10272052~10272259:-
LAML	cis	rs716804	0.765	rs11042719	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10288882	chr11:10272052~10272259:-
LAML	cis	rs716804	0.715	rs56776911	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10299801	chr11:10272052~10272259:-
LAML	cis	rs716804	0.691	rs7924631	ENSG00000254719.1	RP11-351I24.3	-4.71	1.16e-05	0.022	-0.58	-0.49	Neuroticism;	chr11:10302514	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs11042702	ENSG00000254719.1	RP11-351I24.3	4.71	1.16e-05	0.022	0.58	0.49	Neuroticism;	chr11:10266441	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs10500724	ENSG00000254719.1	RP11-351I24.3	4.71	1.16e-05	0.022	0.58	0.49	Neuroticism;	chr11:10280469	chr11:10272052~10272259:-
LAML	cis	rs2404602	0.647	rs12904417	ENSG00000259422.1	RP11-593F23.1	4.71	1.16e-05	0.022	0.6	0.49	Blood metabolite levels;	chr15:76671811	chr15:76174891~76181486:-
LAML	cis	rs2742417	1	rs2673067	ENSG00000244357.3	RN7SL145P	4.71	1.16e-05	0.022	0.51	0.49	Response to anti-depressant treatment in major depressive disorder;	chr3:45728595	chr3:45742675~45742970:+
LAML	cis	rs471756	0.523	rs604470	ENSG00000235880.1	RP11-59O6.3	4.71	1.17e-05	0.022	0.4	0.49	Mean platelet volume;	chr9:223979	chr9:267966~273002:-
LAML	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-4.71	1.17e-05	0.022	-0.58	-0.49	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-4.71	1.17e-05	0.022	-0.58	-0.49	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
LAML	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-4.71	1.17e-05	0.022	-0.58	-0.49	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
LAML	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-4.71	1.17e-05	0.022	-0.58	-0.49	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
LAML	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-4.71	1.17e-05	0.022	-0.58	-0.49	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-4.71	1.17e-05	0.022	-0.58	-0.49	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-4.71	1.17e-05	0.022	-0.58	-0.49	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
LAML	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
LAML	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	4.71	1.17e-05	0.022	0.58	0.49	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
LAML	cis	rs10463316	0.817	rs2112419	ENSG00000260581.1	CTB-113P19.4	4.71	1.17e-05	0.022	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151418243	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.779	rs6871318	ENSG00000260581.1	CTB-113P19.4	4.71	1.17e-05	0.022	0.44	0.49	Metabolite levels (Pyroglutamine);	chr5:151421984	chr5:151652275~151655449:+
LAML	cis	rs7426056	0.671	rs12616709	ENSG00000224791.1	KRT18P39	4.71	1.17e-05	0.022	0.67	0.49	Primary sclerosing cholangitis;	chr2:203744595	chr2:203764295~203765593:-
LAML	cis	rs67311347	1	rs9835219	ENSG00000230274.1	PGAM1P3	4.71	1.17e-05	0.022	0.62	0.49	Renal cell carcinoma;	chr3:40382602	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs7642552	ENSG00000230274.1	PGAM1P3	4.71	1.17e-05	0.022	0.62	0.49	Renal cell carcinoma;	chr3:40383325	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs112619360	ENSG00000230274.1	PGAM1P3	4.71	1.17e-05	0.022	0.62	0.49	Renal cell carcinoma;	chr3:40391154	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs72861689	ENSG00000230274.1	PGAM1P3	4.71	1.17e-05	0.022	0.62	0.49	Renal cell carcinoma;	chr3:40394399	chr3:40322715~40323279:-
LAML	cis	rs7089973	0.511	rs7071812	ENSG00000252611.1	RNU6-1121P	4.71	1.17e-05	0.0221	1.22	0.49	Bipolar disorder or attention deficit hyperactivity disorder;	chr10:114954482	chr10:114969460~114969568:-
LAML	cis	rs9457247	0.534	rs1130033	ENSG00000231654.1	RPS6KA2-AS1	-4.71	1.17e-05	0.0221	-0.47	-0.49	Crohn's disease;	chr6:166972135	chr6:166903698~166904835:+
LAML	cis	rs56233836	1	rs55784313	ENSG00000235358.1	RP11-399E6.1	4.71	1.17e-05	0.0221	0.93	0.49	Intelligence (multi-trait analysis);	chr1:41379869	chr1:41242373~41284861:+
LAML	cis	rs7714584	1	rs17800886	ENSG00000197083.10	ZNF300P1	4.71	1.17e-05	0.0221	1.07	0.49	Crohn's disease;	chr5:150929977	chr5:150930645~150946289:-
LAML	cis	rs12052801	0.868	rs6757906	ENSG00000221443.1	AC017083.1	-4.71	1.17e-05	0.0221	-0.57	-0.49	Schizophrenia;	chr2:68127595	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.838	rs6753107	ENSG00000221443.1	AC017083.1	4.71	1.17e-05	0.0221	0.57	0.49	Schizophrenia;	chr2:68133368	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.868	rs6546356	ENSG00000221443.1	AC017083.1	4.71	1.17e-05	0.0221	0.57	0.49	Schizophrenia;	chr2:68142806	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.903	rs2278788	ENSG00000221443.1	AC017083.1	4.71	1.17e-05	0.0221	0.57	0.49	Schizophrenia;	chr2:68149424	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.903	rs4671205	ENSG00000221443.1	AC017083.1	4.71	1.17e-05	0.0221	0.57	0.49	Schizophrenia;	chr2:68152256	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.903	rs2044693	ENSG00000221443.1	AC017083.1	4.71	1.17e-05	0.0221	0.57	0.49	Schizophrenia;	chr2:68157965	chr2:68273104~68273206:+
LAML	cis	rs7495132	0.563	rs35907368	ENSG00000259314.1	CTD-3065B20.3	4.71	1.17e-05	0.0221	0.52	0.49	Ulcerative colitis;Inflammatory bowel disease;	chr15:90651460	chr15:90604225~90614558:-
LAML	cis	rs7165170	0.808	rs11852380	ENSG00000259314.1	CTD-3065B20.3	4.71	1.17e-05	0.0221	0.52	0.49	Crohn's disease;Inflammatory bowel disease;	chr15:90652502	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.563	rs4404048	ENSG00000259314.1	CTD-3065B20.3	4.71	1.17e-05	0.0221	0.52	0.49	Ulcerative colitis;Inflammatory bowel disease;	chr15:90653192	chr15:90604225~90614558:-
LAML	cis	rs71537559	1	rs71537559	ENSG00000220721.1	OR1F12	4.71	1.17e-05	0.0221	0.81	0.49	Squamous cell lung carcinoma;	chr6:27342000	chr6:28073316~28074233:+
LAML	cis	rs4604234	0.711	rs73463560	ENSG00000272129.1	RP11-250B2.6	-4.71	1.18e-05	0.0221	-0.76	-0.49	Cancer;	chr6:80288806	chr6:80355424~80356859:+
LAML	cis	rs4604234	0.803	rs112533182	ENSG00000272129.1	RP11-250B2.6	-4.71	1.18e-05	0.0221	-0.76	-0.49	Cancer;	chr6:80295792	chr6:80355424~80356859:+
LAML	cis	rs4604234	0.803	rs28888768	ENSG00000272129.1	RP11-250B2.6	-4.71	1.18e-05	0.0221	-0.76	-0.49	Cancer;	chr6:80311913	chr6:80355424~80356859:+
LAML	cis	rs56233836	1	rs56233836	ENSG00000235358.1	RP11-399E6.1	4.71	1.18e-05	0.0222	0.93	0.49	Intelligence (multi-trait analysis);	chr1:41371501	chr1:41242373~41284861:+
LAML	cis	rs2980439	0.818	rs2948294	ENSG00000268955.2	RP11-556O5.6	-4.71	1.18e-05	0.0222	-0.6	-0.49	Neuroticism;	chr8:8237439	chr8:8188535~8189195:-
LAML	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	4.71	1.18e-05	0.0222	0.6	0.49	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
LAML	cis	rs2404602	0.735	rs11629888	ENSG00000259422.1	RP11-593F23.1	-4.71	1.18e-05	0.0222	-0.57	-0.49	Blood metabolite levels;	chr15:76427539	chr15:76174891~76181486:-
LAML	cis	rs67311347	1	rs13095055	ENSG00000230274.1	PGAM1P3	-4.71	1.18e-05	0.0222	-0.63	-0.49	Renal cell carcinoma;	chr3:40464175	chr3:40322715~40323279:-
LAML	cis	rs10500715	0.638	rs11042575	ENSG00000254719.1	RP11-351I24.3	-4.71	1.18e-05	0.0222	-0.6	-0.49	Pancreatic cancer;	chr11:9973852	chr11:10272052~10272259:-
LAML	cis	rs62070183	0.873	rs113602044	ENSG00000266599.1	RP11-466A19.3	4.71	1.18e-05	0.0223	0.79	0.49	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32691685	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs77819475	ENSG00000266599.1	RP11-466A19.3	4.71	1.18e-05	0.0223	0.79	0.49	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32699823	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs17183113	ENSG00000266599.1	RP11-466A19.3	4.71	1.18e-05	0.0223	0.79	0.49	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702107	chr17:32518953~32531492:+
LAML	cis	rs62070183	0.938	rs78418651	ENSG00000266599.1	RP11-466A19.3	4.71	1.18e-05	0.0223	0.79	0.49	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32702530	chr17:32518953~32531492:+
LAML	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	4.71	1.18e-05	0.0223	0.55	0.49	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
LAML	cis	rs8067354	0.574	rs2531899	ENSG00000266960.1	FAM106DP	-4.71	1.18e-05	0.0223	-0.74	-0.49	Hemoglobin concentration;	chr17:59929832	chr17:60173322~60173822:+
LAML	cis	rs45509595	0.841	rs17751184	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Breast cancer;	chr6:27807250	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs67101035	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Depression;	chr6:27831109	chr6:28033947~28034855:+
LAML	cis	rs853679	0.556	rs34706883	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Depression;	chr6:27837477	chr6:28033947~28034855:+
LAML	cis	rs67340775	0.748	rs13212651	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Lung cancer in ever smokers;	chr6:27839207	chr6:28033947~28034855:+
LAML	cis	rs853679	0.546	rs35819751	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Depression;	chr6:27842791	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13194781	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Depression;	chr6:27847861	chr6:28033947~28034855:+
LAML	cis	rs853679	0.546	rs36116761	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Depression;	chr6:27850704	chr6:28033947~28034855:+
LAML	cis	rs853679	0.546	rs34194357	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Depression;	chr6:27850757	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13199772	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Depression;	chr6:27866307	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13199906	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Depression;	chr6:27866361	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs17763089	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Depression;	chr6:27867440	chr6:28033947~28034855:+
LAML	cis	rs853679	0.546	rs17695758	ENSG00000217315.1	OR2W2P	4.71	1.19e-05	0.0223	0.88	0.49	Depression;	chr6:27869405	chr6:28033947~28034855:+
LAML	cis	rs2404602	0.735	rs2957614	ENSG00000259422.1	RP11-593F23.1	4.71	1.19e-05	0.0223	0.55	0.49	Blood metabolite levels;	chr15:76404294	chr15:76174891~76181486:-
LAML	cis	rs11577318	0.537	rs12030833	ENSG00000225854.2	RP11-569G9.7	-4.71	1.19e-05	0.0223	-0.65	-0.49	Granulocyte percentage of myeloid white cells;	chr1:26362729	chr1:26326688~26327033:+
LAML	cis	rs11577318	0.579	rs10794532	ENSG00000225854.2	RP11-569G9.7	-4.71	1.19e-05	0.0223	-0.65	-0.49	Granulocyte percentage of myeloid white cells;	chr1:26367769	chr1:26326688~26327033:+
LAML	cis	rs2120335	0.701	rs62143863	ENSG00000221443.1	AC017083.1	4.71	1.19e-05	0.0224	0.64	0.48	Height;	chr2:68232972	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.701	rs58503743	ENSG00000221443.1	AC017083.1	4.71	1.19e-05	0.0224	0.64	0.48	Height;	chr2:68236244	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.701	rs59663815	ENSG00000221443.1	AC017083.1	4.71	1.19e-05	0.0224	0.64	0.48	Height;	chr2:68246623	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.671	rs7580304	ENSG00000221443.1	AC017083.1	4.71	1.19e-05	0.0224	0.64	0.48	Height;	chr2:68268144	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.701	rs7592177	ENSG00000221443.1	AC017083.1	-4.71	1.19e-05	0.0224	-0.64	-0.48	Height;	chr2:68271751	chr2:68273104~68273206:+
LAML	cis	rs11577318	0.579	rs11247934	ENSG00000225854.2	RP11-569G9.7	-4.7	1.2e-05	0.0224	-0.66	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26369267	chr1:26326688~26327033:+
LAML	cis	rs11577318	0.579	rs11548246	ENSG00000225854.2	RP11-569G9.7	-4.7	1.2e-05	0.0224	-0.66	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26370675	chr1:26326688~26327033:+
LAML	cis	rs6558530	0.625	rs7459507	ENSG00000253982.1	CTD-2336O2.1	4.7	1.2e-05	0.0224	0.75	0.48	Systolic blood pressure;	chr8:1750026	chr8:1761990~1764502:-
LAML	cis	rs79040073	0.598	rs11636296	ENSG00000276593.1	RP11-295H24.5	4.7	1.2e-05	0.0225	0.57	0.48	Lung cancer in ever smokers;	chr15:49034864	chr15:49353485~49354034:+
LAML	cis	rs6558530	0.965	rs6558529	ENSG00000253982.1	CTD-2336O2.1	4.7	1.2e-05	0.0225	0.67	0.48	Systolic blood pressure;	chr8:1758040	chr8:1761990~1764502:-
LAML	cis	rs6500550	0.605	rs2285813	ENSG00000263235.1	RP11-461A8.4	-4.7	1.21e-05	0.0226	-0.48	-0.48	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3516102	chr16:3650636~3651703:-
LAML	cis	rs76917914	1	rs76917914	ENSG00000236896.1	RP11-535C21.3	4.7	1.21e-05	0.0227	0.47	0.48	Immature fraction of reticulocytes;	chr9:98009158	chr9:97986551~97987656:-
LAML	cis	rs76917914	1	rs4742711	ENSG00000236896.1	RP11-535C21.3	4.7	1.21e-05	0.0227	0.47	0.48	Immature fraction of reticulocytes;	chr9:98018508	chr9:97986551~97987656:-
LAML	cis	rs10463316	0.817	rs6880228	ENSG00000260581.1	CTB-113P19.4	-4.7	1.21e-05	0.0227	-0.43	-0.48	Metabolite levels (Pyroglutamine);	chr5:151398584	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.784	rs906678	ENSG00000260581.1	CTB-113P19.4	4.7	1.21e-05	0.0227	0.43	0.48	Metabolite levels (Pyroglutamine);	chr5:151399479	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.817	rs906679	ENSG00000260581.1	CTB-113P19.4	4.7	1.21e-05	0.0227	0.43	0.48	Metabolite levels (Pyroglutamine);	chr5:151399741	chr5:151652275~151655449:+
LAML	cis	rs12931792	0.712	rs4787495	ENSG00000273724.1	RP11-347C12.12	-4.7	1.22e-05	0.0228	-0.52	-0.48	Tonsillectomy;	chr16:30154404	chr16:30336400~30343336:+
LAML	cis	rs716804	0.566	rs7119000	ENSG00000254719.1	RP11-351I24.3	-4.7	1.22e-05	0.0228	-0.61	-0.48	Neuroticism;	chr11:10074693	chr11:10272052~10272259:-
LAML	cis	rs67311347	1	rs73080138	ENSG00000230274.1	PGAM1P3	4.7	1.22e-05	0.0228	0.63	0.48	Renal cell carcinoma;	chr3:40474926	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs9882171	ENSG00000230274.1	PGAM1P3	4.7	1.22e-05	0.0228	0.63	0.48	Renal cell carcinoma;	chr3:40477330	chr3:40322715~40323279:-
LAML	cis	rs10457838	0.742	rs6911677	ENSG00000220848.4	RPS18P9	4.7	1.22e-05	0.0228	0.54	0.48	Post-traumatic stress disorder;	chr6:149006087	chr6:149594084~149594543:+
LAML	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-4.7	1.22e-05	0.0228	-0.61	-0.48	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-4.7	1.22e-05	0.0228	-0.61	-0.48	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
LAML	cis	rs785830	0.538	rs573071	ENSG00000235880.1	RP11-59O6.3	4.7	1.22e-05	0.0228	0.43	0.48	Platelet distribution width;	chr9:256994	chr9:267966~273002:-
LAML	cis	rs785830	0.558	rs573860	ENSG00000235880.1	RP11-59O6.3	4.7	1.22e-05	0.0228	0.43	0.48	Platelet distribution width;	chr9:257034	chr9:267966~273002:-
LAML	cis	rs785830	0.558	rs517616	ENSG00000235880.1	RP11-59O6.3	4.7	1.22e-05	0.0228	0.43	0.48	Platelet distribution width;	chr9:258376	chr9:267966~273002:-
LAML	cis	rs785830	0.558	rs2479326	ENSG00000235880.1	RP11-59O6.3	4.7	1.22e-05	0.0228	0.43	0.48	Platelet distribution width;	chr9:258914	chr9:267966~273002:-
LAML	cis	rs785830	0.538	rs581500	ENSG00000235880.1	RP11-59O6.3	4.7	1.22e-05	0.0228	0.43	0.48	Platelet distribution width;	chr9:259331	chr9:267966~273002:-
LAML	cis	rs785830	0.558	rs549624	ENSG00000235880.1	RP11-59O6.3	4.7	1.22e-05	0.0228	0.43	0.48	Platelet distribution width;	chr9:259554	chr9:267966~273002:-
LAML	cis	rs785830	0.558	rs549707	ENSG00000235880.1	RP11-59O6.3	4.7	1.22e-05	0.0228	0.43	0.48	Platelet distribution width;	chr9:259575	chr9:267966~273002:-
LAML	cis	rs785830	0.558	rs9408082	ENSG00000235880.1	RP11-59O6.3	4.7	1.22e-05	0.0228	0.43	0.48	Platelet distribution width;	chr9:262207	chr9:267966~273002:-
LAML	cis	rs13631	0.697	rs1018330	ENSG00000268996.3	MAN1B1-AS1	4.7	1.22e-05	0.0228	0.68	0.48	Cerebrospinal fluid biomarker levels;	chr9:137085933	chr9:137084946~137086817:-
LAML	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-4.7	1.22e-05	0.0228	-0.65	-0.48	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
LAML	cis	rs2404602	0.735	rs3765115	ENSG00000259422.1	RP11-593F23.1	-4.7	1.22e-05	0.0228	-0.56	-0.48	Blood metabolite levels;	chr15:76381375	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.735	rs56246286	ENSG00000259422.1	RP11-593F23.1	-4.7	1.22e-05	0.0228	-0.56	-0.48	Blood metabolite levels;	chr15:76398390	chr15:76174891~76181486:-
LAML	cis	rs747650	0.504	rs10838640	ENSG00000271350.1	CTD-2384B9.1	-4.7	1.22e-05	0.0228	-0.59	-0.48	Acne (severe);	chr11:46963078	chr11:47041027~47041945:-
LAML	cis	rs747650	0.504	rs7128193	ENSG00000271350.1	CTD-2384B9.1	-4.7	1.22e-05	0.0228	-0.59	-0.48	Acne (severe);	chr11:46967432	chr11:47041027~47041945:-
LAML	cis	rs747650	0.504	rs4394802	ENSG00000271350.1	CTD-2384B9.1	-4.7	1.22e-05	0.0228	-0.59	-0.48	Acne (severe);	chr11:46969036	chr11:47041027~47041945:-
LAML	cis	rs2742417	1	rs2742373	ENSG00000244357.3	RN7SL145P	4.7	1.22e-05	0.0228	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45742554	chr3:45742675~45742970:+
LAML	cis	rs10463316	0.817	rs11167545	ENSG00000260581.1	CTB-113P19.4	4.7	1.22e-05	0.0228	0.43	0.48	Metabolite levels (Pyroglutamine);	chr5:151398515	chr5:151652275~151655449:+
LAML	cis	rs7555523	0.83	rs6660601	ENSG00000224358.1	RP11-466F5.8	-4.7	1.22e-05	0.0228	-0.73	-0.48	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165726618	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-4.7	1.22e-05	0.0228	-0.73	-0.48	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-4.7	1.22e-05	0.0228	-0.73	-0.48	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-4.7	1.22e-05	0.0228	-0.73	-0.48	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
LAML	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-4.7	1.22e-05	0.0228	-0.73	-0.48	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
LAML	cis	rs716804	0.621	rs11042717	ENSG00000254719.1	RP11-351I24.3	4.7	1.22e-05	0.0228	0.57	0.48	Neuroticism;	chr11:10282392	chr11:10272052~10272259:-
LAML	cis	rs11039798	0.92	rs11040013	ENSG00000263693.1	MIR3161	4.7	1.23e-05	0.0229	0.49	0.48	Axial length;	chr11:48761310	chr11:48096782~48096858:+
LAML	cis	rs10463316	0.817	rs3846713	ENSG00000260581.1	CTB-113P19.4	4.7	1.23e-05	0.0229	0.43	0.48	Metabolite levels (Pyroglutamine);	chr5:151420178	chr5:151652275~151655449:+
LAML	cis	rs4803480	0.766	rs723902	ENSG00000239736.2	CEACAMP3	-4.7	1.23e-05	0.023	-0.66	-0.48	Schizophrenia;	chr19:41577830	chr19:41599735~41605984:+
LAML	cis	rs747650	0.504	rs7938169	ENSG00000271350.1	CTD-2384B9.1	-4.7	1.23e-05	0.023	-0.59	-0.48	Acne (severe);	chr11:46949988	chr11:47041027~47041945:-
LAML	cis	rs7301826	0.651	rs7956851	ENSG00000256299.1	RP11-989F5.3	-4.7	1.23e-05	0.023	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130834554	chr12:130810821~130812622:-
LAML	cis	rs561341	0.739	rs4795663	ENSG00000266379.5	RP11-640N20.8	-4.7	1.23e-05	0.023	-0.67	-0.48	Hip circumference adjusted for BMI;	chr17:31887523	chr17:32088160~32094933:-
LAML	cis	rs7131987	0.527	rs7308534	ENSG00000274315.1	RP11-996F15.5	4.7	1.23e-05	0.023	0.5	0.48	QT interval;	chr12:29300269	chr12:29331434~29331936:-
LAML	cis	rs9322193	0.886	rs4039600	ENSG00000216906.2	RP11-350J20.9	4.7	1.24e-05	0.023	0.69	0.48	Lung cancer;	chr6:149576319	chr6:149904243~149906418:+
LAML	cis	rs12931792	0.712	rs56399904	ENSG00000273724.1	RP11-347C12.12	4.7	1.24e-05	0.0231	0.52	0.48	Tonsillectomy;	chr16:30154862	chr16:30336400~30343336:+
LAML	cis	rs9457247	0.967	rs387733	ENSG00000231654.1	RPS6KA2-AS1	4.7	1.24e-05	0.0231	0.49	0.48	Crohn's disease;	chr6:166996283	chr6:166903698~166904835:+
LAML	cis	rs7301826	0.651	rs4514465	ENSG00000256250.1	RP11-989F5.1	-4.7	1.24e-05	0.0231	-0.61	-0.48	Plasma plasminogen activator levels;	chr12:130829124	chr12:130810606~130812438:+
LAML	cis	rs8067354	0.574	rs1296279	ENSG00000266960.1	FAM106DP	4.69	1.24e-05	0.0231	0.77	0.48	Hemoglobin concentration;	chr17:59888370	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.527	rs1292039	ENSG00000266960.1	FAM106DP	4.69	1.24e-05	0.0231	0.77	0.48	Hemoglobin concentration;	chr17:59897552	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.574	rs2526353	ENSG00000266960.1	FAM106DP	4.69	1.24e-05	0.0231	0.77	0.48	Hemoglobin concentration;	chr17:59911246	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.574	rs1292035	ENSG00000266960.1	FAM106DP	4.69	1.24e-05	0.0231	0.77	0.48	Hemoglobin concentration;	chr17:59912196	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.574	rs9789060	ENSG00000266960.1	FAM106DP	4.69	1.24e-05	0.0231	0.77	0.48	Hemoglobin concentration;	chr17:59941209	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.574	rs7219089	ENSG00000266960.1	FAM106DP	4.69	1.24e-05	0.0231	0.77	0.48	Hemoglobin concentration;	chr17:59955504	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.54	rs7221472	ENSG00000266960.1	FAM106DP	4.69	1.24e-05	0.0231	0.77	0.48	Hemoglobin concentration;	chr17:59959376	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.54	rs12600680	ENSG00000266960.1	FAM106DP	4.69	1.24e-05	0.0231	0.77	0.48	Hemoglobin concentration;	chr17:59960013	chr17:60173322~60173822:+
LAML	cis	rs2980439	0.846	rs2980437	ENSG00000253893.2	FAM85B	4.69	1.24e-05	0.0231	0.61	0.48	Neuroticism;	chr8:8237241	chr8:8167819~8226614:-
LAML	cis	rs2980439	0.818	rs2945249	ENSG00000253893.2	FAM85B	-4.69	1.24e-05	0.0231	-0.61	-0.48	Neuroticism;	chr8:8237204	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.511	rs2980426	ENSG00000253893.2	FAM85B	-4.69	1.25e-05	0.0232	-0.58	-0.48	Mood instability;	chr8:8288087	chr8:8167819~8226614:-
LAML	cis	rs2404602	0.735	rs11857015	ENSG00000259422.1	RP11-593F23.1	-4.69	1.25e-05	0.0232	-0.57	-0.48	Blood metabolite levels;	chr15:76357049	chr15:76174891~76181486:-
LAML	cis	rs2742417	1	rs2742417	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45689959	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2251954	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45690292	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742418	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45690428	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs2742419	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45690437	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742420	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45690745	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673051	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45690917	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742422	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45691328	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742423	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45691938	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs17328701	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45692766	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs9877499	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45692912	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs1969625	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45693483	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs1609553	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45693650	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs1609554	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45693700	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673058	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45694126	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673057	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45694238	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs2742426	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45694409	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673056	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45696310	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs9829631	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45699066	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs1534875	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45699551	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs1534876	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45699765	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673047	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45701621	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742438	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45701898	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs2742439	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45702756	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs938363	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45704872	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs938362	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45704873	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs1969626	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45705344	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.904	rs2373047	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45706005	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs2742441	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45706937	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.935	rs2742442	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45707107	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673038	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45707140	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673037	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45707602	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs1883096	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45708523	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs6800556	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45710737	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673036	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45710979	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs1877934	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45711803	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs1877933	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45711995	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs1877932	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45712047	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742369	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45712995	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.935	rs2248991	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45713257	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673034	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45713646	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742385	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45714778	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742386	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45714818	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742389	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45715191	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.935	rs2742393	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45715925	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673025	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45718991	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742452	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45724216	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2673065	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45729730	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs2742462	ENSG00000244357.3	RN7SL145P	4.69	1.25e-05	0.0232	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45733204	chr3:45742675~45742970:+
LAML	cis	rs2742417	0.967	rs2742427	ENSG00000244357.3	RN7SL145P	-4.69	1.25e-05	0.0232	-0.51	-0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45694931	chr3:45742675~45742970:+
LAML	cis	rs2742417	1	rs2742390	ENSG00000244357.3	RN7SL145P	-4.69	1.25e-05	0.0232	-0.51	-0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45715230	chr3:45742675~45742970:+
LAML	cis	rs716804	0.74	rs7116147	ENSG00000254719.1	RP11-351I24.3	-4.69	1.25e-05	0.0232	-0.58	-0.48	Neuroticism;	chr11:10265763	chr11:10272052~10272259:-
LAML	cis	rs716804	0.703	rs12419593	ENSG00000254719.1	RP11-351I24.3	-4.69	1.25e-05	0.0232	-0.58	-0.48	Neuroticism;	chr11:10267483	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs726102	ENSG00000254719.1	RP11-351I24.3	-4.69	1.25e-05	0.0232	-0.58	-0.48	Neuroticism;	chr11:10262431	chr11:10272052~10272259:-
LAML	cis	rs11096990	0.964	rs6835064	ENSG00000206675.1	RNU6-32P	-4.69	1.25e-05	0.0232	-0.49	-0.48	Cognitive function;	chr4:39264346	chr4:39297605~39297711:-
LAML	cis	rs5769707	0.777	rs739243	ENSG00000264139.1	MIR3667	-4.69	1.25e-05	0.0232	-0.56	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49663563	chr22:49543393~49543466:-
LAML	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	4.69	1.25e-05	0.0232	0.63	0.48	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
LAML	cis	rs561341	0.7	rs2074101	ENSG00000266379.5	RP11-640N20.8	4.69	1.25e-05	0.0232	0.66	0.48	Hip circumference adjusted for BMI;	chr17:31901637	chr17:32088160~32094933:-
LAML	cis	rs561341	0.7	rs886223	ENSG00000266379.5	RP11-640N20.8	4.69	1.25e-05	0.0232	0.66	0.48	Hip circumference adjusted for BMI;	chr17:31902858	chr17:32088160~32094933:-
LAML	cis	rs7224685	0.569	rs8070737	ENSG00000234203.1	RP5-1050D4.2	-4.69	1.25e-05	0.0232	-0.86	-0.48	Type 2 diabetes;	chr17:4077772	chr17:4972851~4974681:+
LAML	cis	rs7224685	0.53	rs36019144	ENSG00000234203.1	RP5-1050D4.2	-4.69	1.25e-05	0.0232	-0.86	-0.48	Type 2 diabetes;	chr17:4084205	chr17:4972851~4974681:+
LAML	cis	rs9916302	0.904	rs755500	ENSG00000223091.1	RNU6-981P	-4.69	1.25e-05	0.0232	-0.6	-0.48	Glomerular filtration rate (creatinine);	chr17:39253612	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs587343	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39284350	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs679995	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39285426	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs801419	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39310074	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.8	rs8081220	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39316904	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs9944411	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39327346	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs10221223	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39332847	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs9898170	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39353839	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8068427	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39355264	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs6503503	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39358120	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs9894500	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39359482	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs8076494	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39360469	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs7223438	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39365102	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs68178216	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39369988	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs10491128	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39395735	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs4795357	ENSG00000223091.1	RNU6-981P	-4.69	1.25e-05	0.0232	-0.6	-0.48	Glomerular filtration rate (creatinine);	chr17:39413298	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.821	rs12938268	ENSG00000223091.1	RNU6-981P	-4.69	1.25e-05	0.0232	-0.6	-0.48	Glomerular filtration rate (creatinine);	chr17:39415886	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs4239222	ENSG00000223091.1	RNU6-981P	4.69	1.25e-05	0.0232	0.6	0.48	Glomerular filtration rate (creatinine);	chr17:39539982	chr17:39482486~39482590:-
LAML	cis	rs911555	0.504	rs745079	ENSG00000252469.1	RNU7-160P	-4.69	1.26e-05	0.0233	-0.57	-0.48	Intelligence (multi-trait analysis);	chr14:103607214	chr14:103550345~103550406:+
LAML	cis	rs911555	0.504	rs8006526	ENSG00000252469.1	RNU7-160P	-4.69	1.26e-05	0.0233	-0.57	-0.48	Intelligence (multi-trait analysis);	chr14:103608678	chr14:103550345~103550406:+
LAML	cis	rs911555	0.504	rs61995761	ENSG00000252469.1	RNU7-160P	-4.69	1.26e-05	0.0233	-0.57	-0.48	Intelligence (multi-trait analysis);	chr14:103609375	chr14:103550345~103550406:+
LAML	cis	rs10463316	0.709	rs3857426	ENSG00000260581.1	CTB-113P19.4	4.69	1.26e-05	0.0233	0.43	0.48	Metabolite levels (Pyroglutamine);	chr5:151410270	chr5:151652275~151655449:+
LAML	cis	rs911555	0.504	rs4906340	ENSG00000252469.1	RNU7-160P	4.69	1.26e-05	0.0233	0.63	0.48	Intelligence (multi-trait analysis);	chr14:103610308	chr14:103550345~103550406:+
LAML	cis	rs5769707	0.967	rs9616327	ENSG00000213279.2	RP1-29C18.9	-4.69	1.26e-05	0.0234	-0.57	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49617243	chr22:49572264~49575426:-
LAML	cis	rs367615	0.552	rs2963022	ENSG00000249476.1	CTD-2587M2.1	-4.69	1.27e-05	0.0234	-0.56	-0.48	Colorectal cancer (SNP x SNP interaction);	chr5:109391484	chr5:109237120~109326369:-
LAML	cis	rs9355610	0.727	rs2247315	ENSG00000231654.1	RPS6KA2-AS1	4.69	1.27e-05	0.0234	0.48	0.48	Graves' disease;	chr6:166956723	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.515	rs2757039	ENSG00000231654.1	RPS6KA2-AS1	4.69	1.27e-05	0.0234	0.48	0.48	Crohn's disease;	chr6:166956865	chr6:166903698~166904835:+
LAML	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-4.69	1.27e-05	0.0234	-0.61	-0.48	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
LAML	cis	rs950169	0.887	rs35986397	ENSG00000259728.4	LINC00933	4.69	1.27e-05	0.0234	0.71	0.48	Schizophrenia;	chr15:84400409	chr15:84570649~84580175:+
LAML	cis	rs4853012	1	rs2280643	ENSG00000257800.1	FNBP1P1	4.69	1.27e-05	0.0235	0.8	0.48	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74120680~74123218:+
LAML	cis	rs4853012	0.887	rs2280644	ENSG00000257800.1	FNBP1P1	4.69	1.27e-05	0.0235	0.8	0.48	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74120680~74123218:+
LAML	cis	rs12145833	0.538	rs61833885	ENSG00000214837.7	LINC01347	-4.69	1.27e-05	0.0235	-0.81	-0.48	Obesity (early onset extreme);	chr1:243233886	chr1:243056307~243101744:-
LAML	cis	rs12145833	0.538	rs10926977	ENSG00000214837.7	LINC01347	-4.69	1.27e-05	0.0235	-0.81	-0.48	Obesity (early onset extreme);	chr1:243248065	chr1:243056307~243101744:-
LAML	cis	rs7131987	0.868	rs737160	ENSG00000273680.1	RP11-996F15.6	4.69	1.28e-05	0.0236	0.49	0.48	QT interval;	chr12:29276079	chr12:29332733~29333383:-
LAML	cis	rs990871	1	rs2568958	ENSG00000227207.2	RPL31P12	-4.69	1.28e-05	0.0236	-0.67	-0.48	Subcutaneous adipose tissue;	chr1:72299433	chr1:72301472~72301829:+
LAML	cis	rs4713118	0.662	rs149961	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28047791	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.629	rs149899	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28052201	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.629	rs172165	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28053036	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.597	rs172166	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28053042	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.629	rs203888	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28053811	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.629	rs203889	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28053997	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.629	rs203890	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28054470	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.662	rs9357060	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28056708	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.662	rs9468271	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28056792	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.662	rs9380045	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28057501	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.616	rs9348789	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28057708	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.662	rs9468274	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28058299	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.662	rs9468275	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28058358	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.662	rs9468276	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28059910	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.662	rs9468277	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28060612	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.662	rs9468278	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28060704	chr6:28046434~28047367:+
LAML	cis	rs4713118	0.662	rs13218430	ENSG00000187763.3	OR2B7P	4.69	1.28e-05	0.0236	0.71	0.48	Parkinson's disease;	chr6:28062059	chr6:28046434~28047367:+
LAML	cis	rs7458938	0.593	rs34709194	ENSG00000224897.5	POT1-AS1	4.69	1.28e-05	0.0237	0.59	0.48	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125787622	chr7:124929873~125179315:+
LAML	cis	rs7426056	0.671	rs3116491	ENSG00000224791.1	KRT18P39	4.69	1.28e-05	0.0237	0.72	0.48	Primary sclerosing cholangitis;	chr2:203721953	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs3115966	ENSG00000224791.1	KRT18P39	4.69	1.28e-05	0.0237	0.72	0.48	Primary sclerosing cholangitis;	chr2:203725612	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs3181106	ENSG00000224791.1	KRT18P39	-4.69	1.28e-05	0.0237	-0.72	-0.48	Primary sclerosing cholangitis;	chr2:203726430	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs72932400	ENSG00000224791.1	KRT18P39	4.69	1.28e-05	0.0237	0.72	0.48	Primary sclerosing cholangitis;	chr2:203730497	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs3116497	ENSG00000224791.1	KRT18P39	-4.69	1.28e-05	0.0237	-0.72	-0.48	Primary sclerosing cholangitis;	chr2:203730796	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs17449270	ENSG00000224791.1	KRT18P39	4.69	1.28e-05	0.0237	0.72	0.48	Primary sclerosing cholangitis;	chr2:203732965	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs17533727	ENSG00000224791.1	KRT18P39	4.69	1.28e-05	0.0237	0.72	0.48	Primary sclerosing cholangitis;	chr2:203738206	chr2:203764295~203765593:-
LAML	cis	rs853679	0.769	rs7752448	ENSG00000217315.1	OR2W2P	4.69	1.28e-05	0.0237	0.79	0.48	Depression;	chr6:28333322	chr6:28033947~28034855:+
LAML	cis	rs7131987	0.903	rs7970390	ENSG00000273680.1	RP11-996F15.6	4.69	1.29e-05	0.0237	0.5	0.48	QT interval;	chr12:29245722	chr12:29332733~29333383:-
LAML	cis	rs2242330	0.749	rs13110187	ENSG00000248049.5	UBA6-AS1	-4.69	1.29e-05	0.0237	-0.51	-0.48	Parkinson's disease;	chr4:67575857	chr4:67701280~68080952:+
LAML	cis	rs2242330	0.749	rs17088473	ENSG00000248049.5	UBA6-AS1	-4.69	1.29e-05	0.0237	-0.51	-0.48	Parkinson's disease;	chr4:67577590	chr4:67701280~68080952:+
LAML	cis	rs2242330	0.798	rs3775866	ENSG00000248049.5	UBA6-AS1	-4.69	1.29e-05	0.0237	-0.51	-0.48	Parkinson's disease;	chr4:67578462	chr4:67701280~68080952:+
LAML	cis	rs2242330	0.798	rs13119230	ENSG00000248049.5	UBA6-AS1	-4.69	1.29e-05	0.0237	-0.51	-0.48	Parkinson's disease;	chr4:67579559	chr4:67701280~68080952:+
LAML	cis	rs7301826	0.934	rs10773826	ENSG00000256250.1	RP11-989F5.1	-4.69	1.29e-05	0.0237	-0.61	-0.48	Plasma plasminogen activator levels;	chr12:130836629	chr12:130810606~130812438:+
LAML	cis	rs1075265	0.548	rs2542575	ENSG00000235937.1	AC008280.1	4.69	1.29e-05	0.0237	0.38	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54029552~54030682:-
LAML	cis	rs1075265	0.568	rs2542577	ENSG00000235937.1	AC008280.1	4.69	1.29e-05	0.0237	0.38	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54029552~54030682:-
LAML	cis	rs7927771	0.931	rs4752801	ENSG00000280615.1	Y_RNA	-4.69	1.29e-05	0.0237	-0.64	-0.48	Subjective well-being;	chr11:47886089	chr11:47614898~47614994:-
LAML	cis	rs763121	0.853	rs2072794	ENSG00000230912.1	RP3-508I15.10	-4.69	1.29e-05	0.0237	-0.41	-0.48	Menopause (age at onset);	chr22:38754538	chr22:38666508~38668750:-
LAML	cis	rs911186	0.509	rs6934329	ENSG00000187763.3	OR2B7P	4.69	1.29e-05	0.0237	0.72	0.48	Autism spectrum disorder or schizophrenia;	chr6:27190254	chr6:28046434~28047367:+
LAML	cis	rs2980439	0.818	rs2948300	ENSG00000253893.2	FAM85B	-4.68	1.29e-05	0.0237	-0.61	-0.48	Neuroticism;	chr8:8248986	chr8:8167819~8226614:-
LAML	cis	rs7301826	0.651	rs10848206	ENSG00000256250.1	RP11-989F5.1	-4.68	1.29e-05	0.0237	-0.63	-0.48	Plasma plasminogen activator levels;	chr12:130796926	chr12:130810606~130812438:+
LAML	cis	rs10829156	0.732	rs7075678	ENSG00000240291.1	RP11-499P20.2	4.68	1.29e-05	0.0237	0.68	0.48	Sudden cardiac arrest;	chr10:18585174	chr10:18513115~18545651:-
LAML	cis	rs716804	0.566	rs11042617	ENSG00000254719.1	RP11-351I24.3	4.68	1.29e-05	0.0237	0.6	0.48	Neuroticism;	chr11:10086937	chr11:10272052~10272259:-
LAML	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	4.68	1.29e-05	0.0237	0.59	0.48	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
LAML	cis	rs12200782	0.53	rs9379892	ENSG00000241549.7	GUSBP2	4.68	1.29e-05	0.0237	0.59	0.48	Small cell lung carcinoma;	chr6:26582186	chr6:26871484~26956554:-
LAML	cis	rs990871	1	rs11209948	ENSG00000227207.2	RPL31P12	4.68	1.29e-05	0.0238	0.65	0.48	Subcutaneous adipose tissue;	chr1:72346221	chr1:72301472~72301829:+
LAML	cis	rs990871	1	rs2568960	ENSG00000227207.2	RPL31P12	-4.68	1.29e-05	0.0238	-0.65	-0.48	Subcutaneous adipose tissue;	chr1:72346566	chr1:72301472~72301829:+
LAML	cis	rs990871	1	rs2815753	ENSG00000227207.2	RPL31P12	-4.68	1.29e-05	0.0238	-0.65	-0.48	Subcutaneous adipose tissue;	chr1:72346641	chr1:72301472~72301829:+
LAML	cis	rs990871	1	rs2613494	ENSG00000227207.2	RPL31P12	-4.68	1.29e-05	0.0238	-0.65	-0.48	Subcutaneous adipose tissue;	chr1:72346974	chr1:72301472~72301829:+
LAML	cis	rs990871	0.927	rs2568961	ENSG00000227207.2	RPL31P12	-4.68	1.29e-05	0.0238	-0.65	-0.48	Subcutaneous adipose tissue;	chr1:72347064	chr1:72301472~72301829:+
LAML	cis	rs990871	0.962	rs1460942	ENSG00000227207.2	RPL31P12	-4.68	1.29e-05	0.0238	-0.65	-0.48	Subcutaneous adipose tissue;	chr1:72347573	chr1:72301472~72301829:+
LAML	cis	rs12931792	0.682	rs12373113	ENSG00000273724.1	RP11-347C12.12	4.68	1.29e-05	0.0238	0.51	0.48	Tonsillectomy;	chr16:30176192	chr16:30336400~30343336:+
LAML	cis	rs12931792	0.682	rs12373078	ENSG00000273724.1	RP11-347C12.12	4.68	1.29e-05	0.0238	0.51	0.48	Tonsillectomy;	chr16:30176355	chr16:30336400~30343336:+
LAML	cis	rs10500715	0.589	rs4910085	ENSG00000254719.1	RP11-351I24.3	-4.68	1.3e-05	0.0239	-0.55	-0.48	Pancreatic cancer;	chr11:9959750	chr11:10272052~10272259:-
LAML	cis	rs6500550	0.597	rs2285814	ENSG00000263235.1	RP11-461A8.4	-4.68	1.3e-05	0.0239	-0.47	-0.48	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3515123	chr16:3650636~3651703:-
LAML	cis	rs2742417	1	rs2673035	ENSG00000244357.3	RN7SL145P	4.68	1.3e-05	0.0239	0.51	0.48	Response to anti-depressant treatment in major depressive disorder;	chr3:45712173	chr3:45742675~45742970:+
LAML	cis	rs9788721	0.836	rs2656065	ENSG00000259474.1	RP11-650L12.1	-4.68	1.3e-05	0.0239	-0.49	-0.48	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78458207	chr15:78480057~78481820:-
LAML	cis	rs3093024	1	rs3093023	ENSG00000265828.1	MIR3939	4.68	1.3e-05	0.024	0.69	0.48	Rheumatoid arthritis;	chr6:167120802	chr6:166997807~166997912:-
LAML	cis	rs9457247	0.529	rs6907666	ENSG00000227598.1	RP1-167A14.2	4.68	1.3e-05	0.024	0.69	0.48	Crohn's disease;	chr6:167109907	chr6:166969626~166999065:-
LAML	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-4.68	1.31e-05	0.024	-0.85	-0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
LAML	cis	rs7495132	0.688	rs5011653	ENSG00000259314.1	CTD-3065B20.3	4.68	1.31e-05	0.0241	0.52	0.48	Ulcerative colitis;Inflammatory bowel disease;	chr15:90623262	chr15:90604225~90614558:-
LAML	cis	rs2980439	0.783	rs2955587	ENSG00000268955.2	RP11-556O5.6	-4.68	1.31e-05	0.0241	-0.6	-0.48	Neuroticism;	chr8:8240557	chr8:8188535~8189195:-
LAML	cis	rs9322193	0.884	rs62439837	ENSG00000216906.2	RP11-350J20.9	4.68	1.32e-05	0.0241	0.71	0.48	Lung cancer;	chr6:149670380	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs4870509	ENSG00000216906.2	RP11-350J20.9	4.68	1.32e-05	0.0241	0.71	0.48	Lung cancer;	chr6:149702212	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.887	rs9767113	ENSG00000216906.2	RP11-350J20.9	4.68	1.32e-05	0.0241	0.71	0.48	Lung cancer;	chr6:149718157	chr6:149904243~149906418:+
LAML	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	4.68	1.32e-05	0.0241	0.66	0.48	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
LAML	cis	rs11338569	1	rs11338569	ENSG00000236896.1	RP11-535C21.3	4.68	1.32e-05	0.0241	0.47	0.48	Mean corpuscular hemoglobin;Red blood cell count;	chr9:98001175	chr9:97986551~97987656:-
LAML	cis	rs5769707	0.967	rs739241	ENSG00000188511.11	C22orf34	-4.68	1.32e-05	0.0242	-0.5	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49659273	chr22:49414524~49657542:-
LAML	cis	rs950169	0.763	rs35372971	ENSG00000259728.4	LINC00933	4.68	1.32e-05	0.0242	0.71	0.48	Schizophrenia;	chr15:84387097	chr15:84570649~84580175:+
LAML	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	4.68	1.32e-05	0.0242	0.6	0.48	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	4.68	1.32e-05	0.0242	0.6	0.48	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	4.68	1.32e-05	0.0242	0.6	0.48	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	4.68	1.32e-05	0.0242	0.6	0.48	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
LAML	cis	rs67311347	0.955	rs73080163	ENSG00000230274.1	PGAM1P3	4.68	1.32e-05	0.0242	0.64	0.48	Renal cell carcinoma;	chr3:40491570	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs73080165	ENSG00000230274.1	PGAM1P3	4.68	1.32e-05	0.0242	0.64	0.48	Renal cell carcinoma;	chr3:40491571	chr3:40322715~40323279:-
LAML	cis	rs7587476	0.501	rs11888027	ENSG00000229267.2	AC072062.1	4.68	1.32e-05	0.0242	0.55	0.48	Neuroblastoma;	chr2:214774888	chr2:214810229~214963274:+
LAML	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	4.68	1.33e-05	0.0243	0.69	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
LAML	cis	rs709400	0.593	rs12898029	ENSG00000258851.1	RP11-894P9.2	4.68	1.33e-05	0.0243	0.57	0.48	Body mass index;	chr14:103411547	chr14:103553421~103561877:+
LAML	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.959	rs16876540	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85902801	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs35761942	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85919786	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs955227	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85941314	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs10944163	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85948975	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1577917	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85982222	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12196037	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85984913	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs68171315	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:85997682	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.874	rs11756621	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86030345	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12196411	ENSG00000203875.9	SNHG5	-4.68	1.33e-05	0.0243	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86070044	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	4.68	1.33e-05	0.0243	0.61	0.48	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	4.68	1.33e-05	0.0243	0.61	0.48	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
LAML	cis	rs911186	0.73	rs2393911	ENSG00000187763.3	OR2B7P	4.68	1.33e-05	0.0243	0.64	0.48	Autism spectrum disorder or schizophrenia;	chr6:27089300	chr6:28046434~28047367:+
LAML	cis	rs7426056	0.671	rs62183988	ENSG00000224791.1	KRT18P39	4.68	1.33e-05	0.0243	0.72	0.48	Primary sclerosing cholangitis;	chr2:203740306	chr2:203764295~203765593:-
LAML	cis	rs12052801	0.903	rs10195757	ENSG00000221443.1	AC017083.1	4.68	1.33e-05	0.0244	0.54	0.48	Schizophrenia;	chr2:68266450	chr2:68273104~68273206:+
LAML	cis	rs7301826	0.651	rs7968675	ENSG00000256250.1	RP11-989F5.1	-4.68	1.34e-05	0.0244	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130818832	chr12:130810606~130812438:+
LAML	cis	rs7301826	1	rs2001483	ENSG00000256250.1	RP11-989F5.1	-4.68	1.34e-05	0.0244	-0.61	-0.48	Plasma plasminogen activator levels;	chr12:130834100	chr12:130810606~130812438:+
LAML	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-4.68	1.34e-05	0.0244	-0.61	-0.48	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
LAML	cis	rs7829975	0.624	rs7823056	ENSG00000268955.2	RP11-556O5.6	-4.68	1.34e-05	0.0244	-0.64	-0.48	Mood instability;	chr8:8525195	chr8:8188535~8189195:-
LAML	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-4.67	1.34e-05	0.0246	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-4.67	1.34e-05	0.0246	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-4.67	1.34e-05	0.0246	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
LAML	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-4.67	1.34e-05	0.0246	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
LAML	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-4.67	1.34e-05	0.0246	-0.61	-0.48	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
LAML	cis	rs8031584	0.678	rs35098644	ENSG00000260382.1	RP11-540B6.2	4.67	1.35e-05	0.0246	0.56	0.48	Huntington's disease progression;	chr15:30853237	chr15:30882267~30883231:-
LAML	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-4.67	1.35e-05	0.0246	-0.58	-0.48	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
LAML	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-4.67	1.35e-05	0.0246	-0.58	-0.48	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
LAML	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-4.67	1.35e-05	0.0246	-0.58	-0.48	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
LAML	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-4.67	1.35e-05	0.0246	-0.53	-0.48	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
LAML	cis	rs293748	0.571	rs13177573	ENSG00000270558.1	CTD-2124B8.2	4.67	1.35e-05	0.0246	0.56	0.48	Obesity-related traits;	chr5:37233335	chr5:37286449~37286977:-
LAML	cis	rs7829975	0.564	rs2921060	ENSG00000253893.2	FAM85B	4.67	1.35e-05	0.0246	0.59	0.48	Mood instability;	chr8:8460307	chr8:8167819~8226614:-
LAML	cis	rs2404602	0.735	rs4886493	ENSG00000259422.1	RP11-593F23.1	-4.67	1.35e-05	0.0246	-0.56	-0.48	Blood metabolite levels;	chr15:76386685	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.735	rs12903874	ENSG00000259422.1	RP11-593F23.1	-4.67	1.35e-05	0.0246	-0.56	-0.48	Blood metabolite levels;	chr15:76400977	chr15:76174891~76181486:-
LAML	cis	rs10500715	0.715	rs2403228	ENSG00000254719.1	RP11-351I24.3	-4.67	1.35e-05	0.0246	-0.59	-0.48	Pancreatic cancer;	chr11:9965481	chr11:10272052~10272259:-
LAML	cis	rs2980439	0.818	rs2948294	ENSG00000253893.2	FAM85B	-4.67	1.35e-05	0.0246	-0.6	-0.48	Neuroticism;	chr8:8237439	chr8:8167819~8226614:-
LAML	cis	rs7613595	0.507	rs11549706	ENSG00000272498.1	RP11-415F23.3	4.67	1.36e-05	0.0247	0.63	0.48	Sum eosinophil basophil counts;	chr3:17090009	chr3:16339308~16339871:+
LAML	cis	rs12200782	0.929	rs72836467	ENSG00000275846.1	RP11-457M11.7	-4.67	1.36e-05	0.0247	-1.02	-0.48	Small cell lung carcinoma;	chr6:26353699	chr6:26602733~26606661:+
LAML	cis	rs12200782	0.929	rs116018523	ENSG00000275846.1	RP11-457M11.7	-4.67	1.36e-05	0.0247	-1.02	-0.48	Small cell lung carcinoma;	chr6:26357006	chr6:26602733~26606661:+
LAML	cis	rs12200782	0.929	rs72841519	ENSG00000275846.1	RP11-457M11.7	-4.67	1.36e-05	0.0247	-1.02	-0.48	Small cell lung carcinoma;	chr6:26371673	chr6:26602733~26606661:+
LAML	cis	rs853679	0.546	rs35017208	ENSG00000220721.1	OR1F12	4.67	1.36e-05	0.0247	0.77	0.48	Depression;	chr6:28377505	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs36092177	ENSG00000220721.1	OR1F12	4.67	1.36e-05	0.0247	0.77	0.48	Depression;	chr6:28390030	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs2232429	ENSG00000220721.1	OR1F12	4.67	1.36e-05	0.0247	0.77	0.48	Depression;	chr6:28391855	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs2232426	ENSG00000220721.1	OR1F12	4.67	1.36e-05	0.0247	0.77	0.48	Depression;	chr6:28392882	chr6:28073316~28074233:+
LAML	cis	rs853679	0.546	rs2232423	ENSG00000220721.1	OR1F12	4.67	1.36e-05	0.0247	0.77	0.48	Depression;	chr6:28398374	chr6:28073316~28074233:+
LAML	cis	rs8067354	0.574	rs1295923	ENSG00000266960.1	FAM106DP	4.67	1.36e-05	0.0247	0.77	0.48	Hemoglobin concentration;	chr17:59883075	chr17:60173322~60173822:+
LAML	cis	rs67311347	1	rs56992941	ENSG00000230274.1	PGAM1P3	4.67	1.36e-05	0.0247	0.6	0.48	Renal cell carcinoma;	chr3:40430943	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs4974017	ENSG00000230274.1	PGAM1P3	4.67	1.36e-05	0.0247	0.6	0.48	Renal cell carcinoma;	chr3:40432028	chr3:40322715~40323279:-
LAML	cis	rs3130844	1	rs3130844	ENSG00000187763.3	OR2B7P	4.67	1.36e-05	0.0247	0.93	0.48	Urinary tract infection frequency;	chr6:28948817	chr6:28046434~28047367:+
LAML	cis	rs148696809	1	rs148696809	ENSG00000187763.3	OR2B7P	4.67	1.36e-05	0.0247	0.93	0.48	Lung cancer;Squamous cell lung carcinoma;	chr6:28966575	chr6:28046434~28047367:+
LAML	cis	rs8031584	0.678	rs798127	ENSG00000259845.1	HERC2P10	-4.67	1.36e-05	0.0247	-0.53	-0.48	Huntington's disease progression;	chr15:30825200	chr15:30815271~30844153:+
LAML	cis	rs10108033	1	rs6470937	ENSG00000253507.4	CTD-2501M5.1	-4.67	1.37e-05	0.0248	-0.6	-0.48	IgG glycosylation;	chr8:131329435	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.822	rs6993203	ENSG00000253507.4	CTD-2501M5.1	-4.67	1.37e-05	0.0248	-0.6	-0.48	IgG glycosylation;	chr8:131345610	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs7011278	ENSG00000253507.4	CTD-2501M5.1	-4.67	1.37e-05	0.0248	-0.6	-0.48	IgG glycosylation;	chr8:131345826	chr8:131308545~131317632:+
LAML	cis	rs1789	0.903	rs4616746	ENSG00000249930.1	AC007016.3	-4.67	1.37e-05	0.0248	-0.58	-0.48	Blood protein levels;	chr4:15671475	chr4:15492729~15492972:-
LAML	cis	rs1789	0.868	rs4631041	ENSG00000249930.1	AC007016.3	-4.67	1.37e-05	0.0248	-0.58	-0.48	Blood protein levels;	chr4:15671772	chr4:15492729~15492972:-
LAML	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	4.67	1.37e-05	0.0249	0.93	0.48	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
LAML	cis	rs785830	0.717	rs617453	ENSG00000235880.1	RP11-59O6.3	4.67	1.37e-05	0.0249	0.41	0.48	Platelet distribution width;	chr9:223339	chr9:267966~273002:-
LAML	cis	rs785830	0.689	rs1536608	ENSG00000235880.1	RP11-59O6.3	4.67	1.37e-05	0.0249	0.41	0.48	Platelet distribution width;	chr9:223613	chr9:267966~273002:-
LAML	cis	rs785830	0.717	rs602742	ENSG00000235880.1	RP11-59O6.3	4.67	1.37e-05	0.0249	0.41	0.48	Platelet distribution width;	chr9:224338	chr9:267966~273002:-
LAML	cis	rs4879656	0.525	rs35995793	ENSG00000225693.1	LAGE3P1	4.67	1.37e-05	0.0249	0.54	0.48	Menopause (age at onset);	chr9:32947841	chr9:33019682~33020165:-
LAML	cis	rs7829975	0.755	rs3789849	ENSG00000268955.2	RP11-556O5.6	-4.67	1.37e-05	0.0249	-0.59	-0.48	Mood instability;	chr8:8829544	chr8:8188535~8189195:-
LAML	cis	rs10463316	0.817	rs7701271	ENSG00000260581.1	CTB-113P19.4	-4.67	1.37e-05	0.0249	-0.42	-0.48	Metabolite levels (Pyroglutamine);	chr5:151397147	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.817	rs58892766	ENSG00000260581.1	CTB-113P19.4	4.67	1.37e-05	0.0249	0.42	0.48	Metabolite levels (Pyroglutamine);	chr5:151396554	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.779	rs1810084	ENSG00000260581.1	CTB-113P19.4	4.67	1.37e-05	0.0249	0.42	0.48	Metabolite levels (Pyroglutamine);	chr5:151397487	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.779	rs6896444	ENSG00000260581.1	CTB-113P19.4	4.67	1.37e-05	0.0249	0.42	0.48	Metabolite levels (Pyroglutamine);	chr5:151397796	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.817	rs10476770	ENSG00000260581.1	CTB-113P19.4	4.67	1.37e-05	0.0249	0.42	0.48	Metabolite levels (Pyroglutamine);	chr5:151398159	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.817	rs6897109	ENSG00000260581.1	CTB-113P19.4	4.67	1.37e-05	0.0249	0.42	0.48	Metabolite levels (Pyroglutamine);	chr5:151398177	chr5:151652275~151655449:+
LAML	cis	rs9322193	0.516	rs1999632	ENSG00000216906.2	RP11-350J20.9	4.67	1.37e-05	0.0249	0.73	0.48	Lung cancer;	chr6:149866737	chr6:149904243~149906418:+
LAML	cis	rs4753788	0.668	rs7949240	ENSG00000261098.1	RP11-819C21.1	-4.67	1.38e-05	0.025	-0.44	-0.48	Coronary artery disease;	chr11:107189253	chr11:107312132~107316271:-
LAML	cis	rs4753788	0.787	rs7129056	ENSG00000261098.1	RP11-819C21.1	-4.67	1.38e-05	0.025	-0.44	-0.48	Coronary artery disease;	chr11:107193079	chr11:107312132~107316271:-
LAML	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	4.67	1.38e-05	0.025	0.65	0.48	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
LAML	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	4.67	1.38e-05	0.025	0.65	0.48	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
LAML	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-4.67	1.38e-05	0.0251	-0.59	-0.48	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
LAML	cis	rs8037137	0.822	rs2890156	ENSG00000258725.1	PRC1-AS1	-4.66	1.39e-05	0.0252	-0.84	-0.48	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:90969927	chr15:90966345~90988624:+
LAML	cis	rs10108033	0.749	rs6470947	ENSG00000253507.4	CTD-2501M5.1	4.66	1.39e-05	0.0252	0.49	0.48	IgG glycosylation;	chr8:131342032	chr8:131308545~131317632:+
LAML	cis	rs12052801	0.967	rs6712038	ENSG00000221443.1	AC017083.1	4.66	1.39e-05	0.0252	0.54	0.48	Schizophrenia;	chr2:68265755	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs6759433	ENSG00000221443.1	AC017083.1	4.66	1.39e-05	0.0252	0.54	0.48	Schizophrenia;	chr2:68268331	chr2:68273104~68273206:+
LAML	cis	rs904251	0.861	rs2776875	ENSG00000204110.6	RP1-153P14.8	-4.66	1.39e-05	0.0252	-0.62	-0.48	Cognitive performance;	chr6:37519020	chr6:37507348~37535616:+
LAML	cis	rs4713118	0.662	rs175954	ENSG00000187763.3	OR2B7P	4.66	1.39e-05	0.0252	0.71	0.48	Parkinson's disease;	chr6:28043807	chr6:28046434~28047367:+
LAML	cis	rs9322193	0.566	rs6912330	ENSG00000216906.2	RP11-350J20.9	-4.66	1.39e-05	0.0252	-0.71	-0.48	Lung cancer;	chr6:149908811	chr6:149904243~149906418:+
LAML	cis	rs11577318	0.626	rs11806568	ENSG00000225854.2	RP11-569G9.7	-4.66	1.39e-05	0.0252	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26360346	chr1:26326688~26327033:+
LAML	cis	rs11577318	0.579	rs35456934	ENSG00000225854.2	RP11-569G9.7	-4.66	1.39e-05	0.0252	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26360373	chr1:26326688~26327033:+
LAML	cis	rs11577318	0.538	rs10902745	ENSG00000225854.2	RP11-569G9.7	-4.66	1.39e-05	0.0252	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26360579	chr1:26326688~26327033:+
LAML	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	4.66	1.39e-05	0.0252	0.69	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
LAML	cis	rs8037137	0.915	rs79253100	ENSG00000258725.1	PRC1-AS1	-4.66	1.39e-05	0.0252	-0.85	-0.48	Platelet count;Invasive epithelial ovarian cancer;Serous invasive ovarian cancer;High-grade serous ovarian cancer;	chr15:91008646	chr15:90966345~90988624:+
LAML	cis	rs7917772	0.503	rs7902306	ENSG00000228657.1	RP11-170J3.2	-4.66	1.4e-05	0.0252	-0.6	-0.48	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;	chr10:102530705	chr10:102572757~102573225:-
LAML	cis	rs11096990	0.964	rs6831700	ENSG00000206675.1	RNU6-32P	4.66	1.4e-05	0.0253	0.46	0.48	Cognitive function;	chr4:39255344	chr4:39297605~39297711:-
LAML	cis	rs9399135	1	rs6569988	ENSG00000232876.1	CTA-212D2.2	-4.66	1.4e-05	0.0253	-0.63	-0.48	Red blood cell count;	chr6:135031165	chr6:135055033~135060550:+
LAML	cis	rs9399135	1	rs4896130	ENSG00000232876.1	CTA-212D2.2	-4.66	1.4e-05	0.0253	-0.63	-0.48	Red blood cell count;	chr6:135033980	chr6:135055033~135060550:+
LAML	cis	rs9399135	1	rs11754265	ENSG00000232876.1	CTA-212D2.2	-4.66	1.4e-05	0.0253	-0.63	-0.48	Red blood cell count;	chr6:135035078	chr6:135055033~135060550:+
LAML	cis	rs9399135	1	rs9399135	ENSG00000232876.1	CTA-212D2.2	-4.66	1.4e-05	0.0253	-0.63	-0.48	Red blood cell count;	chr6:135047176	chr6:135055033~135060550:+
LAML	cis	rs6951245	0.554	rs10270249	ENSG00000229043.2	AC091729.9	-4.66	1.4e-05	0.0253	-0.59	-0.48	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112250	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.529	rs76001997	ENSG00000229043.2	AC091729.9	-4.66	1.4e-05	0.0253	-0.59	-0.48	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112979	chr7:1160374~1165267:+
LAML	cis	rs6951245	0.554	rs79367977	ENSG00000229043.2	AC091729.9	-4.66	1.4e-05	0.0253	-0.59	-0.48	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1113021	chr7:1160374~1165267:+
LAML	cis	rs785830	0.717	rs542669	ENSG00000235880.1	RP11-59O6.3	4.66	1.4e-05	0.0254	0.41	0.48	Platelet distribution width;	chr9:224367	chr9:267966~273002:-
LAML	cis	rs9952991	0.654	rs35923716	ENSG00000260302.1	RP11-973H7.1	4.66	1.4e-05	0.0254	0.9	0.48	Inflammatory skin disease;	chr18:12885578	chr18:12774651~12775923:-
LAML	cis	rs9952991	0.599	rs35954636	ENSG00000260302.1	RP11-973H7.1	4.66	1.4e-05	0.0254	0.9	0.48	Inflammatory skin disease;	chr18:12886442	chr18:12774651~12775923:-
LAML	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	4.66	1.4e-05	0.0254	0.5	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
LAML	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	4.66	1.41e-05	0.0254	0.62	0.48	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
LAML	cis	rs2120335	0.671	rs62641636	ENSG00000221443.1	AC017083.1	4.66	1.41e-05	0.0254	0.64	0.48	Height;	chr2:68198295	chr2:68273104~68273206:+
LAML	cis	rs2120335	0.701	rs62145959	ENSG00000221443.1	AC017083.1	4.66	1.41e-05	0.0254	0.64	0.48	Height;	chr2:68209611	chr2:68273104~68273206:+
LAML	cis	rs785830	0.636	rs601023	ENSG00000235880.1	RP11-59O6.3	4.66	1.41e-05	0.0255	0.41	0.48	Platelet distribution width;	chr9:224693	chr9:267966~273002:-
LAML	cis	rs785830	0.717	rs600951	ENSG00000235880.1	RP11-59O6.3	4.66	1.41e-05	0.0255	0.41	0.48	Platelet distribution width;	chr9:224742	chr9:267966~273002:-
LAML	cis	rs6452524	0.967	rs2662243	ENSG00000249664.1	CTD-2227C6.2	4.66	1.41e-05	0.0255	0.66	0.48	Hypertension (SNP x SNP interaction);	chr5:83192630	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs2731846	ENSG00000249664.1	CTD-2227C6.2	4.66	1.41e-05	0.0255	0.66	0.48	Hypertension (SNP x SNP interaction);	chr5:83193781	chr5:83012285~83013109:-
LAML	cis	rs747782	0.527	rs3741410	ENSG00000263693.1	MIR3161	4.66	1.42e-05	0.0256	0.42	0.48	Intraocular pressure;	chr11:48147112	chr11:48096782~48096858:+
LAML	cis	rs6897545	1	rs6897545	ENSG00000188002.9	RP11-43F13.1	-4.66	1.42e-05	0.0256	-0.69	-0.48	Lung adenocarcinoma;	chr5:1619020	chr5:1598920~1634005:-
LAML	cis	rs12931792	0.687	rs8057425	ENSG00000273724.1	RP11-347C12.12	4.66	1.42e-05	0.0256	0.48	0.48	Tonsillectomy;	chr16:30171220	chr16:30336400~30343336:+
LAML	cis	rs12931792	0.748	rs11150585	ENSG00000273724.1	RP11-347C12.12	4.66	1.42e-05	0.0256	0.48	0.48	Tonsillectomy;	chr16:30172965	chr16:30336400~30343336:+
LAML	cis	rs7534824	1	rs76502103	ENSG00000213421.4	RP11-84O12.2	-4.66	1.42e-05	0.0256	-1.05	-0.48	Refractive astigmatism;	chr1:101167786	chr1:100586649~100587431:-
LAML	cis	rs7534824	1	rs114734967	ENSG00000213421.4	RP11-84O12.2	-4.66	1.42e-05	0.0256	-1.05	-0.48	Refractive astigmatism;	chr1:101172296	chr1:100586649~100587431:-
LAML	cis	rs12594515	1	rs7162201	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45700460	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8029209	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45701291	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs12592190	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45701830	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs11854554	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45702348	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs12185095	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45702437	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs35182335	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45702986	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs11855509	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45703276	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs11855562	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45703461	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8043291	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45704049	chr15:45702640~45703183:+
LAML	cis	rs12594515	0.935	rs8042519	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45704143	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs56412446	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45704226	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs57299255	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45704334	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs56220882	ENSG00000273972.1	CTD-2306A12.1	-4.66	1.42e-05	0.0256	-0.49	-0.48	Weight;Waist circumference;	chr15:45704877	chr15:45702640~45703183:+
LAML	cis	rs7826238	0.566	rs2945886	ENSG00000253893.2	FAM85B	-4.66	1.42e-05	0.0256	-0.58	-0.48	Systolic blood pressure;	chr8:8290748	chr8:8167819~8226614:-
LAML	cis	rs5769707	0.609	rs2007024	ENSG00000280224.1	CTA-722E9.1	-4.66	1.42e-05	0.0257	-0.67	-0.48	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49500568~49501585:+
LAML	cis	rs2980439	0.558	rs2955584	ENSG00000268955.2	RP11-556O5.6	-4.66	1.43e-05	0.0257	-0.6	-0.48	Neuroticism;	chr8:8234652	chr8:8188535~8189195:-
LAML	cis	rs7944735	0.702	rs60515486	ENSG00000263693.1	MIR3161	4.66	1.43e-05	0.0257	0.38	0.48	Intraocular pressure;	chr11:47661173	chr11:48096782~48096858:+
LAML	cis	rs12220777	0.585	rs11201146	ENSG00000230091.5	TMEM254-AS1	-4.66	1.43e-05	0.0258	-0.91	-0.48	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80007581	chr10:80046860~80078912:-
LAML	cis	rs10457838	0.713	rs12201653	ENSG00000220848.4	RPS18P9	4.66	1.43e-05	0.0258	0.52	0.48	Post-traumatic stress disorder;	chr6:149016029	chr6:149594084~149594543:+
LAML	cis	rs10463316	0.817	rs10040628	ENSG00000260581.1	CTB-113P19.4	4.66	1.43e-05	0.0258	0.42	0.48	Metabolite levels (Pyroglutamine);	chr5:151441466	chr5:151652275~151655449:+
LAML	cis	rs2799081	1	rs2799081	ENSG00000220721.1	OR1F12	4.66	1.44e-05	0.0259	0.49	0.48	Myopia;	chr6:28302807	chr6:28073316~28074233:+
LAML	cis	rs12052801	0.967	rs2902065	ENSG00000221443.1	AC017083.1	4.66	1.44e-05	0.0259	0.55	0.48	Schizophrenia;	chr2:68255195	chr2:68273104~68273206:+
LAML	cis	rs7746199	0.736	rs13195636	ENSG00000182477.5	OR2B8P	4.66	1.44e-05	0.0259	0.95	0.48	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28053228~28054165:-
LAML	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	4.66	1.44e-05	0.0259	0.57	0.48	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	4.66	1.44e-05	0.0259	0.57	0.48	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
LAML	cis	rs10108033	0.915	rs10092998	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131318294	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.841	rs10093111	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131318394	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs10093320	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131318426	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs10108033	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131318469	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs55699404	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131319209	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.841	rs6470933	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131319475	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.687	rs7463506	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131320074	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7463535	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131320118	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7830043	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131326434	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7833395	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131326502	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7817237	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131326513	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7834038	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131326714	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.722	rs6470934	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131327669	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs6470935	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131328158	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs6470936	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131328959	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs6987231	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131329247	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7461211	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131329526	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs10956593	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131330216	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs10956594	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131330228	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.778	rs7464808	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131330442	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7462177	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131330614	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.673	rs7460334	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131332450	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs7463943	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131332594	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs7008706	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131333299	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs10100486	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131333649	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.524	rs10113504	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131333691	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs7461952	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131333950	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7464914	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131334042	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7465001	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131334111	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.822	rs6470945	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131340519	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs6415542	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131340665	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs6413554	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131340944	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs6413555	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131341015	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs4593523	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131342243	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.822	rs4615555	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131342374	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs7461993	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131343080	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.822	rs7465333	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131343235	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs6470950	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.44e-05	0.0259	-0.6	-0.48	IgG glycosylation;	chr8:131343978	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs4495407	ENSG00000253507.4	CTD-2501M5.1	4.65	1.44e-05	0.0259	0.6	0.48	IgG glycosylation;	chr8:131325776	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7833545	ENSG00000253507.4	CTD-2501M5.1	4.65	1.44e-05	0.0259	0.6	0.48	IgG glycosylation;	chr8:131326651	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs10956595	ENSG00000253507.4	CTD-2501M5.1	4.65	1.44e-05	0.0259	0.6	0.48	IgG glycosylation;	chr8:131331205	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7002724	ENSG00000253507.4	CTD-2501M5.1	4.65	1.44e-05	0.0259	0.6	0.48	IgG glycosylation;	chr8:131331668	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs7008898	ENSG00000253507.4	CTD-2501M5.1	4.65	1.44e-05	0.0259	0.6	0.48	IgG glycosylation;	chr8:131333451	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs4279577	ENSG00000253507.4	CTD-2501M5.1	4.65	1.44e-05	0.0259	0.6	0.48	IgG glycosylation;	chr8:131342422	chr8:131308545~131317632:+
LAML	cis	rs7301826	0.651	rs1554807	ENSG00000256250.1	RP11-989F5.1	4.65	1.44e-05	0.0259	0.62	0.48	Plasma plasminogen activator levels;	chr12:130795872	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs2037789	ENSG00000256250.1	RP11-989F5.1	4.65	1.44e-05	0.0259	0.62	0.48	Plasma plasminogen activator levels;	chr12:130803747	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.61	rs7957899	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130794531	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs1973834	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130795612	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs4759517	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130799153	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs7132657	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130800642	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs7971046	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130802262	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs10734979	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130804409	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs4759519	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130804963	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.627	rs10773823	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130809956	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.627	rs73162873	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130811468	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs12228957	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130811521	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs12228959	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130811523	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.61	rs4759789	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130811835	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.61	rs4759791	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130811950	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs4759521	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130812768	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs10734981	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130813350	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs10744483	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130813661	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs10744484	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130813961	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs10773825	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130814368	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs7295705	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130817340	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs10848210	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130827475	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.627	rs4325342	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130827937	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.627	rs1077317	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130830432	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.651	rs4759525	ENSG00000256250.1	RP11-989F5.1	-4.65	1.44e-05	0.0259	-0.62	-0.48	Plasma plasminogen activator levels;	chr12:130831736	chr12:130810606~130812438:+
LAML	cis	rs6951245	0.655	rs80116805	ENSG00000229043.2	AC091729.9	-4.65	1.45e-05	0.0259	-0.78	-0.48	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:946128	chr7:1160374~1165267:+
LAML	cis	rs853679	0.556	rs13200214	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Depression;	chr6:28049472	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs71559070	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Depression;	chr6:28071151	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs35902873	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Depression;	chr6:28091171	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13197574	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Depression;	chr6:28092461	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs34166054	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Depression;	chr6:28098023	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs34662244	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Depression;	chr6:28106103	chr6:28033947~28034855:+
LAML	cis	rs35952432	1	rs35952432	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Lung cancer;	chr6:28107123	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13203816	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Depression;	chr6:28111820	chr6:28033947~28034855:+
LAML	cis	rs853679	0.556	rs34588114	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Depression;	chr6:28112850	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs68188794	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Depression;	chr6:28112999	chr6:28033947~28034855:+
LAML	cis	rs853679	0.546	rs34371502	ENSG00000217315.1	OR2W2P	4.65	1.45e-05	0.0259	0.92	0.48	Depression;	chr6:28113980	chr6:28033947~28034855:+
LAML	cis	rs8067354	0.574	rs2526358	ENSG00000266960.1	FAM106DP	4.65	1.45e-05	0.0259	0.78	0.48	Hemoglobin concentration;	chr17:59865224	chr17:60173322~60173822:+
LAML	cis	rs13217239	0.646	rs10946888	ENSG00000243307.2	POM121L6P	4.65	1.45e-05	0.026	0.57	0.48	Schizophrenia;	chr6:26983899	chr6:26896952~26898777:+
LAML	cis	rs9426935	0.932	rs11264736	ENSG00000273026.1	RP11-422P24.10	-4.65	1.45e-05	0.026	-0.61	-0.48	Lentiform nucleus volume;	chr1:153966654	chr1:153966516~153966930:+
LAML	cis	rs709400	0.628	rs6575983	ENSG00000258851.1	RP11-894P9.2	-4.65	1.45e-05	0.026	-0.57	-0.48	Body mass index;	chr14:103403512	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs12879085	ENSG00000258851.1	RP11-894P9.2	4.65	1.45e-05	0.026	0.57	0.48	Body mass index;	chr14:103408083	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs6575984	ENSG00000258851.1	RP11-894P9.2	4.65	1.45e-05	0.026	0.57	0.48	Body mass index;	chr14:103410117	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs7154246	ENSG00000258851.1	RP11-894P9.2	4.65	1.45e-05	0.026	0.57	0.48	Body mass index;	chr14:103410457	chr14:103553421~103561877:+
LAML	cis	rs916888	0.697	rs199516	ENSG00000280985.1	AC217773.1	-4.65	1.45e-05	0.026	-0.66	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:46172089~46172239:-
LAML	cis	rs916888	0.821	rs199514	ENSG00000280985.1	AC217773.1	-4.65	1.45e-05	0.026	-0.66	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:46172089~46172239:-
LAML	cis	rs916888	0.821	rs199513	ENSG00000280985.1	AC217773.1	-4.65	1.45e-05	0.026	-0.66	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:46172089~46172239:-
LAML	cis	rs916888	0.821	rs199512	ENSG00000280985.1	AC217773.1	-4.65	1.45e-05	0.026	-0.66	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:46172089~46172239:-
LAML	cis	rs916888	0.821	rs199509	ENSG00000280985.1	AC217773.1	-4.65	1.45e-05	0.026	-0.66	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:46172089~46172239:-
LAML	cis	rs916888	0.821	rs199507	ENSG00000280985.1	AC217773.1	-4.65	1.45e-05	0.026	-0.66	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:46172089~46172239:-
LAML	cis	rs916888	0.821	rs199505	ENSG00000280985.1	AC217773.1	-4.65	1.45e-05	0.026	-0.66	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:46172089~46172239:-
LAML	cis	rs916888	0.821	rs70602	ENSG00000280985.1	AC217773.1	-4.65	1.45e-05	0.026	-0.66	-0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:46172089~46172239:-
LAML	cis	rs10457838	0.602	rs12205788	ENSG00000220848.4	RPS18P9	4.65	1.45e-05	0.026	0.54	0.48	Post-traumatic stress disorder;	chr6:149014493	chr6:149594084~149594543:+
LAML	cis	rs2120335	0.701	rs62145950	ENSG00000221443.1	AC017083.1	4.65	1.45e-05	0.026	0.61	0.48	Height;	chr2:68171972	chr2:68273104~68273206:+
LAML	cis	rs10108033	0.841	rs11994987	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.45e-05	0.026	-0.6	-0.48	IgG glycosylation;	chr8:131315839	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs10956587	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.45e-05	0.026	-0.6	-0.48	IgG glycosylation;	chr8:131317721	chr8:131308545~131317632:+
LAML	cis	rs2120335	0.701	rs12465425	ENSG00000221443.1	AC017083.1	4.65	1.45e-05	0.026	0.63	0.48	Height;	chr2:68243293	chr2:68273104~68273206:+
LAML	cis	rs763121	0.776	rs4820346	ENSG00000230912.1	RP3-508I15.10	4.65	1.45e-05	0.026	0.41	0.48	Menopause (age at onset);	chr22:38729069	chr22:38666508~38668750:-
LAML	cis	rs9788721	0.836	rs55983731	ENSG00000259474.1	RP11-650L12.1	-4.65	1.46e-05	0.0261	-0.51	-0.48	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78442927	chr15:78480057~78481820:-
LAML	cis	rs9788721	0.836	rs72738718	ENSG00000259474.1	RP11-650L12.1	-4.65	1.46e-05	0.0261	-0.51	-0.48	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78443096	chr15:78480057~78481820:-
LAML	cis	rs9788721	0.802	rs56219465	ENSG00000259474.1	RP11-650L12.1	-4.65	1.46e-05	0.0261	-0.51	-0.48	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78450237	chr15:78480057~78481820:-
LAML	cis	rs904251	0.965	rs1317563	ENSG00000227920.2	RP1-153P14.5	-4.65	1.46e-05	0.0261	-0.57	-0.48	Cognitive performance;	chr6:37484078	chr6:37545145~37550860:+
LAML	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	4.65	1.46e-05	0.0261	0.63	0.48	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
LAML	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	4.65	1.46e-05	0.0261	0.63	0.48	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
LAML	cis	rs7165170	0.719	rs5011652	ENSG00000259314.1	CTD-3065B20.3	-4.65	1.46e-05	0.0261	-0.49	-0.48	Crohn's disease;Inflammatory bowel disease;	chr15:90623376	chr15:90604225~90614558:-
LAML	cis	rs7165170	0.719	rs5011651	ENSG00000259314.1	CTD-3065B20.3	-4.65	1.46e-05	0.0261	-0.49	-0.48	Crohn's disease;Inflammatory bowel disease;	chr15:90623381	chr15:90604225~90614558:-
LAML	cis	rs9399135	0.967	rs4895434	ENSG00000232876.1	CTA-212D2.2	-4.65	1.46e-05	0.0262	-0.63	-0.48	Red blood cell count;	chr6:134972227	chr6:135055033~135060550:+
LAML	cis	rs9399135	1	rs4895435	ENSG00000232876.1	CTA-212D2.2	-4.65	1.46e-05	0.0262	-0.63	-0.48	Red blood cell count;	chr6:134972325	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4896123	ENSG00000232876.1	CTA-212D2.2	-4.65	1.46e-05	0.0262	-0.63	-0.48	Red blood cell count;	chr6:134974272	chr6:135055033~135060550:+
LAML	cis	rs2980439	0.729	rs2955585	ENSG00000268955.2	RP11-556O5.6	-4.65	1.46e-05	0.0262	-0.6	-0.48	Neuroticism;	chr8:8235989	chr8:8188535~8189195:-
LAML	cis	rs6968355	0.789	rs2430480	ENSG00000225329.2	LHFPL3-AS2	4.65	1.46e-05	0.0262	0.73	0.48	Myopia (pathological);	chr7:104953901	chr7:104894628~104926645:-
LAML	cis	rs67311347	0.713	rs73073505	ENSG00000230274.1	PGAM1P3	4.65	1.46e-05	0.0262	0.62	0.48	Renal cell carcinoma;	chr3:40269202	chr3:40322715~40323279:-
LAML	cis	rs4713118	0.614	rs9468209	ENSG00000216915.2	RP1-97D16.1	-4.65	1.46e-05	0.0262	-0.55	-0.48	Parkinson's disease;	chr6:27726642	chr6:27737000~27738494:-
LAML	cis	rs4713118	0.662	rs4713120	ENSG00000216915.2	RP1-97D16.1	-4.65	1.46e-05	0.0262	-0.55	-0.48	Parkinson's disease;	chr6:27754056	chr6:27737000~27738494:-
LAML	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-4.65	1.46e-05	0.0262	-0.53	-0.48	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
LAML	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
LAML	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
LAML	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
LAML	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
LAML	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
LAML	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0262	-0.49	-0.48	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	4.65	1.47e-05	0.0262	0.49	0.48	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-4.65	1.47e-05	0.0263	-0.49	-0.48	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
LAML	cis	rs67311347	1	rs13073003	ENSG00000230274.1	PGAM1P3	-4.65	1.48e-05	0.0263	-0.62	-0.48	Renal cell carcinoma;	chr3:40462835	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs6801185	ENSG00000230274.1	PGAM1P3	-4.65	1.48e-05	0.0263	-0.62	-0.48	Renal cell carcinoma;	chr3:40463569	chr3:40322715~40323279:-
LAML	cis	rs67311347	0.956	rs9822870	ENSG00000230274.1	PGAM1P3	-4.65	1.48e-05	0.0263	-0.62	-0.48	Renal cell carcinoma;	chr3:40473399	chr3:40322715~40323279:-
LAML	cis	rs716804	0.566	rs9645625	ENSG00000254719.1	RP11-351I24.3	-4.65	1.48e-05	0.0264	-0.57	-0.48	Neuroticism;	chr11:10049286	chr11:10272052~10272259:-
LAML	cis	rs716804	0.515	rs6483883	ENSG00000254719.1	RP11-351I24.3	-4.65	1.48e-05	0.0264	-0.59	-0.48	Neuroticism;	chr11:10011718	chr11:10272052~10272259:-
LAML	cis	rs716804	0.593	rs2403290	ENSG00000254719.1	RP11-351I24.3	-4.65	1.48e-05	0.0264	-0.59	-0.48	Neuroticism;	chr11:10104045	chr11:10272052~10272259:-
LAML	cis	rs7458938	0.629	rs4731266	ENSG00000224897.5	POT1-AS1	4.65	1.48e-05	0.0264	0.55	0.48	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125803883	chr7:124929873~125179315:+
LAML	cis	rs7458938	0.629	rs4731267	ENSG00000224897.5	POT1-AS1	4.65	1.48e-05	0.0264	0.55	0.48	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125805111	chr7:124929873~125179315:+
LAML	cis	rs7458938	0.605	rs10270570	ENSG00000224897.5	POT1-AS1	4.65	1.48e-05	0.0264	0.55	0.48	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125806544	chr7:124929873~125179315:+
LAML	cis	rs7458938	0.629	rs2107084	ENSG00000224897.5	POT1-AS1	-4.65	1.48e-05	0.0264	-0.55	-0.48	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125805528	chr7:124929873~125179315:+
LAML	cis	rs10108033	0.915	rs11775509	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.48e-05	0.0264	-0.61	-0.48	IgG glycosylation;	chr8:131318118	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.778	rs4526341	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.48e-05	0.0264	-0.61	-0.48	IgG glycosylation;	chr8:131318699	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs6470932	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.48e-05	0.0264	-0.61	-0.48	IgG glycosylation;	chr8:131319445	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs6415534	ENSG00000253507.4	CTD-2501M5.1	4.65	1.48e-05	0.0264	0.61	0.48	IgG glycosylation;	chr8:131320973	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.841	rs10103835	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.48e-05	0.0264	-0.61	-0.48	IgG glycosylation;	chr8:131326206	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs9642895	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.48e-05	0.0264	-0.61	-0.48	IgG glycosylation;	chr8:131327024	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs7464564	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.48e-05	0.0264	-0.61	-0.48	IgG glycosylation;	chr8:131329539	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs10956596	ENSG00000253507.4	CTD-2501M5.1	-4.65	1.48e-05	0.0264	-0.61	-0.48	IgG glycosylation;	chr8:131331318	chr8:131308545~131317632:+
LAML	cis	rs13113518	0.783	rs7690837	ENSG00000249700.7	SRD5A3-AS1	4.65	1.48e-05	0.0264	0.5	0.48	Height;	chr4:55575856	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.783	rs12510400	ENSG00000249700.7	SRD5A3-AS1	4.65	1.48e-05	0.0264	0.5	0.48	Height;	chr4:55577294	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.783	rs13111128	ENSG00000249700.7	SRD5A3-AS1	4.65	1.48e-05	0.0264	0.5	0.48	Height;	chr4:55578154	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.783	rs1586555	ENSG00000249700.7	SRD5A3-AS1	4.65	1.48e-05	0.0264	0.5	0.48	Height;	chr4:55587104	chr4:55363971~55395847:-
LAML	cis	rs7829975	0.593	rs2921061	ENSG00000253893.2	FAM85B	-4.65	1.48e-05	0.0265	-0.59	-0.48	Mood instability;	chr8:8460105	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.564	rs2921057	ENSG00000253893.2	FAM85B	-4.65	1.48e-05	0.0265	-0.59	-0.48	Mood instability;	chr8:8461157	chr8:8167819~8226614:-
LAML	cis	rs916888	0.773	rs199439	ENSG00000280985.1	AC217773.1	4.65	1.49e-05	0.0265	0.67	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:46172089~46172239:-
LAML	cis	rs7927771	1	rs2290850	ENSG00000280615.1	Y_RNA	-4.65	1.49e-05	0.0265	-0.66	-0.48	Subjective well-being;	chr11:47786222	chr11:47614898~47614994:-
LAML	cis	rs3093024	1	rs3093023	ENSG00000227598.1	RP1-167A14.2	4.65	1.49e-05	0.0265	0.67	0.48	Rheumatoid arthritis;	chr6:167120802	chr6:166969626~166999065:-
LAML	cis	rs2404602	0.735	rs2454450	ENSG00000259422.1	RP11-593F23.1	-4.65	1.49e-05	0.0265	-0.55	-0.48	Blood metabolite levels;	chr15:76538895	chr15:76174891~76181486:-
LAML	cis	rs6951245	0.938	rs112425403	ENSG00000229043.2	AC091729.9	-4.65	1.49e-05	0.0265	-0.79	-0.48	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1031895	chr7:1160374~1165267:+
LAML	cis	rs6452524	0.901	rs12514607	ENSG00000249664.1	CTD-2227C6.2	-4.65	1.49e-05	0.0265	-0.66	-0.48	Hypertension (SNP x SNP interaction);	chr5:83209710	chr5:83012285~83013109:-
LAML	cis	rs9916302	0.904	rs12600751	ENSG00000223091.1	RNU6-981P	4.65	1.49e-05	0.0265	0.59	0.48	Glomerular filtration rate (creatinine);	chr17:39397398	chr17:39482486~39482590:-
LAML	cis	rs933769	1	rs933770	ENSG00000242295.1	RP11-522B15.1	4.65	1.49e-05	0.0265	0.66	0.48	Alcoholism (alcohol dependence factor score);	chr15:95509493	chr15:96448154~96448493:+
LAML	cis	rs933769	1	rs933769	ENSG00000242295.1	RP11-522B15.1	4.65	1.49e-05	0.0265	0.66	0.48	Alcoholism (alcohol dependence factor score);	chr15:95509513	chr15:96448154~96448493:+
LAML	cis	rs673253	0.65	rs2819335	ENSG00000227163.2	RP5-1198O20.5	4.65	1.49e-05	0.0265	0.59	0.48	Intelligence (multi-trait analysis);	chr1:43549154	chr1:44087958~44088477:-
LAML	cis	rs12931792	0.782	rs6565176	ENSG00000273724.1	RP11-347C12.12	4.65	1.49e-05	0.0265	0.48	0.48	Tonsillectomy;	chr16:30163605	chr16:30336400~30343336:+
LAML	cis	rs12931792	0.72	rs12102320	ENSG00000273724.1	RP11-347C12.12	4.65	1.49e-05	0.0265	0.48	0.48	Tonsillectomy;	chr16:30167195	chr16:30336400~30343336:+
LAML	cis	rs7746199	0.736	rs35037868	ENSG00000217315.1	OR2W2P	4.65	1.49e-05	0.0266	0.92	0.48	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28033947~28034855:+
LAML	cis	rs853679	0.546	rs35744819	ENSG00000182477.5	OR2B8P	4.64	1.5e-05	0.0266	0.91	0.48	Depression;	chr6:28350554	chr6:28053228~28054165:-
LAML	cis	rs6921919	0.562	rs13198809	ENSG00000182477.5	OR2B8P	4.64	1.5e-05	0.0266	0.91	0.48	Autism spectrum disorder or schizophrenia;	chr6:28355925	chr6:28053228~28054165:-
LAML	cis	rs11039798	1	rs9667626	ENSG00000263693.1	MIR3161	4.64	1.5e-05	0.0267	0.5	0.48	Axial length;	chr11:48464325	chr11:48096782~48096858:+
LAML	cis	rs875971	0.862	rs2460432	ENSG00000222364.1	RNU6-96P	4.64	1.5e-05	0.0267	0.6	0.48	Aortic root size;	chr7:66089398	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs1167408	ENSG00000222364.1	RNU6-96P	4.64	1.5e-05	0.0267	0.6	0.48	Aortic root size;	chr7:66091121	chr7:66395191~66395286:+
LAML	cis	rs875971	0.83	rs1167406	ENSG00000222364.1	RNU6-96P	4.64	1.5e-05	0.0267	0.6	0.48	Aortic root size;	chr7:66091949	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs709609	ENSG00000222364.1	RNU6-96P	4.64	1.5e-05	0.0267	0.6	0.48	Aortic root size;	chr7:66095574	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs1167399	ENSG00000222364.1	RNU6-96P	4.64	1.5e-05	0.0267	0.6	0.48	Aortic root size;	chr7:66096890	chr7:66395191~66395286:+
LAML	cis	rs875971	0.862	rs57866200	ENSG00000222364.1	RNU6-96P	4.64	1.5e-05	0.0267	0.6	0.48	Aortic root size;	chr7:66100405	chr7:66395191~66395286:+
LAML	cis	rs9380516	0.524	rs2273000	ENSG00000264878.1	Z85986.1	4.64	1.5e-05	0.0267	0.54	0.48	Hepatitis C induced liver fibrosis;	chr6:35510691	chr6:36510517~36510598:-
LAML	cis	rs9916302	0.904	rs3964723	ENSG00000223091.1	RNU6-981P	-4.64	1.5e-05	0.0267	-0.6	-0.48	Glomerular filtration rate (creatinine);	chr17:39247726	chr17:39482486~39482590:-
LAML	cis	rs2980439	0.558	rs2955584	ENSG00000253893.2	FAM85B	-4.64	1.51e-05	0.0267	-0.6	-0.48	Neuroticism;	chr8:8234652	chr8:8167819~8226614:-
LAML	cis	rs11096990	0.964	rs16988409	ENSG00000206675.1	RNU6-32P	4.64	1.51e-05	0.0268	0.49	0.48	Cognitive function;	chr4:39267730	chr4:39297605~39297711:-
LAML	cis	rs7301826	0.932	rs1007246	ENSG00000256250.1	RP11-989F5.1	-4.64	1.51e-05	0.0268	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130795585	chr12:130810606~130812438:+
LAML	cis	rs7301826	1	rs10773822	ENSG00000256250.1	RP11-989F5.1	-4.64	1.51e-05	0.0268	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130804562	chr12:130810606~130812438:+
LAML	cis	rs7301826	1	rs4759787	ENSG00000256250.1	RP11-989F5.1	-4.64	1.51e-05	0.0268	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130805635	chr12:130810606~130812438:+
LAML	cis	rs7301826	1	rs7301826	ENSG00000256250.1	RP11-989F5.1	-4.64	1.51e-05	0.0268	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130806556	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.966	rs10734980	ENSG00000256250.1	RP11-989F5.1	-4.64	1.51e-05	0.0268	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130810081	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.967	rs4759790	ENSG00000256250.1	RP11-989F5.1	-4.64	1.51e-05	0.0268	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130811845	chr12:130810606~130812438:+
LAML	cis	rs7301826	1	rs4759793	ENSG00000256250.1	RP11-989F5.1	-4.64	1.51e-05	0.0268	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130812693	chr12:130810606~130812438:+
LAML	cis	rs7301826	1	rs1106369	ENSG00000256250.1	RP11-989F5.1	-4.64	1.51e-05	0.0268	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130815550	chr12:130810606~130812438:+
LAML	cis	rs7301826	1	rs4759523	ENSG00000256250.1	RP11-989F5.1	-4.64	1.51e-05	0.0268	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130830867	chr12:130810606~130812438:+
LAML	cis	rs7301826	1	rs4759524	ENSG00000256250.1	RP11-989F5.1	-4.64	1.51e-05	0.0268	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130831065	chr12:130810606~130812438:+
LAML	cis	rs9393777	0.557	rs6933999	ENSG00000187763.3	OR2B7P	4.64	1.51e-05	0.0269	0.64	0.48	Intelligence (multi-trait analysis);	chr6:27107150	chr6:28046434~28047367:+
LAML	cis	rs747650	0.504	rs7130947	ENSG00000271350.1	CTD-2384B9.1	-4.64	1.51e-05	0.0269	-0.59	-0.48	Acne (severe);	chr11:46980454	chr11:47041027~47041945:-
LAML	cis	rs747650	0.504	rs10838641	ENSG00000271350.1	CTD-2384B9.1	-4.64	1.51e-05	0.0269	-0.59	-0.48	Acne (severe);	chr11:46981753	chr11:47041027~47041945:-
LAML	cis	rs11790388	0.745	rs3739554	ENSG00000228487.2	RP13-225O21.2	-4.64	1.52e-05	0.0269	-0.63	-0.48	Schizophrenia;	chr9:127178366	chr9:127213783~127221907:-
LAML	cis	rs9426935	0.932	rs11800001	ENSG00000273026.1	RP11-422P24.10	4.64	1.52e-05	0.0269	0.62	0.48	Lentiform nucleus volume;	chr1:153898374	chr1:153966516~153966930:+
LAML	cis	rs597539	0.552	rs4930616	ENSG00000250508.1	RP11-757G1.6	4.64	1.52e-05	0.0269	0.46	0.48	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68831657	chr11:68870664~68874542:+
LAML	cis	rs12052801	0.903	rs6546357	ENSG00000221443.1	AC017083.1	-4.64	1.52e-05	0.027	-0.59	-0.48	Schizophrenia;	chr2:68151906	chr2:68273104~68273206:+
LAML	cis	rs9457247	1	rs400063	ENSG00000231654.1	RPS6KA2-AS1	-4.64	1.52e-05	0.027	-0.46	-0.48	Crohn's disease;	chr6:166973104	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs439553	ENSG00000231654.1	RPS6KA2-AS1	-4.64	1.52e-05	0.027	-0.46	-0.48	Crohn's disease;	chr6:166977724	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs408087	ENSG00000231654.1	RPS6KA2-AS1	-4.64	1.52e-05	0.027	-0.46	-0.48	Crohn's disease;	chr6:166985464	chr6:166903698~166904835:+
LAML	cis	rs2383876	1	rs4301445	ENSG00000254273.1	RP11-181D18.4	-4.64	1.52e-05	0.027	-0.48	-0.48	Corneal curvature;	chr8:73163140	chr8:73511276~73511654:-
LAML	cis	rs7458938	0.659	rs2402796	ENSG00000224897.5	POT1-AS1	4.64	1.53e-05	0.027	0.56	0.48	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125790648	chr7:124929873~125179315:+
LAML	cis	rs785830	0.729	rs560608	ENSG00000235880.1	RP11-59O6.3	4.64	1.53e-05	0.0271	0.44	0.48	Platelet distribution width;	chr9:270216	chr9:267966~273002:-
LAML	cis	rs2015599	0.56	rs11050147	ENSG00000273680.1	RP11-996F15.6	-4.64	1.53e-05	0.0271	-0.5	-0.48	Platelet count;Mean platelet volume;	chr12:29242746	chr12:29332733~29333383:-
LAML	cis	rs2015599	0.56	rs3948497	ENSG00000273680.1	RP11-996F15.6	-4.64	1.53e-05	0.0271	-0.5	-0.48	Platelet count;Mean platelet volume;	chr12:29247552	chr12:29332733~29333383:-
LAML	cis	rs7301826	0.967	rs4759792	ENSG00000256250.1	RP11-989F5.1	-4.64	1.53e-05	0.0271	-0.6	-0.48	Plasma plasminogen activator levels;	chr12:130812086	chr12:130810606~130812438:+
LAML	cis	rs9309473	0.607	rs10196402	ENSG00000163016.8	ALMS1P	4.64	1.53e-05	0.0271	0.53	0.48	Metabolite levels;	chr2:73344953	chr2:73644919~73685576:+
LAML	cis	rs904251	0.523	rs2776872	ENSG00000229559.2	RP1-153P14.3	-4.64	1.53e-05	0.0272	-0.5	-0.48	Cognitive performance;	chr6:37515011	chr6:37543553~37547280:-
LAML	cis	rs561341	0.7	rs8079471	ENSG00000266379.5	RP11-640N20.8	4.64	1.54e-05	0.0272	0.65	0.48	Hip circumference adjusted for BMI;	chr17:31891298	chr17:32088160~32094933:-
LAML	cis	rs950169	0.922	rs12906983	ENSG00000259728.4	LINC00933	4.64	1.54e-05	0.0272	0.7	0.48	Schizophrenia;	chr15:84262270	chr15:84570649~84580175:+
LAML	cis	rs9399135	0.967	rs6923827	ENSG00000232876.1	CTA-212D2.2	-4.64	1.54e-05	0.0273	-0.63	-0.48	Red blood cell count;	chr6:135014244	chr6:135055033~135060550:+
LAML	cis	rs11098499	0.866	rs7665125	ENSG00000260091.1	RP11-33B1.4	4.64	1.54e-05	0.0273	0.42	0.48	Corneal astigmatism;	chr4:119480924	chr4:119409333~119410233:+
LAML	cis	rs904251	0.523	rs1757191	ENSG00000229559.2	RP1-153P14.3	-4.64	1.55e-05	0.0273	-0.5	-0.48	Cognitive performance;	chr6:37515095	chr6:37543553~37547280:-
LAML	cis	rs9916302	0.8	rs8069451	ENSG00000223091.1	RNU6-981P	-4.64	1.55e-05	0.0273	-0.57	-0.48	Glomerular filtration rate (creatinine);	chr17:39348680	chr17:39482486~39482590:-
LAML	cis	rs12468226	0.746	rs75987655	ENSG00000226261.1	AC064836.3	4.64	1.55e-05	0.0274	0.9	0.48	Urate levels;	chr2:202581913	chr2:202336024~202336727:-
LAML	cis	rs853679	1	rs853685	ENSG00000217315.1	OR2W2P	4.64	1.55e-05	0.0274	0.71	0.48	Depression;	chr6:28321008	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs853679	ENSG00000217315.1	OR2W2P	4.64	1.55e-05	0.0274	0.71	0.48	Depression;	chr6:28329086	chr6:28033947~28034855:+
LAML	cis	rs853679	1	rs853678	ENSG00000217315.1	OR2W2P	4.64	1.55e-05	0.0274	0.71	0.48	Depression;	chr6:28329536	chr6:28033947~28034855:+
LAML	cis	rs9322193	0.847	rs56103941	ENSG00000216906.2	RP11-350J20.9	4.64	1.55e-05	0.0274	0.71	0.48	Lung cancer;	chr6:149816095	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.847	rs12210605	ENSG00000216906.2	RP11-350J20.9	4.64	1.55e-05	0.0274	0.71	0.48	Lung cancer;	chr6:149817267	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9371199	ENSG00000216906.2	RP11-350J20.9	4.64	1.55e-05	0.0274	0.71	0.48	Lung cancer;	chr6:149817526	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs7740784	ENSG00000216906.2	RP11-350J20.9	4.64	1.55e-05	0.0274	0.71	0.48	Lung cancer;	chr6:149833364	chr6:149904243~149906418:+
LAML	cis	rs6964833	1	rs6967152	ENSG00000277053.3	GTF2IP1	-4.64	1.55e-05	0.0274	-0.65	-0.48	Menarche (age at onset);	chr7:74684983	chr7:75185385~75237696:-
LAML	cis	rs17780086	0.529	rs7406406	ENSG00000266379.5	RP11-640N20.8	4.63	1.55e-05	0.0275	0.65	0.48	Height;	chr17:31893134	chr17:32088160~32094933:-
LAML	cis	rs10457838	0.851	rs62426150	ENSG00000220848.4	RPS18P9	4.63	1.56e-05	0.0275	0.52	0.48	Post-traumatic stress disorder;	chr6:149026330	chr6:149594084~149594543:+
LAML	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-4.63	1.56e-05	0.0275	-0.61	-0.48	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
LAML	cis	rs4713118	0.506	rs9366697	ENSG00000216915.2	RP1-97D16.1	-4.63	1.56e-05	0.0275	-0.51	-0.48	Parkinson's disease;	chr6:27665239	chr6:27737000~27738494:-
LAML	cis	rs7301826	1	rs10848205	ENSG00000256250.1	RP11-989F5.1	-4.63	1.56e-05	0.0276	-0.59	-0.48	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810606~130812438:+
LAML	cis	rs7301826	1	rs10744482	ENSG00000256250.1	RP11-989F5.1	-4.63	1.56e-05	0.0276	-0.59	-0.48	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810606~130812438:+
LAML	cis	rs7301826	0.966	rs4759795	ENSG00000256250.1	RP11-989F5.1	-4.63	1.56e-05	0.0276	-0.59	-0.48	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810606~130812438:+
LAML	cis	rs7429990	0.828	rs10446426	ENSG00000228638.1	FCF1P2	4.63	1.56e-05	0.0276	0.51	0.48	Educational attainment (years of education);	chr3:48129031	chr3:48290793~48291375:-
LAML	cis	rs716804	0.566	rs2403265	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10043699	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs2403264	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10043906	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs12360854	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10045480	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs2403230	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10053507	chr11:10272052~10272259:-
LAML	cis	rs716804	0.599	rs4284389	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10053668	chr11:10272052~10272259:-
LAML	cis	rs716804	0.594	rs10840349	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10054883	chr11:10272052~10272259:-
LAML	cis	rs716804	0.621	rs7128591	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10055509	chr11:10272052~10272259:-
LAML	cis	rs716804	0.536	rs10770084	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10056493	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs10840353	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10057887	chr11:10272052~10272259:-
LAML	cis	rs716804	0.562	rs4350354	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10060518	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs10840354	ENSG00000254719.1	RP11-351I24.3	-4.63	1.57e-05	0.0276	-0.59	-0.48	Neuroticism;	chr11:10061784	chr11:10272052~10272259:-
LAML	cis	rs916888	0.821	rs70600	ENSG00000280985.1	AC217773.1	4.63	1.57e-05	0.0277	0.67	0.48	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:46172089~46172239:-
LAML	cis	rs16978956	0.779	rs6045352	ENSG00000214612.3	RPS19P1	-4.63	1.57e-05	0.0277	-0.49	-0.48	Body mass index;	chr20:18346462	chr20:18504633~18505066:+
LAML	cis	rs7131987	0.903	rs67150462	ENSG00000275278.1	RP11-946L16.2	4.63	1.57e-05	0.0277	0.58	0.48	QT interval;	chr12:29240392	chr12:29156448~29156991:-
LAML	cis	rs9322193	0.923	rs12205092	ENSG00000216906.2	RP11-350J20.9	4.63	1.57e-05	0.0277	0.71	0.48	Lung cancer;	chr6:149761375	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs10872651	ENSG00000216906.2	RP11-350J20.9	4.63	1.57e-05	0.0277	0.71	0.48	Lung cancer;	chr6:149768273	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs3805749	ENSG00000216906.2	RP11-350J20.9	4.63	1.57e-05	0.0277	0.71	0.48	Lung cancer;	chr6:149772546	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.847	rs9505972	ENSG00000216906.2	RP11-350J20.9	4.63	1.57e-05	0.0277	0.71	0.48	Lung cancer;	chr6:149775255	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs3805752	ENSG00000216906.2	RP11-350J20.9	4.63	1.57e-05	0.0277	0.71	0.48	Lung cancer;	chr6:149795490	chr6:149904243~149906418:+
LAML	cis	rs6940638	0.744	rs858964	ENSG00000220721.1	OR1F12	-4.63	1.58e-05	0.0277	-0.53	-0.48	Intelligence (multi-trait analysis);	chr6:27174835	chr6:28073316~28074233:+
LAML	cis	rs11096990	0.964	rs6842390	ENSG00000206675.1	RNU6-32P	-4.63	1.58e-05	0.0277	-0.46	-0.48	Cognitive function;	chr4:39261862	chr4:39297605~39297711:-
LAML	cis	rs7429990	0.901	rs7374482	ENSG00000229759.1	MRPS18AP1	-4.63	1.58e-05	0.0278	-0.57	-0.48	Educational attainment (years of education);	chr3:48126900	chr3:48256350~48256938:-
LAML	cis	rs9457247	1	rs416131	ENSG00000231654.1	RPS6KA2-AS1	4.63	1.58e-05	0.0278	0.47	0.48	Crohn's disease;	chr6:166993056	chr6:166903698~166904835:+
LAML	cis	rs853679	1	rs853676	ENSG00000182477.5	OR2B8P	4.63	1.59e-05	0.0278	0.71	0.48	Depression;	chr6:28331910	chr6:28053228~28054165:-
LAML	cis	rs7849270	0.837	rs10819463	ENSG00000268707.1	RP11-247A12.7	-4.63	1.59e-05	0.0279	-0.6	-0.48	Blood metabolite ratios;	chr9:129100958	chr9:129170434~129170940:+
LAML	cis	rs1007738	0.597	rs10838635	ENSG00000271557.1	YPEL5P2	4.63	1.59e-05	0.0279	0.6	0.48	Bone mineral density (hip);	chr11:46923676	chr11:47841324~47841682:+
LAML	cis	rs11096990	0.821	rs76235093	ENSG00000206675.1	RNU6-32P	-4.63	1.59e-05	0.0279	-0.47	-0.48	Cognitive function;	chr4:39281157	chr4:39297605~39297711:-
LAML	cis	rs1150668	0.965	rs1150690	ENSG00000220721.1	OR1F12	4.63	1.59e-05	0.0279	0.5	0.48	Pubertal anthropometrics;	chr6:28197520	chr6:28073316~28074233:+
LAML	cis	rs716804	0.515	rs7128698	ENSG00000254719.1	RP11-351I24.3	4.63	1.59e-05	0.028	0.59	0.48	Neuroticism;	chr11:10034949	chr11:10272052~10272259:-
LAML	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	4.63	1.59e-05	0.028	0.56	0.48	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
LAML	cis	rs8031584	0.678	rs4779496	ENSG00000259845.1	HERC2P10	4.63	1.6e-05	0.028	0.53	0.48	Huntington's disease progression;	chr15:30858851	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.678	rs4779497	ENSG00000259845.1	HERC2P10	4.63	1.6e-05	0.028	0.53	0.48	Huntington's disease progression;	chr15:30859162	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.678	rs8028173	ENSG00000259845.1	HERC2P10	4.63	1.6e-05	0.028	0.53	0.48	Huntington's disease progression;	chr15:30863546	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.706	rs2177670	ENSG00000259845.1	HERC2P10	4.63	1.6e-05	0.028	0.53	0.48	Huntington's disease progression;	chr15:30865548	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.678	rs36047941	ENSG00000259845.1	HERC2P10	4.63	1.6e-05	0.028	0.53	0.48	Huntington's disease progression;	chr15:30867032	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.678	rs4779790	ENSG00000259845.1	HERC2P10	4.63	1.6e-05	0.028	0.53	0.48	Huntington's disease progression;	chr15:30872392	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.678	rs8035703	ENSG00000259845.1	HERC2P10	4.63	1.6e-05	0.028	0.53	0.48	Huntington's disease progression;	chr15:30876269	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.678	rs798125	ENSG00000259845.1	HERC2P10	-4.63	1.6e-05	0.028	-0.53	-0.48	Huntington's disease progression;	chr15:30824597	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.697	rs798080	ENSG00000259845.1	HERC2P10	-4.63	1.6e-05	0.028	-0.53	-0.48	Huntington's disease progression;	chr15:30829966	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.723	rs711224	ENSG00000259845.1	HERC2P10	-4.63	1.6e-05	0.028	-0.53	-0.48	Huntington's disease progression;	chr15:30835718	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.652	rs2691683	ENSG00000259845.1	HERC2P10	-4.63	1.6e-05	0.028	-0.53	-0.48	Huntington's disease progression;	chr15:30842857	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.578	rs1088473	ENSG00000259845.1	HERC2P10	-4.63	1.6e-05	0.028	-0.53	-0.48	Huntington's disease progression;	chr15:30847095	chr15:30815271~30844153:+
LAML	cis	rs7829975	0.5	rs7841082	ENSG00000253893.2	FAM85B	4.63	1.6e-05	0.0281	0.55	0.48	Mood instability;	chr8:8311465	chr8:8167819~8226614:-
LAML	cis	rs9457247	0.905	rs377232	ENSG00000231654.1	RPS6KA2-AS1	-4.63	1.6e-05	0.0281	-0.46	-0.48	Crohn's disease;	chr6:166996150	chr6:166903698~166904835:+
LAML	cis	rs7944735	0.545	rs4752805	ENSG00000263693.1	MIR3161	4.63	1.61e-05	0.0282	0.34	0.48	Intraocular pressure;	chr11:47996803	chr11:48096782~48096858:+
LAML	cis	rs7944735	0.607	rs34895872	ENSG00000263693.1	MIR3161	4.63	1.61e-05	0.0282	0.34	0.48	Intraocular pressure;	chr11:48000226	chr11:48096782~48096858:+
LAML	cis	rs2921071	1	rs2921071	ENSG00000268955.2	RP11-556O5.6	-4.63	1.61e-05	0.0282	-0.59	-0.48	White blood cell count (basophil);	chr8:8450534	chr8:8188535~8189195:-
LAML	cis	rs9322193	0.884	rs11155675	ENSG00000216906.2	RP11-350J20.9	4.62	1.61e-05	0.0282	0.72	0.48	Lung cancer;	chr6:149742883	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs10872647	ENSG00000216906.2	RP11-350J20.9	4.62	1.61e-05	0.0282	0.72	0.48	Lung cancer;	chr6:149758687	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs10872648	ENSG00000216906.2	RP11-350J20.9	4.62	1.61e-05	0.0282	0.72	0.48	Lung cancer;	chr6:149758699	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs11155679	ENSG00000216906.2	RP11-350J20.9	4.62	1.61e-05	0.0282	0.72	0.48	Lung cancer;	chr6:149758881	chr6:149904243~149906418:+
LAML	cis	rs9952991	0.566	rs34846641	ENSG00000260302.1	RP11-973H7.1	4.62	1.61e-05	0.0282	0.84	0.48	Inflammatory skin disease;	chr18:12875976	chr18:12774651~12775923:-
LAML	cis	rs9952991	0.566	rs7234029	ENSG00000260302.1	RP11-973H7.1	-4.62	1.61e-05	0.0282	-0.84	-0.48	Inflammatory skin disease;	chr18:12877061	chr18:12774651~12775923:-
LAML	cis	rs6558530	0.666	rs10113471	ENSG00000253982.1	CTD-2336O2.1	4.62	1.61e-05	0.0283	0.75	0.48	Systolic blood pressure;	chr8:1747661	chr8:1761990~1764502:-
LAML	cis	rs6558530	0.666	rs7845723	ENSG00000253982.1	CTD-2336O2.1	4.62	1.61e-05	0.0283	0.75	0.48	Systolic blood pressure;	chr8:1748920	chr8:1761990~1764502:-
LAML	cis	rs709400	0.627	rs55859054	ENSG00000258851.1	RP11-894P9.2	-4.62	1.62e-05	0.0283	-0.57	-0.48	Body mass index;	chr14:103487329	chr14:103553421~103561877:+
LAML	cis	rs67311347	0.955	rs6764102	ENSG00000230274.1	PGAM1P3	4.62	1.62e-05	0.0283	0.61	0.48	Renal cell carcinoma;	chr3:40336662	chr3:40322715~40323279:-
LAML	cis	rs716804	0.566	rs7110312	ENSG00000254719.1	RP11-351I24.3	-4.62	1.62e-05	0.0283	-0.59	-0.48	Neuroticism;	chr11:10121566	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs7125593	ENSG00000254719.1	RP11-351I24.3	-4.62	1.62e-05	0.0284	-0.59	-0.48	Neuroticism;	chr11:10113247	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs10840369	ENSG00000254719.1	RP11-351I24.3	-4.62	1.62e-05	0.0284	-0.59	-0.48	Neuroticism;	chr11:10114881	chr11:10272052~10272259:-
LAML	cis	rs1789	0.903	rs4453929	ENSG00000249930.1	AC007016.3	-4.62	1.62e-05	0.0284	-0.58	-0.48	Blood protein levels;	chr4:15670550	chr4:15492729~15492972:-
LAML	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	4.62	1.63e-05	0.0285	0.57	0.48	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	4.62	1.63e-05	0.0285	0.57	0.48	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	4.62	1.63e-05	0.0285	0.57	0.48	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	4.62	1.63e-05	0.0285	0.57	0.48	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	4.62	1.63e-05	0.0285	0.57	0.48	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
LAML	cis	rs7131987	0.903	rs11050153	ENSG00000273680.1	RP11-996F15.6	4.62	1.63e-05	0.0285	0.5	0.48	QT interval;	chr12:29252215	chr12:29332733~29333383:-
LAML	cis	rs7131987	1	rs7131987	ENSG00000273680.1	RP11-996F15.6	4.62	1.63e-05	0.0285	0.5	0.48	QT interval;	chr12:29253555	chr12:29332733~29333383:-
LAML	cis	rs716804	0.566	rs4635071	ENSG00000254719.1	RP11-351I24.3	-4.62	1.63e-05	0.0285	-0.59	-0.48	Neuroticism;	chr11:10104068	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs57153895	ENSG00000254719.1	RP11-351I24.3	-4.62	1.63e-05	0.0285	-0.58	-0.48	Neuroticism;	chr11:10301173	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs11042625	ENSG00000254719.1	RP11-351I24.3	-4.62	1.63e-05	0.0285	-0.59	-0.48	Neuroticism;	chr11:10096731	chr11:10272052~10272259:-
LAML	cis	rs10518325	0.585	rs705841	ENSG00000250412.1	KLHL2P1	-4.62	1.63e-05	0.0285	-0.86	-0.48	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118335141	chr4:119334329~119378233:+
LAML	cis	rs10518325	0.636	rs4834681	ENSG00000250412.1	KLHL2P1	-4.62	1.63e-05	0.0285	-0.86	-0.48	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118349395	chr4:119334329~119378233:+
LAML	cis	rs10518325	0.585	rs788656	ENSG00000250412.1	KLHL2P1	4.62	1.63e-05	0.0285	0.86	0.48	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118340784	chr4:119334329~119378233:+
LAML	cis	rs673253	0.686	rs2819334	ENSG00000227163.2	RP5-1198O20.5	4.62	1.63e-05	0.0285	0.58	0.48	Intelligence (multi-trait analysis);	chr1:43549064	chr1:44087958~44088477:-
LAML	cis	rs716804	0.566	rs10770090	ENSG00000254719.1	RP11-351I24.3	-4.62	1.63e-05	0.0286	-0.59	-0.48	Neuroticism;	chr11:10100344	chr11:10272052~10272259:-
LAML	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	4.62	1.63e-05	0.0286	0.59	0.48	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
LAML	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	4.62	1.63e-05	0.0286	0.59	0.48	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
LAML	cis	rs853679	0.546	rs35017208	ENSG00000187763.3	OR2B7P	4.62	1.64e-05	0.0286	0.87	0.48	Depression;	chr6:28377505	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs36092177	ENSG00000187763.3	OR2B7P	4.62	1.64e-05	0.0286	0.87	0.48	Depression;	chr6:28390030	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs2232429	ENSG00000187763.3	OR2B7P	4.62	1.64e-05	0.0286	0.87	0.48	Depression;	chr6:28391855	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs2232426	ENSG00000187763.3	OR2B7P	4.62	1.64e-05	0.0286	0.87	0.48	Depression;	chr6:28392882	chr6:28046434~28047367:+
LAML	cis	rs853679	0.546	rs2232423	ENSG00000187763.3	OR2B7P	4.62	1.64e-05	0.0286	0.87	0.48	Depression;	chr6:28398374	chr6:28046434~28047367:+
LAML	cis	rs785830	0.521	rs543442	ENSG00000235880.1	RP11-59O6.3	4.62	1.64e-05	0.0286	0.43	0.48	Platelet distribution width;	chr9:265491	chr9:267966~273002:-
LAML	cis	rs785830	0.521	rs679520	ENSG00000235880.1	RP11-59O6.3	4.62	1.64e-05	0.0286	0.43	0.48	Platelet distribution width;	chr9:265495	chr9:267966~273002:-
LAML	cis	rs2933343	0.951	rs789251	ENSG00000231305.3	RP11-723O4.2	4.62	1.64e-05	0.0286	0.58	0.48	IgG glycosylation;	chr3:128857927	chr3:128861313~128871540:-
LAML	cis	rs7495132	0.541	rs6496717	ENSG00000259314.1	CTD-3065B20.3	-4.62	1.64e-05	0.0286	-0.48	-0.48	Ulcerative colitis;Inflammatory bowel disease;	chr15:90638335	chr15:90604225~90614558:-
LAML	cis	rs7495132	0.512	rs3743401	ENSG00000259314.1	CTD-3065B20.3	4.62	1.64e-05	0.0286	0.48	0.48	Ulcerative colitis;Inflammatory bowel disease;	chr15:90642762	chr15:90604225~90614558:-
LAML	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-4.62	1.64e-05	0.0286	-0.61	-0.48	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
LAML	cis	rs2980439	0.729	rs2955585	ENSG00000253893.2	FAM85B	-4.62	1.64e-05	0.0286	-0.6	-0.48	Neuroticism;	chr8:8235989	chr8:8167819~8226614:-
LAML	cis	rs9393777	0.528	rs9467989	ENSG00000187763.3	OR2B7P	4.62	1.64e-05	0.0287	0.64	0.48	Intelligence (multi-trait analysis);	chr6:27096496	chr6:28046434~28047367:+
LAML	cis	rs8031584	0.752	rs1852035	ENSG00000259845.1	HERC2P10	4.62	1.64e-05	0.0287	0.5	0.48	Huntington's disease progression;	chr15:30892600	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.752	rs2001686	ENSG00000259845.1	HERC2P10	4.62	1.64e-05	0.0287	0.5	0.48	Huntington's disease progression;	chr15:30893569	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.663	rs1917421	ENSG00000259845.1	HERC2P10	4.62	1.64e-05	0.0287	0.5	0.48	Huntington's disease progression;	chr15:30895460	chr15:30815271~30844153:+
LAML	cis	rs8031584	0.707	rs4556757	ENSG00000259845.1	HERC2P10	4.62	1.64e-05	0.0287	0.5	0.48	Huntington's disease progression;	chr15:30895976	chr15:30815271~30844153:+
LAML	cis	rs9322193	0.962	rs1889473	ENSG00000216906.2	RP11-350J20.9	4.62	1.65e-05	0.0287	0.66	0.48	Lung cancer;	chr6:149825485	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs6903998	ENSG00000216906.2	RP11-350J20.9	4.62	1.65e-05	0.0287	0.66	0.48	Lung cancer;	chr6:149831357	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs1984111	ENSG00000216906.2	RP11-350J20.9	4.62	1.65e-05	0.0287	0.66	0.48	Lung cancer;	chr6:149831720	chr6:149904243~149906418:+
LAML	cis	rs7301826	1	rs10848205	ENSG00000256299.1	RP11-989F5.3	-4.62	1.65e-05	0.0287	-0.59	-0.48	Plasma plasminogen activator levels;	chr12:130796169	chr12:130810821~130812622:-
LAML	cis	rs7301826	1	rs10744482	ENSG00000256299.1	RP11-989F5.3	-4.62	1.65e-05	0.0287	-0.59	-0.48	Plasma plasminogen activator levels;	chr12:130813650	chr12:130810821~130812622:-
LAML	cis	rs7301826	0.966	rs4759795	ENSG00000256299.1	RP11-989F5.3	-4.62	1.65e-05	0.0287	-0.59	-0.48	Plasma plasminogen activator levels;	chr12:130816355	chr12:130810821~130812622:-
LAML	cis	rs6964833	1	rs6964833	ENSG00000277053.3	GTF2IP1	-4.62	1.65e-05	0.0287	-0.65	-0.48	Menarche (age at onset);	chr7:74687575	chr7:75185385~75237696:-
LAML	cis	rs6964833	1	rs35203738	ENSG00000277053.3	GTF2IP1	-4.62	1.65e-05	0.0287	-0.65	-0.48	Menarche (age at onset);	chr7:74690864	chr7:75185385~75237696:-
LAML	cis	rs67311347	0.955	rs4974068	ENSG00000230274.1	PGAM1P3	4.62	1.66e-05	0.0288	0.62	0.48	Renal cell carcinoma;	chr3:40335438	chr3:40322715~40323279:-
LAML	cis	rs716804	0.566	rs6483966	ENSG00000254719.1	RP11-351I24.3	-4.62	1.66e-05	0.0288	-0.59	-0.48	Neuroticism;	chr11:10075889	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs6483970	ENSG00000254719.1	RP11-351I24.3	-4.62	1.66e-05	0.0288	-0.59	-0.48	Neuroticism;	chr11:10079644	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs4366476	ENSG00000254719.1	RP11-351I24.3	-4.62	1.66e-05	0.0288	-0.59	-0.48	Neuroticism;	chr11:10079974	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs4509749	ENSG00000254719.1	RP11-351I24.3	-4.62	1.66e-05	0.0288	-0.59	-0.48	Neuroticism;	chr11:10080376	chr11:10272052~10272259:-
LAML	cis	rs716804	0.536	rs11600852	ENSG00000254719.1	RP11-351I24.3	-4.62	1.66e-05	0.0289	-0.59	-0.48	Neuroticism;	chr11:10062403	chr11:10272052~10272259:-
LAML	cis	rs785830	0.63	rs526509	ENSG00000235880.1	RP11-59O6.3	4.62	1.66e-05	0.0289	0.43	0.48	Platelet distribution width;	chr9:268740	chr9:267966~273002:-
LAML	cis	rs8062405	0.931	rs12928404	ENSG00000259982.1	CDC37P1	4.62	1.67e-05	0.029	0.54	0.48	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835925	chr16:28700294~28701540:-
LAML	cis	rs709400	0.633	rs10141433	ENSG00000258851.1	RP11-894P9.2	-4.62	1.67e-05	0.029	-0.58	-0.48	Body mass index;	chr14:103496222	chr14:103553421~103561877:+
LAML	cis	rs7115242	0.699	rs12285074	ENSG00000254851.1	RP11-109L13.1	4.61	1.67e-05	0.0291	1.06	0.48	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116891312	chr11:117135528~117138582:+
LAML	cis	rs7426056	0.671	rs13390252	ENSG00000224791.1	KRT18P39	4.61	1.67e-05	0.0291	0.71	0.48	Primary sclerosing cholangitis;	chr2:203732006	chr2:203764295~203765593:-
LAML	cis	rs9788721	0.836	rs2009746	ENSG00000259474.1	RP11-650L12.1	-4.61	1.68e-05	0.0291	-0.5	-0.48	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78461760	chr15:78480057~78481820:-
LAML	cis	rs716804	0.566	rs7126376	ENSG00000254719.1	RP11-351I24.3	-4.61	1.68e-05	0.0292	-0.6	-0.48	Neuroticism;	chr11:10046439	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs10770082	ENSG00000254719.1	RP11-351I24.3	-4.61	1.68e-05	0.0292	-0.6	-0.48	Neuroticism;	chr11:10046866	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs10770083	ENSG00000254719.1	RP11-351I24.3	-4.61	1.68e-05	0.0292	-0.6	-0.48	Neuroticism;	chr11:10046956	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs7121704	ENSG00000254719.1	RP11-351I24.3	-4.61	1.68e-05	0.0292	-0.6	-0.48	Neuroticism;	chr11:10051071	chr11:10272052~10272259:-
LAML	cis	rs716804	0.535	rs12288355	ENSG00000254719.1	RP11-351I24.3	-4.61	1.68e-05	0.0292	-0.6	-0.48	Neuroticism;	chr11:10051302	chr11:10272052~10272259:-
LAML	cis	rs7426056	0.671	rs3116486	ENSG00000224791.1	KRT18P39	4.61	1.68e-05	0.0292	0.7	0.48	Primary sclerosing cholangitis;	chr2:203720779	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs3116487	ENSG00000224791.1	KRT18P39	4.61	1.68e-05	0.0292	0.7	0.48	Primary sclerosing cholangitis;	chr2:203721314	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs3116492	ENSG00000224791.1	KRT18P39	4.61	1.68e-05	0.0292	0.7	0.48	Primary sclerosing cholangitis;	chr2:203723659	chr2:203764295~203765593:-
LAML	cis	rs10463316	0.78	rs6894899	ENSG00000260581.1	CTB-113P19.4	4.61	1.69e-05	0.0293	0.44	0.48	Metabolite levels (Pyroglutamine);	chr5:151396352	chr5:151652275~151655449:+
LAML	cis	rs282544	1	rs282556	ENSG00000271455.1	RP11-269M20.2	-4.61	1.69e-05	0.0293	-0.49	-0.48	Myopia (pathological);	chr5:50736451	chr5:50603229~50603511:+
LAML	cis	rs282544	1	rs166863	ENSG00000271455.1	RP11-269M20.2	-4.61	1.69e-05	0.0293	-0.49	-0.48	Myopia (pathological);	chr5:50741617	chr5:50603229~50603511:+
LAML	cis	rs7301826	0.934	rs10848212	ENSG00000256250.1	RP11-989F5.1	4.61	1.69e-05	0.0293	0.58	0.48	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810606~130812438:+
LAML	cis	rs716804	0.54	rs10840346	ENSG00000254719.1	RP11-351I24.3	-4.61	1.69e-05	0.0293	-0.6	-0.48	Neuroticism;	chr11:10041452	chr11:10272052~10272259:-
LAML	cis	rs7581030	0.55	rs918192	ENSG00000236469.1	AC007040.8	4.61	1.69e-05	0.0294	0.57	0.48	Testicular germ cell tumor;	chr2:71236998	chr2:71002531~71064743:-
LAML	cis	rs67311347	1	rs7641495	ENSG00000230274.1	PGAM1P3	-4.61	1.7e-05	0.0294	-0.62	-0.48	Renal cell carcinoma;	chr3:40453199	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs962847	ENSG00000230274.1	PGAM1P3	-4.61	1.7e-05	0.0294	-0.62	-0.48	Renal cell carcinoma;	chr3:40453665	chr3:40322715~40323279:-
LAML	cis	rs747650	0.504	rs34340483	ENSG00000271350.1	CTD-2384B9.1	-4.61	1.7e-05	0.0294	-0.57	-0.48	Acne (severe);	chr11:46931603	chr11:47041027~47041945:-
LAML	cis	rs9309473	0.607	rs7604588	ENSG00000163016.8	ALMS1P	4.61	1.7e-05	0.0294	0.51	0.48	Metabolite levels;	chr2:73344289	chr2:73644919~73685576:+
LAML	cis	rs9916302	0.821	rs412430	ENSG00000223091.1	RNU6-981P	-4.61	1.7e-05	0.0294	-0.59	-0.48	Glomerular filtration rate (creatinine);	chr17:39580841	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs1619021	ENSG00000223091.1	RNU6-981P	-4.61	1.7e-05	0.0294	-0.59	-0.48	Glomerular filtration rate (creatinine);	chr17:39583021	chr17:39482486~39482590:-
LAML	cis	rs9322193	0.884	rs7450246	ENSG00000216906.2	RP11-350J20.9	4.61	1.71e-05	0.0295	0.71	0.48	Lung cancer;	chr6:149702517	chr6:149904243~149906418:+
LAML	cis	rs6772849	0.662	rs12494372	ENSG00000277250.1	Metazoa_SRP	-4.61	1.71e-05	0.0295	-0.65	-0.48	Monocyte percentage of white cells;Monocyte count;	chr3:128682850	chr3:128673681~128674021:-
LAML	cis	rs6772849	0.775	rs9828414	ENSG00000277250.1	Metazoa_SRP	-4.61	1.71e-05	0.0295	-0.65	-0.48	Monocyte percentage of white cells;Monocyte count;	chr3:128693874	chr3:128673681~128674021:-
LAML	cis	rs6772849	0.804	rs9832430	ENSG00000277250.1	Metazoa_SRP	-4.61	1.71e-05	0.0295	-0.65	-0.48	Monocyte percentage of white cells;Monocyte count;	chr3:128694054	chr3:128673681~128674021:-
LAML	cis	rs6772849	0.775	rs66822528	ENSG00000277250.1	Metazoa_SRP	-4.61	1.71e-05	0.0295	-0.65	-0.48	Monocyte percentage of white cells;Monocyte count;	chr3:128696254	chr3:128673681~128674021:-
LAML	cis	rs6772849	0.775	rs67105978	ENSG00000277250.1	Metazoa_SRP	-4.61	1.71e-05	0.0295	-0.65	-0.48	Monocyte percentage of white cells;Monocyte count;	chr3:128696337	chr3:128673681~128674021:-
LAML	cis	rs6772849	0.768	rs9820741	ENSG00000277250.1	Metazoa_SRP	-4.61	1.71e-05	0.0295	-0.65	-0.48	Monocyte percentage of white cells;Monocyte count;	chr3:128697237	chr3:128673681~128674021:-
LAML	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	4.61	1.71e-05	0.0295	0.73	0.48	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
LAML	cis	rs7131987	0.903	rs11050163	ENSG00000273680.1	RP11-996F15.6	4.61	1.71e-05	0.0295	0.49	0.48	QT interval;	chr12:29267465	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.903	rs10843373	ENSG00000273680.1	RP11-996F15.6	4.61	1.71e-05	0.0295	0.49	0.48	QT interval;	chr12:29267675	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.934	rs2216854	ENSG00000273680.1	RP11-996F15.6	4.61	1.71e-05	0.0295	0.49	0.48	QT interval;	chr12:29270527	chr12:29332733~29333383:-
LAML	cis	rs17665162	0.826	rs73739912	ENSG00000277043.1	EEF1A1P42	4.61	1.71e-05	0.0295	0.82	0.48	Body mass index;	chr6:50040892	chr6:49358185~49360420:-
LAML	cis	rs6728642	0.808	rs113319086	ENSG00000235833.1	AC159540.14	4.61	1.71e-05	0.0295	0.89	0.48	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96967530	chr2:97523949~97524976:-
LAML	cis	rs6728642	1	rs113863815	ENSG00000235833.1	AC159540.14	4.61	1.71e-05	0.0295	0.89	0.48	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96992076	chr2:97523949~97524976:-
LAML	cis	rs9393777	0.92	rs13212562	ENSG00000220721.1	OR1F12	4.61	1.71e-05	0.0295	0.69	0.48	Intelligence (multi-trait analysis);	chr6:27332531	chr6:28073316~28074233:+
LAML	cis	rs10457838	0.781	rs6938335	ENSG00000220848.4	RPS18P9	4.61	1.71e-05	0.0295	0.52	0.48	Post-traumatic stress disorder;	chr6:149028192	chr6:149594084~149594543:+
LAML	cis	rs10457838	0.713	rs7756263	ENSG00000220848.4	RPS18P9	4.61	1.71e-05	0.0295	0.52	0.48	Post-traumatic stress disorder;	chr6:149032140	chr6:149594084~149594543:+
LAML	cis	rs10518325	0.585	rs1514657	ENSG00000250412.1	KLHL2P1	4.61	1.71e-05	0.0295	0.85	0.48	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118357943	chr4:119334329~119378233:+
LAML	cis	rs10518325	0.585	rs1110948	ENSG00000250412.1	KLHL2P1	-4.61	1.71e-05	0.0295	-0.85	-0.48	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118359672	chr4:119334329~119378233:+
LAML	cis	rs10518325	0.585	rs1040105	ENSG00000250412.1	KLHL2P1	-4.61	1.71e-05	0.0295	-0.85	-0.48	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118363401	chr4:119334329~119378233:+
LAML	cis	rs10518325	0.585	rs908152	ENSG00000250412.1	KLHL2P1	-4.61	1.71e-05	0.0295	-0.85	-0.48	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118366584	chr4:119334329~119378233:+
LAML	cis	rs10518325	0.585	rs871770	ENSG00000250412.1	KLHL2P1	-4.61	1.71e-05	0.0295	-0.85	-0.48	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118367645	chr4:119334329~119378233:+
LAML	cis	rs9322193	1	rs58189451	ENSG00000216906.2	RP11-350J20.9	4.61	1.72e-05	0.0296	0.71	0.48	Lung cancer;	chr6:149600252	chr6:149904243~149906418:+
LAML	cis	rs2921073	0.51	rs2976944	ENSG00000253893.2	FAM85B	-4.61	1.72e-05	0.0296	-0.52	-0.48	Parkinson's disease;	chr8:8413404	chr8:8167819~8226614:-
LAML	cis	rs6951245	0.554	rs11761322	ENSG00000229043.2	AC091729.9	-4.61	1.72e-05	0.0297	-0.58	-0.48	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112021	chr7:1160374~1165267:+
LAML	cis	rs8042680	0.554	rs8026781	ENSG00000258725.1	PRC1-AS1	-4.61	1.72e-05	0.0297	-0.69	-0.48	Type 2 diabetes;	chr15:90987445	chr15:90966345~90988624:+
LAML	cis	rs12052801	0.934	rs7579440	ENSG00000221443.1	AC017083.1	4.61	1.72e-05	0.0297	0.54	0.48	Schizophrenia;	chr2:68271376	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.934	rs6546368	ENSG00000221443.1	AC017083.1	4.61	1.72e-05	0.0297	0.54	0.48	Schizophrenia;	chr2:68271700	chr2:68273104~68273206:+
LAML	cis	rs7613595	0.507	rs13073832	ENSG00000272498.1	RP11-415F23.3	4.61	1.73e-05	0.0297	0.62	0.48	Sum eosinophil basophil counts;	chr3:17089590	chr3:16339308~16339871:+
LAML	cis	rs7613595	0.507	rs35185988	ENSG00000272498.1	RP11-415F23.3	4.61	1.73e-05	0.0297	0.62	0.48	Sum eosinophil basophil counts;	chr3:17089929	chr3:16339308~16339871:+
LAML	cis	rs9380516	0.524	rs4267954	ENSG00000264878.1	Z85986.1	4.61	1.73e-05	0.0297	0.53	0.48	Hepatitis C induced liver fibrosis;	chr6:35517013	chr6:36510517~36510598:-
LAML	cis	rs7131987	0.834	rs1989478	ENSG00000273680.1	RP11-996F15.6	4.61	1.73e-05	0.0298	0.49	0.48	QT interval;	chr12:29289296	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.834	rs12228468	ENSG00000273680.1	RP11-996F15.6	-4.61	1.73e-05	0.0298	-0.49	-0.48	QT interval;	chr12:29300677	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.801	rs6487804	ENSG00000273680.1	RP11-996F15.6	4.61	1.73e-05	0.0298	0.49	0.48	QT interval;	chr12:29302001	chr12:29332733~29333383:-
LAML	cis	rs7916697	0.52	rs4745957	ENSG00000234102.1	KRT19P4	4.61	1.73e-05	0.0299	0.63	0.48	Optic disc area;	chr10:68284945	chr10:68260557~68261499:+
LAML	cis	rs13113518	0.812	rs12500686	ENSG00000249700.7	SRD5A3-AS1	4.6	1.74e-05	0.0299	0.5	0.48	Height;	chr4:55457922	chr4:55363971~55395847:-
LAML	cis	rs7927771	1	rs4752797	ENSG00000280615.1	Y_RNA	-4.6	1.74e-05	0.0299	-0.65	-0.48	Subjective well-being;	chr11:47852812	chr11:47614898~47614994:-
LAML	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-4.6	1.74e-05	0.0299	-0.87	-0.48	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
LAML	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-4.6	1.74e-05	0.03	-0.49	-0.48	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-4.6	1.74e-05	0.03	-0.49	-0.48	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	4.6	1.74e-05	0.03	0.49	0.48	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
LAML	cis	rs34792	0.554	rs12919246	ENSG00000275910.1	RP11-680G24.6	-4.6	1.74e-05	0.03	-0.5	-0.48	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:15015828~15016390:-
LAML	cis	rs34792	0.525	rs12708795	ENSG00000275910.1	RP11-680G24.6	-4.6	1.74e-05	0.03	-0.5	-0.48	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:15015828~15016390:-
LAML	cis	rs34792	0.554	rs12708796	ENSG00000275910.1	RP11-680G24.6	-4.6	1.74e-05	0.03	-0.5	-0.48	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:15015828~15016390:-
LAML	cis	rs6951245	0.608	rs10252234	ENSG00000229043.2	AC091729.9	-4.6	1.75e-05	0.03	-0.59	-0.48	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1074745	chr7:1160374~1165267:+
LAML	cis	rs11118620	0.622	rs11118618	ENSG00000272823.1	RP11-295M18.6	4.6	1.75e-05	0.03	0.7	0.48	Heart failure;	chr1:220838204	chr1:220828676~220829211:-
LAML	cis	rs12052801	0.967	rs1375371	ENSG00000221443.1	AC017083.1	-4.6	1.75e-05	0.03	-0.55	-0.48	Schizophrenia;	chr2:68236480	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs6711175	ENSG00000221443.1	AC017083.1	4.6	1.75e-05	0.03	0.55	0.48	Schizophrenia;	chr2:68230148	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs12468533	ENSG00000221443.1	AC017083.1	4.6	1.75e-05	0.03	0.55	0.48	Schizophrenia;	chr2:68230441	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.934	rs12476697	ENSG00000221443.1	AC017083.1	4.6	1.75e-05	0.03	0.55	0.48	Schizophrenia;	chr2:68230722	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs6730444	ENSG00000221443.1	AC017083.1	4.6	1.75e-05	0.03	0.55	0.48	Schizophrenia;	chr2:68231288	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs6546362	ENSG00000221443.1	AC017083.1	4.6	1.75e-05	0.03	0.55	0.48	Schizophrenia;	chr2:68236189	chr2:68273104~68273206:+
LAML	cis	rs1555322	0.53	rs2425049	ENSG00000261582.1	RP4-614O4.11	-4.6	1.75e-05	0.03	-0.51	-0.48	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35267885~35280043:-
LAML	cis	rs11098499	0.866	rs10518329	ENSG00000260091.1	RP11-33B1.4	4.6	1.75e-05	0.0301	0.42	0.48	Corneal astigmatism;	chr4:119480680	chr4:119409333~119410233:+
LAML	cis	rs10463316	0.608	rs13360453	ENSG00000260581.1	CTB-113P19.4	4.6	1.75e-05	0.0301	0.44	0.48	Metabolite levels (Pyroglutamine);	chr5:151389582	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.608	rs7700423	ENSG00000260581.1	CTB-113P19.4	4.6	1.75e-05	0.0301	0.44	0.48	Metabolite levels (Pyroglutamine);	chr5:151389594	chr5:151652275~151655449:+
LAML	cis	rs9322193	0.705	rs9286597	ENSG00000216906.2	RP11-350J20.9	4.6	1.75e-05	0.0301	0.7	0.48	Lung cancer;	chr6:149563244	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.81	rs9498371	ENSG00000216906.2	RP11-350J20.9	4.6	1.75e-05	0.0301	0.7	0.48	Lung cancer;	chr6:149563461	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.847	rs9498372	ENSG00000216906.2	RP11-350J20.9	4.6	1.75e-05	0.0301	0.7	0.48	Lung cancer;	chr6:149567128	chr6:149904243~149906418:+
LAML	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-4.6	1.75e-05	0.0301	-0.59	-0.48	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
LAML	cis	rs9322193	0.923	rs9322214	ENSG00000216906.2	RP11-350J20.9	4.6	1.75e-05	0.0301	0.7	0.48	Lung cancer;	chr6:149703986	chr6:149904243~149906418:+
LAML	cis	rs7826238	0.539	rs2945891	ENSG00000249188.1	ENPP7P1	-4.6	1.76e-05	0.0302	-0.55	-0.48	Systolic blood pressure;	chr8:8297953	chr8:8154308~8216916:+
LAML	cis	rs950027	0.549	rs9920634	ENSG00000259520.4	CTD-2651B20.3	4.6	1.76e-05	0.0303	0.7	0.48	Response to fenofibrate (adiponectin levels);	chr15:45304348	chr15:45251580~45279251:-
LAML	cis	rs6728642	1	rs75297860	ENSG00000235833.1	AC159540.14	4.6	1.76e-05	0.0303	0.9	0.48	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96934341	chr2:97523949~97524976:-
LAML	cis	rs673253	0.686	rs2842188	ENSG00000227163.2	RP5-1198O20.5	4.6	1.77e-05	0.0303	0.59	0.48	Intelligence (multi-trait analysis);	chr1:43548609	chr1:44087958~44088477:-
LAML	cis	rs1863918	0.533	rs58887996	ENSG00000272431.1	RP11-281O15.8	4.6	1.77e-05	0.0303	0.79	0.48	Depression in response to interferon-based therapy in chronic hepatitis C;	chr5:179142940	chr5:178938677~178939223:-
LAML	cis	rs11577318	0.579	rs58034207	ENSG00000225854.2	RP11-569G9.7	-4.6	1.77e-05	0.0304	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26357084	chr1:26326688~26327033:+
LAML	cis	rs11577318	0.579	rs11583205	ENSG00000225854.2	RP11-569G9.7	-4.6	1.77e-05	0.0304	-0.65	-0.48	Granulocyte percentage of myeloid white cells;	chr1:26357650	chr1:26326688~26327033:+
LAML	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	4.6	1.77e-05	0.0304	0.51	0.48	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
LAML	cis	rs282544	1	rs2463797	ENSG00000271455.1	RP11-269M20.2	-4.6	1.77e-05	0.0304	-0.51	-0.48	Myopia (pathological);	chr5:50748788	chr5:50603229~50603511:+
LAML	cis	rs8031584	0.918	rs61997139	ENSG00000260382.1	RP11-540B6.2	4.6	1.78e-05	0.0305	0.56	0.48	Huntington's disease progression;	chr15:30981399	chr15:30882267~30883231:-
LAML	cis	rs1292059	1	rs1292059	ENSG00000266960.1	FAM106DP	4.6	1.78e-05	0.0305	0.72	0.48	Eosinophil percentage of granulocytes;	chr17:59880527	chr17:60173322~60173822:+
LAML	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-4.6	1.78e-05	0.0305	-0.53	-0.48	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-4.6	1.78e-05	0.0305	-0.53	-0.48	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	4.6	1.78e-05	0.0305	0.53	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
LAML	cis	rs12052801	0.874	rs2122126	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68190585	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs10191352	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68191736	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs6757863	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68192355	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs6761378	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68192938	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs9677635	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68193917	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.934	rs4671878	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68195639	chr2:68273104~68273206:+
LAML	cis	rs12052801	1	rs12052801	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68196086	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs12713635	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68196398	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs13004649	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68198285	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs7574378	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68203793	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs7577586	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68204127	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.932	rs6736178	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68206699	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.934	rs7572554	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68208148	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.934	rs6758449	ENSG00000221443.1	AC017083.1	4.6	1.78e-05	0.0305	0.57	0.48	Schizophrenia;	chr2:68209976	chr2:68273104~68273206:+
LAML	cis	rs282544	1	rs6450384	ENSG00000271455.1	RP11-269M20.2	4.6	1.78e-05	0.0305	0.49	0.48	Myopia (pathological);	chr5:50762850	chr5:50603229~50603511:+
LAML	cis	rs282544	1	rs2404958	ENSG00000271455.1	RP11-269M20.2	4.6	1.78e-05	0.0305	0.49	0.48	Myopia (pathological);	chr5:50767201	chr5:50603229~50603511:+
LAML	cis	rs282544	1	rs6450391	ENSG00000271455.1	RP11-269M20.2	4.6	1.78e-05	0.0305	0.49	0.48	Myopia (pathological);	chr5:50768553	chr5:50603229~50603511:+
LAML	cis	rs282544	1	rs154136	ENSG00000271455.1	RP11-269M20.2	4.6	1.78e-05	0.0305	0.49	0.48	Myopia (pathological);	chr5:50775731	chr5:50603229~50603511:+
LAML	cis	rs282544	1	rs26072	ENSG00000271455.1	RP11-269M20.2	4.6	1.78e-05	0.0305	0.49	0.48	Myopia (pathological);	chr5:50807784	chr5:50603229~50603511:+
LAML	cis	rs282544	0.965	rs282548	ENSG00000271455.1	RP11-269M20.2	-4.6	1.78e-05	0.0305	-0.49	-0.48	Myopia (pathological);	chr5:50760601	chr5:50603229~50603511:+
LAML	cis	rs1005224	0.853	rs2360035	ENSG00000258454.1	RP11-361H10.3	-4.6	1.78e-05	0.0305	-0.65	-0.48	Large artery stroke;	chr14:75830750	chr14:76235817~76263474:+
LAML	cis	rs8067354	0.574	rs2531898	ENSG00000266960.1	FAM106DP	4.6	1.78e-05	0.0305	0.76	0.48	Hemoglobin concentration;	chr17:59934990	chr17:60173322~60173822:+
LAML	cis	rs716804	0.54	rs11042638	ENSG00000254719.1	RP11-351I24.3	-4.6	1.78e-05	0.0305	-0.59	-0.48	Neuroticism;	chr11:10125337	chr11:10272052~10272259:-
LAML	cis	rs8081395	0.836	rs2150879	ENSG00000267302.4	RP11-178C3.2	-4.6	1.78e-05	0.0305	-0.62	-0.48	White blood cell count;	chr17:59781849	chr17:59964832~59996972:+
LAML	cis	rs7613595	0.507	rs13077235	ENSG00000272498.1	RP11-415F23.3	4.6	1.78e-05	0.0306	0.62	0.48	Sum eosinophil basophil counts;	chr3:17085333	chr3:16339308~16339871:+
LAML	cis	rs911555	0.539	rs4374097	ENSG00000252469.1	RNU7-160P	-4.6	1.78e-05	0.0306	-0.57	-0.48	Intelligence (multi-trait analysis);	chr14:103606429	chr14:103550345~103550406:+
LAML	cis	rs2069590	0.661	rs10142830	ENSG00000247092.5	SNHG10	-4.6	1.79e-05	0.0306	-0.43	-0.48	Gout;	chr14:96251460	chr14:95532297~95534872:-
LAML	cis	rs4299518	0.504	rs2673052	ENSG00000244357.3	RN7SL145P	4.6	1.79e-05	0.0306	0.53	0.48	Hirschsprung disease;	chr3:45692335	chr3:45742675~45742970:+
LAML	cis	rs716804	0.566	rs10840363	ENSG00000254719.1	RP11-351I24.3	-4.6	1.79e-05	0.0306	-0.59	-0.48	Neuroticism;	chr11:10092573	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs11042621	ENSG00000254719.1	RP11-351I24.3	-4.6	1.79e-05	0.0306	-0.59	-0.48	Neuroticism;	chr11:10093751	chr11:10272052~10272259:-
LAML	cis	rs716804	0.536	rs11042622	ENSG00000254719.1	RP11-351I24.3	-4.6	1.79e-05	0.0306	-0.59	-0.48	Neuroticism;	chr11:10095104	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs7131203	ENSG00000254719.1	RP11-351I24.3	-4.6	1.79e-05	0.0306	-0.59	-0.48	Neuroticism;	chr11:10098349	chr11:10272052~10272259:-
LAML	cis	rs716804	0.562	rs10128601	ENSG00000254719.1	RP11-351I24.3	-4.6	1.79e-05	0.0306	-0.59	-0.48	Neuroticism;	chr11:10101230	chr11:10272052~10272259:-
LAML	cis	rs716804	0.507	rs7106491	ENSG00000254719.1	RP11-351I24.3	-4.6	1.79e-05	0.0306	-0.59	-0.48	Neuroticism;	chr11:10063257	chr11:10272052~10272259:-
LAML	cis	rs785830	0.523	rs2484966	ENSG00000235880.1	RP11-59O6.3	4.6	1.79e-05	0.0306	0.39	0.48	Platelet distribution width;	chr9:216493	chr9:267966~273002:-
LAML	cis	rs785830	0.523	rs529045	ENSG00000235880.1	RP11-59O6.3	4.6	1.79e-05	0.0306	0.39	0.48	Platelet distribution width;	chr9:217397	chr9:267966~273002:-
LAML	cis	rs471756	0.523	rs663552	ENSG00000235880.1	RP11-59O6.3	4.6	1.79e-05	0.0306	0.39	0.48	Mean platelet volume;	chr9:219896	chr9:267966~273002:-
LAML	cis	rs10500715	0.715	rs10840332	ENSG00000254719.1	RP11-351I24.3	-4.6	1.79e-05	0.0307	-0.56	-0.48	Pancreatic cancer;	chr11:9958954	chr11:10272052~10272259:-
LAML	cis	rs716804	0.594	rs7110664	ENSG00000254719.1	RP11-351I24.3	-4.6	1.8e-05	0.0307	-0.59	-0.48	Neuroticism;	chr11:10064092	chr11:10272052~10272259:-
LAML	cis	rs2948294	0.566	rs13261997	ENSG00000253893.2	FAM85B	-4.6	1.8e-05	0.0307	-0.62	-0.48	Red cell distribution width;	chr8:8254773	chr8:8167819~8226614:-
LAML	cis	rs904251	0.523	rs1776454	ENSG00000229559.2	RP1-153P14.3	-4.6	1.8e-05	0.0308	-0.52	-0.48	Cognitive performance;	chr6:37514323	chr6:37543553~37547280:-
LAML	cis	rs716804	0.594	rs7950240	ENSG00000254719.1	RP11-351I24.3	-4.59	1.8e-05	0.0308	-0.59	-0.48	Neuroticism;	chr11:10064652	chr11:10272052~10272259:-
LAML	cis	rs2957692	0.621	rs10840358	ENSG00000254719.1	RP11-351I24.3	-4.59	1.8e-05	0.0308	-0.59	-0.48	Circulating vasoactive peptide levels;	chr11:10069445	chr11:10272052~10272259:-
LAML	cis	rs2957692	0.563	rs7932988	ENSG00000254719.1	RP11-351I24.3	-4.59	1.8e-05	0.0308	-0.59	-0.48	Circulating vasoactive peptide levels;	chr11:10072929	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs6483964	ENSG00000254719.1	RP11-351I24.3	-4.59	1.8e-05	0.0308	-0.59	-0.48	Neuroticism;	chr11:10074069	chr11:10272052~10272259:-
LAML	cis	rs716804	0.541	rs6483965	ENSG00000254719.1	RP11-351I24.3	-4.59	1.8e-05	0.0308	-0.59	-0.48	Neuroticism;	chr11:10074327	chr11:10272052~10272259:-
LAML	cis	rs716804	0.566	rs7104821	ENSG00000254719.1	RP11-351I24.3	-4.59	1.8e-05	0.0308	-0.59	-0.48	Neuroticism;	chr11:10075189	chr11:10272052~10272259:-
LAML	cis	rs716804	0.536	rs10840364	ENSG00000254719.1	RP11-351I24.3	-4.59	1.8e-05	0.0308	-0.59	-0.48	Neuroticism;	chr11:10093396	chr11:10272052~10272259:-
LAML	cis	rs34792	0.554	rs12919246	ENSG00000260872.1	RP11-680G24.5	-4.59	1.81e-05	0.0309	-0.49	-0.48	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533103	chr16:15018106~15020488:-
LAML	cis	rs34792	0.525	rs12708795	ENSG00000260872.1	RP11-680G24.5	-4.59	1.81e-05	0.0309	-0.49	-0.48	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15533861	chr16:15018106~15020488:-
LAML	cis	rs34792	0.554	rs12708796	ENSG00000260872.1	RP11-680G24.5	-4.59	1.81e-05	0.0309	-0.49	-0.48	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15535980	chr16:15018106~15020488:-
LAML	cis	rs7555523	0.779	rs6662839	ENSG00000224358.1	RP11-466F5.8	-4.59	1.81e-05	0.0309	-0.72	-0.48	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165753409	chr1:165768929~165775176:+
LAML	cis	rs716804	0.566	rs4466825	ENSG00000254719.1	RP11-351I24.3	-4.59	1.81e-05	0.0309	-0.59	-0.48	Neuroticism;	chr11:10082407	chr11:10272052~10272259:-
LAML	cis	rs6940638	0.513	rs4424065	ENSG00000241549.7	GUSBP2	-4.59	1.81e-05	0.0309	-0.5	-0.48	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26871484~26956554:-
LAML	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	4.59	1.81e-05	0.031	0.54	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	4.59	1.81e-05	0.031	0.54	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
LAML	cis	rs9788721	0.836	rs72738736	ENSG00000259474.1	RP11-650L12.1	-4.59	1.82e-05	0.031	-0.5	-0.48	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78472780	chr15:78480057~78481820:-
LAML	cis	rs9788721	0.836	rs17483721	ENSG00000259474.1	RP11-650L12.1	4.59	1.82e-05	0.031	0.5	0.48	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78441389	chr15:78480057~78481820:-
LAML	cis	rs62103177	0.608	rs4442895	ENSG00000261126.6	RP11-795F19.1	-4.59	1.82e-05	0.031	-0.58	-0.48	Opioid sensitivity;	chr18:80066399	chr18:80046900~80095482:+
LAML	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	4.59	1.82e-05	0.031	0.58	0.48	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
LAML	cis	rs7927771	1	rs12363232	ENSG00000280615.1	Y_RNA	-4.59	1.82e-05	0.031	-0.63	-0.48	Subjective well-being;	chr11:47602338	chr11:47614898~47614994:-
LAML	cis	rs853679	0.546	rs35353359	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Depression;	chr6:28356601	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs13213152	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Depression;	chr6:28381921	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs13213986	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Depression;	chr6:28390232	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs34546986	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Depression;	chr6:28394532	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs34871267	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Depression;	chr6:28396455	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs35883476	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Depression;	chr6:28400731	chr6:28053228~28054165:-
LAML	cis	rs6921919	0.673	rs13201681	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Autism spectrum disorder or schizophrenia;	chr6:28426903	chr6:28053228~28054165:-
LAML	cis	rs6921919	0.778	rs67381177	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Autism spectrum disorder or schizophrenia;	chr6:28444164	chr6:28053228~28054165:-
LAML	cis	rs138024639	1	rs138024639	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Breast cancer;	chr6:28468244	chr6:28053228~28054165:-
LAML	cis	rs853679	0.546	rs55690788	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Depression;	chr6:28468368	chr6:28053228~28054165:-
LAML	cis	rs13191038	1	rs13191038	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Urinary tract infection frequency;	chr6:28515140	chr6:28053228~28054165:-
LAML	cis	rs34119086	1	rs34119086	ENSG00000182477.5	OR2B8P	4.59	1.82e-05	0.031	0.9	0.48	Breast cancer;	chr6:28594471	chr6:28053228~28054165:-
LAML	cis	rs9952991	0.654	rs34799913	ENSG00000260302.1	RP11-973H7.1	4.59	1.83e-05	0.0311	0.86	0.48	Inflammatory skin disease;	chr18:12863841	chr18:12774651~12775923:-
LAML	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-4.59	1.83e-05	0.0311	-0.71	-0.48	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
LAML	cis	rs3096299	0.935	rs3114890	ENSG00000274627.1	RP11-104N10.2	4.59	1.83e-05	0.0311	0.53	0.48	Multiple myeloma (IgH translocation);	chr16:89383138	chr16:89516797~89522217:+
LAML	cis	rs7165170	0.72	rs724925	ENSG00000259314.1	CTD-3065B20.3	4.59	1.83e-05	0.0311	0.53	0.48	Crohn's disease;Inflammatory bowel disease;	chr15:90678076	chr15:90604225~90614558:-
LAML	cis	rs2283792	0.792	rs151680	ENSG00000228050.1	TOP3BP1	4.59	1.83e-05	0.0312	0.54	0.48	Multiple sclerosis;	chr22:21918869	chr22:22223187~22224566:-
LAML	cis	rs561341	0.663	rs72821936	ENSG00000266379.5	RP11-640N20.8	4.59	1.84e-05	0.0312	0.64	0.48	Hip circumference adjusted for BMI;	chr17:31897049	chr17:32088160~32094933:-
LAML	cis	rs673078	0.571	rs17440823	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118353023	chr12:118428281~118428870:+
LAML	cis	rs673078	0.66	rs17512609	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118354072	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs17512644	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118359963	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs17440893	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118362532	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943367	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118366316	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943368	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118366568	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943385	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118370339	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943388	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118374590	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943389	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118377467	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs7299040	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118380660	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs7967900	ENSG00000275759.1	RP11-131L12.3	4.59	1.84e-05	0.0312	0.7	0.48	Glucose homeostasis traits;	chr12:118381902	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs7968011	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118382001	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943392	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118382618	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943393	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118383650	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs73205576	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118384268	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs2055534	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118386527	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs56157623	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118388162	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs4767669	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118390651	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs4767670	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118390737	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943399	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118393628	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs17440942	ENSG00000275759.1	RP11-131L12.3	4.59	1.84e-05	0.0312	0.7	0.48	Glucose homeostasis traits;	chr12:118394030	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs7137055	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118395030	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs7137184	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118395163	chr12:118428281~118428870:+
LAML	cis	rs673078	0.562	rs4767672	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118397048	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs73205594	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118397168	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943400	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118398236	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943401	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118398527	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943402	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118398808	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs17512763	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118400974	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943404	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118402062	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs7136676	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118403605	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs17441033	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118404101	chr12:118428281~118428870:+
LAML	cis	rs673078	0.562	rs61943405	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118405030	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943406	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118405767	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs17441061	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118409847	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs17441075	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118410542	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs965524	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118412361	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs74685643	ENSG00000275759.1	RP11-131L12.3	-4.59	1.84e-05	0.0312	-0.7	-0.48	Glucose homeostasis traits;	chr12:118412761	chr12:118428281~118428870:+
LAML	cis	rs2257205	0.667	rs6503876	ENSG00000212195.2	U3	-4.59	1.84e-05	0.0312	-0.96	-0.48	Pancreatic cancer;	chr17:58737627	chr17:58631641~58631836:-
LAML	cis	rs7495132	0.688	rs4932358	ENSG00000259314.1	CTD-3065B20.3	4.59	1.84e-05	0.0312	0.5	0.48	Ulcerative colitis;Inflammatory bowel disease;	chr15:90628867	chr15:90604225~90614558:-
LAML	cis	rs62070183	0.882	rs17183295	ENSG00000279781.1	RP11-466A19.7	4.59	1.85e-05	0.0313	0.69	0.48	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32751254	chr17:32518322~32518934:-
LAML	cis	rs10500715	0.715	rs10840335	ENSG00000254719.1	RP11-351I24.3	-4.59	1.85e-05	0.0314	-0.56	-0.48	Pancreatic cancer;	chr11:9961198	chr11:10272052~10272259:-
LAML	cis	rs673078	0.607	rs61943391	ENSG00000275759.1	RP11-131L12.3	-4.59	1.85e-05	0.0314	-0.7	-0.48	Glucose homeostasis traits;	chr12:118382603	chr12:118428281~118428870:+
LAML	cis	rs1075265	0.836	rs11687324	ENSG00000235937.1	AC008280.1	4.59	1.85e-05	0.0314	0.41	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54046589	chr2:54029552~54030682:-
LAML	cis	rs785830	0.558	rs557716	ENSG00000235880.1	RP11-59O6.3	4.59	1.85e-05	0.0315	0.43	0.48	Platelet distribution width;	chr9:263321	chr9:267966~273002:-
LAML	cis	rs7131987	0.868	rs7958210	ENSG00000273680.1	RP11-996F15.6	4.59	1.86e-05	0.0315	0.49	0.48	QT interval;	chr12:29242248	chr12:29332733~29333383:-
LAML	cis	rs10463316	0.894	rs1876619	ENSG00000260581.1	CTB-113P19.4	4.59	1.86e-05	0.0315	0.41	0.48	Metabolite levels (Pyroglutamine);	chr5:151365212	chr5:151652275~151655449:+
LAML	cis	rs10500715	0.715	rs4910089	ENSG00000254719.1	RP11-351I24.3	4.59	1.86e-05	0.0315	0.58	0.48	Pancreatic cancer;	chr11:9981702	chr11:10272052~10272259:-
LAML	cis	rs4774565	0.724	rs606118	ENSG00000244879.4	GABPB1-AS1	-4.59	1.86e-05	0.0315	-0.52	-0.48	Breast cancer;	chr15:50362974	chr15:50354959~50372202:+
LAML	cis	rs4774565	0.724	rs2555486	ENSG00000244879.4	GABPB1-AS1	4.59	1.86e-05	0.0315	0.52	0.48	Breast cancer;	chr15:50363924	chr15:50354959~50372202:+
LAML	cis	rs4774565	0.762	rs7182201	ENSG00000244879.4	GABPB1-AS1	-4.59	1.86e-05	0.0315	-0.52	-0.48	Breast cancer;	chr15:50364377	chr15:50354959~50372202:+
LAML	cis	rs4774565	0.762	rs1056682	ENSG00000244879.4	GABPB1-AS1	-4.59	1.86e-05	0.0315	-0.52	-0.48	Breast cancer;	chr15:50368004	chr15:50354959~50372202:+
LAML	cis	rs4774565	0.762	rs17431095	ENSG00000244879.4	GABPB1-AS1	-4.59	1.86e-05	0.0315	-0.52	-0.48	Breast cancer;	chr15:50369252	chr15:50354959~50372202:+
LAML	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-4.59	1.86e-05	0.0315	-0.52	-0.48	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
LAML	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-4.59	1.86e-05	0.0315	-0.52	-0.48	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
LAML	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-4.59	1.86e-05	0.0315	-0.52	-0.48	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
LAML	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	4.59	1.86e-05	0.0316	0.58	0.48	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	4.59	1.86e-05	0.0316	0.58	0.48	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	4.59	1.86e-05	0.0316	0.58	0.48	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	4.59	1.86e-05	0.0316	0.58	0.48	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
LAML	cis	rs12477438	0.52	rs2632276	ENSG00000231822.1	AC019097.7	4.59	1.87e-05	0.0316	0.61	0.48	Chronic sinus infection;	chr2:99163192	chr2:99102018~99102752:+
LAML	cis	rs6728642	0.572	rs1320147	ENSG00000235833.1	AC159540.14	-4.58	1.87e-05	0.0317	-0.67	-0.48	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96934889	chr2:97523949~97524976:-
LAML	cis	rs6728642	0.572	rs13403225	ENSG00000235833.1	AC159540.14	4.58	1.87e-05	0.0317	0.67	0.48	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96935090	chr2:97523949~97524976:-
LAML	cis	rs6728642	0.572	rs13387563	ENSG00000235833.1	AC159540.14	4.58	1.87e-05	0.0317	0.67	0.48	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96935179	chr2:97523949~97524976:-
LAML	cis	rs6728642	0.572	rs2872686	ENSG00000235833.1	AC159540.14	4.58	1.87e-05	0.0317	0.67	0.48	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96935287	chr2:97523949~97524976:-
LAML	cis	rs2257205	0.667	rs8080281	ENSG00000212195.2	U3	4.58	1.87e-05	0.0317	0.96	0.48	Pancreatic cancer;	chr17:58861197	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs7342862	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58739200	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs16943200	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58752250	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs8081074	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58759235	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs7211439	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58770471	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.588	rs7214266	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58774559	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs7213035	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58779920	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs8068677	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58792025	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs9912325	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58796573	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs6503879	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58810822	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs74961279	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58827630	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs77326197	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58828257	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs28605629	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58828796	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs6503881	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58833890	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs7342841	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58838795	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs7214805	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58854534	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs4453568	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58857182	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs6503884	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58862665	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.588	rs7219856	ENSG00000212195.2	U3	-4.58	1.87e-05	0.0317	-0.96	-0.48	Pancreatic cancer;	chr17:58863659	chr17:58631641~58631836:-
LAML	cis	rs716804	0.593	rs7122422	ENSG00000254719.1	RP11-351I24.3	-4.58	1.87e-05	0.0317	-0.56	-0.48	Neuroticism;	chr11:10045715	chr11:10272052~10272259:-
LAML	cis	rs716804	0.621	rs11042602	ENSG00000254719.1	RP11-351I24.3	-4.58	1.87e-05	0.0317	-0.56	-0.48	Neuroticism;	chr11:10056557	chr11:10272052~10272259:-
LAML	cis	rs9392556	0.6	rs2326408	ENSG00000272248.1	RP3-406P24.4	4.58	1.87e-05	0.0317	0.51	0.48	Blood metabolite levels;	chr6:4119282	chr6:4018713~4019202:+
LAML	cis	rs9392556	0.6	rs661404	ENSG00000272248.1	RP3-406P24.4	4.58	1.87e-05	0.0317	0.51	0.48	Blood metabolite levels;	chr6:4125863	chr6:4018713~4019202:+
LAML	cis	rs9392556	0.6	rs611500	ENSG00000272248.1	RP3-406P24.4	4.58	1.87e-05	0.0317	0.51	0.48	Blood metabolite levels;	chr6:4126529	chr6:4018713~4019202:+
LAML	cis	rs763121	0.815	rs4821799	ENSG00000230912.1	RP3-508I15.10	-4.58	1.87e-05	0.0317	-0.36	-0.48	Menopause (age at onset);	chr22:38625321	chr22:38666508~38668750:-
LAML	cis	rs785830	0.6	rs535550	ENSG00000235880.1	RP11-59O6.3	-4.58	1.88e-05	0.0317	-0.43	-0.48	Platelet distribution width;	chr9:245752	chr9:267966~273002:-
LAML	cis	rs7927771	1	rs11039255	ENSG00000280615.1	Y_RNA	-4.58	1.88e-05	0.0318	-0.62	-0.48	Subjective well-being;	chr11:47474194	chr11:47614898~47614994:-
LAML	cis	rs853679	0.607	rs66886492	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28121953	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs35345226	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28123802	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs35749575	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28147040	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs72846780	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28151277	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13205911	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28156336	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13197176	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28161454	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13201308	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28162311	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs34765154	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28162672	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs34505829	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28165461	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs35098436	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28166443	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs72846794	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28169721	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13217984	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28171932	chr6:28033947~28034855:+
LAML	cis	rs853679	0.556	rs67297533	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28173475	chr6:28033947~28034855:+
LAML	cis	rs853679	0.505	rs35781323	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28177054	chr6:28033947~28034855:+
LAML	cis	rs853679	0.546	rs13195291	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28201463	chr6:28033947~28034855:+
LAML	cis	rs853679	0.556	rs13197633	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28206979	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs35001169	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28219854	chr6:28033947~28034855:+
LAML	cis	rs853679	0.546	rs35656932	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28223510	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13204012	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28233753	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13205211	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28235278	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13208096	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28257533	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13207345	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28297795	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs72854513	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28298177	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs33932084	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28301047	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs56189111	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28304196	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs35072899	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28313764	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs56075693	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28322551	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs34218844	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28322870	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs35030260	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28337731	chr6:28033947~28034855:+
LAML	cis	rs853679	0.607	rs13217619	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28338894	chr6:28033947~28034855:+
LAML	cis	rs853679	0.546	rs35016036	ENSG00000217315.1	OR2W2P	4.58	1.88e-05	0.0318	0.9	0.48	Depression;	chr6:28347103	chr6:28033947~28034855:+
LAML	cis	rs17035378	0.883	rs17035374	ENSG00000221443.1	AC017083.1	4.58	1.88e-05	0.0318	0.64	0.48	Celiac disease;	chr2:68369369	chr2:68273104~68273206:+
LAML	cis	rs2283792	0.812	rs240064	ENSG00000228050.1	TOP3BP1	-4.58	1.88e-05	0.0318	-0.53	-0.48	Multiple sclerosis;	chr22:21927265	chr22:22223187~22224566:-
LAML	cis	rs41563	0.516	rs2470951	ENSG00000225329.2	LHFPL3-AS2	4.58	1.89e-05	0.0318	0.56	0.48	Autism spectrum disorder or schizophrenia;	chr7:104953266	chr7:104894628~104926645:-
LAML	cis	rs7165170	0.678	rs13379889	ENSG00000259314.1	CTD-3065B20.3	4.58	1.89e-05	0.0318	0.49	0.48	Crohn's disease;Inflammatory bowel disease;	chr15:90651808	chr15:90604225~90614558:-
LAML	cis	rs7131987	0.845	rs7299861	ENSG00000273680.1	RP11-996F15.6	4.58	1.89e-05	0.0318	0.49	0.48	QT interval;	chr12:29256734	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.934	rs7316004	ENSG00000273680.1	RP11-996F15.6	4.58	1.89e-05	0.0318	0.49	0.48	QT interval;	chr12:29258765	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.903	rs2216853	ENSG00000273680.1	RP11-996F15.6	4.58	1.89e-05	0.0318	0.49	0.48	QT interval;	chr12:29260315	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.868	rs10771508	ENSG00000273680.1	RP11-996F15.6	4.58	1.89e-05	0.0318	0.49	0.48	QT interval;	chr12:29261278	chr12:29332733~29333383:-
LAML	cis	rs9322193	0.926	rs9766562	ENSG00000216906.2	RP11-350J20.9	4.58	1.89e-05	0.0319	0.64	0.48	Lung cancer;	chr6:149788709	chr6:149904243~149906418:+
LAML	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	4.58	1.89e-05	0.0319	0.54	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
LAML	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	4.58	1.89e-05	0.0319	0.54	0.48	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
LAML	cis	rs9788721	0.806	rs4887056	ENSG00000259474.1	RP11-650L12.1	-4.58	1.89e-05	0.0319	-0.5	-0.48	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78442243	chr15:78480057~78481820:-
LAML	cis	rs9457247	0.565	rs2239824	ENSG00000227598.1	RP1-167A14.2	-4.58	1.89e-05	0.0319	-0.72	-0.48	Crohn's disease;	chr6:167098311	chr6:166969626~166999065:-
LAML	cis	rs9457247	0.565	rs12193698	ENSG00000227598.1	RP1-167A14.2	-4.58	1.89e-05	0.0319	-0.72	-0.48	Crohn's disease;	chr6:167098585	chr6:166969626~166999065:-
LAML	cis	rs9457247	0.565	rs2239823	ENSG00000227598.1	RP1-167A14.2	-4.58	1.89e-05	0.0319	-0.72	-0.48	Crohn's disease;	chr6:167098643	chr6:166969626~166999065:-
LAML	cis	rs9457247	0.565	rs12178491	ENSG00000227598.1	RP1-167A14.2	-4.58	1.89e-05	0.0319	-0.72	-0.48	Crohn's disease;	chr6:167098986	chr6:166969626~166999065:-
LAML	cis	rs67311347	1	rs6801859	ENSG00000230274.1	PGAM1P3	-4.58	1.89e-05	0.0319	-0.61	-0.48	Renal cell carcinoma;	chr3:40451727	chr3:40322715~40323279:-
LAML	cis	rs597539	0.521	rs2060982	ENSG00000250508.1	RP11-757G1.6	-4.58	1.9e-05	0.032	-0.45	-0.48	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68845459	chr11:68870664~68874542:+
LAML	cis	rs11672691	0.519	rs10407939	ENSG00000239736.2	CEACAMP3	-4.58	1.9e-05	0.0321	-0.6	-0.47	Prostate cancer;	chr19:41502561	chr19:41599735~41605984:+
LAML	cis	rs13113518	0.812	rs13140173	ENSG00000249700.7	SRD5A3-AS1	4.58	1.9e-05	0.0321	0.5	0.47	Height;	chr4:55527164	chr4:55363971~55395847:-
LAML	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	4.58	1.91e-05	0.0321	0.58	0.47	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-4.58	1.91e-05	0.0321	-0.58	-0.47	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
LAML	cis	rs881375	0.933	rs1548784	ENSG00000226752.6	PSMD5-AS1	-4.58	1.91e-05	0.0321	-0.58	-0.47	Rheumatoid arthritis;	chr9:120923002	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-4.58	1.91e-05	0.0321	-0.58	-0.47	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
LAML	cis	rs9891572	1	rs9891572	ENSG00000262884.1	CTD-3060P21.1	-4.58	1.91e-05	0.0321	-0.56	-0.47	HDL cholesterol;	chr17:2525214	chr17:2962248~2965895:-
LAML	cis	rs7458938	0.93	rs7795027	ENSG00000224897.5	POT1-AS1	4.58	1.91e-05	0.0322	0.59	0.47	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125806034	chr7:124929873~125179315:+
LAML	cis	rs7458938	0.93	rs10270552	ENSG00000224897.5	POT1-AS1	4.58	1.91e-05	0.0322	0.59	0.47	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125806508	chr7:124929873~125179315:+
LAML	cis	rs7219014	1	rs7219014	ENSG00000223091.1	RNU6-981P	-4.58	1.91e-05	0.0322	-0.59	-0.47	Urinary metabolites;	chr17:39468537	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.851	rs11868029	ENSG00000223091.1	RNU6-981P	-4.58	1.91e-05	0.0322	-0.59	-0.47	Glomerular filtration rate (creatinine);	chr17:39494051	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs4794813	ENSG00000223091.1	RNU6-981P	-4.58	1.91e-05	0.0322	-0.59	-0.47	Glomerular filtration rate (creatinine);	chr17:39514741	chr17:39482486~39482590:-
LAML	cis	rs9916302	0.904	rs4795384	ENSG00000223091.1	RNU6-981P	-4.58	1.91e-05	0.0322	-0.59	-0.47	Glomerular filtration rate (creatinine);	chr17:39560518	chr17:39482486~39482590:-
LAML	cis	rs7829975	0.511	rs2980423	ENSG00000253893.2	FAM85B	-4.58	1.91e-05	0.0322	-0.59	-0.47	Mood instability;	chr8:8285053	chr8:8167819~8226614:-
LAML	cis	rs5769707	0.554	rs10854876	ENSG00000280224.1	CTA-722E9.1	-4.58	1.91e-05	0.0322	-0.73	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49616922	chr22:49500568~49501585:+
LAML	cis	rs6772849	0.896	rs35535737	ENSG00000277250.1	Metazoa_SRP	-4.58	1.91e-05	0.0322	-0.61	-0.47	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:128673681~128674021:-
LAML	cis	rs1075265	0.626	rs805412	ENSG00000235937.1	AC008280.1	4.58	1.91e-05	0.0322	0.38	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54029552~54030682:-
LAML	cis	rs916888	0.773	rs9896243	ENSG00000280985.1	AC217773.1	4.58	1.92e-05	0.0323	0.65	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:46172089~46172239:-
LAML	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-4.58	1.93e-05	0.0324	-0.52	-0.47	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
LAML	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-4.58	1.93e-05	0.0324	-0.52	-0.47	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
LAML	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-4.58	1.93e-05	0.0324	-0.52	-0.47	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
LAML	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-4.58	1.93e-05	0.0324	-0.52	-0.47	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
LAML	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-4.58	1.93e-05	0.0324	-0.52	-0.47	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
LAML	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-4.58	1.93e-05	0.0324	-0.52	-0.47	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
LAML	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-4.58	1.93e-05	0.0324	-0.52	-0.47	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
LAML	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-4.58	1.93e-05	0.0324	-0.52	-0.47	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
LAML	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-4.58	1.93e-05	0.0324	-0.52	-0.47	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
LAML	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	4.58	1.93e-05	0.0324	0.52	0.47	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
LAML	cis	rs7165170	0.529	rs4932356	ENSG00000259314.1	CTD-3065B20.3	4.58	1.93e-05	0.0324	0.48	0.47	Crohn's disease;Inflammatory bowel disease;	chr15:90617275	chr15:90604225~90614558:-
LAML	cis	rs10883723	0.579	rs1967815	ENSG00000228657.1	RP11-170J3.2	-4.58	1.93e-05	0.0325	-0.61	-0.47	Allergic disease (asthma, hay fever or eczema);	chr10:102527294	chr10:102572757~102573225:-
LAML	cis	rs4604234	0.803	rs79048064	ENSG00000219547.1	RPL17P25	-4.58	1.94e-05	0.0325	-0.82	-0.47	Cancer;	chr6:80267381	chr6:80374015~80374569:-
LAML	cis	rs4604234	0.803	rs76568328	ENSG00000219547.1	RPL17P25	-4.58	1.94e-05	0.0325	-0.82	-0.47	Cancer;	chr6:80267384	chr6:80374015~80374569:-
LAML	cis	rs6502050	0.736	rs11658040	ENSG00000266654.1	RP11-1376P16.1	4.57	1.94e-05	0.0325	0.54	0.47	Life satisfaction;	chr17:82102015	chr17:82160056~82160452:+
LAML	cis	rs6502050	0.761	rs9908277	ENSG00000266654.1	RP11-1376P16.1	4.57	1.94e-05	0.0325	0.54	0.47	Life satisfaction;	chr17:82102953	chr17:82160056~82160452:+
LAML	cis	rs6502050	0.761	rs12150321	ENSG00000266654.1	RP11-1376P16.1	4.57	1.94e-05	0.0325	0.54	0.47	Life satisfaction;	chr17:82103682	chr17:82160056~82160452:+
LAML	cis	rs6502050	0.736	rs12150322	ENSG00000266654.1	RP11-1376P16.1	4.57	1.94e-05	0.0325	0.54	0.47	Life satisfaction;	chr17:82103706	chr17:82160056~82160452:+
LAML	cis	rs11039798	0.844	rs6485820	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Axial length;	chr11:48243159	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.699	rs7120775	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Axial length;	chr11:48245184	chr11:48096782~48096858:+
LAML	cis	rs747782	0.585	rs1604655	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Intraocular pressure;	chr11:48253226	chr11:48096782~48096858:+
LAML	cis	rs747782	0.585	rs1316604	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Intraocular pressure;	chr11:48258244	chr11:48096782~48096858:+
LAML	cis	rs747782	0.528	rs16905753	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Intraocular pressure;	chr11:48264354	chr11:48096782~48096858:+
LAML	cis	rs747782	0.528	rs7937670	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Intraocular pressure;	chr11:48291664	chr11:48096782~48096858:+
LAML	cis	rs747782	0.528	rs11039669	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Intraocular pressure;	chr11:48307266	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.858	rs7121333	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Axial length;	chr11:48310586	chr11:48096782~48096858:+
LAML	cis	rs747782	0.528	rs11039674	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Intraocular pressure;	chr11:48314564	chr11:48096782~48096858:+
LAML	cis	rs747782	0.528	rs10838881	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Intraocular pressure;	chr11:48365723	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.764	rs10838882	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Axial length;	chr11:48371483	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs12223271	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Axial length;	chr11:48395868	chr11:48096782~48096858:+
LAML	cis	rs747782	0.528	rs4370963	ENSG00000263693.1	MIR3161	4.57	1.94e-05	0.0325	0.47	0.47	Intraocular pressure;	chr11:48412391	chr11:48096782~48096858:+
LAML	cis	rs747782	0.582	rs7949865	ENSG00000263693.1	MIR3161	-4.57	1.94e-05	0.0325	-0.47	-0.47	Intraocular pressure;	chr11:48324650	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.764	rs4357721	ENSG00000263693.1	MIR3161	-4.57	1.94e-05	0.0325	-0.47	-0.47	Axial length;	chr11:48333355	chr11:48096782~48096858:+
LAML	cis	rs1351696	1	rs1351696	ENSG00000263693.1	MIR3161	-4.57	1.94e-05	0.0325	-0.47	-0.47	D-dimer levels;	chr11:48360919	chr11:48096782~48096858:+
LAML	cis	rs747782	0.528	rs624348	ENSG00000263693.1	MIR3161	-4.57	1.94e-05	0.0325	-0.47	-0.47	Intraocular pressure;	chr11:48379243	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.623	rs584851	ENSG00000263693.1	MIR3161	-4.57	1.94e-05	0.0325	-0.47	-0.47	Axial length;	chr11:48394769	chr11:48096782~48096858:+
LAML	cis	rs6951245	0.554	rs75075857	ENSG00000229043.2	AC091729.9	-4.57	1.94e-05	0.0325	-0.58	-0.47	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1100662	chr7:1160374~1165267:+
LAML	cis	rs202065757	1	rs202065757	ENSG00000220721.1	OR1F12	4.57	1.94e-05	0.0325	0.73	0.47	Tuberculosis;	chr6:28798582	chr6:28073316~28074233:+
LAML	cis	rs5769707	0.605	rs6009791	ENSG00000212939.2	RP1-29C18.10	-4.57	1.94e-05	0.0325	-0.68	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49631617	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.605	rs9616702	ENSG00000212939.2	RP1-29C18.10	-4.57	1.94e-05	0.0325	-0.68	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49632290	chr22:49548681~49556473:+
LAML	cis	rs5769707	0.667	rs4824069	ENSG00000212939.2	RP1-29C18.10	-4.57	1.94e-05	0.0325	-0.68	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49636677	chr22:49548681~49556473:+
LAML	cis	rs67311347	0.955	rs60554147	ENSG00000230274.1	PGAM1P3	4.57	1.94e-05	0.0325	0.6	0.47	Renal cell carcinoma;	chr3:40431012	chr3:40322715~40323279:-
LAML	cis	rs1032757	0.655	rs17205306	ENSG00000236447.2	ATG10-IT1	-4.57	1.94e-05	0.0325	-0.85	-0.47	Eosinophilic esophagitis (pediatric);	chr5:82636206	chr5:81991995~81992481:+
LAML	cis	rs1032757	0.655	rs78302725	ENSG00000236447.2	ATG10-IT1	-4.57	1.94e-05	0.0325	-0.85	-0.47	Eosinophilic esophagitis (pediatric);	chr5:82636318	chr5:81991995~81992481:+
LAML	cis	rs935334	1	rs12879642	ENSG00000280078.1	RP11-361H10.5	4.57	1.95e-05	0.0326	0.75	0.47	Blood pressure;	chr14:76216624	chr14:76279173~76283103:+
LAML	cis	rs282544	0.965	rs27243	ENSG00000271455.1	RP11-269M20.2	-4.57	1.95e-05	0.0326	-0.5	-0.47	Myopia (pathological);	chr5:50843524	chr5:50603229~50603511:+
LAML	cis	rs7829975	0.627	rs2979172	ENSG00000253893.2	FAM85B	-4.57	1.95e-05	0.0326	-0.58	-0.47	Mood instability;	chr8:8452998	chr8:8167819~8226614:-
LAML	cis	rs2581794	1	rs2581794	ENSG00000242142.1	SERBP1P3	4.57	1.95e-05	0.0326	0.56	0.47	Schizophrenia;	chr3:53002190	chr3:53064283~53065091:-
LAML	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-4.57	1.96e-05	0.0326	-0.61	-0.47	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
LAML	cis	rs7534824	0.872	rs79551246	ENSG00000213421.4	RP11-84O12.2	-4.57	1.96e-05	0.0326	-1.02	-0.47	Refractive astigmatism;	chr1:101165866	chr1:100586649~100587431:-
LAML	cis	rs7458938	0.93	rs757188	ENSG00000224897.5	POT1-AS1	4.57	1.96e-05	0.0327	0.59	0.47	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125808653	chr7:124929873~125179315:+
LAML	cis	rs7458938	0.895	rs2107086	ENSG00000224897.5	POT1-AS1	4.57	1.96e-05	0.0327	0.59	0.47	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125809612	chr7:124929873~125179315:+
LAML	cis	rs7458938	0.93	rs2107087	ENSG00000224897.5	POT1-AS1	4.57	1.96e-05	0.0327	0.59	0.47	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125809721	chr7:124929873~125179315:+
LAML	cis	rs4273100	0.646	rs6587216	ENSG00000262319.1	CTC-457L16.2	4.57	1.96e-05	0.0327	0.85	0.47	Schizophrenia;	chr17:19321084	chr17:19141017~19143689:-
LAML	cis	rs1419607	0.814	rs4731265	ENSG00000224897.5	POT1-AS1	4.57	1.96e-05	0.0327	0.54	0.47	Obesity-related traits;	chr7:125803420	chr7:124929873~125179315:+
LAML	cis	rs7927771	0.965	rs4752881	ENSG00000280615.1	Y_RNA	-4.57	1.96e-05	0.0327	-0.65	-0.47	Subjective well-being;	chr11:47876983	chr11:47614898~47614994:-
LAML	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	4.57	1.96e-05	0.0327	0.59	0.47	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
LAML	cis	rs9393777	0.557	rs7759741	ENSG00000187763.3	OR2B7P	4.57	1.96e-05	0.0327	0.63	0.47	Intelligence (multi-trait analysis);	chr6:27273264	chr6:28046434~28047367:+
LAML	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	4.57	1.97e-05	0.0327	0.56	0.47	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
LAML	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	4.57	1.97e-05	0.0327	0.56	0.47	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
LAML	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	4.57	1.97e-05	0.0327	0.56	0.47	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
LAML	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	4.57	1.97e-05	0.0327	0.56	0.47	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
LAML	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	4.57	1.97e-05	0.0327	0.56	0.47	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
LAML	cis	rs4713118	0.621	rs9295756	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28065618	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.621	rs10484403	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28065745	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.621	rs4713132	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28066257	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.621	rs4713133	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28066263	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.621	rs4713134	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28066343	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.621	rs9368548	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28066959	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.587	rs61471148	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28069254	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380047	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28070115	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs7755442	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28071237	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4713135	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28071808	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs12174753	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28074687	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs55747925	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28076559	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs56310871	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28076704	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs34716816	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28078391	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393884	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28079011	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380049	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28080757	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380050	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28080760	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393885	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28082231	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393886	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28082261	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.515	rs9368549	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28082269	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs56364346	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28082984	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9357061	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28083994	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9368550	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28084025	chr6:28033947~28034855:+
LAML	cis	rs853679	0.542	rs2295594	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28085319	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs2273564	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28089816	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs1853097	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28090857	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393887	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28091242	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393888	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28091439	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs3734573	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28091659	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9357063	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28092227	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs3823180	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28093966	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9368551	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28094014	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393890	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28096077	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380052	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28096845	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9366715	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28096855	chr6:28033947~28034855:+
LAML	cis	rs853679	0.598	rs9380054	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28099759	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.547	rs2116981	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28100173	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9368552	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28100648	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs2281588	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28104824	chr6:28033947~28034855:+
LAML	cis	rs853679	0.542	rs34131763	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28107222	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs35193936	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28108492	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs36078605	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28110254	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.516	rs6931858	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28110633	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393891	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28111382	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9468286	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28111650	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.516	rs7739216	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28112168	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs35512245	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28112175	chr6:28033947~28034855:+
LAML	cis	rs853679	0.542	rs9393892	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28113616	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380055	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28113851	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9368553	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28114487	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9368554	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28114933	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4713137	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28115743	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9348793	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28116411	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.586	rs6905516	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28118700	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.586	rs6905522	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28118701	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.586	rs9468290	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28119896	chr6:28033947~28034855:+
LAML	cis	rs853679	0.542	rs6934769	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28123153	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs17711801	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28124529	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs6922063	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28126588	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs2275508	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28126953	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.527	rs9461433	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28127394	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9468292	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28127577	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs1947863	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28131566	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4713141	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28133900	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs1340004	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28135913	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380056	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28136698	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380057	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28136856	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs1947862	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28137418	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs6941992	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28138363	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.516	rs4713142	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28138569	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4713143	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28138981	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4713144	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28139012	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4713145	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28139049	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs3757187	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28139876	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs3757185	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28139998	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs1904841	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28140307	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs1904840	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28140454	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9368555	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28141189	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393893	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28141484	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4713146	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28143758	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393894	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28144784	chr6:28033947~28034855:+
LAML	cis	rs853679	0.513	rs9468296	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28145952	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4711164	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28147378	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4711165	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28147406	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4713148	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28148143	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9348794	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28149979	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9468297	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28151096	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9295758	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28152885	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs17774663	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28153120	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9468298	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28154567	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9295759	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28156691	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9348796	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28158424	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs11552219	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28159056	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380058	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28159666	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393895	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28159843	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393896	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28159925	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393897	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28159932	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9357065	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28161802	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9357066	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28162053	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393898	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28162598	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9368556	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28163375	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9368557	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28163759	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380059	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28164580	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380060	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28164825	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs35227624	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28164948	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380061	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28165025	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9368558	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28165528	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.587	rs9393899	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28165750	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4713150	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28168434	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.527	rs4713151	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Parkinson's disease;	chr6:28168578	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9393901	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28169019	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs3173443	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28169249	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs4713152	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28169676	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9348797	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28169755	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380062	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28169791	chr6:28033947~28034855:+
LAML	cis	rs853679	0.542	rs9380063	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28170075	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs12332979	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28173770	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs67878650	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28174809	chr6:28033947~28034855:+
LAML	cis	rs853679	0.569	rs9348798	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28175233	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9380065	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28176973	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9295761	ENSG00000217315.1	OR2W2P	4.57	1.97e-05	0.0327	0.75	0.47	Depression;	chr6:28180209	chr6:28033947~28034855:+
LAML	cis	rs4713118	0.621	rs9295755	ENSG00000217315.1	OR2W2P	-4.57	1.97e-05	0.0327	-0.75	-0.47	Parkinson's disease;	chr6:28065396	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs16893666	ENSG00000217315.1	OR2W2P	-4.57	1.97e-05	0.0327	-0.75	-0.47	Depression;	chr6:28086929	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs17711344	ENSG00000217315.1	OR2W2P	-4.57	1.97e-05	0.0327	-0.75	-0.47	Depression;	chr6:28109824	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs6932109	ENSG00000217315.1	OR2W2P	-4.57	1.97e-05	0.0327	-0.75	-0.47	Depression;	chr6:28110525	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs868987	ENSG00000217315.1	OR2W2P	-4.57	1.97e-05	0.0327	-0.75	-0.47	Depression;	chr6:28142370	chr6:28033947~28034855:+
LAML	cis	rs853679	0.517	rs9283884	ENSG00000217315.1	OR2W2P	-4.57	1.97e-05	0.0327	-0.75	-0.47	Depression;	chr6:28167882	chr6:28033947~28034855:+
LAML	cis	rs10463316	0.928	rs4958267	ENSG00000260581.1	CTB-113P19.4	4.57	1.97e-05	0.0327	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151373082	chr5:151652275~151655449:+
LAML	cis	rs4713118	0.523	rs2179096	ENSG00000216915.2	RP1-97D16.1	-4.57	1.97e-05	0.0327	-0.52	-0.47	Parkinson's disease;	chr6:27698141	chr6:27737000~27738494:-
LAML	cis	rs9426935	0.966	rs12738361	ENSG00000273026.1	RP11-422P24.10	4.57	1.97e-05	0.0327	0.59	0.47	Lentiform nucleus volume;	chr1:153796264	chr1:153966516~153966930:+
LAML	cis	rs9426935	1	rs61803655	ENSG00000273026.1	RP11-422P24.10	4.57	1.97e-05	0.0327	0.59	0.47	Lentiform nucleus volume;	chr1:153796856	chr1:153966516~153966930:+
LAML	cis	rs9426935	1	rs9426935	ENSG00000273026.1	RP11-422P24.10	4.57	1.97e-05	0.0327	0.59	0.47	Lentiform nucleus volume;	chr1:153796924	chr1:153966516~153966930:+
LAML	cis	rs748404	0.534	rs489509	ENSG00000249839.1	AC011330.5	-4.57	1.97e-05	0.0327	-0.54	-0.47	Lung cancer;	chr15:43294709	chr15:43663654~43684339:-
LAML	cis	rs7826238	0.564	rs2921053	ENSG00000268955.2	RP11-556O5.6	-4.57	1.98e-05	0.0328	-0.57	-0.47	Systolic blood pressure;	chr8:8462453	chr8:8188535~8189195:-
LAML	cis	rs9426935	0.966	rs4341393	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153804190	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.934	rs4451582	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153805193	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.966	rs9426938	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153807822	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.966	rs6668066	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153813706	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.966	rs9427232	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153820482	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.902	rs4596938	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153822221	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.865	rs6427300	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153833201	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.932	rs6427306	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153839643	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.872	rs4370789	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153840689	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.934	rs4581307	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153842067	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.966	rs72694233	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153845279	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.966	rs7554469	ENSG00000273026.1	RP11-422P24.10	4.57	1.98e-05	0.0328	0.59	0.47	Lentiform nucleus volume;	chr1:153855076	chr1:153966516~153966930:+
LAML	cis	rs6929812	0.934	rs2064221	ENSG00000216915.2	RP1-97D16.1	4.57	1.98e-05	0.0328	0.53	0.47	Neuroticism (multi-trait analysis);	chr6:27420669	chr6:27737000~27738494:-
LAML	cis	rs6929812	0.967	rs34185469	ENSG00000216915.2	RP1-97D16.1	4.57	1.98e-05	0.0328	0.53	0.47	Neuroticism (multi-trait analysis);	chr6:27424156	chr6:27737000~27738494:-
LAML	cis	rs718433	0.782	rs11157216	ENSG00000256081.2	AE000658.25	-4.57	1.98e-05	0.0328	-0.56	-0.47	Intraocular pressure;	chr14:21773507	chr14:21585290~21586280:-
LAML	cis	rs9426935	0.934	rs7414227	ENSG00000273026.1	RP11-422P24.10	4.57	1.99e-05	0.0329	0.59	0.47	Lentiform nucleus volume;	chr1:153876520	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.899	rs7415004	ENSG00000273026.1	RP11-422P24.10	4.57	1.99e-05	0.0329	0.59	0.47	Lentiform nucleus volume;	chr1:153892985	chr1:153966516~153966930:+
LAML	cis	rs1577917	0.876	rs12190735	ENSG00000203875.9	SNHG5	-4.57	1.99e-05	0.0329	-0.62	-0.47	Response to antipsychotic treatment;	chr6:85976749	chr6:85660950~85678736:-
LAML	cis	rs2439831	0.702	rs7171750	ENSG00000275601.1	AC011330.13	-4.57	1.99e-05	0.0329	-0.88	-0.47	Lung cancer in ever smokers;	chr15:43733660	chr15:43642389~43643023:-
LAML	cis	rs8141529	0.732	rs2239815	ENSG00000226471.5	CTA-292E10.6	4.57	1.99e-05	0.0329	0.47	0.47	Lymphocyte counts;	chr22:28796682	chr22:28800683~28848559:+
LAML	cis	rs7426056	0.627	rs17533699	ENSG00000224791.1	KRT18P39	4.57	1.99e-05	0.0329	0.7	0.47	Primary sclerosing cholangitis;	chr2:203732310	chr2:203764295~203765593:-
LAML	cis	rs1144	0.505	rs2252074	ENSG00000225329.2	LHFPL3-AS2	4.57	1.99e-05	0.0329	0.56	0.47	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;	chr7:104953806	chr7:104894628~104926645:-
LAML	cis	rs8081395	0.651	rs1292067	ENSG00000266960.1	FAM106DP	-4.57	1.99e-05	0.0329	-0.57	-0.47	White blood cell count;	chr17:59853285	chr17:60173322~60173822:+
LAML	cis	rs6700559	0.643	rs4915451	ENSG00000260088.1	RP11-92G12.3	4.57	1.99e-05	0.0329	0.57	0.47	Coronary artery disease;	chr1:200690726	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.643	rs6427844	ENSG00000260088.1	RP11-92G12.3	4.57	1.99e-05	0.0329	0.57	0.47	Coronary artery disease;	chr1:200692216	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.643	rs1540683	ENSG00000260088.1	RP11-92G12.3	4.57	1.99e-05	0.0329	0.57	0.47	Coronary artery disease;	chr1:200693050	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.643	rs1540682	ENSG00000260088.1	RP11-92G12.3	4.57	1.99e-05	0.0329	0.57	0.47	Coronary artery disease;	chr1:200693231	chr1:200669507~200694250:+
LAML	cis	rs6700559	0.643	rs4556395	ENSG00000260088.1	RP11-92G12.3	4.57	1.99e-05	0.0329	0.57	0.47	Coronary artery disease;	chr1:200693813	chr1:200669507~200694250:+
LAML	cis	rs7829975	0.54	rs2976909	ENSG00000268955.2	RP11-556O5.6	4.57	1.99e-05	0.0329	0.55	0.47	Mood instability;	chr8:8489180	chr8:8188535~8189195:-
LAML	cis	rs7165170	0.678	rs10083558	ENSG00000259314.1	CTD-3065B20.3	4.57	1.99e-05	0.0329	0.49	0.47	Crohn's disease;Inflammatory bowel disease;	chr15:90659273	chr15:90604225~90614558:-
LAML	cis	rs7927771	0.965	rs3817335	ENSG00000280615.1	Y_RNA	-4.57	1.99e-05	0.0329	-0.62	-0.47	Subjective well-being;	chr11:47622339	chr11:47614898~47614994:-
LAML	cis	rs10463316	0.862	rs1983171	ENSG00000260581.1	CTB-113P19.4	4.57	1.99e-05	0.0329	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151399130	chr5:151652275~151655449:+
LAML	cis	rs17608059	0.518	rs4792436	ENSG00000265494.1	RP11-131K5.2	-4.57	1.99e-05	0.033	-0.58	-0.47	Temperament;	chr17:14068990	chr17:13909231~13911212:+
LAML	cis	rs875971	0.825	rs1129531	ENSG00000222364.1	RNU6-96P	4.57	1.99e-05	0.033	0.61	0.47	Aortic root size;	chr7:66154117	chr7:66395191~66395286:+
LAML	cis	rs6502050	0.761	rs7225637	ENSG00000266654.1	RP11-1376P16.1	-4.57	1.99e-05	0.033	-0.53	-0.47	Life satisfaction;	chr17:82101882	chr17:82160056~82160452:+
LAML	cis	rs6558530	0.579	rs6558528	ENSG00000253982.1	CTD-2336O2.1	4.57	2e-05	0.033	0.71	0.47	Systolic blood pressure;	chr8:1754897	chr8:1761990~1764502:-
LAML	cis	rs6951245	0.529	rs10262070	ENSG00000229043.2	AC091729.9	-4.57	2e-05	0.033	-0.58	-0.47	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1102102	chr7:1160374~1165267:+
LAML	cis	rs9322193	0.847	rs868375	ENSG00000217733.2	CCT7P1	4.57	2e-05	0.033	0.75	0.47	Lung cancer;	chr6:149844905	chr6:149879962~149881572:+
LAML	cis	rs36051354	0.554	rs4687662	ENSG00000242142.1	SERBP1P3	4.57	2e-05	0.0331	0.62	0.47	Intelligence (multi-trait analysis);	chr3:52836308	chr3:53064283~53065091:-
LAML	cis	rs7131987	0.903	rs67517901	ENSG00000274315.1	RP11-996F15.5	4.57	2e-05	0.0331	0.49	0.47	QT interval;	chr12:29268413	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.903	rs7308125	ENSG00000274315.1	RP11-996F15.5	4.57	2e-05	0.0331	0.49	0.47	QT interval;	chr12:29272278	chr12:29331434~29331936:-
LAML	cis	rs10463316	0.817	rs12653378	ENSG00000260581.1	CTB-113P19.4	4.57	2.01e-05	0.0331	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151422805	chr5:151652275~151655449:+
LAML	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	4.57	2.01e-05	0.0331	0.8	0.47	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
LAML	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	4.57	2.01e-05	0.0331	0.8	0.47	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
LAML	cis	rs898534	0.646	rs898533	ENSG00000262172.1	CTD-2529O21.1	4.57	2.01e-05	0.0332	0.74	0.47	Urate levels (BMI interaction);	chr17:79277537	chr17:79991944~79992841:-
LAML	cis	rs8067354	0.574	rs2250526	ENSG00000266960.1	FAM106DP	4.57	2.01e-05	0.0332	0.75	0.47	Hemoglobin concentration;	chr17:59874612	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.574	rs1292050	ENSG00000266960.1	FAM106DP	4.57	2.01e-05	0.0332	0.75	0.47	Hemoglobin concentration;	chr17:59887808	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.574	rs1292033	ENSG00000266960.1	FAM106DP	4.57	2.01e-05	0.0332	0.75	0.47	Hemoglobin concentration;	chr17:59913236	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.574	rs1291947	ENSG00000266960.1	FAM106DP	4.57	2.01e-05	0.0332	0.75	0.47	Hemoglobin concentration;	chr17:59918975	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.507	rs2645478	ENSG00000266960.1	FAM106DP	4.57	2.01e-05	0.0332	0.75	0.47	Hemoglobin concentration;	chr17:59937351	chr17:60173322~60173822:+
LAML	cis	rs9921222	0.565	rs10903014	ENSG00000230428.1	RP1-196A12.1	-4.56	2.01e-05	0.0332	-0.57	-0.47	Bone mineral density (spine);Bone mineral density;	chr16:327623	chr16:451404~453461:+
LAML	cis	rs7746199	0.673	rs72847313	ENSG00000217315.1	OR2W2P	4.56	2.02e-05	0.0333	0.88	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.611	rs17750747	ENSG00000217315.1	OR2W2P	4.56	2.02e-05	0.0333	0.88	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.673	rs35501037	ENSG00000217315.1	OR2W2P	4.56	2.02e-05	0.0333	0.88	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28033947~28034855:+
LAML	cis	rs8054556	0.787	rs12921753	ENSG00000183604.13	SMG1P5	4.56	2.02e-05	0.0334	0.57	0.47	Autism spectrum disorder or schizophrenia;	chr16:30007399	chr16:30267553~30335374:-
LAML	cis	rs2412819	0.597	rs2412821	ENSG00000249839.1	AC011330.5	-4.56	2.03e-05	0.0334	-0.68	-0.47	Lung cancer;	chr15:43864966	chr15:43663654~43684339:-
LAML	cis	rs8031584	0.723	rs11632229	ENSG00000259845.1	HERC2P10	-4.56	2.03e-05	0.0335	-0.52	-0.47	Huntington's disease progression;	chr15:30887331	chr15:30815271~30844153:+
LAML	cis	rs4879656	0.872	rs511183	ENSG00000225693.1	LAGE3P1	4.56	2.03e-05	0.0335	0.57	0.47	Menopause (age at onset);	chr9:33098950	chr9:33019682~33020165:-
LAML	cis	rs367615	0.552	rs3828603	ENSG00000249476.1	CTD-2587M2.1	-4.56	2.03e-05	0.0335	-0.55	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109376367	chr5:109237120~109326369:-
LAML	cis	rs367615	0.552	rs2963023	ENSG00000249476.1	CTD-2587M2.1	-4.56	2.03e-05	0.0335	-0.55	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109394369	chr5:109237120~109326369:-
LAML	cis	rs13113518	0.812	rs13107810	ENSG00000249700.7	SRD5A3-AS1	4.56	2.03e-05	0.0335	0.49	0.47	Height;	chr4:55542243	chr4:55363971~55395847:-
LAML	cis	rs709400	0.663	rs7158822	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103421531	chr14:103553421~103561877:+
LAML	cis	rs709400	0.633	rs3783395	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103428683	chr14:103553421~103561877:+
LAML	cis	rs709400	0.567	rs28496120	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103431562	chr14:103553421~103561877:+
LAML	cis	rs709400	0.597	rs1013650	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103442866	chr14:103553421~103561877:+
LAML	cis	rs11623869	0.711	rs2403173	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Bone mineral density;	chr14:103442952	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs2273703	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103451692	chr14:103553421~103561877:+
LAML	cis	rs709400	0.633	rs10143247	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103454590	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs7150317	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103455354	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs10141120	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103456671	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs2273699	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103457138	chr14:103553421~103561877:+
LAML	cis	rs709400	0.628	rs7146506	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103458140	chr14:103553421~103561877:+
LAML	cis	rs709400	0.663	rs28444993	ENSG00000258851.1	RP11-894P9.2	-4.56	2.04e-05	0.0335	-0.56	-0.47	Body mass index;	chr14:103464227	chr14:103553421~103561877:+
LAML	cis	rs4803480	0.543	rs7257282	ENSG00000239736.2	CEACAMP3	-4.56	2.04e-05	0.0335	-0.68	-0.47	Schizophrenia;	chr19:41536585	chr19:41599735~41605984:+
LAML	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-4.56	2.04e-05	0.0335	-0.67	-0.47	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs4766900	ENSG00000275759.1	RP11-131L12.3	-4.56	2.04e-05	0.0335	-0.67	-0.47	Glucose homeostasis traits;	chr12:118375139	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs884844	ENSG00000275759.1	RP11-131L12.3	-4.56	2.04e-05	0.0335	-0.67	-0.47	Glucose homeostasis traits;	chr12:118377033	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs7304342	ENSG00000275759.1	RP11-131L12.3	-4.56	2.04e-05	0.0335	-0.67	-0.47	Glucose homeostasis traits;	chr12:118390166	chr12:118428281~118428870:+
LAML	cis	rs673078	0.615	rs61943397	ENSG00000275759.1	RP11-131L12.3	-4.56	2.04e-05	0.0335	-0.67	-0.47	Glucose homeostasis traits;	chr12:118390996	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943398	ENSG00000275759.1	RP11-131L12.3	-4.56	2.04e-05	0.0335	-0.67	-0.47	Glucose homeostasis traits;	chr12:118393280	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943403	ENSG00000275759.1	RP11-131L12.3	-4.56	2.04e-05	0.0335	-0.67	-0.47	Glucose homeostasis traits;	chr12:118399887	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs882927	ENSG00000275759.1	RP11-131L12.3	-4.56	2.04e-05	0.0335	-0.67	-0.47	Glucose homeostasis traits;	chr12:118406737	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-4.56	2.04e-05	0.0335	-0.67	-0.47	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
LAML	cis	rs4591358	0.608	rs72927762	ENSG00000223466.1	AC064834.2	-4.56	2.04e-05	0.0335	-0.82	-0.47	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544921	chr2:195533035~195538681:+
LAML	cis	rs4713118	0.591	rs2056924	ENSG00000216915.2	RP1-97D16.1	-4.56	2.04e-05	0.0335	-0.53	-0.47	Parkinson's disease;	chr6:27722395	chr6:27737000~27738494:-
LAML	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-4.56	2.04e-05	0.0335	-0.57	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
LAML	cis	rs67311347	0.955	rs1129200	ENSG00000230274.1	PGAM1P3	4.56	2.04e-05	0.0336	0.63	0.47	Renal cell carcinoma;	chr3:40490766	chr3:40322715~40323279:-
LAML	cis	rs67311347	1	rs67680017	ENSG00000230274.1	PGAM1P3	4.56	2.04e-05	0.0336	0.63	0.47	Renal cell carcinoma;	chr3:40491673	chr3:40322715~40323279:-
LAML	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-4.56	2.04e-05	0.0336	-0.65	-0.47	QT interval;	chr16:28824579	chr16:28700294~28701540:-
LAML	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-4.56	2.04e-05	0.0336	-0.65	-0.47	QT interval;	chr16:28845498	chr16:28700294~28701540:-
LAML	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-4.56	2.04e-05	0.0336	-0.65	-0.47	QT interval;	chr16:28857143	chr16:28700294~28701540:-
LAML	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-4.56	2.04e-05	0.0336	-0.65	-0.47	QT interval;	chr16:28877088	chr16:28700294~28701540:-
LAML	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	4.56	2.04e-05	0.0336	0.65	0.47	QT interval;	chr16:28860645	chr16:28700294~28701540:-
LAML	cis	rs8044188	1	rs8044188	ENSG00000260247.1	SUB1P4	4.56	2.05e-05	0.0336	0.76	0.47	Multiple system atrophy;	chr16:23019939	chr16:23537061~23537556:+
LAML	cis	rs7534824	1	rs76841451	ENSG00000213421.4	RP11-84O12.2	-4.56	2.05e-05	0.0337	-1.03	-0.47	Refractive astigmatism;	chr1:101190885	chr1:100586649~100587431:-
LAML	cis	rs9916302	0.904	rs4357971	ENSG00000223091.1	RNU6-981P	-4.56	2.05e-05	0.0337	-0.59	-0.47	Glomerular filtration rate (creatinine);	chr17:39561027	chr17:39482486~39482590:-
LAML	cis	rs7247513	0.856	rs6511828	ENSG00000230310.1	CTD-2192J16.11	-4.56	2.05e-05	0.0337	-0.6	-0.47	Bipolar disorder;	chr19:12634985	chr19:12552597~12553644:+
LAML	cis	rs801193	0.742	rs9969300	ENSG00000224316.1	RP11-479O9.2	-4.56	2.05e-05	0.0337	-0.49	-0.47	Aortic root size;	chr7:66316659	chr7:65773620~65802067:+
LAML	cis	rs9900497	0.536	rs4646785	ENSG00000230528.6	NOS2P3	4.56	2.05e-05	0.0337	0.86	0.47	Response to paliperidone in schizophrenia (CGI-S score);	chr17:19748589	chr17:20436337~20447249:+
LAML	cis	rs13108904	0.652	rs2878539	ENSG00000196810.4	CTBP1-AS2	4.56	2.06e-05	0.0338	0.47	0.47	Obesity-related traits;	chr4:1250089	chr4:1249300~1288291:+
LAML	cis	rs10463316	0.817	rs1810083	ENSG00000260581.1	CTB-113P19.4	-4.56	2.06e-05	0.0338	-0.44	-0.47	Metabolite levels (Pyroglutamine);	chr5:151397246	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6579860	ENSG00000260581.1	CTB-113P19.4	4.56	2.06e-05	0.0338	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151372777	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7709994	ENSG00000260581.1	CTB-113P19.4	4.56	2.06e-05	0.0338	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151374036	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.862	rs13354553	ENSG00000260581.1	CTB-113P19.4	4.56	2.06e-05	0.0338	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151378567	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6891252	ENSG00000260581.1	CTB-113P19.4	4.56	2.06e-05	0.0338	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151383246	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.862	rs11747047	ENSG00000260581.1	CTB-113P19.4	4.56	2.06e-05	0.0338	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151398392	chr5:151652275~151655449:+
LAML	cis	rs716804	0.593	rs7107021	ENSG00000254719.1	RP11-351I24.3	-4.56	2.06e-05	0.0338	-0.57	-0.47	Neuroticism;	chr11:10050263	chr11:10272052~10272259:-
LAML	cis	rs6728642	1	rs7580504	ENSG00000235833.1	AC159540.14	4.56	2.06e-05	0.0339	0.87	0.47	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96939860	chr2:97523949~97524976:-
LAML	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	4.56	2.07e-05	0.0339	0.57	0.47	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
LAML	cis	rs5760092	0.572	rs738806	ENSG00000273295.1	AP000350.5	4.56	2.07e-05	0.034	0.76	0.47	Urinary 1,3-butadiene metabolite levels in smokers;	chr22:23891985	chr22:23901432~23907068:-
LAML	cis	rs5769707	0.521	rs739244	ENSG00000213279.2	RP1-29C18.9	-4.56	2.07e-05	0.034	-0.58	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49666510	chr22:49572264~49575426:-
LAML	cis	rs7131987	0.903	rs6487796	ENSG00000274315.1	RP11-996F15.5	4.56	2.07e-05	0.034	0.48	0.47	QT interval;	chr12:29269831	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.903	rs2194519	ENSG00000274315.1	RP11-996F15.5	-4.56	2.07e-05	0.034	-0.48	-0.47	QT interval;	chr12:29270650	chr12:29331434~29331936:-
LAML	cis	rs7849270	1	rs7849160	ENSG00000268707.1	RP11-247A12.7	-4.56	2.07e-05	0.034	-0.55	-0.47	Blood metabolite ratios;	chr9:129112273	chr9:129170434~129170940:+
LAML	cis	rs7849270	1	rs7849270	ENSG00000268707.1	RP11-247A12.7	-4.56	2.07e-05	0.034	-0.55	-0.47	Blood metabolite ratios;	chr9:129112362	chr9:129170434~129170940:+
LAML	cis	rs7849270	1	rs10819464	ENSG00000268707.1	RP11-247A12.7	-4.56	2.07e-05	0.034	-0.55	-0.47	Blood metabolite ratios;	chr9:129113998	chr9:129170434~129170940:+
LAML	cis	rs7849270	0.885	rs10760588	ENSG00000268707.1	RP11-247A12.7	-4.56	2.07e-05	0.034	-0.55	-0.47	Blood metabolite ratios;	chr9:129115195	chr9:129170434~129170940:+
LAML	cis	rs7849270	0.921	rs6478864	ENSG00000268707.1	RP11-247A12.7	-4.56	2.07e-05	0.034	-0.55	-0.47	Blood metabolite ratios;	chr9:129118351	chr9:129170434~129170940:+
LAML	cis	rs7849270	0.851	rs7861663	ENSG00000268707.1	RP11-247A12.7	-4.56	2.07e-05	0.034	-0.55	-0.47	Blood metabolite ratios;	chr9:129118667	chr9:129170434~129170940:+
LAML	cis	rs7849270	1	rs10819466	ENSG00000268707.1	RP11-247A12.7	-4.56	2.07e-05	0.034	-0.55	-0.47	Blood metabolite ratios;	chr9:129119213	chr9:129170434~129170940:+
LAML	cis	rs2980439	0.783	rs2948305	ENSG00000268955.2	RP11-556O5.6	-4.56	2.08e-05	0.034	-0.61	-0.47	Neuroticism;	chr8:8241055	chr8:8188535~8189195:-
LAML	cis	rs7581030	0.55	rs4852258	ENSG00000236469.1	AC007040.8	4.56	2.08e-05	0.034	0.63	0.47	Testicular germ cell tumor;	chr2:71451402	chr2:71002531~71064743:-
LAML	cis	rs4604234	0.803	rs73463518	ENSG00000219547.1	RPL17P25	-4.56	2.08e-05	0.034	-0.81	-0.47	Cancer;	chr6:80266300	chr6:80374015~80374569:-
LAML	cis	rs1144	0.536	rs2428162	ENSG00000225329.2	LHFPL3-AS2	4.56	2.08e-05	0.0341	0.56	0.47	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;	chr7:104955217	chr7:104894628~104926645:-
LAML	cis	rs2015599	0.549	rs3782508	ENSG00000273680.1	RP11-996F15.6	4.56	2.08e-05	0.0341	0.47	0.47	Platelet count;Mean platelet volume;	chr12:29298446	chr12:29332733~29333383:-
LAML	cis	rs2015599	0.516	rs10450679	ENSG00000273680.1	RP11-996F15.6	4.56	2.08e-05	0.0341	0.47	0.47	Platelet count;Mean platelet volume;	chr12:29298823	chr12:29332733~29333383:-
LAML	cis	rs2015599	0.549	rs6487802	ENSG00000273680.1	RP11-996F15.6	4.56	2.08e-05	0.0341	0.47	0.47	Platelet count;Mean platelet volume;	chr12:29299480	chr12:29332733~29333383:-
LAML	cis	rs2015599	0.549	rs6487803	ENSG00000273680.1	RP11-996F15.6	4.56	2.08e-05	0.0341	0.47	0.47	Platelet count;Mean platelet volume;	chr12:29299760	chr12:29332733~29333383:-
LAML	cis	rs2015599	0.549	rs7954990	ENSG00000273680.1	RP11-996F15.6	4.56	2.08e-05	0.0341	0.47	0.47	Platelet count;Mean platelet volume;	chr12:29299841	chr12:29332733~29333383:-
LAML	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	4.56	2.08e-05	0.0341	0.56	0.47	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
LAML	cis	rs9847710	0.696	rs2244461	ENSG00000242142.1	SERBP1P3	4.56	2.08e-05	0.0341	0.56	0.47	Ulcerative colitis;	chr3:53021826	chr3:53064283~53065091:-
LAML	cis	rs9847710	0.733	rs2581806	ENSG00000242142.1	SERBP1P3	4.56	2.08e-05	0.0341	0.56	0.47	Ulcerative colitis;	chr3:53029344	chr3:53064283~53065091:-
LAML	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-4.56	2.08e-05	0.0341	-0.8	-0.47	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
LAML	cis	rs7131987	0.903	rs11050152	ENSG00000274315.1	RP11-996F15.5	4.56	2.09e-05	0.0341	0.48	0.47	QT interval;	chr12:29251491	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.903	rs10843367	ENSG00000274315.1	RP11-996F15.5	4.56	2.09e-05	0.0341	0.48	0.47	QT interval;	chr12:29255447	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.903	rs7302129	ENSG00000274315.1	RP11-996F15.5	4.56	2.09e-05	0.0341	0.48	0.47	QT interval;	chr12:29262347	chr12:29331434~29331936:-
LAML	cis	rs9921222	0.585	rs7195617	ENSG00000230428.1	RP1-196A12.1	4.55	2.09e-05	0.0341	0.56	0.47	Bone mineral density (spine);Bone mineral density;	chr16:326781	chr16:451404~453461:+
LAML	cis	rs67311347	0.64	rs7434088	ENSG00000230274.1	PGAM1P3	4.55	2.09e-05	0.0342	0.61	0.47	Renal cell carcinoma;	chr3:40255797	chr3:40322715~40323279:-
LAML	cis	rs7511633	0.535	rs11102810	ENSG00000225650.2	EIF2S2P5	4.55	2.09e-05	0.0342	0.35	0.47	Autism;	chr1:114527285	chr1:114468315~114469282:+
LAML	cis	rs709400	0.633	rs10135868	ENSG00000258851.1	RP11-894P9.2	-4.55	2.09e-05	0.0342	-0.57	-0.47	Body mass index;	chr14:103537810	chr14:103553421~103561877:+
LAML	cis	rs9457247	1	rs416131	ENSG00000227598.1	RP1-167A14.2	4.55	2.09e-05	0.0342	0.58	0.47	Crohn's disease;	chr6:166993056	chr6:166969626~166999065:-
LAML	cis	rs7301826	1	rs4619189	ENSG00000256250.1	RP11-989F5.1	-4.55	2.1e-05	0.0343	-0.59	-0.47	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810606~130812438:+
LAML	cis	rs12052801	0.967	rs6546363	ENSG00000221443.1	AC017083.1	4.55	2.1e-05	0.0343	0.54	0.47	Schizophrenia;	chr2:68240778	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs6721447	ENSG00000221443.1	AC017083.1	4.55	2.1e-05	0.0343	0.54	0.47	Schizophrenia;	chr2:68245110	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs6546364	ENSG00000221443.1	AC017083.1	4.55	2.1e-05	0.0343	0.54	0.47	Schizophrenia;	chr2:68247936	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs4671887	ENSG00000221443.1	AC017083.1	4.55	2.1e-05	0.0343	0.54	0.47	Schizophrenia;	chr2:68248463	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs4671888	ENSG00000221443.1	AC017083.1	4.55	2.1e-05	0.0343	0.54	0.47	Schizophrenia;	chr2:68250116	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs4347819	ENSG00000221443.1	AC017083.1	4.55	2.1e-05	0.0343	0.54	0.47	Schizophrenia;	chr2:68252539	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.934	rs12329083	ENSG00000221443.1	AC017083.1	4.55	2.1e-05	0.0343	0.54	0.47	Schizophrenia;	chr2:68254587	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.903	rs7569914	ENSG00000221443.1	AC017083.1	4.55	2.1e-05	0.0343	0.54	0.47	Schizophrenia;	chr2:68259977	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs6546366	ENSG00000221443.1	AC017083.1	4.55	2.1e-05	0.0343	0.54	0.47	Schizophrenia;	chr2:68262535	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs12713637	ENSG00000221443.1	AC017083.1	4.55	2.1e-05	0.0343	0.54	0.47	Schizophrenia;	chr2:68263838	chr2:68273104~68273206:+
LAML	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	4.55	2.1e-05	0.0343	0.58	0.47	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
LAML	cis	rs9392556	0.734	rs648900	ENSG00000272248.1	RP3-406P24.4	4.55	2.1e-05	0.0343	0.51	0.47	Blood metabolite levels;	chr6:4109188	chr6:4018713~4019202:+
LAML	cis	rs9392556	0.6	rs664299	ENSG00000272248.1	RP3-406P24.4	4.55	2.1e-05	0.0343	0.51	0.47	Blood metabolite levels;	chr6:4112007	chr6:4018713~4019202:+
LAML	cis	rs9392556	0.533	rs619439	ENSG00000272248.1	RP3-406P24.4	4.55	2.1e-05	0.0343	0.51	0.47	Blood metabolite levels;	chr6:4113695	chr6:4018713~4019202:+
LAML	cis	rs9322193	0.847	rs4870054	ENSG00000217733.2	CCT7P1	4.55	2.1e-05	0.0343	0.76	0.47	Lung cancer;	chr6:149848402	chr6:149879962~149881572:+
LAML	cis	rs7458938	0.629	rs757187	ENSG00000224897.5	POT1-AS1	4.55	2.1e-05	0.0343	0.55	0.47	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125808215	chr7:124929873~125179315:+
LAML	cis	rs6506900	0.901	rs4459623	ENSG00000263823.1	RP11-326K13.4	4.55	2.11e-05	0.0344	0.57	0.47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr18:31218470	chr18:31942575~31944156:+
LAML	cis	rs9399135	0.967	rs6909975	ENSG00000232876.1	CTA-212D2.2	-4.55	2.11e-05	0.0344	-0.63	-0.47	Red blood cell count;	chr6:134994432	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs7773126	ENSG00000232876.1	CTA-212D2.2	-4.55	2.11e-05	0.0344	-0.63	-0.47	Red blood cell count;	chr6:134997252	chr6:135055033~135060550:+
LAML	cis	rs2980439	0.558	rs2955584	ENSG00000249188.1	ENPP7P1	-4.55	2.11e-05	0.0344	-0.59	-0.47	Neuroticism;	chr8:8234652	chr8:8154308~8216916:+
LAML	cis	rs5769707	0.837	rs5770599	ENSG00000213279.2	RP1-29C18.9	-4.55	2.11e-05	0.0345	-0.59	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49626333	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.837	rs5769709	ENSG00000213279.2	RP1-29C18.9	-4.55	2.11e-05	0.0345	-0.59	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49628109	chr22:49572264~49575426:-
LAML	cis	rs785830	0.749	rs663309	ENSG00000235880.1	RP11-59O6.3	4.55	2.11e-05	0.0345	0.4	0.47	Platelet distribution width;	chr9:266795	chr9:267966~273002:-
LAML	cis	rs881375	0.967	rs1008382	ENSG00000226752.6	PSMD5-AS1	-4.55	2.13e-05	0.0347	-0.59	-0.47	Rheumatoid arthritis;	chr9:120918977	chr9:120824828~120854385:+
LAML	cis	rs13113518	0.841	rs7699867	ENSG00000249700.7	SRD5A3-AS1	4.55	2.13e-05	0.0347	0.49	0.47	Height;	chr4:55483718	chr4:55363971~55395847:-
LAML	cis	rs6772849	0.796	rs9841521	ENSG00000277250.1	Metazoa_SRP	-4.55	2.13e-05	0.0347	-0.63	-0.47	Monocyte percentage of white cells;Monocyte count;	chr3:128673431	chr3:128673681~128674021:-
LAML	cis	rs2404602	0.735	rs437131	ENSG00000259422.1	RP11-593F23.1	4.55	2.13e-05	0.0347	0.52	0.47	Blood metabolite levels;	chr15:76488710	chr15:76174891~76181486:-
LAML	cis	rs881375	0.967	rs7034492	ENSG00000226752.6	PSMD5-AS1	-4.55	2.14e-05	0.0348	-0.58	-0.47	Rheumatoid arthritis;	chr9:120924933	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs7034653	ENSG00000226752.6	PSMD5-AS1	-4.55	2.14e-05	0.0348	-0.58	-0.47	Rheumatoid arthritis;	chr9:120925094	chr9:120824828~120854385:+
LAML	cis	rs10457838	0.675	rs11967885	ENSG00000220848.4	RPS18P9	4.55	2.14e-05	0.0348	0.54	0.47	Post-traumatic stress disorder;	chr6:149011326	chr6:149594084~149594543:+
LAML	cis	rs7165170	0.55	rs76750851	ENSG00000259314.1	CTD-3065B20.3	4.55	2.14e-05	0.0348	0.48	0.47	Crohn's disease;Inflammatory bowel disease;	chr15:90652970	chr15:90604225~90614558:-
LAML	cis	rs561341	0.556	rs41290963	ENSG00000266379.5	RP11-640N20.8	4.55	2.14e-05	0.0349	0.95	0.47	Hip circumference adjusted for BMI;	chr17:32069371	chr17:32088160~32094933:-
LAML	cis	rs12477438	0.834	rs1563107	ENSG00000231822.1	AC019097.7	4.55	2.14e-05	0.0349	0.62	0.47	Chronic sinus infection;	chr2:99084813	chr2:99102018~99102752:+
LAML	cis	rs2404602	0.647	rs907594	ENSG00000259422.1	RP11-593F23.1	-4.55	2.15e-05	0.0349	-0.58	-0.47	Blood metabolite levels;	chr15:76905404	chr15:76174891~76181486:-
LAML	cis	rs8081395	0.729	rs12453125	ENSG00000267302.4	RP11-178C3.2	-4.55	2.15e-05	0.0349	-0.59	-0.47	White blood cell count;	chr17:59968715	chr17:59964832~59996972:+
LAML	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	4.55	2.15e-05	0.0349	0.68	0.47	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
LAML	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-4.55	2.15e-05	0.0349	-0.5	-0.47	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.572	rs9379958	ENSG00000241549.7	GUSBP2	-4.55	2.15e-05	0.0349	-0.5	-0.47	Schizophrenia;	chr6:27098384	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs9393789	ENSG00000241549.7	GUSBP2	-4.55	2.15e-05	0.0349	-0.5	-0.47	Schizophrenia;	chr6:27099249	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs6456767	ENSG00000241549.7	GUSBP2	-4.55	2.15e-05	0.0349	-0.5	-0.47	Schizophrenia;	chr6:27102764	chr6:26871484~26956554:-
LAML	cis	rs2980439	0.517	rs793753	ENSG00000268955.2	RP11-556O5.6	4.55	2.15e-05	0.035	0.55	0.47	Neuroticism;	chr8:8247837	chr8:8188535~8189195:-
LAML	cis	rs673078	0.607	rs17512652	ENSG00000275759.1	RP11-131L12.3	-4.55	2.16e-05	0.035	-0.7	-0.47	Glucose homeostasis traits;	chr12:118361278	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs950288	ENSG00000275759.1	RP11-131L12.3	-4.55	2.16e-05	0.035	-0.7	-0.47	Glucose homeostasis traits;	chr12:118392201	chr12:118428281~118428870:+
LAML	cis	rs62070183	0.656	rs17780664	ENSG00000266718.1	RP11-466A19.1	4.55	2.16e-05	0.0351	0.78	0.47	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32675720	chr17:32495536~32499333:+
LAML	cis	rs9921222	0.692	rs11860497	ENSG00000230428.1	RP1-196A12.1	-4.55	2.16e-05	0.0351	-0.58	-0.47	Bone mineral density (spine);Bone mineral density;	chr16:355416	chr16:451404~453461:+
LAML	cis	rs2120335	0.701	rs875	ENSG00000221443.1	AC017083.1	4.55	2.16e-05	0.0351	0.62	0.47	Height;	chr2:68180794	chr2:68273104~68273206:+
LAML	cis	rs9399135	1	rs4475342	ENSG00000232876.1	CTA-212D2.2	-4.54	2.17e-05	0.0351	-0.63	-0.47	Red blood cell count;	chr6:134962210	chr6:135055033~135060550:+
LAML	cis	rs9399135	0.967	rs4896120	ENSG00000232876.1	CTA-212D2.2	-4.54	2.17e-05	0.0351	-0.63	-0.47	Red blood cell count;	chr6:134972374	chr6:135055033~135060550:+
LAML	cis	rs9399135	1	rs35123050	ENSG00000232876.1	CTA-212D2.2	-4.54	2.17e-05	0.0351	-0.63	-0.47	Red blood cell count;	chr6:134981602	chr6:135055033~135060550:+
LAML	cis	rs12052801	0.967	rs2861814	ENSG00000221443.1	AC017083.1	-4.54	2.17e-05	0.0352	-0.56	-0.47	Schizophrenia;	chr2:68211482	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs2861815	ENSG00000221443.1	AC017083.1	4.54	2.17e-05	0.0352	0.56	0.47	Schizophrenia;	chr2:68211697	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs4296409	ENSG00000221443.1	AC017083.1	4.54	2.17e-05	0.0352	0.56	0.47	Schizophrenia;	chr2:68212036	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs2861816	ENSG00000221443.1	AC017083.1	4.54	2.17e-05	0.0352	0.56	0.47	Schizophrenia;	chr2:68212105	chr2:68273104~68273206:+
LAML	cis	rs7224685	0.722	rs12945048	ENSG00000234203.1	RP5-1050D4.2	-4.54	2.17e-05	0.0353	-0.77	-0.47	Type 2 diabetes;	chr17:4255949	chr17:4972851~4974681:+
LAML	cis	rs7131987	0.874	rs10843366	ENSG00000274315.1	RP11-996F15.5	4.54	2.17e-05	0.0353	0.47	0.47	QT interval;	chr12:29254970	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.845	rs2042511	ENSG00000274315.1	RP11-996F15.5	4.54	2.17e-05	0.0353	0.47	0.47	QT interval;	chr12:29255847	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.903	rs10843371	ENSG00000274315.1	RP11-996F15.5	4.54	2.17e-05	0.0353	0.47	0.47	QT interval;	chr12:29261299	chr12:29331434~29331936:-
LAML	cis	rs7587476	0.689	rs10498025	ENSG00000227769.6	AC072062.3	-4.54	2.18e-05	0.0354	-0.52	-0.47	Neuroblastoma;	chr2:214884532	chr2:215004782~215085488:+
LAML	cis	rs10458771	1	rs13415	ENSG00000212332.1	RNU6-780P	-4.54	2.18e-05	0.0354	-0.77	-0.47	Amyotrophic lateral sclerosis (sporadic);	chr10:86402122	chr10:86488446~86488549:+
LAML	cis	rs10458771	1	rs10458771	ENSG00000212332.1	RNU6-780P	-4.54	2.18e-05	0.0354	-0.77	-0.47	Amyotrophic lateral sclerosis (sporadic);	chr10:86402481	chr10:86488446~86488549:+
LAML	cis	rs4879656	0.705	rs10813910	ENSG00000225693.1	LAGE3P1	-4.54	2.18e-05	0.0354	-0.55	-0.47	Menopause (age at onset);	chr9:32965209	chr9:33019682~33020165:-
LAML	cis	rs11039100	0.512	rs7126020	ENSG00000232381.1	OR52U1P	4.54	2.18e-05	0.0354	0.56	0.47	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5762957	chr11:5719290~5720212:+
LAML	cis	rs853679	0.723	rs1736904	ENSG00000187763.3	OR2B7P	4.54	2.19e-05	0.0354	0.62	0.47	Depression;	chr6:28251492	chr6:28046434~28047367:+
LAML	cis	rs6558530	0.615	rs12674711	ENSG00000253982.1	CTD-2336O2.1	4.54	2.19e-05	0.0354	0.73	0.47	Systolic blood pressure;	chr8:1751442	chr8:1761990~1764502:-
LAML	cis	rs6558530	0.692	rs12335115	ENSG00000253982.1	CTD-2336O2.1	4.54	2.19e-05	0.0354	0.73	0.47	Systolic blood pressure;	chr8:1751686	chr8:1761990~1764502:-
LAML	cis	rs673078	0.607	rs55929628	ENSG00000275759.1	RP11-131L12.3	-4.54	2.19e-05	0.0354	-0.68	-0.47	Glucose homeostasis traits;	chr12:118371332	chr12:118428281~118428870:+
LAML	cis	rs673078	0.517	rs73205578	ENSG00000275759.1	RP11-131L12.3	-4.54	2.19e-05	0.0354	-0.68	-0.47	Glucose homeostasis traits;	chr12:118385113	chr12:118428281~118428870:+
LAML	cis	rs673078	0.66	rs73205579	ENSG00000275759.1	RP11-131L12.3	-4.54	2.19e-05	0.0354	-0.68	-0.47	Glucose homeostasis traits;	chr12:118385125	chr12:118428281~118428870:+
LAML	cis	rs747650	0.504	rs7935346	ENSG00000271350.1	CTD-2384B9.1	-4.54	2.19e-05	0.0355	-0.59	-0.47	Acne (severe);	chr11:46986828	chr11:47041027~47041945:-
LAML	cis	rs471756	0.523	rs2479319	ENSG00000235880.1	RP11-59O6.3	4.54	2.2e-05	0.0355	0.39	0.47	Mean platelet volume;	chr9:219528	chr9:267966~273002:-
LAML	cis	rs471756	0.523	rs575307	ENSG00000235880.1	RP11-59O6.3	4.54	2.2e-05	0.0355	0.39	0.47	Mean platelet volume;	chr9:219774	chr9:267966~273002:-
LAML	cis	rs471756	0.523	rs574399	ENSG00000235880.1	RP11-59O6.3	4.54	2.2e-05	0.0355	0.39	0.47	Mean platelet volume;	chr9:219875	chr9:267966~273002:-
LAML	cis	rs471756	0.554	rs2484967	ENSG00000235880.1	RP11-59O6.3	4.54	2.2e-05	0.0355	0.39	0.47	Mean platelet volume;	chr9:221874	chr9:267966~273002:-
LAML	cis	rs10463316	0.894	rs954339	ENSG00000260581.1	CTB-113P19.4	4.54	2.2e-05	0.0355	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151372600	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6864722	ENSG00000260581.1	CTB-113P19.4	4.54	2.2e-05	0.0355	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151373381	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs12652733	ENSG00000260581.1	CTB-113P19.4	4.54	2.2e-05	0.0355	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151374438	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6875014	ENSG00000260581.1	CTB-113P19.4	4.54	2.2e-05	0.0355	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151374784	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs6579862	ENSG00000260581.1	CTB-113P19.4	4.54	2.2e-05	0.0355	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151382156	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7707745	ENSG00000260581.1	CTB-113P19.4	4.54	2.2e-05	0.0355	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151385637	chr5:151652275~151655449:+
LAML	cis	rs8062405	0.679	rs72793818	ENSG00000271623.1	RP11-435I10.5	-4.54	2.2e-05	0.0356	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28364700~28365333:+
LAML	cis	rs34792	0.76	rs153808	ENSG00000260872.1	RP11-680G24.5	4.54	2.21e-05	0.0356	0.49	0.47	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464485	chr16:15018106~15020488:-
LAML	cis	rs34792	0.821	rs153809	ENSG00000260872.1	RP11-680G24.5	4.54	2.21e-05	0.0356	0.49	0.47	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15464514	chr16:15018106~15020488:-
LAML	cis	rs34792	0.821	rs2450357	ENSG00000260872.1	RP11-680G24.5	4.54	2.21e-05	0.0356	0.49	0.47	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15474475	chr16:15018106~15020488:-
LAML	cis	rs7829975	0.51	rs2921073	ENSG00000253893.2	FAM85B	-4.54	2.21e-05	0.0356	-0.56	-0.47	Mood instability;	chr8:8450133	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.51	rs2979160	ENSG00000253893.2	FAM85B	-4.54	2.21e-05	0.0356	-0.56	-0.47	Mood instability;	chr8:8450156	chr8:8167819~8226614:-
LAML	cis	rs67311347	1	rs67311347	ENSG00000230274.1	PGAM1P3	4.54	2.21e-05	0.0357	0.63	0.47	Renal cell carcinoma;	chr3:40491752	chr3:40322715~40323279:-
LAML	cis	rs62070183	0.517	rs17182935	ENSG00000264458.1	RP11-220C2.1	4.54	2.22e-05	0.0358	0.82	0.47	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32627207	chr17:32627739~32686484:+
LAML	cis	rs904251	0.523	rs2797794	ENSG00000229559.2	RP1-153P14.3	-4.54	2.22e-05	0.0358	-0.5	-0.47	Cognitive performance;	chr6:37512828	chr6:37543553~37547280:-
LAML	cis	rs904251	0.523	rs2776920	ENSG00000229559.2	RP1-153P14.3	-4.54	2.22e-05	0.0358	-0.5	-0.47	Cognitive performance;	chr6:37512829	chr6:37543553~37547280:-
LAML	cis	rs904251	0.504	rs2797795	ENSG00000229559.2	RP1-153P14.3	-4.54	2.22e-05	0.0358	-0.5	-0.47	Cognitive performance;	chr6:37512907	chr6:37543553~37547280:-
LAML	cis	rs904251	0.523	rs2797796	ENSG00000229559.2	RP1-153P14.3	-4.54	2.22e-05	0.0358	-0.5	-0.47	Cognitive performance;	chr6:37513110	chr6:37543553~37547280:-
LAML	cis	rs904251	0.523	rs2776870	ENSG00000229559.2	RP1-153P14.3	-4.54	2.22e-05	0.0358	-0.5	-0.47	Cognitive performance;	chr6:37513588	chr6:37543553~37547280:-
LAML	cis	rs904251	0.523	rs2797798	ENSG00000229559.2	RP1-153P14.3	-4.54	2.22e-05	0.0358	-0.5	-0.47	Cognitive performance;	chr6:37513661	chr6:37543553~37547280:-
LAML	cis	rs904251	0.523	rs2776871	ENSG00000229559.2	RP1-153P14.3	-4.54	2.22e-05	0.0358	-0.5	-0.47	Cognitive performance;	chr6:37513983	chr6:37543553~37547280:-
LAML	cis	rs17645023	0.512	rs11079674	ENSG00000201547.1	Y_RNA	-4.54	2.22e-05	0.0358	-1.03	-0.47	Bipolar disorder and schizophrenia;	chr17:66933218	chr17:67408774~67408881:-
LAML	cis	rs904251	0.523	rs10947675	ENSG00000204110.6	RP1-153P14.8	-4.54	2.23e-05	0.0358	-0.54	-0.47	Cognitive performance;	chr6:37512196	chr6:37507348~37535616:+
LAML	cis	rs8062405	0.755	rs17640009	ENSG00000271623.1	RP11-435I10.5	-4.54	2.23e-05	0.0359	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28364700~28365333:+
LAML	cis	rs7829975	0.511	rs2980512	ENSG00000253893.2	FAM85B	-4.54	2.24e-05	0.036	-0.59	-0.47	Mood instability;	chr8:8283379	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.539	rs35571782	ENSG00000253893.2	FAM85B	-4.54	2.24e-05	0.036	-0.59	-0.47	Mood instability;	chr8:8284301	chr8:8167819~8226614:-
LAML	cis	rs716804	0.59	rs7935242	ENSG00000254719.1	RP11-351I24.3	-4.54	2.24e-05	0.036	-0.57	-0.47	Neuroticism;	chr11:10302281	chr11:10272052~10272259:-
LAML	cis	rs763121	0.962	rs5757135	ENSG00000230912.1	RP3-508I15.10	-4.54	2.24e-05	0.0361	-0.38	-0.47	Menopause (age at onset);	chr22:38556568	chr22:38666508~38668750:-
LAML	cis	rs747650	0.504	rs6485715	ENSG00000271350.1	CTD-2384B9.1	4.54	2.24e-05	0.0361	0.56	0.47	Acne (severe);	chr11:46953574	chr11:47041027~47041945:-
LAML	cis	rs2742417	1	rs2245705	ENSG00000244357.3	RN7SL145P	4.54	2.25e-05	0.0361	0.5	0.47	Response to anti-depressant treatment in major depressive disorder;	chr3:45708230	chr3:45742675~45742970:+
LAML	cis	rs8081395	0.737	rs4968401	ENSG00000267302.4	RP11-178C3.2	-4.53	2.25e-05	0.0362	-0.59	-0.47	White blood cell count;	chr17:59963369	chr17:59964832~59996972:+
LAML	cis	rs7829975	0.681	rs2271342	ENSG00000268955.2	RP11-556O5.6	-4.53	2.26e-05	0.0363	-0.52	-0.47	Mood instability;	chr8:8786428	chr8:8188535~8189195:-
LAML	cis	rs471756	0.618	rs511364	ENSG00000235880.1	RP11-59O6.3	4.53	2.26e-05	0.0363	0.4	0.47	Mean platelet volume;	chr9:264265	chr9:267966~273002:-
LAML	cis	rs34792	0.554	rs4597346	ENSG00000275910.1	RP11-680G24.6	-4.53	2.26e-05	0.0363	-0.51	-0.47	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:15015828~15016390:-
LAML	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-4.53	2.26e-05	0.0363	-0.62	-0.47	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
LAML	cis	rs1009077	0.716	rs13147817	ENSG00000178636.7	RP11-455G16.1	4.53	2.26e-05	0.0363	0.83	0.47	Endometriosis;	chr4:119634500	chr4:119192773~119212644:-
LAML	cis	rs8031584	0.541	rs1983459	ENSG00000260382.1	RP11-540B6.2	4.53	2.26e-05	0.0363	0.48	0.47	Huntington's disease progression;	chr15:30916546	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.541	rs2955797	ENSG00000260382.1	RP11-540B6.2	-4.53	2.26e-05	0.0363	-0.48	-0.47	Huntington's disease progression;	chr15:30918778	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.541	rs2959037	ENSG00000260382.1	RP11-540B6.2	-4.53	2.26e-05	0.0363	-0.48	-0.47	Huntington's disease progression;	chr15:30925961	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.505	rs2959036	ENSG00000260382.1	RP11-540B6.2	-4.53	2.26e-05	0.0363	-0.48	-0.47	Huntington's disease progression;	chr15:30927539	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.541	rs2955777	ENSG00000260382.1	RP11-540B6.2	-4.53	2.26e-05	0.0363	-0.48	-0.47	Huntington's disease progression;	chr15:30927585	chr15:30882267~30883231:-
LAML	cis	rs9393777	0.668	rs72839449	ENSG00000243307.2	POM121L6P	-4.53	2.27e-05	0.0364	-0.65	-0.47	Intelligence (multi-trait analysis);	chr6:27293882	chr6:26896952~26898777:+
LAML	cis	rs9393777	0.668	rs3800318	ENSG00000243307.2	POM121L6P	-4.53	2.27e-05	0.0364	-0.65	-0.47	Intelligence (multi-trait analysis);	chr6:27295862	chr6:26896952~26898777:+
LAML	cis	rs9393777	0.623	rs13211166	ENSG00000243307.2	POM121L6P	-4.53	2.27e-05	0.0364	-0.65	-0.47	Intelligence (multi-trait analysis);	chr6:27298161	chr6:26896952~26898777:+
LAML	cis	rs9322193	0.923	rs17745062	ENSG00000216906.2	RP11-350J20.9	4.53	2.27e-05	0.0364	0.64	0.47	Lung cancer;	chr6:149721079	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs62441279	ENSG00000216906.2	RP11-350J20.9	4.53	2.27e-05	0.0364	0.64	0.47	Lung cancer;	chr6:149721194	chr6:149904243~149906418:+
LAML	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-4.53	2.27e-05	0.0364	-0.48	-0.47	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-4.53	2.27e-05	0.0364	-0.48	-0.47	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
LAML	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-4.53	2.27e-05	0.0364	-0.48	-0.47	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
LAML	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-4.53	2.27e-05	0.0364	-0.48	-0.47	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
LAML	cis	rs2404602	0.647	rs11072607	ENSG00000259422.1	RP11-593F23.1	-4.53	2.27e-05	0.0364	-0.58	-0.47	Blood metabolite levels;	chr15:76616188	chr15:76174891~76181486:-
LAML	cis	rs9457247	0.934	rs2345571	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.27e-05	0.0365	-0.46	-0.47	Crohn's disease;	chr6:166989912	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.756	rs1811123	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.27e-05	0.0365	-0.46	-0.47	Crohn's disease;	chr6:166989955	chr6:166903698~166904835:+
LAML	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	4.53	2.28e-05	0.0365	0.49	0.47	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
LAML	cis	rs11098499	0.78	rs7692994	ENSG00000260091.1	RP11-33B1.4	4.53	2.28e-05	0.0365	0.44	0.47	Corneal astigmatism;	chr4:119506334	chr4:119409333~119410233:+
LAML	cis	rs57024841	0.819	rs908839	ENSG00000238268.2	RP11-229P13.19	-4.53	2.28e-05	0.0365	-0.56	-0.47	Beta-trace protein levels;	chr9:136962187	chr9:136975094~136976981:+
LAML	cis	rs57024841	0.819	rs11145949	ENSG00000238268.2	RP11-229P13.19	-4.53	2.28e-05	0.0365	-0.56	-0.47	Beta-trace protein levels;	chr9:136963506	chr9:136975094~136976981:+
LAML	cis	rs9322193	0.923	rs11155671	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149650996	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9689723	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149655935	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9767123	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149660323	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs62439836	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149669173	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs4869812	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149669447	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs4870267	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149671572	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs4380763	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149678086	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs4354168	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149696642	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs4455682	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149700161	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs4870529	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149716436	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9767309	ENSG00000216906.2	RP11-350J20.9	4.53	2.28e-05	0.0365	0.64	0.47	Lung cancer;	chr6:149716807	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9371207	ENSG00000217733.2	CCT7P1	4.53	2.28e-05	0.0365	0.78	0.47	Lung cancer;	chr6:149858087	chr6:149879962~149881572:+
LAML	cis	rs9322193	0.923	rs2880436	ENSG00000217733.2	CCT7P1	4.53	2.28e-05	0.0365	0.78	0.47	Lung cancer;	chr6:149859123	chr6:149879962~149881572:+
LAML	cis	rs950169	0.84	rs72748702	ENSG00000259728.4	LINC00933	4.53	2.28e-05	0.0365	0.68	0.47	Schizophrenia;	chr15:84246494	chr15:84570649~84580175:+
LAML	cis	rs950169	0.922	rs4338765	ENSG00000259728.4	LINC00933	4.53	2.28e-05	0.0365	0.68	0.47	Schizophrenia;	chr15:84248084	chr15:84570649~84580175:+
LAML	cis	rs950169	0.922	rs62028133	ENSG00000259728.4	LINC00933	4.53	2.28e-05	0.0365	0.68	0.47	Schizophrenia;	chr15:84250623	chr15:84570649~84580175:+
LAML	cis	rs950169	0.723	rs17589320	ENSG00000259728.4	LINC00933	4.53	2.28e-05	0.0365	0.68	0.47	Schizophrenia;	chr15:84251244	chr15:84570649~84580175:+
LAML	cis	rs950169	0.845	rs4502182	ENSG00000259728.4	LINC00933	4.53	2.28e-05	0.0365	0.68	0.47	Schizophrenia;	chr15:84254768	chr15:84570649~84580175:+
LAML	cis	rs950169	0.724	rs11632668	ENSG00000259728.4	LINC00933	4.53	2.28e-05	0.0365	0.68	0.47	Schizophrenia;	chr15:84393989	chr15:84570649~84580175:+
LAML	cis	rs785830	0.721	rs682251	ENSG00000235880.1	RP11-59O6.3	-4.53	2.28e-05	0.0366	-0.4	-0.47	Platelet distribution width;	chr9:271455	chr9:267966~273002:-
LAML	cis	rs4753788	0.688	rs7926602	ENSG00000261098.1	RP11-819C21.1	-4.53	2.28e-05	0.0366	-0.43	-0.47	Coronary artery disease;	chr11:107183916	chr11:107312132~107316271:-
LAML	cis	rs7131987	0.903	rs11050153	ENSG00000274315.1	RP11-996F15.5	4.53	2.29e-05	0.0366	0.48	0.47	QT interval;	chr12:29252215	chr12:29331434~29331936:-
LAML	cis	rs7131987	1	rs7131987	ENSG00000274315.1	RP11-996F15.5	4.53	2.29e-05	0.0366	0.48	0.47	QT interval;	chr12:29253555	chr12:29331434~29331936:-
LAML	cis	rs6452524	0.836	rs10041617	ENSG00000249664.1	CTD-2227C6.2	4.53	2.29e-05	0.0366	0.65	0.47	Hypertension (SNP x SNP interaction);	chr5:83096535	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs3901654	ENSG00000249664.1	CTD-2227C6.2	4.53	2.29e-05	0.0366	0.65	0.47	Hypertension (SNP x SNP interaction);	chr5:83110519	chr5:83012285~83013109:-
LAML	cis	rs6452524	0.935	rs1478480	ENSG00000249664.1	CTD-2227C6.2	4.53	2.29e-05	0.0366	0.65	0.47	Hypertension (SNP x SNP interaction);	chr5:83112117	chr5:83012285~83013109:-
LAML	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	4.53	2.29e-05	0.0367	0.58	0.47	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
LAML	cis	rs7927771	0.965	rs35184771	ENSG00000280615.1	Y_RNA	-4.53	2.29e-05	0.0367	-0.63	-0.47	Subjective well-being;	chr11:47453637	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs1317149	ENSG00000280615.1	Y_RNA	-4.53	2.29e-05	0.0367	-0.63	-0.47	Subjective well-being;	chr11:47465333	chr11:47614898~47614994:-
LAML	cis	rs7927771	0.725	rs11039265	ENSG00000280615.1	Y_RNA	-4.53	2.29e-05	0.0367	-0.63	-0.47	Subjective well-being;	chr11:47501662	chr11:47614898~47614994:-
LAML	cis	rs7927771	0.965	rs4752845	ENSG00000280615.1	Y_RNA	-4.53	2.29e-05	0.0367	-0.63	-0.47	Subjective well-being;	chr11:47518145	chr11:47614898~47614994:-
LAML	cis	rs7927771	0.965	rs34958982	ENSG00000280615.1	Y_RNA	-4.53	2.29e-05	0.0367	-0.63	-0.47	Subjective well-being;	chr11:47525494	chr11:47614898~47614994:-
LAML	cis	rs7927771	0.929	rs66749409	ENSG00000280615.1	Y_RNA	-4.53	2.29e-05	0.0367	-0.63	-0.47	Subjective well-being;	chr11:47546522	chr11:47614898~47614994:-
LAML	cis	rs7927771	0.894	rs12798346	ENSG00000280615.1	Y_RNA	-4.53	2.29e-05	0.0367	-0.63	-0.47	Subjective well-being;	chr11:47561569	chr11:47614898~47614994:-
LAML	cis	rs7927771	0.965	rs56400411	ENSG00000280615.1	Y_RNA	-4.53	2.29e-05	0.0367	-0.63	-0.47	Subjective well-being;	chr11:47564824	chr11:47614898~47614994:-
LAML	cis	rs7534824	1	rs76094275	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-1.03	-0.47	Refractive astigmatism;	chr1:101173716	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.929	rs7534215	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-1.03	-0.47	Refractive astigmatism;	chr1:101174787	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.79	rs79628995	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-1.03	-0.47	Refractive astigmatism;	chr1:101183265	chr1:100586649~100587431:-
LAML	cis	rs7458938	0.629	rs6467052	ENSG00000224897.5	POT1-AS1	4.53	2.3e-05	0.0367	0.55	0.47	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125810288	chr7:124929873~125179315:+
LAML	cis	rs1930961	0.85	rs5996945	ENSG00000265978.1	AL008721.1	4.53	2.3e-05	0.0367	0.95	0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25532720~25532809:-
LAML	cis	rs1075265	0.73	rs6713088	ENSG00000235937.1	AC008280.1	4.53	2.3e-05	0.0367	0.41	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54118332	chr2:54029552~54030682:-
LAML	cis	rs7224685	0.569	rs34859684	ENSG00000234203.1	RP5-1050D4.2	-4.53	2.3e-05	0.0367	-0.84	-0.47	Type 2 diabetes;	chr17:4079334	chr17:4972851~4974681:+
LAML	cis	rs13113518	0.812	rs11945371	ENSG00000249700.7	SRD5A3-AS1	4.53	2.3e-05	0.0367	0.48	0.47	Height;	chr4:55409063	chr4:55363971~55395847:-
LAML	cis	rs7534824	0.789	rs7515711	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-0.98	-0.47	Refractive astigmatism;	chr1:101076508	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.789	rs61782096	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-0.98	-0.47	Refractive astigmatism;	chr1:101089587	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.719	rs61782097	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-0.98	-0.47	Refractive astigmatism;	chr1:101090565	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.789	rs61782098	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-0.98	-0.47	Refractive astigmatism;	chr1:101097631	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.789	rs61782099	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-0.98	-0.47	Refractive astigmatism;	chr1:101100011	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.789	rs61782100	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-0.98	-0.47	Refractive astigmatism;	chr1:101103965	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.789	rs61782102	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-0.98	-0.47	Refractive astigmatism;	chr1:101111116	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.651	rs61782142	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-0.98	-0.47	Refractive astigmatism;	chr1:101117940	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.789	rs7526789	ENSG00000213421.4	RP11-84O12.2	-4.53	2.3e-05	0.0367	-0.98	-0.47	Refractive astigmatism;	chr1:101118562	chr1:100586649~100587431:-
LAML	cis	rs7534824	0.789	rs17409729	ENSG00000213421.4	RP11-84O12.2	4.53	2.3e-05	0.0367	0.98	0.47	Refractive astigmatism;	chr1:101070222	chr1:100586649~100587431:-
LAML	cis	rs9457247	0.967	rs433191	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166996174	chr6:166903698~166904835:+
LAML	cis	rs785830	0.558	rs2479328	ENSG00000235880.1	RP11-59O6.3	4.53	2.3e-05	0.0367	0.42	0.47	Platelet distribution width;	chr9:261855	chr9:267966~273002:-
LAML	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	4.53	2.3e-05	0.0367	0.56	0.47	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
LAML	cis	rs9457247	1	rs1819333	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166960059	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs1211447	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166968491	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs1187532	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166968532	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs448060	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166969134	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs365189	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166971057	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs376551	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166971435	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs402749	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166972616	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs385863	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166973127	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs397713	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166973226	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.905	rs453184	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166973916	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs436707	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166975355	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs377753	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166976008	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs430477	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166976363	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs443570	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166976437	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs376574	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166976468	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs439237	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166977904	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs9457247	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166978686	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs405553	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166981570	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.935	rs1794697	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166981922	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.902	rs34560498	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166982374	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs421214	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166983141	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs422094	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166983545	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs393558	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166984262	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs394522	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166984583	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs393727	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166985144	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs408040	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166985415	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs408918	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166985794	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs413232	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166987484	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs86755	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166989620	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs382009	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166989633	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs428805	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166989644	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.902	rs366938	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166990050	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.871	rs1811121	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166990051	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs385460	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166990400	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs385113	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166990483	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs932644	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166990699	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs10946198	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166990944	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs10946199	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166991004	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs1794694	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166991263	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs430293	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166991470	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs430097	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166991585	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs409356	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166991738	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs447042	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166991947	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs402191	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166992065	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs1794693	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166992182	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.935	rs401260	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166992400	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs422694	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166992586	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs422780	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166992721	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs400176	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166992750	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs422562	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166992830	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs415842	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166993193	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs389956	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166993766	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs389946	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166993780	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs407515	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166994056	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs406095	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166995599	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.646	rs4710160	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166995753	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs388406	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166996074	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs430145	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166996881	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs425039	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166997039	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs376097	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166997390	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs424185	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166997419	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs400837	ENSG00000231654.1	RPS6KA2-AS1	-4.53	2.3e-05	0.0367	-0.46	-0.47	Crohn's disease;	chr6:166997520	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs2149090	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166959276	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs2149091	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166959298	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs2149092	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166959490	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs2013815	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166960324	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs4710147	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166960751	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.935	rs2757046	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166960865	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs2757047	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166961001	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.935	rs1187530	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166963324	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.935	rs2757050	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166963677	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs1590257	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166964294	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs2769354	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166966283	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.846	rs2757052	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166966686	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs2769355	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166967005	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs2757054	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166967013	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.967	rs2015864	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166967988	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs386548	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166972045	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs415890	ENSG00000231654.1	RPS6KA2-AS1	4.53	2.3e-05	0.0367	0.46	0.47	Crohn's disease;	chr6:166993145	chr6:166903698~166904835:+
LAML	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	4.53	2.3e-05	0.0367	0.55	0.47	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
LAML	cis	rs12554020	1	rs4552973	ENSG00000227603.1	RP11-165J3.6	4.53	2.3e-05	0.0367	0.69	0.47	Schizophrenia;	chr9:93539437	chr9:93435332~93437121:-
LAML	cis	rs76917914	0.954	rs7855432	ENSG00000236896.1	RP11-535C21.3	4.53	2.31e-05	0.0367	0.47	0.47	Immature fraction of reticulocytes;	chr9:97997831	chr9:97986551~97987656:-
LAML	cis	rs7587476	0.689	rs10498025	ENSG00000229267.2	AC072062.1	-4.53	2.31e-05	0.0367	-0.53	-0.47	Neuroblastoma;	chr2:214884532	chr2:214810229~214963274:+
LAML	cis	rs716804	0.535	rs4444073	ENSG00000254719.1	RP11-351I24.3	-4.53	2.31e-05	0.0368	-0.55	-0.47	Neuroticism;	chr11:10310117	chr11:10272052~10272259:-
LAML	cis	rs6728642	1	rs116171118	ENSG00000235833.1	AC159540.14	4.53	2.31e-05	0.0368	0.91	0.47	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97029299	chr2:97523949~97524976:-
LAML	cis	rs8067354	0.54	rs72840315	ENSG00000266960.1	FAM106DP	4.53	2.31e-05	0.0368	0.74	0.47	Hemoglobin concentration;	chr17:59940781	chr17:60173322~60173822:+
LAML	cis	rs763121	0.849	rs12004	ENSG00000230912.1	RP3-508I15.10	-4.53	2.31e-05	0.0368	-0.4	-0.47	Menopause (age at onset);	chr22:38481456	chr22:38666508~38668750:-
LAML	cis	rs8081395	0.741	rs1292055	ENSG00000267302.4	RP11-178C3.2	4.53	2.32e-05	0.0368	0.59	0.47	White blood cell count;	chr17:59881707	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.741	rs2645462	ENSG00000267302.4	RP11-178C3.2	4.53	2.32e-05	0.0368	0.59	0.47	White blood cell count;	chr17:59906198	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.711	rs1292034	ENSG00000267302.4	RP11-178C3.2	4.53	2.32e-05	0.0368	0.59	0.47	White blood cell count;	chr17:59912499	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.741	rs180532	ENSG00000267302.4	RP11-178C3.2	4.53	2.32e-05	0.0368	0.59	0.47	White blood cell count;	chr17:59925936	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.741	rs180530	ENSG00000267302.4	RP11-178C3.2	4.53	2.32e-05	0.0368	0.59	0.47	White blood cell count;	chr17:59926233	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.741	rs180519	ENSG00000267302.4	RP11-178C3.2	4.53	2.32e-05	0.0368	0.59	0.47	White blood cell count;	chr17:59938910	chr17:59964832~59996972:+
LAML	cis	rs8081395	0.711	rs11368	ENSG00000267302.4	RP11-178C3.2	4.53	2.32e-05	0.0368	0.59	0.47	White blood cell count;	chr17:59954051	chr17:59964832~59996972:+
LAML	cis	rs2980439	0.729	rs2955585	ENSG00000249188.1	ENPP7P1	-4.53	2.32e-05	0.0368	-0.59	-0.47	Neuroticism;	chr8:8235989	chr8:8154308~8216916:+
LAML	cis	rs12468226	1	rs3731696	ENSG00000272966.1	RP11-686O6.1	4.53	2.32e-05	0.0369	0.83	0.47	Urate levels;	chr2:202567081	chr2:202336739~202337200:+
LAML	cis	rs12468226	0.81	rs115255999	ENSG00000272966.1	RP11-686O6.1	4.53	2.32e-05	0.0369	0.83	0.47	Urate levels;	chr2:202572326	chr2:202336739~202337200:+
LAML	cis	rs7131987	0.903	rs2194520	ENSG00000273680.1	RP11-996F15.6	4.53	2.32e-05	0.0369	0.48	0.47	QT interval;	chr12:29270779	chr12:29332733~29333383:-
LAML	cis	rs904251	0.861	rs1776456	ENSG00000229559.2	RP1-153P14.3	-4.53	2.32e-05	0.0369	-0.54	-0.47	Cognitive performance;	chr6:37516922	chr6:37543553~37547280:-
LAML	cis	rs9468186	1	rs9468186	ENSG00000216915.2	RP1-97D16.1	-4.53	2.32e-05	0.037	-0.54	-0.47	Neuroticism;	chr6:27658852	chr6:27737000~27738494:-
LAML	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-4.53	2.33e-05	0.037	-0.59	-0.47	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
LAML	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	4.53	2.33e-05	0.037	0.63	0.47	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
LAML	cis	rs747650	0.892	rs7937101	ENSG00000271350.1	CTD-2384B9.1	-4.52	2.33e-05	0.0371	-0.46	-0.47	Acne (severe);	chr11:47204937	chr11:47041027~47041945:-
LAML	cis	rs747650	0.699	rs4237547	ENSG00000271350.1	CTD-2384B9.1	-4.52	2.33e-05	0.0371	-0.46	-0.47	Acne (severe);	chr11:47214854	chr11:47041027~47041945:-
LAML	cis	rs7829975	0.711	rs4481596	ENSG00000268955.2	RP11-556O5.6	-4.52	2.33e-05	0.0371	-0.53	-0.47	Mood instability;	chr8:8846820	chr8:8188535~8189195:-
LAML	cis	rs4728142	1	rs4728142	ENSG00000275106.1	RP11-309L24.10	-4.52	2.34e-05	0.0371	-0.42	-0.47	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128933913	chr7:128952527~128953316:-
LAML	cis	rs62103177	0.584	rs9956207	ENSG00000261126.6	RP11-795F19.1	-4.52	2.34e-05	0.0371	-0.59	-0.47	Opioid sensitivity;	chr18:80210509	chr18:80046900~80095482:+
LAML	cis	rs716804	0.566	rs7938891	ENSG00000254719.1	RP11-351I24.3	-4.52	2.34e-05	0.0371	-0.59	-0.47	Neuroticism;	chr11:10084661	chr11:10272052~10272259:-
LAML	cis	rs2143950	0.765	rs17113838	ENSG00000241052.1	RP11-173D9.1	-4.52	2.34e-05	0.0372	-0.76	-0.47	Atopic dermatitis;	chr14:35235461	chr14:35144021~35144480:-
LAML	cis	rs2143950	0.765	rs75359261	ENSG00000241052.1	RP11-173D9.1	-4.52	2.34e-05	0.0372	-0.76	-0.47	Atopic dermatitis;	chr14:35235851	chr14:35144021~35144480:-
LAML	cis	rs2143950	0.749	rs57275892	ENSG00000241052.1	RP11-173D9.1	-4.52	2.34e-05	0.0372	-0.76	-0.47	Atopic dermatitis;	chr14:35278065	chr14:35144021~35144480:-
LAML	cis	rs5769707	0.681	rs9616329	ENSG00000279597.1	RP4-566L20.1	-4.52	2.34e-05	0.0372	-0.61	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49632666	chr22:49534062~49534926:+
LAML	cis	rs2337406	0.714	rs115401799	ENSG00000265929.1	MIR5195	4.52	2.35e-05	0.0373	0.75	0.47	Alzheimer's disease (late onset);	chr14:106813739	chr14:106850885~106850999:-
LAML	cis	rs9322193	0.566	rs9397070	ENSG00000216906.2	RP11-350J20.9	-4.52	2.35e-05	0.0373	-0.7	-0.47	Lung cancer;	chr6:149922073	chr6:149904243~149906418:+
LAML	cis	rs7131987	0.565	rs7974254	ENSG00000273680.1	RP11-996F15.6	4.52	2.35e-05	0.0373	0.47	0.47	QT interval;	chr12:29246592	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs6487787	ENSG00000273680.1	RP11-996F15.6	4.52	2.35e-05	0.0373	0.47	0.47	QT interval;	chr12:29248353	chr12:29332733~29333383:-
LAML	cis	rs7131987	0.565	rs6487791	ENSG00000273680.1	RP11-996F15.6	4.52	2.35e-05	0.0373	0.47	0.47	QT interval;	chr12:29250989	chr12:29332733~29333383:-
LAML	cis	rs6500550	0.53	rs6501178	ENSG00000263235.1	RP11-461A8.4	-4.52	2.35e-05	0.0373	-0.48	-0.47	Sum neutrophil eosinophil counts;White blood cell count;Sum basophil neutrophil counts;Neutrophil count;Granulocyte count;	chr16:3516362	chr16:3650636~3651703:-
LAML	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	4.52	2.35e-05	0.0373	0.55	0.47	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
LAML	cis	rs9322193	0.884	rs9371201	ENSG00000216906.2	RP11-350J20.9	4.52	2.35e-05	0.0374	0.7	0.47	Lung cancer;	chr6:149823865	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9371486	ENSG00000216906.2	RP11-350J20.9	4.52	2.35e-05	0.0374	0.7	0.47	Lung cancer;	chr6:149832090	chr6:149904243~149906418:+
LAML	cis	rs12922317	0.625	rs350221	ENSG00000260224.1	UBL5P4	-4.52	2.36e-05	0.0375	-0.6	-0.47	Schizophrenia;	chr16:12052698	chr16:11968508~11968743:-
LAML	cis	rs7746199	0.736	rs17693963	ENSG00000182477.5	OR2B8P	4.52	2.37e-05	0.0376	0.85	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28053228~28054165:-
LAML	cis	rs11096990	0.964	rs11096987	ENSG00000206675.1	RNU6-32P	-4.52	2.38e-05	0.0377	-0.48	-0.47	Cognitive function;	chr4:39257570	chr4:39297605~39297711:-
LAML	cis	rs7201929	1	rs11644151	ENSG00000259982.1	CDC37P1	-4.52	2.38e-05	0.0377	-0.64	-0.47	QT interval;	chr16:28884339	chr16:28700294~28701540:-
LAML	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	4.52	2.38e-05	0.0377	0.83	0.47	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
LAML	cis	rs10851411	0.862	rs8033412	ENSG00000260490.2	RP11-265N6.3	-4.52	2.38e-05	0.0377	-0.54	-0.47	Glucose homeostasis traits;	chr15:42530091	chr15:42571927~42572433:+
LAML	cis	rs10851411	0.862	rs11022	ENSG00000260490.2	RP11-265N6.3	-4.52	2.38e-05	0.0377	-0.54	-0.47	Glucose homeostasis traits;	chr15:42532380	chr15:42571927~42572433:+
LAML	cis	rs10851411	0.862	rs4923948	ENSG00000260490.2	RP11-265N6.3	-4.52	2.38e-05	0.0377	-0.54	-0.47	Glucose homeostasis traits;	chr15:42534625	chr15:42571927~42572433:+
LAML	cis	rs916888	0.773	rs1378358	ENSG00000280985.1	AC217773.1	4.52	2.38e-05	0.0377	0.66	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:46172089~46172239:-
LAML	cis	rs916888	0.773	rs538628	ENSG00000280985.1	AC217773.1	4.52	2.38e-05	0.0377	0.66	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:46172089~46172239:-
LAML	cis	rs916888	0.773	rs169201	ENSG00000280985.1	AC217773.1	4.52	2.38e-05	0.0377	0.66	0.47	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:46172089~46172239:-
LAML	cis	rs2257205	0.667	rs9909763	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58552279	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs9889494	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58552403	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs9889631	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58552998	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs9893027	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58576087	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs8075108	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58579887	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs7209498	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58603281	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs16943134	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58604028	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs8077548	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58613487	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs8076021	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58617285	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs6503872	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58618647	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs8070007	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58631808	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs8070407	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58631811	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs9904996	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58634346	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs16943147	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58643391	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs79155614	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58645135	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs7217890	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58653904	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs11651859	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58654565	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs4340382	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58661558	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.588	rs7209327	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58664473	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs7220884	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58666587	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs9909635	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58674798	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs9899893	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58677236	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs7221142	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58681425	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs9916423	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58696473	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs7208872	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58700288	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs8071942	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58700910	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs6503874	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58703098	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs73996262	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58707065	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs28363312	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58710932	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs16943186	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58724487	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.588	rs77430462	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58726724	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs78253932	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58726740	chr17:58631641~58631836:-
LAML	cis	rs2257205	0.667	rs1018051	ENSG00000212195.2	U3	-4.52	2.38e-05	0.0377	-1.01	-0.47	Pancreatic cancer;	chr17:58832565	chr17:58631641~58631836:-
LAML	cis	rs8042680	0.554	rs59278520	ENSG00000258725.1	PRC1-AS1	-4.52	2.39e-05	0.0378	-0.67	-0.47	Type 2 diabetes;	chr15:90971477	chr15:90966345~90988624:+
LAML	cis	rs2404602	0.647	rs11072616	ENSG00000259422.1	RP11-593F23.1	-4.52	2.39e-05	0.0378	-0.57	-0.47	Blood metabolite levels;	chr15:76692928	chr15:76174891~76181486:-
LAML	cis	rs13113518	0.595	rs13120635	ENSG00000249700.7	SRD5A3-AS1	4.52	2.4e-05	0.0379	0.48	0.47	Height;	chr4:55361200	chr4:55363971~55395847:-
LAML	cis	rs6467136	0.901	rs990032	ENSG00000273270.1	RP11-212P7.2	4.52	2.4e-05	0.0379	1.29	0.47	Type 2 diabetes;	chr7:127574556	chr7:128524016~128531069:-
LAML	cis	rs12477438	0.834	rs1563108	ENSG00000231822.1	AC019097.7	-4.52	2.4e-05	0.0379	-0.62	-0.47	Chronic sinus infection;	chr2:99084690	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.834	rs1563106	ENSG00000231822.1	AC019097.7	-4.52	2.4e-05	0.0379	-0.62	-0.47	Chronic sinus infection;	chr2:99084918	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.834	rs11903311	ENSG00000231822.1	AC019097.7	-4.52	2.4e-05	0.0379	-0.62	-0.47	Chronic sinus infection;	chr2:99085344	chr2:99102018~99102752:+
LAML	cis	rs8062405	0.755	rs4788073	ENSG00000271623.1	RP11-435I10.5	-4.52	2.4e-05	0.0379	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.755	rs55792032	ENSG00000271623.1	RP11-435I10.5	-4.52	2.4e-05	0.0379	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28364700~28365333:+
LAML	cis	rs7131987	0.903	rs11050163	ENSG00000274315.1	RP11-996F15.5	4.52	2.4e-05	0.0379	0.48	0.47	QT interval;	chr12:29267465	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.903	rs10843373	ENSG00000274315.1	RP11-996F15.5	4.52	2.4e-05	0.0379	0.48	0.47	QT interval;	chr12:29267675	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.934	rs2216854	ENSG00000274315.1	RP11-996F15.5	4.52	2.4e-05	0.0379	0.48	0.47	QT interval;	chr12:29270527	chr12:29331434~29331936:-
LAML	cis	rs5769707	0.967	rs5770585	ENSG00000213279.2	RP1-29C18.9	-4.52	2.4e-05	0.0379	-0.54	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49614226	chr22:49572264~49575426:-
LAML	cis	rs7301826	1	rs4619189	ENSG00000256299.1	RP11-989F5.3	-4.52	2.41e-05	0.038	-0.59	-0.47	Plasma plasminogen activator levels;	chr12:130829252	chr12:130810821~130812622:-
LAML	cis	rs6686842	1	rs2749418	ENSG00000235358.1	RP11-399E6.1	-4.52	2.41e-05	0.038	-0.51	-0.47	Height;	chr1:41044002	chr1:41242373~41284861:+
LAML	cis	rs2015599	0.584	rs7299283	ENSG00000274315.1	RP11-996F15.5	4.52	2.41e-05	0.0381	0.46	0.47	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.623	rs1006410	ENSG00000274315.1	RP11-996F15.5	4.52	2.41e-05	0.0381	0.46	0.47	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29331434~29331936:-
LAML	cis	rs30380	0.573	rs469783	ENSG00000248734.2	CTD-2260A17.1	4.52	2.42e-05	0.0381	0.46	0.47	Cerebrospinal fluid biomarker levels;	chr5:96785820	chr5:96784777~96785999:+
LAML	cis	rs7495132	0.563	rs62025078	ENSG00000259314.1	CTD-3065B20.3	4.52	2.42e-05	0.0381	0.51	0.47	Ulcerative colitis;Inflammatory bowel disease;	chr15:90665187	chr15:90604225~90614558:-
LAML	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	4.51	2.42e-05	0.0382	0.49	0.47	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
LAML	cis	rs2836974	0.666	rs4818015	ENSG00000238141.2	BRWD1-AS1	4.51	2.42e-05	0.0382	0.57	0.47	Cognitive function;	chr21:39303567	chr21:39315707~39323218:+
LAML	cis	rs10457838	0.851	rs1934220	ENSG00000220848.4	RPS18P9	4.51	2.42e-05	0.0382	0.5	0.47	Post-traumatic stress disorder;	chr6:149046975	chr6:149594084~149594543:+
LAML	cis	rs10457838	0.851	rs11759315	ENSG00000220848.4	RPS18P9	4.51	2.42e-05	0.0382	0.5	0.47	Post-traumatic stress disorder;	chr6:149049197	chr6:149594084~149594543:+
LAML	cis	rs10457838	0.814	rs56358125	ENSG00000220848.4	RPS18P9	4.51	2.42e-05	0.0382	0.5	0.47	Post-traumatic stress disorder;	chr6:149054909	chr6:149594084~149594543:+
LAML	cis	rs6728642	0.572	rs7574488	ENSG00000235833.1	AC159540.14	4.51	2.42e-05	0.0382	0.66	0.47	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:96933881	chr2:97523949~97524976:-
LAML	cis	rs3096299	0.967	rs2911255	ENSG00000274627.1	RP11-104N10.2	4.51	2.43e-05	0.0383	0.58	0.47	Multiple myeloma (IgH translocation);	chr16:89420729	chr16:89516797~89522217:+
LAML	cis	rs2404602	0.647	rs2404604	ENSG00000259422.1	RP11-593F23.1	-4.51	2.43e-05	0.0383	-0.59	-0.47	Blood metabolite levels;	chr15:76698764	chr15:76174891~76181486:-
LAML	cis	rs7581030	0.55	rs7570429	ENSG00000236469.1	AC007040.8	-4.51	2.43e-05	0.0383	-0.54	-0.47	Testicular germ cell tumor;	chr2:71238733	chr2:71002531~71064743:-
LAML	cis	rs13113518	0.783	rs6843722	ENSG00000249700.7	SRD5A3-AS1	4.51	2.43e-05	0.0383	0.48	0.47	Height;	chr4:55465165	chr4:55363971~55395847:-
LAML	cis	rs5769707	0.967	rs5769698	ENSG00000213279.2	RP1-29C18.9	-4.51	2.43e-05	0.0383	-0.51	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49604058	chr22:49572264~49575426:-
LAML	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-4.51	2.43e-05	0.0383	-0.48	-0.47	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-4.51	2.43e-05	0.0383	-0.48	-0.47	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-4.51	2.43e-05	0.0383	-0.48	-0.47	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
LAML	cis	rs9393777	0.72	rs56401801	ENSG00000187763.3	OR2B7P	4.51	2.44e-05	0.0384	0.86	0.47	Intelligence (multi-trait analysis);	chr6:27333733	chr6:28046434~28047367:+
LAML	cis	rs716804	0.515	rs2403268	ENSG00000254719.1	RP11-351I24.3	-4.51	2.44e-05	0.0385	-0.58	-0.47	Neuroticism;	chr11:10015456	chr11:10272052~10272259:-
LAML	cis	rs11039100	0.527	rs10769249	ENSG00000232381.1	OR52U1P	4.51	2.44e-05	0.0385	0.68	0.47	Peripheral arterial disease (traffic-related air pollution interaction);	chr11:5818096	chr11:5719290~5720212:+
LAML	cis	rs853679	0.882	rs4713140	ENSG00000217315.1	OR2W2P	4.51	2.44e-05	0.0385	0.84	0.47	Depression;	chr6:28129415	chr6:28033947~28034855:+
LAML	cis	rs950169	0.922	rs62029585	ENSG00000259728.4	LINC00933	4.51	2.44e-05	0.0385	0.7	0.47	Schizophrenia;	chr15:84397176	chr15:84570649~84580175:+
LAML	cis	rs853679	0.607	rs67998226	ENSG00000182477.5	OR2B8P	4.51	2.45e-05	0.0385	0.85	0.47	Depression;	chr6:28270281	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs34878803	ENSG00000182477.5	OR2B8P	4.51	2.45e-05	0.0385	0.85	0.47	Depression;	chr6:28282402	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs34396849	ENSG00000182477.5	OR2B8P	4.51	2.45e-05	0.0385	0.85	0.47	Depression;	chr6:28283178	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13211507	ENSG00000182477.5	OR2B8P	4.51	2.45e-05	0.0385	0.85	0.47	Depression;	chr6:28289600	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs34691223	ENSG00000182477.5	OR2B8P	4.51	2.45e-05	0.0385	0.85	0.47	Depression;	chr6:28290431	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs34950484	ENSG00000182477.5	OR2B8P	4.51	2.45e-05	0.0385	0.85	0.47	Depression;	chr6:28310911	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs34661125	ENSG00000182477.5	OR2B8P	4.51	2.45e-05	0.0385	0.85	0.47	Depression;	chr6:28314117	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs13190888	ENSG00000182477.5	OR2B8P	4.51	2.45e-05	0.0385	0.85	0.47	Depression;	chr6:28318208	chr6:28053228~28054165:-
LAML	cis	rs853679	0.607	rs67340775	ENSG00000182477.5	OR2B8P	4.51	2.45e-05	0.0385	0.85	0.47	Depression;	chr6:28336607	chr6:28053228~28054165:-
LAML	cis	rs2980439	0.846	rs2980437	ENSG00000249188.1	ENPP7P1	4.51	2.45e-05	0.0386	0.59	0.47	Neuroticism;	chr8:8237241	chr8:8154308~8216916:+
LAML	cis	rs2980439	0.818	rs2945249	ENSG00000249188.1	ENPP7P1	-4.51	2.45e-05	0.0386	-0.59	-0.47	Neuroticism;	chr8:8237204	chr8:8154308~8216916:+
LAML	cis	rs9952991	0.654	rs34153303	ENSG00000260302.1	RP11-973H7.1	4.51	2.45e-05	0.0386	0.84	0.47	Inflammatory skin disease;	chr18:12855865	chr18:12774651~12775923:-
LAML	cis	rs9952991	0.654	rs12955302	ENSG00000260302.1	RP11-973H7.1	4.51	2.45e-05	0.0386	0.84	0.47	Inflammatory skin disease;	chr18:12864763	chr18:12774651~12775923:-
LAML	cis	rs9952991	0.654	rs12964314	ENSG00000260302.1	RP11-973H7.1	4.51	2.45e-05	0.0386	0.84	0.47	Inflammatory skin disease;	chr18:12871973	chr18:12774651~12775923:-
LAML	cis	rs10457838	0.549	rs2500542	ENSG00000220848.4	RPS18P9	-4.51	2.45e-05	0.0386	-0.52	-0.47	Post-traumatic stress disorder;	chr6:149010068	chr6:149594084~149594543:+
LAML	cis	rs4713118	0.615	rs9295747	ENSG00000216915.2	RP1-97D16.1	4.51	2.45e-05	0.0386	0.53	0.47	Parkinson's disease;	chr6:27769214	chr6:27737000~27738494:-
LAML	cis	rs4713118	0.615	rs57252182	ENSG00000216915.2	RP1-97D16.1	-4.51	2.45e-05	0.0386	-0.53	-0.47	Parkinson's disease;	chr6:27752470	chr6:27737000~27738494:-
LAML	cis	rs34034915	1	rs34034915	ENSG00000216915.2	RP1-97D16.1	-4.51	2.45e-05	0.0386	-0.53	-0.47	Hepatitis A;	chr6:27752924	chr6:27737000~27738494:-
LAML	cis	rs4713118	0.527	rs36042294	ENSG00000216915.2	RP1-97D16.1	-4.51	2.45e-05	0.0386	-0.53	-0.47	Parkinson's disease;	chr6:27752933	chr6:27737000~27738494:-
LAML	cis	rs8062405	0.737	rs11861132	ENSG00000271623.1	RP11-435I10.5	-4.51	2.45e-05	0.0386	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28364700~28365333:+
LAML	cis	rs2239547	0.522	rs6770957	ENSG00000280417.1	RP11-5O17.1	4.51	2.46e-05	0.0387	0.71	0.47	Schizophrenia;	chr3:52961400	chr3:53046166~53048122:+
LAML	cis	rs904251	0.523	rs914348	ENSG00000229559.2	RP1-153P14.3	-4.51	2.46e-05	0.0387	-0.47	-0.47	Cognitive performance;	chr6:37516953	chr6:37543553~37547280:-
LAML	cis	rs8141529	0.732	rs5762784	ENSG00000226471.5	CTA-292E10.6	-4.51	2.47e-05	0.0388	-0.48	-0.47	Lymphocyte counts;	chr22:28775310	chr22:28800683~28848559:+
LAML	cis	rs8141529	0.732	rs6005872	ENSG00000226471.5	CTA-292E10.6	-4.51	2.47e-05	0.0388	-0.48	-0.47	Lymphocyte counts;	chr22:28776910	chr22:28800683~28848559:+
LAML	cis	rs8141529	0.732	rs5762788	ENSG00000226471.5	CTA-292E10.6	-4.51	2.47e-05	0.0388	-0.48	-0.47	Lymphocyte counts;	chr22:28778782	chr22:28800683~28848559:+
LAML	cis	rs8141529	0.644	rs5752795	ENSG00000226471.5	CTA-292E10.6	-4.51	2.47e-05	0.0388	-0.48	-0.47	Lymphocyte counts;	chr22:28782832	chr22:28800683~28848559:+
LAML	cis	rs8141529	0.732	rs2347447	ENSG00000226471.5	CTA-292E10.6	-4.51	2.47e-05	0.0388	-0.48	-0.47	Lymphocyte counts;	chr22:28783751	chr22:28800683~28848559:+
LAML	cis	rs6951245	0.554	rs76243429	ENSG00000229043.2	AC091729.9	-4.51	2.47e-05	0.0388	-0.58	-0.47	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1112907	chr7:1160374~1165267:+
LAML	cis	rs2933343	1	rs1683782	ENSG00000231305.3	RP11-723O4.2	4.51	2.47e-05	0.0388	0.56	0.47	IgG glycosylation;	chr3:128921434	chr3:128861313~128871540:-
LAML	cis	rs2933343	1	rs6785869	ENSG00000231305.3	RP11-723O4.2	4.51	2.47e-05	0.0388	0.56	0.47	IgG glycosylation;	chr3:128924301	chr3:128861313~128871540:-
LAML	cis	rs2933343	1	rs1680784	ENSG00000231305.3	RP11-723O4.2	4.51	2.47e-05	0.0388	0.56	0.47	IgG glycosylation;	chr3:128925615	chr3:128861313~128871540:-
LAML	cis	rs2933343	1	rs1683778	ENSG00000231305.3	RP11-723O4.2	4.51	2.47e-05	0.0388	0.56	0.47	IgG glycosylation;	chr3:128925752	chr3:128861313~128871540:-
LAML	cis	rs2933343	1	rs2933343	ENSG00000231305.3	RP11-723O4.2	4.51	2.47e-05	0.0388	0.56	0.47	IgG glycosylation;	chr3:128939649	chr3:128861313~128871540:-
LAML	cis	rs425277	0.628	rs3128340	ENSG00000223663.2	RP5-890O3.3	4.51	2.47e-05	0.0388	0.64	0.47	Height;	chr1:2116057	chr1:1378666~1379032:+
LAML	cis	rs6782228	1	rs6801509	ENSG00000277250.1	Metazoa_SRP	4.51	2.47e-05	0.0388	0.7	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128673681~128674021:-
LAML	cis	rs2439831	0.85	rs28504496	ENSG00000275601.1	AC011330.13	-4.51	2.48e-05	0.0389	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43724685	chr15:43642389~43643023:-
LAML	cis	rs3758911	0.822	rs10749903	ENSG00000261098.1	RP11-819C21.1	-4.51	2.48e-05	0.0389	-0.44	-0.47	Coronary artery disease;	chr11:107336840	chr11:107312132~107316271:-
LAML	cis	rs10463316	0.894	rs869196	ENSG00000260581.1	CTB-113P19.4	4.51	2.48e-05	0.0389	0.41	0.47	Metabolite levels (Pyroglutamine);	chr5:151366726	chr5:151652275~151655449:+
LAML	cis	rs1009077	0.536	rs35708340	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119442215	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.536	rs13116789	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119494057	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.536	rs13124532	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119495290	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.627	rs3775846	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119511372	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs62319606	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119544091	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs17358524	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119570559	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs34676199	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119589154	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs2389868	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119594344	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs35850447	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119597610	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs62319647	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119597862	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs35999787	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119597949	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.671	rs13120581	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119602481	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.582	rs3756155	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119602915	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs78520912	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119604576	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs34601943	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119607869	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs35967840	ENSG00000178636.7	RP11-455G16.1	4.51	2.48e-05	0.0389	0.82	0.47	Endometriosis;	chr4:119612287	chr4:119192773~119212644:-
LAML	cis	rs7495132	0.512	rs6496713	ENSG00000259314.1	CTD-3065B20.3	-4.51	2.48e-05	0.0389	-0.48	-0.47	Ulcerative colitis;Inflammatory bowel disease;	chr15:90630567	chr15:90604225~90614558:-
LAML	cis	rs7131987	0.903	rs7974221	ENSG00000275278.1	RP11-946L16.2	4.51	2.49e-05	0.0389	0.58	0.47	QT interval;	chr12:29246515	chr12:29156448~29156991:-
LAML	cis	rs2581828	0.58	rs4687570	ENSG00000280417.1	RP11-5O17.1	4.51	2.49e-05	0.0389	0.68	0.47	Crohn's disease;	chr3:53136484	chr3:53046166~53048122:+
LAML	cis	rs3096299	0.967	rs16965692	ENSG00000274627.1	RP11-104N10.2	4.51	2.49e-05	0.0389	0.55	0.47	Multiple myeloma (IgH translocation);	chr16:89405074	chr16:89516797~89522217:+
LAML	cis	rs10463316	0.928	rs4958451	ENSG00000260581.1	CTB-113P19.4	4.51	2.49e-05	0.0389	0.41	0.47	Metabolite levels (Pyroglutamine);	chr5:151360446	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs3846711	ENSG00000260581.1	CTB-113P19.4	4.51	2.49e-05	0.0389	0.41	0.47	Metabolite levels (Pyroglutamine);	chr5:151361188	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs4246024	ENSG00000260581.1	CTB-113P19.4	4.51	2.49e-05	0.0389	0.41	0.47	Metabolite levels (Pyroglutamine);	chr5:151361426	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7718085	ENSG00000260581.1	CTB-113P19.4	4.51	2.49e-05	0.0389	0.41	0.47	Metabolite levels (Pyroglutamine);	chr5:151363396	chr5:151652275~151655449:+
LAML	cis	rs7131987	0.845	rs7299861	ENSG00000274315.1	RP11-996F15.5	4.51	2.49e-05	0.0389	0.48	0.47	QT interval;	chr12:29256734	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.934	rs7316004	ENSG00000274315.1	RP11-996F15.5	4.51	2.49e-05	0.0389	0.48	0.47	QT interval;	chr12:29258765	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.903	rs2216853	ENSG00000274315.1	RP11-996F15.5	4.51	2.49e-05	0.0389	0.48	0.47	QT interval;	chr12:29260315	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.868	rs10771508	ENSG00000274315.1	RP11-996F15.5	4.51	2.49e-05	0.0389	0.48	0.47	QT interval;	chr12:29261278	chr12:29331434~29331936:-
LAML	cis	rs6502050	0.723	rs4789698	ENSG00000266654.1	RP11-1376P16.1	-4.51	2.49e-05	0.039	-0.51	-0.47	Life satisfaction;	chr17:82221910	chr17:82160056~82160452:+
LAML	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-4.51	2.49e-05	0.039	-0.57	-0.47	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
LAML	cis	rs9457247	0.756	rs2345572	ENSG00000231654.1	RPS6KA2-AS1	-4.51	2.5e-05	0.039	-0.45	-0.47	Crohn's disease;	chr6:166989953	chr6:166903698~166904835:+
LAML	cis	rs11039798	1	rs10160423	ENSG00000263693.1	MIR3161	4.51	2.5e-05	0.039	0.49	0.47	Axial length;	chr11:48435675	chr11:48096782~48096858:+
LAML	cis	rs11039798	1	rs7102865	ENSG00000263693.1	MIR3161	4.51	2.5e-05	0.039	0.49	0.47	Axial length;	chr11:48436809	chr11:48096782~48096858:+
LAML	cis	rs7581030	0.55	rs35963842	ENSG00000236469.1	AC007040.8	4.51	2.5e-05	0.0391	0.65	0.47	Testicular germ cell tumor;	chr2:71214248	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.517	rs35073357	ENSG00000236469.1	AC007040.8	4.51	2.5e-05	0.0391	0.65	0.47	Testicular germ cell tumor;	chr2:71215623	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.517	rs17038417	ENSG00000236469.1	AC007040.8	4.51	2.5e-05	0.0391	0.65	0.47	Testicular germ cell tumor;	chr2:71216978	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.517	rs13033146	ENSG00000236469.1	AC007040.8	4.51	2.5e-05	0.0391	0.65	0.47	Testicular germ cell tumor;	chr2:71217798	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs71414897	ENSG00000236469.1	AC007040.8	4.51	2.5e-05	0.0391	0.65	0.47	Testicular germ cell tumor;	chr2:71218839	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs35686144	ENSG00000236469.1	AC007040.8	4.51	2.5e-05	0.0391	0.65	0.47	Testicular germ cell tumor;	chr2:71219877	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs113903407	ENSG00000236469.1	AC007040.8	4.51	2.5e-05	0.0391	0.65	0.47	Testicular germ cell tumor;	chr2:71223323	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs12993988	ENSG00000236469.1	AC007040.8	4.51	2.5e-05	0.0391	0.65	0.47	Testicular germ cell tumor;	chr2:71231288	chr2:71002531~71064743:-
LAML	cis	rs716804	0.74	rs7938543	ENSG00000254719.1	RP11-351I24.3	4.51	2.5e-05	0.0391	0.56	0.47	Neuroticism;	chr11:10208304	chr11:10272052~10272259:-
LAML	cis	rs34792	0.554	rs4597346	ENSG00000260872.1	RP11-680G24.5	-4.51	2.5e-05	0.0391	-0.5	-0.47	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15529889	chr16:15018106~15020488:-
LAML	cis	rs7927771	1	rs35624992	ENSG00000280615.1	Y_RNA	-4.5	2.51e-05	0.0392	-0.63	-0.47	Subjective well-being;	chr11:47594246	chr11:47614898~47614994:-
LAML	cis	rs7927771	0.965	rs1064608	ENSG00000280615.1	Y_RNA	-4.5	2.51e-05	0.0392	-0.63	-0.47	Subjective well-being;	chr11:47618877	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs4752857	ENSG00000280615.1	Y_RNA	-4.5	2.51e-05	0.0392	-0.63	-0.47	Subjective well-being;	chr11:47634200	chr11:47614898~47614994:-
LAML	cis	rs7927771	0.896	rs12794570	ENSG00000280615.1	Y_RNA	-4.5	2.51e-05	0.0392	-0.63	-0.47	Subjective well-being;	chr11:47636762	chr11:47614898~47614994:-
LAML	cis	rs7927771	1	rs10838738	ENSG00000280615.1	Y_RNA	-4.5	2.51e-05	0.0392	-0.63	-0.47	Subjective well-being;	chr11:47641497	chr11:47614898~47614994:-
LAML	cis	rs9322193	0.772	rs7738696	ENSG00000217733.2	CCT7P1	4.5	2.51e-05	0.0392	0.74	0.47	Lung cancer;	chr6:149848985	chr6:149879962~149881572:+
LAML	cis	rs7146198	0.826	rs7144262	ENSG00000259158.2	ADAM20P1	-4.5	2.51e-05	0.0393	-0.81	-0.47	Corneal curvature;	chr14:70180391	chr14:70468881~70483756:-
LAML	cis	rs7146198	0.865	rs1999052	ENSG00000259158.2	ADAM20P1	-4.5	2.51e-05	0.0393	-0.81	-0.47	Corneal curvature;	chr14:70180474	chr14:70468881~70483756:-
LAML	cis	rs9322193	0.926	rs9383546	ENSG00000216906.2	RP11-350J20.9	4.5	2.51e-05	0.0393	0.64	0.47	Lung cancer;	chr6:149822743	chr6:149904243~149906418:+
LAML	cis	rs67311347	1	rs11129876	ENSG00000230274.1	PGAM1P3	-4.5	2.51e-05	0.0393	-0.59	-0.47	Renal cell carcinoma;	chr3:40360145	chr3:40322715~40323279:-
LAML	cis	rs7849270	1	rs7036236	ENSG00000268707.1	RP11-247A12.7	-4.5	2.52e-05	0.0393	-0.55	-0.47	Blood metabolite ratios;	chr9:129137020	chr9:129170434~129170940:+
LAML	cis	rs7849270	0.959	rs7039031	ENSG00000268707.1	RP11-247A12.7	-4.5	2.52e-05	0.0393	-0.55	-0.47	Blood metabolite ratios;	chr9:129137116	chr9:129170434~129170940:+
LAML	cis	rs933769	1	rs9920980	ENSG00000242295.1	RP11-522B15.1	-4.5	2.52e-05	0.0393	-0.65	-0.47	Alcoholism (alcohol dependence factor score);	chr15:95518808	chr15:96448154~96448493:+
LAML	cis	rs7617773	0.817	rs936426	ENSG00000228638.1	FCF1P2	-4.5	2.52e-05	0.0393	-0.48	-0.47	Coronary artery disease;	chr3:48173763	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-4.5	2.52e-05	0.0393	-0.48	-0.47	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
LAML	cis	rs2404602	0.622	rs11637296	ENSG00000259422.1	RP11-593F23.1	-4.5	2.52e-05	0.0393	-0.58	-0.47	Blood metabolite levels;	chr15:76915544	chr15:76174891~76181486:-
LAML	cis	rs716804	0.593	rs12419064	ENSG00000254719.1	RP11-351I24.3	-4.5	2.52e-05	0.0393	-0.56	-0.47	Neuroticism;	chr11:10299061	chr11:10272052~10272259:-
LAML	cis	rs12554020	0.892	rs6479487	ENSG00000227603.1	RP11-165J3.6	4.5	2.52e-05	0.0393	0.66	0.47	Schizophrenia;	chr9:93475091	chr9:93435332~93437121:-
LAML	cis	rs950169	0.8	rs4842847	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84262447	chr15:84570649~84580175:+
LAML	cis	rs950169	0.881	rs4842852	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84387263	chr15:84570649~84580175:+
LAML	cis	rs950169	0.84	rs4842853	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84387606	chr15:84570649~84580175:+
LAML	cis	rs950169	0.922	rs4842946	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84387633	chr15:84570649~84580175:+
LAML	cis	rs950169	0.84	rs4842854	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84387641	chr15:84570649~84580175:+
LAML	cis	rs950169	0.887	rs3860265	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84390487	chr15:84570649~84580175:+
LAML	cis	rs950169	0.922	rs2033284	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84391575	chr15:84570649~84580175:+
LAML	cis	rs950169	0.881	rs34591918	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84396135	chr15:84570649~84580175:+
LAML	cis	rs950169	0.887	rs12903946	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84399732	chr15:84570649~84580175:+
LAML	cis	rs950169	0.887	rs62029593	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84400482	chr15:84570649~84580175:+
LAML	cis	rs950169	0.81	rs62029594	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84400554	chr15:84570649~84580175:+
LAML	cis	rs950169	0.84	rs62029595	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84400603	chr15:84570649~84580175:+
LAML	cis	rs950169	0.881	rs62029596	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84400736	chr15:84570649~84580175:+
LAML	cis	rs950169	0.881	rs4081123	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84401537	chr15:84570649~84580175:+
LAML	cis	rs950169	0.881	rs62029599	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84401867	chr15:84570649~84580175:+
LAML	cis	rs950169	0.8	rs4099846	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84402196	chr15:84570649~84580175:+
LAML	cis	rs950169	0.881	rs150965	ENSG00000259728.4	LINC00933	4.5	2.52e-05	0.0393	0.68	0.47	Schizophrenia;	chr15:84537296	chr15:84570649~84580175:+
LAML	cis	rs9457247	0.935	rs9348211	ENSG00000231654.1	RPS6KA2-AS1	4.5	2.52e-05	0.0393	0.45	0.47	Crohn's disease;	chr6:166961685	chr6:166903698~166904835:+
LAML	cis	rs6920364	1	rs6920364	ENSG00000231654.1	RPS6KA2-AS1	4.5	2.52e-05	0.0393	0.45	0.47	Lung cancer;	chr6:166962978	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs2769352	ENSG00000231654.1	RPS6KA2-AS1	4.5	2.52e-05	0.0393	0.45	0.47	Crohn's disease;	chr6:166965131	chr6:166903698~166904835:+
LAML	cis	rs9457247	1	rs364451	ENSG00000231654.1	RPS6KA2-AS1	-4.5	2.52e-05	0.0393	-0.45	-0.47	Crohn's disease;	chr6:166971268	chr6:166903698~166904835:+
LAML	cis	rs9457247	0.935	rs427824	ENSG00000231654.1	RPS6KA2-AS1	-4.5	2.52e-05	0.0393	-0.45	-0.47	Crohn's disease;	chr6:166990430	chr6:166903698~166904835:+
LAML	cis	rs2015599	0.514	rs10843376	ENSG00000274315.1	RP11-996F15.5	4.5	2.52e-05	0.0393	0.46	0.47	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29331434~29331936:-
LAML	cis	rs3096299	0.967	rs28644774	ENSG00000274627.1	RP11-104N10.2	4.5	2.52e-05	0.0393	0.55	0.47	Multiple myeloma (IgH translocation);	chr16:89405773	chr16:89516797~89522217:+
LAML	cis	rs13113518	0.812	rs6849474	ENSG00000249700.7	SRD5A3-AS1	4.5	2.53e-05	0.0394	0.48	0.47	Height;	chr4:55452295	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs4864996	ENSG00000249700.7	SRD5A3-AS1	4.5	2.53e-05	0.0394	0.48	0.47	Height;	chr4:55452921	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs2412648	ENSG00000249700.7	SRD5A3-AS1	4.5	2.53e-05	0.0394	0.48	0.47	Height;	chr4:55454900	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs12512737	ENSG00000249700.7	SRD5A3-AS1	4.5	2.53e-05	0.0394	0.48	0.47	Height;	chr4:55454938	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs13125984	ENSG00000249700.7	SRD5A3-AS1	4.5	2.53e-05	0.0394	0.48	0.47	Height;	chr4:55455102	chr4:55363971~55395847:-
LAML	cis	rs709400	0.633	rs45441198	ENSG00000258851.1	RP11-894P9.2	-4.5	2.53e-05	0.0394	-0.58	-0.47	Body mass index;	chr14:103536274	chr14:103553421~103561877:+
LAML	cis	rs7829975	0.536	rs2980439	ENSG00000249188.1	ENPP7P1	-4.5	2.53e-05	0.0394	-0.59	-0.47	Mood instability;	chr8:8237348	chr8:8154308~8216916:+
LAML	cis	rs2980439	0.783	rs2955587	ENSG00000249188.1	ENPP7P1	-4.5	2.53e-05	0.0394	-0.59	-0.47	Neuroticism;	chr8:8240557	chr8:8154308~8216916:+
LAML	cis	rs7746199	0.736	rs58616630	ENSG00000182477.5	OR2B8P	4.5	2.53e-05	0.0394	0.9	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28053228~28054165:-
LAML	cis	rs7746199	0.736	rs34573979	ENSG00000182477.5	OR2B8P	4.5	2.53e-05	0.0394	0.9	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28053228~28054165:-
LAML	cis	rs471756	0.594	rs4741691	ENSG00000235880.1	RP11-59O6.3	4.5	2.53e-05	0.0394	0.4	0.47	Mean platelet volume;	chr9:255713	chr9:267966~273002:-
LAML	cis	rs6502050	0.723	rs66871014	ENSG00000266654.1	RP11-1376P16.1	-4.5	2.53e-05	0.0394	-0.51	-0.47	Life satisfaction;	chr17:82223998	chr17:82160056~82160452:+
LAML	cis	rs7849270	1	rs3739843	ENSG00000268707.1	RP11-247A12.7	-4.5	2.53e-05	0.0394	-0.55	-0.47	Blood metabolite ratios;	chr9:129120682	chr9:129170434~129170940:+
LAML	cis	rs7849270	1	rs10988214	ENSG00000268707.1	RP11-247A12.7	-4.5	2.53e-05	0.0394	-0.55	-0.47	Blood metabolite ratios;	chr9:129121473	chr9:129170434~129170940:+
LAML	cis	rs7849270	1	rs932833	ENSG00000268707.1	RP11-247A12.7	-4.5	2.53e-05	0.0394	-0.55	-0.47	Blood metabolite ratios;	chr9:129121762	chr9:129170434~129170940:+
LAML	cis	rs7849270	0.959	rs7032712	ENSG00000268707.1	RP11-247A12.7	-4.5	2.53e-05	0.0394	-0.55	-0.47	Blood metabolite ratios;	chr9:129130808	chr9:129170434~129170940:+
LAML	cis	rs5769707	0.632	rs1476037	ENSG00000212939.2	RP1-29C18.10	-4.5	2.53e-05	0.0394	-0.64	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49597729	chr22:49548681~49556473:+
LAML	cis	rs62070183	0.656	rs17780628	ENSG00000266718.1	RP11-466A19.1	4.5	2.53e-05	0.0394	0.77	0.47	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32668202	chr17:32495536~32499333:+
LAML	cis	rs5769707	0.632	rs135871	ENSG00000212939.2	RP1-29C18.10	-4.5	2.54e-05	0.0395	-0.66	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49615321	chr22:49548681~49556473:+
LAML	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	4.5	2.55e-05	0.0396	0.55	0.47	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
LAML	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	4.5	2.55e-05	0.0397	0.89	0.47	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
LAML	cis	rs7944735	0.575	rs34972471	ENSG00000263693.1	MIR3161	4.5	2.55e-05	0.0397	0.34	0.47	Intraocular pressure;	chr11:48028839	chr11:48096782~48096858:+
LAML	cis	rs7826238	0.594	rs2948285	ENSG00000253893.2	FAM85B	-4.5	2.55e-05	0.0397	-0.59	-0.47	Systolic blood pressure;	chr8:8273016	chr8:8167819~8226614:-
LAML	cis	rs7829975	0.511	rs2955578	ENSG00000253893.2	FAM85B	-4.5	2.55e-05	0.0397	-0.59	-0.47	Mood instability;	chr8:8279561	chr8:8167819~8226614:-
LAML	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-4.5	2.55e-05	0.0397	-0.48	-0.47	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-4.5	2.55e-05	0.0397	-0.48	-0.47	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
LAML	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-4.5	2.55e-05	0.0397	-0.48	-0.47	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
LAML	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-4.5	2.55e-05	0.0397	-0.48	-0.47	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
LAML	cis	rs1075265	0.836	rs1363063	ENSG00000235937.1	AC008280.1	4.5	2.56e-05	0.0397	0.4	0.47	Chronotype;Morning vs. evening chronotype;	chr2:54047433	chr2:54029552~54030682:-
LAML	cis	rs172166	0.538	rs149956	ENSG00000220721.1	OR1F12	4.5	2.56e-05	0.0398	0.45	0.47	Cardiac Troponin-T levels;	chr6:28068473	chr6:28073316~28074233:+
LAML	cis	rs4834770	0.718	rs4833618	ENSG00000260091.1	RP11-33B1.4	-4.5	2.56e-05	0.0398	-0.43	-0.47	Blood protein levels;	chr4:119388345	chr4:119409333~119410233:+
LAML	cis	rs9891572	0.929	rs56806829	ENSG00000262884.1	CTD-3060P21.1	-4.5	2.56e-05	0.0398	-0.58	-0.47	HDL cholesterol;	chr17:2520438	chr17:2962248~2965895:-
LAML	cis	rs10129255	0.589	rs78599641	ENSG00000211970.3	IGHV4-61	-4.5	2.56e-05	0.0398	-0.71	-0.47	Kawasaki disease;	chr14:106637576	chr14:106639119~106639657:-
LAML	cis	rs904251	0.6	rs12211110	ENSG00000204110.6	RP1-153P14.8	-4.5	2.56e-05	0.0398	-0.53	-0.47	Cognitive performance;	chr6:37498456	chr6:37507348~37535616:+
LAML	cis	rs2439831	0.702	rs2467402	ENSG00000275601.1	AC011330.13	4.5	2.57e-05	0.0398	0.86	0.47	Lung cancer in ever smokers;	chr15:43732292	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs11070408	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43742590	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs16950562	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43744166	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs28718261	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43751595	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs28595038	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43752661	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs10163054	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43755440	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs7168158	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43758178	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs7174208	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43760484	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs12101756	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43761689	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs12442129	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43763658	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.702	rs7175032	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43768038	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs7169988	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43768237	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs12441861	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43768685	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs3862142	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43772608	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.702	rs2788	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43772688	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs2277531	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43776871	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs28891769	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43780662	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs28578398	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43782848	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs60883262	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43784305	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs8023458	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43788741	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs16963953	ENSG00000275601.1	AC011330.13	-4.5	2.57e-05	0.0398	-0.86	-0.47	Lung cancer in ever smokers;	chr15:43789521	chr15:43642389~43643023:-
LAML	cis	rs838147	0.78	rs2287922	ENSG00000232871.7	SEC1P	4.5	2.57e-05	0.0399	0.47	0.47	Dietary macronutrient intake;	chr19:48728969	chr19:48638071~48682245:+
LAML	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-4.5	2.57e-05	0.0399	-0.59	-0.47	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-4.5	2.57e-05	0.0399	-0.59	-0.47	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
LAML	cis	rs4324798	1	rs4324798	ENSG00000220721.1	OR1F12	4.5	2.57e-05	0.0399	0.74	0.47	Lung adenocarcinoma;	chr6:28808340	chr6:28073316~28074233:+
LAML	cis	rs8031584	0.918	rs1425292	ENSG00000260382.1	RP11-540B6.2	4.5	2.57e-05	0.0399	0.55	0.47	Huntington's disease progression;	chr15:30993219	chr15:30882267~30883231:-
LAML	cis	rs10458771	0.527	rs2353826	ENSG00000212332.1	RNU6-780P	-4.5	2.57e-05	0.0399	-0.63	-0.47	Amyotrophic lateral sclerosis (sporadic);	chr10:86478215	chr10:86488446~86488549:+
LAML	cis	rs7826238	0.566	rs2945886	ENSG00000268955.2	RP11-556O5.6	-4.5	2.58e-05	0.04	-0.56	-0.47	Systolic blood pressure;	chr8:8290748	chr8:8188535~8189195:-
LAML	cis	rs8031584	0.918	rs34331396	ENSG00000260382.1	RP11-540B6.2	4.5	2.58e-05	0.04	0.55	0.47	Huntington's disease progression;	chr15:30956533	chr15:30882267~30883231:-
LAML	cis	rs2945232	1	rs2945232	ENSG00000249188.1	ENPP7P1	-4.5	2.58e-05	0.04	-0.59	-0.47	Schizophrenia;	chr8:8240516	chr8:8154308~8216916:+
LAML	cis	rs6558530	0.965	rs4372027	ENSG00000253982.1	CTD-2336O2.1	4.5	2.59e-05	0.0402	0.65	0.47	Systolic blood pressure;	chr8:1759792	chr8:1761990~1764502:-
LAML	cis	rs6558530	0.932	rs4370560	ENSG00000253982.1	CTD-2336O2.1	4.5	2.59e-05	0.0402	0.65	0.47	Systolic blood pressure;	chr8:1760028	chr8:1761990~1764502:-
LAML	cis	rs6558530	0.932	rs10102731	ENSG00000253982.1	CTD-2336O2.1	4.5	2.59e-05	0.0402	0.65	0.47	Systolic blood pressure;	chr8:1760854	chr8:1761990~1764502:-
LAML	cis	rs7927771	1	rs4752856	ENSG00000280615.1	Y_RNA	-4.5	2.59e-05	0.0402	-0.62	-0.47	Subjective well-being;	chr11:47626490	chr11:47614898~47614994:-
LAML	cis	rs9952991	0.654	rs12969241	ENSG00000260302.1	RP11-973H7.1	4.5	2.6e-05	0.0402	0.85	0.47	Inflammatory skin disease;	chr18:12842481	chr18:12774651~12775923:-
LAML	cis	rs9952991	0.654	rs35967540	ENSG00000260302.1	RP11-973H7.1	4.5	2.6e-05	0.0402	0.85	0.47	Inflammatory skin disease;	chr18:12842568	chr18:12774651~12775923:-
LAML	cis	rs9952991	0.654	rs35320197	ENSG00000260302.1	RP11-973H7.1	4.5	2.6e-05	0.0402	0.85	0.47	Inflammatory skin disease;	chr18:12842682	chr18:12774651~12775923:-
LAML	cis	rs13113518	0.812	rs11932712	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55436423	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs12501746	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55437438	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs11133385	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55460485	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.783	rs11133389	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55486718	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs1522114	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55489895	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs4865001	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55490176	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs4864543	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55490228	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs6825774	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55491150	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs3805153	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55493557	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.776	rs13124436	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55502504	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.783	rs6843997	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55508982	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.783	rs12508367	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55509442	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs2272073	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55510177	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs12649507	ENSG00000249700.7	SRD5A3-AS1	-4.5	2.6e-05	0.0402	-0.48	-0.47	Height;	chr4:55514317	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs4865003	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55514802	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.756	rs12510275	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55516548	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs12510327	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55516744	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs11939580	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55517185	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs6830409	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55522229	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs2035692	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55528801	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs4507426	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55529387	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs2035691	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55529786	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.756	rs11939652	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55532542	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs56055342	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55540928	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs7667741	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55544621	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs13140590	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55548666	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.812	rs12500456	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55561053	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.783	rs2171618	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55564241	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.783	rs11943206	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55570843	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.783	rs34534635	ENSG00000249700.7	SRD5A3-AS1	4.5	2.6e-05	0.0402	0.48	0.47	Height;	chr4:55573424	chr4:55363971~55395847:-
LAML	cis	rs9426935	0.932	rs6661009	ENSG00000273026.1	RP11-422P24.10	-4.49	2.6e-05	0.0403	-0.6	-0.47	Lentiform nucleus volume;	chr1:153968263	chr1:153966516~153966930:+
LAML	cis	rs7581030	0.55	rs34913732	ENSG00000236469.1	AC007040.8	4.49	2.61e-05	0.0403	0.65	0.47	Testicular germ cell tumor;	chr2:71214033	chr2:71002531~71064743:-
LAML	cis	rs8031584	0.56	rs1056118	ENSG00000260382.1	RP11-540B6.2	-4.49	2.61e-05	0.0403	-0.47	-0.47	Huntington's disease progression;	chr15:30911583	chr15:30882267~30883231:-
LAML	cis	rs6728642	0.708	rs115507803	ENSG00000235833.1	AC159540.14	4.49	2.61e-05	0.0404	0.9	0.47	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97086317	chr2:97523949~97524976:-
LAML	cis	rs6728642	0.614	rs113485946	ENSG00000235833.1	AC159540.14	4.49	2.61e-05	0.0404	0.9	0.47	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97200705	chr2:97523949~97524976:-
LAML	cis	rs6728642	0.808	rs114192053	ENSG00000235833.1	AC159540.14	4.49	2.61e-05	0.0404	0.9	0.47	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97206169	chr2:97523949~97524976:-
LAML	cis	rs149026780	1	rs149026780	ENSG00000235833.1	AC159540.14	4.49	2.61e-05	0.0404	0.9	0.47	Monocyte chemoattractant protein-3 levels;	chr2:97215875	chr2:97523949~97524976:-
LAML	cis	rs6728642	1	rs113934577	ENSG00000235833.1	AC159540.14	4.49	2.61e-05	0.0404	0.9	0.47	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97222310	chr2:97523949~97524976:-
LAML	cis	rs6728642	1	rs17037402	ENSG00000235833.1	AC159540.14	4.49	2.61e-05	0.0404	0.9	0.47	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:97358816	chr2:97523949~97524976:-
LAML	cis	rs16978956	0.901	rs2424167	ENSG00000214612.3	RPS19P1	-4.49	2.61e-05	0.0404	-0.48	-0.47	Body mass index;	chr20:18344711	chr20:18504633~18505066:+
LAML	cis	rs16978956	0.901	rs2424168	ENSG00000214612.3	RPS19P1	-4.49	2.61e-05	0.0404	-0.48	-0.47	Body mass index;	chr20:18345356	chr20:18504633~18505066:+
LAML	cis	rs5769707	0.732	rs135865	ENSG00000213279.2	RP1-29C18.9	-4.49	2.62e-05	0.0405	-0.54	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49611181	chr22:49572264~49575426:-
LAML	cis	rs17711722	0.583	rs11768292	ENSG00000224316.1	RP11-479O9.2	-4.49	2.62e-05	0.0405	-0.53	-0.47	Calcium levels;	chr7:66009814	chr7:65773620~65802067:+
LAML	cis	rs282544	1	rs7717033	ENSG00000271455.1	RP11-269M20.2	-4.49	2.62e-05	0.0405	-0.5	-0.47	Myopia (pathological);	chr5:50686892	chr5:50603229~50603511:+
LAML	cis	rs9355610	0.927	rs2757041	ENSG00000265828.1	MIR3939	4.49	2.62e-05	0.0405	0.6	0.47	Graves' disease;	chr6:166957044	chr6:166997807~166997912:-
LAML	cis	rs9393777	0.844	rs28360634	ENSG00000220721.1	OR1F12	4.49	2.62e-05	0.0405	0.76	0.47	Intelligence (multi-trait analysis);	chr6:27365112	chr6:28073316~28074233:+
LAML	cis	rs9393777	0.841	rs34332556	ENSG00000220721.1	OR1F12	4.49	2.62e-05	0.0405	0.76	0.47	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28073316~28074233:+
LAML	cis	rs9393777	0.92	rs34953377	ENSG00000220721.1	OR1F12	4.49	2.62e-05	0.0405	0.76	0.47	Intelligence (multi-trait analysis);	chr6:27413881	chr6:28073316~28074233:+
LAML	cis	rs9393777	0.778	rs66841633	ENSG00000220721.1	OR1F12	4.49	2.62e-05	0.0405	0.76	0.47	Intelligence (multi-trait analysis);	chr6:27414607	chr6:28073316~28074233:+
LAML	cis	rs9393777	0.92	rs34071253	ENSG00000220721.1	OR1F12	4.49	2.62e-05	0.0405	0.76	0.47	Intelligence (multi-trait analysis);	chr6:27424023	chr6:28073316~28074233:+
LAML	cis	rs9393777	0.92	rs41269265	ENSG00000220721.1	OR1F12	4.49	2.62e-05	0.0405	0.76	0.47	Intelligence (multi-trait analysis);	chr6:27457570	chr6:28073316~28074233:+
LAML	cis	rs3096299	0.967	rs11648663	ENSG00000274627.1	RP11-104N10.2	4.49	2.63e-05	0.0405	0.55	0.47	Multiple myeloma (IgH translocation);	chr16:89399899	chr16:89516797~89522217:+
LAML	cis	rs9952991	0.566	rs7241016	ENSG00000260302.1	RP11-973H7.1	4.49	2.63e-05	0.0405	0.85	0.47	Inflammatory skin disease;	chr18:12880207	chr18:12774651~12775923:-
LAML	cis	rs8083786	1	rs8083786	ENSG00000260302.1	RP11-973H7.1	4.49	2.63e-05	0.0405	0.85	0.47	Rheumatoid arthritis;	chr18:12881362	chr18:12774651~12775923:-
LAML	cis	rs673253	0.686	rs2819336	ENSG00000227163.2	RP5-1198O20.5	4.49	2.63e-05	0.0405	0.57	0.47	Intelligence (multi-trait analysis);	chr1:43550138	chr1:44087958~44088477:-
LAML	cis	rs673253	0.686	rs11580258	ENSG00000227163.2	RP5-1198O20.5	-4.49	2.63e-05	0.0405	-0.57	-0.47	Intelligence (multi-trait analysis);	chr1:43550344	chr1:44087958~44088477:-
LAML	cis	rs9322193	0.961	rs2064520	ENSG00000216906.2	RP11-350J20.9	4.49	2.63e-05	0.0406	0.67	0.47	Lung cancer;	chr6:149603650	chr6:149904243~149906418:+
LAML	cis	rs5769707	0.521	rs5769719	ENSG00000213279.2	RP1-29C18.9	-4.49	2.63e-05	0.0406	-0.57	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49668453	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.521	rs5769720	ENSG00000213279.2	RP1-29C18.9	-4.49	2.63e-05	0.0406	-0.57	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49668485	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.521	rs5770633	ENSG00000213279.2	RP1-29C18.9	-4.49	2.63e-05	0.0406	-0.57	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49668779	chr22:49572264~49575426:-
LAML	cis	rs597539	0.532	rs11228372	ENSG00000250508.1	RP11-757G1.6	4.49	2.63e-05	0.0406	0.46	0.47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68829110	chr11:68870664~68874542:+
LAML	cis	rs716804	0.642	rs11042598	ENSG00000254719.1	RP11-351I24.3	-4.49	2.64e-05	0.0406	-0.56	-0.47	Neuroticism;	chr11:10045331	chr11:10272052~10272259:-
LAML	cis	rs4960162	1	rs4960162	ENSG00000217239.3	RP1-182O16.1	4.49	2.64e-05	0.0406	0.43	0.47	Night sleep phenotypes;	chr6:6065527	chr6:5788346~5788699:-
LAML	cis	rs8141529	0.778	rs5762795	ENSG00000226471.5	CTA-292E10.6	-4.49	2.64e-05	0.0407	-0.46	-0.47	Lymphocyte counts;	chr22:28786512	chr22:28800683~28848559:+
LAML	cis	rs8141529	0.732	rs6005881	ENSG00000226471.5	CTA-292E10.6	-4.49	2.64e-05	0.0407	-0.46	-0.47	Lymphocyte counts;	chr22:28787145	chr22:28800683~28848559:+
LAML	cis	rs9322193	0.884	rs9688794	ENSG00000216906.2	RP11-350J20.9	4.49	2.64e-05	0.0407	0.66	0.47	Lung cancer;	chr6:149632121	chr6:149904243~149906418:+
LAML	cis	rs8067354	0.54	rs1051424	ENSG00000266960.1	FAM106DP	4.49	2.64e-05	0.0407	0.75	0.47	Hemoglobin concentration;	chr17:59946963	chr17:60173322~60173822:+
LAML	cis	rs10463316	0.894	rs869198	ENSG00000260581.1	CTB-113P19.4	-4.49	2.65e-05	0.0407	-0.42	-0.47	Metabolite levels (Pyroglutamine);	chr5:151366332	chr5:151652275~151655449:+
LAML	cis	rs8062405	0.755	rs12447461	ENSG00000271623.1	RP11-435I10.5	-4.49	2.65e-05	0.0407	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.755	rs111693583	ENSG00000271623.1	RP11-435I10.5	-4.49	2.65e-05	0.0407	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.755	rs56209193	ENSG00000271623.1	RP11-435I10.5	-4.49	2.65e-05	0.0407	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.755	rs7186573	ENSG00000271623.1	RP11-435I10.5	-4.49	2.65e-05	0.0407	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28364700~28365333:+
LAML	cis	rs172166	0.585	rs149963	ENSG00000220721.1	OR1F12	4.49	2.65e-05	0.0408	0.45	0.47	Cardiac Troponin-T levels;	chr6:28049354	chr6:28073316~28074233:+
LAML	cis	rs8067354	0.574	rs1292043	ENSG00000266960.1	FAM106DP	4.49	2.65e-05	0.0408	0.74	0.47	Hemoglobin concentration;	chr17:59856808	chr17:60173322~60173822:+
LAML	cis	rs8141529	0.732	rs3788409	ENSG00000226471.5	CTA-292E10.6	-4.49	2.66e-05	0.0409	-0.47	-0.47	Lymphocyte counts;	chr22:28802163	chr22:28800683~28848559:+
LAML	cis	rs7146198	1	rs4902785	ENSG00000259158.2	ADAM20P1	-4.49	2.66e-05	0.0409	-0.81	-0.47	Corneal curvature;	chr14:70183657	chr14:70468881~70483756:-
LAML	cis	rs1930961	0.702	rs1930966	ENSG00000100058.11	CRYBB2P1	-4.49	2.66e-05	0.0409	-0.78	-0.47	Bipolar disorder with mood-incongruent psychosis;	chr22:25489737	chr22:25448105~25520854:+
LAML	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-4.49	2.66e-05	0.0409	-0.55	-0.47	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
LAML	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	4.49	2.66e-05	0.0409	0.55	0.47	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
LAML	cis	rs9847710	0.696	rs2581822	ENSG00000242142.1	SERBP1P3	4.49	2.66e-05	0.0409	0.55	0.47	Ulcerative colitis;	chr3:52987733	chr3:53064283~53065091:-
LAML	cis	rs9847710	0.67	rs2564933	ENSG00000242142.1	SERBP1P3	4.49	2.66e-05	0.0409	0.55	0.47	Ulcerative colitis;	chr3:52989357	chr3:53064283~53065091:-
LAML	cis	rs2015599	0.549	rs7311081	ENSG00000273680.1	RP11-996F15.6	4.49	2.66e-05	0.0409	0.47	0.47	Platelet count;Mean platelet volume;	chr12:29278235	chr12:29332733~29333383:-
LAML	cis	rs2015599	0.517	rs7295212	ENSG00000273680.1	RP11-996F15.6	4.49	2.66e-05	0.0409	0.47	0.47	Platelet count;Mean platelet volume;	chr12:29278432	chr12:29332733~29333383:-
LAML	cis	rs4728142	0.726	rs3778754	ENSG00000275106.1	RP11-309L24.10	-4.49	2.66e-05	0.0409	-0.43	-0.47	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128935498	chr7:128952527~128953316:-
LAML	cis	rs2404602	0.591	rs11635162	ENSG00000259422.1	RP11-593F23.1	-4.49	2.66e-05	0.0409	-0.59	-0.47	Blood metabolite levels;	chr15:76658764	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.575	rs11633309	ENSG00000259422.1	RP11-593F23.1	-4.49	2.66e-05	0.0409	-0.59	-0.47	Blood metabolite levels;	chr15:76670008	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.53	rs12915184	ENSG00000259422.1	RP11-593F23.1	-4.49	2.66e-05	0.0409	-0.59	-0.47	Blood metabolite levels;	chr15:76673581	chr15:76174891~76181486:-
LAML	cis	rs11696739	0.501	rs2243603	ENSG00000280922.1	AL121760.1	4.49	2.67e-05	0.0409	0.56	0.47	Mean platelet volume;	chr20:1566265	chr20:1870053~1870185:+
LAML	cis	rs1783925	0.549	rs11220082	ENSG00000254671.2	STT3A-AS1	-4.49	2.67e-05	0.0409	-0.59	-0.47	Formal thought disorder in schizophrenia;	chr11:125454069	chr11:125570284~125592568:-
LAML	cis	rs2455601	0.786	rs3763914	ENSG00000254860.4	TMEM9B-AS1	4.49	2.67e-05	0.0409	0.65	0.47	Schizophrenia;	chr11:8919156	chr11:8964675~8977527:+
LAML	cis	rs7746199	0.736	rs13209332	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs34965299	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28033947~28034855:+
LAML	cis	rs35491132	1	rs35491132	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Urinary tract infection frequency;	chr6:27559449	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs10484399	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs34105070	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.673	rs72845046	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs67652222	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs13212093	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs34038546	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28033947~28034855:+
LAML	cis	rs141342723	1	rs141342723	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs34543938	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs56405707	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs13210634	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs13215275	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs17749927	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs13192965	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28033947~28034855:+
LAML	cis	rs45509595	0.556	rs34409918	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Breast cancer;	chr6:27717569	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs34064842	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs13212318	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs13202291	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs17750424	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs13193542	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs13193480	ENSG00000217315.1	OR2W2P	4.49	2.67e-05	0.041	0.87	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28033947~28034855:+
LAML	cis	rs1419607	0.807	rs73233309	ENSG00000224897.5	POT1-AS1	4.49	2.67e-05	0.041	0.55	0.47	Obesity-related traits;	chr7:125800812	chr7:124929873~125179315:+
LAML	cis	rs1419607	0.807	rs73233311	ENSG00000224897.5	POT1-AS1	4.49	2.67e-05	0.041	0.55	0.47	Obesity-related traits;	chr7:125800813	chr7:124929873~125179315:+
LAML	cis	rs1419607	0.814	rs2107088	ENSG00000224897.5	POT1-AS1	4.49	2.67e-05	0.041	0.55	0.47	Obesity-related traits;	chr7:125801087	chr7:124929873~125179315:+
LAML	cis	rs1035144	0.606	rs12896769	ENSG00000258915.1	BHLHB9P1	-4.49	2.67e-05	0.041	-0.59	-0.47	Male sexual orientation;	chr14:81000708	chr14:80981988~80983638:+
LAML	cis	rs1035144	0.606	rs929630	ENSG00000258915.1	BHLHB9P1	-4.49	2.67e-05	0.041	-0.59	-0.47	Male sexual orientation;	chr14:81001114	chr14:80981988~80983638:+
LAML	cis	rs881375	0.935	rs7034390	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120884210	chr9:120824828~120854385:+
LAML	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
LAML	cis	rs881375	1	rs10760121	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120885637	chr9:120824828~120854385:+
LAML	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
LAML	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
LAML	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
LAML	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
LAML	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
LAML	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs1548783	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120896361	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	4.49	2.68e-05	0.0411	0.57	0.47	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
LAML	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
LAML	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
LAML	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
LAML	cis	rs881375	0.933	rs4837799	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120906048	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
LAML	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-4.49	2.68e-05	0.0411	-0.57	-0.47	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
LAML	cis	rs7746199	0.736	rs72845070	ENSG00000182477.5	OR2B8P	4.49	2.68e-05	0.0411	0.9	0.47	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27700521	chr6:28053228~28054165:-
LAML	cis	rs5769707	0.681	rs135879	ENSG00000279597.1	RP4-566L20.1	-4.49	2.68e-05	0.0411	-0.63	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49625003	chr22:49534062~49534926:+
LAML	cis	rs5769707	0.642	rs135880	ENSG00000279597.1	RP4-566L20.1	-4.49	2.68e-05	0.0411	-0.63	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49625006	chr22:49534062~49534926:+
LAML	cis	rs2980439	0.818	rs2948294	ENSG00000249188.1	ENPP7P1	-4.49	2.69e-05	0.0411	-0.59	-0.47	Neuroticism;	chr8:8237439	chr8:8154308~8216916:+
LAML	cis	rs7426056	0.671	rs716611	ENSG00000224791.1	KRT18P39	4.49	2.69e-05	0.0411	0.7	0.47	Primary sclerosing cholangitis;	chr2:203742051	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs17449312	ENSG00000224791.1	KRT18P39	-4.49	2.69e-05	0.0411	-0.7	-0.47	Primary sclerosing cholangitis;	chr2:203740620	chr2:203764295~203765593:-
LAML	cis	rs3758911	0.964	rs7358296	ENSG00000261098.1	RP11-819C21.1	-4.49	2.69e-05	0.0412	-0.46	-0.47	Coronary artery disease;	chr11:107403212	chr11:107312132~107316271:-
LAML	cis	rs5769707	0.706	rs763128	ENSG00000279597.1	RP4-566L20.1	-4.49	2.69e-05	0.0412	-0.62	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49624397	chr22:49534062~49534926:+
LAML	cis	rs7581030	0.55	rs11680206	ENSG00000236469.1	AC007040.8	4.49	2.7e-05	0.0412	0.57	0.47	Testicular germ cell tumor;	chr2:71234244	chr2:71002531~71064743:-
LAML	cis	rs9788721	0.836	rs17483548	ENSG00000259474.1	RP11-650L12.1	-4.49	2.7e-05	0.0412	-0.49	-0.47	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78437971	chr15:78480057~78481820:-
LAML	cis	rs9788721	0.836	rs17405217	ENSG00000259474.1	RP11-650L12.1	-4.49	2.7e-05	0.0412	-0.49	-0.47	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78438807	chr15:78480057~78481820:-
LAML	cis	rs763121	0.888	rs2235229	ENSG00000230912.1	RP3-508I15.10	-4.49	2.7e-05	0.0413	-0.36	-0.47	Menopause (age at onset);	chr22:38728907	chr22:38666508~38668750:-
LAML	cis	rs935334	1	rs2121067	ENSG00000280078.1	RP11-361H10.5	4.49	2.7e-05	0.0413	0.74	0.47	Blood pressure;	chr14:76151308	chr14:76279173~76283103:+
LAML	cis	rs6782228	1	rs35871360	ENSG00000277250.1	Metazoa_SRP	4.48	2.7e-05	0.0413	0.71	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128673681~128674021:-
LAML	cis	rs867371	1	rs1392976	ENSG00000259429.4	UBE2Q2P2	4.48	2.71e-05	0.0413	0.63	0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82153834	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs11855089	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82154924	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs1174543	ENSG00000259429.4	UBE2Q2P2	4.48	2.71e-05	0.0413	0.63	0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82155732	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs9944197	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82158261	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs7181655	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163275	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs7180584	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82163493	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs6495642	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82165156	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs8037224	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82172189	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs8042464	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173195	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs7166570	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82173880	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs1501372	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176114	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs1846911	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82176309	chr15:82355142~82420075:+
LAML	cis	rs867371	0.929	rs7176075	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82178998	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs8041868	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82179985	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs8041924	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82181320	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs2088858	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182408	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs4778982	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82182931	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs2867579	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183043	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs881308	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82183456	chr15:82355142~82420075:+
LAML	cis	rs867371	0.964	rs7169961	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186588	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs6495643	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82186913	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs13380317	ENSG00000259429.4	UBE2Q2P2	4.48	2.71e-05	0.0413	0.63	0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214449	chr15:82355142~82420075:+
LAML	cis	rs867371	1	rs13380319	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82214526	chr15:82355142~82420075:+
LAML	cis	rs867371	0.896	rs6495647	ENSG00000259429.4	UBE2Q2P2	-4.48	2.71e-05	0.0413	-0.63	-0.47	Cognitive ability;Cognitive ability (multi-trait analysis);	chr15:82244708	chr15:82355142~82420075:+
LAML	cis	rs5769707	0.542	rs739242	ENSG00000213279.2	RP1-29C18.9	-4.48	2.71e-05	0.0414	-0.58	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49663468	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.521	rs7285764	ENSG00000213279.2	RP1-29C18.9	-4.48	2.71e-05	0.0414	-0.58	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49664913	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.521	rs9616715	ENSG00000213279.2	RP1-29C18.9	-4.48	2.71e-05	0.0414	-0.58	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49664934	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.521	rs6009805	ENSG00000213279.2	RP1-29C18.9	-4.48	2.71e-05	0.0414	-0.58	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49665067	chr22:49572264~49575426:-
LAML	cis	rs5769707	0.521	rs6009807	ENSG00000213279.2	RP1-29C18.9	-4.48	2.71e-05	0.0414	-0.58	-0.47	Monocyte percentage of white cells;Monocyte count;	chr22:49665274	chr22:49572264~49575426:-
LAML	cis	rs881375	0.967	rs2239658	ENSG00000226752.6	PSMD5-AS1	-4.48	2.71e-05	0.0414	-0.57	-0.47	Rheumatoid arthritis;	chr9:120909559	chr9:120824828~120854385:+
LAML	cis	rs7829975	0.711	rs1039916	ENSG00000268955.2	RP11-556O5.6	-4.48	2.71e-05	0.0414	-0.54	-0.47	Mood instability;	chr8:8828344	chr8:8188535~8189195:-
LAML	cis	rs2404602	0.608	rs17361504	ENSG00000260235.1	CTD-2026K11.3	-4.48	2.71e-05	0.0414	-0.53	-0.47	Blood metabolite levels;	chr15:76309530	chr15:75624793~75625690:+
LAML	cis	rs7224685	0.501	rs11652060	ENSG00000280254.1	RP11-81A22.4	4.48	2.72e-05	0.0414	0.56	0.47	Type 2 diabetes;	chr17:4107118	chr17:4787057~4789162:+
LAML	cis	rs7224685	0.501	rs4790559	ENSG00000280254.1	RP11-81A22.4	4.48	2.72e-05	0.0414	0.56	0.47	Type 2 diabetes;	chr17:4107184	chr17:4787057~4789162:+
LAML	cis	rs7224685	0.501	rs11650023	ENSG00000280254.1	RP11-81A22.4	4.48	2.72e-05	0.0414	0.56	0.47	Type 2 diabetes;	chr17:4109556	chr17:4787057~4789162:+
LAML	cis	rs2273156	0.5	rs17103120	ENSG00000241052.1	RP11-173D9.1	4.48	2.72e-05	0.0414	0.81	0.47	Immunoglobulin light chain (AL) amyloidosis;	chr14:35234633	chr14:35144021~35144480:-
LAML	cis	rs9633402	0.586	rs6678102	ENSG00000230576.1	OR6R1P	4.48	2.72e-05	0.0414	0.58	0.47	Systemic juvenile idiopathic arthritis;	chr1:247836373	chr1:247833349~247834288:-
LAML	cis	rs9921222	0.597	rs7193109	ENSG00000230428.1	RP1-196A12.1	-4.48	2.72e-05	0.0414	-0.53	-0.47	Bone mineral density (spine);Bone mineral density;	chr16:363523	chr16:451404~453461:+
LAML	cis	rs7829975	0.511	rs2980426	ENSG00000268955.2	RP11-556O5.6	-4.48	2.72e-05	0.0414	-0.56	-0.47	Mood instability;	chr8:8288087	chr8:8188535~8189195:-
LAML	cis	rs62070183	0.656	rs17780628	ENSG00000280245.1	RP11-466A19.4	4.48	2.72e-05	0.0414	0.72	0.47	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32668202	chr17:32504567~32505644:-
LAML	cis	rs3913363	0.666	rs56054326	ENSG00000243398.3	RN7SL141P	-4.48	2.72e-05	0.0415	-0.38	-0.47	Response to angiotensin II receptor blocker therapy;	chr3:171916607	chr3:172237326~172237591:+
LAML	cis	rs3913363	0.666	rs6801882	ENSG00000243398.3	RN7SL141P	4.48	2.72e-05	0.0415	0.38	0.47	Response to angiotensin II receptor blocker therapy;	chr3:171915658	chr3:172237326~172237591:+
LAML	cis	rs67311347	0.713	rs4974018	ENSG00000230274.1	PGAM1P3	4.48	2.72e-05	0.0415	0.59	0.47	Renal cell carcinoma;	chr3:40265928	chr3:40322715~40323279:-
LAML	cis	rs7617773	0.817	rs745116	ENSG00000228638.1	FCF1P2	-4.48	2.72e-05	0.0415	-0.48	-0.47	Coronary artery disease;	chr3:48231046	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-4.48	2.72e-05	0.0415	-0.48	-0.47	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-4.48	2.72e-05	0.0415	-0.48	-0.47	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-4.48	2.72e-05	0.0415	-0.48	-0.47	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-4.48	2.72e-05	0.0415	-0.48	-0.47	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-4.48	2.72e-05	0.0415	-0.48	-0.47	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-4.48	2.72e-05	0.0415	-0.48	-0.47	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-4.48	2.72e-05	0.0415	-0.48	-0.47	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	4.48	2.72e-05	0.0415	0.48	0.47	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
LAML	cis	rs2439831	0.702	rs3759791	ENSG00000275601.1	AC011330.13	-4.48	2.73e-05	0.0416	-0.88	-0.47	Lung cancer in ever smokers;	chr15:43798600	chr15:43642389~43643023:-
LAML	cis	rs2143950	0.834	rs1048990	ENSG00000241052.1	RP11-173D9.1	-4.48	2.74e-05	0.0416	-0.76	-0.47	Atopic dermatitis;	chr14:35292469	chr14:35144021~35144480:-
LAML	cis	rs2143950	0.834	rs78426265	ENSG00000241052.1	RP11-173D9.1	-4.48	2.74e-05	0.0416	-0.76	-0.47	Atopic dermatitis;	chr14:35293785	chr14:35144021~35144480:-
LAML	cis	rs12145833	0.538	rs4658547	ENSG00000214837.7	LINC01347	4.48	2.74e-05	0.0417	0.77	0.47	Obesity (early onset extreme);	chr1:243227829	chr1:243056307~243101744:-
LAML	cis	rs12145833	0.538	rs9803701	ENSG00000214837.7	LINC01347	4.48	2.74e-05	0.0417	0.77	0.47	Obesity (early onset extreme);	chr1:243228332	chr1:243056307~243101744:-
LAML	cis	rs10463316	0.817	rs7709507	ENSG00000260581.1	CTB-113P19.4	4.48	2.74e-05	0.0417	0.42	0.47	Metabolite levels (Pyroglutamine);	chr5:151403788	chr5:151652275~151655449:+
LAML	cis	rs992157	0.764	rs2382827	ENSG00000261338.2	RP11-378A13.1	4.48	2.75e-05	0.0417	0.63	0.47	Colorectal cancer;	chr2:218319664	chr2:218255319~218257366:+
LAML	cis	rs992157	0.764	rs2891076	ENSG00000261338.2	RP11-378A13.1	4.48	2.75e-05	0.0417	0.63	0.47	Colorectal cancer;	chr2:218319675	chr2:218255319~218257366:+
LAML	cis	rs992157	0.73	rs2382828	ENSG00000261338.2	RP11-378A13.1	4.48	2.75e-05	0.0417	0.63	0.47	Colorectal cancer;	chr2:218319769	chr2:218255319~218257366:+
LAML	cis	rs992157	0.672	rs2382829	ENSG00000261338.2	RP11-378A13.1	4.48	2.75e-05	0.0417	0.63	0.47	Colorectal cancer;	chr2:218319894	chr2:218255319~218257366:+
LAML	cis	rs992157	0.764	rs2891079	ENSG00000261338.2	RP11-378A13.1	4.48	2.75e-05	0.0417	0.63	0.47	Colorectal cancer;	chr2:218319968	chr2:218255319~218257366:+
LAML	cis	rs992157	0.73	rs4280446	ENSG00000261338.2	RP11-378A13.1	4.48	2.75e-05	0.0417	0.63	0.47	Colorectal cancer;	chr2:218319998	chr2:218255319~218257366:+
LAML	cis	rs992157	0.764	rs4552182	ENSG00000261338.2	RP11-378A13.1	4.48	2.75e-05	0.0417	0.63	0.47	Colorectal cancer;	chr2:218320149	chr2:218255319~218257366:+
LAML	cis	rs2404602	0.608	rs12439484	ENSG00000260235.1	CTD-2026K11.3	-4.48	2.75e-05	0.0417	-0.53	-0.47	Blood metabolite levels;	chr15:76310596	chr15:75624793~75625690:+
LAML	cis	rs7587476	0.643	rs6714373	ENSG00000229267.2	AC072062.1	-4.48	2.75e-05	0.0417	-0.55	-0.47	Neuroblastoma;	chr2:214854290	chr2:214810229~214963274:+
LAML	cis	rs9467773	0.511	rs17278688	ENSG00000243307.2	POM121L6P	4.48	2.75e-05	0.0417	0.58	0.47	Intelligence (multi-trait analysis);	chr6:26922357	chr6:26896952~26898777:+
LAML	cis	rs9467773	0.511	rs11755443	ENSG00000243307.2	POM121L6P	4.48	2.75e-05	0.0417	0.58	0.47	Intelligence (multi-trait analysis);	chr6:26923824	chr6:26896952~26898777:+
LAML	cis	rs7131987	0.903	rs2194520	ENSG00000274315.1	RP11-996F15.5	4.48	2.75e-05	0.0417	0.47	0.47	QT interval;	chr12:29270779	chr12:29331434~29331936:-
LAML	cis	rs13217239	0.646	rs9379956	ENSG00000241549.7	GUSBP2	-4.48	2.76e-05	0.0417	-0.49	-0.47	Schizophrenia;	chr6:27065956	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs7747454	ENSG00000241549.7	GUSBP2	-4.48	2.76e-05	0.0417	-0.49	-0.47	Schizophrenia;	chr6:27066474	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.608	rs6930508	ENSG00000241549.7	GUSBP2	-4.48	2.76e-05	0.0417	-0.49	-0.47	Schizophrenia;	chr6:27085363	chr6:26871484~26956554:-
LAML	cis	rs13217239	0.646	rs2142685	ENSG00000241549.7	GUSBP2	-4.48	2.76e-05	0.0417	-0.49	-0.47	Schizophrenia;	chr6:27086718	chr6:26871484~26956554:-
LAML	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-4.48	2.76e-05	0.0418	-0.66	-0.47	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
LAML	cis	rs76917914	1	rs4743150	ENSG00000236896.1	RP11-535C21.3	4.48	2.76e-05	0.0418	0.46	0.47	Immature fraction of reticulocytes;	chr9:97977842	chr9:97986551~97987656:-
LAML	cis	rs114633080	0.744	rs9373445	ENSG00000220739.2	RP11-277I20.3	4.48	2.76e-05	0.0418	0.66	0.47	Response to mepolizumab in severe asthma;	chr6:145161680	chr6:144708106~144708497:-
LAML	cis	rs12052801	0.934	rs7340307	ENSG00000221443.1	AC017083.1	4.48	2.76e-05	0.0418	0.56	0.47	Schizophrenia;	chr2:68166012	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs6756198	ENSG00000221443.1	AC017083.1	4.48	2.76e-05	0.0418	0.56	0.47	Schizophrenia;	chr2:68167052	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs10182832	ENSG00000221443.1	AC017083.1	4.48	2.76e-05	0.0418	0.56	0.47	Schizophrenia;	chr2:68167852	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.932	rs10173501	ENSG00000221443.1	AC017083.1	4.48	2.76e-05	0.0418	0.56	0.47	Schizophrenia;	chr2:68168499	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.866	rs4671876	ENSG00000221443.1	AC017083.1	4.48	2.76e-05	0.0418	0.56	0.47	Schizophrenia;	chr2:68168781	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs12713633	ENSG00000221443.1	AC017083.1	4.48	2.76e-05	0.0418	0.56	0.47	Schizophrenia;	chr2:68169064	chr2:68273104~68273206:+
LAML	cis	rs9393777	0.528	rs35982103	ENSG00000187763.3	OR2B7P	4.48	2.77e-05	0.0419	0.62	0.47	Intelligence (multi-trait analysis);	chr6:27275355	chr6:28046434~28047367:+
LAML	cis	rs12052801	0.845	rs1947025	ENSG00000221443.1	AC017083.1	4.48	2.77e-05	0.0419	0.54	0.47	Schizophrenia;	chr2:68251787	chr2:68273104~68273206:+
LAML	cis	rs6951245	0.507	rs11976805	ENSG00000229043.2	AC091729.9	-4.48	2.77e-05	0.0419	-0.58	-0.47	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1099080	chr7:1160374~1165267:+
LAML	cis	rs9847710	0.744	rs2115780	ENSG00000242142.1	SERBP1P3	4.48	2.77e-05	0.0419	0.54	0.47	Ulcerative colitis;	chr3:53108964	chr3:53064283~53065091:-
LAML	cis	rs875971	0.825	rs59466412	ENSG00000222364.1	RNU6-96P	4.48	2.77e-05	0.0419	0.58	0.47	Aortic root size;	chr7:66100371	chr7:66395191~66395286:+
LAML	cis	rs12554020	0.892	rs75625893	ENSG00000227603.1	RP11-165J3.6	4.48	2.77e-05	0.042	0.77	0.47	Schizophrenia;	chr9:93605006	chr9:93435332~93437121:-
LAML	cis	rs12554020	0.892	rs76488437	ENSG00000227603.1	RP11-165J3.6	4.48	2.77e-05	0.042	0.77	0.47	Schizophrenia;	chr9:93605514	chr9:93435332~93437121:-
LAML	cis	rs12554020	0.681	rs80062429	ENSG00000227603.1	RP11-165J3.6	4.48	2.77e-05	0.042	0.77	0.47	Schizophrenia;	chr9:93608830	chr9:93435332~93437121:-
LAML	cis	rs12554020	0.786	rs12551314	ENSG00000227603.1	RP11-165J3.6	4.48	2.77e-05	0.042	0.77	0.47	Schizophrenia;	chr9:93617515	chr9:93435332~93437121:-
LAML	cis	rs3913363	0.6	rs4894517	ENSG00000243398.3	RN7SL141P	-4.48	2.78e-05	0.042	-0.38	-0.47	Response to angiotensin II receptor blocker therapy;	chr3:171914980	chr3:172237326~172237591:+
LAML	cis	rs17203055	0.714	rs12636459	ENSG00000276607.2	AC092910.1	-4.48	2.78e-05	0.042	-0.66	-0.47	Schizophrenia;	chr3:119368987	chr3:120084550~120084657:-
LAML	cis	rs17203055	0.714	rs10934492	ENSG00000276607.2	AC092910.1	-4.48	2.78e-05	0.042	-0.66	-0.47	Schizophrenia;	chr3:119370923	chr3:120084550~120084657:-
LAML	cis	rs9847710	0.566	rs2564951	ENSG00000242142.1	SERBP1P3	4.48	2.78e-05	0.0421	0.56	0.47	Ulcerative colitis;	chr3:53026433	chr3:53064283~53065091:-
LAML	cis	rs7165170	0.554	rs12903655	ENSG00000259314.1	CTD-3065B20.3	4.48	2.78e-05	0.0421	0.48	0.47	Crohn's disease;Inflammatory bowel disease;	chr15:90605398	chr15:90604225~90614558:-
LAML	cis	rs7165170	0.554	rs7175560	ENSG00000259314.1	CTD-3065B20.3	4.48	2.78e-05	0.0421	0.48	0.47	Crohn's disease;Inflammatory bowel disease;	chr15:90606847	chr15:90604225~90614558:-
LAML	cis	rs7165170	0.554	rs10438437	ENSG00000259314.1	CTD-3065B20.3	4.48	2.78e-05	0.0421	0.48	0.47	Crohn's disease;Inflammatory bowel disease;	chr15:90612753	chr15:90604225~90614558:-
LAML	cis	rs7458938	0.762	rs10234006	ENSG00000224897.5	POT1-AS1	4.48	2.79e-05	0.0421	0.55	0.47	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125780879	chr7:124929873~125179315:+
LAML	cis	rs9633402	0.586	rs8179377	ENSG00000230576.1	OR6R1P	4.48	2.79e-05	0.0421	0.58	0.47	Systemic juvenile idiopathic arthritis;	chr1:247836839	chr1:247833349~247834288:-
LAML	cis	rs10463316	0.894	rs13357969	ENSG00000260581.1	CTB-113P19.4	4.48	2.79e-05	0.0421	0.41	0.47	Metabolite levels (Pyroglutamine);	chr5:151371996	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs4099169	ENSG00000260581.1	CTB-113P19.4	4.48	2.79e-05	0.0421	0.41	0.47	Metabolite levels (Pyroglutamine);	chr5:151386965	chr5:151652275~151655449:+
LAML	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-4.48	2.79e-05	0.0422	-0.57	-0.47	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
LAML	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	4.48	2.79e-05	0.0422	0.57	0.47	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
LAML	cis	rs9393777	0.92	rs35120058	ENSG00000220721.1	OR1F12	4.48	2.8e-05	0.0422	0.76	0.47	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28073316~28074233:+
LAML	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	4.48	2.8e-05	0.0422	0.58	0.47	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
LAML	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	4.48	2.8e-05	0.0422	0.58	0.47	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
LAML	cis	rs2404602	0.611	rs2404734	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76643824	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs12914196	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76649020	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs12440965	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76666250	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.684	rs1011084	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76715139	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs11629727	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76716697	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs11072618	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76727001	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs1443115	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76749488	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs12898416	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76749951	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs12904149	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76751311	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.672	rs35374222	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76779053	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs11852395	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76795444	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs12439141	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76803082	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.622	rs9635380	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76811138	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs4312276	ENSG00000259422.1	RP11-593F23.1	-4.47	2.81e-05	0.0423	-0.59	-0.47	Blood metabolite levels;	chr15:76872020	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs11072625	ENSG00000259422.1	RP11-593F23.1	4.47	2.81e-05	0.0423	0.59	0.47	Blood metabolite levels;	chr15:76792643	chr15:76174891~76181486:-
LAML	cis	rs9502570	0.578	rs76831056	ENSG00000230570.1	RP11-69L16.6	-4.47	2.81e-05	0.0423	-0.73	-0.47	Type 2 diabetes;	chr6:7269190	chr6:7340854~7342056:-
LAML	cis	rs9502570	0.578	rs7763140	ENSG00000230570.1	RP11-69L16.6	-4.47	2.81e-05	0.0423	-0.73	-0.47	Type 2 diabetes;	chr6:7269334	chr6:7340854~7342056:-
LAML	cis	rs8062405	0.964	rs78613234	ENSG00000271623.1	RP11-435I10.5	-4.47	2.81e-05	0.0423	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs62036624	ENSG00000271623.1	RP11-435I10.5	-4.47	2.81e-05	0.0423	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs55991577	ENSG00000271623.1	RP11-435I10.5	-4.47	2.81e-05	0.0423	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs56358680	ENSG00000271623.1	RP11-435I10.5	-4.47	2.81e-05	0.0423	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs62036626	ENSG00000271623.1	RP11-435I10.5	-4.47	2.81e-05	0.0423	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs62036657	ENSG00000271623.1	RP11-435I10.5	-4.47	2.81e-05	0.0423	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs12444171	ENSG00000271623.1	RP11-435I10.5	-4.47	2.81e-05	0.0423	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs56404918	ENSG00000271623.1	RP11-435I10.5	-4.47	2.81e-05	0.0423	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs55719896	ENSG00000271623.1	RP11-435I10.5	-4.47	2.81e-05	0.0423	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs55830740	ENSG00000271623.1	RP11-435I10.5	-4.47	2.81e-05	0.0423	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28364700~28365333:+
LAML	cis	rs6772849	0.768	rs4521246	ENSG00000277250.1	Metazoa_SRP	4.47	2.81e-05	0.0423	0.66	0.47	Monocyte percentage of white cells;Monocyte count;	chr3:128702323	chr3:128673681~128674021:-
LAML	cis	rs6772849	0.708	rs12491942	ENSG00000277250.1	Metazoa_SRP	-4.47	2.81e-05	0.0423	-0.66	-0.47	Monocyte percentage of white cells;Monocyte count;	chr3:128702626	chr3:128673681~128674021:-
LAML	cis	rs8141529	0.732	rs5752798	ENSG00000226471.5	CTA-292E10.6	-4.47	2.81e-05	0.0424	-0.47	-0.47	Lymphocyte counts;	chr22:28785880	chr22:28800683~28848559:+
LAML	cis	rs8141529	0.719	rs2097461	ENSG00000226471.5	CTA-292E10.6	-4.47	2.81e-05	0.0424	-0.47	-0.47	Lymphocyte counts;	chr22:28795891	chr22:28800683~28848559:+
LAML	cis	rs8141529	0.732	rs2269577	ENSG00000226471.5	CTA-292E10.6	-4.47	2.81e-05	0.0424	-0.47	-0.47	Lymphocyte counts;	chr22:28800769	chr22:28800683~28848559:+
LAML	cis	rs1419607	0.777	rs9649483	ENSG00000224897.5	POT1-AS1	4.47	2.82e-05	0.0424	0.53	0.47	Obesity-related traits;	chr7:125797121	chr7:124929873~125179315:+
LAML	cis	rs79040073	0.637	rs73398264	ENSG00000276593.1	RP11-295H24.5	4.47	2.82e-05	0.0424	0.52	0.47	Lung cancer in ever smokers;	chr15:49414220	chr15:49353485~49354034:+
LAML	cis	rs79040073	0.516	rs4338740	ENSG00000276593.1	RP11-295H24.5	4.47	2.82e-05	0.0424	0.52	0.47	Lung cancer in ever smokers;	chr15:49443100	chr15:49353485~49354034:+
LAML	cis	rs7580658	0.929	rs2276583	ENSG00000236682.1	AC068282.3	-4.47	2.82e-05	0.0424	-0.62	-0.47	Protein C levels;	chr2:127257108	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.929	rs4662575	ENSG00000236682.1	AC068282.3	-4.47	2.82e-05	0.0424	-0.62	-0.47	Protein C levels;	chr2:127264639	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.929	rs11886231	ENSG00000236682.1	AC068282.3	-4.47	2.82e-05	0.0424	-0.62	-0.47	Protein C levels;	chr2:127270554	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.929	rs4150496	ENSG00000236682.1	AC068282.3	-4.47	2.82e-05	0.0424	-0.62	-0.47	Protein C levels;	chr2:127271927	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.891	rs3768866	ENSG00000236682.1	AC068282.3	-4.47	2.82e-05	0.0424	-0.62	-0.47	Protein C levels;	chr2:127287839	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.891	rs55998967	ENSG00000236682.1	AC068282.3	-4.47	2.82e-05	0.0424	-0.62	-0.47	Protein C levels;	chr2:127291098	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.963	rs12463451	ENSG00000236682.1	AC068282.3	-4.47	2.82e-05	0.0424	-0.62	-0.47	Protein C levels;	chr2:127296307	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.963	rs4233584	ENSG00000236682.1	AC068282.3	-4.47	2.82e-05	0.0424	-0.62	-0.47	Protein C levels;	chr2:127302587	chr2:127389130~127400580:+
LAML	cis	rs7580658	0.929	rs4150477	ENSG00000236682.1	AC068282.3	4.47	2.82e-05	0.0424	0.62	0.47	Protein C levels;	chr2:127274970	chr2:127389130~127400580:+
LAML	cis	rs7458938	0.77	rs6467047	ENSG00000224897.5	POT1-AS1	4.47	2.82e-05	0.0424	0.58	0.47	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125799024	chr7:124929873~125179315:+
LAML	cis	rs9911578	0.839	rs1871751	ENSG00000252212.1	RNU2-58P	4.47	2.82e-05	0.0424	0.48	0.47	Intelligence (multi-trait analysis);	chr17:59113007	chr17:59129276~59129458:-
LAML	cis	rs9457247	0.555	rs2247325	ENSG00000231654.1	RPS6KA2-AS1	4.47	2.82e-05	0.0424	0.45	0.47	Crohn's disease;	chr6:166956504	chr6:166903698~166904835:+
LAML	cis	rs7581030	0.55	rs10207928	ENSG00000236469.1	AC007040.8	-4.47	2.82e-05	0.0424	-0.61	-0.47	Testicular germ cell tumor;	chr2:71447703	chr2:71002531~71064743:-
LAML	cis	rs763121	0.853	rs4821816	ENSG00000230912.1	RP3-508I15.10	-4.47	2.83e-05	0.0425	-0.37	-0.47	Menopause (age at onset);	chr22:38717129	chr22:38666508~38668750:-
LAML	cis	rs763121	0.853	rs2267395	ENSG00000230912.1	RP3-508I15.10	-4.47	2.83e-05	0.0425	-0.37	-0.47	Menopause (age at onset);	chr22:38717898	chr22:38666508~38668750:-
LAML	cis	rs2948294	0.566	rs13274039	ENSG00000253893.2	FAM85B	-4.47	2.83e-05	0.0426	-0.61	-0.47	Red cell distribution width;	chr8:8254137	chr8:8167819~8226614:-
LAML	cis	rs8031584	0.918	rs34693097	ENSG00000260382.1	RP11-540B6.2	4.47	2.83e-05	0.0426	0.55	0.47	Huntington's disease progression;	chr15:30961781	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.918	rs35784593	ENSG00000260382.1	RP11-540B6.2	4.47	2.83e-05	0.0426	0.55	0.47	Huntington's disease progression;	chr15:30962385	chr15:30882267~30883231:-
LAML	cis	rs8031584	1	rs1474380	ENSG00000260382.1	RP11-540B6.2	4.47	2.83e-05	0.0426	0.55	0.47	Huntington's disease progression;	chr15:30977032	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.918	rs34095794	ENSG00000260382.1	RP11-540B6.2	4.47	2.83e-05	0.0426	0.55	0.47	Huntington's disease progression;	chr15:30977488	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.918	rs61997138	ENSG00000260382.1	RP11-540B6.2	4.47	2.83e-05	0.0426	0.55	0.47	Huntington's disease progression;	chr15:30978573	chr15:30882267~30883231:-
LAML	cis	rs8031584	0.918	rs61997140	ENSG00000260382.1	RP11-540B6.2	4.47	2.83e-05	0.0426	0.55	0.47	Huntington's disease progression;	chr15:30985109	chr15:30882267~30883231:-
LAML	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	4.47	2.83e-05	0.0426	0.56	0.47	Depression;	chr6:28363475	chr6:28176188~28176674:+
LAML	cis	rs7617773	0.744	rs2125482	ENSG00000228638.1	FCF1P2	-4.47	2.83e-05	0.0426	-0.48	-0.47	Coronary artery disease;	chr3:48281643	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs6800492	ENSG00000228638.1	FCF1P2	-4.47	2.83e-05	0.0426	-0.48	-0.47	Coronary artery disease;	chr3:48282400	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-4.47	2.83e-05	0.0426	-0.48	-0.47	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-4.47	2.83e-05	0.0426	-0.48	-0.47	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-4.47	2.83e-05	0.0426	-0.48	-0.47	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-4.47	2.83e-05	0.0426	-0.48	-0.47	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-4.47	2.83e-05	0.0426	-0.48	-0.47	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-4.47	2.83e-05	0.0426	-0.48	-0.47	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-4.47	2.83e-05	0.0426	-0.48	-0.47	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-4.47	2.83e-05	0.0426	-0.48	-0.47	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
LAML	cis	rs8062405	1	rs3088215	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs28403629	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs61737565	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs4788099	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs9972693	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.964	rs9972768	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.965	rs56040780	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs80275162	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.965	rs62037363	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs7205323	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs4788101	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs62037364	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs62037365	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.929	rs11150609	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs11861174	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs4788102	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs62037367	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs7198606	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.929	rs11864750	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.964	rs7193733	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs8055982	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs7498665	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.964	rs11864107	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs62037371	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs8055138	ENSG00000271623.1	RP11-435I10.5	-4.47	2.84e-05	0.0426	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28364700~28365333:+
LAML	cis	rs7301826	0.627	rs10744480	ENSG00000256299.1	RP11-989F5.3	-4.47	2.84e-05	0.0426	-0.64	-0.47	Plasma plasminogen activator levels;	chr12:130792602	chr12:130810821~130812622:-
LAML	cis	rs2404602	0.647	rs12910820	ENSG00000259422.1	RP11-593F23.1	-4.47	2.85e-05	0.0427	-0.57	-0.47	Blood metabolite levels;	chr15:76730484	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs12910081	ENSG00000259422.1	RP11-593F23.1	-4.47	2.85e-05	0.0427	-0.57	-0.47	Blood metabolite levels;	chr15:76730618	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs10851889	ENSG00000259422.1	RP11-593F23.1	-4.47	2.85e-05	0.0427	-0.57	-0.47	Blood metabolite levels;	chr15:76730995	chr15:76174891~76181486:-
LAML	cis	rs9457247	1	rs364283	ENSG00000227598.1	RP1-167A14.2	-4.47	2.85e-05	0.0427	-0.58	-0.47	Crohn's disease;	chr6:166970262	chr6:166969626~166999065:-
LAML	cis	rs9457247	1	rs429083	ENSG00000227598.1	RP1-167A14.2	-4.47	2.85e-05	0.0427	-0.58	-0.47	Crohn's disease;	chr6:166970484	chr6:166969626~166999065:-
LAML	cis	rs933769	1	rs8026212	ENSG00000242295.1	RP11-522B15.1	-4.47	2.86e-05	0.0428	-0.63	-0.47	Alcoholism (alcohol dependence factor score);	chr15:95510383	chr15:96448154~96448493:+
LAML	cis	rs4713118	0.568	rs9468213	ENSG00000216915.2	RP1-97D16.1	-4.47	2.86e-05	0.0428	-0.52	-0.47	Parkinson's disease;	chr6:27738401	chr6:27737000~27738494:-
LAML	cis	rs7146198	1	rs7146198	ENSG00000259158.2	ADAM20P1	-4.47	2.86e-05	0.0428	-0.8	-0.47	Corneal curvature;	chr14:70177452	chr14:70468881~70483756:-
LAML	cis	rs10463316	0.817	rs6879238	ENSG00000260581.1	CTB-113P19.4	4.47	2.86e-05	0.0428	0.41	0.47	Metabolite levels (Pyroglutamine);	chr5:151441013	chr5:151652275~151655449:+
LAML	cis	rs561341	0.654	rs6505265	ENSG00000266379.5	RP11-640N20.8	-4.47	2.86e-05	0.0428	-0.79	-0.47	Hip circumference adjusted for BMI;	chr17:31845561	chr17:32088160~32094933:-
LAML	cis	rs7500321	1	rs7500321	ENSG00000259982.1	CDC37P1	-4.47	2.87e-05	0.0429	-0.65	-0.47	Intelligence (multi-trait analysis);	chr16:28965699	chr16:28700294~28701540:-
LAML	cis	rs17270561	0.578	rs76182885	ENSG00000272462.2	U91328.19	-4.47	2.87e-05	0.0429	-0.67	-0.47	Iron status biomarkers;	chr6:25903857	chr6:25992662~26001775:+
LAML	cis	rs17270561	0.541	rs12192932	ENSG00000272462.2	U91328.19	-4.47	2.87e-05	0.0429	-0.67	-0.47	Iron status biomarkers;	chr6:25911274	chr6:25992662~26001775:+
LAML	cis	rs17270561	0.579	rs10456326	ENSG00000272462.2	U91328.19	-4.47	2.87e-05	0.0429	-0.67	-0.47	Iron status biomarkers;	chr6:25919434	chr6:25992662~26001775:+
LAML	cis	rs12216125	0.537	rs12207059	ENSG00000272462.2	U91328.19	-4.47	2.87e-05	0.0429	-0.67	-0.47	Iron status biomarkers;	chr6:25922157	chr6:25992662~26001775:+
LAML	cis	rs911555	0.655	rs10141157	ENSG00000258851.1	RP11-894P9.2	-4.47	2.87e-05	0.0429	-0.54	-0.47	Intelligence (multi-trait analysis);	chr14:103551768	chr14:103553421~103561877:+
LAML	cis	rs12052801	0.903	rs6742014	ENSG00000221443.1	AC017083.1	4.47	2.87e-05	0.0429	0.55	0.47	Schizophrenia;	chr2:68158823	chr2:68273104~68273206:+
LAML	cis	rs8062405	1	rs62036617	ENSG00000271623.1	RP11-435I10.5	-4.47	2.87e-05	0.0429	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs4788095	ENSG00000271623.1	RP11-435I10.5	-4.47	2.87e-05	0.0429	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28364700~28365333:+
LAML	cis	rs10851411	0.733	rs2899051	ENSG00000260490.2	RP11-265N6.3	-4.47	2.87e-05	0.043	-0.53	-0.47	Glucose homeostasis traits;	chr15:42493962	chr15:42571927~42572433:+
LAML	cis	rs7131987	0.868	rs737160	ENSG00000274315.1	RP11-996F15.5	4.47	2.87e-05	0.043	0.47	0.47	QT interval;	chr12:29276079	chr12:29331434~29331936:-
LAML	cis	rs62070183	0.517	rs17780538	ENSG00000264458.1	RP11-220C2.1	4.47	2.88e-05	0.043	0.82	0.47	Reticulocyte fraction of red cells;Reticulocyte count;	chr17:32626096	chr17:32627739~32686484:+
LAML	cis	rs16978956	0.779	rs2424169	ENSG00000214612.3	RPS19P1	-4.47	2.88e-05	0.0431	-0.47	-0.47	Body mass index;	chr20:18346801	chr20:18504633~18505066:+
LAML	cis	rs11951515	0.508	rs10059993	ENSG00000248240.1	RP11-159F24.5	-4.47	2.88e-05	0.0431	-0.58	-0.47	Metabolite levels  (X-11787);	chr5:43598250	chr5:43515274~43525310:+
LAML	cis	rs11951515	0.508	rs1366410	ENSG00000248240.1	RP11-159F24.5	-4.47	2.88e-05	0.0431	-0.58	-0.47	Metabolite levels  (X-11787);	chr5:43601508	chr5:43515274~43525310:+
LAML	cis	rs11951515	0.508	rs6860493	ENSG00000248240.1	RP11-159F24.5	-4.47	2.88e-05	0.0431	-0.58	-0.47	Metabolite levels  (X-11787);	chr5:43602611	chr5:43515274~43525310:+
LAML	cis	rs11951515	0.508	rs10065689	ENSG00000248240.1	RP11-159F24.5	-4.47	2.88e-05	0.0431	-0.58	-0.47	Metabolite levels  (X-11787);	chr5:43604156	chr5:43515274~43525310:+
LAML	cis	rs11951515	0.508	rs67261887	ENSG00000248240.1	RP11-159F24.5	-4.47	2.88e-05	0.0431	-0.58	-0.47	Metabolite levels  (X-11787);	chr5:43612339	chr5:43515274~43525310:+
LAML	cis	rs8062405	1	rs3888190	ENSG00000271623.1	RP11-435I10.5	-4.47	2.88e-05	0.0431	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28364700~28365333:+
LAML	cis	rs9952991	0.566	rs11875687	ENSG00000260302.1	RP11-973H7.1	4.47	2.88e-05	0.0431	0.82	0.47	Inflammatory skin disease;	chr18:12843138	chr18:12774651~12775923:-
LAML	cis	rs11123694	1	rs11123694	ENSG00000214184.3	AC012487.2	-4.47	2.88e-05	0.0431	-0.45	-0.47	Mean platelet volume;	chr2:108448107	chr2:108507515~108534196:-
LAML	cis	rs367615	0.506	rs246102	ENSG00000249476.1	CTD-2587M2.1	-4.47	2.88e-05	0.0431	-0.52	-0.47	Colorectal cancer (SNP x SNP interaction);	chr5:109363994	chr5:109237120~109326369:-
LAML	cis	rs8062405	1	rs62036622	ENSG00000271623.1	RP11-435I10.5	-4.47	2.88e-05	0.0431	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs72793811	ENSG00000271623.1	RP11-435I10.5	-4.47	2.88e-05	0.0431	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs72793812	ENSG00000271623.1	RP11-435I10.5	-4.47	2.88e-05	0.0431	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs12443881	ENSG00000271623.1	RP11-435I10.5	-4.47	2.88e-05	0.0431	-0.52	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28364700~28365333:+
LAML	cis	rs7587476	0.906	rs2070096	ENSG00000229267.2	AC072062.1	-4.47	2.89e-05	0.0431	-0.58	-0.47	Neuroblastoma;	chr2:214780821	chr2:214810229~214963274:+
LAML	cis	rs7587476	0.906	rs16852750	ENSG00000229267.2	AC072062.1	-4.47	2.89e-05	0.0431	-0.58	-0.47	Neuroblastoma;	chr2:214781959	chr2:214810229~214963274:+
LAML	cis	rs2921073	0.51	rs2976945	ENSG00000249188.1	ENPP7P1	-4.47	2.89e-05	0.0431	-0.51	-0.47	Parkinson's disease;	chr8:8413361	chr8:8154308~8216916:+
LAML	cis	rs11951515	0.508	rs11958046	ENSG00000248240.1	RP11-159F24.5	-4.47	2.89e-05	0.0431	-0.58	-0.47	Metabolite levels  (X-11787);	chr5:43583287	chr5:43515274~43525310:+
LAML	cis	rs11951515	0.508	rs7706431	ENSG00000248240.1	RP11-159F24.5	-4.47	2.89e-05	0.0431	-0.58	-0.47	Metabolite levels  (X-11787);	chr5:43582321	chr5:43515274~43525310:+
LAML	cis	rs11951515	0.508	rs6898866	ENSG00000248240.1	RP11-159F24.5	-4.47	2.89e-05	0.0431	-0.58	-0.47	Metabolite levels  (X-11787);	chr5:43586273	chr5:43515274~43525310:+
LAML	cis	rs11951515	0.508	rs7705166	ENSG00000248240.1	RP11-159F24.5	-4.47	2.89e-05	0.0431	-0.58	-0.47	Metabolite levels  (X-11787);	chr5:43587346	chr5:43515274~43525310:+
LAML	cis	rs7581030	0.55	rs13012800	ENSG00000236469.1	AC007040.8	4.47	2.89e-05	0.0432	0.65	0.47	Testicular germ cell tumor;	chr2:71208961	chr2:71002531~71064743:-
LAML	cis	rs12571093	0.656	rs3858147	ENSG00000234102.1	KRT19P4	-4.47	2.9e-05	0.0432	-0.75	-0.47	Optic nerve measurement (disc area);	chr10:68253507	chr10:68260557~68261499:+
LAML	cis	rs7131987	0.903	rs1991114	ENSG00000274315.1	RP11-996F15.5	4.47	2.9e-05	0.0433	0.47	0.47	QT interval;	chr12:29239149	chr12:29331434~29331936:-
LAML	cis	rs7131987	0.903	rs1035604	ENSG00000274315.1	RP11-996F15.5	4.47	2.9e-05	0.0433	0.47	0.47	QT interval;	chr12:29240169	chr12:29331434~29331936:-
LAML	cis	rs1419607	0.777	rs984925	ENSG00000224897.5	POT1-AS1	4.47	2.9e-05	0.0433	0.53	0.47	Obesity-related traits;	chr7:125789487	chr7:124929873~125179315:+
LAML	cis	rs6496044	0.568	rs2880765	ENSG00000259407.1	RP11-158M2.3	4.46	2.91e-05	0.0434	0.46	0.47	Interstitial lung disease;	chr15:85513231	chr15:85744109~85750281:-
LAML	cis	rs9322193	0.923	rs9800871	ENSG00000216906.2	RP11-350J20.9	4.46	2.91e-05	0.0434	0.66	0.47	Lung cancer;	chr6:149644540	chr6:149904243~149906418:+
LAML	cis	rs10108033	1	rs6470938	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.91e-05	0.0434	-0.59	-0.47	IgG glycosylation;	chr8:131334390	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs6470939	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.91e-05	0.0434	-0.59	-0.47	IgG glycosylation;	chr8:131334570	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs6415537	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.91e-05	0.0434	-0.59	-0.47	IgG glycosylation;	chr8:131334661	chr8:131308545~131317632:+
LAML	cis	rs10108033	1	rs6470940	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.91e-05	0.0434	-0.59	-0.47	IgG glycosylation;	chr8:131334722	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.915	rs6470941	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.91e-05	0.0434	-0.59	-0.47	IgG glycosylation;	chr8:131335397	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs6415539	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.91e-05	0.0434	-0.59	-0.47	IgG glycosylation;	chr8:131337406	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs6470942	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.91e-05	0.0434	-0.59	-0.47	IgG glycosylation;	chr8:131338018	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs7460903	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.91e-05	0.0434	-0.59	-0.47	IgG glycosylation;	chr8:131338318	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.822	rs6415541	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.91e-05	0.0434	-0.59	-0.47	IgG glycosylation;	chr8:131340410	chr8:131308545~131317632:+
LAML	cis	rs716804	0.74	rs7950461	ENSG00000254719.1	RP11-351I24.3	-4.46	2.91e-05	0.0434	-0.57	-0.47	Neuroticism;	chr11:10289258	chr11:10272052~10272259:-
LAML	cis	rs35740288	0.706	rs2614664	ENSG00000259407.1	RP11-158M2.3	-4.46	2.92e-05	0.0435	-0.49	-0.47	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85755485	chr15:85744109~85750281:-
LAML	cis	rs10108033	0.908	rs7461870	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.92e-05	0.0435	-0.6	-0.47	IgG glycosylation;	chr8:131342825	chr8:131308545~131317632:+
LAML	cis	rs10108033	0.908	rs7461928	ENSG00000253507.4	CTD-2501M5.1	-4.46	2.92e-05	0.0435	-0.6	-0.47	IgG glycosylation;	chr8:131342832	chr8:131308545~131317632:+
LAML	cis	rs7581030	0.55	rs34813993	ENSG00000236469.1	AC007040.8	4.46	2.92e-05	0.0435	0.64	0.47	Testicular germ cell tumor;	chr2:71228215	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs75208789	ENSG00000236469.1	AC007040.8	4.46	2.92e-05	0.0435	0.64	0.47	Testicular germ cell tumor;	chr2:71229309	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs35420218	ENSG00000236469.1	AC007040.8	4.46	2.92e-05	0.0435	0.64	0.47	Testicular germ cell tumor;	chr2:71230291	chr2:71002531~71064743:-
LAML	cis	rs7581030	0.55	rs12987750	ENSG00000236469.1	AC007040.8	4.46	2.92e-05	0.0435	0.64	0.47	Testicular germ cell tumor;	chr2:71230525	chr2:71002531~71064743:-
LAML	cis	rs3096299	0.9	rs2911258	ENSG00000274627.1	RP11-104N10.2	4.46	2.92e-05	0.0435	0.56	0.47	Multiple myeloma (IgH translocation);	chr16:89414352	chr16:89516797~89522217:+
LAML	cis	rs3096299	0.967	rs2911253	ENSG00000274627.1	RP11-104N10.2	4.46	2.93e-05	0.0436	0.57	0.47	Multiple myeloma (IgH translocation);	chr16:89422179	chr16:89516797~89522217:+
LAML	cis	rs12906542	0.58	rs4509986	ENSG00000214646.7	RP11-114H24.4	4.46	2.93e-05	0.0436	0.69	0.47	Breast cancer;	chr15:77975043	chr15:77941442~77944582:-
LAML	cis	rs1419607	1	rs1592396	ENSG00000224897.5	POT1-AS1	4.46	2.94e-05	0.0437	0.52	0.47	Obesity-related traits;	chr7:125770584	chr7:124929873~125179315:+
LAML	cis	rs2412819	0.597	rs541871	ENSG00000249839.1	AC011330.5	-4.46	2.94e-05	0.0437	-0.66	-0.47	Lung cancer;	chr15:43868656	chr15:43663654~43684339:-
LAML	cis	rs2412819	0.597	rs514311	ENSG00000249839.1	AC011330.5	-4.46	2.94e-05	0.0437	-0.66	-0.47	Lung cancer;	chr15:43869376	chr15:43663654~43684339:-
LAML	cis	rs8062405	1	rs12325113	ENSG00000271623.1	RP11-435I10.5	-4.46	2.94e-05	0.0437	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28364700~28365333:+
LAML	cis	rs56163509	1	rs56163509	ENSG00000271623.1	RP11-435I10.5	-4.46	2.94e-05	0.0437	-0.53	-0.47	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.964	rs7187333	ENSG00000271623.1	RP11-435I10.5	-4.46	2.94e-05	0.0437	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs12446589	ENSG00000271623.1	RP11-435I10.5	-4.46	2.94e-05	0.0437	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs62037369	ENSG00000271623.1	RP11-435I10.5	-4.46	2.94e-05	0.0437	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.965	rs7359397	ENSG00000271623.1	RP11-435I10.5	-4.46	2.94e-05	0.0437	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs7498555	ENSG00000271623.1	RP11-435I10.5	-4.46	2.94e-05	0.0437	-0.53	-0.47	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28364700~28365333:+
LAML	cis	rs2439831	0.702	rs8033995	ENSG00000275601.1	AC011330.13	-4.46	2.94e-05	0.0437	-0.85	-0.47	Lung cancer in ever smokers;	chr15:43721311	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs10438303	ENSG00000275601.1	AC011330.13	-4.46	2.94e-05	0.0437	-0.85	-0.47	Lung cancer in ever smokers;	chr15:43724219	chr15:43642389~43643023:-
LAML	cis	rs2439831	0.85	rs12441127	ENSG00000275601.1	AC011330.13	-4.46	2.94e-05	0.0437	-0.85	-0.47	Lung cancer in ever smokers;	chr15:43728977	chr15:43642389~43643023:-
LAML	cis	rs7301826	0.61	rs36051740	ENSG00000256299.1	RP11-989F5.3	4.46	2.95e-05	0.0437	0.61	0.47	Plasma plasminogen activator levels;	chr12:130808177	chr12:130810821~130812622:-
LAML	cis	rs2404602	0.684	rs3910756	ENSG00000259422.1	RP11-593F23.1	-4.46	2.95e-05	0.0438	-0.57	-0.47	Blood metabolite levels;	chr15:76653028	chr15:76174891~76181486:-
LAML	cis	rs716804	0.561	rs10770101	ENSG00000254719.1	RP11-351I24.3	4.46	2.95e-05	0.0438	0.59	0.47	Neuroticism;	chr11:10216883	chr11:10272052~10272259:-
LAML	cis	rs716804	0.504	rs11042725	ENSG00000254719.1	RP11-351I24.3	-4.46	2.96e-05	0.0439	-0.54	-0.47	Neuroticism;	chr11:10303778	chr11:10272052~10272259:-
LAML	cis	rs9426935	0.687	rs10494303	ENSG00000273026.1	RP11-422P24.10	-4.46	2.96e-05	0.0439	-0.61	-0.47	Lentiform nucleus volume;	chr1:153920547	chr1:153966516~153966930:+
LAML	cis	rs7301826	0.585	rs6486600	ENSG00000256250.1	RP11-989F5.1	-4.46	2.97e-05	0.044	-0.61	-0.47	Plasma plasminogen activator levels;	chr12:130808432	chr12:130810606~130812438:+
LAML	cis	rs8067354	0.645	rs11079389	ENSG00000266960.1	FAM106DP	4.46	2.97e-05	0.044	0.71	0.47	Hemoglobin concentration;	chr17:59810591	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.645	rs2665403	ENSG00000266960.1	FAM106DP	4.46	2.97e-05	0.044	0.71	0.47	Hemoglobin concentration;	chr17:59812624	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.645	rs2173120	ENSG00000266960.1	FAM106DP	4.46	2.97e-05	0.044	0.71	0.47	Hemoglobin concentration;	chr17:59815279	chr17:60173322~60173822:+
LAML	cis	rs4835473	0.715	rs1849124	ENSG00000250345.2	RP11-780M14.1	-4.46	2.97e-05	0.044	-0.48	-0.47	Immature fraction of reticulocytes;	chr4:143978494	chr4:143760399~143762093:-
LAML	cis	rs4835473	0.689	rs1849123	ENSG00000250345.2	RP11-780M14.1	-4.46	2.97e-05	0.044	-0.48	-0.47	Immature fraction of reticulocytes;	chr4:143978495	chr4:143760399~143762093:-
LAML	cis	rs11231629	1	rs11231629	ENSG00000181908.5	AP003774.4	4.46	2.97e-05	0.044	0.57	0.47	Schizophrenia;	chr11:63881101	chr11:64449074~64451657:+
LAML	cis	rs2581828	0.618	rs6792345	ENSG00000280417.1	RP11-5O17.1	-4.46	2.98e-05	0.0441	-0.68	-0.47	Crohn's disease;	chr3:53131178	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.618	rs6792363	ENSG00000280417.1	RP11-5O17.1	-4.46	2.98e-05	0.0441	-0.68	-0.47	Crohn's disease;	chr3:53131247	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.618	rs6445565	ENSG00000280417.1	RP11-5O17.1	-4.46	2.98e-05	0.0441	-0.68	-0.47	Crohn's disease;	chr3:53131448	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.591	rs6445566	ENSG00000280417.1	RP11-5O17.1	-4.46	2.98e-05	0.0441	-0.68	-0.47	Crohn's disease;	chr3:53131611	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.618	rs13319872	ENSG00000280417.1	RP11-5O17.1	-4.46	2.98e-05	0.0441	-0.68	-0.47	Crohn's disease;	chr3:53132082	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.618	rs9828221	ENSG00000280417.1	RP11-5O17.1	-4.46	2.98e-05	0.0441	-0.68	-0.47	Crohn's disease;	chr3:53132643	chr3:53046166~53048122:+
LAML	cis	rs2581828	0.618	rs6784207	ENSG00000280417.1	RP11-5O17.1	-4.46	2.98e-05	0.0441	-0.68	-0.47	Crohn's disease;	chr3:53133458	chr3:53046166~53048122:+
LAML	cis	rs7932354	0.617	rs2306035	ENSG00000271557.1	YPEL5P2	4.46	2.98e-05	0.0441	0.64	0.47	Bone mineral density (hip);Bone mineral density;	chr11:46889906	chr11:47841324~47841682:+
LAML	cis	rs10851411	0.817	rs56357092	ENSG00000260490.2	RP11-265N6.3	-4.46	2.98e-05	0.0441	-0.53	-0.47	Glucose homeostasis traits;	chr15:42498331	chr15:42571927~42572433:+
LAML	cis	rs11951515	0.509	rs12521249	ENSG00000248240.1	RP11-159F24.5	4.46	3e-05	0.0444	0.57	0.46	Metabolite levels  (X-11787);	chr5:43558527	chr5:43515274~43525310:+
LAML	cis	rs5769707	0.749	rs7286706	ENSG00000264139.1	MIR3667	-4.46	3.01e-05	0.0444	-0.54	-0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49664698	chr22:49543393~49543466:-
LAML	cis	rs7714584	1	rs76548544	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150843953	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs73282255	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150844085	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs80075680	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150844175	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs4958843	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150845362	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs4958424	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150845474	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs2004711	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150845506	chr5:150930645~150946289:-
LAML	cis	rs7714584	0.793	rs35707106	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150845815	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs34156253	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150846668	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs61270113	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150846701	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11748151	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150846730	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11748158	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150846783	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs10058821	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150846823	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs10051804	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150846862	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs10058943	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150847024	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs10051924	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150847077	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs17111376	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150847337	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs10065172	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150848436	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs7705542	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150848756	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs11749391	ENSG00000197083.10	ZNF300P1	4.46	3.01e-05	0.0444	0.91	0.46	Crohn's disease;	chr5:150849504	chr5:150930645~150946289:-
LAML	cis	rs7829975	0.667	rs1877119	ENSG00000268955.2	RP11-556O5.6	-4.46	3.01e-05	0.0444	-0.59	-0.46	Mood instability;	chr8:8849687	chr8:8188535~8189195:-
LAML	cis	rs11038871	1	rs10838601	ENSG00000271350.1	CTD-2384B9.1	4.45	3.02e-05	0.0445	0.49	0.46	Immunoglobulin A;	chr11:46371275	chr11:47041027~47041945:-
LAML	cis	rs853679	0.55	rs1225598	ENSG00000217315.1	OR2W2P	4.45	3.02e-05	0.0445	0.67	0.46	Depression;	chr6:28193021	chr6:28033947~28034855:+
LAML	cis	rs853679	0.55	rs1150689	ENSG00000217315.1	OR2W2P	4.45	3.02e-05	0.0445	0.67	0.46	Depression;	chr6:28197321	chr6:28033947~28034855:+
LAML	cis	rs853679	0.55	rs1225599	ENSG00000217315.1	OR2W2P	4.45	3.02e-05	0.0445	0.67	0.46	Depression;	chr6:28197412	chr6:28033947~28034855:+
LAML	cis	rs853679	0.574	rs1233705	ENSG00000217315.1	OR2W2P	4.45	3.02e-05	0.0445	0.67	0.46	Depression;	chr6:28198669	chr6:28033947~28034855:+
LAML	cis	rs853679	0.55	rs1233704	ENSG00000217315.1	OR2W2P	-4.45	3.02e-05	0.0445	-0.67	-0.46	Depression;	chr6:28199145	chr6:28033947~28034855:+
LAML	cis	rs853679	0.55	rs1233701	ENSG00000217315.1	OR2W2P	-4.45	3.02e-05	0.0445	-0.67	-0.46	Depression;	chr6:28200948	chr6:28033947~28034855:+
LAML	cis	rs853679	0.55	rs1237875	ENSG00000217315.1	OR2W2P	-4.45	3.02e-05	0.0445	-0.67	-0.46	Depression;	chr6:28205232	chr6:28033947~28034855:+
LAML	cis	rs916888	0.821	rs199504	ENSG00000280985.1	AC217773.1	-4.45	3.02e-05	0.0445	-0.64	-0.46	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:46172089~46172239:-
LAML	cis	rs935334	1	rs935334	ENSG00000280078.1	RP11-361H10.5	4.45	3.02e-05	0.0445	0.7	0.46	Blood pressure;	chr14:76147335	chr14:76279173~76283103:+
LAML	cis	rs7903338	0.821	rs76940283	ENSG00000231025.1	RP11-175O19.4	4.45	3.02e-05	0.0446	0.62	0.46	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);	chr10:97801888	chr10:96992450~96995959:+
LAML	cis	rs7224685	0.501	rs2727060	ENSG00000280254.1	RP11-81A22.4	4.45	3.03e-05	0.0446	0.56	0.46	Type 2 diabetes;	chr17:4086674	chr17:4787057~4789162:+
LAML	cis	rs7224685	0.501	rs2727074	ENSG00000280254.1	RP11-81A22.4	4.45	3.03e-05	0.0446	0.56	0.46	Type 2 diabetes;	chr17:4091376	chr17:4787057~4789162:+
LAML	cis	rs7224685	0.501	rs2603025	ENSG00000280254.1	RP11-81A22.4	4.45	3.03e-05	0.0446	0.56	0.46	Type 2 diabetes;	chr17:4093670	chr17:4787057~4789162:+
LAML	cis	rs2933343	0.951	rs789220	ENSG00000231305.3	RP11-723O4.2	-4.45	3.03e-05	0.0446	-0.58	-0.46	IgG glycosylation;	chr3:128873292	chr3:128861313~128871540:-
LAML	cis	rs2015599	0.623	rs12581107	ENSG00000274315.1	RP11-996F15.5	-4.45	3.03e-05	0.0447	-0.47	-0.46	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.645	rs12578931	ENSG00000274315.1	RP11-996F15.5	-4.45	3.03e-05	0.0447	-0.47	-0.46	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29331434~29331936:-
LAML	cis	rs2015599	0.623	rs4931174	ENSG00000274315.1	RP11-996F15.5	-4.45	3.03e-05	0.0447	-0.47	-0.46	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29331434~29331936:-
LAML	cis	rs12477438	0.52	rs11695751	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99091784	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs4340581	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99108562	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs36071868	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99120657	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs34252185	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99121183	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs13023744	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99121761	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs6751927	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99123712	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs7604557	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99131366	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs13010904	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99137826	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs13012481	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99137827	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs6717723	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99140467	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs11685759	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99149754	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs11123765	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99151601	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.501	rs2632260	ENSG00000231822.1	AC019097.7	4.45	3.04e-05	0.0447	0.57	0.46	Chronic sinus infection;	chr2:99155127	chr2:99102018~99102752:+
LAML	cis	rs12477438	0.52	rs4851187	ENSG00000231822.1	AC019097.7	-4.45	3.04e-05	0.0447	-0.57	-0.46	Chronic sinus infection;	chr2:99129397	chr2:99102018~99102752:+
LAML	cis	rs8067354	0.574	rs1292042	ENSG00000266960.1	FAM106DP	4.45	3.04e-05	0.0447	0.75	0.46	Hemoglobin concentration;	chr17:59857634	chr17:60173322~60173822:+
LAML	cis	rs7247513	0.866	rs2861405	ENSG00000230310.1	CTD-2192J16.11	-4.45	3.04e-05	0.0448	-0.57	-0.46	Bipolar disorder;	chr19:12611518	chr19:12552597~12553644:+
LAML	cis	rs10500715	0.715	rs10840331	ENSG00000254719.1	RP11-351I24.3	-4.45	3.04e-05	0.0448	-0.54	-0.46	Pancreatic cancer;	chr11:9950932	chr11:10272052~10272259:-
LAML	cis	rs6940638	0.688	rs7764984	ENSG00000187763.3	OR2B7P	4.45	3.05e-05	0.0448	0.55	0.46	Intelligence (multi-trait analysis);	chr6:27066402	chr6:28046434~28047367:+
LAML	cis	rs3750082	0.889	rs6962267	ENSG00000222741.1	RNA5SP229	-4.45	3.05e-05	0.0448	-0.53	-0.46	Glomerular filtration rate (creatinine);	chr7:32900162	chr7:33177740~33177838:+
LAML	cis	rs3750082	0.889	rs11766608	ENSG00000222741.1	RNA5SP229	-4.45	3.05e-05	0.0448	-0.53	-0.46	Glomerular filtration rate (creatinine);	chr7:32900474	chr7:33177740~33177838:+
LAML	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-4.45	3.05e-05	0.0448	-0.87	-0.46	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
LAML	cis	rs7555523	0.778	rs4233408	ENSG00000224358.1	RP11-466F5.8	-4.45	3.05e-05	0.0449	-0.65	-0.46	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165743723	chr1:165768929~165775176:+
LAML	cis	rs2980439	0.556	rs2921059	ENSG00000268955.2	RP11-556O5.6	-4.45	3.05e-05	0.0449	-0.56	-0.46	Neuroticism;	chr8:8460377	chr8:8188535~8189195:-
LAML	cis	rs2980439	0.557	rs2976876	ENSG00000268955.2	RP11-556O5.6	-4.45	3.05e-05	0.0449	-0.56	-0.46	Neuroticism;	chr8:8461340	chr8:8188535~8189195:-
LAML	cis	rs4141404	0.737	rs5998058	ENSG00000202019.1	Y_RNA	-4.45	3.06e-05	0.0449	-0.7	-0.46	Paclitaxel-induced neuropathy;	chr22:31610422	chr22:31230071~31230172:-
LAML	cis	rs6766510	0.826	rs3806662	ENSG00000251774.1	RNU6-377P	4.45	3.06e-05	0.045	0.64	0.46	Prostate cancer (SNP x SNP interaction);	chr3:12484507	chr3:12514706~12514807:+
LAML	cis	rs10492681	0.555	rs61954177	ENSG00000239827.7	SUGT1P3	-4.45	3.07e-05	0.0452	-0.61	-0.46	Select biomarker traits;	chr13:40212899	chr13:40908159~40921774:-
LAML	cis	rs2404602	0.647	rs11637096	ENSG00000259422.1	RP11-593F23.1	-4.45	3.08e-05	0.0452	-0.58	-0.46	Blood metabolite levels;	chr15:76638761	chr15:76174891~76181486:-
LAML	cis	rs79040073	0.563	rs17479003	ENSG00000276593.1	RP11-295H24.5	4.45	3.08e-05	0.0452	0.53	0.46	Lung cancer in ever smokers;	chr15:49453223	chr15:49353485~49354034:+
LAML	cis	rs79040073	0.607	rs17400706	ENSG00000276593.1	RP11-295H24.5	4.45	3.08e-05	0.0452	0.53	0.46	Lung cancer in ever smokers;	chr15:49455148	chr15:49353485~49354034:+
LAML	cis	rs11098499	0.78	rs10013652	ENSG00000260091.1	RP11-33B1.4	4.45	3.08e-05	0.0453	0.44	0.46	Corneal astigmatism;	chr4:119371101	chr4:119409333~119410233:+
LAML	cis	rs10129255	0.585	rs2008440	ENSG00000211970.3	IGHV4-61	-4.45	3.09e-05	0.0454	-0.68	-0.46	Kawasaki disease;	chr14:106654988	chr14:106639119~106639657:-
LAML	cis	rs992157	0.764	rs4423579	ENSG00000261338.2	RP11-378A13.1	4.45	3.1e-05	0.0454	0.63	0.46	Colorectal cancer;	chr2:218320310	chr2:218255319~218257366:+
LAML	cis	rs992157	0.764	rs62183964	ENSG00000261338.2	RP11-378A13.1	4.45	3.1e-05	0.0454	0.63	0.46	Colorectal cancer;	chr2:218321869	chr2:218255319~218257366:+
LAML	cis	rs10851411	0.862	rs1900921	ENSG00000260490.2	RP11-265N6.3	-4.45	3.1e-05	0.0454	-0.53	-0.46	Glucose homeostasis traits;	chr15:42494946	chr15:42571927~42572433:+
LAML	cis	rs716804	0.566	rs7927874	ENSG00000254719.1	RP11-351I24.3	-4.45	3.1e-05	0.0455	-0.54	-0.46	Neuroticism;	chr11:10302644	chr11:10272052~10272259:-
LAML	cis	rs12052801	0.874	rs2122126	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68190585	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.967	rs10191352	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68191736	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.967	rs6757863	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68192355	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.967	rs6761378	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68192938	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.967	rs9677635	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68193917	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.934	rs4671878	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68195639	chr2:68252870~68253848:+
LAML	cis	rs12052801	1	rs12052801	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68196086	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.967	rs12713635	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68196398	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.967	rs13004649	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68198285	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.967	rs7574378	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68203793	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.967	rs7577586	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68204127	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.932	rs6736178	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68206699	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.934	rs7572554	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68208148	chr2:68252870~68253848:+
LAML	cis	rs12052801	0.934	rs6758449	ENSG00000273064.1	RP11-474G23.3	4.45	3.1e-05	0.0455	0.46	0.46	Schizophrenia;	chr2:68209976	chr2:68252870~68253848:+
LAML	cis	rs11038871	1	rs7949371	ENSG00000271350.1	CTD-2384B9.1	4.45	3.1e-05	0.0455	0.52	0.46	Immunoglobulin A;	chr11:46500754	chr11:47041027~47041945:-
LAML	cis	rs11038871	1	rs7949282	ENSG00000271350.1	CTD-2384B9.1	4.45	3.1e-05	0.0455	0.52	0.46	Immunoglobulin A;	chr11:46500756	chr11:47041027~47041945:-
LAML	cis	rs7115242	0.699	rs17174502	ENSG00000254851.1	RP11-109L13.1	4.45	3.1e-05	0.0455	1.05	0.46	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116888939	chr11:117135528~117138582:+
LAML	cis	rs564349	1	rs477748	ENSG00000204758.6	CTC-308K20.1	-4.45	3.1e-05	0.0455	-0.51	-0.46	Inflammatory bowel disease;Ulcerative colitis;	chr5:172898112	chr5:172954786~172959392:-
LAML	cis	rs7580658	0.751	rs1799808	ENSG00000236682.1	AC068282.3	-4.45	3.1e-05	0.0455	-0.7	-0.46	Protein C levels;	chr2:127418286	chr2:127389130~127400580:+
LAML	cis	rs716804	0.74	rs12290748	ENSG00000254719.1	RP11-351I24.3	-4.45	3.11e-05	0.0455	-0.58	-0.46	Neuroticism;	chr11:10240659	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs12279861	ENSG00000254719.1	RP11-351I24.3	-4.45	3.11e-05	0.0455	-0.58	-0.46	Neuroticism;	chr11:10241678	chr11:10272052~10272259:-
LAML	cis	rs716804	0.74	rs55933041	ENSG00000254719.1	RP11-351I24.3	-4.45	3.11e-05	0.0455	-0.58	-0.46	Neuroticism;	chr11:10242007	chr11:10272052~10272259:-
LAML	cis	rs17270561	0.525	rs12201678	ENSG00000272462.2	U91328.19	-4.45	3.12e-05	0.0457	-0.66	-0.46	Iron status biomarkers;	chr6:25978765	chr6:25992662~26001775:+
LAML	cis	rs17270561	0.525	rs10484432	ENSG00000272462.2	U91328.19	-4.45	3.12e-05	0.0457	-0.66	-0.46	Iron status biomarkers;	chr6:26008648	chr6:25992662~26001775:+
LAML	cis	rs17270561	0.562	rs74293932	ENSG00000272462.2	U91328.19	-4.45	3.12e-05	0.0457	-0.66	-0.46	Iron status biomarkers;	chr6:26014583	chr6:25992662~26001775:+
LAML	cis	rs12477438	0.539	rs720228	ENSG00000231822.1	AC019097.7	4.44	3.13e-05	0.0457	0.57	0.46	Chronic sinus infection;	chr2:99088084	chr2:99102018~99102752:+
LAML	cis	rs898534	0.646	rs898532	ENSG00000262172.1	CTD-2529O21.1	4.44	3.14e-05	0.0458	0.75	0.46	Urate levels (BMI interaction);	chr17:79277592	chr17:79991944~79992841:-
LAML	cis	rs7746199	0.736	rs35848276	ENSG00000217315.1	OR2W2P	4.44	3.14e-05	0.0459	0.88	0.46	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28033947~28034855:+
LAML	cis	rs7746199	0.736	rs13202295	ENSG00000217315.1	OR2W2P	4.44	3.14e-05	0.0459	0.88	0.46	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28033947~28034855:+
LAML	cis	rs7587476	0.689	rs78989396	ENSG00000229267.2	AC072062.1	-4.44	3.14e-05	0.0459	-0.55	-0.46	Neuroblastoma;	chr2:214850092	chr2:214810229~214963274:+
LAML	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-4.44	3.14e-05	0.0459	-0.57	-0.46	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
LAML	cis	rs904251	0.523	rs1776455	ENSG00000229559.2	RP1-153P14.3	-4.44	3.14e-05	0.0459	-0.48	-0.46	Cognitive performance;	chr6:37515147	chr6:37543553~37547280:-
LAML	cis	rs7829975	0.711	rs12682352	ENSG00000268955.2	RP11-556O5.6	-4.44	3.15e-05	0.046	-0.53	-0.46	Mood instability;	chr8:8788736	chr8:8188535~8189195:-
LAML	cis	rs4713118	0.588	rs200994	ENSG00000187763.3	OR2B7P	-4.44	3.15e-05	0.046	-0.63	-0.46	Parkinson's disease;	chr6:27846035	chr6:28046434~28047367:+
LAML	cis	rs115056730	0.52	rs113247402	ENSG00000235833.1	AC159540.14	4.44	3.15e-05	0.046	1.21	0.46	Monocyte chemoattractant protein-3 levels;	chr2:97552110	chr2:97523949~97524976:-
LAML	cis	rs9788721	0.836	rs17483929	ENSG00000259474.1	RP11-650L12.1	-4.44	3.15e-05	0.046	-0.49	-0.46	Post bronchodilator FEV1/FVC ratio in COPD;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Post bronchodilator FEV1;Local histogram emphysema pattern;	chr15:78450034	chr15:78480057~78481820:-
LAML	cis	rs2980439	0.525	rs2945238	ENSG00000253893.2	FAM85B	-4.44	3.16e-05	0.0461	-0.53	-0.46	Neuroticism;	chr8:8312614	chr8:8167819~8226614:-
LAML	cis	rs202065757	1	rs202065757	ENSG00000182477.5	OR2B8P	4.44	3.16e-05	0.0461	0.82	0.46	Tuberculosis;	chr6:28798582	chr6:28053228~28054165:-
LAML	cis	rs12210905	0.841	rs116485609	ENSG00000275846.1	RP11-457M11.7	-4.44	3.16e-05	0.0461	-0.86	-0.46	Hip circumference adjusted for BMI;	chr6:26896426	chr6:26602733~26606661:+
LAML	cis	rs12210905	0.61	rs12216370	ENSG00000275846.1	RP11-457M11.7	-4.44	3.16e-05	0.0461	-0.86	-0.46	Hip circumference adjusted for BMI;	chr6:26911151	chr6:26602733~26606661:+
LAML	cis	rs12210905	0.565	rs9689239	ENSG00000275846.1	RP11-457M11.7	-4.44	3.16e-05	0.0461	-0.86	-0.46	Hip circumference adjusted for BMI;	chr6:26914100	chr6:26602733~26606661:+
LAML	cis	rs7131987	0.868	rs737160	ENSG00000275278.1	RP11-946L16.2	4.44	3.16e-05	0.0461	0.56	0.46	QT interval;	chr12:29276079	chr12:29156448~29156991:-
LAML	cis	rs9399135	0.66	rs4646868	ENSG00000232876.1	CTA-212D2.2	-4.44	3.16e-05	0.0461	-0.72	-0.46	Red blood cell count;	chr6:134950808	chr6:135055033~135060550:+
LAML	cis	rs692804	0.56	rs10790370	ENSG00000259541.4	RP11-778O17.4	-4.44	3.17e-05	0.0462	-0.68	-0.46	Blood protein levels;	chr11:120207685	chr11:120249759~120265932:-
LAML	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-4.44	3.17e-05	0.0462	-0.53	-0.46	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
LAML	cis	rs7587476	0.906	rs3768713	ENSG00000229267.2	AC072062.1	-4.44	3.17e-05	0.0463	-0.58	-0.46	Neuroblastoma;	chr2:214772781	chr2:214810229~214963274:+
LAML	cis	rs853679	0.766	rs9368561	ENSG00000217315.1	OR2W2P	4.44	3.18e-05	0.0463	0.84	0.46	Depression;	chr6:28200565	chr6:28033947~28034855:+
LAML	cis	rs5769707	0.933	rs2157444	ENSG00000279597.1	RP4-566L20.1	-4.44	3.18e-05	0.0463	-0.54	-0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49600644	chr22:49534062~49534926:+
LAML	cis	rs13113518	0.812	rs2048564	ENSG00000249700.7	SRD5A3-AS1	4.44	3.19e-05	0.0465	0.48	0.46	Height;	chr4:55407965	chr4:55363971~55395847:-
LAML	cis	rs9952991	0.582	rs658158	ENSG00000260302.1	RP11-973H7.1	-4.44	3.2e-05	0.0465	-0.78	-0.46	Inflammatory skin disease;	chr18:12823403	chr18:12774651~12775923:-
LAML	cis	rs9952991	0.622	rs8091566	ENSG00000260302.1	RP11-973H7.1	-4.44	3.2e-05	0.0465	-0.78	-0.46	Inflammatory skin disease;	chr18:12826386	chr18:12774651~12775923:-
LAML	cis	rs10851411	0.817	rs1060265	ENSG00000260490.2	RP11-265N6.3	-4.44	3.2e-05	0.0465	-0.54	-0.46	Glucose homeostasis traits;	chr15:42532384	chr15:42571927~42572433:+
LAML	cis	rs7224685	0.906	rs2278524	ENSG00000234203.1	RP5-1050D4.2	4.44	3.2e-05	0.0465	0.67	0.46	Type 2 diabetes;	chr17:4178680	chr17:4972851~4974681:+
LAML	cis	rs2856321	0.967	rs10743967	ENSG00000271215.1	RPL21P136	-4.44	3.2e-05	0.0466	-0.46	-0.46	Height;	chr12:11728595	chr12:12614359~12615907:-
LAML	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-4.44	3.2e-05	0.0466	-0.57	-0.46	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
LAML	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-4.44	3.2e-05	0.0466	-0.57	-0.46	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
LAML	cis	rs7580658	0.963	rs4233583	ENSG00000236682.1	AC068282.3	-4.44	3.2e-05	0.0466	-0.62	-0.46	Protein C levels;	chr2:127302492	chr2:127389130~127400580:+
LAML	cis	rs2856321	0.902	rs11054433	ENSG00000271215.1	RPL21P136	4.44	3.21e-05	0.0466	0.44	0.46	Height;	chr12:11734512	chr12:12614359~12615907:-
LAML	cis	rs6558530	0.626	rs6558524	ENSG00000253982.1	CTD-2336O2.1	4.44	3.21e-05	0.0467	0.69	0.46	Systolic blood pressure;	chr8:1754346	chr8:1761990~1764502:-
LAML	cis	rs6558530	0.692	rs6558525	ENSG00000253982.1	CTD-2336O2.1	4.44	3.21e-05	0.0467	0.69	0.46	Systolic blood pressure;	chr8:1754357	chr8:1761990~1764502:-
LAML	cis	rs6558530	0.666	rs6558526	ENSG00000253982.1	CTD-2336O2.1	4.44	3.21e-05	0.0467	0.69	0.46	Systolic blood pressure;	chr8:1754406	chr8:1761990~1764502:-
LAML	cis	rs12705849	1	rs12705849	ENSG00000214194.7	LINC00998	-4.44	3.21e-05	0.0467	-0.45	-0.46	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Eosinophil counts;	chr7:113142501	chr7:113116718~113118613:-
LAML	cis	rs881375	0.902	rs2900180	ENSG00000226752.6	PSMD5-AS1	-4.44	3.21e-05	0.0467	-0.57	-0.46	Rheumatoid arthritis;	chr9:120944104	chr9:120824828~120854385:+
LAML	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-4.44	3.21e-05	0.0467	-0.56	-0.46	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	4.44	3.21e-05	0.0467	0.56	0.46	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	4.44	3.21e-05	0.0467	0.56	0.46	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	4.44	3.21e-05	0.0467	0.56	0.46	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	4.44	3.21e-05	0.0467	0.56	0.46	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
LAML	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	4.44	3.21e-05	0.0467	0.56	0.46	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
LAML	cis	rs2856321	0.834	rs10845407	ENSG00000271215.1	RPL21P136	4.44	3.21e-05	0.0467	0.44	0.46	Height;	chr12:11724298	chr12:12614359~12615907:-
LAML	cis	rs6772849	0.775	rs12486377	ENSG00000277250.1	Metazoa_SRP	-4.44	3.22e-05	0.0468	-0.65	-0.46	Monocyte percentage of white cells;Monocyte count;	chr3:128696010	chr3:128673681~128674021:-
LAML	cis	rs5769707	0.632	rs135876	ENSG00000212939.2	RP1-29C18.10	-4.44	3.22e-05	0.0468	-0.66	-0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49619925	chr22:49548681~49556473:+
LAML	cis	rs7684446	1	rs7684446	ENSG00000249930.1	AC007016.3	4.44	3.22e-05	0.0468	0.59	0.46	Red blood cell count;	chr4:15591241	chr4:15492729~15492972:-
LAML	cis	rs1789	0.653	rs13142069	ENSG00000249930.1	AC007016.3	4.44	3.22e-05	0.0468	0.59	0.46	Blood protein levels;	chr4:15592069	chr4:15492729~15492972:-
LAML	cis	rs911186	0.74	rs6938200	ENSG00000187763.3	OR2B7P	4.44	3.22e-05	0.0468	0.59	0.46	Autism spectrum disorder or schizophrenia;	chr6:27263371	chr6:28046434~28047367:+
LAML	cis	rs763121	0.853	rs138712	ENSG00000230912.1	RP3-508I15.10	-4.44	3.22e-05	0.0468	-0.37	-0.46	Menopause (age at onset);	chr22:38745595	chr22:38666508~38668750:-
LAML	cis	rs3913363	0.632	rs9832169	ENSG00000243398.3	RN7SL141P	4.44	3.22e-05	0.0468	0.38	0.46	Response to angiotensin II receptor blocker therapy;	chr3:171928252	chr3:172237326~172237591:+
LAML	cis	rs3913363	0.666	rs9855075	ENSG00000243398.3	RN7SL141P	-4.44	3.22e-05	0.0468	-0.38	-0.46	Response to angiotensin II receptor blocker therapy;	chr3:171920272	chr3:172237326~172237591:+
LAML	cis	rs13113518	0.812	rs12500601	ENSG00000249700.7	SRD5A3-AS1	4.44	3.23e-05	0.0469	0.48	0.46	Height;	chr4:55451489	chr4:55363971~55395847:-
LAML	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	4.44	3.23e-05	0.047	0.57	0.46	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
LAML	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	4.44	3.23e-05	0.047	0.57	0.46	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
LAML	cis	rs2742417	1	rs2742368	ENSG00000244357.3	RN7SL145P	4.44	3.23e-05	0.047	0.49	0.46	Response to anti-depressant treatment in major depressive disorder;	chr3:45710801	chr3:45742675~45742970:+
LAML	cis	rs801193	1	rs13239306	ENSG00000224316.1	RP11-479O9.2	-4.43	3.25e-05	0.0471	-0.48	-0.46	Aortic root size;	chr7:66671030	chr7:65773620~65802067:+
LAML	cis	rs9916302	0.904	rs4511574	ENSG00000223091.1	RNU6-981P	-4.43	3.25e-05	0.0471	-0.55	-0.46	Glomerular filtration rate (creatinine);	chr17:39376663	chr17:39482486~39482590:-
LAML	cis	rs7131987	0.903	rs11050163	ENSG00000275278.1	RP11-946L16.2	4.43	3.25e-05	0.0471	0.57	0.46	QT interval;	chr12:29267465	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.903	rs10843373	ENSG00000275278.1	RP11-946L16.2	4.43	3.25e-05	0.0471	0.57	0.46	QT interval;	chr12:29267675	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.934	rs2216854	ENSG00000275278.1	RP11-946L16.2	4.43	3.25e-05	0.0471	0.57	0.46	QT interval;	chr12:29270527	chr12:29156448~29156991:-
LAML	cis	rs747782	0.537	rs10838835	ENSG00000263693.1	MIR3161	-4.43	3.25e-05	0.0472	-0.44	-0.46	Intraocular pressure;	chr11:48224905	chr11:48096782~48096858:+
LAML	cis	rs8067354	0.645	rs2102507	ENSG00000266960.1	FAM106DP	4.43	3.26e-05	0.0472	0.65	0.46	Hemoglobin concentration;	chr17:59798546	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.645	rs2645491	ENSG00000266960.1	FAM106DP	4.43	3.26e-05	0.0472	0.65	0.46	Hemoglobin concentration;	chr17:59799688	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.645	rs2665400	ENSG00000266960.1	FAM106DP	4.43	3.26e-05	0.0472	0.65	0.46	Hemoglobin concentration;	chr17:59802840	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.645	rs2645489	ENSG00000266960.1	FAM106DP	4.43	3.26e-05	0.0472	0.65	0.46	Hemoglobin concentration;	chr17:59806010	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.645	rs2645486	ENSG00000266960.1	FAM106DP	4.43	3.26e-05	0.0472	0.65	0.46	Hemoglobin concentration;	chr17:59808540	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.645	rs2645487	ENSG00000266960.1	FAM106DP	4.43	3.26e-05	0.0472	0.65	0.46	Hemoglobin concentration;	chr17:59808764	chr17:60173322~60173822:+
LAML	cis	rs1051424	0.642	rs115869798	ENSG00000266960.1	FAM106DP	4.43	3.26e-05	0.0472	0.65	0.46	Obesity-related traits;	chr17:59815468	chr17:60173322~60173822:+
LAML	cis	rs1051424	0.651	rs1292063	ENSG00000266960.1	FAM106DP	-4.43	3.26e-05	0.0472	-0.65	-0.46	Obesity-related traits;	chr17:59830407	chr17:60173322~60173822:+
LAML	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	4.43	3.26e-05	0.0473	0.55	0.46	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
LAML	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	4.43	3.26e-05	0.0473	0.55	0.46	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
LAML	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	4.43	3.26e-05	0.0473	0.55	0.46	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
LAML	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	4.43	3.26e-05	0.0473	0.55	0.46	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
LAML	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	4.43	3.26e-05	0.0473	0.55	0.46	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
LAML	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	4.43	3.26e-05	0.0473	0.55	0.46	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
LAML	cis	rs6502050	0.761	rs13949	ENSG00000266654.1	RP11-1376P16.1	4.43	3.27e-05	0.0473	0.54	0.46	Life satisfaction;	chr17:82101720	chr17:82160056~82160452:+
LAML	cis	rs8067354	0.645	rs2132715	ENSG00000266960.1	FAM106DP	4.43	3.27e-05	0.0474	0.71	0.46	Hemoglobin concentration;	chr17:59781013	chr17:60173322~60173822:+
LAML	cis	rs8067354	0.645	rs2173119	ENSG00000266960.1	FAM106DP	4.43	3.27e-05	0.0474	0.71	0.46	Hemoglobin concentration;	chr17:59782344	chr17:60173322~60173822:+
LAML	cis	rs8062405	0.964	rs11860513	ENSG00000271623.1	RP11-435I10.5	-4.43	3.27e-05	0.0474	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28364700~28365333:+
LAML	cis	rs8062405	1	rs1987472	ENSG00000271623.1	RP11-435I10.5	-4.43	3.27e-05	0.0474	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.895	rs56186137	ENSG00000271623.1	RP11-435I10.5	-4.43	3.27e-05	0.0474	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28364700~28365333:+
LAML	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	4.43	3.27e-05	0.0474	0.57	0.46	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
LAML	cis	rs716804	0.703	rs4910115	ENSG00000254719.1	RP11-351I24.3	-4.43	3.27e-05	0.0474	-0.57	-0.46	Neuroticism;	chr11:10247828	chr11:10272052~10272259:-
LAML	cis	rs12931792	0.782	rs12927190	ENSG00000273724.1	RP11-347C12.12	4.43	3.27e-05	0.0474	0.47	0.46	Tonsillectomy;	chr16:30158072	chr16:30336400~30343336:+
LAML	cis	rs12931792	0.782	rs13331817	ENSG00000273724.1	RP11-347C12.12	4.43	3.27e-05	0.0474	0.47	0.46	Tonsillectomy;	chr16:30161306	chr16:30336400~30343336:+
LAML	cis	rs2280018	0.609	rs2941253	ENSG00000260735.1	RP11-72I8.1	-4.43	3.28e-05	0.0474	-0.55	-0.46	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15079889	chr16:15094411~15109197:+
LAML	cis	rs7426056	0.671	rs10490574	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203743941	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.627	rs10497872	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203744551	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs62183989	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203744679	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs55828835	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203744832	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs2142371	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203745264	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs62183991	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203747193	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs62183992	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203748931	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs62184012	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203750953	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs62184013	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203752084	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.627	rs62184014	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203755891	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs62184015	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203755970	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs62184016	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203758758	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs56209416	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203762777	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.671	rs56216383	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203766989	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.627	rs10187250	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203777599	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.627	rs10211209	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203777810	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.627	rs55828908	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203779295	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.627	rs13406632	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203784615	chr2:203764295~203765593:-
LAML	cis	rs7426056	0.585	rs13404978	ENSG00000224791.1	KRT18P39	4.43	3.29e-05	0.0476	0.7	0.46	Primary sclerosing cholangitis;	chr2:203789163	chr2:203764295~203765593:-
LAML	cis	rs6968355	0.745	rs2430485	ENSG00000225329.2	LHFPL3-AS2	4.43	3.29e-05	0.0476	0.71	0.46	Myopia (pathological);	chr7:104942644	chr7:104894628~104926645:-
LAML	cis	rs7829975	0.593	rs2921051	ENSG00000249188.1	ENPP7P1	-4.43	3.29e-05	0.0476	-0.58	-0.46	Mood instability;	chr8:8462594	chr8:8154308~8216916:+
LAML	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-4.43	3.29e-05	0.0476	-0.48	-0.46	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.817	rs9311421	ENSG00000228638.1	FCF1P2	-4.43	3.29e-05	0.0476	-0.48	-0.46	Coronary artery disease;	chr3:48251588	chr3:48290793~48291375:-
LAML	cis	rs7617773	0.779	rs11718329	ENSG00000228638.1	FCF1P2	-4.43	3.29e-05	0.0476	-0.48	-0.46	Coronary artery disease;	chr3:48268338	chr3:48290793~48291375:-
LAML	cis	rs282544	1	rs1375128	ENSG00000271455.1	RP11-269M20.2	-4.43	3.3e-05	0.0477	-0.49	-0.46	Myopia (pathological);	chr5:50718840	chr5:50603229~50603511:+
LAML	cis	rs282544	1	rs10737958	ENSG00000271455.1	RP11-269M20.2	-4.43	3.3e-05	0.0477	-0.49	-0.46	Myopia (pathological);	chr5:50727540	chr5:50603229~50603511:+
LAML	cis	rs282544	1	rs2594708	ENSG00000271455.1	RP11-269M20.2	-4.43	3.3e-05	0.0477	-0.49	-0.46	Myopia (pathological);	chr5:50728834	chr5:50603229~50603511:+
LAML	cis	rs282544	1	rs2463796	ENSG00000271455.1	RP11-269M20.2	-4.43	3.3e-05	0.0477	-0.49	-0.46	Myopia (pathological);	chr5:50729856	chr5:50603229~50603511:+
LAML	cis	rs7932354	0.528	rs1872896	ENSG00000271350.1	CTD-2384B9.1	-4.43	3.3e-05	0.0477	-0.49	-0.46	Bone mineral density (hip);Bone mineral density;	chr11:47139072	chr11:47041027~47041945:-
LAML	cis	rs17270561	0.562	rs12199626	ENSG00000272462.2	U91328.19	-4.43	3.31e-05	0.0478	-0.66	-0.46	Iron status biomarkers;	chr6:26013376	chr6:25992662~26001775:+
LAML	cis	rs673078	0.607	rs17440956	ENSG00000275759.1	RP11-131L12.3	4.43	3.31e-05	0.0478	0.69	0.46	Glucose homeostasis traits;	chr12:118394639	chr12:118428281~118428870:+
LAML	cis	rs1555322	0.745	rs681147	ENSG00000279253.1	RP4-614O4.13	-4.43	3.31e-05	0.0478	-0.67	-0.46	Attention deficit hyperactivity disorder;	chr20:35216707	chr20:35262727~35264187:-
LAML	cis	rs282544	1	rs27934	ENSG00000213956.4	RP11-269M20.1	4.43	3.32e-05	0.0479	0.53	0.46	Myopia (pathological);	chr5:50823125	chr5:50633124~50633602:+
LAML	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-4.43	3.32e-05	0.0479	-0.82	-0.46	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
LAML	cis	rs301901	0.556	rs13176996	ENSG00000270558.1	CTD-2124B8.2	-4.43	3.32e-05	0.0479	-0.48	-0.46	Height;	chr5:37178659	chr5:37286449~37286977:-
LAML	cis	rs12554020	0.892	rs3815563	ENSG00000227603.1	RP11-165J3.6	4.43	3.32e-05	0.0479	0.66	0.46	Schizophrenia;	chr9:93450864	chr9:93435332~93437121:-
LAML	cis	rs12554020	1	rs7853605	ENSG00000227603.1	RP11-165J3.6	4.43	3.32e-05	0.0479	0.66	0.46	Schizophrenia;	chr9:93451247	chr9:93435332~93437121:-
LAML	cis	rs10463316	0.855	rs352701	ENSG00000260581.1	CTB-113P19.4	4.43	3.33e-05	0.0479	0.42	0.46	Metabolite levels (Pyroglutamine);	chr5:151356913	chr5:151652275~151655449:+
LAML	cis	rs10500715	0.529	rs11042563	ENSG00000254719.1	RP11-351I24.3	-4.43	3.33e-05	0.0479	-0.56	-0.46	Pancreatic cancer;	chr11:9942799	chr11:10272052~10272259:-
LAML	cis	rs10500715	0.529	rs11042564	ENSG00000254719.1	RP11-351I24.3	-4.43	3.33e-05	0.0479	-0.56	-0.46	Pancreatic cancer;	chr11:9942800	chr11:10272052~10272259:-
LAML	cis	rs7165170	0.706	rs8026105	ENSG00000259314.1	CTD-3065B20.3	-4.43	3.33e-05	0.0479	-0.48	-0.46	Crohn's disease;Inflammatory bowel disease;	chr15:90599653	chr15:90604225~90614558:-
LAML	cis	rs7165170	0.7	rs11631150	ENSG00000259314.1	CTD-3065B20.3	-4.43	3.33e-05	0.0479	-0.48	-0.46	Crohn's disease;Inflammatory bowel disease;	chr15:90600677	chr15:90604225~90614558:-
LAML	cis	rs853679	0.546	rs34676049	ENSG00000187763.3	OR2B7P	4.43	3.33e-05	0.0479	0.91	0.46	Depression;	chr6:28485841	chr6:28046434~28047367:+
LAML	cis	rs7131987	0.903	rs7974221	ENSG00000274315.1	RP11-996F15.5	4.43	3.33e-05	0.048	0.47	0.46	QT interval;	chr12:29246515	chr12:29331434~29331936:-
LAML	cis	rs7932354	0.528	rs6485739	ENSG00000271350.1	CTD-2384B9.1	-4.43	3.33e-05	0.048	-0.49	-0.46	Bone mineral density (hip);Bone mineral density;	chr11:47123521	chr11:47041027~47041945:-
LAML	cis	rs747650	0.926	rs10838659	ENSG00000271350.1	CTD-2384B9.1	-4.43	3.33e-05	0.048	-0.49	-0.46	Acne (severe);	chr11:47126659	chr11:47041027~47041945:-
LAML	cis	rs13098911	0.54	rs61650989	ENSG00000223552.1	RP11-24F11.2	-4.43	3.34e-05	0.048	-0.6	-0.46	Celiac disease;	chr3:46012664	chr3:46364955~46407059:-
LAML	cis	rs10463316	0.832	rs1019467	ENSG00000260581.1	CTB-113P19.4	4.43	3.34e-05	0.0481	0.42	0.46	Metabolite levels (Pyroglutamine);	chr5:151354762	chr5:151652275~151655449:+
LAML	cis	rs10829156	0.741	rs9731044	ENSG00000240291.1	RP11-499P20.2	4.43	3.35e-05	0.0481	0.66	0.46	Sudden cardiac arrest;	chr10:18605356	chr10:18513115~18545651:-
LAML	cis	rs10829156	0.538	rs61840846	ENSG00000240291.1	RP11-499P20.2	4.43	3.35e-05	0.0481	0.66	0.46	Sudden cardiac arrest;	chr10:18606393	chr10:18513115~18545651:-
LAML	cis	rs10463316	0.832	rs246484	ENSG00000260581.1	CTB-113P19.4	4.43	3.35e-05	0.0482	0.42	0.46	Metabolite levels (Pyroglutamine);	chr5:151351377	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.832	rs246483	ENSG00000260581.1	CTB-113P19.4	4.43	3.35e-05	0.0482	0.42	0.46	Metabolite levels (Pyroglutamine);	chr5:151351501	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.832	rs246486	ENSG00000260581.1	CTB-113P19.4	-4.43	3.35e-05	0.0482	-0.42	-0.46	Metabolite levels (Pyroglutamine);	chr5:151348319	chr5:151652275~151655449:+
LAML	cis	rs7849270	1	rs10819471	ENSG00000268707.1	RP11-247A12.7	-4.43	3.35e-05	0.0482	-0.55	-0.46	Blood metabolite ratios;	chr9:129134046	chr9:129170434~129170940:+
LAML	cis	rs2933343	0.859	rs789245	ENSG00000231305.3	RP11-723O4.2	4.43	3.36e-05	0.0483	0.57	0.46	IgG glycosylation;	chr3:128864737	chr3:128861313~128871540:-
LAML	cis	rs2933343	0.951	rs789218	ENSG00000231305.3	RP11-723O4.2	4.43	3.36e-05	0.0483	0.57	0.46	IgG glycosylation;	chr3:128873827	chr3:128861313~128871540:-
LAML	cis	rs6502050	0.712	rs8077079	ENSG00000266654.1	RP11-1376P16.1	4.43	3.36e-05	0.0483	0.54	0.46	Life satisfaction;	chr17:82101135	chr17:82160056~82160452:+
LAML	cis	rs9426935	0.816	rs12133492	ENSG00000273026.1	RP11-422P24.10	4.42	3.36e-05	0.0483	0.6	0.46	Lentiform nucleus volume;	chr1:153859689	chr1:153966516~153966930:+
LAML	cis	rs2404602	0.647	rs12903586	ENSG00000259422.1	RP11-593F23.1	-4.42	3.36e-05	0.0483	-0.57	-0.46	Blood metabolite levels;	chr15:76875899	chr15:76174891~76181486:-
LAML	cis	rs2404602	0.647	rs12903331	ENSG00000259422.1	RP11-593F23.1	-4.42	3.36e-05	0.0483	-0.57	-0.46	Blood metabolite levels;	chr15:76875927	chr15:76174891~76181486:-
LAML	cis	rs7714584	1	rs1428554	ENSG00000197083.10	ZNF300P1	4.42	3.36e-05	0.0483	0.9	0.46	Crohn's disease;	chr5:150878054	chr5:150930645~150946289:-
LAML	cis	rs7714584	1	rs7715981	ENSG00000197083.10	ZNF300P1	4.42	3.36e-05	0.0483	0.9	0.46	Crohn's disease;	chr5:150878545	chr5:150930645~150946289:-
LAML	cis	rs8054556	0.733	rs35467921	ENSG00000183604.13	SMG1P5	4.42	3.37e-05	0.0484	0.55	0.46	Autism spectrum disorder or schizophrenia;	chr16:30037232	chr16:30267553~30335374:-
LAML	cis	rs8054556	0.76	rs11642740	ENSG00000183604.13	SMG1P5	-4.42	3.37e-05	0.0484	-0.55	-0.46	Autism spectrum disorder or schizophrenia;	chr16:30049334	chr16:30267553~30335374:-
LAML	cis	rs4713118	0.539	rs200988	ENSG00000220721.1	OR1F12	4.42	3.37e-05	0.0484	0.48	0.46	Parkinson's disease;	chr6:27851575	chr6:28073316~28074233:+
LAML	cis	rs597539	0.597	rs35956171	ENSG00000250508.1	RP11-757G1.6	4.42	3.37e-05	0.0484	0.45	0.46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68835267	chr11:68870664~68874542:+
LAML	cis	rs28386778	1	rs2665810	ENSG00000240280.5	TCAM1P	-4.42	3.37e-05	0.0484	-0.64	-0.46	Prudent dietary pattern;	chr17:63892850	chr17:63849292~63864379:+
LAML	cis	rs10518325	0.585	rs10000812	ENSG00000250412.1	KLHL2P1	-4.42	3.37e-05	0.0485	-0.82	-0.46	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118349639	chr4:119334329~119378233:+
LAML	cis	rs9322193	0.847	rs12191643	ENSG00000216906.2	RP11-350J20.9	4.42	3.37e-05	0.0485	0.67	0.46	Lung cancer;	chr6:149628912	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs11155670	ENSG00000216906.2	RP11-350J20.9	4.42	3.37e-05	0.0485	0.67	0.46	Lung cancer;	chr6:149644992	chr6:149904243~149906418:+
LAML	cis	rs67311347	0.713	rs9861194	ENSG00000230274.1	PGAM1P3	4.42	3.38e-05	0.0485	0.59	0.46	Renal cell carcinoma;	chr3:40267734	chr3:40322715~40323279:-
LAML	cis	rs763121	0.853	rs138706	ENSG00000230912.1	RP3-508I15.10	-4.42	3.38e-05	0.0485	-0.37	-0.46	Menopause (age at onset);	chr22:38741829	chr22:38666508~38668750:-
LAML	cis	rs4713118	0.615	rs9348772	ENSG00000216915.2	RP1-97D16.1	-4.42	3.38e-05	0.0485	-0.51	-0.46	Parkinson's disease;	chr6:27688311	chr6:27737000~27738494:-
LAML	cis	rs67311347	0.506	rs55962832	ENSG00000230274.1	PGAM1P3	4.42	3.38e-05	0.0485	0.62	0.46	Renal cell carcinoma;	chr3:40202960	chr3:40322715~40323279:-
LAML	cis	rs7587476	0.906	rs62201985	ENSG00000227769.6	AC072062.3	-4.42	3.38e-05	0.0485	-0.58	-0.46	Neuroblastoma;	chr2:214793914	chr2:215004782~215085488:+
LAML	cis	rs1823874	0.581	rs9920347	ENSG00000182397.13	DNM1P46	4.42	3.38e-05	0.0486	0.59	0.46	IgG glycosylation;	chr15:99799126	chr15:99790156~99806927:-
LAML	cis	rs9952991	0.566	rs482160	ENSG00000260302.1	RP11-973H7.1	-4.42	3.39e-05	0.0486	-0.8	-0.46	Inflammatory skin disease;	chr18:12855647	chr18:12774651~12775923:-
LAML	cis	rs10457838	0.638	rs11155611	ENSG00000220848.4	RPS18P9	4.42	3.39e-05	0.0486	0.53	0.46	Post-traumatic stress disorder;	chr6:148997152	chr6:149594084~149594543:+
LAML	cis	rs13217239	0.646	rs7768407	ENSG00000241549.7	GUSBP2	4.42	3.39e-05	0.0486	0.48	0.46	Schizophrenia;	chr6:27049016	chr6:26871484~26956554:-
LAML	cis	rs13113518	0.812	rs13140173	ENSG00000223305.1	RN7SKP30	4.42	3.39e-05	0.0486	0.56	0.46	Height;	chr4:55527164	chr4:55540502~55540835:-
LAML	cis	rs13217239	0.646	rs62401067	ENSG00000241549.7	GUSBP2	4.42	3.39e-05	0.0487	0.48	0.46	Schizophrenia;	chr6:27050322	chr6:26871484~26956554:-
LAML	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-4.42	3.4e-05	0.0487	-0.57	-0.46	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-4.42	3.4e-05	0.0487	-0.57	-0.46	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
LAML	cis	rs2230307	0.908	rs529244	ENSG00000202259.1	RNU6-1318P	-4.42	3.4e-05	0.0487	-0.9	-0.46	Carotid intima media thickness;	chr1:100025919	chr1:100000637~100000739:-
LAML	cis	rs2230307	0.831	rs700531	ENSG00000202259.1	RNU6-1318P	-4.42	3.4e-05	0.0487	-0.9	-0.46	Carotid intima media thickness;	chr1:100027777	chr1:100000637~100000739:-
LAML	cis	rs2230307	0.831	rs559833	ENSG00000202259.1	RNU6-1318P	-4.42	3.4e-05	0.0487	-0.9	-0.46	Carotid intima media thickness;	chr1:100040150	chr1:100000637~100000739:-
LAML	cis	rs2230307	0.831	rs555778	ENSG00000202259.1	RNU6-1318P	-4.42	3.4e-05	0.0487	-0.9	-0.46	Carotid intima media thickness;	chr1:100040859	chr1:100000637~100000739:-
LAML	cis	rs2230307	0.831	rs528969	ENSG00000202259.1	RNU6-1318P	-4.42	3.4e-05	0.0487	-0.9	-0.46	Carotid intima media thickness;	chr1:100049251	chr1:100000637~100000739:-
LAML	cis	rs6686842	0.965	rs2802551	ENSG00000235358.1	RP11-399E6.1	4.42	3.4e-05	0.0487	0.5	0.46	Height;	chr1:41031771	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.866	rs2802550	ENSG00000235358.1	RP11-399E6.1	4.42	3.4e-05	0.0487	0.5	0.46	Height;	chr1:41031956	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.965	rs2802548	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41035441	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs6686842	ENSG00000235358.1	RP11-399E6.1	4.42	3.4e-05	0.0487	0.5	0.46	Height;	chr1:41065199	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.897	rs2802565	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41086147	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.965	rs2802566	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41086309	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.864	rs6662279	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41087889	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs6600365	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41090581	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.932	rs1008505	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41094563	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs6663565	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41098016	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs17571940	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41100519	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs479493	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41101530	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs656917	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41104036	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs213734	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41110027	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs213733	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41111317	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs213754	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41133176	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs213748	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41163058	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs213747	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41163066	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs2363803	ENSG00000235358.1	RP11-399E6.1	4.42	3.4e-05	0.0487	0.5	0.46	Height;	chr1:41171857	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs34454389	ENSG00000235358.1	RP11-399E6.1	4.42	3.4e-05	0.0487	0.5	0.46	Height;	chr1:41197564	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs11209718	ENSG00000235358.1	RP11-399E6.1	4.42	3.4e-05	0.0487	0.5	0.46	Height;	chr1:41223266	chr1:41242373~41284861:+
LAML	cis	rs6686842	1	rs12134073	ENSG00000235358.1	RP11-399E6.1	4.42	3.4e-05	0.0487	0.5	0.46	Height;	chr1:41223611	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.896	rs11209725	ENSG00000235358.1	RP11-399E6.1	4.42	3.4e-05	0.0487	0.5	0.46	Height;	chr1:41228345	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.965	rs1121866	ENSG00000235358.1	RP11-399E6.1	4.42	3.4e-05	0.0487	0.5	0.46	Height;	chr1:41242427	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.965	rs1472570	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41248412	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.965	rs10157966	ENSG00000235358.1	RP11-399E6.1	-4.42	3.4e-05	0.0487	-0.5	-0.46	Height;	chr1:41256904	chr1:41242373~41284861:+
LAML	cis	rs6686842	0.931	rs4360513	ENSG00000235358.1	RP11-399E6.1	4.42	3.41e-05	0.0488	0.5	0.46	Height;	chr1:41015127	chr1:41242373~41284861:+
LAML	cis	rs13217239	0.646	rs4269366	ENSG00000241549.7	GUSBP2	4.42	3.42e-05	0.0489	0.48	0.46	Schizophrenia;	chr6:27048634	chr6:26871484~26956554:-
LAML	cis	rs5769707	0.967	rs9616713	ENSG00000264139.1	MIR3667	-4.42	3.42e-05	0.0489	-0.59	-0.46	Monocyte percentage of white cells;Monocyte count;	chr22:49655461	chr22:49543393~49543466:-
LAML	cis	rs16828019	0.561	rs12025777	ENSG00000213987.4	RP11-399E6.2	4.42	3.42e-05	0.0489	0.89	0.46	Intelligence (multi-trait analysis);	chr1:41283225	chr1:41264550~41264862:-
LAML	cis	rs7301826	0.934	rs10848212	ENSG00000256299.1	RP11-989F5.3	4.42	3.42e-05	0.0489	0.56	0.46	Plasma plasminogen activator levels;	chr12:130837455	chr12:130810821~130812622:-
LAML	cis	rs564349	1	rs564109	ENSG00000204758.6	CTC-308K20.1	-4.42	3.42e-05	0.0489	-0.49	-0.46	Inflammatory bowel disease;Ulcerative colitis;	chr5:172897894	chr5:172954786~172959392:-
LAML	cis	rs7534824	1	rs111759324	ENSG00000213421.4	RP11-84O12.2	-4.42	3.42e-05	0.049	-1	-0.46	Refractive astigmatism;	chr1:101186966	chr1:100586649~100587431:-
LAML	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-4.42	3.43e-05	0.049	-0.46	-0.46	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
LAML	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-4.42	3.43e-05	0.049	-0.46	-0.46	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
LAML	cis	rs12052801	0.868	rs7586731	ENSG00000221443.1	AC017083.1	4.42	3.43e-05	0.049	0.55	0.46	Schizophrenia;	chr2:68136767	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.838	rs7560014	ENSG00000221443.1	AC017083.1	4.42	3.43e-05	0.049	0.55	0.46	Schizophrenia;	chr2:68136771	chr2:68273104~68273206:+
LAML	cis	rs1789	0.558	rs10021522	ENSG00000249930.1	AC007016.3	-4.42	3.43e-05	0.049	-0.59	-0.46	Blood protein levels;	chr4:15522985	chr4:15492729~15492972:-
LAML	cis	rs13113518	0.812	rs12505880	ENSG00000249700.7	SRD5A3-AS1	4.42	3.43e-05	0.0491	0.48	0.46	Height;	chr4:55440988	chr4:55363971~55395847:-
LAML	cis	rs13113518	0.783	rs6843722	ENSG00000223305.1	RN7SKP30	4.42	3.43e-05	0.0491	0.56	0.46	Height;	chr4:55465165	chr4:55540502~55540835:-
LAML	cis	rs28386778	0.897	rs2137144	ENSG00000240280.5	TCAM1P	-4.42	3.43e-05	0.0491	-0.63	-0.46	Prudent dietary pattern;	chr17:63728247	chr17:63849292~63864379:+
LAML	cis	rs6951245	0.832	rs79808627	ENSG00000229043.2	AC091729.9	-4.42	3.44e-05	0.0491	-0.69	-0.46	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1052883	chr7:1160374~1165267:+
LAML	cis	rs9426935	0.604	rs2790685	ENSG00000273026.1	RP11-422P24.10	-4.42	3.44e-05	0.0492	-0.59	-0.46	Lentiform nucleus volume;	chr1:154052717	chr1:153966516~153966930:+
LAML	cis	rs9426935	0.604	rs1819663	ENSG00000273026.1	RP11-422P24.10	-4.42	3.44e-05	0.0492	-0.59	-0.46	Lentiform nucleus volume;	chr1:154053415	chr1:153966516~153966930:+
LAML	cis	rs4853012	0.887	rs2122290	ENSG00000257800.1	FNBP1P1	4.42	3.44e-05	0.0492	0.77	0.46	Gestational age at birth (maternal effect);	chr2:74131774	chr2:74120680~74123218:+
LAML	cis	rs8031584	0.958	rs34294266	ENSG00000260382.1	RP11-540B6.2	4.42	3.46e-05	0.0493	0.55	0.46	Huntington's disease progression;	chr15:30954637	chr15:30882267~30883231:-
LAML	cis	rs67311347	1	rs1119179	ENSG00000230274.1	PGAM1P3	-4.42	3.46e-05	0.0494	-0.57	-0.46	Renal cell carcinoma;	chr3:40383438	chr3:40322715~40323279:-
LAML	cis	rs12052801	0.934	rs6738957	ENSG00000221443.1	AC017083.1	4.42	3.47e-05	0.0494	0.55	0.46	Schizophrenia;	chr2:68212828	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.739	rs10180892	ENSG00000221443.1	AC017083.1	4.42	3.47e-05	0.0494	0.55	0.46	Schizophrenia;	chr2:68216470	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.934	rs10191980	ENSG00000221443.1	AC017083.1	4.42	3.47e-05	0.0494	0.55	0.46	Schizophrenia;	chr2:68216519	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.934	rs10192179	ENSG00000221443.1	AC017083.1	4.42	3.47e-05	0.0494	0.55	0.46	Schizophrenia;	chr2:68216703	chr2:68273104~68273206:+
LAML	cis	rs12052801	0.967	rs10208241	ENSG00000221443.1	AC017083.1	4.42	3.47e-05	0.0494	0.55	0.46	Schizophrenia;	chr2:68219804	chr2:68273104~68273206:+
LAML	cis	rs2273156	0.5	rs17103104	ENSG00000241052.1	RP11-173D9.1	-4.42	3.48e-05	0.0494	-0.8	-0.46	Immunoglobulin light chain (AL) amyloidosis;	chr14:35221772	chr14:35144021~35144480:-
LAML	cis	rs1009077	0.716	rs13106925	ENSG00000178636.7	RP11-455G16.1	4.42	3.48e-05	0.0494	0.81	0.46	Endometriosis;	chr4:119617953	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.669	rs11730798	ENSG00000178636.7	RP11-455G16.1	4.42	3.48e-05	0.0494	0.81	0.46	Endometriosis;	chr4:119618704	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.626	rs11731568	ENSG00000178636.7	RP11-455G16.1	4.42	3.48e-05	0.0494	0.81	0.46	Endometriosis;	chr4:119618796	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs62319657	ENSG00000178636.7	RP11-455G16.1	4.42	3.48e-05	0.0494	0.81	0.46	Endometriosis;	chr4:119621367	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs13136296	ENSG00000178636.7	RP11-455G16.1	4.42	3.48e-05	0.0494	0.81	0.46	Endometriosis;	chr4:119622000	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs62319658	ENSG00000178636.7	RP11-455G16.1	4.42	3.48e-05	0.0494	0.81	0.46	Endometriosis;	chr4:119623849	chr4:119192773~119212644:-
LAML	cis	rs1009077	0.716	rs2892870	ENSG00000178636.7	RP11-455G16.1	4.42	3.48e-05	0.0494	0.81	0.46	Endometriosis;	chr4:119642218	chr4:119192773~119212644:-
LAML	cis	rs673078	0.607	rs61943443	ENSG00000275759.1	RP11-131L12.3	-4.42	3.48e-05	0.0494	-0.68	-0.46	Glucose homeostasis traits;	chr12:118416602	chr12:118428281~118428870:+
LAML	cis	rs56080343	0.808	rs1045552	ENSG00000275759.1	RP11-131L12.3	-4.42	3.48e-05	0.0494	-0.68	-0.46	Neuroticism;	chr12:118417678	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs7305647	ENSG00000275759.1	RP11-131L12.3	-4.42	3.48e-05	0.0494	-0.68	-0.46	Glucose homeostasis traits;	chr12:118417761	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs7132753	ENSG00000275759.1	RP11-131L12.3	-4.42	3.48e-05	0.0494	-0.68	-0.46	Glucose homeostasis traits;	chr12:118420383	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs61943444	ENSG00000275759.1	RP11-131L12.3	-4.42	3.48e-05	0.0494	-0.68	-0.46	Glucose homeostasis traits;	chr12:118421641	chr12:118428281~118428870:+
LAML	cis	rs673078	0.607	rs73207504	ENSG00000275759.1	RP11-131L12.3	-4.42	3.48e-05	0.0494	-0.68	-0.46	Glucose homeostasis traits;	chr12:118427914	chr12:118428281~118428870:+
LAML	cis	rs10463316	0.894	rs12153347	ENSG00000260581.1	CTB-113P19.4	4.42	3.48e-05	0.0494	0.42	0.46	Metabolite levels (Pyroglutamine);	chr5:151385910	chr5:151652275~151655449:+
LAML	cis	rs10463316	0.894	rs7707964	ENSG00000260581.1	CTB-113P19.4	4.42	3.48e-05	0.0494	0.42	0.46	Metabolite levels (Pyroglutamine);	chr5:151385914	chr5:151652275~151655449:+
LAML	cis	rs9322193	0.962	rs9688412	ENSG00000216906.2	RP11-350J20.9	-4.42	3.48e-05	0.0494	-0.62	-0.46	Lung cancer;	chr6:149803147	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9322206	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149641481	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9688750	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149657633	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs12175504	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149664079	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs35443312	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149670625	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs62439843	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149676521	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs35031906	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149677438	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs7753812	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149690150	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs12195866	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149693334	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9285524	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149694122	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs10872645	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149742840	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs12211511	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149745206	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9479810	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149751359	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs12175575	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149763351	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs4869966	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149763714	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs1112730	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149766383	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs1112729	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149766491	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs10452626	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149767481	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs62441303	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149767547	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9765929	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149769680	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs3805748	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149772542	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.736	rs10457851	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149775216	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.886	rs10872652	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149775303	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.886	rs12525871	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149775882	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.886	rs17672976	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149776207	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs2184369	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149776681	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs2342861	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149777561	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.926	rs2342860	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149777641	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs10872653	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149778907	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs11155683	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149779341	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9372044	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149780867	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs11155685	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149781649	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9322220	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149782897	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs10214845	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149783124	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9767122	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149783553	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs1413654	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149783956	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.683	rs113281309	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149787289	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9688809	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149787920	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9689242	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149787970	chr6:149904243~149906418:+
LAML	cis	rs9322193	1	rs9767077	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149788479	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs9688938	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149788941	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9688940	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149788977	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9689447	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149789350	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.632	rs3828700	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149791033	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs9689269	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149791861	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs62441335	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149792658	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs4816	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149793609	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs3805753	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149795662	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.926	rs952166	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149798774	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs952165	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149798900	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.926	rs9285525	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149801253	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs2342858	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149805967	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs6914319	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149806304	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs2095375	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149807037	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs4869730	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149808187	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs11155689	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149808470	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs2151913	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149809506	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs2342857	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149809537	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.884	rs933055	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149809701	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs4869731	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149810072	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs4552	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149811183	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs6899661	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149818093	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.923	rs14314	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149820395	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs2151912	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149831772	chr6:149904243~149906418:+
LAML	cis	rs9322193	0.962	rs7745915	ENSG00000216906.2	RP11-350J20.9	4.42	3.48e-05	0.0494	0.62	0.46	Lung cancer;	chr6:149834111	chr6:149904243~149906418:+
LAML	cis	rs8062405	1	rs4451951	ENSG00000271623.1	RP11-435I10.5	-4.42	3.48e-05	0.0494	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28364700~28365333:+
LAML	cis	rs7458938	0.659	rs7805133	ENSG00000224897.5	POT1-AS1	4.41	3.49e-05	0.0494	0.54	0.46	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr7:125798826	chr7:124929873~125179315:+
LAML	cis	rs782212	0.592	rs782240	ENSG00000227207.2	RPL31P12	-4.41	3.49e-05	0.0494	-0.76	-0.46	Depression;	chr1:72440702	chr1:72301472~72301829:+
LAML	cis	rs6940116	1	rs6940116	ENSG00000187763.3	OR2B7P	4.41	3.49e-05	0.0494	0.68	0.46	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28046434~28047367:+
LAML	cis	rs12922317	0.86	rs2541583	ENSG00000260224.1	UBL5P4	4.41	3.49e-05	0.0494	0.56	0.46	Schizophrenia;	chr16:12037264	chr16:11968508~11968743:-
LAML	cis	rs1150668	0.835	rs203869	ENSG00000220721.1	OR1F12	4.41	3.49e-05	0.0494	0.45	0.46	Pubertal anthropometrics;	chr6:28073041	chr6:28073316~28074233:+
LAML	cis	rs172166	0.56	rs203878	ENSG00000220721.1	OR1F12	4.41	3.49e-05	0.0494	0.45	0.46	Cardiac Troponin-T levels;	chr6:28081218	chr6:28073316~28074233:+
LAML	cis	rs172166	0.516	rs2791333	ENSG00000220721.1	OR1F12	4.41	3.49e-05	0.0494	0.45	0.46	Cardiac Troponin-T levels;	chr6:28143336	chr6:28073316~28074233:+
LAML	cis	rs172166	0.516	rs2622322	ENSG00000220721.1	OR1F12	4.41	3.49e-05	0.0494	0.45	0.46	Cardiac Troponin-T levels;	chr6:28149665	chr6:28073316~28074233:+
LAML	cis	rs172166	0.516	rs1225618	ENSG00000220721.1	OR1F12	4.41	3.49e-05	0.0494	0.45	0.46	Cardiac Troponin-T levels;	chr6:28161935	chr6:28073316~28074233:+
LAML	cis	rs172166	0.516	rs1150670	ENSG00000220721.1	OR1F12	4.41	3.49e-05	0.0494	0.45	0.46	Cardiac Troponin-T levels;	chr6:28162781	chr6:28073316~28074233:+
LAML	cis	rs172166	0.516	rs2021826	ENSG00000220721.1	OR1F12	4.41	3.49e-05	0.0494	0.45	0.46	Cardiac Troponin-T levels;	chr6:28164978	chr6:28073316~28074233:+
LAML	cis	rs1150668	0.835	rs1233696	ENSG00000220721.1	OR1F12	4.41	3.49e-05	0.0494	0.45	0.46	Pubertal anthropometrics;	chr6:28175232	chr6:28073316~28074233:+
LAML	cis	rs172166	0.538	rs1150686	ENSG00000220721.1	OR1F12	4.41	3.49e-05	0.0494	0.45	0.46	Cardiac Troponin-T levels;	chr6:28193493	chr6:28073316~28074233:+
LAML	cis	rs1150688	1	rs1150688	ENSG00000220721.1	OR1F12	4.41	3.49e-05	0.0494	0.45	0.46	Autism spectrum disorder or schizophrenia;	chr6:28195002	chr6:28073316~28074233:+
LAML	cis	rs172166	0.516	rs1225710	ENSG00000220721.1	OR1F12	-4.41	3.49e-05	0.0494	-0.45	-0.46	Cardiac Troponin-T levels;	chr6:28132862	chr6:28073316~28074233:+
LAML	cis	rs172166	0.516	rs1225715	ENSG00000220721.1	OR1F12	-4.41	3.49e-05	0.0494	-0.45	-0.46	Cardiac Troponin-T levels;	chr6:28145595	chr6:28073316~28074233:+
LAML	cis	rs2404602	0.647	rs36114653	ENSG00000259422.1	RP11-593F23.1	-4.41	3.49e-05	0.0495	-0.59	-0.46	Blood metabolite levels;	chr15:76733052	chr15:76174891~76181486:-
LAML	cis	rs2462686	1	rs2471553	ENSG00000229628.1	AC073115.7	-4.41	3.49e-05	0.0495	-0.59	-0.46	Major depressive disorder;	chr7:45938524	chr7:45990905~46000898:+
LAML	cis	rs6480314	0.542	rs7894859	ENSG00000234102.1	KRT19P4	-4.41	3.5e-05	0.0495	-0.74	-0.46	Optic nerve measurement (disc area);	chr10:68234620	chr10:68260557~68261499:+
LAML	cis	rs8062405	0.755	rs4788076	ENSG00000271623.1	RP11-435I10.5	-4.41	3.5e-05	0.0495	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.755	rs12445823	ENSG00000271623.1	RP11-435I10.5	-4.41	3.5e-05	0.0495	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.723	rs12445744	ENSG00000271623.1	RP11-435I10.5	-4.41	3.5e-05	0.0495	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.755	rs4787455	ENSG00000271623.1	RP11-435I10.5	-4.41	3.5e-05	0.0495	-0.52	-0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28364700~28365333:+
LAML	cis	rs8062405	0.755	rs4788074	ENSG00000271623.1	RP11-435I10.5	4.41	3.5e-05	0.0495	0.52	0.46	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28364700~28365333:+
LAML	cis	rs11790388	0.86	rs13298677	ENSG00000228487.2	RP13-225O21.2	4.41	3.5e-05	0.0496	0.61	0.46	Schizophrenia;	chr9:127100717	chr9:127213783~127221907:-
LAML	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	4.41	3.51e-05	0.0496	0.76	0.46	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
LAML	cis	rs6502050	0.787	rs8080682	ENSG00000266654.1	RP11-1376P16.1	4.41	3.51e-05	0.0496	0.54	0.46	Life satisfaction;	chr17:82101025	chr17:82160056~82160452:+
LAML	cis	rs881375	0.967	rs1930781	ENSG00000226752.6	PSMD5-AS1	-4.41	3.51e-05	0.0496	-0.57	-0.46	Rheumatoid arthritis;	chr9:120925556	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs2416806	ENSG00000226752.6	PSMD5-AS1	-4.41	3.51e-05	0.0496	-0.57	-0.46	Rheumatoid arthritis;	chr9:120928014	chr9:120824828~120854385:+
LAML	cis	rs881375	0.933	rs7028641	ENSG00000226752.6	PSMD5-AS1	-4.41	3.51e-05	0.0496	-0.57	-0.46	Rheumatoid arthritis;	chr9:120928863	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-4.41	3.51e-05	0.0496	-0.57	-0.46	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-4.41	3.51e-05	0.0496	-0.57	-0.46	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
LAML	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-4.41	3.51e-05	0.0496	-0.57	-0.46	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
LAML	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-4.41	3.51e-05	0.0496	-0.57	-0.46	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
LAML	cis	rs6686842	1	rs12125555	ENSG00000235358.1	RP11-399E6.1	4.41	3.52e-05	0.0497	0.5	0.46	Height;	chr1:41241439	chr1:41242373~41284861:+
LAML	cis	rs7944735	0.817	rs7101582	ENSG00000263693.1	MIR3161	4.41	3.52e-05	0.0497	0.37	0.46	Intraocular pressure;	chr11:47693058	chr11:48096782~48096858:+
LAML	cis	rs11039798	0.698	rs6485805	ENSG00000263693.1	MIR3161	4.41	3.52e-05	0.0498	0.48	0.46	Axial length;	chr11:48080171	chr11:48096782~48096858:+
LAML	cis	rs8067354	0.645	rs2645467	ENSG00000266960.1	FAM106DP	4.41	3.53e-05	0.0498	0.65	0.46	Hemoglobin concentration;	chr17:59777422	chr17:60173322~60173822:+
LAML	cis	rs7131987	0.621	rs3782506	ENSG00000275278.1	RP11-946L16.2	-4.41	3.53e-05	0.0498	-0.59	-0.46	QT interval;	chr12:29292489	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.621	rs6487805	ENSG00000275278.1	RP11-946L16.2	-4.41	3.53e-05	0.0498	-0.59	-0.46	QT interval;	chr12:29304617	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.65	rs6487808	ENSG00000275278.1	RP11-946L16.2	-4.41	3.53e-05	0.0498	-0.59	-0.46	QT interval;	chr12:29310426	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.65	rs4331146	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29287150	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.65	rs67146951	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29297620	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.65	rs10843382	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29298788	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.65	rs3782509	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29300845	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.65	rs7301398	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29302457	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.65	rs7301188	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29302458	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.65	rs7957339	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29303562	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.683	rs7954278	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29306357	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.65	rs7954871	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29306799	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.65	rs7973786	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29309811	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.718	rs7976961	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29310155	chr12:29156448~29156991:-
LAML	cis	rs7131987	0.621	rs11050181	ENSG00000275278.1	RP11-946L16.2	4.41	3.53e-05	0.0498	0.59	0.46	QT interval;	chr12:29314736	chr12:29156448~29156991:-
LAML	cis	rs2243480	1	rs410128	ENSG00000226824.5	RP4-756H11.3	-4.41	3.54e-05	0.0499	-0.83	-0.46	Diabetic kidney disease;	chr7:66138186	chr7:66654538~66669855:+
LAML	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	4.41	3.54e-05	0.0499	0.56	0.46	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
LAML	cis	rs1153858	1	rs2056493	ENSG00000259520.4	CTD-2651B20.3	-4.41	3.54e-05	0.0499	-0.67	-0.46	Homoarginine levels;	chr15:45356074	chr15:45251580~45279251:-
LAML	cis	rs2242330	0.705	rs7670716	ENSG00000248049.5	UBA6-AS1	-4.41	3.55e-05	0.0499	-0.45	-0.46	Parkinson's disease;	chr4:67582656	chr4:67701280~68080952:+
LAML	cis	rs2242330	0.651	rs7692528	ENSG00000248049.5	UBA6-AS1	-4.41	3.55e-05	0.0499	-0.45	-0.46	Parkinson's disease;	chr4:67589584	chr4:67701280~68080952:+
LAML	cis	rs2242330	0.651	rs10050076	ENSG00000248049.5	UBA6-AS1	4.41	3.55e-05	0.0499	0.45	0.46	Parkinson's disease;	chr4:67589682	chr4:67701280~68080952:+
LAML	cis	rs367615	0.552	rs2416210	ENSG00000249476.1	CTD-2587M2.1	-4.41	3.55e-05	0.05	-0.51	-0.46	Colorectal cancer (SNP x SNP interaction);	chr5:109405436	chr5:109237120~109326369:-
LAML	cis	rs7511633	0.621	rs11102800	ENSG00000225650.2	EIF2S2P5	4.41	3.55e-05	0.05	0.35	0.46	Autism;	chr1:114498310	chr1:114468315~114469282:+
LAML	cis	rs7534824	0.86	rs7513526	ENSG00000213421.4	RP11-84O12.2	-4.41	3.55e-05	0.05	-0.96	-0.46	Refractive astigmatism;	chr1:101137894	chr1:100586649~100587431:-
LAML	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	4.41	3.55e-05	0.05	0.69	0.46	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
LAML	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	4.41	3.55e-05	0.05	0.69	0.46	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
LAML	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	4.41	3.55e-05	0.05	0.69	0.46	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
LAML	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	4.41	3.55e-05	0.05	0.69	0.46	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
LAML	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	4.41	3.55e-05	0.05	0.69	0.46	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
LAML	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	4.41	3.55e-05	0.05	0.69	0.46	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
LAML	cis	rs9322193	0.884	rs9397036	ENSG00000217733.2	CCT7P1	4.41	3.55e-05	0.05	0.73	0.46	Lung cancer;	chr6:149851787	chr6:149879962~149881572:+
LAML	cis	rs9322193	0.884	rs9383864	ENSG00000217733.2	CCT7P1	4.41	3.55e-05	0.05	0.73	0.46	Lung cancer;	chr6:149851969	chr6:149879962~149881572:+
LAML	cis	rs9322193	0.884	rs9383865	ENSG00000217733.2	CCT7P1	4.41	3.55e-05	0.05	0.73	0.46	Lung cancer;	chr6:149852043	chr6:149879962~149881572:+
LAML	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	4.41	3.56e-05	0.05	0.57	0.46	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
LAML	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	23.08	5.37e-35	3.72e-24	1.25	0.94	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	22.58	2.14e-34	3.72e-24	1.25	0.94	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	22.58	2.14e-34	3.72e-24	1.25	0.94	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	22.57	2.22e-34	3.72e-24	1.25	0.94	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	22.57	2.22e-34	3.72e-24	1.25	0.94	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	22.45	3.05e-34	4.4e-24	1.24	0.94	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	21.17	1.23e-32	1.24e-22	1.22	0.93	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	21.17	1.23e-32	1.24e-22	1.22	0.93	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	20.65	5.72e-32	4.8e-22	1.22	0.92	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	20.2	2.21e-31	1.19e-21	1.24	0.92	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	20.19	2.25e-31	1.19e-21	1.22	0.92	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	20.19	2.25e-31	1.19e-21	1.22	0.92	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	20.15	2.56e-31	1.23e-21	1.22	0.92	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.622	rs34894392	ENSG00000186676.3	EEF1GP1	19.51	1.82e-30	7.99e-21	1.22	0.92	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62607349	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-19.21	4.71e-30	1.98e-20	-1.22	-0.91	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	19.04	8.05e-30	2.92e-20	1.2	0.91	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	19.04	8.05e-30	2.92e-20	1.2	0.91	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	19	8.99e-30	2.92e-20	1.2	0.91	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	19	8.99e-30	2.92e-20	1.2	0.91	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	18.89	1.28e-29	4.02e-20	1.22	0.91	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	18.83	1.59e-29	4.84e-20	1.22	0.91	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	18.7	2.35e-29	6.96e-20	1.2	0.91	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-18.43	5.7e-29	1.6e-19	-1.25	-0.91	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
LAML	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-18.43	5.7e-29	1.6e-19	-1.25	-0.91	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
LAML	trans	rs916888	0.773	rs199447	ENSG00000280022.1	RP11-707O23.1	17.09	4.86e-27	3.08e-18	1.24	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs199448	ENSG00000263503.1	RP11-707O23.5	17.04	5.63e-27	3.24e-18	1.22	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199445	ENSG00000263503.1	RP11-707O23.5	17.04	5.63e-27	3.24e-18	1.22	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199443	ENSG00000263503.1	RP11-707O23.5	17.04	5.63e-27	3.24e-18	1.22	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199534	ENSG00000263503.1	RP11-707O23.5	17.04	5.63e-27	3.24e-18	1.22	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199533	ENSG00000263503.1	RP11-707O23.5	17.04	5.63e-27	3.24e-18	1.22	0.9	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199535	ENSG00000263503.1	RP11-707O23.5	17	6.54e-27	3.74e-18	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199451	ENSG00000263503.1	RP11-707O23.5	16.99	6.73e-27	3.83e-18	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45600869~45602340:-
LAML	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	16.94	8.08e-27	4.57e-18	1.2	0.89	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
LAML	trans	rs916888	0.773	rs199457	ENSG00000263503.1	RP11-707O23.5	16.91	8.97e-27	5.02e-18	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45600869~45602340:-
LAML	trans	rs916888	0.687	rs199456	ENSG00000263503.1	RP11-707O23.5	16.91	8.97e-27	5.02e-18	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199439	ENSG00000263503.1	RP11-707O23.5	16.87	1.03e-26	5.72e-18	1.24	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199448	ENSG00000280022.1	RP11-707O23.1	16.76	1.45e-26	7.63e-18	1.22	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs199445	ENSG00000280022.1	RP11-707O23.1	16.76	1.45e-26	7.63e-18	1.22	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs199443	ENSG00000280022.1	RP11-707O23.1	16.76	1.45e-26	7.63e-18	1.22	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs199534	ENSG00000280022.1	RP11-707O23.1	16.76	1.45e-26	7.63e-18	1.22	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs199533	ENSG00000280022.1	RP11-707O23.1	16.76	1.45e-26	7.63e-18	1.22	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45592621~45593369:+
LAML	trans	rs916888	0.779	rs199528	ENSG00000280022.1	RP11-707O23.1	16.55	3.08e-26	1.6e-17	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs199525	ENSG00000280022.1	RP11-707O23.1	16.55	3.08e-26	1.6e-17	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs199457	ENSG00000280022.1	RP11-707O23.1	16.45	4.27e-26	2.19e-17	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45592621~45593369:+
LAML	trans	rs916888	0.687	rs199456	ENSG00000280022.1	RP11-707O23.1	16.45	4.27e-26	2.19e-17	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs1378358	ENSG00000263503.1	RP11-707O23.5	16.37	5.75e-26	2.88e-17	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs538628	ENSG00000263503.1	RP11-707O23.5	16.37	5.75e-26	2.88e-17	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs169201	ENSG00000263503.1	RP11-707O23.5	16.37	5.75e-26	2.88e-17	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45600869~45602340:-
LAML	trans	rs916888	0.821	rs199506	ENSG00000263503.1	RP11-707O23.5	-16.25	8.55e-26	4.2e-17	-1.2	-0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199447	ENSG00000263503.1	RP11-707O23.5	16.24	8.89e-26	4.35e-17	1.23	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45600869~45602340:-
LAML	trans	rs916888	0.779	rs199528	ENSG00000263503.1	RP11-707O23.5	16.23	9.21e-26	4.46e-17	1.22	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45600869~45602340:-
LAML	trans	rs916888	0.821	rs199525	ENSG00000263503.1	RP11-707O23.5	16.23	9.21e-26	4.46e-17	1.22	0.89	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199451	ENSG00000280022.1	RP11-707O23.1	16.09	1.5e-25	7.16e-17	1.22	0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs199506	ENSG00000280022.1	RP11-707O23.1	-16.01	2.02e-25	9.61e-17	-1.2	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs199439	ENSG00000280022.1	RP11-707O23.1	15.82	3.93e-25	1.82e-16	1.23	0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs415430	ENSG00000280022.1	RP11-707O23.1	-15.8	4.25e-25	1.95e-16	-1.25	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45592621~45593369:+
LAML	trans	rs916888	0.779	rs430685	ENSG00000280022.1	RP11-707O23.1	-15.8	4.25e-25	1.95e-16	-1.25	-0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45592621~45593369:+
LAML	trans	rs13177918	0.677	rs4841	ENSG00000213058.3	RP4-765C7.2	15.7	6.06e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs13183077	ENSG00000213058.3	RP4-765C7.2	15.7	6.06e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs3797622	ENSG00000213058.3	RP4-765C7.2	15.7	6.06e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs13161099	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.629	rs13161261	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs13161417	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs13161156	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs13181401	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs4541646	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs3900644	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs2070844	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs2073472	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.629	rs2070842	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs13171800	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs2070841	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs13177951	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs13177970	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs13164105	ENSG00000213058.3	RP4-765C7.2	15.69	6.28e-25	2.57e-16	1.28	0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs3857421	ENSG00000213058.3	RP4-765C7.2	-15.69	6.28e-25	2.57e-16	-1.28	-0.88	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr1:178411616~178411972:+
LAML	trans	rs7949030	0.695	rs11231161	ENSG00000186676.3	EEF1GP1	15.51	1.18e-24	4.78e-16	1.24	0.88	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62610749	chr7:125033453~125035301:+
LAML	trans	rs916888	0.821	rs70600	ENSG00000280022.1	RP11-707O23.1	15.47	1.39e-24	5.53e-16	1.21	0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45592621~45593369:+
LAML	trans	rs7949030	0.725	rs12808829	ENSG00000186676.3	EEF1GP1	15.43	1.59e-24	6.31e-16	1.26	0.88	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62611188	chr7:125033453~125035301:+
LAML	trans	rs916888	0.773	rs9896243	ENSG00000263503.1	RP11-707O23.5	15.41	1.72e-24	6.8e-16	1.19	0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs1378358	ENSG00000280022.1	RP11-707O23.1	15.36	2.02e-24	7.84e-16	1.22	0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs538628	ENSG00000280022.1	RP11-707O23.1	15.36	2.02e-24	7.84e-16	1.22	0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs169201	ENSG00000280022.1	RP11-707O23.1	15.36	2.02e-24	7.84e-16	1.22	0.88	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45592621~45593369:+
LAML	trans	rs916888	0.738	rs199515	ENSG00000280022.1	RP11-707O23.1	-15.33	2.26e-24	8.48e-16	-1.44	-0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45592621~45593369:+
LAML	trans	rs916888	0.697	rs199516	ENSG00000280022.1	RP11-707O23.1	-15.31	2.47e-24	8.99e-16	-1.19	-0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs199514	ENSG00000280022.1	RP11-707O23.1	-15.31	2.47e-24	8.99e-16	-1.19	-0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs199513	ENSG00000280022.1	RP11-707O23.1	-15.31	2.47e-24	8.99e-16	-1.19	-0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs199512	ENSG00000280022.1	RP11-707O23.1	-15.31	2.47e-24	8.99e-16	-1.19	-0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs199509	ENSG00000280022.1	RP11-707O23.1	-15.31	2.47e-24	8.99e-16	-1.19	-0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs199507	ENSG00000280022.1	RP11-707O23.1	-15.31	2.47e-24	8.99e-16	-1.19	-0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs199505	ENSG00000280022.1	RP11-707O23.1	-15.31	2.47e-24	8.99e-16	-1.19	-0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs70602	ENSG00000280022.1	RP11-707O23.1	-15.31	2.47e-24	8.99e-16	-1.19	-0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45592621~45593369:+
LAML	trans	rs916888	0.773	rs199535	ENSG00000280022.1	RP11-707O23.1	15.22	3.41e-24	1.23e-15	1.21	0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45592621~45593369:+
LAML	trans	rs916888	0.821	rs199504	ENSG00000280022.1	RP11-707O23.1	-14.84	1.33e-23	4.64e-15	-1.19	-0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45592621~45593369:+
LAML	trans	rs13177918	0.626	rs12186649	ENSG00000213058.3	RP4-765C7.2	14.84	1.33e-23	4.64e-15	1.27	0.87	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr1:178411616~178411972:+
LAML	trans	rs916888	0.821	rs70600	ENSG00000263503.1	RP11-707O23.5	14.75	1.87e-23	6.45e-15	1.19	0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs9896243	ENSG00000280022.1	RP11-707O23.1	14.65	2.76e-23	9.46e-15	1.18	0.87	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45592621~45593369:+
LAML	trans	rs916888	0.697	rs199516	ENSG00000263503.1	RP11-707O23.5	-14.5	4.72e-23	1.57e-14	-1.17	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45600869~45602340:-
LAML	trans	rs916888	0.821	rs199514	ENSG00000263503.1	RP11-707O23.5	-14.5	4.72e-23	1.57e-14	-1.17	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45600869~45602340:-
LAML	trans	rs916888	0.821	rs199513	ENSG00000263503.1	RP11-707O23.5	-14.5	4.72e-23	1.57e-14	-1.17	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45600869~45602340:-
LAML	trans	rs916888	0.821	rs199512	ENSG00000263503.1	RP11-707O23.5	-14.5	4.72e-23	1.57e-14	-1.17	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45600869~45602340:-
LAML	trans	rs916888	0.821	rs199509	ENSG00000263503.1	RP11-707O23.5	-14.5	4.72e-23	1.57e-14	-1.17	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45600869~45602340:-
LAML	trans	rs916888	0.821	rs199507	ENSG00000263503.1	RP11-707O23.5	-14.5	4.72e-23	1.57e-14	-1.17	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45600869~45602340:-
LAML	trans	rs916888	0.821	rs199505	ENSG00000263503.1	RP11-707O23.5	-14.5	4.72e-23	1.57e-14	-1.17	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45600869~45602340:-
LAML	trans	rs916888	0.821	rs70602	ENSG00000263503.1	RP11-707O23.5	-14.5	4.72e-23	1.57e-14	-1.17	-0.86	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45600869~45602340:-
LAML	trans	rs13177918	0.686	rs12654827	ENSG00000213058.3	RP4-765C7.2	14.35	8.32e-23	2.69e-14	1.25	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.677	rs13160685	ENSG00000213058.3	RP4-765C7.2	14.35	8.32e-23	2.69e-14	1.25	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr1:178411616~178411972:+
LAML	trans	rs1816752	0.905	rs1050112	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24435159	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs13428	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24435303	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs8000215	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24435648	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs11839006	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24435893	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs2033955	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24436406	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs2033954	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24436429	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs9511260	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24437038	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs7320102	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24437435	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs7339140	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24437764	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs9511261	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24437880	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs9511262	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24437885	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs9511266	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24438366	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.817	rs7985394	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24438714	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.789	rs7986037	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24438715	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs7995909	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24439159	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs6490927	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24439802	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs6490928	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24439921	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs6490929	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24440114	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs3825449	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24440303	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs7998797	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24440850	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs7981337	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24440915	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs7981480	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24440966	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.837	rs4769355	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24441059	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs4770680	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24441110	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.805	rs61614647	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24441829	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.774	rs55888616	ENSG00000237917.1	PARP4P1	14.27	1.11e-22	3.22e-14	1.17	0.86	Obesity-related traits;	chr13:24441954	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs9511264	ENSG00000237917.1	PARP4P1	-14.27	1.11e-22	3.22e-14	-1.17	-0.86	Obesity-related traits;	chr13:24438079	chrY:26594851~26634652:-
LAML	trans	rs13177918	0.75	rs58256223	ENSG00000213058.3	RP4-765C7.2	14.26	1.16e-22	3.33e-14	1.18	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.75	rs59354956	ENSG00000213058.3	RP4-765C7.2	14.26	1.16e-22	3.33e-14	1.18	0.86	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.651	rs13184111	ENSG00000213058.3	RP4-765C7.2	13.94	3.84e-22	1.08e-13	1.3	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	13.89	4.7e-22	1.32e-13	1.28	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
LAML	trans	rs1816752	0.633	rs9578729	ENSG00000237917.1	PARP4P1	13.8	6.5e-22	1.82e-13	1.16	0.85	Obesity-related traits;	chr13:24425106	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs7995492	ENSG00000237917.1	PARP4P1	13.79	6.72e-22	1.87e-13	1.17	0.85	Obesity-related traits;	chr13:24438885	chrY:26594851~26634652:-
LAML	trans	rs916888	0.61	rs199529	ENSG00000280022.1	RP11-707O23.1	13.78	7.14e-22	1.98e-13	1.14	0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45592621~45593369:+
LAML	trans	rs1816752	0.806	rs3816218	ENSG00000237917.1	PARP4P1	13.73	8.57e-22	2.36e-13	1.16	0.85	Obesity-related traits;	chr13:24443033	chrY:26594851~26634652:-
LAML	trans	rs916888	0.821	rs415430	ENSG00000263503.1	RP11-707O23.5	-13.72	9e-22	2.46e-13	-1.2	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45600869~45602340:-
LAML	trans	rs916888	0.779	rs430685	ENSG00000263503.1	RP11-707O23.5	-13.72	9e-22	2.46e-13	-1.2	-0.85	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45600869~45602340:-
LAML	trans	rs13177918	0.677	rs57890152	ENSG00000213058.3	RP4-765C7.2	13.66	1.13e-21	3.09e-13	1.24	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr1:178411616~178411972:+
LAML	trans	rs1816752	0.87	rs73469543	ENSG00000237917.1	PARP4P1	13.64	1.23e-21	3.33e-13	1.15	0.85	Obesity-related traits;	chr13:24424832	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.776	rs9511268	ENSG00000237917.1	PARP4P1	13.57	1.57e-21	4.23e-13	1.17	0.85	Obesity-related traits;	chr13:24444182	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.666	rs7994022	ENSG00000237917.1	PARP4P1	13.55	1.69e-21	4.46e-13	1.17	0.85	Obesity-related traits;	chr13:24443092	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.776	rs7998843	ENSG00000237917.1	PARP4P1	13.55	1.69e-21	4.46e-13	1.17	0.85	Obesity-related traits;	chr13:24443147	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.712	rs6490932	ENSG00000237917.1	PARP4P1	13.55	1.69e-21	4.46e-13	1.17	0.85	Obesity-related traits;	chr13:24443313	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.713	rs7336357	ENSG00000237917.1	PARP4P1	13.55	1.69e-21	4.46e-13	1.17	0.85	Obesity-related traits;	chr13:24443452	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.683	rs7330532	ENSG00000237917.1	PARP4P1	13.55	1.69e-21	4.46e-13	1.17	0.85	Obesity-related traits;	chr13:24443453	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.59	rs61947036	ENSG00000237917.1	PARP4P1	13.55	1.69e-21	4.46e-13	1.17	0.85	Obesity-related traits;	chr13:24443544	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.746	rs9511270	ENSG00000237917.1	PARP4P1	13.55	1.69e-21	4.46e-13	1.17	0.85	Obesity-related traits;	chr13:24444542	chrY:26594851~26634652:-
LAML	trans	rs6477998	0.58	rs9299214	ENSG00000238072.1	RP11-305M3.2	13.09	1.02e-20	2.61e-12	1.2	0.84	Hematology traits;	chr9:113273416	chr7:129410113~129410370:-
LAML	trans	rs6477998	0.603	rs10117451	ENSG00000238072.1	RP11-305M3.2	13.09	1.02e-20	2.61e-12	1.2	0.84	Hematology traits;	chr9:113273610	chr7:129410113~129410370:-
LAML	trans	rs916888	0.773	rs199535	ENSG00000214425.5	LRRC37A4P	-13.09	1.02e-20	2.61e-12	-1.22	-0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45506741~45550335:-
LAML	trans	rs6477998	0.535	rs3750535	ENSG00000238072.1	RP11-305M3.2	12.99	1.49e-20	3.74e-12	1.19	0.84	Hematology traits;	chr9:113297453	chr7:129410113~129410370:-
LAML	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	12.99	1.49e-20	3.74e-12	1.19	0.84	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
LAML	trans	rs916888	0.821	rs199504	ENSG00000263503.1	RP11-707O23.5	-12.96	1.68e-20	4.21e-12	-1.14	-0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45600869~45602340:-
LAML	trans	rs1816752	0.905	rs1348110	ENSG00000237917.1	PARP4P1	12.94	1.8e-20	4.5e-12	1.16	0.84	Obesity-related traits;	chr13:24406537	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs2000153	ENSG00000237917.1	PARP4P1	12.92	2e-20	4.96e-12	1.16	0.84	Obesity-related traits;	chr13:24405752	chrY:26594851~26634652:-
LAML	trans	rs916888	0.773	rs199448	ENSG00000214425.5	LRRC37A4P	-12.88	2.27e-20	5.56e-12	-1.21	-0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs199445	ENSG00000214425.5	LRRC37A4P	-12.88	2.27e-20	5.56e-12	-1.21	-0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs199443	ENSG00000214425.5	LRRC37A4P	-12.88	2.27e-20	5.56e-12	-1.21	-0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs199534	ENSG00000214425.5	LRRC37A4P	-12.88	2.27e-20	5.56e-12	-1.21	-0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs199533	ENSG00000214425.5	LRRC37A4P	-12.88	2.27e-20	5.56e-12	-1.21	-0.84	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45506741~45550335:-
LAML	trans	rs1816752	0.875	rs1050110	ENSG00000237917.1	PARP4P1	12.85	2.61e-20	6.37e-12	1.14	0.83	Obesity-related traits;	chr13:24435347	chrY:26594851~26634652:-
LAML	trans	rs916888	0.773	rs199447	ENSG00000214425.5	LRRC37A4P	-12.84	2.72e-20	6.62e-12	-1.22	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45506741~45550335:-
LAML	trans	rs13177918	0.578	rs35919198	ENSG00000213058.3	RP4-765C7.2	12.83	2.75e-20	6.68e-12	1.19	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr1:178411616~178411972:+
LAML	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	12.79	3.33e-20	8.01e-12	1.18	0.83	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
LAML	trans	rs916888	0.61	rs199529	ENSG00000263503.1	RP11-707O23.5	12.73	4.2e-20	1e-11	1.11	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199457	ENSG00000214425.5	LRRC37A4P	-12.68	5.15e-20	1.23e-11	-1.22	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45506741~45550335:-
LAML	trans	rs916888	0.687	rs199456	ENSG00000214425.5	LRRC37A4P	-12.68	5.15e-20	1.23e-11	-1.22	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs199451	ENSG00000214425.5	LRRC37A4P	-12.63	6.18e-20	1.47e-11	-1.21	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45506741~45550335:-
LAML	trans	rs1816752	0.719	rs11841989	ENSG00000237917.1	PARP4P1	12.58	7.41e-20	1.74e-11	1.15	0.83	Obesity-related traits;	chr13:24423560	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.638	rs9578730	ENSG00000237917.1	PARP4P1	12.58	7.41e-20	1.74e-11	1.15	0.83	Obesity-related traits;	chr13:24425545	chrY:26594851~26634652:-
LAML	trans	rs916888	0.773	rs1378358	ENSG00000214425.5	LRRC37A4P	-12.54	8.67e-20	2.01e-11	-1.22	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs538628	ENSG00000214425.5	LRRC37A4P	-12.54	8.67e-20	2.01e-11	-1.22	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs169201	ENSG00000214425.5	LRRC37A4P	-12.54	8.67e-20	2.01e-11	-1.22	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45506741~45550335:-
LAML	trans	rs1816752	0.905	rs4769348	ENSG00000237917.1	PARP4P1	12.51	9.86e-20	2.26e-11	1.15	0.83	Obesity-related traits;	chr13:24400975	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs8002309	ENSG00000237917.1	PARP4P1	12.51	9.86e-20	2.26e-11	1.15	0.83	Obesity-related traits;	chr13:24402217	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs4770666	ENSG00000237917.1	PARP4P1	12.47	1.18e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24414891	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs7400631	ENSG00000237917.1	PARP4P1	12.47	1.18e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24415927	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs8002215	ENSG00000237917.1	PARP4P1	12.47	1.18e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24416229	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs9511242	ENSG00000237917.1	PARP4P1	12.47	1.18e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24419261	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs7317850	ENSG00000237917.1	PARP4P1	12.47	1.18e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24419899	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs9581025	ENSG00000237917.1	PARP4P1	12.47	1.18e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24423687	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs9581026	ENSG00000237917.1	PARP4P1	12.47	1.18e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24423788	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs9581027	ENSG00000237917.1	PARP4P1	12.47	1.18e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24423790	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.87	rs9318529	ENSG00000237917.1	PARP4P1	12.47	1.18e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24424190	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs9511249	ENSG00000237917.1	PARP4P1	12.47	1.18e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24425457	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.837	rs7139748	ENSG00000237917.1	PARP4P1	12.46	1.19e-19	2.63e-11	1.15	0.83	Obesity-related traits;	chr13:24411531	chrY:26594851~26634652:-
LAML	trans	rs916888	0.773	rs199457	ENSG00000264057.1	RP11-583F2.1	12.45	1.26e-19	2.76e-11	1.16	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:64927634~64934203:+
LAML	trans	rs916888	0.687	rs199456	ENSG00000264057.1	RP11-583F2.1	12.45	1.26e-19	2.76e-11	1.16	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:64927634~64934203:+
LAML	trans	rs916888	0.773	rs199439	ENSG00000214425.5	LRRC37A4P	-12.43	1.33e-19	2.93e-11	-1.21	-0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs199447	ENSG00000264057.1	RP11-583F2.1	12.43	1.35e-19	2.97e-11	1.16	0.83	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:64927634~64934203:+
LAML	trans	rs13177918	0.603	rs13175992	ENSG00000213058.3	RP4-765C7.2	12.41	1.5e-19	3.25e-11	1.18	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr1:178411616~178411972:+
LAML	trans	rs916888	0.61	rs199454	ENSG00000263503.1	RP11-707O23.5	-12.3	2.3e-19	4.93e-11	-1.05	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45600869~45602340:-
LAML	trans	rs916888	0.61	rs199446	ENSG00000263503.1	RP11-707O23.5	-12.3	2.3e-19	4.93e-11	-1.05	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45600869~45602340:-
LAML	trans	rs916888	0.61	rs199536	ENSG00000263503.1	RP11-707O23.5	-12.3	2.3e-19	4.93e-11	-1.05	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45600869~45602340:-
LAML	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	12.27	2.6e-19	5.54e-11	1.12	0.82	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
LAML	trans	rs916888	0.779	rs199528	ENSG00000214425.5	LRRC37A4P	-12.26	2.68e-19	5.64e-11	-1.2	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45506741~45550335:-
LAML	trans	rs916888	0.821	rs199525	ENSG00000214425.5	LRRC37A4P	-12.26	2.68e-19	5.64e-11	-1.2	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs199448	ENSG00000264057.1	RP11-583F2.1	12.26	2.68e-19	5.64e-11	1.14	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:64927634~64934203:+
LAML	trans	rs916888	0.773	rs199445	ENSG00000264057.1	RP11-583F2.1	12.26	2.68e-19	5.64e-11	1.14	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:64927634~64934203:+
LAML	trans	rs916888	0.773	rs199443	ENSG00000264057.1	RP11-583F2.1	12.26	2.68e-19	5.64e-11	1.14	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:64927634~64934203:+
LAML	trans	rs916888	0.773	rs199534	ENSG00000264057.1	RP11-583F2.1	12.26	2.68e-19	5.64e-11	1.14	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:64927634~64934203:+
LAML	trans	rs916888	0.773	rs199533	ENSG00000264057.1	RP11-583F2.1	12.26	2.68e-19	5.64e-11	1.14	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:64927634~64934203:+
LAML	trans	rs1816752	0.87	rs9581029	ENSG00000237917.1	PARP4P1	12.2	3.42e-19	7.08e-11	1.14	0.82	Obesity-related traits;	chr13:24425147	chrY:26594851~26634652:-
LAML	trans	rs7949030	0.504	rs2516633	ENSG00000186676.3	EEF1GP1	-12.19	3.61e-19	7.44e-11	-1.13	-0.82	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62604301	chr7:125033453~125035301:+
LAML	trans	rs916888	0.531	rs183211	ENSG00000263503.1	RP11-707O23.5	12.07	5.75e-19	1.17e-10	1.05	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45600869~45602340:-
LAML	trans	rs916888	0.61	rs199438	ENSG00000263503.1	RP11-707O23.5	12.07	5.75e-19	1.17e-10	1.05	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45600869~45602340:-
LAML	trans	rs1816752	0.837	rs9318530	ENSG00000237917.1	PARP4P1	-12.05	6.17e-19	1.25e-10	-1.13	-0.82	Obesity-related traits;	chr13:24424419	chrY:26594851~26634652:-
LAML	trans	rs916888	0.773	rs199439	ENSG00000264057.1	RP11-583F2.1	12.02	7e-19	1.41e-10	1.15	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:64927634~64934203:+
LAML	trans	rs1816752	0.719	rs11843470	ENSG00000237917.1	PARP4P1	11.94	9.49e-19	1.9e-10	1.13	0.82	Obesity-related traits;	chr13:24423561	chrY:26594851~26634652:-
LAML	trans	rs916888	0.61	rs199436	ENSG00000263503.1	RP11-707O23.5	-11.94	9.76e-19	1.94e-10	-1.04	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45600869~45602340:-
LAML	trans	rs916888	0.61	rs142167	ENSG00000263503.1	RP11-707O23.5	-11.94	9.76e-19	1.94e-10	-1.04	-0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45600869~45602340:-
LAML	trans	rs916888	0.61	rs199452	ENSG00000263503.1	RP11-707O23.5	11.94	9.76e-19	1.94e-10	1.04	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45600869~45602340:-
LAML	trans	rs916888	0.647	rs199449	ENSG00000263503.1	RP11-707O23.5	11.94	9.76e-19	1.94e-10	1.04	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45600869~45602340:-
LAML	trans	rs916888	0.61	rs199444	ENSG00000263503.1	RP11-707O23.5	11.94	9.76e-19	1.94e-10	1.04	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45600869~45602340:-
LAML	trans	rs916888	0.61	rs199442	ENSG00000263503.1	RP11-707O23.5	11.94	9.76e-19	1.94e-10	1.04	0.82	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45600869~45602340:-
LAML	trans	rs13177918	0.626	rs3819332	ENSG00000213058.3	RP4-765C7.2	11.93	1.02e-18	2.02e-10	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.626	rs13170300	ENSG00000213058.3	RP4-765C7.2	11.93	1.02e-18	2.02e-10	1.16	0.81	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr1:178411616~178411972:+
LAML	trans	rs916888	0.773	rs199535	ENSG00000264070.1	DND1P1	11.9	1.12e-18	2.2e-10	1.02	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199506	ENSG00000214425.5	LRRC37A4P	11.89	1.2e-18	2.36e-10	1.17	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45506741~45550335:-
LAML	trans	rs1816752	0.819	rs4770664	ENSG00000237917.1	PARP4P1	11.88	1.23e-18	2.36e-10	1.11	0.81	Obesity-related traits;	chr13:24414695	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.819	rs4770665	ENSG00000237917.1	PARP4P1	11.88	1.23e-18	2.36e-10	1.11	0.81	Obesity-related traits;	chr13:24414810	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.721	rs7399656	ENSG00000237917.1	PARP4P1	11.88	1.23e-18	2.36e-10	1.11	0.81	Obesity-related traits;	chr13:24415708	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	11.88	1.23e-18	2.36e-10	1.11	0.81	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.749	rs77832754	ENSG00000237917.1	PARP4P1	11.88	1.23e-18	2.36e-10	1.11	0.81	Obesity-related traits;	chr13:24416016	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.633	rs8002387	ENSG00000237917.1	PARP4P1	11.88	1.23e-18	2.36e-10	1.11	0.81	Obesity-related traits;	chr13:24416306	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.819	rs7985478	ENSG00000237917.1	PARP4P1	11.88	1.23e-18	2.36e-10	1.11	0.81	Obesity-related traits;	chr13:24417135	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.819	rs6490917	ENSG00000237917.1	PARP4P1	11.88	1.23e-18	2.36e-10	1.11	0.81	Obesity-related traits;	chr13:24423119	chrY:26594851~26634652:-
LAML	trans	rs916888	0.738	rs199515	ENSG00000263503.1	RP11-707O23.5	-11.86	1.32e-18	2.51e-10	-1.34	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45600869~45602340:-
LAML	trans	rs916888	0.773	rs199451	ENSG00000264057.1	RP11-583F2.1	11.84	1.45e-18	2.74e-10	1.13	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:64927634~64934203:+
LAML	trans	rs916888	0.61	rs199453	ENSG00000263503.1	RP11-707O23.5	11.84	1.46e-18	2.75e-10	1.03	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45600869~45602340:-
LAML	trans	rs916888	0.779	rs199528	ENSG00000264070.1	DND1P1	11.81	1.66e-18	3.11e-10	1.02	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199525	ENSG00000264070.1	DND1P1	11.81	1.66e-18	3.11e-10	1.02	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199506	ENSG00000264070.1	DND1P1	-11.79	1.74e-18	3.25e-10	-1	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199506	ENSG00000264057.1	RP11-583F2.1	-11.79	1.77e-18	3.3e-10	-1.11	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:64927634~64934203:+
LAML	trans	rs1816752	0.905	rs7991450	ENSG00000237917.1	PARP4P1	11.77	1.89e-18	3.45e-10	1.13	0.81	Obesity-related traits;	chr13:24425898	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.774	rs7986162	ENSG00000237917.1	PARP4P1	11.77	1.89e-18	3.45e-10	1.13	0.81	Obesity-related traits;	chr13:24425941	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs4769352	ENSG00000237917.1	PARP4P1	11.77	1.89e-18	3.45e-10	1.13	0.81	Obesity-related traits;	chr13:24426237	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.805	rs4769353	ENSG00000237917.1	PARP4P1	11.77	1.89e-18	3.45e-10	1.13	0.81	Obesity-related traits;	chr13:24426318	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.905	rs7571	ENSG00000237917.1	PARP4P1	11.77	1.89e-18	3.45e-10	1.13	0.81	Obesity-related traits;	chr13:24426479	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.837	rs7324645	ENSG00000237917.1	PARP4P1	11.77	1.89e-18	3.45e-10	1.13	0.81	Obesity-related traits;	chr13:24426717	chrY:26594851~26634652:-
LAML	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	11.73	2.26e-18	4.08e-10	1.1	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
LAML	trans	rs916888	0.773	rs199448	ENSG00000264070.1	DND1P1	11.72	2.35e-18	4.2e-10	1.01	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45585871~45586929:+
LAML	trans	rs916888	0.773	rs199445	ENSG00000264070.1	DND1P1	11.72	2.35e-18	4.2e-10	1.01	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45585871~45586929:+
LAML	trans	rs916888	0.773	rs199443	ENSG00000264070.1	DND1P1	11.72	2.35e-18	4.2e-10	1.01	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45585871~45586929:+
LAML	trans	rs916888	0.773	rs199534	ENSG00000264070.1	DND1P1	11.72	2.35e-18	4.2e-10	1.01	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45585871~45586929:+
LAML	trans	rs916888	0.773	rs199533	ENSG00000264070.1	DND1P1	11.72	2.35e-18	4.2e-10	1.01	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45585871~45586929:+
LAML	trans	rs916888	0.773	rs1378358	ENSG00000264057.1	RP11-583F2.1	11.7	2.53e-18	4.5e-10	1.14	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:64927634~64934203:+
LAML	trans	rs916888	0.773	rs538628	ENSG00000264057.1	RP11-583F2.1	11.7	2.53e-18	4.5e-10	1.14	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:64927634~64934203:+
LAML	trans	rs916888	0.773	rs169201	ENSG00000264057.1	RP11-583F2.1	11.7	2.53e-18	4.5e-10	1.14	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:64927634~64934203:+
LAML	trans	rs916888	0.779	rs199528	ENSG00000264057.1	RP11-583F2.1	11.68	2.75e-18	4.87e-10	1.13	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:64927634~64934203:+
LAML	trans	rs916888	0.821	rs199525	ENSG00000264057.1	RP11-583F2.1	11.68	2.75e-18	4.87e-10	1.13	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:64927634~64934203:+
LAML	trans	rs916888	0.773	rs199457	ENSG00000264070.1	DND1P1	11.67	2.92e-18	4.99e-10	1.02	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45585871~45586929:+
LAML	trans	rs916888	0.687	rs199456	ENSG00000264070.1	DND1P1	11.67	2.92e-18	4.99e-10	1.02	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45585871~45586929:+
LAML	trans	rs916888	0.773	rs9896243	ENSG00000264057.1	RP11-583F2.1	11.66	3e-18	4.99e-10	1.11	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:64927634~64934203:+
LAML	trans	rs1552244	1	rs61077902	ENSG00000230342.2	FANCD2P2	11.66	3.01e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10084469	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs55822690	ENSG00000230342.2	FANCD2P2	11.66	3.01e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10086319	chr3:11859674~11891172:+
LAML	trans	rs916888	0.773	rs199447	ENSG00000264070.1	DND1P1	11.66	3.06e-18	4.99e-10	1.02	0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45585871~45586929:+
LAML	trans	rs1552244	0.935	rs41520445	ENSG00000230342.2	FANCD2P2	-11.65	3.09e-18	4.99e-10	-1.19	-0.81	Alzheimer's disease;	chr3:10111457	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs17032396	ENSG00000230342.2	FANCD2P2	-11.65	3.09e-18	4.99e-10	-1.19	-0.81	Alzheimer's disease;	chr3:10111875	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs66838678	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10108666	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs56394721	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10109111	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs7618815	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10109361	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7652935	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10109454	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs67134728	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10109747	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs68045038	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10110144	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs67006488	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10111309	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6764068	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10112158	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs113522867	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10112819	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.872	rs115331527	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10112820	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs113153120	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10114714	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs112509186	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10114849	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs67852463	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10115521	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs113268531	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10125385	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.938	rs67667957	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10125580	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.938	rs56274701	ENSG00000230342.2	FANCD2P2	11.65	3.09e-18	4.99e-10	1.19	0.81	Alzheimer's disease;	chr3:10126106	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs12374115	ENSG00000230342.2	FANCD2P2	-11.63	3.34e-18	4.99e-10	-1.18	-0.81	Alzheimer's disease;	chr3:10093082	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7648104	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10031627	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs113771705	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10034299	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs111392584	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10034307	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs17032276	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10035291	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs17032277	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10035339	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs17032278	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10036271	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs66797209	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10036842	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs76041173	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10037011	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7631678	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10037132	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7637888	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10039038	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs17032283	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10039861	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7615764	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10040908	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs35220123	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10041485	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs4441636	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10042192	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs17032295	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10044996	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs17032299	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10045954	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs35741213	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10045977	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.81	rs7612908	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10047464	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs7649243	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10047786	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7615646	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10048089	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.81	rs6809572	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10058461	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs112847840	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10059968	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs722509	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10060693	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs35198334	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10062869	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs7652190	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10063466	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7619340	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10066494	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6793396	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10069243	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs7621551	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10072521	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs35148833	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10075253	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.81	rs35711405	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10075255	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6786638	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10076391	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6442150	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10080891	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6764168	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10082121	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs2272123	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10098431	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs58275763	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10101590	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs61052895	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10105832	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs68067759	ENSG00000230342.2	FANCD2P2	11.63	3.34e-18	4.99e-10	1.18	0.81	Alzheimer's disease;	chr3:10108851	chr3:11859674~11891172:+
LAML	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	11.62	3.48e-18	5.17e-10	1.09	0.81	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
LAML	trans	rs1552244	1	rs6772315	ENSG00000230342.2	FANCD2P2	11.62	3.52e-18	5.23e-10	1.19	0.81	Alzheimer's disease;	chr3:10071960	chr3:11859674~11891172:+
LAML	trans	rs916888	0.61	rs199454	ENSG00000280022.1	RP11-707O23.1	-11.61	3.68e-18	5.42e-10	-1.04	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45592621~45593369:+
LAML	trans	rs916888	0.61	rs199446	ENSG00000280022.1	RP11-707O23.1	-11.61	3.68e-18	5.42e-10	-1.04	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45592621~45593369:+
LAML	trans	rs916888	0.61	rs199536	ENSG00000280022.1	RP11-707O23.1	-11.61	3.68e-18	5.42e-10	-1.04	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45592621~45593369:+
LAML	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	11.59	4e-18	5.85e-10	1.09	0.81	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
LAML	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	11.59	4e-18	5.85e-10	1.09	0.81	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
LAML	trans	rs1552244	1	rs7628448	ENSG00000230342.2	FANCD2P2	11.58	4.17e-18	6.09e-10	1.19	0.81	Alzheimer's disease;	chr3:10105144	chr3:11859674~11891172:+
LAML	trans	rs916888	0.61	rs199529	ENSG00000214425.5	LRRC37A4P	-11.57	4.26e-18	6.2e-10	-1.14	-0.81	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs199451	ENSG00000264070.1	DND1P1	11.5	5.78e-18	8.39e-10	1.01	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45585871~45586929:+
LAML	trans	rs13177918	0.626	rs13175436	ENSG00000213058.3	RP4-765C7.2	11.5	5.82e-18	8.41e-10	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.626	rs67026795	ENSG00000213058.3	RP4-765C7.2	11.5	5.82e-18	8.41e-10	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.603	rs10447222	ENSG00000213058.3	RP4-765C7.2	11.5	5.82e-18	8.41e-10	1.15	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr1:178411616~178411972:+
LAML	trans	rs1552244	0.748	rs113890152	ENSG00000230342.2	FANCD2P2	11.48	6.27e-18	9.04e-10	1.18	0.8	Alzheimer's disease;	chr3:10044302	chr3:11859674~11891172:+
LAML	trans	rs916888	0.821	rs70600	ENSG00000264070.1	DND1P1	11.48	6.29e-18	9.05e-10	1.01	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45585871~45586929:+
LAML	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-11.45	7e-18	9.96e-10	-1.15	-0.8	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
LAML	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	11.45	7e-18	9.96e-10	1.15	0.8	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
LAML	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	11.45	7e-18	9.96e-10	1.15	0.8	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
LAML	trans	rs916888	0.773	rs199439	ENSG00000264070.1	DND1P1	11.45	7.02e-18	9.96e-10	1.01	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45585871~45586929:+
LAML	trans	rs916888	0.697	rs199516	ENSG00000214425.5	LRRC37A4P	11.44	7.36e-18	1.03e-09	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45506741~45550335:-
LAML	trans	rs916888	0.821	rs199514	ENSG00000214425.5	LRRC37A4P	11.44	7.36e-18	1.03e-09	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45506741~45550335:-
LAML	trans	rs916888	0.821	rs199513	ENSG00000214425.5	LRRC37A4P	11.44	7.36e-18	1.03e-09	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45506741~45550335:-
LAML	trans	rs916888	0.821	rs199512	ENSG00000214425.5	LRRC37A4P	11.44	7.36e-18	1.03e-09	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45506741~45550335:-
LAML	trans	rs916888	0.821	rs199509	ENSG00000214425.5	LRRC37A4P	11.44	7.36e-18	1.03e-09	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45506741~45550335:-
LAML	trans	rs916888	0.821	rs199507	ENSG00000214425.5	LRRC37A4P	11.44	7.36e-18	1.03e-09	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45506741~45550335:-
LAML	trans	rs916888	0.821	rs199505	ENSG00000214425.5	LRRC37A4P	11.44	7.36e-18	1.03e-09	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45506741~45550335:-
LAML	trans	rs916888	0.821	rs70602	ENSG00000214425.5	LRRC37A4P	11.44	7.36e-18	1.03e-09	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45506741~45550335:-
LAML	trans	rs916888	0.697	rs199516	ENSG00000264070.1	DND1P1	-11.4	8.66e-18	1.2e-09	-0.99	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199514	ENSG00000264070.1	DND1P1	-11.4	8.66e-18	1.2e-09	-0.99	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199513	ENSG00000264070.1	DND1P1	-11.4	8.66e-18	1.2e-09	-0.99	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199512	ENSG00000264070.1	DND1P1	-11.4	8.66e-18	1.2e-09	-0.99	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199509	ENSG00000264070.1	DND1P1	-11.4	8.66e-18	1.2e-09	-0.99	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199507	ENSG00000264070.1	DND1P1	-11.4	8.66e-18	1.2e-09	-0.99	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199505	ENSG00000264070.1	DND1P1	-11.4	8.66e-18	1.2e-09	-0.99	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs70602	ENSG00000264070.1	DND1P1	-11.4	8.66e-18	1.2e-09	-0.99	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45585871~45586929:+
LAML	trans	rs13177918	0.677	rs4841	ENSG00000239528.1	RPS14P8	11.39	8.94e-18	1.23e-09	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446963	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs13183077	ENSG00000239528.1	RPS14P8	11.39	8.94e-18	1.23e-09	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447009	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs3797622	ENSG00000239528.1	RPS14P8	11.39	8.94e-18	1.23e-09	1.04	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447535	chr5:116562562~116562930:+
LAML	trans	rs1552244	1	rs35993975	ENSG00000230342.2	FANCD2P2	11.38	9.27e-18	1.27e-09	1.18	0.8	Alzheimer's disease;	chr3:10026110	chr3:11859674~11891172:+
LAML	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	11.36	1.02e-17	1.38e-09	1.08	0.8	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
LAML	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	11.36	1.02e-17	1.38e-09	1.08	0.8	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
LAML	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-11.36	1.02e-17	1.38e-09	-1.08	-0.8	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
LAML	trans	rs7949030	0.596	rs11231137	ENSG00000186676.3	EEF1GP1	11.36	1.03e-17	1.4e-09	1.09	0.8	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548227	chr7:125033453~125035301:+
LAML	trans	rs916888	0.821	rs70600	ENSG00000214425.5	LRRC37A4P	-11.31	1.26e-17	1.68e-09	-1.17	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45506741~45550335:-
LAML	trans	rs13177918	0.677	rs13161099	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442799	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.629	rs13161261	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442844	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs13161417	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442937	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs13161156	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443023	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs13181401	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443033	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs4541646	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443355	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs3900644	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443359	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs2070844	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444222	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs2073472	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444504	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.629	rs2070842	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444660	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs13171800	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444792	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs2070841	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150444908	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs13177951	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446376	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs13177970	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446447	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs13164105	ENSG00000239528.1	RPS14P8	11.29	1.36e-17	1.75e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446503	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs3857421	ENSG00000239528.1	RPS14P8	-11.29	1.36e-17	1.75e-09	-1.03	-0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443584	chr5:116562562~116562930:+
LAML	trans	rs916888	0.821	rs415430	ENSG00000264070.1	DND1P1	-11.28	1.39e-17	1.8e-09	-1.03	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45585871~45586929:+
LAML	trans	rs916888	0.779	rs430685	ENSG00000264070.1	DND1P1	-11.28	1.39e-17	1.8e-09	-1.03	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs199504	ENSG00000214425.5	LRRC37A4P	11.26	1.55e-17	2e-09	1.16	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45506741~45550335:-
LAML	trans	rs916888	0.821	rs199504	ENSG00000264070.1	DND1P1	-11.2	1.98e-17	2.54e-09	-0.99	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45585871~45586929:+
LAML	trans	rs13177918	0.626	rs12186649	ENSG00000239528.1	RPS14P8	11.19	2.09e-17	2.66e-09	1.03	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150438963	chr5:116562562~116562930:+
LAML	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-11.16	2.36e-17	2.99e-09	-1.08	-0.8	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
LAML	trans	rs916888	0.773	rs1378358	ENSG00000264070.1	DND1P1	11.15	2.4e-17	3.03e-09	1	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45585871~45586929:+
LAML	trans	rs916888	0.773	rs538628	ENSG00000264070.1	DND1P1	11.15	2.4e-17	3.03e-09	1	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45585871~45586929:+
LAML	trans	rs916888	0.773	rs169201	ENSG00000264070.1	DND1P1	11.15	2.4e-17	3.03e-09	1	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45585871~45586929:+
LAML	trans	rs916888	0.61	rs199436	ENSG00000280022.1	RP11-707O23.1	-11.15	2.43e-17	3.05e-09	-1.02	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45592621~45593369:+
LAML	trans	rs916888	0.61	rs142167	ENSG00000280022.1	RP11-707O23.1	-11.15	2.43e-17	3.05e-09	-1.02	-0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45592621~45593369:+
LAML	trans	rs916888	0.61	rs199452	ENSG00000280022.1	RP11-707O23.1	11.15	2.43e-17	3.05e-09	1.02	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45592621~45593369:+
LAML	trans	rs916888	0.647	rs199449	ENSG00000280022.1	RP11-707O23.1	11.15	2.43e-17	3.05e-09	1.02	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45592621~45593369:+
LAML	trans	rs916888	0.61	rs199444	ENSG00000280022.1	RP11-707O23.1	11.15	2.43e-17	3.05e-09	1.02	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45592621~45593369:+
LAML	trans	rs916888	0.61	rs199442	ENSG00000280022.1	RP11-707O23.1	11.15	2.43e-17	3.05e-09	1.02	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45592621~45593369:+
LAML	trans	rs1552244	0.938	rs34750074	ENSG00000230342.2	FANCD2P2	11.14	2.51e-17	3.14e-09	1.17	0.8	Alzheimer's disease;	chr3:10050056	chr3:11859674~11891172:+
LAML	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-11.14	2.52e-17	3.15e-09	-1.14	-0.8	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
LAML	trans	rs916888	0.773	rs199535	ENSG00000264057.1	RP11-583F2.1	11.14	2.57e-17	3.2e-09	1.11	0.8	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:64927634~64934203:+
LAML	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	11.12	2.71e-17	3.36e-09	1.14	0.8	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
LAML	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	11.12	2.71e-17	3.36e-09	1.14	0.8	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
LAML	trans	rs916888	0.697	rs199516	ENSG00000264057.1	RP11-583F2.1	-11.12	2.75e-17	3.38e-09	-1.1	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:64927634~64934203:+
LAML	trans	rs916888	0.821	rs199514	ENSG00000264057.1	RP11-583F2.1	-11.12	2.75e-17	3.38e-09	-1.1	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:64927634~64934203:+
LAML	trans	rs916888	0.821	rs199513	ENSG00000264057.1	RP11-583F2.1	-11.12	2.75e-17	3.38e-09	-1.1	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:64927634~64934203:+
LAML	trans	rs916888	0.821	rs199512	ENSG00000264057.1	RP11-583F2.1	-11.12	2.75e-17	3.38e-09	-1.1	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:64927634~64934203:+
LAML	trans	rs916888	0.821	rs199509	ENSG00000264057.1	RP11-583F2.1	-11.12	2.75e-17	3.38e-09	-1.1	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:64927634~64934203:+
LAML	trans	rs916888	0.821	rs199507	ENSG00000264057.1	RP11-583F2.1	-11.12	2.75e-17	3.38e-09	-1.1	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:64927634~64934203:+
LAML	trans	rs916888	0.821	rs199505	ENSG00000264057.1	RP11-583F2.1	-11.12	2.75e-17	3.38e-09	-1.1	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:64927634~64934203:+
LAML	trans	rs916888	0.821	rs70602	ENSG00000264057.1	RP11-583F2.1	-11.12	2.75e-17	3.38e-09	-1.1	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:64927634~64934203:+
LAML	trans	rs916888	0.738	rs199515	ENSG00000264057.1	RP11-583F2.1	-11.1	2.95e-17	3.61e-09	-1.32	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:64927634~64934203:+
LAML	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	11.1	3.02e-17	3.61e-09	1.07	0.79	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
LAML	trans	rs1816752	1	rs7999554	ENSG00000237917.1	PARP4P1	11.06	3.46e-17	3.78e-09	1.09	0.79	Obesity-related traits;	chr13:24435631	chrY:26594851~26634652:-
LAML	trans	rs1816752	1	rs9511265	ENSG00000237917.1	PARP4P1	11.06	3.46e-17	3.78e-09	1.09	0.79	Obesity-related traits;	chr13:24438221	chrY:26594851~26634652:-
LAML	trans	rs1552244	0.938	rs7652951	ENSG00000230342.2	FANCD2P2	11.06	3.55e-17	3.83e-09	1.17	0.79	Alzheimer's disease;	chr3:10022079	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7611218	ENSG00000230342.2	FANCD2P2	11.06	3.55e-17	3.83e-09	1.17	0.79	Alzheimer's disease;	chr3:10022276	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.872	rs6803517	ENSG00000230342.2	FANCD2P2	11.06	3.55e-17	3.83e-09	1.17	0.79	Alzheimer's disease;	chr3:10023742	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9834980	ENSG00000230342.2	FANCD2P2	11.06	3.55e-17	3.83e-09	1.17	0.79	Alzheimer's disease;	chr3:10023844	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7651058	ENSG00000230342.2	FANCD2P2	11.06	3.55e-17	3.83e-09	1.17	0.79	Alzheimer's disease;	chr3:10025280	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs17032268	ENSG00000230342.2	FANCD2P2	11.06	3.55e-17	3.83e-09	1.17	0.79	Alzheimer's disease;	chr3:10026288	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs3846177	ENSG00000230342.2	FANCD2P2	11.06	3.55e-17	3.83e-09	1.17	0.79	Alzheimer's disease;	chr3:10026888	chr3:11859674~11891172:+
LAML	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	11	4.51e-17	4.63e-09	1.06	0.79	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
LAML	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	10.97	5e-17	5.11e-09	1.12	0.79	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
LAML	trans	rs916888	0.821	rs415430	ENSG00000264057.1	RP11-583F2.1	-10.97	5.19e-17	5.29e-09	-1.13	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:64927634~64934203:+
LAML	trans	rs916888	0.779	rs430685	ENSG00000264057.1	RP11-583F2.1	-10.97	5.19e-17	5.29e-09	-1.13	-0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:64927634~64934203:+
LAML	trans	rs1552244	0.935	rs66493421	ENSG00000230342.2	FANCD2P2	10.96	5.41e-17	5.51e-09	1.17	0.79	Alzheimer's disease;	chr3:10050885	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.938	rs9873794	ENSG00000230342.2	FANCD2P2	10.94	5.8e-17	5.9e-09	1.12	0.79	Alzheimer's disease;	chr3:10032469	chr3:11859674~11891172:+
LAML	trans	rs916888	0.773	rs9896243	ENSG00000264070.1	DND1P1	10.92	6.16e-17	6.23e-09	0.98	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45585871~45586929:+
LAML	trans	rs1816752	0.819	rs1981276	ENSG00000237917.1	PARP4P1	10.87	7.76e-17	7.7e-09	1.09	0.79	Obesity-related traits;	chr13:24409361	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.837	rs57052031	ENSG00000237917.1	PARP4P1	10.87	7.76e-17	7.7e-09	1.09	0.79	Obesity-related traits;	chr13:24409730	chrY:26594851~26634652:-
LAML	trans	rs1552244	1	rs1552244	ENSG00000230342.2	FANCD2P2	10.86	7.92e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10093893	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7610821	ENSG00000230342.2	FANCD2P2	10.86	7.92e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10094466	chr3:11859674~11891172:+
LAML	trans	rs13177918	0.651	rs13184111	ENSG00000239528.1	RPS14P8	10.86	8.03e-17	7.7e-09	1.06	0.79	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150434649	chr5:116562562~116562930:+
LAML	trans	rs1552244	1	rs17032414	ENSG00000230342.2	FANCD2P2	10.85	8.22e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10116618	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6781811	ENSG00000230342.2	FANCD2P2	-10.85	8.39e-17	7.7e-09	-1.12	-0.79	Alzheimer's disease;	chr3:10080238	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs13319597	ENSG00000230342.2	FANCD2P2	-10.85	8.39e-17	7.7e-09	-1.12	-0.79	Alzheimer's disease;	chr3:10084628	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9849434	ENSG00000230342.2	FANCD2P2	-10.85	8.39e-17	7.7e-09	-1.12	-0.79	Alzheimer's disease;	chr3:10092026	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6804473	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10018741	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs28815328	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10020543	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9845756	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10025864	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs33917318	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10026113	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs35515831	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10029678	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs28684871	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10030951	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9881859	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10031130	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6442146	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10031860	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6414438	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10032140	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6442147	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10036563	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6442148	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10036605	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs2160869	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10037571	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9875081	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10042251	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9879080	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10042540	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9809061	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10043446	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs113134644	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10044602	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs56270432	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10045833	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.808	rs17032306	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10049715	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.872	rs7646073	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10055721	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs3895942	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10067061	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.938	rs66915020	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10068490	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.81	rs4019706	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10071178	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.872	rs6771931	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10071724	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9824585	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10073118	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.938	rs7625049	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10073935	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6782602	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10074857	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs35586456	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10075254	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9820598	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10076228	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs57631744	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10077278	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.872	rs6792951	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10077919	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs6805869	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10078233	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9827740	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10078847	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs4260416	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10083599	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs4269070	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10084399	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs9811771	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10092265	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6807846	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10092807	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs2272125	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10096385	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs2272124	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10096505	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs55882090	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10097398	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7622963	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10098141	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs7622966	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10098149	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs34179822	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10098333	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.938	rs7647987	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10099012	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs3826	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10099381	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.935	rs11926481	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10100418	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs12152512	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10102086	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs12152515	ENSG00000230342.2	FANCD2P2	10.85	8.39e-17	7.7e-09	1.12	0.79	Alzheimer's disease;	chr3:10102292	chr3:11859674~11891172:+
LAML	trans	rs1552244	1	rs6768102	ENSG00000230342.2	FANCD2P2	10.84	8.58e-17	7.86e-09	1.16	0.79	Alzheimer's disease;	chr3:10107696	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs17050660	ENSG00000230342.2	FANCD2P2	-10.84	8.67e-17	7.94e-09	-1.13	-0.79	Alzheimer's disease;	chr3:9960088	chr3:11859674~11891172:+
LAML	trans	rs916888	0.821	rs70600	ENSG00000264057.1	RP11-583F2.1	10.81	9.96e-17	9.05e-09	1.1	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:64927634~64934203:+
LAML	trans	rs1816752	0.748	rs6490912	ENSG00000237917.1	PARP4P1	10.8	1.03e-16	9.34e-09	1.09	0.79	Obesity-related traits;	chr13:24408941	chrY:26594851~26634652:-
LAML	trans	rs916888	0.531	rs183211	ENSG00000280022.1	RP11-707O23.1	10.77	1.17e-16	1.05e-08	1.01	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45592621~45593369:+
LAML	trans	rs916888	0.61	rs199438	ENSG00000280022.1	RP11-707O23.1	10.77	1.17e-16	1.05e-08	1.01	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45592621~45593369:+
LAML	trans	rs1552244	1	rs6789156	ENSG00000230342.2	FANCD2P2	10.76	1.19e-16	1.07e-08	1.07	0.79	Alzheimer's disease;	chr3:10082436	chr3:11859674~11891172:+
LAML	trans	rs916888	0.61	rs199453	ENSG00000280022.1	RP11-707O23.1	10.76	1.24e-16	1.12e-08	1	0.79	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45592621~45593369:+
LAML	trans	rs1816752	0.819	rs4769349	ENSG00000237917.1	PARP4P1	-10.74	1.32e-16	1.19e-08	-1.09	-0.78	Obesity-related traits;	chr13:24408694	chrY:26594851~26634652:-
LAML	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	10.74	1.35e-16	1.21e-08	1.07	0.78	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
LAML	trans	rs1816752	0.935	rs3816219	ENSG00000237917.1	PARP4P1	10.72	1.43e-16	1.28e-08	1.08	0.78	Obesity-related traits;	chr13:24442995	chrY:26594851~26634652:-
LAML	trans	rs1552244	0.882	rs34706481	ENSG00000230342.2	FANCD2P2	10.71	1.51e-16	1.35e-08	1.13	0.78	Alzheimer's disease;	chr3:9962439	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs17050672	ENSG00000230342.2	FANCD2P2	10.71	1.51e-16	1.35e-08	1.13	0.78	Alzheimer's disease;	chr3:9983779	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs3755783	ENSG00000230342.2	FANCD2P2	10.71	1.51e-16	1.35e-08	1.13	0.78	Alzheimer's disease;	chr3:9987605	chr3:11859674~11891172:+
LAML	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	10.7	1.57e-16	1.36e-08	1.04	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
LAML	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-10.69	1.66e-16	1.39e-08	-1.06	-0.78	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
LAML	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-10.69	1.66e-16	1.39e-08	-1.06	-0.78	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
LAML	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-10.69	1.66e-16	1.39e-08	-1.06	-0.78	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
LAML	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-10.69	1.66e-16	1.39e-08	-1.06	-0.78	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
LAML	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-10.69	1.66e-16	1.39e-08	-1.06	-0.78	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
LAML	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-10.69	1.66e-16	1.39e-08	-1.06	-0.78	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
LAML	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-10.69	1.66e-16	1.39e-08	-1.06	-0.78	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
LAML	trans	rs1816752	0.774	rs2862895	ENSG00000237917.1	PARP4P1	10.64	1.98e-16	1.65e-08	1.08	0.78	Obesity-related traits;	chr13:24410328	chrY:26594851~26634652:-
LAML	trans	rs1552244	0.832	rs61056817	ENSG00000230342.2	FANCD2P2	10.61	2.27e-16	1.87e-08	1.13	0.78	Alzheimer's disease;	chr3:9985957	chr3:11859674~11891172:+
LAML	trans	rs1816752	0.755	rs1981277	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24409375	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.712	rs9507335	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24409766	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.811	rs9507337	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24410807	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.783	rs7317439	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24410939	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.819	rs7316961	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24411039	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.819	rs7317504	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24411287	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.783	rs7317712	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24411365	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.783	rs7139527	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24411374	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.819	rs9511240	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24411768	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.819	rs7988388	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24412675	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.875	rs7993132	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24412903	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.792	rs7330956	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24413174	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.777	rs6490915	ENSG00000237917.1	PARP4P1	10.61	2.29e-16	1.87e-08	1.08	0.78	Obesity-related traits;	chr13:24413724	chrY:26594851~26634652:-
LAML	trans	rs1552244	0.882	rs13064570	ENSG00000230342.2	FANCD2P2	10.6	2.39e-16	1.95e-08	1.13	0.78	Alzheimer's disease;	chr3:9955861	chr3:11859674~11891172:+
LAML	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	10.59	2.44e-16	1.97e-08	1.11	0.78	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
LAML	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	10.59	2.44e-16	1.97e-08	1.11	0.78	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
LAML	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	10.59	2.44e-16	1.97e-08	1.11	0.78	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
LAML	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	10.59	2.44e-16	1.97e-08	1.11	0.78	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
LAML	trans	rs941207	0.855	rs2256341	ENSG00000121089.4	NACA3P	-10.57	2.73e-16	2.19e-08	-1.04	-0.78	Platelet count;	chr12:56599930	chr4:164943290~164943937:+
LAML	trans	rs941207	0.805	rs2958139	ENSG00000121089.4	NACA3P	-10.57	2.73e-16	2.19e-08	-1.04	-0.78	Platelet count;	chr12:56610884	chr4:164943290~164943937:+
LAML	trans	rs1816752	1	rs7988810	ENSG00000237917.1	PARP4P1	10.57	2.75e-16	2.2e-08	1.08	0.78	Obesity-related traits;	chr13:24444958	chrY:26594851~26634652:-
LAML	trans	rs13177918	0.686	rs12654827	ENSG00000239528.1	RPS14P8	10.56	2.77e-16	2.2e-08	1.01	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442527	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.677	rs13160685	ENSG00000239528.1	RPS14P8	10.56	2.77e-16	2.2e-08	1.01	0.78	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442768	chr5:116562562~116562930:+
LAML	trans	rs1816752	0.875	rs8001187	ENSG00000237917.1	PARP4P1	10.55	2.97e-16	2.35e-08	1.08	0.78	Obesity-related traits;	chr13:24402276	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.783	rs9507333	ENSG00000237917.1	PARP4P1	10.55	2.97e-16	2.35e-08	1.08	0.78	Obesity-related traits;	chr13:24404172	chrY:26594851~26634652:-
LAML	trans	rs1552244	0.882	rs28366039	ENSG00000230342.2	FANCD2P2	10.52	3.34e-16	2.64e-08	1.13	0.78	Alzheimer's disease;	chr3:9987304	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.748	rs9862221	ENSG00000230342.2	FANCD2P2	10.51	3.41e-16	2.68e-08	1.17	0.78	Alzheimer's disease;	chr3:10017974	chr3:11859674~11891172:+
LAML	trans	rs916888	0.61	rs199530	ENSG00000263503.1	RP11-707O23.5	-10.45	4.46e-16	3.49e-08	-0.96	-0.78	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45600869~45602340:-
LAML	trans	rs11098499	0.954	rs4309825	ENSG00000275858.1	RP11-291L22.8	-10.44	4.64e-16	3.62e-08	-1.16	-0.78	Corneal astigmatism;	chr4:119393726	chr10:38450738~38451069:-
LAML	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	10.43	4.76e-16	3.71e-08	1.1	0.78	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
LAML	trans	rs1552244	0.882	rs13084194	ENSG00000230342.2	FANCD2P2	10.41	5.17e-16	4e-08	1.12	0.78	Alzheimer's disease;	chr3:9989808	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13099507	ENSG00000230342.2	FANCD2P2	10.41	5.17e-16	4e-08	1.12	0.78	Alzheimer's disease;	chr3:9989919	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs55962400	ENSG00000230342.2	FANCD2P2	10.41	5.17e-16	4e-08	1.12	0.78	Alzheimer's disease;	chr3:10002773	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13089863	ENSG00000230342.2	FANCD2P2	-10.41	5.17e-16	4e-08	-1.12	-0.78	Alzheimer's disease;	chr3:9990575	chr3:11859674~11891172:+
LAML	trans	rs13177918	0.677	rs57890152	ENSG00000239528.1	RPS14P8	10.4	5.42e-16	4.16e-08	1	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150441909	chr5:116562562~116562930:+
LAML	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	10.4	5.48e-16	4.2e-08	1.14	0.77	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
LAML	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	10.4	5.48e-16	4.2e-08	1.14	0.77	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
LAML	trans	rs1552244	0.882	rs67631672	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9963084	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs6443276	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9967221	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13063098	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9968235	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.816	rs13059144	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9968513	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13063929	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9968624	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs66559400	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9970867	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs68153882	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9971426	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.832	rs3732968	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9971589	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs35056669	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9972487	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs67762674	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9972801	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs7636817	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9973192	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs3732967	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9973753	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs3732966	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9974056	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13062917	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9975348	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs2130813	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:9997022	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs17081288	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:10000429	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.816	rs56271597	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:10001106	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13066757	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:10003346	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs6443279	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:10011915	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs36006511	ENSG00000230342.2	FANCD2P2	10.37	6.29e-16	4.65e-08	1.12	0.77	Alzheimer's disease;	chr3:10012507	chr3:11859674~11891172:+
LAML	trans	rs9611565	0.694	rs79008	ENSG00000268568.1	AC007228.9	-10.35	6.82e-16	4.97e-08	-1.13	-0.77	Vitiligo;	chr22:41454496	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.685	rs169363	ENSG00000268568.1	AC007228.9	10.35	6.82e-16	4.97e-08	1.13	0.77	Vitiligo;	chr22:41457113	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202639	ENSG00000268568.1	AC007228.9	10.35	6.82e-16	4.97e-08	1.13	0.77	Vitiligo;	chr22:41460133	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs5758365	ENSG00000268568.1	AC007228.9	10.35	6.82e-16	4.97e-08	1.13	0.77	Vitiligo;	chr22:41462653	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs79009	ENSG00000268568.1	AC007228.9	10.35	6.82e-16	4.97e-08	1.13	0.77	Vitiligo;	chr22:41464860	chr19:56672574~56673901:-
LAML	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	10.34	7.08e-16	5.14e-08	1.16	0.77	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
LAML	trans	rs916888	0.61	rs199529	ENSG00000264070.1	DND1P1	10.33	7.37e-16	5.35e-08	0.94	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45585871~45586929:+
LAML	trans	rs916888	0.821	rs415430	ENSG00000214425.5	LRRC37A4P	10.29	8.8e-16	6.34e-08	1.15	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45506741~45550335:-
LAML	trans	rs916888	0.779	rs430685	ENSG00000214425.5	LRRC37A4P	10.29	8.8e-16	6.34e-08	1.15	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45506741~45550335:-
LAML	trans	rs11098499	0.863	rs3775841	ENSG00000275858.1	RP11-291L22.8	10.26	9.95e-16	7.15e-08	1.07	0.77	Corneal astigmatism;	chr4:119504622	chr10:38450738~38451069:-
LAML	trans	rs916888	0.647	rs199524	ENSG00000263503.1	RP11-707O23.5	-10.24	1.08e-15	7.58e-08	-0.98	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45600869~45602340:-
LAML	trans	rs9611565	0.649	rs202645	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41402516	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs5758344	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41421681	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs2142505	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41424537	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs5758347	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41425015	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202613	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41425989	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs202614	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41426146	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202616	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41426217	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.569	rs188057	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41426301	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202617	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41426789	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202622	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41429338	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs202625	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41431078	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs5751101	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41432107	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs7285041	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41433145	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202656	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41446199	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs202657	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41448782	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs5751107	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41461808	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs5751108	ENSG00000268568.1	AC007228.9	10.24	1.08e-15	7.58e-08	1.13	0.77	Vitiligo;	chr22:41462031	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs106860	ENSG00000268568.1	AC007228.9	-10.24	1.08e-15	7.58e-08	-1.13	-0.77	Vitiligo;	chr22:41444403	chr19:56672574~56673901:-
LAML	trans	rs13177918	0.559	rs10447224	ENSG00000213058.3	RP4-765C7.2	10.23	1.13e-15	7.9e-08	1.1	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr1:178411616~178411972:+
LAML	trans	rs13177918	0.559	rs10447225	ENSG00000213058.3	RP4-765C7.2	10.23	1.13e-15	7.9e-08	1.1	0.77	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr1:178411616~178411972:+
LAML	trans	rs941207	1	rs941207	ENSG00000121089.4	NACA3P	-10.21	1.24e-15	8.6e-08	-1.02	-0.77	Platelet count;	chr12:56629500	chr4:164943290~164943937:+
LAML	trans	rs1816752	0.712	rs2862898	ENSG00000237917.1	PARP4P1	10.2	1.25e-15	8.67e-08	1.08	0.77	Obesity-related traits;	chr13:24414323	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.652	rs2902356	ENSG00000237917.1	PARP4P1	10.2	1.25e-15	8.67e-08	1.08	0.77	Obesity-related traits;	chr13:24414333	chrY:26594851~26634652:-
LAML	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	10.2	1.27e-15	8.67e-08	1.03	0.77	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
LAML	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-10.2	1.27e-15	8.67e-08	-1.03	-0.77	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
LAML	trans	rs1552244	0.816	rs13076197	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9978089	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.688	rs7645137	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9978865	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs34779351	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9980117	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13077641	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9981251	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13074282	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9983015	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs68080705	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9984059	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs67895180	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9984395	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs3755782	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9987621	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13099136	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9989747	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.744	rs6763366	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9991860	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.51	rs13075308	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9993241	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.808	rs7615088	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9994212	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs61429272	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9995636	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs56332224	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9995637	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.626	rs2886396	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9995986	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs2030564	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9997360	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs9757159	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9997482	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.816	rs17050701	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:9999870	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs55840655	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:10001006	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.816	rs56387520	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:10001098	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs56224841	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:10002330	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13088350	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:10002942	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs55808392	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:10012997	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs13075842	ENSG00000230342.2	FANCD2P2	10.2	1.29e-15	8.67e-08	1.11	0.77	Alzheimer's disease;	chr3:10014129	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs17050699	ENSG00000230342.2	FANCD2P2	10.17	1.43e-15	8.93e-08	1.12	0.77	Alzheimer's disease;	chr3:9995483	chr3:11859674~11891172:+
LAML	trans	rs5758343	1	rs5758343	ENSG00000268568.1	AC007228.9	10.17	1.46e-15	8.93e-08	1.13	0.77	Allergic disease (asthma, hay fever or eczema);	chr22:41420648	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.954	rs9993199	ENSG00000275858.1	RP11-291L22.8	-10.16	1.49e-15	8.93e-08	-1.08	-0.77	Corneal astigmatism;	chr4:119471718	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs13145352	ENSG00000275858.1	RP11-291L22.8	-10.16	1.49e-15	8.93e-08	-1.08	-0.77	Corneal astigmatism;	chr4:119488808	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs12508173	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119397371	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.908	rs12504149	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119397422	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10008392	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119397684	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.58	rs12509234	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119398279	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs10014719	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119399560	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10017543	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119400265	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.908	rs7695996	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119400878	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10518331	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119402440	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs13133522	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119403269	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs35091806	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119404374	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs35165976	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119404475	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs6846442	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119405168	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs71614422	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119438185	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.738	rs34566984	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119440115	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.738	rs34965784	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119440431	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs17009122	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119441248	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.505	rs75122014	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119441271	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs9685777	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119444810	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs71614438	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119450097	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs66506550	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119450290	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs7659501	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119450397	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.697	rs28655325	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119451844	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.779	rs80242894	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119454597	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.779	rs28495013	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119454676	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.657	rs71614442	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119458191	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs2892848	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119460186	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.697	rs11941899	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119461603	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs7681978	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119462620	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.821	rs28665282	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119463031	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.738	rs10026493	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119463039	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs7681214	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119464165	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.908	rs28559989	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119465472	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs28632018	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119465575	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.908	rs71614449	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119465900	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs35063680	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119465947	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs34858317	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119465955	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs17046116	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119466104	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs17046118	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119466341	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs7654587	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119467251	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs11098525	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119468997	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.821	rs10032151	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119470473	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs10032158	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119470477	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs6838814	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119471288	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs7436506	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119472614	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10008459	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119473076	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs2127821	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119473380	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs12508504	ENSG00000275858.1	RP11-291L22.8	10.16	1.49e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119489452	chr10:38450738~38451069:-
LAML	trans	rs916888	0.738	rs199515	ENSG00000264070.1	DND1P1	-10.16	1.51e-15	8.93e-08	-1.15	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45585871~45586929:+
LAML	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	10.16	1.53e-15	8.93e-08	1.02	0.77	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
LAML	trans	rs11098499	0.954	rs12502423	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.09	0.77	Corneal astigmatism;	chr4:119503017	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-10.15	1.54e-15	8.93e-08	-1.08	-0.77	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs1022145	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119309824	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs11722872	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119311875	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs1546502	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119314743	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs878373	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119316329	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs1546504	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119320024	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs1546505	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119320069	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10006877	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119321638	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs12505469	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119328430	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.908	rs2017057	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119336556	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.908	rs1002152	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119352232	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10017371	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119372621	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.908	rs7696649	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119401022	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs3890049	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119405128	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs67265404	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119438115	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs9759478	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119446843	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs71629403	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119451412	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs28571712	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119454825	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs9994730	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119460409	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs11098526	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119469204	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs12499324	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119472631	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs1480931	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119474654	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs9998585	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119475647	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs6842762	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119477081	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.908	rs11098527	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119478751	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10518328	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119480624	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs6848389	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119481467	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs6822679	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119481547	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs4577559	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119482888	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs7656252	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119483113	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs28845498	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119484031	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs28753180	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119484212	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs56270433	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119484875	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10006525	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119487776	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10006706	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119487997	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs7681544	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119490100	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs17005535	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119490407	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs11940028	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119490752	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs11935596	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119491302	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs12507964	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119491906	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs11098530	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119491999	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs6834796	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119493538	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs11729521	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119495633	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs11734241	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119495717	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs17006190	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119497683	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs28685688	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119499179	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs7687843	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119500056	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs2306455	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119500814	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10031483	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119501481	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10031665	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119501697	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs3733519	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119502293	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs3733523	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119502564	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs12510138	ENSG00000275858.1	RP11-291L22.8	10.15	1.54e-15	8.93e-08	1.08	0.77	Corneal astigmatism;	chr4:119502780	chr10:38450738~38451069:-
LAML	trans	rs916888	0.61	rs199454	ENSG00000214425.5	LRRC37A4P	10.15	1.6e-15	9.22e-08	1.04	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45506741~45550335:-
LAML	trans	rs916888	0.61	rs199446	ENSG00000214425.5	LRRC37A4P	10.15	1.6e-15	9.22e-08	1.04	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45506741~45550335:-
LAML	trans	rs916888	0.61	rs199536	ENSG00000214425.5	LRRC37A4P	10.15	1.6e-15	9.22e-08	1.04	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45506741~45550335:-
LAML	trans	rs1552244	0.832	rs17050674	ENSG00000230342.2	FANCD2P2	10.14	1.64e-15	9.46e-08	1.11	0.77	Alzheimer's disease;	chr3:9985574	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.765	rs17050675	ENSG00000230342.2	FANCD2P2	10.14	1.64e-15	9.46e-08	1.11	0.77	Alzheimer's disease;	chr3:9986002	chr3:11859674~11891172:+
LAML	trans	rs916888	0.61	rs199529	ENSG00000264057.1	RP11-583F2.1	10.12	1.77e-15	1.02e-07	1.04	0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:64927634~64934203:+
LAML	trans	rs916888	0.647	rs199523	ENSG00000263503.1	RP11-707O23.5	-10.1	1.94e-15	1.11e-07	-0.96	-0.77	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45600869~45602340:-
LAML	trans	rs2657294	0.62	rs7475340	ENSG00000172974.11	AC007318.5	10.1	1.94e-15	1.11e-07	0.9	0.77	Pneumonia;	chr10:75079597	chr2:65205108~65205988:+
LAML	trans	rs1552244	1	rs67569278	ENSG00000230342.2	FANCD2P2	10.09	1.98e-15	1.13e-07	1.14	0.77	Alzheimer's disease;	chr3:10108209	chr3:11859674~11891172:+
LAML	trans	rs877636	0.562	rs10876864	ENSG00000225071.1	GS1-184P14.2	-10.06	2.27e-15	1.29e-07	-0.9	-0.76	Cognitive function;	chr12:56007301	chrX:24429573~24429920:-
LAML	trans	rs877636	0.692	rs2271194	ENSG00000233778.3	RP11-777J24.1	-10.05	2.39e-15	1.36e-07	-0.83	-0.76	Cognitive function;	chr12:56083910	chr8:92144088~92144435:-
LAML	trans	rs877636	0.692	rs10876870	ENSG00000233778.3	RP11-777J24.1	-10.05	2.39e-15	1.36e-07	-0.83	-0.76	Cognitive function;	chr12:56084218	chr8:92144088~92144435:-
LAML	trans	rs877636	0.692	rs7971751	ENSG00000233778.3	RP11-777J24.1	-10.05	2.39e-15	1.36e-07	-0.83	-0.76	Cognitive function;	chr12:56084874	chr8:92144088~92144435:-
LAML	trans	rs1552244	0.766	rs34232505	ENSG00000230342.2	FANCD2P2	10.02	2.76e-15	1.56e-07	1.14	0.76	Alzheimer's disease;	chr3:10144532	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.832	rs66597916	ENSG00000230342.2	FANCD2P2	10	2.94e-15	1.65e-07	1.14	0.76	Alzheimer's disease;	chr3:10153723	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.832	rs115415687	ENSG00000230342.2	FANCD2P2	10	2.94e-15	1.65e-07	1.14	0.76	Alzheimer's disease;	chr3:10154020	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.832	rs67145301	ENSG00000230342.2	FANCD2P2	10	2.94e-15	1.65e-07	1.14	0.76	Alzheimer's disease;	chr3:10155630	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.832	rs73024575	ENSG00000230342.2	FANCD2P2	10	2.94e-15	1.65e-07	1.14	0.76	Alzheimer's disease;	chr3:10156516	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.832	rs73024591	ENSG00000230342.2	FANCD2P2	10	2.94e-15	1.65e-07	1.14	0.76	Alzheimer's disease;	chr3:10161510	chr3:11859674~11891172:+
LAML	trans	rs11098499	0.69	rs7674713	ENSG00000275858.1	RP11-291L22.8	9.99	3.02e-15	1.69e-07	1.07	0.76	Corneal astigmatism;	chr4:119401102	chr10:38450738~38451069:-
LAML	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-9.98	3.15e-15	1.77e-07	-1.07	-0.76	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
LAML	trans	rs11098499	0.954	rs2389802	ENSG00000275858.1	RP11-291L22.8	9.97	3.32e-15	1.86e-07	1.08	0.76	Corneal astigmatism;	chr4:119404577	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs28634456	ENSG00000275858.1	RP11-291L22.8	9.97	3.38e-15	1.88e-07	1.08	0.76	Corneal astigmatism;	chr4:119454623	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs78332141	ENSG00000275858.1	RP11-291L22.8	9.97	3.38e-15	1.88e-07	1.08	0.76	Corneal astigmatism;	chr4:119454627	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs10026736	ENSG00000275858.1	RP11-291L22.8	9.97	3.39e-15	1.89e-07	1.07	0.76	Corneal astigmatism;	chr4:119463167	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs11722183	ENSG00000275858.1	RP11-291L22.8	9.94	3.75e-15	2.07e-07	1.06	0.76	Corneal astigmatism;	chr4:119359442	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.618	rs35265692	ENSG00000275858.1	RP11-291L22.8	9.94	3.75e-15	2.07e-07	1.06	0.76	Corneal astigmatism;	chr4:119403980	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs6849171	ENSG00000275858.1	RP11-291L22.8	9.94	3.75e-15	2.07e-07	1.06	0.76	Corneal astigmatism;	chr4:119488394	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs3733520	ENSG00000275858.1	RP11-291L22.8	9.94	3.75e-15	2.07e-07	1.06	0.76	Corneal astigmatism;	chr4:119502325	chr10:38450738~38451069:-
LAML	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	9.93	4.02e-15	2.21e-07	1.14	0.76	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
LAML	trans	rs2657294	0.62	rs7903537	ENSG00000172974.11	AC007318.5	9.89	4.62e-15	2.53e-07	0.91	0.76	Pneumonia;	chr10:75087732	chr2:65205108~65205988:+
LAML	trans	rs2657294	0.62	rs2395136	ENSG00000172974.11	AC007318.5	9.89	4.62e-15	2.53e-07	0.91	0.76	Pneumonia;	chr10:75088213	chr2:65205108~65205988:+
LAML	trans	rs2657294	0.62	rs9783273	ENSG00000172974.11	AC007318.5	9.88	4.82e-15	2.64e-07	0.91	0.76	Pneumonia;	chr10:75081982	chr2:65205108~65205988:+
LAML	trans	rs2657294	0.62	rs4746259	ENSG00000172974.11	AC007318.5	9.88	4.82e-15	2.64e-07	0.91	0.76	Pneumonia;	chr10:75082310	chr2:65205108~65205988:+
LAML	trans	rs13177918	0.578	rs35919198	ENSG00000239528.1	RPS14P8	9.88	4.84e-15	2.65e-07	0.96	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452428	chr5:116562562~116562930:+
LAML	trans	rs9611565	0.694	rs202664	ENSG00000268568.1	AC007228.9	9.88	4.89e-15	2.67e-07	1.12	0.76	Vitiligo;	chr22:41417882	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202665	ENSG00000268568.1	AC007228.9	9.88	4.89e-15	2.67e-07	1.12	0.76	Vitiligo;	chr22:41418397	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs202666	ENSG00000268568.1	AC007228.9	9.88	4.89e-15	2.67e-07	1.12	0.76	Vitiligo;	chr22:41418715	chr19:56672574~56673901:-
LAML	trans	rs2657294	0.62	rs2395132	ENSG00000172974.11	AC007318.5	9.88	4.94e-15	2.69e-07	0.91	0.76	Pneumonia;	chr10:75080840	chr2:65205108~65205988:+
LAML	trans	rs11098499	0.954	rs6847248	ENSG00000275858.1	RP11-291L22.8	9.85	5.51e-15	2.96e-07	1.08	0.76	Corneal astigmatism;	chr4:119304800	chr10:38450738~38451069:-
LAML	trans	rs916888	0.61	rs199436	ENSG00000214425.5	LRRC37A4P	9.84	5.72e-15	3.06e-07	1.03	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45506741~45550335:-
LAML	trans	rs916888	0.61	rs142167	ENSG00000214425.5	LRRC37A4P	9.84	5.72e-15	3.06e-07	1.03	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45506741~45550335:-
LAML	trans	rs916888	0.61	rs199452	ENSG00000214425.5	LRRC37A4P	-9.84	5.72e-15	3.06e-07	-1.03	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45506741~45550335:-
LAML	trans	rs916888	0.647	rs199449	ENSG00000214425.5	LRRC37A4P	-9.84	5.72e-15	3.06e-07	-1.03	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45506741~45550335:-
LAML	trans	rs916888	0.61	rs199444	ENSG00000214425.5	LRRC37A4P	-9.84	5.72e-15	3.06e-07	-1.03	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45506741~45550335:-
LAML	trans	rs916888	0.61	rs199442	ENSG00000214425.5	LRRC37A4P	-9.84	5.72e-15	3.06e-07	-1.03	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45506741~45550335:-
LAML	trans	rs11098499	0.908	rs9995234	ENSG00000275858.1	RP11-291L22.8	9.83	6.06e-15	3.23e-07	1.08	0.76	Corneal astigmatism;	chr4:119400672	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs3733524	ENSG00000275858.1	RP11-291L22.8	9.83	6.06e-15	3.23e-07	1.08	0.76	Corneal astigmatism;	chr4:119502574	chr10:38450738~38451069:-
LAML	trans	rs1552244	1	rs6791810	ENSG00000230342.2	FANCD2P2	-9.82	6.45e-15	3.41e-07	-1.1	-0.76	Alzheimer's disease;	chr3:10082760	chr3:11859674~11891172:+
LAML	trans	rs916888	0.779	rs199498	ENSG00000263503.1	RP11-707O23.5	9.81	6.57e-15	3.47e-07	1	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45600869~45602340:-
LAML	trans	rs916888	0.821	rs199504	ENSG00000264057.1	RP11-583F2.1	-9.81	6.62e-15	3.5e-07	-1.05	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:64927634~64934203:+
LAML	trans	rs1552244	1	rs7626117	ENSG00000230342.2	FANCD2P2	9.8	6.89e-15	3.64e-07	1.04	0.76	Alzheimer's disease;	chr3:10098987	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.688	rs9875667	ENSG00000230342.2	FANCD2P2	9.79	7.18e-15	3.78e-07	1.07	0.76	Alzheimer's disease;	chr3:10138357	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs7633769	ENSG00000230342.2	FANCD2P2	9.79	7.25e-15	3.81e-07	1.06	0.76	Alzheimer's disease;	chr3:9978938	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.751	rs12715665	ENSG00000230342.2	FANCD2P2	9.79	7.25e-15	3.81e-07	1.06	0.76	Alzheimer's disease;	chr3:9979917	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs9312044	ENSG00000230342.2	FANCD2P2	9.79	7.25e-15	3.81e-07	1.06	0.76	Alzheimer's disease;	chr3:9995797	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.882	rs6796419	ENSG00000230342.2	FANCD2P2	9.79	7.25e-15	3.81e-07	1.06	0.76	Alzheimer's disease;	chr3:9999128	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.752	rs9867091	ENSG00000230342.2	FANCD2P2	9.79	7.25e-15	3.81e-07	1.06	0.76	Alzheimer's disease;	chr3:10001745	chr3:11859674~11891172:+
LAML	trans	rs916888	0.779	rs199498	ENSG00000280022.1	RP11-707O23.1	9.79	7.34e-15	3.85e-07	1	0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45592621~45593369:+
LAML	trans	rs11098499	0.909	rs11723839	ENSG00000275858.1	RP11-291L22.8	9.78	7.52e-15	3.93e-07	1.1	0.76	Corneal astigmatism;	chr4:119378518	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs12506546	ENSG00000275858.1	RP11-291L22.8	9.78	7.52e-15	3.93e-07	1.1	0.76	Corneal astigmatism;	chr4:119380463	chr10:38450738~38451069:-
LAML	trans	rs916888	0.531	rs183211	ENSG00000214425.5	LRRC37A4P	-9.78	7.63e-15	3.99e-07	-1.03	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45506741~45550335:-
LAML	trans	rs916888	0.61	rs199438	ENSG00000214425.5	LRRC37A4P	-9.78	7.63e-15	3.99e-07	-1.03	-0.76	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45506741~45550335:-
LAML	trans	rs877636	0.562	rs1131017	ENSG00000233778.3	RP11-777J24.1	-9.77	7.73e-15	4.03e-07	-0.84	-0.76	Cognitive function;	chr12:56042145	chr8:92144088~92144435:-
LAML	trans	rs9611565	0.659	rs169361	ENSG00000268568.1	AC007228.9	9.76	8.21e-15	4.27e-07	1.11	0.75	Vitiligo;	chr22:41481985	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.729	rs2413646	ENSG00000268568.1	AC007228.9	-9.76	8.21e-15	4.27e-07	-1.11	-0.75	Vitiligo;	chr22:41510321	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.729	rs2413647	ENSG00000268568.1	AC007228.9	-9.76	8.21e-15	4.27e-07	-1.11	-0.75	Vitiligo;	chr22:41511144	chr19:56672574~56673901:-
LAML	trans	rs1552244	0.882	rs3846168	ENSG00000230342.2	FANCD2P2	9.75	8.37e-15	4.36e-07	1.1	0.75	Alzheimer's disease;	chr3:9955241	chr3:11859674~11891172:+
LAML	trans	rs916888	0.61	rs199454	ENSG00000264057.1	RP11-583F2.1	-9.74	8.93e-15	4.62e-07	-0.98	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:64927634~64934203:+
LAML	trans	rs916888	0.61	rs199446	ENSG00000264057.1	RP11-583F2.1	-9.74	8.93e-15	4.62e-07	-0.98	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:64927634~64934203:+
LAML	trans	rs916888	0.61	rs199536	ENSG00000264057.1	RP11-583F2.1	-9.74	8.93e-15	4.62e-07	-0.98	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:64927634~64934203:+
LAML	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	9.71	9.97e-15	5.12e-07	1.05	0.75	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
LAML	trans	rs1552244	0.882	rs13100734	ENSG00000230342.2	FANCD2P2	9.7	1.06e-14	5.41e-07	1.09	0.75	Alzheimer's disease;	chr3:9981194	chr3:11859674~11891172:+
LAML	trans	rs11098499	0.909	rs10017335	ENSG00000275858.1	RP11-291L22.8	-9.68	1.15e-14	5.86e-07	-1.07	-0.75	Corneal astigmatism;	chr4:119460368	chr10:38450738~38451069:-
LAML	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-9.67	1.19e-14	6.07e-07	-0.84	-0.75	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
LAML	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-9.67	1.19e-14	6.07e-07	-0.84	-0.75	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
LAML	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-9.67	1.19e-14	6.07e-07	-0.84	-0.75	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
LAML	trans	rs9611565	0.918	rs4822024	ENSG00000268568.1	AC007228.9	-9.66	1.27e-14	6.44e-07	-1.11	-0.75	Vitiligo;	chr22:41361643	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs79005	ENSG00000268568.1	AC007228.9	9.65	1.33e-14	6.68e-07	1.11	0.75	Vitiligo;	chr22:41439540	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.608	rs202652	ENSG00000268568.1	AC007228.9	9.65	1.33e-14	6.68e-07	1.11	0.75	Vitiligo;	chr22:41442788	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs202653	ENSG00000268568.1	AC007228.9	9.65	1.33e-14	6.68e-07	1.11	0.75	Vitiligo;	chr22:41444154	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs202655	ENSG00000268568.1	AC007228.9	9.65	1.33e-14	6.68e-07	1.11	0.75	Vitiligo;	chr22:41445560	chr19:56672574~56673901:-
LAML	trans	rs727563	0.58	rs202626	ENSG00000268568.1	AC007228.9	9.65	1.33e-14	6.68e-07	1.11	0.75	Crohn's disease;Inflammatory bowel disease;	chr22:41451186	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.532	rs202627	ENSG00000268568.1	AC007228.9	9.65	1.33e-14	6.68e-07	1.11	0.75	Vitiligo;	chr22:41451363	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202628	ENSG00000268568.1	AC007228.9	-9.65	1.33e-14	6.68e-07	-1.11	-0.75	Vitiligo;	chr22:41453509	chr19:56672574~56673901:-
LAML	trans	rs202629	1	rs202629	ENSG00000268568.1	AC007228.9	9.65	1.33e-14	6.68e-07	1.11	0.75	Cannabis dependence symptom count;	chr22:41453971	chr19:56672574~56673901:-
LAML	trans	rs877636	0.692	rs11171739	ENSG00000233778.3	RP11-777J24.1	9.64	1.36e-14	6.87e-07	0.83	0.75	Cognitive function;	chr12:56076841	chr8:92144088~92144435:-
LAML	trans	rs1552244	0.872	rs35988239	ENSG00000230342.2	FANCD2P2	9.63	1.4e-14	7.03e-07	1.13	0.75	Alzheimer's disease;	chr3:10032461	chr3:11859674~11891172:+
LAML	trans	rs13177918	0.75	rs58256223	ENSG00000239528.1	RPS14P8	9.63	1.4e-14	7.05e-07	0.91	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442456	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.75	rs59354956	ENSG00000239528.1	RPS14P8	9.63	1.4e-14	7.05e-07	0.91	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442457	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.603	rs13175992	ENSG00000239528.1	RPS14P8	9.63	1.43e-14	7.18e-07	0.95	0.75	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150451026	chr5:116562562~116562930:+
LAML	trans	rs916888	0.61	rs199453	ENSG00000214425.5	LRRC37A4P	-9.61	1.53e-14	7.66e-07	-1.01	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45506741~45550335:-
LAML	trans	rs916888	0.773	rs9896243	ENSG00000214425.5	LRRC37A4P	-9.61	1.54e-14	7.69e-07	-1.08	-0.75	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45506741~45550335:-
LAML	trans	rs9611565	0.729	rs73176686	ENSG00000268568.1	AC007228.9	-9.6	1.58e-14	7.92e-07	-1.11	-0.75	Vitiligo;	chr22:41386115	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.729	rs4822027	ENSG00000268568.1	AC007228.9	-9.6	1.58e-14	7.92e-07	-1.11	-0.75	Vitiligo;	chr22:41390223	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.729	rs73176689	ENSG00000268568.1	AC007228.9	-9.6	1.59e-14	7.92e-07	-1.11	-0.75	Vitiligo;	chr22:41386629	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs5758368	ENSG00000268568.1	AC007228.9	-9.57	1.79e-14	8.89e-07	-1.11	-0.75	Vitiligo;	chr22:41466284	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202631	ENSG00000268568.1	AC007228.9	9.57	1.79e-14	8.89e-07	1.11	0.75	Vitiligo;	chr22:41467419	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs19573	ENSG00000268568.1	AC007228.9	9.57	1.79e-14	8.89e-07	1.11	0.75	Vitiligo;	chr22:41469805	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs79011	ENSG00000268568.1	AC007228.9	9.57	1.79e-14	8.89e-07	1.11	0.75	Vitiligo;	chr22:41470934	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.863	rs1155576	ENSG00000275858.1	RP11-291L22.8	9.57	1.85e-14	9.05e-07	1.02	0.75	Corneal astigmatism;	chr4:119529004	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs6858592	ENSG00000275858.1	RP11-291L22.8	9.57	1.85e-14	9.05e-07	1.02	0.75	Corneal astigmatism;	chr4:119537537	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs9997631	ENSG00000275858.1	RP11-291L22.8	9.57	1.85e-14	9.05e-07	1.02	0.75	Corneal astigmatism;	chr4:119548840	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs10018280	ENSG00000275858.1	RP11-291L22.8	9.57	1.85e-14	9.05e-07	1.02	0.75	Corneal astigmatism;	chr4:119556984	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs6534141	ENSG00000275858.1	RP11-291L22.8	9.57	1.85e-14	9.05e-07	1.02	0.75	Corneal astigmatism;	chr4:119564068	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs2127823	ENSG00000275858.1	RP11-291L22.8	9.57	1.85e-14	9.05e-07	1.02	0.75	Corneal astigmatism;	chr4:119564515	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3775858	ENSG00000275858.1	RP11-291L22.8	9.57	1.85e-14	9.05e-07	1.02	0.75	Corneal astigmatism;	chr4:119564873	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs10020034	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119373176	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.618	rs28491261	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119373745	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs59394118	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119374396	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs9996417	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119374707	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs59866101	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119375436	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.618	rs6858383	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119375617	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.697	rs6832410	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119375645	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs1112817	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119376645	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.779	rs10016060	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119377257	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10005644	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119377322	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.697	rs10016448	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119377690	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.657	rs9996569	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119377849	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs11723757	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119378514	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.908	rs11729050	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119378911	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs28429722	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119378938	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10014845	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119379922	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.779	rs7674500	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119382438	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs28884220	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119386056	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs28793658	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119386059	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs4507344	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119386330	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.697	rs4373140	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119386543	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs13113483	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119387884	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.542	rs10440343	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119388632	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs28668716	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119388720	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.779	rs10011097	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119389204	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.542	rs7677836	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119389483	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs10002083	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119389997	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10024844	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119390373	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs7437420	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119391748	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs4345162	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119391804	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.657	rs4463052	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119392103	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.697	rs4560394	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119392280	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs13151285	ENSG00000275858.1	RP11-291L22.8	9.56	1.91e-14	9.05e-07	1.08	0.75	Corneal astigmatism;	chr4:119393586	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs2389803	ENSG00000275858.1	RP11-291L22.8	-9.52	2.24e-14	1.05e-06	-1.03	-0.75	Corneal astigmatism;	chr4:119472356	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs28714195	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119395795	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.738	rs72918577	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119405546	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs72676074	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119438686	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.738	rs28408407	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119454875	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs1809406	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119455967	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs2389809	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119456244	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs9994810	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119460435	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.697	rs10020027	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119460724	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.779	rs7356491	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119460819	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.908	rs28499576	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119465522	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs13107475	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119471856	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.954	rs10034623	ENSG00000275858.1	RP11-291L22.8	9.52	2.24e-14	1.05e-06	1.03	0.75	Corneal astigmatism;	chr4:119476674	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.765	rs132907	ENSG00000268568.1	AC007228.9	9.52	2.26e-14	1.06e-06	1.09	0.75	Vitiligo;	chr22:41405264	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.681	rs6002372	ENSG00000268568.1	AC007228.9	9.52	2.26e-14	1.06e-06	1.09	0.75	Vitiligo;	chr22:41405295	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs132908	ENSG00000268568.1	AC007228.9	9.52	2.26e-14	1.06e-06	1.09	0.75	Vitiligo;	chr22:41405791	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.643	rs202634	ENSG00000268568.1	AC007228.9	9.52	2.26e-14	1.06e-06	1.09	0.75	Vitiligo;	chr22:41413619	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.918	rs7290404	ENSG00000268568.1	AC007228.9	-9.51	2.41e-14	1.12e-06	-1.1	-0.75	Vitiligo;	chr22:41353792	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.918	rs12484074	ENSG00000268568.1	AC007228.9	-9.51	2.41e-14	1.12e-06	-1.1	-0.75	Vitiligo;	chr22:41356743	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.918	rs9538	ENSG00000268568.1	AC007228.9	-9.51	2.41e-14	1.12e-06	-1.1	-0.75	Vitiligo;	chr22:41359853	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.918	rs9611561	ENSG00000268568.1	AC007228.9	-9.51	2.41e-14	1.12e-06	-1.1	-0.75	Vitiligo;	chr22:41361230	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.918	rs9611562	ENSG00000268568.1	AC007228.9	-9.51	2.41e-14	1.12e-06	-1.1	-0.75	Vitiligo;	chr22:41364168	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.918	rs9611566	ENSG00000268568.1	AC007228.9	9.51	2.41e-14	1.12e-06	1.1	0.75	Vitiligo;	chr22:41372621	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs9611602	ENSG00000268568.1	AC007228.9	-9.49	2.6e-14	1.17e-06	-1.1	-0.75	Vitiligo;	chr22:41512401	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.863	rs13134665	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119505275	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3775843	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119506689	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3775844	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119506878	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs7699064	ENSG00000275858.1	RP11-291L22.8	-9.49	2.61e-14	1.17e-06	-1.06	-0.75	Corneal astigmatism;	chr4:119507154	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs7664986	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119508797	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.818	rs10008791	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119510314	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs11736416	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119510506	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3775845	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119511292	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs1383532	ENSG00000275858.1	RP11-291L22.8	-9.49	2.61e-14	1.17e-06	-1.06	-0.75	Corneal astigmatism;	chr4:119513249	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs1383533	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119513421	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs2291185	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119513678	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs10030660	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119515549	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs13149407	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119516670	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs34868248	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119521275	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3733525	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119525893	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3775847	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119526487	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3775848	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119526569	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs10013305	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119529269	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3775849	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119529753	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.818	rs7688802	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119530513	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs7695620	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119531621	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs12502389	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119533036	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.821	rs3775852	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119533401	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.82	rs6534140	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119534156	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs7657849	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119534339	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs10034450	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119534494	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs1480939	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119535772	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs1480940	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119536527	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.82	rs13128602	ENSG00000275858.1	RP11-291L22.8	-9.49	2.61e-14	1.17e-06	-1.06	-0.75	Corneal astigmatism;	chr4:119538211	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs58452170	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119538519	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs1552095	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119539151	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs7678400	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119540802	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs1480936	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119541706	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs1010740	ENSG00000275858.1	RP11-291L22.8	-9.49	2.61e-14	1.17e-06	-1.06	-0.75	Corneal astigmatism;	chr4:119542254	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs11098531	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119543846	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs28718422	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119545149	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs12498539	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119547215	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.818	rs12498599	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119547348	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs10009626	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119548850	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3822194	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119550493	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3822195	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119550505	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3775854	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119550816	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs2306456	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119551267	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs2306457	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119551684	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs11947234	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119553704	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs6853998	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119554705	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs6858777	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119554811	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs11933966	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119555560	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs36040693	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119556461	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs11731756	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119557541	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs34308924	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119560276	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs2170276	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119564669	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs1552092	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119567341	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3736115	ENSG00000275858.1	RP11-291L22.8	-9.49	2.61e-14	1.17e-06	-1.06	-0.75	Corneal astigmatism;	chr4:119567548	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs59732491	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119568433	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs9884402	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119568827	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.731	rs9995026	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119569344	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs11723090	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119569437	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs11098532	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119569571	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs13140391	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119582282	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs13140409	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119582305	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs6833334	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119583072	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.82	rs6829903	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119585729	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs7669520	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119594123	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.82	rs11737395	ENSG00000275858.1	RP11-291L22.8	9.49	2.61e-14	1.17e-06	1.06	0.75	Corneal astigmatism;	chr4:119599549	chr10:38450738~38451069:-
LAML	trans	rs2657294	0.62	rs4746261	ENSG00000172974.11	AC007318.5	-9.47	2.8e-14	1.25e-06	-0.9	-0.74	Pneumonia;	chr10:75085874	chr2:65205108~65205988:+
LAML	trans	rs9611565	0.918	rs4820438	ENSG00000268568.1	AC007228.9	-9.46	2.95e-14	1.32e-06	-1.08	-0.74	Vitiligo;	chr22:41371131	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs1569516	ENSG00000268568.1	AC007228.9	-9.43	3.38e-14	1.5e-06	-1.09	-0.74	Vitiligo;	chr22:41514240	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs9611603	ENSG00000268568.1	AC007228.9	-9.43	3.38e-14	1.5e-06	-1.09	-0.74	Vitiligo;	chr22:41516746	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs17367716	ENSG00000268568.1	AC007228.9	-9.43	3.38e-14	1.5e-06	-1.09	-0.74	Vitiligo;	chr22:41517840	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs9611604	ENSG00000268568.1	AC007228.9	-9.43	3.38e-14	1.5e-06	-1.09	-0.74	Vitiligo;	chr22:41519997	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs12484694	ENSG00000268568.1	AC007228.9	-9.43	3.38e-14	1.5e-06	-1.09	-0.74	Vitiligo;	chr22:41523326	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.579	rs73178621	ENSG00000268568.1	AC007228.9	-9.43	3.38e-14	1.5e-06	-1.09	-0.74	Vitiligo;	chr22:41525661	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs28530678	ENSG00000268568.1	AC007228.9	-9.43	3.38e-14	1.5e-06	-1.09	-0.74	Vitiligo;	chr22:41538957	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.527	rs73178638	ENSG00000268568.1	AC007228.9	-9.43	3.38e-14	1.5e-06	-1.09	-0.74	Vitiligo;	chr22:41546900	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs4822038	ENSG00000268568.1	AC007228.9	-9.43	3.38e-14	1.5e-06	-1.09	-0.74	Vitiligo;	chr22:41562491	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.865	rs4001305	ENSG00000275858.1	RP11-291L22.8	9.42	3.48e-14	1.54e-06	1.03	0.74	Corneal astigmatism;	chr4:119438081	chr10:38450738~38451069:-
LAML	trans	rs916888	0.61	rs199453	ENSG00000264057.1	RP11-583F2.1	9.42	3.51e-14	1.55e-06	0.96	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:64927634~64934203:+
LAML	trans	rs877636	0.562	rs10876864	ENSG00000233778.3	RP11-777J24.1	-9.41	3.63e-14	1.6e-06	-0.86	-0.74	Cognitive function;	chr12:56007301	chr8:92144088~92144435:-
LAML	trans	rs11098499	0.82	rs28394116	ENSG00000275858.1	RP11-291L22.8	9.39	3.9e-14	1.72e-06	1.05	0.74	Corneal astigmatism;	chr4:119603128	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs3756156	ENSG00000275858.1	RP11-291L22.8	9.39	3.9e-14	1.72e-06	1.05	0.74	Corneal astigmatism;	chr4:119603686	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.82	rs28535956	ENSG00000275858.1	RP11-291L22.8	-9.39	3.9e-14	1.72e-06	-1.05	-0.74	Corneal astigmatism;	chr4:119615703	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.82	rs28578366	ENSG00000275858.1	RP11-291L22.8	-9.39	3.9e-14	1.72e-06	-1.05	-0.74	Corneal astigmatism;	chr4:119615750	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs13136462	ENSG00000275858.1	RP11-291L22.8	9.39	3.9e-14	1.72e-06	1.05	0.74	Corneal astigmatism;	chr4:119622018	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.82	rs13122709	ENSG00000275858.1	RP11-291L22.8	9.39	3.9e-14	1.72e-06	1.05	0.74	Corneal astigmatism;	chr4:119634201	chr10:38450738~38451069:-
LAML	trans	rs1552244	0.882	rs9812006	ENSG00000230342.2	FANCD2P2	9.38	4.03e-14	1.77e-06	1.05	0.74	Alzheimer's disease;	chr3:9980974	chr3:11859674~11891172:+
LAML	trans	rs11098499	0.863	rs6835635	ENSG00000275858.1	RP11-291L22.8	9.38	4.08e-14	1.79e-06	1.05	0.74	Corneal astigmatism;	chr4:119537712	chr10:38450738~38451069:-
LAML	trans	rs916888	0.61	rs199436	ENSG00000264057.1	RP11-583F2.1	-9.38	4.12e-14	1.8e-06	-0.96	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:64927634~64934203:+
LAML	trans	rs916888	0.61	rs142167	ENSG00000264057.1	RP11-583F2.1	-9.38	4.12e-14	1.8e-06	-0.96	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:64927634~64934203:+
LAML	trans	rs916888	0.61	rs199452	ENSG00000264057.1	RP11-583F2.1	9.38	4.12e-14	1.8e-06	0.96	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:64927634~64934203:+
LAML	trans	rs916888	0.647	rs199449	ENSG00000264057.1	RP11-583F2.1	9.38	4.12e-14	1.8e-06	0.96	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:64927634~64934203:+
LAML	trans	rs916888	0.61	rs199444	ENSG00000264057.1	RP11-583F2.1	9.38	4.12e-14	1.8e-06	0.96	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:64927634~64934203:+
LAML	trans	rs916888	0.61	rs199442	ENSG00000264057.1	RP11-583F2.1	9.38	4.12e-14	1.8e-06	0.96	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:64927634~64934203:+
LAML	trans	rs1816752	1	rs1816752	ENSG00000237917.1	PARP4P1	9.38	4.15e-14	1.82e-06	1.02	0.74	Obesity-related traits;	chr13:24406811	chrY:26594851~26634652:-
LAML	trans	rs11098499	0.78	rs12504773	ENSG00000275858.1	RP11-291L22.8	9.38	4.16e-14	1.82e-06	1.07	0.74	Corneal astigmatism;	chr4:119640994	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.78	rs7680914	ENSG00000275858.1	RP11-291L22.8	9.38	4.16e-14	1.82e-06	1.07	0.74	Corneal astigmatism;	chr4:119641898	chr10:38450738~38451069:-
LAML	trans	rs1816752	0.935	rs4770676	ENSG00000237917.1	PARP4P1	9.38	4.17e-14	1.82e-06	1.01	0.74	Obesity-related traits;	chr13:24429745	chrY:26594851~26634652:-
LAML	trans	rs1816752	1	rs7326932	ENSG00000237917.1	PARP4P1	9.38	4.17e-14	1.82e-06	1.01	0.74	Obesity-related traits;	chr13:24430355	chrY:26594851~26634652:-
LAML	trans	rs7949030	0.523	rs67308910	ENSG00000186676.3	EEF1GP1	9.37	4.23e-14	1.84e-06	1.05	0.74	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62609887	chr7:125033453~125035301:+
LAML	trans	rs9611565	0.659	rs4822035	ENSG00000268568.1	AC007228.9	9.37	4.32e-14	1.85e-06	1.08	0.74	Vitiligo;	chr22:41539908	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs17367849	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41527640	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs1810460	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41531696	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs1810461	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41531816	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.625	rs73178625	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41532316	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs73178626	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41532367	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs4822034	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41535006	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.625	rs9611606	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41535070	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs116959331	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41536770	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs56319767	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41537833	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs73178632	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41538569	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs12483998	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41539358	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs4822036	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41540015	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs12483786	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41542532	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs12484228	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41543735	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs9607812	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41545239	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs9607813	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41545475	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs4822037	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41549109	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs9611609	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41549353	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs9611610	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41553255	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs9607815	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41554667	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs9607816	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41554893	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs56364401	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41555239	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs73178641	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41556071	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.659	rs12484175	ENSG00000268568.1	AC007228.9	-9.37	4.32e-14	1.85e-06	-1.08	-0.74	Vitiligo;	chr22:41557735	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.909	rs73842633	ENSG00000275858.1	RP11-291L22.8	9.36	4.44e-14	1.9e-06	1.05	0.74	Corneal astigmatism;	chr4:119454309	chr10:38450738~38451069:-
LAML	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	9.35	4.64e-14	1.99e-06	0.84	0.74	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
LAML	trans	rs877636	0.562	rs1131017	ENSG00000225071.1	GS1-184P14.2	-9.35	4.71e-14	2.01e-06	-0.84	-0.74	Cognitive function;	chr12:56042145	chrX:24429573~24429920:-
LAML	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	9.35	4.73e-14	2.02e-06	1.14	0.74	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
LAML	trans	rs9611565	0.659	rs28623192	ENSG00000268568.1	AC007228.9	-9.33	5.05e-14	2.15e-06	-1.07	-0.74	Vitiligo;	chr22:41544520	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.863	rs3822190	ENSG00000275858.1	RP11-291L22.8	9.31	5.52e-14	2.35e-06	1.05	0.74	Corneal astigmatism;	chr4:119506943	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3822191	ENSG00000275858.1	RP11-291L22.8	9.31	5.52e-14	2.35e-06	1.05	0.74	Corneal astigmatism;	chr4:119506946	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.592	rs12484467	ENSG00000268568.1	AC007228.9	-9.3	5.72e-14	2.43e-06	-1.09	-0.74	Vitiligo;	chr22:41561606	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.605	rs202638	ENSG00000268568.1	AC007228.9	9.3	5.73e-14	2.44e-06	1.05	0.74	Vitiligo;	chr22:41459454	chr19:56672574~56673901:-
LAML	trans	rs916888	0.61	rs199454	ENSG00000264070.1	DND1P1	-9.3	5.82e-14	2.47e-06	-0.86	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46722744	chr17:45585871~45586929:+
LAML	trans	rs916888	0.61	rs199446	ENSG00000264070.1	DND1P1	-9.3	5.82e-14	2.47e-06	-0.86	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46735803	chr17:45585871~45586929:+
LAML	trans	rs916888	0.61	rs199536	ENSG00000264070.1	DND1P1	-9.3	5.82e-14	2.47e-06	-0.86	-0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46743059	chr17:45585871~45586929:+
LAML	trans	rs11098499	0.73	rs12505735	ENSG00000275858.1	RP11-291L22.8	9.29	6.01e-14	2.55e-06	1.09	0.74	Corneal astigmatism;	chr4:119611801	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.765	rs132905	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41403102	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs132909	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41406027	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.681	rs5751094	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41407275	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs132914	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41409745	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs132915	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41409778	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.681	rs132918	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41412346	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.722	rs202635	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41413633	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs132920	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41414166	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs202659	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41415616	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs132921	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41416040	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs202663	ENSG00000268568.1	AC007228.9	9.28	6.44e-14	2.7e-06	1.08	0.74	Vitiligo;	chr22:41416815	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.729	rs132902	ENSG00000268568.1	AC007228.9	-9.26	6.95e-14	2.91e-06	-1.09	-0.74	Vitiligo;	chr22:41401754	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.909	rs79026312	ENSG00000275858.1	RP11-291L22.8	9.24	7.49e-14	3.13e-06	1.07	0.74	Corneal astigmatism;	chr4:119519522	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs35111518	ENSG00000275858.1	RP11-291L22.8	9.24	7.49e-14	3.13e-06	1.07	0.74	Corneal astigmatism;	chr4:119519527	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.559	rs1006407	ENSG00000268568.1	AC007228.9	-9.24	7.49e-14	3.13e-06	-1.15	-0.74	Vitiligo;	chr22:41576028	chr19:56672574~56673901:-
LAML	trans	rs916888	0.779	rs199498	ENSG00000264070.1	DND1P1	9.21	8.44e-14	3.52e-06	0.88	0.74	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45585871~45586929:+
LAML	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-9.2	8.94e-14	3.72e-06	-1.05	-0.74	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
LAML	trans	rs1552244	0.816	rs9847657	ENSG00000230342.2	FANCD2P2	9.2	9.02e-14	3.75e-06	1.1	0.73	Alzheimer's disease;	chr3:10131808	chr3:11859674~11891172:+
LAML	trans	rs12145833	0.538	rs61833885	ENSG00000154608.12	CEP170P1	-9.18	9.8e-14	4.07e-06	-1.06	-0.73	Obesity (early onset extreme);	chr1:243233886	chr4:118467590~118554204:+
LAML	trans	rs12145833	0.538	rs10926977	ENSG00000154608.12	CEP170P1	-9.18	9.8e-14	4.07e-06	-1.06	-0.73	Obesity (early onset extreme);	chr1:243248065	chr4:118467590~118554204:+
LAML	trans	rs916888	0.531	rs183211	ENSG00000264057.1	RP11-583F2.1	9.17	9.98e-14	4.14e-06	0.95	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:64927634~64934203:+
LAML	trans	rs916888	0.61	rs199438	ENSG00000264057.1	RP11-583F2.1	9.17	9.98e-14	4.14e-06	0.95	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:64927634~64934203:+
LAML	trans	rs12145833	0.538	rs12026408	ENSG00000154608.12	CEP170P1	-9.16	1.05e-13	4.35e-06	-1.06	-0.73	Obesity (early onset extreme);	chr1:243203503	chr4:118467590~118554204:+
LAML	trans	rs9611565	0.838	rs4239894	ENSG00000268568.1	AC007228.9	-9.15	1.1e-13	4.55e-06	-1.08	-0.73	Vitiligo;	chr22:41349544	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.954	rs28572238	ENSG00000275858.1	RP11-291L22.8	9.13	1.18e-13	4.86e-06	1.04	0.73	Corneal astigmatism;	chr4:119395531	chr10:38450738~38451069:-
LAML	trans	rs916888	0.61	rs199436	ENSG00000264070.1	DND1P1	-9.13	1.2e-13	4.92e-06	-0.85	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46711919	chr17:45585871~45586929:+
LAML	trans	rs916888	0.61	rs142167	ENSG00000264070.1	DND1P1	-9.13	1.2e-13	4.92e-06	-0.85	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46717868	chr17:45585871~45586929:+
LAML	trans	rs916888	0.61	rs199452	ENSG00000264070.1	DND1P1	9.13	1.2e-13	4.92e-06	0.85	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723974	chr17:45585871~45586929:+
LAML	trans	rs916888	0.647	rs199449	ENSG00000264070.1	DND1P1	9.13	1.2e-13	4.92e-06	0.85	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731536	chr17:45585871~45586929:+
LAML	trans	rs916888	0.61	rs199444	ENSG00000264070.1	DND1P1	9.13	1.2e-13	4.92e-06	0.85	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740910	chr17:45585871~45586929:+
LAML	trans	rs916888	0.61	rs199442	ENSG00000264070.1	DND1P1	9.13	1.2e-13	4.92e-06	0.85	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742756	chr17:45585871~45586929:+
LAML	trans	rs12145833	0.538	rs4658547	ENSG00000154608.12	CEP170P1	9.12	1.23e-13	5.05e-06	1.04	0.73	Obesity (early onset extreme);	chr1:243227829	chr4:118467590~118554204:+
LAML	trans	rs12145833	0.538	rs9803701	ENSG00000154608.12	CEP170P1	9.12	1.23e-13	5.05e-06	1.04	0.73	Obesity (early onset extreme);	chr1:243228332	chr4:118467590~118554204:+
LAML	trans	rs9611565	0.592	rs5758427	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41703684	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs5751139	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41703977	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs5758428	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41710212	chr19:56672574~56673901:-
LAML	trans	rs727563	0.636	rs2413653	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41710992	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.546	rs5758430	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41713840	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.546	rs5758431	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41713913	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.545	rs5758432	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41715689	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.546	rs739129	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41722245	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.546	rs739132	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41727095	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.546	rs2092274	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41727733	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs5758436	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41728261	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs7291736	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41728870	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs5758439	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41735758	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs5751145	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41737548	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs768414	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41739747	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs8141103	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41740926	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs5751147	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41743050	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs5751148	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41743074	chr19:56672574~56673901:-
LAML	trans	rs727563	0.635	rs5751149	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41743497	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs715498	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41752463	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs1534932	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41754142	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs2050031	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41756262	chr19:56672574~56673901:-
LAML	trans	rs5751150	1	rs5751150	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Cannabis dependence symptom count;	chr22:41757288	chr19:56672574~56673901:-
LAML	trans	rs727563	0.562	rs5758458	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41758128	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs2899347	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41762200	chr19:56672574~56673901:-
LAML	trans	rs727563	0.635	rs713988	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41763068	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs2050033	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41763225	chr19:56672574~56673901:-
LAML	trans	rs727563	0.593	rs5758461	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41766185	chr19:56672574~56673901:-
LAML	trans	rs727563	0.635	rs2899348	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41768512	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs2899349	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41768656	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs1983576	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41770482	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.503	rs5996062	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41771460	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs6002474	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41772177	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs5996063	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41772763	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.503	rs5751156	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41774021	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs6519289	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41774428	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs5758464	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41775296	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs5758465	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41779310	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs5751160	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41779691	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs139561	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41799406	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs4820444	ENSG00000268568.1	AC007228.9	9.09	1.45e-13	5.72e-06	1.12	0.73	Vitiligo;	chr22:41806602	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs739136	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41704271	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs964898	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41746302	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs45500192	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41781895	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs9607841	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41790834	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs9611667	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41791011	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs9607842	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41796718	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs4822052	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41797737	chr19:56672574~56673901:-
LAML	trans	rs727563	0.638	rs4820443	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41797909	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs139560	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41798958	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs139562	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41800680	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs139566	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41803273	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs4512	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41810080	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs9611672	ENSG00000268568.1	AC007228.9	-9.09	1.45e-13	5.72e-06	-1.12	-0.73	Vitiligo;	chr22:41813918	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.84	rs4822025	ENSG00000268568.1	AC007228.9	-9.08	1.5e-13	5.9e-06	-1.07	-0.73	Vitiligo;	chr22:41380642	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.527	rs2234053	ENSG00000268568.1	AC007228.9	-9.08	1.5e-13	5.9e-06	-1.07	-0.73	Vitiligo;	chr22:41381311	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.802	rs2234058	ENSG00000268568.1	AC007228.9	-9.08	1.5e-13	5.9e-06	-1.07	-0.73	Vitiligo;	chr22:41381879	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.84	rs2234059	ENSG00000268568.1	AC007228.9	-9.08	1.5e-13	5.9e-06	-1.07	-0.73	Vitiligo;	chr22:41381909	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.84	rs3788584	ENSG00000268568.1	AC007228.9	-9.08	1.5e-13	5.9e-06	-1.07	-0.73	Vitiligo;	chr22:41383069	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs767593	ENSG00000268568.1	AC007228.9	-9.08	1.5e-13	5.9e-06	-1.07	-0.73	Vitiligo;	chr22:41383967	chr19:56672574~56673901:-
LAML	trans	rs916888	0.61	rs199530	ENSG00000280022.1	RP11-707O23.1	-9.07	1.55e-13	6.1e-06	-0.91	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45592621~45593369:+
LAML	trans	rs916888	0.647	rs199523	ENSG00000280022.1	RP11-707O23.1	-9.06	1.62e-13	6.37e-06	-0.92	-0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45592621~45593369:+
LAML	trans	rs9611565	0.802	rs9611571	ENSG00000268568.1	AC007228.9	-9.05	1.72e-13	6.73e-06	-1.07	-0.73	Vitiligo;	chr22:41388863	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.865	rs11098513	ENSG00000275858.1	RP11-291L22.8	9.04	1.72e-13	6.76e-06	1.04	0.73	Corneal astigmatism;	chr4:119394920	chr10:38450738~38451069:-
LAML	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	9.04	1.78e-13	6.96e-06	0.77	0.73	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
LAML	trans	rs9611565	0.765	rs9607800	ENSG00000268568.1	AC007228.9	-9.04	1.79e-13	6.99e-06	-1.07	-0.73	Vitiligo;	chr22:41388558	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.802	rs73176692	ENSG00000268568.1	AC007228.9	-9.04	1.79e-13	6.99e-06	-1.07	-0.73	Vitiligo;	chr22:41389731	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs28604950	ENSG00000268568.1	AC007228.9	-9.04	1.79e-13	6.99e-06	-1.07	-0.73	Vitiligo;	chr22:41389808	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.802	rs73176694	ENSG00000268568.1	AC007228.9	-9.04	1.79e-13	6.99e-06	-1.07	-0.73	Vitiligo;	chr22:41390784	chr19:56672574~56673901:-
LAML	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-9.04	1.8e-13	7.01e-06	-0.76	-0.73	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
LAML	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-9.04	1.8e-13	7.01e-06	-0.76	-0.73	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
LAML	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-9.04	1.8e-13	7.01e-06	-0.76	-0.73	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
LAML	trans	rs13177918	0.626	rs13175436	ENSG00000239528.1	RPS14P8	9.03	1.86e-13	7.23e-06	0.92	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150450974	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.626	rs67026795	ENSG00000239528.1	RPS14P8	9.03	1.86e-13	7.23e-06	0.92	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150452097	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.603	rs10447222	ENSG00000239528.1	RPS14P8	9.03	1.86e-13	7.23e-06	0.92	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150453104	chr5:116562562~116562930:+
LAML	trans	rs727563	0.569	rs73178647	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41568164	chr19:56672574~56673901:-
LAML	trans	rs727563	0.648	rs6002406	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41569233	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs4822044	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Vitiligo;	chr22:41583664	chr19:56672574~56673901:-
LAML	trans	rs727563	0.608	rs2076200	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41589952	chr19:56672574~56673901:-
LAML	trans	rs727563	0.552	rs4822045	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41589954	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs9611619	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Vitiligo;	chr22:41590710	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs4822046	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Vitiligo;	chr22:41591539	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs4822048	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Vitiligo;	chr22:41592221	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs4822049	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Vitiligo;	chr22:41597492	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs8779	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Vitiligo;	chr22:41674272	chr19:56672574~56673901:-
LAML	trans	rs727563	0.594	rs132807	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41675580	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs1811113	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Vitiligo;	chr22:41677130	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs5758405	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Vitiligo;	chr22:41680377	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs5758406	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Vitiligo;	chr22:41680637	chr19:56672574~56673901:-
LAML	trans	rs727563	0.594	rs5758408	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41681733	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs5758412	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Vitiligo;	chr22:41684799	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs13056262	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Vitiligo;	chr22:41685917	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.5	rs10775759	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Vitiligo;	chr22:41692154	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.546	rs739134	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Vitiligo;	chr22:41693619	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.513	rs739135	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Vitiligo;	chr22:41694065	chr19:56672574~56673901:-
LAML	trans	rs727563	0.636	rs2187795	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Crohn's disease;Inflammatory bowel disease;	chr22:41696221	chr19:56672574~56673901:-
LAML	trans	rs4822044	0.68	rs8138780	ENSG00000268568.1	AC007228.9	9.01	2.04e-13	7.82e-06	1.12	0.73	Cannabis dependence symptom count;	chr22:41701458	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs139571	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Vitiligo;	chr22:41818234	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs139573	ENSG00000268568.1	AC007228.9	-9.01	2.04e-13	7.82e-06	-1.12	-0.73	Vitiligo;	chr22:41818781	chr19:56672574~56673901:-
LAML	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	8.98	2.24e-13	8.57e-06	0.89	0.73	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
LAML	trans	rs11098499	0.863	rs10004484	ENSG00000275858.1	RP11-291L22.8	8.98	2.29e-13	8.75e-06	1.03	0.73	Corneal astigmatism;	chr4:119521273	chr10:38450738~38451069:-
LAML	trans	rs1816752	1	rs9507341	ENSG00000237917.1	PARP4P1	-8.96	2.43e-13	9.28e-06	-0.98	-0.73	Obesity-related traits;	chr13:24432440	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.669	rs7984513	ENSG00000237917.1	PARP4P1	-8.96	2.49e-13	9.49e-06	-1.02	-0.73	Obesity-related traits;	chr13:24445117	chrY:26594851~26634652:-
LAML	trans	rs916888	0.531	rs183211	ENSG00000264070.1	DND1P1	8.94	2.66e-13	1.01e-05	0.85	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46710944	chr17:45585871~45586929:+
LAML	trans	rs916888	0.61	rs199438	ENSG00000264070.1	DND1P1	8.94	2.66e-13	1.01e-05	0.85	0.73	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46714277	chr17:45585871~45586929:+
LAML	trans	rs13177918	0.626	rs3819332	ENSG00000239528.1	RPS14P8	8.94	2.68e-13	1.02e-05	0.92	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449187	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.626	rs13170300	ENSG00000239528.1	RPS14P8	8.94	2.68e-13	1.02e-05	0.92	0.73	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449748	chr5:116562562~116562930:+
LAML	trans	rs9611565	1	rs9611565	ENSG00000268568.1	AC007228.9	-8.94	2.76e-13	1.05e-05	-1.05	-0.73	Vitiligo;	chr22:41371482	chr19:56672574~56673901:-
LAML	trans	rs13177918	0.559	rs12109637	ENSG00000213058.3	RP4-765C7.2	8.93	2.85e-13	1.08e-05	1.02	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr1:178411616~178411972:+
LAML	trans	rs11098499	0.863	rs17050695	ENSG00000275858.1	RP11-291L22.8	8.93	2.87e-13	1.09e-05	0.95	0.72	Corneal astigmatism;	chr4:119568372	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.512	rs964899	ENSG00000268568.1	AC007228.9	8.92	2.99e-13	1.13e-05	1.08	0.72	Vitiligo;	chr22:41746382	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202618	ENSG00000268568.1	AC007228.9	8.92	3e-13	1.13e-05	1.1	0.72	Vitiligo;	chr22:41426852	chr19:56672574~56673901:-
LAML	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	8.91	3.07e-13	1.16e-05	0.9	0.72	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
LAML	trans	rs916888	0.61	rs199453	ENSG00000264070.1	DND1P1	8.9	3.16e-13	1.19e-05	0.84	0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46723580	chr17:45585871~45586929:+
LAML	trans	rs11098499	0.566	rs7664440	ENSG00000275858.1	RP11-291L22.8	8.9	3.23e-13	1.22e-05	1.03	0.72	Corneal astigmatism;	chr4:119657385	chr10:38450738~38451069:-
LAML	trans	rs13177918	1	rs13161334	ENSG00000213058.3	RP4-765C7.2	8.87	3.65e-13	1.37e-05	1.3	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr1:178411616~178411972:+
LAML	trans	rs13177918	1	rs35007082	ENSG00000213058.3	RP4-765C7.2	8.87	3.65e-13	1.37e-05	1.3	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr1:178411616~178411972:+
LAML	trans	rs13177918	1	rs13177918	ENSG00000213058.3	RP4-765C7.2	8.87	3.65e-13	1.37e-05	1.3	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr1:178411616~178411972:+
LAML	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-8.86	3.82e-13	1.44e-05	-0.81	-0.72	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
LAML	trans	rs877636	0.692	rs2271194	ENSG00000243538.1	CTB-55B8.1	-8.85	3.95e-13	1.48e-05	-0.87	-0.72	Cognitive function;	chr12:56083910	chr5:16902294~16902641:-
LAML	trans	rs877636	0.692	rs10876870	ENSG00000243538.1	CTB-55B8.1	-8.85	3.95e-13	1.48e-05	-0.87	-0.72	Cognitive function;	chr12:56084218	chr5:16902294~16902641:-
LAML	trans	rs877636	0.692	rs7971751	ENSG00000243538.1	CTB-55B8.1	-8.85	3.95e-13	1.48e-05	-0.87	-0.72	Cognitive function;	chr12:56084874	chr5:16902294~16902641:-
LAML	trans	rs11098499	0.866	rs12374244	ENSG00000275858.1	RP11-291L22.8	8.84	4.08e-13	1.53e-05	0.98	0.72	Corneal astigmatism;	chr4:119360817	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs12374352	ENSG00000275858.1	RP11-291L22.8	8.84	4.08e-13	1.53e-05	0.98	0.72	Corneal astigmatism;	chr4:119360822	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.84	rs9607799	ENSG00000268568.1	AC007228.9	-8.84	4.23e-13	1.58e-05	-1.05	-0.72	Vitiligo;	chr22:41381554	chr19:56672574~56673901:-
LAML	trans	rs727563	0.635	rs5758444	ENSG00000268568.1	AC007228.9	8.83	4.38e-13	1.64e-05	1.12	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41737917	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.84	rs2234052	ENSG00000268568.1	AC007228.9	-8.82	4.53e-13	1.69e-05	-1.05	-0.72	Vitiligo;	chr22:41381237	chr19:56672574~56673901:-
LAML	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-8.81	4.64e-13	1.73e-05	-0.76	-0.72	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
LAML	trans	rs727563	0.638	rs5996058	ENSG00000268568.1	AC007228.9	8.81	4.67e-13	1.74e-05	1.1	0.72	Crohn's disease;Inflammatory bowel disease;	chr22:41745448	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs5758450	ENSG00000268568.1	AC007228.9	8.81	4.67e-13	1.74e-05	1.1	0.72	Vitiligo;	chr22:41745636	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.802	rs4822028	ENSG00000268568.1	AC007228.9	-8.81	4.76e-13	1.77e-05	-1.06	-0.72	Vitiligo;	chr22:41393404	chr19:56672574~56673901:-
LAML	trans	rs1816752	0.716	rs9553289	ENSG00000237917.1	PARP4P1	-8.8	4.91e-13	1.83e-05	-1.02	-0.72	Obesity-related traits;	chr13:24400640	chrY:26594851~26634652:-
LAML	trans	rs916888	0.647	rs199524	ENSG00000280022.1	RP11-707O23.1	-8.8	4.92e-13	1.83e-05	-0.92	-0.72	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45592621~45593369:+
LAML	trans	rs11098499	0.954	rs6857105	ENSG00000275858.1	RP11-291L22.8	8.79	5.06e-13	1.88e-05	1.02	0.72	Corneal astigmatism;	chr4:119301143	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs1010739	ENSG00000275858.1	RP11-291L22.8	8.79	5.2e-13	1.93e-05	1.06	0.72	Corneal astigmatism;	chr4:119542316	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.802	rs9611577	ENSG00000268568.1	AC007228.9	-8.79	5.22e-13	1.94e-05	-1.06	-0.72	Vitiligo;	chr22:41397086	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs9611612	ENSG00000268568.1	AC007228.9	-8.78	5.41e-13	2.01e-05	-1.1	-0.72	Vitiligo;	chr22:41565185	chr19:56672574~56673901:-
LAML	trans	rs11098499	1	rs1011054	ENSG00000275858.1	RP11-291L22.8	-8.78	5.46e-13	2.02e-05	-0.99	-0.72	Corneal astigmatism;	chr4:119281232	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.729	rs137831	ENSG00000268568.1	AC007228.9	-8.78	5.47e-13	2.03e-05	-1.01	-0.72	Vitiligo;	chr22:41507809	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs202641	ENSG00000268568.1	AC007228.9	8.76	5.72e-13	2.12e-05	1.06	0.72	Vitiligo;	chr22:41437112	chr19:56672574~56673901:-
LAML	trans	rs1552244	0.882	rs56125067	ENSG00000230342.2	FANCD2P2	8.75	5.99e-13	2.21e-05	1.06	0.72	Alzheimer's disease;	chr3:9942446	chr3:11859674~11891172:+
LAML	trans	rs11098499	0.954	rs11098524	ENSG00000275858.1	RP11-291L22.8	8.75	6.06e-13	2.24e-05	1.02	0.72	Corneal astigmatism;	chr4:119468877	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.625	rs9607819	ENSG00000268568.1	AC007228.9	-8.74	6.34e-13	2.34e-05	-1.02	-0.72	Vitiligo;	chr22:41562858	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.921	rs6002333	ENSG00000268568.1	AC007228.9	-8.74	6.41e-13	2.36e-05	-1.04	-0.72	Vitiligo;	chr22:41323465	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.921	rs3927	ENSG00000268568.1	AC007228.9	-8.74	6.41e-13	2.36e-05	-1.04	-0.72	Vitiligo;	chr22:41326860	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.921	rs761366	ENSG00000268568.1	AC007228.9	-8.74	6.41e-13	2.36e-05	-1.04	-0.72	Vitiligo;	chr22:41348018	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.754	rs9999724	ENSG00000275858.1	RP11-291L22.8	8.71	7.37e-13	2.69e-05	1	0.72	Corneal astigmatism;	chr4:119318789	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs714899	ENSG00000275858.1	RP11-291L22.8	8.71	7.37e-13	2.69e-05	1	0.72	Corneal astigmatism;	chr4:119321880	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs66900435	ENSG00000275858.1	RP11-291L22.8	8.71	7.37e-13	2.69e-05	1	0.72	Corneal astigmatism;	chr4:119328270	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs17595608	ENSG00000275858.1	RP11-291L22.8	8.71	7.37e-13	2.69e-05	1	0.72	Corneal astigmatism;	chr4:119329351	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs1980027	ENSG00000275858.1	RP11-291L22.8	8.71	7.37e-13	2.69e-05	1	0.72	Corneal astigmatism;	chr4:119330422	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.662	rs13108589	ENSG00000275858.1	RP11-291L22.8	8.71	7.37e-13	2.69e-05	1	0.72	Corneal astigmatism;	chr4:119346947	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs10213554	ENSG00000275858.1	RP11-291L22.8	-8.71	7.37e-13	2.69e-05	-1	-0.72	Corneal astigmatism;	chr4:119339630	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.592	rs9611613	ENSG00000268568.1	AC007228.9	-8.7	7.68e-13	2.79e-05	-1.1	-0.72	Vitiligo;	chr22:41565827	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs12483860	ENSG00000268568.1	AC007228.9	-8.7	7.68e-13	2.79e-05	-1.1	-0.72	Vitiligo;	chr22:41565912	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs12484254	ENSG00000268568.1	AC007228.9	-8.7	7.68e-13	2.79e-05	-1.1	-0.72	Vitiligo;	chr22:41565999	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs7290990	ENSG00000268568.1	AC007228.9	-8.7	7.68e-13	2.79e-05	-1.1	-0.72	Vitiligo;	chr22:41568353	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs7290991	ENSG00000268568.1	AC007228.9	-8.7	7.68e-13	2.79e-05	-1.1	-0.72	Vitiligo;	chr22:41568357	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs5996037	ENSG00000268568.1	AC007228.9	-8.7	7.68e-13	2.79e-05	-1.1	-0.72	Vitiligo;	chr22:41569288	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs5996038	ENSG00000268568.1	AC007228.9	-8.7	7.68e-13	2.79e-05	-1.1	-0.72	Vitiligo;	chr22:41569296	chr19:56672574~56673901:-
LAML	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	8.7	7.69e-13	2.8e-05	1.04	0.72	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
LAML	trans	rs877636	0.669	rs7297175	ENSG00000233778.3	RP11-777J24.1	-8.69	7.92e-13	2.88e-05	-0.79	-0.72	Cognitive function;	chr12:56080024	chr8:92144088~92144435:-
LAML	trans	rs9611565	0.802	rs132916	ENSG00000268568.1	AC007228.9	8.69	8.06e-13	2.93e-05	1.02	0.72	Vitiligo;	chr22:41410764	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.921	rs8137373	ENSG00000268568.1	AC007228.9	8.67	8.49e-13	3.08e-05	1.03	0.71	Vitiligo;	chr22:41333212	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.921	rs4822021	ENSG00000268568.1	AC007228.9	-8.67	8.49e-13	3.08e-05	-1.03	-0.71	Vitiligo;	chr22:41330049	chr19:56672574~56673901:-
LAML	trans	rs916888	0.773	rs199448	ENSG00000204652.6	RPS26P8	8.66	8.88e-13	3.21e-05	1.08	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45608571~45608918:+
LAML	trans	rs916888	0.773	rs199445	ENSG00000204652.6	RPS26P8	8.66	8.88e-13	3.21e-05	1.08	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45608571~45608918:+
LAML	trans	rs916888	0.773	rs199443	ENSG00000204652.6	RPS26P8	8.66	8.88e-13	3.21e-05	1.08	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45608571~45608918:+
LAML	trans	rs916888	0.773	rs199534	ENSG00000204652.6	RPS26P8	8.66	8.88e-13	3.21e-05	1.08	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45608571~45608918:+
LAML	trans	rs916888	0.773	rs199533	ENSG00000204652.6	RPS26P8	8.66	8.88e-13	3.21e-05	1.08	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45608571~45608918:+
LAML	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	8.66	9.06e-13	3.27e-05	1.12	0.71	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
LAML	trans	rs11098499	0.863	rs10019674	ENSG00000275858.1	RP11-291L22.8	-8.66	9.11e-13	3.29e-05	-1.02	-0.71	Corneal astigmatism;	chr4:119522334	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.863	rs3822192	ENSG00000275858.1	RP11-291L22.8	8.66	9.11e-13	3.29e-05	1.02	0.71	Corneal astigmatism;	chr4:119524565	chr10:38450738~38451069:-
LAML	trans	rs1552244	0.572	rs7645667	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10115653	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs7645759	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10115684	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs41464050	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10116709	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs73117481	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10118448	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs57268864	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10122549	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs58862481	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10122624	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs59074548	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10122663	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs3774208	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10123038	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs6783705	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10123099	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs68013239	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10124027	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs68121641	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10124161	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.515	rs67342818	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10124722	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs66514627	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10124948	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.515	rs111560858	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10125161	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs17032426	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10125428	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs6785976	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10126963	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs6442154	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10127101	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs6797536	ENSG00000230342.2	FANCD2P2	-8.62	1.05e-12	3.68e-05	-1.29	-0.71	Alzheimer's disease;	chr3:10127118	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs3894321	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10127208	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs3894322	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10127281	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs3894323	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10127283	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs67439440	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10127819	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs59132826	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10128041	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs58223482	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10128062	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs17032440	ENSG00000230342.2	FANCD2P2	-8.62	1.05e-12	3.68e-05	-1.29	-0.71	Alzheimer's disease;	chr3:10128135	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs113406084	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10128506	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs12107622	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10130214	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs2054478	ENSG00000230342.2	FANCD2P2	8.62	1.05e-12	3.68e-05	1.29	0.71	Alzheimer's disease;	chr3:10130527	chr3:11859674~11891172:+
LAML	trans	rs928391	0.689	rs2644600	ENSG00000227183.3	HDGFP1	8.62	1.07e-12	3.75e-05	1.2	0.71	Platelet count;	chr1:156820891	chrX:131646639~131646890:+
LAML	trans	rs928391	0.689	rs2644599	ENSG00000227183.3	HDGFP1	8.62	1.07e-12	3.75e-05	1.2	0.71	Platelet count;	chr1:156821114	chrX:131646639~131646890:+
LAML	trans	rs13177918	0.559	rs10447224	ENSG00000239528.1	RPS14P8	8.62	1.07e-12	3.77e-05	0.9	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454802	chr5:116562562~116562930:+
LAML	trans	rs13177918	0.559	rs10447225	ENSG00000239528.1	RPS14P8	8.62	1.07e-12	3.77e-05	0.9	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150454891	chr5:116562562~116562930:+
LAML	trans	rs9611565	0.546	rs132793	ENSG00000268568.1	AC007228.9	8.61	1.13e-12	3.99e-05	1.11	0.71	Vitiligo;	chr22:41667677	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.779	rs7699346	ENSG00000275858.1	RP11-291L22.8	8.6	1.19e-12	4.16e-05	1.03	0.71	Corneal astigmatism;	chr4:119389387	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.559	rs132761	ENSG00000268568.1	AC007228.9	8.59	1.22e-12	4.26e-05	1.09	0.71	Vitiligo;	chr22:41608367	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs132765	ENSG00000268568.1	AC007228.9	8.59	1.22e-12	4.26e-05	1.09	0.71	Vitiligo;	chr22:41612064	chr19:56672574~56673901:-
LAML	trans	rs4822044	0.56	rs7284839	ENSG00000268568.1	AC007228.9	8.59	1.22e-12	4.26e-05	1.09	0.71	Cannabis dependence symptom count;	chr22:41614898	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs132768	ENSG00000268568.1	AC007228.9	8.59	1.22e-12	4.26e-05	1.09	0.71	Vitiligo;	chr22:41617519	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs5758397	ENSG00000268568.1	AC007228.9	8.59	1.22e-12	4.26e-05	1.09	0.71	Vitiligo;	chr22:41623247	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs132771	ENSG00000268568.1	AC007228.9	8.59	1.22e-12	4.26e-05	1.09	0.71	Vitiligo;	chr22:41629346	chr19:56672574~56673901:-
LAML	trans	rs727563	0.52	rs132773	ENSG00000268568.1	AC007228.9	8.59	1.22e-12	4.26e-05	1.09	0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41635764	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.82	rs2389885	ENSG00000275858.1	RP11-291L22.8	8.58	1.26e-12	4.39e-05	1.02	0.71	Corneal astigmatism;	chr4:119612776	chr10:38450738~38451069:-
LAML	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	8.56	1.37e-12	4.77e-05	1.09	0.71	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
LAML	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	8.56	1.37e-12	4.77e-05	1.09	0.71	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
LAML	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	8.56	1.37e-12	4.77e-05	1.09	0.71	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
LAML	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	8.56	1.37e-12	4.77e-05	1.09	0.71	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
LAML	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	8.56	1.37e-12	4.77e-05	1.09	0.71	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
LAML	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	8.56	1.37e-12	4.77e-05	1.09	0.71	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
LAML	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	8.56	1.37e-12	4.77e-05	1.09	0.71	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
LAML	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	8.56	1.37e-12	4.77e-05	1.09	0.71	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
LAML	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	8.56	1.37e-12	4.77e-05	1.09	0.71	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
LAML	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	8.56	1.37e-12	4.77e-05	1.09	0.71	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
LAML	trans	rs11098499	1	rs35643470	ENSG00000275858.1	RP11-291L22.8	8.56	1.4e-12	4.82e-05	0.98	0.71	Corneal astigmatism;	chr4:119263793	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs6849889	ENSG00000275858.1	RP11-291L22.8	8.56	1.4e-12	4.82e-05	0.98	0.71	Corneal astigmatism;	chr4:119265193	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs58601355	ENSG00000275858.1	RP11-291L22.8	8.56	1.4e-12	4.82e-05	0.98	0.71	Corneal astigmatism;	chr4:119265212	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs11098499	ENSG00000275858.1	RP11-291L22.8	8.56	1.4e-12	4.82e-05	0.98	0.71	Corneal astigmatism;	chr4:119266456	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs7659194	ENSG00000275858.1	RP11-291L22.8	8.56	1.4e-12	4.82e-05	0.98	0.71	Corneal astigmatism;	chr4:119285992	chr10:38450738~38451069:-
LAML	trans	rs13177918	0.626	rs2748240	ENSG00000213058.3	RP4-765C7.2	8.56	1.4e-12	4.82e-05	0.91	0.71	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150449305	chr1:178411616~178411972:+
LAML	trans	rs916888	0.779	rs199528	ENSG00000204652.6	RPS26P8	8.54	1.49e-12	5.13e-05	1.08	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45608571~45608918:+
LAML	trans	rs916888	0.821	rs199525	ENSG00000204652.6	RPS26P8	8.54	1.49e-12	5.13e-05	1.08	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45608571~45608918:+
LAML	trans	rs11098499	0.738	rs28687057	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119359657	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.775	rs67281037	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119360002	chr10:38450738~38451069:-
LAML	trans	rs10028773	0.506	rs12374346	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Educational attainment;	chr4:119360550	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.775	rs10021601	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119361408	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs6857892	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119361541	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs28581362	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119362393	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.82	rs12503082	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119363162	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs12499602	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119363232	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.774	rs11098505	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119363472	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs11098506	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119363816	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs13105020	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119364533	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs6824111	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119364813	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.779	rs10857066	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119365441	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.775	rs10029303	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119365600	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs9995136	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119365690	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs13125526	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119366864	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs12513310	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119366884	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.564	rs11098507	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119367131	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs12510451	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119367988	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.774	rs73842616	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119369528	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.645	rs72676059	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119369673	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.569	rs55845118	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119369758	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs7677068	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119370549	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs9991221	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119370952	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.731	rs6846966	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119372053	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.866	rs6847778	ENSG00000275858.1	RP11-291L22.8	8.53	1.54e-12	5.22e-05	0.93	0.71	Corneal astigmatism;	chr4:119372427	chr10:38450738~38451069:-
LAML	trans	rs1552244	0.572	rs67227131	ENSG00000230342.2	FANCD2P2	8.53	1.59e-12	5.38e-05	1.29	0.71	Alzheimer's disease;	chr3:10131060	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.572	rs3843008	ENSG00000230342.2	FANCD2P2	8.53	1.59e-12	5.38e-05	1.29	0.71	Alzheimer's disease;	chr3:10132058	chr3:11859674~11891172:+
LAML	trans	rs916888	0.61	rs199530	ENSG00000264057.1	RP11-583F2.1	-8.52	1.63e-12	5.49e-05	-0.89	-0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:64927634~64934203:+
LAML	trans	rs9611565	0.659	rs11090049	ENSG00000268568.1	AC007228.9	-8.52	1.67e-12	5.62e-05	-1.1	-0.71	Vitiligo;	chr22:41519325	chr19:56672574~56673901:-
LAML	trans	rs877636	0.562	rs10876864	ENSG00000243538.1	CTB-55B8.1	-8.49	1.83e-12	6.15e-05	-0.9	-0.71	Cognitive function;	chr12:56007301	chr5:16902294~16902641:-
LAML	trans	rs11098499	1	rs13116504	ENSG00000275858.1	RP11-291L22.8	8.49	1.83e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119288257	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.909	rs28555550	ENSG00000275858.1	RP11-291L22.8	8.49	1.83e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119289885	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs28419773	ENSG00000275858.1	RP11-291L22.8	8.49	1.83e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119289906	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs11726229	ENSG00000275858.1	RP11-291L22.8	8.49	1.83e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119290425	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs11098500	ENSG00000275858.1	RP11-291L22.8	8.49	1.83e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119298084	chr10:38450738~38451069:-
LAML	trans	rs727563	0.555	rs5751136	ENSG00000268568.1	AC007228.9	8.49	1.84e-12	6.15e-05	1.08	0.71	Crohn's disease;Inflammatory bowel disease;	chr22:41679577	chr19:56672574~56673901:-
LAML	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-8.49	1.84e-12	6.15e-05	-0.83	-0.71	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
LAML	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-8.49	1.84e-12	6.15e-05	-0.83	-0.71	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
LAML	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-8.49	1.84e-12	6.15e-05	-0.83	-0.71	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
LAML	trans	rs7312770	0.637	rs705700	ENSG00000212994.5	RPS26P6	8.49	1.85e-12	6.15e-05	0.79	0.71	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:100895771~100896118:+
LAML	trans	rs11098499	0.955	rs13129661	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119231754	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs56386062	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119233980	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs4145951	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119234662	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs35916640	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119234697	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs13113112	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119234885	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs13114751	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119235462	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.913	rs35271032	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119235504	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs6815725	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119237255	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs11931312	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119237868	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs11944880	ENSG00000275858.1	RP11-291L22.8	-8.49	1.85e-12	6.15e-05	-0.97	-0.71	Corneal astigmatism;	chr4:119238179	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs1511018	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119240425	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs1397608	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119240589	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs7685268	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119241033	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs7684942	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119241046	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.913	rs10010696	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119243148	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs1511019	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119244852	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.913	rs11098496	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119246311	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs35197422	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119248159	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs35434465	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119248223	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.955	rs1511015	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119249318	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs10029750	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119251388	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs6837898	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119257999	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs28374891	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119262395	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs12506395	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119263939	chr10:38450738~38451069:-
LAML	trans	rs11098499	1	rs3749591	ENSG00000275858.1	RP11-291L22.8	8.49	1.85e-12	6.15e-05	0.97	0.71	Corneal astigmatism;	chr4:119292875	chr10:38450738~38451069:-
LAML	trans	rs7399018	0.739	rs10747608	ENSG00000223825.5	DAZAP2P1	8.48	1.91e-12	6.32e-05	0.86	0.71	Cisplatin-induced ototoxicity;	chr12:51222798	chr2:202201384~202201886:-
LAML	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-8.48	1.96e-12	6.5e-05	-1.17	-0.71	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
LAML	trans	rs1552244	0.515	rs67626468	ENSG00000230342.2	FANCD2P2	8.47	2.01e-12	6.63e-05	1.28	0.71	Alzheimer's disease;	chr3:10119834	chr3:11859674~11891172:+
LAML	trans	rs9611565	0.592	rs4822040	ENSG00000268568.1	AC007228.9	-8.47	2.04e-12	6.7e-05	-1.07	-0.71	Vitiligo;	chr22:41567549	chr19:56672574~56673901:-
LAML	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	8.46	2.1e-12	6.9e-05	0.84	0.71	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
LAML	trans	rs11098499	0.69	rs34818745	ENSG00000275858.1	RP11-291L22.8	8.46	2.13e-12	6.99e-05	0.96	0.71	Corneal astigmatism;	chr4:119335900	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.687	rs71610270	ENSG00000275858.1	RP11-291L22.8	8.45	2.22e-12	7.24e-05	0.93	0.71	Corneal astigmatism;	chr4:119366281	chr10:38450738~38451069:-
LAML	trans	rs916888	0.773	rs199457	ENSG00000204652.6	RPS26P8	8.45	2.23e-12	7.28e-05	1.07	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45608571~45608918:+
LAML	trans	rs916888	0.687	rs199456	ENSG00000204652.6	RPS26P8	8.45	2.23e-12	7.28e-05	1.07	0.71	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45608571~45608918:+
LAML	trans	rs11098499	0.866	rs12501602	ENSG00000275858.1	RP11-291L22.8	8.44	2.29e-12	7.45e-05	0.93	0.71	Corneal astigmatism;	chr4:119366780	chr10:38450738~38451069:-
LAML	trans	rs877636	0.562	rs1131017	ENSG00000235459.5	RPS26P31	-8.44	2.32e-12	7.52e-05	-0.75	-0.71	Cognitive function;	chr12:56042145	chr7:122681315~122681662:+
LAML	trans	rs9611565	0.625	rs12483991	ENSG00000268568.1	AC007228.9	-8.42	2.47e-12	7.99e-05	-0.98	-0.7	Vitiligo;	chr22:41539281	chr19:56672574~56673901:-
LAML	trans	rs916888	0.773	rs199535	ENSG00000204652.6	RPS26P8	8.41	2.66e-12	8.54e-05	1.07	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45608571~45608918:+
LAML	trans	rs1552244	0.608	rs2075310	ENSG00000230342.2	FANCD2P2	8.41	2.68e-12	8.57e-05	0.97	0.7	Alzheimer's disease;	chr3:10025967	chr3:11859674~11891172:+
LAML	trans	rs9611565	0.918	rs73176685	ENSG00000268568.1	AC007228.9	-8.4	2.78e-12	8.9e-05	-1.02	-0.7	Vitiligo;	chr22:41385090	chr19:56672574~56673901:-
LAML	trans	rs12145833	0.596	rs12043646	ENSG00000154608.12	CEP170P1	-8.39	2.83e-12	9.03e-05	-1.02	-0.7	Obesity (early onset extreme);	chr1:243118690	chr4:118467590~118554204:+
LAML	trans	rs12145833	0.596	rs12123491	ENSG00000154608.12	CEP170P1	-8.39	2.83e-12	9.03e-05	-1.02	-0.7	Obesity (early onset extreme);	chr1:243134622	chr4:118467590~118554204:+
LAML	trans	rs12145833	0.538	rs10754798	ENSG00000154608.12	CEP170P1	8.39	2.83e-12	9.03e-05	1.02	0.7	Obesity (early onset extreme);	chr1:243146656	chr4:118467590~118554204:+
LAML	trans	rs916888	0.773	rs9896243	ENSG00000204652.6	RPS26P8	8.39	2.85e-12	9.08e-05	1.05	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46748690	chr17:45608571~45608918:+
LAML	trans	rs2657294	0.796	rs4746272	ENSG00000172974.11	AC007318.5	8.39	2.86e-12	9.09e-05	0.97	0.7	Pneumonia;	chr10:75203869	chr2:65205108~65205988:+
LAML	trans	rs2657294	0.796	rs2657290	ENSG00000172974.11	AC007318.5	8.39	2.86e-12	9.09e-05	0.97	0.7	Pneumonia;	chr10:75207404	chr2:65205108~65205988:+
LAML	trans	rs2657294	0.765	rs2804533	ENSG00000172974.11	AC007318.5	8.39	2.86e-12	9.09e-05	0.97	0.7	Pneumonia;	chr10:75207723	chr2:65205108~65205988:+
LAML	trans	rs2657294	0.726	rs4746275	ENSG00000172974.11	AC007318.5	8.39	2.86e-12	9.09e-05	0.97	0.7	Pneumonia;	chr10:75214940	chr2:65205108~65205988:+
LAML	trans	rs2657294	0.796	rs2804534	ENSG00000172974.11	AC007318.5	-8.39	2.86e-12	9.09e-05	-0.97	-0.7	Pneumonia;	chr10:75208023	chr2:65205108~65205988:+
LAML	trans	rs2657294	0.796	rs2804535	ENSG00000172974.11	AC007318.5	-8.39	2.86e-12	9.09e-05	-0.97	-0.7	Pneumonia;	chr10:75212086	chr2:65205108~65205988:+
LAML	trans	rs2657294	0.761	rs1259498	ENSG00000172974.11	AC007318.5	8.39	2.88e-12	9.14e-05	0.97	0.7	Pneumonia;	chr10:75226983	chr2:65205108~65205988:+
LAML	trans	rs11098499	0.73	rs78971550	ENSG00000275858.1	RP11-291L22.8	8.39	2.88e-12	9.14e-05	0.97	0.7	Corneal astigmatism;	chr4:119359886	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.645	rs78422072	ENSG00000275858.1	RP11-291L22.8	8.39	2.88e-12	9.14e-05	0.97	0.7	Corneal astigmatism;	chr4:119359887	chr10:38450738~38451069:-
LAML	trans	rs916888	0.773	rs199451	ENSG00000204652.6	RPS26P8	8.38	2.96e-12	9.37e-05	1.06	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45608571~45608918:+
LAML	trans	rs13177918	0.906	rs12652032	ENSG00000213058.3	RP4-765C7.2	8.38	3.03e-12	9.6e-05	1.27	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr1:178411616~178411972:+
LAML	trans	rs2657294	0.796	rs1259501	ENSG00000172974.11	AC007318.5	8.37	3.17e-12	9.96e-05	0.97	0.7	Pneumonia;	chr10:75230427	chr2:65205108~65205988:+
LAML	trans	rs2657294	0.796	rs1259499	ENSG00000172974.11	AC007318.5	8.36	3.19e-12	9.96e-05	0.97	0.7	Pneumonia;	chr10:75228308	chr2:65205108~65205988:+
LAML	trans	rs727563	0.593	rs132770	ENSG00000268568.1	AC007228.9	8.36	3.27e-12	9.96e-05	1.08	0.7	Crohn's disease;Inflammatory bowel disease;	chr22:41621260	chr19:56672574~56673901:-
LAML	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	8.36	3.29e-12	9.98e-05	0.75	0.7	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
LAML	trans	rs1816752	0.679	rs8181826	ENSG00000237917.1	PARP4P1	-8.35	3.36e-12	0.000102	-1.02	-0.7	Obesity-related traits;	chr13:24396570	chrY:26594851~26634652:-
LAML	trans	rs877636	0.562	rs1131017	ENSG00000234513.1	AC073072.7	-8.35	3.41e-12	0.000103	-0.84	-0.7	Cognitive function;	chr12:56042145	chr7:22773646~22773993:-
LAML	trans	rs11098499	0.644	rs10050092	ENSG00000275858.1	RP11-291L22.8	8.33	3.77e-12	0.00011	0.99	0.7	Corneal astigmatism;	chr4:119610930	chr10:38450738~38451069:-
LAML	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	8.32	3.86e-12	0.000113	0.86	0.7	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
LAML	trans	rs1816752	0.905	rs3818938	ENSG00000237917.1	PARP4P1	8.31	3.97e-12	0.000116	1.08	0.7	Obesity-related traits;	chr13:24454945	chrY:26594851~26634652:-
LAML	trans	rs9611565	0.918	rs28638318	ENSG00000268568.1	AC007228.9	-8.3	4.24e-12	0.000123	-1.03	-0.7	Vitiligo;	chr22:41357055	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs80477	ENSG00000268568.1	AC007228.9	8.29	4.35e-12	0.000126	1.05	0.7	Vitiligo;	chr22:41605179	chr19:56672574~56673901:-
LAML	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	8.29	4.36e-12	0.000127	1.08	0.7	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
LAML	trans	rs11098499	0.818	rs55825515	ENSG00000275858.1	RP11-291L22.8	8.29	4.38e-12	0.000127	1.04	0.7	Corneal astigmatism;	chr4:119565247	chr10:38450738~38451069:-
LAML	trans	rs877636	0.562	rs1131017	ENSG00000243538.1	CTB-55B8.1	-8.29	4.41e-12	0.000128	-0.85	-0.7	Cognitive function;	chr12:56042145	chr5:16902294~16902641:-
LAML	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	8.28	4.56e-12	0.000132	0.78	0.7	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
LAML	trans	rs7312770	0.637	rs705700	ENSG00000233778.3	RP11-777J24.1	8.28	4.59e-12	0.000132	0.8	0.7	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:92144088~92144435:-
LAML	trans	rs6708331	0.504	rs2169837	ENSG00000232654.1	FAM136BP	8.28	4.6e-12	0.000132	0.86	0.7	Obesity-related traits;	chr2:70324775	chr6:3045384~3045800:+
LAML	trans	rs9611565	0.592	rs4481089	ENSG00000268568.1	AC007228.9	-8.27	4.83e-12	0.000138	-1.05	-0.7	Vitiligo;	chr22:41584888	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs5996039	ENSG00000268568.1	AC007228.9	-8.27	4.83e-12	0.000138	-1.05	-0.7	Vitiligo;	chr22:41585953	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs57102627	ENSG00000268568.1	AC007228.9	-8.27	4.83e-12	0.000138	-1.05	-0.7	Vitiligo;	chr22:41591623	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.592	rs28750375	ENSG00000268568.1	AC007228.9	-8.27	4.83e-12	0.000138	-1.05	-0.7	Vitiligo;	chr22:41594640	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.559	rs8139993	ENSG00000268568.1	AC007228.9	-8.27	4.83e-12	0.000138	-1.05	-0.7	Vitiligo;	chr22:41599331	chr19:56672574~56673901:-
LAML	trans	rs7312770	0.637	rs705699	ENSG00000212994.5	RPS26P6	8.27	4.84e-12	0.000138	0.78	0.7	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:100895771~100896118:+
LAML	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-8.26	5.04e-12	0.000143	-1.17	-0.7	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
LAML	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-8.26	5.04e-12	0.000143	-1.17	-0.7	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
LAML	trans	rs10940346	1	rs1328254	ENSG00000231752.4	EMBP1	-8.25	5.15e-12	0.000146	-0.82	-0.7	Schizophrenia;	chr5:50265025	chr1:121519112~121571892:+
LAML	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-8.25	5.2e-12	0.000147	-0.83	-0.7	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
LAML	trans	rs11098499	0.78	rs10013652	ENSG00000275858.1	RP11-291L22.8	8.24	5.36e-12	0.000151	0.91	0.7	Corneal astigmatism;	chr4:119371101	chr10:38450738~38451069:-
LAML	trans	rs10940346	1	rs2883164	ENSG00000231752.4	EMBP1	8.24	5.45e-12	0.000154	0.82	0.7	Schizophrenia;	chr5:50397624	chr1:121519112~121571892:+
LAML	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-8.23	5.65e-12	0.000159	-0.85	-0.7	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
LAML	trans	rs11098499	0.644	rs7693919	ENSG00000275858.1	RP11-291L22.8	8.23	5.7e-12	0.00016	1	0.7	Corneal astigmatism;	chr4:119619416	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.57	rs6832740	ENSG00000275858.1	RP11-291L22.8	8.23	5.7e-12	0.00016	1	0.7	Corneal astigmatism;	chr4:119624981	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.644	rs6855918	ENSG00000275858.1	RP11-291L22.8	8.23	5.7e-12	0.00016	1	0.7	Corneal astigmatism;	chr4:119625144	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.644	rs28787668	ENSG00000275858.1	RP11-291L22.8	8.23	5.7e-12	0.00016	1	0.7	Corneal astigmatism;	chr4:119633532	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.566	rs17051356	ENSG00000275858.1	RP11-291L22.8	8.23	5.74e-12	0.000161	1.01	0.7	Corneal astigmatism;	chr4:119664153	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.913	rs67073020	ENSG00000275858.1	RP11-291L22.8	8.23	5.75e-12	0.000162	0.96	0.7	Corneal astigmatism;	chr4:119231402	chr10:38450738~38451069:-
LAML	trans	rs916888	0.821	rs70600	ENSG00000204652.6	RPS26P8	8.23	5.76e-12	0.000162	1.06	0.7	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45608571~45608918:+
LAML	trans	rs4822044	0.561	rs132781	ENSG00000268568.1	AC007228.9	8.23	5.78e-12	0.000162	1.12	0.7	Cannabis dependence symptom count;	chr22:41650118	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs132784	ENSG00000268568.1	AC007228.9	8.23	5.78e-12	0.000162	1.12	0.7	Vitiligo;	chr22:41656359	chr19:56672574~56673901:-
LAML	trans	rs928391	0.592	rs1888861	ENSG00000227183.3	HDGFP1	-8.22	5.85e-12	0.000164	-1.16	-0.7	Platelet count;	chr1:156828169	chrX:131646639~131646890:+
LAML	trans	rs1552244	0.7	rs9833566	ENSG00000230342.2	FANCD2P2	8.22	5.86e-12	0.000164	1	0.7	Alzheimer's disease;	chr3:9939987	chr3:11859674~11891172:+
LAML	trans	rs928391	0.689	rs2234883	ENSG00000227183.3	HDGFP1	8.22	6.06e-12	0.00017	1.18	0.7	Platelet count;	chr1:156817318	chrX:131646639~131646890:+
LAML	trans	rs916888	0.773	rs199447	ENSG00000204652.6	RPS26P8	8.2	6.47e-12	0.000181	1.06	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45608571~45608918:+
LAML	trans	rs916888	0.773	rs199439	ENSG00000204652.6	RPS26P8	8.18	7.02e-12	0.000196	1.06	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45608571~45608918:+
LAML	trans	rs7312770	0.637	rs705699	ENSG00000233778.3	RP11-777J24.1	8.17	7.25e-12	0.000203	0.79	0.69	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:92144088~92144435:-
LAML	trans	rs9611565	0.694	rs202637	ENSG00000268568.1	AC007228.9	8.17	7.27e-12	0.000203	1.13	0.69	Vitiligo;	chr22:41457924	chr19:56672574~56673901:-
LAML	trans	rs877636	0.562	rs10876864	ENSG00000235459.5	RPS26P31	-8.17	7.31e-12	0.000204	-0.77	-0.69	Cognitive function;	chr12:56007301	chr7:122681315~122681662:+
LAML	trans	rs877636	0.562	rs1131017	ENSG00000212994.5	RPS26P6	-8.17	7.46e-12	0.000208	-0.75	-0.69	Cognitive function;	chr12:56042145	chr8:100895771~100896118:+
LAML	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	8.16	7.86e-12	0.000218	1.1	0.69	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
LAML	trans	rs928391	0.689	rs2768764	ENSG00000227183.3	HDGFP1	8.15	8.08e-12	0.000224	1.19	0.69	Platelet count;	chr1:156817136	chrX:131646639~131646890:+
LAML	trans	rs916888	0.61	rs199530	ENSG00000214425.5	LRRC37A4P	8.15	8.15e-12	0.000226	0.91	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45506741~45550335:-
LAML	trans	rs11098499	0.604	rs2389882	ENSG00000275858.1	RP11-291L22.8	8.15	8.18e-12	0.000226	0.99	0.69	Corneal astigmatism;	chr4:119645578	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.604	rs2389886	ENSG00000275858.1	RP11-291L22.8	8.15	8.18e-12	0.000226	0.99	0.69	Corneal astigmatism;	chr4:119649267	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.604	rs2389887	ENSG00000275858.1	RP11-291L22.8	8.15	8.18e-12	0.000226	0.99	0.69	Corneal astigmatism;	chr4:119649489	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.604	rs34278750	ENSG00000275858.1	RP11-291L22.8	8.15	8.18e-12	0.000226	0.99	0.69	Corneal astigmatism;	chr4:119649981	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.604	rs10022185	ENSG00000275858.1	RP11-291L22.8	8.15	8.18e-12	0.000226	0.99	0.69	Corneal astigmatism;	chr4:119650610	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.604	rs12642411	ENSG00000275858.1	RP11-291L22.8	8.15	8.18e-12	0.000226	0.99	0.69	Corneal astigmatism;	chr4:119659370	chr10:38450738~38451069:-
LAML	trans	rs7312770	0.612	rs773114	ENSG00000233778.3	RP11-777J24.1	8.14	8.33e-12	0.00023	0.79	0.69	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:92144088~92144435:-
LAML	trans	rs11098499	0.532	rs4504231	ENSG00000275858.1	RP11-291L22.8	8.14	8.48e-12	0.000234	1.06	0.69	Corneal astigmatism;	chr4:119665736	chr10:38450738~38451069:-
LAML	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	8.14	8.49e-12	0.000234	1.09	0.69	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
LAML	trans	rs11098499	0.604	rs17051352	ENSG00000275858.1	RP11-291L22.8	8.13	8.61e-12	0.000237	1	0.69	Corneal astigmatism;	chr4:119660272	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.644	rs7676296	ENSG00000275858.1	RP11-291L22.8	8.13	8.74e-12	0.00024	1	0.69	Corneal astigmatism;	chr4:119634532	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.826	rs4472123	ENSG00000275858.1	RP11-291L22.8	8.12	9.01e-12	0.000247	0.91	0.69	Corneal astigmatism;	chr4:119315475	chr10:38450738~38451069:-
LAML	trans	rs7312770	0.637	rs705700	ENSG00000234513.1	AC073072.7	8.12	9.34e-12	0.000256	0.85	0.69	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:22773646~22773993:-
LAML	trans	rs916888	0.773	rs1378358	ENSG00000204652.6	RPS26P8	8.11	9.58e-12	0.000263	1.06	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45608571~45608918:+
LAML	trans	rs916888	0.773	rs538628	ENSG00000204652.6	RPS26P8	8.11	9.58e-12	0.000263	1.06	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45608571~45608918:+
LAML	trans	rs916888	0.773	rs169201	ENSG00000204652.6	RPS26P8	8.11	9.58e-12	0.000263	1.06	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45608571~45608918:+
LAML	trans	rs877636	0.669	rs7297175	ENSG00000243538.1	CTB-55B8.1	-8.11	9.63e-12	0.000264	-0.84	-0.69	Cognitive function;	chr12:56080024	chr5:16902294~16902641:-
LAML	trans	rs727563	0.635	rs5751141	ENSG00000268568.1	AC007228.9	8.1	1.01e-11	0.000275	1.05	0.69	Crohn's disease;Inflammatory bowel disease;	chr22:41711741	chr19:56672574~56673901:-
LAML	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-8.08	1.08e-11	0.000295	-1.04	-0.69	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
LAML	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	8.08	1.08e-11	0.000295	1.04	0.69	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
LAML	trans	rs11098499	1	rs13435802	ENSG00000275858.1	RP11-291L22.8	-8.07	1.12e-11	0.000305	-1	-0.69	Corneal astigmatism;	chr4:119256805	chr10:38450738~38451069:-
LAML	trans	rs877636	0.692	rs2271194	ENSG00000227887.1	RPS26P13	-8.07	1.13e-11	0.000307	-0.73	-0.69	Cognitive function;	chr12:56083910	chr1:208697369~208697698:-
LAML	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-8.07	1.13e-11	0.000307	-0.73	-0.69	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
LAML	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-8.07	1.13e-11	0.000307	-0.73	-0.69	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
LAML	trans	rs66887589	0.616	rs6822808	ENSG00000275858.1	RP11-291L22.8	8.07	1.14e-11	0.000311	0.8	0.69	Diastolic blood pressure;	chr4:119296210	chr10:38450738~38451069:-
LAML	trans	rs10940346	0.846	rs8175378	ENSG00000231752.4	EMBP1	-8.06	1.17e-11	0.000317	-0.83	-0.69	Schizophrenia;	chr5:50182876	chr1:121519112~121571892:+
LAML	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-8.06	1.21e-11	0.000328	-0.83	-0.69	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
LAML	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-8.06	1.21e-11	0.000328	-0.83	-0.69	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
LAML	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-8.06	1.21e-11	0.000328	-0.83	-0.69	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
LAML	trans	rs11098499	0.821	rs56155624	ENSG00000275858.1	RP11-291L22.8	8.05	1.26e-11	0.000342	0.95	0.69	Corneal astigmatism;	chr4:119369871	chr10:38450738~38451069:-
LAML	trans	rs916888	0.779	rs199498	ENSG00000264057.1	RP11-583F2.1	8.04	1.29e-11	0.00035	0.92	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:64927634~64934203:+
LAML	trans	rs916888	0.647	rs199523	ENSG00000264057.1	RP11-583F2.1	-8.02	1.39e-11	0.000376	-0.87	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:64927634~64934203:+
LAML	trans	rs916888	0.697	rs199516	ENSG00000204652.6	RPS26P8	-8.01	1.48e-11	0.000398	-1.03	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45608571~45608918:+
LAML	trans	rs916888	0.821	rs199514	ENSG00000204652.6	RPS26P8	-8.01	1.48e-11	0.000398	-1.03	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45608571~45608918:+
LAML	trans	rs916888	0.821	rs199513	ENSG00000204652.6	RPS26P8	-8.01	1.48e-11	0.000398	-1.03	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45608571~45608918:+
LAML	trans	rs916888	0.821	rs199512	ENSG00000204652.6	RPS26P8	-8.01	1.48e-11	0.000398	-1.03	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45608571~45608918:+
LAML	trans	rs916888	0.821	rs199509	ENSG00000204652.6	RPS26P8	-8.01	1.48e-11	0.000398	-1.03	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45608571~45608918:+
LAML	trans	rs916888	0.821	rs199507	ENSG00000204652.6	RPS26P8	-8.01	1.48e-11	0.000398	-1.03	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45608571~45608918:+
LAML	trans	rs916888	0.821	rs199505	ENSG00000204652.6	RPS26P8	-8.01	1.48e-11	0.000398	-1.03	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45608571~45608918:+
LAML	trans	rs916888	0.821	rs70602	ENSG00000204652.6	RPS26P8	-8.01	1.48e-11	0.000398	-1.03	-0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45608571~45608918:+
LAML	trans	rs916888	0.61	rs199529	ENSG00000204652.6	RPS26P8	8	1.52e-11	0.000409	1.01	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45608571~45608918:+
LAML	trans	rs13177918	0.603	rs2748241	ENSG00000213058.3	RP4-765C7.2	8	1.54e-11	0.000414	0.85	0.69	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150447931	chr1:178411616~178411972:+
LAML	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	8	1.54e-11	0.000415	0.84	0.69	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
LAML	trans	rs916888	0.647	rs199524	ENSG00000214425.5	LRRC37A4P	7.98	1.64e-11	0.000441	0.92	0.69	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45506741~45550335:-
LAML	trans	rs877636	0.562	rs10876864	ENSG00000212994.5	RPS26P6	-7.97	1.76e-11	0.000472	-0.77	-0.68	Cognitive function;	chr12:56007301	chr8:100895771~100896118:+
LAML	trans	rs10940346	0.537	rs8188099	ENSG00000231752.4	EMBP1	-7.97	1.77e-11	0.000476	-0.8	-0.68	Schizophrenia;	chr5:50183445	chr1:121519112~121571892:+
LAML	trans	rs9611565	0.592	rs5751129	ENSG00000268568.1	AC007228.9	7.95	1.87e-11	0.000499	1.03	0.68	Vitiligo;	chr22:41619761	chr19:56672574~56673901:-
LAML	trans	rs13358908	0.595	rs4975942	ENSG00000231752.4	EMBP1	-7.95	1.92e-11	0.00051	-0.79	-0.68	Schizophrenia;	chr5:46371833	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.599	rs34899679	ENSG00000231752.4	EMBP1	-7.95	1.92e-11	0.00051	-0.79	-0.68	Schizophrenia;	chr5:46372360	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.632	rs35088345	ENSG00000231752.4	EMBP1	-7.95	1.92e-11	0.00051	-0.79	-0.68	Schizophrenia;	chr5:46372364	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs13185587	ENSG00000231752.4	EMBP1	7.95	1.92e-11	0.00051	0.79	0.68	Schizophrenia;	chr5:50365409	chr1:121519112~121571892:+
LAML	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	7.95	1.92e-11	0.000511	0.77	0.68	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
LAML	trans	rs13358908	0.631	rs6882540	ENSG00000231752.4	EMBP1	-7.95	1.93e-11	0.000511	-0.79	-0.68	Schizophrenia;	chr5:46345971	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs6450134	ENSG00000231752.4	EMBP1	-7.94	1.97e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50471121	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs7380816	ENSG00000231752.4	EMBP1	-7.94	1.97e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50472059	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs2016360	ENSG00000231752.4	EMBP1	-7.94	1.97e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50491064	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs7378983	ENSG00000231752.4	EMBP1	-7.94	1.97e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50491889	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs6450164	ENSG00000231752.4	EMBP1	-7.94	1.97e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50502814	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs1962832	ENSG00000231752.4	EMBP1	-7.94	1.97e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50502962	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs7712749	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50400441	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs2036901	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50401306	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs13154223	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50403152	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs2271236	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50405921	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs62365887	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50408254	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs34044167	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50410136	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.875	rs13159506	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50415061	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs13173678	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50422314	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs6450108	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50434427	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs28445612	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50439676	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs2353436	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50445695	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs1849200	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50448053	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs6899048	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50451256	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs2353437	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50452078	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs2102454	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50452446	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.875	rs13172257	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50462916	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs10074196	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50464713	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs13186891	ENSG00000231752.4	EMBP1	7.94	1.97e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50467244	chr1:121519112~121571892:+
LAML	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-7.94	2e-11	0.000513	-0.73	-0.68	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
LAML	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-7.94	2e-11	0.000513	-0.73	-0.68	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
LAML	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-7.94	2e-11	0.000513	-0.73	-0.68	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
LAML	trans	rs13358908	0.712	rs28873151	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:46378558	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.621	rs28847123	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:46378829	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.593	rs28855077	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:46378855	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.715	rs12522625	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:46389266	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.712	rs10941823	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:46389481	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.622	rs12652607	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:46392338	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.902	rs4865727	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50145945	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.714	rs12523073	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50153697	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.846	rs8188203	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50161448	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.905	rs10053631	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50164086	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.728	rs10053639	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50164113	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.934	rs2353222	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50174249	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.716	rs8188088	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50215591	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.653	rs4371800	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50225349	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.584	rs496108	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50236794	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.744	rs498951	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50238681	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs510897	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50263017	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs507396	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50263374	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs11960661	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50266528	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs489407	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50266701	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs491470	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50266988	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs492337	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50274706	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs1328253	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50286916	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs6449782	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50291694	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs4865522	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50303674	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs10068272	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50313688	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs10940129	ENSG00000231752.4	EMBP1	-7.94	2.01e-11	0.000513	-0.79	-0.68	Schizophrenia;	chr5:50315257	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.936	rs10940171	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50324613	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs35250488	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50331004	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs6874697	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50344307	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs2137132	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50353988	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs1995795	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50356233	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs6874829	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50357573	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs7721808	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50363136	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs1812994	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50364397	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs3849670	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50365641	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.905	rs4030569	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50371779	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs4030570	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50371829	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.967	rs4030572	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50375897	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.875	rs10076490	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50389037	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs4643959	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000513	0.79	0.68	Schizophrenia;	chr5:50391631	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs10040323	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000514	0.79	0.68	Schizophrenia;	chr5:50336779	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs2055909	ENSG00000231752.4	EMBP1	7.94	2.01e-11	0.000514	0.79	0.68	Schizophrenia;	chr5:50337474	chr1:121519112~121571892:+
LAML	trans	rs66887589	0.616	rs11098498	ENSG00000275858.1	RP11-291L22.8	7.92	2.18e-11	0.000555	0.78	0.68	Diastolic blood pressure;	chr4:119265964	chr10:38450738~38451069:-
LAML	trans	rs928391	0.541	rs1888863	ENSG00000227183.3	HDGFP1	-7.92	2.19e-11	0.000556	-1.14	-0.68	Platelet count;	chr1:156828046	chrX:131646639~131646890:+
LAML	trans	rs928391	0.592	rs1888862	ENSG00000227183.3	HDGFP1	-7.92	2.19e-11	0.000556	-1.14	-0.68	Platelet count;	chr1:156828113	chrX:131646639~131646890:+
LAML	trans	rs928391	0.592	rs7516856	ENSG00000227183.3	HDGFP1	-7.92	2.19e-11	0.000556	-1.14	-0.68	Platelet count;	chr1:156828324	chrX:131646639~131646890:+
LAML	trans	rs7312770	0.637	rs705700	ENSG00000235459.5	RPS26P31	7.92	2.19e-11	0.000557	0.74	0.68	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr7:122681315~122681662:+
LAML	trans	rs1552244	0.706	rs279545	ENSG00000230342.2	FANCD2P2	7.91	2.3e-11	0.000582	0.89	0.68	Alzheimer's disease;	chr3:9930809	chr3:11859674~11891172:+
LAML	trans	rs916888	0.647	rs199524	ENSG00000264057.1	RP11-583F2.1	-7.9	2.33e-11	0.00059	-0.88	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:64927634~64934203:+
LAML	trans	rs9611565	0.57	rs12159188	ENSG00000268568.1	AC007228.9	7.89	2.43e-11	0.000614	1.03	0.68	Vitiligo;	chr22:41725121	chr19:56672574~56673901:-
LAML	trans	rs7312770	0.637	rs705699	ENSG00000234513.1	AC073072.7	7.89	2.49e-11	0.00063	0.84	0.68	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr7:22773646~22773993:-
LAML	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	7.89	2.5e-11	0.000631	0.83	0.68	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
LAML	trans	rs7312770	0.612	rs773114	ENSG00000234513.1	AC073072.7	7.88	2.59e-11	0.000654	0.83	0.68	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:22773646~22773993:-
LAML	trans	rs916888	0.821	rs199506	ENSG00000204652.6	RPS26P8	-7.86	2.77e-11	0.000698	-1.01	-0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45608571~45608918:+
LAML	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	7.86	2.85e-11	0.000717	1.02	0.68	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
LAML	trans	rs877636	0.562	rs1131017	ENSG00000223416.3	RPS26P15	-7.85	2.89e-11	0.000729	-0.83	-0.68	Cognitive function;	chr12:56042145	chr1:58056133~58056480:-
LAML	trans	rs11098499	0.754	rs938056	ENSG00000275858.1	RP11-291L22.8	7.84	3.1e-11	0.000779	0.94	0.68	Corneal astigmatism;	chr4:119316298	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs878376	ENSG00000275858.1	RP11-291L22.8	7.84	3.1e-11	0.000779	0.94	0.68	Corneal astigmatism;	chr4:119316547	chr10:38450738~38451069:-
LAML	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	7.84	3.1e-11	0.00078	0.93	0.68	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
LAML	trans	rs26067	0.74	rs26079	ENSG00000231752.4	EMBP1	-7.82	3.31e-11	0.000831	-0.76	-0.68	Breast cancer;	chr5:50863180	chr1:121519112~121571892:+
LAML	trans	rs1552244	0.554	rs6796411	ENSG00000230342.2	FANCD2P2	7.82	3.39e-11	0.000849	0.9	0.68	Alzheimer's disease;	chr3:9968997	chr3:11859674~11891172:+
LAML	trans	rs916888	0.738	rs199515	ENSG00000214425.5	LRRC37A4P	7.81	3.43e-11	0.000859	1.18	0.68	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45506741~45550335:-
LAML	trans	rs10940346	1	rs555458	ENSG00000231752.4	EMBP1	-7.78	3.87e-11	0.000966	-0.78	-0.68	Schizophrenia;	chr5:50262772	chr1:121519112~121571892:+
LAML	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	7.78	4e-11	0.000997	0.73	0.68	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
LAML	trans	rs877636	0.562	rs10876864	ENSG00000196656.7	AC004057.1	-7.77	4.03e-11	0.001	-0.81	-0.68	Cognitive function;	chr12:56007301	chr4:113214046~113217170:-
LAML	trans	rs9611565	0.649	rs126092	ENSG00000268568.1	AC007228.9	7.75	4.49e-11	0.00112	0.97	0.67	Vitiligo;	chr22:41782437	chr19:56672574~56673901:-
LAML	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	7.75	4.51e-11	0.00112	0.83	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
LAML	trans	rs877636	0.562	rs10876864	ENSG00000223416.3	RPS26P15	-7.75	4.57e-11	0.00114	-0.86	-0.67	Cognitive function;	chr12:56007301	chr1:58056133~58056480:-
LAML	trans	rs9611565	0.879	rs5758311	ENSG00000268568.1	AC007228.9	-7.74	4.7e-11	0.00117	-0.91	-0.67	Vitiligo;	chr22:41363371	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.512	rs139572	ENSG00000268568.1	AC007228.9	-7.73	4.82e-11	0.00119	-0.98	-0.67	Vitiligo;	chr22:41818528	chr19:56672574~56673901:-
LAML	trans	rs66887589	0.616	rs13113885	ENSG00000275858.1	RP11-291L22.8	7.72	5e-11	0.00124	0.8	0.67	Diastolic blood pressure;	chr4:119300021	chr10:38450738~38451069:-
LAML	trans	rs10940346	0.818	rs472278	ENSG00000231752.4	EMBP1	-7.72	5e-11	0.00124	-0.81	-0.67	Schizophrenia;	chr5:50215972	chr1:121519112~121571892:+
LAML	trans	rs66887589	0.616	rs11098497	ENSG00000275858.1	RP11-291L22.8	7.72	5.08e-11	0.00126	0.79	0.67	Diastolic blood pressure;	chr4:119265913	chr10:38450738~38451069:-
LAML	trans	rs66887589	0.616	rs10032299	ENSG00000275858.1	RP11-291L22.8	7.72	5.08e-11	0.00126	0.79	0.67	Diastolic blood pressure;	chr4:119285264	chr10:38450738~38451069:-
LAML	trans	rs66887589	0.616	rs7659403	ENSG00000275858.1	RP11-291L22.8	7.72	5.08e-11	0.00126	0.79	0.67	Diastolic blood pressure;	chr4:119286099	chr10:38450738~38451069:-
LAML	trans	rs10940346	0.653	rs72768421	ENSG00000231752.4	EMBP1	-7.72	5.1e-11	0.00126	-0.79	-0.67	Schizophrenia;	chr5:50246898	chr1:121519112~121571892:+
LAML	trans	rs66887589	0.616	rs11731675	ENSG00000275858.1	RP11-291L22.8	7.72	5.1e-11	0.00126	0.79	0.67	Diastolic blood pressure;	chr4:119291359	chr10:38450738~38451069:-
LAML	trans	rs66887589	0.616	rs11732621	ENSG00000275858.1	RP11-291L22.8	7.72	5.1e-11	0.00126	0.79	0.67	Diastolic blood pressure;	chr4:119291728	chr10:38450738~38451069:-
LAML	trans	rs66887589	0.616	rs1052633	ENSG00000275858.1	RP11-291L22.8	7.72	5.1e-11	0.00126	0.79	0.67	Diastolic blood pressure;	chr4:119294159	chr10:38450738~38451069:-
LAML	trans	rs66887589	0.592	rs2175383	ENSG00000275858.1	RP11-291L22.8	7.72	5.1e-11	0.00126	0.79	0.67	Diastolic blood pressure;	chr4:119294681	chr10:38450738~38451069:-
LAML	trans	rs877636	0.562	rs10876864	ENSG00000227887.1	RPS26P13	-7.72	5.15e-11	0.00127	-0.75	-0.67	Cognitive function;	chr12:56007301	chr1:208697369~208697698:-
LAML	trans	rs877636	0.562	rs10876864	ENSG00000234513.1	AC073072.7	-7.71	5.3e-11	0.0013	-0.84	-0.67	Cognitive function;	chr12:56007301	chr7:22773646~22773993:-
LAML	trans	rs7312770	0.637	rs705700	ENSG00000225071.1	GS1-184P14.2	7.7	5.67e-11	0.00139	0.78	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chrX:24429573~24429920:-
LAML	trans	rs916888	0.773	rs199447	ENSG00000267198.1	RP11-798G7.6	-7.69	5.68e-11	0.0014	-0.84	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45545804~45563230:+
LAML	trans	rs10940346	0.728	rs12655271	ENSG00000231752.4	EMBP1	-7.69	5.73e-11	0.00141	-0.79	-0.67	Schizophrenia;	chr5:50212921	chr1:121519112~121571892:+
LAML	trans	rs916888	0.773	rs199448	ENSG00000267198.1	RP11-798G7.6	-7.69	5.77e-11	0.00142	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45545804~45563230:+
LAML	trans	rs916888	0.773	rs199445	ENSG00000267198.1	RP11-798G7.6	-7.69	5.77e-11	0.00142	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45545804~45563230:+
LAML	trans	rs916888	0.773	rs199443	ENSG00000267198.1	RP11-798G7.6	-7.69	5.77e-11	0.00142	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45545804~45563230:+
LAML	trans	rs916888	0.773	rs199534	ENSG00000267198.1	RP11-798G7.6	-7.69	5.77e-11	0.00142	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45545804~45563230:+
LAML	trans	rs916888	0.773	rs199533	ENSG00000267198.1	RP11-798G7.6	-7.69	5.77e-11	0.00142	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45545804~45563230:+
LAML	trans	rs916888	0.773	rs1378358	ENSG00000267198.1	RP11-798G7.6	-7.69	5.83e-11	0.00143	-0.84	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45545804~45563230:+
LAML	trans	rs916888	0.773	rs538628	ENSG00000267198.1	RP11-798G7.6	-7.69	5.83e-11	0.00143	-0.84	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45545804~45563230:+
LAML	trans	rs916888	0.773	rs169201	ENSG00000267198.1	RP11-798G7.6	-7.69	5.83e-11	0.00143	-0.84	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45545804~45563230:+
LAML	trans	rs66887589	0.616	rs6843509	ENSG00000275858.1	RP11-291L22.8	7.68	5.99e-11	0.00147	0.79	0.67	Diastolic blood pressure;	chr4:119299041	chr10:38450738~38451069:-
LAML	trans	rs916888	0.647	rs199523	ENSG00000214425.5	LRRC37A4P	7.68	6.11e-11	0.00149	0.89	0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45506741~45550335:-
LAML	trans	rs26067	0.689	rs27266	ENSG00000231752.4	EMBP1	-7.67	6.23e-11	0.00152	-0.77	-0.67	Breast cancer;	chr5:50865793	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs8185185	ENSG00000231752.4	EMBP1	7.67	6.35e-11	0.00155	0.77	0.67	P wave duration;	chr5:46214358	chr1:121519112~121571892:+
LAML	trans	rs11098499	0.874	rs13139045	ENSG00000275858.1	RP11-291L22.8	7.66	6.53e-11	0.00157	0.89	0.67	Corneal astigmatism;	chr4:119247433	chr10:38450738~38451069:-
LAML	trans	rs2950393	0.794	rs1563897	ENSG00000121089.4	NACA3P	7.66	6.53e-11	0.00157	0.82	0.67	Platelet distribution width;	chr12:56699316	chr4:164943290~164943937:+
LAML	trans	rs4276421	0.684	rs8185055	ENSG00000231752.4	EMBP1	-7.66	6.54e-11	0.00157	-0.77	-0.67	P wave duration;	chr5:46262149	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.695	rs8185255	ENSG00000231752.4	EMBP1	-7.66	6.54e-11	0.00157	-0.77	-0.67	P wave duration;	chr5:46263336	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.587	rs4975957	ENSG00000231752.4	EMBP1	-7.66	6.54e-11	0.00157	-0.77	-0.67	P wave duration;	chr5:46265200	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.657	rs10941759	ENSG00000231752.4	EMBP1	-7.66	6.54e-11	0.00157	-0.77	-0.67	P wave duration;	chr5:46266862	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.657	rs10941760	ENSG00000231752.4	EMBP1	-7.66	6.54e-11	0.00157	-0.77	-0.67	P wave duration;	chr5:46267360	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.596	rs9717195	ENSG00000231752.4	EMBP1	-7.66	6.54e-11	0.00157	-0.77	-0.67	Schizophrenia;	chr5:46302679	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.602	rs4975977	ENSG00000231752.4	EMBP1	-7.66	6.54e-11	0.00157	-0.77	-0.67	Schizophrenia;	chr5:46307988	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.715	rs8185301	ENSG00000231752.4	EMBP1	-7.66	6.54e-11	0.00157	-0.77	-0.67	Schizophrenia;	chr5:46312149	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.652	rs7293494	ENSG00000231752.4	EMBP1	-7.66	6.54e-11	0.00157	-0.77	-0.67	Schizophrenia;	chr5:46313550	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs10040808	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46123599	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.716	rs12656601	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46124483	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.777	rs8185098	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46125388	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.684	rs8175395	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46125498	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.716	rs13156708	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46128924	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.744	rs13157345	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46129304	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.805	rs7293302	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46131077	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.657	rs13186103	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46131553	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs10038249	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46160595	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.652	rs8185226	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46160685	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.656	rs8185376	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46165191	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.684	rs8185217	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46169215	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.684	rs11958686	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46173456	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs13155792	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46176452	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs11950077	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46179798	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.654	rs8185114	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46181843	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.652	rs8188276	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46182731	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.656	rs8185101	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46183248	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.656	rs13188002	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46184203	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.623	rs8188231	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46186924	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.684	rs8188258	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46187284	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs10065920	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46190593	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs8188292	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46191402	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.684	rs10064829	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46192959	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.657	rs8175415	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46193360	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.657	rs8188010	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46194057	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.633	rs62370770	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46195784	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.625	rs61187820	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46199336	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs8188050	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46201372	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.656	rs13188786	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46201856	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs10064792	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46202002	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.597	rs10072776	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46202178	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs10941746	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46202737	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.656	rs7293337	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46203395	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs13168431	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46205598	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.656	rs11960110	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46210055	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.537	rs13166566	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46210486	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.656	rs13172097	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46211694	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.657	rs8188296	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46221948	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.716	rs34186279	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46221966	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.656	rs10064681	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46222829	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.623	rs12109835	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46222967	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs12697543	ENSG00000231752.4	EMBP1	7.66	6.54e-11	0.00157	0.77	0.67	P wave duration;	chr5:46235824	chr1:121519112~121571892:+
LAML	trans	rs877636	0.562	rs1131017	ENSG00000227887.1	RPS26P13	-7.66	6.55e-11	0.00157	-0.72	-0.67	Cognitive function;	chr12:56042145	chr1:208697369~208697698:-
LAML	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-7.66	6.59e-11	0.00158	-0.72	-0.67	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
LAML	trans	rs1552244	0.554	rs6800204	ENSG00000230342.2	FANCD2P2	7.65	6.84e-11	0.00163	0.9	0.67	Alzheimer's disease;	chr3:9953720	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs6762594	ENSG00000230342.2	FANCD2P2	7.65	6.84e-11	0.00163	0.9	0.67	Alzheimer's disease;	chr3:9953832	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs3846167	ENSG00000230342.2	FANCD2P2	7.65	6.84e-11	0.00163	0.9	0.67	Alzheimer's disease;	chr3:9954742	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.608	rs6764807	ENSG00000230342.2	FANCD2P2	7.65	6.84e-11	0.00163	0.9	0.67	Alzheimer's disease;	chr3:9957119	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs34391585	ENSG00000230342.2	FANCD2P2	7.65	6.84e-11	0.00163	0.9	0.67	Alzheimer's disease;	chr3:9957524	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.515	rs7613004	ENSG00000230342.2	FANCD2P2	7.65	6.84e-11	0.00163	0.9	0.67	Alzheimer's disease;	chr3:9958229	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.608	rs7615408	ENSG00000230342.2	FANCD2P2	7.65	6.84e-11	0.00163	0.9	0.67	Alzheimer's disease;	chr3:9958502	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs6443275	ENSG00000230342.2	FANCD2P2	7.65	6.84e-11	0.00163	0.9	0.67	Alzheimer's disease;	chr3:9967135	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs6768339	ENSG00000230342.2	FANCD2P2	-7.65	6.84e-11	0.00163	-0.9	-0.67	Alzheimer's disease;	chr3:9964395	chr3:11859674~11891172:+
LAML	trans	rs916888	0.773	rs199535	ENSG00000267198.1	RP11-798G7.6	-7.65	6.96e-11	0.00166	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45545804~45563230:+
LAML	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-7.64	7.12e-11	0.0017	-0.72	-0.67	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
LAML	trans	rs916888	0.647	rs199524	ENSG00000264070.1	DND1P1	-7.64	7.12e-11	0.0017	-0.77	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771072	chr17:45585871~45586929:+
LAML	trans	rs9611565	0.729	rs12165508	ENSG00000268568.1	AC007228.9	7.64	7.13e-11	0.0017	0.9	0.67	Vitiligo;	chr22:41423956	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.729	rs169362	ENSG00000268568.1	AC007228.9	7.64	7.13e-11	0.0017	0.9	0.67	Vitiligo;	chr22:41431585	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs9611591	ENSG00000268568.1	AC007228.9	7.64	7.13e-11	0.0017	0.9	0.67	Vitiligo;	chr22:41434208	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.729	rs202654	ENSG00000268568.1	AC007228.9	7.64	7.13e-11	0.0017	0.9	0.67	Vitiligo;	chr22:41445030	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.729	rs505533	ENSG00000268568.1	AC007228.9	7.64	7.13e-11	0.0017	0.9	0.67	Vitiligo;	chr22:41468212	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.765	rs727563	ENSG00000268568.1	AC007228.9	7.64	7.13e-11	0.0017	0.9	0.67	Vitiligo;	chr22:41471373	chr19:56672574~56673901:-
LAML	trans	rs916888	0.773	rs199457	ENSG00000267198.1	RP11-798G7.6	-7.64	7.27e-11	0.00172	-0.84	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45545804~45563230:+
LAML	trans	rs916888	0.687	rs199456	ENSG00000267198.1	RP11-798G7.6	-7.64	7.27e-11	0.00172	-0.84	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45545804~45563230:+
LAML	trans	rs773125	1	rs773125	ENSG00000212994.5	RPS26P6	7.64	7.35e-11	0.00174	0.74	0.67	Rheumatoid arthritis;	chr12:56001170	chr8:100895771~100896118:+
LAML	trans	rs9611565	0.729	rs203319	ENSG00000268568.1	AC007228.9	-7.63	7.39e-11	0.00175	-0.93	-0.67	Vitiligo;	chr22:41518589	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs5758389	ENSG00000268568.1	AC007228.9	-7.63	7.39e-11	0.00175	-0.93	-0.67	Vitiligo;	chr22:41545745	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.955	rs1551	ENSG00000275858.1	RP11-291L22.8	7.61	8.12e-11	0.00191	0.92	0.67	Corneal astigmatism;	chr4:119237345	chr10:38450738~38451069:-
LAML	trans	rs7312770	0.637	rs705700	ENSG00000243538.1	CTB-55B8.1	7.6	8.41e-11	0.00198	0.84	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr5:16902294~16902641:-
LAML	trans	rs66887589	0.592	rs28580295	ENSG00000275858.1	RP11-291L22.8	7.6	8.5e-11	0.002	0.81	0.67	Diastolic blood pressure;	chr4:119357718	chr10:38450738~38451069:-
LAML	trans	rs66887589	0.592	rs62320740	ENSG00000275858.1	RP11-291L22.8	7.6	8.5e-11	0.002	0.81	0.67	Diastolic blood pressure;	chr4:119358331	chr10:38450738~38451069:-
LAML	trans	rs10940346	1	rs12520874	ENSG00000231752.4	EMBP1	-7.6	8.64e-11	0.00203	-0.77	-0.67	Schizophrenia;	chr5:50523857	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs56387400	ENSG00000231752.4	EMBP1	-7.6	8.7e-11	0.00204	-0.78	-0.67	Schizophrenia;	chr5:50517577	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs7708897	ENSG00000231752.4	EMBP1	-7.6	8.7e-11	0.00204	-0.78	-0.67	Schizophrenia;	chr5:50528209	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs7380858	ENSG00000231752.4	EMBP1	-7.59	8.72e-11	0.00205	-0.79	-0.67	Schizophrenia;	chr5:50537022	chr1:121519112~121571892:+
LAML	trans	rs916888	0.647	rs199523	ENSG00000264070.1	DND1P1	-7.59	8.75e-11	0.00205	-0.76	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46771151	chr17:45585871~45586929:+
LAML	trans	rs26067	0.74	rs27683	ENSG00000231752.4	EMBP1	7.59	9.1e-11	0.00213	0.75	0.67	Breast cancer;	chr5:50865708	chr1:121519112~121571892:+
LAML	trans	rs916888	0.773	rs199451	ENSG00000267198.1	RP11-798G7.6	-7.58	9.22e-11	0.00216	-0.83	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45545804~45563230:+
LAML	trans	rs10940346	1	rs10940359	ENSG00000231752.4	EMBP1	-7.58	9.27e-11	0.00217	-0.77	-0.67	Schizophrenia;	chr5:50538645	chr1:121519112~121571892:+
LAML	trans	rs26067	0.689	rs152839	ENSG00000231752.4	EMBP1	-7.58	9.34e-11	0.00218	-0.75	-0.67	Breast cancer;	chr5:50849432	chr1:121519112~121571892:+
LAML	trans	rs1816752	0.704	rs7995968	ENSG00000237917.1	PARP4P1	-7.58	9.39e-11	0.0022	-0.98	-0.67	Obesity-related traits;	chr13:24392754	chrY:26594851~26634652:-
LAML	trans	rs1552244	0.554	rs6786636	ENSG00000230342.2	FANCD2P2	7.58	9.44e-11	0.00221	0.89	0.67	Alzheimer's disease;	chr3:10004019	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs6762702	ENSG00000230342.2	FANCD2P2	7.58	9.44e-11	0.00221	0.89	0.67	Alzheimer's disease;	chr3:10014105	chr3:11859674~11891172:+
LAML	trans	rs10940346	0.601	rs11960276	ENSG00000231752.4	EMBP1	-7.58	9.5e-11	0.00222	-0.83	-0.67	Schizophrenia;	chr5:50265194	chr1:121519112~121571892:+
LAML	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	7.57	9.69e-11	0.00226	0.73	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
LAML	trans	rs1552244	0.554	rs4488814	ENSG00000230342.2	FANCD2P2	-7.57	9.74e-11	0.00227	-0.89	-0.67	Alzheimer's disease;	chr3:9960716	chr3:11859674~11891172:+
LAML	trans	rs7312770	1	rs7312770	ENSG00000223416.3	RPS26P15	-7.57	9.78e-11	0.00228	-0.79	-0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:58056133~58056480:-
LAML	trans	rs916888	0.821	rs415430	ENSG00000204652.6	RPS26P8	-7.57	9.84e-11	0.00229	-1.04	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781778	chr17:45608571~45608918:+
LAML	trans	rs916888	0.779	rs430685	ENSG00000204652.6	RPS26P8	-7.57	9.84e-11	0.00229	-1.04	-0.67	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781782	chr17:45608571~45608918:+
LAML	trans	rs4276421	0.688	rs8188054	ENSG00000231752.4	EMBP1	7.57	9.89e-11	0.00231	0.77	0.67	P wave duration;	chr5:46215556	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.688	rs10061101	ENSG00000231752.4	EMBP1	7.57	9.89e-11	0.00231	0.77	0.67	P wave duration;	chr5:46217831	chr1:121519112~121571892:+
LAML	trans	rs1552244	0.554	rs3846169	ENSG00000230342.2	FANCD2P2	-7.56	1.01e-10	0.00233	-0.88	-0.67	Alzheimer's disease;	chr3:9955370	chr3:11859674~11891172:+
LAML	trans	rs727563	0.565	rs132774	ENSG00000268568.1	AC007228.9	-7.55	1.05e-10	0.00243	-0.98	-0.66	Crohn's disease;Inflammatory bowel disease;	chr22:41635949	chr19:56672574~56673901:-
LAML	trans	rs877636	0.692	rs2271194	ENSG00000242206.2	RPS26P35	-7.54	1.08e-10	0.0025	-0.73	-0.66	Cognitive function;	chr12:56083910	chr8:118761856~118762201:-
LAML	trans	rs877636	0.692	rs10876870	ENSG00000242206.2	RPS26P35	-7.54	1.08e-10	0.0025	-0.73	-0.66	Cognitive function;	chr12:56084218	chr8:118761856~118762201:-
LAML	trans	rs877636	0.692	rs7971751	ENSG00000242206.2	RPS26P35	-7.54	1.08e-10	0.0025	-0.73	-0.66	Cognitive function;	chr12:56084874	chr8:118761856~118762201:-
LAML	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	7.53	1.13e-10	0.0026	0.72	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
LAML	trans	rs916888	0.773	rs199439	ENSG00000267198.1	RP11-798G7.6	-7.53	1.15e-10	0.00264	-0.83	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45545804~45563230:+
LAML	trans	rs7312770	0.637	rs705699	ENSG00000235459.5	RPS26P31	7.53	1.16e-10	0.00266	0.72	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr7:122681315~122681662:+
LAML	trans	rs11098499	0.526	rs10026625	ENSG00000275858.1	RP11-291L22.8	7.53	1.17e-10	0.00269	0.8	0.66	Corneal astigmatism;	chr4:119358981	chr10:38450738~38451069:-
LAML	trans	rs773125	1	rs773125	ENSG00000233778.3	RP11-777J24.1	7.51	1.28e-10	0.00293	0.75	0.66	Rheumatoid arthritis;	chr12:56001170	chr8:92144088~92144435:-
LAML	trans	rs916888	0.821	rs199504	ENSG00000204652.6	RPS26P8	-7.49	1.37e-10	0.0031	-1	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45608571~45608918:+
LAML	trans	rs10940346	1	rs7704686	ENSG00000231752.4	EMBP1	-7.49	1.38e-10	0.00312	-0.77	-0.66	Schizophrenia;	chr5:50548995	chr1:121519112~121571892:+
LAML	trans	rs916888	0.61	rs199530	ENSG00000264070.1	DND1P1	-7.48	1.42e-10	0.00322	-0.75	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759287	chr17:45585871~45586929:+
LAML	trans	rs9611565	0.879	rs2235845	ENSG00000268568.1	AC007228.9	-7.47	1.48e-10	0.00335	-0.91	-0.66	Vitiligo;	chr22:41333290	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.921	rs5751080	ENSG00000268568.1	AC007228.9	-7.47	1.48e-10	0.00335	-0.91	-0.66	Vitiligo;	chr22:41340263	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.921	rs2235846	ENSG00000268568.1	AC007228.9	-7.47	1.48e-10	0.00335	-0.91	-0.66	Vitiligo;	chr22:41345038	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.921	rs5751081	ENSG00000268568.1	AC007228.9	-7.47	1.48e-10	0.00335	-0.91	-0.66	Vitiligo;	chr22:41346784	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.921	rs2281332	ENSG00000268568.1	AC007228.9	-7.47	1.48e-10	0.00335	-0.91	-0.66	Vitiligo;	chr22:41350208	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.697	rs35280960	ENSG00000275858.1	RP11-291L22.8	7.47	1.49e-10	0.00336	0.9	0.66	Corneal astigmatism;	chr4:119335904	chr10:38450738~38451069:-
LAML	trans	rs10940346	0.936	rs7705285	ENSG00000231752.4	EMBP1	7.47	1.49e-10	0.00336	0.77	0.66	Schizophrenia;	chr5:50325579	chr1:121519112~121571892:+
LAML	trans	rs13358908	0.652	rs8185385	ENSG00000231752.4	EMBP1	-7.46	1.54e-10	0.00346	-0.77	-0.66	Schizophrenia;	chr5:46318532	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs2668024	ENSG00000231752.4	EMBP1	-7.46	1.56e-10	0.00346	-0.78	-0.66	Schizophrenia;	chr5:50414421	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs10940346	ENSG00000231752.4	EMBP1	-7.46	1.56e-10	0.00346	-0.78	-0.66	Schizophrenia;	chr5:50510208	chr1:121519112~121571892:+
LAML	trans	rs916888	0.61	rs199529	ENSG00000267198.1	RP11-798G7.6	-7.46	1.56e-10	0.00346	-0.8	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45545804~45563230:+
LAML	trans	rs11098499	0.789	rs9991166	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119316696	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.708	rs10005237	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119316742	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.575	rs907204	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119317499	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.575	rs907205	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119317509	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs878372	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119317625	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs10213267	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119317919	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs10212775	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119318089	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs11732087	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119318676	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs2964	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119318976	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs1511025	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119319083	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs12711071	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119319779	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs1546503	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119320012	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.708	rs1546506	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119320085	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs12506610	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119320504	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.743	rs10003567	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119320519	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs10006259	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119320990	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs28652763	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119321157	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs28643450	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119324087	chr10:38450738~38451069:-
LAML	trans	rs10028773	0.7	rs7671797	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Educational attainment;	chr4:119327002	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs7672372	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119327251	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs7672594	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119327388	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs7672778	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119327430	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs2036860	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119327779	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs12513083	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119328457	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs12509621	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119328505	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs1511017	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119329650	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.789	rs12498994	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119329663	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs12507565	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119329966	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.826	rs12511640	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119330093	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs1980026	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119330488	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.722	rs28713555	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119330840	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.743	rs11098501	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119330862	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs11098502	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119330908	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.708	rs11732686	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119331175	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs11724409	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119331206	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.789	rs1980024	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119331892	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs34425882	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119332022	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs4107728	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119332755	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.789	rs10212719	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119333282	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs17049949	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119334135	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs7689729	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119335037	chr10:38450738~38451069:-
LAML	trans	rs10028773	0.7	rs7690338	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Educational attainment;	chr4:119335313	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.865	rs3956464	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119335609	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.619	rs28502463	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119335868	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.648	rs2002047	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119336073	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.775	rs2002049	ENSG00000275858.1	RP11-291L22.8	7.46	1.56e-10	0.00346	0.89	0.66	Corneal astigmatism;	chr4:119336262	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs10518300	ENSG00000275858.1	RP11-291L22.8	-7.46	1.56e-10	0.00346	-0.89	-0.66	Corneal astigmatism;	chr4:119328344	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs1980025	ENSG00000275858.1	RP11-291L22.8	-7.46	1.56e-10	0.00346	-0.89	-0.66	Corneal astigmatism;	chr4:119331651	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs9991959	ENSG00000275858.1	RP11-291L22.8	-7.46	1.56e-10	0.00346	-0.89	-0.66	Corneal astigmatism;	chr4:119332618	chr10:38450738~38451069:-
LAML	trans	rs773125	1	rs773125	ENSG00000234513.1	AC073072.7	7.46	1.58e-10	0.0035	0.81	0.66	Rheumatoid arthritis;	chr12:56001170	chr7:22773646~22773993:-
LAML	trans	rs1552244	0.507	rs6443274	ENSG00000230342.2	FANCD2P2	7.45	1.59e-10	0.00353	0.88	0.66	Alzheimer's disease;	chr3:9953604	chr3:11859674~11891172:+
LAML	trans	rs7312770	0.612	rs1873914	ENSG00000234354.3	RPS26P47	7.45	1.59e-10	0.00354	0.85	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr13:100539901~100540248:-
LAML	trans	rs7312770	0.637	rs705699	ENSG00000225071.1	GS1-184P14.2	7.45	1.65e-10	0.00365	0.77	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chrX:24429573~24429920:-
LAML	trans	rs877636	0.562	rs1131017	ENSG00000243328.1	RP11-520P18.1	-7.44	1.7e-10	0.00376	-0.72	-0.66	Cognitive function;	chr12:56042145	chr8:143065915~143066587:-
LAML	trans	rs877636	1	rs877636	ENSG00000233778.3	RP11-777J24.1	-7.43	1.74e-10	0.00383	-0.84	-0.66	Cognitive function;	chr12:56086799	chr8:92144088~92144435:-
LAML	trans	rs916888	0.779	rs199528	ENSG00000267198.1	RP11-798G7.6	-7.43	1.74e-10	0.00385	-0.82	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45545804~45563230:+
LAML	trans	rs916888	0.821	rs199525	ENSG00000267198.1	RP11-798G7.6	-7.43	1.74e-10	0.00385	-0.82	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45545804~45563230:+
LAML	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-7.43	1.78e-10	0.00393	-1.01	-0.66	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
LAML	trans	rs9611565	0.512	rs132767	ENSG00000268568.1	AC007228.9	-7.43	1.8e-10	0.00396	-1.03	-0.66	Vitiligo;	chr22:41613516	chr19:56672574~56673901:-
LAML	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	7.42	1.81e-10	0.00398	0.76	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
LAML	trans	rs13358908	0.715	rs10053628	ENSG00000231752.4	EMBP1	-7.42	1.81e-10	0.00399	-0.77	-0.66	Schizophrenia;	chr5:46383233	chr1:121519112~121571892:+
LAML	trans	rs9611565	0.625	rs2076199	ENSG00000268568.1	AC007228.9	-7.42	1.85e-10	0.00406	-0.89	-0.66	Vitiligo;	chr22:41507739	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.879	rs4820437	ENSG00000268568.1	AC007228.9	-7.41	1.89e-10	0.00412	-0.89	-0.66	Vitiligo;	chr22:41365286	chr19:56672574~56673901:-
LAML	trans	rs4276421	0.63	rs10054134	ENSG00000231752.4	EMBP1	-7.41	1.89e-10	0.00413	-0.75	-0.66	P wave duration;	chr5:46292175	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.574	rs80150384	ENSG00000231752.4	EMBP1	-7.41	1.89e-10	0.00413	-0.75	-0.66	P wave duration;	chr5:46296183	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.609	rs4975911	ENSG00000231752.4	EMBP1	-7.41	1.89e-10	0.00413	-0.75	-0.66	P wave duration;	chr5:46297143	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.578	rs8185314	ENSG00000231752.4	EMBP1	-7.41	1.89e-10	0.00413	-0.75	-0.66	P wave duration;	chr5:46299648	chr1:121519112~121571892:+
LAML	trans	rs941207	0.762	rs10450	ENSG00000121089.4	NACA3P	7.41	1.92e-10	0.00419	0.85	0.66	Platelet count;	chr12:56590822	chr4:164943290~164943937:+
LAML	trans	rs9611565	0.512	rs4820446	ENSG00000268568.1	AC007228.9	-7.4	1.98e-10	0.0043	-1.1	-0.66	Vitiligo;	chr22:41819680	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.691	rs9996644	ENSG00000275858.1	RP11-291L22.8	7.4	2.01e-10	0.00435	0.89	0.66	Corneal astigmatism;	chr4:119317722	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.691	rs9996494	ENSG00000275858.1	RP11-291L22.8	7.4	2.01e-10	0.00435	0.89	0.66	Corneal astigmatism;	chr4:119317725	chr10:38450738~38451069:-
LAML	trans	rs2950393	0.787	rs4759254	ENSG00000121089.4	NACA3P	7.4	2.01e-10	0.00436	0.85	0.66	Platelet distribution width;	chr12:56702890	chr4:164943290~164943937:+
LAML	trans	rs941207	0.526	rs12229457	ENSG00000121089.4	NACA3P	-7.38	2.14e-10	0.00464	-0.76	-0.66	Platelet count;	chr12:56639896	chr4:164943290~164943937:+
LAML	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-7.38	2.14e-10	0.00464	-0.76	-0.66	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
LAML	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-7.38	2.14e-10	0.00464	-0.76	-0.66	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
LAML	trans	rs9611565	0.559	rs6002408	ENSG00000268568.1	AC007228.9	-7.38	2.15e-10	0.00466	-1.06	-0.66	Vitiligo;	chr22:41571866	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.722	rs1814814	ENSG00000275858.1	RP11-291L22.8	7.38	2.19e-10	0.00473	0.83	0.66	Corneal astigmatism;	chr4:119336969	chr10:38450738~38451069:-
LAML	trans	rs916888	0.773	rs1378358	ENSG00000267246.1	RP11-798G7.7	-7.38	2.23e-10	0.00482	-0.92	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709946	chr17:45549781~45558738:-
LAML	trans	rs916888	0.773	rs538628	ENSG00000267246.1	RP11-798G7.7	-7.38	2.23e-10	0.00482	-0.92	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46709947	chr17:45549781~45558738:-
LAML	trans	rs916888	0.773	rs169201	ENSG00000267246.1	RP11-798G7.7	-7.38	2.23e-10	0.00482	-0.92	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46712837	chr17:45549781~45558738:-
LAML	trans	rs1816752	0.583	rs6490918	ENSG00000237917.1	PARP4P1	-7.36	2.35e-10	0.00506	-0.9	-0.66	Obesity-related traits;	chr13:24427977	chrY:26594851~26634652:-
LAML	trans	rs1816752	0.74	rs6490924	ENSG00000237917.1	PARP4P1	-7.36	2.35e-10	0.00506	-0.9	-0.66	Obesity-related traits;	chr13:24432914	chrY:26594851~26634652:-
LAML	trans	rs26067	0.643	rs693082	ENSG00000231752.4	EMBP1	7.36	2.36e-10	0.00509	0.74	0.66	Breast cancer;	chr5:50808537	chr1:121519112~121571892:+
LAML	trans	rs11098499	0.754	rs1814813	ENSG00000275858.1	RP11-291L22.8	-7.36	2.39e-10	0.00514	-0.84	-0.66	Corneal astigmatism;	chr4:119337052	chr10:38450738~38451069:-
LAML	trans	rs66887589	0.87	rs10518336	ENSG00000275858.1	RP11-291L22.8	7.36	2.4e-10	0.00516	0.82	0.66	Diastolic blood pressure;	chr4:119601779	chr10:38450738~38451069:-
LAML	trans	rs916888	0.738	rs199515	ENSG00000204652.6	RPS26P8	-7.36	2.42e-10	0.00521	-1.19	-0.66	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779275	chr17:45608571~45608918:+
LAML	trans	rs877636	0.562	rs10876864	ENSG00000234192.1	RP11-57C13.5	-7.35	2.51e-10	0.00538	-0.75	-0.65	Cognitive function;	chr12:56007301	chr10:87642607~87642954:+
LAML	trans	rs1552244	0.554	rs6762397	ENSG00000230342.2	FANCD2P2	7.34	2.64e-10	0.00565	0.88	0.65	Alzheimer's disease;	chr3:9966156	chr3:11859674~11891172:+
LAML	trans	rs9611565	0.918	rs2281333	ENSG00000268568.1	AC007228.9	-7.32	2.79e-10	0.00597	-0.88	-0.65	Vitiligo;	chr22:41353626	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.918	rs6002351	ENSG00000268568.1	AC007228.9	-7.32	2.79e-10	0.00597	-0.88	-0.65	Vitiligo;	chr22:41361219	chr19:56672574~56673901:-
LAML	trans	rs877636	0.692	rs2271194	ENSG00000234192.1	RP11-57C13.5	-7.32	2.88e-10	0.00615	-0.71	-0.65	Cognitive function;	chr12:56083910	chr10:87642607~87642954:+
LAML	trans	rs877636	0.692	rs10876870	ENSG00000234192.1	RP11-57C13.5	-7.32	2.88e-10	0.00615	-0.71	-0.65	Cognitive function;	chr12:56084218	chr10:87642607~87642954:+
LAML	trans	rs877636	0.692	rs7971751	ENSG00000234192.1	RP11-57C13.5	-7.32	2.88e-10	0.00615	-0.71	-0.65	Cognitive function;	chr12:56084874	chr10:87642607~87642954:+
LAML	trans	rs9611565	0.921	rs2143695	ENSG00000268568.1	AC007228.9	-7.31	2.96e-10	0.00631	-0.89	-0.65	Vitiligo;	chr22:41332616	chr19:56672574~56673901:-
LAML	trans	rs13177918	0.559	rs12109637	ENSG00000239528.1	RPS14P8	7.31	2.96e-10	0.00632	0.81	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150455155	chr5:116562562~116562930:+
LAML	trans	rs4276421	0.688	rs7293424	ENSG00000231752.4	EMBP1	7.31	3e-10	0.00638	0.76	0.65	P wave duration;	chr5:46184874	chr1:121519112~121571892:+
LAML	trans	rs9611565	0.879	rs5758307	ENSG00000268568.1	AC007228.9	-7.3	3.07e-10	0.00653	-0.88	-0.65	Vitiligo;	chr22:41354215	chr19:56672574~56673901:-
LAML	trans	rs4276421	0.565	rs7720870	ENSG00000231752.4	EMBP1	7.3	3.09e-10	0.00657	0.76	0.65	P wave duration;	chr5:46139574	chr1:121519112~121571892:+
LAML	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-7.3	3.09e-10	0.00657	-0.74	-0.65	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
LAML	trans	rs877636	0.692	rs10876870	ENSG00000196656.7	AC004057.1	-7.3	3.09e-10	0.00657	-0.74	-0.65	Cognitive function;	chr12:56084218	chr4:113214046~113217170:-
LAML	trans	rs877636	0.692	rs7971751	ENSG00000196656.7	AC004057.1	-7.3	3.09e-10	0.00657	-0.74	-0.65	Cognitive function;	chr12:56084874	chr4:113214046~113217170:-
LAML	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-7.3	3.12e-10	0.00663	-0.76	-0.65	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
LAML	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	7.29	3.18e-10	0.00676	0.76	0.65	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
LAML	trans	rs773125	1	rs773125	ENSG00000235459.5	RPS26P31	7.29	3.19e-10	0.00676	0.71	0.65	Rheumatoid arthritis;	chr12:56001170	chr7:122681315~122681662:+
LAML	trans	rs877636	0.562	rs1131017	ENSG00000234192.1	RP11-57C13.5	-7.29	3.23e-10	0.00684	-0.72	-0.65	Cognitive function;	chr12:56042145	chr10:87642607~87642954:+
LAML	trans	rs13177918	1	rs13161334	ENSG00000239528.1	RPS14P8	7.29	3.23e-10	0.00684	1.04	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150443110	chr5:116562562~116562930:+
LAML	trans	rs13177918	1	rs35007082	ENSG00000239528.1	RPS14P8	7.29	3.23e-10	0.00684	1.04	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150445015	chr5:116562562~116562930:+
LAML	trans	rs13177918	1	rs13177918	ENSG00000239528.1	RPS14P8	7.29	3.23e-10	0.00684	1.04	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150446307	chr5:116562562~116562930:+
LAML	trans	rs26067	0.689	rs282546	ENSG00000231752.4	EMBP1	-7.28	3.3e-10	0.00699	-0.74	-0.65	Breast cancer;	chr5:50762209	chr1:121519112~121571892:+
LAML	trans	rs1552244	0.554	rs9878047	ENSG00000230342.2	FANCD2P2	7.28	3.38e-10	0.00715	0.87	0.65	Alzheimer's disease;	chr3:9943773	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs3774207	ENSG00000230342.2	FANCD2P2	7.28	3.38e-10	0.00715	0.87	0.65	Alzheimer's disease;	chr3:9943972	chr3:11859674~11891172:+
LAML	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-7.28	3.4e-10	0.0072	-0.81	-0.65	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
LAML	trans	rs10940346	0.557	rs2168922	ENSG00000231752.4	EMBP1	-7.27	3.51e-10	0.00739	-0.76	-0.65	Schizophrenia;	chr5:50151950	chr1:121519112~121571892:+
LAML	trans	rs877636	0.692	rs11171739	ENSG00000242206.2	RPS26P35	7.27	3.53e-10	0.00745	0.73	0.65	Cognitive function;	chr12:56076841	chr8:118761856~118762201:-
LAML	trans	rs877636	0.562	rs1131017	ENSG00000242206.2	RPS26P35	-7.27	3.53e-10	0.00745	-0.73	-0.65	Cognitive function;	chr12:56042145	chr8:118761856~118762201:-
LAML	trans	rs11098499	0.657	rs10434028	ENSG00000275858.1	RP11-291L22.8	7.26	3.6e-10	0.00758	0.88	0.65	Corneal astigmatism;	chr4:119373309	chr10:38450738~38451069:-
LAML	trans	rs5022636	0.525	rs6681163	ENSG00000180764.13	PIPSL	7.26	3.62e-10	0.00763	0.94	0.65	Gut microbiota (functional units);	chr1:151259161	chr10:93958191~93961540:-
LAML	trans	rs11098499	0.913	rs56122576	ENSG00000275858.1	RP11-291L22.8	7.26	3.73e-10	0.00785	0.92	0.65	Corneal astigmatism;	chr4:119208181	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.913	rs68128210	ENSG00000275858.1	RP11-291L22.8	7.26	3.73e-10	0.00785	0.92	0.65	Corneal astigmatism;	chr4:119216664	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.913	rs13126596	ENSG00000275858.1	RP11-291L22.8	7.26	3.73e-10	0.00785	0.92	0.65	Corneal astigmatism;	chr4:119219574	chr10:38450738~38451069:-
LAML	trans	rs5022636	0.564	rs2275900	ENSG00000180764.13	PIPSL	7.25	3.74e-10	0.00785	0.94	0.65	Gut microbiota (functional units);	chr1:151265746	chr10:93958191~93961540:-
LAML	trans	rs5022636	0.594	rs11204791	ENSG00000180764.13	PIPSL	7.25	3.74e-10	0.00785	0.94	0.65	Gut microbiota (functional units);	chr1:151268066	chr10:93958191~93961540:-
LAML	trans	rs773125	1	rs773125	ENSG00000225071.1	GS1-184P14.2	7.25	3.75e-10	0.00787	0.75	0.65	Rheumatoid arthritis;	chr12:56001170	chrX:24429573~24429920:-
LAML	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	7.25	3.82e-10	0.00801	0.76	0.65	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
LAML	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	7.25	3.82e-10	0.00801	0.76	0.65	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
LAML	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	7.25	3.82e-10	0.00801	0.76	0.65	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
LAML	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	7.25	3.82e-10	0.00801	0.76	0.65	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
LAML	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-7.25	3.82e-10	0.00801	-0.76	-0.65	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
LAML	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	7.25	3.84e-10	0.00805	0.75	0.65	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
LAML	trans	rs7312770	0.612	rs1873914	ENSG00000233778.3	RP11-777J24.1	7.24	3.98e-10	0.00834	0.74	0.65	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:92144088~92144435:-
LAML	trans	rs5022636	0.594	rs7489	ENSG00000180764.13	PIPSL	7.23	4.08e-10	0.00854	0.94	0.65	Gut microbiota (functional units);	chr1:151266575	chr10:93958191~93961540:-
LAML	trans	rs5022636	0.594	rs12048670	ENSG00000180764.13	PIPSL	7.23	4.1e-10	0.00858	0.96	0.65	Gut microbiota (functional units);	chr1:151272510	chr10:93958191~93961540:-
LAML	trans	rs11098499	0.754	rs12510269	ENSG00000275858.1	RP11-291L22.8	7.23	4.11e-10	0.00859	0.88	0.65	Corneal astigmatism;	chr4:119320491	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.921	rs5758297	ENSG00000268568.1	AC007228.9	-7.23	4.12e-10	0.00861	-0.89	-0.65	Vitiligo;	chr22:41324693	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.921	rs5751077	ENSG00000268568.1	AC007228.9	-7.23	4.12e-10	0.00861	-0.89	-0.65	Vitiligo;	chr22:41324724	chr19:56672574~56673901:-
LAML	trans	rs66887589	0.967	rs59516282	ENSG00000275858.1	RP11-291L22.8	-7.23	4.21e-10	0.00878	-0.77	-0.65	Diastolic blood pressure;	chr4:119580861	chr10:38450738~38451069:-
LAML	trans	rs66887589	0.934	rs12648182	ENSG00000275858.1	RP11-291L22.8	-7.23	4.21e-10	0.00878	-0.77	-0.65	Diastolic blood pressure;	chr4:119582736	chr10:38450738~38451069:-
LAML	trans	rs4276421	0.684	rs10072945	ENSG00000231752.4	EMBP1	7.23	4.23e-10	0.0088	0.75	0.65	P wave duration;	chr5:46151307	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.716	rs13155082	ENSG00000231752.4	EMBP1	7.23	4.23e-10	0.0088	0.75	0.65	P wave duration;	chr5:46155135	chr1:121519112~121571892:+
LAML	trans	rs5022636	0.594	rs10888408	ENSG00000180764.13	PIPSL	7.22	4.32e-10	0.00897	0.94	0.65	Gut microbiota (functional units);	chr1:151267094	chr10:93958191~93961540:-
LAML	trans	rs2950393	0.804	rs1026565	ENSG00000121089.4	NACA3P	7.22	4.39e-10	0.00913	0.75	0.65	Platelet distribution width;	chr12:56744044	chr4:164943290~164943937:+
LAML	trans	rs7312770	0.637	rs705699	ENSG00000243538.1	CTB-55B8.1	7.2	4.67e-10	0.00969	0.81	0.65	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr5:16902294~16902641:-
LAML	trans	rs877636	0.562	rs10876864	ENSG00000242206.2	RPS26P35	-7.2	4.69e-10	0.00972	-0.75	-0.65	Cognitive function;	chr12:56007301	chr8:118761856~118762201:-
LAML	trans	rs9611565	0.765	rs132906	ENSG00000268568.1	AC007228.9	7.19	4.87e-10	0.0101	0.85	0.65	Vitiligo;	chr22:41403763	chr19:56672574~56673901:-
LAML	trans	rs7312770	0.612	rs773114	ENSG00000243538.1	CTB-55B8.1	7.19	4.95e-10	0.0102	0.81	0.65	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr5:16902294~16902641:-
LAML	trans	rs916888	0.779	rs199498	ENSG00000214425.5	LRRC37A4P	-7.19	5.02e-10	0.0104	-0.9	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46788237	chr17:45506741~45550335:-
LAML	trans	rs9611565	0.877	rs3817999	ENSG00000268568.1	AC007228.9	7.18	5.03e-10	0.0104	0.87	0.65	Vitiligo;	chr22:41351713	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.754	rs2036857	ENSG00000275858.1	RP11-291L22.8	7.18	5.11e-10	0.0105	0.87	0.65	Corneal astigmatism;	chr4:119328085	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs2036856	ENSG00000275858.1	RP11-291L22.8	7.18	5.11e-10	0.0105	0.87	0.65	Corneal astigmatism;	chr4:119328133	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs4443261	ENSG00000275858.1	RP11-291L22.8	7.18	5.11e-10	0.0105	0.87	0.65	Corneal astigmatism;	chr4:119328146	chr10:38450738~38451069:-
LAML	trans	rs877636	0.692	rs11171739	ENSG00000234192.1	RP11-57C13.5	7.18	5.24e-10	0.0108	0.71	0.65	Cognitive function;	chr12:56076841	chr10:87642607~87642954:+
LAML	trans	rs916888	0.773	rs199451	ENSG00000267246.1	RP11-798G7.7	-7.18	5.24e-10	0.0108	-0.89	-0.65	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46724418	chr17:45549781~45558738:-
LAML	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	7.17	5.33e-10	0.011	0.8	0.65	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
LAML	trans	rs1552244	0.554	rs59465469	ENSG00000230342.2	FANCD2P2	7.17	5.37e-10	0.011	0.86	0.65	Alzheimer's disease;	chr3:9949116	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs55847233	ENSG00000230342.2	FANCD2P2	7.17	5.37e-10	0.011	0.86	0.65	Alzheimer's disease;	chr3:9949417	chr3:11859674~11891172:+
LAML	trans	rs10940346	0.846	rs13356208	ENSG00000231752.4	EMBP1	-7.17	5.38e-10	0.011	-0.75	-0.65	Schizophrenia;	chr5:50197970	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.721	rs60147402	ENSG00000231752.4	EMBP1	-7.17	5.38e-10	0.011	-0.75	-0.65	Schizophrenia;	chr5:50230794	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs4865674	ENSG00000231752.4	EMBP1	-7.17	5.38e-10	0.011	-0.75	-0.65	Schizophrenia;	chr5:50277531	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs13360100	ENSG00000231752.4	EMBP1	-7.17	5.38e-10	0.011	-0.75	-0.65	Schizophrenia;	chr5:50323389	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs12514818	ENSG00000231752.4	EMBP1	-7.17	5.38e-10	0.011	-0.75	-0.65	Schizophrenia;	chr5:50349925	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.935	rs2353959	ENSG00000231752.4	EMBP1	-7.17	5.38e-10	0.011	-0.75	-0.65	Schizophrenia;	chr5:50473217	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.934	rs2353960	ENSG00000231752.4	EMBP1	-7.17	5.38e-10	0.011	-0.75	-0.65	Schizophrenia;	chr5:50481153	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.935	rs4971258	ENSG00000231752.4	EMBP1	-7.17	5.38e-10	0.011	-0.75	-0.65	Schizophrenia;	chr5:50498560	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs11948752	ENSG00000231752.4	EMBP1	-7.17	5.38e-10	0.011	-0.75	-0.65	Schizophrenia;	chr5:50504082	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.936	rs303219	ENSG00000231752.4	EMBP1	7.17	5.38e-10	0.011	0.75	0.65	Schizophrenia;	chr5:50407795	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.846	rs2663076	ENSG00000231752.4	EMBP1	7.17	5.38e-10	0.011	0.75	0.65	Schizophrenia;	chr5:50430593	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.934	rs303231	ENSG00000231752.4	EMBP1	7.17	5.38e-10	0.011	0.75	0.65	Schizophrenia;	chr5:50447369	chr1:121519112~121571892:+
LAML	trans	rs66887589	0.66	rs4833613	ENSG00000275858.1	RP11-291L22.8	-7.15	5.74e-10	0.0117	-0.8	-0.64	Diastolic blood pressure;	chr4:119229001	chr10:38450738~38451069:-
LAML	trans	rs916888	0.773	rs199439	ENSG00000267246.1	RP11-798G7.7	-7.15	5.91e-10	0.012	-0.9	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46716137	chr17:45549781~45558738:-
LAML	trans	rs7312770	0.612	rs773114	ENSG00000234354.3	RPS26P47	7.15	5.91e-10	0.012	0.82	0.64	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr13:100539901~100540248:-
LAML	trans	rs5022636	0.631	rs6587562	ENSG00000180764.13	PIPSL	-7.14	5.99e-10	0.0122	-0.93	-0.64	Gut microbiota (functional units);	chr1:151273765	chr10:93958191~93961540:-
LAML	trans	rs916888	0.821	rs199506	ENSG00000267198.1	RP11-798G7.6	7.14	6.07e-10	0.0124	0.79	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781665	chr17:45545804~45563230:+
LAML	trans	rs11098499	0.78	rs7692994	ENSG00000275858.1	RP11-291L22.8	7.14	6.13e-10	0.0125	0.83	0.64	Corneal astigmatism;	chr4:119506334	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs10212714	ENSG00000275858.1	RP11-291L22.8	7.13	6.42e-10	0.0131	0.9	0.64	Corneal astigmatism;	chr4:119333147	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.754	rs1849457	ENSG00000275858.1	RP11-291L22.8	7.13	6.42e-10	0.0131	0.9	0.64	Corneal astigmatism;	chr4:119333200	chr10:38450738~38451069:-
LAML	trans	rs7312770	0.637	rs705699	ENSG00000234354.3	RPS26P47	7.12	6.52e-10	0.0132	0.82	0.64	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr13:100539901~100540248:-
LAML	trans	rs11098499	0.663	rs9996501	ENSG00000275858.1	RP11-291L22.8	7.12	6.58e-10	0.0134	0.87	0.64	Corneal astigmatism;	chr4:119317763	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.697	rs28458294	ENSG00000275858.1	RP11-291L22.8	7.12	6.58e-10	0.0134	0.87	0.64	Corneal astigmatism;	chr4:119317769	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.663	rs28369503	ENSG00000275858.1	RP11-291L22.8	7.12	6.58e-10	0.0134	0.87	0.64	Corneal astigmatism;	chr4:119317770	chr10:38450738~38451069:-
LAML	trans	rs13177918	0.906	rs12652032	ENSG00000239528.1	RPS14P8	7.11	6.91e-10	0.014	1.03	0.64	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150442060	chr5:116562562~116562930:+
LAML	trans	rs5022636	0.559	rs41302131	ENSG00000180764.13	PIPSL	7.11	6.99e-10	0.0141	0.95	0.64	Gut microbiota (functional units);	chr1:151267532	chr10:93958191~93961540:-
LAML	trans	rs916888	0.821	rs199504	ENSG00000267198.1	RP11-798G7.6	7.11	7.01e-10	0.0142	0.79	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46783637	chr17:45545804~45563230:+
LAML	trans	rs916888	0.773	rs199447	ENSG00000267246.1	RP11-798G7.7	-7.1	7.13e-10	0.0144	-0.9	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46734822	chr17:45549781~45558738:-
LAML	trans	rs12727131	0.81	rs1440574	ENSG00000279520.1	RP11-20I23.2	-7.1	7.26e-10	0.0146	-0.68	-0.64	Neutrophil count;	chr1:59594787	chr16:2516658~2517999:+
LAML	trans	rs12145833	0.596	rs3926866	ENSG00000154608.12	CEP170P1	-7.09	7.65e-10	0.0154	-1.1	-0.64	Obesity (early onset extreme);	chr1:243274330	chr4:118467590~118554204:+
LAML	trans	rs7312770	0.637	rs705700	ENSG00000234354.3	RPS26P47	7.08	7.72e-10	0.0155	0.82	0.64	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr13:100539901~100540248:-
LAML	trans	rs9611565	0.729	rs203320	ENSG00000268568.1	AC007228.9	-7.08	7.73e-10	0.0155	-0.86	-0.64	Vitiligo;	chr22:41517473	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs4822032	ENSG00000268568.1	AC007228.9	-7.08	7.73e-10	0.0155	-0.86	-0.64	Vitiligo;	chr22:41529531	chr19:56672574~56673901:-
LAML	trans	rs877636	0.692	rs2271194	ENSG00000243328.1	RP11-520P18.1	-7.08	7.83e-10	0.0157	-0.69	-0.64	Cognitive function;	chr12:56083910	chr8:143065915~143066587:-
LAML	trans	rs877636	0.692	rs10876870	ENSG00000243328.1	RP11-520P18.1	-7.08	7.83e-10	0.0157	-0.69	-0.64	Cognitive function;	chr12:56084218	chr8:143065915~143066587:-
LAML	trans	rs877636	0.692	rs7971751	ENSG00000243328.1	RP11-520P18.1	-7.08	7.83e-10	0.0157	-0.69	-0.64	Cognitive function;	chr12:56084874	chr8:143065915~143066587:-
LAML	trans	rs11098499	0.722	rs7673476	ENSG00000275858.1	RP11-291L22.8	7.08	7.87e-10	0.0158	0.88	0.64	Corneal astigmatism;	chr4:119327528	chr10:38450738~38451069:-
LAML	trans	rs3738443	0.599	rs1934986	ENSG00000235271.4	RP1-90L6.3	-7.06	8.48e-10	0.0169	-1.1	-0.64	Alcohol dependence;	chr1:247235696	chr22:26903292~26920611:+
LAML	trans	rs9611565	0.649	rs6002480	ENSG00000268568.1	AC007228.9	-7.06	8.71e-10	0.0174	-0.92	-0.64	Vitiligo;	chr22:41780913	chr19:56672574~56673901:-
LAML	trans	rs2950393	0.804	rs1466382	ENSG00000121089.4	NACA3P	-7.06	8.73e-10	0.0174	-0.74	-0.64	Platelet distribution width;	chr12:56723050	chr4:164943290~164943937:+
LAML	trans	rs916888	0.697	rs199516	ENSG00000267198.1	RP11-798G7.6	7.05	8.95e-10	0.0178	0.79	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779119	chr17:45545804~45563230:+
LAML	trans	rs916888	0.821	rs199514	ENSG00000267198.1	RP11-798G7.6	7.05	8.95e-10	0.0178	0.79	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779515	chr17:45545804~45563230:+
LAML	trans	rs916888	0.821	rs199513	ENSG00000267198.1	RP11-798G7.6	7.05	8.95e-10	0.0178	0.79	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779566	chr17:45545804~45563230:+
LAML	trans	rs916888	0.821	rs199512	ENSG00000267198.1	RP11-798G7.6	7.05	8.95e-10	0.0178	0.79	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46779986	chr17:45545804~45563230:+
LAML	trans	rs916888	0.821	rs199509	ENSG00000267198.1	RP11-798G7.6	7.05	8.95e-10	0.0178	0.79	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781362	chr17:45545804~45563230:+
LAML	trans	rs916888	0.821	rs199507	ENSG00000267198.1	RP11-798G7.6	7.05	8.95e-10	0.0178	0.79	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46781489	chr17:45545804~45563230:+
LAML	trans	rs916888	0.821	rs199505	ENSG00000267198.1	RP11-798G7.6	7.05	8.95e-10	0.0178	0.79	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782044	chr17:45545804~45563230:+
LAML	trans	rs916888	0.821	rs70602	ENSG00000267198.1	RP11-798G7.6	7.05	8.95e-10	0.0178	0.79	0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782349	chr17:45545804~45563230:+
LAML	trans	rs66887589	0.807	rs7694483	ENSG00000275858.1	RP11-291L22.8	7.04	9.15e-10	0.0182	0.78	0.64	Diastolic blood pressure;	chr4:119484774	chr10:38450738~38451069:-
LAML	trans	rs916888	0.821	rs70600	ENSG00000267198.1	RP11-798G7.6	-7.04	9.17e-10	0.0182	-0.8	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46782655	chr17:45545804~45563230:+
LAML	trans	rs11098499	0.532	rs4833624	ENSG00000275858.1	RP11-291L22.8	7.04	9.24e-10	0.0183	0.95	0.64	Corneal astigmatism;	chr4:119664342	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.592	rs6519270	ENSG00000268568.1	AC007228.9	7.04	9.24e-10	0.0184	0.92	0.64	Vitiligo;	chr22:41682662	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.546	rs5758426	ENSG00000268568.1	AC007228.9	7.04	9.24e-10	0.0184	0.92	0.64	Vitiligo;	chr22:41702759	chr19:56672574~56673901:-
LAML	trans	rs877636	0.562	rs10876864	ENSG00000243328.1	RP11-520P18.1	-7.04	9.29e-10	0.0184	-0.73	-0.64	Cognitive function;	chr12:56007301	chr8:143065915~143066587:-
LAML	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	7.04	9.33e-10	0.0185	0.75	0.64	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
LAML	trans	rs66820110	1	rs1504016	ENSG00000225972.1	MTND1P23	-7.04	9.39e-10	0.0186	-1.11	-0.64	Post bronchodilator FEV1/FVC ratio;	chr2:124611405	chr1:629062~629433:+
LAML	trans	rs66820110	1	rs4848946	ENSG00000225972.1	MTND1P23	-7.04	9.39e-10	0.0186	-1.11	-0.64	Post bronchodilator FEV1/FVC ratio;	chr2:124616329	chr1:629062~629433:+
LAML	trans	rs1552244	0.554	rs7638846	ENSG00000230342.2	FANCD2P2	7.04	9.39e-10	0.0186	0.9	0.64	Alzheimer's disease;	chr3:10006917	chr3:11859674~11891172:+
LAML	trans	rs9611565	1	rs5758314	ENSG00000268568.1	AC007228.9	-7.04	9.42e-10	0.0186	-0.85	-0.64	Vitiligo;	chr22:41366519	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.913	rs10006304	ENSG00000275858.1	RP11-291L22.8	7.04	9.47e-10	0.0187	0.91	0.64	Corneal astigmatism;	chr4:119203150	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.644	rs3806808	ENSG00000275858.1	RP11-291L22.8	7.03	9.6e-10	0.019	0.85	0.64	Corneal astigmatism;	chr4:119629930	chr10:38450738~38451069:-
LAML	trans	rs10940346	0.694	rs2219454	ENSG00000231752.4	EMBP1	-7.03	9.75e-10	0.0192	-0.74	-0.64	Schizophrenia;	chr5:50212798	chr1:121519112~121571892:+
LAML	trans	rs928391	0.602	rs1800601	ENSG00000227183.3	HDGFP1	-7.03	9.78e-10	0.0192	-0.95	-0.64	Platelet count;	chr1:156815825	chrX:131646639~131646890:+
LAML	trans	rs877636	0.562	rs10876864	ENSG00000234354.3	RPS26P47	-7.03	9.86e-10	0.0193	-0.83	-0.64	Cognitive function;	chr12:56007301	chr13:100539901~100540248:-
LAML	trans	rs9611565	0.649	rs139540	ENSG00000268568.1	AC007228.9	-7.01	1.05e-09	0.0205	-0.92	-0.64	Vitiligo;	chr22:41782036	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs139559	ENSG00000268568.1	AC007228.9	-7.01	1.05e-09	0.0205	-0.92	-0.64	Vitiligo;	chr22:41795632	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs139553	ENSG00000268568.1	AC007228.9	7.01	1.05e-09	0.0205	0.92	0.64	Vitiligo;	chr22:41791195	chr19:56672574~56673901:-
LAML	trans	rs916888	0.61	rs199529	ENSG00000267246.1	RP11-798G7.7	-7.01	1.07e-09	0.0209	-0.86	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46759851	chr17:45549781~45558738:-
LAML	trans	rs11098499	0.644	rs10009566	ENSG00000275858.1	RP11-291L22.8	7	1.09e-09	0.0212	0.86	0.64	Corneal astigmatism;	chr4:119637453	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.644	rs10012252	ENSG00000275858.1	RP11-291L22.8	7	1.09e-09	0.0212	0.86	0.64	Corneal astigmatism;	chr4:119637984	chr10:38450738~38451069:-
LAML	trans	rs916888	0.773	rs199448	ENSG00000267246.1	RP11-798G7.7	-7	1.09e-09	0.0212	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46731635	chr17:45549781~45558738:-
LAML	trans	rs916888	0.773	rs199445	ENSG00000267246.1	RP11-798G7.7	-7	1.09e-09	0.0212	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46740042	chr17:45549781~45558738:-
LAML	trans	rs916888	0.773	rs199443	ENSG00000267246.1	RP11-798G7.7	-7	1.09e-09	0.0212	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46742199	chr17:45549781~45558738:-
LAML	trans	rs916888	0.773	rs199534	ENSG00000267246.1	RP11-798G7.7	-7	1.09e-09	0.0212	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46746847	chr17:45549781~45558738:-
LAML	trans	rs916888	0.773	rs199533	ENSG00000267246.1	RP11-798G7.7	-7	1.09e-09	0.0212	-0.88	-0.64	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46751565	chr17:45549781~45558738:-
LAML	trans	rs10940346	0.644	rs62365309	ENSG00000231752.4	EMBP1	-7	1.1e-09	0.0213	-0.72	-0.64	Schizophrenia;	chr5:50568902	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.807	rs4865843	ENSG00000231752.4	EMBP1	-7	1.1e-09	0.0213	-0.72	-0.64	Schizophrenia;	chr5:50569681	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs16879414	ENSG00000231752.4	EMBP1	6.99	1.14e-09	0.0221	0.75	0.64	Schizophrenia;	chr5:50337969	chr1:121519112~121571892:+
LAML	trans	rs773125	1	rs773125	ENSG00000234354.3	RPS26P47	6.98	1.19e-09	0.0229	0.81	0.64	Rheumatoid arthritis;	chr12:56001170	chr13:100539901~100540248:-
LAML	trans	rs877636	0.562	rs1131017	ENSG00000196656.7	AC004057.1	-6.97	1.24e-09	0.0238	-0.73	-0.63	Cognitive function;	chr12:56042145	chr4:113214046~113217170:-
LAML	trans	rs916888	0.773	rs199457	ENSG00000267246.1	RP11-798G7.7	-6.97	1.24e-09	0.0238	-0.88	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46718103	chr17:45549781~45558738:-
LAML	trans	rs916888	0.687	rs199456	ENSG00000267246.1	RP11-798G7.7	-6.97	1.24e-09	0.0238	-0.88	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46720553	chr17:45549781~45558738:-
LAML	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-6.97	1.24e-09	0.0238	-0.67	-0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
LAML	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-6.97	1.26e-09	0.0242	-0.78	-0.63	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
LAML	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-6.97	1.26e-09	0.0242	-0.78	-0.63	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
LAML	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-6.97	1.26e-09	0.0242	-0.78	-0.63	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
LAML	trans	rs877636	0.692	rs11171739	ENSG00000243328.1	RP11-520P18.1	6.96	1.33e-09	0.0254	0.69	0.63	Cognitive function;	chr12:56076841	chr8:143065915~143066587:-
LAML	trans	rs1552244	0.554	rs2272119	ENSG00000230342.2	FANCD2P2	6.95	1.34e-09	0.0256	0.88	0.63	Alzheimer's disease;	chr3:10007668	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.608	rs9837460	ENSG00000230342.2	FANCD2P2	6.95	1.34e-09	0.0256	0.88	0.63	Alzheimer's disease;	chr3:10008238	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs28667821	ENSG00000230342.2	FANCD2P2	6.95	1.34e-09	0.0256	0.88	0.63	Alzheimer's disease;	chr3:10009083	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.543	rs28719585	ENSG00000230342.2	FANCD2P2	6.95	1.34e-09	0.0256	0.88	0.63	Alzheimer's disease;	chr3:10009129	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs7349576	ENSG00000230342.2	FANCD2P2	6.95	1.34e-09	0.0256	0.88	0.63	Alzheimer's disease;	chr3:10009209	chr3:11859674~11891172:+
LAML	trans	rs10940346	0.807	rs6898102	ENSG00000231752.4	EMBP1	-6.95	1.38e-09	0.0263	-0.72	-0.63	Schizophrenia;	chr5:50578496	chr1:121519112~121571892:+
LAML	trans	rs11098499	0.644	rs2389880	ENSG00000275858.1	RP11-291L22.8	6.94	1.41e-09	0.0268	0.86	0.63	Corneal astigmatism;	chr4:119638715	chr10:38450738~38451069:-
LAML	trans	rs1552244	0.554	rs17050704	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10004050	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs34883592	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10004481	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs17050705	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10004714	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs2272120	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10005019	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs13079240	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10005562	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs2272121	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10005996	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs2272122	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10006291	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs3732965	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10007076	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs3732964	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10007155	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs3732963	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10007201	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.608	rs3732962	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10007267	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs2272118	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10007603	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs58020561	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10012998	chr3:11859674~11891172:+
LAML	trans	rs1552244	0.554	rs13081079	ENSG00000230342.2	FANCD2P2	6.94	1.43e-09	0.0272	0.89	0.63	Alzheimer's disease;	chr3:10014664	chr3:11859674~11891172:+
LAML	trans	rs11098499	0.535	rs7671759	ENSG00000275858.1	RP11-291L22.8	6.93	1.46e-09	0.0277	0.86	0.63	Corneal astigmatism;	chr4:119326939	chr10:38450738~38451069:-
LAML	trans	rs9611565	0.649	rs5751144	ENSG00000268568.1	AC007228.9	-6.93	1.47e-09	0.0277	-0.91	-0.63	Vitiligo;	chr22:41732093	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs4822050	ENSG00000268568.1	AC007228.9	-6.93	1.47e-09	0.0277	-0.91	-0.63	Vitiligo;	chr22:41781449	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.573	rs9306355	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41715892	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs5758434	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41720159	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.5	rs2011053	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41725274	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs738422	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41727395	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs2064189	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41731995	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.568	rs2413656	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41733353	chr19:56672574~56673901:-
LAML	trans	rs4822044	0.617	rs13054514	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Cannabis dependence symptom count;	chr22:41734379	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.568	rs5758441	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41736884	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs5758442	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41737056	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.58	rs5758449	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41744156	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.504	rs5758452	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41748923	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.571	rs2050032	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41756425	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.532	rs4401299	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41760513	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs2413659	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41768858	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs9623450	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41779227	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.568	rs5751159	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41779361	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.649	rs5758466	ENSG00000268568.1	AC007228.9	6.93	1.47e-09	0.0277	0.91	0.63	Vitiligo;	chr22:41780055	chr19:56672574~56673901:-
LAML	trans	rs1552244	0.608	rs2302786	ENSG00000230342.2	FANCD2P2	6.93	1.5e-09	0.0282	0.85	0.63	Alzheimer's disease;	chr3:9937976	chr3:11859674~11891172:+
LAML	trans	rs4276421	0.874	rs71618219	ENSG00000231752.4	EMBP1	6.92	1.54e-09	0.0289	0.8	0.63	P wave duration;	chr5:45950598	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.967	rs10062508	ENSG00000231752.4	EMBP1	6.92	1.54e-09	0.0289	0.8	0.63	P wave duration;	chr5:45961764	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs11739291	ENSG00000231752.4	EMBP1	-6.91	1.59e-09	0.0298	-0.74	-0.63	Schizophrenia;	chr5:50550394	chr1:121519112~121571892:+
LAML	trans	rs11098499	0.954	rs6820115	ENSG00000275858.1	RP11-291L22.8	6.91	1.61e-09	0.03	0.77	0.63	Corneal astigmatism;	chr4:119477027	chr10:38450738~38451069:-
LAML	trans	rs2690837	0.783	rs2694935	ENSG00000259216.2	RP11-227D13.2	-6.91	1.63e-09	0.0304	-0.71	-0.63	Neuroticism;	chr7:114334692	chr15:48725338~48725827:+
LAML	trans	rs2690837	0.783	rs2030910	ENSG00000259216.2	RP11-227D13.2	-6.91	1.63e-09	0.0304	-0.71	-0.63	Neuroticism;	chr7:114337659	chr15:48725338~48725827:+
LAML	trans	rs2690837	0.783	rs2253478	ENSG00000259216.2	RP11-227D13.2	-6.91	1.65e-09	0.0308	-0.7	-0.63	Neuroticism;	chr7:114337941	chr15:48725338~48725827:+
LAML	trans	rs916888	0.773	rs199535	ENSG00000267246.1	RP11-798G7.7	-6.9	1.66e-09	0.0309	-0.87	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46745296	chr17:45549781~45558738:-
LAML	trans	rs7312770	0.637	rs705700	ENSG00000223416.3	RPS26P15	6.9	1.66e-09	0.0309	0.8	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr1:58056133~58056480:-
LAML	trans	rs896655	0.631	rs1414243	ENSG00000207450.1	Y_RNA	-6.9	1.68e-09	0.0312	-0.73	-0.63	Coronary artery disease;	chr9:21748434	chr8:47805079~47805179:-
LAML	trans	rs896655	0.631	rs1335510	ENSG00000207450.1	Y_RNA	-6.9	1.68e-09	0.0312	-0.73	-0.63	Coronary artery disease;	chr9:21757804	chr8:47805079~47805179:-
LAML	trans	rs12091564	1	rs12091564	ENSG00000259169.1	GNRHR2P1	-6.9	1.68e-09	0.0312	-1.38	-0.63	Coronary heart disease (SNP X SNP interaction);	chr1:146039391	chr14:60398934~60400013:-
LAML	trans	rs11098499	0.644	rs34835603	ENSG00000275858.1	RP11-291L22.8	6.9	1.69e-09	0.0313	0.9	0.63	Corneal astigmatism;	chr4:119632273	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.615	rs28850368	ENSG00000275858.1	RP11-291L22.8	6.9	1.69e-09	0.0313	0.9	0.63	Corneal astigmatism;	chr4:119633158	chr10:38450738~38451069:-
LAML	trans	rs1882538	0.503	rs13240997	ENSG00000278818.1	Metazoa_SRP	-6.9	1.7e-09	0.0314	-0.57	-0.63	Intelligence (multi-trait analysis);	chr7:133450619	chr14:55285227~55285558:+
LAML	trans	rs10254118	0.757	rs13241123	ENSG00000278818.1	Metazoa_SRP	-6.9	1.7e-09	0.0314	-0.57	-0.63	Intelligence (multi-trait analysis);	chr7:133450753	chr14:55285227~55285558:+
LAML	trans	rs4276421	0.805	rs13165481	ENSG00000231752.4	EMBP1	6.9	1.72e-09	0.0319	0.79	0.63	P wave duration;	chr5:46034214	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs7446951	ENSG00000231752.4	EMBP1	-6.9	1.72e-09	0.0319	-0.75	-0.63	Schizophrenia;	chr5:50314949	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.682	rs10067983	ENSG00000231752.4	EMBP1	6.89	1.73e-09	0.032	0.79	0.63	P wave duration;	chr5:46064294	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.743	rs10060199	ENSG00000231752.4	EMBP1	6.89	1.73e-09	0.032	0.79	0.63	P wave duration;	chr5:46064524	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.682	rs12657581	ENSG00000231752.4	EMBP1	6.89	1.73e-09	0.032	0.79	0.63	P wave duration;	chr5:46080471	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.774	rs4601053	ENSG00000231752.4	EMBP1	6.89	1.75e-09	0.0323	0.8	0.63	P wave duration;	chr5:46101734	chr1:121519112~121571892:+
LAML	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-6.89	1.77e-09	0.0327	-0.82	-0.63	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
LAML	trans	rs4276421	0.753	rs7443976	ENSG00000231752.4	EMBP1	6.89	1.8e-09	0.0331	0.78	0.63	P wave duration;	chr5:45936323	chr1:121519112~121571892:+
LAML	trans	rs26067	0.689	rs285529	ENSG00000231752.4	EMBP1	-6.87	1.93e-09	0.0352	-0.82	-0.63	Breast cancer;	chr5:50843452	chr1:121519112~121571892:+
LAML	trans	rs9532669	0.926	rs2039119	ENSG00000232963.1	HMGN2P20	6.87	1.94e-09	0.0352	0.7	0.63	Cervical cancer;	chr13:40872432	chr2:24330402~24330674:+
LAML	trans	rs7312770	0.637	rs705700	ENSG00000243328.1	RP11-520P18.1	6.87	1.96e-09	0.0352	0.7	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55995509	chr8:143065915~143066587:-
LAML	trans	rs10940346	0.601	rs1841104	ENSG00000231752.4	EMBP1	-6.86	1.99e-09	0.0352	-0.73	-0.63	Schizophrenia;	chr5:50263930	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs6892142	ENSG00000231752.4	EMBP1	-6.86	1.99e-09	0.0352	-0.73	-0.63	Schizophrenia;	chr5:50276518	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs567248	ENSG00000231752.4	EMBP1	-6.86	1.99e-09	0.0352	-0.73	-0.63	Schizophrenia;	chr5:50277650	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.562	rs10051529	ENSG00000231752.4	EMBP1	-6.86	1.99e-09	0.0352	-0.73	-0.63	Schizophrenia;	chr5:50303103	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs10042601	ENSG00000231752.4	EMBP1	-6.86	1.99e-09	0.0352	-0.73	-0.63	Schizophrenia;	chr5:50315248	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.668	rs6884426	ENSG00000231752.4	EMBP1	-6.86	1.99e-09	0.0352	-0.73	-0.63	Schizophrenia;	chr5:50492782	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.54	rs34645496	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50322419	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs35330444	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50322606	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs6875734	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50323203	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs6868380	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50328473	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs13172932	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50345364	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs12651834	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50351199	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs34616519	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50353638	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs1039798	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50355909	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs10072182	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50356818	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs7442762	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50358137	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.54	rs12109228	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50383135	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.562	rs13182357	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50404060	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs6860503	ENSG00000231752.4	EMBP1	6.86	1.99e-09	0.0352	0.73	0.63	Schizophrenia;	chr5:50446340	chr1:121519112~121571892:+
LAML	trans	rs66887589	0.592	rs11731571	ENSG00000275858.1	RP11-291L22.8	6.86	1.99e-09	0.0352	0.75	0.63	Diastolic blood pressure;	chr4:119300030	chr10:38450738~38451069:-
LAML	trans	rs10940346	0.601	rs4865676	ENSG00000231752.4	EMBP1	6.86	2e-09	0.0353	0.77	0.63	Schizophrenia;	chr5:50279343	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs12697055	ENSG00000231752.4	EMBP1	6.86	2e-09	0.0353	0.77	0.63	Schizophrenia;	chr5:50317827	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs1033108	ENSG00000231752.4	EMBP1	6.86	2e-09	0.0353	0.77	0.63	Schizophrenia;	chr5:50327764	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs13174293	ENSG00000231752.4	EMBP1	6.86	2e-09	0.0353	0.77	0.63	Schizophrenia;	chr5:50352191	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs3849669	ENSG00000231752.4	EMBP1	6.86	2e-09	0.0353	0.77	0.63	Schizophrenia;	chr5:50365710	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs579279	ENSG00000231752.4	EMBP1	-6.86	2e-09	0.0353	-0.77	-0.63	Schizophrenia;	chr5:50277308	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.601	rs5011669	ENSG00000231752.4	EMBP1	-6.86	2e-09	0.0353	-0.77	-0.63	Schizophrenia;	chr5:50311788	chr1:121519112~121571892:+
LAML	trans	rs10940346	1	rs1423645	ENSG00000231752.4	EMBP1	-6.86	2.04e-09	0.0359	-0.73	-0.63	Schizophrenia;	chr5:50540881	chr1:121519112~121571892:+
LAML	trans	rs773125	1	rs773125	ENSG00000243538.1	CTB-55B8.1	6.85	2.06e-09	0.0362	0.79	0.63	Rheumatoid arthritis;	chr12:56001170	chr5:16902294~16902641:-
LAML	trans	rs2690837	0.783	rs2694936	ENSG00000259216.2	RP11-227D13.2	-6.85	2.13e-09	0.0373	-0.7	-0.63	Neuroticism;	chr7:114341009	chr15:48725338~48725827:+
LAML	trans	rs76329678	1	rs76329678	ENSG00000231752.4	EMBP1	-6.84	2.15e-09	0.0376	-0.73	-0.63	Schizophrenia;	chr5:50534452	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.967	rs6878425	ENSG00000231752.4	EMBP1	6.84	2.16e-09	0.0377	0.76	0.63	P wave duration;	chr5:45843153	chr1:121519112~121571892:+
LAML	trans	rs4276421	1	rs13175559	ENSG00000231752.4	EMBP1	6.84	2.16e-09	0.0377	0.76	0.63	P wave duration;	chr5:45854525	chr1:121519112~121571892:+
LAML	trans	rs4276421	1	rs11748089	ENSG00000231752.4	EMBP1	-6.84	2.16e-09	0.0377	-0.76	-0.63	P wave duration;	chr5:45810733	chr1:121519112~121571892:+
LAML	trans	rs4276421	1	rs10037766	ENSG00000231752.4	EMBP1	-6.84	2.16e-09	0.0377	-0.76	-0.63	P wave duration;	chr5:45813215	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.967	rs10755272	ENSG00000231752.4	EMBP1	-6.84	2.16e-09	0.0377	-0.76	-0.63	P wave duration;	chr5:45815434	chr1:121519112~121571892:+
LAML	trans	rs4276421	1	rs4866982	ENSG00000231752.4	EMBP1	-6.84	2.16e-09	0.0377	-0.76	-0.63	P wave duration;	chr5:45816754	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.935	rs6898824	ENSG00000231752.4	EMBP1	-6.84	2.16e-09	0.0377	-0.76	-0.63	P wave duration;	chr5:45842058	chr1:121519112~121571892:+
LAML	trans	rs2690837	0.783	rs2694933	ENSG00000259216.2	RP11-227D13.2	-6.84	2.16e-09	0.0377	-0.7	-0.63	Neuroticism;	chr7:114333043	chr15:48725338~48725827:+
LAML	trans	rs10940346	0.601	rs1674512	ENSG00000231752.4	EMBP1	6.84	2.17e-09	0.0377	0.76	0.63	Schizophrenia;	chr5:50268794	chr1:121519112~121571892:+
LAML	trans	rs9611565	0.694	rs5758411	ENSG00000268568.1	AC007228.9	6.84	2.17e-09	0.0377	0.9	0.63	Vitiligo;	chr22:41683730	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.608	rs2003816	ENSG00000268568.1	AC007228.9	6.84	2.17e-09	0.0377	0.9	0.63	Vitiligo;	chr22:41699136	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.694	rs11090056	ENSG00000268568.1	AC007228.9	6.84	2.17e-09	0.0377	0.9	0.63	Vitiligo;	chr22:41699900	chr19:56672574~56673901:-
LAML	trans	rs9611565	0.644	rs2413652	ENSG00000268568.1	AC007228.9	6.84	2.17e-09	0.0377	0.9	0.63	Vitiligo;	chr22:41701234	chr19:56672574~56673901:-
LAML	trans	rs11098499	0.675	rs11098534	ENSG00000275858.1	RP11-291L22.8	6.84	2.19e-09	0.038	0.9	0.63	Corneal astigmatism;	chr4:119635617	chr10:38450738~38451069:-
LAML	trans	rs4276421	0.904	rs6862657	ENSG00000231752.4	EMBP1	-6.83	2.25e-09	0.0391	-0.76	-0.63	P wave duration;	chr5:45905895	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.967	rs10069793	ENSG00000231752.4	EMBP1	6.83	2.25e-09	0.0391	0.76	0.63	P wave duration;	chr5:45803049	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.935	rs4502836	ENSG00000231752.4	EMBP1	6.83	2.26e-09	0.0392	0.78	0.63	P wave duration;	chr5:45956617	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.934	rs7443410	ENSG00000231752.4	EMBP1	6.83	2.26e-09	0.0392	0.78	0.63	P wave duration;	chr5:45960831	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.762	rs10043270	ENSG00000231752.4	EMBP1	6.83	2.26e-09	0.0392	0.78	0.63	P wave duration;	chr5:45967846	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.774	rs8188072	ENSG00000231752.4	EMBP1	6.82	2.36e-09	0.0408	0.77	0.63	P wave duration;	chr5:46061883	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.935	rs4473777	ENSG00000231752.4	EMBP1	6.82	2.39e-09	0.0414	0.78	0.63	P wave duration;	chr5:45968760	chr1:121519112~121571892:+
LAML	trans	rs7312770	0.612	rs773114	ENSG00000243328.1	RP11-520P18.1	6.82	2.42e-09	0.0417	0.7	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:143065915~143066587:-
LAML	trans	rs4276421	0.774	rs4428422	ENSG00000231752.4	EMBP1	6.81	2.42e-09	0.0418	0.79	0.63	P wave duration;	chr5:46017216	chr1:121519112~121571892:+
LAML	trans	rs11098499	0.605	rs6833140	ENSG00000275858.1	RP11-291L22.8	6.81	2.43e-09	0.0419	0.81	0.63	Corneal astigmatism;	chr4:119345667	chr10:38450738~38451069:-
LAML	trans	rs1816752	0.875	rs17384871	ENSG00000237917.1	PARP4P1	6.81	2.45e-09	0.0422	0.99	0.63	Obesity-related traits;	chr13:24484959	chrY:26594851~26634652:-
LAML	trans	rs12145833	0.596	rs10737887	ENSG00000154608.12	CEP170P1	6.81	2.46e-09	0.0424	0.92	0.63	Obesity (early onset extreme);	chr1:243260844	chr4:118467590~118554204:+
LAML	trans	rs12145833	0.596	rs61833906	ENSG00000154608.12	CEP170P1	-6.81	2.47e-09	0.0425	-1.04	-0.63	Obesity (early onset extreme);	chr1:243256404	chr4:118467590~118554204:+
LAML	trans	rs12145833	0.665	rs78871868	ENSG00000154608.12	CEP170P1	-6.81	2.47e-09	0.0425	-1.04	-0.63	Obesity (early onset extreme);	chr1:243259020	chr4:118467590~118554204:+
LAML	trans	rs12145833	0.596	rs1060643	ENSG00000154608.12	CEP170P1	-6.81	2.47e-09	0.0425	-1.04	-0.63	Obesity (early onset extreme);	chr1:243266674	chr4:118467590~118554204:+
LAML	trans	rs773125	1	rs773125	ENSG00000223416.3	RPS26P15	6.81	2.49e-09	0.0428	0.79	0.63	Rheumatoid arthritis;	chr12:56001170	chr1:58056133~58056480:-
LAML	trans	rs4276421	0.967	rs6865429	ENSG00000231752.4	EMBP1	-6.81	2.51e-09	0.0431	-0.77	-0.63	P wave duration;	chr5:45830406	chr1:121519112~121571892:+
LAML	trans	rs10940346	0.777	rs11744698	ENSG00000231752.4	EMBP1	-6.81	2.51e-09	0.0431	-0.7	-0.63	Schizophrenia;	chr5:50586024	chr1:121519112~121571892:+
LAML	trans	rs10484100	0.518	rs4899899	ENSG00000256538.1	RP11-847H18.3	6.8	2.53e-09	0.0434	1.09	0.63	Blood trace element (Zn levels);	chr14:86349119	chr12:34037438~34056740:+
LAML	trans	rs7312770	0.612	rs773114	ENSG00000242206.2	RPS26P35	6.8	2.53e-09	0.0435	0.72	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:118761856~118762201:-
LAML	trans	rs10940346	0.58	rs34185098	ENSG00000231752.4	EMBP1	6.8	2.56e-09	0.044	0.73	0.63	Schizophrenia;	chr5:50330100	chr1:121519112~121571892:+
LAML	trans	rs7312770	0.637	rs705699	ENSG00000242206.2	RPS26P35	6.8	2.58e-09	0.0443	0.72	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55991020	chr8:118761856~118762201:-
LAML	trans	rs2521634	0.938	rs71537272	ENSG00000238290.1	RP11-431K24.1	6.8	2.59e-09	0.0444	1	0.63	Periodontitis;	chr7:24317280	chr1:8026738~8122702:+
LAML	trans	rs916888	0.779	rs199528	ENSG00000267246.1	RP11-798G7.7	-6.8	2.61e-09	0.0448	-0.87	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46765770	chr17:45549781~45558738:-
LAML	trans	rs916888	0.821	rs199525	ENSG00000267246.1	RP11-798G7.7	-6.8	2.61e-09	0.0448	-0.87	-0.63	Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis);	chr17:46770468	chr17:45549781~45558738:-
LAML	trans	rs1816752	0.875	rs59686377	ENSG00000237917.1	PARP4P1	6.79	2.64e-09	0.0453	0.98	0.63	Obesity-related traits;	chr13:24475869	chrY:26594851~26634652:-
LAML	trans	rs11098499	0.532	rs12512646	ENSG00000275858.1	RP11-291L22.8	6.79	2.65e-09	0.0454	0.93	0.62	Corneal astigmatism;	chr4:119664578	chr10:38450738~38451069:-
LAML	trans	rs11098499	0.739	rs9996382	ENSG00000275858.1	RP11-291L22.8	6.79	2.67e-09	0.0457	0.85	0.62	Corneal astigmatism;	chr4:119229857	chr10:38450738~38451069:-
LAML	trans	rs10940346	1	rs6874016	ENSG00000231752.4	EMBP1	-6.79	2.69e-09	0.046	-0.73	-0.62	Schizophrenia;	chr5:50549640	chr1:121519112~121571892:+
LAML	trans	rs7312770	1	rs7312770	ENSG00000233778.3	RP11-777J24.1	-6.79	2.69e-09	0.0461	-0.67	-0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:92144088~92144435:-
LAML	trans	rs4276421	0.745	rs10079238	ENSG00000231752.4	EMBP1	-6.78	2.76e-09	0.0471	-0.78	-0.62	P wave duration;	chr5:46066531	chr1:121519112~121571892:+
LAML	trans	rs2690837	0.783	rs2694932	ENSG00000259216.2	RP11-227D13.2	-6.78	2.82e-09	0.048	-0.7	-0.62	Neuroticism;	chr7:114332113	chr15:48725338~48725827:+
LAML	trans	rs10940346	0.562	rs7380318	ENSG00000231752.4	EMBP1	-6.78	2.83e-09	0.0481	-0.77	-0.62	Schizophrenia;	chr5:50510557	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.714	rs4259174	ENSG00000231752.4	EMBP1	-6.77	2.88e-09	0.049	-0.77	-0.62	P wave duration;	chr5:46074351	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.745	rs11957047	ENSG00000231752.4	EMBP1	-6.77	2.88e-09	0.049	-0.77	-0.62	P wave duration;	chr5:46080090	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.694	rs10941732	ENSG00000231752.4	EMBP1	-6.77	2.88e-09	0.049	-0.77	-0.62	P wave duration;	chr5:46080260	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.661	rs4455569	ENSG00000231752.4	EMBP1	-6.77	2.88e-09	0.049	-0.77	-0.62	P wave duration;	chr5:46081782	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.657	rs4975885	ENSG00000231752.4	EMBP1	-6.77	2.88e-09	0.049	-0.77	-0.62	P wave duration;	chr5:46083476	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.774	rs11949490	ENSG00000231752.4	EMBP1	-6.77	2.88e-09	0.049	-0.77	-0.62	P wave duration;	chr5:46085951	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.745	rs10041478	ENSG00000231752.4	EMBP1	-6.77	2.88e-09	0.049	-0.77	-0.62	P wave duration;	chr5:46103187	chr1:121519112~121571892:+
LAML	trans	rs4276421	0.743	rs4455568	ENSG00000231752.4	EMBP1	6.77	2.88e-09	0.049	0.77	0.62	P wave duration;	chr5:46079755	chr1:121519112~121571892:+
LAML	trans	rs877636	1	rs2292239	ENSG00000233778.3	RP11-777J24.1	6.77	2.94e-09	0.0499	0.79	0.62	Cognitive function;	chr12:56088396	chr8:92144088~92144435:-
LAML	trans	rs9611565	1	rs5751086	ENSG00000268568.1	AC007228.9	-6.77	2.94e-09	0.05	-0.8	-0.62	Vitiligo;	chr22:41372858	chr19:56672574~56673901:-